ASSI,CUB,ASTAI,ASSTT,SRI,TISI,ASSCA,Descr,RELATIT,ASSUBFR,CEI,Ti,CONSCO,SRASI,CHI,BFOR,VARII
1,Autocuration,,,1,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 30 uM,H,,,12052,8,,CHEMBL615117,BAO_0000019,
2,Autocuration,,,1,,,Compound was evaluated for its ability to mobilize calcium in 1321NI cells,U,,,22226,0,,CHEMBL615118,BAO_0000219,
3,Autocuration,,,1,,,,U,,,22226,0,,CHEMBL615119,BAO_0000019,
4,Autocuration,9913.0,,1,,,Binding affinity against A2 adenosine receptor in bovine striatal membranes using [3H]CGS-21680,H,,,104729,4,,CHEMBL615120,BAO_0000249,
5,Intermediate,9606.0,,1,,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),N,,163.0,80001,1,,CHEMBL615121,BAO_0000219,
6,Intermediate,9606.0,,1,,,In vitro cell cytotoxicity against 143-B cell lines (Human osteosarcoma cell line),N,,163.0,80001,1,,CHEMBL615122,BAO_0000219,
7,Intermediate,10090.0,,1,,,Cytotoxic Activity was evaluated against 143B (TK-) tumor cells,N,,163.0,80001,1,,CHEMBL615123,BAO_0000219,
8,Expert,9606.0,,1,,,In vitro cell cytotoxicity was determined against 143B cell line,N,,163.0,80001,1,,CHEMBL615124,BAO_0000219,
9,Intermediate,9606.0,,1,,,Inhibitory activity against tumor osteosarcoma cell line 143B after 72 hr continuous exposure to compound,N,,163.0,80001,1,,CHEMBL615125,BAO_0000219,
10,Intermediate,9606.0,,1,,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,N,,163.0,80001,1,,CHEMBL615126,BAO_0000219,
11,Intermediate,9606.0,,1,,,In vitro cell cytotoxicity against 143B-LTK cell lines expressed in HSV-1 TK,N,,163.0,80001,1,,CHEMBL615127,BAO_0000219,
12,Expert,9606.0,,1,,,In vitro cell cytotoxicity was determined against 143B-LTK cell line,N,,163.0,80001,1,,CHEMBL615128,BAO_0000219,
13,Intermediate,1280.0,,1,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,,,50185,1,,CHEMBL857900,BAO_0000218,
14,Intermediate,1280.0,,1,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,,,50185,1,,CHEMBL615129,BAO_0000218,
15,Intermediate,1280.0,,1,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,,,50185,1,,CHEMBL615130,BAO_0000218,
16,Intermediate,1280.0,,1,,,"The compound was tested for minimum inhibitory concentration in Staphylococcus aureus,147N penicillin sensitive Staphylococcus aureus",N,,,50185,1,,CHEMBL615131,BAO_0000218,
17,Expert,10116.0,,1,,,Inhibition of cytochrome P450 progesterone 15-alpha hydroxylase,D,,,100122,9,,CHEMBL884521,BAO_0000357,
18,Autocuration,,,1,,,Concentration that cause 50% activation of human reticulocyte 15-lipoxygenase (15-HLO),H,,,12054,8,,CHEMBL615132,BAO_0000357,
19,Autocuration,,,1,,,Inhibition of partially purified 15-lipoxygenase from human leukocytes,H,,,12054,8,,CHEMBL615133,BAO_0000019,
20,Autocuration,,,1,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),H,,,12054,8,,CHEMBL615134,BAO_0000357,
21,Autocuration,,,1,,,Compound was evaluated for the percent increase in activation concentration of human reticulocyte 15-lipoxygenase (15-HLO),H,,,12054,8,,CHEMBL615135,BAO_0000357,
22,Autocuration,,,1,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO),H,,,12054,8,,CHEMBL615136,BAO_0000357,
23,Autocuration,,,1,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,H,,,12054,8,,CHEMBL615137,BAO_0000357,
24,Autocuration,,,1,,,Inhibitory activity against human reticulocyte 15-lipoxygenase (15-HLO); NI is no inhibition,H,,,12054,8,,CHEMBL615138,BAO_0000357,
25,Autocuration,,,1,,,"Inhibitory concentration against 15-lipoxygenase, by inhibiting 15-HETE production by human umbilical vein endothelial cells (HUVEC) stimulated by calcium ionophore A 23187 at concentration of 10e-5 M.",U,,,22226,0,,CHEMBL836324,BAO_0000219,
26,Autocuration,9986.0,,1,,,In vitro inhibitory activity of compound on rabbit reticulocyte 15-lipoxygenase,H,,,12054,8,,CHEMBL615139,BAO_0000357,
27,Autocuration,9986.0,,1,,,Inhibition of rabbit reticulocyte 15-lipoxygenase by compound (30 uM),H,,,12054,8,,CHEMBL615140,BAO_0000357,
28,Autocuration,,,1,,,Inhibitory activity against 15-lipoxygenase in rat polymorphonuclear leukocytes,H,,,12426,8,,CHEMBL615141,BAO_0000219,
29,Autocuration,3847.0,,1,,,Inhibitory activity against 15-lipoxygenase was determined obtained from soya bean,H,,,12054,8,,CHEMBL615142,BAO_0000357,
30,Autocuration,3847.0,,1,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated,H,,,12054,8,,CHEMBL615143,BAO_0000357,
31,Autocuration,3847.0,,1,,,Inhibitory activity against soybean 15-lipoxygenase was evaluated at 100 uM,H,,,12054,8,,CHEMBL615144,BAO_0000357,
32,Autocuration,3847.0,,1,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 10 uM,H,,,12054,8,,CHEMBL872867,BAO_0000357,
33,Autocuration,3847.0,,1,,,The compound was tested for the in vitro inhibition of 15-lipoxygenase of soybean at a concentration of 100 uM,H,,,12054,8,,CHEMBL615145,BAO_0000357,
34,Autocuration,3847.0,,1,,,Compound was tested in vitro for inhibition of 15-lipoxygenase soybean,H,,,12054,8,,CHEMBL615146,BAO_0000357,
35,Autocuration,3847.0,,1,,,Compound at 100 uM was tested in vitro for inhibition of 15-lipoxygenase soybean,H,,,12054,8,,CHEMBL615147,BAO_0000357,
36,Autocuration,10116.0,,1,,,Inhibition of cytochrome P450 progesterone 16-alpha hydroxylase,U,,,22226,0,,CHEMBL615148,BAO_0000019,
37,Autocuration,562.0,,1,,,Binding affinity against bacterial 16S rRNA using mass spectrometry based assay,U,,,22226,0,,CHEMBL615149,BAO_0000019,
38,Autocuration,,,1,,,Dissociation constant with dimeric 16S rRNA RNA construct B,U,,,22226,0,,CHEMBL615150,BAO_0000019,
39,Intermediate,,,1,,,Dissociation constant towards 16S rRNA construct A,M,,,22222,3,,CHEMBL615151,BAO_0000225,
40,Intermediate,,,1,,,Dissociation constant towards 16S rRNA construct B,M,,,22222,3,,CHEMBL615152,BAO_0000225,
41,Expert,562.0,,1,,,Binding affinity of aminoglycoside to 16S ribosomal RNA A-site in Escherichia coli,M,,,100263,3,,CHEMBL615153,BAO_0000225,
42,Expert,562.0,,1,,,Binding affinity for the 16S ribosomal RNA A-site of Escherichia coli,M,,,100263,3,,CHEMBL615154,BAO_0000225,
43,Autocuration,,,1,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),H,,,13053,8,,CHEMBL615155,BAO_0000019,
44,Autocuration,,,1,,,Inhibitory constant against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),H,,,13053,8,,CHEMBL615156,BAO_0000019,
45,Autocuration,9606.0,,1,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,H,,,20001,8,,CHEMBL615157,BAO_0000019,
46,Autocuration,9606.0,,1,,,The compound was tested at a concentration of 1 uM for inhibitory activity against 17 beta-hydroxysteroid dehydrogenase from human placental microsomes,H,,,20001,8,,CHEMBL615158,BAO_0000019,
47,Expert,10116.0,,1,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",D,,,12971,9,,CHEMBL615159,BAO_0000019,
48,Expert,10116.0,,1,,,"Inhibition of 17-alpha-hydroxylase/17,20 lyase from rat testes microsomal preparation",D,,,12971,9,,CHEMBL615172,BAO_0000019,
49,Expert,10116.0,,1,,,"Percent inhibition of 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",D,,,12971,9,,CHEMBL615173,BAO_0000019,
50,Expert,10116.0,,1,,,"Percent inhibition of Steroid 17-alpha-hydroxylase/17,20 lyase of rat testes microsomes at 100 uM",D,,,12971,9,,CHEMBL615174,BAO_0000019,
51,Autocuration,,,1,,,Inhibitory activity against human placenta 17-beta-hydroxysteroid dehydrogenase type 2 (17-beta-HSD type 2),H,,,13053,8,,CHEMBL884518,BAO_0000019,
52,Autocuration,,,1,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1),H,,,11512,8,,CHEMBL615175,BAO_0000357,
53,Autocuration,,,1,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 1 uM concentration,H,,,11512,8,,CHEMBL615176,BAO_0000357,
54,Autocuration,,,1,,,Compound was tested for the inhibition of 17-beta-hydroxysteroid dehydrogenase type 1(17-beta-HSD type 1) at 10 uM concentration,H,,,11512,8,,CHEMBL615177,BAO_0000357,
55,Autocuration,10116.0,,1,,,Selectivity ratio of binding affinity towards mu to delta receptors of rat brain membranes,D,Membranes,,104740,5,,CHEMBL615178,BAO_0000249,
56,Intermediate,9606.0,,1,,,Cytotoxicity against ovarian cancer cell line (1A-9) of humans was determined,N,,506.0,80002,1,,CHEMBL615179,BAO_0000219,
57,Autocuration,10116.0,,1,,,Functional antagonism by electrical assays in Xenopus oocytes expressing 1A/2A NMDA receptor subtype,D,,,104835,7,,CHEMBL615180,BAO_0000219,
58,Autocuration,10116.0,,1,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2B NMDA receptor,D,,,104821,7,,CHEMBL615181,BAO_0000219,
59,Autocuration,10116.0,,1,,,Functional antagonism by electrical assays in Xenopus oocytes expressing the 1A/2C NMDA receptor,D,,,104848,7,,CHEMBL615182,BAO_0000219,
60,Expert,9606.0,,1,,,In vitro effective concentration required to reduce the number of human ovarian cancer (1A9) after 3-day incubation,N,,506.0,80002,1,,CHEMBL615183,BAO_0000219,
61,Intermediate,9606.0,,1,,,In vitro effective concentration required to reduce the number of human ovarian cancer cells (1A9) after 3-day incubation,N,,506.0,80002,1,,CHEMBL615184,BAO_0000219,
62,Intermediate,9606.0,,1,,,Cytotoxic activity against human ovarian cancer (1A9) cell line,N,,506.0,80002,1,,CHEMBL615185,BAO_0000219,
63,Intermediate,9606.0,,1,,,Cytotoxic activity against human ovarian cancer (1A9) cell line; ND=Not determined,N,,506.0,80002,1,,CHEMBL615186,BAO_0000219,
64,Intermediate,9606.0,,1,,,Effective dose of compound against replication of 1A9 cell line was evaluated,N,,506.0,80002,1,,CHEMBL615187,BAO_0000219,
65,Expert,9606.0,,1,,,In vitro cytotoxic activity was determined against ovarian cancer (1A9) cell line,N,,506.0,80002,1,,CHEMBL885343,BAO_0000219,
66,Intermediate,9606.0,,1,,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line),N,,506.0,80002,1,,CHEMBL615188,BAO_0000219,
67,Intermediate,9606.0,,1,,,In vitro cytotoxicity evaluated against human ovarian cancer (1A9 cell line); NA is not active,N,,506.0,80002,1,,CHEMBL615189,BAO_0000219,
68,Intermediate,9606.0,,1,,,In vitro percent inhibition evaluated against human ovarian cancer (1A9 cell line) at >20 ug/mL,N,,506.0,80002,1,,CHEMBL615190,BAO_0000219,
69,Intermediate,9606.0,,1,,,Inhibitory activity against Taxol resistant 1A9 cell lines,N,,506.0,80002,1,,CHEMBL615191,BAO_0000219,
70,Expert,9606.0,,1,,,Cytotoxicity against human ovarian cancer (1A9) cell lines.,N,,506.0,80002,1,,CHEMBL615192,BAO_0000219,
71,Expert,9606.0,,1,,,Percentage inhibition of human ovarian cancer (1A9) cell lines.,N,,506.0,80002,1,,CHEMBL827083,BAO_0000219,
72,Expert,9606.0,,1,,,Effective dose required for inhibitory activity against 1A9 human tumor cell line.,N,,506.0,80002,1,,CHEMBL615193,BAO_0000219,
73,Intermediate,9606.0,,1,,,Percent inhibition against 1A9 human tumor cell line at 0.10 ug/mL,N,,506.0,80002,1,,CHEMBL615194,BAO_0000219,
74,Intermediate,9606.0,,1,,,Percent inhibition against 1A9 human tumor cell line at <0.00008 ug/mL,N,,506.0,80002,1,,CHEMBL615195,BAO_0000219,
75,Intermediate,9606.0,,1,,,Percent inhibition against 1A9 human tumor cell line at >10 ug/mL,N,,506.0,80002,1,,CHEMBL615196,BAO_0000219,
76,Intermediate,9606.0,,1,,,Inhibitory concentration against Jurkat cells,N,,503.0,81072,1,,CHEMBL615197,BAO_0000219,
77,Intermediate,,,1,,,In vitro anticancer activity against 2 NCI SCLC cell lines; inactive,U,,,22226,0,,CHEMBL615198,BAO_0000019,
78,Expert,10116.0,,1,,,Inhibition of cytochrome P450 progesterone 2-alpha-hydroxylase,D,,,100121,9,,CHEMBL615199,BAO_0000357,
79,Expert,,,1,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",H,,,11231,8,,CHEMBL615200,BAO_0000357,
80,Expert,,,1,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase.",H,,,11231,8,,CHEMBL615201,BAO_0000357,
81,Expert,,,1,,,"In vitro inhibition of human 2,3-oxidosqualene cyclase at 100 nM.",H,,,11231,8,,CHEMBL615202,BAO_0000357,
82,Autocuration,5476.0,,1,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Candida albicans microsomes",H,Microsomes,,11231,8,,CHEMBL615203,BAO_0000251,
83,Autocuration,5476.0,,1,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Candida albicans microsomes",H,Microsomes,,11231,8,,CHEMBL615204,BAO_0000251,
84,Autocuration,4932.0,,1,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in Saccharomyces cerevisiae microsomes",H,Microsomes,,11231,8,,CHEMBL615205,BAO_0000251,
85,Autocuration,4932.0,,1,,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in Saccharomyces cerevisiae microsomes",H,Microsomes,,11231,8,,CHEMBL615206,BAO_0000251,
86,Autocuration,9823.0,,1,2107.0,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in pig liver microsomes",H,Microsomes,,12083,8,,CHEMBL615207,BAO_0000251,
87,Autocuration,10116.0,,1,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase",H,,,11231,8,,CHEMBL827084,BAO_0000019,
88,Autocuration,10116.0,,1,,,"Concentration required to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase (OSC)",H,,,11231,8,,CHEMBL615208,BAO_0000019,
89,Autocuration,10116.0,,1,,,"Evaluated for its activity to inhibit rat liver 2,3-oxidosqualene-lanosterol cyclase, activity expressed as Ki",H,,,11231,8,,CHEMBL615209,BAO_0000019,
90,Autocuration,10116.0,,1,2107.0,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene cyclase in rat liver microsomes",D,Microsomes,,12083,9,,CHEMBL615210,BAO_0000251,
91,Autocuration,10116.0,,1,2107.0,,"Compound was evaluated for the inhibition of microsomal 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",D,Microsomes,,12083,9,,CHEMBL615211,BAO_0000251,
92,Autocuration,10116.0,,1,2107.0,,"Compound was evaluated for inhibitory activity against 2,3-oxidosqualene-lanosterol cyclase in rat liver microsomes",D,Microsomes,,12083,9,,CHEMBL615212,BAO_0000251,
93,Expert,,,1,,,Molar concentration needed to give 50% prevention of 2-5A (Adenosine dependent endoribonuclease),H,,,11377,8,,CHEMBL615213,BAO_0000357,
94,Expert,,,1,,,Molar concentration required to displace 50% of the radiolabeled probe from 2-5A (Adenosine dependent endoribonuclease) in endonuclease-nitrocellulose complex,H,,,11377,8,,CHEMBL615273,BAO_0000357,
95,Expert,9606.0,,1,,,In vitro cytotoxic concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,N,,726.0,81020,1,,CHEMBL615274,BAO_0000219,
96,Intermediate,9606.0,,1,,,50% Effective concentration of compound required for inhibiting intracellular viral replicative intermediate DNA in HBV-transfected 2.2.15 cell line.,N,,726.0,81020,1,,CHEMBL615275,BAO_0000219,
97,Intermediate,9606.0,,1,,,Antiviral activity against Hepatitis B virus in 2.2.15 cell line,N,,726.0,81020,1,,CHEMBL615276,BAO_0000219,
98,Intermediate,9606.0,,1,,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells,N,,726.0,81020,1,,CHEMBL615277,BAO_0000219,
99,Intermediate,9606.0,,1,,,In vitro effective concentration against hepatitis B virus was determined in 2.2.15 cells; Not determined,N,,726.0,81020,1,,CHEMBL615326,BAO_0000219,
100,Expert,10407.0,,1,,,In vitro effective concentration required to inhibit hepatitisB virus (HBV) replication in 2.2.15 cell line,N,,,50606,1,,CHEMBL883130,BAO_0000218,
101,Intermediate,9606.0,,1,,,Ability to inhibit the episomal HBV-DNA in 2.2.15 cells.,N,,726.0,81020,1,,CHEMBL884519,BAO_0000219,
102,Intermediate,9606.0,,1,,,Concentration required to inhibit 50% of 2.2.15 cell line,N,,726.0,81020,1,,CHEMBL615327,BAO_0000219,
103,Intermediate,9606.0,,1,,,Anti viral activity against 2.2.15 cells (concentration required to reduce the log phase cell growth by 50%).,N,,726.0,81020,1,,CHEMBL615328,BAO_0000219,
104,Intermediate,9606.0,,1,,,Cytotoxic activity of compound against uninfected 2.2.15 cells.,N,,,50587,1,,CHEMBL615329,BAO_0000218,
105,Intermediate,9606.0,,1,,,Anti hepatitis-B virus activity was evaluated in 2.2.15 cells.,N,,,50587,1,,CHEMBL615330,BAO_0000218,
106,Expert,10407.0,,1,,,"Inhibition of the replication of HBV in 2.2.15 cells, by DNA hybridization assay",N,,,50606,1,,CHEMBL615331,BAO_0000218,
107,Intermediate,9606.0,,1,,,In vitro anti-HBV activity in 2.2.15 cells,N,,,50587,1,,CHEMBL615332,BAO_0000218,
108,Intermediate,9606.0,,1,,,In vitro anti-HBV activity in 2.2.15 cells; Not determined,N,,,50587,1,,CHEMBL615333,BAO_0000218,
109,Intermediate,9606.0,,1,,,The compound was tested in vitro for the anti-HBV activity against 2.2.15 cells,N,,,50587,1,,CHEMBL615334,BAO_0000218,
110,Intermediate,9606.0,,1,,,The compound was tested in vitro for the anti-HBV activity in 2.2.15 cells,N,,,50587,1,,CHEMBL615335,BAO_0000218,
111,Intermediate,9606.0,,1,,,Cytotoxicity in 2.2.15 cells,N,,,50587,1,,CHEMBL615336,BAO_0000218,
112,Intermediate,9606.0,,1,,,Cytotoxicity in 2.2.15 cells; Not determined,N,,,50587,1,,CHEMBL615337,BAO_0000218,
113,Intermediate,9606.0,,1,,,Inhibitory activity of compound against hepatitis B virus (HBV) in growing cultures of 2.2.15 cells,N,,,50587,1,,CHEMBL615338,BAO_0000218,
114,Intermediate,9606.0,,1,,,The growth inhibition activity for the compound was evaluated in 2.2.15 cells.,N,,,50587,1,,CHEMBL615339,BAO_0000218,
115,Intermediate,9606.0,,1,,,Selectivity index was determined from the ratio of IC50 to the EC50 values evaluated in 2.2.15 cells.,N,,,50587,1,,CHEMBL615340,BAO_0000218,
116,Intermediate,9606.0,,1,,,Antiviral activity against HBV was determined in 2.215 cell line,N,,726.0,81020,1,,CHEMBL615341,BAO_0000219,
117,Autocuration,9606.0,,1,,,Inhibition of 20-HETE synthesis in human renal microsomes,U,Microsomes,,22226,0,,CHEMBL615342,BAO_0000251,
118,Autocuration,,,1,,,Inhibitory activity against 20-HETE production from arachidonic acid using human renal microsome 20-HETE synthase.,U,,,22226,0,,CHEMBL615343,BAO_0000019,
119,Intermediate,9606.0,,1,,,Inhibitory concentration against 2008 (ovarian) cells,N,,388.0,80612,1,,CHEMBL615344,BAO_0000219,
120,Intermediate,9606.0,,1,,,50% Growth inhibitory concentration( GI 50 ) by using 2008 human ovarian carcinoma cell lines.,N,,388.0,80612,1,,CHEMBL615345,BAO_0000219,
121,Intermediate,9606.0,,1,,,Compound was tested for 50% growth inhibitory concentration by using human ovarian carcinoma cell lines (2008),N,,388.0,80612,1,,CHEMBL615346,BAO_0000219,
122,Intermediate,9606.0,,1,,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells,N,,388.0,80612,1,,CHEMBL615347,BAO_0000219,
123,Intermediate,9606.0,,1,,,Direct cytotoxicity against the selected tumor cell line 2008 was determined especially on ovarian adenocarcinoma derived cells; not detected,N,,388.0,80612,1,,CHEMBL615348,BAO_0000219,
124,Intermediate,9606.0,,1,,,In vitro inhibition of 2008/R ovarian cancer cell line,N,,561.0,80613,1,,CHEMBL827085,BAO_0000219,
125,Intermediate,9606.0,,1,,,In vitro inhibition of 2008/R ovarian cancer cell line; NA= Not achievable,N,,561.0,80613,1,,CHEMBL615349,BAO_0000219,
126,Intermediate,9606.0,,1,,,In vitro inhibition of 2008/S ovarian cancer cell line,N,,389.0,80614,1,,CHEMBL615350,BAO_0000219,
127,Intermediate,9606.0,,1,,,In vitro inhibition of 2008/S ovarian cancer cell line; NA= Not achievable,N,,389.0,80614,1,,CHEMBL615351,BAO_0000219,
128,Expert,9606.0,,1,,,Tested in vitro for inhibition of chymotrypsin like activity of purified human 20S proteasome,S,,,100256,2,,CHEMBL615352,BAO_0000220,
129,Intermediate,9606.0,,1,,,Compound was evaluated for inhibitory activity against 20S proteasome from human liver and brain,S,,,100256,2,,CHEMBL615353,BAO_0000220,
130,Expert,,,1,,,Inhibition of chymotrypsin-like activity of 20S proteasome,S,,,100256,2,,CHEMBL615354,BAO_0000220,
131,Expert,,,1,,,Inhibition of chymotrypsin-like activity of 20S proteasome; value ranges from 10-20 uM,S,,,100256,2,,CHEMBL615355,BAO_0000220,
132,Intermediate,,,1,,,Inhibitory activity against 20S proteosome,S,,,100256,2,,CHEMBL615356,BAO_0000220,
133,Autocuration,9606.0,,1,,,Compound was tested for inhibitory activity against tryptase,U,,,22226,0,,CHEMBL615357,BAO_0000019,
134,Intermediate,9606.0,,1,,,Concentration required to inhibit 50% of extracellular circular replication of HBV DNA using 2215 cell line,N,,726.0,81020,1,,CHEMBL615358,BAO_0000219,
135,Intermediate,9606.0,,1,,,Concentration required to inhibit 50% of intracellular circular replication of HBV DNA using 2215 cell line,N,,726.0,81020,1,,CHEMBL827086,BAO_0000219,
136,Autocuration,,,1,,,Compound was tested for the inhibition of Alpha-glucosidase,U,,,22226,0,,CHEMBL615359,BAO_0000019,
137,Autocuration,,,1,,,Inhibitory concentration against human neutrophil elastase (HNE),H,,,235,8,,CHEMBL615360,BAO_0000357,
138,Autocuration,10116.0,,1,948.0,,Change in heart rate was expressed in percent at at a dose 0.002 mg/kg iv in anesthetized rat,U,,,22226,0,,CHEMBL615361,BAO_0000218,
139,Autocuration,,,1,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,H,,,19640,8,,CHEMBL615362,BAO_0000019,
140,Expert,,,1,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,H,,,19640,8,,CHEMBL615363,BAO_0000019,
141,Autocuration,,,1,,,Minimum inhibitory concentration of compound against 20 Mycobacterium avium complex (MAC) clinical isolates,H,,,19640,8,,CHEMBL615364,BAO_0000357,
142,Expert,,,1,,,90% inhibition of the 20 Mycobacterium avium complex (MAC) clinical isolates,H,,,19640,8,,CHEMBL615365,BAO_0000019,
143,Intermediate,10090.0,,1,,,In Vitro evaluation for the growth inhibition of Subline (P388/AMSA) Leukemia cell lines,N,,524.0,80360,1,,CHEMBL615366,BAO_0000219,
144,Intermediate,10090.0,,1,,,In Vitro evaluation for the growth inhibition of Subline (P388/CP) Leukemia cell lines,N,,524.0,80360,1,,CHEMBL615367,BAO_0000219,
145,Intermediate,9606.0,,1,,,Compound was evaluated for the inhibition of cell replication human peripheral blood lymphocytes (PBL's).,N,,554.0,80384,1,,CHEMBL615368,BAO_0000219,
146,Autocuration,9940.0,,1,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells,U,,,22226,0,,CHEMBL615369,BAO_0000019,
147,Autocuration,9940.0,,1,,,Compound was evaluated for the inhibition of cell replication sheep choroid plexus (SCP) cells.,U,,,22226,0,,CHEMBL615370,BAO_0000019,
148,Autocuration,,,1,,,Compound is evaluated in vitro for the inhibition single mutant of HIV-1 RT (Y181C),H,,,191,8,,CHEMBL615673,BAO_0000357,
149,Autocuration,9606.0,,1,,,Compound was evaluated for its inhibitory effect on thymidine [3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-5,U,,,22226,0,,CHEMBL615674,BAO_0000019,
150,Autocuration,9606.0,,1,,,Compound was evaluated for its inhibitory effect on thymidine [3H]-dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-6,U,,,22226,0,,CHEMBL615675,BAO_0000019,
151,Autocuration,9606.0,,1,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in at conc. 10e-7,U,,635.0,22226,0,,CHEMBL615676,BAO_0000219,
152,Autocuration,9606.0,,1,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM cells in culture at conc. 10e-4,U,,635.0,22226,0,,CHEMBL615677,BAO_0000219,
153,Autocuration,9606.0,,1,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-5,U,,635.0,22226,0,,CHEMBL615678,BAO_0000219,
154,Autocuration,9606.0,,1,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM cells in culture at conc. 10e-6,U,,635.0,22226,0,,CHEMBL615679,BAO_0000219,
155,Autocuration,9606.0,,1,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]-dThd) incorporation into DNA of CEM/MTX cells in at conc. 10e-7.,U,,,22226,0,,CHEMBL615680,BAO_0000019,
156,Autocuration,9606.0,,1,,,Compound was evaluated for its inhibitory effect on thymidine ([3H]dThd) incorporation into DNA of CEM/MTX cells in culture at conc. 10e-4,U,,,22226,0,,CHEMBL615681,BAO_0000019,
157,Autocuration,,,1,,,In vitro binding affinity towards (alpha-4)2(beta-2)3 neuronal nicotinic acetylcholine receptor in P2 membrane fractions of rat forebrain,H,,,104290,6,,CHEMBL857972,BAO_0000249,
158,Intermediate,1314.0,,1,,,Minimum inhibitory concentration of compound against Streptococcus pyogenus septicemia in the mouse,N,,,50264,1,,CHEMBL857899,BAO_0000218,
159,Intermediate,10335.0,,1,,,Antiviral activity against 07/1 strain of thymidine kinase negative (TK-) Varicella-Zoster Virus (VZV),N,,,50527,1,,CHEMBL615371,BAO_0000218,
160,Expert,10335.0,,1,,,Antiviral activity against 07/1 strain of VZV in HEL (human erythroleukemia) cells.,N,,468.0,50527,1,,CHEMBL615372,BAO_0000218,
161,Intermediate,10335.0,,1,,,Antiviral activity against 07/1 strain of VZV; ND: No data,N,,,50527,1,,CHEMBL615373,BAO_0000218,
162,Intermediate,10335.0,,1,,,Antiviral activity against 07/1 strain of VZV; ND=No data,N,,,50527,1,,CHEMBL615374,BAO_0000218,
163,Intermediate,561.0,,1,,,"Antibacterial activity was determined against gram negative organism, Enterobacter cloacae (MA2646)",N,,,50145,1,,CHEMBL615375,BAO_0000218,
164,Autocuration,,,1,,,Ratio of Ki at A2 to Ki at A1 receptors,U,,,22226,0,,CHEMBL615376,BAO_0000019,
165,Expert,5476.0,,1,,,"In vitro inhibition of 1,3-beta-glucan synthase in Candida albicans membrane assay.",H,,,11143,8,,CHEMBL615377,BAO_0000249,
166,Expert,284593.0,,1,,,"Inhibition of 1,3-beta-glucan synthase",H,,,18077,8,,CHEMBL615378,BAO_0000357,
167,Intermediate,9606.0,,1,,,Inhibition of growth of 1-87 human tumor cell line,N,,832.0,80609,1,,CHEMBL615379,BAO_0000219,
168,Expert,10116.0,,1,,,Inhibition of 1-lipoxygenase (LOX)in RBL cells,D,,,12166,9,,CHEMBL615380,BAO_0000219,
169,Autocuration,3847.0,,1,,,Inhibitory activity against soybean 1-lipoxygenase (SLO),D,,,100171,9,,CHEMBL615381,BAO_0000357,
170,Autocuration,3847.0,,1,,,Inhibitory activity against soybean 1-lipoxygenase (SLO); no effect,D,,,100171,9,,CHEMBL615382,BAO_0000357,
171,Autocuration,3847.0,,1,,,% inhibition against soybean 1-lipoxygenase (SLO),D,,,100171,9,,CHEMBL615383,BAO_0000357,
172,Autocuration,3847.0,,1,,,percent inhibition against soybean 1-lipoxygenase (SLO);NI is no inhibition,D,,,100171,9,,CHEMBL615384,BAO_0000357,
173,Autocuration,3847.0,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 10:90,D,,,100171,9,,CHEMBL615385,BAO_0000357,
174,Autocuration,3847.0,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 1:99,D,,,100171,9,,CHEMBL615386,BAO_0000357,
175,Autocuration,3847.0,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 25:75,D,,,100171,9,,CHEMBL615387,BAO_0000357,
176,Autocuration,3847.0,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 35:65,D,,,100171,9,,CHEMBL615388,BAO_0000357,
177,Autocuration,3847.0,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 50:50,D,,,100171,9,,CHEMBL615214,BAO_0000357,
178,Autocuration,3847.0,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 76:24,D,,,100171,9,,CHEMBL827087,BAO_0000357,
179,Autocuration,3847.0,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 87:13,D,,,100171,9,,CHEMBL615215,BAO_0000357,
180,Autocuration,3847.0,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 89:11,D,,,100171,9,,CHEMBL615216,BAO_0000357,
181,Autocuration,3847.0,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 95:5,D,,,100171,9,,CHEMBL615217,BAO_0000357,
182,Autocuration,3847.0,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 97:3,D,,,100171,9,,CHEMBL615218,BAO_0000357,
183,Autocuration,3847.0,,1,,,Ratio of proximal to distal region oxidation by 1-lipoxygenase isolated from soybean; Ratio of proximal and distal was 99:1,D,,,100171,9,,CHEMBL615219,BAO_0000357,
184,Autocuration,10090.0,,1,,,Evaluated for inhibitory activity on 10-formyltetrahydrofolate synthetase(L cell) at folate substrate concentration of 100 uM,U,,,22226,0,,CHEMBL615220,BAO_0000019,
185,Intermediate,10090.0,,1,,,Cells were harvested and were assayed for luciferase and -galactosidase activities (Transcriptional activity),N,,294.0,80049,1,,CHEMBL615221,BAO_0000219,
186,Intermediate,,,1,,,In vitro anticancer activity against 11 NCI NSCLC cell lines; inactive,U,,,22226,0,,CHEMBL615222,BAO_0000019,
187,Autocuration,,,1,,,In vitro inhibitory activity against human 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),H,,,11489,8,,CHEMBL615223,BAO_0000357,
188,Autocuration,,,1,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA),H,,,11862,8,,CHEMBL615224,BAO_0000357,
189,Autocuration,,,1,,,In vitro inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 1 using scintillation proximity assay (SPA).,H,,,11862,8,,CHEMBL615225,BAO_0000357,
190,Autocuration,,,1,,,Ability to convert [3H]cortisol to the tritium labeled cortisone in the presence of human 11 beta hydroxysteroid dehydrogenase type 2,H,,,11489,8,,CHEMBL615226,BAO_0000357,
191,Autocuration,,,1,,,Inhibitory activity against mouse 11 beta hydroxysteroid dehydrogenase type 2 at a concentration of 0.2 mM; NI means no inhibition,H,,,11862,8,,CHEMBL615227,BAO_0000357,
192,Expert,9913.0,,1,,,Evaluated for inhibition of bovine adrenal cortical mitochondrial 11 beta-hydroxylase,D,,,12347,9,,CHEMBL615228,BAO_0000019,
193,Expert,10116.0,,1,,,Effect on adrenal 11-beta-hydroxylase activity at 10e-4 M; No significant effect,D,,,100120,9,,CHEMBL615229,BAO_0000357,
194,Expert,10116.0,,1,2369.0,,Inhibition of 11 beta-hydroxylase from rat adrenal gland,D,,,100120,9,,CHEMBL615230,BAO_0000357,
195,Expert,10116.0,,1,,,Inhibition of rat adrenal 11-beta-hydroxylase,D,,,100120,9,,CHEMBL615231,BAO_0000357,
196,Expert,10116.0,,1,,,Inhibition of rat adrenal 11-beta-hydroxylase,D,,,100120,9,,CHEMBL884520,BAO_0000357,
197,Expert,10116.0,,1,,,Inhibition of rat adrenal 11-beta-hydroxylase at 10e-5 M,D,,,100120,9,,CHEMBL615232,BAO_0000357,
198,Autocuration,,,1,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 1 of wistar rat liver cytosol at 10 uM was determined using [3H]cortisone,H,,,10328,8,,CHEMBL615233,BAO_0000019,
199,Autocuration,,,1,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,H,,,11490,8,,CHEMBL827088,BAO_0000357,
200,Autocuration,,,1,,,Percent inhibition against 11-beta-hydroxysteroid dehydrogenase 2 of wistar rat kidney at 10 uM was determined using [3H]cortisol,H,,,11490,8,,CHEMBL615234,BAO_0000357,
201,Autocuration,,,1,,,Compound was tested for the percent of inhibition against 12-LO at 10 uM,H,,,11134,8,,CHEMBL615235,BAO_0000019,
202,Autocuration,,,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,H,,,12052,8,,CHEMBL615236,BAO_0000019,
203,Autocuration,,,1,,,Compound was tested in vitro for inhibition of 12-LO human platelet,H,,,11134,8,,CHEMBL615237,BAO_0000019,
204,Autocuration,,,1,,,Inhibitory concentration against human platelet 12-lipoxygenase,H,,,11134,8,,CHEMBL615238,BAO_0000019,
205,Autocuration,,,1,,,Compound at 100 uM was tested in vitro for inhibition of 12-LO human platelet,H,,,11134,8,,CHEMBL615239,BAO_0000019,
206,Autocuration,9606.0,,1,,,Inhibitory concentration against human platelet 12-lipoxygenase,D,,,11134,9,,CHEMBL615240,BAO_0000019,
207,Expert,,,1,,,Tested for inhibition of 12-LO (12-lipoxygenase) as an inhibitor of 12(S)-HETE biosynthesis in mouse epidermal homogenates,H,,,11835,8,,CHEMBL615241,BAO_0000019,
208,Expert,,,1,,,Inhibitory activity against conversion of [1-14C]arachidonic acid to 12-HPETE and its reduction product 12-HETE by porcine leukocyte type 12-lipoxygenase,H,,,11601,8,,CHEMBL615242,BAO_0000357,
209,Autocuration,,,1,,,Inhibitory activity against human platelet 12-lipoxygenase (12-HLO),H,,,11134,8,,CHEMBL615243,BAO_0000019,
210,Autocuration,,,1,,,Inhibitory activity against human platelet 12-lipoxygenase,H,,,11134,8,,CHEMBL615244,BAO_0000019,
211,Autocuration,,,1,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated,H,,,11134,8,,CHEMBL615245,BAO_0000019,
212,Autocuration,,,1,,,% inhibition against human platelet 12-lipoxygenase (12-HLO),H,,,11134,8,,CHEMBL615246,BAO_0000019,
213,Autocuration,,,1,,,Inhibitory activity against human platelet 12-lipoxygenase was evaluated at 100 uM,H,,,11134,8,,CHEMBL615247,BAO_0000019,
214,Autocuration,,,1,,,percent inhibition against human platelet 12-lipoxygenase (12-HLO); NI is no inhibition,H,,,11134,8,,CHEMBL615248,BAO_0000019,
215,Autocuration,,,1,,,Inhibitory activity towards porcine 12-lipoxygenase,H,,,11601,8,,CHEMBL615249,BAO_0000357,
216,Autocuration,,,1,,,Tested for inhibition against porcine 12-LO,H,,,11601,8,,CHEMBL615250,BAO_0000357,
217,Autocuration,,,1,,,Inhibition of 12-lipoxygenase was evaluated in rat platelets stimulated by thrombin up to a concentration of 10 uM; NE means No effect,H,,,12052,8,,CHEMBL615251,BAO_0000019,
218,Autocuration,,,1,,,Inhibitory activity against 12-lipoxygenase in rat platelet rich plasma,H,,,12052,8,,CHEMBL615252,BAO_0000019,
219,Expert,,,1,,,In vitro inhibition of rat platelet 12-lipoxygenase,H,,,12052,8,,CHEMBL828340,BAO_0000019,
220,Autocuration,,,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,H,,,12052,8,,CHEMBL615253,BAO_0000019,
221,Autocuration,,,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 100 uM,H,,,12052,8,,CHEMBL615254,BAO_0000019,
222,Autocuration,,,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 30 uM,H,,,12052,8,,CHEMBL615255,BAO_0000019,
223,Autocuration,,,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase at 10 uM,H,,,12052,8,,CHEMBL615256,BAO_0000019,
224,Autocuration,,,1,,,In vitro inhibitory activity against rat platelet 12-lipoxygenase,H,,,12052,8,,CHEMBL615257,BAO_0000019,
225,Autocuration,,,1,,,The compound was tested for the in vitro inhibition of platelet 12-lipoxygenase at a concentration of 100 uM,H,,,12052,8,,CHEMBL615258,BAO_0000019,
226,Intermediate,9606.0,,1,,,Cytotoxic activity in a panel of Human ovarian tumor 41M cell line after 96h of drug exposure,N,,621.0,80007,1,,CHEMBL615259,BAO_0000219,
227,Expert,9606.0,,1,,,In vitro antitumor activity against 41M cell line.,N,,621.0,80007,1,,CHEMBL615260,BAO_0000219,
228,Intermediate,9606.0,,1,,,cytotoxicity against 41M cells incubated for 24 hr in MTT assay.,N,,621.0,80007,1,,CHEMBL615261,BAO_0000219,
229,Intermediate,9606.0,,1,,,Cytotoxic activity in a panel of Human ovarian tumor 41M/CDDP cell line after 96h of drug exposure,N,,621.0,80007,1,,CHEMBL615262,BAO_0000219,
230,Expert,9606.0,,1,,,In vitro antitumor activity against 41McisR cell line.,N,,621.0,80007,1,,CHEMBL615263,BAO_0000219,
231,Expert,9606.0,,1,,,Resistant factor was determined between IC50 of cisplatin-resistant human tumor cell lines to that of 41McisR cell line,N,,621.0,80007,1,,CHEMBL838393,BAO_0000219,
232,Intermediate,9606.0,,1,,,cytotoxicity against 41McisR cells incubated for 24 hr in MTT assay,N,,621.0,80007,1,,CHEMBL615264,BAO_0000219,
233,Expert,9606.0,,1,,,Inhibition of 5'-inosine monophosphate dehydrogenase type I (IMPDH I),D,,,84,9,,CHEMBL615265,BAO_0000357,
234,Expert,9606.0,,1,,,Inhibition of 5'-inosine monophosphate dehydrogenase type II (IMPDH II),D,,,68,9,,CHEMBL615266,BAO_0000357,
235,Expert,,,1,,,Inhibitory activity against inosine 5'-inosine monophosphate dehydrogenase type II (IMPDH II),H,,,68,8,,CHEMBL615267,BAO_0000357,
236,Expert,,,1,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase,H,,,10201,8,,CHEMBL615268,BAO_0000357,
237,Expert,,,1,,,Equilibrium dissociation constant towards human 5'-methylthioadenosine phosphorylase; nd = Not determined,H,,,10201,8,,CHEMBL615269,BAO_0000357,
238,Expert,,,1,,,Initial dissociation constant towards human 5'-methylthioadenosine phosphorylase,H,,,10201,8,,CHEMBL615270,BAO_0000357,
239,Autocuration,,,1,,,"Evaluated for inhibitory activity on 5,10-Methenyl Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",H,,,12220,8,,CHEMBL615271,BAO_0000357,
240,Autocuration,562.0,,1,,,"Inhibitory activity against 5,10-methylenetetrahydrofolate dehydrogenase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",H,,,11303,8,,CHEMBL615272,BAO_0000357,
241,Autocuration,562.0,,1,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM; NT=Not tested",H,,,11303,8,,CHEMBL615103,BAO_0000357,
242,Autocuration,562.0,,1,,,"Inhibitory activity against 5,10-Methylene Tetrahydrofolate Cyclohydrolase from Escherichia coli at a concentration of 0.1 mM;NT=Not tested",H,,,11303,8,,CHEMBL615104,BAO_0000357,
243,Autocuration,,,1,,,"Evaluated for inhibitory activity on 5,10-Methylene Tetrahydrofolate Cyclohydrolase(L cell) at folate substrate concentration of 100 uM",H,,,12220,8,,CHEMBL615105,BAO_0000357,
244,Autocuration,,,1,,,"Evaluated for inhibitory activity on 5,10-methylenetetrahydrofolate dehydrogenase(L cell) at folate substrate concentration of 100 uM",H,,,12220,8,,CHEMBL872866,BAO_0000357,
245,Autocuration,9823.0,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",H,,,11303,8,,CHEMBL615106,BAO_0000357,
246,Autocuration,9823.0,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (A,porcine liver) enzyme.",H,,,11303,8,,CHEMBL615107,BAO_0000019,
247,Autocuration,9823.0,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-4 M inhibitory concentration",H,,,11303,8,,CHEMBL615108,BAO_0000357,
248,Autocuration,9823.0,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-5 M inhibitory concentration",H,,,11303,8,,CHEMBL615109,BAO_0000357,
249,Autocuration,9823.0,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",H,,,11303,8,,CHEMBL615110,BAO_0000357,
250,Autocuration,9823.0,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",H,,,11303,8,,CHEMBL840105,BAO_0000019,
251,Autocuration,9823.0,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-5 M inhibitory concentration",H,,,11303,8,,CHEMBL615111,BAO_0000019,
252,Autocuration,9823.0,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-6 M inhibitory concentration",H,,,11303,8,,CHEMBL615112,BAO_0000019,
253,Autocuration,9823.0,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-7 M inhibitory concentration",H,,,11303,8,,CHEMBL615113,BAO_0000019,
254,Autocuration,9823.0,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme.",H,,,11303,8,,CHEMBL615114,BAO_0000019,
255,Autocuration,9823.0,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (L1210 tumor tissue) enzyme at 10E-6 M inhibitory concentration",H,,,11303,8,,CHEMBL615115,BAO_0000357,
256,Autocuration,9823.0,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Cyclohydrolase (porcine liver) enzyme at 10E-4 M inhibitory concentration",H,,,11303,8,,CHEMBL615116,BAO_0000019,
257,Autocuration,,,1,,,"Compound was tested for in vitro inhibition of 5,10-Methylene Tetrahydrofolate Cyclohydrolase, competitive against (+)-L-5,10-methenyltetrahydrofolate",H,,,11303,8,,CHEMBL615698,BAO_0000357,
258,Autocuration,9823.0,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme at 10E-4 M inhibitory concentration",U,,,22226,0,,CHEMBL615699,BAO_0000019,
259,Autocuration,9823.0,,1,,,"Percent inhibition was measured against 5,10-Methylene Tetrahydrofolate Reductase (porcine kidney) enzyme.",U,,,22226,0,,CHEMBL615700,BAO_0000019,
260,Expert,4932.0,,1,,,Inhibition of 5-Desaturase involved in ergosterol biosynthesis,H,,,100249,8,,CHEMBL615701,BAO_0000357,
261,Autocuration,10116.0,,1,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,U,,,22226,0,,CHEMBL615702,BAO_0000019,
262,Autocuration,10116.0,,1,,,Ability for reversible inhibition of Walker 256 5-Fluoro-2'-deoxyuridine Phosphorylase,U,,,22226,0,,CHEMBL615703,BAO_0000019,
263,Autocuration,10116.0,,1,,,"Irreversible inhibition of Walker 256 FUDR phosphorylase; expressed as Vo/Vi, velocity without inhibitor to that of velocity with inhibitor",U,,,22226,0,,CHEMBL615704,BAO_0000019,
264,Autocuration,,,1,,,"Tested for 5-HT 3 receptor antagonist potency by ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",H,,,104698,6,,CHEMBL615705,BAO_0000019,
265,Autocuration,,,1,,,"Compound was tested for its 5-HT 3 receptor antagonist potency by their ability to inhibit the reflex bradycardia, the Bezold-Jarisch reflex in the rat",H,,,104698,6,,CHEMBL615706,BAO_0000019,
266,Intermediate,10141.0,,1,2116.0,,Relative ability to increase cholinergically mediated contractions in isolated ileum of guinea pig,D,,,20033,9,,CHEMBL615707,BAO_0000221,
267,Expert,,,1,,,Stimulatory activity of intragastric pressure was tested in the rat,H,,,10623,8,,CHEMBL615708,BAO_0000019,
268,Autocuration,,,1,,,% Decrease of 5-HT carrier-receptor -bound radioactivity using paroxetine as a radioligand.,H,,,121,8,,CHEMBL615709,BAO_0000357,
269,Autocuration,10116.0,,1,,,Dose to reduce neuronal firing against 5-HT cells in rats (iv),U,,,22226,0,,CHEMBL615710,BAO_0000218,
270,Autocuration,,,1,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,H,,,12688,8,,CHEMBL615711,BAO_0000019,
271,Expert,9606.0,,1,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine,D,,,121,9,,CHEMBL615712,BAO_0000357,
272,Expert,9606.0,,1,,,Binding affinity at 5-HT reuptake site labeled with [3H]paroxetine; No data,D,,,121,9,,CHEMBL836325,BAO_0000357,
273,Autocuration,,,1,,,Inhibition of high affinity 5-HT uptake at concentration of 1 uM,H,,,12198,8,,CHEMBL615713,BAO_0000019,
274,Autocuration,,,1,,,Inhibition constant of high-affinity 5-HT uptake,H,,,12198,8,,CHEMBL615714,BAO_0000357,
275,Autocuration,,,1,,,Michaelis-Menten constant was reported for high affinity transport of 5-HT,H,,,12198,8,,CHEMBL615715,BAO_0000019,
276,Autocuration,,,1,,,Maximum rate was determined for high affinity transport of 5-HT,H,,,12198,8,,CHEMBL615716,BAO_0000019,
277,Autocuration,,,1,,,Compound was tested for agonistic activity against 5-HT uptake,H,,,104714,4,,CHEMBL615717,BAO_0000019,
278,Expert,,,1,,,Inhibition affinity against 5-HT-1B receptor in rat frontal cortex using radio binding assay,H,,,10577,8,,CHEMBL881818,BAO_0000019,
279,Expert,9913.0,,1,,,Inhibition affinity against 5-HT-1D receptor in bovine caudate nucleus using radio binding assay,H,,,105,8,,CHEMBL884540,BAO_0000357,
280,Autocuration,10116.0,,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,D,,,104744,5,,CHEMBL615718,BAO_0000224,
281,Autocuration,,,1,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1 using [3H]5-HT as radioligand,H,,,104744,4,,CHEMBL615719,BAO_0000224,
282,Autocuration,,,1,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M,H,Membranes,,104744,4,,CHEMBL615720,BAO_0000249,
283,Autocuration,,,1,,,Percent inhibition of binding of 3.0 nM [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat caudate membranes at 10 e -5 M.,H,Membranes,,104744,4,,CHEMBL615721,BAO_0000249,
284,Autocuration,,,1,,,Displacement of binding of [3H]-5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,,,104744,4,,CHEMBL615722,BAO_0000019,
285,Autocuration,,,1,,,Dose required to reduce neuronal firing of 5-HT1A cells by 50%,H,,,51,8,,CHEMBL615723,BAO_0000019,
286,Autocuration,,,1,10000000.0,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,,51,8,,CHEMBL615724,BAO_0000221,
287,Autocuration,,,1,10000000.0,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,H,,,51,8,,CHEMBL615725,BAO_0000221,
288,Autocuration,,,1,10000000.0,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,,51,8,,CHEMBL615726,BAO_0000221,
289,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-HT1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (.26-3.52),H,,,10576,8,,CHEMBL615727,BAO_0000218,
290,Intermediate,10141.0,,1,,,Effect on forskolin stimulated adenylate cyclase activity at 5-HT1D receptor of guinea pig substantia nigra.,D,,,105570,9,,CHEMBL615728,BAO_0000019,
291,Autocuration,,,1,,,Binding affinity towards 5-HT1F (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,,449.0,279,8,,CHEMBL857971,BAO_0000219,
292,Autocuration,,,1,,,Compound was tested for the displacement of [125I]DOI from clone human 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL615729,BAO_0000357,
293,Expert,10116.0,,1,,,Efficacy against 5-hydroxytryptamine 2A receptor,D,,,12687,9,,CHEMBL615730,BAO_0000019,
294,Expert,,,1,,,Intrinsic activity towards 5-HT2A receptor of rat tail artery,H,,,12687,8,,CHEMBL615731,BAO_0000019,
295,Expert,,,1,,,Relative potency towards 5-HT2A receptor of rat tail artery,H,,,12687,8,,CHEMBL615732,BAO_0000019,
296,Expert,,,1,,,Blocking 5-HT2A receptor-mediated contractions of rat tail artery,H,,,12687,8,,CHEMBL615733,BAO_0000019,
297,Expert,,,1,,,Partial agonism at 5-HT2A receptor was evaluated in presence of ketanserin (3-10 nM) in isolated rat tail artery,H,,,12687,8,,CHEMBL615734,BAO_0000019,
298,Autocuration,,,1,,,Compound was tested for the intrinsic activity against 5-HT2A receptors of rat tail artery.,H,,,12687,8,,CHEMBL615735,BAO_0000019,
299,Expert,,,1,,,Effectiveness in blocking 5-HT2A receptor-mediated contractions of rat tail artery,H,,,12687,8,,CHEMBL615736,BAO_0000019,
300,Intermediate,10141.0,,1,2116.0,,Evaluated for the agonistic activity against 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,D,,,20033,9,,CHEMBL615737,BAO_0000221,
301,Intermediate,10141.0,,1,2116.0,,Agonistic activity against Serotonin 5-HT4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI),D,,,20033,9,,CHEMBL615738,BAO_0000221,
302,Intermediate,10141.0,,1,2116.0,,Evaluated for the agonistic activity against Serotonin 5-HT4 receptor in non-electrically stimulated guinea-pig ileum.,D,,,20033,9,,CHEMBL615739,BAO_0000221,
303,Autocuration,,,1,,,The binding affinity was measured on 5-hydroxytryptamine 4 receptor using [3H]- GR-113808 as radioligand.,H,,,10623,8,,CHEMBL615278,BAO_0000357,
304,Expert,10116.0,,1,,,Antagonist activity against 5-HT4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,D,,,10623,9,,CHEMBL615279,BAO_0000019,
305,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor,H,,,168,8,,CHEMBL615280,BAO_0000357,
306,Autocuration,9031.0,,1,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of chick intestine,U,,,22226,0,,CHEMBL615281,BAO_0000019,
307,Autocuration,9606.0,,1,,,Inhibitory effect (10e-6 M) on the 25-OH-D3-1-hydroxylase activity,U,,,22226,0,,CHEMBL615282,BAO_0000019,
308,Autocuration,9606.0,,1,,,25-OH-D3-1-hydroxylase activity (10e-6 M) was measured as %control,U,,,22226,0,,CHEMBL615283,BAO_0000019,
309,Autocuration,9606.0,,1,,,Relative competitive index values for binding to 25-OH-D3-1-hydroxylase of human HL-60 cells,N,,649.0,80156,1,,CHEMBL615284,BAO_0000219,
310,Autocuration,9606.0,,1,,,Inhibitory effect (10e-6 M) on the 25-hydroxyvitamin D3-1-hydroxylase activity,U,,,22226,0,,CHEMBL615285,BAO_0000019,
311,Autocuration,9606.0,,1,,,25-hydroxyvitamin D3-1-hydroxylase activity (10e-6 M) was measured as %control,U,,,22226,0,,CHEMBL615286,BAO_0000019,
312,Autocuration,9606.0,,1,,,Displacement of [3H]-Ro- 15-1788 from human GABA-A alpha-1-beta-3-gamma-2 receptor subunits expressed in Xenopus oocytes,D,,,104703,7,,CHEMBL615287,BAO_0000219,
313,Intermediate,,,1,,,Chymotryptic inhibitory activity against 26S proteasome,S,,,100256,2,,CHEMBL615288,BAO_0000220,
314,Intermediate,,,1,,,Inhibitory activity against 26S proteasome degradation of IkB,S,,,100256,2,,CHEMBL615289,BAO_0000220,
315,Intermediate,9606.0,,1,,,In vitro inhibition of 2780/DOX ovarian cancer cell line,N,,478.0,81034,1,,CHEMBL615290,BAO_0000219,
316,Intermediate,9606.0,,1,,,In vitro inhibition of 2780/S ovarian cancer cell line,N,,478.0,81034,1,,CHEMBL884522,BAO_0000219,
317,Autocuration,9606.0,,1,,,Relative activity on the cellular accumulation of vincristine in multidrug-resistant (MDR) human ovarian cancer 2780AD cells,U,,,22226,0,,CHEMBL615291,BAO_0000019,
318,Intermediate,,,1,,,Association constant for binding to AATT 28-mer AATT hairpin,M,,,22222,3,,CHEMBL615292,BAO_0000225,
319,Intermediate,,,1,,,Kinetically Defined Association Constant for 28-mer AATT hairpin.,M,,,22222,3,,CHEMBL615293,BAO_0000225,
320,Intermediate,,,1,,,Reaction Rate Parameter for 28-mer AATT hairpin,M,,,22222,3,,CHEMBL615294,BAO_0000225,
321,Intermediate,,,1,,,Reaction Rate Parameter for 28-mer AATT hairpin,M,,,22222,3,,CHEMBL615295,BAO_0000225,
322,Autocuration,9606.0,,1,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 1),U,,,22226,0,,CHEMBL825021,BAO_0000019,
323,Autocuration,9606.0,,1,,,Antiviral activity against envelope deficient HIV-1 in a single cycle replication assay (experiment 2),U,,,22226,0,,CHEMBL615296,BAO_0000019,
324,Autocuration,9606.0,,1,,,Inhibitory concentration by single cycle replication assay using envelope deficient HIV-1,U,,,22226,0,,CHEMBL615297,BAO_0000019,
325,Autocuration,10029.0,,1,,,Cytotoxicity against cell line 2SC/20 determined by MTT test,U,,,22226,0,,CHEMBL615298,BAO_0000019,
326,Autocuration,10029.0,,1,,,Cytotoxicity against cell line 2SC/20 of hamster determined by MTT test,U,,,22226,0,,CHEMBL615299,BAO_0000019,
327,Autocuration,10029.0,,1,,,Inhibitory concentration against the growth of 2SC/20 cell line after 72 hr of drug exposure by MTT test,U,,,22226,0,,CHEMBL615300,BAO_0000019,
328,Autocuration,,,1,,,Binding affinity on 3 beta-hydroxysteroid dehydrogenase,H,,,241,8,,CHEMBL615301,BAO_0000357,
329,Expert,9606.0,,1,,,Binding affinity for 3-beta-hydroxysteroid dehydrogenase,D,,,241,9,,CHEMBL615302,BAO_0000357,
330,Autocuration,10116.0,,1,,,Selectivity ratio of ID50 in liver and heart,U,,,22226,0,,CHEMBL615303,BAO_0000019,
331,Autocuration,,,1,,,"Selectivity, ratio of relative ID50 in liver and heart",H,,,12132,8,,CHEMBL615304,BAO_0000019,
332,Autocuration,,,1,,,Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to T3,H,,,12132,8,,CHEMBL615305,BAO_0000019,
333,Autocuration,,,1,,,"Binding affinity to the receptor was determined in nuclei of heart In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,,,12132,8,,CHEMBL615306,BAO_0000218,
334,Autocuration,,,1,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,,,12132,8,,CHEMBL615307,BAO_0000218,
335,Autocuration,,In vivo,1,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,,,12132,8,,CHEMBL615308,BAO_0000218,
336,Autocuration,,In vivo,1,,,"Binding affinity to the receptor was determined in nuclei of liver in vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,,,12132,8,,CHEMBL615309,BAO_0000218,
337,Autocuration,,,1,,,"Binding affinity to the thyroid hormone receptor was determined in vitro in isolated nuclei of rat liver relative to 3,5,3' triiodothyronine",U,,,22226,0,,CHEMBL615310,BAO_0000019,
338,Autocuration,,,1,,,Binding affinity to the receptor was determined in vitro in isolated nuclei of rat liver relative to T3,H,,,12132,8,,CHEMBL615311,BAO_0000019,
339,Autocuration,9606.0,,1,,,"Binding affinity to thyroid hormone receptor beta, relative to 3,5,3' triiodothyronine receptor, in isolated nuclei of heart",U,,,22226,0,,CHEMBL615312,BAO_0000019,
340,Autocuration,,,1,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,H,,,12132,8,,CHEMBL615313,BAO_0000019,
341,Autocuration,,,1,,,In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to T3,H,,,12132,8,,CHEMBL615314,BAO_0000019,
342,Autocuration,,,1,,,"Binding affinity to the receptor was determined in isolated nuclei of heart(In vitro) relative to 3,5,3' triiodothyronine receptor",H,,,12132,8,,CHEMBL615315,BAO_0000019,
343,Autocuration,10116.0,,1,,,"In vivo binding affinity for 3,5,3'' triiodothyronine receptor of heart nuclei 1 hr after intravenous administration",U,,,22226,0,,CHEMBL615316,BAO_0000218,
344,Autocuration,,In vivo,1,,,Binding affinity to the receptor was determined in nuclei of heart in vivo 1 hour after intravenous administration relative to T3,H,,,12132,8,,CHEMBL615317,BAO_0000218,
345,Autocuration,,,1,,,"Binding affinity to the receptor was determined in nuclei of liver In vivo 1 hour after intravenous administration relative to 3,5,3' triiodothyronine receptor",H,,,12132,8,,CHEMBL615318,BAO_0000218,
346,Autocuration,10116.0,,1,,,"In vivo binding affinity for 3,5,3' triiodothyronine receptor of liver nuclei 1 hour after intravenous administration",U,,,22226,0,,CHEMBL615319,BAO_0000218,
347,Autocuration,,,1,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",H,,,12132,8,,CHEMBL615320,BAO_0000019,
348,Autocuration,,,1,,,"In vitro binding affinity to the receptor was determined in isolated nuclei of heart relative to 3,5,3' triiodothyronine receptor",H,,,12132,8,,CHEMBL615321,BAO_0000019,
349,Autocuration,10116.0,,1,,,"Inhibition of [125I]L-T3 binding to rat hepatic 3,5,3''-triiodo-L-thyronine receptor",U,,,22226,0,,CHEMBL615322,BAO_0000019,
350,Autocuration,562.0,,1,,,Inhibition constant for binding to Co2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,H,,,19690,8,,CHEMBL615323,BAO_0000357,
351,Autocuration,562.0,,1,,,Inhibition constant for binding to Zn2+ form of 3-dehydroquinate synthase (DHQ) purified from Escherichia coli,H,,,19690,8,,CHEMBL615407,BAO_0000357,
352,Autocuration,562.0,,1,,,Kinetics expressed as Michaelis-Menten constant against Co2+ form of 3-dehydroquinate synthase purified from Escherichia coli,H,,,19690,8,,CHEMBL857267,BAO_0000357,
353,Autocuration,562.0,,1,,,Kinetics expressed as Michaelis-Menten constant against Zn2+ form of 3-dehydroquinate synthase purified from Escherichia coli,H,,,19690,8,,CHEMBL615408,BAO_0000357,
354,Autocuration,,,1,,,Type of inhibition of 3-dehydroquinate synthase was determined; R - Slowly reversible,H,,,19690,8,,CHEMBL615409,BAO_0000357,
355,Autocuration,,,1,,,Compound was evaluated for its inhibitory constant against 3-dehydroquinate synthase,H,,,19690,8,,CHEMBL615410,BAO_0000357,
356,Autocuration,,,1,,,Inhibition constant against 3-dehydroquinate synthase,H,,,19690,8,,CHEMBL615411,BAO_0000357,
357,Autocuration,,,1,,,Association rate constant against 3-dehydroquinate synthase,H,,,19690,8,,CHEMBL615412,BAO_0000357,
358,Autocuration,,,1,,,Rate constant against 3-dehydroquinate synthase,H,,,19690,8,,CHEMBL615413,BAO_0000357,
359,Autocuration,,,1,,,Inhibitory activity against fuc-TVII,U,,,22226,0,,CHEMBL615414,BAO_0000019,
360,Autocuration,10116.0,,1,2107.0,,Ability of compound (2.5 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,Microsomes,,12236,9,,CHEMBL615415,BAO_0000251,
361,Autocuration,10116.0,,1,2107.0,,Ability of compound (2500 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,Microsomes,,12236,9,,CHEMBL615416,BAO_0000251,
362,Autocuration,10116.0,,1,2107.0,,Ability of compound (250 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,Microsomes,,12236,9,,CHEMBL615417,BAO_0000251,
363,Autocuration,10116.0,,1,2107.0,,Ability of compound (25 uM) to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,Microsomes,,12236,9,,CHEMBL615418,BAO_0000251,
364,Autocuration,10116.0,,1,2107.0,,Ability of compound at 0 uM to inhibit the activity of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) using [14C]mevalonate in rat liver microsomes,D,Microsomes,,12236,9,,CHEMBL615419,BAO_0000251,
365,Autocuration,10116.0,,1,2107.0,,Ability of compound to inhibit the activity of 3-hydroxy-3-methylglutarylcoenzyme A(HMGR) reductase in rat liver microsomes,D,Microsomes,,12236,9,,CHEMBL615420,BAO_0000251,
366,Autocuration,10116.0,,1,2107.0,,Percentage inhibition of 3-hydroxy-3-methyl glutaryl coenzyme A reductase in rat liver microsomes at 250 uM,D,Microsomes,,12236,9,,CHEMBL615421,BAO_0000251,
367,Autocuration,10116.0,,1,2107.0,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 0 uM,D,Microsomes,,12236,9,,CHEMBL615422,BAO_0000251,
368,Autocuration,10116.0,,1,2107.0,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2.5 uM,D,Microsomes,,12236,9,,CHEMBL615423,BAO_0000251,
369,Autocuration,10116.0,,1,2107.0,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 2500 uM,D,Microsomes,,12236,9,,CHEMBL872868,BAO_0000251,
370,Autocuration,10116.0,,1,2107.0,,Percentage inhibition of 3-hydroxy -3- methyl glutanyl coenzyme A reductase(HMGR) in rat liver microsomes at 25 uM,D,Microsomes,,12236,9,,CHEMBL615424,BAO_0000251,
371,Autocuration,,,1,,,Inhibitory activity against 3-phosphoglycerate kinase.,H,,,104832,4,,CHEMBL825022,BAO_0000224,
372,Autocuration,,,1,,,Binding affinity was evaluated towards 3-phosphoglycerate kinase at 37 degrees Celsius in 0.1 m NaCl pH 7.1,H,,,104832,4,,CHEMBL615425,BAO_0000224,
373,Autocuration,,,1,,,"Michaelis-Menten constant with 1,3-bisphosphoglyceric acid (1,3-BPG) against 3-phosphoglycerate kinase",H,,,104832,4,,CHEMBL615426,BAO_0000224,
374,Expert,9606.0,,1,,,Inhibition of human 3-phosphoinositide-dependent protein kinase 1 at 10 uM,D,,,10612,9,,CHEMBL615427,BAO_0000357,
375,Intermediate,9606.0,,1,,,Cytotoxicity on 3677 melanoma cells,N,,844.0,80616,1,,CHEMBL615428,BAO_0000219,
376,Intermediate,9606.0,,1,,,Cytotoxicity on 3677 melanoma cells in combination with L-49-sFv-bL,N,,844.0,80616,1,,CHEMBL615429,BAO_0000219,
377,Intermediate,10090.0,,1,,,Antitumor activity against Mouse colon 38 at 500 ug/disk in disk diffusion assay,N,,700.0,80617,1,,CHEMBL615430,BAO_0000219,
378,Intermediate,9606.0,,1,,,Compound was evaluated for inhibition of tumor cell growth using sulforhodamine-B assay in 38 human cell lines,U,,,22226,0,,CHEMBL615431,BAO_0000019,
379,Autocuration,,,1,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; NT= Not tested,U,,798.0,22226,0,,CHEMBL615432,BAO_0000218,
380,Autocuration,,,1,,,In vivo antitumor activity against 3B131 intraperitoneally implanted B16 melanoma cells; reproducible significant activity.,U,,798.0,22226,0,,CHEMBL615433,BAO_0000218,
381,Expert,12131.0,,1,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease,D,,,12464,9,,CHEMBL615434,BAO_0000019,
382,Intermediate,169066.0,,1,,,Inhibitory activity against Human RhinoVirus serotype-14 3C Protease; NI means No inhibition to 50 uM,N,,,50085,1,,CHEMBL615435,BAO_0000218,
383,Intermediate,169066.0,,1,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as KI,N,,,50679,1,,CHEMBL615436,BAO_0000218,
384,Intermediate,169066.0,,1,,,Compound was evaluated for the inactivation of HRV 14 3C protease activity expressed as kinact,N,,,50679,1,,CHEMBL615437,BAO_0000218,
385,Expert,12131.0,,1,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,D,,,12464,9,,CHEMBL615438,BAO_0000019,
386,Expert,12131.0,,1,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,D,,,12464,9,,CHEMBL615439,BAO_0000019,
387,Expert,12131.0,,1,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay,D,,,12464,9,,CHEMBL615440,BAO_0000019,
388,Expert,12131.0,,1,,,Antiviral activity against human rhinovirus-14 (HRV-14) 3C protease using enzyme assay; inactive,D,,,12464,9,,CHEMBL615441,BAO_0000019,
389,Intermediate,12059.0,,1,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus 3C protease,N,,,50665,1,,CHEMBL615641,BAO_0000218,
390,Intermediate,12059.0,,1,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-16 3C protease,N,,,50665,1,,CHEMBL872065,BAO_0000218,
391,Intermediate,12059.0,,1,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-2 3C protease,N,,,50665,1,,CHEMBL825023,BAO_0000218,
392,Intermediate,12059.0,,1,,,Compound was tested for the inhibitory activity of compound towards human rhinovirus-89 3C protease,N,,,50665,1,,CHEMBL615642,BAO_0000218,
393,Expert,147712.0,,1,,,Inhibition of human rhinovirus 3C protease,H,,,12464,8,,CHEMBL615643,BAO_0000357,
394,Autocuration,9606.0,,1,,,Compound was tested for inhibition of a proteinase 3CL pro of human coronavirus; Inhibited,U,,,22226,0,,CHEMBL615644,BAO_0000019,
395,Intermediate,10090.0,,1,,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 100 mg/kg (Dose range 200-12.5),N,,833.0,80619,1,,CHEMBL615645,BAO_0000218,
396,Intermediate,10090.0,,1,,,Compound tested for activity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose of 128 mg/kg (Dose range 256-16),N,,833.0,80619,1,,CHEMBL615646,BAO_0000218,
397,Intermediate,10090.0,,1,,,Compound tested for toxicity against 3EM 37 Mouse Ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (10/10),N,,833.0,80619,1,,CHEMBL615647,BAO_0000218,
398,Intermediate,10090.0,,1,,,Compound tested for toxicity against 3EM 37 mouse ependymoblastoma after single ip injection on day 1 at optimal dose (OD) of 100 mg/kg on the 5th day after the injection of the compound; (6/6),N,,833.0,80619,1,,CHEMBL615648,BAO_0000218,
399,Intermediate,10090.0,,1,,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as animal weight difference of the treated and the control (T-C) at OD of 100 mg/kg,N,,833.0,80619,1,,CHEMBL615649,BAO_0000218,
400,Intermediate,10090.0,,1,,,Effect of compound on 3EM 37 mouse ependymoblastoma after single ip injection on day 1 recorded as percentage of cured animals at OD of 100 mg/kg,N,,833.0,80619,1,,CHEMBL615650,BAO_0000218,
401,Intermediate,10090.0,,1,,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing 15 mg/kg b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,N,,847.0,80620,1,,CHEMBL615651,BAO_0000218,
402,Intermediate,10090.0,,1,,,In vivo anti-tumor and anti-metastatic activity was measured after oral dosing b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor,N,,847.0,80620,1,,CHEMBL615652,BAO_0000218,
403,Expert,10090.0,,1,,,In vivo anti-tumor and anti-metastatic activity following p.o. administration b.i.d. to B6D2F1 mice bearing metastatic 3LL Lewis lung tumor; Not tested.,N,,847.0,80620,1,,CHEMBL615653,BAO_0000218,
404,Intermediate,10090.0,,1,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 1 uM dose,N,,847.0,80620,1,,CHEMBL615654,BAO_0000219,
405,Intermediate,10090.0,,1,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 10 uM dose,N,,847.0,80620,1,,CHEMBL615655,BAO_0000219,
406,Intermediate,10090.0,,1,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 250 uM dose,N,,847.0,80620,1,,CHEMBL825024,BAO_0000219,
407,Intermediate,10090.0,,1,,,accumulation of compound in 3LL cells was measured with DFMO by HPLC at 50 uM dose,N,,847.0,80620,1,,CHEMBL615656,BAO_0000219,
408,Intermediate,10090.0,,1,,,accumulation of compound in 3LL cells was measured with DFMO by ICP-AES at 50 uM dose,N,,847.0,80620,1,,CHEMBL615657,BAO_0000219,
409,Intermediate,10090.0,,1,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 1 uM dose,N,,847.0,80620,1,,CHEMBL615658,BAO_0000219,
410,Intermediate,10090.0,,1,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 10 uM dose,N,,847.0,80620,1,,CHEMBL615659,BAO_0000219,
411,Intermediate,10090.0,,1,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 250 uM dose,N,,847.0,80620,1,,CHEMBL615660,BAO_0000219,
412,Intermediate,10090.0,,1,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,N,,847.0,80620,1,,CHEMBL615661,BAO_0000219,
413,Intermediate,10090.0,,1,,,accumulation of compound in 3LL cells was measured without DFMO by ICP-AES at 50 uM dose,N,,847.0,80620,1,,CHEMBL615662,BAO_0000219,
414,Intermediate,10090.0,,1,,,Effect on the growth of 3LL cells by DFMO pretreatment at 48 hr incubation,N,,847.0,80620,1,,CHEMBL615663,BAO_0000219,
415,Intermediate,10090.0,,1,,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 48 hour incubation,N,,847.0,80620,1,,CHEMBL615664,BAO_0000219,
416,Intermediate,10090.0,,1,,,Effect on the growth of 3LL cells was evaluated using an MTT assay at 72 hour incubation,N,,847.0,80620,1,,CHEMBL615665,BAO_0000219,
417,Intermediate,10090.0,,1,,,accumulation of compound in 3LL cells was measured without DFMO by HPLC at 50 uM dose,N,,847.0,80620,1,,CHEMBL615666,BAO_0000219,
418,Intermediate,10090.0,,1,,,putrescine levels in 3LL cells after the treatment of 1 uM of Compound,N,,847.0,80620,1,,CHEMBL615667,BAO_0000219,
419,Intermediate,10090.0,,1,,,putrescine levels in 3LL cells after the treatment of 10 uM of Compound,N,,847.0,80620,1,,CHEMBL615668,BAO_0000219,
420,Intermediate,10090.0,,1,,,putrescine levels in 3LL cells after the treatment of 250 uM of Compound,N,,847.0,80620,1,,CHEMBL615669,BAO_0000219,
421,Intermediate,10090.0,,1,,,putrescine levels in 3LL cells after the treatment of 50 uM of Compound,N,,847.0,80620,1,,CHEMBL615670,BAO_0000219,
422,Intermediate,10090.0,,1,,,spermidine levels in 3LL cells after the treatment of 1 uM of Compound,N,,847.0,80620,1,,CHEMBL836739,BAO_0000219,
423,Intermediate,10090.0,,1,,,spermidine levels in 3LL cells after the treatment of 10 uM of Compound,N,,847.0,80620,1,,CHEMBL615671,BAO_0000219,
424,Intermediate,10090.0,,1,,,spermidine levels in 3LL cells after the treatment of 250 uM of Compound,N,,847.0,80620,1,,CHEMBL615672,BAO_0000219,
425,Intermediate,10090.0,,1,,,spermidine levels in 3LL cells after the treatment of 50 uM of Compound,N,,847.0,80620,1,,CHEMBL615791,BAO_0000219,
426,Intermediate,10090.0,,1,,,spermine levels in 3LL cells after the treatment of 1 uM of Compound,N,,847.0,80620,1,,CHEMBL615792,BAO_0000219,
427,Intermediate,10090.0,,1,,,spermine levels in 3LL cells after the treatment of 10 uM of Compound,N,,847.0,80620,1,,CHEMBL615793,BAO_0000219,
428,Intermediate,10090.0,,1,,,spermine levels in 3LL cells after the treatment of 250 uM of Compound,N,,847.0,80620,1,,CHEMBL615794,BAO_0000219,
429,Intermediate,10090.0,,1,,,spermine levels in 3LL cells after the treatment of 50 uM of Compound,N,,847.0,80620,1,,CHEMBL615795,BAO_0000219,
430,Intermediate,9606.0,,1,,,Concentration required to inhibit the colony formation of lung carcinoma (3LLD122) cell lines by 50%,N,,971.0,80621,1,,CHEMBL615590,BAO_0000219,
431,Autocuration,,,1,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible minimal activity,U,,,22226,0,,CHEMBL615591,BAO_0000218,
432,Autocuration,,,1,,,In vivo antitumor activity against 3M531 is the sarcoma M5076; reproducible significant activity.,U,,,22226,0,,CHEMBL615592,BAO_0000218,
433,Autocuration,,,1,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; NT= Not tested,U,,,22226,0,,CHEMBL615593,BAO_0000218,
434,Autocuration,,,1,,,In vivo antitumor activity against 3MBG5 subrenal capsule mammary carcinoma MX-1 xenograft; reproducible significant activity.,U,,,22226,0,,CHEMBL615594,BAO_0000218,
435,Intermediate,10090.0,,1,,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,N,,723.0,80951,1,,CHEMBL615595,BAO_0000219,
436,Intermediate,10090.0,,1,,,Effective dose required against Trypanosoma cruzi amastigotes in 3T3 Fibroblasts,N,,723.0,80951,1,,CHEMBL615596,BAO_0000219,
437,Expert,,,1,,,Inhibition of 6 nM bombesin induced [3H]thymidine incorporation measured in swiss 3T3 cells using a mitogenicity assay,H,,723.0,11169,8,,CHEMBL615597,BAO_0000219,
438,Intermediate,10090.0,,1,,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; na=Not active,N,,723.0,80951,1,,CHEMBL615598,BAO_0000219,
439,Intermediate,10090.0,,1,,,Ability of the peptide to inhibit 6 nM bombesin induced [3H]thymidine incorporation was measured in swiss 3T3 cells using mitogenicity assay; nt=Not tested,N,,723.0,80951,1,,CHEMBL615599,BAO_0000219,
440,Expert,10090.0,,1,,,Effective dose against murine 3T3 fibroblasts cells,N,,723.0,80951,1,,CHEMBL615600,BAO_0000219,
441,Expert,10090.0,,1,,,Dose required against murine 3T3 fibroblasts cells; 1-10 uM,N,,723.0,80951,1,,CHEMBL615601,BAO_0000219,
442,Expert,10090.0,,1,,,Cytotoxic effect on 3T3 cells,N,,723.0,80951,1,,CHEMBL615602,BAO_0000219,
443,Expert,10090.0,,1,,,Cytotoxic effect on 3T3 cells,N,,723.0,80951,1,,CHEMBL615603,BAO_0000219,
444,Intermediate,10090.0,,1,,,Compound was tested for the concentration necessary to inhibit swiss 3T3 Mouse Fibroblast cell growth rate by 50%.,N,,723.0,80951,1,,CHEMBL615604,BAO_0000219,
445,Intermediate,10090.0,,1,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,N,,723.0,80951,1,,CHEMBL615605,BAO_0000219,
446,Intermediate,10090.0,,1,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration; nd=No data,N,,723.0,80951,1,,CHEMBL615606,BAO_0000219,
447,Expert,10090.0,,1,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration,N,,723.0,80951,1,,CHEMBL884526,BAO_0000219,
448,Expert,10090.0,,1,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.d.=no data,N,,723.0,80951,1,,CHEMBL615607,BAO_0000219,
449,Intermediate,10090.0,,1,,,In vitro cytotoxic concentration against mouse fibroblasts (3T3) cell line using MTT coloration; n.t.=not tested,N,,723.0,80951,1,,CHEMBL615608,BAO_0000219,
450,Expert,10090.0,,1,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration,N,,723.0,80951,1,,CHEMBL615609,BAO_0000219,
451,Expert,10090.0,,1,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.d.=no data,N,,723.0,80951,1,,CHEMBL615682,BAO_0000219,
452,Intermediate,10090.0,,1,,,In vitro inhibitory activity against mouse fibroblasts (3T3) cell line using CV coloration; n.t.=not tested,N,,723.0,80951,1,,CHEMBL615683,BAO_0000219,
453,Expert,10090.0,,1,,,In vivo inhibition of H-ras-transformed 3T3 fibroblasts in nude mouse tumor models,N,,723.0,80951,1,,CHEMBL615684,BAO_0000218,
454,Autocuration,10090.0,,1,,,Inhibition of PDGF-dependent autophosphorylation of PDGF-R in mouse BALB/c3T3 cells,D,,,104860,7,,CHEMBL615685,BAO_0000219,
455,Expert,10090.0,,1,,,Inhibition of Swiss 3T3 Mouse fibroblast proliferation,N,,723.0,80951,1,,CHEMBL615686,BAO_0000219,
456,Intermediate,10090.0,,1,,,Inhibitory activity against 3T3 cell line,N,,723.0,80951,1,,CHEMBL615687,BAO_0000219,
457,Intermediate,10090.0,,1,,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured,N,,723.0,80951,1,,CHEMBL884523,BAO_0000219,
458,Expert,,,1,,,Ability of peptide to inhibit binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane.,H,,,11169,8,,CHEMBL615688,BAO_0000019,
459,Intermediate,10090.0,,1,,,The ability of the peptide to inhibit the binding of 10 pM [125I]gastrin releasing peptide to S-3T3 cell membrane was measured; nt=Not tested,N,,723.0,80951,1,,CHEMBL615689,BAO_0000219,
460,Intermediate,10090.0,,1,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells was measured,N,,723.0,80951,1,,CHEMBL615690,BAO_0000219,
461,Expert,,,1,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells,H,,,11169,8,,CHEMBL615691,BAO_0000019,
462,Expert,,,1,,,The ability of the peptide to inhibit the binding of 50 pM [125I]gastrin releasing peptide to intact S-3T3 cells; nt=Not tested,H,,,11169,8,,CHEMBL615692,BAO_0000019,
463,Intermediate,10090.0,,1,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line in the presence of compound was determined using NR coloration,N,,723.0,80951,1,,CHEMBL615693,BAO_0000219,
464,Expert,10090.0,,1,,,Concentration of NO in supernatant generated by mouse fibroblasts (3T3) cell line was determined using NR coloration; n.d.=no data,N,,723.0,80951,1,,CHEMBL615324,BAO_0000219,
465,Expert,9606.0,,1,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells,D,,723.0,9,9,,CHEMBL615325,BAO_0000219,
466,Expert,9606.0,,1,,,Inhibition of ligand-induced proliferation in human EGF-R Kinase expressing 3T3 cells (Not tested),D,,723.0,9,9,,CHEMBL615490,BAO_0000219,
467,Expert,9606.0,,1,,,Inhibition of ligand induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells,D,,723.0,188,9,,CHEMBL615491,BAO_0000219,
468,Expert,9606.0,,1,,,Inhibition of ligand-induced proliferation in human Her-2 (p185erbB) tyrosine kinase expressing 3T3 cells (Not tested),D,,723.0,188,9,,CHEMBL615492,BAO_0000219,
469,Intermediate,10090.0,,1,,,Inhibitory concentration of compound rwas calculated on 3T3 cells by [3H]Thd incorporation,N,,723.0,80951,1,,CHEMBL615493,BAO_0000219,
470,Intermediate,10090.0,,1,,,Inhibitory concentration of compound was calculated on 3T3 cells by [14C]Leu incorporation,N,,723.0,80951,1,,CHEMBL615494,BAO_0000219,
471,Intermediate,10090.0,,1,,,Inhibitory concentration of compound was calculated on 3T3 cells by using clonal assay,N,,723.0,80951,1,,CHEMBL615495,BAO_0000219,
472,Intermediate,10090.0,,1,,,Inhibitory concentration was calculated on 3T3 cells by using growth assay,N,,723.0,80951,1,,CHEMBL615496,BAO_0000219,
473,Intermediate,10090.0,,1,,,In vitro cytotoxicity was evaluated in mouse embryo BALB/c 3T3 cells,N,,723.0,80951,1,,CHEMBL615497,BAO_0000219,
474,Expert,10090.0,,1,,,Inhibition of Swiss 3T3 mouse fibroblast proliferation,N,,723.0,80951,1,,CHEMBL615498,BAO_0000219,
475,Intermediate,10090.0,,1,,,The compound was tested for cytotoxicity against 3T3 fibroblast murine cell line.,N,,723.0,80951,1,,CHEMBL615499,BAO_0000219,
476,Expert,10090.0,,1,,,Effective concentration required to inhibit the growth of murine 3T3 fibroblasts,N,,723.0,80951,1,,CHEMBL835522,BAO_0000219,
477,Intermediate,10090.0,,1,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014); Not tested,N,,723.0,80951,1,,CHEMBL615500,BAO_0000219,
478,Intermediate,10090.0,,1,,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,,723.0,80951,1,,CHEMBL615501,BAO_0000219,
479,Intermediate,10090.0,,1,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,,723.0,80951,1,,CHEMBL615502,BAO_0000219,
480,Intermediate,10090.0,,1,,,cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,,723.0,80951,1,,CHEMBL615503,BAO_0000219,
481,Intermediate,10090.0,,1,,,Cytotoxicity on 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,,723.0,80951,1,,CHEMBL615504,BAO_0000219,
482,Intermediate,10090.0,,1,,,Cytotoxicity against 3T3 fibroblasts (3T3F) murine cell line (O.D.=0.131+/-0.014),N,,723.0,80951,1,,CHEMBL615505,BAO_0000219,
483,Expert,10090.0,,1,,,Inhibition of swiss 3T3 mouse fibroblast proliferation,N,,723.0,80951,1,,CHEMBL615506,BAO_0000219,
484,Intermediate,10090.0,,1,,,Compound was tested for sublethal concentrations in 3T3 mouse fibroblast lysis.,N,,723.0,80951,1,,CHEMBL615507,BAO_0000219,
485,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,N,,620.0,80006,1,,CHEMBL615508,BAO_0000218,
486,Intermediate,10090.0,,1,,,Concentration required to stimulate glucose uptake in 3T3-L1 adipocytes after 48 hr incubation,N,,620.0,80006,1,,CHEMBL615509,BAO_0000219,
487,Intermediate,10090.0,,1,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 0.3 uM,N,,620.0,80006,1,,CHEMBL615510,BAO_0000219,
488,Intermediate,10090.0,,1,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 3 uM,N,,620.0,80006,1,,CHEMBL615511,BAO_0000219,
489,Intermediate,10090.0,,1,,,Effect on GLUT 1 glucose transporter expression in 3T3-L1 adipocytes at dose of 30 uM,N,,620.0,80006,1,,CHEMBL615512,BAO_0000219,
490,Intermediate,10090.0,,1,,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 24 hr",N,,620.0,80006,1,,CHEMBL615513,BAO_0000218,
491,Intermediate,10090.0,,1,,,"In vitro ability to stimulate glucose transport in 3T3-L1 adipocytes, given at 100 mg/kg in mouse, after 3 hr",N,,620.0,80006,1,,CHEMBL615514,BAO_0000218,
492,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes,N,,620.0,80006,1,,CHEMBL615515,BAO_0000219,
493,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,N,,620.0,80006,1,,CHEMBL615516,BAO_0000219,
494,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,N,,620.0,80006,1,,CHEMBL615517,BAO_0000219,
495,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,N,,620.0,80006,1,,CHEMBL615518,BAO_0000219,
496,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,N,,620.0,80006,1,,CHEMBL615519,BAO_0000219,
497,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.3 uM dose.,N,,620.0,80006,1,,CHEMBL615520,BAO_0000218,
498,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 0.5 uM dose.,N,,620.0,80006,1,,CHEMBL615521,BAO_0000218,
499,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,N,,620.0,80006,1,,CHEMBL615522,BAO_0000218,
500,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,N,,620.0,80006,1,,CHEMBL615523,BAO_0000218,
501,Expert,,,1,,,In vitro measurements 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,N,,620.0,80006,1,,CHEMBL615524,BAO_0000218,
502,Expert,,,1,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,N,,620.0,80006,1,,CHEMBL615525,BAO_0000218,
503,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 1 uM dose.,N,,620.0,80006,1,,CHEMBL615526,BAO_0000218,
504,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,N,,620.0,80006,1,,CHEMBL615527,BAO_0000218,
505,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 300 uM dose.,N,,620.0,80006,1,,CHEMBL615528,BAO_0000218,
506,Expert,,,1,,,Acute effects in vitro by measuring 2-deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,N,,620.0,80006,1,,CHEMBL615529,BAO_0000218,
507,Expert,,,1,,,In vitro by measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,N,,620.0,80006,1,,CHEMBL615530,BAO_0000218,
508,Expert,,,1,,,In vitro measurements of 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,N,,620.0,80006,1,,CHEMBL615531,BAO_0000218,
509,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 10 micro M,N,,620.0,80006,1,,CHEMBL615532,BAO_0000219,
510,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 3 micro M,N,,620.0,80006,1,,CHEMBL615533,BAO_0000219,
511,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at concentration of 30 micro M,N,,620.0,80006,1,,CHEMBL615534,BAO_0000219,
512,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 100 uM dose.,N,,620.0,80006,1,,CHEMBL615535,BAO_0000218,
513,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 10 uM dose.,N,,620.0,80006,1,,CHEMBL615536,BAO_0000218,
514,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 30 uM dose.,N,,620.0,80006,1,,CHEMBL615537,BAO_0000218,
515,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 3 uM dose.,N,,620.0,80006,1,,CHEMBL615538,BAO_0000218,
516,Intermediate,,,1,,,compound was evaluated for their acute effects in vitro by measuring 2-Deoxyglucose (2DG) uptake in vehicle treated 3T3-L1 adipocytes at 60 uM dose.,N,,620.0,80006,1,,CHEMBL836166,BAO_0000218,
517,Expert,,,1,,,Inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells,H,,620.0,11214,8,,CHEMBL615539,BAO_0000219,
518,Intermediate,10090.0,,1,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; ND = No data,N,,620.0,80006,1,,CHEMBL615540,BAO_0000219,
519,Expert,,,1,,,Evaluated for the inhibition of forskolin-stimulated lipolysis in differentiated 3T3-L1 cells; Na = Not active,H,,620.0,11214,8,,CHEMBL615541,BAO_0000219,
520,Expert,10090.0,,1,,,Insulin-sensitizing activity; triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 1 uM expressed as percent activity of pioglitazone,N,,620.0,80006,1,,CHEMBL615542,BAO_0000219,
521,Intermediate,10090.0,,1,,,Compound was tested for insulin-sensitizing activity by measuring triglyceride accumulation from insulin regulated differentiation of 3T3-L1 cells at 10 uM expressed as percent activity of pioglitazone,N,,620.0,80006,1,,CHEMBL615543,BAO_0000219,
522,Expert,10090.0,,1,,,Stimulation of adipogenesis in 3T3-L1 cells is expressed as concentration equivalent to the [ 1-14C] uptake counts after treatment with 0.2 ug/mL troglitazone,N,,620.0,80006,1,,CHEMBL615544,BAO_0000219,
523,Expert,10090.0,,1,,,Effective concentration for enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,N,,620.0,80006,1,,CHEMBL615545,BAO_0000219,
524,Expert,10090.0,,1,,,Effective concentration for 50% enhancement of insulin-induced triglyceride accumulation in 3T3-L1 cells,N,,620.0,80006,1,,CHEMBL615546,BAO_0000219,
525,Expert,10090.0,,1,,,Percentage of rosiglitazone response for insulin-sensitizing activity at 1 uM concentration in 3T3-L1 cells,N,,620.0,80006,1,,CHEMBL615547,BAO_0000219,
526,Expert,10090.0,,1,,,In vitro glucose transport activity in 3T3-LI adipocytes at 10 uM concentration.,N,,620.0,80006,1,,CHEMBL615548,BAO_0000219,
527,Expert,10090.0,,1,,,In vitro glucose transport activity in 3T3-LI adipocytes at 3 uM concentration.,N,,620.0,80006,1,,CHEMBL615549,BAO_0000219,
528,Expert,10090.0,,1,,,In vitro glucose transport activity in 3T3-LI adipocytes at 30 uM concentration.,N,,620.0,80006,1,,CHEMBL615550,BAO_0000219,
529,Intermediate,10116.0,,1,,,Inhibitory activity against rat fibroblast (3Y1) cell line,N,,1118.0,80622,1,,CHEMBL615551,BAO_0000219,
530,Expert,10116.0,,1,,,Mean concentration causing inhibition of cell growth in 3Y1 cells.,N,,1118.0,80622,1,,CHEMBL615552,BAO_0000219,
531,Expert,10116.0,,1,,,Cytotoxicity in 3Y1 cells.,N,,1118.0,80622,1,,CHEMBL615553,BAO_0000219,
532,Expert,10116.0,,1,,,Cytostatic effect in 3Y1 cells.,N,,1118.0,80622,1,,CHEMBL615554,BAO_0000219,
533,Intermediate,10116.0,,1,,,"Mean averaged concentration for total growth inhibition, which signifies cytostatic effect",N,,1118.0,80622,1,,CHEMBL615555,BAO_0000219,
534,Expert,10116.0,,1,,,Concentration to inhibit growth of normal rat fibroblast cells (3Y1-B cells) after 72 h exposure,N,,1118.0,80622,1,,CHEMBL615556,BAO_0000219,
535,Autocuration,,,1,,,In vitro inhibitory activity against human adrenal 3-beta hydroxy-delta 5-teroid isomerase,U,,,22226,0,,CHEMBL615557,BAO_0000019,
536,Autocuration,,,1,,,Inhibition of recombinant human adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,U,,,22226,0,,CHEMBL615558,BAO_0000019,
537,Autocuration,,,1,,,Inhibition of recombinant rat adrenal 3-beta-hydroxy-delta-5-steroid dehydrogenase,U,,,22226,0,,CHEMBL872066,BAO_0000019,
538,Expert,9823.0,,1,,,In vitro inhibition against of 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) from pig liver by the enol borate method,D,,,11607,9,,CHEMBL615559,BAO_0000019,
539,Autocuration,,,1,,,In vitro inhibitory concentration required against 4-hydroxyphenylpyruvate dioxygenase (4-HPPD) taken from pig liver,H,,,11607,8,,CHEMBL615560,BAO_0000019,
540,Autocuration,,,1,,,Inhibition of pig liver 4-Hydroxyphenylpyruvate dioxygenase (4-HPPD) enzyme,H,,,11607,8,,CHEMBL615561,BAO_0000019,
541,Expert,,,1,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver,H,,,11607,8,,CHEMBL857062,BAO_0000019,
542,Expert,,,1,,,Concentration required to achieve 50% inhibition against 4-Hydroxyphenylpyruvate dioxygenase (HPPD) from pig liver; (observed value),H,,,11607,8,,CHEMBL615562,BAO_0000019,
543,Autocuration,,,1,,,In vitro inhibitory activity against HPPD(4-hydroxyphenylpyruvate Dioxygenase) from pig liver using enol borate assay method,H,,,11607,8,,CHEMBL615563,BAO_0000019,
544,Autocuration,,,1,,,Compound was evaluated for complete competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD),H,,,11607,8,,CHEMBL615564,BAO_0000357,
545,Autocuration,,,1,,,In vitro inhibition of 4-hydroxyphenylpyruvate dioxygenase obtained from purified pig liver by enol-borate method,H,,,11607,8,,CHEMBL615565,BAO_0000019,
546,Autocuration,,,1,,,Inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated,H,,,11607,8,,CHEMBL615566,BAO_0000019,
547,Expert,9823.0,,1,,,Inhibition of 4-hydroxyphenylpyruvate dioxygenase of purified pig liver by enol-borate method,D,,,11607,9,,CHEMBL615567,BAO_0000019,
548,Autocuration,,,1,,,The inhibitory activity on pig liver 4-hydroxyphenylpyruvate dioxygenase (HPPD) was evaluated.,H,,,11607,8,,CHEMBL615568,BAO_0000019,
549,Autocuration,,,1,,,Compound was evaluated for competitive inhibition of 4-hydroxyphenylpyruvate dioxygenase (HPPD) (complete inhibition was observed at a concentration of 0.5-1.0 mM),H,,,11607,8,,CHEMBL615569,BAO_0000357,
550,Autocuration,,,1,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver,H,,,11607,8,,CHEMBL615570,BAO_0000019,
551,Autocuration,,,1,,,Concentration required to achieve 50% inhibition against 4-hydroxyphenylpyruvate dioxygenase from pig liver; (observed value),H,,,11607,8,,CHEMBL615571,BAO_0000019,
552,Autocuration,,,1,,,Binding affinity against melatonin (MT1) receptor (pC1),H,,,104733,4,,CHEMBL615572,BAO_0000224,
553,Autocuration,,,1,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 1 receptor,U,,,22226,0,,CHEMBL615573,BAO_0000019,
554,Autocuration,,,1,,,Inhibition of [3H]- 5-HT binding to 5-hydroxytryptamine 1 receptor at 10e-5 M,U,,,22226,0,,CHEMBL615574,BAO_0000019,
555,Autocuration,,,1,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1 receptor of central nervous system,U,,,22226,0,,CHEMBL615575,BAO_0000019,
556,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand at 10e-5 M concentration,H,,,10619,8,,CHEMBL615576,BAO_0000357,
557,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1 receptor using [3H]5-HT as radioligand,H,,,10619,8,,CHEMBL615577,BAO_0000357,
558,Autocuration,,,1,10000000.0,,Binding affinity at 5-hydroxytryptamine 1A receptor in bovine hippocampal preparation using [3H]8-OH-DPAT,H,,,51,8,,CHEMBL615578,BAO_0000221,
559,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor was measured using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL615579,BAO_0000357,
560,Expert,,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL615580,BAO_0000357,
561,Expert,,,1,,,Affinity towards 5-hydroxytryptamine 1A receptor in membranes from bovine hippocampus using [3H]OH-DPAT,H,,,51,8,,CHEMBL615581,BAO_0000019,
562,Autocuration,,,1,10000000.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,,,51,8,,CHEMBL615582,BAO_0000221,
563,Autocuration,,,1,10000000.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,,,51,8,,CHEMBL615583,BAO_0000221,
564,Autocuration,,,1,10000000.0,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,H,,,51,8,,CHEMBL615584,BAO_0000221,
565,Autocuration,,,1,10000000.0,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,,51,8,,CHEMBL833691,BAO_0000221,
566,Autocuration,,,1,10000000.0,,In vitro inhibition of azido-[125I]-IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,H,,,51,8,,CHEMBL615585,BAO_0000221,
567,Autocuration,,,1,10000000.0,,In vitro inhibition of [125I]IPAPP (0.25 nM) binding to 5-HT1A receptor from bovine hippocampus,H,,,51,8,,CHEMBL615586,BAO_0000221,
568,Autocuration,,,1,10000000.0,,In vitro inhibition of [125I]IPAPP (2.5 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,,51,8,,CHEMBL884524,BAO_0000221,
569,Autocuration,,,1,10000000.0,,Inhibitory concentration against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,,,51,8,,CHEMBL615587,BAO_0000221,
570,Autocuration,,,1,10000000.0,,"Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",H,,,51,8,,CHEMBL615588,BAO_0000221,
571,Expert,10116.0,,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampal membranes,D,Membranes,,10576,9,,CHEMBL615589,BAO_0000249,
572,Expert,9913.0,,1,10000000.0,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of bovine hippocampus.,H,,,51,8,,CHEMBL615442,BAO_0000221,
573,Autocuration,,,1,10000000.0,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (0.5 nM) ligand in hippocampus + frontal bovine was determined,H,,,51,8,,CHEMBL615443,BAO_0000221,
574,Autocuration,,,1,10000000.0,,Compound was evaluated for its ability to displace [3H]DPAT from 5-HT1A receptor in homogenates of bovine hippocampus,H,,,51,8,,CHEMBL615444,BAO_0000221,
575,Expert,,,1,10000000.0,,Ability to displace [3H]-DPAT from 5-hydroxytryptamine 1A receptor in homogenates of bovine hippocampus.,H,,,51,8,,CHEMBL615445,BAO_0000221,
576,Autocuration,,,1,10000000.0,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in bovine hippocampus,H,,,51,8,,CHEMBL615446,BAO_0000221,
577,Autocuration,,,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in CHO cells,H,,449.0,51,8,,CHEMBL615447,BAO_0000219,
578,Expert,,,1,10000000.0,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,,,51,8,,CHEMBL615448,BAO_0000221,
579,Expert,,,1,10000000.0,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus,H,,,51,8,,CHEMBL615449,BAO_0000221,
580,Autocuration,,,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,,449.0,51,8,,CHEMBL615450,BAO_0000219,
581,Expert,,,1,10000000.0,,"Binding affinity against 5-hydroxytryptamine 1A receptor from bovine hippocampus, used [3H]8-OH-DPAT as radioligand",H,,,51,8,,CHEMBL615451,BAO_0000221,
582,Autocuration,,,1,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,H,,,51,8,,CHEMBL615452,BAO_0000357,
583,Autocuration,,,1,10000000.0,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-HT1A receptor from bovine hippocampus,H,,,51,8,,CHEMBL615453,BAO_0000221,
584,Autocuration,,,1,10000000.0,,In vitro inhibition of [3H]5-HT (2 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,,51,8,,CHEMBL615454,BAO_0000221,
585,Autocuration,,,1,10000000.0,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,H,,,51,8,,CHEMBL615455,BAO_0000221,
586,Autocuration,,,1,10000000.0,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,,51,8,,CHEMBL615456,BAO_0000221,
587,Autocuration,,,1,10000000.0,,In vitro inhibition of [3H]DPAT (1 nM) binding to 5-HT1A receptor from bovine hippocampus,H,,,51,8,,CHEMBL615457,BAO_0000221,
588,Expert,,,1,10000000.0,,In vivo binding affinity towards [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in bovine hippocampus.,H,,,51,8,,CHEMBL615458,BAO_0000218,
589,Expert,,,1,10000000.0,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,,51,8,,CHEMBL615459,BAO_0000221,
590,Expert,9606.0,,1,,,"Tested in vitro for the inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor, expressed in cloned CHO cells.",D,,449.0,51,9,,CHEMBL615460,BAO_0000219,
591,Autocuration,10141.0,,1,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig,H,,,51,8,,CHEMBL615461,BAO_0000019,
592,Autocuration,10141.0,,1,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor in guinea pig; NT means not tested,H,,,51,8,,CHEMBL615462,BAO_0000019,
593,Autocuration,10141.0,,1,10000000.0,,Effect on forskolin stimulated adenylate cyclase activity at 5-hydroxytryptamine 1A receptor of guinea pig hippocampus.,H,,,51,8,,CHEMBL615463,BAO_0000221,
594,Autocuration,10141.0,,1,2116.0,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,H,,,51,8,,CHEMBL615464,BAO_0000221,
595,Autocuration,10141.0,,1,2116.0,,Ability to antagonize Acetylcholine induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,H,,,51,8,,CHEMBL615465,BAO_0000221,
596,Autocuration,10141.0,,1,2116.0,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor.,H,,,51,8,,CHEMBL615466,BAO_0000221,
597,Autocuration,10141.0,,1,2116.0,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,H,,,51,8,,CHEMBL615467,BAO_0000221,
598,Autocuration,10141.0,,1,2116.0,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor. Inactive at dose level of 1.0 uM,H,,,51,8,,CHEMBL615468,BAO_0000221,
599,Autocuration,10141.0,,1,2116.0,,Ability to antagonize electrical induced contractile responses in Guinea pig ileum for 5-HT1A receptor; Inactive at dose level of 1.0 uM,H,,,51,8,,CHEMBL615469,BAO_0000221,
600,Autocuration,10141.0,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL615470,BAO_0000357,
601,Autocuration,10141.0,,1,,,Compound is evaluated for in vitro receptor binding affinity against 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL615471,BAO_0000357,
602,Autocuration,10141.0,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL615472,BAO_0000357,
603,Autocuration,10141.0,,1,10000000.0,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,H,,,106,8,,CHEMBL883242,BAO_0000221,
604,Autocuration,10141.0,,1,10000000.0,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1A receptor of guinea pig hippocampus,H,,,106,8,,CHEMBL615473,BAO_0000221,
605,Autocuration,10029.0,,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),H,,449.0,11863,8,,CHEMBL615474,BAO_0000218,
606,Autocuration,,,1,,,Fraction involved in salt bridge interactions with Asp3:11 part of the 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL615475,BAO_0000357,
607,Autocuration,,,1,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-HT 1A receptor in HeLa cells; value ranges from 85-370,H,,308.0,51,8,,CHEMBL615476,BAO_0000219,
608,Autocuration,,,1,,,Compound was tested for its ability to inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1A receptor in HeLa cells; value ranges from 95-320,H,,308.0,51,8,,CHEMBL615477,BAO_0000219,
609,Autocuration,,,1,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL615478,BAO_0000019,
610,Autocuration,,,1,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,H,,449.0,51,8,,CHEMBL615160,BAO_0000219,
611,Expert,,,1,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor,H,,449.0,51,8,,CHEMBL615161,BAO_0000219,
612,Autocuration,,,1,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=Not determined,H,,449.0,51,8,,CHEMBL615162,BAO_0000219,
613,Autocuration,,,1,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing human 5-hydroxytryptamine 1A receptor; nd=not determined,H,,449.0,51,8,,CHEMBL615163,BAO_0000219,
614,Expert,,,1,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,,449.0,51,8,,CHEMBL615164,BAO_0000219,
615,Expert,,,1,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,,449.0,51,8,,CHEMBL615165,BAO_0000219,
616,Autocuration,,,1,,,Effective concentration against human 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells; nd=not determined,H,,449.0,51,8,,CHEMBL615166,BAO_0000219,
617,Autocuration,,,1,,,In vitro potency at human 5-hydroxytryptamine 1A receptor in inhibiting forskolin-stimulated accumulation of intracellular cAMP,H,,,51,8,,CHEMBL615167,BAO_0000219,
618,Expert,9606.0,,1,,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,D,,308.0,51,9,,CHEMBL615168,BAO_0000219,
619,Expert,9606.0,,1,,,Stimulation of [35S]- GIPyS binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells; Inverse,D,,308.0,51,9,,CHEMBL615169,BAO_0000219,
620,Expert,9606.0,,1,,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor,D,,449.0,51,9,,CHEMBL615170,BAO_0000219,
621,Expert,9606.0,,1,,,Tested for functional response on CHO cells expressing cloned human 5-hydroxytryptamine 1A receptor; Not determined,D,,449.0,51,9,,CHEMBL615171,BAO_0000219,
622,Autocuration,,,1,,,Eudisimic ratio(ER) is the antilog of the defference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL615694,BAO_0000019,
623,Autocuration,,,1,,,Eudisimic ratio(ER) is the antilog of the difference between the pKb and pD2 values against 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL615695,BAO_0000019,
624,Autocuration,,,1,,,"Percent of maximum effect on binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",H,,,51,8,,CHEMBL615696,BAO_0000019,
625,Autocuration,,,1,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,H,,449.0,51,8,,CHEMBL615697,BAO_0000219,
626,Expert,9606.0,,1,,,Agonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),D,,449.0,51,9,,CHEMBL859410,BAO_0000219,
627,Autocuration,,,1,,,Agonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),H,,449.0,51,8,,CHEMBL615841,BAO_0000219,
628,Expert,9606.0,,1,,,Agonistic efficacy in adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),D,,449.0,51,9,,CHEMBL615842,BAO_0000219,
629,Autocuration,,,1,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,H,,449.0,51,8,,CHEMBL835003,BAO_0000219,
630,Autocuration,,,1,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 1),H,,449.0,51,8,,CHEMBL615843,BAO_0000219,
631,Expert,9606.0,,1,,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 1),D,,449.0,51,9,,CHEMBL615979,BAO_0000219,
632,Autocuration,,,1,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor (experiment 2),H,,449.0,51,8,,CHEMBL615980,BAO_0000219,
633,Expert,9606.0,,1,,,Antagonistic efficacy as adenylyl cyclase assay in CHO cells expressing human 5-HT1A receptor (experiment 2),D,,449.0,51,9,,CHEMBL615981,BAO_0000219,
634,Expert,9606.0,,1,,,Percent efficacy against cloned human 5-hydroxytryptamine 1A receptor normalized to the maximal 5-HT response,D,,,51,9,,CHEMBL615982,BAO_0000019,
635,Expert,9606.0,,1,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",D,,,51,9,,CHEMBL615983,BAO_0000019,
636,Expert,9606.0,,1,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor in vitro using a [35S]GTP-gamma-S, No data",D,,,51,9,,CHEMBL615984,BAO_0000019,
637,Expert,9606.0,,1,,,"Agonist activity at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S,",D,,,51,9,,CHEMBL615985,BAO_0000019,
638,Autocuration,,,1,,,Agonistic effect against 5-HT1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,H,,449.0,51,8,,CHEMBL615986,BAO_0000219,
639,Autocuration,,,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,H,,449.0,51,8,,CHEMBL615987,BAO_0000219,
640,Autocuration,,,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,H,,449.0,51,8,,CHEMBL615988,BAO_0000219,
641,Expert,,,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells,H,,449.0,51,8,,CHEMBL615989,BAO_0000219,
642,Autocuration,,,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=Not determined,H,,449.0,51,8,,CHEMBL615990,BAO_0000219,
643,Autocuration,,,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using cAMP as radioligand relative to 5-HT in inhibiting forskolin-stimulated adenylate cyclase activity in CHO cells; nd=not determined,H,,449.0,51,8,,CHEMBL615991,BAO_0000219,
644,Autocuration,,,1,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,H,,449.0,51,8,,CHEMBL615992,BAO_0000219,
645,Autocuration,,,1,,,Agonistic effect against 5-HT 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=Not determined,H,,449.0,51,8,,CHEMBL615993,BAO_0000219,
646,Expert,,,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,H,,449.0,51,8,,CHEMBL615994,BAO_0000219,
647,Autocuration,,,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT; nd=not determined,H,,449.0,51,8,,CHEMBL615995,BAO_0000219,
648,Autocuration,,,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35S]GTP-gamma-S as radioligand in CHO cells relative to 5-HT,H,,449.0,51,8,,CHEMBL615996,BAO_0000219,
649,Autocuration,,,1,,,Agonistic effect against 5-hydroxytryptamine 1A receptor using [35]GTPgammaS as radioligand in CHO cells relative to 5-HT; nd=Not determined,H,,449.0,51,8,,CHEMBL615997,BAO_0000219,
650,Autocuration,,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,,,51,8,,CHEMBL615998,BAO_0000019,
651,Autocuration,,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,,,51,8,,CHEMBL615999,BAO_0000019,
652,Autocuration,,,1,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,H,,,51,8,,CHEMBL616000,BAO_0000019,
653,Autocuration,,,1,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,,722.0,51,8,,CHEMBL616001,BAO_0000219,
654,Expert,9606.0,,1,,,"Evaluated for stimulation at 1 uM concentration expressed as percent of the maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine",D,,,51,9,,CHEMBL616002,BAO_0000019,
655,Expert,,,1,,,"Stimulation of percent maximal [35S]GTP-gamma-S, binding induced by 5-hydroxytryptamine at 1 uM; nd = not determined",H,,,51,8,,CHEMBL616003,BAO_0000019,
656,Expert,9606.0,,1,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor,D,,,51,9,,CHEMBL616004,BAO_0000019,
657,Expert,9606.0,,1,,,In vitro agonist activity at the 5-hydroxytryptamine 1A receptor; No data,D,,,51,9,,CHEMBL616005,BAO_0000019,
658,Autocuration,,,1,,,"Maximal response as a result of 5-HT1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",H,,,51,8,,CHEMBL616006,BAO_0000019,
659,Expert,,,1,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding",H,,,51,8,,CHEMBL616007,BAO_0000019,
660,Autocuration,,,1,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",H,,,51,8,,CHEMBL616008,BAO_0000019,
661,Autocuration,,,1,,,"Maximal response as a result of 5-hydroxytryptamine 1A receptor-mediated stimulation of [35S]GTP-gamma-S, binding; Not determined",H,,,51,8,,CHEMBL616009,BAO_0000019,
662,Expert,,,1,,,"Maximal stimulation of expressed human 5-hydroxytryptamine 1A receptor assayed by [35S]GTP-gamma-S, binding",H,,,51,8,,CHEMBL616010,BAO_0000019,
663,Expert,9606.0,,1,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND means not determined",D,,,51,9,,CHEMBL616011,BAO_0000019,
664,Expert,9606.0,,1,,,"Maximal response towards 5-hydroxytryptamine 1A receptor in human using [35S]GTP-gamma-S, as radioligand; ND=Not determined",D,,,51,9,,CHEMBL615740,BAO_0000019,
665,Autocuration,,,1,,,"Maximal stimulation was expressed as percentage of the maximal 5-HT response in the [35S]GTP-gamma-S, binding assay on 5-hydroxytryptamine 1A receptor",H,,,51,8,,CHEMBL615741,BAO_0000019,
666,Expert,,,1,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",H,,,51,8,,CHEMBL615742,BAO_0000019,
667,Autocuration,,,1,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Emin (%): not determined",H,,,51,8,,CHEMBL615743,BAO_0000019,
668,Autocuration,,,1,,,Antagonist activity was measured against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay,H,,449.0,51,8,,CHEMBL615744,BAO_0000219,
669,Expert,,,1,,,Antagonist activity against CHO cells expressing the human 5-hydroxytryptamine 1A receptor in a forskolin stimulated adenylate cyclase (FSC) assay.,H,,449.0,51,8,,CHEMBL615745,BAO_0000219,
670,Autocuration,,,1,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,H,,,51,8,,CHEMBL615746,BAO_0000357,
671,Autocuration,,,1,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,H,,,51,8,,CHEMBL615747,BAO_0000357,
672,Autocuration,,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,,,51,8,,CHEMBL615748,BAO_0000019,
673,Autocuration,,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay; NA indicates not available",H,,,51,8,,CHEMBL615749,BAO_0000019,
674,Autocuration,,,1,,,Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by forskolin stimulated cAMP assay,H,,,51,8,,CHEMBL615750,BAO_0000019,
675,Expert,9606.0,,1,,,Forskolin stimulated cAMP assessment of agonist activity for 5-hydroxytryptamine 1A receptor,D,,,51,9,,CHEMBL616259,BAO_0000019,
676,Autocuration,,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,,,51,8,,CHEMBL616260,BAO_0000019,
677,Expert,9606.0,,1,,,Antagonism of 5-hydroxytryptamine 1A receptor determined in vitro,D,,,51,9,,CHEMBL616261,BAO_0000019,
678,Expert,9606.0,,1,,,"Antagonism of 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",D,,,51,9,,CHEMBL616262,BAO_0000019,
679,Expert,9606.0,,1,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",D,,,51,9,,CHEMBL616263,BAO_0000019,
680,Expert,9606.0,,1,,,Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro; No data,D,,,51,9,,CHEMBL616264,BAO_0000019,
681,Expert,9606.0,,1,,,Antagonism at the 5-hydroxytryptamine 1A receptor in vitro,D,,,51,9,,CHEMBL616265,BAO_0000019,
682,Expert,9606.0,,1,,,"Antagonism at the 5-hydroxytryptamine 1A receptor was determined in vitro using a [35S]GTP-gamma-S,",D,,,51,9,,CHEMBL616266,BAO_0000019,
683,Expert,9606.0,,1,,,"Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro using a [35S]GTP-gamma-S, No data",D,,,51,9,,CHEMBL616267,BAO_0000019,
684,Expert,9606.0,,1,,,Antagonism at the 5-hydroxytryptamine 1A receptor determined in vitro; No data,D,,,51,9,,CHEMBL616268,BAO_0000019,
685,Expert,9606.0,,1,,,Inhibition of human 5-hydroxytryptamine 1A receptor,D,,,51,9,,CHEMBL616269,BAO_0000357,
686,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,,449.0,51,8,,CHEMBL884528,BAO_0000219,
687,Expert,,,1,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor alpha expressed in HEK 293 cells,D,,722.0,105,9,,CHEMBL616270,BAO_0000219,
688,Autocuration,,,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1A receptor stably expressed in CHO cells,H,,449.0,51,8,,CHEMBL616271,BAO_0000219,
689,Autocuration,,,1,,,Effective concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,H,,449.0,51,8,,CHEMBL616272,BAO_0000219,
690,Expert,,,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in human CYP3A4 assay,H,,,51,8,,CHEMBL616273,BAO_0000357,
691,Expert,9606.0,,1,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,D,,,51,9,,CHEMBL616274,BAO_0000357,
692,Autocuration,,,1,,,Inhibition concentration against 5-HT 1A receptor using cAMP as radioligand in CHO cells,H,,449.0,51,8,,CHEMBL616275,BAO_0000219,
693,Autocuration,,,1,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,,449.0,51,8,,CHEMBL616276,BAO_0000219,
694,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,U,,,22226,0,,CHEMBL616277,BAO_0000218,
695,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration; Inactive,U,,,22226,0,,CHEMBL616278,BAO_0000218,
696,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration,U,,,22226,0,,CHEMBL616279,BAO_0000218,
697,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,U,,,22226,0,,CHEMBL616280,BAO_0000218,
698,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Partial response at the highest dose tested,U,,,22226,0,,CHEMBL616281,BAO_0000218,
699,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by sc administration; Inactive,U,,,22226,0,,CHEMBL616282,BAO_0000218,
700,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration,U,,,22226,0,,CHEMBL616283,BAO_0000218,
701,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by po administration; Inactive,U,,,22226,0,,CHEMBL616284,BAO_0000218,
702,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration,U,,,22226,0,,CHEMBL616285,BAO_0000218,
703,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; Inactive,U,,,22226,0,,CHEMBL616286,BAO_0000218,
704,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain limbic area by sc administration; partial response at the highest dose tested,U,,,22226,0,,CHEMBL616287,BAO_0000218,
705,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration,U,,,22226,0,,CHEMBL616288,BAO_0000218,
706,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Inactive,U,,,22226,0,,CHEMBL616289,BAO_0000218,
707,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by po administration; Partial response at the highest dose tested,U,,,22226,0,,CHEMBL615610,BAO_0000218,
708,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration,U,,,22226,0,,CHEMBL615611,BAO_0000218,
709,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Inactive,U,,,22226,0,,CHEMBL615612,BAO_0000218,
710,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; Partial response at the highest dose tested,U,,,22226,0,,CHEMBL615613,BAO_0000218,
711,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain striatal area by sc administration; partial response at the highest dose tested,U,,,22226,0,,CHEMBL615614,BAO_0000218,
712,Autocuration,10116.0,In vivo,1,,,Effective dose for half-maximal decrease in the accumulation of 5-hydroxytryptophan (5-HTP) in reserpinized rat brain hemispheral area by po administration,U,,,22226,0,,CHEMBL615615,BAO_0000218,
713,Autocuration,,,1,,,Affinity in displacing [125I](R)-DOI from rat cortical homogenate 5-HT2 receptor.,H,,,105093,4,,CHEMBL615616,BAO_0000019,
714,Autocuration,,,1,1898.0,,Binding affinity towards 5-HT 7 receptor in rat hypothalamus membranes using [3H]5-CT as radioligand,H,,,11923,8,,CHEMBL615617,BAO_0000249,
715,Autocuration,,,1,,,Inhibitory activity against 5-HT1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data,H,,,10577,8,,CHEMBL615618,BAO_0000019,
716,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand; nd is No Data.,H,,,10577,8,,CHEMBL615619,BAO_0000019,
717,Expert,,,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,H,,,10577,8,,CHEMBL615620,BAO_0000019,
718,Autocuration,,,1,,,"Inhibitory activity against human whole blood, LTB4 5-lipoxygenase was evaluated",H,,,55,8,,CHEMBL615621,BAO_0000357,
719,Autocuration,,,1,,,"Inhibitory activity against intact human PMNL, LTB4 5-lipoxygenase was evaluated",H,,,55,8,,CHEMBL615622,BAO_0000357,
720,Autocuration,,,1,,,Compound was evaluated for the inhibition of 5-LO (lipoxygenase),H,,,12166,8,,CHEMBL615623,BAO_0000019,
721,Autocuration,,,1,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,H,,,12166,8,,CHEMBL615624,BAO_0000019,
722,Autocuration,,,1,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,H,,,12166,8,,CHEMBL615625,BAO_0000019,
723,Autocuration,,,1,,,Compound was evaluated for the inhibition of 5-LO (5-lipoxygenase).,H,,,12166,8,,CHEMBL767045,BAO_0000019,
724,Autocuration,10141.0,,1,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN,H,,,55,8,,CHEMBL615626,BAO_0000019,
725,Autocuration,10141.0,,1,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-LO isolated from guinea pig PMN; not active at the highest concentration (3 ug/mL) tested; No activity,H,,,55,8,,CHEMBL615627,BAO_0000019,
726,Autocuration,10141.0,,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in guinea pig polymorphonuclear leukocytes,H,,,55,8,,CHEMBL615628,BAO_0000019,
727,Autocuration,10141.0,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,H,,,55,8,,CHEMBL615629,BAO_0000357,
728,Expert,9606.0,,1,,,Inhibitory concentration against 5-lipoxygenase from human whole blood,D,,,55,9,,CHEMBL615630,BAO_0000357,
729,Autocuration,,,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in human polymorphonuclear leukocytes[PMNS],H,,,55,8,,CHEMBL615631,BAO_0000219,
730,Autocuration,,,1,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,H,,,17087,8,,CHEMBL615632,BAO_0000218,
731,Autocuration,,,1,,,Inhibitory concentration against 5-lipoxygenase from mouse macrophage,H,,,17087,8,,CHEMBL615633,BAO_0000357,
732,Autocuration,,,1,,,In vivo inhibition of 5-lipoxygenase (LTC4) in the mouse zymosan peritonitis assay at an oral dose of 30 mg/Kg,H,,,17087,8,,CHEMBL615634,BAO_0000218,
733,Expert,9823.0,,1,,,Inhibition of arachidonate 5-lipoxygenase purified from porcine leukocytes.,H,,,55,8,,CHEMBL615635,BAO_0000019,
734,Expert,,,1,,,In vitro inhibition of rat 5-Lipoxygenase,H,,,12166,8,,CHEMBL615636,BAO_0000357,
735,Expert,10116.0,,1,,,Inhibitory activity against 5-Lipoxygenase,D,,,12166,9,,CHEMBL615637,BAO_0000357,
736,Expert,,,1,,,Inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells,H,,702.0,12166,8,,CHEMBL615638,BAO_0000219,
737,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),H,,702.0,12166,8,,CHEMBL615639,BAO_0000219,
738,Autocuration,,,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat RBL-1,H,,702.0,12166,8,,CHEMBL615640,BAO_0000219,
739,Autocuration,,,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat blood,H,,,12166,8,,CHEMBL615796,BAO_0000019,
740,Autocuration,,,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase receptor in rat polymorphonuclear leukocytes[PMNS],H,,,12166,8,,CHEMBL615845,BAO_0000219,
741,Autocuration,,,1,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,H,,,12166,8,,CHEMBL615846,BAO_0000357,
742,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,H,,702.0,12166,8,,CHEMBL615847,BAO_0000219,
743,Autocuration,,,1,,,The compound was tested for inhibition of isolated 5-Lipoxygenase,H,,,12166,8,,CHEMBL615848,BAO_0000357,
744,Autocuration,10116.0,,1,,,Ratio of IC50 against 5-LO and COX,U,,,22226,0,,CHEMBL615849,BAO_0000019,
745,Autocuration,,,1,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM,H,,,12166,8,,CHEMBL615850,BAO_0000357,
746,Autocuration,,,1,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) in vitro at 1 uM; range is 20-35%,H,,,12166,8,,CHEMBL615851,BAO_0000357,
747,Autocuration,,,1,,,The compound was tested for inhibition against 5-Lipoxygenase in rat polymorphonuclear leukocytes at 10 uM concentration,H,,,12166,8,,CHEMBL615852,BAO_0000219,
748,Autocuration,,,1,,,Compound was evaluated for the inhibition of 5-Lipoxygenase (5-LO) ex vivo,H,,,12166,8,,CHEMBL615853,BAO_0000019,
749,Autocuration,,,1,2367.0,,Compound was tested for the inhibition of type 2 5-alpha-reductase of human prostates,H,,,120,8,,CHEMBL884527,BAO_0000357,
750,Autocuration,8932.0,,1,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-4 M inhibitory concentration,U,,,22226,0,,CHEMBL872871,BAO_0000019,
751,Autocuration,8932.0,,1,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme at 10E-5 M inhibitory concentration,U,,,22226,0,,CHEMBL615854,BAO_0000019,
752,Autocuration,8932.0,,1,,,Percent inhibition was measured against 5-amino-4-imidazolecarboxamide ribotide transformylase(pigeon liver) enzyme.,U,,,22226,0,,CHEMBL767046,BAO_0000019,
753,Autocuration,,,1,,,Compound was evaluated for the inhibition of 5-aminoimidazole-4-carboxamide ribonucleotide transformylase obtained from human at 100 uM,H,,,10732,8,,CHEMBL615855,BAO_0000357,
754,Expert,10116.0,,1,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT); NT = Not Tested,D,,,12198,9,,CHEMBL615856,BAO_0000019,
755,Expert,10116.0,,1,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),D,,,12198,9,,CHEMBL615857,BAO_0000019,
756,Expert,10116.0,,1,,,Effect on synaptosomal uptake inhibition of 5-hydroxytryptamine (5-HT),D,,,12198,9,,CHEMBL615858,BAO_0000019,
757,Expert,,,1,10000000.0,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,H,,,10576,8,,CHEMBL615859,BAO_0000221,
758,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1 receptor,H,,,51,8,,CHEMBL615860,BAO_0000357,
759,Autocuration,9986.0,,1,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,U,,,22226,0,,CHEMBL615861,BAO_0000019,
760,Autocuration,9986.0,,1,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,U,,,22226,0,,CHEMBL615862,BAO_0000019,
761,Autocuration,9986.0,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor using rabbit saphenous vein assay.,U,,,22226,0,,CHEMBL615863,BAO_0000019,
762,Autocuration,9986.0,,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,U,,,22226,0,,CHEMBL615864,BAO_0000019,
763,Autocuration,,,1,10000000.0,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,H,,,104744,4,,CHEMBL615865,BAO_0000221,
764,Autocuration,,,1,10000000.0,,Ability to bind at 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,H,,,104744,4,,CHEMBL615866,BAO_0000221,
765,Autocuration,,,1,10000000.0,,Ability to bind at serotonin 5-hydroxytryptamine 1 receptor of rat hippocampus by displacing [3H]5-HT,H,,,104744,4,,CHEMBL615867,BAO_0000221,
766,Autocuration,,,1,,,Ability to inhibit binding of titreated serotonin to the 5-hydroxytryptamine 1 receptor in rat brain frontal cortex membranes,H,Membranes,,104744,4,,CHEMBL615868,BAO_0000249,
767,Autocuration,10116.0,,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in brain cortical membranes of rat,D,,,104744,5,,CHEMBL615869,BAO_0000249,
768,Autocuration,10116.0,,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor in rat frontal cortex homogenates using [3H]5-HT as a radioligand,D,,,104744,5,,CHEMBL615870,BAO_0000019,
769,Autocuration,10116.0,,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT as a radioligand from rat frontal cortex homogenates,D,,,104744,5,,CHEMBL615871,BAO_0000019,
770,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was measured using radioligand ([3H]5-HT) binding assay,H,,,104744,4,,CHEMBL615872,BAO_0000224,
771,Autocuration,,,1,10000000.0,,Binding affinity towards hippocampus 5-hydroxytryptamine 1 receptor was measured using radioligand [3H]5-HT,H,,,104744,4,,CHEMBL833492,BAO_0000221,
772,Autocuration,,,1,10000000.0,,Compound was evaluated for the inhibition of [3H]5-HT (concentration of 12 nM) specific binding to rat hippocampus,H,,,104744,4,,CHEMBL615873,BAO_0000221,
773,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 1 receptor by 3H ligand binding experiments.,H,,,104744,4,,CHEMBL615479,BAO_0000224,
774,Autocuration,,,1,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat,H,,,104744,4,,CHEMBL615480,BAO_0000019,
775,Autocuration,10116.0,,1,,,Tested for its binding affinity towards 5-hydroxytryptamine 1 receptor in rat cortical membrane homogenates using radioligand ([3H]5-HT) binding assay.,D,,,104744,5,,CHEMBL615481,BAO_0000249,
776,Autocuration,,,1,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,,,104744,4,,CHEMBL872869,BAO_0000019,
777,Autocuration,,,1,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,,,104744,4,,CHEMBL615482,BAO_0000019,
778,Autocuration,,,1,955.0,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,H,,,104744,4,,CHEMBL615483,BAO_0000221,
779,Autocuration,,,1,955.0,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,H,,,104744,4,,CHEMBL615484,BAO_0000221,
780,Autocuration,,,1,,,Percent inhibition of 5-hydroxytryptamine 1 receptor from rat cortex membrane using [3H]- serotonin as radioligand at 33 uM,H,,,104744,4,,CHEMBL615485,BAO_0000019,
781,Autocuration,10116.0,,1,,,Inhibition of [3H]5-HT radioligand binding against 5-hydroxytryptamine 1 receptor,D,,,104744,5,,CHEMBL615486,BAO_0000224,
782,Autocuration,,,1,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 1 receptor,H,,,104744,4,,CHEMBL615487,BAO_0000224,
783,Autocuration,,,1,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,H,,,104744,4,,CHEMBL615488,BAO_0000224,
784,Autocuration,,,1,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,H,,,104744,4,,CHEMBL615489,BAO_0000224,
785,Autocuration,,,1,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor,H,,,104744,4,,CHEMBL615389,BAO_0000224,
786,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,H,,,104744,4,,CHEMBL615390,BAO_0000019,
787,Autocuration,,,1,,,Binding affinity towards central 5-hydroxytryptamine 1 receptor was determined in rat cerebral cortex using [3H]5-HT as radioligand,H,,,104744,4,,CHEMBL615391,BAO_0000019,
788,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1 receptor was determined,H,,,104744,4,,CHEMBL615392,BAO_0000224,
789,Autocuration,10116.0,,1,,,Affinity for 5-hydroxytryptamine 1 receptor,U,,,22226,0,,CHEMBL615393,BAO_0000019,
790,Autocuration,,,1,955.0,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex,H,,,104744,4,,CHEMBL615394,BAO_0000221,
791,Autocuration,,,1,955.0,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1 receptor using [3H]5-HT in rat brain cortex at 10 uM,H,,,104744,4,,CHEMBL615395,BAO_0000221,
792,Autocuration,,,1,,,Compound was evaluated for 5-hydroxytryptamine 1 receptor binding,H,,,104744,4,,CHEMBL615396,BAO_0000224,
793,Autocuration,,,1,955.0,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 1 receptor in rat brain using [3H]HT radioligand assay,H,,,104744,4,,CHEMBL615397,BAO_0000221,
794,Autocuration,,,1,,,Displacement of binding of [3H]5-HT to 5-hydroxytryptamine 1 receptor in rat cerebral cortex,H,,,104744,4,,CHEMBL615398,BAO_0000019,
795,Autocuration,10116.0,,1,,,Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex,U,,,22226,0,,CHEMBL615399,BAO_0000019,
796,Autocuration,,,1,,,Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.,H,,,104744,4,,CHEMBL615400,BAO_0000019,
797,Autocuration,10116.0,,1,,,Binding affinity for 5-hydroxytryptamine 1 receptor of rat prefrontal cortex,D,,,104744,5,,CHEMBL615401,BAO_0000019,
798,Autocuration,10116.0,,1,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 1 receptor of rat cortical membrane homogenates,U,,,22226,0,,CHEMBL615402,BAO_0000019,
799,Autocuration,,,1,,,The ability to inhibit [3H]5-HT binding to 5-hydroxytryptamine 1 receptor in rat cortex,H,,,104744,4,,CHEMBL615403,BAO_0000019,
800,Autocuration,,,1,955.0,,The binding affinity was measured on serotonin 5-hydroxytryptamine 1 receptor in rat brain tissue,H,,,104744,4,,CHEMBL615404,BAO_0000221,
801,Autocuration,,,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1 receptor by displacing [3H]5-HT radioligand in rat cerebral cortex,H,,,104744,4,,CHEMBL615781,BAO_0000019,
802,Autocuration,,,1,955.0,,Tested for 5-hydroxytryptamine 1 receptor binding ability by displacement of [3H]5-HT from rat brain synaptosomes,H,,,104744,4,,CHEMBL615782,BAO_0000220,
803,Autocuration,,,1,955.0,,Inhibition constant (1 uM) was measured on 5-hydroxytryptamine 1 receptor/uptake using [3H]- serotonin as radioligand in rat brain cortex.,H,,,104744,4,,CHEMBL615783,BAO_0000221,
804,Autocuration,,,1,,,Compound was tested for binding affinity against 5-HT1 receptor,U,,,22226,0,,CHEMBL873481,BAO_0000019,
805,Autocuration,,,1,,,Inhibitory concentration against 5-hydroxytryptamine 1 receptor,U,,,22226,0,,CHEMBL615784,BAO_0000019,
806,Expert,,,1,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,H,,,10576,8,,CHEMBL615785,BAO_0000357,
807,Autocuration,,,1,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",H,,,10576,8,,CHEMBL615786,BAO_0000249,
808,Autocuration,,In vivo,1,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,H,,,10576,8,,CHEMBL615787,BAO_0000218,
809,Autocuration,,In vivo,1,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,H,,,10576,8,,CHEMBL615788,BAO_0000218,
810,Autocuration,,,1,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL767044,BAO_0000019,
811,Autocuration,,In vivo,1,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while iv administration,H,,,10576,8,,CHEMBL615789,BAO_0000218,
812,Autocuration,,In vivo,1,,,Agonistic activity (induction of forepaw treading in rats)on postsynaptic 5-hydroxytryptamine 1A receptor while subcutaneous administration,H,,,10576,8,,CHEMBL615790,BAO_0000218,
813,Autocuration,,,1,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats,H,,,10576,8,,CHEMBL615813,BAO_0000019,
814,Autocuration,,,1,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 10 uM concentration,H,,,10576,8,,CHEMBL615814,BAO_0000219,
815,Expert,,,1,,,Percent inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation in GH4ZD10 cells expressing 5-HT1A receptor at 50 uM relative to 5-HT,H,,,51,8,,CHEMBL615815,BAO_0000219,
816,Autocuration,,,1,,,Percent of maximum response by 5-HT when tested for inhibition of vasoactive intestinal polypeptide-induced (VIP-induced) cAMP formation assessed in GH4ZD10 cells at 50 uM concentration; No effect,H,,,10576,8,,CHEMBL615816,BAO_0000219,
817,Expert,,,1,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes expressed as Hill values,H,,,10576,8,,CHEMBL615817,BAO_0000249,
818,Autocuration,,,1,10000000.0,,Ability to bind at 5-hydroxytryptamine 1A receptor of rat hippocampus by displacing [3H]8-OH-DPAT,H,,,10576,8,,CHEMBL615818,BAO_0000221,
819,Autocuration,,,1,10000000.0,,Ability to bind at serotonin 5-hydroxytryptamine 1A receptors of rat hippocampus by displacing [3H]8-OH-DPAT,H,,,10576,8,,CHEMBL615819,BAO_0000221,
820,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor (5-HT1A) by displacement of [3H]8-OH-DPAT from rat hippocampus membranes,H,Membranes,,10576,8,,CHEMBL615820,BAO_0000249,
821,Expert,10116.0,,1,10000000.0,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]8-OH-DPAT,D,,,10576,9,,CHEMBL615821,BAO_0000221,
822,Expert,10116.0,,1,10000000.0,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,D,,,10576,9,,CHEMBL615822,BAO_0000221,
823,Expert,,,1,10000000.0,,Binding affinity against 5-hydroxytryptamine 1A receptor using in rat hippocampal tissue using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL615823,BAO_0000221,
824,Expert,10116.0,,1,10000000.0,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor; IA-Inactive,D,,,10576,9,,CHEMBL615824,BAO_0000221,
825,Expert,10116.0,,1,10000000.0,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue with [3H]5-HT,D,,,10576,9,,CHEMBL615825,BAO_0000221,
826,Expert,,,1,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor was evaluated using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL615826,BAO_0000357,
827,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL615827,BAO_0000249,
828,Expert,,,1,10000000.0,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus membrane using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL615828,BAO_0000249,
829,Expert,,,1,10000000.0,,Binding affinity by measuring displacement of [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,,10576,8,,CHEMBL615829,BAO_0000221,
830,Autocuration,,,1,10000000.0,,Binding affinity to 5-hydroxytryptamine 1A receptor of rat hippocampus with [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL615830,BAO_0000221,
831,Expert,,,1,10000000.0,,Binding affinity towards serotonin 5-HT1A receptor was determined in rat hippocampus using [3H]8-OH-DPAT as ligand,H,,,10576,8,,CHEMBL615831,BAO_0000221,
832,Autocuration,,,1,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL615832,BAO_0000357,
833,Autocuration,,,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH- DPAT as radioligand,H,,,10576,8,,CHEMBL615833,BAO_0000019,
834,Autocuration,,,1,10000000.0,,Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]-8-OH- DPAT as radioligand,H,,,10576,8,,CHEMBL615834,BAO_0000221,
835,Intermediate,,,1,,,Binding affinity against 5-hydroxytryptamine 1A (5-HT1A) receptor in rat hippocampus membranes,H,,,10576,8,,CHEMBL615835,BAO_0000249,
836,Autocuration,,,1,10000000.0,,Binding affinity was measured at the serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampal membrane.,H,,,10576,8,,CHEMBL615836,BAO_0000249,
837,Expert,10116.0,,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand.,D,,,10576,9,,CHEMBL615837,BAO_0000019,
838,Expert,10116.0,,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor in the rat brain using [3H]8-hydroxy-2-(di-n-propylamine)tetralin as radioligand; ND-Not determined,D,,,10576,9,,CHEMBL615838,BAO_0000019,
839,Expert,,,1,,,"Binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding (NSB)",H,,,10576,8,,CHEMBL615839,BAO_0000249,
840,Autocuration,,,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]-8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL884525,BAO_0000019,
841,Autocuration,,,1,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonin 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,H,,,10576,8,,CHEMBL615840,BAO_0000249,
842,Expert,,,1,10000000.0,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,,10576,8,,CHEMBL615405,BAO_0000221,
843,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,H,,,10576,8,,CHEMBL615406,BAO_0000019,
844,Expert,,,1,10000000.0,,Affinity for 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,H,,,10576,8,,CHEMBL615900,BAO_0000221,
845,Expert,,,1,10000000.0,,Inhibition of [3H]8-OH-DPAT binding at serotonin 5-hydroxytryptamine 1A receptor from rat hippocampus tissue.,H,,,10576,8,,CHEMBL615901,BAO_0000221,
846,Expert,,,1,,,In vitro inhibition of [3H]8-OH-DPAT binding to rat 5-HT 1a receptors.,H,,,10576,8,,CHEMBL615902,BAO_0000357,
847,Autocuration,,,1,10000000.0,,Compound was measured for affinity at 5-hydroxytryptamine 1A receptor labeled with [3H]8-OH-DPAT radioligand in hippocampus tissue,H,,,10576,8,,CHEMBL615903,BAO_0000221,
848,Autocuration,,,1,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor<br>at 1 uM,H,,,10576,8,,CHEMBL615904,BAO_0000357,
849,Expert,,,1,,,Concentration necessary to achieve half maximal inhibition of [3H]8-Hydroxy-2-(di-n-propylamino)tetralin binding to 5-hydroxytryptamine 1A receptor at 1 uM,H,,,10576,8,,CHEMBL615905,BAO_0000357,
850,Autocuration,,,1,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,H,,,10576,8,,CHEMBL615906,BAO_0000019,
851,Autocuration,,,1,,,In vitro Inhibitory activity tested at 5-hydroxytryptamine 1A receptor binding site in rat,H,,,10576,8,,CHEMBL615907,BAO_0000019,
852,Expert,,,1,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,H,,,10576,8,,CHEMBL615908,BAO_0000019,
853,Autocuration,,,1,10000000.0,,In vitro affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT in rat hippocampus,H,,,10576,8,,CHEMBL615909,BAO_0000221,
854,Autocuration,,,1,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]-8-OH-DPAT as the radioligand",H,,,10576,8,,CHEMBL615910,BAO_0000019,
855,Autocuration,,,1,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand.",H,,,10576,8,,CHEMBL615911,BAO_0000019,
856,Autocuration,,,1,,,"In vitro binding activity against 5-hydroxytryptamine 1A receptor from homogenized rat brain, using [3H]8-OH-DPAT as the radioligand",H,,,10576,8,,CHEMBL615912,BAO_0000019,
857,Expert,,,1,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 1A receptor fof rat cerebral cortex using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL615913,BAO_0000019,
858,Expert,,,1,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,H,,,10576,8,,CHEMBL615914,BAO_0000357,
859,Autocuration,,,1,10000000.0,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,H,,,10576,8,,CHEMBL615915,BAO_0000221,
860,Autocuration,,,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 1A receptor was evaluated,H,,,10576,8,,CHEMBL615916,BAO_0000357,
861,Expert,,,1,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 1A receptor by displacement of [3H]- tetralin,H,,,10576,8,,CHEMBL615917,BAO_0000357,
862,Expert,,,1,,,In vitro inhibitory activity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL615918,BAO_0000357,
863,Expert,,,1,10000000.0,,In vitro inhibitory concentration against radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane.,H,,,10576,8,,CHEMBL615919,BAO_0000249,
864,Expert,10116.0,,1,10000000.0,,In vitro radioligand binding assay on 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,D,,,10576,9,,CHEMBL615920,BAO_0000221,
865,Autocuration,,,1,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL615921,BAO_0000357,
866,Expert,,,1,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor (Inactive at >1000 nM concentration),H,,,10576,8,,CHEMBL615922,BAO_0000357,
867,Expert,10116.0,,1,,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",D,,,10576,9,,CHEMBL881290,BAO_0000249,
868,Autocuration,,,1,10000000.0,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Residual radioligand binding higher than 50%",H,,,10576,8,,CHEMBL615923,BAO_0000221,
869,Autocuration,,,1,10000000.0,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,,10576,8,,CHEMBL615924,BAO_0000221,
870,Autocuration,,,1,10000000.0,,Inhibition of forskolin-activated adenylate cyclase (cAMP) activity at 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,,10576,8,,CHEMBL615925,BAO_0000221,
871,Expert,10116.0,,1,,,Inhibition of radiolabeled [3H]-8-OH-DPAT ligand binding to 5-hydroxytryptamine 1A receptor,D,,,10576,9,,CHEMBL615926,BAO_0000357,
872,Expert,10116.0,,1,,,Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor,D,,,10576,9,,CHEMBL615927,BAO_0000019,
873,Autocuration,,,1,10000000.0,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,,,10576,8,,CHEMBL615928,BAO_0000221,
874,Expert,10116.0,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor subtype,D,,,10576,9,,CHEMBL615929,BAO_0000357,
875,Autocuration,,,1,10000000.0,,Inhibitory activity against [3H]DPAT binding to 5-HT1A receptor in rat hippocampus,H,,,10576,8,,CHEMBL615930,BAO_0000221,
876,Autocuration,,,1,,,Inhibition concentration against 5-hydroxytryptamine 1A receptor using cAMP as radioligand in CHO cells,H,,449.0,51,8,,CHEMBL615931,BAO_0000219,
877,Autocuration,,,1,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,H,,449.0,51,8,,CHEMBL615932,BAO_0000219,
878,Autocuration,,,1,,,Inhibition concentration against binding of radioligand [35S]GTP-gamma-S in CHO cells expressing 5-hydroxytryptamine 1A receptor,H,,449.0,51,8,,CHEMBL615933,BAO_0000219,
879,Autocuration,,,1,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL615934,BAO_0000357,
880,Autocuration,,,1,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT; Not tested,H,,,51,8,,CHEMBL615935,BAO_0000357,
881,Autocuration,,,1,,,"Agonistic activity of compound towards 5-hydroxytryptamine 1A receptor was evaluated by [35S]GTP-gamma-S, stimulated cAMP assay",H,,,51,8,,CHEMBL615936,BAO_0000019,
882,Autocuration,,,1,,,Ability to displace [3H]-8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor at a concentration of 1 uM,H,,449.0,51,8,,CHEMBL615937,BAO_0000219,
883,Autocuration,,,1,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL615938,BAO_0000357,
884,Autocuration,,,1,,,In vitro binding affinity against human 5-hydroxytryptamine 1A receptor at a concentration of 100 (nM),H,,,51,8,,CHEMBL615797,BAO_0000357,
885,Autocuration,,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL615798,BAO_0000357,
886,Autocuration,,,1,,,Inhibition of [3H]8-OH-DPAT binding to human 5-hydroxytryptamine 1A receptor at 1000 nM compound concentration,H,,,51,8,,CHEMBL872870,BAO_0000357,
887,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand at 100 nM concentration,H,,,51,8,,CHEMBL615799,BAO_0000357,
888,Autocuration,,,1,,,Percent binding affinity against 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL615800,BAO_0000357,
889,Autocuration,,,1,,,Intrinsic activity for human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,,722.0,51,8,,CHEMBL615801,BAO_0000219,
890,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the absence of endothelium,H,,,51,8,,CHEMBL615802,BAO_0000019,
891,Autocuration,,,1,,,Dissociation constant against human 5-hydroxytryptamine 1A receptor receptor,H,,,51,8,,CHEMBL615803,BAO_0000357,
892,Expert,,,1,,,"Inhibition of 5-HT induced [35S]GTP-gamma-S, binding at human cloned 5-HT 1A receptors.",H,,,51,8,,CHEMBL835002,BAO_0000019,
893,Autocuration,,,1,,,"5-hydroxytryptamine 1A receptor antagonism was evaluated by the ability to inhibit [35S]GTP-gamma-S, binding that was induced by 5-HT; Ki (nM): not determined",H,,,51,8,,CHEMBL615804,BAO_0000019,
894,Expert,,,1,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor,H,,308.0,51,8,,CHEMBL615805,BAO_0000219,
895,Autocuration,,,1,,,Ability to displace [3H]8-OH-DPAT from CHO cells stably transfected with human 5-hydroxytryptamine 1A receptor,H,,449.0,51,8,,CHEMBL615806,BAO_0000219,
896,Expert,9606.0,,1,,,Affinity towards human 5-hydroxytryptamine 1A serotonin receptor,D,,,51,9,,CHEMBL615807,BAO_0000357,
897,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT-as radioligand,H,,,51,8,,CHEMBL615808,BAO_0000357,
898,Expert,9606.0,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,D,,,51,9,,CHEMBL615809,BAO_0000357,
899,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor in HeLa cells was determined using [3H]5-HT,H,,308.0,51,8,,CHEMBL615810,BAO_0000219,
900,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL615811,BAO_0000357,
901,Autocuration,,,1,,,Binding affinity against [3H]- -8-OH-DPAT -labeled 5-hydroxytryptamine 1A sites in cloned CHO cells,H,,449.0,51,8,,CHEMBL615812,BAO_0000219,
902,Autocuration,,,1,,,Binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,,449.0,51,8,,CHEMBL615751,BAO_0000219,
903,Autocuration,,,1,,,Binding affinity against human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL615752,BAO_0000357,
904,Expert,,,1,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand,H,,449.0,51,8,,CHEMBL615753,BAO_0000219,
905,Autocuration,,,1,,,Binding affinity against human 5-hydroxytryptamine 1A receptor in CHO cells labeled with [3H]8-OH-DPAT radioligand; nd=not determined,H,,449.0,51,8,,CHEMBL615754,BAO_0000219,
906,Autocuration,,,1,,,Binding affinity of compound to human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL615755,BAO_0000357,
907,Expert,9606.0,,1,,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,D,,449.0,51,9,,CHEMBL615756,BAO_0000219,
908,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor in HeLa transfected cell type using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL615757,BAO_0000019,
909,Autocuration,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,H,,,51,8,,CHEMBL615758,BAO_0000357,
910,Expert,,,1,,,In vitro affinity at human cloned 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,H,,,51,8,,CHEMBL615759,BAO_0000357,
911,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL615760,BAO_0000357,
912,Expert,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor by the displacement of [3H]5-HT radioligand from the cloned receptor expressed in HeLa cells,H,,308.0,51,8,,CHEMBL615761,BAO_0000219,
913,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1A receptor was determined using [3H]-5-HT as radioligand,H,,,51,8,,CHEMBL872104,BAO_0000357,
914,Autocuration,,,1,,,Binding affinity towards recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL615762,BAO_0000357,
915,Autocuration,,,1,,,Binding affinity towards recombinant human Compound at 1 uM was tested for the inhibition of radioligand [3H]8-OH-DPAT binding to recombinant human 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL615763,BAO_0000357,
916,Autocuration,,,1,,,Binding affinity for recombinant human 5-hydroxytryptamine 1A receptor using [3H]5-HT as radioligand.,H,,,51,8,,CHEMBL615764,BAO_0000357,
917,Autocuration,,,1,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines (He La),H,,1167.0,51,8,,CHEMBL615765,BAO_0000219,
918,Autocuration,,,1,,,Binding affinity on human cloned 5-hydroxytryptamine 1A receptor transfected in human cell lines(He La),H,,,51,8,,CHEMBL615766,BAO_0000019,
919,Autocuration,,,1,,,Binding affinity towards 5-HT1A receptor using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL615767,BAO_0000357,
920,Expert,,,1,,,Binding affinity was determined towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL615768,BAO_0000357,
921,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL615769,BAO_0000357,
922,Expert,,,1,,,Binding affinity was evaluated at 5-hydroxytryptamine 1A receptor labeled with [3H]-8-OH-DPAT,H,,,51,8,,CHEMBL615770,BAO_0000357,
923,Autocuration,,,1,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL615771,BAO_0000357,
924,Expert,,,1,,,Binding affinity to human 5-hydroxytryptamine 1A receptor was measured using [3H]-8-hydroxy-2-(di-n-propylamine) tetraline [3H]8-OH-DPAT) as radioligand,H,,,51,8,,CHEMBL615772,BAO_0000357,
925,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL615773,BAO_0000357,
926,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL615774,BAO_0000357,
927,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL615775,BAO_0000357,
928,Autocuration,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1A receptor was determined,H,,,51,8,,CHEMBL615776,BAO_0000357,
929,Expert,,,1,,,Binding affinity towards human cloned 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL615777,BAO_0000357,
930,Autocuration,,,1,,,Binding affinity was measured on 5-hydroxytryptamine 1A receptor in AK cells transfected with human 5-HT1A gene labeled with [3H]-8-OH-DPAT,H,,,51,8,,CHEMBL615778,BAO_0000219,
931,Expert,9606.0,,1,,,Binding affinity was measured on cloned Human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,D,,,51,9,,CHEMBL615779,BAO_0000357,
932,Autocuration,,,1,,,Binding affinity was measured on cloned human 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,H,,,51,8,,CHEMBL615780,BAO_0000357,
933,Autocuration,,,1,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616298,BAO_0000357,
934,Autocuration,,,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616299,BAO_0000357,
935,Autocuration,,,1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells.,H,,485.0,51,8,,CHEMBL616300,BAO_0000219,
936,Expert,,,1,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1A receptor in CHO-K1 cells,H,,485.0,51,8,,CHEMBL616301,BAO_0000219,
937,Autocuration,,,1,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616302,BAO_0000019,
938,Autocuration,,,1,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 1),H,,,51,8,,CHEMBL616117,BAO_0000019,
939,Autocuration,,,1,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor (Experiment 2),H,,,51,8,,CHEMBL616118,BAO_0000019,
940,Autocuration,,,1,,,In vitro inhibition of [3H]- 8-OH-DPAT binding to cloned cell line containing human 5-hydroxytryptamine 1A receptor by Panlabs assay,H,,,51,8,,CHEMBL616119,BAO_0000019,
941,Expert,9606.0,,1,,,Displacement of specific [3H]- 5-HT binding to cloned human 5-hydroxytryptamine 1A receptor stably expressed in HeLa cells,D,,308.0,51,9,,CHEMBL616120,BAO_0000219,
942,Autocuration,,,1,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616121,BAO_0000357,
943,Autocuration,,,1,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor receptor,H,,,51,8,,CHEMBL616122,BAO_0000357,
944,Autocuration,,,1,,,In vitro binding affinity tested on human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616123,BAO_0000357,
945,Expert,9606.0,,1,,,In vitro binding affinity to human 5-hydroxytryptamine 1A receptor,D,,,51,9,,CHEMBL616124,BAO_0000357,
946,Expert,,,1,,,In vitro binding affinity at 5-hydroxytryptamine 1A receptor by [3H]8-OH-DPAT displacement.,H,,,51,8,,CHEMBL616125,BAO_0000357,
947,Expert,10116.0,,1,,,In vitro binding affinity towards Human 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT,H,,,51,8,,CHEMBL616126,BAO_0000357,
948,Autocuration,,,1,,,In vitro binding affinity towards cloned human 5-hydroxytryptamine 1A receptor expressed in Chinese hamster ovary (CHO) cells using [3H]8-OH-DPAT as radioligand,H,,449.0,51,8,,CHEMBL616127,BAO_0000219,
949,Expert,,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616128,BAO_0000019,
950,Autocuration,,,1,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand,H,,,51,8,,CHEMBL616129,BAO_0000357,
951,Expert,,,1,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616130,BAO_0000357,
952,Autocuration,,,1,,,Inhibition of [3H]- OH-DPAT binding against 5-hydroxytryptamine 1A receptor from human recombinant,H,,,51,8,,CHEMBL616131,BAO_0000357,
953,Autocuration,,,1,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor serotonergic receptor in human HeLa cells,H,,308.0,51,8,,CHEMBL616132,BAO_0000219,
954,Expert,9606.0,,1,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1A receptor in HeLa cells,D,,308.0,51,9,,CHEMBL616133,BAO_0000219,
955,Autocuration,,,1,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL616134,BAO_0000357,
956,Autocuration,,,1,,,The binding affinity at the 5-hydroxytryptamine 1A receptor determined using [3H]5-CT,H,,,51,8,,CHEMBL616135,BAO_0000357,
957,Expert,9606.0,,1,,,Affinity for 5-hydroxytryptamine 1A receptor subtype,D,,,51,9,,CHEMBL616136,BAO_0000357,
958,Autocuration,,,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes,H,,,51,8,,CHEMBL616137,BAO_0000019,
959,Autocuration,,,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1A receptor from cloned Human membranes.,H,,,51,8,,CHEMBL872105,BAO_0000019,
960,Autocuration,,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor receptor,H,,,51,8,,CHEMBL616138,BAO_0000357,
961,Expert,9606.0,,1,,,Binding affinity for cloned human 5-hydroxytryptamine 1A receptor,D,,,51,9,,CHEMBL616139,BAO_0000357,
962,Autocuration,,,1,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor; Not active",H,,,51,8,,CHEMBL616140,BAO_0000019,
963,Expert,,,1,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1A receptor; ND means not determined,H,,,51,8,,CHEMBL616141,BAO_0000019,
964,Autocuration,,,1,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL616142,BAO_0000357,
965,Autocuration,,,1,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; ND means Not determined,H,,,51,8,,CHEMBL616143,BAO_0000357,
966,Autocuration,,,1,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,H,,308.0,51,8,,CHEMBL616144,BAO_0000219,
967,Autocuration,,,1,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT=not tested,H,,308.0,51,8,,CHEMBL616145,BAO_0000219,
968,Autocuration,,,1,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,H,,308.0,51,8,,CHEMBL616012,BAO_0000219,
969,Autocuration,,,1,,,Ability to displace [3H]5-CT (2.0 nM) from HeLa cells of human 5-hydroxytryptamine 1A receptor; NT denotes not tested,H,,308.0,51,8,,CHEMBL616013,BAO_0000219,
970,Autocuration,,,1,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",H,,,51,8,,CHEMBL616014,BAO_0000019,
971,Autocuration,,,1,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",H,,,51,8,,CHEMBL616015,BAO_0000019,
972,Autocuration,,,1,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT.; NT is not tested",H,,,51,8,,CHEMBL616016,BAO_0000019,
973,Autocuration,,In vivo,1,,,Antagonist induction of hypothermia by 8-OH-DPAT in 5-hydroxytryptamine 1A receptor after subcutaneous administration; NT is not tested,H,,,51,8,,CHEMBL616017,BAO_0000218,
974,Autocuration,,,1,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]-8-OH-DPAT binding in Chinese hamster ovary cell line; NT is not tested,H,,,51,8,,CHEMBL616018,BAO_0000019,
975,Autocuration,,,1,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor receptor; Not tested,H,,,51,8,,CHEMBL616019,BAO_0000019,
976,Autocuration,,,1,,,EC50 for inhibition of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor; Not tested,H,,,51,8,,CHEMBL616020,BAO_0000019,
977,Autocuration,,,1,,,Evaluated for the binding constant at [3H]8-OH-DPAT-labeled human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL858018,BAO_0000357,
978,Autocuration,,,1,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,,722.0,51,8,,CHEMBL616021,BAO_0000219,
979,Expert,,,1,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at 1 uM.",H,,,51,8,,CHEMBL616022,BAO_0000019,
980,Autocuration,,,1,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means Not determined",H,,,51,8,,CHEMBL616023,BAO_0000019,
981,Autocuration,,,1,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; ND means not determined",H,,,51,8,,CHEMBL616024,BAO_0000019,
982,Autocuration,,,1,,,"Stimulation of binding of [35S]GTP-gamma-S, to G protein mediated by human cloned 5-hydroxytryptamine 1A receptor tested in vitro at a concentration of 1 uM; Not determined",H,,,51,8,,CHEMBL616025,BAO_0000019,
983,Autocuration,,,1,,,Antagonistic efficacy was evaluated by adenylyl cyclase assay in CHO cells stably expressing the human 5-HT1A receptor,H,,449.0,51,8,,CHEMBL616026,BAO_0000219,
984,Autocuration,,,1,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared with 5-HT",H,,,51,8,,CHEMBL616027,BAO_0000019,
985,Expert,9606.0,,1,,,"Agonist efficacy of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor compared to 5-HT",D,,,51,9,,CHEMBL616028,BAO_0000019,
986,Expert,9606.0,,1,,,Percent efficacy against human 5-hydroxytryptamine 1A receptor relative to maximal 5-HT response,D,,,51,9,,CHEMBL616029,BAO_0000019,
987,Expert,,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by incubating human 5-hydroxytryptamine 1A receptor transfected CHO cells with [3H]8-OH-DPAT,H,,449.0,51,8,,CHEMBL616030,BAO_0000219,
988,Expert,,,1,,,In vitro inhibition of [3H]8-OH-DPAT binding to human cloned 5-hydroxytryptamine 1A receptor on CHO cell membranes.,H,,,51,8,,CHEMBL616031,BAO_0000019,
989,Expert,9606.0,,1,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,D,,,51,9,,CHEMBL616032,BAO_0000019,
990,Expert,9606.0,,1,,,Agonist efficacy on 5-hydroxytryptamine 1A receptor subtype,D,,,51,9,,CHEMBL616033,BAO_0000019,
991,Autocuration,,,1,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,,,51,8,,CHEMBL616034,BAO_0000019,
992,Autocuration,,,1,,,Maximum binding affinity was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,,,51,8,,CHEMBL616035,BAO_0000019,
993,Autocuration,,,1,,,Maximum binding affinity was evaluated as ([35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616036,BAO_0000019,
994,Autocuration,,,1,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,,,51,8,,CHEMBL616037,BAO_0000019,
995,Autocuration,,,1,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,,,51,8,,CHEMBL616038,BAO_0000019,
996,Autocuration,,,1,,,Agonist efficacy was evaluated as ([35S]GTP binding on 5-hydroxytryptamine 1A serotonergic receptors.,H,,,51,8,,CHEMBL616039,BAO_0000019,
997,Autocuration,,,1,,,Agonist efficacy was evaluated as [35S]GTP binding on cloned human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616040,BAO_0000019,
998,Expert,9606.0,,1,,,Concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,D,,308.0,51,9,,CHEMBL616041,BAO_0000219,
999,Expert,9606.0,,1,,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,D,,308.0,51,9,,CHEMBL616042,BAO_0000219,
1000,Expert,9606.0,,1,,,Negative logarithm of concentration required to obtain 50% maximal stimulation of [35S]GTP gamma-S binding to human cloned 5-HT1A receptors of cell membranes from HeLa cells,D,,308.0,51,9,,CHEMBL616043,BAO_0000219,
1001,Autocuration,,,1,,,"Potency (pD2) for the stimulation of [35S]GTP-gamma-S, binding on 5-hydroxytryptamine 1A receptor",H,,,51,8,,CHEMBL616044,BAO_0000019,
1002,Autocuration,,,1,,,"Ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",H,,,51,8,,CHEMBL616045,BAO_0000019,
1003,Autocuration,,,1,,,Binding affinity against human 5-hydroxytryptamine 1A receptors HEK 293 cell membranes using [35S]GTP gamma-S,H,,722.0,51,8,,CHEMBL616046,BAO_0000219,
1004,Autocuration,,,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),H,,449.0,51,8,,CHEMBL616047,BAO_0000219,
1005,Autocuration,,,1,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells,H,,449.0,51,8,,CHEMBL616048,BAO_0000219,
1006,Expert,9606.0,,1,,,Potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 1),D,,449.0,51,9,,CHEMBL616049,BAO_0000219,
1007,Autocuration,,,1,,,Compound was tested for its potency against human 5-hydroxytryptamine 1A receptor expressed in CHO cells (experiment 2),H,,449.0,51,8,,CHEMBL616050,BAO_0000219,
1008,Expert,,,1,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor,H,,,51,8,,CHEMBL616051,BAO_0000219,
1009,Autocuration,,,1,,,In vitro effective concentration required to inhibit forskolin-stimulated cAMP levels in HA7 cells expressing human 5-HT1A receptor; Not tested,H,,,51,8,,CHEMBL616212,BAO_0000219,
1010,Autocuration,,,1,,,"ability to influence the binding of [35S]GTP-gamma-S, to HeLa cell membranes expressing the human 5-hydroxytryptamine 1A receptor",H,,,51,8,,CHEMBL616213,BAO_0000019,
1011,Expert,,In vitro,1,,,Ability to bind to 5-hydroxytryptamine 1A receptor from cloned human expressed in Ha7 cells,H,,,51,8,,CHEMBL616214,BAO_0000219,
1012,Expert,,In vitro,1,,,Ability to bind to 5-hydroxytryptamine 1A receptor subtype from cloned human expressed in Ha7 cells,H,,,51,8,,CHEMBL616215,BAO_0000219,
1013,Autocuration,,,1,,,Binding activity radioligand.,H,,,51,8,,CHEMBL616216,BAO_0000357,
1014,Autocuration,,,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,,,51,8,,CHEMBL616217,BAO_0000019,
1015,Autocuration,,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616218,BAO_0000357,
1016,Autocuration,,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616219,BAO_0000357,
1017,Autocuration,,,1,,,binding affinity towards human recombinant 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616220,BAO_0000357,
1018,Expert,9606.0,,1,,,Displacement of [3H]8-hydroxy-2-(di-n-propylamino)tetralin from human 5-hydroxytryptamine 1A receptor,D,,,51,9,,CHEMBL833493,BAO_0000357,
1019,Autocuration,,,1,,,Ability to displace the radioligand [3H]-8-OH-DPAT from human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616221,BAO_0000357,
1020,Expert,9606.0,,1,,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,D,,449.0,51,9,,CHEMBL616222,BAO_0000219,
1021,Autocuration,,,1,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616223,BAO_0000019,
1022,Autocuration,,,1,,,Antagonistic affinity against cloned human 5-hydroxytryptamine 1A receptor; Not determined,H,,,51,8,,CHEMBL616224,BAO_0000019,
1023,Expert,,,1,,,Binding affinity at human 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding in Chinese hamster ovary cell line,H,,,51,8,,CHEMBL616225,BAO_0000019,
1024,Expert,9606.0,,1,,,Binding affinity to human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]-8-OH- DPAT as radioligand,D,,722.0,51,9,,CHEMBL616226,BAO_0000219,
1025,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells,H,,722.0,51,8,,CHEMBL616227,BAO_0000219,
1026,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A human cloned receptors in HEK293 cells using [3H]8-OH-DPAT as radioligand,H,,722.0,51,8,,CHEMBL616228,BAO_0000219,
1027,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,H,,722.0,51,8,,CHEMBL616229,BAO_0000219,
1028,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand; ND means no data,H,,722.0,51,8,,CHEMBL616230,BAO_0000219,
1029,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;ND means no data.,H,,722.0,51,8,,CHEMBL616231,BAO_0000219,
1030,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in human using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL616232,BAO_0000357,
1031,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor (human cloned receptor) in HEK293 cells using [3H]8-OH-DPAT as radioligand;,H,,722.0,51,8,,CHEMBL616233,BAO_0000219,
1032,Autocuration,,,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT as the radioligand,H,,722.0,51,8,,CHEMBL857973,BAO_0000219,
1033,Autocuration,,,1,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT binding from human 5-hydroxytryptamine 1A receptor in mammalian cells,H,,,51,8,,CHEMBL616234,BAO_0000219,
1034,Autocuration,,,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616235,BAO_0000357,
1035,Expert,,,1,,,Binding affinity at human cloned 5-hydroxytryptamine 1A receptor expressed in HeLa cells by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,H,,308.0,51,8,,CHEMBL616236,BAO_0000219,
1036,Expert,,,1,,,Binding affinity at native 5-hydroxytryptamine 1A receptor in rat by [3H]8-hydroxy-2-(di-n-propylamino)tetraline displacement.,H,,,51,8,,CHEMBL616237,BAO_0000019,
1037,Autocuration,,,1,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1A receptor in human cloned receptors in HEK 293 cells using [3H]8-OH-DPAT,H,,722.0,51,8,,CHEMBL616238,BAO_0000219,
1038,Autocuration,,,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1A receptor in HEK 293 using [3H]5-CT as a radioligand,H,,722.0,51,8,,CHEMBL616239,BAO_0000219,
1039,Autocuration,,,1,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 1A receptor in mammalian cells using 3[H]8-OH-DPAT as the radioligand,H,,,51,8,,CHEMBL616240,BAO_0000219,
1040,Expert,9606.0,,1,,,The binding affinity was evaluated on cloned human 5-hydroxytryptamine 1A receptor expressed in HeLa cells by using DPAT as radioligand.,D,,308.0,51,9,,CHEMBL616241,BAO_0000219,
1041,Autocuration,,,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1A receptor in HEK 293 cells using [3H]8-OH-DPAT.,H,,722.0,51,8,,CHEMBL616242,BAO_0000219,
1042,Autocuration,,,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1A receptor in HEK293 cells, using [3H]8-OH-DPAT as radioligand",H,,722.0,51,8,,CHEMBL616243,BAO_0000219,
1043,Expert,,,1,,,In vitro inhibitory concentration required against [3H]8-OH-DPAT binding to cloned human 5-hydroxytryptamine 1A receptor,D,,,51,9,,CHEMBL616244,BAO_0000357,
1044,Autocuration,9606.0,,1,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1A receptor,D,,,51,9,,CHEMBL616245,BAO_0000357,
1045,Autocuration,,,1,,,Binding affinity towards 5-HT1B receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,H,,,106,8,,CHEMBL616246,BAO_0000357,
1046,Autocuration,,,1,,,Binding affinity against 5-HT1D receptor,H,,,105,8,,CHEMBL616247,BAO_0000357,
1047,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,,,105,8,,CHEMBL616248,BAO_0000357,
1048,Autocuration,,,1,,,Affinity of compound towards 5-hydroxytryptamine 1A receptor was evaluated using radioligand binding technique,H,,,107,8,,CHEMBL616249,BAO_0000357,
1049,Autocuration,9606.0,,1,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,H,,,10576,8,,CHEMBL616250,BAO_0000357,
1050,Autocuration,,,1,,,Inhibition of [3H]- 8-OH-DAPT binding against human recombinant 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616251,BAO_0000357,
1051,Autocuration,,In vivo,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 15 min after administration of the compound,H,,,11863,8,,CHEMBL616252,BAO_0000218,
1052,Autocuration,,In vivo,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 30 min after administration of the compound,H,,,11863,8,,CHEMBL616253,BAO_0000218,
1053,Autocuration,,In vivo,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice 60 min after administration of the compound,H,,,11863,8,,CHEMBL616254,BAO_0000218,
1054,Expert,10090.0,,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 15 min,D,,,11863,9,,CHEMBL616255,BAO_0000218,
1055,Expert,10090.0,,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 30 min,D,,,11863,9,,CHEMBL832872,BAO_0000218,
1056,Expert,10090.0,,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 10 mg/kg after 60 min,D,,,11863,9,,CHEMBL616256,BAO_0000218,
1057,Expert,10090.0,,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 15 min,D,,,11863,9,,CHEMBL616257,BAO_0000218,
1058,Expert,10090.0,,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 30 min,D,,,11863,9,,CHEMBL616258,BAO_0000218,
1059,Expert,10090.0,,1,,,Antagonist activity at 5-hydroxytryptamine 1A receptor against (+)-8-OH-DPAT induced hypothermia in mice at 1 mg/kg after 60 min,D,,,11863,9,,CHEMBL616384,BAO_0000218,
1060,Autocuration,,,1,10000000.0,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,H,,,11863,8,,CHEMBL616385,BAO_0000221,
1061,Expert,,,1,,,Inhibitory activity against serotonin 5-hydroxytryptamine 1A receptor from mice.,H,,,11863,8,,CHEMBL616386,BAO_0000357,
1062,Expert,10090.0,,1,10000000.0,,Inhibitory activity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,D,,,11863,9,,CHEMBL616387,BAO_0000221,
1063,Autocuration,,,1,10000000.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,H,,,11863,8,,CHEMBL616388,BAO_0000221,
1064,Expert,10090.0,,1,10000000.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus,D,,,11863,9,,CHEMBL616389,BAO_0000221,
1065,Autocuration,,,1,10000000.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in mouse hippocampus; Not determined,H,,,11863,8,,CHEMBL616390,BAO_0000221,
1066,Autocuration,,,1,,,Compound was tested for binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as a radioligand,H,,,11863,8,,CHEMBL616391,BAO_0000357,
1067,Expert,10090.0,,1,10000000.0,,Hill number was determined for inhibition of of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in mouse hippocampus,D,,,11863,9,,CHEMBL616392,BAO_0000221,
1068,Autocuration,9823.0,,1,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616393,BAO_0000357,
1069,Autocuration,9823.0,,1,,,Ability to displace [3H]8-OH-DPAT radioligand from porcine 5-hydroxytryptamine 1A receptor; ND denotes not determined,H,,,51,8,,CHEMBL616394,BAO_0000357,
1070,Autocuration,9823.0,,1,,,Binding affinity of compound measured for 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT-labeled porcine brain homogenates,H,,,51,8,,CHEMBL616395,BAO_0000019,
1071,Autocuration,9823.0,,1,,,Compound was evaluated for the binding affinity at 5- HT1A receptor,H,,,51,8,,CHEMBL616396,BAO_0000357,
1072,Autocuration,9823.0,,1,,,Compound was tested in vitro for its ability to compete with [3H]8-OH-DPAT at 5-hydroxytryptamine 1A receptor in porcine brain homogenate,H,,,51,8,,CHEMBL872907,BAO_0000019,
1073,Autocuration,9823.0,,1,,,In vitro for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in porcine brain homogenate,H,,,51,8,,CHEMBL616397,BAO_0000019,
1074,Autocuration,9823.0,,1,,,Compound was tested for its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in pig cortex,H,,,51,8,,CHEMBL616398,BAO_0000019,
1075,Expert,9823.0,,1,,,Displacement of [3H]- 8-OH-DPAT from porcine 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616399,BAO_0000357,
1076,Autocuration,9823.0,,1,,,Binding activity radioligand.,H,,,51,8,,CHEMBL857065,BAO_0000357,
1077,Expert,9823.0,,1,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,H,,,51,8,,CHEMBL616400,BAO_0000019,
1078,Autocuration,9823.0,,1,,,Binding activity against 5-hydroxytryptamine 1A receptor from pig cortex membrane using [3H]8-OH-DPAT-HT as radioligand.,H,,,51,8,,CHEMBL616401,BAO_0000019,
1079,Expert,,,1,,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor from pig cortex,H,,,10624,8,,CHEMBL616402,BAO_0000019,
1080,Expert,9823.0,,1,,,Displacement of [3H]8-OH-DPAT from pig cortex 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616403,BAO_0000019,
1081,Autocuration,9823.0,,1,10000000.0,,Binding affinity for 5-hydroxytryptamine 1A receptor in piglet hippocampus using [3H]8-OH-DPAT,H,,,51,8,,CHEMBL616404,BAO_0000221,
1082,Autocuration,9823.0,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in pig frontal cortex membranes using [8H]-OH-DPAT,H,,,51,8,,CHEMBL616405,BAO_0000249,
1083,Autocuration,9823.0,,1,,,Binding affinity was evaluated by 5-hydroxytryptamine 1A receptor agonism in the pig cortex by displacing 8-OH-DPAT,H,,,51,8,,CHEMBL616406,BAO_0000019,
1084,Expert,9823.0,,1,,,Agonistic activity against 5-hydroxytryptamine 1A receptor in pig cortex using [3H]8-OH-DPAT,H,,,51,8,,CHEMBL616407,BAO_0000019,
1085,Autocuration,9986.0,,1,,,Binding affinity against 5-hydroxytryptamine 1 receptor using rabbit jugular vein assay in the presence of endothelium,H,,,51,8,,CHEMBL616408,BAO_0000019,
1086,Expert,10116.0,,1,,,Inhibition activity against 5-hydroxytryptamine 1A receptor in rat hippocampus membranes using radio binding assays,D,,,10576,9,,CHEMBL616409,BAO_0000249,
1087,Expert,10116.0,,1,10000000.0,,"Inhibition of [3H]8-hydroxy-2-dipropylamino-1,2,3,4-tetrahydronaphthalene binding to 5-hydroxytryptamine 1A receptor in hippocampus region of rat brain; Less active",D,,,10576,9,,CHEMBL616410,BAO_0000221,
1088,Autocuration,,,1,,,Tested for the effect on binding at 5-hydroxytryptamine 1A receptor; No activity,H,,,10576,8,,CHEMBL616411,BAO_0000357,
1089,Expert,10116.0,,1,,,"Antagonist activity to stimulate binding of [35S]GTP-gamma-S, to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",D,Membranes,,10576,9,,CHEMBL616412,BAO_0000249,
1090,Expert,10116.0,,1,10000000.0,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",D,Membranes,,10576,9,,CHEMBL616413,BAO_0000249,
1091,Autocuration,,,1,10000000.0,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,,,10576,8,,CHEMBL616414,BAO_0000221,
1092,Expert,10116.0,,1,10000000.0,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding,D,,,10576,9,,CHEMBL616415,BAO_0000221,
1093,Autocuration,,,1,,,Binding affinity measured at the 5-hydroxytryptamine 1A receptor by the inhibition of [3H]8-OH-DPAT binding to rat cortex using unlabeled buspirone for nonspecific binding.,H,,,10576,8,,CHEMBL616416,BAO_0000019,
1094,Expert,,,1,,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand.,H,,,10576,8,,CHEMBL616417,BAO_0000357,
1095,Autocuration,,,1,,,Binding affinity of [3H]- -8-OH-DPAT labelled towards Rat Hippocampal 5-hydroxytryptamine 1A receptor using radioligand binding assay,H,,,10576,8,,CHEMBL616418,BAO_0000357,
1096,Autocuration,,In vitro,1,,,Binding affinity of [3H]-8-OH-DPAT towards 5-hydroxytryptamine 1A receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,H,,,10576,8,,CHEMBL616419,BAO_0000219,
1097,Autocuration,,,1,,,Binding affinity of compound against 5-hydroxytryptamine 1A receptor binding site using radioligand [3H]8-OH-DPAT,H,,,10576,8,,CHEMBL616420,BAO_0000357,
1098,Autocuration,,,1,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,H,Membranes,,10576,8,,CHEMBL616421,BAO_0000249,
1099,Autocuration,,,1,,,Binding affinity of compound towards 5-HT 1A receptor by measuring ability to displace [3H]OH-DPAT from 5-hydroxytryptamine 1A receptor in rat striatal membranes,H,Membranes,,10576,8,,CHEMBL616422,BAO_0000249,
1100,Expert,,,1,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor in rat striatal membranes by [3H]OH-DPAT displacement.,H,Membranes,,10576,8,,CHEMBL616423,BAO_0000249,
1101,Expert,10116.0,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor with [3H]5-HT,D,,,10576,9,,CHEMBL616424,BAO_0000357,
1102,Expert,,,1,,,Binding affinity to the rat 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616425,BAO_0000357,
1103,Expert,,,1,,,Binding affinity was tested on 5-hydroxytryptamine 1A receptor using radioligand [3H]5-HT binding assay.,H,,,10576,8,,CHEMBL616426,BAO_0000357,
1104,Autocuration,,,1,10000000.0,,Binding affinity against 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as the radioligand.,H,,,10576,8,,CHEMBL616427,BAO_0000221,
1105,Autocuration,,,1,10000000.0,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus tissue.,H,,,10576,8,,CHEMBL616428,BAO_0000221,
1106,Autocuration,,,1,10000000.0,,Binding affinity by measuring displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,,10576,8,,CHEMBL616290,BAO_0000221,
1107,Expert,10116.0,,1,,,Displacement of [3H]8-OH-DPAT from rat striata 5-hydroxytryptamine 1A receptor,D,,,10576,9,,CHEMBL616052,BAO_0000357,
1108,Autocuration,,,1,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616053,BAO_0000357,
1109,Autocuration,,,1,,,Binding affinity towards 5-HT 1A receptor in rat cerebral cortex membranes using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL616054,BAO_0000249,
1110,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616055,BAO_0000357,
1111,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in competitive binding assay,H,,,10576,8,,CHEMBL616056,BAO_0000357,
1112,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,H,,,10576,8,,CHEMBL616057,BAO_0000019,
1113,Expert,10116.0,,1,955.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,D,,,10576,9,,CHEMBL616058,BAO_0000221,
1114,Autocuration,,,1,955.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,H,,,10576,8,,CHEMBL616059,BAO_0000221,
1115,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hypocampus membrane using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL616060,BAO_0000249,
1116,Expert,10116.0,,1,10000000.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor in the rat brain (hippocampus) using [3H]8-OH-DPAT,D,,,10576,9,,CHEMBL616061,BAO_0000221,
1117,Expert,,,1,10000000.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]-8-hydroxy-2-(di-n-propylamine) tetralin (8-OH-DPAT) as a radioligand,H,,,10576,8,,CHEMBL616062,BAO_0000221,
1118,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor sites in cortical membranes using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL616063,BAO_0000249,
1119,Autocuration,,,1,2435.0,,"Binding affinity towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",H,,,10576,8,,CHEMBL616064,BAO_0000249,
1120,Expert,10116.0,,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cortex membranes,D,Membranes,,10576,9,,CHEMBL616065,BAO_0000249,
1121,Expert,10116.0,,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat cerebral cortex membranes,D,Membranes,,10576,9,,CHEMBL616066,BAO_0000249,
1122,Autocuration,,,1,10000000.0,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL616067,BAO_0000221,
1123,Autocuration,,,1,10000000.0,,Binding affinity towards rat hippocampal 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand; Not tested,H,,,10576,8,,CHEMBL616068,BAO_0000221,
1124,Intermediate,,,1,10000000.0,,Binding affinity against rat hippocampal 5-hydroxytryptamine 1A (5-HT1A) receptor determined using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL616069,BAO_0000221,
1125,Expert,,,1,,,Binding was determined on 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,H,,,10576,8,,CHEMBL616070,BAO_0000249,
1126,Autocuration,,,1,10000000.0,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL616071,BAO_0000221,
1127,Expert,,,1,10000000.0,,Binding affinity against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.,H,,,10576,8,,CHEMBL616072,BAO_0000221,
1128,Autocuration,,,1,10000000.0,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand.; ND = Not determined,H,,,10576,8,,CHEMBL616073,BAO_0000221,
1129,Autocuration,,,1,10000000.0,,Binding affinity was evaluated against 5-hydroxytryptamine 1A receptor on rat hippocampus using [3H]8-OH-DPAT as radioligand; ND = Not determined,H,,,10576,8,,CHEMBL616074,BAO_0000221,
1130,Expert,,,1,,,Binding affinity was evaluated by determining in vitro displacement of [3H]8-OH-DPAT from the central 5-hydroxytryptamine 1A receptor recognition site in rat frontal cortex homogenate.,H,,,10576,8,,CHEMBL616075,BAO_0000019,
1131,Autocuration,,,1,,,Binding affinity was evaluated by using [3H]8-OH-DPAT radioligand by using competitive binding assay on 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616076,BAO_0000357,
1132,Expert,10116.0,,1,,,Binding affinity for 5-HT1A measured by displacing [3H]8-OH-DPAT from rat cortical membranes; Not determined,D,,,10576,9,,CHEMBL616077,BAO_0000019,
1133,Expert,10116.0,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes,D,,,10576,9,,CHEMBL616078,BAO_0000019,
1134,Expert,10116.0,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor measured by displacing [3H]8-OH-DPAT from rat cortical membranes;ND-Not determined,D,,,10576,9,,CHEMBL616079,BAO_0000019,
1135,Expert,10116.0,,1,,,Binding affinity against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,D,,485.0,10576,9,,CHEMBL616080,BAO_0000219,
1136,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616081,BAO_0000357,
1137,Expert,10116.0,,1,10000000.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [125I]trans-8-OH-PIPAT in membrane homogenates of hippocampal tissue of rat brain,D,,,10576,9,,CHEMBL616082,BAO_0000221,
1138,Autocuration,,,1,10000000.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in membrane homogenates of hippocampal tissue of rat brain,H,,,10576,8,,CHEMBL616083,BAO_0000221,
1139,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex,H,,,10576,8,,CHEMBL616084,BAO_0000019,
1140,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates,H,,,10576,8,,CHEMBL616085,BAO_0000019,
1141,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT,H,,,10576,8,,CHEMBL616086,BAO_0000019,
1142,Autocuration,,,1,10000000.0,,"Binding affinity towards 5-hydroxytryptamine 1A receptor using 0.1 nM [3H]-8-OH-DPAT (8-hydroxy-2-(di-n-propylamino)tet-ralin), from rat hippocampal homogenate",H,,,10576,8,,CHEMBL616087,BAO_0000221,
1143,Expert,,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor using [3H]WB-4101,H,,,10576,8,,CHEMBL616088,BAO_0000357,
1144,Autocuration,,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1A receptor was determined in male Sprague-Dawley rat brain.,H,,,10576,8,,CHEMBL616089,BAO_0000019,
1145,Expert,10116.0,,1,,,Binding affinity was measured against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT by lysergic acid amides,D,,,10576,9,,CHEMBL616090,BAO_0000357,
1146,Autocuration,,,1,,,Binding affinity was measured on cloned rat 5-hydroxytryptamine 1A receptor which is labeled by [3H]8-OH-DPAT,H,,,10576,8,,CHEMBL616091,BAO_0000357,
1147,Autocuration,,,1,2435.0,,"Binding affinity of the compound towards 5-hydroxytryptamine 1A receptor sites, in rat striatum membranes using [3H]- sandoz 205-501 as radioligand",H,Membranes,,10576,8,,CHEMBL616092,BAO_0000249,
1148,Autocuration,,,1,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vitro),H,,,10576,8,,CHEMBL616093,BAO_0000357,
1149,Autocuration,,In vivo,1,,,Binding constant against 5-hydroxytryptamine 1A receptor (in vivo),H,,,10576,8,,CHEMBL616094,BAO_0000218,
1150,Autocuration,,,1,955.0,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex,H,,,10576,8,,CHEMBL616095,BAO_0000221,
1151,Expert,10116.0,,1,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,D,,,10576,9,,CHEMBL616096,BAO_0000357,
1152,Expert,,,1,,,Binding affinity at [3H]8-OH-DPAT-Labeled 5-hydroxytryptamine 1A receptor sites in rat brain hippocampal membranes,H,,,10576,8,,CHEMBL616097,BAO_0000249,
1153,Expert,10116.0,,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus membranes,D,Membranes,,10576,9,,CHEMBL616098,BAO_0000249,
1154,Autocuration,,,1,10000000.0,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL616099,BAO_0000221,
1155,Autocuration,,,1,10000000.0,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 1A receptor receptor in rat hippocampus using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL616100,BAO_0000221,
1156,Expert,,,1,,,Ability to displace [3H]-8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616101,BAO_0000357,
1157,Expert,,,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes by [3H]8-OH-DPAT displacement.,H,,,10576,8,,CHEMBL616102,BAO_0000249,
1158,Autocuration,,,1,,,Compound was evaluated for its ability to displace [3H]8-OH-DPAT from serotonergic 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616103,BAO_0000357,
1159,Expert,,,1,,,Compound was evaluated for its binding affinity against 5-hydroxytryptamine 1A receptor from rat cerebral cortex,H,,,10576,8,,CHEMBL616104,BAO_0000019,
1160,Expert,,,1,,,"Binding affinity to 5-hydroxytryptamine 1A receptor (5-HT 1A receptor, serotonin receptor) from rat cortex using [3H]8-OH-DPAT as radioligand",H,,,10576,8,,CHEMBL616105,BAO_0000019,
1161,Expert,10116.0,,1,,,Displacement of [3H]prazosin from rat cortex membrane 5-hydroxytryptamine 1A receptor,D,,,10576,9,,CHEMBL616106,BAO_0000019,
1162,Autocuration,,,1,,,Compound was evaluated for its binding affinity with 5-hydroxytryptamine 1A receptor using membranes prepared from rat cerebral cortex,H,,,10576,8,,CHEMBL616107,BAO_0000019,
1163,Expert,,,1,,,Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.,H,,,10576,8,,CHEMBL616108,BAO_0000357,
1164,Expert,,,1,10000000.0,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,H,,,10576,8,,CHEMBL616109,BAO_0000221,
1165,Autocuration,,,1,,,In vitro ability to displace [3H]8-hydroxy-2-(di-n-propylamino) tetralin binding from 5-hydroxytryptamine 1A receptor site.,H,,,10576,8,,CHEMBL616110,BAO_0000357,
1166,Expert,,,1,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor in CHO cells.,H,,449.0,10576,8,,CHEMBL616111,BAO_0000219,
1167,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor from rat brain using [3H]-8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL616112,BAO_0000019,
1168,Autocuration,,,1,10000000.0,,Compound was tested for the Binding affinity against rat hippocampal 5-hydroxytryptamine 1A receptor by Radio ligand [3H]8-OH-DPAT binding assay.,H,,,10576,8,,CHEMBL616113,BAO_0000221,
1169,Autocuration,,,1,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616114,BAO_0000019,
1170,Autocuration,,,1,,,Compound was tested for the displacement of [3H]-8-OH- DPAT from rat brain 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616115,BAO_0000019,
1171,Autocuration,,,1,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616116,BAO_0000357,
1172,Expert,,,1,955.0,,Binding affinity for 5-hydroxytryptamine 1A receptor in rat brain tissue using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL615844,BAO_0000221,
1173,Expert,,,1,10000000.0,,In vitro displacement of [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL615939,BAO_0000221,
1174,Expert,,,1,,,In vitro ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor sites of rat brain cortex.,H,,,10576,8,,CHEMBL615940,BAO_0000019,
1175,Expert,,,1,10000000.0,,In vitro affinity at 5-hydroxytryptamine 1A receptor of rat hippocampus by [3H]8-OH-DPAT displacement.,H,,,10576,8,,CHEMBL615941,BAO_0000221,
1176,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-HT1A receptor of rat hippocampus and the value ranges from 9 - 12,H,,,10576,8,,CHEMBL615942,BAO_0000221,
1177,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,H,,,10576,8,,CHEMBL615943,BAO_0000221,
1178,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 12 to 17,H,,,10576,8,,CHEMBL615944,BAO_0000221,
1179,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus (94%CI) from 391-841,H,,,10576,8,,CHEMBL615945,BAO_0000221,
1180,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 17.,H,,,10576,8,,CHEMBL615946,BAO_0000221,
1181,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 12 to 20.,H,,,10576,8,,CHEMBL615947,BAO_0000221,
1182,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 245 to 736,H,,,10576,8,,CHEMBL615948,BAO_0000221,
1183,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 25 - 84,H,,,10576,8,,CHEMBL615949,BAO_0000221,
1184,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 48 to 59,H,,,10576,8,,CHEMBL615950,BAO_0000221,
1185,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and the value ranges from 3 -5,H,,,10576,8,,CHEMBL615951,BAO_0000221,
1186,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 15 - 31,H,,,10576,8,,CHEMBL615952,BAO_0000221,
1187,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 27 - 42,H,,,10576,8,,CHEMBL615953,BAO_0000221,
1188,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus and value ranges from 6 - 13,H,,,10576,8,,CHEMBL615954,BAO_0000221,
1189,Expert,10116.0,,1,10000000.0,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus,D,,,10576,9,,CHEMBL615955,BAO_0000221,
1190,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.; ND is No Data.,H,,,10576,8,,CHEMBL615956,BAO_0000221,
1191,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus. and the value ranges from 16 - 27,H,,,10576,8,,CHEMBL615957,BAO_0000221,
1192,Expert,,,1,,,Displacement of [3H]2-(di-N-propylamino)-8-hydroxytetralin from central 5-hydroxytryptamine 1A receptor recognition sites in rat frontal cortex homogenates.,H,,,10576,8,,CHEMBL615958,BAO_0000019,
1193,Expert,,,1,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate,H,,,10576,8,,CHEMBL615959,BAO_0000019,
1194,Autocuration,,,1,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 1),H,,,10576,8,,CHEMBL615960,BAO_0000019,
1195,Autocuration,,,1,,,Displacement of radioligand [3H]2-(di-N-propylamino)-8-hydroxytetralin from 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenate (experiment 2),H,,,10576,8,,CHEMBL615961,BAO_0000019,
1196,Expert,,,1,955.0,,Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain,H,,,10576,8,,CHEMBL615962,BAO_0000221,
1197,Expert,,,1,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.,H,,,10576,8,,CHEMBL615963,BAO_0000019,
1198,Autocuration,,,1,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand; ND is no data.,H,,,10576,8,,CHEMBL615964,BAO_0000019,
1199,Autocuration,,,1,,,Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand;ND means no data,H,,,10576,8,,CHEMBL615965,BAO_0000019,
1200,Expert,,,1,,,In vitro displacement of radioactively labeled ligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor site in CHO cells,H,,449.0,10576,8,,CHEMBL615966,BAO_0000219,
1201,Expert,,,1,,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat cortical membranes,H,,,10576,8,,CHEMBL615967,BAO_0000249,
1202,Expert,,,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor of rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,H,,,10576,8,,CHEMBL615968,BAO_0000019,
1203,Autocuration,,,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand in CHO cells (sc),H,,449.0,10576,8,,CHEMBL615969,BAO_0000218,
1204,Autocuration,,,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT (agonist) as radioligand (sc),H,,,10576,8,,CHEMBL615970,BAO_0000218,
1205,Expert,10116.0,,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT,D,,,10576,9,,CHEMBL615971,BAO_0000357,
1206,Expert,,,1,,,In vitro binding affinity at 5-HT1A receptors assayed by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,H,Membranes,,10576,8,,CHEMBL615972,BAO_0000249,
1207,Autocuration,,,1,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes + cortex,H,,,10576,8,,CHEMBL615973,BAO_0000249,
1208,Autocuration,,,1,,,In vitro binding affinity at 5-HT1A receptor by measuring its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampal membranes+cortex,H,,,10576,8,,CHEMBL615974,BAO_0000249,
1209,Expert,9606.0,,1,,,Displacement of [3H]8-OH-DPAT from human 5-hydroxytryptamine 1A receptor expressed in CHO cells,D,,449.0,51,9,,CHEMBL615975,BAO_0000219,
1210,Expert,,,1,,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor in rat hippocampal membranes by [125I]-labeled agonist displacement.,H,,,10576,8,,CHEMBL615976,BAO_0000249,
1211,Expert,10116.0,,1,10000000.0,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus,D,,,10576,9,,CHEMBL872106,BAO_0000221,
1212,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL615977,BAO_0000357,
1213,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=100-230,H,,,10576,8,,CHEMBL615978,BAO_0000357,
1214,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=12-14,H,,,10576,8,,CHEMBL616166,BAO_0000357,
1215,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=16-20,H,,,10576,8,,CHEMBL616167,BAO_0000357,
1216,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=160-430,H,,,10576,8,,CHEMBL616168,BAO_0000357,
1217,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=174-224,H,,,10576,8,,CHEMBL616169,BAO_0000357,
1218,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=184-503,H,,,10576,8,,CHEMBL616170,BAO_0000357,
1219,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=19-23,H,,,10576,8,,CHEMBL616171,BAO_0000357,
1220,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=2.2-3.2,H,,,10576,8,,CHEMBL616172,BAO_0000357,
1221,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=2.7-3.6,H,,,10576,8,,CHEMBL616173,BAO_0000357,
1222,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=20-23,H,,,10576,8,,CHEMBL616174,BAO_0000357,
1223,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=21-28,H,,,10576,8,,CHEMBL616175,BAO_0000357,
1224,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=240-760,H,,,10576,8,,CHEMBL616176,BAO_0000357,
1225,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=39-87,H,,,10576,8,,CHEMBL616177,BAO_0000357,
1226,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=4.6-5.2,H,,,10576,8,,CHEMBL616178,BAO_0000357,
1227,Autocuration,,,1,,,Inhibitory activity tested in vitro at 5-hydroxytryptamine 1A receptor binding site in rat,H,,,10576,8,,CHEMBL616179,BAO_0000019,
1228,Autocuration,,,1,,,Inhibitory concentration against 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616180,BAO_0000357,
1229,Autocuration,,,1,,,Inhibitory concentration against binding of 5-hydroxytryptamine 1A receptor from striata of male Wistar rats by displacement of [3H]8-OH-DPAT,H,,,10576,8,,CHEMBL616181,BAO_0000357,
1230,Autocuration,,,1,,,Inhibitory concentration against radioligand [3H]hydroxy-2-(di-n-propylamino)-tetralin binding to 5-hydroxytryptamine 1A receptor in rat,H,,,10576,8,,CHEMBL616182,BAO_0000019,
1231,Autocuration,,,1,10000000.0,,Inhibitory concentration against radioligand [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616183,BAO_0000221,
1232,Expert,,,1,,,Inhibition of the 5-hydroxytryptamine 1A receptor in rat dorsal raphe,H,,,10576,8,,CHEMBL615874,BAO_0000019,
1233,Expert,10116.0,,1,,,Inhibitory concentration against [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor expressed in CHO-K1 cells,D,,485.0,10576,9,,CHEMBL615875,BAO_0000219,
1234,Autocuration,,,1,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand,H,,,10576,8,,CHEMBL615876,BAO_0000019,
1235,Autocuration,,,1,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1A receptor in rat cortex using [3H]OH-DPAT radioligand; NT means not tested,H,,,10576,8,,CHEMBL615877,BAO_0000019,
1236,Autocuration,,,1,,,The compound was evaluated for the ability to displace [3H]- 8-OH -DPAT from 5-hydroxytryptamine 1A receptor ( striata of male wistar rats),H,,,10576,8,,CHEMBL615878,BAO_0000357,
1237,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor binding site using [3H]8-OH-DPAT. ,H,,,10576,8,,CHEMBL615879,BAO_0000357,
1238,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using receptor binding assay,H,,,10576,8,,CHEMBL615880,BAO_0000357,
1239,Autocuration,,,1,,,"The compound was tested in vitro for inhibitory activity against 5-HT1A receptor in rats, using [3H]8-OH-DPAT as radioligand",H,,,10576,8,,CHEMBL615881,BAO_0000019,
1240,Expert,10116.0,,1,,,"Inhibitory activity against 5-hydroxytryptamine 1A receptor in rats, using [3H]8-OH-DPAT as radioligand",D,,,10576,9,,CHEMBL615882,BAO_0000019,
1241,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat,H,,,10576,8,,CHEMBL615883,BAO_0000218,
1242,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.10-6.20),H,,,10576,8,,CHEMBL615884,BAO_0000218,
1243,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.60),H,,,10576,8,,CHEMBL615885,BAO_0000218,
1244,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.20-1.80),H,,,10576,8,,CHEMBL615886,BAO_0000218,
1245,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.37-4.27),H,,,10576,8,,CHEMBL615887,BAO_0000218,
1246,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-2.70),H,,,10576,8,,CHEMBL615888,BAO_0000218,
1247,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.40-4),H,,,10576,8,,CHEMBL615889,BAO_0000218,
1248,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.45-4.51),H,,,10576,8,,CHEMBL615890,BAO_0000218,
1249,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.50-5.30),H,,,10576,8,,CHEMBL615891,BAO_0000218,
1250,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.60-1.60),H,,,10576,8,,CHEMBL615892,BAO_0000218,
1251,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.72-2.87),H,,,10576,8,,CHEMBL615893,BAO_0000218,
1252,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (0.80-5.80),H,,,10576,8,,CHEMBL615894,BAO_0000218,
1253,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (1.50-16.5),H,,,10576,8,,CHEMBL615895,BAO_0000218,
1254,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges from (2.20-30.5),H,,,10576,8,,CHEMBL615896,BAO_0000218,
1255,Autocuration,,In vivo,1,,,Antagonistic activity at postsynaptic 5-hydroxytryptamine 1A receptor was measured by its ability to inhibit hypothermia elicited by s.c. administration of 8-OH-DPAT in rat;ranges is not computable,H,,,10576,8,,CHEMBL615897,BAO_0000218,
1256,Expert,10116.0,,1,,,"Percent increase of R(+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes",D,Membranes,,10576,9,,CHEMBL615898,BAO_0000249,
1257,Autocuration,,,1,,,% inhibition towards 5-HT1A receptor from rat hippocampal membranes,H,,,10576,8,,CHEMBL615899,BAO_0000019,
1258,Autocuration,,,1,,,% inhibition towards 5-hydroxytryptamine 1A receptor from rat hippocampal membranes,H,,,10576,8,,CHEMBL616291,BAO_0000019,
1259,Autocuration,,,1,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor.,H,,,10576,8,,CHEMBL616292,BAO_0000357,
1260,Autocuration,,,1,,,"Ability to inhibit 5-HT sensitive,forskolin-stimulated adenylyl cyclase(FSC) activity in rat hippocampal membranes mediated through 5-hydroxytryptamine 1A receptor",H,,,10576,8,,CHEMBL616293,BAO_0000249,
1261,Expert,,,1,10000000.0,,Measurement of binding affinity by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,,10576,8,,CHEMBL616294,BAO_0000221,
1262,Autocuration,,,1,10000000.0,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membrane,H,,,10576,8,,CHEMBL616295,BAO_0000249,
1263,Autocuration,,,1,955.0,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]-8-OH- -DPAT in rat brain cortex at 10 uM,H,,,10576,8,,CHEMBL616296,BAO_0000221,
1264,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,H,,,10576,8,,CHEMBL616297,BAO_0000019,
1265,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0+ 1 uM 5-HT.,H,,,10576,8,,CHEMBL616605,BAO_0000019,
1266,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.01 uM+ 1 uM 5-HT.,H,,,10576,8,,CHEMBL616606,BAO_0000019,
1267,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,H,,,10576,8,,CHEMBL616607,BAO_0000019,
1268,Expert,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM,H,,,10576,8,,CHEMBL616608,BAO_0000019,
1269,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.05 uM+ 1 uM 5-HT.,H,,,10576,8,,CHEMBL616609,BAO_0000019,
1270,Expert,10116.0,,1,,,Effect against 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at 0.1 uM dose,D,,,10576,9,,CHEMBL616610,BAO_0000019,
1271,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 10 uM 5-HT.,H,,,10576,8,,CHEMBL616611,BAO_0000019,
1272,Expert,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 1 uM 5-HT.,H,,,10576,8,,CHEMBL616612,BAO_0000019,
1273,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM + 0.1 uM 5-HT.,H,,,10576,8,,CHEMBL616613,BAO_0000019,
1274,Expert,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM,H,,,10576,8,,CHEMBL616614,BAO_0000019,
1275,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 10 uM+ 10 uM 5-HT.,H,,,10576,8,,CHEMBL616615,BAO_0000019,
1276,Expert,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,H,,,10576,8,,CHEMBL616616,BAO_0000019,
1277,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 0.1 uM 5-HT.,H,,,10576,8,,CHEMBL616617,BAO_0000019,
1278,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,H,,,10576,8,,CHEMBL616618,BAO_0000019,
1279,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 1 uM 5-HT.,H,,,10576,8,,CHEMBL616619,BAO_0000019,
1280,Expert,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 3 uM 5-HT.,H,,,10576,8,,CHEMBL616620,BAO_0000019,
1281,Expert,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,H,,,10576,8,,CHEMBL616621,BAO_0000019,
1282,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 30 uM,H,,,10576,8,,CHEMBL616622,BAO_0000019,
1283,Expert,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM,H,,,10576,8,,CHEMBL616146,BAO_0000019,
1284,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 50 uM+ 50 uM 5-HT.,H,,,10576,8,,CHEMBL832873,BAO_0000019,
1285,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 0.1 uM,H,,,10576,8,,CHEMBL616147,BAO_0000019,
1286,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor-mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 10 uM 5-HT.,H,,,10576,8,,CHEMBL872872,BAO_0000019,
1287,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM,H,,,10576,8,,CHEMBL616148,BAO_0000019,
1288,Autocuration,,,1,10000000.0,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue,H,,,10576,8,,CHEMBL616149,BAO_0000221,
1289,Expert,,,1,10000000.0,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue at 1 uM,H,,,10576,8,,CHEMBL616150,BAO_0000221,
1290,Expert,10116.0,,1,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor in rat hippocampal membranes at 10e-7 M,D,Membranes,,10576,9,,CHEMBL616151,BAO_0000249,
1291,Expert,,,1,10000000.0,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue at 1 uM,H,,,10576,8,,CHEMBL872873,BAO_0000221,
1292,Autocuration,,,1,10000000.0,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 0.1 uM concentration,H,,,10576,8,,CHEMBL616670,BAO_0000221,
1293,Autocuration,,,1,10000000.0,,Inhibitory activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor at 1 uM concentration,H,,,10576,8,,CHEMBL616671,BAO_0000221,
1294,Expert,10116.0,,1,,,"Percent inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1A receptor in hippocampal membranes",D,,,10576,9,,CHEMBL884861,BAO_0000249,
1295,Autocuration,,,1,,,Tested in vitro for % inhibition against (serotonin)5-HT 1A receptor,H,,,10576,8,,CHEMBL616672,BAO_0000357,
1296,Autocuration,,,1,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,H,,,10576,8,,CHEMBL616673,BAO_0000019,
1297,Expert,,,1,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand.,H,,,10576,8,,CHEMBL616674,BAO_0000019,
1298,Autocuration,,,1,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,H,,,10576,8,,CHEMBL616675,BAO_0000357,
1299,Autocuration,,,1,10000000.0,,In vitro binding affinity for 5-hydroxytryptamine 1A receptor was determined by measuring specific inhibition of [125I]-binding to rat hippocampal membrane preparations,H,,,10576,8,,CHEMBL616676,BAO_0000221,
1300,Autocuration,,,1,10000000.0,,Inhibition of binding of [125I]-8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,,,10576,8,,CHEMBL616677,BAO_0000221,
1301,Autocuration,,,1,10000000.0,,The binding of [125I]MPPI ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,,,10576,8,,CHEMBL616678,BAO_0000221,
1302,Expert,10116.0,,1,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,D,,,10576,9,,CHEMBL616679,BAO_0000357,
1303,Expert,,,1,10000000.0,,Ability to bind to central serotonin 5-hydroxytryptamine 1A receptor in vitro in hippocampus of the rat brain using [3H]8-OH-DPAT radioligand,H,,,10576,8,,CHEMBL616680,BAO_0000221,
1304,Autocuration,,,1,10000000.0,,Ability to displace [3H]- -OH-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,,10576,8,,CHEMBL616681,BAO_0000221,
1305,Autocuration,,,1,10000000.0,,Ability to displace [3H]- -(OH)-DPAT bound to 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,,10576,8,,CHEMBL616682,BAO_0000221,
1306,Autocuration,,,1,10000000.0,,Ability to displace [3H]8-OH-DPAT binding to rat hippocampal 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616683,BAO_0000221,
1307,Autocuration,,,1,10000000.0,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616684,BAO_0000221,
1308,Autocuration,,,1,10000000.0,,Ability to displace [3H]-8-OH-DPAT from rat hippocampal homogenate 5-hydroxytryptamine 1A receptor; Not tested,H,,,10576,8,,CHEMBL616685,BAO_0000221,
1309,Autocuration,,,1,955.0,,Affinity at [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor in rat brain homogenate was determined,H,,,10576,8,,CHEMBL616686,BAO_0000221,
1310,Autocuration,,,1,,,Affinity for 5-hydroxytryptamine 1A receptor site,H,,,10576,8,,CHEMBL616687,BAO_0000357,
1311,Autocuration,,,1,,,Affinity for 5-hydroxytryptamine 1A receptor site,H,,,10576,8,,CHEMBL616688,BAO_0000357,
1312,Autocuration,,,1,10000000.0,,Affinity in displacing [3H]8-OH-DPAT from rat hippocampal 5-HT1A receptor.,H,,,10576,8,,CHEMBL616689,BAO_0000221,
1313,Autocuration,,,1,,,Affinity on 5-hydroxytryptamine 1A receptor labeled by [3H]8-OH-DPAT,H,,,10576,8,,CHEMBL616690,BAO_0000357,
1314,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]-8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL616691,BAO_0000357,
1315,Expert,10116.0,,1,10000000.0,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor of rat hippocampus mambranes,D,,,10576,9,,CHEMBL616692,BAO_0000221,
1316,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane,H,,,10576,8,,CHEMBL616693,BAO_0000249,
1317,Expert,10116.0,,1,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",D,,,10576,9,,CHEMBL616694,BAO_0000019,
1318,Autocuration,,,1,10000000.0,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal tissue,H,,,10576,8,,CHEMBL616695,BAO_0000221,
1319,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat was determined using [3H]8-OH-DPAT in binding assay,H,,,10576,8,,CHEMBL616696,BAO_0000357,
1320,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor using [3H]DOB as radioligand,H,,,10576,8,,CHEMBL616697,BAO_0000357,
1321,Autocuration,,,1,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616698,BAO_0000357,
1322,Expert,10116.0,,1,,,Binding affinity against rat brain 5-hydroxytryptamine 1A receptor,D,,,10576,9,,CHEMBL616949,BAO_0000019,
1323,Autocuration,,,1,10000000.0,,Binding affinity against the 5-hydroxytryptamine 1A receptor labelled with [3H]8-OH-DPAT in rat hippocampal homogenates,H,,,10576,8,,CHEMBL616950,BAO_0000221,
1324,Autocuration,,,1,,,Binding affinity against serotonin 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT binding assay,H,,,10576,8,,CHEMBL832875,BAO_0000357,
1325,Expert,,,1,955.0,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,H,,,10576,8,,CHEMBL616951,BAO_0000221,
1326,Expert,,,1,955.0,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,H,,,10576,8,,CHEMBL616952,BAO_0000221,
1327,Expert,,,1,,,Binding affinity at rat 5-hydroxytryptamine 1A receptor by [3H]WB-4101 displacement.,H,,,10576,8,,CHEMBL616953,BAO_0000357,
1328,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor by use of [3H]8-OH-DPAT in male rat,H,,,10576,8,,CHEMBL616954,BAO_0000357,
1329,Autocuration,,,1,,,GTPgammaS radioligand binding assay,H,,,106,8,,CHEMBL616955,BAO_0000357,
1330,Autocuration,,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,H,,,106,8,,CHEMBL616956,BAO_0000357,
1331,Autocuration,,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Partial agonist,H,,,106,8,,CHEMBL616957,BAO_0000019,
1332,Autocuration,,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Slient antagonist,H,,,106,8,,CHEMBL616958,BAO_0000019,
1333,Autocuration,,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,H,,,106,8,,CHEMBL616959,BAO_0000357,
1334,Autocuration,,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; Not determined,H,,,106,8,,CHEMBL616960,BAO_0000357,
1335,Autocuration,,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; silent antagonist,H,,,106,8,,CHEMBL616961,BAO_0000019,
1336,Expert,,,1,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor,H,,308.0,106,8,,CHEMBL616962,BAO_0000219,
1337,Autocuration,,,1,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor receptor,H,,308.0,106,8,,CHEMBL616963,BAO_0000219,
1338,Expert,9606.0,,1,,,Affinity towards human 5-hydroxytryptamine 1B serotonin receptor,D,,,106,9,,CHEMBL616524,BAO_0000357,
1339,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,H,,449.0,106,8,,CHEMBL616525,BAO_0000219,
1340,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]5-CT as radioligand,H,,,106,8,,CHEMBL872908,BAO_0000019,
1341,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor in C6-glial transfected cell type using [3H]GR-125743 as radioligand,H,,,106,8,,CHEMBL616526,BAO_0000019,
1342,Expert,9606.0,,1,,,Binding affinity to cloned human 5-hydroxytryptamine 1B receptor,D,,,106,9,,CHEMBL616527,BAO_0000357,
1343,Expert,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,H,,,106,8,,CHEMBL616528,BAO_0000219,
1344,Autocuration,,,1,,,Binding affinity for recombinant human 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,H,,,106,8,,CHEMBL616529,BAO_0000357,
1345,Autocuration,,,1,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1B receptor using [3H]5-CT as radioligand,H,,,106,8,,CHEMBL616530,BAO_0000357,
1346,Expert,,,1,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,H,,,106,8,,CHEMBL616531,BAO_0000357,
1347,Autocuration,,,1,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1B receptor,H,,,106,8,,CHEMBL616532,BAO_0000357,
1348,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,H,,,106,8,,CHEMBL616533,BAO_0000357,
1349,Expert,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,H,,,106,8,,CHEMBL616534,BAO_0000357,
1350,Expert,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT trifluoroacetate as radioligand,H,,,106,8,,CHEMBL616535,BAO_0000357,
1351,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1B receptor using [3H]5-HT radioligand,H,,,106,8,,CHEMBL616536,BAO_0000357,
1352,Autocuration,,,1,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1B receptor,H,,,106,8,,CHEMBL616537,BAO_0000357,
1353,Expert,,,1,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1B receptor in CHO-K1 cells,H,,485.0,106,8,,CHEMBL616538,BAO_0000219,
1354,Expert,,,1,,,Agonist activity to the human recombinant 5-hydroxytryptamine 1B receptor,H,,,106,8,,CHEMBL616539,BAO_0000019,
1355,Expert,,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor,H,,,106,8,,CHEMBL616540,BAO_0000019,
1356,Autocuration,,,1,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,H,,,106,8,,CHEMBL616429,BAO_0000357,
1357,Expert,,,1,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor,H,,,106,8,,CHEMBL616430,BAO_0000357,
1358,Expert,9606.0,,1,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1B receptor in Cos-7 cells,D,,,106,9,,CHEMBL616431,BAO_0000219,
1359,Expert,9606.0,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor,D,,,106,9,,CHEMBL616432,BAO_0000357,
1360,Expert,9606.0,,1,,,Affinity for 5-hydroxytryptamine 1B receptor subtype,D,,,106,9,,CHEMBL616433,BAO_0000357,
1361,Expert,9606.0,,1,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,D,,,106,9,,CHEMBL616434,BAO_0000357,
1362,Autocuration,,,1,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand; Not determined,H,,449.0,106,8,,CHEMBL616435,BAO_0000219,
1363,Expert,,,1,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1B receptor; ND means not determined,H,,,106,8,,CHEMBL616436,BAO_0000019,
1364,Autocuration,,,1,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,H,,308.0,106,8,,CHEMBL616437,BAO_0000219,
1365,Autocuration,,,1,,,Ability to displace [3H]5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT=not tested,H,,308.0,106,8,,CHEMBL616438,BAO_0000219,
1366,Autocuration,,,1,,,Ability to displace [3H]-5-CT (1.5 nM) from HeLa cells of human 5-hydroxytryptamine 1B receptor; NT denotes not tested,H,,308.0,106,8,,CHEMBL616439,BAO_0000219,
1367,Expert,9606.0,,1,,,Binding activity against human 5-hydroxytryptamine 1B receptor; NT means not tested,D,,,106,9,,CHEMBL616440,BAO_0000357,
1368,Autocuration,,,1,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor; not tested,H,,485.0,106,8,,CHEMBL616441,BAO_0000219,
1369,Expert,,,1,,,Selectivity ratio against cloned human 5-HT1B receptor to that of h5-HT1D receptor,H,,,106,8,,CHEMBL616442,BAO_0000357,
1370,Autocuration,,,1,,,Selectivity ratio against cloned human 5-hydroxytryptamine 1B receptor to that of human 5-hydroxytryptamine 1D receptor,H,,,106,8,,CHEMBL616443,BAO_0000357,
1371,Expert,,,1,,,Binding affinity in CHO-K1 cells transfected with human recombinant 5-hydroxytryptamine 1B receptor,H,,485.0,106,8,,CHEMBL616444,BAO_0000219,
1372,Expert,9606.0,,1,,,Binding activity against human 5-hydroxytryptamine 1B receptor,D,,,106,9,,CHEMBL616445,BAO_0000357,
1373,Expert,9606.0,,1,,,Binding activity against human 5-hydroxytryptamine 1B receptor,D,,,106,9,,CHEMBL616446,BAO_0000357,
1374,Expert,9606.0,,1,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as radioligand,D,,449.0,106,9,,CHEMBL616447,BAO_0000219,
1375,Autocuration,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1B receptor was determined,H,,,106,8,,CHEMBL616448,BAO_0000357,
1376,Autocuration,,,1,,,Binding affinity against cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-CT as radioligand,H,,449.0,106,8,,CHEMBL616449,BAO_0000219,
1377,Autocuration,,,1,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells,H,,449.0,106,8,,CHEMBL616450,BAO_0000219,
1378,Autocuration,,,1,,,Binding affinity against human 5-hydroxytryptamine 1B receptor cloned receptors in CHO cells using [3H]5-CT as radioligand,H,,449.0,106,8,,CHEMBL857974,BAO_0000219,
1379,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1B (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,H,,449.0,106,8,,CHEMBL616451,BAO_0000219,
1380,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,H,,449.0,106,8,,CHEMBL616452,BAO_0000219,
1381,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand;ND means no data.,H,,449.0,106,8,,CHEMBL616453,BAO_0000219,
1382,Autocuration,,,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT as the radioligand,H,,449.0,106,8,,CHEMBL616454,BAO_0000219,
1383,Expert,9606.0,,1,,,Binding affinity for human 5-hydroxytryptamine 1B receptor,D,,,106,9,,CHEMBL616455,BAO_0000357,
1384,Autocuration,,,1,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,H,,449.0,106,8,,CHEMBL616456,BAO_0000219,
1385,Autocuration,,,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1B receptor in CHO using [3H]5-HT as a radioligand,H,,,106,8,,CHEMBL616457,BAO_0000357,
1386,Autocuration,,,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1B receptor in CHO cells using [3H]5-HT,H,,449.0,106,8,,CHEMBL616458,BAO_0000219,
1387,Autocuration,,,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1B receptor in CHO cells, using [3H]5-HT as radioligand",H,,449.0,106,8,,CHEMBL616459,BAO_0000219,
1388,Expert,,,1,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 1 uM,H,,,106,8,,CHEMBL616460,BAO_0000019,
1389,Expert,,,1,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1B receptor at concentration 10 uM,H,,,106,8,,CHEMBL616461,BAO_0000019,
1390,Autocuration,,,1,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding CHO cells expressing human 5-hydroxytryptamine 1B receptor",H,,449.0,106,8,,CHEMBL616462,BAO_0000219,
1391,Autocuration,,,1,,,"Effect of compound on [35S]GTP-gamma-S, radioligand binding in CHO cells expressing human 5-hydroxytryptamine 1B receptor",H,,449.0,106,8,,CHEMBL616463,BAO_0000219,
1392,Autocuration,,,1,,,"Compound was tested for maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-HT.",H,,,105,8,,CHEMBL616464,BAO_0000019,
1393,Autocuration,,,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells.,H,,449.0,105,8,,CHEMBL616465,BAO_0000219,
1394,Autocuration,,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,H,,,17105,8,,CHEMBL832874,BAO_0000357,
1395,Autocuration,9986.0,,1,,,5-hydroxytryptamine 1B receptor agonist potency determined in rabbit saphenous vein contraction model,H,,,106,8,,CHEMBL616184,BAO_0000019,
1396,Autocuration,9986.0,,1,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein (RbSV).,H,,,106,8,,CHEMBL616185,BAO_0000019,
1397,Intermediate,9986.0,,1,,,"Binding affinity against vascular 5-hydroxytryptamine 1B receptor, measured using ring preparations of rabbit saphenous vein (RbSV)",H,,,106,8,,CHEMBL616186,BAO_0000019,
1398,Autocuration,9986.0,,1,,,The vascular 5-hydroxytryptamine 1B receptor affinity was assessed using ring preparations of rabbit saphenous vein(RbSV).,H,,,106,8,,CHEMBL616187,BAO_0000019,
1399,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor was measured using [3H]5-HT as radioligand,H,,,10577,8,,CHEMBL616188,BAO_0000357,
1400,Intermediate,,,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor,D,,,10577,9,,CHEMBL873475,BAO_0000357,
1401,Expert,10116.0,,1,2435.0,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Less active,D,,,10577,9,,CHEMBL616189,BAO_0000019,
1402,Expert,,,1,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,H,,,10577,8,,CHEMBL616190,BAO_0000357,
1403,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT as radioligand; range=48-77,H,,,10576,8,,CHEMBL616191,BAO_0000357,
1404,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=63-95,H,,,10576,8,,CHEMBL616192,BAO_0000357,
1405,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=710-980,H,,,10576,8,,CHEMBL616193,BAO_0000357,
1406,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=78-140,H,,,10576,8,,CHEMBL616194,BAO_0000357,
1407,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=85-130,H,,,10576,8,,CHEMBL616195,BAO_0000357,
1408,Autocuration,,,1,,,In vitro binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand; range=89-280,H,,,10576,8,,CHEMBL616196,BAO_0000357,
1409,Autocuration,,,1,10000000.0,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat hippocampus membrane.,H,,,10576,8,,CHEMBL616197,BAO_0000249,
1410,Intermediate,,,1,,,Binding affinity at 5-hydroxytryptamine 1A (5-HT1A) receptor in rat cerebral cortex using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL616198,BAO_0000019,
1411,Autocuration,,,1,10000000.0,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor using [125I](R)-(+)-trans-8-OH-PIPAT as radioligand in rat hippocampal homogenate,H,,,10576,8,,CHEMBL616199,BAO_0000221,
1412,Expert,,,1,10000000.0,,In vitro binding affinity to 5-hydroxytryptamine 1A receptor in rat hippocampal homogenate by [125I](R)-(+)-trans-8-OH-PIPAT displacement.,H,,,10576,8,,CHEMBL616200,BAO_0000221,
1413,Expert,,,1,10000000.0,,In vitro binding affinity to rat hippocampal 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL616201,BAO_0000221,
1414,Expert,,,1,10000000.0,,In vitro binding affinity towards 5-hydroxytryptamine 1A r receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,H,,,10576,8,,CHEMBL616202,BAO_0000221,
1415,Expert,,,1,10000000.0,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates,H,,,10576,8,,CHEMBL616203,BAO_0000221,
1416,Expert,,,1,10000000.0,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; ND=not determined,H,,,10576,8,,CHEMBL616204,BAO_0000221,
1417,Expert,,,1,10000000.0,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; Not determined,H,,,10576,8,,CHEMBL616205,BAO_0000221,
1418,Expert,,,1,10000000.0,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT radioligand in rat hippocampal homogenates; not determined,H,,,10576,8,,CHEMBL616206,BAO_0000221,
1419,Expert,,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes,H,,,10576,8,,CHEMBL616207,BAO_0000249,
1420,Autocuration,,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes,H,,,10576,8,,CHEMBL616208,BAO_0000249,
1421,Autocuration,,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membranes; Inactive,H,,,10576,8,,CHEMBL616209,BAO_0000249,
1422,Expert,,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor was determined using radioligand [3H]-8-OH-DPAT,H,,,10576,8,,CHEMBL616210,BAO_0000357,
1423,Expert,,,1,10000000.0,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue.,H,,,10576,8,,CHEMBL616211,BAO_0000221,
1424,Autocuration,,,1,10000000.0,,In vitro inhibition of [3H]spiperone binding to 5-hydroxytryptamine 1A receptor from rat hippocampal tissue; NT=Not tested,H,,,10576,8,,CHEMBL616504,BAO_0000221,
1425,Expert,10116.0,,1,10000000.0,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,D,,,10576,9,,CHEMBL616505,BAO_0000221,
1426,Autocuration,,,1,,,Inhibition constant of 50 uM forskolin-stimulated cAMP accumulation against 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616506,BAO_0000019,
1427,Autocuration,,,1,10000000.0,,Inhibition of binding of [125I]8-OH-PIPAT ligand to 5-hydroxytryptamine 1A receptor of rat hippocampal homogenates,H,,,10576,8,,CHEMBL872107,BAO_0000221,
1428,Expert,10116.0,,1,10000000.0,,Displacement of [3H]5-HT from rat hippocampal 5-hydroxytryptamine 1A receptor with 10e-6 M ketanserin,D,,,10576,9,,CHEMBL616507,BAO_0000221,
1429,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor in rat cortical membranes using [3H]8-OH-DPAT as a radioligand,H,,,10576,8,,CHEMBL616303,BAO_0000249,
1430,Autocuration,,,1,10000000.0,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue,H,,,10576,8,,CHEMBL616304,BAO_0000221,
1431,Expert,,,1,10000000.0,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,H,,,10576,8,,CHEMBL616305,BAO_0000221,
1432,Intermediate,,,1,10000000.0,,Antagonist activity against rat hippocampal tissue 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616306,BAO_0000221,
1433,Autocuration,,,1,,,Inhibitory affinity constant against 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616307,BAO_0000357,
1434,Expert,10116.0,,1,10000000.0,,Displacement of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat brain hippocampus,D,,,10576,9,,CHEMBL881829,BAO_0000221,
1435,Expert,,,1,,,Affinity against the 5-hydroxytryptamine receptor 1A using [3H]WB-4101.,H,,,10576,8,,CHEMBL616308,BAO_0000357,
1436,Autocuration,,,1,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain,H,,,10576,8,,CHEMBL616309,BAO_0000019,
1437,Expert,,,1,,,Tested for affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in homogenized rat brain tissue,H,,,10576,8,,CHEMBL616310,BAO_0000019,
1438,Autocuration,,,1,,,Tested for affinity against 5-hydroxytryptamine 1A receptors using [3H]8-OH-DPAT in homogenized rat cloned CHO cells,H,,449.0,10576,8,,CHEMBL616311,BAO_0000219,
1439,Expert,,,1,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL616312,BAO_0000357,
1440,Autocuration,,,1,,,Tested for binding affinity against 5-hydroxytryptamine 1A receptor from rat frontal cortical regions using [3H]8-OH-DPAT as radioligand; ND is Not Determined,H,,,10576,8,,CHEMBL616313,BAO_0000357,
1441,Expert,10116.0,,1,10000000.0,,Displacement of [3H]8-OH-DPAT from rat hippocampal 5-hydroxytryptamine 1A receptor,D,,,10576,9,,CHEMBL616314,BAO_0000221,
1442,Autocuration,,,1,10000000.0,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,,10576,8,,CHEMBL616315,BAO_0000221,
1443,Autocuration,,,1,10000000.0,,Tested for binding affinity by measuring displacement of [3H]8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; NA means Not Active,H,,,10576,8,,CHEMBL616567,BAO_0000221,
1444,Autocuration,,,1,10000000.0,,Tested for binding affinity by measuring displacement of [3H]-8-OH-DPAT from rat serotonin 5-hydroxytryptamine 1A receptor in rat hippocampus; ND means Not Determined,H,,,10576,8,,CHEMBL616568,BAO_0000221,
1445,Intermediate,,,1,,,Binding affinity to displace [3H]2-(di-N-propylamino)-8-hydroxy-tetralin from 5-hydroxytryptamine 1A (5-HT1A) receptor in rat frontal cortex homogenates,H,,,10576,8,,CHEMBL616569,BAO_0000019,
1446,Expert,,,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand assay.,H,,,10576,8,,CHEMBL616570,BAO_0000357,
1447,Autocuration,,,1,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 1A receptor agonist [3H]- 8-OH-DPAT,H,,,10576,8,,CHEMBL616571,BAO_0000357,
1448,Autocuration,,,1,10000000.0,,Tested for the inhibitory activity against 5-hydroxytryptamine 1A receptor in rat hippocampal,H,,,10576,8,,CHEMBL616572,BAO_0000221,
1449,Expert,,,1,,,Tested in vitro for binding affinity by measuring its ability to inhibit [3H]8-OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat cerebral cortex membranes.,H,,,10576,8,,CHEMBL616573,BAO_0000249,
1450,Expert,10116.0,,1,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 1A receptor using radioligand [3H]8-OH-DPAT,D,,,10576,9,,CHEMBL616574,BAO_0000357,
1451,Expert,,,1,10000000.0,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation,H,,,10576,8,,CHEMBL616575,BAO_0000221,
1452,Autocuration,,,1,10000000.0,,The binding affinity by measuring its ability to displace [3H]8-OH-DPAT radioligand in 5-hydroxytryptamine 1A receptor on rat hippocampal preparation; ND=not determined,H,,,10576,8,,CHEMBL872108,BAO_0000221,
1453,Autocuration,,,1,,,The binding affinity was measured on 5-hydroxytryptamine 1A receptor using [3H]- 8-OH-DPAT as radioligand.,H,,,10576,8,,CHEMBL616576,BAO_0000357,
1454,Autocuration,,,1,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 1 mM of MnCl2,H,,,10576,8,,CHEMBL616577,BAO_0000249,
1455,Autocuration,,,1,,,The compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor in rat hippocampal membranes using [3H]8-OH-DPAT as radioligand in the presence of 3*10e-5 M GTP gamma S,H,,,10576,8,,CHEMBL616578,BAO_0000249,
1456,Expert,,,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor from striata of wistar rats by [3H]- 8-OH -DPAT displacement.,H,,,10576,8,,CHEMBL616579,BAO_0000357,
1457,Expert,10116.0,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor of rat brain synaptosomal preparations,D,,,10576,9,,CHEMBL616580,BAO_0000019,
1458,Autocuration,,,1,,,The compound was tested binding affinity against 5-hydroxytryptamine 1A receptor from rat brain using [3H]8-OH-DPAT as radioligand at 10e-6 M.,H,,,10576,8,,CHEMBL616581,BAO_0000019,
1459,Autocuration,,,1,10000000.0,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,,10576,8,,CHEMBL616582,BAO_0000221,
1460,Expert,,,1,10000000.0,,The compound was tested for binding affinity on [3H]8-OH-DPAT as specific ligand on 5-hydroxytryptamine 1A receptor in rat hippocampus,H,,,10576,8,,CHEMBL616583,BAO_0000221,
1461,Expert,10116.0,,1,10000000.0,,Binding affinity against 5-hydroxytryptamine 1A receptor of rat hippocampus using [3H]8-OH-DPAT,D,,,10576,9,,CHEMBL616584,BAO_0000221,
1462,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616585,BAO_0000357,
1463,Expert,10116.0,,1,10000000.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 from rat hippocampus,D,,,10576,9,,CHEMBL616586,BAO_0000221,
1464,Autocuration,,,1,10000000.0,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1A receptor by displacing [3H]WB-4101 radioligand in rat hippocampus,H,,,10576,8,,CHEMBL616587,BAO_0000221,
1465,Autocuration,,,1,10000000.0,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]-8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL616588,BAO_0000221,
1466,Autocuration,,,1,10000000.0,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand.,H,,,10576,8,,CHEMBL616589,BAO_0000221,
1467,Expert,,,1,10000000.0,,Binding affinity for 5-hydroxytryptamine 1A receptor from rat hippocampus using [3H]8-OH-DPAT as radioligand,H,,,10576,8,,CHEMBL616590,BAO_0000221,
1468,Expert,,,1,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1A receptor expressed in CHO cells, by using [3H]8-OH-DPAT as radioligand.",H,,449.0,10576,8,,CHEMBL616591,BAO_0000219,
1469,Expert,,,1,,,Displacement of the radioligand [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616592,BAO_0000357,
1470,Autocuration,,,1,,,The inhibition activity of 5-HT1A at 1 uM,H,,,10576,8,,CHEMBL616593,BAO_0000357,
1471,Expert,,,1,,,"Binding affinity against 5-hydroxytryptamine 1A receptor from CHO-K1 cells, using [3H]8-OH-DPAT as the radioligand.",H,,485.0,10576,8,,CHEMBL616594,BAO_0000219,
1472,Expert,,,1,,,Binding affinities against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in rat cerebral cortex membrane,H,,,10576,8,,CHEMBL616595,BAO_0000249,
1473,Autocuration,,,1,,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-HT 1A receptor site.,H,,,10576,8,,CHEMBL616596,BAO_0000357,
1474,Autocuration,,,1,10000000.0,,Compound was evaluated for its ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,H,,,10576,8,,CHEMBL616597,BAO_0000221,
1475,Expert,,,1,10000000.0,,Ability to displace the protonated form of [3H]8-hydroxy-2-(di-n-propylamino)tetralin binding from labeled 5-hydroxytryptamine 1A receptor site in rat brain hippocampus,H,,,10576,8,,CHEMBL616598,BAO_0000221,
1476,Expert,10116.0,,1,,,Antagonist activity to stimulate binding of [35S]-GTP-gamma S binding to 5-hydroxytryptamine 1A receptor in isolated rat hippocampal membranes,D,Membranes,,10576,9,,CHEMBL616599,BAO_0000249,
1477,Expert,10116.0,,1,10000000.0,,"Inhibition of (+)-8-OH-DPAT stimulated [35S]GTP-gamma-S, binding in rat hippocampal membranes",D,Membranes,,10576,9,,CHEMBL616600,BAO_0000249,
1478,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not -determined.,H,,,10576,8,,CHEMBL616601,BAO_0000019,
1479,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not defined.,H,,,10576,8,,CHEMBL616602,BAO_0000019,
1480,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is defined as not determined.,H,,,10576,8,,CHEMBL616603,BAO_0000019,
1481,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND means not determined.,H,,,10576,8,,CHEMBL616604,BAO_0000019,
1482,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; No data,H,,,10576,8,,CHEMBL616316,BAO_0000249,
1483,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor was determined in rat cortex membranes using [3H]8-OH-DPAT as radioligand; Not determined,H,,,10576,8,,CHEMBL616317,BAO_0000249,
1484,Expert,10116.0,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex homogenates; ND means No data,D,,,10576,9,,CHEMBL616318,BAO_0000019,
1485,Autocuration,,,1,10000000.0,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes,H,,,10576,8,,CHEMBL616319,BAO_0000221,
1486,Autocuration,,,1,10000000.0,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT from rat hippocampus mambranes; Not tested,H,,,10576,8,,CHEMBL616320,BAO_0000221,
1487,Expert,10116.0,,1,10000000.0,,Binding affinity for rat hippocampus 5-hydroxytryptamine 1A receptor by inhibition of [3H]8-OH-DPAT binding; Not tested,D,,,10576,9,,CHEMBL616321,BAO_0000221,
1488,Autocuration,,,1,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,H,,,10576,8,,CHEMBL616322,BAO_0000019,
1489,Autocuration,,,1,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; not tested,H,,,10576,8,,CHEMBL616323,BAO_0000019,
1490,Autocuration,,,1,,,Ratio of binding affinity to 5-HT 1A and D2 receptor,H,,,10576,8,,CHEMBL616324,BAO_0000357,
1491,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,H,,,10576,8,,CHEMBL616325,BAO_0000221,
1492,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus at 1 uM,H,,,10576,8,,CHEMBL616326,BAO_0000221,
1493,Autocuration,,,1,10000000.0,,In vitro ability to inhibit [3H]-8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat hippocampus.,H,,,10576,8,,CHEMBL616327,BAO_0000221,
1494,Autocuration,,,1,,,Percentage inhibition against 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616328,BAO_0000357,
1495,Autocuration,,,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),H,,,10576,8,,CHEMBL858110,BAO_0000249,
1496,Autocuration,,,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 1),H,,,10576,8,,CHEMBL616329,BAO_0000249,
1497,Autocuration,,,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),H,,,10576,8,,CHEMBL616330,BAO_0000249,
1498,Autocuration,,,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes (experiment 2),H,,,10576,8,,CHEMBL616331,BAO_0000249,
1499,Autocuration,,,1,,,Compound was tested for its potency against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,H,,,10576,8,,CHEMBL616332,BAO_0000249,
1500,Autocuration,,,1,955.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,,,10576,8,,CHEMBL857063,BAO_0000249,
1501,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat frontal cortex using [3H]8-OH-DPAT as a radioligand,H,,,10576,8,,CHEMBL616333,BAO_0000019,
1502,Expert,,,1,,,Antagonistic activity against 5-hydroxytryptamine 1A receptor in rat cerebral cortex using [3H]-8-OH-DPAT as radioligand.,H,,,10576,8,,CHEMBL616334,BAO_0000019,
1503,Autocuration,,,1,10000000.0,,Binding affinity of 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,H,,,10576,8,,CHEMBL616335,BAO_0000221,
1504,Autocuration,,,1,,,Affinity pKi for 5-hydroxytryptamine 1A receptor was measured in rat cortex homogenates.,H,,,10576,8,,CHEMBL616336,BAO_0000019,
1505,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cerebral cortical membrane using [3H]-8-OH-DPAT as radioligand.,H,,,10576,8,,CHEMBL616337,BAO_0000249,
1506,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor in rat cortex homogenates.,H,,,10576,8,,CHEMBL616338,BAO_0000019,
1507,Autocuration,,,1,10000000.0,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]- 8-hydri\oxy-2-(di-n-propylamino)tetraline) binding assay,H,,,10576,8,,CHEMBL616339,BAO_0000221,
1508,Autocuration,,,1,10000000.0,,Binding affinity against native 5-HT1A-receptors from rat hippocampus using radioligand ([3H]8-hydroxy-2-(di-n-propylamino)-tetraline) binding assay,H,,,10576,8,,CHEMBL616340,BAO_0000221,
1509,Autocuration,,,1,,,Binding affinity of compound towards 5-hydroxytryptamine 1A receptor was determined,H,,,10576,8,,CHEMBL616341,BAO_0000357,
1510,Expert,10116.0,,1,,,Binding affinity against rat 5-hydroxytryptamine 1A receptor,D,,,10576,9,,CHEMBL616342,BAO_0000357,
1511,Expert,10116.0,,1,,,Inhibition of [3H]2-(di-N-propylamino)-8-hydroxytetralin binding to 5-HT1A receptor of rat frontal cortex homogenates,D,,,10576,9,,CHEMBL616343,BAO_0000019,
1512,Expert,,,1,,,Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement,H,,,10576,8,,CHEMBL616344,BAO_0000019,
1513,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,H,,,10576,8,,CHEMBL616345,BAO_0000357,
1514,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat cortex using [3H]8-OH-DPAT as a radioligand,H,,,10576,8,,CHEMBL616346,BAO_0000019,
1515,Autocuration,,,1,10000000.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT in rat hippocampus,H,,,10576,8,,CHEMBL616347,BAO_0000221,
1516,Expert,,,1,,,In vitro by displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor on rat cortical membrane,H,,,10576,8,,CHEMBL616348,BAO_0000019,
1517,Expert,,,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor,H,,,10576,8,,CHEMBL616349,BAO_0000357,
1518,Expert,10116.0,,1,,,Inhibition of [3H]8-OH-DPAT binding to 5-hydroxytryptamine 1A receptor of rat frontal cortex membranes,D,Membranes,,10576,9,,CHEMBL616152,BAO_0000249,
1519,Autocuration,,,1,,,Compound was tested for inhibition constant against 5-hydroxytryptamine 1A receptor in rat frontal cortex membranes.,H,,,10576,8,,CHEMBL616153,BAO_0000249,
1520,Expert,,,1,,,"Binding affinity for rat cortex 5-hydroxytryptamine 1A receptor, by displacement of 0.2 nM [3H]8-OH-DPAT radioligand",H,,,10576,8,,CHEMBL616154,BAO_0000019,
1521,Autocuration,,,1,,,In vitro ability to inhibit binding of radioligand [3H]8-OH-DPAT to 5-hydroxytryptamine 1A receptor in rat cerebral cortex,H,,,10576,8,,CHEMBL616155,BAO_0000019,
1522,Expert,10116.0,,1,10000000.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus using [3H]8-OH-DPAT,D,,,10576,9,,CHEMBL616156,BAO_0000221,
1523,Expert,10116.0,,1,10000000.0,,Binding affinity towards 5-hydroxytryptamine 1A receptor in rat hippocampus with [3H]8-OH-DPAT,D,,,10576,9,,CHEMBL616157,BAO_0000221,
1524,Autocuration,,,1,10000000.0,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]-SB 207710 as radioligand,H,,,10576,8,,CHEMBL616158,BAO_0000221,
1525,Autocuration,,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand.,H,,,10576,8,,CHEMBL616159,BAO_0000357,
1526,Expert,,,1,,,pKi value against rat 5-hydroxytryptamine 1A receptor.,H,,,10576,8,,CHEMBL616160,BAO_0000357,
1527,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor by displacing [3H]8-OH-DPAT radioligand in rat cortex membrane;ND is define as non-determined.,H,,,10576,8,,CHEMBL616161,BAO_0000019,
1528,Autocuration,,,1,,,Evaluated for the 5-hydroxytryptamine 1A receptor agonist activity in LY-293284 trained rats; Not tested,H,,,10576,8,,CHEMBL616162,BAO_0000019,
1529,Expert,10116.0,,1,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,D,,,12687,9,,CHEMBL616163,BAO_0000357,
1530,Expert,,,1,,,Inhibition of specific [3H]OH-DPAT binding at 5-hydroxytryptamine 1A receptor in rat hippocampal membranes,H,Membranes,,10626,8,,CHEMBL616164,BAO_0000249,
1531,Autocuration,,,1,955.0,,Concentration of compound required to inhibit cortical 5-hydroxytryptamine 1A receptor binding sites in rat brain was evaluated,H,,,10576,8,,CHEMBL616165,BAO_0000221,
1532,Autocuration,10116.0,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor isolated from rat hippocampus membranes membrane using [3H]5-HT as radioligand in the presence of 10e-6 M ketanserin as 5-HT2 blocker,H,,,51,8,,CHEMBL616355,BAO_0000019,
1533,Autocuration,,,1,,,Effect on 5-hydroxytryptamine 1A receptor mediated inhibition of VIP-stimulated cAMP production at dose of 1 uM+ 50 uM 5-HT.,H,,,10576,8,,CHEMBL616356,BAO_0000019,
1534,Autocuration,,,1,955.0,,Binding affinity at 5-hydroxytryptamine 1A receptor by the displacement of [3H]8-OH-DPAT in rat brain.,H,,,10576,8,,CHEMBL616357,BAO_0000221,
1535,Autocuration,,,1,,,"Binding affinity against 5-hydroxytryptamine 1A receptor in homogenated rat brain tissue, using by [3H]8-OH-DPAT as radioligand",H,,,10576,8,,CHEMBL616358,BAO_0000019,
1536,Autocuration,,,1,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616359,BAO_0000357,
1537,Expert,,,1,,,Percent decrease in 5-hydroxytryptamine 1A receptor binding using 8-OH-DPAT,H,,,51,8,,CHEMBL616360,BAO_0000357,
1538,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616361,BAO_0000357,
1539,Autocuration,,,1,,,Tested for binding affinity for 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616362,BAO_0000357,
1540,Autocuration,,,1,,,The compound was evaluated for its ability to displace [3H]-8-OH-DPAT from 5-hydroxytryptamine 1A receptor in cellular brain membranes,H,Brain membranes,,51,8,,CHEMBL616363,BAO_0000249,
1541,Autocuration,,,1,,,Inhibition of binding towards 5-hydroxytryptamine 1A receptor at 100 nM concentration,H,,,51,8,,CHEMBL616364,BAO_0000357,
1542,Autocuration,,,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616365,BAO_0000357,
1543,Expert,,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor determined using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL616366,BAO_0000357,
1544,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL872906,BAO_0000357,
1545,Autocuration,,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1A receptor; inactive at 10 uM,H,,,51,8,,CHEMBL616367,BAO_0000357,
1546,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616368,BAO_0000357,
1547,Autocuration,,,1,,,Binding affinity to 5-hydroxytryptamine 1A receptor was determined,H,,,51,8,,CHEMBL616369,BAO_0000357,
1548,Expert,9606.0,,1,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H]-(+)-8-OH-DPAT.,D,,,51,9,,CHEMBL616370,BAO_0000357,
1549,Expert,9606.0,,1,,,Binding affinity towards Serotonin 5-hydroxytryptamine 1A receptor by displacement of [3H](+)-8-OH-DPAT; inactive,D,,,51,9,,CHEMBL616371,BAO_0000357,
1550,Autocuration,,,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,,449.0,51,8,,CHEMBL616372,BAO_0000219,
1551,Expert,,,1,,,Displacement of [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor expressed in CHO cell membranes,H,,,51,8,,CHEMBL616373,BAO_0000219,
1552,Autocuration,,In vivo,1,,,Compound was measured in vivo for its binding affinity at 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand,H,,,51,8,,CHEMBL616374,BAO_0000218,
1553,Autocuration,,,1,10000000.0,,Tested for activity against 5-hydroxytryptamine 1A receptor from bovine hippocampus,H,,,51,8,,CHEMBL616375,BAO_0000221,
1554,Autocuration,,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1A receptor was determined,H,,,51,8,,CHEMBL616376,BAO_0000357,
1555,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1A receptor by displacement of [3H]8-OH-DPAT.,H,,,51,8,,CHEMBL857064,BAO_0000357,
1556,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,H,,,51,8,,CHEMBL616377,BAO_0000357,
1557,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined,H,,,51,8,,CHEMBL616378,BAO_0000357,
1558,Autocuration,,,1,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1A receptor,H,,,51,8,,CHEMBL616379,BAO_0000357,
1559,Autocuration,,,1,,,Ability to displace [3H]8-OH-DPAT from 5-hydroxytryptamine 1A receptor,H,,,11863,8,,CHEMBL616380,BAO_0000357,
1560,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor was determined using [3H]-8-OH-DPAT radioligand,H,,,11863,8,,CHEMBL616381,BAO_0000357,
1561,Autocuration,,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1A receptor,H,,,11863,8,,CHEMBL616382,BAO_0000357,
1562,Autocuration,,,1,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 1A receptor by using [3H]DPAT as radioligand,H,,,11863,8,,CHEMBL616383,BAO_0000357,
1563,Expert,10090.0,,1,,,In vitro binding affinity against 5-hydroxytryptamine 1A receptor in CHO cells,D,,449.0,11863,9,,CHEMBL616350,BAO_0000219,
1564,Autocuration,,,1,,,Inhibition of 5-OH-DPAT binding to 5-hydroxytryptamine 1A receptor,H,,,11863,8,,CHEMBL616351,BAO_0000357,
1565,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand at 10e-5 M concentration,H,,,11863,8,,CHEMBL616352,BAO_0000357,
1566,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,,,11863,8,,CHEMBL616353,BAO_0000357,
1567,Autocuration,,,1,,,Binding affinity against serotonergic 5-HT1a receptor,H,,,11863,8,,CHEMBL616354,BAO_0000357,
1568,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor was determined by using [3H]8-OH-DPAT as radioligand,H,,,11863,8,,CHEMBL616508,BAO_0000357,
1569,Expert,10090.0,,1,,,Binding affinity for 5-hydroxytryptamine 1A receptor,D,,,11863,9,,CHEMBL616559,BAO_0000357,
1570,Autocuration,,,1,,,Binding affinity at 5-hydroxytryptamine 1A receptor,H,,,11863,8,,CHEMBL616560,BAO_0000357,
1571,Autocuration,,,1,,,"Binding affinity towards 5-hydroxytryptamine 1A receptor receptor, using [3H]5-HT as radioligand.",H,,,11863,8,,CHEMBL616561,BAO_0000357,
1572,Autocuration,,,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,,449.0,11863,8,,CHEMBL616562,BAO_0000219,
1573,Autocuration,,,1,,,Compound was evaluated for the binding affinity against [3H]8-OH-DPAT-labeled 5-hydroxytryptamine 1A receptor sites in cloned CHO cells,H,,449.0,11863,8,,CHEMBL616563,BAO_0000219,
1574,Autocuration,,,1,,,Compound was tested for binding affinity using [3H]8-OH-DPAT against 5-hydroxytryptamine 1A receptor,H,,,11863,8,,CHEMBL616564,BAO_0000357,
1575,Autocuration,,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1A receptor by using [3H]-8-OH-DPAT as radioligand,H,,,11863,8,,CHEMBL616565,BAO_0000357,
1576,Autocuration,,,1,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 1A receptor,H,,,11863,8,,CHEMBL616566,BAO_0000218,
1577,Autocuration,,,1,,,The binding affinity towards 5-hydroxytryptamine 1A receptor; No affinity,H,,,11863,8,,CHEMBL616989,BAO_0000357,
1578,Autocuration,,,1,,,Ability to displace [125I]iodosulpiride from 5-hydroxytryptamine 1A receptor,H,,,11863,8,,CHEMBL857975,BAO_0000357,
1579,Expert,10090.0,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,D,,,11863,9,,CHEMBL616990,BAO_0000357,
1580,Autocuration,,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 1A receptor using radioligand binding assay,H,,,11863,8,,CHEMBL616991,BAO_0000357,
1581,Autocuration,,,1,,,Tested against 5-hydroxytryptamine 1A receptor,H,,,11863,8,,CHEMBL616992,BAO_0000357,
1582,Autocuration,,,1,,,The compound's binding affinity against 5-hydroxytryptamine 1A receptor,H,,,11863,8,,CHEMBL616993,BAO_0000357,
1583,Expert,9986.0,,1,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein,H,,,106,8,,CHEMBL616994,BAO_0000019,
1584,Autocuration,9986.0,,1,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 1B like receptor in the rabbit saphenous vein(RbSV); NS=non surmountable,H,,,106,8,,CHEMBL616995,BAO_0000019,
1585,Intermediate,9593.0,,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1B receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,D,,722.0,105571,9,,CHEMBL616996,BAO_0000219,
1586,Autocuration,10141.0,In vivo,1,,,5-HT1B agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,H,,,106,8,,CHEMBL616997,BAO_0000218,
1587,Autocuration,10141.0,In vivo,1,,,5-hydroxytryptamine 1B receptor agonist potency was evaluated as effective dose that induced hypothermia in the guinea-pig upon intraperitoneal administration,H,,,106,8,,CHEMBL616998,BAO_0000218,
1588,Autocuration,10141.0,,1,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery,H,,,106,8,,CHEMBL616999,BAO_0000019,
1589,Autocuration,10141.0,,1,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor in isolated guinea-pig iliac artery; n.d. indicates Not determined,H,,,106,8,,CHEMBL617000,BAO_0000019,
1590,Autocuration,10141.0,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig,H,,,106,8,,CHEMBL617001,BAO_0000019,
1591,Autocuration,10141.0,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 1B receptor of guinea pig; ND means not done,H,,,106,8,,CHEMBL858111,BAO_0000019,
1592,Autocuration,,,1,,,Intrinsic activity for Antagonism of 5-hydroxytryptamine 1B receptor-mediated stimulation of [35S]GTP gamma S binding,H,,,106,8,,CHEMBL617002,BAO_0000019,
1593,Autocuration,,,1,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine (5-CT),H,,,106,8,,CHEMBL617003,BAO_0000019,
1594,Autocuration,,,1,,,Antagonism tested at 1 uM against the agonist-induced inhibitory effect of 10 nM 5-carbamoyltryptamine(5-CT),H,,,106,8,,CHEMBL617004,BAO_0000019,
1595,Expert,9606.0,,1,,,Agonist activity at 5-hydroxytryptamine 1B receptor by measuring the inhibition of forskolin-stimulated cAMP formation,D,,,106,9,,CHEMBL617005,BAO_0000019,
1596,Expert,9606.0,,1,,,Inhibition of forskolin-stimulated c-AMP formation by human 5-hydroxytryptamine 1B receptor expressed in CHO-K1 cells,D,,485.0,106,9,,CHEMBL616623,BAO_0000219,
1597,Autocuration,,,1,,,Effective concentration determined by measuring inhibition of forskolin-stimulated c-AMP formation at 5-hydroxytryptamine 1B receptor stably transfected in CHO cell lines,H,,449.0,106,8,,CHEMBL616624,BAO_0000219,
1598,Autocuration,,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor,H,,,106,8,,CHEMBL883243,BAO_0000357,
1599,Autocuration,,,1,,,The compound was evaluated for intrinsic activity against human cloned 5-hydroxytryptamine 1B receptor; full agonist,H,,,106,8,,CHEMBL616625,BAO_0000019,
1600,Expert,,,1,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1B receptor",H,,449.0,106,8,,CHEMBL616626,BAO_0000219,
1601,Autocuration,,,1,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line,H,,449.0,106,8,,CHEMBL616627,BAO_0000219,
1602,Autocuration,,,1,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Antagonist,H,,449.0,106,8,,CHEMBL616628,BAO_0000219,
1603,Autocuration,,,1,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Full Agonist,H,,449.0,106,8,,CHEMBL616629,BAO_0000219,
1604,Autocuration,,,1,,,The intrinsic activity was evaluated for its ability to inhibit forskolin-stimulated c-AMP formation mediated by cloned 5-hydroxytryptamine 1B receptor in CHO cell line; Partial Agonist,H,,449.0,106,8,,CHEMBL616630,BAO_0000219,
1605,Expert,,,1,,,"Efficacy was evaluated relative to human 5-HT1B receptor using [35S]GTP-gamma-S, as radioligand",H,,,106,8,,CHEMBL616631,BAO_0000019,
1606,Autocuration,,,1,,,"Efficacy of compound was evaluated relative to human 5-hydroxytryptamine 1B receptor using [35S]GTP-gamma-S, as radioligand",H,,,106,8,,CHEMBL616632,BAO_0000019,
1607,Expert,9606.0,,1,,,Percentage Maximal inhibition obtained with 1 uM 5-HT against 5-hydroxytryptamine 1B receptor,D,,,106,9,,CHEMBL616633,BAO_0000357,
1608,Expert,,,1,,,Ability to displace [3H]5-HT from recombinant human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells determined in vitro,H,,449.0,106,8,,CHEMBL616634,BAO_0000219,
1609,Autocuration,,,1,,,Affinity of compound towards 5-hydroxytryptamine 1B receptor was evaluated using radioligand binding technique,H,,,106,8,,CHEMBL616635,BAO_0000357,
1610,Expert,9606.0,,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor,D,,,106,9,,CHEMBL885358,BAO_0000357,
1611,Expert,9606.0,,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1B receptor expressed in CHO cells,D,,449.0,106,9,,CHEMBL616636,BAO_0000219,
1612,Expert,,,1,,,Binding affinity to human cloned 5-hydroxytryptamine 1B receptor in CHO cells by [3H]5-HT binding displacement.,H,,449.0,106,8,,CHEMBL616637,BAO_0000219,
1613,Autocuration,,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1B receptor,H,,,106,8,,CHEMBL616638,BAO_0000357,
1614,Expert,,,1,,,Displacement of [3H]5-HT binding to cloned 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,H,,449.0,106,8,,CHEMBL616639,BAO_0000219,
1615,Expert,,,1,,,Binding affinity at cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells by [3H]5-HT displacement.,H,,449.0,106,8,,CHEMBL616640,BAO_0000219,
1616,Expert,,,1,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells,H,,449.0,106,8,,CHEMBL616641,BAO_0000219,
1617,Expert,,,1,,,Displacement of [3H]5-HT binding from cloned human 5-hydroxytryptamine 1B receptor stably expressed in CHO cells.,H,,449.0,106,8,,CHEMBL616642,BAO_0000219,
1618,Expert,,,1,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1B receptor expressed in CHO cells,H,,449.0,106,8,,CHEMBL616643,BAO_0000219,
1619,Autocuration,,,1,,,In vitro binding affinity against human 5-hydroxytryptamine 1B receptor at a concentration of 100 (nM),H,,,106,8,,CHEMBL616644,BAO_0000357,
1620,Autocuration,,,1,,,Intrinsic activity for each compound is calculated as a percentage of the 5-hydroxytryptamine 1B receptor response,H,,,106,8,,CHEMBL616645,BAO_0000357,
1621,Autocuration,9986.0,,1,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),H,,,105,8,,CHEMBL616646,BAO_0000019,
1622,Expert,9986.0,,1,,,Tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),H,,,105,8,,CHEMBL616647,BAO_0000019,
1623,Autocuration,,,1,,,Affinity at 5-hydroxytryptamine 1D receptor (For sumatriptan = Ki (nM)-12+/-1.9),H,,,105,8,,CHEMBL616509,BAO_0000357,
1624,Autocuration,,,1,,,Affinity at 5-hydroxytryptamine 1D receptor from calf caudate using [3H]5-HT as radioligand (For sumatriptan = Ki(nM)-12+/-1.9),H,,,105,8,,CHEMBL616510,BAO_0000357,
1625,Autocuration,,,1,,,Binding affinity against calf caudate 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616511,BAO_0000357,
1626,Expert,9913.0,,1,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor subtype,H,,,105,8,,CHEMBL616512,BAO_0000357,
1627,Autocuration,9913.0,,1,,,Inhibitory concentration required against 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT,H,,,105,8,,CHEMBL616513,BAO_0000357,
1628,Autocuration,9913.0,,1,2435.0,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,H,,,105,8,,CHEMBL616514,BAO_0000019,
1629,Expert,9913.0,,1,,,Ability to bind to 5-hydroxytryptamine 1D receptor of calf substantia nigra,H,,,105,8,,CHEMBL616515,BAO_0000357,
1630,Autocuration,9913.0,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor in calf caudate homogenates.,H,,,105,8,,CHEMBL616516,BAO_0000019,
1631,Autocuration,9913.0,,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,H,,,105,8,,CHEMBL616517,BAO_0000357,
1632,Autocuration,9913.0,,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]- serotonin as radioligand,H,,,105,8,,CHEMBL616518,BAO_0000357,
1633,Autocuration,9913.0,,1,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,H,,,105,8,,CHEMBL616519,BAO_0000357,
1634,Autocuration,9913.0,,1,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand,H,,,105,8,,CHEMBL616520,BAO_0000357,
1635,Autocuration,9913.0,,1,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand,H,,,105,8,,CHEMBL616521,BAO_0000357,
1636,Autocuration,9913.0,,1,,,Tested in vitro for receptor binding affinity to 5-hydroxytryptamine 1D receptor in bovine caudate using [3H]5-HT radioligand; NT means not tested,H,,,105,8,,CHEMBL616522,BAO_0000357,
1637,Autocuration,9913.0,,1,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,H,,,105,8,,CHEMBL884531,BAO_0000357,
1638,Autocuration,9913.0,,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand,H,,,105,8,,CHEMBL616523,BAO_0000357,
1639,Autocuration,9913.0,,1,2435.0,,Binding affinity towards 5-hydroxytryptamine 1D receptor was determined in calf striatum homogenate,H,,,105,8,,CHEMBL616731,BAO_0000019,
1640,Autocuration,9913.0,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor in bovine caudate homogenate,H,,,105,8,,CHEMBL616732,BAO_0000019,
1641,Autocuration,9913.0,,1,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT,H,,,105,8,,CHEMBL616733,BAO_0000357,
1642,Autocuration,9913.0,,1,,,The binding affinity at 5-hydroxytryptamine 1D receptor was determined using [3H]5-CT; Not tested,H,,,105,8,,CHEMBL616734,BAO_0000357,
1643,Autocuration,9913.0,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP,H,,,105,8,,CHEMBL616735,BAO_0000249,
1644,Autocuration,9913.0,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex membranes using [125]ICYP; Not determined,H,,,105,8,,CHEMBL616736,BAO_0000249,
1645,Expert,9913.0,,1,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,,,105,8,,CHEMBL616737,BAO_0000019,
1646,Autocuration,9913.0,,1,,,Affinity pKi for 5-hydroxytryptamine 1D receptor was measured in calf caudate homogenate,H,,,105,8,,CHEMBL616738,BAO_0000019,
1647,Expert,9913.0,,1,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,,,105,8,,CHEMBL616739,BAO_0000019,
1648,Expert,9913.0,,1,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,,,105,8,,CHEMBL616740,BAO_0000019,
1649,Expert,9913.0,,1,,,Agonistic activity against 5-hydroxytryptamine 1D receptor in calf caudate using [3H]-GTI,H,,,105,8,,CHEMBL616741,BAO_0000019,
1650,Autocuration,9593.0,,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 1D receptor from cloned gorilla membranes expressed in cultured HEK 293 cells,H,,722.0,105,8,,CHEMBL616742,BAO_0000219,
1651,Intermediate,10141.0,,1,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra,D,,,105570,9,,CHEMBL616743,BAO_0000019,
1652,Intermediate,10141.0,,1,,,Compound was tested for the inhibition of forskolin-stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor in guinea pig substantia nigra; NT means not tested,D,,,105570,9,,CHEMBL616744,BAO_0000019,
1653,Intermediate,10141.0,,1,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptor by the agonist GR-46611,D,,,105570,9,,CHEMBL616745,BAO_0000019,
1654,Intermediate,10141.0,,1,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,,,105570,9,,CHEMBL616746,BAO_0000019,
1655,Intermediate,10141.0,,1,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611; range is 2-9,D,,,105570,9,,CHEMBL616747,BAO_0000019,
1656,Intermediate,10141.0,,1,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-0.4,D,,,105570,9,,CHEMBL616748,BAO_0000019,
1657,Intermediate,10141.0,,1,,,Oral effective dose against hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611;range is 0.2-1.2,D,,,105570,9,,CHEMBL616648,BAO_0000019,
1658,Intermediate,10141.0,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor,D,,,105570,9,,CHEMBL616649,BAO_0000357,
1659,Intermediate,10141.0,,1,,,Binding affinity towards guinea pig 5-hydroxytryptamine 1D receptor was determined,D,,,105570,9,,CHEMBL616650,BAO_0000357,
1660,Intermediate,10141.0,,1,,,Compound at 3 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,,,105570,9,,CHEMBL616651,BAO_0000218,
1661,Intermediate,10141.0,,1,,,Compound at 45 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,,,105570,9,,CHEMBL616652,BAO_0000218,
1662,Intermediate,10141.0,,1,,,Compound at 50 mg/kg was tested for the inhibition of hypothermia in the guinea pig caused by stimulation of central 5-hydroxytryptamine 1D receptors by the agonist GR-46611,D,,,105570,9,,CHEMBL616653,BAO_0000218,
1663,Intermediate,10141.0,,1,,,Compound at oral dose of 45 mg/kg was tested for percent inhibition against 5-hydroxytryptamine 1D receptor causes hypothermia in guinea pig,D,,,105570,9,,CHEMBL616654,BAO_0000218,
1664,Intermediate,10141.0,,1,,,Binding affinity of 5-hydroxytryptamine 1D receptor using [3H]-8-HT in guinea pig cortex,D,,,105570,9,,CHEMBL616655,BAO_0000019,
1665,Intermediate,10141.0,,1,,,Binding affinity against guinea pig 5-hydroxytryptamine 1D receptor,D,,,105570,9,,CHEMBL616656,BAO_0000357,
1666,Autocuration,10141.0,,1,,,Binding affinity was determined against 5-hydroxytryptamine 4 receptor using [125I]SB 207710 as radioligand from piglet hippocampal membranes,H,,,105,8,,CHEMBL616657,BAO_0000019,
1667,Intermediate,10141.0,,1,2435.0,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor in guinea-pig striatum in presence of BMY-7378 and mesulergine,D,,,105570,9,,CHEMBL616658,BAO_0000357,
1668,Intermediate,10141.0,,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of guinea pig substantia nigra,D,,,105570,9,,CHEMBL616659,BAO_0000357,
1669,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor,H,,,51,8,,CHEMBL616660,BAO_0000357,
1670,Autocuration,,,1,,,The compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta,H,,,106,8,,CHEMBL616661,BAO_0000357,
1671,Expert,,,1,,,Maximum stimulation of [35S]GTP gamma-S binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616662,BAO_0000019,
1672,Autocuration,,,1,,,Ability to inhibit forskolin-stimulated adenylate cyclase in a cell line expressing human 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616663,BAO_0000019,
1673,Autocuration,,,1,,,Ability to inhibit forskolin-stimulated adenylate cyclase activity in Chinese hamster ovary (CHO) stable cell lines expressing human 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616664,BAO_0000019,
1674,Expert,9606.0,,1,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing 5-hydroxytryptamine 1D receptor",D,,449.0,105,9,,CHEMBL881820,BAO_0000219,
1675,Autocuration,,,1,,,"Compound was evaluated for the stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor.",H,,449.0,105,8,,CHEMBL616665,BAO_0000219,
1676,Expert,,,1,,,Agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,H,,449.0,105,8,,CHEMBL616666,BAO_0000219,
1677,Autocuration,,,1,,,Compound was tested for measuring agonist-induced [35S]- GTPgammaS binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor,H,,449.0,105,8,,CHEMBL616667,BAO_0000219,
1678,Expert,,,1,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",H,,449.0,105,8,,CHEMBL616668,BAO_0000219,
1679,Expert,9606.0,,1,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the 5-hydroxytryptamine 1D receptor",D,,449.0,105,9,,CHEMBL616669,BAO_0000219,
1680,Expert,,,1,,,"Stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing the human 5-hydroxytryptamine 1D receptor.",H,,449.0,105,8,,CHEMBL617040,BAO_0000219,
1681,Autocuration,,,1,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor",H,,449.0,105,8,,CHEMBL617041,BAO_0000219,
1682,Expert,,,1,,,"Measurement of agonist induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor.",H,,449.0,105,8,,CHEMBL617042,BAO_0000219,
1683,Expert,,,1,,,"Agonist-induced [35S]GTP-gamma-S, binding in CHO cells stably transfected with human 5-hydroxytryptamine 1D receptor",H,,449.0,105,8,,CHEMBL617043,BAO_0000219,
1684,Autocuration,,,1,,,Compound was evaluated for its agonistic activity on 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL617044,BAO_0000019,
1685,Expert,,,1,,,Measurement of agonist-induced [35S]-GTP gamma-S binding in CHO cells stably transfected with 5-hydroxytryptamine 1D receptor,H,,449.0,105,8,,CHEMBL617045,BAO_0000219,
1686,Expert,9606.0,,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",D,,449.0,105,9,,CHEMBL617046,BAO_0000219,
1687,Expert,9606.0,,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding in CHO cells expressing human 5-HT-1d relative to 5-HT",D,,449.0,105,9,,CHEMBL617047,BAO_0000219,
1688,Expert,,,1,,,"Efficacy was evaluated relative to human 5-hydroxytryptamine 1D receptor using [35S]GTP-gamma-S, as radioligand",H,,,105,8,,CHEMBL617048,BAO_0000019,
1689,Autocuration,,,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by 5-hydroxytryptamine 1D receptor.",H,,,105,8,,CHEMBL616897,BAO_0000019,
1690,Expert,9606.0,,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding to 5-hydroxytryptamine 1D receptor relative to 5-HT",D,,,105,9,,CHEMBL616898,BAO_0000019,
1691,Expert,9606.0,,1,,,Percent efficacy relative to 5-HT treatment of CHO cells expressing 5-HT 1d receptor,D,,449.0,105,9,,CHEMBL858201,BAO_0000219,
1692,Autocuration,,,1,,,Intrinsic activity for 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616899,BAO_0000019,
1693,Autocuration,,In vitro,1,,,Ability to displace [3H]- -5-HT binding to cloned 5-hydroxytryptamine 1D receptor stably expressed in chinese hamster cells (CHO cells),H,,,105,8,,CHEMBL616900,BAO_0000219,
1694,Expert,,,1,,,Ability to displace [3H]-5-HT from recombinant human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells determined in vitro,H,,449.0,105,8,,CHEMBL616901,BAO_0000219,
1695,Autocuration,,,1,,,Affinity of compound towards 5-hydroxytryptamine 1D receptor was evaluated using radioligand binding technique,H,,,105,8,,CHEMBL616902,BAO_0000357,
1696,Expert,9606.0,,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,D,,449.0,105,9,,CHEMBL616903,BAO_0000219,
1697,Expert,,,1,,,Binding affinity by displacement to human cloned 5-hydroxytryptamine 1D receptor in CHO cells by [3H]5-HT displacement.,H,,449.0,105,8,,CHEMBL616904,BAO_0000219,
1698,Autocuration,,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616905,BAO_0000357,
1699,Expert,,,1,,,Binding affinity at human cloned 5-hydroxytryptamine 1D receptor stably expressed in CHO cells by [3H]5-HT displacement.,H,,449.0,105,8,,CHEMBL616906,BAO_0000219,
1700,Expert,,,1,,,Displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,H,,449.0,105,8,,CHEMBL616907,BAO_0000219,
1701,Expert,,,1,,,Displacement of [3H]5-HT binding from the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,H,,449.0,105,8,,CHEMBL616908,BAO_0000219,
1702,Expert,9606.0,,1,,,Displacement of [3H]5-HT binding from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,D,,449.0,105,9,,CHEMBL616909,BAO_0000219,
1703,Expert,9606.0,,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in CHO cells,D,,449.0,105,9,,CHEMBL616910,BAO_0000219,
1704,Expert,,,1,,,Displacement of [3H]5-HT binding to the cloned human 5-hydroxytryptamine 1D receptor stably expressed in CHO cells,H,,449.0,105,8,,CHEMBL616911,BAO_0000219,
1705,Expert,,,1,,,Displacement of specific [3H]5-HT binding to cloned human 5-hydroxytryptamine 1D receptor expressed in CHO cells,H,,449.0,105,8,,CHEMBL616912,BAO_0000219,
1706,Autocuration,,,1,,,In vitro binding affinity against human 5-hydroxytryptamine 1D receptor at a concentration of 100 (nM),H,,,105,8,,CHEMBL616913,BAO_0000357,
1707,Expert,9606.0,,1,,,Inhibition of [3H]5-HT binding to human 5-hydroxytryptamine 1D receptor expressed in CHO cells at 1 uM,D,,449.0,105,9,,CHEMBL616914,BAO_0000219,
1708,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,H,,449.0,105,8,,CHEMBL616915,BAO_0000219,
1709,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1D receptor in Cos-7 transfected cell type using [3H]5-CT as radioligand,H,,,105,8,,CHEMBL616916,BAO_0000019,
1710,Expert,9606.0,,1,,,Binding affinity to cloned human 5-hydroxytryptamine 1D receptor,D,,,105,9,,CHEMBL616917,BAO_0000357,
1711,Autocuration,,,1,,,"Binding affinity towards 5-HT1D receptor, using [3H]5-HT as radioligand.",H,,,105,8,,CHEMBL616918,BAO_0000357,
1712,Expert,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor in L-M(tk-) cells using [3H]GR-125743 as radioligand,H,,,105,8,,CHEMBL616919,BAO_0000219,
1713,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor was determined using [3H]5-HT as radioligand,H,,,105,8,,CHEMBL616920,BAO_0000357,
1714,Autocuration,,,1,,,Binding affinity for recombinant human 5-hydroxytryptamine 1D receptor using [3H]5-HT as radioligand.,H,,,105,8,,CHEMBL872914,BAO_0000357,
1715,Autocuration,,,1,,,Binding affinity was evaluated at human recombinant 5-hydroxytryptamine 1D receptor using [3H]-5-CT as radioligand,H,,,105,8,,CHEMBL616921,BAO_0000357,
1716,Expert,,,1,,,Binding affinity was evaluated at the cloned human 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616922,BAO_0000357,
1717,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616923,BAO_0000357,
1718,Expert,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616924,BAO_0000357,
1719,Expert,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand,H,,,105,8,,CHEMBL875909,BAO_0000357,
1720,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; Not determined,H,,,105,8,,CHEMBL616925,BAO_0000357,
1721,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1D receptor using [3H]5-HT trifluoroacetate as radioligand; not determined,H,,,105,8,,CHEMBL616926,BAO_0000357,
1722,Autocuration,,,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616927,BAO_0000357,
1723,Expert,,,1,,,Ability to inhibit the forskolin-stimulated c-AMP formation mediated by human 5-hydroxytryptamine 1D receptor in CHO-K1 cells,H,,485.0,105,8,,CHEMBL616928,BAO_0000219,
1724,Expert,9606.0,In vitro,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 1D receptor expressed in Chinese hamster ovary cells (CHO cells),D,,,105,9,,CHEMBL616929,BAO_0000219,
1725,Expert,9606.0,,1,,,In vitro binding affinity to human 5-hydroxytryptamine 1D receptor,D,,,105,9,,CHEMBL616930,BAO_0000357,
1726,Expert,,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616931,BAO_0000019,
1727,Autocuration,,,1,,,In vitro binding affinity was determined towards cloned human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,H,,,105,8,,CHEMBL616932,BAO_0000357,
1728,Expert,,,1,,,In vitro receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616933,BAO_0000357,
1729,Expert,9606.0,,1,,,Receptor binding affinity for cloned human 5-hydroxytryptamine 1D receptor in Cos-7 cells,D,,,105,9,,CHEMBL616934,BAO_0000219,
1730,Expert,9606.0,,1,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,D,,,105,9,,CHEMBL616935,BAO_0000357,
1731,Autocuration,,,1,,,The binding affinity towards the 5-hydroxytryptamine 1D receptor; No affinity,H,,,105,8,,CHEMBL616936,BAO_0000357,
1732,Expert,9606.0,,1,,,Affinity for 5-hydroxytryptamine 1D receptor subtype,D,,,105,9,,CHEMBL616937,BAO_0000357,
1733,Expert,9606.0,,1,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,D,,,105,9,,CHEMBL616938,BAO_0000357,
1734,Autocuration,,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616939,BAO_0000019,
1735,Expert,,,1,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1D receptor; ND means not determined,H,,,105,8,,CHEMBL616940,BAO_0000019,
1736,Expert,9606.0,,1,,,Binding activity against human 5-hydroxytryptamine 1D receptor; NT means not tested,D,,,105,9,,CHEMBL616941,BAO_0000357,
1737,Autocuration,,,1,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; Not tested,H,,485.0,105,8,,CHEMBL616942,BAO_0000219,
1738,Autocuration,,,1,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor; not tested,H,,485.0,105,8,,CHEMBL616943,BAO_0000219,
1739,Autocuration,,,1,,,Selectivity towards 5-HT1D and to that of 5-HT1B in CHO cells,H,,449.0,104802,4,,CHEMBL616944,BAO_0000219,
1740,Autocuration,,,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect produced by the 5-HT",H,,,105,8,,CHEMBL616945,BAO_0000019,
1741,Autocuration,,,1,,,Binding activity radioligand.,H,,,105,8,,CHEMBL616946,BAO_0000357,
1742,Autocuration,,,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,,,105,8,,CHEMBL616947,BAO_0000019,
1743,Expert,,,1,,,Binding affinity in CHO-K1 cells transfected with human 5-hydroxytryptamine 1D receptor,H,,485.0,105,8,,CHEMBL616948,BAO_0000219,
1744,Autocuration,,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616851,BAO_0000357,
1745,Autocuration,,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616852,BAO_0000357,
1746,Autocuration,,,1,,,Measured as -log Ka on 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616853,BAO_0000357,
1747,Expert,9606.0,,1,,,Binding activity against human 5-hydroxytryptamine 1D receptor,D,,,105,9,,CHEMBL616854,BAO_0000357,
1748,Expert,9606.0,,1,,,Binding affinity to human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand,D,,449.0,105,9,,CHEMBL616855,BAO_0000219,
1749,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]-5-HT as radioligand.,H,,449.0,105,8,,CHEMBL616856,BAO_0000219,
1750,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1D (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,,449.0,105,8,,CHEMBL616857,BAO_0000219,
1751,Autocuration,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL616858,BAO_0000357,
1752,Autocuration,,,1,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as radioligand.,H,,449.0,105,8,,CHEMBL616859,BAO_0000219,
1753,Autocuration,,,1,,,Binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]-5-HT as radioligand.;ND means no data.,H,,449.0,105,8,,CHEMBL616860,BAO_0000219,
1754,Autocuration,,,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,H,,722.0,105,8,,CHEMBL616861,BAO_0000219,
1755,Autocuration,,,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand,H,,722.0,105,8,,CHEMBL616541,BAO_0000219,
1756,Autocuration,,,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 1D receptor expressed in HEK 293 cells using [3H]LSD as radioligand; Not determined,H,,722.0,105,8,,CHEMBL616542,BAO_0000219,
1757,Autocuration,,,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT as the radioligand,H,,449.0,105,8,,CHEMBL616543,BAO_0000219,
1758,Expert,9606.0,,1,,,Binding affinity for human 5-hydroxytryptamine 1D receptor,D,,,105,9,,CHEMBL616544,BAO_0000357,
1759,Autocuration,,,1,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT,H,,449.0,105,8,,CHEMBL616545,BAO_0000219,
1760,Autocuration,,,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1D receptor in CHO using [3H]5-HT as a radioligand,H,,,105,8,,CHEMBL616546,BAO_0000357,
1761,Autocuration,,,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1D receptor in CHO cells using [3H]5-HT.,H,,449.0,105,8,,CHEMBL616547,BAO_0000219,
1762,Autocuration,,,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1D receptor in CHO cells, using [3H]5-HT as radioligand",H,,449.0,105,8,,CHEMBL616548,BAO_0000219,
1763,Expert,,,1,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 1 uM,H,,,105,8,,CHEMBL616549,BAO_0000019,
1764,Expert,,,1,,,Adenyl cyclase activity was expressed as percent forskolin response against 5-hydroxytryptamine 1D receptor at concentration 10 uM,H,,,105,8,,CHEMBL616550,BAO_0000019,
1765,Autocuration,,,1,,,Binding affinity against 5-HT2C receptor,H,,,108,8,,CHEMBL857066,BAO_0000357,
1766,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor,H,,,108,8,,CHEMBL616551,BAO_0000357,
1767,Autocuration,,,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,H,,,10577,8,,CHEMBL616552,BAO_0000357,
1768,Autocuration,,,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1B receptor of rat substantia nigra,H,,,10577,8,,CHEMBL832876,BAO_0000019,
1769,Expert,,,1,,,"Binding affinity for 5-hydroxytryptamine 1B receptor in rat cortex, striatum and globus pallidus",H,,,10577,8,,CHEMBL616553,BAO_0000019,
1770,Autocuration,,,1,,,Binding affinity towards 5-HT1B was determined,H,,,10577,8,,CHEMBL616554,BAO_0000357,
1771,Expert,,,1,,,Affinity towards 5-hydroxytryptamine 1B receptor in membranes from rat frontal cortex using [3H]5-HT,H,,,10577,8,,CHEMBL616555,BAO_0000019,
1772,Expert,,,1,,,"Binding affinity to 5-HT1B receptors using rat cortex+striatum + globus pallidus,[3H]-5-OH-tryptamine, and serotonin for NSB",H,,,10577,8,,CHEMBL616556,BAO_0000019,
1773,Autocuration,,,1,,,"Compound was evaluated for binding affinity on 5-HT1B receptors using rat cortex+striatum+ globus pallidus,[ 3H]-5-OH-tryptamine, and serotonin for NSB.",H,,,10577,8,,CHEMBL616557,BAO_0000019,
1774,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,H,,,10577,8,,CHEMBL616558,BAO_0000019,
1775,Expert,10116.0,,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT,D,,,10577,9,,CHEMBL616749,BAO_0000019,
1776,Autocuration,,,1,,,Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM,H,,,10577,8,,CHEMBL616750,BAO_0000357,
1777,Autocuration,,,1,,,"Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol, binds to 5-hydroxytryptamine 1B receptor at 1 uM",H,,,10577,8,,CHEMBL616751,BAO_0000357,
1778,Autocuration,,,1,,,In vitro inhibitory concentration against radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,H,,,10577,8,,CHEMBL616752,BAO_0000249,
1779,Autocuration,,,1,2435.0,,Inhibition of [3H]-5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatum; Residual radioligand binding higher than 50%,H,,,10577,8,,CHEMBL616753,BAO_0000019,
1780,Expert,10116.0,,1,,,Inhibition of radiolabeled [3H]-5-HT ligand binding to 5-hydroxytryptamine 1B receptor,D,,,10577,9,,CHEMBL616754,BAO_0000357,
1781,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT as the radioligand.,H,,,10577,8,,CHEMBL616755,BAO_0000019,
1782,Autocuration,,,1,2435.0,,Inhibitory activity against [3H]5-HT binding to 5-HT1B receptor in rat striatum,H,,,10577,8,,CHEMBL616756,BAO_0000019,
1783,Autocuration,,,1,2435.0,,Inhibitory concentration required against 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT,H,,,10577,8,,CHEMBL616757,BAO_0000019,
1784,Autocuration,,,1,2435.0,,compound was measured for affinity against 5-hydroxytryptamine 1B receptor labelled with [3H]5-HT radioligand in striatum tissue,H,,,10577,8,,CHEMBL616758,BAO_0000357,
1785,Autocuration,,,1,,,Compound at 10E-5 M was tested in vitro for the inhibition of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1B receptor in rat striatal membrane,H,,,10577,8,,CHEMBL616759,BAO_0000249,
1786,Autocuration,,,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 1B receptor at 10 e-6 M,H,,,10577,8,,CHEMBL616760,BAO_0000357,
1787,Autocuration,,,1,2435.0,,Ability to displace [3H]5-HT bound to 5-hydroxytryptamine 1B receptor in rat striatum,H,,,10577,8,,CHEMBL616761,BAO_0000019,
1788,Autocuration,,,1,2435.0,,Binding affinity against 5-HT1B serotonin receptor in rat striatum,H,,,10577,8,,CHEMBL616762,BAO_0000019,
1789,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor in membranes of Rat cerebral cortex,H,,,10577,8,,CHEMBL616763,BAO_0000019,
1790,Expert,,,1,,,Binding affinity at rat 5-hydroxytryptamine 1B receptor by [3H]5-HT displacement.,H,,,10577,8,,CHEMBL872909,BAO_0000357,
1791,Autocuration,,,1,,,Binding affinity determined in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,H,,,10577,8,,CHEMBL616764,BAO_0000357,
1792,Expert,10116.0,,1,,,Inhibition of [3H]5-HT binding to 5-hydroxytryptamine 1B receptor,D,,,10577,9,,CHEMBL616765,BAO_0000357,
1793,Autocuration,,,1,2435.0,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum,H,,,10577,8,,CHEMBL616766,BAO_0000357,
1794,Autocuration,,,1,2435.0,,Binding affinity against 5-hydroxytryptamine 1B receptor of rat striatum.,H,,,10577,8,,CHEMBL616767,BAO_0000357,
1795,Autocuration,,,1,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor,H,,,10577,8,,CHEMBL616768,BAO_0000357,
1796,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,H,,,10577,8,,CHEMBL616769,BAO_0000357,
1797,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor in rat was determined using 50 uL of [125I]ICYP in binding assay,H,,,10577,8,,CHEMBL616770,BAO_0000019,
1798,Autocuration,,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1B receptor was determined in male Sprague-Dawley rat brain.,H,,,10577,8,,CHEMBL616771,BAO_0000019,
1799,Autocuration,,,1,2435.0,,Binding affinity was measured on 5-hydroxytryptamine 1B receptor in rat striatum labeled with [3H]5-HT,H,,,10577,8,,CHEMBL616772,BAO_0000019,
1800,Expert,,,1,,,Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.,H,,,10577,8,,CHEMBL616773,BAO_0000019,
1801,Autocuration,,,1,,,Compound was evaluated for the binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand; ND is no data.,H,,,10577,8,,CHEMBL616774,BAO_0000019,
1802,Autocuration,,,1,,,Evaluated for binding affinity towards 5-hydroxytryptamine 1B receptor,H,,,10577,8,,CHEMBL616775,BAO_0000357,
1803,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor in rat cortical membranes using [3H]5-HT as a radioligand,H,,,10577,8,,CHEMBL616776,BAO_0000249,
1804,Autocuration,,,1,,,The binding affinity was measured on 5-hydroxytryptamine 1B receptor using [3H]- serotonin as radioligand.,H,,,10577,8,,CHEMBL616777,BAO_0000357,
1805,Autocuration,,,1,,,The binding affinity towards the receptor rat 5-hydroxytryptamine 1B receptor; No affinity,H,,,10577,8,,CHEMBL616778,BAO_0000357,
1806,Expert,10116.0,,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor in rat striatal membranes using [3H]5-HT as radioligand,D,,,10577,9,,CHEMBL616779,BAO_0000249,
1807,Expert,10116.0,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor,D,,,10577,9,,CHEMBL616780,BAO_0000357,
1808,Autocuration,,,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 1B receptor by displacing [3H]serotonin radioligand in rat cerebral cortex,H,,,10577,8,,CHEMBL616781,BAO_0000019,
1809,Autocuration,,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand,H,,,10577,8,,CHEMBL616782,BAO_0000357,
1810,Autocuration,,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand.,H,,,10577,8,,CHEMBL616783,BAO_0000357,
1811,Expert,,,1,2435.0,,Binding affinity for 5-hydroxytryptamine 1B receptor in rat striatum using [3H]5-HT as radioligand,H,,,10577,8,,CHEMBL616784,BAO_0000019,
1812,Autocuration,,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 1B receptor from rat striatum using [3H]5-HT as radioligand; Nonactive at 10 uM,H,,,10577,8,,CHEMBL616785,BAO_0000357,
1813,Autocuration,,,1,955.0,,Binding affinity against 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,,,10577,8,,CHEMBL857067,BAO_0000249,
1814,Autocuration,,,1,,,Binding affinity against 5-HT1B receptor in rat frontal cortex using [3H]-5-HT in presence of 0.1 uM [3H]-8-OH-DPAT as a radioligand,H,,,10577,8,,CHEMBL616786,BAO_0000019,
1815,Autocuration,,,1,955.0,,Binding affinity towards 5-HT1B receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,,,10577,8,,CHEMBL616787,BAO_0000249,
1816,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor of porcine choroid plexus using [3H]mesulergine,H,,,10577,8,,CHEMBL616788,BAO_0000357,
1817,Autocuration,,,1,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-hydroxytryptamine 1B receptor,H,,,10577,8,,CHEMBL616789,BAO_0000357,
1818,Expert,10116.0,,1,,,Displacement of [3H]5-HT from 5-HT1B receptor of rat frontal cortex homogenate,D,,,10577,9,,CHEMBL616790,BAO_0000019,
1819,Expert,,,1,,,Binding affinity at 5-hydroxytryptamine 1B receptor,H,,,10577,8,,CHEMBL616791,BAO_0000357,
1820,Autocuration,,,1,,,In vitro binding affinity at 5-hydroxytryptamine 1B receptor in rat striatal muscles using [125I](-)-iodocyanopindolol as the radioligand,H,,,10577,8,,CHEMBL616792,BAO_0000019,
1821,Expert,10116.0,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1B receptor in rat striatal membrane with [125I]- iodocyanopindolol,D,,,10577,9,,CHEMBL616793,BAO_0000249,
1822,Autocuration,,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand,H,,,10577,8,,CHEMBL616794,BAO_0000357,
1823,Autocuration,,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,H,,,10577,8,,CHEMBL616795,BAO_0000357,
1824,Autocuration,,,1,,,Binding affinity towards 5-HT2 receptor by the displacement of [3H]-ketanserin] in rat cerebral cortex,H,,,104686,4,,CHEMBL616796,BAO_0000019,
1825,Autocuration,,,1,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1B receptor,H,,,106,8,,CHEMBL616797,BAO_0000357,
1826,Autocuration,,,1,,,The compound was evaluated for its ability to displace [3H]5-HT from 5-hydroxytryptamine 1B receptor in cellular brain membranes,H,Brain membranes,,106,8,,CHEMBL616798,BAO_0000249,
1827,Autocuration,,,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1B receptor at a concentration of 100 nM using [125I]CYP as radioligand,H,,,106,8,,CHEMBL616799,BAO_0000357,
1828,Autocuration,,,1,,,Inhibition of binding towards 5-hydroxytryptamine 1B receptor at 100 nM concentration,H,,,106,8,,CHEMBL616800,BAO_0000357,
1829,Autocuration,,,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1B receptor,H,,,106,8,,CHEMBL616801,BAO_0000357,
1830,Autocuration,,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1B receptor; inactive at 10 uM,H,,,106,8,,CHEMBL616802,BAO_0000357,
1831,Autocuration,,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1B receptor was determined,H,,,106,8,,CHEMBL616803,BAO_0000357,
1832,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]5-HT.,H,,,106,8,,CHEMBL857068,BAO_0000357,
1833,Autocuration,,,1,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 1B receptor by displacement of [3H]ketanserin.,H,,,106,8,,CHEMBL616804,BAO_0000357,
1834,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined,H,,,106,8,,CHEMBL616805,BAO_0000357,
1835,Autocuration,,,1,,,Evaluated for the binding affinity to 5-hydroxytryptamine 1B receptor,H,,,106,8,,CHEMBL616806,BAO_0000357,
1836,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor,H,,,106,8,,CHEMBL616807,BAO_0000357,
1837,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1B receptor was determined by using [3H]5-HT as radioligand,H,,,106,8,,CHEMBL616808,BAO_0000357,
1838,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1B receptor using [3H]5-HT as radioligand.,H,,,106,8,,CHEMBL616809,BAO_0000357,
1839,Autocuration,,,1,,,Inhibitory constant against 5-hydroxytryptamine 1B receptor using with [125I]- cyanopindolol radioligand,H,,,106,8,,CHEMBL616810,BAO_0000357,
1840,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1B receptor - 5-hydroxytryptamine 1D receptor using [3H]5-HT as the radioligand.,H,,,104802,4,,CHEMBL616811,BAO_0000224,
1841,Autocuration,9913.0,,1,,,Inhibitory concentration required against 5-hydroxytryptamine 1C receptor in bovine choroid plexus using [3H]mesulergine,H,,,108,8,,CHEMBL616812,BAO_0000357,
1842,Autocuration,9823.0,,1,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,H,,,108,8,,CHEMBL616813,BAO_0000357,
1843,Autocuration,9823.0,,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 1C receptor in pig choroid plexus using [3H]mesulergine as radioligand,H,,,108,8,,CHEMBL616814,BAO_0000357,
1844,Autocuration,9823.0,,1,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,H,,,108,8,,CHEMBL616815,BAO_0000357,
1845,Autocuration,9823.0,,1,,,inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand,H,,,108,8,,CHEMBL616816,BAO_0000357,
1846,Autocuration,9823.0,,1,,,Binding affinity of compound towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine (1.2 nM) ligand in choroid Plexus pig was determined,H,,,108,8,,CHEMBL616817,BAO_0000357,
1847,Autocuration,9823.0,,1,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 1C receptor,H,,,108,8,,CHEMBL616818,BAO_0000357,
1848,Expert,9823.0,,1,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.,H,,,108,8,,CHEMBL616819,BAO_0000357,
1849,Expert,9823.0,,1,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 1C receptor of pig choroid Plexus,H,,,108,8,,CHEMBL616820,BAO_0000357,
1850,Expert,9823.0,,1,,,Displacement of [3H]mesulergine from pig cortex 5-hydroxytryptamine 1C receptor,H,,,108,8,,CHEMBL616821,BAO_0000019,
1851,Autocuration,9823.0,,1,,,Binding affinity for 5-hydroxytryptamine 1C receptor in piglet choroid plexus using [3H]5-HT,H,,,108,8,,CHEMBL616822,BAO_0000357,
1852,Autocuration,9986.0,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,H,,,108,8,,CHEMBL616823,BAO_0000019,
1853,Autocuration,10116.0,,1,,,Tested for the effect on binding at 5-hydroxytryptamine 1C receptor; No activity,D,,,12689,9,,CHEMBL616824,BAO_0000357,
1854,Autocuration,10116.0,,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,D,,,12689,9,,CHEMBL616825,BAO_0000357,
1855,Autocuration,10116.0,,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 1C receptor at 10 e-6 M,D,,,12689,9,,CHEMBL616826,BAO_0000357,
1856,Expert,10116.0,,1,,,Binding affinity against 5-hydroxytryptamine 1C receptor in rat using [3H]mesulergine as radioligand,D,,,12689,9,,CHEMBL616827,BAO_0000019,
1857,Autocuration,10116.0,,1,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [125 I]-SCH23982 as radioligand in competitive binding assay,D,,,12689,9,,CHEMBL616828,BAO_0000357,
1858,Autocuration,10116.0,,1,,,Binding affinity towards 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand,D,,,12689,9,,CHEMBL616829,BAO_0000357,
1859,Autocuration,10116.0,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1C receptor was determined in male Sprague-Dawley rat brain.,D,,,12689,9,,CHEMBL616830,BAO_0000019,
1860,Expert,10116.0,,1,,,Binding affinity against 5-hydroxytryptamine 1C receptor,D,,,12689,9,,CHEMBL616831,BAO_0000357,
1861,Autocuration,10116.0,,1,,,"Compound was tested for binding affinity towards 5-HT1C (5-HT1C) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,,,12689,9,,CHEMBL616832,BAO_0000019,
1862,Autocuration,10116.0,,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,,,12689,9,,CHEMBL616833,BAO_0000019,
1863,Expert,10116.0,,1,,,"Binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,,,12689,9,,CHEMBL616834,BAO_0000019,
1864,Autocuration,10116.0,,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 1C receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]mesulergine as radioligand",D,,,12689,9,,CHEMBL829595,BAO_0000019,
1865,Autocuration,10116.0,,1,,,Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 1C receptor binding site by using [3H]- MES as a radioligand.,D,,,12689,9,,CHEMBL616835,BAO_0000357,
1866,Autocuration,10116.0,,1,,,Inhibitory activity against 5-hydroxytryptamine 1C receptor in rat cortical membranes using [3H]mesulergine as a radioligand,D,,,12689,9,,CHEMBL872910,BAO_0000249,
1867,Expert,,,1,,,Tested for binding affinity against 5-hydroxytryptamine 1C receptor from rat frontal cortical regions using [3H]mesulergine as radioligand,H,,,12689,8,,CHEMBL616836,BAO_0000357,
1868,Autocuration,10116.0,,1,,,The binding affinity was measured on 5-hydroxytryptamine 1C receptor using [3H]- serotonin as radioligand.,D,,,12689,9,,CHEMBL616837,BAO_0000357,
1869,Autocuration,10116.0,,1,,,Binding affinity of 5-hydroxytryptamine 1C receptor using [3H]- ketanserin in rat frontal cortex,D,,,12689,9,,CHEMBL616466,BAO_0000019,
1870,Autocuration,10116.0,,1,,,Binding affinity towards rat 5-hydroxytryptamine 1C receptor using [3H]mesulergine as radioligand expressed in 293 cells,D,,722.0,12689,9,,CHEMBL616467,BAO_0000219,
1871,Autocuration,,,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,H,,,108,8,,CHEMBL616468,BAO_0000357,
1872,Autocuration,,,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,H,,,108,8,,CHEMBL616469,BAO_0000357,
1873,Autocuration,,,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1C receptor at a concentration of 100 nM using [3H]mesulergine as radioligand,H,,,108,8,,CHEMBL616470,BAO_0000357,
1874,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1C receptor,H,,,12689,8,,CHEMBL616471,BAO_0000357,
1875,Autocuration,,,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 1C receptor,H,,,12689,8,,CHEMBL616472,BAO_0000357,
1876,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1C receptor,H,,,12689,8,,CHEMBL616473,BAO_0000357,
1877,Autocuration,,,1,,,Binding affinity against serotonergic 5-HT1c receptor,H,,,12689,8,,CHEMBL616474,BAO_0000357,
1878,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined by using [3H]- mesulergine as radioligand,H,,,12689,8,,CHEMBL616475,BAO_0000357,
1879,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1C receptor was determined,H,,,12689,8,,CHEMBL616476,BAO_0000357,
1880,Autocuration,9986.0,,1,,,Compound was tested for 5-hydroxytryptamine 1D like receptor-mediated vascular effect in rabbit saphenous vein (RSV),H,,,105,8,,CHEMBL616477,BAO_0000019,
1881,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [125I]DOI as radioligand.,H,,,104686,4,,CHEMBL616478,BAO_0000224,
1882,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ket as radioligand.,H,,,104686,4,,CHEMBL616479,BAO_0000224,
1883,Autocuration,,,1,,,Binding affinity towards serotonin 5-HT2 receptor was determined in rat cortex using [3H]spiperone as ligand,H,,,104686,4,,CHEMBL616480,BAO_0000019,
1884,Autocuration,10116.0,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor as antagonism of serotonin-induced contractions in rat jugular vein,D,,,104686,5,,CHEMBL616481,BAO_0000019,
1885,Autocuration,10116.0,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain cortical membranes,D,,,104686,5,,CHEMBL616482,BAO_0000249,
1886,Autocuration,10116.0,,1,955.0,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain using [3H]spiroperidol,D,,,104686,5,,CHEMBL884713,BAO_0000221,
1887,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor measured using radioligand ([3H]spiperone) binding assay,H,,,104686,4,,CHEMBL616483,BAO_0000224,
1888,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- spiroperidol,H,,,104686,4,,CHEMBL616484,BAO_0000224,
1889,Autocuration,,,1,,,Binding affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenates by [3H]-spiperone displacement.,H,,,104686,4,,CHEMBL616485,BAO_0000019,
1890,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,H,,,104686,4,,CHEMBL616486,BAO_0000224,
1891,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was measured using radioligand ([3H]spiperone) binding assay,H,,,104686,4,,CHEMBL616487,BAO_0000224,
1892,Autocuration,,,1,,,Binding affinity at serotonin 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,H,,,104686,4,,CHEMBL616488,BAO_0000224,
1893,Autocuration,,,1,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,,,104686,4,,CHEMBL616489,BAO_0000019,
1894,Autocuration,,,1,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,,,104686,4,,CHEMBL616490,BAO_0000019,
1895,Autocuration,,,1,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]-Ketanserin as radioligand; not determined,H,,,104686,4,,CHEMBL616491,BAO_0000019,
1896,Autocuration,,,1,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand; ND-Not determined,H,,,104686,4,,CHEMBL616492,BAO_0000019,
1897,Autocuration,,,1,,,Compound was evaluated In vitro for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,,,104686,4,,CHEMBL616493,BAO_0000019,
1898,Autocuration,,,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [125I]DOI as radioligand,H,,,104686,4,,CHEMBL616494,BAO_0000019,
1899,Autocuration,,,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor in rat anterior cortex using [3H]ketanserin as radioligand,H,,,104686,4,,CHEMBL616495,BAO_0000019,
1900,Autocuration,,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat pre frontal cortex,H,,,104686,4,,CHEMBL616496,BAO_0000019,
1901,Autocuration,,,1,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,,,104686,4,,CHEMBL616497,BAO_0000019,
1902,Autocuration,,,1,,,Compound was evaluated for its activity by binding to 5-hydroxytryptamine 2 receptor in the rat brain using [3H]ketanserin as radioligand.,H,,,104686,4,,CHEMBL616498,BAO_0000019,
1903,Autocuration,,,1,,,Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand,H,,,104686,4,,CHEMBL616499,BAO_0000019,
1904,Autocuration,,,1,,,Compound was measured for affinity at 5-hydroxytryptamine 2 receptor in rat cortical by [3H]spiroperidol displacement.,H,,,104686,4,,CHEMBL616500,BAO_0000019,
1905,Autocuration,10116.0,,1,955.0,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,D,,,104686,5,,CHEMBL616501,BAO_0000221,
1906,Autocuration,,,1,955.0,,Compound was tested for its inhibitory effect on the binding profile in 5-hydroxytryptamine 2 receptor using [3H]spiroperidol in rat brain.,H,,,104686,4,,CHEMBL616502,BAO_0000221,
1907,Autocuration,,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor from rat cortical membranes.,H,Membranes,,104686,4,,CHEMBL884529,BAO_0000249,
1908,Autocuration,,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,H,Membranes,,104686,4,,CHEMBL616503,BAO_0000249,
1909,Autocuration,,,1,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL616964,BAO_0000224,
1910,Autocuration,,,1,,,Compound was tested for the displacement of [3H]ketanserin from serotonin 5-hydroxytryptamine 2 receptor from rat cortical membranes.,H,Membranes,,104686,4,,CHEMBL616965,BAO_0000249,
1911,Autocuration,,,1,,,Inhibition of [3H]ketanserin binding to rat 5-hydroxytryptamine 2 receptors.,H,,,104686,4,,CHEMBL616966,BAO_0000224,
1912,Autocuration,,,1,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor; NT=Not tested,H,,,104686,4,,CHEMBL616967,BAO_0000224,
1913,Autocuration,10116.0,,1,,,Inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor,D,,,104686,5,,CHEMBL616968,BAO_0000224,
1914,Autocuration,,,1,,,Compound was tested for the inhibition of [3H]ketanserin binding to dopamine 5-hydroxytryptamine 2 receptor; NT=Not tested,H,,,104686,4,,CHEMBL616969,BAO_0000224,
1915,Autocuration,,,1,,,Inhibition of [3H]ketanserin binding at 5-hydroxytryptamine 2 receptor from rat frontal cortex.,H,,,104686,4,,CHEMBL884530,BAO_0000019,
1916,Autocuration,,,1,,,Concentration necessary to achieve half maximal inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL616970,BAO_0000224,
1917,Autocuration,,,1,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,H,,,104686,4,,CHEMBL616971,BAO_0000224,
1918,Autocuration,,,1,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",H,,,104686,4,,CHEMBL616972,BAO_0000224,
1919,Autocuration,,,1,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]-spiperone,H,,,104686,4,,CHEMBL616973,BAO_0000224,
1920,Autocuration,,,1,,,Evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using radioligand [3H]spiperone; IA=Inactive,H,,,104686,4,,CHEMBL616974,BAO_0000224,
1921,Autocuration,,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.,H,,,104686,4,,CHEMBL616975,BAO_0000019,
1922,Autocuration,,,1,,,Inhibition of binding of radioligand [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cerebral cortex,H,,,104686,4,,CHEMBL616976,BAO_0000019,
1923,Autocuration,,,1,,,In vitro binding affinity measured on serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand.,H,,,104686,4,,CHEMBL616977,BAO_0000224,
1924,Autocuration,,,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,H,,,104686,4,,CHEMBL616978,BAO_0000224,
1925,Autocuration,,,1,,,In vitro binding affinity was measured on serotonergic 5-hydroxytryptamine 2 receptor by displacement of [3H]- ketanserin,H,,,104686,4,,CHEMBL616979,BAO_0000224,
1926,Autocuration,,,1,,,In vitro inhibitory activity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL616980,BAO_0000224,
1927,Autocuration,,,1,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes,H,Membranes,,104686,4,,CHEMBL616981,BAO_0000249,
1928,Autocuration,,,1,,,Inhibition of [3H]spiperone binding to 5-hydroxytryptamine 2 receptor from rat cortical membranes; Not tested,H,Membranes,,104686,4,,CHEMBL616982,BAO_0000249,
1929,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor by 3H ligand binding experiments.,H,,,104686,4,,CHEMBL616983,BAO_0000224,
1930,Autocuration,,,1,,,Inhibitory activity against [3H]spiroperidol binding to 5-HT2 receptor in rat cortex,H,,,104686,4,,CHEMBL616984,BAO_0000019,
1931,Autocuration,10116.0,,1,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor,D,,,104686,5,,CHEMBL616985,BAO_0000224,
1932,Autocuration,,,1,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,H,,,104686,4,,CHEMBL616986,BAO_0000224,
1933,Autocuration,,,1,,,Inhibitory concentration against binding of 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]-ketanserin,H,,,104686,4,,CHEMBL616987,BAO_0000224,
1934,Autocuration,,,1,,,Inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat,H,,,104686,4,,CHEMBL616988,BAO_0000019,
1935,Autocuration,,,1,,,Inhibitory concentration against radioligand [3H]spiperone binding to 5-hydroxytryptamine 2 receptor in rat cortex,H,,,104686,4,,CHEMBL617243,BAO_0000019,
1936,Autocuration,,,1,,,Inhibitory concentration required against 5-hydroxytryptamine 2 receptor in rat cortex using [3H]spiperone,H,,,104686,4,,CHEMBL617244,BAO_0000019,
1937,Autocuration,10116.0,,1,,,Inhibitory concentration against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,D,,485.0,104686,5,,CHEMBL617245,BAO_0000219,
1938,Autocuration,,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor in rat cortical membranes,H,Membranes,,104686,4,,CHEMBL617246,BAO_0000249,
1939,Autocuration,,,1,,,The compound was evaluated for the ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor ( striata of male wistar rats),H,,,104686,4,,CHEMBL617546,BAO_0000224,
1940,Autocuration,,,1,,,The concentration required to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat brain membranes (in vitro),H,Brain membranes,,104686,4,,CHEMBL617547,BAO_0000249,
1941,Autocuration,,In vitro,1,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,H,,,104686,4,,CHEMBL617548,BAO_0000219,
1942,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617549,BAO_0000224,
1943,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,H,,,104686,4,,CHEMBL617550,BAO_0000224,
1944,Autocuration,,,1,,,In vitro binding affinity towards the 5-hydroxytryptamine 2 receptor at 10 e-6 M,H,,,104686,4,,CHEMBL617551,BAO_0000224,
1945,Autocuration,,,1,,,Percent inhibition of binding of 1.0 nM [3H]ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e -5 M,H,Membranes,,104686,4,,CHEMBL617552,BAO_0000249,
1946,Autocuration,,,1,,,Percent inhibition of binding of 1.0 nM [3H]-ketanserin to 5-hydroxytryptamine 2 receptor in rat cortical membranes at 10 e-5 M.,H,Membranes,,104686,4,,CHEMBL617553,BAO_0000249,
1947,Autocuration,,,1,1515.0,,Tested for antagonistic activity against 5-hydroxytryptamine 2 receptor from rat thoracic aorta,H,,,104686,4,,CHEMBL617554,BAO_0000019,
1948,Autocuration,,,1,,,Binding affinity for membrane-bound 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617555,BAO_0000019,
1949,Autocuration,,,1,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,H,,,104686,4,,CHEMBL617556,BAO_0000224,
1950,Autocuration,,,1,,,Inhibitory constant against human 5-hydroxytryptamine 1B receptor using [3H]5-CT radioligand,H,,,10624,8,,CHEMBL617557,BAO_0000357,
1951,Autocuration,,,1,,,Inhibitory constant against human 5-hydroxytryptamine 1D receptor using [3H]5-CT radioligand,H,,,10624,8,,CHEMBL617558,BAO_0000357,
1952,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor was measured using [3H]5-HT as radioligand,H,,,17106,8,,CHEMBL617559,BAO_0000357,
1953,Expert,,,1,,,Binding affinity for 5-hydroxytryptamine 1D receptor,D,,,17106,9,,CHEMBL617560,BAO_0000357,
1954,Autocuration,,,1,,,Compound was tested for its ability to displace [125I]GTI binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,H,,,17106,8,,CHEMBL617561,BAO_0000249,
1955,Autocuration,,,1,,,Compound was tested for its ability to displace [3H]-5-HT binding to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,H,,,17106,8,,CHEMBL617562,BAO_0000249,
1956,Autocuration,,,1,2435.0,,Binding affinity against 5-hydroxytryptamine 1D receptor using [3H]5-HT in pig striatum + frontalCortex,H,,,17106,8,,CHEMBL617563,BAO_0000357,
1957,Autocuration,,,1,,,Relative agonist efficacy against 1 uM 5-hydroxytryptamine 1D receptor,H,,,17106,8,,CHEMBL617564,BAO_0000019,
1958,Expert,,,1,,,Binding activity against 5-hydroxytryptamine 1D receptor from pig caudate membrane using [3H]5-HT as radioligand,H,,,17106,8,,CHEMBL617565,BAO_0000019,
1959,Autocuration,,,1,,,Binding activity radioligand.,H,,,17106,8,,CHEMBL856076,BAO_0000357,
1960,Autocuration,,,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,H,,,17106,8,,CHEMBL617566,BAO_0000019,
1961,Expert,,,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,,,17106,8,,CHEMBL875911,BAO_0000019,
1962,Autocuration,,,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,H,,,17106,8,,CHEMBL617567,BAO_0000019,
1963,Autocuration,,,1,,,Compound was tested for the displacement of [3H]-5-HT to 5-hydroxytryptamine 1D receptor recognition sites in pig caudate membranes,H,,,17106,8,,CHEMBL617568,BAO_0000249,
1964,Expert,,,1,,,Displacement of [3H]5-HT binding to 5-hydroxytryptamine 1D receptor from pig caudate membrane,H,,,17106,8,,CHEMBL617569,BAO_0000019,
1965,Expert,,,1,,,Displacement of radioligand [3H]5-HT binding to 5-hydroxytryptamine 1D receptor in pig caudate membrane,H,,,17106,8,,CHEMBL617570,BAO_0000249,
1966,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1D receptor in piglet caudate using [3H]5-HT,H,,,17106,8,,CHEMBL617571,BAO_0000357,
1967,Autocuration,9823.0,,1,,,In Vitro Binding affinity againist 5-hydroxytryptamine 1D receptor by displacing [125I]GTI from pig caudate,H,,,105,8,,CHEMBL617572,BAO_0000357,
1968,Expert,9986.0,,1,,,The compound was tested for intrinsic activity against 5-HT1D receptor,H,,,105,8,,CHEMBL617573,BAO_0000357,
1969,Autocuration,9986.0,,1,,,Intrinsic activity against 5-hydroxytryptamine 1 receptor using rabbit saphenous vein assay.,H,,,105,8,,CHEMBL617574,BAO_0000019,
1970,Expert,9986.0,,1,,,The compound was tested for binding affinity against 5-HT1D receptor,H,,,105,8,,CHEMBL617575,BAO_0000357,
1971,Autocuration,,,1,,,Tested for the effect on binding at 5-hydroxytryptamine 1D receptor; No activity,H,,,10578,8,,CHEMBL617576,BAO_0000357,
1972,Autocuration,,,1,,,Inhibition of Forskolin-stimulated adenylate cyclase activity against 5-hydroxytryptamine 1D receptor of rat substantia nigra,H,,,10578,8,,CHEMBL617577,BAO_0000019,
1973,Autocuration,,,1,,,Inhibition of forskolin stimulated adenylate cyclase at 5-hydroxytryptamine 1D receptor,H,,,10578,8,,CHEMBL617578,BAO_0000019,
1974,Autocuration,,,1,,,Binding affinity was measured against serotonin 5-hydroxytryptamine 1D receptor,H,,,10578,8,,CHEMBL617579,BAO_0000357,
1975,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in rat frontal cortex using [125I]iodocyanopindolol as radio-ligand.,H,,,10578,8,,CHEMBL617580,BAO_0000019,
1976,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 1D receptor in rat cortical membranes using [3H]5-HT as a radioligand,H,,,10578,8,,CHEMBL617581,BAO_0000249,
1977,Autocuration,,,1,,,The binding affinity was measured on 5-hydroxytryptamine 1D receptor using [3H]- serotonin as radioligand.,H,,,10578,8,,CHEMBL617582,BAO_0000357,
1978,Expert,,,1,,,Binding affinity to 5-hydroxytryptamine 1D receptor in the rat forebrain by [3H]- SB-204269 displacement.,H,,,10578,8,,CHEMBL617583,BAO_0000019,
1979,Autocuration,,,1,,,Inhibition of binding towards 5-hydroxytryptamine 1D receptor at 100 nM concentration,H,,,105,8,,CHEMBL617584,BAO_0000357,
1980,Autocuration,,,1,,,Compound was tested for binding affinity against 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL617585,BAO_0000357,
1981,Autocuration,,,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 1D receptor at a concentration of 10 uM using [3H]5-HT as radioligand,H,,,105,8,,CHEMBL875912,BAO_0000357,
1982,Autocuration,,,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL617586,BAO_0000357,
1983,Autocuration,,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 1D receptor; inactive at 10 uM,H,,,105,8,,CHEMBL617587,BAO_0000357,
1984,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined,H,,,105,8,,CHEMBL617588,BAO_0000357,
1985,Autocuration,,,1,,,Evaluated for the binding affinity against 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL857980,BAO_0000357,
1986,Autocuration,,,1,,,Tested against 5-hydroxytryptamine 1D receptor,H,,,105,8,,CHEMBL617589,BAO_0000357,
1987,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1D receptor was determined by using [3H]5-HT as radioligand,H,,,105,8,,CHEMBL617590,BAO_0000357,
1988,Autocuration,,,1,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,H,,722.0,105,8,,CHEMBL617591,BAO_0000219,
1989,Expert,9606.0,,1,,,Binding affinity against 5-Hydroxytryptamine 1D receptor,D,,,105,9,,CHEMBL617592,BAO_0000357,
1990,Autocuration,,,1,,,,H,,,105,8,,CHEMBL617593,BAO_0000357,
1991,Autocuration,,,1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,H,,485.0,106,8,,CHEMBL617594,BAO_0000219,
1992,Autocuration,,,1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,H,,485.0,105,8,,CHEMBL617595,BAO_0000219,
1993,Autocuration,,,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line.,H,,722.0,105,8,,CHEMBL617596,BAO_0000219,
1994,Autocuration,,,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor alpha clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,H,,722.0,105,8,,CHEMBL617597,BAO_0000219,
1995,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,H,,,105,8,,CHEMBL617598,BAO_0000019,
1996,Autocuration,,,1,,,Binding affinity of compound against 5-HT1Dalpha Binding affinity of compound against 5-HT1D alpha receptors in human,H,,,105,8,,CHEMBL872916,BAO_0000357,
1997,Expert,,,1,,,In vitro affinity human cloned 5-hydroxytryptamine 1D receptor alpha by [3H]5-HT displacement.,H,,,105,8,,CHEMBL617599,BAO_0000357,
1998,Autocuration,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor alpha was determined,H,,,105,8,,CHEMBL617091,BAO_0000357,
1999,Expert,,,1,,,"Binding affinity against 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells, using [3H]-5-HT as the radioligand.",H,,485.0,105,8,,CHEMBL617092,BAO_0000219,
2000,Autocuration,,,1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor alpha expressed in CHO-K1 cells.,H,,485.0,105,8,,CHEMBL617093,BAO_0000219,
2001,Autocuration,,,1,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor alpha measured as the reduction of forskolin-stimulated cAMP.,H,,,105,8,,CHEMBL617094,BAO_0000019,
2002,Autocuration,,,1,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,H,,,105,8,,CHEMBL617095,BAO_0000019,
2003,Autocuration,,,1,,,Compound was tested for its agonist activity against human 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,H,,,105,8,,CHEMBL617096,BAO_0000019,
2004,Autocuration,,,1,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,H,,,105,8,,CHEMBL617097,BAO_0000019,
2005,Autocuration,,,1,,,Compound was tested for its agonist activity against human recombinant 5-hydroxytryptamine 1D receptor alpha for comparison purpose.,H,,,105,8,,CHEMBL617098,BAO_0000019,
2006,Autocuration,,,1,,,In vitro binding affinity towards 5-HT1D alpha receptor by using [3H]5-HT as radioligand,H,,,105,8,,CHEMBL617301,BAO_0000357,
2007,Autocuration,,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]5-HT as radioligand,H,,,105,8,,CHEMBL617302,BAO_0000357,
2008,Autocuration,,,1,,,Selectivity towards 5-hydroxytryptamine 1D receptor beta to that of 5-hydroxytryptamine 1D receptor alpha,H,,,105,8,,CHEMBL617303,BAO_0000357,
2009,Expert,,,1,,,Binding affinity to recombinant human 5-hydroxytryptamine 1D receptor alpha,H,,,105,8,,CHEMBL617304,BAO_0000357,
2010,Expert,,,1,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor alpha expressed in CHO cells, by using [3H]5-HT as radioligand",H,,449.0,105,8,,CHEMBL617305,BAO_0000219,
2011,Autocuration,9606.0,,1,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor alpha in COS cells transfected with human 5-HT1D alpha gene labeled with [3H]5-HT,D,,,105,9,,CHEMBL617306,BAO_0000219,
2012,Autocuration,,,1,,,Binding affinity (in vitro) against 5-hydroxytryptamine 1D receptor alpha using radio-ligand binding assay,H,,,17106,8,,CHEMBL617307,BAO_0000357,
2013,Autocuration,9986.0,,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor using rabbit saphenous vein assay.,H,,,105,8,,CHEMBL617308,BAO_0000019,
2014,Autocuration,,,1,,,Binding affinities against 5-hydroxytryptamine 1D receptor alpha,H,,,105,8,,CHEMBL617309,BAO_0000357,
2015,Autocuration,,,1,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,H,,,105,8,,CHEMBL617310,BAO_0000357,
2016,Autocuration,,,1,,,Binding affinities towards 5-hydroxytryptamine 1D receptor alpha,H,,,105,8,,CHEMBL617311,BAO_0000357,
2017,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor alpha using [3H]8-OH-DPAT as radioligand,H,,,105,8,,CHEMBL617312,BAO_0000357,
2018,Autocuration,,,1,,,Affinity against 5-hydroxytryptamine 1D receptor alpha,H,,,105,8,,CHEMBL617313,BAO_0000357,
2019,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha,H,,,105,8,,CHEMBL617314,BAO_0000357,
2020,Autocuration,,,1,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,H,,,106,8,,CHEMBL617315,BAO_0000019,
2021,Autocuration,,,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line.,H,,722.0,106,8,,CHEMBL617316,BAO_0000219,
2022,Autocuration,,,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1D receptor beta clones expressed in human embryonic kidney (HEK 293) cells line; NT= not tested,H,,722.0,106,8,,CHEMBL617317,BAO_0000219,
2023,Autocuration,,,1,,,"The compound was tested in vitro for binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",H,,449.0,106,8,,CHEMBL617318,BAO_0000219,
2024,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta using rabbit saphenous vein assay.,H,,,106,8,,CHEMBL617319,BAO_0000019,
2025,Expert,,,1,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,D,,,106,9,,CHEMBL617320,BAO_0000357,
2026,Expert,,,1,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,D,,,106,9,,CHEMBL617321,BAO_0000357,
2027,Expert,,,1,,,Displacement of [3H]-5-HT from human 5-hydroxytryptamine 1D receptor beta,D,,,106,9,,CHEMBL617322,BAO_0000357,
2028,Autocuration,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined using [3H]8-OH-DPAT as radioligand,H,,,106,8,,CHEMBL616862,BAO_0000357,
2029,Autocuration,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor was determined using [3H]8-OH-DPAT as radioligand,H,,,106,8,,CHEMBL616863,BAO_0000357,
2030,Autocuration,,,1,,,Binding affinity was measured on 5-hydroxytryptamine 1D receptor beta in CHO cells transfected with human 5-HT1D beta gene labeled with [3H]5-HT,H,,449.0,106,8,,CHEMBL616864,BAO_0000219,
2031,Autocuration,,,1,,,Compound was tested for binding affinity against cloned human 5-HT1D beta receptor expressed in CHO-K1 cells.,H,,485.0,106,8,,CHEMBL616865,BAO_0000219,
2032,Autocuration,,,1,,,Compound was tested for binding affinity against cloned human 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells.,H,,485.0,106,8,,CHEMBL616866,BAO_0000219,
2033,Autocuration,,,1,,,Compound was tested for intrinsic efficacy against human 5-hydroxytryptamine 1D receptor beta measured as the reduction of forskolin-stimulated cAMP.,H,,,106,8,,CHEMBL616867,BAO_0000019,
2034,Expert,,,1,,,"Binding affinity against 5-hydroxytryptamine 1D receptor beta expressed in CHO-K1 cells, using [3H]5-HT as the radioligand.",H,,485.0,106,8,,CHEMBL616868,BAO_0000219,
2035,Expert,,,1,,,Binding affinity for cloned human 5-hydroxytryptamine 1D receptor beta,H,,,105,8,,CHEMBL616869,BAO_0000357,
2036,Expert,,,1,,,"In vitro binding affinity against cloned mammalian 5-hydroxytryptamine 1D receptor beta expressed in CHO cells, by using [3H]5-HT as radioligand",H,,449.0,106,8,,CHEMBL616870,BAO_0000219,
2037,Autocuration,,,1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.24-0.55,H,,485.0,105,8,,CHEMBL616871,BAO_0000219,
2038,Autocuration,,,1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 0.6-2.0,H,,485.0,105,8,,CHEMBL616872,BAO_0000219,
2039,Autocuration,,,1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 2.8-6.5,H,,485.0,105,8,,CHEMBL616873,BAO_0000219,
2040,Autocuration,,,1,,,Compound was tested for its ability inhibit forskolin-stimulated activity of adenylate cyclase coupled to human 5-hydroxytryptamine 1D receptor beta in CHO-K1 cells; value ranges from 30-70,H,,485.0,105,8,,CHEMBL616838,BAO_0000219,
2041,Autocuration,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1D receptor beta was determined,H,,,105,8,,CHEMBL616839,BAO_0000357,
2042,Autocuration,9986.0,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor using rabbit saphenous vein assay.,H,,,106,8,,CHEMBL616840,BAO_0000019,
2043,Autocuration,,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor alpha by using [3H]-5-HT as radioligand,H,,,105,8,,CHEMBL616841,BAO_0000357,
2044,Autocuration,,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 1D receptor beta by using [3H]5-HT as radioligand,H,,,105,8,,CHEMBL616842,BAO_0000357,
2045,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor beta,H,,,105,8,,CHEMBL857976,BAO_0000357,
2046,Autocuration,,,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1E receptor stably expressed in CHO cells,H,,449.0,10618,8,,CHEMBL616843,BAO_0000219,
2047,Expert,9606.0,,1,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype,D,,,10618,9,,CHEMBL616844,BAO_0000357,
2048,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 1E receptor subtype; NA denotes data not available,H,,,10618,8,,CHEMBL616845,BAO_0000357,
2049,Expert,9606.0,,1,,,Binding affinity to cloned human 5-hydroxytryptamine 1E receptor,D,,,10618,9,,CHEMBL616846,BAO_0000357,
2050,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1E receptor was determined using [3H]5-HT as radioligand,H,,,10618,8,,CHEMBL616847,BAO_0000357,
2051,Autocuration,,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1E receptor in human cortical homogenate,H,,,10618,8,,CHEMBL616848,BAO_0000019,
2052,Autocuration,,,1,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 1E receptor,H,,,10618,8,,CHEMBL616849,BAO_0000357,
2053,Autocuration,,,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 1E receptor,H,,,10618,8,,CHEMBL872911,BAO_0000357,
2054,Autocuration,,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1E receptor,H,,,10618,8,,CHEMBL616850,BAO_0000019,
2055,Expert,9606.0,,1,,,Binding affinity against human 5-hydroxytryptamine 1E receptor expressed in CHO cells,D,,449.0,10618,9,,CHEMBL616699,BAO_0000219,
2056,Autocuration,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1E receptor was determined,H,,,10618,8,,CHEMBL616700,BAO_0000357,
2057,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1E receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,,449.0,10618,8,,CHEMBL616701,BAO_0000219,
2058,Autocuration,,,1,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand.,H,,449.0,10618,8,,CHEMBL616702,BAO_0000219,
2059,Autocuration,,,1,,,Binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as radioligand;ND means no data.,H,,449.0,10618,8,,CHEMBL616703,BAO_0000219,
2060,Autocuration,,,1,,,Binding affinity was determined against 5-hydroxytryptamine 1D receptor,H,,,10618,8,,CHEMBL616704,BAO_0000357,
2061,Autocuration,,,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT as the radioligand,H,,449.0,10618,8,,CHEMBL616705,BAO_0000219,
2062,Autocuration,,,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1E receptor,H,,,10618,8,,CHEMBL616706,BAO_0000357,
2063,Autocuration,,,1,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]-5-HT,H,,449.0,10618,8,,CHEMBL616707,BAO_0000219,
2064,Autocuration,,,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1E receptor in CHO using [3H]5-HT as a radioligand,H,,,10618,8,,CHEMBL616708,BAO_0000357,
2065,Autocuration,,,1,,,Tested for binding affinity towards cloned human 5-hydroxytryptamine 1E receptor using [3H]5-HT as radioligand,H,,,10618,8,,CHEMBL616709,BAO_0000357,
2066,Autocuration,,,1,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1E receptor (cloned human receptors in CHO cells) using [3H]5-HT1E as radioligand,H,,449.0,10618,8,,CHEMBL616710,BAO_0000219,
2067,Autocuration,,,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1E receptor in CHO cells using [3H]5-HT.,H,,449.0,10618,8,,CHEMBL616711,BAO_0000219,
2068,Autocuration,,,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1E receptor in CHO cells, using [3H]5-HT as radioligand",H,,449.0,10618,8,,CHEMBL616712,BAO_0000219,
2069,Autocuration,,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1E receptor was determined,H,,,10618,8,,CHEMBL616713,BAO_0000357,
2070,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1E receptor was determined,H,,,10618,8,,CHEMBL616714,BAO_0000357,
2071,Autocuration,,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1E receptor,H,,,10618,8,,CHEMBL616715,BAO_0000357,
2072,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1E receptor,H,,,10618,8,,CHEMBL616716,BAO_0000357,
2073,Autocuration,,,1,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-HT1F receptor",H,,,279,8,,CHEMBL616717,BAO_0000019,
2074,Expert,,,1,,,"In vitro effective concentration for stimulation of [35S]GTP-gamma-S, binding in mouse LM(tk-)cells expressing the human 5-hydroxytryptamine 1F receptor",H,,,279,8,,CHEMBL616718,BAO_0000019,
2075,Autocuration,,,1,,,In vitro effective concentration for inhibition of skolin-stimulated adenylate cyclase in cell line expressing human 5-hydroxytryptamine 1F receptor,H,,,279,8,,CHEMBL875905,BAO_0000019,
2076,Autocuration,,,1,,,In vitro agonist potency against human 5-hydroxytryptamine 1F receptor,H,,,279,8,,CHEMBL616719,BAO_0000019,
2077,Expert,,,1,,,"Maximum stimulation of of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine 1F receptor",H,,,279,8,,CHEMBL616720,BAO_0000019,
2078,Autocuration,,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 1F receptor,H,,,279,8,,CHEMBL616721,BAO_0000357,
2079,Autocuration,,,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 1F receptor stably expressed in CHO cells,H,,449.0,279,8,,CHEMBL616722,BAO_0000219,
2080,Autocuration,,,1,,,In vitro binding affinity against human 5-hydroxytryptamine 1F receptor at a concentration of 100 (nM),H,,,279,8,,CHEMBL616723,BAO_0000357,
2081,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT radioligand,H,,449.0,279,8,,CHEMBL616724,BAO_0000219,
2082,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT radioligand,H,,,279,8,,CHEMBL616725,BAO_0000357,
2083,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor,H,,,279,8,,CHEMBL616726,BAO_0000357,
2084,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor was determined,H,,,279,8,,CHEMBL616727,BAO_0000357,
2085,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 1F receptor using [3H]-5-HT radioligand,H,,,279,8,,CHEMBL616728,BAO_0000357,
2086,Autocuration,,,1,,,In vitro binding affinity for human 5-hydroxytryptamine 1F receptor,H,,,279,8,,CHEMBL616729,BAO_0000357,
2087,Expert,,,1,,,In vitro binding affinity was determined by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 1F receptor,H,,,279,8,,CHEMBL616730,BAO_0000019,
2088,Autocuration,,,1,,,Binding affinity towards human recombinant 5-hydroxytryptamine 1F receptor,H,,,279,8,,CHEMBL617125,BAO_0000357,
2089,Autocuration,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 1F receptor was determined,H,,,279,8,,CHEMBL857977,BAO_0000357,
2090,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1F receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand.,H,,449.0,279,8,,CHEMBL617126,BAO_0000219,
2091,Autocuration,,,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 1F receptor in CHO cells using [3H]-5-HT as the radioligand,H,,449.0,279,8,,CHEMBL617127,BAO_0000219,
2092,Autocuration,,,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 1F receptor,H,,,279,8,,CHEMBL617128,BAO_0000357,
2093,Autocuration,,,1,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 1F receptor in human cloned receptors in CHO cells using [3H]5-HT,H,,449.0,279,8,,CHEMBL617129,BAO_0000219,
2094,Autocuration,,,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 1F receptor in CHO using [3H]5-HT as a radioligand,H,,,279,8,,CHEMBL617130,BAO_0000357,
2095,Autocuration,,,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 1F receptor in CHO cells using [3H]5-HT.,H,,449.0,279,8,,CHEMBL617131,BAO_0000219,
2096,Autocuration,,,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",H,,449.0,279,8,,CHEMBL617132,BAO_0000219,
2097,Autocuration,,,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 1F receptor in CHO cells, using [3H]5-HT as radioligand",H,,449.0,279,8,,CHEMBL617133,BAO_0000219,
2098,Autocuration,,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 1F receptor was determined,H,,,279,8,,CHEMBL617134,BAO_0000357,
2099,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 1F receptor was determined,H,,,279,8,,CHEMBL617135,BAO_0000357,
2100,Autocuration,,,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 1F receptor,H,,,279,8,,CHEMBL617136,BAO_0000357,
2101,Autocuration,,,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]-ketanserin as radioligand",H,,,104686,4,,CHEMBL617137,BAO_0000019,
2102,Autocuration,,,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",H,,,104686,4,,CHEMBL617138,BAO_0000019,
2103,Autocuration,,,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 (5-hydroxytryptamine-2) receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",H,,,104686,4,,CHEMBL617139,BAO_0000019,
2104,Autocuration,,,1,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617140,BAO_0000019,
2105,Autocuration,,In vivo,1,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-HT2 receptor 1 hr after oral administration",H,,,104686,4,,CHEMBL617141,BAO_0000218,
2106,Autocuration,,,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,,,104686,4,,CHEMBL858112,BAO_0000019,
2107,Intermediate,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in calf frontal cortex,H,,,17005,8,,CHEMBL617142,BAO_0000019,
2108,Autocuration,9913.0,,1,,,"Binding affinity to 5-hydroxytryptamine 2 receptor using calf frontal cortex, [3H]- ketanserin, and spiperone for NSB",U,,,22226,0,,CHEMBL617143,BAO_0000019,
2109,Autocuration,9913.0,,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex at 10e-7 M,U,,,22226,0,,CHEMBL617144,BAO_0000019,
2110,Autocuration,9913.0,,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of bovine frontal cortex,U,,,22226,0,,CHEMBL617145,BAO_0000019,
2111,Autocuration,,,1,,,Binding affinity of compound towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin (0.8 nM) ligand in frontal cortex bovine was determined,U,,,22226,0,,CHEMBL617146,BAO_0000019,
2112,Autocuration,10141.0,,1,,,Binding affinity for serotonin 5-hydroxytryptamine 2 receptor using [3H]ketanserin in guinea pig frontal cortex,H,,,104784,4,,CHEMBL617147,BAO_0000019,
2113,Autocuration,10141.0,,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of guinea pig frontal cortex membranes,H,,,104784,4,,CHEMBL617148,BAO_0000019,
2114,Autocuration,10141.0,,1,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin from guinea pig frontal cortex,H,,,104784,4,,CHEMBL617149,BAO_0000019,
2115,Autocuration,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 2 receptor was determined,H,,,104784,4,,CHEMBL617150,BAO_0000224,
2116,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,H,,,104784,4,,CHEMBL617151,BAO_0000224,
2117,Autocuration,,,1,,,In vitro binding affinity of compound against neuronal 5-hydroxytryptamine 2 receptor,H,,,104784,4,,CHEMBL617201,BAO_0000224,
2118,Autocuration,,,1,,,Binding affinity towards 5-HT7 receptor by the displacement of [3H]-5-CT] in human recombinant receptors in mammalian cell,H,,,10209,8,,CHEMBL617202,BAO_0000357,
2119,Autocuration,,In vivo,1,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,H,,,104826,4,,CHEMBL617203,BAO_0000218,
2120,Autocuration,,,1,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,H,,,104826,4,,CHEMBL617204,BAO_0000019,
2121,Autocuration,,,1,,,Inhibitory activity against serotonin 5-hydroxytryptamine 2 receptor from mice.,H,,,104826,4,,CHEMBL617205,BAO_0000224,
2122,Autocuration,10090.0,,1,,,Inhibitory activity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in mouse cerebral cortex,D,,,104826,5,,CHEMBL617206,BAO_0000019,
2123,Autocuration,,In vivo,1,,,Effective dose through peroral route for in vivo inhibition against 5-hydroxytryptamine 2 receptor in male CF-1 mice by using radioligand [3H]ketanserin,H,,,104826,4,,CHEMBL617207,BAO_0000218,
2124,Autocuration,10090.0,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]-ketanserin in mouse cerebral cortex,D,,,104826,5,,CHEMBL617208,BAO_0000019,
2125,Autocuration,,,1,,,The compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2 receptor,H,,,104826,4,,CHEMBL617209,BAO_0000224,
2126,Autocuration,,,1,,,In vitro binding affinity for serotonin 5-hydroxytryptamine (5-HT) 2 receptors,H,,,104826,4,,CHEMBL617210,BAO_0000224,
2127,Autocuration,,,1,,,The compound was tested in vitro for its binding affinity towards serotonin 5-hydroxytryptamine 2 receptor; nd = no data,H,,,104826,4,,CHEMBL617211,BAO_0000224,
2128,Autocuration,10090.0,,1,,,Hill number was determined for inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in mouse cerebral cortex,D,,,104826,5,,CHEMBL617212,BAO_0000019,
2129,Autocuration,9823.0,,1,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin,H,,,104784,4,,CHEMBL617213,BAO_0000224,
2130,Autocuration,9823.0,,1,,,Binding affinity for porcine 5-hydroxytryptamine 2 receptor using [3H]- ketanserin with 10 uM prazosin,H,,,104784,4,,CHEMBL617214,BAO_0000224,
2131,Autocuration,,,1,,,Compound was tested in vitro for its ability to compete with [3H]-ketanserin at 5-hydroxytryptamine 2 receptor in porcine brain homogenate,U,,,22226,0,,CHEMBL617215,BAO_0000221,
2132,Autocuration,,,1,,,In vitro for its ability to displace [3H]- ketanserin from 5-hydroxytryptamine 2 receptor in porcine brain homogenate,U,,,22226,0,,CHEMBL617216,BAO_0000221,
2133,Autocuration,9823.0,,1,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2 receptor,H,,,17005,8,,CHEMBL617217,BAO_0000357,
2134,Autocuration,,,1,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617218,BAO_0000019,
2135,Autocuration,,,1,,,Inhibition of [3H]- Ketanserin binding against rat brain 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL872913,BAO_0000019,
2136,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat cortical synaptosomal membrane using radioligand [3H]ketanserin.,H,,,104826,4,,CHEMBL617219,BAO_0000019,
2137,Autocuration,,,1,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL873482,BAO_0000224,
2138,Autocuration,10116.0,,1,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; ND means no data,D,,,104686,5,,CHEMBL617220,BAO_0000019,
2139,Autocuration,,,1,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein.,H,,,104686,4,,CHEMBL617221,BAO_0000019,
2140,Autocuration,,,1,,,Affinity towards 5-hydroxytryptamine 2 receptor by measuring its ability to antagonize serotonin-induced contractions in the rat jugular vein; no appreciable 5-HT2 receptor affinity,H,,,104686,4,,CHEMBL617222,BAO_0000019,
2141,Autocuration,,,1,,,Antagonistic activity against (5-hydroxytryptamine 2 receptor) serotonin-induced contractions in the rat jugular vein,H,,,104686,4,,CHEMBL875906,BAO_0000019,
2142,Autocuration,,,1,,,Binding affinity to the 5-hydroxytryptamine 2 receptor assayed by antagonism of serotonin-induced contractions in the rat jugular vein,H,,,104686,4,,CHEMBL617223,BAO_0000019,
2143,Autocuration,,,1,,,Binding affinity against serotonin 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617224,BAO_0000224,
2144,Autocuration,10116.0,,1,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,D,,,104686,5,,CHEMBL617225,BAO_0000224,
2145,Autocuration,,,1,,,Tested for the effect on binding at 5-hydroxytryptamine 2 receptor; No activity,H,,,104686,4,,CHEMBL617226,BAO_0000224,
2146,Autocuration,,,1,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.4 nM dose of [3H]- spiperone as a radioligand.,H,,,104686,4,,CHEMBL617227,BAO_0000224,
2147,Autocuration,,,1,,,Effect of 2 week administration of compound on 5-hydroxytryptamine 2 receptor binding by using 0.6 nM dose of [3H]- spiperone as a radioligand.,H,,,104686,4,,CHEMBL617228,BAO_0000224,
2148,Autocuration,,,1,,,Compound was tested for its effect on 5-hydroxytryptamine 2 receptor saturation analysis,H,,,104686,4,,CHEMBL617229,BAO_0000224,
2149,Autocuration,,,1,,,Concentration necessary to achieve half maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 1 uM,H,,,104686,4,,CHEMBL617230,BAO_0000224,
2150,Autocuration,,,1,,,"Concentration necessary to achieve half maximal inhibition of [3H]ketanserin, binds to 5-hydroxytryptamine 2 receptor at 1 uM",H,,,104686,4,,CHEMBL617231,BAO_0000224,
2151,Autocuration,,,1,,,Compound was tested for the inhibition of quipazine binding at 5-HT2 receptor,H,,,104686,4,,CHEMBL617232,BAO_0000224,
2152,Autocuration,,,1,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617233,BAO_0000224,
2153,Autocuration,,,1,,,Compound was tested for the inhibition of quipazine binding at 5-hydroxytryptamine 2 receptor; NT=Not tested,H,,,104686,4,,CHEMBL617234,BAO_0000224,
2154,Autocuration,,,1,,,Compound was tested for the inhibition of quipazine induced head twitches in rats,H,,,104686,4,,CHEMBL617235,BAO_0000019,
2155,Autocuration,,,1,,,Compound was tested for the inhibition of quipazine induced head twitches in rats; NT=Not tested,H,,,104686,4,,CHEMBL617236,BAO_0000019,
2156,Autocuration,,,1,10000000.0,,Ability to bind at 5-hydroxytryptamine 2 receptor of rat hippocampus by displacing [3H]spiperone,H,,,104686,4,,CHEMBL617237,BAO_0000221,
2157,Autocuration,,,1,10000000.0,,Ability to bind at serotonin 5-hydroxytryptamine 2 receptors of rat hippocampus by displacing [3H]spiperone,H,,,104686,4,,CHEMBL617238,BAO_0000221,
2158,Autocuration,10116.0,,1,955.0,,Displacement of [3H]spiroperidol from 5-hydroxytryptamine 2 receptor in rat brain,D,,,104686,5,,CHEMBL617239,BAO_0000221,
2159,Autocuration,,,1,,,Ability to inhibit binding of [3H]KET to 5-hydroxytryptamine 2 receptor in rat cortex,H,,,104686,4,,CHEMBL617240,BAO_0000019,
2160,Autocuration,,,1,,,Ability to inhibit binding of titreated spiperone to 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,H,Membranes,,104686,4,,CHEMBL617241,BAO_0000249,
2161,Autocuration,,,1,,,Ability to inhibit binding of titreated spiperone to the 5-hydroxytryptamine 2 receptor in rat brain frontal cortex membranes,H,Membranes,,104686,4,,CHEMBL875907,BAO_0000249,
2162,Autocuration,,,1,,,Affinity for 5-hydroxytryptamine 2 receptor binding sites by its ability to displace [3H]spiperone from rat frontal cortex.,H,,,104686,4,,CHEMBL617242,BAO_0000019,
2163,Autocuration,,,1,,,Antagonistic activity against 5-hydroxytryptamine 2 receptor on rat frontal cortex membrane.,H,,,104686,4,,CHEMBL617152,BAO_0000019,
2164,Autocuration,10116.0,,1,955.0,,Binding affinity against serotonin-2 receptor in rat brain using [3H]spiroperidol,D,,,104686,5,,CHEMBL617153,BAO_0000221,
2165,Autocuration,10116.0,,1,,,Binding affinity at 5-hydroxytryptamine 2 receptor by the inhibition of binding to [3H]ketanserin in rat cortical membranes,D,Membranes,,104686,5,,CHEMBL617154,BAO_0000249,
2166,Autocuration,,,1,955.0,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat brain using [3H]ketanserin as radioligand,H,,,104686,4,,CHEMBL617155,BAO_0000221,
2167,Autocuration,,,1,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,H,,,104686,4,,CHEMBL617156,BAO_0000019,
2168,Autocuration,,,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-HT2 receptor in rat thoracic aortic strips,H,,,104686,4,,CHEMBL617157,BAO_0000019,
2169,Autocuration,,,1,,,In vitro antagonistic activity tested against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,,,104686,4,,CHEMBL617158,BAO_0000019,
2170,Autocuration,,,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,H,,,104686,4,,CHEMBL617159,BAO_0000019,
2171,Autocuration,,,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips; NC=non competitive antagonism,H,,,104686,4,,CHEMBL617160,BAO_0000019,
2172,Autocuration,,,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,,,104686,4,,CHEMBL858113,BAO_0000019,
2173,Autocuration,,,1,955.0,,Tested for 5-hydroxytryptamine 2 receptor binding ability by displacement of [3H]spiperone from rat brain frontal cortex synaptosomes,H,,,104686,4,,CHEMBL617247,BAO_0000220,
2174,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,H,,,104686,4,,CHEMBL617248,BAO_0000019,
2175,Autocuration,,,1,955.0,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat brain membrane using [3H]8-OH-DPAT as a selective ligand.,H,,,104686,4,,CHEMBL617249,BAO_0000249,
2176,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex,H,,,104686,4,,CHEMBL617250,BAO_0000019,
2177,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor in rat frontal cortex using [3H]ketanserin as radioligand,H,,,104686,4,,CHEMBL617251,BAO_0000019,
2178,Autocuration,10116.0,,1,,,isplacement of [3H]DOB from rat cortex homogenate 5-hydroxytryptamine 2 receptor,D,,,104686,5,,CHEMBL617252,BAO_0000019,
2179,Autocuration,,,1,,,Binding affinity of 5-hydroxytryptamine 2 receptor using [3H]- ketanserin in rat frontal cortex,H,,,104686,4,,CHEMBL617006,BAO_0000019,
2180,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat frontal cortex,H,,,104686,4,,CHEMBL617007,BAO_0000019,
2181,Autocuration,,,1,,,"5-hydroxytryptamine 2 receptor antagonistic activity at concentrations of<br>3,10 and 30 uM on the rat tail artery.",H,,,104686,4,,CHEMBL617008,BAO_0000019,
2182,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- ketanserin,H,,,104686,4,,CHEMBL617009,BAO_0000019,
2183,Autocuration,10116.0,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor in serotonin-induced contraction of the rat aorta,D,,,104686,5,,CHEMBL617010,BAO_0000224,
2184,Autocuration,10116.0,,1,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,D,,,104686,5,,CHEMBL857978,BAO_0000019,
2185,Autocuration,10116.0,,1,,,Displacement of [3H]ketanserin from rat brain 5-hydroxytryptamine 2 receptor,D,,,104686,5,,CHEMBL617011,BAO_0000019,
2186,Autocuration,10116.0,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat frontal cortex homogenate,D,,,104686,5,,CHEMBL617012,BAO_0000019,
2187,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand.,H,,,104686,4,,CHEMBL617013,BAO_0000224,
2188,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor by the displacement of [3H]ketanserin in rat cerebral cortex membrane,H,,,104686,4,,CHEMBL617014,BAO_0000249,
2189,Autocuration,,,1,,,Compound was evaluated for its ability to displace [3H]ketanserin binding from cloned rat cerebral cortex membranes 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617015,BAO_0000019,
2190,Autocuration,,,1,,,In vitro binding affinity to 5-hydroxytryptamine 2 receptor of rat cerebral cortex membranes using [3H]ketanserin as the radioligand,H,,,104686,4,,CHEMBL617016,BAO_0000019,
2191,Autocuration,,,1,,,pKi value for 5-hydroxytryptamine 2 receptor binding site,H,,,104686,4,,CHEMBL617017,BAO_0000224,
2192,Autocuration,,,1,955.0,,Inhibitory constant (1 uM) was measured on 5-hydroxytryptamine 2 receptor/uptake using [3H]- ketanserin as radioligand in rat brain cortex.,H,,,104686,4,,CHEMBL617018,BAO_0000221,
2193,Autocuration,,,1,,,5-hydroxytryptamine 2 receptor antagonistic activity on the rat tail artery determined by Schild plot.,H,,,104686,4,,CHEMBL617019,BAO_0000019,
2194,Autocuration,,,1,,,Binding affinity at 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,H,,,105075,4,,CHEMBL617020,BAO_0000019,
2195,Autocuration,,,1,,,Binding affinity at 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,H,,,105075,4,,CHEMBL617021,BAO_0000019,
2196,Autocuration,,,1,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,H,,,105075,4,,CHEMBL617022,BAO_0000019,
2197,Autocuration,,,1,,,Binding affinity at [3H]DOB labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,H,,,105075,4,,CHEMBL617023,BAO_0000019,
2198,Autocuration,,,1,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor determined using [125I]- DOI as radioligand in rat frontal cortex,H,,,105075,4,,CHEMBL617024,BAO_0000019,
2199,Autocuration,,,1,,,Binding affinity at [3H]KET labeled sites of 5-hydroxytryptamine 2 receptor was determined using [125I]- DOI as radioligand in rat frontal cortex,H,,,105075,4,,CHEMBL617025,BAO_0000019,
2200,Autocuration,,,1,,,Hill coefficient of compound was determined,H,,,105075,4,,CHEMBL617026,BAO_0000224,
2201,Autocuration,,,1,,,Ancillary Binding affinity towards rat 5-hydroxytryptamine 2 receptor,U,,,22226,0,,CHEMBL617027,BAO_0000019,
2202,Autocuration,10116.0,,1,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-ketanserin) from 5-hydroxytryptamine 2 receptor of rat cerebral cortex membrane,D,,,104686,5,,CHEMBL617028,BAO_0000019,
2203,Expert,,,1,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand,H,,,12687,8,,CHEMBL617029,BAO_0000019,
2204,Expert,,,1,,,Binding affinity against rat 5-hydroxytryptamine 2 receptor in rat cerebral cortex tissue using [3H]spiperone as radioligand; IA-Inactive,H,,,12687,8,,CHEMBL875908,BAO_0000019,
2205,Autocuration,,,1,,,Affinity at 5-hydroxytryptamine 2 receptor (For ketanserin = Ki(nM)= 0.7+/-0.09),H,,,12687,8,,CHEMBL617030,BAO_0000357,
2206,Autocuration,,,1,,,Affinity at 5-hydroxytryptamine 2 receptor from rat frontal cortex using [3H]ketanserin as radioligand (For ketanserin = Ki(nM)=0.7+/-0.09),H,,,12687,8,,CHEMBL617031,BAO_0000019,
2207,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 2 receptor of rat cortical membrane using [3H]DOB radioligand,H,,,12687,8,,CHEMBL617032,BAO_0000019,
2208,Autocuration,10116.0,,1,,,Tested in vitro for receptor binding affinity against 5-hydroxytryptamine 2 receptor using radioligand [3H]ketanserin,D,,,104686,5,,CHEMBL617033,BAO_0000224,
2209,Autocuration,,,1,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand",H,,,104686,4,,CHEMBL617034,BAO_0000224,
2210,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand,H,,,104686,4,,CHEMBL617035,BAO_0000224,
2211,Autocuration,,,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",H,,,104686,4,,CHEMBL617036,BAO_0000019,
2212,Autocuration,,,1,,,Inhibitory concentration against 5-hydroxytryptamine 2 receptor,H,,,104784,4,,CHEMBL617037,BAO_0000224,
2213,Autocuration,,,1,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2 receptor from mammalian clones expressed in CHO cell membranes using [3H]-ketanserin as radioligand,U,,,22226,0,,CHEMBL617038,BAO_0000219,
2214,Autocuration,,,1,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor expressed in CHO cell membranes using [3H]ketanserin (60 Ci/mmol, 1 nM)",H,,,104784,4,,CHEMBL617039,BAO_0000219,
2215,Autocuration,,,1,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor,H,,,104784,4,,CHEMBL617161,BAO_0000224,
2216,Autocuration,,,1,,,Compound was tested for inhibitory activity against 5-hydroxytryptamine 2 receptor,H,,,104784,4,,CHEMBL617162,BAO_0000224,
2217,Autocuration,,,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 2 receptor,H,,,104784,4,,CHEMBL617163,BAO_0000224,
2218,Autocuration,,,1,,,Tested for binding affinity for 5-hydroxytryptamine 2 receptor,H,,,104784,4,,CHEMBL617164,BAO_0000224,
2219,Autocuration,,,1,,,The compound was evaluated for its ability to displace [3H]ketanserin from 5-hydroxytryptamine 2 receptor in cellular brain membranes,H,Brain membranes,,104784,4,,CHEMBL617165,BAO_0000249,
2220,Autocuration,,,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 2 receptor at a concentration of 10 uM using [3H]ketanserin as radioligand,H,,,104784,4,,CHEMBL617166,BAO_0000224,
2221,Autocuration,,,1,,,Binding affinity towards 5-HT2 receptor,H,,,104784,4,,CHEMBL617167,BAO_0000224,
2222,Autocuration,,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,H,,,104784,4,,CHEMBL872912,BAO_0000224,
2223,Autocuration,,,1,,,Compound was evaluated for 5-hydroxytryptamine 2 receptor binding,H,,,104784,4,,CHEMBL617168,BAO_0000224,
2224,Autocuration,,,1,,,In vitro binding affinity against rat 5-hydroxytryptamine 2 receptor.,H,,,104686,4,,CHEMBL617169,BAO_0000224,
2225,Autocuration,,,1,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,H,,,104784,4,,CHEMBL617170,BAO_0000224,
2226,Autocuration,,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2 receptor using ketanserin as radioligand,H,,,104784,4,,CHEMBL617171,BAO_0000224,
2227,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined,H,,,104784,4,,CHEMBL617172,BAO_0000224,
2228,Autocuration,,,1,,,In vitro binding affinity for 5-hydroxytryptamine 2 receptor,H,,,104784,4,,CHEMBL617173,BAO_0000224,
2229,Autocuration,,,1,,,In Vitro binding affinity for 5-hydroxytryptamine 2 receptor,U,,,22226,0,,CHEMBL617174,BAO_0000019,
2230,Autocuration,,,1,,,5-hydroxytryptamine 2 receptor binding affinity,H,,,104784,4,,CHEMBL617175,BAO_0000224,
2231,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor was determined using [ [3H]spiperone radioligand,H,,,17005,8,,CHEMBL617176,BAO_0000357,
2232,Autocuration,,,1,,,Compound was tested for the binding affinity against 5-hydroxytryptamine 2 receptor by using [3H]ketanserin as radioligand,H,,,17005,8,,CHEMBL617177,BAO_0000357,
2233,Autocuration,,,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,H,,,104784,4,,CHEMBL617178,BAO_0000224,
2234,Autocuration,,,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor of central nervous system,H,,,104784,4,,CHEMBL617179,BAO_0000224,
2235,Autocuration,,,1,,,Ketanserin binding to 5-hydroxytryptamine 2 receptor at 10e-5 M,H,,,104784,4,,CHEMBL617180,BAO_0000224,
2236,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor using [3H]-ketanserin as radioligand at 10e-5 M concentration,H,,,17005,8,,CHEMBL617181,BAO_0000357,
2237,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor,H,,,17005,8,,CHEMBL617182,BAO_0000357,
2238,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor,H,,,17005,8,,CHEMBL617183,BAO_0000357,
2239,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,H,,,17005,8,,CHEMBL617184,BAO_0000357,
2240,Autocuration,,,1,,,Binding affinity against serotonergic 5-HT2 receptor,H,,,17005,8,,CHEMBL617185,BAO_0000357,
2241,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 2 receptor was determined by using [3H]ketanserin as radioligand,H,,,17005,8,,CHEMBL617186,BAO_0000357,
2242,Autocuration,,,1,,,Compound was evaluated for the binding affinity at 5- HT2 receptor,H,,,17005,8,,CHEMBL617187,BAO_0000357,
2243,Autocuration,,,1,,,Compound was tested for binding affinity using [3H]ketanserin against 5-hydroxytryptamine 2 receptor,H,,,17005,8,,CHEMBL617188,BAO_0000357,
2244,Autocuration,,,1,,,In vivo binding affinity was evaluated against 5-hydroxytryptamine 2 receptor,H,,,17005,8,,CHEMBL617189,BAO_0000218,
2245,Autocuration,9606.0,,1,,,Inhibitory activity against cloned human 5-HT2 receptor,D,,,104784,5,,CHEMBL617190,BAO_0000224,
2246,Autocuration,9606.0,,1,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells",D,,449.0,104784,5,,CHEMBL617191,BAO_0000219,
2247,Autocuration,9606.0,,1,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells.",D,,449.0,104784,5,,CHEMBL617192,BAO_0000219,
2248,Autocuration,9606.0,,1,,,"Tested in vitro for the inhibition of [3H]-ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; Inactive",D,,449.0,104784,5,,CHEMBL617193,BAO_0000219,
2249,Autocuration,9606.0,,1,,,"Tested in vitro for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor, expressed in cloned CHO cells; not tested",D,,449.0,104784,5,,CHEMBL617194,BAO_0000219,
2250,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,,,104784,4,,CHEMBL617195,BAO_0000224,
2251,Autocuration,,,1,,,Percent decrease in 5-hydroxytryptamine 2 receptor binding using ketanserin,H,,,104784,4,,CHEMBL881830,BAO_0000224,
2252,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,,,17005,8,,CHEMBL617196,BAO_0000357,
2253,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2- receptor using [3H]ketanserin as radioligand in competitive binding assay,H,,,104686,4,,CHEMBL617197,BAO_0000224,
2254,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor was measured using [3H]ketanserin as radioligand,H,,,17005,8,,CHEMBL617198,BAO_0000357,
2255,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,,,17005,8,,CHEMBL873476,BAO_0000357,
2256,Expert,,,1,,,Affinity towards 5-hydroxytryptamine 2A receptor in membranes from bovine frontal cortex using [3H]ketanserin,H,,,17005,8,,CHEMBL617199,BAO_0000019,
2257,Autocuration,10141.0,,1,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617200,BAO_0000357,
2258,Autocuration,,,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,,,51,8,,CHEMBL617484,BAO_0000357,
2259,Autocuration,,,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,,,107,8,,CHEMBL617485,BAO_0000357,
2260,Autocuration,,,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,,,51,8,,CHEMBL617486,BAO_0000357,
2261,Autocuration,,,1,,,Binding affinity analysed on 5-HT 2A human clone using [3H]ketanserin as radioligand,H,,,107,8,,CHEMBL858022,BAO_0000357,
2262,Autocuration,,,1,,,Effective concentration against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,H,,449.0,107,8,,CHEMBL617049,BAO_0000219,
2263,Expert,9606.0,,1,,,Functional activity against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader,D,,449.0,107,9,,CHEMBL617050,BAO_0000219,
2264,Autocuration,,,1,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,H,,,107,8,,CHEMBL617051,BAO_0000219,
2265,Autocuration,,,1,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line; no data,H,,,107,8,,CHEMBL617052,BAO_0000219,
2266,Autocuration,,,1,,,Functional antagonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2a receptor cell line,H,,,107,8,,CHEMBL617053,BAO_0000219,
2267,Autocuration,,,1,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand, expressed as Emax",H,,449.0,107,8,,CHEMBL617054,BAO_0000219,
2268,Autocuration,,,1,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells, expressed as Emax",H,,449.0,107,8,,CHEMBL617055,BAO_0000219,
2269,Autocuration,,,1,,,Affinity of compound towards human 5-hydroxytryptamine 2A receptor was evaluated using radioligand binding technique,H,,,107,8,,CHEMBL882924,BAO_0000357,
2270,Expert,9606.0,,1,,,Inhibition of human 5-hydroxytryptamine 2A receptor,D,,,107,9,,CHEMBL617056,BAO_0000357,
2271,Autocuration,,,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,,449.0,107,8,,CHEMBL617057,BAO_0000219,
2272,Expert,,,1,,,Inhibitory concentration against human 5-HT2A receptor in BEK cells,H,,,107,8,,CHEMBL617058,BAO_0000219,
2273,Autocuration,,,1,,,In vitro binding affinity against human 5-hydroxytryptamine 2A receptor at a concentration of 100 (nM),H,,,107,8,,CHEMBL617059,BAO_0000357,
2274,Autocuration,,,1,,,Ability to displace [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor was determined,H,,449.0,107,8,,CHEMBL617060,BAO_0000219,
2275,Expert,,,1,,,Displacement of [3H]ketanserin from CHO cells expressing human 5-hydroxytryptamine 2A receptor.,H,,449.0,107,8,,CHEMBL617061,BAO_0000219,
2276,Expert,,,1,,,Ability to displace [125I]R91150 from human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells,H,,307.0,107,8,,CHEMBL617062,BAO_0000219,
2277,Expert,,,1,,,Ability to displace [3H]ketanserin binding to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,,449.0,107,8,,CHEMBL617063,BAO_0000219,
2278,Autocuration,,,1,,,Agonist activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand,H,,,107,8,,CHEMBL617064,BAO_0000019,
2279,Autocuration,,,1,,,Agonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,,,107,8,,CHEMBL617065,BAO_0000019,
2280,Autocuration,,,1,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand,H,,449.0,107,8,,CHEMBL617066,BAO_0000219,
2281,Autocuration,,,1,,,Agonistic binding affinity against human 5-hydroxytryptamine 2A receptor in CHO cells using 8-OH-DPA radioligand; Nd means not done,H,,449.0,107,8,,CHEMBL617067,BAO_0000219,
2282,Autocuration,,,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]-Ketanserin radioligand,H,,,107,8,,CHEMBL617068,BAO_0000019,
2283,Autocuration,,,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand; Not tested,H,,,107,8,,CHEMBL617069,BAO_0000019,
2284,Autocuration,,,1,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,,,107,8,,CHEMBL617070,BAO_0000019,
2285,Autocuration,,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [125 I]DOI as radioligand,H,,,107,8,,CHEMBL617071,BAO_0000357,
2286,Autocuration,,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,,,107,8,,CHEMBL872915,BAO_0000357,
2287,Autocuration,,,1,,,Binding activity against cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand.,H,,,107,8,,CHEMBL617072,BAO_0000357,
2288,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor in humans,H,,,107,8,,CHEMBL617073,BAO_0000357,
2289,Autocuration,,,1,,,Binding affinity against the cloned human 5-hydroxytryptamine 2A receptor using [125I]DOI as the radioligand,H,,,107,8,,CHEMBL617074,BAO_0000357,
2290,Expert,,,1,,,Binding affinity for displacement of [3H]ketanserin to human 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,,449.0,107,8,,CHEMBL617075,BAO_0000219,
2291,Autocuration,,,1,,,Binding affinity of compound to human 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617076,BAO_0000357,
2292,Expert,9606.0,,1,,,Affinity for human 5-hydroxytryptamine 2A receptor expressed in mammalian cell line,D,,,107,9,,CHEMBL617077,BAO_0000019,
2293,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI radioligand.,H,,,107,8,,CHEMBL617078,BAO_0000357,
2294,Expert,9606.0,,1,,,Binding affinity to cloned human 5-hydroxytryptamine 2A receptor,D,,,107,9,,CHEMBL617079,BAO_0000357,
2295,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,H,,,107,8,,CHEMBL617080,BAO_0000357,
2296,Expert,,,1,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor by the displacement of [3H]ketanserin radioligand from the cloned receptor expressed in CHO cells,H,,449.0,107,8,,CHEMBL617081,BAO_0000219,
2297,Expert,,,1,,,Binding affinity towards human 5-HT2A receptor in BEK cells,H,,,107,8,,CHEMBL617082,BAO_0000219,
2298,Autocuration,,,1,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617083,BAO_0000357,
2299,Autocuration,,,1,,,Binding affinity for recombinant human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand.,H,,,107,8,,CHEMBL617084,BAO_0000357,
2300,Expert,9606.0,,1,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,D,,,107,9,,CHEMBL617085,BAO_0000357,
2301,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,,,107,8,,CHEMBL617086,BAO_0000357,
2302,Autocuration,,,1,,,Binding affinity was measured on 5-hydroxytryptamine 2A receptor in GF6 cells transfected with human 5-HT2A gene labeled with [3H]ketanserin,H,,,107,8,,CHEMBL617087,BAO_0000219,
2303,Autocuration,,,1,,,Compound was tested for the displacement of [125I]-DOI from clone human 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617088,BAO_0000357,
2304,Autocuration,,,1,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617089,BAO_0000357,
2305,Expert,,,1,,,"Tested on genetically transfected COS7 cell membranes selectively expressing human 5-hydroxytryptamine 2A receptor, using [3H]ketanserin as radioligand",H,,,107,8,,CHEMBL617090,BAO_0000019,
2306,Autocuration,,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in human using [3H]ketanserin as radioligand,H,,,107,8,,CHEMBL617513,BAO_0000357,
2307,Autocuration,,,1,,,In vitro binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells was determined using [3H]ketanserin as radioligand,H,,722.0,107,8,,CHEMBL617514,BAO_0000219,
2308,Autocuration,,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617515,BAO_0000019,
2309,Autocuration,,,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,H,,,107,8,,CHEMBL617516,BAO_0000357,
2310,Expert,9606.0,,1,,,Inhibitory constant determined against cloned human 5-hydroxytryptamine 2A receptor using with [125I]- DOI radioligand,D,,,107,9,,CHEMBL617517,BAO_0000357,
2311,Expert,9606.0,,1,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in CHO cells,D,,449.0,107,9,,CHEMBL617518,BAO_0000219,
2312,Autocuration,,,1,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617519,BAO_0000357,
2313,Expert,9606.0,,1,,,Displacement of [3H]DOB from human 5-hydroxytryptamine 2A receptor,D,,,107,9,,CHEMBL617520,BAO_0000357,
2314,Autocuration,,,1,,,Tested for binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]DOB as labeled ligand; binding data not obtained,H,,,107,8,,CHEMBL617521,BAO_0000357,
2315,Expert,9606.0,,1,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor,D,,,107,9,,CHEMBL617522,BAO_0000357,
2316,Autocuration,,,1,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]5-HT as radioligand,H,,,107,8,,CHEMBL617523,BAO_0000357,
2317,Autocuration,,,1,,,Tested for binding affinity towards human 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,,,107,8,,CHEMBL617524,BAO_0000357,
2318,Autocuration,,,1,,,Ability to displace 0.75 nM [3H]ketanserin in 5-hydroxytryptamine 2 receptor from rat frontal cortex homogenate,H,,,104686,4,,CHEMBL617525,BAO_0000019,
2319,Autocuration,10116.0,,1,,,Ability to inhibit [3H]spiperone binding to 5-hydroxytryptamine 2 receptor determined in rat,D,,,104686,5,,CHEMBL617526,BAO_0000019,
2320,Autocuration,,,1,,,Affinity on 5-hydroxytryptamine 2 receptor labeled by [125I]DOI,H,,,104686,4,,CHEMBL617527,BAO_0000224,
2321,Autocuration,,,1,,,Affinity towards [3H]- DOB -labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,H,,,104686,4,,CHEMBL617528,BAO_0000019,
2322,Autocuration,,,1,,,Affinity towards [3H]- ketanserin-labeled 5-hydroxytryptamine 2 receptor sites in rat cortical homogenates,H,,,104686,4,,CHEMBL617529,BAO_0000019,
2323,Autocuration,,,1,,,Inhibition of 5-hydroxytryptamine 2 induced vasoconstriction of rat caudal artery.,H,,,104686,4,,CHEMBL617530,BAO_0000224,
2324,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,H,,,104686,4,,CHEMBL617531,BAO_0000019,
2325,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortex using [125]-(R)-DOI as radioligand,H,,,104686,4,,CHEMBL617532,BAO_0000019,
2326,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat using [3H]ketanserin as radioligand,H,,,104686,4,,CHEMBL617533,BAO_0000019,
2327,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor of rat frontal cortex using [3H]ketanserin radioligand,H,,,104686,4,,CHEMBL617534,BAO_0000019,
2328,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2 receptor using [3H]ketanserin as radioligand,H,,,104686,4,,CHEMBL617535,BAO_0000224,
2329,Autocuration,,,1,,,Binding affinity at rat 5-hydroxytryptamine 2 receptor by [3H]ketanserin displacement.,H,,,104686,4,,CHEMBL617536,BAO_0000224,
2330,Autocuration,,,1,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617537,BAO_0000224,
2331,Autocuration,,,1,,,Binding affinity determined in radioreceptor binding assay by using [3H]ketanserin radioligand against 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617538,BAO_0000224,
2332,Autocuration,,In vitro,1,,,Binding affinity of [3H]ketanserin towards 5-hydroxytryptamine 2 receptor in cloned mammalian receptor expressed in cultured cells or from rat whole brain.,H,,,104686,4,,CHEMBL617539,BAO_0000219,
2333,Autocuration,10116.0,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor,D,,,104686,5,,CHEMBL617540,BAO_0000224,
2334,Autocuration,10116.0,,1,,,Binding affinity for 5-hydroxytryptamine 2 receptor from striata of male Wistar rats by displacement of [3H]ketanserin,D,,,104686,5,,CHEMBL617541,BAO_0000224,
2335,Autocuration,,,1,,,Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617542,BAO_0000224,
2336,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]DOB as,H,,,104686,4,,CHEMBL617543,BAO_0000224,
2337,Autocuration,10116.0,,1,,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,D,,485.0,104686,5,,CHEMBL617544,BAO_0000219,
2338,Autocuration,10116.0,,1,,,Binding affinity against [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor expressed in CHO-K1 cells,D,,485.0,104686,5,,CHEMBL617545,BAO_0000219,
2339,Autocuration,10116.0,,1,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand,D,,,104686,5,,CHEMBL617413,BAO_0000019,
2340,Autocuration,,,1,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- DOB as a radioligand.,H,,,104686,4,,CHEMBL617414,BAO_0000019,
2341,Autocuration,10116.0,,1,,,Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.,D,,,104686,5,,CHEMBL617415,BAO_0000019,
2342,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617416,BAO_0000224,
2343,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor at 1.0 uM concentration,H,,,104686,4,,CHEMBL617417,BAO_0000224,
2344,Autocuration,,,1,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- 1-(4-bromo-2,5-dimethoxy-phenyl)-2-aminopropane (D) as radioligand in rat frontal cortex",H,,,104686,4,,CHEMBL617418,BAO_0000019,
2345,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]- ketanserin as radioligand in rat frontal cortex,H,,,104686,4,,CHEMBL617419,BAO_0000019,
2346,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor was determined,H,,,104686,4,,CHEMBL617420,BAO_0000224,
2347,Autocuration,10116.0,,1,,,Affinity for 5-hydroxytryptamine 2 receptor,D,,,104686,5,,CHEMBL617421,BAO_0000224,
2348,Autocuration,,,1,,,Binding affinity towards serotonin 5-hydroxytryptamine 2 receptor of rat determined using 0.5 nM of [3H]ketanserin in binding assay,H,,,104686,4,,CHEMBL617422,BAO_0000224,
2349,Autocuration,,,1,,,Binding affinity was determined against 5-hydroxytryptamine 2 receptor from male Sprague-Dawley rat brain.,H,,,104686,4,,CHEMBL617423,BAO_0000019,
2350,Autocuration,,,1,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor from rat tissue homogenate,H,,,104686,4,,CHEMBL617424,BAO_0000019,
2351,Autocuration,,,1,,,Binding affinity which represents concentration giving half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor rat tissue homogenate,H,,,104686,4,,CHEMBL617425,BAO_0000019,
2352,Autocuration,,,1,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vitro),H,,,104686,4,,CHEMBL617426,BAO_0000224,
2353,Autocuration,,In vivo,1,,,Binding constant against 5-hydroxytryptamine 2 receptor (in vivo),H,,,104686,4,,CHEMBL617427,BAO_0000218,
2354,Autocuration,,,1,955.0,,Compound is evaluated for binding affinity towards 5-hydroxytryptamine 2 receptor using [3H]ketanserin in rat brain,H,,,104686,4,,CHEMBL617428,BAO_0000221,
2355,Autocuration,,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2 receptor from rat,H,,,104686,4,,CHEMBL617429,BAO_0000224,
2356,Autocuration,,,1,,,Compound was evaluated for in vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,H,,,104686,4,,CHEMBL617430,BAO_0000019,
2357,Autocuration,,,1,,,Compound was evaluated for in vitro binding affinity towards serotonin 5-hydroxytryptamine 2 receptor in rat cortex using [3H]- spiperone as radioligand,H,,,104686,4,,CHEMBL617431,BAO_0000019,
2358,Autocuration,,,1,1870.0,,Compound was evaluated for its ability to displace 0.25 nM [125I](R)-DOI from binding sites in rat frontal cortex.,H,,,104686,4,,CHEMBL617432,BAO_0000019,
2359,Autocuration,,,1,,,Ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617433,BAO_0000224,
2360,Autocuration,,,1,,,Compound was evaluated for its ability to displace [3H]ketanserin from serotonergic 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617434,BAO_0000224,
2361,Autocuration,10116.0,,1,,,Binding affinity against 5-Hydroxy tryptamine 2 (5-hydroxytryptamine 2)receptor,D,,,104686,5,,CHEMBL617435,BAO_0000224,
2362,Autocuration,,,1,,,Compound was evaluated for its binding affinity to 5-hydroxytryptamine 2 receptor in rat cortex using [3H]ketanserin radioligand assay,H,,,104686,4,,CHEMBL617436,BAO_0000019,
2363,Autocuration,10116.0,,1,2435.0,,Binding affinity against 5-hydroxytryptamine 2 receptor in rat striatum using [3H]-RP62203,D,,,104686,5,,CHEMBL617437,BAO_0000019,
2364,Autocuration,,,1,,,"Binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand",H,,,104686,4,,CHEMBL617438,BAO_0000019,
2365,Autocuration,,,1,,,"Compound was tested for binding affinity towards 5-hydroxytryptamine 2 receptor from frontal cortical regions of male Sprague-Dawley rat homogenates, using [3H]ketanserin as radioligand; Not Determined",H,,,104686,4,,CHEMBL617439,BAO_0000019,
2366,Autocuration,,,1,,,Compound was tested in vitro for binding affinity for 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617440,BAO_0000224,
2367,Autocuration,,,1,,,Evaluated for binding activity against [3H]ketanserin as radioligand for 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617441,BAO_0000224,
2368,Autocuration,10116.0,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortical membrane homogenates,D,,,104686,5,,CHEMBL872918,BAO_0000019,
2369,Autocuration,10116.0,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex,D,,,104686,5,,CHEMBL617442,BAO_0000019,
2370,Autocuration,,,1,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,H,,,104686,4,,CHEMBL617443,BAO_0000019,
2371,Autocuration,,,1,,,Binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 (5-HT2) receptor using [3H]KET as a radioligand,H,,,104686,4,,CHEMBL617444,BAO_0000019,
2372,Autocuration,,,1,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.,H,,,104686,4,,CHEMBL617445,BAO_0000019,
2373,Autocuration,,,1,,,Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.,H,,,104686,4,,CHEMBL617446,BAO_0000019,
2374,Autocuration,,,1,,,Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.,H,,,104686,4,,CHEMBL617447,BAO_0000249,
2375,Autocuration,,,1,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand.;ND is not determined,H,,,104686,4,,CHEMBL617448,BAO_0000019,
2376,Autocuration,,,1,,,Evaluated for the binding affinity to rat frontal cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand;ND means no data,H,,,104686,4,,CHEMBL617449,BAO_0000019,
2377,Autocuration,,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2 receptor in rat cortical tissue by [3H]spiperone displacement; No data.,H,,,104686,4,,CHEMBL617450,BAO_0000019,
2378,Autocuration,,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 165 to 263,H,,,104686,4,,CHEMBL617451,BAO_0000019,
2379,Autocuration,,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 2.4 to 5.3,H,,,104686,4,,CHEMBL617452,BAO_0000019,
2380,Autocuration,,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue.,H,,,104686,4,,CHEMBL617453,BAO_0000019,
2381,Autocuration,,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 140 to 980,H,,,104686,4,,CHEMBL617660,BAO_0000019,
2382,Autocuration,,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue.; value may range from 76 to 299,H,,,104686,4,,CHEMBL617661,BAO_0000019,
2383,Autocuration,,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]-Spiperone as the radioligand in rat cortical tissue; value may range from 12 to 66,H,,,104686,4,,CHEMBL617662,BAO_0000019,
2384,Autocuration,,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 136 to 220,H,,,104686,4,,CHEMBL872919,BAO_0000019,
2385,Autocuration,,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 197 to 341,H,,,104686,4,,CHEMBL617663,BAO_0000019,
2386,Autocuration,,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 23 to 187,H,,,104686,4,,CHEMBL617664,BAO_0000019,
2387,Autocuration,,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 29 to 132,H,,,104686,4,,CHEMBL617665,BAO_0000019,
2388,Autocuration,,,1,,,In vitro 5-hydroxytryptamine 2 receptor affinity by using [3H]spiperone as the radioligand in rat cortical tissue; value may range from 6 to 75,H,,,104686,4,,CHEMBL617666,BAO_0000019,
2389,Autocuration,,,1,,,In vitro binding affinity on 5-hydroxytryptamine 2 receptor is inhibition of binding of [125I]- I-LSD to P11 cells,H,,,104686,4,,CHEMBL617667,BAO_0000019,
2390,Autocuration,,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 2 receptor in rat striatal membranes by [3H]ketanserin displacement.,H,,,104686,4,,CHEMBL617668,BAO_0000249,
2391,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 2 receptor in rat cortical membranes using [3H]ketanserin as a radioligand,H,,,104686,4,,CHEMBL617669,BAO_0000249,
2392,Autocuration,,,1,,,Inhibitory activity against rat cortical 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617670,BAO_0000224,
2393,Autocuration,10116.0,,1,,,Inhibitory constant against 5-hydroxytryptamine 2 receptor,D,,,104686,5,,CHEMBL617671,BAO_0000224,
2394,Autocuration,,,1,,,Percentage specific displacement of radioligand [3H]-ketanserin from 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617672,BAO_0000224,
2395,Autocuration,,,1,,,Potency to displace [3H]- Spiperone from 5-hydroxytryptamine 2 receptor in rat striatum,H,,,104686,4,,CHEMBL617673,BAO_0000019,
2396,Autocuration,,,1,,,Tested for binding affinity against 5-hydroxytryptamine 2 receptor from rat frontal cortical regions using [3H]ketanserin as radioligand,H,,,104686,4,,CHEMBL617674,BAO_0000224,
2397,Autocuration,,,1,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex,H,,,104686,4,,CHEMBL617675,BAO_0000019,
2398,Autocuration,,,1,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; NA means Not Active,H,,,104686,4,,CHEMBL617676,BAO_0000019,
2399,Autocuration,,,1,,,Tested for binding affinity by measuring displacement of [3H]ketanserin from rat serotonin 5-hydroxytryptamine 2 receptor in rat cortex; not determined,H,,,104686,4,,CHEMBL617677,BAO_0000019,
2400,Autocuration,,,1,,,Displacement of [3H]ketanserin from rat prefrontal cortex 5-hydroxytryptamine 2 receptor,D,,,104686,5,,CHEMBL617678,BAO_0000019,
2401,Autocuration,,,1,,,Binding affinity to 5-hydroxytryptamine 2 receptor using [3H]ketanserin radioligand assay.,H,,,104686,4,,CHEMBL617679,BAO_0000224,
2402,Autocuration,,,1,,,Tested for its binding affinity to Tested for its binding affinity to 5-hydroxytryptamine 2 receptor using [3H]-ketanserin radioligand assay using [3H]-ketanserin radioligand assay,H,,,104686,4,,CHEMBL617680,BAO_0000224,
2403,Autocuration,,,1,,,The ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2 receptor in rat whole brain,H,,,104686,4,,CHEMBL617681,BAO_0000019,
2404,Autocuration,,,1,955.0,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor in rat brain tissue,H,,,104686,4,,CHEMBL617682,BAO_0000221,
2405,Autocuration,,,1,,,The binding affinity was measured on 5-hydroxytryptamine 2 receptor using [3H]- spiperone as radioligand.,H,,,104686,4,,CHEMBL617683,BAO_0000224,
2406,Autocuration,,,1,,,Binding affinity at 5-hydroxytryptamine 2 receptor from striata wistar rats by [3H]ketanserin displacement.,H,,,104686,4,,CHEMBL617684,BAO_0000224,
2407,Autocuration,10116.0,,1,,,Binding affinity towards 5-hydroxytryptamine 2 receptor,D,,,104686,5,,CHEMBL617685,BAO_0000224,
2408,Autocuration,,,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [3H]ketanserin radioligand in rat cerebral cortex,H,,,104686,4,,CHEMBL617686,BAO_0000019,
2409,Autocuration,,,1,,,The compound was tested in vitro for binding affinity towards 5-hydroxytryptamine 2 receptor by displacing [125]I-LSD radioligand,H,,,104686,4,,CHEMBL617687,BAO_0000224,
2410,Autocuration,,,1,,,Percentage specific displacement of radioligand [3H]ketanserin from 5-hydroxytryptamine 2 receptor,H,,,104686,4,,CHEMBL617688,BAO_0000224,
2411,Autocuration,,,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,,,104686,4,,CHEMBL617689,BAO_0000019,
2412,Autocuration,,,1,,,In vitro antagonistic activity against the contraction induced by 5-HT through 5-hydroxytryptamine 2 receptor in rat thoracic aortic strips,H,,,104686,4,,CHEMBL617690,BAO_0000019,
2413,Autocuration,,In vivo,1,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",H,,,104686,4,,CHEMBL617691,BAO_0000218,
2414,Autocuration,,In vivo,1,,,"In vivo inhibitory activity of 10 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",H,,,104686,4,,CHEMBL617692,BAO_0000218,
2415,Autocuration,,In vivo,1,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 1 hr after oral administration",H,,,104686,4,,CHEMBL617693,BAO_0000218,
2416,Autocuration,,In vivo,1,,,"In vivo inhibitory activity of 3 mg/kg compound in rats against elevation of BP caused by 5-HT (300 ug/kg, iv) through 5-hydroxytryptamine 2 receptor 3h after oral administration",H,,,104686,4,,CHEMBL617694,BAO_0000218,
2417,Expert,,,1,955.0,,Affinity for 5-hydroxytryptamine 2A receptor in rat brain cortex by ability to displace [3H]ketanserin,H,,,12687,8,,CHEMBL857985,BAO_0000221,
2418,Expert,10116.0,,1,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,D,,,12687,9,,CHEMBL617695,BAO_0000019,
2419,Autocuration,,,1,,,Affinity pKi for 5-hydroxytryptamine 2A receptor was measured in rat cortex homogenates,H,,,12687,8,,CHEMBL617696,BAO_0000019,
2420,Autocuration,,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor was determined,H,,,12687,8,,CHEMBL617697,BAO_0000357,
2421,Expert,10116.0,,1,,,Displacement of [3H]ketanserin from 5-HT2A receptor of rat frontal cortex,D,,,12687,9,,CHEMBL617257,BAO_0000019,
2422,Expert,10116.0,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,D,,,12687,9,,CHEMBL617258,BAO_0000357,
2423,Expert,,,1,,,Binding affinity was evaluated in vitro by displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor on rat cortical membrane,H,,,12687,8,,CHEMBL617259,BAO_0000019,
2424,Autocuration,,,1,,,In vitro affinity against serotonin ( 5-hydroxytryptamine 2A receptor ) receptor,H,,,12687,8,,CHEMBL617260,BAO_0000357,
2425,Expert,10116.0,,1,,,In vitro affinity against serotonin 5-hydroxytryptamine 2A receptor,D,,,12687,9,,CHEMBL617261,BAO_0000357,
2426,Autocuration,,,1,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]-ketanserin as radioligand,H,,,12687,8,,CHEMBL617262,BAO_0000019,
2427,Expert,,,1,,,Half-maximal inhibition of [3H]- Ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,H,,,12687,8,,CHEMBL617263,BAO_0000019,
2428,Autocuration,,,1,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat tissue homogenate,H,,,12687,8,,CHEMBL617264,BAO_0000019,
2429,Expert,10116.0,,1,,,Displacement of [3H]-ketanserin from rat brain 5-hydroxytryptamine 2A receptor,D,,,12687,9,,CHEMBL617265,BAO_0000019,
2430,Autocuration,,,1,,,Inhibition constant for in vitro inhibition of [3H]ketanserin binding to rat frontal cortex membranes 5-hydroxytryptamine 2A receptor,H,Membranes,,12687,8,,CHEMBL617266,BAO_0000249,
2431,Autocuration,,,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor rat frontal cortex membrane,H,,,12687,8,,CHEMBL617267,BAO_0000019,
2432,Expert,,,1,,,Inhibitory constant on 5-hydroxytryptamine 2A receptor of Rat frontal cortex,H,,,12687,8,,CHEMBL617268,BAO_0000019,
2433,Autocuration,,,1,,,Inhibitory constant on human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,H,,449.0,12687,8,,CHEMBL617269,BAO_0000219,
2434,Expert,,,1,,,Kinetic inhibition constant evaluated by measuring serotonergic activity,H,,,12687,8,,CHEMBL617323,BAO_0000357,
2435,Autocuration,,,1,,,Serotonergic activity of the compound.,H,,,12687,8,,CHEMBL617324,BAO_0000357,
2436,Autocuration,,,1,,,Tested in vitro for its ability to inhibit [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat frontal cortex membranes,H,,,12687,8,,CHEMBL617325,BAO_0000249,
2437,Expert,10116.0,,1,,,The binding affinity was evaluated on 5-hydroxytryptamine 2A receptor expressed in rat cortex by using [3H]ketanserin as radioligand.,D,,,12687,9,,CHEMBL617326,BAO_0000019,
2438,Expert,,,1,,,In vitro ability to displace [3H]ketanserin binding from 5-hydroxytryptamine 2A receptor in rat striatal membrane.,H,,,12687,8,,CHEMBL617327,BAO_0000249,
2439,Expert,10116.0,,1,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,,,12687,9,,CHEMBL617328,BAO_0000019,
2440,Expert,10116.0,,1,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,,,12687,9,,CHEMBL617329,BAO_0000019,
2441,Expert,10116.0,,1,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,,,12687,9,,CHEMBL617330,BAO_0000019,
2442,Autocuration,,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,,,12687,8,,CHEMBL617331,BAO_0000357,
2443,Autocuration,,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand.,H,,,12687,8,,CHEMBL617332,BAO_0000357,
2444,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617333,BAO_0000357,
2445,Autocuration,,,1,,,Binding affinity against serotonin 5-hydroxytryptamine 2A receptor was determined using human [125I]-eotaxin,H,,,107,8,,CHEMBL617334,BAO_0000357,
2446,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.000001 mol/L,H,,,107,8,,CHEMBL617335,BAO_0000357,
2447,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor was determined at a concentration of 0.00001 mol/L,H,,,107,8,,CHEMBL617336,BAO_0000357,
2448,Autocuration,,,1,,,Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration,H,,,107,8,,CHEMBL617337,BAO_0000357,
2449,Expert,9606.0,,1,,,Percent inhibition against 5-hydroxytryptamine 2A receptor using [3H]ketanserin at 1 uM,D,,,107,9,,CHEMBL617338,BAO_0000357,
2450,Autocuration,,,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617339,BAO_0000357,
2451,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617340,BAO_0000357,
2452,Autocuration,,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2A receptor; inactive at 10 uM,H,,,107,8,,CHEMBL617341,BAO_0000357,
2453,Expert,,,1,,,Inhibition of [125I]-eotaxin binding to serotonin 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617342,BAO_0000357,
2454,Expert,,,1,,,Affinity for 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617343,BAO_0000357,
2455,Expert,,,1,,,Binding affinity was performed using [3H]ketanserin as the radioligand and stably transfected NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor (GF-62 cells).,H,,723.0,107,8,,CHEMBL617344,BAO_0000219,
2456,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin,H,,,107,8,,CHEMBL617345,BAO_0000357,
2457,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand.,H,,,107,8,,CHEMBL617346,BAO_0000357,
2458,Autocuration,,,1,,,Compound was evaluated for its binding against 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617347,BAO_0000357,
2459,Autocuration,,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2A receptor was determined,H,,,107,8,,CHEMBL617348,BAO_0000357,
2460,Autocuration,,,1,,,Binding affinity relative to indolopiperidine (compound 1)for 5-hydroxytryptamine 2A receptor was determined,H,,,107,8,,CHEMBL617349,BAO_0000357,
2461,Autocuration,,,1,,,Compound was evaluated for its inverse agonist activity against 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617350,BAO_0000019,
2462,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin,H,,,107,8,,CHEMBL872339,BAO_0000357,
2463,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 2A receptor was determined,H,,,107,8,,CHEMBL617351,BAO_0000357,
2464,Expert,,,1,,,Binding affinity towards serotonin 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617352,BAO_0000357,
2465,Autocuration,,,1,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617353,BAO_0000357,
2466,Autocuration,,,1,,,Ability to displace [3H]-ketanserin from 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617354,BAO_0000357,
2467,Autocuration,,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617355,BAO_0000357,
2468,Expert,10090.0,,1,,,In vitro binding affinity against 5-hydroxytryptamine 2A receptor in CHO cells,H,,449.0,107,8,,CHEMBL617356,BAO_0000219,
2469,Autocuration,,,1,,,Inhibition of ketanserin binding to 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617357,BAO_0000357,
2470,Autocuration,,,1,,,Binding affinity at 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617358,BAO_0000357,
2471,Expert,,,1,,,Binding affinity towards Serotonin 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617359,BAO_0000357,
2472,Autocuration,,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor was determined,H,,,107,8,,CHEMBL617360,BAO_0000357,
2473,Autocuration,,,1,,,The binding affinity towards 5-hydroxytryptamine 2A receptor; No affinity,H,,,107,8,,CHEMBL875913,BAO_0000357,
2474,Autocuration,,,1,,,Affinity against 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617361,BAO_0000357,
2475,Expert,9606.0,,1,,,Binding affinity against 5-Hydroxytryptamine 2A receptor,D,,,107,9,,CHEMBL617362,BAO_0000357,
2476,Autocuration,,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using radioligand binding assay,H,,,107,8,,CHEMBL617363,BAO_0000357,
2477,Autocuration,,,1,,,Tested against 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617364,BAO_0000357,
2478,Autocuration,,,1,,,Binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,H,,,105075,4,,CHEMBL617365,BAO_0000224,
2479,Autocuration,,,1,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H] ketanserin,H,,,105075,4,,CHEMBL617366,BAO_0000224,
2480,Autocuration,,,1,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor agonist [125I]- - (+/-)DOI,H,,,105075,4,,CHEMBL617367,BAO_0000224,
2481,Autocuration,,,1,,,Tested for the binding affinity against the site labelled by the 5-hydroxytryptamine 2A receptor - 5-hydroxytryptamine 2C receptor antagonist [3H]- ketanserin,H,,,105075,4,,CHEMBL617368,BAO_0000224,
2482,Autocuration,,,1,,,Selectivity ratio towards 5-hydroxytryptamine 2A receptor to Dopamine receptor D2 (5-HT2A/D2 ),H,,,107,8,,CHEMBL617369,BAO_0000357,
2483,Expert,9606.0,,1,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND means no data,D,,722.0,227,9,,CHEMBL617370,BAO_0000219,
2484,Expert,9606.0,,1,,,Functional activity against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader,D,,449.0,227,9,,CHEMBL617371,BAO_0000219,
2485,Autocuration,,,1,,,In vitro binding affinity against human 5-HT2B receptor at a concentration of 100 (nM),H,,,227,8,,CHEMBL617372,BAO_0000357,
2486,Expert,9606.0,,1,,,Affinity towards human 5-hydroxytryptamine 2B serotonin receptor,D,,,227,9,,CHEMBL617373,BAO_0000357,
2487,Autocuration,,,1,,,Agonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT radioligand,H,,,227,8,,CHEMBL617374,BAO_0000019,
2488,Autocuration,,,1,,,Agonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]-5-HT as radioligand,H,,,227,8,,CHEMBL617375,BAO_0000019,
2489,Autocuration,,,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand,H,,,227,8,,CHEMBL617376,BAO_0000019,
2490,Autocuration,,,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine radioligand; Not tested,H,,,227,8,,CHEMBL617377,BAO_0000019,
2491,Autocuration,,,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine radioligand,H,,,227,8,,CHEMBL617378,BAO_0000019,
2492,Autocuration,,,1,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,H,,,227,8,,CHEMBL617379,BAO_0000019,
2493,Autocuration,,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]- rauwolscine as radioligand,H,,,227,8,,CHEMBL617380,BAO_0000357,
2494,Autocuration,,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT 2B as radioligand,H,,,227,8,,CHEMBL617381,BAO_0000357,
2495,Autocuration,,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand,H,,,227,8,,CHEMBL617382,BAO_0000357,
2496,Autocuration,,,1,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617383,BAO_0000357,
2497,Expert,,,1,,,Affinity against 5-hydroxytryptamine 2A receptor (D) labeled with [125I]DOI.,H,,,107,8,,CHEMBL617384,BAO_0000357,
2498,Expert,,,1,,,Affinity against 5-hydroxytryptamine 2A receptor (K) labeled with [3H]ketanserin.,H,,,107,8,,CHEMBL617385,BAO_0000357,
2499,Autocuration,,,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes,H,,,107,8,,CHEMBL617386,BAO_0000019,
2500,Autocuration,,,1,,,The compound was tested for CNS binding affinity towards 5-hydroxytryptamine 2A receptor from cloned Human membranes.,H,,,107,8,,CHEMBL617387,BAO_0000019,
2501,Autocuration,,,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,,723.0,107,8,,CHEMBL617388,BAO_0000219,
2502,Autocuration,,,1,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,H,,449.0,107,8,,CHEMBL617389,BAO_0000219,
2503,Expert,9606.0,,1,,,Relative efficacy against human 5-hydroxytryptamine 2A receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,,449.0,107,9,,CHEMBL617390,BAO_0000219,
2504,Autocuration,,,1,,,Selectivity ratio of binding affinity of 5-hydroxytryptamine 2A receptor to that of 5-hydroxytryptamine 2C receptor.,H,,,104817,4,,CHEMBL617391,BAO_0000224,
2505,Autocuration,,,1,,,Binding activity radioligand.,H,,,107,8,,CHEMBL617392,BAO_0000357,
2506,Autocuration,,,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,H,,,107,8,,CHEMBL617393,BAO_0000019,
2507,Autocuration,,,1,,,Binding affinity for human cloned 5-HT2A receptor expressed in L929 cells using [125I]R91150 as radioligand,H,,307.0,107,8,,CHEMBL617394,BAO_0000219,
2508,Expert,,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand,H,,307.0,107,8,,CHEMBL617395,BAO_0000219,
2509,Expert,,,1,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells by [125I]R91150 displacement.,H,,307.0,107,8,,CHEMBL617396,BAO_0000219,
2510,Autocuration,,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 2A receptor expressed in L929 cells using [125I]R91150 as radioligand; Not tested,H,,307.0,107,8,,CHEMBL617397,BAO_0000219,
2511,Autocuration,,,1,,,Binding affinity against 5-HT2A receptor,H,,,107,8,,CHEMBL617398,BAO_0000357,
2512,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor,H,,,107,8,,CHEMBL617399,BAO_0000357,
2513,Autocuration,,,1,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2A receptor (human clone expressed in 293 cells) using [3H]ketanserin as radioligand,H,,722.0,107,8,,CHEMBL617400,BAO_0000219,
2514,Autocuration,,,1,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,H,,722.0,107,8,,CHEMBL617401,BAO_0000219,
2515,Expert,9606.0,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells,D,,722.0,107,9,,CHEMBL617402,BAO_0000219,
2516,Expert,9606.0,,1,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,,722.0,107,9,,CHEMBL617403,BAO_0000219,
2517,Expert,,,1,,,Binding affinity against human 5-hydroxytryptamine 2A receptor using displacement of [3H]5-HT,H,,,107,8,,CHEMBL617404,BAO_0000357,
2518,Expert,9606.0,,1,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,,722.0,107,9,,CHEMBL857981,BAO_0000219,
2519,Expert,9606.0,,1,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,,722.0,107,9,,CHEMBL617405,BAO_0000219,
2520,Expert,9606.0,,1,,,Binding affinity to human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]- ketanserin as radioligand,D,,722.0,107,9,,CHEMBL617253,BAO_0000219,
2521,Expert,,,1,,,Binding affinity at human cloned 5-hydroxytryptamine 2A receptor.,H,,,107,8,,CHEMBL617254,BAO_0000357,
2522,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,H,,722.0,107,8,,CHEMBL617255,BAO_0000219,
2523,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptors in HEK 293 cells using [3H]ketanserin as radioligand,H,,722.0,107,8,,CHEMBL617256,BAO_0000219,
2524,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]ketanserin as radioligand,H,,722.0,107,8,,CHEMBL616874,BAO_0000219,
2525,Expert,9606.0,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor (human cloned receptor) in HEK 293 cells using [3H]ketanserin as radioligand.,D,,722.0,107,9,,CHEMBL616875,BAO_0000219,
2526,Expert,,,1,,,Binding affinity towards human 5-hydroxytryptamine 2A receptor expressed in HEK 293 cells using [3H]ketanserin as radioligand,H,,722.0,107,8,,CHEMBL616876,BAO_0000219,
2527,Expert,,,1,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2A in HEK293 cells, using [3H]ketanserin as radioligand.",H,,722.0,107,8,,CHEMBL616877,BAO_0000219,
2528,Expert,9606.0,,1,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2A receptor expressed in HEK293 cells; compound is insoluble,D,,722.0,107,9,,CHEMBL616878,BAO_0000219,
2529,Expert,,,1,,,Binding affinity towards human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by displacement of [3H]ketanserin,H,,722.0,107,8,,CHEMBL616879,BAO_0000219,
2530,Expert,,,1,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2A receptor of HEK293 cells by [3H]ketanserin displacement.,H,,722.0,107,8,,CHEMBL616880,BAO_0000219,
2531,Expert,9606.0,,1,,,Binding affinity against human 5-hydroxytryptamine 2A receptor expressed in 293 cells using [3H]ketanserin,D,,722.0,107,9,,CHEMBL616881,BAO_0000219,
2532,Autocuration,,,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand,H,,723.0,107,8,,CHEMBL616882,BAO_0000219,
2533,Autocuration,,,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,,723.0,107,8,,CHEMBL616883,BAO_0000219,
2534,Autocuration,,,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2A receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,,723.0,107,8,,CHEMBL616884,BAO_0000219,
2535,Autocuration,,,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2A receptor in HEK 293 cells using [3H]ketanserin as the radioligand,H,,722.0,107,8,,CHEMBL616885,BAO_0000219,
2536,Autocuration,,,1,,,Compound was evaluated for displacement of [3H]ketanserin from human cloned 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells,H,,485.0,107,8,,CHEMBL616886,BAO_0000219,
2537,Expert,,,1,,,Displacement of [3H]-ketanserin from human cloned 5-hydroxytryptamine 2A receptor expressed in CHO-K1 cells.,H,,485.0,107,8,,CHEMBL616887,BAO_0000219,
2538,Expert,9606.0,,1,,,Binding affinity for human 5-hydroxytryptamine 2A receptor,D,,,107,9,,CHEMBL616888,BAO_0000357,
2539,Autocuration,,,1,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 2A receptor in human cloned receptors in HEK 293 cells using [3H]ketanserin,H,,722.0,107,8,,CHEMBL616889,BAO_0000219,
2540,Autocuration,,,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2A receptor in HEK 293 using [3H]ketanserin as a radioligand,H,,722.0,107,8,,CHEMBL616890,BAO_0000219,
2541,Expert,9606.0,,1,,,Inhibitory constant for human 5-hydroxytryptamine 2A receptor transfected in to CHO cells,D,,449.0,107,9,,CHEMBL616891,BAO_0000219,
2542,Autocuration,,,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2A receptor in HEK293 cells using [3H]-ketanserin.,H,,722.0,107,8,,CHEMBL616892,BAO_0000219,
2543,Autocuration,,,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2A receptor in HEK293 cells, using [3H]ketanserin as radioligand",H,,722.0,107,8,,CHEMBL616893,BAO_0000219,
2544,Autocuration,,,1,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2A receptor in 3T3 cells,H,,723.0,10620,8,,CHEMBL616894,BAO_0000219,
2545,Expert,,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells,H,,723.0,107,8,,CHEMBL616895,BAO_0000219,
2546,Autocuration,,,1,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2A receptor,H,,,10620,8,,CHEMBL616896,BAO_0000019,
2547,Autocuration,,,1,,,Ability to displace [3H]-Ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor,H,,,10621,8,,CHEMBL617099,BAO_0000357,
2548,Autocuration,,,1,,,Ability to displace [3H]ketanserin radioligand from porcine 5-hydroxytryptamine 2A receptor; ND denotes not determined,H,,,10621,8,,CHEMBL617100,BAO_0000357,
2549,Autocuration,9986.0,,1,,,Binding affinity against rabbit aorta 5-HT2A receptor,H,,,107,8,,CHEMBL884532,BAO_0000357,
2550,Expert,9986.0,,1,,,Binding affinity for 5-hydroxytryptamine 2A receptor of rabbit aorta ring preparations,H,,,107,8,,CHEMBL617101,BAO_0000357,
2551,Expert,9986.0,,1,,,Dissociation equilibrium constant against the vascular 5-hydroxytryptamine 2A receptor in the rabbit saphenous aorta,H,,,107,8,,CHEMBL617102,BAO_0000357,
2552,Autocuration,9986.0,,1,,,Binding affinity against 5-hydroxytryptamine 1D receptor alpha using rabbit saphenous vein assay.,H,,,107,8,,CHEMBL617103,BAO_0000019,
2553,Expert,9986.0,,1,,,The compound was tested for binding affinity against 5-HT2A receptor,H,,,107,8,,CHEMBL617104,BAO_0000357,
2554,Autocuration,,,1,,,Compound was evaluated for displacement of [3H]ketanserin from cloned rat 5-hydroxytryptamine 2A receptor in transfected CHO-K1 cells.,H,,485.0,10576,8,,CHEMBL857979,BAO_0000219,
2555,Autocuration,,,1,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein,H,,,12687,8,,CHEMBL857502,BAO_0000019,
2556,Autocuration,,,1,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,H,,,12687,8,,CHEMBL617105,BAO_0000019,
2557,Autocuration,,,1,945.0,,Binding affinity analysed on 5-HT 2A in rat stomach fundus.,H,,,12687,8,,CHEMBL858021,BAO_0000019,
2558,Expert,10116.0,,1,945.0,,Binding affinity for 5-HT 2A in rat stomach fundus,D,,,12687,9,,CHEMBL875910,BAO_0000019,
2559,Autocuration,,,1,,,Binding affinity analysed towards 5-HT 2A in rat jugular vein.,H,,,12687,8,,CHEMBL617106,BAO_0000019,
2560,Expert,,,1,,,Ability to stimulate phosphoinositide hydrolysis in NIH3T3 cells expressing the 5-hydroxytryptamine 2A receptor,H,,723.0,12687,8,,CHEMBL617107,BAO_0000219,
2561,Autocuration,,,1,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617108,BAO_0000019,
2562,Autocuration,,,1,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast expressing 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617109,BAO_0000019,
2563,Autocuration,,,1,,,Evaluated for the effective concentration at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617110,BAO_0000357,
2564,Autocuration,,,1,,,Functional potency at the rat 5-hydroxytryptamine 2A receptor as effective concentration EC50 for stimulating Phosphoinositide accumulation,H,,,12687,8,,CHEMBL617111,BAO_0000357,
2565,Expert,10116.0,,1,,,In vitro relative agonist activity against 5-hydroxytryptamine 2A using PI assay in rat vascular smooth muscle cells,D,,,12687,9,,CHEMBL617112,BAO_0000019,
2566,Autocuration,,,1,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617113,BAO_0000357,
2567,Autocuration,,,1,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617114,BAO_0000357,
2568,Autocuration,,,1,,,Tested for its ability to activate phospholipase c by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617115,BAO_0000357,
2569,Autocuration,,,1,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,H,,,12687,8,,CHEMBL617116,BAO_0000219,
2570,Autocuration,,,1,,,Efficacy at 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617117,BAO_0000019,
2571,Autocuration,,,1,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),H,,,12687,8,,CHEMBL617118,BAO_0000357,
2572,Expert,10116.0,,1,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor was determined by using CA+ assay (Emax),D,,,12687,9,,CHEMBL617119,BAO_0000357,
2573,Expert,10116.0,,1,,,In vitro efficacy against rat 5-hydroxytryptamine 2A receptor determined by using PI assay (Emax),D,,,12687,9,,CHEMBL617120,BAO_0000357,
2574,Expert,10116.0,,1,,,The receptor (5-hydroxytryptamine 2A ) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,D,,,12687,9,,CHEMBL617121,BAO_0000219,
2575,Autocuration,,,1,,,The receptor (5-hydroxytryptamine 2A) mediated mobilization of intracellular calcium [Ca2+] was studied in rat smooth muscle cells,H,,,12687,8,,CHEMBL617122,BAO_0000219,
2576,Autocuration,,,1,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617123,BAO_0000019,
2577,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes,H,,,12687,8,,CHEMBL617124,BAO_0000019,
2578,Expert,,,1,,,Binding affinity to serotonin 5-hydroxytryptamine 2A receptors using a radioligand [3H]ketanserin binding assay in rat cortical membranes,H,,,12687,8,,CHEMBL617600,BAO_0000249,
2579,Expert,,,1,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was evaluated using [3H]- ketanserin as radioligand,H,,,12687,8,,CHEMBL617601,BAO_0000357,
2580,Expert,,,1,,,In vitro affinity towards 5-hydroxytryptamine 2A receptor using [3H]spiroperidol as radioligand in cortex,H,,,12687,8,,CHEMBL882923,BAO_0000019,
2581,Autocuration,,,1,,,Compound was tested for it's binding affinity towards 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617602,BAO_0000357,
2582,Autocuration,,,1,,,Compound was tested for its ability to displace [3H]DOB from 5-hydroxytryptamine 2A receptor in rat cortex homogenates,H,,,12687,8,,CHEMBL617603,BAO_0000019,
2583,Autocuration,,,1,,,Compound was tested for the inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617604,BAO_0000357,
2584,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor from rat frontal cortex using [3H]ketanserin as radioligand,H,,,12687,8,,CHEMBL617605,BAO_0000019,
2585,Expert,,,1,,,In vitro binding affinity for serotonin 5-hydroxytryptamine 2A receptor of rat cerebral cortex using [3H]ketanserin as radioligand,H,,,12687,8,,CHEMBL617606,BAO_0000019,
2586,Expert,10116.0,,1,,,Inhibition of [3H]ketanserin binding to rat frontal cortex membrane 5-hydroxytryptamine 2A receptor,D,,,12687,9,,CHEMBL617607,BAO_0000019,
2587,Autocuration,,,1,,,In vitro inhibitory concentration against radioligand [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,,,12687,8,,CHEMBL617455,BAO_0000249,
2588,Expert,10116.0,,1,,,In vitro inhibition of [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,D,,,12687,9,,CHEMBL617456,BAO_0000019,
2589,Expert,,,1,,,Inhibitory concentration against 5-hydroxytryptamine 2A receptor (Inactive at >1000 nM concentration),H,,,12687,8,,CHEMBL617457,BAO_0000357,
2590,Expert,10116.0,,1,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2A receptor,D,,,12687,9,,CHEMBL617458,BAO_0000357,
2591,Expert,10116.0,,1,,,Inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor from rat brain,D,,,12687,9,,CHEMBL617459,BAO_0000019,
2592,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor binding site using [3H]ketanserin. ,H,,,12687,8,,CHEMBL617460,BAO_0000357,
2593,Expert,,,1,,,"Binding affinity for 5-hydroxytryptamine 2A receptor, activity is expressed as IC50 values.",H,,,12687,8,,CHEMBL617461,BAO_0000357,
2594,Expert,10116.0,,1,,,Displacement of [3H]ketanserin from rat cortical membrane 5-hydroxytryptamine 2A receptor at 10e-7 M,D,,,12687,9,,CHEMBL617462,BAO_0000019,
2595,Autocuration,,,1,,,Intrinsic activity was determined at 5-hydroxytryptamine 2A receptor which is percentage response given compared with the response produced by 10 uM serotonin.,H,,,12687,8,,CHEMBL617463,BAO_0000357,
2596,Autocuration,,,1,,,"Compound was tested for binding affinity at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate using [125I]-2,5-Dimethoxy -4-iodoamphetamine (DOI).",H,,,12687,8,,CHEMBL617464,BAO_0000019,
2597,Autocuration,,,1,,,"Compound was tested for binding affinity using [3H]MDL-100,907 at 5-hydroxytryptamine 2A receptor sites in rat cortical homogenate.",H,,,12687,8,,CHEMBL617465,BAO_0000019,
2598,Expert,,,1,,,Ability to bind to central serotonin 5-hydroxytryptamine 2A receptor in vitro in cortex of the rat brain using [3H]ketanserin radioligand,H,,,12687,8,,CHEMBL617466,BAO_0000019,
2599,Autocuration,,,1,,,Ability to displace [3H]- ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,H,,,12687,8,,CHEMBL617467,BAO_0000019,
2600,Expert,,,1,,,Displacement of [3H]ketanserin (0.5 nM) from rat cerebral cortex 5-hydroxytryptamine 2A receptors,H,,,12687,8,,CHEMBL617468,BAO_0000019,
2601,Autocuration,,,1,,,Ability to displace [3H]ketanserin bound to 5-hydroxytryptamine 2A receptor in rat pre-frontal cortex,H,,,12687,8,,CHEMBL617469,BAO_0000019,
2602,Autocuration,,,1,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617470,BAO_0000019,
2603,Autocuration,,,1,,,Ability to displace [3H]ketanserin from rat cortical homogenate 5-hydroxytryptamine 2A receptor; Not tested,H,,,12687,8,,CHEMBL617471,BAO_0000019,
2604,Expert,,,1,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor in NIH3T3 cell line membranes,H,,723.0,12687,8,,CHEMBL617472,BAO_0000219,
2605,Expert,,,1,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2A serotonin receptor.,H,,,12687,8,,CHEMBL617473,BAO_0000357,
2606,Expert,10116.0,,1,,,Affinity 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,D,,,12687,9,,CHEMBL617474,BAO_0000019,
2607,Expert,10116.0,,1,,,Affinity at 5-hydroxytryptamine 2A receptor of the rat brain cortex was assessed on the basis of their ability to displace [3H]ketanserin,D,,,12687,9,,CHEMBL617475,BAO_0000019,
2608,Autocuration,,,1,955.0,,Affinity at [3H]ketanserin-labeled 5-hydroxytryptamine 2A receptor in rat brain homogenate was determined,H,,,12687,8,,CHEMBL617476,BAO_0000221,
2609,Expert,,,1,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617477,BAO_0000357,
2610,Expert,,,1,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2A receptor,H,,723.0,12687,8,,CHEMBL617478,BAO_0000219,
2611,Autocuration,,,1,,,"Antagonistic activity measured for 5-hydroxytryptamine 2A receptor using [3H]-MDL- 100,907 as radioligand in rat cortical homogenates.",H,,,12687,8,,CHEMBL617479,BAO_0000221,
2612,Autocuration,,,1,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor was determined using [125I]- DOI as radioligand,H,,,12687,8,,CHEMBL617480,BAO_0000357,
2613,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617481,BAO_0000357,
2614,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat prefrontal cerebral cortex mambranes,H,,,12687,8,,CHEMBL617482,BAO_0000019,
2615,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat forebrain using [3H]ketanserin as radioligand,H,,,12687,8,,CHEMBL617483,BAO_0000019,
2616,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,,,12687,8,,CHEMBL621528,BAO_0000357,
2617,Expert,10116.0,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor expressed NIH3T3 cells using [3H]ketanserin,D,,723.0,12687,9,,CHEMBL621529,BAO_0000219,
2618,Expert,,,1,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,,,12687,8,,CHEMBL621530,BAO_0000357,
2619,Expert,,,1,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,,,12687,8,,CHEMBL621531,BAO_0000357,
2620,Expert,10116.0,,1,,,Binding affinity against rat brain 5-hydroxytryptamine 2A receptor,D,,,12687,9,,CHEMBL621532,BAO_0000019,
2621,Expert,,,1,,,Binding affinity at cloned rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,,,12687,8,,CHEMBL621533,BAO_0000357,
2622,Expert,,,1,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells,H,,449.0,12687,8,,CHEMBL621534,BAO_0000219,
2623,Autocuration,,,1,,,Binding affinity measured at the 5-hydroxytryptamine 2A receptor by the inhibition of [3H]ketanserin binding to rat cortex using unlabeled mianserin for nonspecific binding.,H,,,12687,8,,CHEMBL621535,BAO_0000019,
2624,Autocuration,,,1,,,Binding affinity of [3H]- ketanserin labelled towards Rat cortical 5-hydroxytryptamine 2A receptor using radioligand binding assay,H,,,12687,8,,CHEMBL621536,BAO_0000357,
2625,Autocuration,,,1,,,Binding affinity of compound was tested for 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL621537,BAO_0000357,
2626,Expert,10116.0,,1,,,Binding affinity for 5-hydroxytryptamine 2A receptor,D,,,12687,9,,CHEMBL621538,BAO_0000357,
2627,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as the radioligand.,H,,,12687,8,,CHEMBL621539,BAO_0000019,
2628,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex,H,,,12687,8,,CHEMBL621540,BAO_0000019,
2629,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor of rat pre-frontal cortex.,H,,,12687,8,,CHEMBL621541,BAO_0000019,
2630,Autocuration,,,1,,,Binding affinity towards 5-HT 2A receptor in rat cerebral frontal cortex membranes using [3H]ketanserin as radioligand,H,,,12687,8,,CHEMBL621542,BAO_0000019,
2631,Expert,,,1,,,Binding affinity at 5-hydroxytryptamine 2A receptor of rat.,H,,,12687,8,,CHEMBL621543,BAO_0000357,
2632,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor sites by using [3H]ketanserin as radioligand,H,,,12687,8,,CHEMBL621544,BAO_0000357,
2633,Expert,10116.0,,1,,,Binding affinity for 5-hydroxytryptamine 2A serotonin receptor,D,,,12687,9,,CHEMBL621545,BAO_0000357,
2634,Autocuration,,,1,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,,,12687,8,,CHEMBL621546,BAO_0000357,
2635,Autocuration,,,1,,,Binding affinity towards rat cortical 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand; Not tested,H,,,12687,8,,CHEMBL621547,BAO_0000357,
2636,Expert,,,1,,,Displacement of [3H]ketanserin from NIH3T3 cells stably expressing rat 5-hydroxytryptamine 2A receptor,H,,723.0,12687,8,,CHEMBL618692,BAO_0000219,
2637,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL618693,BAO_0000357,
2638,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor using [125I]DOI as radioligand,H,,,12687,8,,CHEMBL872922,BAO_0000357,
2639,Autocuration,,,1,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor from fundus tissue was determined using [3H]mesulergine as radioligand,H,,,12687,8,,CHEMBL618694,BAO_0000357,
2640,Expert,10116.0,,1,,,Binding affinity for rat 5-hydroxytryptamine 2A receptor using [3H]DOB,D,,,12687,9,,CHEMBL618695,BAO_0000357,
2641,Autocuration,,,1,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor was determined using [3H]DOB as radioligand; ND=No data,H,,,12687,8,,CHEMBL618696,BAO_0000357,
2642,Expert,,,1,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2A receptor by [3H]ketanserin displacement.,H,,,12687,8,,CHEMBL618697,BAO_0000357,
2643,Autocuration,,,1,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]DOB as radioligand,H,,,12687,8,,CHEMBL618892,BAO_0000357,
2644,Autocuration,,,1,,,Binding affinity towards cloned rat Inhibition of binding towards 5-hydroxytryptamine 2A receptor at 100 nM concentration was determined using [3H]ketanserin as radioligand,H,,,12687,8,,CHEMBL618893,BAO_0000357,
2645,Autocuration,,,1,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL618894,BAO_0000357,
2646,Expert,,,1,,,Binding affinity towards rat 5-hydroxytryptamine 2A receptor expressed in NIH3T3 cells using [3H]ketanserin as radioligand,H,,723.0,12687,8,,CHEMBL618895,BAO_0000219,
2647,Expert,10116.0,,1,,,Binding affinity was measured against 5-hydroxytryptamine 2A receptor by displacement of [3H]- ketanserin by lysergic acid amides,D,,,12687,9,,CHEMBL618896,BAO_0000357,
2648,Autocuration,,,1,5383.0,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2A receptor in homogenate of caudate putamen tissue from rat brain,H,,,12687,8,,CHEMBL618897,BAO_0000019,
2649,Autocuration,,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand,H,,,12687,8,,CHEMBL618898,BAO_0000357,
2650,Autocuration,,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2A receptor using [3H]ketanserin as a radioligand; Not determined,H,,,12687,8,,CHEMBL618899,BAO_0000357,
2651,Autocuration,,,1,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2A receptor in cloned rat cell culture,H,,,12687,8,,CHEMBL618900,BAO_0000357,
2652,Autocuration,,,1,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2A receptor in cloned rat prefrontal cortex homogenate,H,,,12687,8,,CHEMBL618901,BAO_0000019,
2653,Autocuration,,,1,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL618902,BAO_0000357,
2654,Expert,10116.0,,1,10000000.0,,Displacement of [3H]8-OH-DPAT from rat hippocampus membrane 5-hydroxytryptamine 2A receptor,D,,,12687,9,,CHEMBL618903,BAO_0000221,
2655,Autocuration,,,1,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL618904,BAO_0000357,
2656,Autocuration,,,1,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]ketanserin radioligand.,H,,,12687,8,,CHEMBL618905,BAO_0000357,
2657,Autocuration,,,1,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2A receptor using [3H]-ketanserin radioligand.,H,,,12687,8,,CHEMBL618906,BAO_0000357,
2658,Expert,,,1,,,Binding affinity against rat 5-hydroxytryptamine 2A receptor in NIH3T3 cells.,H,,723.0,12687,8,,CHEMBL618907,BAO_0000219,
2659,Autocuration,,,1,,,Compound was tested for the Binding affinity against rat frontal cortex 5-hydroxytryptamine 2A receptor by Radio ligand [3H]ketanserin binding assay.,H,,,12687,8,,CHEMBL618908,BAO_0000019,
2660,Autocuration,,,1,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617909,BAO_0000357,
2661,Expert,,,1,,,Half-maximal inhibition of [3H]ketanserin binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex homogenate,H,,,12687,8,,CHEMBL617910,BAO_0000019,
2662,Autocuration,,,1,955.0,,In vitro ability to displace [3H]ketanserin from 5-hydroxytryptamine 2A receptor in rat brain.,H,,,12687,8,,CHEMBL617911,BAO_0000221,
2663,Autocuration,,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,,,12687,8,,CHEMBL872923,BAO_0000249,
2664,Autocuration,,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,,,12687,8,,CHEMBL617912,BAO_0000249,
2665,Expert,10116.0,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor by displacement of [3H]ketanserin from rat cortex,D,,,12687,9,,CHEMBL617913,BAO_0000019,
2666,Expert,,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,,,12687,8,,CHEMBL617914,BAO_0000249,
2667,Autocuration,,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,,,12687,8,,CHEMBL617915,BAO_0000249,
2668,Autocuration,,,1,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane,H,,,12687,8,,CHEMBL617916,BAO_0000249,
2669,Expert,10116.0,,1,,,Displacement of [3H]- Ketanserin from rat cortex 5-hydroxytryptamine 2A receptor,D,,,12687,9,,CHEMBL617917,BAO_0000019,
2670,Expert,,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand,H,,,12687,8,,CHEMBL617918,BAO_0000019,
2671,Autocuration,,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 2A receptor in rat tissue homogenate using [3H]ketanserin as radioligand; Not active at 10-5 M,H,,,12687,8,,CHEMBL617919,BAO_0000019,
2672,Expert,10116.0,,1,,,In vitro inhibitory constant against [125I]DOI binding to 5-hydroxytryptamine 2A receptor in rat cerebral cortex,D,,,12687,9,,CHEMBL617920,BAO_0000019,
2673,Expert,10116.0,,1,,,Displacement of [3H]ketanserin from 5-hydroxytryptamine 2A receptor of rat brain cortex,D,,,12687,9,,CHEMBL617921,BAO_0000019,
2674,Expert,10116.0,,1,,,"Relative binding affinity for D2 receptor and 5-hydroxytryptamine 2A receptor, ratio of Ki",D,,,105102,5,,CHEMBL617922,BAO_0000224,
2675,Autocuration,,,1,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]DOB as radioligand,H,,,12687,8,,CHEMBL617923,BAO_0000357,
2676,Autocuration,,,1,,,Tested for binding affinity towards rat 5-hydroxytryptamine 2A receptor using [3H]ketanserin as radioligand,H,,,12687,8,,CHEMBL617924,BAO_0000357,
2677,Autocuration,,,1,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2A receptor using [125 I]-DOI as radioligand,H,,,12687,8,,CHEMBL617925,BAO_0000357,
2678,Expert,10116.0,,1,,,In vitro binding to 5-hydroxytryptamine 2A receptor using [125 I]-DOI,D,,,12687,9,,CHEMBL617926,BAO_0000357,
2679,Autocuration,,,1,,,The binding affinity at 5-hydroxytryptamine 2A receptor was determined using [3H]ketanserin,H,,,12687,8,,CHEMBL617927,BAO_0000357,
2680,Autocuration,,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2A receptor,H,,,12687,8,,CHEMBL617928,BAO_0000357,
2681,Expert,10116.0,,1,,,Binding affinity for 5-hydroxytryptamine 2A receptor in rat cortex using [3H]ketanserin,D,,,12687,9,,CHEMBL617929,BAO_0000019,
2682,Expert,,,1,,,Binding affinity to 5-hydroxytryptamine 2A receptor from rat cortex assayed using [3H]ketanserin as radioligand.,H,,,12687,8,,CHEMBL617930,BAO_0000019,
2683,Autocuration,,,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]ketanserin as radioligand.; Nonactive at 10 uM,H,,,12687,8,,CHEMBL617931,BAO_0000019,
2684,Autocuration,,,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 2A receptor from rat cortex using [3H]-ketanserin as radioligand; Nonactive at 10 uM,H,,,12687,8,,CHEMBL617932,BAO_0000019,
2685,Autocuration,,,1,,,Binding affinity for displacement of [3H]ketanserin to rat 5-hydroxytryptamine 2A receptor stably expressed in CHO cells; ND is No Data,H,,449.0,12687,8,,CHEMBL617933,BAO_0000219,
2686,Autocuration,,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,H,,,12687,8,,CHEMBL617934,BAO_0000019,
2687,Autocuration,,,1,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 2A receptor in rat cortical membrane; ND means no data,H,,,12687,8,,CHEMBL617935,BAO_0000019,
2688,Autocuration,,,1,,,Tested for its ability to activate phospholipase C by quantification of IP3 at cloned rat 5-hydroxytryptamine 2A receptor; Not determined,H,,,12687,8,,CHEMBL617936,BAO_0000357,
2689,Autocuration,,,1,,,Ability to displace [3H]ketanserin (0.5 nM) from cerebral cortex of rat 5-hydroxytryptamine 2A receptor; NT=not tested,H,,,12687,8,,CHEMBL617937,BAO_0000019,
2690,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor by displacement of [3H]-ketanserin from rat prefrontal cerebral cortex mambranes; Not tested,H,,,12687,8,,CHEMBL617938,BAO_0000019,
2691,Autocuration,,,1,,,Compound was evaluated for effective dose measured in nmol/kg following a dose of 0.04 mg/kg and 0.093 uM/kg (95%CI); range 32-63,H,,,12687,8,,CHEMBL617939,BAO_0000218,
2692,Autocuration,,,1,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.04 mg/kg and 0.097 uM/kg,H,,,12687,8,,CHEMBL617940,BAO_0000218,
2693,Autocuration,,,1,,,Compound was evaluated for the percentage of rats disrupted following a dose of 0.08 mg/kg and 0.194 uM/kg,H,,,12687,8,,CHEMBL617941,BAO_0000218,
2694,Expert,,,1,,,Ratio of pKi of 5-HT2A to that of 5-HT2C receptor,H,,,12687,8,,CHEMBL617942,BAO_0000357,
2695,Expert,,,1,,,Ratio of pKi of 5-HT2A to that of D2 receptor,H,,,12687,8,,CHEMBL617943,BAO_0000357,
2696,Expert,,,1,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,H,,,105093,4,,CHEMBL617944,BAO_0000224,
2697,Expert,,,1,,,Selectivity ratio towards KB of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2B receptor,H,,,105093,4,,CHEMBL617945,BAO_0000224,
2698,Expert,,,1,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor,H,,,105075,4,,CHEMBL617946,BAO_0000224,
2699,Autocuration,,,1,,,Selectivity ratio towards Ki of 5-hydroxytryptamine 2A receptor to 5-hydroxytryptamine 2C receptor; ND is no data,H,,,12687,8,,CHEMBL617947,BAO_0000357,
2700,Expert,,,1,,,Percent maximal 5-HT stimulation at cloned rat 5-hydroxytryptamine 2A receptor (phosphoinositide hydrolysis study) at a conc of 100 uM,H,,,12687,8,,CHEMBL617948,BAO_0000357,
2701,Autocuration,,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat,H,,,12687,8,,CHEMBL858116,BAO_0000019,
2702,Autocuration,,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 2A receptor of rat; ND means not done,H,,,12687,8,,CHEMBL617949,BAO_0000019,
2703,Autocuration,,,1,,,Effectiveness of compound in blocking 5-hydroxytryptamine 2A receptor-mediated contractions of rat tail artery,H,,,12687,8,,CHEMBL617950,BAO_0000019,
2704,Expert,,,1,1515.0,,Negative log concentration of antagonist on 5-hydroxytryptamine 2A receptor in rat thoracic aorta,H,,,12687,8,,CHEMBL617951,BAO_0000019,
2705,Expert,,,1,1515.0,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta,H,,,12687,8,,CHEMBL617952,BAO_0000019,
2706,Autocuration,,,1,1515.0,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2A receptor of Rat thoracic aorta; ND is not determined.,H,,,12687,8,,CHEMBL617953,BAO_0000019,
2707,Autocuration,,,1,,,Binding activity radioligand.,H,,,12687,8,,CHEMBL617954,BAO_0000357,
2708,Expert,,,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,H,,,12687,8,,CHEMBL617955,BAO_0000019,
2709,Autocuration,,,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,H,,,12687,8,,CHEMBL857071,BAO_0000019,
2710,Expert,,,1,,,Displacement of [3H]DOB binding to 5-hydroxytryptamine 2A receptor from rat cortex homogenate,H,,,12687,8,,CHEMBL617270,BAO_0000019,
2711,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930,H,,339.0,12687,8,,CHEMBL617271,BAO_0000219,
2712,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor in membranes of N1E-115 neuroblastoma cells using [3H]-ICS 205-930; Not determined,H,,339.0,12687,8,,CHEMBL617272,BAO_0000219,
2713,Autocuration,,,1,,,Binding affinity was evaluated by 5-hydroxytryptamine 2A receptor agonism in the rat cortex by displacing ketanserin,H,,,12687,8,,CHEMBL617273,BAO_0000019,
2714,Expert,10116.0,,1,,,Agonistic activity against 5-hydroxytryptamine 2A receptor in rat cortex using [3H]-ketanserin,D,,,12687,9,,CHEMBL617274,BAO_0000019,
2715,Autocuration,,,1,,,Binding affinity towards human serotonin 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617275,BAO_0000357,
2716,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617276,BAO_0000357,
2717,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617277,BAO_0000357,
2718,Expert,,,1,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617278,BAO_0000019,
2719,Expert,,,1,,,Binding affinity using [125I]DOI as radioligand with membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor; Not determined,H,,,108,8,,CHEMBL617279,BAO_0000019,
2720,Expert,,,1,,,Binding affinity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617280,BAO_0000019,
2721,Autocuration,,,1,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617281,BAO_0000357,
2722,Autocuration,,,1,,,Compound was tested for the displacement of [125I]DOI from cloned human 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617282,BAO_0000357,
2723,Expert,,,1,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]mesulergine,H,,,108,8,,CHEMBL617283,BAO_0000019,
2724,Expert,,,1,,,Tested on transfected cell membranes selectively expressing human 5-hydroxytryptamine 2C receptor using [3H]-mesulergine; ND is No Data.,H,,,108,8,,CHEMBL617284,BAO_0000019,
2725,Autocuration,,,1,,,In vitro binding affinity towards human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells was determined using [3H]mesulergine as radioligand,H,,722.0,108,8,,CHEMBL617285,BAO_0000219,
2726,Autocuration,,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617286,BAO_0000019,
2727,Expert,9606.0,,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2C receptor using with [125I]- DOI radioligand,D,,,108,9,,CHEMBL617287,BAO_0000357,
2728,Expert,,,1,,,Binding affinity towards human 5-hydroxytryptamine 2C receptor.,H,,,108,8,,CHEMBL617288,BAO_0000357,
2729,Autocuration,,,1,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]DOB as radioligand,H,,,108,8,,CHEMBL617289,BAO_0000357,
2730,Autocuration,,,1,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,,,108,8,,CHEMBL872917,BAO_0000357,
2731,Autocuration,,,1,,,Tested for binding affinity towards human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,H,,,108,8,,CHEMBL617290,BAO_0000357,
2732,Autocuration,,,1,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,H,,449.0,108,8,,CHEMBL617291,BAO_0000219,
2733,Autocuration,,,1,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells; ND is no data,H,,449.0,108,8,,CHEMBL617292,BAO_0000219,
2734,Autocuration,,,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand; Not determined,H,,723.0,108,8,,CHEMBL617293,BAO_0000219,
2735,Expert,9606.0,,1,,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,,449.0,108,9,,CHEMBL617294,BAO_0000219,
2736,Expert,,,1,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,H,,,108,8,,CHEMBL617295,BAO_0000019,
2737,Autocuration,,,1,,,Binding activity radioligand.,H,,,108,8,,CHEMBL617296,BAO_0000357,
2738,Autocuration,,,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from human brain cortex using [3H]mesulergine as radioligand.,H,,,108,8,,CHEMBL617297,BAO_0000019,
2739,Expert,,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand,H,,449.0,108,8,,CHEMBL617298,BAO_0000219,
2740,Expert,,,1,,,Binding affinity at human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells by [3H]mesulergine displacement.,H,,449.0,108,8,,CHEMBL617299,BAO_0000219,
2741,Autocuration,,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells using [3H]mesulergine as radioligand; NT means not tested,H,,449.0,108,8,,CHEMBL617300,BAO_0000219,
2742,Autocuration,,,1,,,Binding affinity against 5-HT2C receptor,H,,,108,8,,CHEMBL617454,BAO_0000357,
2743,Autocuration,,,1,,,Antagonistic binding affinity measured against 5-hydroxytryptamine 2C receptor (human clone expressed in 293 cells) using [3H]mesulergine as radioligand,H,,722.0,108,8,,CHEMBL617505,BAO_0000219,
2744,Expert,9606.0,,1,,,Displacement of [3H]mesulergine from 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells,D,,722.0,108,9,,CHEMBL617506,BAO_0000219,
2745,Expert,9606.0,,1,,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,D,,722.0,108,9,,CHEMBL617507,BAO_0000219,
2746,Expert,,,1,,,Binding affinity against human 5-hydroxytryptamine 2C receptor using displacement of [3H]DOB,H,,,108,8,,CHEMBL617508,BAO_0000357,
2747,Expert,9606.0,,1,,,Binding affinity against human 5-hydroxytryptamine 2C receptor expressed in 293 cells using [3H]mesulergine,D,,722.0,108,9,,CHEMBL857982,BAO_0000219,
2748,Expert,9606.0,,1,,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand,D,,722.0,108,9,,CHEMBL617509,BAO_0000219,
2749,Expert,9606.0,,1,,,Binding affinity to human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]- mesulergine as radioligand; Nd means not determined,D,,722.0,108,9,,CHEMBL617510,BAO_0000219,
2750,Autocuration,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor was determined,H,,,108,8,,CHEMBL617511,BAO_0000357,
2751,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptors in HEK 293 cells using [3H]mesulergine as radioligand,H,,722.0,108,8,,CHEMBL617512,BAO_0000219,
2752,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor human cloned receptorswithouteffect in HEK 293 cells using [3H]mesulergine as radioligand,H,,722.0,108,8,,CHEMBL617749,BAO_0000219,
2753,Autocuration,,,1,,,Binding affinity towards 5-HT2C (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,,722.0,108,8,,CHEMBL617750,BAO_0000219,
2754,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,,722.0,108,8,,CHEMBL617751,BAO_0000219,
2755,Expert,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 2C receptor expressed in HEK 293 cells using [3H]mesulergine as radioligand,H,,722.0,108,8,,CHEMBL617752,BAO_0000219,
2756,Autocuration,,,1,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand",H,,722.0,108,8,,CHEMBL617753,BAO_0000219,
2757,Expert,,,1,,,"Binding affinity towards human cloned 5-hydroxytryptamine receptor 2C in HEK293 cells, using [3H]mesulergine as radioligand.",H,,722.0,108,8,,CHEMBL617754,BAO_0000219,
2758,Expert,9606.0,,1,,,Displacement of [3H]mesulergine from human 5-hydroxytryptamine 2C receptor expressed in HEK293 cells; compound insoluble,D,,722.0,108,9,,CHEMBL617755,BAO_0000219,
2759,Autocuration,,,1,,,"Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]mesulergine as radioligand; no data",H,,722.0,108,8,,CHEMBL617756,BAO_0000219,
2760,Expert,,,1,,,Binding affinity towards human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by displacement of [3H]mesulergine,H,,722.0,108,8,,CHEMBL617757,BAO_0000219,
2761,Expert,,,1,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2C receptor of HEK293 cells by [3H]mesulergine displacement.,H,,722.0,108,8,,CHEMBL617758,BAO_0000219,
2762,Autocuration,,,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 2C receptor expressed in 3T3 cells using [3H]5-HT as radioligand,H,,723.0,108,8,,CHEMBL617759,BAO_0000219,
2763,Autocuration,,,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine as the radioligand,H,,722.0,108,8,,CHEMBL617760,BAO_0000219,
2764,Expert,,,1,,,Displacement of [3H]mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO-K1 cells,H,,485.0,108,8,,CHEMBL617761,BAO_0000219,
2765,Expert,9606.0,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor,D,,,108,9,,CHEMBL617762,BAO_0000357,
2766,Autocuration,,,1,,,Compound was tested for binding affinity against human 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617763,BAO_0000357,
2767,Autocuration,,,1,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 2C receptor in HEK 293 cells using [3H]mesulergine,H,,722.0,108,8,,CHEMBL857983,BAO_0000219,
2768,Autocuration,,,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2C receptor in HEK 293 using [3H]mesulergine as a radioligand,H,,722.0,108,8,,CHEMBL617764,BAO_0000219,
2769,Autocuration,,,1,,,Inhibitory constant on human 5-hydroxytryptamine 2C receptor transfected in to HeLa cells,H,,308.0,108,8,,CHEMBL617765,BAO_0000219,
2770,Autocuration,,,1,,,Selectivity as the ratio of Ki value towards 5-hydroxytryptamine 2C receptor to that of pA2 value towards 5-hydroxytryptamine 2B receptor,H,,,108,8,,CHEMBL617766,BAO_0000019,
2771,Autocuration,,,1,10000000.0,,The binding affinity (pKi) measured against 5-hydroxytryptamine 3 receptor of rat hippocampus and entorhinal cortex using [3H]granisetron as radioligand,H,,,108,8,,CHEMBL617767,BAO_0000221,
2772,Autocuration,,,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2C receptor in HEK293 cells using [3H]mesulergine.,H,,722.0,108,8,,CHEMBL617768,BAO_0000219,
2773,Autocuration,,,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2C receptor in HEK293 cells, using [3H]5-mesulergine as radioligand",H,,722.0,108,8,,CHEMBL617769,BAO_0000219,
2774,Autocuration,,,1,,,Binding affinity analysed on 5-HT 2C in human clone using [3H]mesulergine as radioligand,H,,,11864,8,,CHEMBL858023,BAO_0000357,
2775,Autocuration,,,1,945.0,,Binding affinity analysed on 5-HT 2C in rat stomach fundus,H,,,11864,8,,CHEMBL617770,BAO_0000019,
2776,Autocuration,,,1,945.0,,Binding affinity analysed towards 5-HT 2C in rat stomach fundus,H,,,11864,8,,CHEMBL617771,BAO_0000019,
2777,Autocuration,,,1,,,Percent of maximum stimulation of phosphatidylinositol turnover at cloned 5-hydroxytryptamine 2C receptor in A9 cells,H,,625.0,11864,8,,CHEMBL617772,BAO_0000219,
2778,Autocuration,,,1,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,H,,723.0,11864,8,,CHEMBL617773,BAO_0000219,
2779,Autocuration,,,1,,,Binding affinity to 5-hydroxytryptamine 2C receptor measured using radioligand [3H]Mesulergine in stably transfected NIH3T3 cells,H,,723.0,11864,8,,CHEMBL617850,BAO_0000219,
2780,Autocuration,,,1,,,Binding affinity to 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand in stably transfected NIH3T3 cells,H,,723.0,11864,8,,CHEMBL617851,BAO_0000219,
2781,Autocuration,,,1,,,The maximum responses of [3H]- inositol monophosphate accumulation in cells expressing the 5-hydroxytryptamine 2C receptor,H,,,11864,8,,CHEMBL617852,BAO_0000019,
2782,Autocuration,10090.0,,1,945.0,,Binding affinity analysed on 5-HT 2C in rat stomach fundus.,H,,,12689,8,,CHEMBL858024,BAO_0000019,
2783,Expert,10116.0,,1,945.0,,Binding affinity towards 5-HT 2C receptor in rat stomach fundus,D,,,12689,9,,CHEMBL617853,BAO_0000019,
2784,Expert,,,1,,,Binding affinity against 5-Hydroxytryptamine 2C Receptor was measured using [3H]N-methyl-mesulergine as radioligand,H,,,108,8,,CHEMBL617854,BAO_0000357,
2785,Expert,9823.0,,1,,,Binding affinity for 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL873477,BAO_0000357,
2786,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617855,BAO_0000357,
2787,Expert,,,1,,,Affinity towards 5-hydroxytryptamine 2C receptor in membranes from pig choroid plexus using [3H]N-methyl-mesulergine,H,,,108,8,,CHEMBL617856,BAO_0000019,
2788,Autocuration,,,1,,,Compound was tested for its ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor in pig cortex,H,,,108,8,,CHEMBL617857,BAO_0000019,
2789,Autocuration,,,1,,,In vitro inhibitory concentration against radioligand [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in pig cortical membrane,H,,,108,8,,CHEMBL617858,BAO_0000249,
2790,Autocuration,,,1,,,Binding affinity towards pig 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617859,BAO_0000357,
2791,Autocuration,,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617860,BAO_0000357,
2792,Autocuration,,,1,,,Binding activity radioligand.,H,,,108,8,,CHEMBL617861,BAO_0000357,
2793,Expert,,,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,H,,,108,8,,CHEMBL617862,BAO_0000019,
2794,Autocuration,,,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from pig cortex membrane using [3H]mesulergine as radioligand; NA Not Available,H,,,108,8,,CHEMBL617863,BAO_0000019,
2795,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT,H,,,108,8,,CHEMBL617864,BAO_0000249,
2796,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 1D receptor in calf caudate membranes using [3H]5-HT; Not determined,H,,,108,8,,CHEMBL617649,BAO_0000249,
2797,Expert,9823.0,,1,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,H,,,108,8,,CHEMBL617650,BAO_0000019,
2798,Expert,9823.0,,1,,,Agonistic activity against 5-hydroxytryptamine 2C receptor in pig choroid plexus using [3H]mesulergine,H,,,108,8,,CHEMBL617651,BAO_0000019,
2799,Autocuration,9823.0,,1,,,In vitro binding affinity at 5-hydroxytryptamine 2C receptor in pig choroid plexus using 3[H]mesulergine as the radioligand,H,,,108,8,,CHEMBL617652,BAO_0000357,
2800,Autocuration,9823.0,,1,,,In Vitro Binding affinity againist 5-hydroxytryptamine 2C receptor by displacing [3H]mesulergine from pig cortex,H,,,108,8,,CHEMBL857072,BAO_0000019,
2801,Autocuration,9823.0,,1,,,Ability to displace the radioligand [3H]mesulergine from pig choroid plexus 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617653,BAO_0000357,
2802,Autocuration,,,1,,,Binding activity against 5-hydroxytryptamine 2C receptor from pig cortex membrane using [3H]mesulergine as radioligand.,H,,,12687,8,,CHEMBL617654,BAO_0000019,
2803,Autocuration,,,1,,,Effect on phosphoinositide hydrolysis in NIH 3T3 fibroblast 5-hydroxytryptamine 2C receptor,H,,,12689,8,,CHEMBL617655,BAO_0000019,
2804,Expert,,,1,,,Binding affinity towards 5-HT2C receptor from rat using [3H]mesulergine as radioligand,H,,,12689,8,,CHEMBL617656,BAO_0000357,
2805,Autocuration,,,1,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand,H,,,12689,8,,CHEMBL617657,BAO_0000357,
2806,Autocuration,,,1,,,Compound was tested in vitro for its binding affinity towards 5-hydroxytryptamine 2C receptor from rat using [3H]mesulergine as radioligand; Not tested,H,,,12689,8,,CHEMBL617658,BAO_0000357,
2807,Expert,10116.0,,1,,,Inhibition of radiolabeled [3H]-Ketanserin ligand binding to 5-hydroxytryptamine 2C receptor,D,,,12689,9,,CHEMBL617659,BAO_0000357,
2808,Expert,10116.0,,1,,,Inhibition of radiolabeled [3H]mesulergine ligand binding to 5-hydroxytryptamine 2C receptor,D,,,12689,9,,CHEMBL617838,BAO_0000357,
2809,Expert,10116.0,,1,,,Inhibition of [3H]mesulergine binding to 5-hydroxytryptamine 2C receptor in rat brain membranes,D,Brain membranes,,12689,9,,CHEMBL617839,BAO_0000249,
2810,Autocuration,,,1,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine; Not tested,H,,,12689,8,,CHEMBL617840,BAO_0000357,
2811,Autocuration,,,1,,,Ability to displace [3H]mesulergine bound to 5-hydroxytryptamine 2C receptor in rat cortex,H,,,12689,8,,CHEMBL617841,BAO_0000019,
2812,Autocuration,,,1,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-HT2C receptor,H,,,12689,8,,CHEMBL875915,BAO_0000019,
2813,Expert,,In vitro,1,,,Displacement of [3H]mesulergine (0.5 nM) from rat 5-hydroxytryptamine 2C receptor expressed in SR-3T3 cells,H,,,12689,8,,CHEMBL617842,BAO_0000219,
2814,Expert,,,1,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor in NIH3T3 cell line membranes,H,,723.0,12689,8,,CHEMBL617843,BAO_0000219,
2815,Expert,,,1,,,Ability to inhibit the binding of iodine-125-labelled lysergic acid diethylamide([125I]-LSD) to the S-2C serotonin receptor.,H,,,12689,8,,CHEMBL617844,BAO_0000357,
2816,Expert,,,1,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 2C receptor,H,,,12689,8,,CHEMBL617845,BAO_0000357,
2817,Expert,,,1,,,Affinity was evaluated by inhibition of [125I]LSD binding to NIH 3T3 cells transfected with cloned rat 5-hydroxytryptamine 2C receptor,H,,723.0,12689,8,,CHEMBL617846,BAO_0000219,
2818,Autocuration,,,1,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor was determined using [125I]- DOI as radioligand,H,,,12689,8,,CHEMBL617847,BAO_0000357,
2819,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor,H,,,12689,8,,CHEMBL617848,BAO_0000357,
2820,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,H,,,12689,8,,CHEMBL617849,BAO_0000357,
2821,Expert,,,1,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,,,12689,8,,CHEMBL621507,BAO_0000357,
2822,Expert,,,1,,,Binding affinity at cloned rat 5-hydroxytryptamine 2C receptor using [3H]DOI as radioligand,H,,,12689,8,,CHEMBL621508,BAO_0000357,
2823,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor from rat cortex using [3H]mesulergine as the radioligand.,H,,,12689,8,,CHEMBL621509,BAO_0000019,
2824,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex,H,,,12689,8,,CHEMBL621510,BAO_0000019,
2825,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor of rat cortex.,H,,,12689,8,,CHEMBL621511,BAO_0000019,
2826,Expert,,,1,,,Displacement of [3H]mesulergine from A9 cells stably expressing rat 5-hydroxytryptamine 2C receptor,H,,625.0,12689,8,,CHEMBL621512,BAO_0000219,
2827,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,H,,,12689,8,,CHEMBL621513,BAO_0000357,
2828,Expert,,,1,,,Binding affinity towards cloned rat 5-hydroxytryptamine 2C receptor from fundus tissue by [3H]mesulergine displacement.,H,,,12689,8,,CHEMBL621514,BAO_0000357,
2829,Expert,,In vitro,1,,,Binding affinity towards rat 5-hydroxytryptamine 2C receptor expressed in A-9 cells using [3H]mesulergine as radioligand,H,,,12689,8,,CHEMBL621515,BAO_0000219,
2830,Autocuration,,,1,,,Binding affinity was measured on 5-hydroxytryptamine 2C receptor in J1 cells transfected with rat 5-HT2C gene labeled with [3H]mesulergine,H,,,12689,8,,CHEMBL621516,BAO_0000219,
2831,Autocuration,,,1,5383.0,,Compound was evaluated for affinity towards cerebral 5-hydroxytryptamine 2C receptor in homogenate of caudate putamen tissue from rat brain,H,,,12689,8,,CHEMBL621517,BAO_0000019,
2832,Autocuration,,,1,,,Compound was evaluated for its ability to displace (+/-)[125I]-DOI from 5-hydroxytryptamine 2C receptor in cloned rat cell culture,H,,,12689,8,,CHEMBL621518,BAO_0000357,
2833,Autocuration,,,1,,,Compound was evaluated for its ability to displace [125I](R)-DOI from 5-hydroxytryptamine 2C receptor in cloned rat prefrontal cortex homogenate; ND denotes no data,H,,,12689,8,,CHEMBL621519,BAO_0000019,
2834,Autocuration,,,1,,,Compound was evaluated for its binding affinity for rat 5-hydroxytryptamine 2C receptor,H,,,12689,8,,CHEMBL621520,BAO_0000357,
2835,Autocuration,,,1,,,Compound was evaluated for its binding affinity towards rat 5-hydroxytryptamine 2C receptor,H,,,12689,8,,CHEMBL621521,BAO_0000357,
2836,Autocuration,,,1,,,Compound was evaluated for its binding affinity towards rat r5-hydroxytryptamine 2C receptor,H,,,12689,8,,CHEMBL621522,BAO_0000357,
2837,Expert,,,1,,,Binding affinity against rat 5-hydroxytryptamine 2C receptor in A-9 cells.,H,,,12689,8,,CHEMBL621523,BAO_0000219,
2838,Autocuration,,,1,,,Evaluated for the binding constant at [125I]-DOI-labeled rat 5-hydroxytryptamine 2C receptor,H,,,12689,8,,CHEMBL621524,BAO_0000357,
2839,Expert,10116.0,,1,,,In vitro binding to 5-hydroxytryptamine 2C receptor using [125 I]-DOI,D,,,12689,9,,CHEMBL621525,BAO_0000357,
2840,Autocuration,,,1,,,The binding affinity at 5-hydroxytryptamine 2C receptor was determined using [3H]mesulergine,H,,,12689,8,,CHEMBL872921,BAO_0000357,
2841,Autocuration,,,1,,,The compound evaluated for its affinity against 5-hydroxytryptamine 2C receptor,H,,,12689,8,,CHEMBL621526,BAO_0000357,
2842,Expert,,,1,,,Affinity against 5-hydroxytryptamine 2C receptor in J1 cells transfected with the rat 5-HT2C gene labeled with [3H]mesulergine.,H,,,12689,8,,CHEMBL621527,BAO_0000219,
2843,Expert,10116.0,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat choroid plexus using [3H]N-methyl-mesulergine,D,,,12689,9,,CHEMBL617865,BAO_0000019,
2844,Autocuration,,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor,H,,,12689,8,,CHEMBL617866,BAO_0000357,
2845,Autocuration,,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor from rat cortex using [3H]-citalopram as radioligand; Nonactive at 10 uM,H,,,12689,8,,CHEMBL617867,BAO_0000019,
2846,Autocuration,,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand; Nonactive at 10 uM,H,,,12689,8,,CHEMBL617487,BAO_0000357,
2847,Expert,,,1,,,Binding affinity for 5-hydroxytryptamine 2C receptor,H,,,12689,8,,CHEMBL617488,BAO_0000357,
2848,Autocuration,,,1,,,Tested in vitro for its ability to bind to 5-hydroxytryptamine 2C receptor using [125 I]-DOI as radioligand; Not determined,H,,,12689,8,,CHEMBL617489,BAO_0000357,
2849,Autocuration,,,1,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT denotes not tested,H,,,12689,8,,CHEMBL617490,BAO_0000019,
2850,Autocuration,,,1,,,Ability to displace [3H]mesulergine (0.5 nM) from SR-3T3 cells of rat 5-hydroxytryptamine 2C receptor; NT=not tested,H,,,12689,8,,CHEMBL617491,BAO_0000019,
2851,Autocuration,,,1,,,Affinity pKi for 5-hydroxytryptamine 2C receptor was measured in rat cortex homogenates.,H,,,12689,8,,CHEMBL617492,BAO_0000019,
2852,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor in rat cortex homogenates.,H,,,12689,8,,CHEMBL617493,BAO_0000019,
2853,Autocuration,,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 2C receptor was determined,H,,,12689,8,,CHEMBL617494,BAO_0000357,
2854,Expert,10116.0,,1,,,Displacement of [3H]mesulergine from rat 5-HT2C receptor expressed in HEK293,D,,,12689,9,,CHEMBL617495,BAO_0000019,
2855,Autocuration,,,1,,,Binding affinity was determined against cloned human 5-hydroxytryptamine 2C receptor using [3H]5-HT as radioligand,H,,,12689,8,,CHEMBL617496,BAO_0000357,
2856,Autocuration,,,1,,,Compound was evaluated for displacement of [3H]mesulergine from cloned rat 5-hydroxytryptamine 2C receptor in transfected CHO-K1 cells.,H,,485.0,12689,8,,CHEMBL617497,BAO_0000219,
2857,Autocuration,,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,,,12689,8,,CHEMBL617498,BAO_0000357,
2858,Autocuration,,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 2C receptor using [3H]Mesulergine as radioligand.,H,,,12689,8,,CHEMBL617499,BAO_0000357,
2859,Autocuration,,,1,,,Compound tested for relative response using 0.1 uM 5-HT as agonist against 5-hydroxytryptamine 2C receptor,H,,,12689,8,,CHEMBL617500,BAO_0000019,
2860,Autocuration,,,1,,,Compound was tested for binding affinity against 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617501,BAO_0000357,
2861,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617502,BAO_0000357,
2862,Autocuration,,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2B receptor using [3H]rauwolscine as radioligand; Not Tested,H,,,227,8,,CHEMBL617503,BAO_0000357,
2863,Autocuration,,,1,,,Binding activity against cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand.,H,,,227,8,,CHEMBL617504,BAO_0000357,
2864,Autocuration,,,1,,,Binding affinity against the cloned human 5-hydroxytryptamine 2B receptor using [3H]5-HT as the radioligand,H,,,227,8,,CHEMBL617406,BAO_0000357,
2865,Expert,9606.0,,1,,,Affinity for human 5-hydroxytryptamine 2B receptor expressed in mammalian cell line,D,,,227,9,,CHEMBL617407,BAO_0000019,
2866,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 2B receptor using [3H]5-HT as radioligand,H,,,227,8,,CHEMBL617408,BAO_0000357,
2867,Autocuration,,,1,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,H,,,227,8,,CHEMBL617409,BAO_0000357,
2868,Autocuration,,,1,,,Compound was tested for the displacement of [3H]5-HT from clone human 5-hydroxytryptamine 2B receptor,H,,,227,8,,CHEMBL617410,BAO_0000357,
2869,Autocuration,,,1,,,Compound was tested for the displacement of [3H]5-HT from cloned human 5-hydroxytryptamine 2B receptor,H,,,227,8,,CHEMBL617411,BAO_0000357,
2870,Autocuration,,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 2B receptor,H,,,227,8,,CHEMBL617412,BAO_0000019,
2871,Expert,9606.0,,1,,,Inhibitory constant against cloned human 5-hydroxytryptamine 2B receptor using with [125I]- DOI radioligand,D,,,227,9,,CHEMBL617774,BAO_0000357,
2872,Expert,9606.0,,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,D,,722.0,227,9,,CHEMBL617775,BAO_0000219,
2873,Expert,9606.0,,1,,,Displacement of [3H]ketanserin from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; ND = no data,D,,722.0,227,9,,CHEMBL617776,BAO_0000219,
2874,Expert,9606.0,,1,,,Relative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,,449.0,227,9,,CHEMBL617777,BAO_0000219,
2875,Expert,9606.0,,1,,,Rleative efficacy against human 5-hydroxytryptamine 2B receptor expressed in CHO cells using fluorometric imaging plate reader relative to 10 uM 5-HT,D,,449.0,227,9,,CHEMBL617778,BAO_0000219,
2876,Autocuration,,,1,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",H,,722.0,227,8,,CHEMBL617779,BAO_0000219,
2877,Expert,,,1,,,Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells using [3H]5-HT as radioligand.,H,,722.0,227,8,,CHEMBL617780,BAO_0000219,
2878,Autocuration,,,1,,,"Binding affinities towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand; no data",H,,722.0,227,8,,CHEMBL617781,BAO_0000219,
2879,Expert,9606.0,,1,,,Displacement of [3H]5-HT from 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells,D,,722.0,227,9,,CHEMBL617782,BAO_0000219,
2880,Expert,9606.0,,1,,,Binding affinity to human cloned 5-HT2B receptor in HEK 293 cells using [3H]- -5-HT as radioligand,D,,722.0,227,9,,CHEMBL617783,BAO_0000219,
2881,Autocuration,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor was determined,H,,,227,8,,CHEMBL617784,BAO_0000357,
2882,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2B receptor (human cloned receptor) in HEK 293 cells using [3H]5-HT as radioligand.,H,,722.0,227,8,,CHEMBL617785,BAO_0000219,
2883,Expert,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 2B receptor expressed in HEK 293 cells using [3H]5-HT as radioligand,H,,722.0,227,8,,CHEMBL857984,BAO_0000219,
2884,Expert,,,1,,,Binding affinity towards human cloned 5-HT2B receptor of HEK293 cells by displacement of [3H]5-HT,H,,722.0,227,8,,CHEMBL617786,BAO_0000219,
2885,Expert,,,1,,,In vitro binding affinity at human cloned 5-hydroxytryptamine 2B receptor of HEK293 cells by [3H]5-HT displacement.,H,,722.0,227,8,,CHEMBL617787,BAO_0000219,
2886,Expert,9606.0,,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells,D,,722.0,227,9,,CHEMBL617788,BAO_0000219,
2887,Expert,9606.0,,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 2B receptor expressed in HEK293 cells; compound is insoluble,D,,722.0,227,9,,CHEMBL617789,BAO_0000219,
2888,Autocuration,,,1,,,Compound was evaluated for binding affinity against human cloned 5-HT2B receptor in HEK 293 cells using [3H]5-HT as the radioligand,H,,722.0,227,8,,CHEMBL617790,BAO_0000219,
2889,Expert,,,1,,,Displacement of [3H]-5-5HT from human cloned 5-hydroxytryptamine 2B receptor expressed in CHO-K1 cells,H,,485.0,227,8,,CHEMBL617791,BAO_0000219,
2890,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 2B receptor,H,,,227,8,,CHEMBL617608,BAO_0000357,
2891,Autocuration,,,1,,,Compound was tested for its binding affinity against cloned human 5-hydroxytryptamine 2B receptor in HEK 293 cells using [3H]5-HT,H,,722.0,227,8,,CHEMBL617609,BAO_0000219,
2892,Autocuration,,,1,,,Compound was tested for its binding affinity for human cloned 5-hydroxytryptamine 2B receptor in HEK 293 using [3H]ketanserin as a radioligand,H,,722.0,227,8,,CHEMBL617610,BAO_0000219,
2893,Autocuration,,,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 2B receptors in HEK293 cells using [3H]5-HT.,H,,722.0,227,8,,CHEMBL617611,BAO_0000219,
2894,Autocuration,,,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",H,,722.0,227,8,,CHEMBL617612,BAO_0000219,
2895,Autocuration,,,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 2B receptor in HEK293 cells, using [3H]5-HT as radioligand",H,,722.0,227,8,,CHEMBL617613,BAO_0000219,
2896,Autocuration,9986.0,,1,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 2B receptor in the endothelium intact rabbit jugular vein.,H,,,227,8,,CHEMBL617614,BAO_0000019,
2897,Expert,,,1,945.0,,Binding affinity analysed for 5-HT 2B receptor in rat stomach fundus,H,,,12688,8,,CHEMBL617615,BAO_0000019,
2898,Expert,,,1,945.0,,Affinity against 5-hydroxytryptamine 2B receptor in the isolated rat stomach fundus,H,,,12688,8,,CHEMBL858114,BAO_0000357,
2899,Autocuration,,,1,945.0,,Affinity against serotonergic receptor in the isolated rat stomach fundus,H,,,12688,8,,CHEMBL617616,BAO_0000357,
2900,Expert,10116.0,,1,945.0,,Antagonistic activity against 5-hydroxytryptamine 2B receptor obtained from rat stomach fundus preparation,D,,,12688,9,,CHEMBL617617,BAO_0000019,
2901,Expert,10116.0,,1,,,Antagonistic against 5-hydroxytryptamine 2B receptor,D,,,12688,9,,CHEMBL875914,BAO_0000019,
2902,Autocuration,,,1,945.0,,Antagonistic affinity measured as pA2 value on 5-hydroxytryptamine 2B receptor of the rat stomach fundus,H,,,12688,8,,CHEMBL617618,BAO_0000019,
2903,Expert,10116.0,,1,945.0,,Inhibition of 5-HT binding to 5-HT2B receptor of Rat stomach fundus,D,,,12688,9,,CHEMBL617619,BAO_0000357,
2904,Autocuration,,,1,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor,H,,,12688,8,,CHEMBL617620,BAO_0000019,
2905,Autocuration,,,1,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B receptor ) receptor; No data,H,,,12688,8,,CHEMBL617621,BAO_0000019,
2906,Autocuration,,,1,,,Compound was evaluated for antagonism against serotonin (5-hydroxytryptamine 2B) receptor,H,,,12688,8,,CHEMBL617622,BAO_0000019,
2907,Expert,10116.0,,1,945.0,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,,,12688,9,,CHEMBL617623,BAO_0000357,
2908,Expert,10116.0,,1,945.0,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,,,12688,9,,CHEMBL617624,BAO_0000357,
2909,Expert,10116.0,,1,945.0,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,,,12688,9,,CHEMBL617625,BAO_0000357,
2910,Expert,10116.0,,1,945.0,,Inhibitory potency against rat stomach fundus 5-hydroxytryptamine 2B receptor,D,,,12688,9,,CHEMBL617626,BAO_0000357,
2911,Autocuration,,,1,945.0,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,H,,,12688,8,,CHEMBL617627,BAO_0000019,
2912,Expert,,,1,945.0,,Negative log concentration of antagonist was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,H,,,12688,8,,CHEMBL617628,BAO_0000019,
2913,Autocuration,,,1,945.0,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is No Data.,H,,,12688,8,,CHEMBL617629,BAO_0000019,
2914,Autocuration,,,1,945.0,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus; ND is not determined.,H,,,12688,8,,CHEMBL858115,BAO_0000019,
2915,Expert,10116.0,,1,945.0,,Antagonistic activity on 5-hydroxytryptamine 2B receptor of Rat stomach fundus;ND is not determined,D,,,12688,9,,CHEMBL617630,BAO_0000019,
2916,Autocuration,,,1,1515.0,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat thoracic aorta; ND is not determined,H,,,12688,8,,CHEMBL617631,BAO_0000019,
2917,Autocuration,,,1,,,The binding affinity of compound to 5-HT receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,H,,,12688,8,,CHEMBL617632,BAO_0000357,
2918,Expert,,,1,,,The binding affinity to 5-hydroxytryptamine 2B receptor of rat fundus,H,,,12688,8,,CHEMBL617633,BAO_0000357,
2919,Autocuration,,,1,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus was expressed as pA2 value; Unable to determine valid PA2 value due to slope of Schild plot,H,,,12688,8,,CHEMBL617634,BAO_0000357,
2920,Autocuration,,,1,,,The binding affinity of compound to 5-hydroxytryptamine 2B receptor of rat fundus; Unable to determine valid PA2 value due to slope of Schild plot,H,,,12688,8,,CHEMBL617635,BAO_0000357,
2922,Autocuration,10116.0,,1,945.0,,Negative log concentration of antagonistic compound was determined on 5-hydroxytryptamine 2B receptor of Rat stomach fundus,D,,,12688,9,,CHEMBL617637,BAO_0000019,
2923,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 1A receptor,H,,,227,8,,CHEMBL617638,BAO_0000357,
2924,Autocuration,,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2B receptor was determined,H,,,227,8,,CHEMBL617639,BAO_0000357,
2925,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 2B receptor was determined,H,,,227,8,,CHEMBL617640,BAO_0000357,
2926,Autocuration,,,1,,,Evaluated for the binding affinity to 5-HT 2B receptor,H,,,227,8,,CHEMBL617641,BAO_0000357,
2927,Autocuration,,,1,,,Ability to displace [3H]5-HT from 5-hydroxytryptamine 2B receptor,H,,,227,8,,CHEMBL617642,BAO_0000357,
2928,Autocuration,,,1,,,Binding affinities against 5-hydroxytryptamine 2B receptor,H,,,227,8,,CHEMBL617643,BAO_0000357,
2929,Autocuration,,,1,,,Binding affinities towards 5-hydroxytryptamine 2B receptor,H,,,227,8,,CHEMBL617644,BAO_0000357,
2930,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2B receptor using [125I]DOI as radioligand,H,,,227,8,,CHEMBL617645,BAO_0000357,
2931,Expert,,,1,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,H,,,108,8,,CHEMBL617646,BAO_0000357,
2932,Autocuration,9913.0,,1,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,H,,,108,8,,CHEMBL617647,BAO_0000357,
2933,Autocuration,9913.0,,1,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10E-6 M,H,,,108,8,,CHEMBL617648,BAO_0000357,
2934,Autocuration,9913.0,,1,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at a concentration of 10e-6 M,H,,,108,8,,CHEMBL617875,BAO_0000357,
2935,Autocuration,9913.0,,1,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor at concentration of 10e-6 M,H,,,108,8,,CHEMBL617876,BAO_0000357,
2936,Expert,9913.0,,1,,,Inhibitory constant was determined on 5-hydroxytryptamine 2C receptor of Bovine choroid plexus,H,,,108,8,,CHEMBL617877,BAO_0000357,
2937,Expert,9913.0,,1,,,In vitro ability to displace [3H]mesulergine binding from 5-hydroxytryptamine 2C receptor from bovine choroid plexus.,H,,,108,8,,CHEMBL617878,BAO_0000357,
2938,Autocuration,9913.0,,1,,,In vitro affinity against serotonin (5-hydroxytryptamine 2C) receptor,H,,,108,8,,CHEMBL617879,BAO_0000357,
2939,Autocuration,10141.0,,1,,,Binding affinity against guinea pig cortex 5-HT2C receptor in the presence of [3H]mesulergine,H,,,108,8,,CHEMBL617880,BAO_0000019,
2940,Intermediate,10141.0,,1,2435.0,,Binding affinity towards 5-HT4 receptor by the displacement of [3H]GR-113808 in guinea-pig striatum,D,,,20033,9,,CHEMBL617881,BAO_0000357,
2941,Autocuration,,,1,,,Binding affinity against 5-HT1A receptor,H,,,51,8,,CHEMBL857073,BAO_0000357,
2942,Expert,,,1,,,Agonistic activity for 5-HT2c (5-HT2C) by measuring [3H]inositol monophosphate fromation in CHO cells in which the human 5-HT2C receptor subtype was stably expressed,H,,449.0,108,8,,CHEMBL617882,BAO_0000219,
2943,Expert,9606.0,,1,,,Functional activity against human 5-hydroxytryptamine 2C receptor expressed in CHO cells using fluorometric imaging plate reader,D,,449.0,108,9,,CHEMBL617883,BAO_0000219,
2944,Autocuration,,,1,,,Functional agonist activity of compound was determined by fluorescence-based assay measuring intracellular calcium mobilization for 5-HT2c receptor cell line,H,,,108,8,,CHEMBL617884,BAO_0000219,
2945,Autocuration,,,1,,,Agonistic binding efficacy against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand,H,,449.0,108,8,,CHEMBL617885,BAO_0000219,
2946,Autocuration,,,1,,,"Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI radioligand, expressed as Emax",H,,449.0,108,8,,CHEMBL617886,BAO_0000219,
2947,Expert,9606.0,,1,,,Inhibition of human 5-hydroxytryptamine 2C receptor,D,,,108,9,,CHEMBL617887,BAO_0000357,
2948,Autocuration,,,1,,,In vitro binding affinity against human 5-hydroxytryptamine 2C receptor at a concentration of 100 (nM),H,,,108,8,,CHEMBL617888,BAO_0000357,
2949,Autocuration,,,1,,,Inhibitory activity using [3H]mesulergine as radioligand with receptor membranes isolated from a CHO-k cell line expressing the human 5-hydroxytryptamine 2C receptor at a concentration of 1 uM,H,,,108,8,,CHEMBL617889,BAO_0000019,
2950,Autocuration,,,1,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL617890,BAO_0000357,
2951,Autocuration,,,1,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,H,,,108,8,,CHEMBL617891,BAO_0000357,
2952,Autocuration,,,1,,,Intrinsic efficacy against 5-hydroxytryptamine 2C receptor; Intrinsic efficacy (%) not determined,H,,,108,8,,CHEMBL617892,BAO_0000357,
2953,Expert,,,1,,,Displacement of [H]-mesulergine from CHO cells expressing human 5-hydroxytryptamine 2C receptor.,H,,449.0,108,8,,CHEMBL617893,BAO_0000219,
2954,Expert,,,1,,,Ability to displace [3H]- mesulergine from human cloned 5-hydroxytryptamine 2C receptor expressed in CHO cells,H,,449.0,108,8,,CHEMBL617894,BAO_0000219,
2955,Expert,,,1,,,Ability to displace [3H]mesulergine binding to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,H,,449.0,108,8,,CHEMBL617895,BAO_0000219,
2956,Autocuration,,,1,,,Ability to displace [3H]mesulergine (0.5 nM) from CHO cells of human 5-hydroxytryptamine 2C receptor,H,,449.0,108,8,,CHEMBL617896,BAO_0000219,
2957,Expert,9606.0,,1,,,Affinity towards human 5-hydroxytryptamine 2C serotonin receptor,D,,,108,9,,CHEMBL617897,BAO_0000357,
2958,Autocuration,,,1,,,Agonist activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand,H,,,108,8,,CHEMBL617898,BAO_0000019,
2959,Autocuration,,,1,,,Agonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand,H,,,108,8,,CHEMBL617899,BAO_0000019,
2960,Expert,10116.0,,1,,,Agonistic binding affinity against human 5-hydroxytryptamine 2C receptor in CHO cells using [125I]- DOI ,H,,449.0,108,8,,CHEMBL617900,BAO_0000219,
2961,Autocuration,,,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand,H,,,108,8,,CHEMBL617901,BAO_0000019,
2962,Autocuration,,,1,,,Antagonist activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine radioligand; Not tested,H,,,108,8,,CHEMBL617902,BAO_0000019,
2963,Autocuration,,,1,,,Antagonistic activity at cloned human 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,,,108,8,,CHEMBL617903,BAO_0000019,
2964,Autocuration,,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [125 I]DOI as radioligand,H,,,108,8,,CHEMBL617904,BAO_0000357,
2965,Autocuration,,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand,H,,,108,8,,CHEMBL617905,BAO_0000357,
2966,Autocuration,,,1,,,Binding ability of compound at cloned human 5-hydroxytryptamine 2C receptor using [3H]- mesulergine as radioligand;not tested,H,,,108,8,,CHEMBL617906,BAO_0000357,
2967,Autocuration,,,1,,,Binding activity against cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand.,H,,,108,8,,CHEMBL617907,BAO_0000357,
2968,Autocuration,,,1,,,Binding affinity against the cloned human 5-hydroxytryptamine 2C receptor using [125I]DOI as the radioligand,H,,,108,8,,CHEMBL617908,BAO_0000357,
2969,Expert,,,1,,,Binding affinity for displacement of [3H]mesulergine to human 5-hydroxytryptamine 2C receptor stably expressed in CHO cells,H,,449.0,108,8,,CHEMBL620617,BAO_0000219,
2970,Expert,9606.0,,1,,,Affinity for human 5-hydroxytryptamine 2C receptor expressed in mammalian cell line,D,,,108,9,,CHEMBL620618,BAO_0000019,
2971,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor using [125I]DOI radioligand.,H,,,108,8,,CHEMBL620619,BAO_0000357,
2972,Expert,9606.0,,1,,,Binding affinity to cloned human 5-hydroxytryptamine 2C receptor,D,,,108,9,,CHEMBL620620,BAO_0000357,
2973,Autocuration,,,1,,,Binding affinity towards human 5-HT2C receptor was determined using [125I]- DOI as radioligand,H,,,108,8,,CHEMBL620621,BAO_0000357,
2974,Autocuration,10116.0,,1,,,Binding affinity for 5-HT3 receptor by displacement of [3H]-LY 278584 in rat cerebral cortex membranes,D,Membranes,,104698,7,,CHEMBL872920,BAO_0000249,
2975,Autocuration,,,1,,,Binding affinity towards rat 5-hydroxytryptamine 3 receptor was evaluated,H,,,104698,6,,CHEMBL620622,BAO_0000223,
2976,Autocuration,10116.0,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 in rat posterior cortex,D,,,104698,7,,CHEMBL620623,BAO_0000019,
2977,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex,H,,,104698,6,,CHEMBL620624,BAO_0000019,
2978,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor using [3H]BRL-43694 as radioligand in rat posterior cortex; Not tested,H,,,104698,6,,CHEMBL620625,BAO_0000019,
2979,Autocuration,,,1,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor in NG-108 cells labeled with [3H]GR-65630,H,,,104698,6,,CHEMBL620626,BAO_0000219,
2980,Autocuration,,,1,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex,H,,,104698,6,,CHEMBL621307,BAO_0000019,
2981,Autocuration,,,1,,,Binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]-BRL 43694 as radioligand in rat posterior cortex.,H,,,104698,6,,CHEMBL621308,BAO_0000019,
2982,Autocuration,,,1,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-5-HT,H,,,104698,6,,CHEMBL621309,BAO_0000223,
2983,Autocuration,,,1,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]GR-65630,H,,,104698,6,,CHEMBL621310,BAO_0000223,
2984,Autocuration,,,1,,,Binding affinity for central 5-hydroxytryptamine 3 receptor was determined by displacement of [3H]-ketanserin,H,,,104698,6,,CHEMBL621311,BAO_0000223,
2985,Autocuration,,,1,,,"Compound was evaluated for its in vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",H,,,104698,6,,CHEMBL621502,BAO_0000249,
2986,Autocuration,,,1,,,"In vitro affinity at serotonergic 5-hydroxytryptamine 3 receptor by radioligand binding assay, using [3H]-LY 278584 in rat cerebral cortex membranes.",H,,,104698,6,,CHEMBL621503,BAO_0000249,
2987,Autocuration,,,1,,,Displacement of the 5-hydroxytryptamine 3 receptor ligand [3H]GR-65630 from rat brain cortical membranes.,H,Membranes,,104698,6,,CHEMBL621504,BAO_0000249,
2988,Autocuration,,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor,H,,,104698,6,,CHEMBL621505,BAO_0000223,
2989,Autocuration,,,1,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,H,,,104698,6,,CHEMBL621506,BAO_0000019,
2990,Autocuration,,,1,,,Ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15.,H,,,104698,6,,CHEMBL619781,BAO_0000223,
2991,Autocuration,,,1,,,Compound was evaluated for its ability to displace [3H]quipazine binding to 5-hydroxytryptamine 3 receptor sites in NG 108-15. ,H,,,104698,6,,CHEMBL619782,BAO_0000223,
2992,Autocuration,,,1,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex,H,,,104698,6,,CHEMBL619783,BAO_0000019,
2993,Autocuration,10116.0,,1,,,Displacement of [3H]ketanserin from rat cortex 5-HT3 receptor,D,,,104698,7,,CHEMBL619784,BAO_0000019,
2994,Autocuration,,,1,,,Ability to displace [3H]granisetron specifically bound to 5-hydroxytryptamine 3 receptor in rat cortical membrane,H,,,104698,6,,CHEMBL619785,BAO_0000249,
2995,Autocuration,,,1,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,H,,,104698,6,,CHEMBL619786,BAO_0000223,
2996,Autocuration,,,1,,,Displacement of binding of [3H]-BRL 43694 to 5-hydroxytryptamine 3 receptor in rat cerebral cortex,H,,,104698,6,,CHEMBL619787,BAO_0000019,
2997,Autocuration,,,1,,,In vitro affinity for 5-hydroxytryptamine 3 (5-HT3) receptor by displacement of [3H]BRL-43694 from rat entorhinal cortex,H,,,104698,6,,CHEMBL872925,BAO_0000019,
2998,Autocuration,,,1,,,In vitro binding affinity at serotonin 5-hydroxytryptamine 3 receptor in rat cortex by [3H]granisetron displacement.,H,,,104698,6,,CHEMBL619788,BAO_0000019,
2999,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]- 1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,H,,,104698,6,,CHEMBL619789,BAO_0000249,
3000,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 3 receptor in rat cortical membranes using [3H]-1-Methyl-1H-indazole-3-carboxylic acid (8-methyl-8-aza-bicyclo[3.2.1]oct-3-yl)-amide as a radioligand,H,,,104698,6,,CHEMBL619790,BAO_0000249,
3001,Autocuration,,,1,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,H,,,104698,6,,CHEMBL619791,BAO_0000019,
3002,Autocuration,,,1,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat entorhinal cortex by [3H]BRL-43694 displacement.,H,,,104698,6,,CHEMBL619792,BAO_0000019,
3003,Autocuration,,,1,,,Displacement of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortical membranes,H,Membranes,,104698,6,,CHEMBL619793,BAO_0000249,
3004,Autocuration,10116.0,,1,,,Inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor,D,,,104698,7,,CHEMBL619794,BAO_0000223,
3005,Autocuration,,,1,955.0,,The ability to inhibit [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor in rat brain cortices,H,,,104698,6,,CHEMBL619795,BAO_0000221,
3006,Autocuration,,,1,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat posterior cortex by [3H]-BRL 43694 displacement.,H,,,104698,6,,CHEMBL619796,BAO_0000019,
3007,Autocuration,,,1,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584,H,,,104698,6,,CHEMBL620448,BAO_0000223,
3008,Autocuration,,,1,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,H,,,104698,6,,CHEMBL620449,BAO_0000223,
3009,Autocuration,,,1,,,The binding affinity was measured on 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand.,H,,,104698,6,,CHEMBL620450,BAO_0000223,
3010,Autocuration,,,1,,,The compound was evaluated for the binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630,H,,,104698,6,,CHEMBL620451,BAO_0000223,
3011,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of radioligand [3H]GR-65630.,H,,,104698,6,,CHEMBL620631,BAO_0000223,
3012,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand,H,,,104698,6,,CHEMBL620632,BAO_0000019,
3013,Autocuration,,,1,,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor from rat cortex using [3H]BRL-43694 as radioligand; NA means Not active,H,,,104698,6,,CHEMBL620633,BAO_0000019,
3014,Autocuration,,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 3 receptor; Nonactive at 10 uM,H,,,104698,6,,CHEMBL620634,BAO_0000223,
3015,Autocuration,,,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand; NA Not Available,H,,,104698,6,,CHEMBL620635,BAO_0000019,
3016,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 0.5 hours in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620636,BAO_0000218,
3017,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 1 hour in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620637,BAO_0000218,
3018,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 3 hours in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620638,BAO_0000218,
3019,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg at 6 hours in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620639,BAO_0000218,
3020,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 0.5 hours in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620640,BAO_0000218,
3021,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 1 hour in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620641,BAO_0000218,
3022,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 16 hours in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620642,BAO_0000218,
3023,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 3 hours in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620643,BAO_0000218,
3024,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.1 mg/kg at 6 hours in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620644,BAO_0000218,
3025,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 0.5 hours in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620645,BAO_0000218,
3026,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 1 hour in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620646,BAO_0000218,
3027,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 3 hours in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620647,BAO_0000218,
3028,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.3 mg/kg at 6 hours in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620648,BAO_0000218,
3029,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 0.5 hours in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620649,BAO_0000218,
3030,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 3 hours in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620650,BAO_0000218,
3031,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 1 hour in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620651,BAO_0000218,
3032,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 mg/kg at 3 hours in urethane-anesthetized rats,H,,,104698,6,,CHEMBL872875,BAO_0000218,
3033,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1 mg/kg at 1 hour in urethane-anesthetized rats,H,,,104698,6,,CHEMBL620652,BAO_0000218,
3034,Autocuration,,,1,,,5-hydroxytryptamine 3 receptor antagonist activity was confirmed by its ability to antagonize 5-HT evoked tachycardia of rabbit isolated heart,H,,,104698,6,,CHEMBL620653,BAO_0000019,
3035,Autocuration,,,1,,,Binding activity against 5-hydroxytryptamine 2A receptor from rat cortex homogenates using [3H]DOB as radioligand.,H,,,104698,6,,CHEMBL857076,BAO_0000019,
3036,Autocuration,10116.0,,1,,,Inhibition of [3H]-Q-ICS 205-930 binding to rat cortex homogenate 5-hydroxytryptamine 3 receptor,D,,,104698,7,,CHEMBL620654,BAO_0000019,
3037,Autocuration,,,1,,,Binding activity radioligand.,H,,,104698,6,,CHEMBL620655,BAO_0000223,
3038,Autocuration,,,1,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor in rat brain membranes,H,Brain membranes,,104698,6,,CHEMBL620656,BAO_0000249,
3039,Autocuration,,,1,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes.,H,Brain membranes,,104698,6,,CHEMBL620657,BAO_0000249,
3040,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.000001 mol/L,H,,,108,8,,CHEMBL620658,BAO_0000357,
3041,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor was determined at a concentration of 0.00001 mol/L,H,,,108,8,,CHEMBL620659,BAO_0000357,
3042,Autocuration,,,1,,,Inhibition of binding towards 5-hydroxytryptamine 2C receptor at 100 nM concentration,H,,,108,8,,CHEMBL620660,BAO_0000357,
3043,Autocuration,,,1,,,Percent inhibition (at 1 uM) against 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL620661,BAO_0000357,
3044,Autocuration,,,1,,,Binding affinity of compound towards 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL620662,BAO_0000357,
3045,Expert,,,1,,,Affinity for 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL620663,BAO_0000357,
3046,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [3H]mesulergine as radioligand,H,,,108,8,,CHEMBL620664,BAO_0000357,
3047,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor using [125I]DOI as radioligand.,H,,,108,8,,CHEMBL620665,BAO_0000357,
3048,Autocuration,,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 2C receptor was determined,H,,,108,8,,CHEMBL620666,BAO_0000357,
3049,Autocuration,,,1,,,Compound was evaluated for the binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]-Ketanserin,H,,,108,8,,CHEMBL620667,BAO_0000357,
3050,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 2C receptor by displacement of [3H]N-methyl-mesulergine,H,,,108,8,,CHEMBL620668,BAO_0000357,
3051,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 2C receptor was determined,H,,,108,8,,CHEMBL620669,BAO_0000357,
3052,Expert,,,1,,,Binding affinity towards serotonin 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL620670,BAO_0000357,
3053,Autocuration,,,1,,,Evaluated for the binding affinity to 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL620671,BAO_0000357,
3054,Autocuration,,,1,,,Tested agains t5-hydroxytryptamine 2C receptor in experiment 1,H,,,108,8,,CHEMBL620672,BAO_0000357,
3055,Autocuration,,,1,,,Tested against 5-hydroxytryptamine 2C receptor in experiment 2,H,,,108,8,,CHEMBL620673,BAO_0000357,
3056,Autocuration,,,1,,,Ability to displace [3H]mesulergine from 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL620674,BAO_0000357,
3057,Autocuration,,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL620675,BAO_0000357,
3058,Autocuration,,,1,,,The binding affinity towards 5-hydroxytryptamine 2C receptor; No affinity,H,,,108,8,,CHEMBL620676,BAO_0000357,
3059,Autocuration,,,1,,,Affinity against 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL621382,BAO_0000357,
3060,Expert,9606.0,,1,,,Binding affinity against 5-hydroxytryptamine 2C receptor,D,,,108,9,,CHEMBL621383,BAO_0000357,
3061,Autocuration,,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 2C receptor using radioligand binding assay,H,,,108,8,,CHEMBL621384,BAO_0000357,
3062,Autocuration,9913.0,,1,,,Inhibitory concentration required against 5-HT3 receptor in bovine area postrema using [3H]GR-65630,H,,,144,8,,CHEMBL621385,BAO_0000357,
3063,Autocuration,9913.0,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand,H,,,144,8,,CHEMBL617989,BAO_0000357,
3064,Expert,10141.0,,1,,,Antagonistic potency against serotonin 5-hydroxytryptamine 3 receptor in GPI assay,H,,,104714,4,,CHEMBL617990,BAO_0000019,
3065,Autocuration,10141.0,,1,2116.0,,Binding affinity to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,H,,,104714,4,,CHEMBL875085,BAO_0000221,
3066,Autocuration,10141.0,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig,H,,,104714,4,,CHEMBL617991,BAO_0000019,
3067,Autocuration,10141.0,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 3 receptor of guinea pig; ND means not done,H,,,104714,4,,CHEMBL617992,BAO_0000019,
3068,Autocuration,10141.0,,1,2116.0,,Potency to 5-hydroxytryptamine 3 receptor entirely in guinea pig ileum,H,,,104714,4,,CHEMBL617993,BAO_0000221,
3069,Autocuration,10141.0,,1,2116.0,,In vitro binding affinity was measured for 5-hydroxytryptamine 3 receptor in the guinea pig ileum.,H,,,104714,4,,CHEMBL617994,BAO_0000221,
3070,Autocuration,10141.0,,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea colon at a concentration 0.01 uM,H,,,104714,4,,CHEMBL617995,BAO_0000019,
3071,Autocuration,10141.0,,1,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.1 uM,H,,,104714,4,,CHEMBL617996,BAO_0000019,
3072,Autocuration,10141.0,,1,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM,H,,,104714,4,,CHEMBL617997,BAO_0000019,
3073,Autocuration,10141.0,,1,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 1 uM in the presence of 30 uM MDL 72222,H,,,104714,4,,CHEMBL617998,BAO_0000019,
3074,Autocuration,10141.0,,1,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 0.01 uM,H,,,104714,4,,CHEMBL617999,BAO_0000019,
3075,Autocuration,10141.0,,1,,,Percent of control response to 5-HT3 antagonistic activity on guinea colon at a concentration 1 uM,H,,,104714,4,,CHEMBL618000,BAO_0000019,
3076,Autocuration,10141.0,,1,2116.0,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum",H,,,104714,4,,CHEMBL617815,BAO_0000221,
3077,Autocuration,10141.0,,1,2116.0,,"Concentration required to produce 50% of maximal contraction induced by 5-HT through 5-HT3 receptors in the presence of the compound, in isolated guinea pig ileum.",H,,,104714,4,,CHEMBL617816,BAO_0000221,
3078,Autocuration,10141.0,,1,2116.0,,Tested for the antagonistic activity against 5-hydroxytryptamine 3 receptor from guinea pig ileum,H,,,104714,4,,CHEMBL617817,BAO_0000221,
3079,Autocuration,10141.0,,1,2116.0,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum,H,,,104714,4,,CHEMBL617818,BAO_0000221,
3080,Autocuration,10141.0,,1,2116.0,,In vitro 5-hydroxytryptamine 3 receptor activity in guinea pig ileum; Not tested,H,,,104714,4,,CHEMBL617819,BAO_0000221,
3081,Autocuration,10141.0,,1,,,Binding affinity towards [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in HG108-15,H,,,104714,4,,CHEMBL617820,BAO_0000223,
3082,Autocuration,10141.0,,1,2116.0,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,H,,,104714,4,,CHEMBL617821,BAO_0000221,
3083,Autocuration,10141.0,,1,2116.0,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),H,,,104714,4,,CHEMBL617822,BAO_0000221,
3084,Autocuration,10141.0,,1,2116.0,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor of isolated guinea pig ileum (GPI),H,,,104714,4,,CHEMBL617823,BAO_0000221,
3085,Autocuration,10141.0,,1,2116.0,,Tested for antagonistic activity on 5-hydroxytryptamine 3 receptor mediated effects of 5-HT in guinea pig isolated ileum,H,,,104714,4,,CHEMBL617824,BAO_0000221,
3086,Autocuration,10141.0,,1,2116.0,,Agonistic activity against 5-hydroxytryptamine 3 receptor in guinea pig ileum assay,H,,,104714,4,,CHEMBL617825,BAO_0000221,
3087,Autocuration,10141.0,,1,2116.0,,5-hydroxytryptamine 3 receptor agonism in the guinea pig ileum by functional 5-HT3 receptor assay,H,,,104714,4,,CHEMBL617826,BAO_0000221,
3088,Autocuration,10141.0,,1,2116.0,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,H,,,104714,4,,CHEMBL617827,BAO_0000221,
3089,Autocuration,10141.0,,1,2116.0,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),H,,,104714,4,,CHEMBL617828,BAO_0000221,
3090,Autocuration,10141.0,,1,2116.0,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum,H,,,104714,4,,CHEMBL617829,BAO_0000221,
3091,Autocuration,10141.0,,1,2116.0,,Binding affinity against 5-hydroxytryptamine 3 receptor of guinea pig ileum; Not determined,H,,,104714,4,,CHEMBL617830,BAO_0000221,
3092,Autocuration,10141.0,,1,2116.0,,Binding affinity towards 5-hydroxytryptamine 3 receptor of guinea pig ileum; not determined,H,,,104714,4,,CHEMBL617831,BAO_0000221,
3093,Autocuration,10141.0,,1,2116.0,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor in guinea pig ileum.,H,,,104714,4,,CHEMBL617832,BAO_0000221,
3094,Autocuration,10141.0,,1,,,Binding affinity was determined against 5-hydroxytryptamine 2A receptor,U,,,22226,0,,CHEMBL617833,BAO_0000019,
3095,Autocuration,,,1,,,Binding affinity towards 5-HT1A receptor by the displacement of [3H]-8-OH-DPAT] in human recombinant receptors in mammalian cell,H,,,51,8,,CHEMBL617834,BAO_0000357,
3096,Expert,9606.0,,1,,,Affinity towards human 5-hydroxytryptamine 3 serotonin receptor,D,,,104714,5,,CHEMBL617835,BAO_0000223,
3097,Autocuration,,,1,,,Binding affinity towards 5-HT3 receptor,H,,,104714,4,,CHEMBL617836,BAO_0000223,
3098,Autocuration,,,1,,,Binding activity radioligand.,H,,,104714,4,,CHEMBL617837,BAO_0000223,
3099,Autocuration,,,1,,,Binding activity against 5-hydroxytryptamine 1A receptor from human brain cortex using [3H]8-OH-DPAT-HT as radioligand.,H,,,104714,4,,CHEMBL620392,BAO_0000019,
3100,Autocuration,,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,H,,,104714,4,,CHEMBL620393,BAO_0000223,
3101,Autocuration,,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor,H,,,104714,4,,CHEMBL620394,BAO_0000223,
3102,Autocuration,,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 3 receptor; NT means Not tested,H,,,104714,4,,CHEMBL620395,BAO_0000223,
3103,Autocuration,,,1,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 3 receptor,U,,,22226,0,,CHEMBL620396,BAO_0000019,
3104,Expert,,,1,,,Displacement of [3H]-BRC 36694 from 5-hydroxytryptamine 3 receptor in NG108-15 cells,H,,433.0,105030,4,,CHEMBL620582,BAO_0000219,
3105,Autocuration,,In vivo,1,,,"Percent inhibition of [3H]5 binding to 5-hydroxytryptamine 3 receptor was evaluated by injection of compound (75 microCi/kg, 1.32 ug/kg) into the tail vein of mice (in vivo)",H,,,105030,4,,CHEMBL620583,BAO_0000218,
3106,Autocuration,,,1,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),H,,,105030,4,,CHEMBL620584,BAO_0000019,
3107,Autocuration,,,1,,,Compound was evaluated for the binding affinity at 5- HT3 receptor subtype,H,,,105030,4,,CHEMBL620585,BAO_0000224,
3108,Autocuration,,,1,,,Compound was evaluated for the binding affinity at 5- HT3 receptor,H,,,105030,4,,CHEMBL620586,BAO_0000224,
3109,Autocuration,,,1,,,The binding affinity was measured for 5-hydroxytryptamine 3 receptor on NG 108-15 cell line of mouse neuroblastoma-glioma cells in presence of [3H]5 radioligand (in vitro),H,,,105030,4,,CHEMBL620587,BAO_0000019,
3110,Autocuration,,,1,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,H,,,105030,4,,CHEMBL620588,BAO_0000019,
3111,Autocuration,,,1,,,5-hydroxytryptamine 3 receptor agonism in mouse,H,,,105030,4,,CHEMBL620589,BAO_0000218,
3112,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor was determined by using [3H]-ICS 205-930 as radioligand in mouse N1E 115 cells,H,,,105030,4,,CHEMBL620590,BAO_0000219,
3113,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,H,,,105030,4,,CHEMBL617956,BAO_0000019,
3114,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 2A receptor in rat cortex preparations using [3H]ketanserin,H,,,105030,4,,CHEMBL617957,BAO_0000019,
3115,Autocuration,,,1,,,Binding affinity was evaluated by 5-hydroxytryptamine 3 receptor agonism in the mouse NIE-115 by displacing tropisetron,H,,,105030,4,,CHEMBL617958,BAO_0000224,
3116,Autocuration,,,1,,,Compound was evaluated for binding to 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,H,,,105030,4,,CHEMBL617959,BAO_0000219,
3117,Autocuration,,,1,,,Compound was evaluated for binding to Serotonin 5-hydroxytryptamine 3 receptor in N1E cells using [3H]- -Tropisetron as radioligand,H,,,105030,4,,CHEMBL617960,BAO_0000219,
3118,Autocuration,,,1,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,H,,,105030,4,,CHEMBL617961,BAO_0000224,
3119,Autocuration,,In vitro,1,,,Ability to displace the radioligand [3H]GR-65630 from 5-hydroxytryptamine 3 receptor expressed in NIE-115 cells,H,,,105030,4,,CHEMBL617962,BAO_0000219,
3120,Autocuration,,,1,,,In vitro binding affinity at 5-hydroxytryptamine 3 receptor in N1E-115 cells using 3[H]GR-65630 as the radioligand,H,,339.0,105030,4,,CHEMBL617963,BAO_0000219,
3121,Autocuration,,,1,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,H,,,11765,8,,CHEMBL617964,BAO_0000019,
3122,Autocuration,,,1,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in NG cells 108-15,H,,,11765,8,,CHEMBL617965,BAO_0000219,
3123,Autocuration,10090.0,,1,,,Compound was tested for the Binding affinity against N1e-115 neuroblastoma 5-hydroxytryptamine 3 receptor by Radio ligand [3H]GR-65630 binding assay.,D,,,10630,9,,CHEMBL617966,BAO_0000357,
3124,Autocuration,,,1,,,Binding activity against 5-hydroxytryptamine 3 receptor from rat cortex homogenate using [3H]-Q-ICS 205-930 as radioligand.,H,,,17106,8,,CHEMBL857074,BAO_0000019,
3125,Autocuration,9823.0,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor,H,,,144,8,,CHEMBL617967,BAO_0000357,
3126,Autocuration,9823.0,,1,,,Binding activity radioligand.,H,,,144,8,,CHEMBL617968,BAO_0000357,
3127,Autocuration,9986.0,,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor of neuronal in the afferent rabbit vagus,H,,,104714,4,,CHEMBL617969,BAO_0000223,
3128,Autocuration,9986.0,,1,,,Potency at neuronal 5-hydroxytryptamine 3 receptor in the rabbit heart,H,,,104714,4,,CHEMBL617970,BAO_0000223,
3129,Autocuration,9986.0,,1,,,Potency at neuronal 5-hydroxytryptamine 3 receptors in the rabbit heart,H,,,104714,4,,CHEMBL617971,BAO_0000223,
3130,Autocuration,9986.0,,1,,,Potency to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,H,,,104714,4,,CHEMBL617972,BAO_0000019,
3131,Autocuration,9986.0,,1,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),H,,,104714,4,,CHEMBL617973,BAO_0000019,
3132,Autocuration,9986.0,,1,,,Evaluated for the antagonistic activity against 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),H,,,104714,4,,CHEMBL617974,BAO_0000019,
3133,Autocuration,9986.0,,1,2116.0,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated guinea pig ileum (GPI),H,,,104714,4,,CHEMBL617975,BAO_0000221,
3134,Autocuration,9986.0,,1,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),H,,,104714,4,,CHEMBL617976,BAO_0000019,
3135,Autocuration,9986.0,,1,,,Antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),H,,,104714,4,,CHEMBL617977,BAO_0000019,
3136,Autocuration,9986.0,,1,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated perfused rabbit heart (RH),H,,,104714,4,,CHEMBL617978,BAO_0000019,
3137,Autocuration,9986.0,,1,,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 3 receptor in isolated rabbit vagus nerve (RVN),H,,,104714,4,,CHEMBL617979,BAO_0000019,
3138,Autocuration,9986.0,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor in CHO cells using [3H]5-HT as radioligand,H,,449.0,104714,4,,CHEMBL617980,BAO_0000219,
3139,Autocuration,10116.0,,1,,,In vitro displacement of [3H]-LY 278584 from rat cerebral cortex 5-hydroxytryptamine 3 receptor,D,,,104698,7,,CHEMBL617981,BAO_0000019,
3140,Autocuration,,,1,,,Affinity at 5-hydroxytryptamine 3 receptor from rat frontal cortex using [3H]granisetron as radioligand (For granisetron = Ki(nM)=0.3+/-0.01),H,,,12020,8,,CHEMBL617982,BAO_0000019,
3141,Autocuration,,,1,,,Affinity at 5-hydroxytryptamine 3 receptor (For granisetron = Ki (nM)=0.3+/-0.01),H,,,12020,8,,CHEMBL617983,BAO_0000357,
3142,Autocuration,10116.0,,1,,,In vitro displacement of [3H]ICS-205-930 from 5-hydroxytryptamine 3 receptor in cultured NG-108-15 rat glioma cells,D,,,104698,7,,CHEMBL617984,BAO_0000019,
3143,Autocuration,,,1,,,"Binding affinity for 5-hydroxytryptamine 3 receptor in rat cerebral cortex, determined by displacement of [3H]GR-65630",H,,,104698,6,,CHEMBL617985,BAO_0000019,
3144,Autocuration,,In vivo,1,948.0,,"5-Hydroxy tryptamine 3 receptor showing agonist activity (in vivo) in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",H,,,104698,6,,CHEMBL617986,BAO_0000218,
3145,Autocuration,,,1,948.0,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",H,,,104698,6,,CHEMBL617987,BAO_0000019,
3146,Autocuration,,,1,948.0,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 120 (ug/kg), evaluated as change in heart rate",H,,,104698,6,,CHEMBL617988,BAO_0000019,
3147,Autocuration,,,1,948.0,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as change in heart rate",H,,,104698,6,,CHEMBL617792,BAO_0000019,
3148,Autocuration,,,1,948.0,,"Agonistic activity of compound towards 5-hydroxytryptamine 3 receptorr in Von Bezold-Jarisch Reflex in rats at 100 (ug/kg), evaluated as change in heart rate",H,,,104698,6,,CHEMBL617793,BAO_0000019,
3149,Autocuration,,,1,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 100(ug/kg), evaluated as percent inhibition of bradycardia",H,,,104698,6,,CHEMBL617794,BAO_0000019,
3150,Autocuration,,,1,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch Reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",H,,,104698,6,,CHEMBL617795,BAO_0000019,
3151,Autocuration,,,1,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60 (ug/kg), evaluated as percent inhibition of bradycardia",H,,,104698,6,,CHEMBL617796,BAO_0000019,
3152,Autocuration,,,1,,,"Antagonistic activity of compound towards 5-hydroxytryptamine 3 receptor in Von Bezold-Jarisch reflex in rats at 60(ug/kg), evaluated as percent inhibition of bradycardia",H,,,104698,6,,CHEMBL617797,BAO_0000019,
3153,Autocuration,10116.0,In vivo,1,,,Antagonism of 5-HT-induced Von Bezold-Jarisch reflex in rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor antagonism),D,,,104698,7,,CHEMBL617798,BAO_0000218,
3154,Autocuration,,In vivo,1,,,Ability to antagonise the 5-HT- induced Von Bezold-Jarisch reflex in the rat after intravenous administration of 30 ug/kg of HT (5-hydroxytryptamine 3 receptor),H,,,104698,6,,CHEMBL617799,BAO_0000218,
3155,Autocuration,10116.0,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,D,,,104698,7,,CHEMBL617800,BAO_0000218,
3156,Autocuration,10116.0,,1,,,Inhibition of 5-HT-induced bradycardia by 5-hydroxytryptamine 3+,D,,,104698,7,,CHEMBL617801,BAO_0000019,
3157,Autocuration,10116.0,In vivo,1,,,In vivo inhibitory concentration after 5 minutes against 5-hydroxytryptamine 3 receptor induced bradycardia [bezold-jarisch (B-J) reflex test] in rat by intravenous administration,D,,,104698,7,,CHEMBL617802,BAO_0000218,
3158,Autocuration,10116.0,,1,,,Inhibition of 5-HT (1 ug/mL) induced depolarization in rat vagus nerve (5-hydroxytryptamine 3 receptor antagonism),D,,,104698,7,,CHEMBL617803,BAO_0000019,
3159,Autocuration,,,1,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,H,,,104698,6,,CHEMBL617804,BAO_0000019,
3160,Autocuration,10116.0,,1,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane 5-hydroxytryptamine 3 receptor,D,,,104698,7,,CHEMBL617805,BAO_0000019,
3161,Autocuration,,,1,,,Binding affinity was evaluated in vitro by displacement of [3H]zacopride radioligand from 5-hydroxytryptamine 3 receptor,H,,,104698,6,,CHEMBL617806,BAO_0000223,
3162,Autocuration,,,1,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement [3H]GR-65630 in rat cerebral cortex.,H,,,104698,6,,CHEMBL617807,BAO_0000019,
3163,Autocuration,,,1,,,Compound was evaluated for its binding affinity for 5-hydroxytryptamine 3 receptor by measuring displacement of [3H]granisetron from rat cerebral cortex,H,,,104698,6,,CHEMBL617808,BAO_0000019,
3164,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor in rat cortical membrane using [3H]GR-65630 as radioligand,H,,,104698,6,,CHEMBL617809,BAO_0000249,
3165,Autocuration,,,1,,,Compound was tested for its ability to displace [3H]-Q-ICS 205-930 from 5-hydroxytryptamine 3 receptor in rat cortex homogenates,H,,,104698,6,,CHEMBL617810,BAO_0000019,
3166,Autocuration,,,1,955.0,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to 5-hydroxytryptamine 3 receptor in rat brain cortical membrane,H,,,104698,6,,CHEMBL617811,BAO_0000249,
3167,Autocuration,,,1,955.0,,Concentration required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine-3 receptor (5-HT 3 receptor)in rat brain cortical membrane,H,,,104698,6,,CHEMBL617812,BAO_0000221,
3168,Autocuration,,,1,,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-65630 to serotonin 5-hydroxytryptamine 3 receptor in rat cortical membrane,H,,,104698,6,,CHEMBL617813,BAO_0000249,
3169,Autocuration,,,1,,,In vitro inhibitory concentration against radioligand [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor in rat cortical membrane,H,,,104698,6,,CHEMBL617814,BAO_0000249,
3170,Autocuration,,,1,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate.,H,,,104698,6,,CHEMBL617698,BAO_0000019,
3171,Autocuration,10116.0,,1,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; Not active at 10000 nm,D,,,104698,7,,CHEMBL617699,BAO_0000019,
3172,Autocuration,10116.0,,1,,,Inhibition of [3H]BRL-43694 binding to 5-hydroxytryptamine 3 receptor of rat cortical homogenate; not active at 10000 nM,D,,,104698,7,,CHEMBL617700,BAO_0000019,
3173,Autocuration,10116.0,,1,,,Inhibition of radiolabeled [3H]-Zacopride ligand binding to 5-hydroxytryptamine 3 receptor,D,,,104698,7,,CHEMBL617701,BAO_0000223,
3174,Autocuration,,,1,,,Inhibitory concentration against 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-LY 278584 as radioligand,H,,,104698,6,,CHEMBL617702,BAO_0000019,
3175,Autocuration,,,1,,,"Tested for inhibition of binding of [3H]GR-65630 to rat cortical membranes, expressed as IC50",H,Membranes,,104698,6,,CHEMBL617703,BAO_0000249,
3176,Autocuration,10116.0,,1,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 3 receptor,D,,,104698,7,,CHEMBL617704,BAO_0000019,
3177,Autocuration,,,1,,,The binding affinity at 5-hydroxytryptamine 3 receptor was determined using [3H]LY-278584; Not tested,H,,,104698,6,,CHEMBL617705,BAO_0000223,
3178,Autocuration,10116.0,,1,,,Inhibition of [3H]BRL-43694 binding to rat 5-hydroxytryptamine 3 receptor,D,,,104698,7,,CHEMBL617706,BAO_0000223,
3179,Autocuration,,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells (using [3H]zacopride as radioligand),H,,433.0,104698,6,,CHEMBL617707,BAO_0000219,
3180,Autocuration,,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from NG108-15 cells using [3H]zacopride as radioligand,H,,433.0,104698,6,,CHEMBL617708,BAO_0000219,
3181,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor from rat cortical homogenate using [3H]zacopride as radioligand,H,,,104698,6,,CHEMBL617709,BAO_0000019,
3182,Autocuration,,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA= Not active,H,,,104698,6,,CHEMBL617710,BAO_0000019,
3183,Autocuration,,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; NA=Not active,H,,,104698,6,,CHEMBL882925,BAO_0000019,
3184,Autocuration,,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 3 receptor from rat cortical homogenate using [3H]zacopride as radioligand; not active,H,,,104698,6,,CHEMBL617711,BAO_0000019,
3185,Autocuration,,,1,,,Antagonist potency to 5-hydroxytryptamine 3 receptor was assayed by antagonism of the 5-HT-evoked reflex bradycardia [Bezold-Jarisch(BJ) reflex] in rats,H,,,104698,6,,CHEMBL617712,BAO_0000019,
3186,Autocuration,10116.0,,1,,,Antagonistic activity against 5-hydroxytryptamine 3 receptor as inhibition of 5-HT-induced bradycardia (von Bezold-jarisch reflex) in anesthetized rat,D,,,104698,7,,CHEMBL617713,BAO_0000019,
3187,Autocuration,,,1,,,"Compound was tested as a 5-hydroxytryptamine 3 receptor antagonist in the rat by assessment of the inhibition of the Bezold-Jarisch effect, when administered intravenously",H,,,104698,6,,CHEMBL617714,BAO_0000019,
3188,Autocuration,,,1,,,In vivo 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) antagonistic activity expressed as ability to inhibit Bezold-Jarich reflex evoked by 5-HT in rats,H,,,104698,6,,CHEMBL617715,BAO_0000218,
3189,Autocuration,,In vivo,1,,,Inhibition dose for 50 percent antagonism for 5-hydroxytryptamine 3 receptor in vivo in rats,H,,,104698,6,,CHEMBL617716,BAO_0000218,
3190,Autocuration,,,1,,,Inhibition of 5-HT evoked reflex bradycardia in rat.,H,,,104698,6,,CHEMBL617717,BAO_0000218,
3191,Autocuration,,In vivo,1,,,5-HT3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617718,BAO_0000218,
3192,Autocuration,,In vivo,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617719,BAO_0000218,
3193,Autocuration,,In vivo,1,,,5-hydroxytryptamine 3 receptor antagonistic activity measured by inhibition of 5-HT-induced bradycardia (iv administration 10 ug/kg dose in urethane-anesthetized rats),H,,,104698,6,,CHEMBL617720,BAO_0000218,
3194,Autocuration,10116.0,In vivo,1,,,5-hydroxytryptamine 3 receptor antagonistic activity as inhibition of 5-HT-induced bradycardia after iv administration of 100 ug/kg dose in urethane-anesthetized rats,D,,,104698,7,,CHEMBL617721,BAO_0000218,
3195,Autocuration,,In vivo,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617722,BAO_0000218,
3196,Autocuration,,In vivo,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 1000 ug/kgetized rats,H,,,104698,6,,CHEMBL617723,BAO_0000218,
3197,Autocuration,,In vivo,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after iv administration of 3 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617724,BAO_0000218,
3198,Autocuration,,In vivo,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 10 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617725,BAO_0000218,
3199,Autocuration,,In vivo,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 100 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617726,BAO_0000218,
3200,Autocuration,,In vivo,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 1000 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617727,BAO_0000218,
3201,Autocuration,,In vivo,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 30 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617728,BAO_0000218,
3202,Autocuration,,In vivo,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 300 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617729,BAO_0000218,
3203,Autocuration,,In vivo,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5H+ T-induced bradycardia after po administration of 3ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617730,BAO_0000218,
3204,Autocuration,,In vivo,1,,,5-hydroxytryptamine 3 receptor antagonistic activity was measured by the inhibition of 5-HT-induced bradycardia after iv administration of 1000 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617731,BAO_0000218,
3205,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 0.3 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617732,BAO_0000218,
3206,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 1 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617733,BAO_0000218,
3207,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after intravenous administration of 30 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617734,BAO_0000218,
3208,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 0.05 hour,H,,,104698,6,,CHEMBL872874,BAO_0000218,
3209,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 1 hour,H,,,104698,6,,CHEMBL617735,BAO_0000218,
3210,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 16 hour,H,,,104698,6,,CHEMBL617736,BAO_0000218,
3211,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 3 hour,H,,,104698,6,,CHEMBL617737,BAO_0000218,
3212,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 0.03 mg/kg dose in urethane-anesthetized rats at 6 hour,H,,,104698,6,,CHEMBL617738,BAO_0000218,
3213,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617739,BAO_0000218,
3214,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 100 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617740,BAO_0000218,
3215,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 1000 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617741,BAO_0000218,
3216,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 10 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617742,BAO_0000218,
3217,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 3 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617743,BAO_0000218,
3218,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 30 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617744,BAO_0000218,
3219,Autocuration,,In vivo,1,,,Compound was tested for the inhibition of 5-HT-induced bradycardia after peroral administration of 300 ug/kg dose in urethane-anesthetized rats,H,,,104698,6,,CHEMBL617745,BAO_0000218,
3220,Autocuration,,,1,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.)",H,,,104698,6,,CHEMBL617746,BAO_0000218,
3221,Autocuration,,,1,,,"In vivo 5-hydroxytryptamine 3 receptor antagonist activity by antagonism of the von Bezold-Jarisch (B-J) reflex in anesthetized rats, (i.v.); Not tested",H,,,104698,6,,CHEMBL617747,BAO_0000218,
3222,Autocuration,,In vivo,1,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 10 ug/Kg,H,,,104698,6,,CHEMBL617748,BAO_0000218,
3223,Autocuration,,In vivo,1,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 100 ug/Kg,H,,,104698,6,,CHEMBL618909,BAO_0000218,
3224,Autocuration,,In vivo,1,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 2 ug/Kg,H,,,104698,6,,CHEMBL618910,BAO_0000218,
3225,Autocuration,,In vivo,1,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 20 ug/Kg,H,,,104698,6,,CHEMBL618911,BAO_0000218,
3226,Autocuration,,In vivo,1,,,Serotonin receptor antagonist activity was measured as ability to block the serotonin-induced Bezold-Jarisch reflex in rats after iv administration of 5 ug/Kg,H,,,104698,6,,CHEMBL618912,BAO_0000218,
3227,Autocuration,,In vivo,1,,,Tested for inhibition of Bezold-Jarisch (B-J) reflex mediated by 5-hydroxytryptamine 3 receptor in rats after intravenous administration (2.0 ug/kg),H,,,104698,6,,CHEMBL618913,BAO_0000218,
3228,Autocuration,,,1,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,H,,,104698,6,,CHEMBL618914,BAO_0000019,
3229,Autocuration,,,1,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; A means pure agonist,H,,,104698,6,,CHEMBL618915,BAO_0000019,
3230,Autocuration,10116.0,,1,,,Intrinsic efficacy for rat 5-hydroxytryptamine 3 receptor,D,,,104698,7,,CHEMBL618916,BAO_0000223,
3231,Autocuration,,,1,,,Intrinsic efficacy against 5-hydroxytryptamine 3 receptor; PA means partial agonist,H,,,104698,6,,CHEMBL618917,BAO_0000019,
3232,Intermediate,,,1,10000000.0,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor (5-HT 3 receptor) of rat cortex and hippocampus tissue,D,,,104698,7,,CHEMBL618918,BAO_0000221,
3233,Autocuration,10116.0,,1,,,Inhibition of [3H]granisetron binding to 5-hydroxytryptamine 3 receptor of rat cortical membrane,D,,,104698,7,,CHEMBL618919,BAO_0000019,
3234,Autocuration,10116.0,,1,,,Inhibition of [3H]GR-65630 binding to rat cortical membrane serotonin 5-hydroxytryptamine 3 receptor,D,,,104698,7,,CHEMBL618920,BAO_0000019,
3235,Autocuration,,,1,,,Affinity was evaluated as inhibition constant for serotonin 5-hydroxytryptamine 3 receptor,H,,,104698,6,,CHEMBL618921,BAO_0000223,
3236,Autocuration,,,1,,,Affinity was evaluated by inhibition of [3H]GR-65630 binding to NG108-15 cell transfected with cloned rat 5-hydroxytryptamine 3 receptor,H,,,104698,6,,CHEMBL618922,BAO_0000019,
3237,Autocuration,,,1,,,Binding affinity against radioligand [3H]quipazine labeled 5-hydroxytryptamine 3 receptor sites in neuroblastoma-glioma (NG108-15) cells.,H,,,104698,6,,CHEMBL618923,BAO_0000019,
3238,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 3 receptor was determined by measuring displacement of [3H]GR-65630 from rat brain cortices,H,,,104698,6,,CHEMBL618924,BAO_0000019,
3239,Autocuration,,,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor in rat entorhinal cortex using [3H]-BRL 43694 as radioligand,H,,,104698,6,,CHEMBL618925,BAO_0000019,
3240,Autocuration,,,1,,,Binding affinity towards 5-HT3 receptor in rat was evaluated,H,,,104698,6,,CHEMBL618926,BAO_0000019,
3241,Intermediate,10141.0,,1,2116.0,,5-hydroxytryptamine 4 receptor agonist activity as increased response to electrical stimulation in guinea pig ileum,D,,,20033,9,,CHEMBL618927,BAO_0000221,
3242,Intermediate,10141.0,,1,2116.0,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum; Not tested,D,,,20033,9,,CHEMBL618928,BAO_0000221,
3243,Intermediate,10141.0,,1,2116.0,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum",D,,,20033,9,,CHEMBL618929,BAO_0000221,
3244,Intermediate,10141.0,,1,2116.0,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Inactive up to 10E-5 M",D,,,20033,9,,CHEMBL618930,BAO_0000221,
3245,Intermediate,10141.0,,1,2116.0,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",D,,,20033,9,,CHEMBL618931,BAO_0000221,
3246,Intermediate,10141.0,,1,2116.0,,"5-hydroxytryptamine 4 receptor agonist activity, concentration which gave 50% increase in the response to electrically-stimulated myenteric plexus and longitudinal muscle of the guinea pig ileum; Not tested",D,,,20033,9,,CHEMBL619594,BAO_0000221,
3247,Intermediate,10141.0,,1,2116.0,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not capable of evaluation",D,,,20033,9,,CHEMBL619595,BAO_0000221,
3248,Intermediate,10141.0,,1,2116.0,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum.,D,,,20033,9,,CHEMBL619596,BAO_0000221,
3249,Intermediate,10141.0,,1,2116.0,,concentration which gave a 50% increase in the response to electrical stimulation against 5-hydroxytryptamine 4 receptor in the guinea pig ileum. Activity expressed as percent of the maximum 5-HT response given in brackets.,D,,,20033,9,,CHEMBL619755,BAO_0000221,
3250,Intermediate,10141.0,,1,2116.0,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum,D,,,20033,9,,CHEMBL619756,BAO_0000221,
3251,Intermediate,10141.0,,1,2116.0,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not evaluable,D,,,20033,9,,CHEMBL619757,BAO_0000221,
3252,Intermediate,10141.0,,1,2116.0,,5-hydroxytryptamine 4 receptor antagonist activity expressed as the concentration which produced a 50% reduction of 5-HT induced contraction in guinea pig ileum; Not tested,D,,,20033,9,,CHEMBL619758,BAO_0000221,
3253,Intermediate,10141.0,,1,2116.0,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum",D,,,20033,9,,CHEMBL619759,BAO_0000221,
3254,Intermediate,10141.0,,1,2116.0,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10-5 M",D,,,20033,9,,CHEMBL619760,BAO_0000221,
3255,Intermediate,10141.0,,1,2116.0,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Inactive up to 10E-5 M",D,,,20033,9,,CHEMBL619761,BAO_0000221,
3256,Intermediate,10141.0,,1,2116.0,,5-hydroxytryptamine 4 receptor antagonist activity as inhibition of 5-HT-induced contractions in guinea pig ileum; Not capable of evaluation.,D,,,20033,9,,CHEMBL619762,BAO_0000221,
3257,Intermediate,10141.0,,1,2116.0,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",D,,,20033,9,,CHEMBL619763,BAO_0000221,
3258,Intermediate,10141.0,,1,2116.0,,"5-hydroxytryptamine 4 receptor antagonist activity, concentration which gave 50% reduction of the 5-HT-induced contractions in the guinea pig ileum; Not tested",D,,,20033,9,,CHEMBL617868,BAO_0000221,
3259,Intermediate,10141.0,,1,,,Displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor in guinea pig striatum,D,,,20033,9,,CHEMBL617869,BAO_0000357,
3260,Intermediate,10141.0,,1,2435.0,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,D,,,20033,9,,CHEMBL882926,BAO_0000249,
3261,Intermediate,10141.0,,1,2435.0,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,D,,,20033,9,,CHEMBL617870,BAO_0000249,
3262,Intermediate,10141.0,,1,2435.0,,Inhibitory activity against 5-hydroxytryptamine 4 receptor of guinea pig striatum using [3H]GR-113808 as radioligand,D,,,20033,9,,CHEMBL617871,BAO_0000357,
3263,Intermediate,10141.0,,1,2435.0,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea pig striatum,D,,,20033,9,,CHEMBL617872,BAO_0000357,
3264,Intermediate,10141.0,,1,2435.0,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to 5-hydroxytryptamine 4 receptor in guinea-pig striatum,D,,,20033,9,,CHEMBL617873,BAO_0000357,
3265,Intermediate,10141.0,,1,2435.0,,Concentration of compound required to inhibit the binding of radioligand [3H]GR-113808 to serotonin 5-hydroxytryptamine 4 receptor in guinea-pig striatum,D,,,20033,9,,CHEMBL617874,BAO_0000357,
3266,Intermediate,10141.0,,1,2116.0,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum.,D,,,20033,9,,CHEMBL619067,BAO_0000221,
3267,Intermediate,10141.0,,1,2116.0,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum. 95% confidence limits are in brackets.,D,,,20033,9,,CHEMBL619068,BAO_0000221,
3268,Intermediate,10141.0,,1,2116.0,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,D,,,20033,9,,CHEMBL619069,BAO_0000221,
3269,Intermediate,10141.0,,1,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-6 M in guinea pig,D,,,20033,9,,CHEMBL619070,BAO_0000357,
3270,Intermediate,10141.0,,1,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor at concentration of 10e-8 M in guinea pig,D,,,20033,9,,CHEMBL619071,BAO_0000357,
3271,Intermediate,10141.0,,1,,,Agonistic activity against 5-hydroxytryptamine 4 receptor,D,,,20033,9,,CHEMBL619072,BAO_0000019,
3272,Intermediate,10141.0,,1,,,Agonistic activity against 5-hydroxytryptamine 4 receptor; not tested,D,,,20033,9,,CHEMBL619073,BAO_0000019,
3273,Intermediate,10141.0,,1,,,Compound was evaluated for the relative potency with respect to serotonin against 5-hydroxytryptamine 4 receptor,D,,,20033,9,,CHEMBL619074,BAO_0000019,
3274,Intermediate,10141.0,,1,,,Ability to displace [3H]GR-113808 from 5-hydroxytryptamine 4 receptor,D,,,20033,9,,CHEMBL619075,BAO_0000357,
3275,Intermediate,10141.0,,1,2435.0,,Inhibition of [3H]GR-113808 binding to guinea pig striatum 5-hydroxytryptamine 4 receptor,D,,,20033,9,,CHEMBL619076,BAO_0000357,
3276,Intermediate,10141.0,,1,2435.0,,Binding affinity against 5-hydroxytryptamine 4 receptor in guinea pig striatum using [3H]GR-113808 as radioligand,D,,,20033,9,,CHEMBL619077,BAO_0000357,
3277,Intermediate,10141.0,,1,2435.0,,Binding affinity towards 5-HT4 receptor in striatum membranes of guinea-pig brain was evaluated,D,,,20033,9,,CHEMBL619078,BAO_0000249,
3278,Intermediate,10141.0,,1,2435.0,,Binding affinity towards 5-hydroxytryptamine 4 receptor in striatum membranes of guinea-pig brain was evaluated,D,,,20033,9,,CHEMBL619079,BAO_0000249,
3279,Intermediate,10141.0,,1,2116.0,,Tested for affinity against 5-hydroxytryptamine 4 receptor in the myenteric plexus of the guinea pig ileum.,D,,,20033,9,,CHEMBL619080,BAO_0000221,
3280,Expert,10141.0,,1,,,Displacement of [3H]-GR113808 from 5-HT4 receptor of guinea pig striatum,D,,,20033,9,,CHEMBL619081,BAO_0000357,
3281,Intermediate,10141.0,,1,,,The compound was tested for their binding affinity towards 5-HT4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,D,,,20033,9,,CHEMBL619082,BAO_0000357,
3282,Intermediate,10141.0,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand.,D,,,20033,9,,CHEMBL619083,BAO_0000357,
3283,Intermediate,10141.0,,1,,,The compound was tested for their binding affinity towards 5-hydroxytryptamine 4 receptor from guinea pig striatum using [3H]GR-113808 as radioligand; Nonactive at 10 uM,D,,,20033,9,,CHEMBL619084,BAO_0000357,
3284,Intermediate,10141.0,,1,2116.0,,Evaluated for the antagonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,D,,,20033,9,,CHEMBL859397,BAO_0000221,
3285,Intermediate,10141.0,,1,2116.0,,5-hydroxytryptamine 4 receptor agonist activity in the guinea pig ileum assay,D,,,20033,9,,CHEMBL619085,BAO_0000221,
3286,Intermediate,10141.0,,1,2116.0,,5-hydroxytryptamine 4 receptor agonistic activity was measured by twitch response enhancing activity in electrically stimulated guinea pig ileum preparation,D,,,20033,9,,CHEMBL619086,BAO_0000221,
3287,Intermediate,10141.0,,1,2116.0,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in low frequency field stimulation of guinea-pig ileum (FSGPI).,D,,,20033,9,,CHEMBL619087,BAO_0000221,
3288,Intermediate,10141.0,,1,2116.0,,Agonistic activity against Serotonin 5-hydroxytryptamine 4 receptor in non-electrically stimulated guinea-pig ileum.,D,,,20033,9,,CHEMBL619088,BAO_0000221,
3289,Intermediate,10141.0,,1,,,Ability to antagonize 5-HT-evoked contractions mediated through 5-hydroxytryptamine 4 receptor activation in the guinea pig distal colon LMMP,D,,,20033,9,,CHEMBL619089,BAO_0000357,
3290,Autocuration,10141.0,,1,,,Binding affinity was determined against 5-hydroxytryptamine 3 receptor,H,,,168,8,,CHEMBL619090,BAO_0000357,
3291,Intermediate,10141.0,,1,,,Antagonistic activity against 5-hydroxytryptamine 4 receptor,D,,,20033,9,,CHEMBL619091,BAO_0000019,
3292,Intermediate,10141.0,,1,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-hydroxytryptamine 4 receptor,D,,,20033,9,,CHEMBL619092,BAO_0000357,
3293,Intermediate,10141.0,,1,,,Binding affinity for 5-hydroxytryptamine 4 receptor by displacement of [3H]GR-113808 from guinea pig brain striatum.,D,,,20033,9,,CHEMBL619093,BAO_0000019,
3294,Autocuration,10141.0,,1,,,Binding affinity was determined against 5-hydroxytryptamine 2C receptor using cloned rat receptors expressed in 293 cells radiolabeled with [3H]mesulergine,H,,722.0,168,8,,CHEMBL619094,BAO_0000219,
3295,Intermediate,10141.0,,1,,,In vitro by displacement of [3H]GR-113808 from 5-hydroxytryptamine 4 receptor on guinea pig striatal membrane,D,,,20033,9,,CHEMBL619095,BAO_0000019,
3296,Intermediate,10141.0,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 4 receptor using radioligand binding assay using [3H]GR as radioligand,D,,,20033,9,,CHEMBL857988,BAO_0000357,
3297,Intermediate,10141.0,,1,,,Compound was evaluated for its ability to displace [3H]GR-113808 binding from 5-hydroxytryptamine 4 receptor in guinea pig striatum.,D,,,20033,9,,CHEMBL619096,BAO_0000357,
3298,Intermediate,10141.0,,1,2435.0,,In vitro binding affinity at 5-hydroxytryptamine 4 receptor in guinea pig striatum using 3[H]GR-113808 as the radioligand,D,,,20033,9,,CHEMBL619097,BAO_0000357,
3299,Intermediate,10141.0,,1,10000000.0,,The compound was tested for its binding affinity towards 5-hydroxytryptamine 4 receptor in guinea pig hippocampus using [125I]SB-207710.,D,,,20033,9,,CHEMBL619098,BAO_0000221,
3300,Intermediate,10141.0,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand,D,,,20033,9,,CHEMBL619751,BAO_0000357,
3301,Intermediate,10141.0,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand.,D,,,20033,9,,CHEMBL619752,BAO_0000357,
3302,Intermediate,10141.0,,1,2116.0,,The antagonist activity was calculated as the concentration which produced a 50% reduction against 5-hydroxytryptamine 4 receptor in guinea pig ileum;ne=not capable of evaluation.,D,,,20033,9,,CHEMBL875096,BAO_0000221,
3303,Autocuration,,,1,,,Binding affinity towards 5-HT2C receptor by the displacement of [3H]mesulergine] in human recombinant receptors in mammalian cell,H,,,108,8,,CHEMBL619004,BAO_0000357,
3304,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 4 receptor using [3H]5-HT as radioligand,H,,,168,8,,CHEMBL619005,BAO_0000357,
3305,Autocuration,,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 4 receptor,H,,,168,8,,CHEMBL619006,BAO_0000019,
3306,Autocuration,,,1,,,Compound was evaluated for the binding affinity against human cloned 5-hydroxytryptamine 4 receptor in HeLa cells using [3H]-LSD as the radioligand,H,,308.0,168,8,,CHEMBL619007,BAO_0000219,
3307,Autocuration,,,1,,,Compound was tested for its binding affinity against 5-hydroxytryptamine 4 receptor,H,,,168,8,,CHEMBL619008,BAO_0000357,
3308,Autocuration,,,1,,,Compound was tested for its binding affinity for 5-hydroxytryptamine 4 receptor,H,,,168,8,,CHEMBL619009,BAO_0000357,
3309,Autocuration,,,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 4 receptor in HeLa cells, using [3H]LSD as radioligand",H,,308.0,168,8,,CHEMBL619010,BAO_0000219,
3310,Autocuration,,,1,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons,H,,,10622,8,,CHEMBL619011,BAO_0000357,
3311,Autocuration,,,1,,,Tested for ability to stimulate production of cAMP mediated by 5-hydroxytryptamine 4 receptor in mouse Coliculi neurons; IA means inactive,H,,,10622,8,,CHEMBL619012,BAO_0000357,
3312,Autocuration,,,1,,,Ability to displace [3H]GR-113808 from mouse 5-hydroxytryptamine 4 receptor in COS7 cells,H,,,10622,8,,CHEMBL619013,BAO_0000219,
3313,Autocuration,,,1,,,Tested for ability to stimulate 5-hydroxytryptamine 4 receptors in mouse Coliculi neurons,H,,,10622,8,,CHEMBL619014,BAO_0000357,
3314,Autocuration,,,1,2081.0,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model,H,,,11249,8,,CHEMBL857503,BAO_0000019,
3315,Autocuration,,,1,2081.0,,Evaluated for the 5-hydroxytryptamine 4 receptor antagonistic activity in piglet atrium model; compound found inactive at 1 uM,H,,,11249,8,,CHEMBL619015,BAO_0000019,
3316,Autocuration,,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 4 receptor,H,,,11249,8,,CHEMBL619016,BAO_0000357,
3317,Autocuration,,,1,10000000.0,,Compound was tested for binding affinity against piglet hippocampus 5-hydroxytryptamine 4 receptor,H,,,11249,8,,CHEMBL619017,BAO_0000221,
3318,Autocuration,9823.0,,1,10000000.0,,The binding affinity (pKi) was measured against 5-hydroxytryptamine 4 receptor of piglet hippocampus using [125I]SB 207710 as radioligand,H,,,168,8,,CHEMBL619018,BAO_0000221,
3319,Autocuration,9986.0,,1,,,Binding affinity against 5-hydroxytryptamine 2A receptor using rabbit saphenous vein assay.,H,,,168,8,,CHEMBL619019,BAO_0000019,
3320,Expert,10116.0,,1,,,Displacement of [3H]GR-113808 from rat striatum 5-hydroxytryptamine 4 receptor,D,,,10623,9,,CHEMBL619020,BAO_0000357,
3321,Autocuration,,,1,,,Tested for its agonist potency against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,H,,,10623,8,,CHEMBL619021,BAO_0000019,
3322,Autocuration,,,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in relaxation of rat oesophagus,H,,,10623,8,,CHEMBL619022,BAO_0000357,
3323,Autocuration,,,1,,,Tested for the effect on binding at 5-hydroxytryptamine 4 receptor; No activity,H,,,10623,8,,CHEMBL619023,BAO_0000357,
3324,Autocuration,,,1,,,lntrinsic activity relative to 5-HT receptor,H,,,10623,8,,CHEMBL619024,BAO_0000019,
3325,Autocuration,,,1,,,Compound was evaluated for the agonistic activity towards 5-hydroxytryptamine 4 receptor using the rat tunica muscularis mucosae (TMM) esophagus strip assay,H,,,10623,8,,CHEMBL619025,BAO_0000019,
3326,Expert,,,1,,,In vitro relaxation of carbachol pre-contracted rat oesophageal TMM.,H,,,10623,8,,CHEMBL619026,BAO_0000019,
3327,Autocuration,,,1,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay,H,,,10623,8,,CHEMBL619027,BAO_0000019,
3328,Autocuration,,,1,,,Compound was tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay; IN = Inactive,H,,,10623,8,,CHEMBL619028,BAO_0000019,
3329,Autocuration,,,1,,,Efficient 5-hydroxytryptamine 4 agonist in the rat tunica muscularis mucosae,H,,,10623,8,,CHEMBL619029,BAO_0000019,
3330,Autocuration,,,1,,,Tested for agonist activity at the 5-hydroxytryptamine 4 receptor in the rat tunica muscularis mucosae (TMM) assay of racemate mixture,H,,,10623,8,,CHEMBL619030,BAO_0000019,
3331,Expert,,,1,,,Relaxation of carbachol induced contractions of rat tunica muscularis mucosae,H,,,10623,8,,CHEMBL619031,BAO_0000357,
3332,Autocuration,,,1,,,5-hydroxytryptamine 4 receptor agonist activity was determined by the relaxation of the carbachol-contracted rat esophageal tunica muscularis mucosae,H,,,10623,8,,CHEMBL619032,BAO_0000019,
3333,Expert,10116.0,,1,,,Inhibition of radiolabeled [3H]GR-113808 ligand binding to 5-hydroxytryptamine 4 receptor,D,,,10623,9,,CHEMBL619033,BAO_0000357,
3334,Autocuration,,,1,,,Tested for its efficacy against the 5-hydroxytryptamine 4 receptor located in the rat esophageal tunica muscularis mucosae,H,,,10623,8,,CHEMBL619034,BAO_0000357,
3335,Autocuration,,,1,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae.,H,,,10623,8,,CHEMBL619035,BAO_0000357,
3336,Autocuration,,,1,,,In vitro 5-hydroxytryptamine 4 receptor activity by using carbachol-precontracted esophageal tunica muscularis mucosae; No activity up to 104M concentration,H,,,10623,8,,CHEMBL619036,BAO_0000357,
3337,Expert,10116.0,,1,,,Binding affinity (Ki+/-SEM) against 5-hydroxytryptamine 4 receptor from cheng Prusoff equation by using [3H]GR-113808 in rat striatum,D,,,10623,9,,CHEMBL619037,BAO_0000019,
3338,Autocuration,,,1,2435.0,,Binding affinity towards 5-HT 4 receptor in rat striatum membranes using [3H]GR-113808 as radioligand,H,,,10623,8,,CHEMBL619038,BAO_0000249,
3339,Autocuration,,,1,,,Binding affinity towards 5-HT4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand; Not tested,H,,,10623,8,,CHEMBL619039,BAO_0000249,
3340,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor was determined in rat striatal membranes using [3H]GR-113808 as radioligand,H,,,10623,8,,CHEMBL619040,BAO_0000249,
3341,Expert,10116.0,,1,2435.0,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,D,,,10623,9,,CHEMBL619041,BAO_0000019,
3342,Autocuration,,,1,2435.0,,Binding affinity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum,H,,,10623,8,,CHEMBL619042,BAO_0000019,
3343,Expert,,,1,2435.0,,Binding affinity to 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand in rat striatum membrane,H,,,10623,8,,CHEMBL619043,BAO_0000249,
3344,Expert,,,1,2435.0,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatum by [3H]GR-113808 displacement.,H,,,10623,8,,CHEMBL619044,BAO_0000019,
3345,Expert,,,1,2435.0,,In vitro affinity at serotonergic 5-hydroxytryptamine 4 receptor by radioligand binding assay using [3H]GR-113808 in rat striatum membranes.,H,,,10623,8,,CHEMBL619045,BAO_0000249,
3346,Expert,,,1,2435.0,,In vitro binding affinity to 5-hydroxytryptamine 4 receptor in rat striatum membrane,H,,,10623,8,,CHEMBL619046,BAO_0000249,
3347,Expert,,,1,,,Binding affinity at 5-hydroxytryptamine 4 receptor in rat striatal membranes by [3H]GR-113808 displacement.,H,,,10623,8,,CHEMBL619047,BAO_0000249,
3348,Autocuration,,,1,955.0,,Tested for potency against 5-hydroxytryptamine 4 receptor agonist in rat brain,H,,,10623,8,,CHEMBL619048,BAO_0000221,
3349,Autocuration,,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat,H,,,10623,8,,CHEMBL859398,BAO_0000019,
3350,Autocuration,,,1,,,Compound was evaluated for its antagonist affinity towards 5-hydroxytryptamine 4 receptor of rat; ND means not done,H,,,10623,8,,CHEMBL619049,BAO_0000019,
3351,Autocuration,,,1,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae,H,,,10623,8,,CHEMBL857886,BAO_0000019,
3352,Autocuration,,,1,,,5-hydroxytryptamine 4 receptor agonist activity in the rat esophageal muscularis mucosae; Not tested,H,,,10623,8,,CHEMBL619050,BAO_0000019,
3353,Autocuration,,,1,,,Antagonist activity against 5-hydroxytryptamine 4 receptor mediated relaxation of rat carbachol contracted esophageal muscularis mucosae,H,,,10623,8,,CHEMBL620591,BAO_0000019,
3354,Expert,10116.0,,1,,,Binding affinity against rat 5-hydroxytryptamine 4 receptor,D,,,10623,9,,CHEMBL620592,BAO_0000357,
3355,Expert,,,1,2435.0,,pKi against 5-hydroxytryptamine 4 receptor in rat striatum membrane,H,,,10623,8,,CHEMBL620593,BAO_0000249,
3356,Expert,10116.0,,1,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-5 M.,D,,,10623,9,,CHEMBL620594,BAO_0000019,
3357,Expert,,,1,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-6 M.,H,,,10623,8,,CHEMBL875079,BAO_0000019,
3358,Expert,,,1,,,Antagonistic activity by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,H,,,10623,8,,CHEMBL620595,BAO_0000019,
3359,Expert,10116.0,,1,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-8 M.,D,,,10623,9,,CHEMBL620596,BAO_0000019,
3360,Autocuration,,,1,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-7 M.,H,,,10623,8,,CHEMBL620597,BAO_0000019,
3361,Expert,,,1,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation (via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 3*10e-8 M.,H,,,10623,8,,CHEMBL620598,BAO_0000019,
3362,Expert,,,1,,,Antagonistic activity evaluated by ability to block serotonin induced relaxation via 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 0.1 mg/kg (p.o.),H,,,10623,8,,CHEMBL620599,BAO_0000218,
3363,Autocuration,,,1,,,Antagonistic activity of compound was evaluated by ability to block serotonin induced relaxation (mediated by activation of 5-hydroxytryptamine 4 receptor) in carbamylcholine (10e-6 M) contracted esophagus at a concentration of 10e-7 M.,H,,,10623,8,,CHEMBL620600,BAO_0000019,
3364,Autocuration,10116.0,,1,,,Estimate from relaxation of carbachol-contracted rat esophageal muscularis mucosae,H,,,168,8,,CHEMBL620601,BAO_0000019,
3365,Autocuration,,,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 4 receptor on guinea colon at a concentration 0.1 uM,H,,,168,8,,CHEMBL620602,BAO_0000019,
3366,Autocuration,,,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor,H,,,168,8,,CHEMBL620603,BAO_0000357,
3367,Autocuration,,,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor.,H,,,168,8,,CHEMBL620604,BAO_0000357,
3368,Autocuration,,,1,,,Compound was tested for 5-hydroxytryptamine 4 binding affinity,H,,,168,8,,CHEMBL620605,BAO_0000357,
3369,Autocuration,,,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 4 receptor,H,,,168,8,,CHEMBL620606,BAO_0000357,
3370,Autocuration,,,1,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,H,,,168,8,,CHEMBL620607,BAO_0000019,
3371,Autocuration,,,1,,,In vitro binding affinity towards 5-HT4 receptor was determined,H,,,168,8,,CHEMBL620608,BAO_0000357,
3372,Autocuration,,,1,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,H,,,168,8,,CHEMBL620609,BAO_0000019,
3373,Autocuration,,,1,,,Tested for agonist activity against 5-hydroxytryptamine 4 receptor,H,,,168,8,,CHEMBL620610,BAO_0000019,
3374,Autocuration,,,1,,,Tested for selectivity for 5-hydroxytryptamine 4 receptor,H,,,168,8,,CHEMBL620611,BAO_0000357,
3375,Autocuration,,,1,,,Tested for 5-hydroxytryptamine 4 binding affinity against cisapride,H,,,168,8,,CHEMBL620612,BAO_0000357,
3376,Autocuration,,,1,,,Tested for 5-hydroxytryptamine 4 binding affinity against renzapride,H,,,168,8,,CHEMBL620613,BAO_0000357,
3377,Autocuration,,,1,,,Tested for 5-hydroxytryptamine 4 binding affinity against zacopride,H,,,168,8,,CHEMBL620614,BAO_0000357,
3378,Expert,,,1,,,Binding affinity against 5-Hydroxytryptamine 4 receptor,H,,,168,8,,CHEMBL620615,BAO_0000357,
3379,Autocuration,,,1,,,Compound was evaluated for the displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 recognition sites in rat brain membranes,H,Brain membranes,,104698,6,,CHEMBL857075,BAO_0000249,
3380,Autocuration,,,1,,,Compound was evaluated for the displacement of [3H]Q-ICS-205-930 from 5-HT3 recognition sites in rat brain membranes,H,Brain membranes,,104698,6,,CHEMBL620616,BAO_0000249,
3381,Autocuration,,,1,,,Displacement of [3H]Q-ICS-205-930 from 5-hydroxytryptamine 3 receptor recognition sites in rat brain membranes,H,Brain membranes,,104698,6,,CHEMBL619411,BAO_0000249,
3382,Autocuration,,,1,,,Displacement of [3H]-Q-ICS 205-930 binding to 5-hydroxytryptamine 3 receptor from rat cortex homogenate,H,,,104698,6,,CHEMBL619412,BAO_0000019,
3383,Autocuration,10116.0,,1,,,Displacement of [3H]-Q-ICS 205-930 from rat cortex homogenate 5-hydroxytryptamine 3 receptor,D,,,104698,7,,CHEMBL619413,BAO_0000019,
3384,Autocuration,,,1,10000000.0,,Binding affinity of 5-hydroxytryptamine 3 receptor using [3H]granisetron in rat hippocampus and entorhinal cortex,H,,,104698,6,,CHEMBL619414,BAO_0000221,
3385,Autocuration,,,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]GR-65630 as radioligand in rat cortex,H,,,104698,6,,CHEMBL619415,BAO_0000019,
3386,Autocuration,,,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor using [3H]quipazine as radioligand in rat cortex,H,,,104698,6,,CHEMBL619416,BAO_0000019,
3387,Autocuration,,,1,,,Rat 5-hydroxytryptamine 3 receptor (5-HT3) antagonist,H,,,104698,6,,CHEMBL619417,BAO_0000019,
3388,Autocuration,10116.0,,1,,,Binding affinity against rat 5-hydroxytryptamine 3 receptor,D,,,104698,7,,CHEMBL619418,BAO_0000223,
3389,Autocuration,10116.0,,1,,,Binding affinity against 5-Hydroxytryptamine 3 receptor,D,,,104698,7,,CHEMBL619419,BAO_0000223,
3390,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of racemic [3H]zacopride from rat cortex,H,,,104698,6,,CHEMBL619420,BAO_0000019,
3391,Autocuration,,,1,,,Binding affinity to 5-hydroxytryptamine 3 receptor was determined in rat cerebro cortical membranes using [3H]quipazine.,H,,,104698,6,,CHEMBL619421,BAO_0000249,
3392,Autocuration,10116.0,,1,,,Displacement of [3H]granisetron from 5-hydroxytryptamine 3 receptor of rat cortex,D,,,104698,7,,CHEMBL619422,BAO_0000019,
3393,Autocuration,,,1,,,In vitro by displacement of [3H]LY-278584 from 5-hydroxytryptamine 3 receptor on rat entorhinal cortex,H,,,104698,6,,CHEMBL619423,BAO_0000019,
3394,Autocuration,,,1,,,Tested for its binding affinity by measuring its ability to displace [3H]granisetron from 5-hydroxytryptamine 3 receptor in rat cortex,H,,,104698,6,,CHEMBL875080,BAO_0000019,
3395,Autocuration,,,1,,,The binding affinity (pKi) measured against 5-hydroxytryptamine 1A receptor of rat cortex using [3H]8-OH-DPAT as radioligand,H,,,104698,6,,CHEMBL619424,BAO_0000019,
3396,Autocuration,,,1,,,Binding affinity at 5-hydroxytryptamine 3 receptor in rat cortical membrane by [3H]graniestron displacement.,H,,,104698,6,,CHEMBL619425,BAO_0000249,
3397,Autocuration,,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand,H,,,104698,6,,CHEMBL619426,BAO_0000223,
3398,Autocuration,,,1,,,The compound was tested for the binding affinity against 5-hydroxytryptamine 3 receptor using [3H]zacopride as radioligand.,H,,,104698,6,,CHEMBL619427,BAO_0000223,
3399,Autocuration,10116.0,,1,,,pKi value for inhibition of [3H]LY-278584 binding to 5-hydroxytryptamine 3 receptor,D,,,104698,7,,CHEMBL619645,BAO_0000223,
3400,Expert,,,1,,,"Compound was evaluated for binding affinity on 5-hydroxytryptamine 1A receptor in rat hippocampus membranes,3H-8-OH-DPAT and buspirone for nonspecific binding",D,,,10576,9,,CHEMBL619646,BAO_0000249,
3401,Autocuration,,,1,955.0,,Compound was tested for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat brain using [3H]zacopride as the radioligand.,H,,,12020,8,,CHEMBL619647,BAO_0000221,
3402,Autocuration,,,1,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor,H,,,12020,8,,CHEMBL619648,BAO_0000019,
3403,Autocuration,,,1,,,Compound was tested in vitro for its antagonistic activity against 5-hydroxytryptamine 3 receptor in rat CNS.,H,,,12020,8,,CHEMBL619165,BAO_0000019,
3404,Autocuration,,In vivo,1,,,Compound was evaluated in vivo for the antagonistic activity towards 5-hydroxytryptamine 3 receptor,H,,,12020,8,,CHEMBL620719,BAO_0000218,
3405,Autocuration,,,1,,,Compound was tested for its binding affinity towards 5-HT-3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,H,,,12020,8,,CHEMBL872924,BAO_0000019,
3406,Autocuration,,,1,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor,H,,,12020,8,,CHEMBL620720,BAO_0000357,
3407,Autocuration,,,1,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using (S)-[125I]-zacopride as the radioligand.,H,,,12020,8,,CHEMBL620721,BAO_0000019,
3408,Autocuration,,,1,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 3 receptor in whole rat brain using [125I]DAIZAC as the radioligand.,H,,,12020,8,,CHEMBL620722,BAO_0000019,
3409,Autocuration,,,1,,,"Concentration that inhibits the binding of radioligand, [3H]-ICS 205930, to 5-hydroxytryptamine 3 receptor from rat cortex",H,,,104698,6,,CHEMBL620723,BAO_0000019,
3410,Autocuration,,,1,,,In Vitro Binding affinity againist 5-hydroxytryptamine 3 receptor by displacing [3H]-Q-ICS 205-930 from rat cortex homogenates,H,,,12020,8,,CHEMBL620724,BAO_0000019,
3411,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 3 (5-HT3) receptor in rat brain cortical membranes using radioligand [3H]quipazine,H,,,104698,6,,CHEMBL620725,BAO_0000249,
3412,Autocuration,10116.0,,1,,,Antagonist activity (100 ug/kg) for the Bezold Jarisch reflex evoked by 30 (ug/Kg) of 5-hydroxytryptamine 3 receptor in ethylurethane anesthetized rats i.v.,D,,,12020,9,,CHEMBL620726,BAO_0000019,
3413,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,,,144,8,,CHEMBL620727,BAO_0000357,
3414,Autocuration,,,1,,,Compound was evaluated for 5-hydroxytryptamine 3 receptor binding,H,,,104714,4,,CHEMBL620728,BAO_0000223,
3415,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,U,,,22226,0,,CHEMBL620729,BAO_0000019,
3416,Autocuration,,,1,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity by inhibiting the 5-HT evoked Bezold-Jarisch reflex,H,,,104714,4,,CHEMBL858288,BAO_0000019,
3417,Autocuration,,,1,,,Compound was tested for binding affinity towards 5-hydroxytryptamine 3 receptor,H,,,104714,4,,CHEMBL620730,BAO_0000223,
3418,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,,,104714,4,,CHEMBL620731,BAO_0000223,
3419,Autocuration,10141.0,,1,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 0.3 uM,H,,,104714,4,,CHEMBL620732,BAO_0000019,
3420,Autocuration,10141.0,,1,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,H,,,104714,4,,CHEMBL618042,BAO_0000019,
3421,Autocuration,10141.0,,1,,,Compound was tested for antagonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 30 uM,H,,,104714,4,,CHEMBL618043,BAO_0000019,
3422,Autocuration,,,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,H,,,104714,4,,CHEMBL618044,BAO_0000223,
3423,Autocuration,,,1,,,Evaluated for the 5-hydroxytryptamine 3 receptor antagonistic activity in Bezold-Jarisch model expressed as inhibition of the reflex bradycardia induced by an intravenous injection,H,,,104714,4,,CHEMBL618045,BAO_0000019,
3424,Autocuration,,,1,,,Compound was measured for its binding affinity at 5-hydroxytryptamine 3 receptor at a concentration of 10 uM using [3H]BRL-43694 as radioligand,H,,,104714,4,,CHEMBL618046,BAO_0000223,
3425,Autocuration,,,1,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); A: agonist,H,,,104714,4,,CHEMBL618047,BAO_0000019,
3426,Autocuration,,,1,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: agonist,H,,,104714,4,,CHEMBL875084,BAO_0000019,
3427,Autocuration,,,1,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); ANT: antagonist,H,,,104714,4,,CHEMBL618048,BAO_0000019,
3428,Autocuration,,,1,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); NA means data not available,H,,,104714,4,,CHEMBL618049,BAO_0000223,
3429,Autocuration,,,1,,,Intrinsic activity towards 5-hydroxytryptamine 3 receptor was determined by Benzold-Jarisch reflex (peripheral assay); PA: Partial agonist,H,,,104714,4,,CHEMBL619764,BAO_0000019,
3430,Autocuration,,,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; A: agonist,H,,,104714,4,,CHEMBL619765,BAO_0000019,
3431,Autocuration,,,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; ANT: Antagonist,H,,,104714,4,,CHEMBL619766,BAO_0000019,
3432,Autocuration,,,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA: not active,H,,,104714,4,,CHEMBL619767,BAO_0000223,
3433,Autocuration,,,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; NA means data not available,H,,,104714,4,,CHEMBL619768,BAO_0000223,
3434,Autocuration,,,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; PA: Partial agonist,H,,,104714,4,,CHEMBL619769,BAO_0000019,
3435,Autocuration,,,1,,,Intrinsic activity towards CNS 5-hydroxytryptamine 3 receptor was determined; na means data not available,H,,,104714,4,,CHEMBL619770,BAO_0000223,
3436,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,,,104714,4,,CHEMBL619771,BAO_0000223,
3437,Autocuration,,,1,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor using [3H]-BRL-43694 (1 nM) ligand in NG cells 108-15 was determined,H,,,104714,4,,CHEMBL619772,BAO_0000219,
3438,Autocuration,,,1,,,Binding affinity of compound towards 5-hydroxytryptamine 3 receptor; NA: not active,H,,,104714,4,,CHEMBL619773,BAO_0000223,
3439,Autocuration,,,1,,,Binding affinity for 5-HT3 receptor of NG108-15 cells using [3H]GR-65630,H,,433.0,104714,4,,CHEMBL619774,BAO_0000219,
3440,Autocuration,,,1,,,Binding affinity to 5-HT3 serotonin receptor in NG 108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand.,H,,,104714,4,,CHEMBL875083,BAO_0000019,
3441,Autocuration,,,1,,,Binding affinity to 5-HT3 serotonin receptor in NG108-15 neuroblastoma glioma cells using [3H]GR-65630 radioligand,H,,433.0,104714,4,,CHEMBL620718,BAO_0000219,
3442,Autocuration,,,1,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,H,,,104714,4,,CHEMBL618127,BAO_0000223,
3443,Autocuration,,,1,,,Compound was tested for selectivity against 5-hydroxytryptamine 3 receptor binding affinity,H,,,104714,4,,CHEMBL618128,BAO_0000223,
3444,Autocuration,,In vitro,1,,,Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells,H,,,104714,4,,CHEMBL618129,BAO_0000219,
3445,Autocuration,,,1,,,In vitro Binding affinity towards 5-hydroxytryptamine 3 receptor was determined,H,,,104714,4,,CHEMBL618130,BAO_0000223,
3446,Autocuration,,,1,,,Tested for 5-hydroxytryptamine 3 receptor antagonist activity,H,,,104714,4,,CHEMBL618131,BAO_0000019,
3447,Autocuration,10141.0,,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 1 uM,H,,,104714,4,,CHEMBL618132,BAO_0000019,
3448,Autocuration,10141.0,,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM,H,,,104714,4,,CHEMBL618133,BAO_0000019,
3449,Autocuration,10141.0,,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 10 uM in the presence of 30 uM MDL 72222,H,,,104714,4,,CHEMBL618134,BAO_0000019,
3450,Autocuration,10141.0,,1,,,Compound was tested for agonistic activity against 5-hydroxytryptamine 3 receptor on guinea pig colon at a concentration of 3 uM,H,,,104714,4,,CHEMBL618135,BAO_0000019,
3451,Autocuration,,,1,,,Binding affinity for the 5-hydroxytryptamine 3 receptor was evaluated in vitro by examining its ability to displace [3H]-BRL 43694.,H,,,104714,4,,CHEMBL618136,BAO_0000223,
3452,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,,,104714,4,,CHEMBL618137,BAO_0000223,
3453,Autocuration,,,1,,,Compound was evaluated for binding affinity against 5-hydroxytryptamine 3 receptor using radioligand binding assay,H,,,104714,4,,CHEMBL618138,BAO_0000223,
3454,Autocuration,,,1,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 1,H,,,104714,4,,CHEMBL618139,BAO_0000223,
3455,Autocuration,,,1,,,Tested against 5-hydroxytryptamine 3 receptor in experiment 2,H,,,104714,4,,CHEMBL618140,BAO_0000223,
3456,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 3 receptor was measured using [3H]granisetron as radioligand,H,,,104714,4,,CHEMBL618141,BAO_0000223,
3457,Expert,,,1,,,Binding affinity for 5-hydroxytryptamine 2C receptor,H,,,108,8,,CHEMBL873478,BAO_0000357,
3458,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor,H,,,104698,6,,CHEMBL618142,BAO_0000223,
3459,Autocuration,,,1,,,Compound was evaluated for the affinity at 5-hydroxytryptamine 3 receptor,H,,,144,8,,CHEMBL618143,BAO_0000357,
3460,Autocuration,,,1,,,Compound was tested for its affinity towards 5-hydroxytryptamine 3 receptor,H,,,144,8,,CHEMBL618144,BAO_0000357,
3461,Autocuration,,,1,,,Inhibition of GR-65630 binding to 5-hydroxytryptamine 3 receptor,H,,,144,8,,CHEMBL618145,BAO_0000357,
3462,Autocuration,,,1,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,H,,,104714,4,,CHEMBL618146,BAO_0000223,
3463,Autocuration,,,1,,,Inhibition of [3H]-BRL 43 694 binding to 5-hydroxytryptamine 3 receptor of central nervous system,H,,,104714,4,,CHEMBL618147,BAO_0000223,
3464,Autocuration,,,1,,,Inhibition of [3H]- BRL 43 694 binding to 5-hydroxytryptamine 3 receptor at 10e-5 M,H,,,104714,4,,CHEMBL618148,BAO_0000223,
3465,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 3 receptor by displacement of [3H]2 in Neuroblastoma-Glioma NG-108-15 cells,H,,,144,8,,CHEMBL618149,BAO_0000019,
3466,Autocuration,,,1,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,H,,,144,8,,CHEMBL872927,BAO_0000357,
3467,Autocuration,,,1,,,Compound was evaluated for its binding affinity towards 5-hydroxytryptamine 3 receptor,H,,,144,8,,CHEMBL618150,BAO_0000357,
3468,Autocuration,,,1,,,Compound was tested for 5-hydroxytryptamine 3 receptor binding affinity,H,,,144,8,,CHEMBL618151,BAO_0000357,
3469,Autocuration,,,1,,,Compound was tested for its binding affinity for the 5-hydroxytryptamine 3 receptor,H,,,144,8,,CHEMBL875094,BAO_0000357,
3470,Autocuration,,,1,,,In vitro binding affinity for the 5-hydroxytryptamine 3 receptor was determined with NG-108-15 mouse neuroblastoma-glioma cells,H,,,144,8,,CHEMBL618152,BAO_0000019,
3471,Autocuration,,,1,,,In vitro binding affinity towards 5-hydroxytryptamine 3 receptor was determined,H,,,144,8,,CHEMBL618153,BAO_0000357,
3472,Autocuration,,,1,,,Inhibitory constant against 5-hydroxytryptamine 3 receptor using [3H]GR-65630 radioligand,H,,,144,8,,CHEMBL618888,BAO_0000357,
3473,Autocuration,,,1,,,Tested for 5-hydroxytryptamine 3 receptor agonist activity,H,,,144,8,,CHEMBL618889,BAO_0000019,
3474,Autocuration,,,1,,,The binding affinity towards 5-hydroxytryptamine 3 receptor; No affinity,H,,,144,8,,CHEMBL618890,BAO_0000357,
3475,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H](R)-zacopride from ondansetron-treated NG-108-15 cell membranes,H,,,144,8,,CHEMBL618891,BAO_0000019,
3476,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 3 receptor by displacement of [3H]-BRL 43694 from NG-108-15 cell membranes,H,,,144,8,,CHEMBL619054,BAO_0000019,
3477,Autocuration,,,1,,,Binding affinity against the 5-hydroxytryptamine 3 receptor,H,,,104714,4,,CHEMBL619055,BAO_0000223,
3478,Autocuration,,,1,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,H,,,144,8,,CHEMBL619056,BAO_0000357,
3479,Autocuration,,,1,,,Percent efficacy against 5-hydroxytryptamine 3A receptor,H,,,144,8,,CHEMBL619057,BAO_0000019,
3480,Autocuration,,,1,,,Binding affinity against human 5-hydroxytryptamine 3A receptor,H,,,144,8,,CHEMBL619058,BAO_0000357,
3481,Expert,10116.0,,1,,,Response at rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes,D,,,12020,9,,CHEMBL619059,BAO_0000219,
3482,Expert,10116.0,,1,,,Ability to block serotonin (30 uM)-evoked responses at rat 5HT3-alpha receptor expressed in xenopus oocytes,D,,,12020,9,,CHEMBL619060,BAO_0000219,
3483,Expert,10116.0,,1,,,Effect on rat 5-hydroxytryptamine 3a receptor expressed in xenopus oocytes at concentration up to 100 uM,D,,,12020,9,,CHEMBL875095,BAO_0000219,
3484,Intermediate,10141.0,,1,2116.0,,5-hydroxytryptamine 4 receptor agonist activity as percent maximum 5-HT effect in response to electrical stimulation in male guinea pig ileum,D,,,20033,9,,CHEMBL619061,BAO_0000221,
3485,Intermediate,10141.0,,1,2116.0,,5-hydroxytryptamine 4 receptor agonist activity expressed as the concentration which gave a 50% increase in the response to the electrical stimulation in male guinea pig ileum,D,,,20033,9,,CHEMBL619062,BAO_0000221,
3486,Intermediate,10141.0,,1,,,5-hydroxytryptamine 4 receptor agonist activity is expressed as percent of the maximum 5-HT response,D,,,20033,9,,CHEMBL619063,BAO_0000019,
3487,Intermediate,10141.0,,1,2116.0,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in electrically stimulated longitudinal muscle preparation of guinea pig ileum,D,,,20033,9,,CHEMBL619064,BAO_0000221,
3488,Intermediate,10141.0,,1,,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in guinea pig distal colon preparation,D,,,20033,9,,CHEMBL619065,BAO_0000357,
3489,Intermediate,10141.0,,1,2116.0,,Tested for affinity towards 5-hydroxytryptamine 4 receptor in isolated guinea pig ileum longitudinal muscle preparation,D,,,20033,9,,CHEMBL619066,BAO_0000221,
3490,Autocuration,,,1,2116.0,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,H,,,10209,8,,CHEMBL619775,BAO_0000221,
3491,Autocuration,,,1,,,Affinity against 5-hydroxytryptamine 7 receptor,H,,,10209,8,,CHEMBL619776,BAO_0000357,
3492,Autocuration,10141.0,,1,,,Ability to displace [3H]5-HT binding from 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,H,,,104841,4,,CHEMBL619777,BAO_0000224,
3493,Autocuration,10141.0,,1,,,Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand,H,,,104841,4,,CHEMBL619778,BAO_0000224,
3494,Autocuration,10141.0,,1,2116.0,,Evaluated for inhibition of 5-hydroxytryptamine receptor on guinea pig ileum at 10 uM; No effect,H,,,104841,4,,CHEMBL619779,BAO_0000221,
3495,Autocuration,10141.0,,1,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor site using 1 uM LSD as masking ligand, activity is expressed as Kd.",H,,,104841,4,,CHEMBL619780,BAO_0000224,
3496,Autocuration,10141.0,,1,,,"Ability to displace [3H]5-HT binding to 5-hydroxytryptamine receptor using 1 uM LSD as masking ligand, activity is expressed as Kd.",H,,,104841,4,,CHEMBL619166,BAO_0000224,
3497,Autocuration,10141.0,,1,,,5-HT level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,H,,,104841,4,,CHEMBL619167,BAO_0000019,
3498,Autocuration,10141.0,,1,,,5-hydroxytryptamine level in K+ induced 5-hydroxytryptamine release in guinea pig cortex.,H,,,104841,4,,CHEMBL619168,BAO_0000019,
3499,Expert,9606.0,,1,2081.0,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor in the presence of 10 nM compound in isolated human atrial myocytes,D,,,168,9,,CHEMBL619169,BAO_0000219,
3500,Expert,9606.0,,1,2081.0,,Concentration required to produce half-maximal response against 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes,D,,,168,9,,CHEMBL619170,BAO_0000219,
3501,Autocuration,9606.0,,1,,,"Maximum stimulation of [35S]GTP-gamma-S, binding expressed relative to the maximal effect of 5-hydroxytryptamine",D,,,104841,5,,CHEMBL619171,BAO_0000019,
3502,Expert,9606.0,,1,2081.0,,",Antagonism of stimulation of 5-hydroxytryptamine receptor on the L-type calcium current (I Ca) in isolated human atrial myocytes",D,,,168,9,,CHEMBL619172,BAO_0000219,
3503,Autocuration,10090.0,,1,,,Ability (10 ug/kg) to inhibit binding of [125I]iododexetimide to 5-hydroxytryptamine receptor in mice,U,,,22226,0,,CHEMBL619173,BAO_0000019,
3504,Autocuration,10090.0,,1,,,Percent inhibition of radioligand [3H]-LSD binding to 5-HT receptor at 10 uM concentration,U,,,22226,0,,CHEMBL619174,BAO_0000019,
3505,Autocuration,,,1,,,5-hydroxytryptamine receptor binding affinity was determined in rats,H,,,104705,4,,CHEMBL619175,BAO_0000019,
3506,Autocuration,,,1,,,Binding affinity at rat 5-hydroxytryptamine receptor.,H,,,104705,4,,CHEMBL619176,BAO_0000224,
3507,Autocuration,,,1,,,Affinity against 5-hydroxytryptamine receptors in rat fundus model,H,,,104705,4,,CHEMBL619177,BAO_0000019,
3508,Autocuration,,,1,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation,H,,,104705,4,,CHEMBL619178,BAO_0000224,
3509,Autocuration,,,1,,,Affinity for 5-hydroxytryptamine receptor was determined using male Dawley rat fundus preparation; Not determined,H,,,104705,4,,CHEMBL619179,BAO_0000224,
3510,Autocuration,,,1,945.0,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation,H,,,104705,4,,CHEMBL619180,BAO_0000019,
3511,Autocuration,,,1,945.0,,Antagonistic activity against serotonin 5-HT receptor obtained from rat stomach fundus preparation (resulted in discoloration in the oxygenated muscle bath to give varying results).,H,,,104705,4,,CHEMBL619181,BAO_0000019,
3512,Autocuration,,,1,,,Antagonistic activity of corresponding methoxy compound against serotonin 5-HT receptor,H,,,104705,4,,CHEMBL619182,BAO_0000019,
3513,Autocuration,,,1,,,Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2,H,,,104705,4,,CHEMBL619183,BAO_0000224,
3514,Autocuration,,,1,,,"Compound was evaluated for binding affinity towards 5-hydroxytryptamine receptor in isolated rat fundus preparation measured as pA2; Valid pA2, can not be determined because of slope of Schild plot.",H,,,104705,4,,CHEMBL619184,BAO_0000224,
3515,Autocuration,,,1,10000000.0,,In vitro affinity towards 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT as radioligand in hippocampus,H,,,10576,8,,CHEMBL619185,BAO_0000221,
3516,Expert,,,1,,,Binding affinity for rat 5-hydroxytryptamine transporter.,H,,,12198,8,,CHEMBL619186,BAO_0000357,
3517,Autocuration,,,1,,,Evaluated for inhibition of specific [3H]5-HT receptor binding in rat cortex.,H,,,104705,4,,CHEMBL619187,BAO_0000019,
3518,Autocuration,10116.0,,1,,,Binding affinity at serotonin 5-HT1-type site receptor in rat cortex by displacing [3H]5-HT,D,,,104705,5,,CHEMBL619188,BAO_0000019,
3519,Autocuration,10116.0,,1,,,Compound was tested for its inhibitory activity against 5-hydroxytryptamine receptor,D,,,104705,5,,CHEMBL619189,BAO_0000224,
3520,Expert,10116.0,,1,955.0,,Inhibitory activity against [3H]- 5-hydroxytryptamine reuptake in whole rat brain minus cerebellum,D,,,12198,9,,CHEMBL619190,BAO_0000019,
3521,Expert,10116.0,,1,2037.0,,Inhibition of [3H]5-HT reuptake in whole rat brain (minus cerebellum) homogenate.,D,,,12198,9,,CHEMBL619191,BAO_0000221,
3522,Autocuration,10116.0,,1,,,Displacement of [3H]-citalopram from rat forebrain membrane 5-hydroxytryptamine receptor at 10e-7 M,D,,,104705,5,,CHEMBL619192,BAO_0000019,
3523,Autocuration,10116.0,,1,,,Percent binding affinity against 5-hydroxytryptamine receptor,D,,,104705,5,,CHEMBL619193,BAO_0000224,
3524,Autocuration,,,1,,,Ability to displace 0.4 nM [3H]paroxetine binding to 5-hydroxytryptamine receptor in rat frontal cortex,U,,,22226,0,,CHEMBL619194,BAO_0000019,
3525,Autocuration,10116.0,,1,,,The binding affinity was measured on 5-hydroxytryptamine receptor uptake receptor using [3H]- paroxetine as radioligand.,D,,,104705,5,,CHEMBL619195,BAO_0000224,
3526,Autocuration,10116.0,,1,,,Affinity against 5-hydroxytryptamine receptor was determined,D,,,104705,5,,CHEMBL619196,BAO_0000224,
3527,Autocuration,10116.0,,1,945.0,,Affinity against 5-hydroxytryptamine receptor was determined in rat stomach fundus strip,D,,,104705,5,,CHEMBL619197,BAO_0000019,
3528,Expert,9606.0,In vitro,1,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,D,,,121,9,,CHEMBL619198,BAO_0000219,
3529,Expert,9606.0,In vitro,1,,,Inhibition of [3H]5-HT uptake in HEK cells expressing human SERT,D,,,121,9,,CHEMBL875081,BAO_0000219,
3530,Autocuration,,,1,,,Ability to compete with radioactive ligands specific to the Serotonergic 5-HT receptor at 10 uM; NA means compound failed to compete,H,,,18065,8,,CHEMBL884712,BAO_0000357,
3531,Expert,,,1,,,Inhibition of 5-hydroxytryptamine reuptake,H,,,121,8,,CHEMBL884710,BAO_0000357,
3532,Autocuration,,,1,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding",H,,,18065,8,,CHEMBL619199,BAO_0000019,
3533,Autocuration,,,1,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 1)",H,,,18065,8,,CHEMBL619200,BAO_0000019,
3534,Autocuration,,,1,,,"Receptor-linked G protein activation at 5-hydroxytryptamine receptor was determined by measuring the stimulation of [35S]GTP-gamma-S, binding (Experiment 2)",H,,,18065,8,,CHEMBL619201,BAO_0000019,
3535,Autocuration,,,1,,,Tested for 5-hydroxytryptamine receptor uptake,H,,,18065,8,,CHEMBL619202,BAO_0000019,
3536,Expert,9606.0,,1,,,Affinity constant on CHO cells expressing Human recombinant 5-hydroxytryptamine receptor 1A,D,,449.0,51,9,,CHEMBL619203,BAO_0000219,
3537,Expert,9606.0,,1,,,Antagonistic affinity tested against isolated human cloned alpha-1d adrenoceptor subtype,D,,,51,9,,CHEMBL619204,BAO_0000019,
3538,Autocuration,9606.0,,1,,,In vitro binding affinity towards 5-hydroxytryptamine receptor 1A receptor by using [3H]8-OH-DPAT in rat hippocampal membranes.,H,,,10576,8,,CHEMBL619205,BAO_0000249,
3539,Autocuration,,,1,,,Tested in vitro for % inhibition against 5-hydroxytryptamine receptor 1A,H,,,10576,8,,CHEMBL619206,BAO_0000357,
3540,Expert,,,1,,,In vitro binding affinity at 5-hydroxytryptamine receptor 1A receptor in rat hippocampal membranes by [3H]8-OH-DPAT displacement.,H,,,10576,8,,CHEMBL619207,BAO_0000249,
3541,Autocuration,,,1,2435.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 0.10 umol/kg,H,,,10825,8,,CHEMBL619208,BAO_0000019,
3542,Autocuration,,,1,2435.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats corpus striatum at a dosage of 10 umol/kg,H,,,10825,8,,CHEMBL619209,BAO_0000019,
3543,Autocuration,,,1,2435.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 0.32 umol/kg,H,,,10825,8,,CHEMBL619210,BAO_0000019,
3544,Autocuration,,,1,2435.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 3.2 umol/kg,H,,,10825,8,,CHEMBL619211,BAO_0000019,
3545,Autocuration,,,1,2435.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP in rats in corpus striatum at a dosage of 32 umol/kg,H,,,10825,8,,CHEMBL619212,BAO_0000019,
3546,Autocuration,,,1,2435.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 0.032 umol/kg,H,,,10825,8,,CHEMBL620681,BAO_0000019,
3547,Autocuration,,,1,2435.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 1.0 umol/kg,H,,,10825,8,,CHEMBL620682,BAO_0000019,
3548,Autocuration,,,1,2435.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 10 umol/kg,H,,,10825,8,,CHEMBL620683,BAO_0000019,
3549,Autocuration,,,1,2435.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 100 umol/kg,H,,,10825,8,,CHEMBL620684,BAO_0000019,
3550,Autocuration,,,1,2435.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 3.2 umol/kg,H,,,10825,8,,CHEMBL620685,BAO_0000019,
3551,Autocuration,,,1,2435.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in corpus striatum at a dosage of 32 umol/kg,H,,,10825,8,,CHEMBL620686,BAO_0000019,
3552,Autocuration,,,1,349.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.032 umol/kg,H,,,10825,8,,CHEMBL620687,BAO_0000019,
3553,Autocuration,,,1,349.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,H,,,10825,8,,CHEMBL620688,BAO_0000019,
3554,Autocuration,,,1,349.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.32 umol/kg,H,,,10825,8,,CHEMBL620689,BAO_0000019,
3555,Autocuration,,,1,349.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 1.0 umol/kg,H,,,10825,8,,CHEMBL620690,BAO_0000019,
3556,Autocuration,,,1,349.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 10 umol/kg,H,,,10825,8,,CHEMBL620691,BAO_0000019,
3557,Autocuration,,,1,349.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 100 umol/kg,H,,,10825,8,,CHEMBL620692,BAO_0000019,
3558,Autocuration,,,1,349.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 3.2 umol/kg,H,,,10825,8,,CHEMBL620693,BAO_0000019,
3559,Expert,,,1,,,Binding affinity against 5-hydroxytryptamine 4 receptor,H,,,168,8,,CHEMBL620694,BAO_0000357,
3560,Autocuration,,,1,,,Tested for 5-hydroxytryptamine 4 receptor antagonist activity,H,,,168,8,,CHEMBL857986,BAO_0000019,
3561,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 as radioligand at 10e-5 M concentration,H,,,168,8,,CHEMBL620695,BAO_0000357,
3562,Expert,,,1,,,Binding affinity towards Serotonin 5-hydroxytryptamine 4 receptor,H,,,168,8,,CHEMBL620696,BAO_0000357,
3563,Autocuration,,,1,,,Inhibitory constant against 5-hydroxytryptamine 4 receptor using [3H]GR-113808 radioligand,H,,,168,8,,CHEMBL620697,BAO_0000357,
3564,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor,H,,,168,8,,CHEMBL620698,BAO_0000357,
3565,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,H,,,168,8,,CHEMBL620699,BAO_0000357,
3566,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 4 receptor; ND means no data.,H,,,168,8,,CHEMBL620700,BAO_0000357,
3567,Autocuration,,,1,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4A receptor isoform expressed in COS-7 cells,H,,643.0,168,8,,CHEMBL620701,BAO_0000219,
3568,Autocuration,,,1,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4B receptor isoform expressed in COS-7 cells,H,,643.0,168,8,,CHEMBL875082,BAO_0000219,
3569,Autocuration,,,1,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4C receptor isoform expressed in COS-7 cells,H,,643.0,168,8,,CHEMBL620702,BAO_0000219,
3570,Autocuration,,,1,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4D receptor isoform expressed in COS-7 cells,H,,643.0,168,8,,CHEMBL620703,BAO_0000219,
3571,Autocuration,,,1,,,Binding affinity of compound towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,H,,673.0,168,8,,CHEMBL620704,BAO_0000219,
3572,Expert,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand,H,,673.0,168,8,,CHEMBL620705,BAO_0000219,
3573,Expert,,,1,,,Binding affinity was determined against cloned 5-hydroxytryptamine 4E receptor isoform expressed in C6 glial cells incubated with 0.2 nM [3H]GR-113808,H,,673.0,168,8,,CHEMBL620706,BAO_0000219,
3574,Expert,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 4E receptor expressed in C6 glial cells using [3H]GR-113808 as radioligand; Not determined,H,,673.0,168,8,,CHEMBL620707,BAO_0000219,
3575,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 5 receptor,H,,,10624,8,,CHEMBL620708,BAO_0000357,
3576,Autocuration,,,1,,,Inhibitory constant against human 5-hydroxytryptamine 5A receptor using [3H]LSD radioligand,H,,,105,8,,CHEMBL620709,BAO_0000357,
3577,Expert,9606.0,,1,,,Binding affinity against 5-hydroxytryptamine 5A receptor,D,,,10624,9,,CHEMBL620710,BAO_0000357,
3578,Autocuration,,,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned human 5-hydroxytryptamine 5A receptor stably expressed in CHO cells,H,,449.0,10624,8,,CHEMBL620711,BAO_0000219,
3579,Expert,9606.0,,1,,,Affinity towards human 5-hydroxytryptamine 5A serotonin receptor,D,,,10624,9,,CHEMBL620712,BAO_0000357,
3580,Expert,9606.0,,1,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor,D,,,10624,9,,CHEMBL620713,BAO_0000357,
3581,Expert,9606.0,,1,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor was evaluated using [3H]-5-CT as radioligand,D,,,10624,9,,CHEMBL620714,BAO_0000357,
3582,Expert,9606.0,,1,,,Binding affinity to cloned human 5-hydroxytryptamine 5A receptor,D,,,10624,9,,CHEMBL620715,BAO_0000357,
3583,Autocuration,,,1,,,Binding affinity towards 5-HT5A receptor,H,,,10624,8,,CHEMBL620716,BAO_0000357,
3584,Expert,,,1,,,Binding affinity towards human 5-hydroxytryptamine 5A receptor using LSD as radioligand,H,,,10624,8,,CHEMBL620717,BAO_0000357,
3585,Autocuration,,,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 5A receptor,H,,,10624,8,,CHEMBL618072,BAO_0000357,
3586,Autocuration,,,1,,,Binding affinity towards cloned human 5-HT5A receptor was determined,H,,,10624,8,,CHEMBL857987,BAO_0000357,
3587,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,,722.0,10624,8,,CHEMBL618073,BAO_0000219,
3588,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 5A receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,H,,722.0,10624,8,,CHEMBL618074,BAO_0000219,
3589,Autocuration,,,1,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 5A receptor (using human cloned receptors in HEK 293 and [3H]5-CTas a radioligand ),H,,722.0,10624,8,,CHEMBL618075,BAO_0000219,
3590,Expert,10090.0,,1,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor,D,,,10625,9,,CHEMBL618076,BAO_0000357,
3591,Expert,10090.0,,1,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [125I]-2-iodo LSD as radioligand,D,,,10625,9,,CHEMBL618077,BAO_0000357,
3592,Expert,10090.0,,1,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]- LSD as radioligand,D,,,10625,9,,CHEMBL618078,BAO_0000357,
3593,Expert,10090.0,,1,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor was evaluated using [3H]LSD as radioligand,D,,,10625,9,,CHEMBL881821,BAO_0000357,
3594,Expert,10090.0,,1,,,Binding affinity towards murine 5-hydroxytryptamine 5A receptor,D,,,10625,9,,CHEMBL618079,BAO_0000357,
3595,Expert,,,1,,,Binding affinity towards mouse 5-hydroxytryptamine 5A receptor using LSD as radioligand,H,,,10625,8,,CHEMBL618080,BAO_0000357,
3596,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,H,,722.0,10576,8,,CHEMBL618081,BAO_0000219,
3597,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 5A receptor in HEK 293 cells was determined using [3H]LSD as radioligand,H,,722.0,10626,8,,CHEMBL618082,BAO_0000219,
3598,Expert,,,1,,,Binding affinity towards 5-HT5a receptor,H,,,10624,8,,CHEMBL618083,BAO_0000357,
3599,Expert,9606.0,,1,,,Binding affinity towards 5-hydroxytryptamine 5A receptor,D,,,10624,9,,CHEMBL618084,BAO_0000357,
3600,Expert,,,1,,,Binding affinity for rodent 5-hydroxytryptamine 5A receptor,H,,,10624,8,,CHEMBL618085,BAO_0000357,
3601,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 5A receptor using lysergic acid diethylamide (LSD) as radioligand,H,,,10624,8,,CHEMBL618086,BAO_0000357,
3602,Autocuration,,,1,,,Binding affinities against 5-hydroxytryptamine 5A receptor,H,,,10624,8,,CHEMBL875092,BAO_0000357,
3603,Autocuration,,,1,,,Binding affinities towards 5-hydroxytryptamine 5A receptor,H,,,10624,8,,CHEMBL618087,BAO_0000357,
3604,Autocuration,,,1,,,The binding affinity towards 5-hydroxytryptamine 5A receptor; No affinity,H,,,10624,8,,CHEMBL872926,BAO_0000357,
3605,Autocuration,10141.0,,1,,,Percent of control response to 5-HT3 agonistic activity on guinea colon at a concentration 0.01 uM,H,,,104714,4,,CHEMBL618088,BAO_0000019,
3606,Autocuration,,,1,,,Binding affinity towards 5-HT3 receptor by the displacement of [3H]GR-65630] in human recombinant receptors in mammalian cell,H,,,104714,4,,CHEMBL618089,BAO_0000223,
3607,Expert,9606.0,,1,,,Inhibition of human 5-hydroxytryptamine 6 receptor,D,,,10627,9,,CHEMBL618090,BAO_0000357,
3608,Expert,9606.0,,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor using [3H]- LSD as radioligand,D,,,10627,9,,CHEMBL618091,BAO_0000357,
3609,Autocuration,,,1,,,Inhibition against human 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL618092,BAO_0000357,
3610,Expert,9606.0,,1,,,Affinity towards human 5-hydroxytryptamine 6 serotonin receptor,D,,,10627,9,,CHEMBL618093,BAO_0000357,
3611,Expert,,,1,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells.,H,,308.0,10627,8,,CHEMBL618094,BAO_0000219,
3612,Expert,9606.0,,1,,,Binding affinity towards [3H]LSD-labeled human 5-hydroxytryptamine 6 receptor,D,,,10627,9,,CHEMBL618095,BAO_0000357,
3613,Expert,9606.0,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,D,,,10627,9,,CHEMBL875093,BAO_0000357,
3614,Expert,9606.0,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [125I]-2-iodo LSD as radioligand,D,,,10627,9,,CHEMBL618096,BAO_0000357,
3615,Expert,9606.0,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor was evaluated using [3H]-LSD as radioligand,D,,,10627,9,,CHEMBL618118,BAO_0000357,
3616,Expert,9606.0,,1,,,Binding affinity against 5-hydroxytryptamine 6 receptor,D,,,10627,9,,CHEMBL618119,BAO_0000357,
3617,Expert,,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL618120,BAO_0000357,
3618,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL618121,BAO_0000357,
3619,Expert,,,1,,,"Binding affinity for human 5-hydroxytryptamine 6 receptor expressed in HEK 293 human embryonic kidney cells, [3H]-lysergic acid diethylamide as radioligand",H,,722.0,10627,8,,CHEMBL618122,BAO_0000219,
3620,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor using [3H]LSD as radioligand,H,,,10627,8,,CHEMBL618123,BAO_0000357,
3621,Expert,,,1,,,Binding affinity against human 5-hydroxytryptamine 6 receptor stably transfected to HEK 293 human embryonic kidney cells using [3H]-lysergic acid diethylamide as radioligand,H,,722.0,10627,8,,CHEMBL618124,BAO_0000219,
3622,Autocuration,,,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL618125,BAO_0000357,
3623,Expert,9606.0,,1,,,Displacement of [3H]LSD from human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,D,,722.0,10627,9,,CHEMBL618126,BAO_0000219,
3624,Expert,,,1,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD,H,,,10627,8,,CHEMBL618236,BAO_0000019,
3625,Expert,,,1,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 6 receptor incubated with 1 nM [3H]LSD; ND is No Data.,H,,,10627,8,,CHEMBL618237,BAO_0000019,
3626,Expert,,,1,,,Ability to displace [3H]LSD from human 5-hydroxytryptamine 6 receptor transiently expressed in COS-7 cells,H,,643.0,10627,8,,CHEMBL618238,BAO_0000219,
3627,Expert,9606.0,,1,,,In vitro binding affinity to human 5-hydroxytryptamine 6 receptor,D,,,10627,9,,CHEMBL618239,BAO_0000357,
3628,Autocuration,,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL618240,BAO_0000019,
3629,Autocuration,,,1,,,Inhibitory constant against human 5-hydroxytryptamine 6 receptor using [3H]LSD radioligand,H,,,10627,8,,CHEMBL618241,BAO_0000357,
3630,Autocuration,,,1,,,Antagonism assessed in a functional cAMP binding assay using 5-CT to stimulate human 5-hydroxytryptamine 6 receptor expressed in HEK 293 cells,H,,722.0,10627,8,,CHEMBL859399,BAO_0000219,
3631,Autocuration,,,1,,,The compound was tested for antagonist activity by inhibition of human 5-HT6 stimulated adenylate cyclase,H,,,10627,8,,CHEMBL618242,BAO_0000019,
3632,Autocuration,,,1,,,Ability to displace the radioligand [3H]LSD from human 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL857991,BAO_0000357,
3633,Expert,,,1,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL619951,BAO_0000357,
3634,Expert,9606.0,,1,,,Binding affinity to human cloned 5-HT6 receptor in HeLa cells using [3H]- LSD as radioligand,D,,308.0,10627,9,,CHEMBL619952,BAO_0000219,
3635,Expert,9606.0,,1,,,Binding affinity to human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]- LSD as radioligand,D,,308.0,10627,9,,CHEMBL619953,BAO_0000219,
3636,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells,H,,308.0,10627,8,,CHEMBL619954,BAO_0000219,
3637,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,H,,308.0,10627,8,,CHEMBL619955,BAO_0000219,
3638,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 6 human cloned receptors in HeLa cells using [3H]LSD as radioligand,H,,308.0,10627,8,,CHEMBL619956,BAO_0000219,
3639,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in CHO cells using [3H]5-HT as radioligand,H,,449.0,10627,8,,CHEMBL619957,BAO_0000219,
3640,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand.,H,,722.0,10627,8,,CHEMBL619958,BAO_0000219,
3641,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand; ND means no data.,H,,722.0,10627,8,,CHEMBL620627,BAO_0000219,
3642,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HEK 293 cells using [3H]mesulergine as radioligand;ND means no data.,H,,722.0,10627,8,,CHEMBL620628,BAO_0000219,
3643,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor (human cloned receptor) in HeLa cells using [3H]LSD as radioligand;ND means no data.,H,,308.0,10627,8,,CHEMBL620629,BAO_0000219,
3644,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL620630,BAO_0000357,
3645,Autocuration,,,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 6 receptor expressed in HeLa cells using [3H]LSD as radioligand,H,,308.0,10627,8,,CHEMBL620782,BAO_0000219,
3646,Autocuration,,,1,,,Compound was evaluated for its ability to displace [3H]LSD binding from human recombinant 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL620783,BAO_0000357,
3647,Expert,,,1,,,Binding affinity against human 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL620784,BAO_0000357,
3648,Expert,,,1,,,Binding affinity against human cloned 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]LSD,H,,308.0,10627,8,,CHEMBL620785,BAO_0000219,
3649,Autocuration,,,1,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 6 receptor (using human cloned receptors in HeLa and [3H]LSD as a radioligand ),H,,,10627,8,,CHEMBL857992,BAO_0000357,
3650,Autocuration,,,1,,,In vitro binding affinity at human recombinant 5-hydroxytryptamine 6 receptor in mammalian cells using 3[H]LSD as the radioligand,H,,,10627,8,,CHEMBL620786,BAO_0000219,
3651,Autocuration,,,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 6 receptor in HeLa cells using [3H]5-LSD.,H,,308.0,10627,8,,CHEMBL620787,BAO_0000219,
3652,Autocuration,,,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=3",H,,308.0,10627,8,,CHEMBL620788,BAO_0000219,
3653,Autocuration,,,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]5-LSD as radioligand; n=9",H,,308.0,10627,8,,CHEMBL620789,BAO_0000219,
3654,Autocuration,,,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 6 receptor in HeLa cells, using [3H]LSD as radioligand; n=3",H,,308.0,10627,8,,CHEMBL620790,BAO_0000219,
3655,Autocuration,,,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 6 receptor stably expressed in CHO cells,H,,449.0,10628,8,,CHEMBL620791,BAO_0000219,
3656,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 6 receptor from CHO cell membranes using [3H]5-HT as the radioligand.,H,,,10628,8,,CHEMBL620792,BAO_0000019,
3657,Autocuration,,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 6 receptor,H,,,10628,8,,CHEMBL620793,BAO_0000357,
3658,Autocuration,,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor was determined,H,,,10628,8,,CHEMBL620794,BAO_0000357,
3659,Autocuration,9606.0,,1,,,Binding affinity as displacement of [3H]5-HT binding to 5-hydroxytryptamine 6 receptor in HeLa cells,D,,308.0,10627,9,,CHEMBL620795,BAO_0000219,
3660,Expert,,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL620796,BAO_0000357,
3661,Autocuration,,,1,,,Percentage of displacement at 5-hydroxytryptamine 6 receptor at 10e-8 M,H,,,10627,8,,CHEMBL620797,BAO_0000357,
3662,Expert,9606.0,,1,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,D,,,10627,9,,CHEMBL620798,BAO_0000019,
3663,Autocuration,,,1,,,Inhibition of binding towards 5-hydroxytryptamine 6 receptor at 100 nM concentration,H,,,10627,8,,CHEMBL620799,BAO_0000357,
3664,Expert,,,1,,,Binding affinity towards human 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL620800,BAO_0000357,
3665,Autocuration,,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 6 receptor; inactive at 10 uM,H,,,10627,8,,CHEMBL620801,BAO_0000357,
3666,Autocuration,,,1,,,Compound was tested for its binding affinity towards 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL875100,BAO_0000357,
3667,Autocuration,,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 6 receptor was determined,H,,,10627,8,,CHEMBL620802,BAO_0000357,
3668,Expert,,,1,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL620803,BAO_0000019,
3669,Expert,,,1,,,Antagonistic activity towards 5-hydroxytryptamine 6 receptor was evaluated in cAMP assay,H,,,10627,8,,CHEMBL620804,BAO_0000019,
3670,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 6 receptor was determined,H,,,10627,8,,CHEMBL620805,BAO_0000357,
3671,Autocuration,,,1,,,Evaluated for the binding affinity towards 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL620806,BAO_0000357,
3672,Autocuration,,,1,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-6 M,H,,,10627,8,,CHEMBL620807,BAO_0000357,
3673,Autocuration,,,1,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 6 receptor at concentration of 10e-8 M,H,,,10627,8,,CHEMBL620808,BAO_0000357,
3674,Autocuration,,,1,,,Binding affinities against 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL620809,BAO_0000357,
3675,Autocuration,,,1,,,Binding affinities towards 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL620810,BAO_0000357,
3676,Expert,9606.0,,1,,,Binding affinity towards 5-hydroxytryptamine 6 receptor,D,,,10627,9,,CHEMBL620811,BAO_0000357,
3677,Autocuration,,,1,,,The binding affinity towards 5-hydroxytryptamine 6 receptor; No affinity,H,,,10627,8,,CHEMBL620812,BAO_0000357,
3678,Autocuration,,,1,,,Affinity against 5-hydroxytryptamine 6 receptor,H,,,10627,8,,CHEMBL620813,BAO_0000357,
3679,Autocuration,,,1,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-CT],H,,,10627,8,,CHEMBL620814,BAO_0000357,
3680,Expert,9606.0,,1,,,Inhibition of human 5-hydroxytryptamine 7 receptor,D,,,10209,9,,CHEMBL620815,BAO_0000357,
3681,Autocuration,,,1,,,Compound was tested for its binding affinity towards human 5-hydroxytryptamine 7 receptor from HEK293 cells using radioligand [3H]LSD,H,,722.0,10209,8,,CHEMBL620816,BAO_0000219,
3682,Autocuration,,,1,,,Compound at 1 uM was tested for the inhibition of radioligand [3H]LSD binding to recombinant human 5-hydroxytryptamine 7 receptor,H,,,10209,8,,CHEMBL620817,BAO_0000357,
3683,Autocuration,,,1,,,In vitro binding affinity against human 5-hydroxytryptamine 7 receptor at a concentration of 100 (nM),H,,,10209,8,,CHEMBL620818,BAO_0000357,
3684,Expert,,,1,,,Inhibition (at 1 uM) of radioligand [3H]LSD binding to human 5-hydroxytryptamine 7 receptor on HEK293 cells,H,,722.0,10209,8,,CHEMBL620819,BAO_0000219,
3685,Expert,9606.0,,1,,,Affinity towards human 5-hydroxytryptamine 7 serotonin receptor,D,,,10209,9,,CHEMBL620820,BAO_0000357,
3686,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 7 receptor human cloned receptors in CHO cells using [3H]5-HT,H,,449.0,10209,8,,CHEMBL620821,BAO_0000219,
3687,Expert,9606.0,,1,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,D,,,10209,9,,CHEMBL620822,BAO_0000357,
3688,Expert,9606.0,,1,,,Displacement of [3H]5-HT from human 5-hydroxytryptamine 7 receptor,D,,,10209,9,,CHEMBL620823,BAO_0000357,
3689,Expert,9606.0,,1,,,Binding affinity against 5-hydroxytryptamine 7 receptor,D,,,10209,9,,CHEMBL620824,BAO_0000357,
3690,Expert,,,1,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor by the displacement of [3H]-5-HT radioligand from the cloned receptor expressed in CHO cells,H,,449.0,10209,8,,CHEMBL620825,BAO_0000219,
3691,Autocuration,,,1,,,Binding affinity towards recombinant human 5-hydroxytryptamine 7 receptor was determined using [3H]LSD as radioligand,H,,,10209,8,,CHEMBL872930,BAO_0000357,
3692,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,H,,,10209,8,,CHEMBL620826,BAO_0000357,
3693,Autocuration,,,1,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,H,,,10209,8,,CHEMBL620827,BAO_0000357,
3694,Autocuration,,,1,,,Compound was evaluated for its binding affinity for human 5-hydroxytryptamine 7 receptor,H,,,10209,8,,CHEMBL620828,BAO_0000357,
3695,Autocuration,,,1,,,Compound was evaluated for its binding affinity towards human 5-hydroxytryptamine 7 receptor,H,,,10209,8,,CHEMBL620829,BAO_0000357,
3696,Expert,,,1,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor on HEK293 cells using radioligand [3H]LSD,H,,722.0,10209,8,,CHEMBL620830,BAO_0000219,
3697,Expert,,,1,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD,H,,,10209,8,,CHEMBL620831,BAO_0000019,
3698,Expert,,,1,,,Tested on cell membranes from transfected cells selectively expressing human 5-hydroxytryptamine 7 receptor incubated with 1 nM [3H]LSD; ND is No Data.,H,,,10209,8,,CHEMBL620832,BAO_0000019,
3699,Expert,9606.0,,1,,,In vitro binding affinity to human 5-hydroxytryptamine 7 receptor,D,,,10209,9,,CHEMBL621548,BAO_0000357,
3700,Autocuration,,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor,H,,,10209,8,,CHEMBL621549,BAO_0000019,
3701,Autocuration,,,1,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]LSD radioligand,H,,,10209,8,,CHEMBL621550,BAO_0000357,
3702,Autocuration,,,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]-LSD as radioligand; Not determined,H,,449.0,10209,8,,CHEMBL621551,BAO_0000219,
3703,Autocuration,,,1,,,In vitro binding affinity by radioligand binding assay using cell line expressing human 5-hydroxytryptamine 7 receptor; ND means not determined,H,,,10209,8,,CHEMBL621552,BAO_0000019,
3704,Autocuration,,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor,H,,,10209,8,,CHEMBL857077,BAO_0000357,
3705,Autocuration,,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor; Not tested,H,,,10209,8,,CHEMBL618158,BAO_0000357,
3706,Expert,9606.0,,1,,,Ability to displace the radioligand [3H]5-carboxyamidotryptamine ([3H]5-CT) from human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,D,,643.0,10209,9,,CHEMBL618159,BAO_0000219,
3707,Autocuration,,,1,,,Ability to displace the radioligand [3H]5-carboximidotryptamine ([3H]-5-CT) from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells,H,,643.0,10209,8,,CHEMBL875101,BAO_0000219,
3708,Expert,9606.0,,1,,,Binding affinity to human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]-5-CT as radioligand,D,,722.0,10209,9,,CHEMBL618160,BAO_0000219,
3709,Expert,,,1,,,Binding affinity at human cloned 5-hydroxytryptamine 7 receptor.,H,,,10209,8,,CHEMBL618161,BAO_0000357,
3710,Expert,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor was determined in HEK293 cells using [3H]5-CT as radioligand,H,,722.0,10209,8,,CHEMBL618162,BAO_0000219,
3711,Expert,,,1,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor was determined using [3H]5-CT as radioligand,H,,,10209,8,,CHEMBL618163,BAO_0000357,
3712,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 7 human receptors,H,,,10209,8,,CHEMBL618164,BAO_0000357,
3713,Expert,,,1,,,Binding affinity to human recombinant 5-hydroxytryptamine 7 receptor in mammalian cells using [3H]5-CT as radioligand,H,,,10209,8,,CHEMBL618165,BAO_0000219,
3714,Autocuration,,,1,,,Binding affinity toward 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]-5-CT as radioligand.,H,,722.0,10209,8,,CHEMBL618166,BAO_0000219,
3715,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (a) (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,H,,722.0,10209,8,,CHEMBL857989,BAO_0000219,
3716,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,H,,722.0,10209,8,,CHEMBL619888,BAO_0000219,
3717,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor (human cloned receptor) in HEK 293 cells using [3H]5-CT as radioligand.,H,,722.0,10209,8,,CHEMBL619889,BAO_0000219,
3718,Autocuration,,,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor 7(a) (human cloned receptor in HEK 293 cells using [3H]5-CT as radioligand.,H,,722.0,10209,8,,CHEMBL619890,BAO_0000219,
3719,Autocuration,,,1,,,Binding constant towards serotonin receptor subtype 5-hydroxytryptamine 7 receptor expressed in CHO cells using [3H]LSD as radioligand,H,,449.0,10209,8,,CHEMBL619891,BAO_0000219,
3720,Autocuration,,,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand (n=3),H,,722.0,10209,8,,CHEMBL619892,BAO_0000219,
3721,Expert,,,1,,,Displacement of [3H]-5-CT from human 5-hydroxytryptamine 7 receptor expressed in HEK-293 cells,D,,722.0,10209,9,,CHEMBL619893,BAO_0000219,
3722,Autocuration,,,1,,,Compound was evaluated for binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT as the radioligand(n=6),H,,722.0,10209,8,,CHEMBL619894,BAO_0000219,
3723,Intermediate,,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells,D,,722.0,10209,9,,CHEMBL619895,BAO_0000219,
3724,Intermediate,,,1,,,Binding affinity towards human recombinant 5-hydroxytryptamine 7 receptor using [3H]5-CT as radioligand,D,,,10209,9,,CHEMBL619896,BAO_0000357,
3725,Autocuration,,,1,,,Compound was evaluated for its ability to displace [3H]5-CT binding from cloned human 5-hydroxytryptamine 7 receptor expressed in COS-7 cells.,H,,643.0,10209,8,,CHEMBL619897,BAO_0000219,
3726,Autocuration,,,1,,,Compound was tested for its binding affinity against human cloned 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT,H,,722.0,10209,8,,CHEMBL619898,BAO_0000219,
3727,Expert,,,1,,,Binding affinity for human cloned 5-hydroxytryptamine 7 receptor in HEK 293 using [3H]5-CT as a radioligand,H,,722.0,10209,8,,CHEMBL619899,BAO_0000219,
3728,Autocuration,,,1,,,Compound was tested for its binding affinity in 5-hydroxytryptamine 7 receptor (using human cloned receptors in HEK 293 and [3H]5-CT as a radioligand ),H,,722.0,10209,8,,CHEMBL619900,BAO_0000219,
3729,Expert,9606.0,,1,,,Binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT,D,,722.0,10209,9,,CHEMBL619901,BAO_0000219,
3730,Autocuration,,,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor expressed in HEK 293 cells using [3H]5-CT. ,H,,722.0,10209,8,,CHEMBL620580,BAO_0000219,
3731,Autocuration,,,1,,,The compound was tested for its binding affinity towards cloned human 5-hydroxytryptamine 7 receptor in HEK 293 cells using [3H]5-CT.,H,,722.0,10209,8,,CHEMBL620581,BAO_0000219,
3732,Autocuration,,,1,,,"The compound was tested for the binding affinity towards human cloned 5-hydroxytryptamine 7 receptor in HEK293 cells, using [3H]5-CT as radioligand",H,,722.0,10209,8,,CHEMBL620733,BAO_0000219,
3733,Autocuration,9606.0,,1,,,Inhibitory constant against human 5-hydroxytryptamine 7 receptor using [3H]-LSD radioligand; Not determined,D,,,10209,9,,CHEMBL620734,BAO_0000357,
3734,Expert,10090.0,,1,,,Binding affinity towards mouse 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,D,,,10022,9,,CHEMBL620735,BAO_0000357,
3735,Autocuration,9986.0,,1,,,The dissociation equilibrium constant (pKB=-log KB) of compound was determined against the vascular 5-hydroxytryptamine 7 receptor in the endothelium denuded rabbit jugular vein.,H,,,10209,8,,CHEMBL620736,BAO_0000019,
3736,Autocuration,,,1,,,Compound was tested for the displacement of [3H]5-HT binding to cloned rat 5-hydroxytryptamine 7 receptor stably expressed in CHO cells,H,,449.0,11923,8,,CHEMBL620737,BAO_0000219,
3737,Autocuration,,,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 10000 nM,H,,449.0,11923,8,,CHEMBL620738,BAO_0000219,
3738,Autocuration,,,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 100 nM,H,,449.0,11923,8,,CHEMBL620739,BAO_0000219,
3739,Autocuration,,,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors at a concentration of 1 nM,H,,449.0,11923,8,,CHEMBL620740,BAO_0000219,
3740,Autocuration,,,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 10000 nM 5-HT.,H,,449.0,11923,8,,CHEMBL620741,BAO_0000219,
3741,Autocuration,,,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 100 nM 5-HT.,H,,449.0,11923,8,,CHEMBL620742,BAO_0000219,
3742,Autocuration,,,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT 7 receptors by 1 nM 5-HT,H,,449.0,11923,8,,CHEMBL620743,BAO_0000219,
3743,Autocuration,,,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 10000 nM,H,,449.0,11923,8,,CHEMBL620744,BAO_0000219,
3744,Autocuration,,,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 100 nM,H,,449.0,11923,8,,CHEMBL620745,BAO_0000219,
3745,Autocuration,,,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM,H,,449.0,11923,8,,CHEMBL620746,BAO_0000219,
3746,Autocuration,,,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 10000 nM 5-HT.,H,,449.0,11923,8,,CHEMBL620747,BAO_0000219,
3747,Autocuration,,,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 100 nM 5-HT.,H,,449.0,11923,8,,CHEMBL620748,BAO_0000219,
3748,Autocuration,,,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT.,H,,449.0,11923,8,,CHEMBL620749,BAO_0000219,
3749,Expert,,,1,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor,H,,,11923,8,,CHEMBL620750,BAO_0000357,
3750,Expert,10116.0,,1,,,Binding affinity towards rat 5-hydroxytryptamine 7 receptor was evaluated using [3H]5-HT as radioligand,D,,,11923,9,,CHEMBL620751,BAO_0000357,
3751,Expert,,,1,,,Binding affinity to the rat 5-hydroxytryptamine 7 receptor,H,,,11923,8,,CHEMBL620752,BAO_0000357,
3752,Autocuration,,,1,,,Binding affinity against 5-hydroxytryptamine 7 receptor using from CHO cell membranes [3H]5-HT as the radioligand.,H,,,11923,8,,CHEMBL872929,BAO_0000019,
3753,Expert,10116.0,,1,,,Binding affinity against Rat 5-hydroxytryptamine 7 receptor using [3H]5-HT,D,,,11923,9,,CHEMBL620753,BAO_0000357,
3754,Expert,10116.0,,1,,,Displacement of [3H]5-HT from over-expressed rat 5-hydroxytryptamine 7 receptor,D,,,11923,9,,CHEMBL620754,BAO_0000357,
3755,Expert,10116.0,,1,,,Displacement of [3H]5-HT from rat 5-hydroxytryptamine 7 receptor expressed in CHO cells,D,,449.0,11923,9,,CHEMBL620755,BAO_0000219,
3756,Autocuration,,,1,,,In vitro binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor using [3H]5-HT as radioligand,H,,,11923,8,,CHEMBL620756,BAO_0000357,
3757,Autocuration,,,1,,,The compound was tested for binding affinity against 5-hydroxytryptamine 7 receptor,H,,,11923,8,,CHEMBL620757,BAO_0000357,
3758,Autocuration,,,1,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; Not tested",H,,449.0,11923,8,,CHEMBL620758,BAO_0000219,
3759,Autocuration,,,1,,,"Effect of compound on stimulation of cAMP production in CHO cells expressing rat 5-HT7 receptors at 1, 10, 100 1000 and 10000 nM conc; not tested",H,,449.0,11923,8,,CHEMBL620759,BAO_0000219,
3760,Autocuration,,,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors at a concentration of 1 nM; not tested,H,,449.0,11923,8,,CHEMBL620760,BAO_0000219,
3761,Autocuration,,,1,,,Percent inhibition of 5-HT7-induced stimulation of cAMP production in CHO cells expressing rat 5-HT receptors by 1 nM 5-HT; Not tested,H,,449.0,11923,8,,CHEMBL620761,BAO_0000219,
3762,Autocuration,,,1,2116.0,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,H,,,11923,8,,CHEMBL620762,BAO_0000221,
3763,Autocuration,,,1,2116.0,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor nondesensitization,H,,,11923,8,,CHEMBL620763,BAO_0000221,
3764,Autocuration,,,1,2116.0,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine receptor desensitization,H,,,11923,8,,CHEMBL620764,BAO_0000221,
3765,Expert,10116.0,,1,,,Inhibition of [3H]-5-CT binding to 5-hydroxytryptamine 7 receptor of rat cortical membranes,D,Membranes,,11923,9,,CHEMBL857990,BAO_0000249,
3766,Autocuration,,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor was determined,H,,,11923,8,,CHEMBL620765,BAO_0000357,
3767,Expert,,,1,,,Binding affinity at rat 5-hydroxytryptamine 7 receptor.,H,,,11923,8,,CHEMBL620766,BAO_0000357,
3768,Expert,,,1,1898.0,,Binding affinity towards 5-hydroxytryptamine receptor 7 on rat hypothalamus membranes using [3H]5-CT as radioligand.,H,,,11923,8,,CHEMBL620767,BAO_0000019,
3769,Autocuration,,,1,,,Binding affinity towards cloned rat 5-hydroxytryptamine 7 receptor was determined using [3H]5-HT as radioligand,H,,,11923,8,,CHEMBL620768,BAO_0000357,
3770,Expert,,,1,1898.0,,Binding affinity against 5-hydroxytryptamine 7 receptor using [3H]-5-CT in rat hypothalamus membranes,H,,,11923,8,,CHEMBL619051,BAO_0000249,
3771,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,H,,,11923,8,,CHEMBL619052,BAO_0000357,
3772,Expert,10116.0,,1,,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed by HEK293 cells,D,,722.0,11923,9,,CHEMBL619053,BAO_0000219,
3773,Expert,10116.0,,1,,,Agonistic activity against rat 5-HT7 adenyl cyclase expressed in HEK293 cells; Active,D,,722.0,11923,9,,CHEMBL619703,BAO_0000219,
3774,Autocuration,10116.0,,1,,,Agonistic activity against rat 5-HT7-adenyl cyclase expressed by HEK293 cells; Active,D,,722.0,11923,9,,CHEMBL619704,BAO_0000219,
3775,Expert,,,1,,,Binding affinity towards 5-hydroxytryptamine 7 receptor,H,,,10209,8,,CHEMBL619851,BAO_0000357,
3776,Autocuration,,,1,,,Percentage of displacement at 5-hydroxytryptamine 7 receptor at 10e-8 M,H,,,10209,8,,CHEMBL619852,BAO_0000357,
3777,Autocuration,,,1,,,Inhibition of binding towards 5-hydroxytryptamine 7 receptor at 100 nM concentration,H,,,10209,8,,CHEMBL619853,BAO_0000357,
3778,Expert,9606.0,,1,,,Binding affinity towards human 5-hydroxytryptamine 7 receptor,D,,,10209,9,,CHEMBL619854,BAO_0000357,
3779,Expert,,,1,,,Binding affinity of compound towards rodent 5-hydroxytryptamine 7 receptor,H,,,10209,8,,CHEMBL619855,BAO_0000357,
3780,Autocuration,,,1,,,Binding affinity of compound towards serotonin 5-hydroxytryptamine 7 receptor; inactive at 10 uM,H,,,10209,8,,CHEMBL619856,BAO_0000357,
3781,Autocuration,,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,H,,,10209,8,,CHEMBL619857,BAO_0000357,
3782,Expert,,,1,,,Antagonistic activity towards 5-hydroxytryptamine 7 receptor was evaluated by cAMP assay,H,,,10209,8,,CHEMBL619858,BAO_0000019,
3783,Autocuration,,,1,,,Binding affinity for 5-hydroxytryptamine 7 receptor was determined,H,,,10209,8,,CHEMBL619859,BAO_0000357,
3784,Autocuration,,,1,,,Binding affinity relative to indolopiperidine (compound 1) for 5-hydroxytryptamine 7 receptor was determined,H,,,10209,8,,CHEMBL619860,BAO_0000357,
3785,Autocuration,,,1,,,Evaluated for the binding affinity to 5-hydroxytryptamine 7 receptor,H,,,10209,8,,CHEMBL619861,BAO_0000357,
3786,Expert,,,1,,,Non-selective inhibitory activity was determined against 5-hydroxytryptamine 7 receptor,H,,,10209,8,,CHEMBL619862,BAO_0000357,
3787,Autocuration,,,1,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-6 M,H,,,10209,8,,CHEMBL619863,BAO_0000357,
3788,Autocuration,,,1,,,Ability to displace [125I]LSD 113808 from 5-hydroxytryptamine 7 receptor at concentration of 10e-8 M,H,,,10209,8,,CHEMBL619864,BAO_0000357,
3789,Autocuration,,,1,,,Binding affinities against 5-hydroxytryptamine 7 receptor,H,,,10209,8,,CHEMBL872928,BAO_0000357,
3790,Autocuration,,,1,,,Binding affinities towards 5-hydroxytryptamine 7 receptor,H,,,10209,8,,CHEMBL619865,BAO_0000357,
3791,Expert,,,1,,,Binding affinity towards rodent 5-hydroxytryptamine 7 receptor,H,,,10209,8,,CHEMBL619866,BAO_0000357,
3792,Autocuration,,,1,,,The binding affinity towards 5-hydroxytryptamine 7 receptor; No affinity,H,,,10209,8,,CHEMBL619867,BAO_0000357,
3793,Autocuration,,,1,2116.0,,Maximal relaxation effect induced by 3 uM compound on substance P stimulated guinea pig ileum with 5-hydroxytryptamine 7 receptor desensitization,H,,,10209,8,,CHEMBL619868,BAO_0000221,
3794,Autocuration,,,1,,,Compound was evaluated for the potency to inhibit oxidation of arachidonic acid by human recombinant 5-Lipoxygenase using a spectrophotometric assay,H,,,55,8,,CHEMBL619869,BAO_0000019,
3795,Expert,9606.0,,1,,,Inhibition of oxidation of arachidonic acid by human 5-Lipoxygenase using spectrophotometric assay,D,,,55,9,,CHEMBL619870,BAO_0000019,
3796,Autocuration,,,1,,,In vitro inhibition of human recombinant 5-lipoxygenase enzyme,H,,,55,8,,CHEMBL619871,BAO_0000357,
3797,Autocuration,,,1,,,In vitro inhibition of human recombinant lipoxygenase enzyme,H,,,55,8,,CHEMBL619872,BAO_0000357,
3798,Autocuration,,,1,,,In vitro inhibition of human recombinant lipoxygenase enzyme; No inhibition,H,,,55,8,,CHEMBL619873,BAO_0000357,
3799,Expert,,,1,178.0,,Inhibition of 5-lipoxygenase in human whole blood.,H,,,55,8,,CHEMBL619874,BAO_0000357,
3800,Expert,,,1,178.0,,Inhibition of 5-lipoxygenase in human whole blood.,H,,,55,8,,CHEMBL619875,BAO_0000357,
3801,Autocuration,,,1,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of 5-HETE,H,,,55,8,,CHEMBL619876,BAO_0000357,
3802,Autocuration,,,1,,,Compound was tested for the inhibition of 5-lipoxygenase of human PMN stimulated by calcium ionophore A-23187 for the formation of leukotriene B4 (LTB4),H,,,55,8,,CHEMBL619877,BAO_0000357,
3803,Expert,,,1,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human polymorphonuclear leukocytes.,H,,,55,8,,CHEMBL619878,BAO_0000219,
3804,Autocuration,,,1,178.0,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in human whole blood,H,,,55,8,,CHEMBL619879,BAO_0000019,
3805,Autocuration,,,1,,,In vitro inhibition of 5-lipoxygenase from human polymorphs,H,,,55,8,,CHEMBL619880,BAO_0000357,
3806,Autocuration,,,1,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-LPO (5-lipoxygenase),H,,,55,8,,CHEMBL619881,BAO_0000357,
3807,Expert,,,1,,,In vitro inhibition of leukotriene B4 synthesis in human whole blood by inhibiting 5-lipoxygenase,H,,,55,8,,CHEMBL619882,BAO_0000357,
3808,Autocuration,,,1,,,In vitro inhibitory activity against 5-lipoxygenase in a human whole blood assay,H,,,55,8,,CHEMBL619883,BAO_0000357,
3809,Expert,9606.0,,1,178.0,,Inhibition of 5-Lipoxygenase (5-LO) of human whole blood (HWB),D,,,55,9,,CHEMBL619884,BAO_0000357,
3810,Autocuration,,,1,,,In vitro potency against human 5-Lipoxygenase,H,,,55,8,,CHEMBL619885,BAO_0000357,
3811,Expert,9606.0,,1,,,Inhibitory activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay,D,,,55,9,,CHEMBL619886,BAO_0000019,
3812,Autocuration,,,1,178.0,,Inhibition activity against 5-lipoxygenase in Human whole blood (HWBL) stimulated with calcium ionophore (A23187) and LTB4 measured by enzyme immunoassay; No data,H,,,55,8,,CHEMBL619887,BAO_0000019,
3813,Autocuration,,,1,,,Inhibition of 5-lipoxygenase activity of compound evaluated as determined by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,H,,,55,8,,CHEMBL875097,BAO_0000019,
3814,Autocuration,,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE,H,,,55,8,,CHEMBL618001,BAO_0000219,
3815,Autocuration,,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE; NA means Not active,H,,,55,8,,CHEMBL618002,BAO_0000219,
3816,Autocuration,,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4,H,,,55,8,,CHEMBL618003,BAO_0000219,
3817,Autocuration,,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4; NA means Not active,H,,,55,8,,CHEMBL618004,BAO_0000219,
3818,Autocuration,,,1,,,Inhibition of human 5-lipoxygenase in human cells,H,,,55,8,,CHEMBL618005,BAO_0000219,
3819,Expert,,,1,,,Inhibition of human neutrophil 5-lipoxygenase,H,,,55,8,,CHEMBL618006,BAO_0000357,
3820,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase expressed from human polymorphonuclear cells,H,,,55,8,,CHEMBL875086,BAO_0000019,
3821,Expert,,,1,178.0,,Inhibition of 5-lipoxygenase from human whole blood,H,,,55,8,,CHEMBL618007,BAO_0000357,
3822,Autocuration,,,1,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,H,,,55,8,,CHEMBL618008,BAO_0000357,
3823,Autocuration,,,1,,,Inhibitory concentration required against 5-lipoxygenase activity in intact cells of human neutrophils,H,,,55,8,,CHEMBL618009,BAO_0000219,
3824,Expert,,,1,,,In vitro inhibition of polymorphonuclear leukocyte derived human 5-lipoxygenase,H,,,55,8,,CHEMBL618010,BAO_0000357,
3825,Autocuration,,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,H,,,55,8,,CHEMBL618011,BAO_0000357,
3826,Expert,,,1,,,Potency to inhibit oxidation of arachidonic acid by recombinant human 5-lipoxygenase,H,,,55,8,,CHEMBL618012,BAO_0000357,
3827,Autocuration,,,1,,,Tested against 5-lipoxygenase,H,,,55,8,,CHEMBL882927,BAO_0000357,
3828,Autocuration,,,1,,,Tested for activity against 5-Lipoxygenase (5-LO),H,,,55,8,,CHEMBL618013,BAO_0000357,
3829,Autocuration,,,1,,,Tested for activity against 5-lipoxygenase,H,,,55,8,,CHEMBL618014,BAO_0000357,
3830,Autocuration,,,1,,,Tested for inhibition of 5-HPETE production by human 5-LO,H,,,55,8,,CHEMBL618015,BAO_0000357,
3831,Autocuration,,,1,,,The 5-lipoxygenase activity by the inhibition of calcium ionophore-induced leukotriene B4 production in human blood.,H,,,55,8,,CHEMBL618016,BAO_0000019,
3832,Expert,,,1,,,Inhibition of Human 5-lipoxygenase,H,,,55,8,,CHEMBL618017,BAO_0000357,
3833,Autocuration,,,1,,,The compound was evaluated for its inhibitory activity against 5-lipoxygenase using granulocytes-type cells,H,,,55,8,,CHEMBL618018,BAO_0000019,
3834,Autocuration,,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in human polymorphonuclear leukocytes[PMNS],H,,,55,8,,CHEMBL875087,BAO_0000219,
3835,Autocuration,,,1,,,The compound was tested for inhibitory activity against LT synthesis in human polymorphonuclear leukocytes[PMNS],H,,,55,8,,CHEMBL618019,BAO_0000219,
3836,Autocuration,,,1,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50.,H,,,55,8,,CHEMBL618020,BAO_0000019,
3837,Autocuration,,,1,,,The compound was tested for the concentration (in uM) to inhibit 50% of 5-Lipoxygenase (5-LOX) and is expressed in IC50; Not tested,H,,,55,8,,CHEMBL618021,BAO_0000019,
3838,Autocuration,,,1,178.0,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in human whole blood (HWBL),H,,,55,8,,CHEMBL618022,BAO_0000357,
3839,Autocuration,,,1,,,The compound was tested in vitro for inhibition against 5-lipoxygenase in intact human neutrophils,H,,,55,8,,CHEMBL618023,BAO_0000357,
3840,Autocuration,,,1,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),H,,,55,8,,CHEMBL618024,BAO_0000357,
3841,Expert,,,1,,,In vitro inhibitory activity against 5-lipoxygenase in human polymorphonuclear (PMN) cells,H,,,55,8,,CHEMBL873950,BAO_0000019,
3842,Autocuration,,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,H,,,55,8,,CHEMBL618025,BAO_0000357,
3843,Autocuration,,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM,H,,,55,8,,CHEMBL618026,BAO_0000219,
3844,Autocuration,,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of 5-HETE at 10 uM; NA means Inactive,H,,,55,8,,CHEMBL618027,BAO_0000219,
3845,Autocuration,,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM,H,,,55,8,,CHEMBL618028,BAO_0000219,
3846,Autocuration,,,1,,,Inhibition of 5-lipoxygenase was evaluated in human polymorphonuclear leukocytes stimulated by calcium ionophore A-23187 for formation of LTB4 at 10 uM; NA means Inactive,H,,,55,8,,CHEMBL618029,BAO_0000219,
3847,Expert,,,1,,,Inhibitory activity against 5-lipoxygenase at 10 uM concentration,H,,,55,8,,CHEMBL618030,BAO_0000357,
3848,Expert,,,1,,,Inhibitory activity against 5-lipoxygenase at 1 uM concentration,H,,,55,8,,CHEMBL618031,BAO_0000357,
3849,Autocuration,,,1,,,Inhibitory activity against lipoxygenase (LO) at 10 uM concentration,H,,,55,8,,CHEMBL618032,BAO_0000357,
3850,Autocuration,,,1,,,Inhibitory concentration required against 5-lipoxygenase activity in cytosolic fractions of human neutrophils,H,,,55,8,,CHEMBL618033,BAO_0000357,
3851,Autocuration,,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 1 uM,H,,,55,8,,CHEMBL618034,BAO_0000357,
3852,Autocuration,,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell at 10 uM,H,,,55,8,,CHEMBL875088,BAO_0000357,
3853,Autocuration,,,1,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; IA= Inactive,H,,,55,8,,CHEMBL618035,BAO_0000019,
3854,Autocuration,,,1,,,Tested for the inhibition of 5-lipoxygenase from human polymorphonuclear leukocytes(PMN) at 10 uM concentration of the compound; value ranges from 70-90,H,,,55,8,,CHEMBL618036,BAO_0000019,
3855,Expert,,,1,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 0.1 uM,H,,,55,8,,CHEMBL618037,BAO_0000357,
3856,Expert,,,1,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,H,,,55,8,,CHEMBL618038,BAO_0000357,
3857,Autocuration,,,1,,,Inhibition of human neutrophil 5-lipoxygenase at the concentration of 1 uM,H,,,55,8,,CHEMBL618761,BAO_0000019,
3858,Expert,,,1,,,Inhibition of lipoxygenase at the concentration of 0.1 uM,H,,,55,8,,CHEMBL618762,BAO_0000357,
3859,Expert,,,1,,,Inhibition of lipoxygenase at the concentration of 1 uM,H,,,55,8,,CHEMBL618763,BAO_0000357,
3860,Autocuration,,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in human cell,H,,,55,8,,CHEMBL618764,BAO_0000357,
3861,Expert,9606.0,,1,,,Inhibition of 5-Lipoxygenase (5-LOX),D,,,55,9,,CHEMBL618765,BAO_0000357,
3862,Expert,,,1,,,Inhibition of 5-lipoxygenase in mouse macrophages.,H,,,17087,8,,CHEMBL618766,BAO_0000357,
3863,Expert,,,1,,,Inhibition of 5-lipoxygenase in mouse macrophages.,H,,,17087,8,,CHEMBL618767,BAO_0000357,
3864,Autocuration,,,1,,,Inhibitory activity against lipoxygenase-2 in mice,H,,,17087,8,,CHEMBL619380,BAO_0000357,
3865,Expert,,,1,,,Inhibitory activity against murine lipoxygenase-2.,H,,,17087,8,,CHEMBL619381,BAO_0000357,
3866,Expert,10090.0,,1,,,Inhibition of 5-lipoxygenase from mouse macrophage,D,,,17087,9,,CHEMBL619382,BAO_0000357,
3867,Autocuration,,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse macrophages,H,,,17087,8,,CHEMBL619383,BAO_0000357,
3868,Autocuration,9823.0,,1,,,The compound was tested for the inhibition of Arachidonate 5-lipoxygenase purified from porcine leukocytes.,H,,,55,8,,CHEMBL619384,BAO_0000019,
3869,Autocuration,9823.0,,1,,,Inhibition of 5-lipoxygenase reaction catalyzed by purified enzyme from porcine leukocytes,H,,,55,8,,CHEMBL619385,BAO_0000019,
3870,Autocuration,9986.0,,1,,,Inhibitory concentration against 5-lipoxygenase from isolated rabbit granulocytes,H,,,55,8,,CHEMBL882928,BAO_0000019,
3871,Expert,10116.0,,1,,,5-lipoxygenase Inhibitory activity against rat polymorphonuclear leucocytes using 5-HETE,D,,,12166,9,,CHEMBL619386,BAO_0000019,
3872,Autocuration,,,1,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE. ",H,,,12166,8,,CHEMBL619387,BAO_0000019,
3873,Autocuration,,,1,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",H,,,12166,8,,CHEMBL619388,BAO_0000019,
3874,Autocuration,,,1,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4.",H,,,12166,8,,CHEMBL619389,BAO_0000019,
3875,Expert,,,1,,,Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay (inhibition of 5-HETE formation),H,,,12166,8,,CHEMBL619390,BAO_0000019,
3876,Expert,,,1,,,"Inhibition of 5-lipoxygenase pathway in rat polymorphonuclear assay, by ability to inhibit formation of LTB4 AT 10 uM",H,,,12166,8,,CHEMBL619391,BAO_0000019,
3877,Autocuration,,,1,,,Inhibition of 5-lipoxygenase pathway was evaluated in rat polymorphonuclear assay by compound (50 uM) ability to inhibit formation of 5-HETE,H,,,12166,8,,CHEMBL619392,BAO_0000019,
3878,Autocuration,,,1,,,The effective dose for inhibition of 5-lipoxygenase in rat blood leukocyte (ex vivo),H,,,12166,8,,CHEMBL619393,BAO_0000019,
3879,Autocuration,,,1,,,The effective dose for inhibition of 5-lipoxygenase in rat passive Arthus model after oral administration,H,,,12166,8,,CHEMBL619394,BAO_0000019,
3880,Autocuration,,,1,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",H,,702.0,12166,8,,CHEMBL619395,BAO_0000219,
3881,Autocuration,,,1,,,"In vitro inhibition of 5-lipoxygenase HETE (5-hydroperoxyeicosatetraenoic acid) in RBL-1 macrophage, a cell-free enzyme assay",H,,702.0,12166,8,,CHEMBL619396,BAO_0000219,
3882,Autocuration,,,1,,,Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),H,,,12166,8,,CHEMBL619397,BAO_0000357,
3883,Autocuration,,,1,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO),",H,,,12166,8,,CHEMBL619398,BAO_0000357,
3884,Autocuration,,,1,,,"Inhibition of rat neutrophil 5- Lipoxygenase (5-LO), (at a concentration of 0.2 nM ),",H,,,12166,8,,CHEMBL619399,BAO_0000357,
3885,Autocuration,,,1,,,5-LO inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,H,,,12166,8,,CHEMBL619400,BAO_0000357,
3886,Autocuration,,,1,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using 5-HETE.",H,,,12166,8,,CHEMBL619401,BAO_0000019,
3887,Autocuration,,,1,,,"5-lipoxygenase inhibitory activity against rat polymorphonuclear leucocytes from female wistar rat, by using LTB4. ",H,,,12166,8,,CHEMBL619402,BAO_0000019,
3888,Expert,10116.0,,1,,,Inhibition of 5-lipoxygenase mediated conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cells,D,,663.0,12166,9,,CHEMBL619403,BAO_0000219,
3889,Autocuration,,,1,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography; Not determined,H,,,12166,8,,CHEMBL619404,BAO_0000357,
3890,Autocuration,,,1,,,5-lipoxygenase inhibitory activity determined by measuring the conversion of [14C]arachidonic acid to leukotrienes in RBL-2H3 cell using thin-layer chromatography.,H,,,12166,8,,CHEMBL619405,BAO_0000357,
3891,Expert,,,1,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line,H,,702.0,12166,8,,CHEMBL619406,BAO_0000219,
3892,Expert,10116.0,,1,,,Inhibition of 5-Lipoxygenase of rat basophilic leukemia cells,D,,702.0,12166,9,,CHEMBL619407,BAO_0000219,
3893,Autocuration,,,1,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase),H,,,12166,8,,CHEMBL619408,BAO_0000357,
3894,Autocuration,,,1,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) in intact RBL-1 cell line assay,H,,702.0,12166,8,,CHEMBL619409,BAO_0000219,
3895,Expert,,,1,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-lipoxygenase,H,,702.0,12166,8,,CHEMBL619410,BAO_0000219,
3896,Autocuration,,,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,H,,702.0,12166,8,,CHEMBL619753,BAO_0000219,
3897,Autocuration,,,1,,,Compound was evaluated in an intact RBL-1 cell line for inhibition of 5-lipoxygenase,H,,702.0,12166,8,,CHEMBL619754,BAO_0000219,
3898,Expert,,,1,,,Evaluated in vitro for its inhibitory activity against 5-lipoxygenase,H,,,12166,8,,CHEMBL619903,BAO_0000357,
3899,Expert,,,1,,,"Evaluated in vitro for its inhibitory activity against 5-lipoxygenase; N=Inactive, <50% inhibition at 10 uM concentration",H,,,12166,8,,CHEMBL619904,BAO_0000357,
3900,Expert,,,1,,,Inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase in vitro,H,,,12166,8,,CHEMBL619905,BAO_0000357,
3901,Autocuration,,,1,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells,H,,,12166,8,,CHEMBL619906,BAO_0000019,
3902,Autocuration,,,1,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 32 uM; Not active,H,,,12166,8,,CHEMBL619907,BAO_0000019,
3903,Autocuration,,,1,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells at concentration of 50 uM; Not active,H,,,12166,8,,CHEMBL619908,BAO_0000019,
3904,Autocuration,,,1,,,Compound was tested for inhibition of 5-lipoxygenase activity in a broken cell supernatant rat basophilic leukemia cells; No data,H,,,12166,8,,CHEMBL619909,BAO_0000019,
3905,Expert,,,1,,,Inhibition of 5-lipoxygenase by measuring 5-HETE levels in RBL-1 cell-free supernatant,H,,702.0,12166,8,,CHEMBL619910,BAO_0000219,
3906,Expert,,,1,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells,H,,702.0,12166,8,,CHEMBL882929,BAO_0000219,
3907,Expert,,,1,,,Ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells.,H,,702.0,12166,8,,CHEMBL619911,BAO_0000219,
3908,Autocuration,,,1,,,Compound was tested for its ability to inhibit 5-lipoxygenase in rat basophilic leukemia cells; No data,H,,,12166,8,,CHEMBL619912,BAO_0000019,
3909,Expert,10116.0,,1,,,Inhibition of rat basophilic leukemia cell 5-lipoxygenase,D,,,12166,9,,CHEMBL619913,BAO_0000357,
3910,Expert,,,1,,,In vitro inhibitory activity against RBL-1 5-LO,H,,702.0,12166,8,,CHEMBL619914,BAO_0000219,
3911,Autocuration,,,1,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (insoluble above 45 uM),H,,702.0,12166,8,,CHEMBL619915,BAO_0000219,
3912,Autocuration,,,1,,,Compound was tested for its in vitro inhibitory activity against RBL-1 5-LO (time dependent),H,,702.0,12166,8,,CHEMBL619916,BAO_0000219,
3913,Autocuration,,,1,,,Compound was tested for its inhibition activity against 5-LO of the whole cell in vitro in rat.,H,,,12166,8,,CHEMBL619917,BAO_0000218,
3914,Autocuration,,,1,,,Compound was tested for its inhibition activity against the 5-LO in isolated enzyme,H,,,12166,8,,CHEMBL619918,BAO_0000357,
3915,Autocuration,,,1,,,Compound was tested for its inhibitory activity against 5-lipoxygenase in rat.,H,,,12166,8,,CHEMBL619919,BAO_0000218,
3916,Autocuration,,,1,,,Compound was tested for the inhibition of 5-lipoxygenase (5-LPO) in rat basophilic leukemia (RBL) cells.,H,,702.0,12166,8,,CHEMBL883710,BAO_0000219,
3917,Autocuration,,,1,178.0,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in rat whole blood.,H,,,12166,8,,CHEMBL619920,BAO_0000019,
3918,Expert,,,1,,,Concentration required for 50 % inhibition of arachidonic acid oxidation by rat 5-lipoxygenase,H,,,12166,8,,CHEMBL619921,BAO_0000357,
3919,Autocuration,,,1,,,Concentration that produces 50% inhibition of A-23187-stimulated radiolabeled 5-HETE and TXB2 synthesis by PMN 5-lipoxygenase.,H,,,12166,8,,CHEMBL619922,BAO_0000019,
3920,Autocuration,,,1,,,In vitro 5-lipoxygenase inhibitory activity against calcium ionophore (A23187) induced LTB4 formation in rat polymorphonuclear leukocytes,H,,,12166,8,,CHEMBL619923,BAO_0000219,
3921,Expert,,,1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined,H,,702.0,12166,8,,CHEMBL619924,BAO_0000219,
3922,Expert,,,1,,,In vitro inhibition of 5-lipoxygenase (5-HETE) derived from the 9000xg supernatant of RBL broken cell assay,H,,,12166,8,,CHEMBL619925,BAO_0000357,
3923,Expert,,,1,,,In vitro inhibition of 5-lipoxygenase from RBL-1 cells,H,,702.0,12166,8,,CHEMBL619926,BAO_0000219,
3924,Autocuration,,,1,,,In vitro inhibition of 5-lipoxygenase in RBL-1 cells,H,,702.0,12166,8,,CHEMBL619927,BAO_0000219,
3925,Expert,,,1,,,In vitro inhibition of 5-lipoxygenase pathway in rat basophilic leukemia (RBL-1) cells,H,,702.0,12166,8,,CHEMBL619928,BAO_0000219,
3926,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase,H,,702.0,12166,8,,CHEMBL619929,BAO_0000219,
3927,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.18-0.31,H,,702.0,12166,8,,CHEMBL875089,BAO_0000219,
3928,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.3-1.6,H,,702.0,12166,8,,CHEMBL619930,BAO_0000219,
3929,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.4-2.2,H,,702.0,12166,8,,CHEMBL619931,BAO_0000219,
3930,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.72-1.07,H,,702.0,12166,8,,CHEMBL619932,BAO_0000219,
3931,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 0.9-4.0,H,,702.0,12166,8,,CHEMBL619933,BAO_0000219,
3932,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.5,H,,702.0,12166,8,,CHEMBL619934,BAO_0000219,
3933,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-1.7,H,,702.0,12166,8,,CHEMBL619935,BAO_0000219,
3934,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.0-2.4,H,,702.0,12166,8,,CHEMBL619936,BAO_0000219,
3935,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.07-5.54,H,,702.0,12166,8,,CHEMBL619937,BAO_0000219,
3936,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.1-1.6,H,,702.0,12166,8,,CHEMBL619938,BAO_0000219,
3937,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.3-2.8,H,,702.0,12166,8,,CHEMBL619939,BAO_0000219,
3938,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.4-3.2,H,,702.0,12166,8,,CHEMBL619940,BAO_0000219,
3939,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.7-2.6,H,,702.0,12166,8,,CHEMBL875090,BAO_0000219,
3940,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-2.8,H,,702.0,12166,8,,CHEMBL619941,BAO_0000219,
3941,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.8-5.7,H,,702.0,12166,8,,CHEMBL619942,BAO_0000219,
3942,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 1.9-2.4,H,,702.0,12166,8,,CHEMBL883711,BAO_0000219,
3943,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.3-.8,H,,702.0,12166,8,,CHEMBL619943,BAO_0000219,
3944,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 2.46-2.63,H,,702.0,12166,8,,CHEMBL619944,BAO_0000219,
3945,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.3-3.5,H,,702.0,12166,8,,CHEMBL619945,BAO_0000219,
3946,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 3.8-7.1,H,,702.0,12166,8,,CHEMBL619946,BAO_0000219,
3947,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.0-6.4,H,,702.0,12166,8,,CHEMBL619947,BAO_0000219,
3948,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 4.9-11.6,H,,702.0,12166,8,,CHEMBL619948,BAO_0000219,
3949,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase; Value ranges from 7.5-11.8,H,,702.0,12166,8,,CHEMBL619949,BAO_0000219,
3950,Expert,,,1,,,In vitro inhibitory activity against 5-lipoxygenase from rat basophilic leukemia cells.,H,,,12166,8,,CHEMBL619950,BAO_0000019,
3951,Autocuration,,,1,,,In vitro inhibitory activity against 5-Lipoxygenase in rat by Peritoneal 5-lipoxygenase assay,H,,,12166,8,,CHEMBL618050,BAO_0000019,
3952,Expert,,,1,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells.,H,,663.0,12166,8,,CHEMBL875091,BAO_0000219,
3953,Expert,,,1,,,In vitro inhibition of 5-lipoxygenase in RBL-2H3 (Rat basophilic leukemia) cells; Not tested,H,,663.0,12166,8,,CHEMBL618051,BAO_0000219,
3954,Expert,10116.0,,1,,,Inhibition of 5-lipoxygenase from rat basophilic leukemia(RBL-1) cells,D,,702.0,12166,9,,CHEMBL618052,BAO_0000219,
3955,Autocuration,,,1,,,In vitro inhibitory activity against 5-lipoxygenase in an RBL-2H3 cell lysate,H,,,12166,8,,CHEMBL618053,BAO_0000019,
3956,Expert,,,1,,,In vitro inhibition of 5-lipoxygenase in rat (peritoneal assay),H,,,12166,8,,CHEMBL618054,BAO_0000019,
3957,Expert,10116.0,,1,,,In vitro inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,D,,702.0,12166,9,,CHEMBL618055,BAO_0000219,
3958,Expert,,,1,,,inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cell line.,H,,702.0,12166,8,,CHEMBL618056,BAO_0000219,
3959,Autocuration,,,1,,,In vitro inhibitory activity against 5-lipoxygenase was determined,H,,,12166,8,,CHEMBL618057,BAO_0000357,
3960,Autocuration,,,1,,,In vitro inhibitory concentration against 5-lipoxygenase in RBL-1 cells,H,,702.0,12166,8,,CHEMBL618058,BAO_0000219,
3961,Expert,,,1,,,Inhibition of 5-lipoxygenase in intact RBL-1 cell line,H,,702.0,12166,8,,CHEMBL618059,BAO_0000219,
3962,Expert,10116.0,,1,,,Inhibitory activity against 5-lipoxygenase catalysis (5-LO) in sonicated rat basophilic leukemia cell lysate,D,,,12166,9,,CHEMBL618060,BAO_0000019,
3963,Autocuration,,,1,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemia cells,H,,702.0,12166,8,,CHEMBL618061,BAO_0000219,
3964,Autocuration,,,1,,,Inhibition of 5-Lipoxygenase (5-LO) in rat basophilic leukemic cells,H,,,12166,8,,CHEMBL618062,BAO_0000019,
3965,Expert,,,1,,,Inhibition of 5-lipoxygenase catalysis in rat basophilic leukemia (RBL) cells by measuring 5-HETE product formation,H,,702.0,12166,8,,CHEMBL618063,BAO_0000219,
3966,Autocuration,,,1,,,Inhibition of 5-lipoxygenase from rat peritoneal neutrophils after oral administration,H,,,12166,8,,CHEMBL618064,BAO_0000357,
3967,Expert,10116.0,,1,,,Inhibition of 5-lipoxygenase of rat basophilic leukemia (RBL) cell cytosolic enzymes,D,,702.0,12166,9,,CHEMBL618065,BAO_0000219,
3968,Expert,10116.0,,1,,,Inhibition 5-lipoxygenase mediated LTB4 formation in rat basophilic leukemia (RBL-1) cells,D,,702.0,12166,9,,CHEMBL618066,BAO_0000219,
3969,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),H,,702.0,12166,8,,CHEMBL618067,BAO_0000219,
3970,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),H,,702.0,12166,8,,CHEMBL618068,BAO_0000219,
3971,Expert,10116.0,,1,,,Inhibition of 5-lipoxygenase in rat RBL-1 cells,D,,702.0,12166,9,,CHEMBL618069,BAO_0000219,
3972,Expert,,,1,,,Inhibition of 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,,702.0,12166,8,,CHEMBL618070,BAO_0000219,
3973,Autocuration,,,1,349.0,,Compound was tested for its effect on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 32 umol/kg,H,,,10825,8,,CHEMBL618071,BAO_0000019,
3974,Autocuration,,,1,349.0,,Compound was tested for its effects on NSD 1015 induced accumulation of 5-HTP(ng/g) in rats in limbic system at a dosage of 0.10 umol/kg,H,,,10825,8,,CHEMBL619247,BAO_0000019,
3975,Autocuration,,,1,,,Approximate dose levels for a half maximal reduction of 5-HTP levels,H,,,10825,8,,CHEMBL619248,BAO_0000019,
3976,Autocuration,,,1,10000000.0,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,H,,,10576,8,,CHEMBL619249,BAO_0000221,
3977,Autocuration,,,1,10000000.0,,Inhibitory activity against 5-hydroxytryptamine 1A receptor of rat hippocampal tissue using [3H]OH-DPAT as radioligand.,H,,,10576,8,,CHEMBL619250,BAO_0000221,
3978,Autocuration,,,1,,,Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat striatal membrane homogenate using [3H]5-HT as the radioligand.,H,,,10577,8,,CHEMBL619251,BAO_0000019,
3979,Autocuration,9615.0,,1,178.0,,Inhibitory concentration against human platelet 5-lipoxygenase in dog whole blood,H,,,55,8,,CHEMBL619252,BAO_0000019,
3980,Autocuration,,,1,178.0,,Inhibitory concentration against human platelet 5-lipoxygenase in human whole blood,H,,,55,8,,CHEMBL619253,BAO_0000019,
3981,Autocuration,,,1,,,The compound was tested for inhibitory activity against 5-Lipoxygenase in rat polymorphonuclear leukocytes[PMNS],H,,,12166,8,,CHEMBL619254,BAO_0000219,
3982,Expert,,,1,,,Inhibition of 5-lipoxygenase in bovine polymorphonuclear leukocytes,H,,,17140,8,,CHEMBL619255,BAO_0000219,
3983,Expert,,,1,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL).,H,,,17140,8,,CHEMBL619256,BAO_0000219,
3984,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL),H,,,17140,8,,CHEMBL875418,BAO_0000219,
3985,Expert,,,1,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,H,,,17140,8,,CHEMBL619257,BAO_0000219,
3986,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase (inhibition of 5-HETE and LTB4 biosynthesis) in bovine polymorphonuclear leukocytes (PMNL) at 30 uM,H,,,17140,8,,CHEMBL619258,BAO_0000219,
3987,Expert,,,1,,,Inhibition of 5-lipoxygenase in bovine PMNL cell assay.,H,,,17140,8,,CHEMBL619259,BAO_0000357,
3988,Expert,,,1,,,Tested for inhibition of 5-lipoxygenase as inhibition of 5-HETE and LTB4 biosynthesis in bovine PMNL,H,,,17140,8,,CHEMBL619260,BAO_0000357,
3989,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL619261,BAO_0000218,
3990,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL619263,BAO_0000218,
3991,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL619264,BAO_0000218,
3992,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL619265,BAO_0000218,
3993,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL619266,BAO_0000218,
3994,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL619902,BAO_0000218,
3995,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620058,BAO_0000218,
3996,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-LO was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620059,BAO_0000218,
3997,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620060,BAO_0000218,
3998,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620061,BAO_0000218,
3999,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 0.3 mg/kg",H,,,55,8,,CHEMBL620062,BAO_0000218,
4000,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620063,BAO_0000218,
4001,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 3.0 mg/kg",H,,,55,8,,CHEMBL620064,BAO_0000218,
4002,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620065,BAO_0000218,
4003,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 0.3 mg/kg",H,,,55,8,,CHEMBL620066,BAO_0000218,
4004,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620067,BAO_0000218,
4005,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following peroral administration at the dose of 3.0 mg/kg",H,,,55,8,,CHEMBL620068,BAO_0000218,
4006,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620069,BAO_0000218,
4007,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 0.3 mg/kg",H,,,55,8,,CHEMBL620070,BAO_0000218,
4008,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620071,BAO_0000218,
4009,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following peroral administration at the dose of 3.0 mg/kg",H,,,55,8,,CHEMBL620072,BAO_0000218,
4010,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620036,BAO_0000218,
4011,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 0.3 mg/kg",H,,,55,8,,CHEMBL857702,BAO_0000218,
4012,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620037,BAO_0000218,
4013,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following peroral administration at the dose of 3.0 mg/kg",H,,,55,8,,CHEMBL620038,BAO_0000218,
4014,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620039,BAO_0000218,
4015,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 0.3 mg/kg",H,,,55,8,,CHEMBL620040,BAO_0000218,
4016,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620041,BAO_0000218,
4017,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following peroral administration at the dose of 3.0 mg/kg",H,,,55,8,,CHEMBL620042,BAO_0000218,
4018,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620043,BAO_0000218,
4019,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 0.3 mg/kg",H,,,55,8,,CHEMBL620044,BAO_0000218,
4020,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620045,BAO_0000218,
4021,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following peroral administration at the dose of 3.0 mg/kg",H,,,55,8,,CHEMBL620046,BAO_0000218,
4022,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620047,BAO_0000218,
4023,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 0.3 mg/kg",H,,,55,8,,CHEMBL620048,BAO_0000218,
4024,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL857703,BAO_0000218,
4025,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following peroral administration at the dose of 3.0 mg/kg",H,,,55,8,,CHEMBL620049,BAO_0000218,
4026,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.08h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620050,BAO_0000218,
4027,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620051,BAO_0000218,
4028,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.5h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL619213,BAO_0000218,
4029,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 1.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL619214,BAO_0000218,
4030,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 3.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL619804,BAO_0000218,
4031,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 0.25h, following peroral administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL619805,BAO_0000218,
4032,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 24h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL619806,BAO_0000218,
4033,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 6.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL619807,BAO_0000218,
4034,Autocuration,9615.0,In vivo,1,178.0,,"Ex vivo inhibition was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 9.0h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL619808,BAO_0000218,
4035,Autocuration,9615.0,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r,H,,,55,8,,CHEMBL619809,BAO_0000218,
4036,Autocuration,9615.0,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 24 hr r to canine,H,,,55,8,,CHEMBL619810,BAO_0000218,
4037,Autocuration,9615.0,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr,H,,,55,8,,CHEMBL619811,BAO_0000218,
4038,Autocuration,9615.0,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 2 hr to canine,H,,,55,8,,CHEMBL620769,BAO_0000218,
4039,Autocuration,9615.0,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr,H,,,55,8,,CHEMBL620770,BAO_0000218,
4040,Autocuration,9615.0,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 4 hr to canine,H,,,55,8,,CHEMBL620771,BAO_0000218,
4041,Autocuration,9615.0,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr,H,,,55,8,,CHEMBL620772,BAO_0000218,
4042,Autocuration,9615.0,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in after oral administration of 5 mg/kg at 8 hr to canine,H,,,55,8,,CHEMBL620773,BAO_0000218,
4043,Autocuration,10141.0,,1,,,Ability to inhibit 5-lipoxygenase in guinea pig,H,,,55,8,,CHEMBL620774,BAO_0000357,
4044,Expert,10141.0,,1,,,Inhibition of [14C]arachidonic acid conversion to 5-HETE by broken cell 5-lipoxygenase in vitro (guinea pig PMN),H,,,55,8,,CHEMBL620775,BAO_0000357,
4045,Autocuration,10141.0,,1,,,Compound was tested for the inhibition of 5-lipoxygenase (5-Lpo) in guinea pig.,H,,,55,8,,CHEMBL620776,BAO_0000357,
4046,Autocuration,10141.0,,1,178.0,,"Ex vivo inhibition of 5-lipoxygenase was determined by the measurement of A-23187-stimulated LTB4 production in dog blood at 12 h, following intravenous administration at the dose of 1.0 mg/kg",H,,,55,8,,CHEMBL620777,BAO_0000218,
4047,Autocuration,10141.0,,1,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on 5-hydroxyeicosapentaenoic acid (5-HETE) production,H,,,55,8,,CHEMBL620778,BAO_0000357,
4048,Autocuration,10141.0,,1,,,In vitro 5-lipoxygenase inhibition in guinea pig PMNs was determined based on LTB4 production,H,,,55,8,,CHEMBL620779,BAO_0000357,
4049,Expert,10141.0,,1,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]-AA to 5-HETE in guinea pig peritoneal polymorphonuclear leukocytes,H,,,55,8,,CHEMBL621500,BAO_0000019,
4050,Expert,10141.0,,1,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,H,,,55,8,,CHEMBL621501,BAO_0000019,
4051,Autocuration,10141.0,,1,,,In vitro 5-lipoxygenase inhibitory activity against A-23187-stimulated conversion of [14C]AA to LTB4 in guinea pig peritoneal polymorphonuclear leukocytes,H,,,55,8,,CHEMBL618098,BAO_0000019,
4052,Autocuration,10141.0,,1,,,Inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,H,,,55,8,,CHEMBL618099,BAO_0000019,
4053,Autocuration,10141.0,,1,,,Inhibitory activity against 5-lipoxygenase,H,,,55,8,,CHEMBL618100,BAO_0000357,
4054,Autocuration,10141.0,,1,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte,H,,,55,8,,CHEMBL618101,BAO_0000357,
4055,Autocuration,10141.0,,1,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant,H,,,55,8,,CHEMBL618102,BAO_0000357,
4056,Autocuration,10141.0,,1,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase,H,,,55,8,,CHEMBL618103,BAO_0000357,
4057,Autocuration,10141.0,,1,,,Inhibitory activity uM,H,,,55,8,,CHEMBL618104,BAO_0000357,
4058,Autocuration,10141.0,,1,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocytes was determined,H,,,55,8,,CHEMBL883712,BAO_0000219,
4059,Autocuration,10141.0,,1,,,Inhibitory activity against 5-lipoxygenase at 10 uM,H,,,55,8,,CHEMBL618105,BAO_0000357,
4060,Autocuration,10141.0,,1,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,H,,,55,8,,CHEMBL618106,BAO_0000357,
4061,Autocuration,10141.0,,1,,,Inhibitory activity against 5-lipoxygenase in guinea pig leukocyte at 30 uM,H,,,55,8,,CHEMBL618107,BAO_0000357,
4062,Autocuration,10141.0,,1,,,Inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase using guinea pig supernatant at 10 uM,H,,,55,8,,CHEMBL618108,BAO_0000357,
4063,Autocuration,10141.0,,1,,,Inhibitory activity uM,H,,,55,8,,CHEMBL618109,BAO_0000357,
4064,Autocuration,10141.0,,1,,,Inhibitory activity against partially-purified Guinea pig PMN 5-lipoxygenase at 10 uM,H,,,55,8,,CHEMBL618110,BAO_0000357,
4065,Expert,10141.0,,1,,,Inhibitory activity uM,H,,,55,8,,CHEMBL618111,BAO_0000357,
4066,Autocuration,10141.0,,1,,,Inhibitory activity uM,H,,,55,8,,CHEMBL618112,BAO_0000019,
4067,Autocuration,10141.0,,1,,,Percent inhibition against 5-lipoxygenase from guinea pig polymorphonuclear lymphocytes,H,,,55,8,,CHEMBL618113,BAO_0000019,
4068,Autocuration,10141.0,,1,,,Inhibitory activity against 5-lipoxygenase at a dose of 0.1 mM,H,,,55,8,,CHEMBL618114,BAO_0000357,
4069,Expert,10141.0,,1,2116.0,,Evaluated for inhibition of the formation and release of 5-lipoxygenase in isolated guinea pig ileum,H,,,55,8,,CHEMBL620871,BAO_0000221,
4070,Autocuration,,,1,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),H,,,55,8,,CHEMBL620872,BAO_0000357,
4071,Autocuration,,,1,,,5-lipoxygenase Inhibitory activity was measured by enzyme immunoassay using human whole blood stimulated with calcium ionophore (A23187) and LTB4 (leukotriene B4),H,,,55,8,,CHEMBL620873,BAO_0000357,
4072,Autocuration,,,1,,,Compound was evaluated for in vitro inhibition of recombinant human 5-lipoxygenase (5-LO),H,,,55,8,,CHEMBL620874,BAO_0000357,
4073,Expert,,,1,,,In vitro inhibition of human 5-Lipoxygenase.,H,,,55,8,,CHEMBL620875,BAO_0000357,
4074,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,U,Microsomes,,22226,0,,CHEMBL620876,BAO_0000251,
4075,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,U,Microsomes,,22226,0,,CHEMBL620877,BAO_0000251,
4076,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,U,Microsomes,,22226,0,,CHEMBL857854,BAO_0000251,
4077,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM exposed 100 uM,U,Microsomes,,22226,0,,CHEMBL620878,BAO_0000251,
4078,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,U,Microsomes,,22226,0,,CHEMBL620879,BAO_0000251,
4079,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,U,Microsomes,,22226,0,,CHEMBL620880,BAO_0000251,
4080,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,U,Microsomes,,22226,0,,CHEMBL620881,BAO_0000251,
4081,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,U,Microsomes,,22226,0,,CHEMBL620882,BAO_0000251,
4082,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,U,Microsomes,,22226,0,,CHEMBL620883,BAO_0000251,
4083,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,U,Microsomes,,22226,0,,CHEMBL620884,BAO_0000251,
4084,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,U,Microsomes,,22226,0,,CHEMBL620885,BAO_0000251,
4085,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 27.5 uM,U,Microsomes,,22226,0,,CHEMBL620886,BAO_0000251,
4086,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,U,Microsomes,,22226,0,,CHEMBL620887,BAO_0000251,
4087,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,U,Microsomes,,22226,0,,CHEMBL618039,BAO_0000251,
4088,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,U,Microsomes,,22226,0,,CHEMBL618040,BAO_0000251,
4089,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to exposed to 3-methylcholanthrene at concentration of 200 uM,U,Microsomes,,22226,0,,CHEMBL618041,BAO_0000251,
4090,Autocuration,10116.0,,1,2107.0,,"Compound was evaluated for inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",U,Microsomes,,22226,0,,CHEMBL618216,BAO_0000251,
4091,Autocuration,10116.0,,1,2107.0,,"Compound was evaluated for inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",U,Microsomes,,22226,0,,CHEMBL618217,BAO_0000251,
4092,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 100 uM,U,Microsomes,,22226,0,,CHEMBL618218,BAO_0000251,
4093,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 200 uM,U,Microsomes,,22226,0,,CHEMBL618219,BAO_0000251,
4094,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at concentration of 50 uM,U,Microsomes,,22226,0,,CHEMBL618220,BAO_0000251,
4095,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 5 uM,U,Microsomes,,22226,0,,CHEMBL618221,BAO_0000251,
4096,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at 50 uM,U,Microsomes,,22226,0,,CHEMBL618222,BAO_0000251,
4097,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,U,Microsomes,,22226,0,,CHEMBL618223,BAO_0000251,
4098,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,U,Microsomes,,22226,0,,CHEMBL618224,BAO_0000251,
4099,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 1 uM,U,Microsomes,,22226,0,,CHEMBL618225,BAO_0000251,
4100,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 20 uM,U,Microsomes,,22226,0,,CHEMBL618226,BAO_0000251,
4101,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,U,Microsomes,,22226,0,,CHEMBL618227,BAO_0000251,
4102,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,U,Microsomes,,22226,0,,CHEMBL618228,BAO_0000251,
4103,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,U,Microsomes,,22226,0,,CHEMBL618229,BAO_0000251,
4104,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 75 uM,U,Microsomes,,22226,0,,CHEMBL618230,BAO_0000251,
4105,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1 uM,U,Microsomes,,22226,0,,CHEMBL618231,BAO_0000251,
4106,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 10 uM,U,Microsomes,,22226,0,,CHEMBL618232,BAO_0000251,
4107,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 100 uM,U,Microsomes,,22226,0,,CHEMBL618233,BAO_0000251,
4108,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1000 uM,U,Microsomes,,22226,0,,CHEMBL618234,BAO_0000251,
4109,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 150 uM,U,Microsomes,,22226,0,,CHEMBL618235,BAO_0000251,
4110,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 1500 uM,U,Microsomes,,22226,0,,CHEMBL618115,BAO_0000251,
4111,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 2.5 uM,U,Microsomes,,22226,0,,CHEMBL618116,BAO_0000251,
4112,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 200 uM,U,Microsomes,,22226,0,,CHEMBL618117,BAO_0000251,
4113,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 5 uM,U,Microsomes,,22226,0,,CHEMBL619968,BAO_0000251,
4114,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,U,Microsomes,,22226,0,,CHEMBL619969,BAO_0000251,
4115,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 500 uM,U,Microsomes,,22226,0,,CHEMBL619970,BAO_0000251,
4116,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1000 uM,U,Microsomes,,22226,0,,CHEMBL619971,BAO_0000251,
4117,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 1500 uM,U,Microsomes,,22226,0,,CHEMBL619972,BAO_0000251,
4118,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 27.5 uM,U,Microsomes,,22226,0,,CHEMBL619973,BAO_0000251,
4119,Autocuration,10116.0,,1,2107.0,,Maximum rate constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at concentration of 500 uM,U,Microsomes,,22226,0,,CHEMBL619974,BAO_0000251,
4120,Autocuration,10116.0,,1,2107.0,,Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to beta-naphthoflavone at 50 uM,U,Microsomes,,22226,0,,CHEMBL619975,BAO_0000251,
4121,Autocuration,10116.0,,1,,,Vmax determined by 7-ethoxycoumarin deethylation in the presence by liver microsomes from rats exposed to 3-methylcholanthrene at concentration of 10 uM,U,Microsomes,,22226,0,,CHEMBL619976,BAO_0000251,
4122,Autocuration,10116.0,,1,2107.0,,"Compound was evaluated for alpha -rate constant, in liver microsomes from 3-methylcholanthrene-exposed rats",U,Microsomes,,22226,0,,CHEMBL619977,BAO_0000251,
4123,Autocuration,10116.0,,1,2107.0,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats",U,Microsomes,,22226,0,,CHEMBL619978,BAO_0000251,
4124,Autocuration,10116.0,,1,2107.0,,"Compound was evaluated for alpha -rate constant, in liver microsomes from beta-naphthoflavone-exposed rats; competitive inhibition",U,Microsomes,,22226,0,,CHEMBL619979,BAO_0000251,
4125,Autocuration,10116.0,,1,2107.0,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from 3-methylcholanthrene-exposed rats",U,Microsomes,,22226,0,,CHEMBL619980,BAO_0000251,
4126,Autocuration,10116.0,,1,2107.0,,"Compound was evaluated for alpha inhibition constant, in liver microsomes from beta-naphthoflavone-exposed rats",U,Microsomes,,22226,0,,CHEMBL619981,BAO_0000251,
4127,Intermediate,9606.0,,1,,,In vitro inhibition of 7226/S myeloma cancer cell line,N,,741.0,80433,1,,CHEMBL619982,BAO_0000219,
4128,Intermediate,9606.0,,1,,,In vitro antitumor activity of compound against 7404 cell line (human liver carcinoma cells),N,,993.0,80698,1,,CHEMBL619983,BAO_0000219,
4129,Intermediate,9606.0,,1,,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,N,,391.0,80640,1,,CHEMBL620031,BAO_0000219,
4130,Intermediate,9606.0,,1,,,In vitro growth inhibition of compound was determined against 768-0 cell lines of Renal cancer,N,,391.0,80640,1,,CHEMBL620032,BAO_0000219,
4131,Expert,10029.0,,1,,,Net accumulation of the [99mTc]Isonitrile complex was measured in 77A cell lines in the presence of Verapamil.,N,,505.0,81264,1,,CHEMBL620033,BAO_0000219,
4132,Expert,10029.0,,1,,,Verapamil index represents the ratio of net uptake in the presense of verapamil over control in 77A cell lines.,N,,505.0,81264,1,,CHEMBL620034,BAO_0000219,
4133,Intermediate,10116.0,,1,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 10 ug/mL dose,N,,1119.0,80635,1,,CHEMBL620035,BAO_0000219,
4134,Intermediate,10116.0,,1,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 2 ug/mL dose,N,,1119.0,80635,1,,CHEMBL618318,BAO_0000219,
4135,Intermediate,10116.0,,1,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 20 ug/mL dose,N,,1119.0,80635,1,,CHEMBL618319,BAO_0000219,
4136,Intermediate,10116.0,,1,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 5 ug/mL dose,N,,1119.0,80635,1,,CHEMBL618320,BAO_0000219,
4137,Intermediate,10116.0,,1,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 50 ug/mL dose,N,,1119.0,80635,1,,CHEMBL618321,BAO_0000219,
4138,Intermediate,10116.0,,1,,,Tested for its cytotoxic effect on the growth of the cell strain 7800C1 (1 x 10e 4 (MEM)) at 75 ug/mL dose,N,,1119.0,80635,1,,CHEMBL883118,BAO_0000219,
4139,Intermediate,9606.0,,1,,,In vitro antitumor activity against renal 786-0 tumor cell lines,N,,391.0,80640,1,,CHEMBL883795,BAO_0000219,
4140,Intermediate,9606.0,,1,,,Cytotoxic activity against 786-0 Renal cancer cell line,N,,391.0,80640,1,,CHEMBL618322,BAO_0000219,
4141,Intermediate,9606.0,,1,,,Growth inhibitory activity was determined against 786-0 cancer cell line of Renal cancer,N,,391.0,80640,1,,CHEMBL618323,BAO_0000219,
4142,Intermediate,9606.0,,1,,,Growth inhibitory activity was determined against 786-0 cancer cell line of renal cancer,N,,391.0,80640,1,,CHEMBL618324,BAO_0000219,
4143,Intermediate,9606.0,,1,,,In vitro antitumor activity against human renal 786-0 cell line,N,,391.0,80640,1,,CHEMBL618325,BAO_0000219,
4144,Intermediate,9606.0,,1,,,Inhibition of Renal cancer in 786-0 cancer cell lines,N,,391.0,80640,1,,CHEMBL875416,BAO_0000219,
4145,Intermediate,9606.0,,1,,,Inhibition of the growth of renal cancer(786-0) cell line. value in parentheses is percent inhibition at 0.01 uM,N,,391.0,80640,1,,CHEMBL618326,BAO_0000219,
4146,Intermediate,9606.0,,1,,,The compound was tested for its cytotoxic activity against the following renal cancer cell lines 786-0,N,,391.0,80640,1,,CHEMBL618327,BAO_0000219,
4147,Intermediate,9606.0,,1,,,inhibition of the growth of renal cancer(786-0) cell line,N,,391.0,80640,1,,CHEMBL619215,BAO_0000219,
4148,Intermediate,9606.0,,1,,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),N,,391.0,80640,1,,CHEMBL619216,BAO_0000219,
4149,Intermediate,9606.0,,1,,,Compound was tested for the growth inhibition of 786-0 renal tumor cell line,N,,391.0,80640,1,,CHEMBL619217,BAO_0000219,
4150,Intermediate,9606.0,,1,,,The IC50 value was measured on 786-0 cell line in ovarian tumor,N,,391.0,80640,1,,CHEMBL619218,BAO_0000219,
4151,Intermediate,9606.0,,1,,,The IC50 value was measured on 786-0 cell line in ovarian tumor t,N,,391.0,80640,1,,CHEMBL619219,BAO_0000219,
4152,Intermediate,9606.0,,1,,,The IC50 value was measured on 786-0 cell line in renal tumor type.,N,,391.0,80640,1,,CHEMBL619220,BAO_0000219,
4153,Intermediate,9606.0,,1,,,Inhibition of the growth of renal cancer(786-0) cell line at 0.01 uM,N,,391.0,80640,1,,CHEMBL619221,BAO_0000219,
4154,Intermediate,9606.0,,1,,,Tested for cytotoxic activity against renal cancer 786-0 cell line,N,,391.0,80640,1,,CHEMBL619222,BAO_0000219,
4155,Intermediate,9606.0,,1,,,Compound was tested for growth inhibitory activity against 786-0 cell line,N,,391.0,80640,1,,CHEMBL857454,BAO_0000219,
4156,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; Inactive(N)= <50% inhibition at 10 uM,H,,702.0,12166,8,,CHEMBL619223,BAO_0000219,
4157,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187; N=Inactive,H,,702.0,12166,8,,CHEMBL619224,BAO_0000219,
4158,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,H,,,12166,8,,CHEMBL619225,BAO_0000019,
4159,Expert,,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) in intact rat barophilic leukemia cells (RBL-1),H,,702.0,12166,8,,CHEMBL619226,BAO_0000219,
4160,Expert,,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1),H,,702.0,12166,8,,CHEMBL619227,BAO_0000219,
4161,Autocuration,,,1,,,Inhibitory activity against rat basophilic leukemia 5-lipoxygenase,H,,,12166,8,,CHEMBL619228,BAO_0000357,
4162,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes,H,,,12166,8,,CHEMBL619229,BAO_0000219,
4163,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase of RBL-1 cell line,H,,702.0,12166,8,,CHEMBL619230,BAO_0000219,
4164,Autocuration,,,1,,,Inhibitory activity against RBL broken cell-supematant 5-lipoxygenase was evaluated,H,,,12166,8,,CHEMBL619231,BAO_0000357,
4165,Autocuration,,,1,,,"Inhibitory activity against intact rat PMNL, LTB4 5-lipoxygenase was evaluated",H,,,12166,8,,CHEMBL619232,BAO_0000357,
4166,Expert,,,1,,,Inhibitory activity against rat 5-lipoxygenase by using continuous oxygen consumption assay.,H,,,12166,8,,CHEMBL619233,BAO_0000357,
4167,Autocuration,,,1,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase,H,,,12166,8,,CHEMBL619234,BAO_0000357,
4168,Autocuration,,,1,,,Inhibitory activity against rat basophilic leukemia cell 5-lipoxygenase (5-LO),H,,,12166,8,,CHEMBL619235,BAO_0000357,
4169,Expert,10116.0,,1,,,"Inhibitory activity against 5-lipoxygenase in rat neutrophils as inhibition of A 23,187-induced LTB4 production",D,,,12166,9,,CHEMBL619236,BAO_0000019,
4170,Autocuration,,,1,,,Inhibitory concentration against 5-lipoxygenase in rat RBL-1 cells,H,,702.0,12166,8,,CHEMBL619237,BAO_0000219,
4171,Autocuration,,,1,,,Inhibitory concentration to inhibit 5-lipoxygenase in the rat,H,,,12166,8,,CHEMBL619238,BAO_0000357,
4172,Expert,,,1,,,In vitro inhibition of rat polymorphonuclear leukocyte 5-lipoxygenase,H,,,12166,8,,CHEMBL619239,BAO_0000357,
4173,Autocuration,,,1,,,Tested for inhibition of 5-HPETE production by rat 5-LO; value ranges from 16-36 nM,H,,,12166,8,,CHEMBL619240,BAO_0000357,
4174,Autocuration,,,1,,,Tested for inhibition of 5-LO by measuring the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,H,,,12166,8,,CHEMBL875417,BAO_0000019,
4175,Autocuration,,,1,,,Tested for inhibition of 5-Lipoxygenase (ARBL) in calcium-stimulated rat basophilic leukemia cells(RBL-1),H,,702.0,12166,8,,CHEMBL619241,BAO_0000219,
4176,Expert,,,1,,,Inhibition of 5-lipoxygenase measured by the reduction of leukotriene B4 (LTB4) in intact basophilic rat leukemia cells,H,,,12166,8,,CHEMBL619242,BAO_0000019,
4177,Autocuration,,,1,,,Tested for inhibitory activity against 5-lipoxygenase in microsome of RBL-1 cells,H,,702.0,12166,8,,CHEMBL883796,BAO_0000219,
4178,Autocuration,,,1,,,Tested for its inhibitory activity against 5-lipoxygenase,H,,,12166,8,,CHEMBL619243,BAO_0000357,
4179,Autocuration,,,1,,,Tested for its inhibitory activity against 5-lipoxygenase; Not determined,H,,,12166,8,,CHEMBL619244,BAO_0000357,
4180,Expert,,,1,,,"Iin vitro inhibition of 5-lipoxygenase activity in rat basophil leukemia type 1(RBL1) cell homogenates, (reduction of [14C]-5-HETE formation)",H,,,12166,8,,CHEMBL619245,BAO_0000019,
4181,Expert,,,1,,,In vitro test for inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,H,,,12166,8,,CHEMBL619246,BAO_0000019,
4182,Expert,,,1,,,In vitro inhibition of 5-lipoxygenase activity in RBL-1 cells.,H,,702.0,12166,8,,CHEMBL619984,BAO_0000219,
4183,Autocuration,,,1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells; No significant inhibitory activity up to 30 uM,H,,702.0,12166,8,,CHEMBL619985,BAO_0000219,
4184,Autocuration,,,1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,H,,702.0,12166,8,,CHEMBL619986,BAO_0000219,
4185,Expert,,,1,,,In vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells.,H,,702.0,12166,8,,CHEMBL619987,BAO_0000219,
4186,Autocuration,,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in mouse,H,,,12166,8,,CHEMBL619988,BAO_0000218,
4187,Autocuration,,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1,H,,702.0,12166,8,,CHEMBL619989,BAO_0000219,
4188,Autocuration,,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat RBL-1 cells,H,,702.0,12166,8,,CHEMBL619990,BAO_0000219,
4189,Autocuration,,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS],H,,,12166,8,,CHEMBL619991,BAO_0000219,
4190,Autocuration,,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vitro),H,,,12166,8,,CHEMBL619992,BAO_0000219,
4191,Autocuration,,In vivo,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] (in vivo),H,,,12166,8,,CHEMBL619993,BAO_0000218,
4192,Autocuration,,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in RBL-2H3 cells,H,,663.0,12166,8,,CHEMBL619994,BAO_0000219,
4193,Autocuration,,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase translocation inhibitor in rat RBL-2H3 cells,H,,663.0,12166,8,,CHEMBL619995,BAO_0000219,
4194,Autocuration,,,1,,,The compound was tested for inhibitory activity against 5-lipoxygenase using rat polymorphonuclear leukocytes[PMNS],H,,,12166,8,,CHEMBL619996,BAO_0000019,
4195,Autocuration,,,1,,,The compound was tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase,H,,,12166,8,,CHEMBL619997,BAO_0000019,
4196,Expert,,,1,,,Tested for its inhibitory activity against arachidonic acid in rat 5-lipoxygenase.,H,,,12166,8,,CHEMBL619998,BAO_0000019,
4197,Expert,,,1,,,In vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells,H,,,12166,8,,CHEMBL619999,BAO_0000019,
4198,Autocuration,,,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells,H,,,12166,8,,CHEMBL620000,BAO_0000019,
4199,Autocuration,,,1,,,The compound was tested for the inhibition of 5-lipoxygenase (5-lo) in homogenized rat basophilic leukemia (RBL-1) cells,H,,702.0,12166,8,,CHEMBL620001,BAO_0000219,
4200,Expert,10116.0,,1,,,Inhibition of 5-lipoxygenase (5-lo) in intact rat polymorphonuclear leukocyte RPMNL,D,,,12166,9,,CHEMBL620002,BAO_0000357,
4201,Autocuration,,,1,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells,H,,702.0,12166,8,,CHEMBL620003,BAO_0000219,
4202,Expert,,,1,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell line lysate (RBL-1 2H3 subline) by measuring 5-HETE production,H,,702.0,12166,8,,CHEMBL620004,BAO_0000219,
4203,Autocuration,,,1,,,Compound was evaluated for the inhibition of 5-lipoxygenase,H,,,12166,8,,CHEMBL874063,BAO_0000357,
4204,Autocuration,,,1,,,Ability to inhibit 5-lipoxygenase by using a crude preparation of the cytosolic enzyme from the rat basophilic leukemia (RBL-1) cell line at a concentration of 25 uM,H,,702.0,12166,8,,CHEMBL620005,BAO_0000219,
4205,Autocuration,,,1,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay,H,,702.0,12166,8,,CHEMBL620006,BAO_0000219,
4206,Autocuration,,,1,,,Compound was evaluated for its inhibitory activity against 5-LO (5-lipoxygenase) at 10 uM concentration in intact RBL-1 cell line assay; Less than 5% inhibition at 10 uM reported as not active,H,,702.0,12166,8,,CHEMBL620007,BAO_0000219,
4207,Autocuration,,,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 10 uM,H,,702.0,12166,8,,CHEMBL620008,BAO_0000219,
4208,Expert,10116.0,,1,,,Inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM,D,,702.0,12166,9,,CHEMBL620009,BAO_0000219,
4209,Autocuration,,,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 100 uM; NS = no significant activity,H,,702.0,12166,8,,CHEMBL620010,BAO_0000219,
4210,Autocuration,,,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 30 uM,H,,702.0,12166,8,,CHEMBL620011,BAO_0000219,
4211,Autocuration,,,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 300 uM,H,,702.0,12166,8,,CHEMBL620677,BAO_0000219,
4212,Autocuration,,,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 33 uM,H,,702.0,12166,8,,CHEMBL620678,BAO_0000219,
4213,Autocuration,,,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 40 uM,H,,702.0,12166,8,,CHEMBL620679,BAO_0000219,
4214,Autocuration,,,1,,,Compound was evaluated for the inhibition of rat basophilic leukemia-1 (RBL-1) 5-Lipoxygenase at 75 uM,H,,702.0,12166,8,,CHEMBL620680,BAO_0000219,
4215,Expert,10116.0,,1,,,Inhibitory activity against 5-lipoxygenase at 10 uM,D,,,12166,9,,CHEMBL620838,BAO_0000357,
4216,Autocuration,,,1,,,In vitro inhibition of 5-lipoxygenase; NS means no significant inhibition,H,,,12166,8,,CHEMBL620839,BAO_0000357,
4217,Expert,,,1,,,In vitro inhibition of rat polymorphonuclear leukocyte (PMN) 5-Lipoxygenase at 10 uM,H,,,12166,8,,CHEMBL620840,BAO_0000357,
4218,Expert,,,1,,,Inhibitory activity against 5-lipoxygenase enzyme from RBL-1 cells at 20 uM,H,,702.0,12166,8,,CHEMBL620841,BAO_0000219,
4219,Autocuration,,,1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 100 uM,H,,702.0,12166,8,,CHEMBL620842,BAO_0000219,
4220,Autocuration,,,1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determined at 10e-4 M,H,,702.0,12166,8,,CHEMBL620843,BAO_0000219,
4221,Autocuration,,,1,,,In vitro inhibition against 5-lipoxygenase in RBL-1 cells was determinedb at 100 uM,H,,702.0,12166,8,,CHEMBL620844,BAO_0000219,
4222,Autocuration,,,1,,,In vitro inhibition of RBL-1 5-lipoxygenase at 20 uM,H,,702.0,12166,8,,CHEMBL620845,BAO_0000219,
4223,Autocuration,,,1,,,In vitro inhibitory activity against 5-Lipoxygenase from rat basophilic leukemia cells at 30 uM concentration,H,,,12166,8,,CHEMBL620846,BAO_0000019,
4224,Autocuration,,,1,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,H,,,12166,8,,CHEMBL873951,BAO_0000357,
4225,Autocuration,,,1,,,In vitro inhibitory activity against 5-lipoxygenase was determined at 16 uM,H,,,12166,8,,CHEMBL620847,BAO_0000357,
4226,Autocuration,,,1,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,H,,702.0,12166,8,,CHEMBL620848,BAO_0000219,
4227,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,H,,702.0,12166,8,,CHEMBL620849,BAO_0000219,
4228,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at 40 uM concentration,H,,702.0,12166,8,,CHEMBL620850,BAO_0000219,
4229,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM,H,,702.0,12166,8,,CHEMBL620851,BAO_0000219,
4230,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase in RBL-1 cells at a concentration 40 uM.,H,,702.0,12166,8,,CHEMBL620852,BAO_0000219,
4231,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,,702.0,12166,8,,CHEMBL875098,BAO_0000219,
4232,Expert,10116.0,,1,,,Inhibition of 5-lipoxygenase of rat basophilic leukemia cells at 30 uM,D,,702.0,12166,9,,CHEMBL620853,BAO_0000219,
4233,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells at 30 uM concentration; NT=Not tested,H,,,12166,8,,CHEMBL620854,BAO_0000019,
4234,Autocuration,,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1) at 10 uM,H,,702.0,12166,8,,CHEMBL620855,BAO_0000219,
4235,Expert,,,1,,,Inhibitory activity against 5-lipoxygenase (5-LO) using broken rat barophilic leukemia cells (RBL-1)at 10 uM,H,,702.0,12166,8,,CHEMBL839884,BAO_0000219,
4236,Autocuration,,,1,,,Inhibitory activity at 10 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,,702.0,12166,8,,CHEMBL620856,BAO_0000219,
4237,Autocuration,,,1,,,Inhibitory activity at 1 uM against 5-lipoxygenase in intact rat basophilic leukemia cells stimulated with the calcium ionophore A-23187,H,,702.0,12166,8,,CHEMBL620857,BAO_0000219,
4238,Autocuration,,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,H,,,12166,8,,CHEMBL620858,BAO_0000019,
4239,Autocuration,,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,H,,,12166,8,,CHEMBL620859,BAO_0000019,
4240,Autocuration,,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 1 uM,H,,,12166,8,,CHEMBL620860,BAO_0000019,
4241,Autocuration,,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 3 uM,H,,,12166,8,,CHEMBL620861,BAO_0000019,
4242,Expert,,,1,,,Percent inhibition of rat neutrophil 5-lipoxygenase (5-LO),H,,,12166,8,,CHEMBL620862,BAO_0000357,
4243,Autocuration,,,1,,,Percent inhibition of rat neutrophil 5- Lipoxygenase (5-LO) at 100 uM,H,,,12166,8,,CHEMBL620863,BAO_0000357,
4244,Autocuration,,,1,,,Tested in vitro for the inhibition of 5-lipoxygenase in cell-free preparations from rat PMN leukocytes,H,,,12166,8,,CHEMBL620864,BAO_0000019,
4245,Autocuration,,,1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 100 uM,H,,702.0,12166,8,,CHEMBL620865,BAO_0000219,
4246,Autocuration,,,1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 30 uM,H,,702.0,12166,8,,CHEMBL620866,BAO_0000219,
4247,Autocuration,,,1,,,The compound was tested for inhibition of 5-lipoxygenase in rat RBL-2H3 cells,H,,663.0,12166,8,,CHEMBL620867,BAO_0000219,
4248,Autocuration,,,1,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,H,,663.0,12166,8,,CHEMBL620868,BAO_0000219,
4249,Autocuration,,,1,,,The compound was tested for inhibition of 5-lipoxygenase translocation in SAR in rat RBL-2H3 cells,H,,663.0,12166,8,,CHEMBL620869,BAO_0000219,
4250,Autocuration,,,1,,,The compound was tested for inhibition of LTB4 synthesis on isolated 5-lipoxygenase,H,,,12166,8,,CHEMBL873952,BAO_0000019,
4251,Autocuration,,,1,,,The compound was tested for inhibition of isolated 5-lipoxygenase,H,,,12166,8,,CHEMBL875099,BAO_0000357,
4252,Autocuration,,,1,,,The compound was tested for inhibition of isolated 5-lipoxygenase translocation into rat RBL-2H3 cells,H,,663.0,12166,8,,CHEMBL620870,BAO_0000219,
4253,Autocuration,,,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 30 uM,H,,,12166,8,,CHEMBL618261,BAO_0000019,
4254,Autocuration,,,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells at a concentration of 32 uM,H,,,12166,8,,CHEMBL618262,BAO_0000019,
4255,Autocuration,,,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells measured at a concentration of 30 uM,H,,,12166,8,,CHEMBL619428,BAO_0000019,
4256,Autocuration,,,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase (5-lo) from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,H,,,12166,8,,CHEMBL619429,BAO_0000019,
4257,Autocuration,,,1,,,The compound was tested for the in vitro inhibition of 5-lipoxygenase from the 20000 g supernatant of RBI-1 cells; NS indicates nonsignificant inhibition at 32 uM concentration,H,,,12166,8,,CHEMBL619430,BAO_0000019,
4258,Autocuration,,,1,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 1.0 uM,H,,702.0,12166,8,,CHEMBL620017,BAO_0000219,
4259,Autocuration,,,1,,,The compound was tested for the inhibition of 5-lipoxygenase in intact basophilic rat leukemia cells at 10 uM,H,,702.0,12166,8,,CHEMBL620018,BAO_0000219,
4260,Autocuration,,,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.1 uM,H,,702.0,12166,8,,CHEMBL620019,BAO_0000219,
4261,Autocuration,,,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.195 uM,H,,702.0,12166,8,,CHEMBL620020,BAO_0000219,
4262,Autocuration,,,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.2 at uM,H,,702.0,12166,8,,CHEMBL620021,BAO_0000219,
4263,Autocuration,,,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.25 uM,H,,702.0,12166,8,,CHEMBL620022,BAO_0000219,
4264,Autocuration,,,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39,H,,702.0,12166,8,,CHEMBL620023,BAO_0000219,
4265,Autocuration,,,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by 5-HETE production at 0.39 uM,H,,702.0,12166,8,,CHEMBL620024,BAO_0000219,
4266,Autocuration,,,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.195 uM,H,,702.0,12166,8,,CHEMBL620025,BAO_0000219,
4267,Autocuration,,,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.2 uM,H,,702.0,12166,8,,CHEMBL620026,BAO_0000219,
4268,Autocuration,,,1,,,The compound was tested for the inhibition of 5-lipoxygenase on rat basophil leukemia (RBL-1) cell (2H3 subline) lysate by measuring 5-HETE production at 0.39 uM,H,,702.0,12166,8,,CHEMBL620027,BAO_0000219,
4269,Expert,10116.0,,1,,,Inhibition of 5-lipoxygenase on rat basophil leukemia cell (RBL-2H3) lysate as 5-HETE production at 32 uM,D,,,12166,9,,CHEMBL620028,BAO_0000019,
4270,Autocuration,,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase,H,,,12166,8,,CHEMBL620029,BAO_0000357,
4271,Autocuration,,,1,,,Compound was tested for the percent of inhibition against 5-LO at 10 uM,H,,,12166,8,,CHEMBL620030,BAO_0000357,
4272,Autocuration,,,1,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 1 uM concentration,H,,702.0,12166,8,,CHEMBL875415,BAO_0000219,
4273,Autocuration,,,1,,,In vitro percent inhibition against 5-lipoxygenase in RBL-1 cells at 10 uM concentration,H,,702.0,12166,8,,CHEMBL618256,BAO_0000219,
4274,Autocuration,,,1,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line,H,,702.0,12166,8,,CHEMBL618257,BAO_0000219,
4275,Autocuration,,,1,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 10 uM,H,,702.0,12166,8,,CHEMBL618258,BAO_0000219,
4276,Autocuration,,,1,,,Inhibition of LTB4 in whole cell 5-lipoxygenase assay in an intact rat basophilic leukemia (RBL-1) cell line at 16 uM,H,,702.0,12166,8,,CHEMBL618259,BAO_0000219,
4277,Autocuration,,,1,,,In vitro inhibitory activity against polymorphonuclear leukocyte 5-lipoxygenase in rat cell at 10 uM,H,,,12166,8,,CHEMBL618260,BAO_0000019,
4278,Autocuration,,,1,,,Percent inhibition against RBL-1 5-LO in vitro at 10 uM,H,,702.0,12166,8,,CHEMBL618215,BAO_0000219,
4279,Autocuration,,,1,,,Percent inhibition against RBL-1 5-LO in vitro at 100 uM,H,,702.0,12166,8,,CHEMBL618390,BAO_0000219,
4280,Autocuration,,,1,,,Percent inhibition against RBL-1 5-LO in vitro at 30 uM,H,,702.0,12166,8,,CHEMBL618391,BAO_0000219,
4281,Autocuration,,,1,,,Percent inhibition against RBL-1 5-LO in vitro at 300 uM,H,,702.0,12166,8,,CHEMBL618392,BAO_0000219,
4282,Autocuration,,,1,,,The compound was evaluated in vitro for inhibition of 5-lipoxygenase activity in RBL-1 cells at 20 uM,H,,702.0,12166,8,,CHEMBL618393,BAO_0000219,
4283,Autocuration,,,1,,,The compound was tested for inhibition against 5-lipoxygenase in rat polymorphonuclear leukocytes[PMNS] at 10 uM concentration,H,,,12166,8,,CHEMBL618394,BAO_0000219,
4284,Expert,9606.0,,1,,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),H,,702.0,12166,8,,CHEMBL618395,BAO_0000219,
4285,Expert,10116.0,,1,,,In vitro inhibitory activity against 5-lipoxygenase in rat basophilic leukemia cells(RBL-1),D,,702.0,12166,9,,CHEMBL618396,BAO_0000219,
4286,Expert,10116.0,,1,,,Logarithmic value of inhibitory concentration against 5-lipoxygenase in rat basophilic leukemia cells (RBL-1),D,,702.0,12166,9,,CHEMBL858253,BAO_0000219,
4287,Autocuration,10116.0,,1,,,Inhibitory activity against 5-lipoxygenase obtained from rat basophilic leukemia cells,D,,,12166,9,,CHEMBL618397,BAO_0000019,
4288,Autocuration,3847.0,,1,,,Compound was tested for the percent of inhibition against soybean 15-LO (at 100 uM),H,,,12054,8,,CHEMBL618398,BAO_0000357,
4289,Autocuration,,,1,,,"Inhibitory activity against 5-lipoxygenase, by using soybean lipoxygenase spectrophotometric assay",U,,,22226,0,,CHEMBL618399,BAO_0000019,
4290,Expert,,,1,,,In vitro inhibition of 5-Lipoxygenase; Inactive.,H,,,55,8,,CHEMBL618400,BAO_0000357,
4291,Autocuration,,,1,,,Inhibitory concentration against 5-lipoxygenase was determined; No inhibition,H,,,55,8,,CHEMBL618401,BAO_0000357,
4292,Autocuration,,,1,,,Inhibitory concentration against 5-lipoxygenase; No inhibition,H,,,55,8,,CHEMBL618402,BAO_0000357,
4293,Autocuration,,,1,,,Evaluated for inhibitory activity against RBL-1 cell 5-lipoxygenase in guinea pig,H,,702.0,55,8,,CHEMBL876400,BAO_0000219,
4294,Expert,,,1,,,Inhibitory activity against 5-lipoxygenase.,H,,,55,8,,CHEMBL618403,BAO_0000357,
4295,Autocuration,,,1,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive,H,,,55,8,,CHEMBL618404,BAO_0000357,
4296,Autocuration,,,1,,,Inhibitory Activity against 5-Lipoxygenase was determined; IA=Inactive at concentrations less than 32 uM,H,,,55,8,,CHEMBL618405,BAO_0000357,
4297,Autocuration,,,1,,,Inhibitory Activity against 5-Lipoxygenase was determined; NA=No significant inhibitory activity up to 300 uM,H,,,55,8,,CHEMBL618406,BAO_0000357,
4298,Expert,,,1,,,Inhibitory concentration against arachidonic acid 5-lipoxygenation,H,,,55,8,,CHEMBL618407,BAO_0000019,
4299,Autocuration,,,1,,,Tested for the inhibitory activity against 5-lipoxygenase,H,,,55,8,,CHEMBL618408,BAO_0000357,
4300,Autocuration,,,1,,,Compound was tested for its inhibitory activity against 5-lipoxygenase,H,,,55,8,,CHEMBL618409,BAO_0000357,
4301,Autocuration,,,1,,,Compound was tested for inhibition of 5-lipoxygenase at 50 uM; NI means no inhibition was observed,H,,,55,8,,CHEMBL618410,BAO_0000357,
4302,Autocuration,,,1,,,Inhibitory Activity against 5-Lipoxygenase at 30 uM was determined; Weakly active,H,,,55,8,,CHEMBL618411,BAO_0000357,
4303,Autocuration,,,1,,,Inhibitory Activity against 5-Lipoxygenase at concentration 32 uM was determined,H,,,55,8,,CHEMBL618412,BAO_0000357,
4304,Autocuration,,,1,,,Concentration required to inhibit RBL-1 supernatant 5-lipoxygenase,H,,702.0,12166,8,,CHEMBL618413,BAO_0000219,
4305,Autocuration,,,1,,,,H,,,12166,8,,CHEMBL618414,BAO_0000357,
4306,Autocuration,,,1,,,Compound was tested for its binding activity towards 5-lipoxygenase activating protein (FLAP),H,,,10102,8,,CHEMBL618415,BAO_0000357,
4307,Autocuration,,,1,,,Inhibition of 5-lipoxygenase activating protein using human leukocyte membrane preparations,H,,,10102,8,,CHEMBL618416,BAO_0000019,
4308,Autocuration,,,1,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-Lipoxygenase activating protein (FLAP) by using [125I]L-691831 as radioligand.,H,,,10102,8,,CHEMBL876401,BAO_0000357,
4309,Expert,,,1,,,Measuring the affinity of leukotriene synthesis inhibitor for 5-lipoxygenase activating protein by using [125I]L-691831 as radioligand.,H,,,10102,8,,CHEMBL618417,BAO_0000357,
4310,Autocuration,,,1,,,Tested for inhibition of leukotriene biosynthesis by binding to 5-lipoxygenase activating protein,H,,,10102,8,,CHEMBL618418,BAO_0000357,
4311,Autocuration,,,1,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein",H,,,10102,8,,CHEMBL618419,BAO_0000357,
4312,Autocuration,,,1,,,"The compound was tested for the inhibition of binding of [125I]- L- 691,831 binding to 5-lipoxygenase activating protein (FLAP)",H,,,10102,8,,CHEMBL618420,BAO_0000357,
4313,Autocuration,,,1,,,Binding affinity of compound for 5-lipoxygenase activating protein protein by FLAP binding assay,H,,,10102,8,,CHEMBL618421,BAO_0000357,
4314,Autocuration,,,1,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane,H,,,11238,8,,CHEMBL618422,BAO_0000019,
4315,Autocuration,,,1,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (R metabolically resistant),H,,,11238,8,,CHEMBL618423,BAO_0000019,
4316,Autocuration,,,1,,,Tested for inhibition of 5-phosphatase isolated from human erythrocyte membrane (S substrate),H,,,11238,8,,CHEMBL618424,BAO_0000019,
4317,Intermediate,,,1,,,Inhibition of protein biosynthesis at the level of the peptidyl transferase center of the 50 s ribosomal subunit,S,,,100284,2,,CHEMBL618425,BAO_0000220,
4318,Autocuration,9606.0,,1,,,The dark toxicity against 543 human galactophore carcinoma cells,U,,,22226,0,,CHEMBL618426,BAO_0000019,
4319,Expert,9606.0,,1,,,Tested in vitro for cytotoxicity against 56 human tumor cell lines,N,,390.0,80623,1,,CHEMBL618427,BAO_0000219,
4320,Expert,9606.0,,1,,,Cytotoxic activity against human 5637 cell line at 20 uM expressed as percent growth value,N,,345.0,80008,1,,CHEMBL618428,BAO_0000219,
4321,Intermediate,9606.0,,1,,,Antitumor activity was evaluated against human bladder carcinoma cell line 5637.,N,,345.0,80008,1,,CHEMBL618429,BAO_0000219,
4322,Intermediate,9606.0,,1,,,"Compound was tested for antiproliferative activity against 5637, human bladder carcinoma cell line",N,,345.0,80008,1,,CHEMBL618430,BAO_0000219,
4323,Expert,9606.0,,1,,,Growth inhibition against human 5637 cell lines,N,,345.0,80008,1,,CHEMBL618431,BAO_0000219,
4324,Expert,9606.0,,1,,,Antitumor activity against human bladder carcinoma 5637 cells.,N,,345.0,80008,1,,CHEMBL883799,BAO_0000219,
4325,Intermediate,9606.0,,1,,,Antitumor activity against human bladder carcinoma 5637 cells,N,,345.0,80008,1,,CHEMBL618432,BAO_0000219,
4326,Intermediate,9606.0,,1,,,Antitumor activity against human bladder carcinoma 5637 cells,N,,345.0,80008,1,,CHEMBL618433,BAO_0000219,
4327,Expert,9913.0,,1,,,In vitro inhibition of bovine trypsin(Trp).,D,,,10443,9,,CHEMBL618434,BAO_0000357,
4328,Expert,9527.0,,1,,,Transcriptional activation in CV-1 cells expressing retinoic acid gamma receptor,H,,407.0,240,8,,CHEMBL618435,BAO_0000219,
4329,Autocuration,,,1,,,Ability to displace the radioligand [125I](-)-iodocyanopindolol from rat striatal 5-HT1B receptor,H,,,10577,8,,CHEMBL876402,BAO_0000357,
4330,Autocuration,,,1,,,In vitro antagonism of the 5-HT-3 receptor determined by inhibition of 5-HT-induced depolarization of the isolated rat vagus nerve.,H,,,104698,6,,CHEMBL618436,BAO_0000019,
4331,Autocuration,,In vivo,1,,,Concentration required to inhibit pressor response to serotonin after 15 min i.v. administration of compound mediated via activation of vascular 5-HT2 receptors in rat,U,,,22226,0,,CHEMBL618437,BAO_0000218,
4332,Intermediate,10141.0,,1,,,Ability to displace the radioligand [3H]GR-113808 from guinea pig striatum 5-HT4 receptor,D,,,20033,9,,CHEMBL618438,BAO_0000357,
4333,Expert,10116.0,,1,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,H,Microsomes,,17045,8,,CHEMBL883800,BAO_0000251,
4334,Expert,10116.0,,1,,,Inhibition of progesterone 6-beta-hydroxylase in rat hepatic microsomes,H,Microsomes,,17045,8,,CHEMBL618439,BAO_0000251,
4335,Intermediate,,,1,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,U,,,22226,0,,CHEMBL618440,BAO_0000019,
4336,Intermediate,,,1,,,In vitro anticancer activity against 6 NCI ovarian cancer cell lines; inactive,U,,,22226,0,,CHEMBL618441,BAO_0000019,
4337,Expert,5691.0,,1,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli,H,,,11938,8,,CHEMBL618442,BAO_0000019,
4338,Autocuration,5691.0,,1,,,Inhibition constant against 6-phosphogluconate dehydrogenase of Trypanosoma brucei expressed in Escherichia coli; NI denotes no inhibition,H,,,11938,8,,CHEMBL618443,BAO_0000019,
4339,Expert,9940.0,,1,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver,H,,,11938,8,,CHEMBL619158,BAO_0000019,
4340,Autocuration,9940.0,,1,,,Inhibition constant against 6-phosphogluconate dehydrogenase of sheep liver; NI denotes no inhibition,H,,,11938,8,,CHEMBL620974,BAO_0000019,
4341,Autocuration,,,1,,,log Kd which is the binding affinity against 6-phosphogluconate dehydrogenase,H,,,11938,8,,CHEMBL620975,BAO_0000357,
4342,Intermediate,9606.0,,1,,,Average inhibitory concentration against 60 human cell lines was reported,U,,,22226,0,,CHEMBL620976,BAO_0000019,
4343,Expert,9606.0,,1,,,Inhibition of proliferation in NCI panel of 60 human tumor cell lines,U,,,22226,0,,CHEMBL620977,BAO_0000019,
4344,Intermediate,9606.0,,1,,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line,N,,542.0,80315,1,,CHEMBL620978,BAO_0000219,
4345,Intermediate,9606.0,,1,,,Cancer specificity was measured from the +/- value under average log LC50 60-cell line. ,N,,542.0,80315,1,,CHEMBL620979,BAO_0000219,
4346,Expert,,,1,,,In vitro mean growth inhibitory activity against 60-cell panel,N,,542.0,80315,1,,CHEMBL620980,BAO_0000219,
4347,Expert,,,1,,,In vitro mean growth lethal concentration against 60-cell panel,N,,542.0,80315,1,,CHEMBL620981,BAO_0000219,
4348,Expert,,,1,,,In vitro mean growth lethal concentration in colon subpanel against 60-cell panel,N,,542.0,80315,1,,CHEMBL620982,BAO_0000219,
4349,Expert,,,1,,,In vitro mean growth lethal concentration in renal subpanel against 60-cell panel,N,,542.0,80315,1,,CHEMBL620983,BAO_0000219,
4350,Autocuration,,,1,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,H,,,104775,4,,CHEMBL620984,BAO_0000019,
4351,Autocuration,,,1,,,Inhibition of CK-II-mediated 60S acidic ribosomal P protein activity at 10 uM,H,,,104775,4,,CHEMBL620985,BAO_0000019,
4352,Expert,,,1,,,Transcriptional activation in CV-1 expressing retinoid X receptor RXR alpha,H,,,275,8,,CHEMBL620986,BAO_0000357,
4353,Expert,5833.0,,1,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase,N,,,50425,1,,CHEMBL620987,BAO_0000218,
4354,Expert,5833.0,,1,,,In vitro inhibition of Plasmodium falciparum 68 neutral proteinase activity by reinvasion of red blood cells,N,,,50425,1,,CHEMBL620988,BAO_0000218,
4355,Expert,5833.0,,1,,,Inhibitory activity against Plasmodium falciparum 68 neutral proteinase.,N,,,50425,1,,CHEMBL620989,BAO_0000218,
4356,Expert,5833.0,,1,,,Substrate affinity for Plasmodium falciparum 68 neutral proteinase.,N,,,50425,1,,CHEMBL620990,BAO_0000218,
4357,Intermediate,5833.0,,1,,,Reaction velocity for Plasmodium falciparum 68 neutral proteinase.,N,,,50425,1,,CHEMBL620991,BAO_0000218,
4358,Intermediate,10090.0,,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,N,,850.0,80628,1,,CHEMBL620992,BAO_0000218,
4359,Intermediate,10090.0,,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,N,,850.0,80628,1,,CHEMBL620993,BAO_0000218,
4360,Intermediate,10090.0,,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 200 mg/kg in C3H mice,N,,850.0,80628,1,,CHEMBL620994,BAO_0000218,
4361,Intermediate,10090.0,,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,N,,850.0,80628,1,,CHEMBL620995,BAO_0000218,
4362,Intermediate,10090.0,,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,N,,850.0,80628,1,,CHEMBL620996,BAO_0000218,
4363,Intermediate,10090.0,,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 6 mg/kg in C3H mice,N,,850.0,80628,1,,CHEMBL875581,BAO_0000218,
4364,Autocuration,10090.0,In vivo,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 100 mg/kg,U,,,22224,0,,CHEMBL620997,BAO_0000218,
4365,Autocuration,10090.0,In vivo,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 150 mg/kg,U,,,22224,0,,CHEMBL620998,BAO_0000218,
4366,Autocuration,10090.0,In vivo,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 1600 mg/kg (intraperitoneal dosing for 8 days),U,,,22224,0,,CHEMBL620999,BAO_0000218,
4367,Autocuration,10090.0,In vivo,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 200 mg/kg,U,,,22224,0,,CHEMBL621000,BAO_0000218,
4368,Autocuration,10090.0,In vivo,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 225 mg/kg,U,,,22224,0,,CHEMBL621001,BAO_0000218,
4369,Autocuration,10090.0,In vivo,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 270 mg/kg,U,,,22224,0,,CHEMBL621002,BAO_0000218,
4370,Autocuration,10090.0,In vivo,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 275 mg/kg,U,,,22224,0,,CHEMBL621003,BAO_0000218,
4371,Autocuration,10090.0,In vivo,1,,,"Antitumor activity in vivo against the 6C3HED lymphosarcoma, dosed for 10 days at 300 mg/kg",U,,,22224,0,,CHEMBL621004,BAO_0000218,
4372,Autocuration,10090.0,In vivo,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (intraperitoneal dosing for 8 days),U,,,22224,0,,CHEMBL621005,BAO_0000218,
4373,Autocuration,10090.0,In vivo,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 300 mg/kg (ip dosing daily for 8 days),U,,,22224,0,,CHEMBL621006,BAO_0000218,
4374,Autocuration,10090.0,In vivo,1,,,Antitumor activity in vivo against the 6C3HED lymphosarcoma dosed for 10 days at 600 mg/kg,U,,,22224,0,,CHEMBL621007,BAO_0000218,
4375,Autocuration,10090.0,,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 100 mg/kg in C3H mice,U,,,22224,0,,CHEMBL621008,BAO_0000218,
4376,Autocuration,10090.0,,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 12.5 mg/kg in C3H mice,U,,,22224,0,,CHEMBL621009,BAO_0000218,
4377,Autocuration,10090.0,,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 25 mg/kg in C3H mice,U,,,22224,0,,CHEMBL857705,BAO_0000218,
4378,Autocuration,10090.0,,1,,,Percent inhibition against 6C3HED lymphosarcoma at dose 50 mg/kg in C3H mice,U,,,22224,0,,CHEMBL619828,BAO_0000218,
4379,Autocuration,10090.0,,1,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 100 mg/kg dosage administered for 8 days intraperitoneally,U,,,22224,0,,CHEMBL619829,BAO_0000218,
4380,Autocuration,10090.0,,1,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 10 days intraperitoneally,U,,,22224,0,,CHEMBL619830,BAO_0000218,
4381,Autocuration,10090.0,,1,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 200 mg/kg dosage administered for 8 days intraperitoneally,U,,,22224,0,,CHEMBL619831,BAO_0000218,
4382,Autocuration,10090.0,,1,,,Tested on 6C3HED lymphosarcoma and percent inhibition was determined at 50 mg/kg dosage administered for 8 days intraperitoneally,U,,,22224,0,,CHEMBL619832,BAO_0000218,
4383,Autocuration,10090.0,,1,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 100 mg/kg dosage administered for 8 days intraperitoneally; 0/10,U,,,22224,0,,CHEMBL619833,BAO_0000218,
4384,Autocuration,10090.0,,1,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 8 days perorally; 1/10,U,,,22224,0,,CHEMBL619834,BAO_0000218,
4385,Autocuration,10090.0,,1,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 200 mg/kg dosage administered for 10 days intraperitoneally; 1/10,U,,,22224,0,,CHEMBL619835,BAO_0000218,
4386,Autocuration,10090.0,,1,,,Tested on 6 C3 HED lymphosarcoma and number of drug related deaths/total animals in treatment group was determined at 50 mg/kg dosage administered for 8 days perorally; 3/10,U,,,22224,0,,CHEMBL619836,BAO_0000218,
4387,Intermediate,10090.0,,1,,,"Compound was evaluated for the antitumor activity against 6C3HED lymphosarcoma for ip administration and daily x 8 schedule; Number of toxic deaths over total number of mice per group (T/C), 0/10 at dose of 35 mg/kg",N,,850.0,80628,1,,CHEMBL619837,BAO_0000218,
4388,Autocuration,,In vivo,1,,,In vivo antitumor activity against 6C3HED tumor type after intraperitoneal administration of 400 mg/kg,U,,,22224,0,,CHEMBL619838,BAO_0000218,
4389,Intermediate,10090.0,,1,,,In vivo antitumor activity against 6C3HED tumor type was expressed as toxic deaths/total treated mice at 400 mg/kg dose; 2/10,N,,,50594,1,,CHEMBL619839,BAO_0000218,
4390,Intermediate,10090.0,In vivo,1,,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line,N,,850.0,80628,1,,CHEMBL619840,BAO_0000218,
4391,Intermediate,10090.0,In vivo,1,,,Antitumor activity in vivo expressed as percent of inhibition in 6C3HED-lymphosarcoma tumor cell line; 95-100% inhibition,N,,850.0,80628,1,,CHEMBL619841,BAO_0000218,
4392,Expert,10090.0,,1,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 150 mg/kg given orally(daily x 8),N,,850.0,80628,1,,CHEMBL857704,BAO_0000218,
4393,Intermediate,10090.0,,1,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 200 mg/kg given orally(daily x 8),N,,850.0,80628,1,,CHEMBL619842,BAO_0000218,
4394,Expert,10090.0,,1,,,Inhibition of tumor growth of 6C3HED lymphosarcoma tumor cell line in mice at a dose of 300 mg/kg given orally (daily x 8),N,,850.0,80628,1,,CHEMBL619843,BAO_0000218,
4395,Autocuration,1280.0,,1,,,"Inhibition of Staphylococcus aureus 7,8-dihydroneopterin aldolase",U,,,22226,0,,CHEMBL619844,BAO_0000019,
4396,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes 3-methylcholanthrene at a concentration of 5 uM,U,Microsomes,,22226,0,,CHEMBL857855,BAO_0000251,
4397,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 10 uM,U,Microsomes,,22226,0,,CHEMBL619845,BAO_0000251,
4398,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 1 uM,U,Microsomes,,22226,0,,CHEMBL619846,BAO_0000251,
4399,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 20 uM,U,Microsomes,,22226,0,,CHEMBL619847,BAO_0000251,
4400,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 25 uM,U,Microsomes,,22226,0,,CHEMBL619848,BAO_0000251,
4401,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 50 uM,U,Microsomes,,22226,0,,CHEMBL620893,BAO_0000251,
4402,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at a concentration of 5 uM,U,Microsomes,,22226,0,,CHEMBL620894,BAO_0000251,
4403,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 10 uM,U,Microsomes,,22226,0,,CHEMBL620895,BAO_0000251,
4404,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 100 uM,U,Microsomes,,22226,0,,CHEMBL620896,BAO_0000251,
4405,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 200 uM,U,Microsomes,,22226,0,,CHEMBL620897,BAO_0000251,
4406,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 25 uM,U,Microsomes,,22226,0,,CHEMBL620898,BAO_0000251,
4407,Autocuration,10116.0,,1,2107.0,,Michaelis-Menten constant for 7-ethoxycoumarin deethylation in rat liver microsomes exposed to 3-methylcholanthrene at concentration of 50 uM,U,Microsomes,,22226,0,,CHEMBL620899,BAO_0000251,
4408,Autocuration,9527.0,In vivo,1,1969.0,,The apparent total plasma clearance in monkey,U,,,22224,0,,CHEMBL620900,BAO_0000218,
4409,Autocuration,9527.0,In vivo,1,,,Compound was evaluated for Hepatic clearance in monkey,U,,,22224,0,,CHEMBL620901,BAO_0000218,
4410,Autocuration,9527.0,In vivo,1,,,Lower clearance in monkey (i.v.) at 0.5 mpk,U,,,22224,0,,CHEMBL620902,BAO_0000218,
4411,Autocuration,9527.0,In vivo,1,,,Plasma clearance in rhesus monkey,U,,,22224,0,,CHEMBL620903,BAO_0000218,
4412,Autocuration,9527.0,In vivo,1,,,Plasma clearance for the compound was measured in monkey after an iv dose of 1 mg/kg,U,,,22224,0,,CHEMBL620904,BAO_0000218,
4413,Autocuration,9527.0,In vivo,1,,,Plasma clearance of compound was determined in monkey,U,,,22224,0,,CHEMBL620905,BAO_0000218,
4414,Autocuration,9527.0,In vivo,1,,,Plasma clearance was calculated in rhesus monkey,U,,,22224,0,,CHEMBL620906,BAO_0000218,
4415,Autocuration,9527.0,In vivo,1,,,Plasma clearance in rhesus monkey,U,,,22224,0,,CHEMBL875420,BAO_0000218,
4416,Autocuration,9527.0,In vivo,1,,,Plasma clearance in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,,,22224,0,,CHEMBL620907,BAO_0000218,
4417,Autocuration,9527.0,In vivo,1,,,Plasma clearance was evaluated in rhesus,U,,,22224,0,,CHEMBL620908,BAO_0000218,
4418,Autocuration,9527.0,In vivo,1,,,Plasma clearance value was determined in monkey after a 3 mg/kg of iv dose,U,,,22224,0,,CHEMBL620909,BAO_0000218,
4419,Autocuration,9527.0,In vivo,1,,,Plasma clearance was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,U,,,22224,0,,CHEMBL620910,BAO_0000218,
4420,Autocuration,9527.0,In vivo,1,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,,,22224,0,,CHEMBL620911,BAO_0000218,
4421,Autocuration,9527.0,In vivo,1,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,,,22224,0,,CHEMBL620912,BAO_0000218,
4422,Autocuration,9527.0,In vivo,1,,,Cmax 24 hr after 2 mg/kg oral administration in monkeys,U,,,22224,0,,CHEMBL620913,BAO_0000218,
4423,Autocuration,9527.0,In vivo,1,,,Cmax in monkey after administration of 1 mg/kg iv,U,,,22224,0,,CHEMBL620914,BAO_0000218,
4424,Autocuration,9527.0,In vivo,1,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,U,,,22224,0,,CHEMBL620915,BAO_0000218,
4425,Autocuration,9527.0,In vivo,1,,,Cmax in cynomolgus monkey by iv administration,U,,,22224,0,,CHEMBL620916,BAO_0000218,
4426,Autocuration,9527.0,In vivo,1,,,Cmax in cynomolgus monkey by po administration,U,,,22224,0,,CHEMBL620917,BAO_0000218,
4427,Autocuration,9527.0,In vivo,1,,,Cmax value evaluated in monkey,U,,,22224,0,,CHEMBL620918,BAO_0000218,
4428,Autocuration,9527.0,In vivo,1,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,,,22224,0,,CHEMBL620919,BAO_0000218,
4429,Autocuration,9527.0,In vivo,1,1969.0,,Maximal concentration (Cmax) in rhesus monkey plasma at a dose of 5 mg/kg,U,,,22224,0,,CHEMBL620920,BAO_0000218,
4430,Autocuration,9527.0,In vivo,1,1969.0,,Maximal concentration (Cmax) in squirrel monkey plasma at a dose of 5 mg/kg,U,,,22224,0,,CHEMBL620921,BAO_0000218,
4431,Autocuration,9527.0,In vivo,1,1969.0,,Maximal plasma concentration in squirrel monkeys,U,,,22224,0,,CHEMBL620922,BAO_0000218,
4432,Autocuration,9527.0,In vivo,1,,,Maximum concentration was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,,,22224,0,,CHEMBL620923,BAO_0000218,
4433,Autocuration,9527.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) in rhesus monkey(in vivo) at a dose of 5 mg/kg,U,,,22224,0,,CHEMBL620924,BAO_0000218,
4434,Autocuration,9527.0,In vivo,1,,,Pharmacokinetic parameter Cmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,,,22224,0,,CHEMBL620925,BAO_0000218,
4435,Autocuration,9527.0,In vivo,1,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means Not applicable,U,,,22224,0,,CHEMBL620926,BAO_0000218,
4436,Autocuration,9527.0,In vivo,1,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys; NA means not applicable,U,,,22224,0,,CHEMBL620927,BAO_0000218,
4437,Autocuration,9527.0,In vivo,1,,,The peak concentration (Cmax) value after intravenous administration in cynomolgus monkeys;NA means not applicable,U,,,22224,0,,CHEMBL620928,BAO_0000218,
4438,Autocuration,9527.0,In vivo,1,,,The peak concentration (Cmax) value after oral administration in cynomolgus monkeys,U,,,22224,0,,CHEMBL620929,BAO_0000218,
4439,Autocuration,9527.0,In vivo,1,1969.0,,The peak plasma concentration after 5 hr administration (2.5 mg/kg) in monkey was determined,U,,,22224,0,,CHEMBL620930,BAO_0000218,
4440,Autocuration,9527.0,,1,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 0.4 hours,U,,,22224,0,,CHEMBL620931,BAO_0000218,
4441,Autocuration,9527.0,,1,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Monkey at maximum of 1.0 hours,U,,,22224,0,,CHEMBL620932,BAO_0000218,
4442,Autocuration,9443.0,In vivo,1,,,Absolute bioavailability was evaluated in monkey,U,,,22224,0,,CHEMBL620933,BAO_0000218,
4443,Autocuration,9443.0,In vivo,1,,,Bioavailability after oral administration (2.5 mg/kg) in monkey was determined,U,,,22224,0,,CHEMBL620934,BAO_0000218,
4444,Autocuration,9443.0,In vivo,1,,,Bioavailability of compound at 3 mg/kg in monkey after i.v. administration,U,,,22224,0,,CHEMBL620935,BAO_0000218,
4445,Autocuration,9544.0,In vivo,1,,,Bioavailability of compound was determined in rhesus monkey,U,,,22224,0,,CHEMBL620936,BAO_0000218,
4446,Autocuration,38020.0,In vivo,1,,,Bioavailability determined after oral administration in marmoset,U,,,22224,0,,CHEMBL620937,BAO_0000218,
4447,Autocuration,9541.0,In vivo,1,,,Oral bioavailability in cynomolgus monkey,U,,,22224,0,,CHEMBL620938,BAO_0000218,
4448,Autocuration,9443.0,In vivo,1,,,Bioavailability in monkey (p.o.) at 2.0 mpk,U,,,22224,0,,CHEMBL620939,BAO_0000218,
4449,Autocuration,9443.0,In vivo,1,,,Bioavailability was evaluated after oral administration in monkey,U,,,22224,0,,CHEMBL620940,BAO_0000218,
4450,Autocuration,9541.0,In vivo,1,,,Bioavailability was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,,,22224,0,,CHEMBL620941,BAO_0000218,
4451,Autocuration,9544.0,In vivo,1,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,,,22224,0,,CHEMBL620942,BAO_0000218,
4452,Autocuration,9544.0,In vivo,1,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,,,22224,0,,CHEMBL620943,BAO_0000218,
4453,Autocuration,9443.0,In vivo,1,,,Bioavailability of the compound was determined in monkey,U,,,22224,0,,CHEMBL620944,BAO_0000218,
4454,Autocuration,9521.0,In vivo,1,,,Bioavailability in squirrel monkey (dose 5 mg/kg),U,,,22224,0,,CHEMBL620945,BAO_0000218,
4455,Autocuration,9443.0,In vivo,1,,,Bioavailability was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,,,22224,0,,CHEMBL620946,BAO_0000218,
4456,Autocuration,9443.0,In vivo,1,,,Oral bioavailability in monkey,U,,,22224,0,,CHEMBL620947,BAO_0000218,
4457,Autocuration,9521.0,In vivo,1,,,Compound was tested for bioavailability in squirrel monkey,U,,,22224,0,,CHEMBL620948,BAO_0000218,
4458,Autocuration,9544.0,In vivo,1,,,Oral bioavailability in Rhesus monkey,U,,,22224,0,,CHEMBL620949,BAO_0000218,
4459,Autocuration,9544.0,In vivo,1,,,Oral bioavailability in Rhesus monkey (dose of 0.75 mg/kg i.v. and 1.5 mg/kg p.o.),U,,,22224,0,,CHEMBL620950,BAO_0000218,
4460,Autocuration,9541.0,In vivo,1,,,Oral bioavailability in cynomolgus monkeys for the compound was determined; Acceptable,U,,,22224,0,,CHEMBL620951,BAO_0000218,
4461,Autocuration,9541.0,In vivo,1,,,Oral bioavailability in cynomolgus monkeys was determined; Acceptable,U,,,22224,0,,CHEMBL620952,BAO_0000218,
4462,Autocuration,9443.0,In vivo,1,,,Oral bioavailability in monkey (dose 5 mg/kg),U,,,22224,0,,CHEMBL875421,BAO_0000218,
4463,Autocuration,9443.0,In vivo,1,,,Oral bioavailability of compound at 5 mg/kg in monkey,U,,,22224,0,,CHEMBL620953,BAO_0000218,
4464,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic profile in terms of half life was determined at a dose of 0.5 mg/kg administered intravenously in dog,N,,,50588,1,,CHEMBL873491,BAO_0000218,
4465,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic profile in terms of half life was determined at a dose of 5 mg/kg administered intravenously in dog,N,,,50588,1,,CHEMBL620954,BAO_0000218,
4466,Intermediate,9615.0,,1,1969.0,,Plasma half life determined,N,,,50588,1,,CHEMBL620955,BAO_0000218,
4467,Intermediate,9615.0,,1,1969.0,,Plasma half life in dog,N,,,50588,1,,CHEMBL618097,BAO_0000218,
4468,Intermediate,9615.0,,1,1969.0,,Plasma half-life in Beagle dogs,N,,,50588,1,,CHEMBL618268,BAO_0000218,
4469,Intermediate,9615.0,In vivo,1,1969.0,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),N,,,50588,1,,CHEMBL618269,BAO_0000218,
4470,Intermediate,9615.0,In vivo,1,1969.0,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg respectively in Beagle dog (male),N,,,50588,1,,CHEMBL618270,BAO_0000218,
4471,Intermediate,9615.0,In vivo,1,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in dog,N,,,50588,1,,CHEMBL618271,BAO_0000218,
4472,Intermediate,9615.0,In vivo,1,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in dog,N,,,50588,1,,CHEMBL873493,BAO_0000218,
4473,Intermediate,9615.0,,1,,,Tested for the half life period in dog,N,,,50588,1,,CHEMBL621031,BAO_0000218,
4474,Intermediate,9615.0,In vivo,1,,,Tested for the half life period in dog at dosage of 10 mpk,N,,,50588,1,,CHEMBL621032,BAO_0000218,
4475,Intermediate,9615.0,,1,,,The compound was tested for half life in dog,N,,,50588,1,,CHEMBL621033,BAO_0000218,
4476,Intermediate,9615.0,,1,1969.0,,"The compound was tested for time taken to decrease, half of its initial concentration in dog plasma.",N,,,50588,1,,CHEMBL621034,BAO_0000218,
4477,Intermediate,9615.0,,1,,,The half life was determined,N,,,50588,1,,CHEMBL621035,BAO_0000218,
4478,Intermediate,9615.0,,1,1969.0,,The plasma half-life in dogs,N,,,50588,1,,CHEMBL621036,BAO_0000218,
4479,Intermediate,9615.0,,1,1969.0,,suboptimal plasma half-life caused a10% prolongation of QTc interval in dogs at a plasma level of 2.5 M,N,,,50588,1,,CHEMBL621037,BAO_0000218,
4480,Intermediate,9615.0,,1,,,Half life in dog,N,,,50588,1,,CHEMBL619812,BAO_0000218,
4481,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic property (t1/2beta) was measured in dog at the dose of 0.032 mg/kg i.v.,N,,,50588,1,,CHEMBL619813,BAO_0000218,
4482,Intermediate,9615.0,In vivo,1,,,tmax upon peroral administration of 10.0 mg/Kg dose in dog,N,,,50588,1,,CHEMBL873335,BAO_0000218,
4483,Intermediate,9615.0,In vivo,1,,,Volume of distribution in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,,,50588,1,,CHEMBL619814,BAO_0000218,
4484,Expert,9669.0,In vivo,1,,,Cmax in ferrets after 30 mg/kg oral dose,N,,,50506,1,,CHEMBL619815,BAO_0000218,
4485,Expert,9669.0,In vivo,1,,,Emesis in ferrets at 30 mg/kg oral dose,N,,,50506,1,,CHEMBL619816,BAO_0000218,
4486,Autocuration,9541.0,In vivo,1,,,Bioavailability in cynomolgus monkey,U,,,22224,0,,CHEMBL619817,BAO_0000218,
4487,Intermediate,9541.0,In vivo,1,,,Volume of distribution in cynomolgus,N,,,100710,1,,CHEMBL619818,BAO_0000218,
4488,Autocuration,10141.0,,1,1969.0,,AUC tested in guinea pig when 3 mg/kg dose was given perorally,U,,,22224,0,,CHEMBL619819,BAO_0000218,
4489,Autocuration,10141.0,,1,,,Tested for concentration as Area Under Curve against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,U,,,22224,0,,CHEMBL619820,BAO_0000218,
4490,Autocuration,10141.0,,1,,,"Tested for the pharmacokinetic parameter in guinea pig, administered orally at 5 mg/kg",U,,,22224,0,,CHEMBL875419,BAO_0000218,
4491,Autocuration,10141.0,In vivo,1,1969.0,,AUC in guinea pig after 3mg/kg oral dose,U,,,22224,0,,CHEMBL619821,BAO_0000218,
4492,Autocuration,10141.0,In vivo,1,,,Bioavailability in guinea pig was tested,U,,,22224,0,,CHEMBL619822,BAO_0000218,
4493,Autocuration,10141.0,In vivo,1,,,Tested for oral bioavailability in guinea pig at 5 mg/kg,U,,,22224,0,,CHEMBL619823,BAO_0000218,
4494,Autocuration,10141.0,In vivo,1,,,Tested for the oral bioavailability of the compound,U,,,22224,0,,CHEMBL619824,BAO_0000218,
4495,Autocuration,10141.0,In vivo,1,,,Compound at a dose 5 mg/kg was administered orally to guinea pig and the pharmacokinetic parameter (Cmax) was reported,U,,,22224,0,,CHEMBL619825,BAO_0000218,
4496,Autocuration,10141.0,In vivo,1,,,Maximum plsma drug concentration in guinea pig when 3 mg/kg dose was given perorally,U,,,22224,0,,CHEMBL619826,BAO_0000218,
4497,Autocuration,10141.0,In vivo,1,2048.0,,Tested for maximum concentration against PDE4 in guinea pig lung eosinophilia orally at 5 mg/kg,U,,,22224,0,,CHEMBL619827,BAO_0000218,
4498,Autocuration,10141.0,In vivo,1,,,Cmax in guinea pig after 3mg/kg oral dose,U,,,22224,0,,CHEMBL618167,BAO_0000218,
4499,Autocuration,10141.0,,1,178.0,,Distribution in blood expressed as [18F]- organ uptake in % of injected activity/gram,U,,,22224,0,,CHEMBL618168,BAO_0000019,
4500,Autocuration,10141.0,,1,955.0,,Distribution in brain expressed as [18F]- organ uptake in % of injected activity/gram,U,,,22224,0,,CHEMBL618169,BAO_0000019,
4501,Autocuration,10141.0,,1,,,Distribution in heart expressed as [18F]- organ uptake in % of injected activity/gram,U,,,22224,0,,CHEMBL618170,BAO_0000019,
4502,Autocuration,10141.0,,1,160.0,,Distribution in intestine expressed as [18F]- organ uptake in % of injected activity/gram,U,,,22224,0,,CHEMBL618171,BAO_0000019,
4503,Autocuration,10141.0,,1,2113.0,,Distribution in kidney expressed as [18F]- organ uptake in % of injected activity/gram,U,,,22224,0,,CHEMBL618172,BAO_0000019,
4504,Autocuration,10141.0,,1,2107.0,,Distribution in liver expressed as [18F]- organ uptake in % of injected activity/gram,U,,,22224,0,,CHEMBL618173,BAO_0000019,
4505,Autocuration,10141.0,,1,,,Distribution in lung expressed as [18F]- organ uptake in % of injected activity/gram,U,,,22224,0,,CHEMBL618174,BAO_0000019,
4506,Autocuration,10141.0,,1,2106.0,,Distribution in spleen expressed as [18F]- organ uptake in % of injected activity/gram,U,,,22224,0,,CHEMBL875408,BAO_0000019,
4507,Autocuration,10141.0,In vivo,1,,,Elimination T1/2 in Guinea pig (PO dose),U,,,22224,0,,CHEMBL839827,BAO_0000218,
4508,Autocuration,10141.0,,1,,,Partition coefficient was measured as -log (counts per min ),U,,,22224,0,,CHEMBL618175,BAO_0000019,
4509,Autocuration,10141.0,In vivo,1,,,Biological half life when administered at 0.1 umol/kg intravenously to guinea pig in GR-64349 antagonism,U,,,22224,0,,CHEMBL618176,BAO_0000218,
4510,Autocuration,10141.0,In vivo,1,,,Biological half life when administered at 5 umol/kg intravenously to guinea pig in GR-64349 antagonism,U,,,22224,0,,CHEMBL618177,BAO_0000218,
4511,Autocuration,10141.0,In vivo,1,,,Elimination T1/2 in Guinea pig (PO dose),U,,,22224,0,,CHEMBL618178,BAO_0000218,
4512,Autocuration,10141.0,In vivo,1,,,"Tested for the half life period of the compound, intravenously",U,,,22224,0,,CHEMBL618179,BAO_0000218,
4513,Autocuration,10141.0,,1,,,Half-life was measured,U,,,22224,0,,CHEMBL873489,BAO_0000019,
4514,Autocuration,10141.0,,1,,,The time required for onset of inotropy after addition of a single dose of delta F75,U,,,22224,0,,CHEMBL618180,BAO_0000019,
4515,Autocuration,10141.0,In vivo,1,,,Bioavailability of compound at 10 mg/kg in guinea pig after i.v. administration,U,,,22224,0,,CHEMBL618181,BAO_0000218,
4516,Autocuration,10141.0,In vivo,1,,,Bioavailability of compound at 3 mg/kg in guinea pig after i.v. administration,U,,,22224,0,,CHEMBL618182,BAO_0000218,
4517,Autocuration,10029.0,In vivo,1,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,U,,,22224,0,,CHEMBL618183,BAO_0000218,
4518,Intermediate,10090.0,In vivo,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,,50594,1,,CHEMBL618184,BAO_0000218,
4519,Intermediate,10090.0,In vivo,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,,50594,1,,CHEMBL618185,BAO_0000218,
4520,Intermediate,10090.0,In vivo,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,,50594,1,,CHEMBL618186,BAO_0000218,
4521,Intermediate,10090.0,In vivo,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,,50594,1,,CHEMBL618187,BAO_0000218,
4522,Intermediate,10090.0,In vivo,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hr,N,,,50594,1,,CHEMBL618188,BAO_0000218,
4523,Intermediate,10090.0,In vivo,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,,50594,1,,CHEMBL875409,BAO_0000218,
4524,Intermediate,10090.0,In vivo,1,,,Biodistribution of intravenously injected [82Br]-labeled compound in tumor of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,,50594,1,,CHEMBL618189,BAO_0000218,
4525,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of the injected compound in blood of female BALB/C mice for 0.5 hours,N,,,50594,1,,CHEMBL618190,BAO_0000218,
4526,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of the injected compound in blood of female BALB/C mice for 2.5 hours,N,,,50594,1,,CHEMBL618191,BAO_0000218,
4527,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of the injected compound in blood of female BALB/C mice for 5 hours,N,,,50594,1,,CHEMBL618192,BAO_0000218,
4528,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution of the injected compound in bone of female BALB/C mice for 0.5 hours,N,,,50594,1,,CHEMBL618193,BAO_0000218,
4529,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution of the injected compound in bone of female BALB/C mice for 2.5 hours,N,,,50594,1,,CHEMBL618194,BAO_0000218,
4530,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution of the injected compound in bone of female BALB/C mice for 5 hours,N,,,50594,1,,CHEMBL618195,BAO_0000218,
4531,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of the injected compound in brain of female BALB/C mice for 0.5 hours,N,,,50594,1,,CHEMBL618196,BAO_0000218,
4532,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of the injected compound in brain of female BALB/C mice for 2.5 hours,N,,,50594,1,,CHEMBL618197,BAO_0000218,
4533,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of the injected compound in brain of female BALB/C mice for 5 hours,N,,,50594,1,,CHEMBL618198,BAO_0000218,
4534,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of the injected compound in heart of female BALB/C mice for 0.5 hours,N,,,50594,1,,CHEMBL618199,BAO_0000218,
4535,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of the injected compound in heart of female BALB/C mice for 2.5 hours,N,,,50594,1,,CHEMBL618200,BAO_0000218,
4536,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of the injected compound in heart of female BALB/C mice for 5 hours,N,,,50594,1,,CHEMBL618201,BAO_0000218,
4537,Intermediate,10090.0,In vivo,1,160.0,,Biodistribution of the injected compound in intestines of female BALB/C mice for 0.5 hours,N,,,50594,1,,CHEMBL618202,BAO_0000218,
4538,Intermediate,10090.0,In vivo,1,160.0,,Biodistribution of the injected compound in intestines of female BALB/C mice for 2.5 hours,N,,,50594,1,,CHEMBL618203,BAO_0000218,
4539,Intermediate,10090.0,In vivo,1,160.0,,Biodistribution of the injected compound in intestines of female BALB/C mice for 5 hours,N,,,50594,1,,CHEMBL618204,BAO_0000218,
4540,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 0.5 hours,N,,,50594,1,,CHEMBL618205,BAO_0000218,
4541,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 2.5 hours,N,,,50594,1,,CHEMBL618206,BAO_0000218,
4542,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of the injected compound in kidneys of female BALB/C mice for 5 hours,N,,,50594,1,,CHEMBL618207,BAO_0000218,
4543,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of the injected compound in liver of female BALB/C mice for 0.5 hours,N,,,50594,1,,CHEMBL618208,BAO_0000218,
4544,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of the injected compound in liver of female BALB/C mice for 2.5 hours,N,,,50594,1,,CHEMBL618932,BAO_0000218,
4545,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of the injected compound in liver of female BALB/C mice for 5 hours,N,,,50594,1,,CHEMBL618933,BAO_0000218,
4546,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of the injected compound in lung of female BALB/C mice for 0.5 hours,N,,,50594,1,,CHEMBL618934,BAO_0000218,
4547,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of the injected compound in lung of female BALB/C mice for 2.5 hours,N,,,50594,1,,CHEMBL618935,BAO_0000218,
4548,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of the injected compound in lung of female BALB/C mice for 5 hours,N,,,50594,1,,CHEMBL618936,BAO_0000218,
4549,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of the injected compound in muscle of female BALB/C mice for 0.5 hours,N,,,50594,1,,CHEMBL618937,BAO_0000218,
4550,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of the injected compound in muscle of female BALB/C mice for 2.5 hours,N,,,50594,1,,CHEMBL618938,BAO_0000218,
4551,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of the injected compound in muscle of female BALB/C mice for 5 hours,N,,,50594,1,,CHEMBL619104,BAO_0000218,
4552,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of the injected compound in spleen of female BALB/C mice for 0.5 hours,N,,,50594,1,,CHEMBL619105,BAO_0000218,
4553,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of the injected compound in spleen of female BALB/C mice for 2.5 hours,N,,,50594,1,,CHEMBL619106,BAO_0000218,
4554,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of the injected compound in spleen of female BALB/C mice for 5 hours,N,,,50594,1,,CHEMBL619107,BAO_0000218,
4555,Intermediate,10090.0,In vivo,1,945.0,,Biodistribution of the injected compound in stomach of female BALB/C mice for 0.5 hours,N,,,50594,1,,CHEMBL875410,BAO_0000218,
4556,Intermediate,10090.0,In vivo,1,945.0,,Biodistribution of the injected compound in stomach of female BALB/C mice for 2.5 hours,N,,,50594,1,,CHEMBL619108,BAO_0000218,
4557,Intermediate,10090.0,In vivo,1,945.0,,Biodistribution of the injected compound in stomach of female BALB/C mice for 5 hours,N,,,50594,1,,CHEMBL619109,BAO_0000218,
4558,Intermediate,10090.0,In vivo,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,N,,,50594,1,,CHEMBL619110,BAO_0000218,
4559,Intermediate,10090.0,In vivo,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for MRT,N,,,50594,1,,CHEMBL619111,BAO_0000218,
4560,Intermediate,10090.0,In vivo,1,,,MRT value at a dose of 10 mg/kg intravenous administration in mice.,N,,,50594,1,,CHEMBL619112,BAO_0000218,
4561,Intermediate,10090.0,In vivo,1,,,MRT value at a dose of 10 mg/kg peroral administration in mice.,N,,,50594,1,,CHEMBL619113,BAO_0000218,
4562,Intermediate,10090.0,In vivo,1,,,Mean-residence time of compound after intravenous administration in mice at 24 uM/kg,N,,,50594,1,,CHEMBL619114,BAO_0000218,
4563,Intermediate,10090.0,In vivo,1,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 18 uM/kg,N,,,50594,1,,CHEMBL619115,BAO_0000218,
4564,Intermediate,9606.0,,1,,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C after 96 hr,N,,478.0,81034,1,,CHEMBL619116,BAO_0000219,
4565,Intermediate,9606.0,,1,,,In vitro cytotoxicity of compound was determined against A2780 cell lines (cisplatin resistant) at 37 degree C for 96 hr,N,,478.0,81034,1,,CHEMBL619117,BAO_0000219,
4566,Intermediate,9606.0,,1,,,Compound was evaluated for cytotoxicity against A2780 cell lines.,N,,478.0,81034,1,,CHEMBL619118,BAO_0000219,
4567,Intermediate,9606.0,,1,,,Potentiation of growth inhibition of A2780 by compound alone in experiment 1,N,,478.0,81034,1,,CHEMBL619119,BAO_0000219,
4568,Intermediate,9606.0,,1,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,N,,478.0,81034,1,,CHEMBL619120,BAO_0000219,
4569,Intermediate,9606.0,,1,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,N,,478.0,81034,1,,CHEMBL619121,BAO_0000219,
4570,Intermediate,9606.0,,1,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,N,,478.0,81034,1,,CHEMBL619122,BAO_0000219,
4571,Intermediate,9606.0,,1,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,N,,478.0,81034,1,,CHEMBL619123,BAO_0000219,
4572,Intermediate,9606.0,,1,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,N,,478.0,81034,1,,CHEMBL619124,BAO_0000219,
4573,Intermediate,9606.0,,1,,,Compound was evaluated for cytotoxicity against A2780 cell line,N,,478.0,81034,1,,CHEMBL619125,BAO_0000219,
4574,Intermediate,9606.0,,1,,,In vitro inhibitory activity against human tumor cell line A2780,N,,478.0,81034,1,,CHEMBL875411,BAO_0000219,
4575,Intermediate,9606.0,,1,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 1,N,,478.0,81034,1,,CHEMBL619126,BAO_0000219,
4576,Intermediate,9606.0,,1,,,Potentiation of growth inhibition of A2780 cells by compound alone in experiment 2,N,,478.0,81034,1,,CHEMBL619127,BAO_0000219,
4577,Intermediate,9606.0,,1,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 1,N,,478.0,81034,1,,CHEMBL619128,BAO_0000219,
4578,Intermediate,9606.0,,1,,,Potentiation of growth inhibition of A2780 cells along with 10 uM NU1085 in experiment 2,N,,478.0,81034,1,,CHEMBL619129,BAO_0000219,
4579,Intermediate,9606.0,,1,,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines,N,,478.0,81034,1,,CHEMBL619130,BAO_0000219,
4580,Intermediate,9606.0,,1,,,The compound was tested for cytotoxic potency against A2780 human tumor cell lines.,N,,478.0,81034,1,,CHEMBL619131,BAO_0000219,
4581,Intermediate,9606.0,,1,,,cytotoxicity against A2780 cells incubated for 24 hr in MTT assay.,N,,478.0,81034,1,,CHEMBL619132,BAO_0000219,
4582,Expert,9606.0,,1,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,N,,478.0,81034,1,,CHEMBL619133,BAO_0000218,
4583,Intermediate,9606.0,,1,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 1,N,,478.0,81034,1,,CHEMBL619134,BAO_0000219,
4584,Intermediate,9606.0,,1,,,Potentiation factor at 50% growth inhibition (IC50 of compound to that of compound along with PARP inhibitor) in experiment 2,N,,478.0,81034,1,,CHEMBL619135,BAO_0000219,
4585,Intermediate,9606.0,,1,,,Compound was evaluated for cytotoxicity against A2780 cis cell lines.,N,,478.0,81034,1,,CHEMBL619136,BAO_0000219,
4586,Intermediate,9606.0,,1,,,Relative resistance factor in A2780 cisplatin-resistant line,N,,478.0,81034,1,,CHEMBL619137,BAO_0000219,
4587,Intermediate,9606.0,,1,,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells,N,,478.0,81034,1,,CHEMBL883713,BAO_0000219,
4588,Intermediate,9606.0,,1,,,Concentration required to inhibit 50% growth of A2780 human ovarian cancer cells.,N,,478.0,81034,1,,CHEMBL875412,BAO_0000219,
4589,Expert,9606.0,,1,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,N,,478.0,81034,1,,CHEMBL619138,BAO_0000218,
4590,Expert,9606.0,,1,,,In vitro antitumor activity against A2780 human ovarian carcinoma at 7.5 mg/kg i.p. /qd x7,N,,478.0,81034,1,,CHEMBL619262,BAO_0000218,
4591,Intermediate,9606.0,,1,,,Cytotoxicity against A2780 ovarian carcinoma cells was evaluated using standard sulforhodamine 96h assay test,N,,478.0,81034,1,,CHEMBL619139,BAO_0000219,
4592,Intermediate,9606.0,,1,,,In vitro cytotoxicity was determined against A2780 human ovarian cell line using NCI screen,N,,478.0,81034,1,,CHEMBL619140,BAO_0000219,
4593,Intermediate,9606.0,,1,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin,N,,478.0,81034,1,,CHEMBL619141,BAO_0000219,
4594,Intermediate,9606.0,,1,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 1,N,,478.0,81034,1,,CHEMBL619142,BAO_0000219,
4595,Intermediate,9606.0,,1,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 2,N,,478.0,81034,1,,CHEMBL619143,BAO_0000219,
4596,Intermediate,9606.0,,1,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 3,N,,478.0,81034,1,,CHEMBL619144,BAO_0000219,
4597,Intermediate,9606.0,,1,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 5,N,,478.0,81034,1,,CHEMBL619145,BAO_0000219,
4598,Intermediate,9606.0,,1,,,cytotoxic activity toward A2780 ovarian human cell line sensitive (S) to cisplatin in experiment 8,N,,478.0,81034,1,,CHEMBL619146,BAO_0000219,
4599,Intermediate,9606.0,,1,,,Cytotoxic activity in a panel of Human ovarian tumor A2780/CDDP cell line after 96h of drug exposure,N,,478.0,81034,1,,CHEMBL619147,BAO_0000219,
4600,Intermediate,9606.0,,1,,,Antiproliferative effect of compound on A2780/DX cell line,N,,478.0,81034,1,,CHEMBL619148,BAO_0000219,
4601,Intermediate,9606.0,,1,,,Antiproliferative effect of compound on A2780/DX cell line; n.d. indicates not determined,N,,478.0,81034,1,,CHEMBL619149,BAO_0000219,
4602,Intermediate,9606.0,,1,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/DX(RI),N,,478.0,81034,1,,CHEMBL619150,BAO_0000219,
4603,Intermediate,9606.0,,1,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780/Dx(RI),N,,478.0,81034,1,,CHEMBL619151,BAO_0000219,
4604,Intermediate,9606.0,,1,,,Cytotoxicity against ovarian carcinoma A2780/cis tumor cell lines,N,,478.0,81034,1,,CHEMBL883794,BAO_0000219,
4605,Intermediate,9606.0,,1,,,Cytotoxicity against ovarian carcinoma A2780/cis90 tumor cell lines,N,,478.0,81034,1,,CHEMBL619152,BAO_0000219,
4606,Intermediate,9606.0,,1,,,In vitro cytotoxicity against A2780ADR cell line,N,,478.0,81034,1,,CHEMBL619153,BAO_0000219,
4607,Intermediate,9606.0,,1,,,In vitro cytotoxicity against A2780CIS cell line,N,,478.0,81034,1,,CHEMBL619154,BAO_0000219,
4608,Intermediate,9606.0,,1,,,In vitro cytotoxic activity against human tumor cell line A2780CisR after incubation for 96 hours,N,,478.0,81034,1,,CHEMBL619155,BAO_0000219,
4609,Intermediate,9606.0,,1,,,The compound was tested for cytotoxic potency against A2780R human tumor cell lines.,N,,478.0,81034,1,,CHEMBL619156,BAO_0000219,
4610,Intermediate,9606.0,,1,,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-resistant A2780/R human tumor cell lines",N,,478.0,81034,1,,CHEMBL619157,BAO_0000219,
4611,Intermediate,9606.0,,1,,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-resistant A2780/R human tumor cell lines",N,,478.0,81034,1,,CHEMBL619797,BAO_0000219,
4612,Autocuration,9544.0,In vivo,1,,,Oral bioavailability of compound in rhesus macaques,U,,,22224,0,,CHEMBL619798,BAO_0000218,
4613,Autocuration,9443.0,In vivo,1,,,Oral bioavailability in monkey,U,,,22224,0,,CHEMBL619799,BAO_0000218,
4614,Autocuration,9443.0,In vivo,1,,,Oral bioavailability evaluated in monkey,U,,,22224,0,,CHEMBL619800,BAO_0000218,
4615,Autocuration,9443.0,In vivo,1,,,Oral bioavailability in monkey (dose 1 mg/kg p.o.),U,,,22224,0,,CHEMBL619801,BAO_0000218,
4616,Autocuration,9544.0,In vivo,1,,,Oral bioavailability in Rhesus monkey,U,,,22224,0,,CHEMBL619802,BAO_0000218,
4617,Autocuration,9544.0,In vivo,1,,,Oral bioavailability was calculated in rhesus monkey,U,,,22224,0,,CHEMBL619803,BAO_0000218,
4618,Autocuration,9541.0,In vivo,1,,,Oral bioavailability in cynomolgus monkey,U,,,22224,0,,CHEMBL619965,BAO_0000218,
4619,Autocuration,9443.0,In vivo,1,,,Oral bioavailability in monkey,U,,,22224,0,,CHEMBL619966,BAO_0000218,
4620,Autocuration,9443.0,In vivo,1,,,Oral bioavailability in monkey,U,,,22224,0,,CHEMBL619967,BAO_0000218,
4621,Autocuration,9443.0,In vivo,1,,,Oral bioavailability in monkey (dose 1 mg/kg),U,,,22224,0,,CHEMBL620073,BAO_0000218,
4622,Autocuration,9443.0,In vivo,1,,,Oral bioavailability in monkey (dose 5 mg/kg),U,,,22224,0,,CHEMBL620074,BAO_0000218,
4623,Autocuration,9443.0,In vivo,1,,,Oral bioavailability in monkey,U,,,22224,0,,CHEMBL620075,BAO_0000218,
4624,Autocuration,9443.0,In vivo,1,,,Oral bioavailability in monkey,U,,,22224,0,,CHEMBL620076,BAO_0000218,
4625,Autocuration,9544.0,In vivo,1,,,Oral bioavailability in rhesus monkey,U,,,22224,0,,CHEMBL620077,BAO_0000218,
4626,Autocuration,9544.0,In vivo,1,,,Oral bioavailability in rhesus monkey at a dose of 2 mg/kg by po administration,U,,,22224,0,,CHEMBL620078,BAO_0000218,
4627,Autocuration,9521.0,In vivo,1,,,Oral bioavailability in squirrel monkey at a dose of 10 mg/kg,U,,,22224,0,,CHEMBL620079,BAO_0000218,
4628,Autocuration,9443.0,In vivo,1,,,Oral bioavailability in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,,,22224,0,,CHEMBL620080,BAO_0000218,
4629,Autocuration,9544.0,In vivo,1,,,Oral bioavailability in Rhesus monkey,U,,,22224,0,,CHEMBL620081,BAO_0000218,
4630,Autocuration,9544.0,In vivo,1,,,Oral bioavailability in Rhesus monkey (dose 10 mg/kg p.o.),U,,,22224,0,,CHEMBL620082,BAO_0000218,
4631,Autocuration,9443.0,In vivo,1,,,Oral bioavailability in monkey at 10 mg/kg of the compound,U,,,22224,0,,CHEMBL620083,BAO_0000218,
4632,Autocuration,9544.0,In vivo,1,,,Bioavailability in Rhesus monkey,U,,,22224,0,,CHEMBL620084,BAO_0000218,
4633,Autocuration,9527.0,,1,,,Glomerular Filtration Rate(GFR) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,,22224,0,,CHEMBL620085,BAO_0000218,
4634,Autocuration,9527.0,,1,,,Glomerular Filtration Rate(GFR)of the compound compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,,22224,0,,CHEMBL874595,BAO_0000218,
4635,Autocuration,9527.0,In vivo,1,,,Half life by ''Cr'' assay in rhesus monkey at a dose of 5 mg/kg,U,,,22224,0,,CHEMBL873352,BAO_0000218,
4636,Autocuration,9527.0,In vivo,1,,,Half life the of compound was determined by ''Cr'' assay in squirrel monkey at a dose of 5 mg/kg,U,,,22224,0,,CHEMBL620086,BAO_0000218,
4637,Autocuration,9527.0,In vivo,1,,,Mean residence time was determined after intravenous administration in cynomolgus monkeys,U,,,22224,0,,CHEMBL620087,BAO_0000218,
4638,Autocuration,9527.0,In vivo,1,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means Not applicable,U,,,22224,0,,CHEMBL620088,BAO_0000218,
4639,Autocuration,9527.0,In vivo,1,,,Mean residence time was determined after oral administration in cynomolgus monkeys; NA means not applicable,U,,,22224,0,,CHEMBL620089,BAO_0000218,
4640,Autocuration,9527.0,In vivo,1,,,Pharmacokinetic parameter MRT was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,,,22224,0,,CHEMBL620090,BAO_0000218,
4641,Autocuration,9527.0,In vivo,1,,,Pharmacokinetic parameter MRT was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,,,22224,0,,CHEMBL620091,BAO_0000218,
4642,Autocuration,9527.0,,1,,,Metabolism of compound in monkey S9 microsomes ('+''indicates <20% largest observed peak),U,Microsomes,,22224,0,,CHEMBL620092,BAO_0000251,
4643,Autocuration,9527.0,,1,,,Metabolism of compound in monkey S9 microsomes ('++''indicates 20-50% largest observed peak),U,Microsomes,,22224,0,,CHEMBL620093,BAO_0000251,
4644,Autocuration,9527.0,,1,,,Metabolism of compound in monkey S9 microsomes ('+++'indicates 50-80% largest observed peak),U,Microsomes,,22224,0,,CHEMBL620094,BAO_0000251,
4645,Autocuration,9527.0,,1,,,Metabolism of compound in monkey S9 microsomes ('++++' indicates largest observed peak),U,Microsomes,,22224,0,,CHEMBL620095,BAO_0000251,
4646,Autocuration,9527.0,In vivo,1,,,Plasma clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,,22224,0,,CHEMBL620096,BAO_0000218,
4647,Autocuration,9527.0,In vivo,1,,,Plasma clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,,22224,0,,CHEMBL620097,BAO_0000218,
4648,Autocuration,9527.0,,1,,,Clearance from plasma(with matabolite-corrected plasma radioactivity-time integral) at 30 min after administration.,U,,,22224,0,,CHEMBL620098,BAO_0000019,
4649,Autocuration,9527.0,,1,,,Renal clearance evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,,22224,0,,CHEMBL620099,BAO_0000218,
4650,Autocuration,9527.0,,1,,,Renal clearance compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,,22224,0,,CHEMBL620100,BAO_0000218,
4651,Autocuration,9527.0,,1,,,Elimination Half-life of compound was determined in monkey,U,,,22224,0,,CHEMBL620101,BAO_0000019,
4652,Autocuration,9527.0,,1,,,Half life of compound was determined in rhesus monkey,U,,,22224,0,,CHEMBL620102,BAO_0000019,
4653,Autocuration,9527.0,,1,1969.0,,Half life in monkey plasma,U,,,22224,0,,CHEMBL620103,BAO_0000366,
4654,Autocuration,9527.0,,1,1969.0,,Half life in monkey plasma; Not detected,U,,,22224,0,,CHEMBL620104,BAO_0000366,
4655,Autocuration,9527.0,In vivo,1,,,Half life period was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,,,22224,0,,CHEMBL874596,BAO_0000218,
4656,Autocuration,9527.0,In vivo,1,,,Half-life 24 hr after 2 mg/kg iv administration in monkeys,U,,,22224,0,,CHEMBL873490,BAO_0000218,
4657,Autocuration,9527.0,,1,,,Terminal half life of the compound.,U,,,22224,0,,CHEMBL620105,BAO_0000019,
4658,Autocuration,9527.0,In vivo,1,,,Maximum time was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,,,22224,0,,CHEMBL620780,BAO_0000218,
4659,Autocuration,9527.0,In vivo,1,,,Pharmacokinetic parameter Tmax was determined in monkey after (po) administration of a dose of 50 (uM/kg),U,,,22224,0,,CHEMBL620781,BAO_0000218,
4660,Autocuration,9527.0,,1,,,Unbound plasma was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,U,,,22224,0,,CHEMBL620956,BAO_0000218,
4661,Autocuration,9527.0,,1,1088.0,,Urinary recovery evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,,22224,0,,CHEMBL620957,BAO_0000218,
4662,Autocuration,9527.0,,1,1088.0,,Urinary recovery compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,,22224,0,,CHEMBL620958,BAO_0000218,
4663,Autocuration,9527.0,In vivo,1,,,Volume of distribution was determined in monkey after a 3 mg/kg of iv dose,U,,,22224,0,,CHEMBL620959,BAO_0000218,
4664,Autocuration,9527.0,In vivo,1,,,Volume distribution after oral administration (2.5 mg/kg) in monkey was determined,U,,,22224,0,,CHEMBL620960,BAO_0000218,
4665,Autocuration,9527.0,In vivo,1,,,Volume of distribution was evaluated in rhesus,U,,,22224,0,,CHEMBL620961,BAO_0000218,
4666,Autocuration,10029.0,In vivo,1,,,Plasma clearance was measured in hamster at the dose of 10 mg/kg by peroral administration,U,,,22224,0,,CHEMBL620962,BAO_0000218,
4667,Autocuration,10029.0,In vivo,1,,,Plasma clearance was measured in hamster at the dose of 3 mg/kg by intravenous administration,U,,,22224,0,,CHEMBL620963,BAO_0000218,
4668,Autocuration,10029.0,In vivo,1,,,Bioavailability in hamster was determined,U,,,22224,0,,CHEMBL620964,BAO_0000218,
4669,Autocuration,10029.0,In vivo,1,,,Bioavailability in hamster at a dose of 3 mg/kg by intravenous administration,U,,,22224,0,,CHEMBL620965,BAO_0000218,
4670,Autocuration,10029.0,In vivo,1,,,Bioavailability in hamster at a dose of 3 mg/kg by oral administration,U,,,22224,0,,CHEMBL620966,BAO_0000218,
4671,Autocuration,10029.0,,1,178.0,,Half life of compound was determined in hamster blood,U,,,22224,0,,CHEMBL620967,BAO_0000221,
4672,Autocuration,9823.0,,1,,,Michaelis-Menten constant of the compound.,U,,,22224,0,,CHEMBL620968,BAO_0000019,
4673,Autocuration,9823.0,,1,,,Vmax value was measured at 0 uM concentration of silyl ether.,U,,,22224,0,,CHEMBL874597,BAO_0000019,
4674,Autocuration,9823.0,,1,,,Vmax value was measured at 10 uM concentration of silyl ether.,U,,,22224,0,,CHEMBL620969,BAO_0000019,
4675,Autocuration,9823.0,,1,,,Vmax value was measured at 5 uM concentration of silyl ether.,U,,,22224,0,,CHEMBL620970,BAO_0000019,
4676,Expert,9606.0,,1,,,Inactivation of human leukocyte (neutrophil) elastase(HLE)(HNE) as rate constant,D,,,235,9,,CHEMBL620971,BAO_0000357,
4677,Autocuration,9606.0,,1,,,Area under curve was evaluated against man at a dose of 10 mg/kg after po administration,U,,,22224,0,,CHEMBL620972,BAO_0000218,
4678,Autocuration,9606.0,,1,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),U,,,22224,0,,CHEMBL620973,BAO_0000019,
4679,Autocuration,9606.0,,1,,,Active metabolite of ifosfamide determined in humans; A-Active,U,,,22224,0,,CHEMBL618243,BAO_0000019,
4680,Autocuration,9606.0,,1,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis,U,,,22224,0,,CHEMBL618244,BAO_0000019,
4681,Autocuration,9606.0,,1,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; -0.5 to 1,U,,,22224,0,,CHEMBL618245,BAO_0000019,
4682,Autocuration,9606.0,,1,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; 1-2,U,,,22224,0,,CHEMBL618246,BAO_0000019,
4683,Autocuration,9606.0,,1,,,Amount of tecadenoson present after 30 min in the liver S-9 assay as determined by mass specanalysis; trace,U,,,22224,0,,CHEMBL618247,BAO_0000019,
4684,Autocuration,9606.0,,1,,,Compound was evaluated for oral bioavailability in human,U,,,22224,0,,CHEMBL618248,BAO_0000218,
4685,Autocuration,9606.0,,1,1088.0,,Metabolite of ifosfamide determined in urine; NF-Not found,U,,,22224,0,,CHEMBL618249,BAO_0000019,
4686,Autocuration,9606.0,,1,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection (Group A and B),U,,,22224,0,,CHEMBL618250,BAO_0000019,
4687,Autocuration,9606.0,,1,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics,U,,,22224,0,,CHEMBL874598,BAO_0000019,
4688,Autocuration,9606.0,,1,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection after dosing with normal antibiotics and lactose,U,,,22224,0,,CHEMBL618251,BAO_0000019,
4689,Autocuration,9606.0,,1,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics,U,,,22224,0,,CHEMBL618252,BAO_0000019,
4690,Autocuration,9606.0,,1,,,Percent of compound in cirrhotic patients of spontaneous ascitic fluid infection before dosing with normal antibiotics and lactose,U,,,22224,0,,CHEMBL618253,BAO_0000019,
4691,Autocuration,9606.0,,1,,,Percent of compound in cirrhotic patients of sterile ascitic fluid (Group C),U,,,22224,0,,CHEMBL618254,BAO_0000019,
4692,Autocuration,9606.0,,1,,,Percent of compound in healthy individuals (Group D),U,,,22224,0,,CHEMBL618255,BAO_0000019,
4693,Autocuration,9606.0,,1,2107.0,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,U,Microsomes,,22224,0,,CHEMBL618983,BAO_0000251,
4694,Autocuration,9606.0,,1,,,Binding towards human plasma protein at 10 uM,U,,,22224,0,,CHEMBL618984,BAO_0000019,
4695,Autocuration,9606.0,,1,,,Binding towards human plasma protein at 100 uM,U,,,22224,0,,CHEMBL618985,BAO_0000019,
4696,Autocuration,9606.0,,1,,,Human plasma protein binding activity was determined,U,,,22224,0,,CHEMBL618986,BAO_0000019,
4697,Autocuration,9606.0,,1,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),U,,,22224,0,,CHEMBL618987,BAO_0000019,
4698,Autocuration,9606.0,,1,,,Percent binding of compound towards human plasma protein was determined,U,,,22224,0,,CHEMBL618988,BAO_0000019,
4699,Autocuration,9606.0,In vitro,1,2107.0,,Plasma clearance in human liver microsomes,U,Microsomes,,22224,0,,CHEMBL618989,BAO_0000251,
4700,Autocuration,9606.0,In vitro,1,2107.0,,In vitro intrinsic clearance in human liver microsome,U,Microsomes,,22224,0,,CHEMBL618990,BAO_0000251,
4701,Autocuration,9606.0,In vitro,1,2107.0,,In vitro intrinsic clearance in human liver microsome,U,Microsomes,,22224,0,,CHEMBL618991,BAO_0000251,
4702,Autocuration,9606.0,In vitro,1,,,In vitro microsome metabolism clearance in human was determined,U,Microsomes,,22224,0,,CHEMBL876725,BAO_0000251,
4703,Autocuration,9606.0,In vitro,1,,,In vitro microsome metabolism clearance in human was determined; High,U,Microsomes,,22224,0,,CHEMBL618992,BAO_0000251,
4704,Autocuration,9606.0,In vitro,1,,,In vitro microsome metabolism clearance in human was determined; ND denotes no data,U,Microsomes,,22224,0,,CHEMBL618993,BAO_0000251,
4705,Autocuration,9606.0,In vitro,1,2107.0,,Pharmacokinetic property (clearance) in human liver microsome,U,Microsomes,,22224,0,,CHEMBL618994,BAO_0000251,
4706,Autocuration,9606.0,In vitro,1,2107.0,,Plasma clearance in human liver microsomes,U,Microsomes,,22224,0,,CHEMBL618995,BAO_0000251,
4707,Autocuration,9606.0,In vitro,1,2107.0,,In vitro clearance in human liver microsomes,U,Microsomes,,22224,0,,CHEMBL618996,BAO_0000251,
4708,Autocuration,9606.0,In vitro,1,2107.0,,Intrinsic clearance in human liver microsomes was determined,U,Microsomes,,22224,0,,CHEMBL618997,BAO_0000251,
4709,Autocuration,9606.0,In vitro,1,2107.0,,Intrinsic clearance in human liver microsomes was determined,U,Microsomes,,22224,0,,CHEMBL618998,BAO_0000251,
4710,Autocuration,9606.0,In vivo,1,,,Cmax (Tissue distribution) of compound was determined at a dose of 5 mg/kg in human,U,,,22224,0,,CHEMBL618999,BAO_0000218,
4711,Autocuration,9606.0,In vivo,1,,,Maximum concentration was evaluated against man at a dose of 10 mg/kg after po administration,U,,,22224,0,,CHEMBL620223,BAO_0000218,
4712,Autocuration,9606.0,,1,,,Cmin (Clearance) of compound was determined at a dose of 5 mg/kg in human,U,,,22224,0,,CHEMBL620224,BAO_0000218,
4713,Autocuration,9606.0,,1,,,Stability in human plasma 2 hr after incubation expressed as percent concentration,U,,,22224,0,,CHEMBL620225,BAO_0000019,
4714,Autocuration,9606.0,,1,,,Stability in human plasma 4 hr after incubation expressed as percent concentration,U,,,22224,0,,CHEMBL620226,BAO_0000019,
4715,Autocuration,9606.0,,1,1088.0,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 3 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,,22224,0,,CHEMBL620227,BAO_0000019,
4716,Autocuration,9606.0,,1,1088.0,,Portion of holoxan excreted in the form of the metabolite from 1200 mL of urine on day 7 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,,22224,0,,CHEMBL876726,BAO_0000019,
4717,Autocuration,9606.0,,1,1088.0,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 6 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,,22224,0,,CHEMBL620228,BAO_0000019,
4718,Autocuration,9606.0,,1,1088.0,,Portion of holoxan excreted in the form of the metabolite from 1300 mL of urine on day 8 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,,22224,0,,CHEMBL620229,BAO_0000019,
4719,Intermediate,10090.0,In vivo,1,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 23 uM/kg,N,,,50594,1,,CHEMBL620230,BAO_0000218,
4720,Intermediate,10090.0,In vivo,1,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 25 uM/kg,N,,,50594,1,,CHEMBL620231,BAO_0000218,
4721,Intermediate,10090.0,In vivo,1,,,Mean-residence time was determined for compound after intraperitoneal administration in mice at 26 uM/kg,N,,,50594,1,,CHEMBL620232,BAO_0000218,
4722,Intermediate,10090.0,In vivo,1,,,Mean-residence time was determined for compound intravenous administration in mice at 23 uM/kg,N,,,50594,1,,CHEMBL620233,BAO_0000218,
4723,Intermediate,10090.0,,1,,,Metabolism of compound in Mouse S9 microsomes ('++++'indicates largest observed peak),N,,,50594,1,,CHEMBL620234,BAO_0000218,
4724,Intermediate,10090.0,,1,,,Metabolism of compound in mouse S9 microsomes ('+''indicates <20% largest observed peak),N,,,50594,1,,CHEMBL620235,BAO_0000218,
4725,Intermediate,10090.0,,1,,,Metabolism of compound in mouse S9 microsomes ('++++' indicates largest observed peak),N,,,50594,1,,CHEMBL620236,BAO_0000218,
4726,Intermediate,10090.0,,1,2107.0,,In vitro metabolic potential in mouse liver microsomes,N,,,50594,1,,CHEMBL620237,BAO_0000218,
4727,Intermediate,10090.0,,1,,,Ability of compound to bind to plasma protein was evaluated in HSA cells,N,,,50594,1,,CHEMBL620238,BAO_0000218,
4728,Intermediate,10090.0,,1,2369.0,,Compound was tested for radioactivity level in mice adrenal glands (Compound is radiolabeled),N,,,50594,1,,CHEMBL620239,BAO_0000218,
4729,Intermediate,10090.0,,1,955.0,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.2-4.9% ID/g,N,,,50594,1,,CHEMBL620240,BAO_0000218,
4730,Intermediate,10090.0,,1,955.0,,Compound was tested for radioactivity level in mice brain (Compound is radiolabeled); 2.6-4.4% ID/g,N,,,50594,1,,CHEMBL620241,BAO_0000218,
4731,Intermediate,10090.0,,1,,,Compound was tested for radioactivity level in mice heart (Compound is radiolabeled),N,,,50594,1,,CHEMBL876727,BAO_0000218,
4732,Intermediate,10090.0,,1,2113.0,,Compound was tested for radioactivity level in mice kidney (Compound is radiolabeled),N,,,50594,1,,CHEMBL620242,BAO_0000218,
4733,Intermediate,10090.0,,1,,,Compound was tested for radioactivity level in mice lungs (Compound is radiolabeled),N,,,50594,1,,CHEMBL620243,BAO_0000218,
4734,Intermediate,10090.0,,1,,,Tested for urinary recovery in mice after subcutaneous administration of 20 mg/Kg,N,,,50594,1,,CHEMBL620244,BAO_0000218,
4735,Intermediate,10090.0,,1,1977.0,,Compound was evaluated for its potency in CDF1 mice and the serum cholesterol levels were determined,N,,,50594,1,,CHEMBL620245,BAO_0000218,
4736,Intermediate,10090.0,,1,1977.0,,Compound was evaluated for its potency in CDF1 mice and the serum metabolite levels were determined,N,,,50594,1,,CHEMBL620246,BAO_0000218,
4737,Intermediate,10090.0,,1,1977.0,,Compound was evaluated for its potency in CDF1 mice and the serum triglyceride levels were determined,N,,,50594,1,,CHEMBL620247,BAO_0000218,
4738,Intermediate,10090.0,In vivo,1,1969.0,,Half life of compound was determined in plasma of mice at 24 mg/Kg,N,,,50594,1,,CHEMBL620248,BAO_0000218,
4739,Intermediate,10090.0,In vivo,1,1969.0,,Half life of compound was determined in plasma of mice at 40 mg/Kg,N,,,50594,1,,CHEMBL873497,BAO_0000218,
4740,Intermediate,10090.0,In vivo,1,1969.0,,Half life of compound was determined in plasma of mice at 5 mg/Kg,N,,,50594,1,,CHEMBL620249,BAO_0000218,
4741,Intermediate,10090.0,In vivo,1,,,Half life after intraperitoneal administration in mice at 18 uM/kg,N,,,50594,1,,CHEMBL620250,BAO_0000218,
4742,Intermediate,10090.0,In vivo,1,,,Half life after intraperitoneal administration in mice at 23 uM/kg,N,,,50594,1,,CHEMBL620251,BAO_0000218,
4743,Intermediate,10090.0,In vivo,1,,,Half life after intraperitoneal administration in mice at 25 uM/kg,N,,,50594,1,,CHEMBL620252,BAO_0000218,
4744,Intermediate,10090.0,In vivo,1,,,Half life after intraperitoneal administration in mice at 26 uM/kg,N,,,50594,1,,CHEMBL620253,BAO_0000218,
4745,Intermediate,10090.0,In vivo,1,,,Half life after intravenous administration in mice at 23 uM/kg,N,,,50594,1,,CHEMBL620254,BAO_0000218,
4746,Intermediate,10090.0,In vivo,1,,,Half life after intravenous administration in mice at 24 uM/kg,N,,,50594,1,,CHEMBL620255,BAO_0000218,
4747,Intermediate,10090.0,In vivo,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,N,,,50594,1,,CHEMBL620256,BAO_0000218,
4748,Intermediate,10090.0,In vivo,1,,,Maximum time required to reach Cp max was evaluated in mice after intravenous administration; T max Not determined,N,,,50594,1,,CHEMBL876728,BAO_0000218,
4749,Intermediate,10090.0,In vivo,1,,,Maximum time required to reach Cp max was evaluated in mice after oral administration,N,,,50594,1,,CHEMBL620257,BAO_0000218,
4750,Intermediate,10090.0,In vivo,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),N,,,50594,1,,CHEMBL620258,BAO_0000218,
4751,Intermediate,10090.0,In vivo,1,,,"Compound was evaluated for the pharmacokinetic parameter, Terminal half life period",N,,,50594,1,,CHEMBL620259,BAO_0000218,
4752,Intermediate,10090.0,In vivo,1,,,Evaluated for pharmacokinetic parameter half-life in mouse at the dose 20 mg/kg,N,,,50594,1,,CHEMBL620260,BAO_0000218,
4753,Intermediate,10090.0,In vivo,1,178.0,,Half life of compound in mouse blood following i.v. administration of 10 mg/kg,N,,,50594,1,,CHEMBL620261,BAO_0000218,
4754,Intermediate,10090.0,In vivo,1,,,Half life at a dose of 10 mg/kg intravenous administration in mice.,N,,,50594,1,,CHEMBL620262,BAO_0000218,
4755,Intermediate,10090.0,In vivo,1,,,Half life at a dose of 10 mg/kg peroral administration in mice.,N,,,50594,1,,CHEMBL620263,BAO_0000218,
4756,Intermediate,10090.0,,1,,,Half life in ob/ob mice,N,,,50594,1,,CHEMBL620264,BAO_0000218,
4757,Intermediate,10090.0,In vivo,1,,,Half-life at a single subcutaneous administration of 40 mg/kg in mice,N,,,50594,1,,CHEMBL620265,BAO_0000218,
4758,Intermediate,10090.0,,1,,,Half-life was measured in mouse,N,,,50594,1,,CHEMBL620266,BAO_0000218,
4759,Intermediate,10090.0,In vivo,1,,,In vivo half life period was determined in murine septicemia at dose of 50 mg/kg,N,,,50594,1,,CHEMBL620267,BAO_0000218,
4760,Intermediate,10090.0,,1,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation,N,,,50594,1,,CHEMBL619364,BAO_0000218,
4761,Intermediate,10090.0,,1,,,Time for esterases in unfractionated mouse serum to reduce the concentration due to thio ester deacylation; 10 % hydrolysis at 60 mins,N,,,50594,1,,CHEMBL619365,BAO_0000218,
4762,Intermediate,10090.0,,1,955.0,,T2 in brain of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL619366,BAO_0000218,
4763,Intermediate,10090.0,,1,2113.0,,T2 in kidney of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL619367,BAO_0000218,
4764,Intermediate,10090.0,,1,2107.0,,T2 in liver of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL619368,BAO_0000218,
4765,Intermediate,10090.0,,1,2048.0,,T2 in lungs of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL619369,BAO_0000218,
4766,Intermediate,10090.0,,1,2106.0,,T2 in spleen of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL876729,BAO_0000218,
4767,Intermediate,10090.0,In vivo,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for T max,N,,,50594,1,,CHEMBL619370,BAO_0000218,
4768,Intermediate,10090.0,In vivo,1,,,"Compound was evaluated for the pharmacokinetic parameter, maximum time constant",N,,,50594,1,,CHEMBL619371,BAO_0000218,
4769,Intermediate,10090.0,In vivo,1,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg,N,,,50594,1,,CHEMBL619372,BAO_0000218,
4770,Intermediate,10090.0,In vivo,1,,,Evaluated for pharmacokinetic parameter tmax in mouse at the dose 20 mg/kg was determined,N,,,50594,1,,CHEMBL620012,BAO_0000218,
4771,Intermediate,10090.0,In vivo,1,,,In vivo Tmax was determined in murine septicemia at dose of 100 mg/kg,N,,,50594,1,,CHEMBL620013,BAO_0000218,
4772,Intermediate,9606.0,,1,,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",N,,478.0,81034,1,,CHEMBL620014,BAO_0000219,
4773,Intermediate,9606.0,,1,,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-resistant A2780/R human tumor cell lines",N,,478.0,81034,1,,CHEMBL620015,BAO_0000219,
4774,Intermediate,9606.0,,1,,,"Inhibitory effect of Gold(III) complex, 2,2' bipy on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,,478.0,81034,1,,CHEMBL621010,BAO_0000219,
4775,Intermediate,9606.0,,1,,,"Inhibitory effect of Gold(III) complex, CDDP on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,,478.0,81034,1,,CHEMBL621011,BAO_0000219,
4776,Intermediate,9606.0,,1,,,"Inhibitory effect of Gold(III) complex, [Au(bipy)-(OH)2]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,,478.0,81034,1,,CHEMBL621012,BAO_0000219,
4777,Intermediate,9606.0,,1,,,"Inhibitory effect of Gold(III) complex, [Au(bipy-H)(OH)]-[PF6] on growth of cisplatin-sensitive A2780/S human tumor cell lines",N,,478.0,81034,1,,CHEMBL621013,BAO_0000219,
4778,Intermediate,9606.0,,1,,,In vitro cytotoxicity against A2780TAX cell line,N,,478.0,81034,1,,CHEMBL621014,BAO_0000219,
4779,Intermediate,9606.0,,1,,,In vitro inhibitory activity against human tumor cell line A2780cis,N,,481.0,80017,1,,CHEMBL618154,BAO_0000219,
4780,Expert,9606.0,,1,,,Growth inhibition against A2780 cisplatin resistant wild-type ovarian cell lines,N,,478.0,81034,1,,CHEMBL618155,BAO_0000219,
4781,Intermediate,9606.0,,1,,,Antitumor activity of compound for 96-h exposure in A2780cisR (acquired resistance to cisplatin) human ovarian cell line,N,,481.0,80017,1,,CHEMBL618156,BAO_0000219,
4782,Intermediate,9606.0,,1,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),N,,481.0,80017,1,,CHEMBL618157,BAO_0000219,
4783,Intermediate,9606.0,,1,,,Concentration required to inhibit A2780cisR cell growth when compared with control after incubation for 96 h at 37 C,N,,478.0,81034,1,,CHEMBL618328,BAO_0000219,
4784,Intermediate,9606.0,,1,,,Compound was evaluated against human Ovarian carcinoma cell line A2780cisR,N,,478.0,81034,1,,CHEMBL618329,BAO_0000219,
4785,Intermediate,9606.0,,1,,,Cytotoxicity against human ovarian carcinoma A2780cisR cell line,N,,478.0,81034,1,,CHEMBL618330,BAO_0000219,
4786,Expert,9606.0,,1,,,In vitro antitumor activity against A2780cisR cell line.,N,,478.0,81034,1,,CHEMBL618331,BAO_0000219,
4787,Intermediate,9606.0,,1,,,Tested for the cytotoxicity in A2780cisR ovarian cell line (cisR denotes resistance to cisplatin),N,,478.0,81034,1,,CHEMBL618332,BAO_0000219,
4788,Expert,9606.0,,1,,,Resistant factor determined between IC50 of resistant line to that of A2780cisR cell line,N,,478.0,81034,1,,CHEMBL618333,BAO_0000219,
4789,Intermediate,9606.0,,1,,,cytotoxicity against A2780cisR cells incubated for 24 hr in MTT assay,N,,481.0,80017,1,,CHEMBL618334,BAO_0000219,
4790,Expert,9606.0,,1,,,Inhibition of A2780 / DDP-S human ovarian carcinoma cell proliferation,N,,478.0,81034,1,,CHEMBL618335,BAO_0000219,
4791,Expert,10116.0,,1,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes,D,,,11736,9,,CHEMBL618336,BAO_0000019,
4792,Expert,,,1,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),H,,,11736,8,,CHEMBL618337,BAO_0000019,
4793,Expert,10116.0,,1,,,Inhibition against A2A-Adenosine Receptor of rat PC12 cell membranes (functional antagonist activity),D,,,11736,9,,CHEMBL618338,BAO_0000019,
4794,Expert,9606.0,,1,,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells uisng [3H]ZM-241385 or [125I]-IABOPX,D,,722.0,278,9,,CHEMBL618339,BAO_0000219,
4795,Expert,9606.0,,1,,,Antagonist activity against human A2B adenosine receptor expressed in HEK293 cells using [3H]ZM-241385 (or) [125 I]IABOPX at 10e-5 M,D,,722.0,278,9,,CHEMBL618340,BAO_0000219,
4796,Expert,10090.0,,1,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes,D,,,11831,9,,CHEMBL618341,BAO_0000019,
4797,Expert,,,1,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),H,,,11831,8,,CHEMBL618342,BAO_0000019,
4798,Expert,10090.0,,1,,,Inhibition against A2B-Adenosine Receptor in mouse NIH 3T3 fibroblast cell membranes (functional antagonist activity),D,,,11831,9,,CHEMBL618343,BAO_0000019,
4799,Expert,,,1,,,Ability to displace the binding of [3H]-MRE 3008-F20 to the ligand binding site of CHO:hA3 (human Adenosine receptor) at concentration of 10 uM,H,,,280,8,,CHEMBL621038,BAO_0000357,
4800,Autocuration,9606.0,,1,,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01),U,,574.0,22226,0,,CHEMBL621039,BAO_0000219,
4801,Autocuration,9606.0,,1,,,Compound was tested in vitro for inhibition of cytopathogenicity of LAV(IIIB) in CD4+ T-cells (A3.01); Not active,U,,574.0,22226,0,,CHEMBL621040,BAO_0000219,
4802,Intermediate,9606.0,,1,,,Compound was evaluated for cytotoxic activity against human melanoma cell line A375,N,,455.0,80018,1,,CHEMBL621041,BAO_0000219,
4803,Intermediate,9606.0,,1,,,In vitro antitumor activity against A375 (melanoma) human tumor cell lines.,N,,455.0,80018,1,,CHEMBL621042,BAO_0000219,
4804,Intermediate,9606.0,,1,,,In vitro antitumor activity against A375cell line extracted form melanoma,N,,455.0,80018,1,,CHEMBL621043,BAO_0000219,
4805,Expert,9606.0,,1,,,Inhibition of cell growth in (A375) melan cell line,N,,455.0,80018,1,,CHEMBL621044,BAO_0000219,
4806,Intermediate,9606.0,,1,,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines A375,N,,455.0,80018,1,,CHEMBL621045,BAO_0000219,
4807,Intermediate,9606.0,,1,,,In vitro tumor cell growth inhibitory activity against Human melanoma cell lines. A375,N,,455.0,80018,1,,CHEMBL621046,BAO_0000219,
4808,Intermediate,9606.0,,1,,,Compound was tested in vitro for cytotoxicity against A375 cell lines from melanoma.,N,,455.0,80018,1,,CHEMBL621047,BAO_0000219,
4809,Intermediate,9606.0,,1,,,Antiproliferative activity measured against A427 human lung carcinoma,N,,797.0,80019,1,,CHEMBL621048,BAO_0000219,
4810,Intermediate,9606.0,,1,,,Antiproliferative activity measured against A427 human lung carcinoma,N,,797.0,80019,1,,CHEMBL883798,BAO_0000219,
4811,Intermediate,9606.0,,1,,,Cytotoxicity against lung carcinoma A427 tumor cell lines,N,,797.0,80019,1,,CHEMBL621049,BAO_0000219,
4812,Intermediate,9606.0,,1,,,Inhibition of large cell lung carcinoma (A427),N,,797.0,80019,1,,CHEMBL621050,BAO_0000219,
4813,Intermediate,9606.0,,1,,,Inhibition of large cell lung carcinoma (A427) after 48-h treatment,N,,797.0,80019,1,,CHEMBL621051,BAO_0000219,
4814,Intermediate,9606.0,,1,,,Inhibitory activity against A427 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,N,,797.0,80019,1,,CHEMBL621052,BAO_0000219,
4815,Intermediate,9606.0,,1,,,Inhibitory concentration in human lung carcinoma A427 cell line,N,,797.0,80019,1,,CHEMBL621053,BAO_0000219,
4816,Intermediate,9606.0,,1,,,Inhibitory concentration in human lung carcinoma A427/VCR cell line,N,,797.0,80019,1,,CHEMBL621054,BAO_0000219,
4817,Autocuration,9527.0,In vivo,1,,,Terminal phase volume of distribution was measured in monkey after an iv dose of 1 mg/kg,U,,,22224,0,,CHEMBL621055,BAO_0000218,
4818,Autocuration,9527.0,In vivo,1,,,Tested for volume of distribution upon iv administration to african green monkey,U,,,22224,0,,CHEMBL876398,BAO_0000218,
4819,Autocuration,9527.0,In vivo,1,,,Volume of distribution in monkey,U,,,22224,0,,CHEMBL621056,BAO_0000218,
4820,Autocuration,9544.0,In vivo,1,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,,,22224,0,,CHEMBL621057,BAO_0000218,
4821,Autocuration,9544.0,In vivo,1,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,U,,,22224,0,,CHEMBL621058,BAO_0000218,
4822,Autocuration,9527.0,In vivo,1,,,Pharmacokinetic property(Vdss) in cynomolgus monkey,U,,,22224,0,,CHEMBL621059,BAO_0000218,
4823,Autocuration,9527.0,In vivo,1,,,The distribution volume after intravenous administration in cynomolgus monkeys,U,,,22224,0,,CHEMBL621060,BAO_0000218,
4824,Autocuration,9527.0,In vivo,1,,,The distribution volume after oral administration in cynomolgus monkeys; NA means Not applicable,U,,,22224,0,,CHEMBL621061,BAO_0000218,
4825,Autocuration,9527.0,In vivo,1,,,The distribution volume after oral administration in cynomolgus monkeys; NA means not applicable,U,,,22224,0,,CHEMBL621062,BAO_0000218,
4826,Autocuration,9527.0,In vivo,1,,,Volume displacement was calculated in rhesus monkey,U,,,22224,0,,CHEMBL621063,BAO_0000218,
4827,Autocuration,9527.0,In vivo,1,,,Volume of distribution in steady state was determined in rhesus monkey,U,,,22224,0,,CHEMBL621064,BAO_0000218,
4828,Autocuration,9527.0,In vivo,1,,,Volume of distribution of compound was determined in monkey,U,,,22224,0,,CHEMBL621065,BAO_0000218,
4829,Autocuration,9527.0,In vivo,1,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,,,22224,0,,CHEMBL621066,BAO_0000218,
4830,Autocuration,9527.0,In vivo,1,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,,,22224,0,,CHEMBL621067,BAO_0000218,
4831,Autocuration,9527.0,In vivo,1,,,Volumes of distribution in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,,,22224,0,,CHEMBL621068,BAO_0000218,
4832,Autocuration,9527.0,In vivo,1,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,,,22224,0,,CHEMBL876399,BAO_0000218,
4833,Autocuration,9527.0,In vivo,1,,,Volume distribution in monkey after administration of 1 mg/kg iv,U,,,22224,0,,CHEMBL621069,BAO_0000218,
4834,Autocuration,9527.0,In vivo,1,,,Volume distribution was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,,,22224,0,,CHEMBL621070,BAO_0000218,
4835,Autocuration,9527.0,In vivo,1,,,Volume of distribution was measured in monkey after an iv dose of 1 mg/kg,U,,,22224,0,,CHEMBL621071,BAO_0000218,
4836,Autocuration,9527.0,In vivo,1,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,,22224,0,,CHEMBL621072,BAO_0000218,
4837,Autocuration,9527.0,In vivo,1,,,Oral systemic bioavailability upon iv administration to african green monkey,U,,,22224,0,,CHEMBL618209,BAO_0000218,
4838,Autocuration,9527.0,In vivo,1,,,Plasma clearance was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,,,22224,0,,CHEMBL618210,BAO_0000218,
4839,Autocuration,9527.0,,1,,,Baboon plasma free fraction. ,U,,,22224,0,,CHEMBL618211,BAO_0000019,
4840,Autocuration,9527.0,,1,,,Area under the curve was calculated in rhesus monkey after iv administration,U,,,22224,0,,CHEMBL618212,BAO_0000218,
4841,Autocuration,9527.0,,1,,,Area under the curve was calculated in rhesus monkey after peroral administration,U,,,22224,0,,CHEMBL618213,BAO_0000019,
4842,Autocuration,9527.0,,1,,,Dose-normalized area under curve in monkey (p.o.) at 2.0 mpk,U,,,22224,0,,CHEMBL618214,BAO_0000019,
4843,Autocuration,9527.0,In vivo,1,,,Half life period in monkey after 5 mg/kg dose,U,,,22224,0,,CHEMBL873492,BAO_0000218,
4844,Autocuration,9527.0,In vivo,1,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose,U,,,22224,0,,CHEMBL618272,BAO_0000218,
4845,Autocuration,9527.0,In vivo,1,,,Half-life was determined in monkey after 3 mg/kg of i.v. dose; Not determined,U,,,22224,0,,CHEMBL618273,BAO_0000218,
4846,Autocuration,9527.0,In vivo,1,1969.0,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,U,,,22224,0,,CHEMBL618274,BAO_0000218,
4847,Autocuration,9527.0,In vivo,1,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for half life after administration into monkey at 3 mg/kg,U,,,22224,0,,CHEMBL618275,BAO_0000218,
4848,Autocuration,9527.0,In vivo,1,,,Compound was evaluated for half-life after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,,,22224,0,,CHEMBL618276,BAO_0000218,
4849,Autocuration,9527.0,,1,,,Compound was evaluated for terminal half life in monkey,U,,,22224,0,,CHEMBL618277,BAO_0000019,
4850,Autocuration,9527.0,In vivo,1,,,Compound was evaluated for the half life period after iv administration in cynomolgus monkey,U,,,22224,0,,CHEMBL618278,BAO_0000218,
4851,Autocuration,9544.0,In vivo,1,1969.0,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,,,22224,0,,CHEMBL618279,BAO_0000218,
4852,Autocuration,9527.0,,1,,,Half life of compound was determined in squirrel monkey,U,,,22224,0,,CHEMBL618280,BAO_0000019,
4853,Autocuration,9541.0,In vivo,1,,,Half life after iv administration in cynomolgus monkey,U,,,22224,0,,CHEMBL618281,BAO_0000218,
4854,Autocuration,9527.0,In vivo,1,1969.0,,Half life in monkey plasma after administration of 1 mg/kg iv,U,,,22224,0,,CHEMBL618282,BAO_0000218,
4855,Autocuration,9527.0,,1,,,Half life was calculated in rhesus monkey,U,,,22224,0,,CHEMBL618283,BAO_0000019,
4856,Autocuration,9527.0,,1,,,Half life in monkey,U,,,22224,0,,CHEMBL618284,BAO_0000019,
4857,Autocuration,9527.0,In vivo,1,,,Half life in monkey (dosed at 0.5 mpk iv and 2.0 mpk orally),U,,,22224,0,,CHEMBL618285,BAO_0000218,
4858,Autocuration,9527.0,,1,,,Half life was evaluated in rhesus,U,,,22224,0,,CHEMBL618286,BAO_0000019,
4859,Autocuration,9527.0,In vivo,1,,,Half life period after oral administration (2.5 mg/kg) in monkey was determined,U,,,22224,0,,CHEMBL618287,BAO_0000218,
4860,Autocuration,9527.0,In vivo,1,,,Half life period was determine after peroral administration at 10 mpk in Rhesus,U,,,22224,0,,CHEMBL618288,BAO_0000218,
4861,Autocuration,9527.0,In vivo,1,,,Half life period was determined in monkey after (iv) administration of a dose of 13 (uM/kg),U,,,22224,0,,CHEMBL876393,BAO_0000218,
4862,Autocuration,9527.0,In vivo,1,,,Half life period was determined in rhesus monkey at a dose of 1 mg/kg by iv administration,U,,,22224,0,,CHEMBL618289,BAO_0000218,
4863,Autocuration,9527.0,In vivo,1,,,Half life period was determined in squirrel monkey after iv administration at a dose of 5 mg/kg,U,,,22224,0,,CHEMBL618290,BAO_0000218,
4864,Autocuration,9527.0,,1,,,Half-life was calculated in monkey,U,,,22224,0,,CHEMBL618291,BAO_0000019,
4865,Autocuration,9527.0,,1,,,Half-life in Squirrel monkey,U,,,22224,0,,CHEMBL618292,BAO_0000019,
4866,Autocuration,9527.0,,1,,,Half-life in rhesus monkey,U,,,22224,0,,CHEMBL618293,BAO_0000019,
4867,Autocuration,9527.0,In vivo,1,,,Half-life was measured in monkey after an iv dose of 1 mg/kg,U,,,22224,0,,CHEMBL618294,BAO_0000218,
4868,Autocuration,9527.0,In vivo,1,,,Half-life period after intravenous administration in cynomolgus monkeys,U,,,22224,0,,CHEMBL618295,BAO_0000218,
4869,Autocuration,9527.0,In vivo,1,,,Half-life period after oral administration in cynomolgus monkeys,U,,,22224,0,,CHEMBL618296,BAO_0000218,
4870,Autocuration,9527.0,In vivo,1,,,Half-life period after oral administration in cynomolgus monkeys; ND meansn Not determined,U,,,22224,0,,CHEMBL618297,BAO_0000218,
4871,Autocuration,9606.0,,1,1088.0,,Portion of holoxan excreted in the form of the metabolite from 1500 mL of urine on day 9 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,,22224,0,,CHEMBL618298,BAO_0000019,
4872,Autocuration,9606.0,,1,1088.0,,Portion of holoxan excreted in the form of the metabolite from 1600 mL of urine on day 10 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,,22224,0,,CHEMBL618299,BAO_0000019,
4873,Autocuration,9606.0,,1,1088.0,,Portion of holoxan excreted in the form of the metabolite from 1700 mL of urine on day 5 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,,22224,0,,CHEMBL618300,BAO_0000019,
4874,Autocuration,9606.0,,1,1088.0,,Portion of holoxan excreted in the form of the metabolite from 2310 mL of urine on day 4 was determined in embryonal rhabdomyosarcoma patients treated with ifosfamide,U,,,22224,0,,CHEMBL618301,BAO_0000019,
4875,Autocuration,9606.0,,1,1088.0,,Percent ratio of the enantiomeric form (+)R extracted from the urine of alveolar rhabdomyosarcoma patients was determined,U,,,22224,0,,CHEMBL618302,BAO_0000019,
4876,Autocuration,9606.0,,1,1088.0,,Percent ratio of the enantiomeric form (+)R extracted from the urine of embryonal rhabdomyosarcoma patients was determined,U,,,22224,0,,CHEMBL876394,BAO_0000019,
4877,Autocuration,9606.0,,1,1088.0,,Percent ratio of the enantiomeric form (-)S extracted from the urine of alveolar rhabdomyosarcoma patients was determined,U,,,22224,0,,CHEMBL618303,BAO_0000019,
4878,Autocuration,9606.0,,1,1088.0,,Percent ratio of the enantiomeric form (-)S extracted from the urine of embryonal rhabdomyosarcoma patients was determined,U,,,22224,0,,CHEMBL618304,BAO_0000019,
4879,Autocuration,9606.0,In vivo,1,,,Bioavailability was evaluated in man at a dose of 10 mg/kg after po administration; not determined,U,,,22224,0,,CHEMBL618305,BAO_0000218,
4880,Autocuration,9606.0,In vivo,1,,,Oral bioavailability in human,U,,,22224,0,,CHEMBL618306,BAO_0000218,
4881,Autocuration,9606.0,,1,,,Compound was tested for human plasma protein binding,U,,,22224,0,,CHEMBL618307,BAO_0000019,
4882,Autocuration,9606.0,,1,,,Compound was tested for human plasma protein binding; Not determined,U,,,22224,0,,CHEMBL618308,BAO_0000019,
4883,Autocuration,9606.0,,1,,,Protein binding activity of compound in human plasma; % Free,U,,,22224,0,,CHEMBL618309,BAO_0000019,
4884,Autocuration,9606.0,,1,,,Unbound fraction (plasma),U,,,22224,0,,CHEMBL618310,BAO_0000019,
4885,Autocuration,9606.0,,1,1969.0,,Half life for the hydrolysis of compound in human blood serum,U,,,22224,0,,CHEMBL873353,BAO_0000366,
4886,Autocuration,9606.0,,1,1969.0,,Half life period in human plasma using phosphate buffer (0.08 M),U,,,22224,0,,CHEMBL618311,BAO_0000366,
4887,Autocuration,9606.0,,1,1969.0,,Half life period in human plasma using phosphate buffer (0.1 M),U,,,22224,0,,CHEMBL618312,BAO_0000366,
4888,Autocuration,9606.0,,1,1969.0,,Half-life in human plasma was determined,U,,,22224,0,,CHEMBL618313,BAO_0000366,
4889,Autocuration,9606.0,,1,,,Concentration required for 50% toxicity in metastatic lung carcinoma (MV522) cells.,U,,,22224,0,,CHEMBL618314,BAO_0000019,
4890,Autocuration,9606.0,,1,,,Effect of compound on gelation time of human serum induced by dithiothreitol (DTT),U,,,22224,0,,CHEMBL618315,BAO_0000019,
4891,Autocuration,9606.0,,1,,,"Rate constant in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",U,,,22224,0,,CHEMBL618316,BAO_0000019,
4892,Autocuration,9606.0,,1,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",U,,,22224,0,,CHEMBL618317,BAO_0000019,
4893,Autocuration,9606.0,,1,,,"Rate constant in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",U,,,22224,0,,CHEMBL620138,BAO_0000019,
4894,Autocuration,9606.0,,1,,,Partition coefficient (logP),U,,,22224,0,,CHEMBL858280,BAO_0000019,
4895,Autocuration,9606.0,,1,,,In vitro metabolic stability in human was measured as pmol/min/mg/protein,U,,,22224,0,,CHEMBL620139,BAO_0000019,
4896,Autocuration,9606.0,,1,,,In vitro metabolic stability determined after 30 min of incubation in human hepatic microsomes,U,Microsomes,,22224,0,,CHEMBL620140,BAO_0000251,
4897,Autocuration,9606.0,,1,,,Metabolism of compound in human liver slices (male) ('+''indicates <20% largest observed peak),U,,,22224,0,,CHEMBL620141,BAO_0000019,
4898,Autocuration,9606.0,,1,,,Metabolism of compound in human liver slices (male) ('++''indicates 20-50% largest observed peak),U,,,22224,0,,CHEMBL620142,BAO_0000019,
4899,Autocuration,9606.0,,1,,,Metabolism of compound in human liver slices (male) ('++++' indicates largest observed peak),U,,,22224,0,,CHEMBL620143,BAO_0000019,
4900,Autocuration,9606.0,,1,,,Metabolism of compound in human microsomes ('+''indicates <20% largest observed peak),U,Microsomes,,22224,0,,CHEMBL620144,BAO_0000251,
4901,Autocuration,9606.0,,1,,,Metabolism of compound in human microsomes ('++++' indicates largest observed peak),U,Microsomes,,22224,0,,CHEMBL620145,BAO_0000251,
4902,Autocuration,9606.0,,1,,,Metabolism of compound in human microsomes; Trace,U,Microsomes,,22224,0,,CHEMBL620146,BAO_0000251,
4903,Autocuration,9606.0,,1,2107.0,,Percent of compound remaining after 120 min of Metabolization upon incubation with human liver microsomes,U,Microsomes,,22224,0,,CHEMBL620147,BAO_0000251,
4904,Autocuration,9606.0,,1,,,Percent metabolized in an in vitro human liver microsomal incubation assay after 60 min,U,Microsomes,,22224,0,,CHEMBL620148,BAO_0000251,
4905,Autocuration,9606.0,,1,2107.0,,In vitro metabolic potential in human liver microsomes,U,Microsomes,,22224,0,,CHEMBL620149,BAO_0000251,
4906,Autocuration,9606.0,,1,,,Metabolism by recombinant human NAD(P)H:quinone oxidoreductase (NQO1) was evaluated,U,,,22224,0,,CHEMBL876412,BAO_0000019,
4907,Autocuration,9606.0,,1,,,Tested for human plasma protein binding of the compound; Not tested,U,,,22224,0,,CHEMBL619352,BAO_0000019,
4908,Autocuration,9606.0,,1,,,Compound was tested for percent protein binding (PB) in human,U,,,22224,0,,CHEMBL619353,BAO_0000019,
4909,Autocuration,9606.0,,1,1969.0,,Protein binding in human plasma,U,,,22224,0,,CHEMBL619354,BAO_0000019,
4910,Autocuration,9606.0,,1,,,Permeability coefficient (B to A) in Caco-2 cell,U,,,22224,0,,CHEMBL619355,BAO_0000019,
4911,Autocuration,9606.0,,1,,,Permeability directional ratio (PB-A/PA-B) in Caco-2 cell,U,,,22224,0,,CHEMBL619356,BAO_0000019,
4912,Autocuration,9606.0,,1,,,Apparent permeability coefficient (Papp) was determined in human Caco-2 cell monolayer (n = 3),U,,,22224,0,,CHEMBL619357,BAO_0000019,
4913,Autocuration,9606.0,,1,,,In vitro rate of absorption observed as Caco-2 permeability in humans,U,,,22224,0,,CHEMBL619358,BAO_0000019,
4914,Autocuration,9606.0,,1,,,Cellular permeability of compound was determined in Caco-2 cells; High,U,,495.0,22224,0,,CHEMBL619359,BAO_0000219,
4915,Autocuration,9606.0,,1,,,Permeability in Caco-2 cells of compound,U,,495.0,22224,0,,CHEMBL619360,BAO_0000219,
4916,Autocuration,9606.0,,1,,,Permeability coefficient (A to B) in Caco-2 cell,U,,,22224,0,,CHEMBL619361,BAO_0000019,
4917,Autocuration,9606.0,,1,,,Permeability coefficient (B to A) in Caco-2 cell,U,,,22224,0,,CHEMBL619362,BAO_0000019,
4918,Autocuration,9606.0,,1,,,Permeability coefficient (Papp) (Caco-2 cell monolayer),U,,,22224,0,,CHEMBL619363,BAO_0000019,
4919,Autocuration,9606.0,,1,,,Compound was measured for binding rate for human serum at a carbapenem concentration of 10 ug/mL,U,,,22224,0,,CHEMBL618942,BAO_0000019,
4920,Autocuration,9606.0,,1,,,Compound was tested for protein binding in human plasma,U,,,22224,0,,CHEMBL618943,BAO_0000019,
4921,Autocuration,9606.0,,1,,,Transcellular permeability of the [(PA-B+PB-A)/2)] compound was determined in Caco-2 cell,U,,,22224,0,,CHEMBL618944,BAO_0000019,
4922,Autocuration,9606.0,,1,1088.0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 3,U,,,22224,0,,CHEMBL618945,BAO_0000019,
4923,Intermediate,10090.0,In vivo,1,,,In vivo Tmax was determined in murine septicemia at dose of 50 mg/kg,N,,,50594,1,,CHEMBL618946,BAO_0000218,
4924,Intermediate,10090.0,In vivo,1,,,Maximum time was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),N,,,50594,1,,CHEMBL876413,BAO_0000218,
4925,Intermediate,10090.0,In vivo,1,,,Tested for Tmax value at the dose of 10 mg/kg when administered perorally in mouse,N,,,50594,1,,CHEMBL618947,BAO_0000218,
4926,Intermediate,10090.0,In vivo,1,1969.0,,Time taken to reach maximum concentration in plasma upon oral administration in mouse,N,,,50594,1,,CHEMBL618948,BAO_0000218,
4927,Intermediate,10090.0,In vivo,1,1969.0,,Time to reach maximum plasma concentration was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,,,50594,1,,CHEMBL618949,BAO_0000218,
4928,Intermediate,10090.0,In vivo,1,,,Tmax after intraperitoneal administration in mice at 23 uM/kg,N,,,50594,1,,CHEMBL618950,BAO_0000218,
4929,Intermediate,10090.0,In vivo,1,,,Tmax after oral administration at 30 mg/kg in ICR mouse,N,,,50594,1,,CHEMBL618951,BAO_0000218,
4930,Intermediate,10090.0,In vivo,1,,,Tmax after peroral administration in mice at 2.4 uM/kg,N,,,50594,1,,CHEMBL618952,BAO_0000218,
4931,Intermediate,10090.0,In vivo,1,,,Tmax at a single subcutaneous administration of 40 mg/kg in mice,N,,,50594,1,,CHEMBL618953,BAO_0000218,
4932,Intermediate,10090.0,In vivo,1,955.0,,Tmax in brain of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL618954,BAO_0000218,
4933,Intermediate,10090.0,In vivo,1,2113.0,,Tmax in kidney of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL618955,BAO_0000218,
4934,Intermediate,10090.0,In vivo,1,2107.0,,Tmax in liver of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL618956,BAO_0000218,
4935,Intermediate,10090.0,In vivo,1,2048.0,,Tmax in lungs of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL618957,BAO_0000218,
4936,Intermediate,10090.0,In vivo,1,,,Tmax in mice at 18 uM/kg i.p. administration,N,,,50594,1,,CHEMBL618958,BAO_0000218,
4937,Intermediate,10090.0,In vivo,1,,,Tmax in mice at 23 uM/kg i.v. administration,N,,,50594,1,,CHEMBL618959,BAO_0000218,
4938,Intermediate,10090.0,In vivo,1,,,Tmax in mice at 25 uM/kg i.p. administration,N,,,50594,1,,CHEMBL618960,BAO_0000218,
4939,Intermediate,10090.0,In vivo,1,,,Tmax in mice at 26 uM/kg i.p. administration,N,,,50594,1,,CHEMBL876723,BAO_0000218,
4940,Intermediate,10090.0,In vivo,1,2106.0,,Tmax in spleen of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL618961,BAO_0000218,
4941,Intermediate,10090.0,In vivo,1,,,Tmax value at a dose of 10 mg/kg intravenous administration in mice.,N,,,50594,1,,CHEMBL618962,BAO_0000218,
4942,Intermediate,10090.0,In vivo,1,,,Tmax value at a dose of 10 mg/kg peroral administration in mice.,N,,,50594,1,,CHEMBL618963,BAO_0000218,
4943,Intermediate,10090.0,,1,,,Tmax value in IRC mice,N,,,50594,1,,CHEMBL618964,BAO_0000218,
4944,Intermediate,10090.0,In vivo,1,,,Tmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,N,,,50594,1,,CHEMBL618965,BAO_0000218,
4945,Intermediate,10090.0,In vivo,1,,,Tmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,N,,,50594,1,,CHEMBL618966,BAO_0000218,
4946,Intermediate,10090.0,,1,1088.0,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg ( 0-24 hr ),N,,,50594,1,,CHEMBL618967,BAO_0000218,
4947,Intermediate,10090.0,,1,1088.0,,Evaluated for pharmacokinetic parameter urine recovery in mouse at the dose 20 mg/kg (0-24 hr),N,,,50594,1,,CHEMBL618968,BAO_0000218,
4948,Intermediate,10090.0,,1,1088.0,,Urinary recovery by disk method using Streptococcus pyogenes (0-24 h),N,,,50594,1,,CHEMBL618969,BAO_0000218,
4949,Intermediate,10090.0,,1,,,The first compartment constitutes the majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,N,,,50594,1,,CHEMBL618970,BAO_0000218,
4950,Intermediate,10090.0,,1,,,The second majority of the volume of distribution after intraperitoneal administration of 100 mg/kg in mice,N,,,50594,1,,CHEMBL618971,BAO_0000218,
4951,Intermediate,10090.0,In vivo,1,,,Terminal phase volume of distribution was measured in mouse after an iv dose of 1 mg/kg,N,,,50594,1,,CHEMBL618972,BAO_0000218,
4952,Intermediate,10090.0,In vivo,1,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 100 mg/kg,N,,,50594,1,,CHEMBL618973,BAO_0000218,
4953,Intermediate,10090.0,In vivo,1,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg,N,,,50594,1,,CHEMBL618974,BAO_0000218,
4954,Intermediate,10090.0,In vivo,1,,,In vivo volume distribution (Vd) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,N,,,50594,1,,CHEMBL618975,BAO_0000218,
4955,Intermediate,10090.0,In vivo,1,,,Vd in mice,N,,,50594,1,,CHEMBL618976,BAO_0000218,
4956,Intermediate,10090.0,In vivo,1,,,Volume of distribution in mouse,N,,,50594,1,,CHEMBL618977,BAO_0000218,
4957,Intermediate,10090.0,In vivo,1,,,Volume of distribution was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,,,50594,1,,CHEMBL876724,BAO_0000218,
4958,Intermediate,10090.0,In vivo,1,,,Volume of distribution of compound in plasma was determined at 24 mg/Kg,N,,,50594,1,,CHEMBL618978,BAO_0000218,
4959,Intermediate,10090.0,In vivo,1,,,Volume of distribution of compound in plasma was determined at 40 mg/Kg,N,,,50594,1,,CHEMBL618979,BAO_0000218,
4960,Intermediate,10090.0,In vivo,1,,,Volume of distribution of compound in plasma was determined at 5 mg/Kg,N,,,50594,1,,CHEMBL618980,BAO_0000218,
4961,Intermediate,10090.0,In vivo,1,,,Pharmacokinetic property (vdss) was measured in mouse,N,,,50594,1,,CHEMBL618981,BAO_0000218,
4962,Intermediate,10090.0,In vivo,1,,,Value distribution upon iv administration in mouse,N,,,50594,1,,CHEMBL618982,BAO_0000218,
4963,Intermediate,10090.0,In vivo,1,,,Volume of distribution after intraperitoneal administration of 100 mg/kg in mice,N,,,50594,1,,CHEMBL620150,BAO_0000218,
4964,Intermediate,10090.0,In vivo,1,,,Volume of distribution was evaluated in mice after intravenous administration,N,,,50594,1,,CHEMBL620151,BAO_0000218,
4965,Intermediate,10090.0,In vivo,1,,,Volume of distribution was evaluated in mice after oral administration,N,,,50594,1,,CHEMBL620152,BAO_0000218,
4966,Intermediate,10090.0,In vivo,1,,,Steady state volume of distribution of compound in mouse blood following i.v. administration of 10 mg/kg,N,,,50594,1,,CHEMBL620153,BAO_0000218,
4967,Intermediate,10090.0,In vivo,1,,,Steady state volume of distribution was determined in mice,N,,,50594,1,,CHEMBL876395,BAO_0000218,
4968,Intermediate,10090.0,In vivo,1,,,Volume distribution (steady state) of compound was determined in mouse,N,,,50594,1,,CHEMBL620154,BAO_0000218,
4969,Intermediate,10090.0,In vivo,1,,,Volume of solubility in solution after intravenous administration in mice at 24 uM/kg,N,,,50594,1,,CHEMBL620155,BAO_0000218,
4970,Intermediate,10090.0,In vivo,1,,,Vss value at a dose of 10 mg/kg intravenous administration in mice.,N,,,50594,1,,CHEMBL620156,BAO_0000218,
4971,Intermediate,10090.0,In vivo,1,,,Volume of distribution was measured in mouse after an iv dose of 1 mg/kg,N,,,50594,1,,CHEMBL620157,BAO_0000218,
4972,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of compound (oxidized form) in in kidney tissue,N,,,50594,1,,CHEMBL620158,BAO_0000218,
4973,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip administration in DMSO solution,N,,,50594,1,,CHEMBL620159,BAO_0000218,
4974,Intermediate,10090.0,In vivo,1,178.0,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",N,,,50594,1,,CHEMBL620160,BAO_0000218,
4975,Intermediate,10090.0,In vivo,1,178.0,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL620161,BAO_0000218,
4976,Intermediate,9606.0,,1,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A427Mer- cell line of lung using the MTT Cytotoxicity Assay,N,,797.0,80019,1,,CHEMBL620162,BAO_0000219,
4977,Expert,9606.0,,1,,,Inhibition of A431 human squamous cell carcinoma cell proliferation,N,,500.0,80852,1,,CHEMBL620163,BAO_0000219,
4978,Expert,9606.0,,1,,,Inhibition of cell growth of human epidermoid carcinoma xenograft (A431) model using cell based assay,N,,500.0,80852,1,,CHEMBL620833,BAO_0000219,
4979,Expert,9606.0,,1,,,Inhibition of human epidermoid carcinoma xenograft (A431) tumor growth,N,,500.0,80852,1,,CHEMBL876396,BAO_0000219,
4980,Expert,9606.0,,1,,,Concentration required to inhibit growth of human carcinoma epidermoid (A431) cell line,N,,500.0,80852,1,,CHEMBL620834,BAO_0000219,
4981,Expert,9606.0,,1,,,Inhibition of A431 human carcinoma cell proliferation,N,,500.0,80852,1,,CHEMBL620835,BAO_0000219,
4982,Expert,9606.0,,1,,,In vitro inhibition of A431 (human carcinoma) cell basal growth.,N,,500.0,80852,1,,CHEMBL620836,BAO_0000219,
4983,Intermediate,9606.0,,1,,,Inhibitory concentration of compound against growth of human A431 cell line; Resistant,N,,500.0,80852,1,,CHEMBL620837,BAO_0000219,
4984,Intermediate,9606.0,,1,,,In vitro cytotoxicity against epidermoid carcinoma cell line,N,,500.0,80852,1,,CHEMBL621017,BAO_0000219,
4985,Expert,9606.0,,1,,,"In vivo efficacy following oral administration in nude mouse tumor model, xenograft A431 cells expressing EGF-R",D,,500.0,9,9,,CHEMBL621018,BAO_0000218,
4986,Intermediate,9606.0,,1,,,Antiproliferative activity of compound was measured on human tumor cell line A431.,N,,500.0,80852,1,,CHEMBL621019,BAO_0000219,
4987,Intermediate,9606.0,,1,,,Antiproliferative effect of compound on A431 cell line expressing mutant p53,N,,500.0,80852,1,,CHEMBL621020,BAO_0000219,
4988,Intermediate,9606.0,,1,,,Compound was evaluated for cell growth inhibition against A 431 cell line by irradiation in the presence of examined compound,N,,500.0,80852,1,,CHEMBL621021,BAO_0000219,
4989,Expert,,,1,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells.,H,,500.0,9,8,,CHEMBL621022,BAO_0000219,
4990,Expert,9606.0,,1,,,Tested for antiproliferative activity against human A431 cells,N,,500.0,80852,1,,CHEMBL621023,BAO_0000219,
4991,Expert,9606.0,,1,,,Inhibition of epidermal growth factor receptor (EGF-R) autophosphorylation in A431 cells,D,,500.0,9,9,,CHEMBL621024,BAO_0000219,
4992,Expert,9606.0,,1,,,Concentration needed to inhibit 50% growth of the human A431 (epidermoid carcinoma) cell lines,N,,500.0,80852,1,,CHEMBL621025,BAO_0000219,
4993,Expert,9606.0,,1,,,Inhibition of A431 cell proliferation,N,,500.0,80852,1,,CHEMBL621026,BAO_0000219,
4994,Expert,9606.0,,1,,,Cytotoxic effect on A431 human epidermoid carcinoma cells,N,,500.0,80852,1,,CHEMBL621027,BAO_0000219,
4995,Expert,9606.0,,1,,,Cytotoxic effect on A431 human epidermoid carcinoma cells (No response to 1 mM),N,,500.0,80852,1,,CHEMBL876397,BAO_0000219,
4996,Intermediate,9606.0,,1,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line,N,,500.0,80852,1,,CHEMBL883797,BAO_0000219,
4997,Intermediate,9606.0,,1,,,Cytotoxicity expressed as inhibitory concentration required to reduce the cell growth of A431 human epidermal carcinoma cell line; NT=Not tested,N,,500.0,80852,1,,CHEMBL621028,BAO_0000219,
4998,Intermediate,9606.0,,1,,,In vitro Growth Inhibitory activity against A431 Human vulva cancer cell line,N,,500.0,80852,1,,CHEMBL621029,BAO_0000219,
4999,Intermediate,9606.0,,1,,,In vitro cytotoxicity of compound against human A431 (epidermoid) cancer cell line after 72 hr of drug exposure,N,,500.0,80852,1,,CHEMBL621030,BAO_0000219,
5000,Expert,,,1,,,Inhibition of EGF-stimulated tyrosine phosphorylation in A431 cells expressing EGF-R,H,,500.0,9,8,,CHEMBL621147,BAO_0000219,
5001,Intermediate,9606.0,,1,,,In vivo antiproliferative activity against A431 cell line,N,,500.0,80852,1,,CHEMBL621148,BAO_0000218,
5002,Expert,9606.0,,1,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in human A431 cells,D,,500.0,9,9,,CHEMBL621149,BAO_0000219,
5003,Expert,9606.0,,1,,,Inhibition of A431 human epidermoid carcinoma cell proliferation,N,,500.0,80852,1,,CHEMBL621150,BAO_0000219,
5004,Expert,9606.0,,1,,,Inhibition of autophosphorylation of human epidermal growth factor-receptor (EGF-R) expressed in A431 cells,D,,500.0,9,9,,CHEMBL621151,BAO_0000219,
5005,Intermediate,9606.0,,1,,,Inhibitory effect on nonphospho-Src after EGF (100 uM) stimulation of A431 cells (control=178),N,,500.0,80852,1,,CHEMBL621152,BAO_0000219,
5006,Intermediate,9606.0,,1,,,Inhibitory effect on phospho-Src (Tyr416) after EGF (100 uM) stimulation of A431 cells (38),N,,500.0,80852,1,,CHEMBL621153,BAO_0000219,
5007,Intermediate,9606.0,,1,,,Inhibitory effect on phospho-Src/nonphospho after EGF (100 uM) stimulation of A431 cells (21),N,,500.0,80852,1,,CHEMBL884000,BAO_0000219,
5008,Expert,9606.0,,1,,,Inhibition of EGFR overexpressing A431 cell proliferation,D,,,9,9,,CHEMBL621154,BAO_0000019,
5009,Expert,9606.0,,1,,,Inhibition of A431 cell proliferation,N,,500.0,80852,1,,CHEMBL621155,BAO_0000219,
5010,Expert,9606.0,,1,,,No inhibition of EGFR phosphorylation in A431 cells 8 hour after washing cells free of the inhibitor,D,,500.0,9,9,,CHEMBL621156,BAO_0000219,
5011,Expert,9606.0,,1,,,"Partial inhibition of EGFR phosphorylation in A431 cells, 8 hour after washing cells free of the inhibitor",D,,500.0,9,9,,CHEMBL621157,BAO_0000219,
5012,Expert,,,1,,,Irreversible inhibition of ATP binding site of EGFR (lack of phosphorylated EGFR) in A431 cells 8 hour after washing cells free of the inhibitor),H,,500.0,9,8,,CHEMBL621158,BAO_0000219,
5013,Intermediate,9606.0,,1,,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,N,,500.0,80852,1,,CHEMBL621159,BAO_0000219,
5014,Intermediate,9606.0,,1,,,The compound was tested in vitro for antiproliferative activity against A431 tumor cell lines,N,,500.0,80852,1,,CHEMBL621160,BAO_0000219,
5015,Intermediate,9606.0,,1,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration at 2 uM after 48 h; Did not affect the viability,N,,500.0,80852,1,,CHEMBL621161,BAO_0000219,
5016,Intermediate,9606.0,,1,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration in the range of 1-10 uM after 48 h; Did not affect the viability,N,,500.0,80852,1,,CHEMBL621162,BAO_0000219,
5017,Intermediate,9606.0,,1,,,Cell viability in A431 cells unstimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,N,,500.0,80852,1,,CHEMBL621163,BAO_0000219,
5018,Intermediate,9606.0,,1,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 0.01 uM after 48 h; Cell death,N,,500.0,80852,1,,CHEMBL621164,BAO_0000219,
5019,Intermediate,9606.0,,1,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration 2 uM after 48 h; Cell death,N,,500.0,80852,1,,CHEMBL621165,BAO_0000219,
5020,Autocuration,9527.0,,1,,,Half-life period in cynomolgus monkey,U,,,22224,0,,CHEMBL619159,BAO_0000019,
5021,Autocuration,9527.0,In vitro,1,1969.0,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in monkey plasma",U,,,22224,0,,CHEMBL619160,BAO_0000366,
5022,Autocuration,9527.0,In vivo,1,,,Longer half-life in monkey (i.v.) at 0.5 mpk,U,,,22224,0,,CHEMBL619161,BAO_0000218,
5023,Autocuration,9527.0,,1,1969.0,,Plasma half life in monkey,U,,,22224,0,,CHEMBL619162,BAO_0000366,
5024,Autocuration,9527.0,,1,1969.0,,Plasma half-life in rhesus monkey,U,,,22224,0,,CHEMBL619163,BAO_0000366,
5025,Autocuration,9527.0,In vivo,1,1969.0,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Rhesus monkey (male),U,,,22224,0,,CHEMBL619164,BAO_0000218,
5026,Autocuration,9527.0,In vivo,1,1969.0,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Rhesus monkey (male),U,,,22224,0,,CHEMBL619320,BAO_0000218,
5027,Autocuration,9527.0,In vivo,1,,,Tested for half life upon iv administration to african green monkey,U,,,22224,0,,CHEMBL619321,BAO_0000218,
5028,Autocuration,9527.0,In vivo,1,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,,,22224,0,,CHEMBL873336,BAO_0000218,
5029,Autocuration,9527.0,In vivo,1,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means Not applicable,U,,,22224,0,,CHEMBL619322,BAO_0000218,
5030,Autocuration,9527.0,In vivo,1,,,The time for peak concentration value after intravenous administration in cynomolgus monkeys; NA means not applicable,U,,,22224,0,,CHEMBL619323,BAO_0000218,
5031,Autocuration,9527.0,In vivo,1,,,The time for peak concentration value after oral administration in cynomolgus monkeys,U,,,22224,0,,CHEMBL619324,BAO_0000218,
5032,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 10 min after injection of the compound,U,,,22224,0,,CHEMBL619325,BAO_0000019,
5033,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 1 min after injection of the compound,U,,,22224,0,,CHEMBL876411,BAO_0000019,
5034,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 30 min after injection of the compound,U,,,22224,0,,CHEMBL619326,BAO_0000019,
5035,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite (CO2) in baboon plasma at 5 min after injection of the compound,U,,,22224,0,,CHEMBL619327,BAO_0000019,
5036,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite(EME) in baboon plasma at 10 min after injection of the compound,U,,,22224,0,,CHEMBL619328,BAO_0000019,
5037,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite(EME) in baboon plasma at 1 min after injection of the compound,U,,,22224,0,,CHEMBL619329,BAO_0000019,
5038,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite(EME) in baboon plasma at 30 min after injection of the compound,U,,,22224,0,,CHEMBL619330,BAO_0000019,
5039,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite(EME) in baboon plasma at 5 min after injection of the compound,U,,,22224,0,,CHEMBL619331,BAO_0000019,
5040,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 10 min after injection of the compound,U,,,22224,0,,CHEMBL619332,BAO_0000019,
5041,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 1 min after injection of the compound,U,,,22224,0,,CHEMBL619333,BAO_0000019,
5042,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 30 min after injection of the compound,U,,,22224,0,,CHEMBL619334,BAO_0000019,
5043,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite (acid metabolites) in baboon plasma at 5 min after injection of the compound,U,,,22224,0,,CHEMBL619335,BAO_0000019,
5044,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 10 min after injection of the compound,U,,,22224,0,,CHEMBL619336,BAO_0000019,
5045,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 1 min after injection of the compound,U,,,22224,0,,CHEMBL619337,BAO_0000019,
5046,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 30 min after injection of the compound,U,,,22224,0,,CHEMBL619338,BAO_0000019,
5047,Autocuration,9527.0,,1,,,Percentage of tracer or metabolite (unchanged) in baboon plasma at 5 min after injection of the compound,U,,,22224,0,,CHEMBL619339,BAO_0000019,
5048,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),N,,,50597,1,,CHEMBL619340,BAO_0000218,
5049,Intermediate,10116.0,In vivo,1,1969.0,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,N,,,50597,1,,CHEMBL873496,BAO_0000218,
5050,Intermediate,10116.0,,1,1969.0,,AUC value in rat after IV administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL619341,BAO_0000218,
5051,Intermediate,10116.0,,1,1969.0,,AUC value in rat after oral administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL619342,BAO_0000218,
5052,Intermediate,10116.0,In vivo,1,,,Cmax value in rat after oral administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL619343,BAO_0000218,
5053,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat after oral administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL619344,BAO_0000218,
5054,Intermediate,10116.0,In vivo,1,,,Tmax value in rat after oral administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL619345,BAO_0000218,
5055,Intermediate,10116.0,,1,,,Vc value in rat after IV administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL619346,BAO_0000218,
5056,Intermediate,10116.0,In vivo,1,,,Half life period in rat after IV administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL619347,BAO_0000218,
5057,Autocuration,9557.0,,1,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,U,,,22224,0,,CHEMBL619348,BAO_0000019,
5058,Autocuration,9557.0,,1,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 0.5 min after injection in baboon; (Range = 0.08-0.11),U,,,22224,0,,CHEMBL619349,BAO_0000019,
5059,Autocuration,9557.0,,1,,,Peak plasma radioactivity for the carbon-11 labeled compound was determined at 1.5 min after injection in baboon; (Range = 0.08-0.11),U,,,22224,0,,CHEMBL619350,BAO_0000019,
5060,Autocuration,9557.0,,1,,,The amount of unchanged tracer in baboon plasma was determined 1 min after injection of the carbon-11 labeled compound,U,,,22224,0,,CHEMBL619351,BAO_0000019,
5061,Autocuration,9557.0,,1,,,The amount of unchanged tracer in baboon plasma was determined 10 min after injection of the carbon-11 labeled compound,U,,,22224,0,,CHEMBL875953,BAO_0000019,
5062,Autocuration,9557.0,,1,,,The amount of unchanged tracer in baboon plasma was determined 30 min after injection of the carbon-11 labeled compound,U,,,22224,0,,CHEMBL621716,BAO_0000019,
5063,Autocuration,9557.0,,1,,,The amount of unchanged tracer in baboon plasma was determined 60 min after injection of the carbon-11 labeled compound,U,,,22224,0,,CHEMBL621717,BAO_0000019,
5064,Autocuration,9557.0,,1,,,The absolute striatal uptake of the carbon-11 labeled compound at 60 min was determined in baboon,U,,,22224,0,,CHEMBL621718,BAO_0000019,
5065,Autocuration,9615.0,,1,,,Area under curve after 1 mpk peroral administration to beagles,U,,,22224,0,,CHEMBL621719,BAO_0000019,
5066,Autocuration,9615.0,,1,,,Area under curve after 2 mpk peroral administration to beagles,U,,,22224,0,,CHEMBL621720,BAO_0000019,
5067,Autocuration,9615.0,In vivo,1,,,Cmax value after 1 mpk peroral administration to beagles,U,,,22224,0,,CHEMBL621721,BAO_0000218,
5068,Autocuration,9606.0,,1,1088.0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1200 mL of urine tested on day 7,U,,,22224,0,,CHEMBL621722,BAO_0000019,
5069,Autocuration,9606.0,,1,1088.0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 6,U,,,22224,0,,CHEMBL621723,BAO_0000019,
5070,Autocuration,9606.0,,1,1088.0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1300 mL of urine tested on day 8,U,,,22224,0,,CHEMBL621724,BAO_0000019,
5071,Autocuration,9606.0,,1,1088.0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1500 mL of urine tested on day 9,U,,,22224,0,,CHEMBL623443,BAO_0000019,
5072,Autocuration,9606.0,,1,1088.0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1600 mL of urine tested on day 10,U,,,22224,0,,CHEMBL623444,BAO_0000019,
5073,Autocuration,9606.0,,1,1088.0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 1700 mL of urine tested on day 5,U,,,22224,0,,CHEMBL623445,BAO_0000019,
5074,Autocuration,9606.0,,1,1088.0,,Quantity of the metabolite found in the urine of the embryonal rhabdomyosarcoma patients treated with ifosfamide from 2310 mL of urine tested on day 4,U,,,22224,0,,CHEMBL623446,BAO_0000019,
5075,Autocuration,9606.0,,1,2107.0,,Metabolic stability observed at 30 min after administration in human liver microsomes,U,Microsomes,,22224,0,,CHEMBL623447,BAO_0000251,
5076,Autocuration,9606.0,,1,,,Percent recovery of 100 ug/mL compound after administration in cirrhotic patients,U,,,22224,0,,CHEMBL623448,BAO_0000019,
5077,Autocuration,9606.0,,1,,,Percent recovery of 10 ug/mL compound after administration in cirrhotic patients,U,,,22224,0,,CHEMBL623449,BAO_0000019,
5078,Autocuration,9606.0,,1,,,Percent recovery of 500 ug/mL compound after administration in cirrhotic patients,U,,,22224,0,,CHEMBL623450,BAO_0000019,
5079,Autocuration,9606.0,,1,2107.0,,"Compound remaining after incubation with 2 mg/mL of human liver microsomes at 37 degrees C for 30 min in a pH 7.4, 0.05 M phosphate buffer",U,Microsomes,,22224,0,,CHEMBL623451,BAO_0000251,
5080,Autocuration,9606.0,,1,,,Metabolic stability (% remaining at 30 mins) in human S9.,U,,,22224,0,,CHEMBL623452,BAO_0000019,
5081,Autocuration,9606.0,,1,,,Metabolic stability determined as remaining percent after 30 min of incubation in human isolated liver S9 preparations; N/D= Not determined,U,,,22224,0,,CHEMBL623453,BAO_0000019,
5082,Autocuration,9606.0,,1,2107.0,,Percent parent compound remaining after 20 min incubation with human liver microsomes,U,Microsomes,,22224,0,,CHEMBL623454,BAO_0000251,
5083,Autocuration,9606.0,,1,2107.0,,Percent parent compound remaining after 20 min incubation with human liver microsomes; ND=No data,U,Microsomes,,22224,0,,CHEMBL623455,BAO_0000251,
5084,Autocuration,9606.0,,1,2107.0,,Percent parent compound remaining after 20 min incubation with human liver microsomes; No data,U,Microsomes,,22224,0,,CHEMBL624371,BAO_0000251,
5085,Autocuration,9606.0,,1,,,First pass metabolism and metabolic bioavailability using human hepatic microsomes,U,,,22224,0,,CHEMBL624372,BAO_0000218,
5086,Autocuration,9606.0,,1,,,Percent compound remaining in human plasma after incubation for 60 min at 37 C.,U,,,22224,0,,CHEMBL624373,BAO_0000019,
5087,Autocuration,9606.0,,1,,,Percent remaining in human plasma after incubation for 60 min at 37 C.,U,,,22224,0,,CHEMBL624374,BAO_0000019,
5088,Autocuration,9606.0,,1,,,The percent remaining in human plasma after 30 min was determined,U,,,22224,0,,CHEMBL624556,BAO_0000019,
5089,Autocuration,9606.0,,1,1969.0,,Conversion rate of the prodrug in human plasma,U,,,22224,0,,CHEMBL624557,BAO_0000366,
5090,Autocuration,9606.0,,1,1969.0,,Conversion rate of the prodrug in human plasma; ND means no data,U,,,22224,0,,CHEMBL624558,BAO_0000366,
5091,Autocuration,9606.0,,1,178.0,,Half life of compound was determined in human blood,U,,,22224,0,,CHEMBL624559,BAO_0000221,
5092,Autocuration,9606.0,,1,,,Half life of compound was determined in man with once daily dosing,U,,,22224,0,,CHEMBL624560,BAO_0000019,
5093,Autocuration,9606.0,In vitro,1,,,Half life in human microsomes,U,Microsomes,,22224,0,,CHEMBL624561,BAO_0000251,
5094,Autocuration,9606.0,,1,1969.0,,Half life in human plasma,U,,,22224,0,,CHEMBL624562,BAO_0000366,
5095,Autocuration,9606.0,,1,1969.0,,Half life in human plasma; Not detected,U,,,22224,0,,CHEMBL624563,BAO_0000366,
5096,Autocuration,9606.0,In vivo,1,,,Half life period was evaluated against man at a dose of 10 mg/kg after po administration,U,,,22224,0,,CHEMBL624564,BAO_0000218,
5097,Autocuration,9606.0,In vitro,1,2107.0,,Half-life for oxidative metabolic stability was determined using rat liver microsomes,U,Microsomes,,22224,0,,CHEMBL624565,BAO_0000251,
5098,Autocuration,9606.0,,1,1969.0,,Half-life in human plasma,U,,,22224,0,,CHEMBL875152,BAO_0000366,
5099,Autocuration,9606.0,,1,1969.0,,Half-life of the parent prodrug in plasma,U,,,22224,0,,CHEMBL624566,BAO_0000366,
5100,Autocuration,9606.0,In vitro,1,1969.0,,In vitro half life in human plasma was determined,U,,,22224,0,,CHEMBL873805,BAO_0000366,
5101,Autocuration,9606.0,In vitro,1,2107.0,,The compound was tested In Vitro for half life in human liver microsomes.,U,Microsomes,,22224,0,,CHEMBL624567,BAO_0000251,
5102,Autocuration,9606.0,In vivo,1,,,Maximum time was evaluated against man at a dose of 10 mg/kg after po administration,U,,,22224,0,,CHEMBL624568,BAO_0000218,
5103,Autocuration,9606.0,In vivo,1,,,Observed volume of distribution,U,,,22224,0,,CHEMBL624569,BAO_0000218,
5104,Autocuration,9606.0,In vivo,1,,,Oral bioavailability in human,U,,,22224,0,,CHEMBL624570,BAO_0000218,
5105,Autocuration,9606.0,,1,,,Tested for human plasma protein binding of the compound,U,,,22224,0,,CHEMBL624571,BAO_0000019,
5106,Autocuration,9606.0,,1,,,"First order rate constant, k was determined in human plasma",U,,,22224,0,,CHEMBL624572,BAO_0000019,
5107,Autocuration,9606.0,,1,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,U,,,22224,0,,CHEMBL624573,BAO_0000019,
5108,Autocuration,9606.0,,1,,,Observed rate constant in 80% human plasma at 37 degree Centigrade,U,,,22224,0,,CHEMBL875153,BAO_0000019,
5109,Autocuration,9606.0,,1,2107.0,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,U,Microsomes,,22224,0,,CHEMBL624574,BAO_0000251,
5110,Autocuration,9606.0,,1,,,The compound was tested for the plasma binding in human,U,,,22224,0,,CHEMBL624575,BAO_0000019,
5111,Autocuration,9606.0,,1,,,Plasma protein binding (human),U,,,22224,0,,CHEMBL624576,BAO_0000019,
5112,Autocuration,9606.0,In vitro,1,2107.0,,Compound was evaluated for half-life in human liver microsomes,U,Microsomes,,22224,0,,CHEMBL624577,BAO_0000251,
5113,Autocuration,9606.0,In vitro,1,178.0,,Half life measured in vitro for its stability in human blood,U,,,22224,0,,CHEMBL624578,BAO_0000221,
5114,Autocuration,9606.0,,1,1977.0,,Half life in human serum,U,,,22224,0,,CHEMBL622796,BAO_0000019,
5115,Autocuration,9606.0,,1,1977.0,,Half life in human serum; ND=not determined,U,,,22224,0,,CHEMBL622797,BAO_0000019,
5116,Autocuration,9606.0,,1,,,Half life were determined in CEM-SS cell extract in decomposition step 1,U,,,22224,0,,CHEMBL622798,BAO_0000019,
5117,Autocuration,9606.0,,1,,,Half life were determined in CEM-SS cell extract in decomposition step 2,U,,,22224,0,,CHEMBL622799,BAO_0000019,
5118,Autocuration,9606.0,,1,1969.0,,Half life of the in human plasma,U,,,22224,0,,CHEMBL622800,BAO_0000366,
5119,Autocuration,9606.0,In vitro,1,,,Half life period in human hepatic S9 fraction was determined,U,S9,,22224,0,,CHEMBL622801,BAO_0000220,
5120,Autocuration,9606.0,In vitro,1,2107.0,,Half life period in human liver microsome was determined,U,Microsomes,,22224,0,,CHEMBL622802,BAO_0000251,
5121,Autocuration,9606.0,,1,,,Half life period was determined; 6-7,U,,,22224,0,,CHEMBL622803,BAO_0000019,
5122,Autocuration,9606.0,,1,,,Half life period was evaluated in human,U,,,22224,0,,CHEMBL875154,BAO_0000019,
5123,Autocuration,9606.0,,1,1969.0,,Half life time in human plasma,U,,,22224,0,,CHEMBL622804,BAO_0000366,
5124,Intermediate,10090.0,In vivo,1,955.0,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL622805,BAO_0000218,
5125,Intermediate,10090.0,In vivo,1,948.0,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL622611,BAO_0000218,
5126,Intermediate,10090.0,In vivo,1,948.0,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL622612,BAO_0000218,
5127,Intermediate,10090.0,In vivo,1,2113.0,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL875160,BAO_0000218,
5128,Intermediate,10090.0,In vivo,1,2113.0,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",N,,,50594,1,,CHEMBL622613,BAO_0000218,
5129,Intermediate,10090.0,In vivo,1,2113.0,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL622614,BAO_0000218,
5130,Intermediate,10090.0,In vivo,1,2107.0,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL622615,BAO_0000218,
5131,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution in mice as total concentration of both oxidized and reduced forms in liver and animals were sacrificed 10 minutes after ip administration in DMSO solution,N,,,50594,1,,CHEMBL622616,BAO_0000218,
5132,Intermediate,10090.0,In vivo,1,2107.0,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL622617,BAO_0000218,
5133,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip administration in DMSO solution,N,,,50594,1,,CHEMBL622618,BAO_0000218,
5134,Intermediate,10090.0,In vivo,1,2106.0,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen and animals were sacrificed 10 minutes after ip dosing, in DMSO solution",N,,,50594,1,,CHEMBL622619,BAO_0000218,
5135,Intermediate,10090.0,In vivo,1,2106.0,,"Biodistribution in mice as total concentration of both oxidized and reduced forms in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL622620,BAO_0000218,
5136,Intermediate,10090.0,In vivo,1,955.0,,"Biodistribution in mice, total concentration of both oxidized and reduced forms in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,,50594,1,,CHEMBL622621,BAO_0000218,
5137,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of compound (oxidized form) in blood tissue,N,,,50594,1,,CHEMBL622622,BAO_0000218,
5138,Intermediate,10090.0,In vivo,1,178.0,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL622623,BAO_0000218,
5139,Intermediate,10090.0,In vivo,1,178.0,,"Biodistribution of compound (oxidized form) in blood tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",N,,,50594,1,,CHEMBL622624,BAO_0000218,
5140,Intermediate,10090.0,In vivo,1,178.0,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,,50594,1,,CHEMBL622625,BAO_0000218,
5141,Intermediate,10090.0,In vivo,1,178.0,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL622626,BAO_0000218,
5142,Intermediate,10090.0,In vivo,1,178.0,,"Biodistribution of compound (oxidized form) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,,,50594,1,,CHEMBL622627,BAO_0000218,
5143,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of compound (oxidized form) in brain tissue of mice,N,,,50594,1,,CHEMBL622628,BAO_0000218,
5144,Intermediate,10090.0,In vivo,1,955.0,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL622629,BAO_0000218,
5145,Intermediate,10090.0,In vivo,1,955.0,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO",N,,,50594,1,,CHEMBL622630,BAO_0000218,
5146,Intermediate,10090.0,In vivo,1,955.0,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL622631,BAO_0000218,
5147,Intermediate,10090.0,In vivo,1,955.0,,"Biodistribution of compound (oxidized form) in brain tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,,,50594,1,,CHEMBL622632,BAO_0000218,
5148,Intermediate,10090.0,In vivo,1,955.0,,"Biodistribution of compound (oxidized form) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO solution",N,,,50594,1,,CHEMBL622633,BAO_0000218,
5149,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of compound (oxidized form) in heart tissue of mice,N,,,50594,1,,CHEMBL622634,BAO_0000218,
5150,Intermediate,10090.0,In vivo,1,948.0,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL622635,BAO_0000218,
5151,Intermediate,10090.0,In vivo,1,948.0,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL875161,BAO_0000218,
5152,Intermediate,10090.0,In vivo,1,948.0,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO",N,,,50594,1,,CHEMBL622636,BAO_0000218,
5153,Intermediate,10090.0,In vivo,1,948.0,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL623335,BAO_0000218,
5154,Intermediate,10090.0,In vivo,1,948.0,,"Biodistribution of compound (oxidized form) in heart tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,,,50594,1,,CHEMBL623336,BAO_0000218,
5155,Intermediate,10090.0,In vivo,1,2113.0,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL623337,BAO_0000218,
5156,Intermediate,10090.0,In vivo,1,2113.0,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",N,,,50594,1,,CHEMBL623338,BAO_0000218,
5157,Intermediate,10090.0,In vivo,1,2113.0,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO",N,,,50594,1,,CHEMBL623339,BAO_0000218,
5158,Intermediate,10090.0,In vivo,1,2113.0,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL623524,BAO_0000218,
5159,Intermediate,10090.0,In vivo,1,2113.0,,"Biodistribution of compound (oxidized form) in kidney tissue, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,,,50594,1,,CHEMBL623525,BAO_0000218,
5160,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of compound (oxidized form) in liver tissue,N,,,50594,1,,CHEMBL623526,BAO_0000218,
5161,Intermediate,10090.0,In vivo,1,2107.0,,"Biodistribution of compound (oxidized form) in liver tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL623527,BAO_0000218,
5162,Intermediate,10090.0,In vivo,1,2107.0,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,,50594,1,,CHEMBL623528,BAO_0000218,
5163,Intermediate,9606.0,,1,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration in the range of 1-10 uM of the compound after 48 h; Cell death,N,,500.0,80852,1,,CHEMBL624615,BAO_0000219,
5164,Intermediate,9606.0,,1,,,Cell viability in A431 cells when stimulated with EGF was tested when incubated with concentration up to 10 uM after 48 h; Did not affect the viability,N,,500.0,80852,1,,CHEMBL621672,BAO_0000219,
5165,Expert,,,1,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 10-24 days)",N,,500.0,80852,1,,CHEMBL621673,BAO_0000218,
5166,Expert,,,1,,,"In vivo activity in A431 tumor bearing mice, maximum dose (schedule 12-26 days)",N,,500.0,80852,1,,CHEMBL621674,BAO_0000218,
5167,Expert,9606.0,,1,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,D,,500.0,9,9,,CHEMBL884002,BAO_0000219,
5168,Intermediate,9606.0,,1,,,"Concentration required to inhibit the epidermoid A431 cell growth by 50%, P53 status of cell line used was wild-type. ",N,,500.0,80852,1,,CHEMBL621850,BAO_0000219,
5169,Intermediate,9606.0,,1,,,Inhibitory activity against proliferation of human epidermoid carcinoma (A431) cells,N,,500.0,80852,1,,CHEMBL621851,BAO_0000219,
5170,Expert,9606.0,,1,,,Inhibition of EGF-dependent autophosphorylation of EGF-R in A431 cells,D,,500.0,9,9,,CHEMBL621852,BAO_0000219,
5171,Expert,9606.0,,1,,,Inhibition of autophosphorylation of epidermal growth factor receptor in A431 cells in culture,D,,500.0,9,9,,CHEMBL621853,BAO_0000219,
5172,Expert,,,1,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 10-24 days)",N,,500.0,80852,1,,CHEMBL621854,BAO_0000218,
5173,Expert,,,1,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",N,,500.0,80852,1,,CHEMBL621855,BAO_0000218,
5174,Expert,,,1,,,"In vivo activity in A431 tumor bearing mice, relative time required for treated and control tumors to reach 750 mg (schedule 12-26 days)",N,,500.0,80852,1,,CHEMBL623724,BAO_0000218,
5175,Expert,,,1,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 24",N,,500.0,80852,1,,CHEMBL623725,BAO_0000218,
5176,Expert,,,1,,,"In vivo activity in A431 tumor bearing mice, ratio of treated and control tumor mass day 26",N,,500.0,80852,1,,CHEMBL623726,BAO_0000218,
5177,Expert,9606.0,,1,,,"Irreversible inhibition of EGF-R phosphorylation in A431 cells, 8 hr after washing cells free of compound",D,,500.0,9,9,,CHEMBL623727,BAO_0000219,
5178,Expert,,,1,,,Irreversible inhibition of formation of phosphorylated EGFR in A431 cells 8 hr after washing cells free of compound,H,,500.0,9,8,,CHEMBL623728,BAO_0000219,
5179,Expert,,,1,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 10-24",N,,500.0,80852,1,,CHEMBL623729,BAO_0000218,
5180,Expert,,,1,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",N,,500.0,80852,1,,CHEMBL623730,BAO_0000218,
5181,Expert,,,1,,,"In vivo activity in A431 tumor bearing mice, maximum weight loss days 12-26",N,,500.0,80852,1,,CHEMBL623731,BAO_0000218,
5182,Expert,10090.0,,1,,,"Ratio of treated and control A431 cell tumor mass in mice at 5 mg/kg peroral dose, days 7-21 administration",N,,500.0,80852,1,,CHEMBL623732,BAO_0000218,
5183,Expert,10090.0,,1,,,"Difference in days for treated (T) and control (C) A431 cell tumors to reach 750 mg in mice at 5 mg/kg peroral dose, days 7-21 administration",N,,500.0,80852,1,,CHEMBL623733,BAO_0000218,
5184,Expert,10090.0,,1,,,"Net reduction in tumor burden between first and last treatments of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",N,,500.0,80852,1,,CHEMBL623734,BAO_0000218,
5185,Expert,10090.0,,1,,,"Weight change of A431 cell tumors in mice at 5 mg/kg peroral dose, days 7-21 administration",N,,500.0,80852,1,,CHEMBL623735,BAO_0000218,
5186,Expert,9606.0,,1,,,In vitro antiproliferative effect against A431 human epidermoid carcinoma cells,N,,500.0,80852,1,,CHEMBL623736,BAO_0000219,
5187,Intermediate,9606.0,,1,,,In vitro tumor cell growth inhibitory activity against Human leiomyosarcoma A431 cell lines,N,,500.0,80852,1,,CHEMBL623737,BAO_0000219,
5188,Intermediate,9606.0,,1,,,Cytotoxicity against A437 cells is the dose giving 50% decrease in the formation of formazan dye,N,,500.0,80852,1,,CHEMBL623738,BAO_0000219,
5189,Intermediate,9606.0,,1,,,Dose giving a 50% decrease in the living cell number (A437 cells),N,,500.0,80852,1,,CHEMBL875168,BAO_0000219,
5190,Expert,9606.0,,1,,,In vitro inhibitory concentration against proliferation of A459 cell line.,N,,646.0,80682,1,,CHEMBL623739,BAO_0000219,
5191,Intermediate,9606.0,,1,,,Inhibitory concentration of compound for cytotoxicity against A459 human lung cells was determined,N,,646.0,80682,1,,CHEMBL623740,BAO_0000219,
5192,Intermediate,9606.0,,1,,,Inhibition of growth of human NSCL non small cell lung carcinoma cell line (A459) after 72 hr of drug exposure,N,,646.0,80682,1,,CHEMBL624424,BAO_0000219,
5193,Intermediate,9606.0,,1,,,In vitro antitumor activity against renal A498 tumor cell lines,N,,624.0,80021,1,,CHEMBL624425,BAO_0000219,
5194,Intermediate,9606.0,,1,,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors",N,,624.0,80021,1,,CHEMBL624426,BAO_0000219,
5195,Intermediate,9606.0,,1,,,"In vitro growth inhibition of human kidney carcinoma cell line, A498 with low levels of folate receptors in folate deficient medium",N,,624.0,80021,1,,CHEMBL624427,BAO_0000219,
5196,Intermediate,9606.0,,1,,,Cytotoxicity against A498 Tumor cell line in SRB Cell viability test,N,,624.0,80021,1,,CHEMBL624428,BAO_0000219,
5197,Intermediate,9606.0,,1,,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line,N,,624.0,80021,1,,CHEMBL624429,BAO_0000219,
5198,Intermediate,9606.0,,1,,,Cytotoxicity concentration against human kidney carcinoma A-498 cell line; NT =Not tested,N,,624.0,80021,1,,CHEMBL624620,BAO_0000219,
5199,Intermediate,9606.0,,1,,,Cytotoxicity on kidney carcinoma (A-498) cell line,N,,624.0,80021,1,,CHEMBL624621,BAO_0000219,
5200,Intermediate,9606.0,,1,,,Compound was evaluated against Human cell line renal A498,N,,624.0,80021,1,,CHEMBL624622,BAO_0000219,
5201,Intermediate,9606.0,,1,,,Compound was tested for inhibition of A498 human renal cancer cell line,N,,624.0,80021,1,,CHEMBL624623,BAO_0000219,
5202,Intermediate,9606.0,,1,,,Growth inhibitory activity against A498 human cancer cell line,N,,624.0,80021,1,,CHEMBL874365,BAO_0000219,
5203,Intermediate,9606.0,,1,,,In vitro antitumor activity against human renal A498 cell line,N,,624.0,80021,1,,CHEMBL624624,BAO_0000219,
5204,Intermediate,9606.0,,1,,,In vitro cytotoxic activity against renal (A498) cell line,N,,624.0,80021,1,,CHEMBL624625,BAO_0000219,
5205,Intermediate,9606.0,,1,,,In vitro cytotoxic activity against human renal cancer (A498) cell line,N,,624.0,80021,1,,CHEMBL624626,BAO_0000219,
5206,Intermediate,9606.0,,1,,,Tested for cytostatic activity against renal A498 cell line,N,,624.0,80021,1,,CHEMBL624627,BAO_0000219,
5207,Intermediate,9606.0,,1,,,The compound was tested for the concentration to inhibit 50% of renal A498 cell lines.,N,,624.0,80021,1,,CHEMBL883157,BAO_0000219,
5208,Expert,9606.0,,1,,,In vitro cytotoxic activity against renal (A498) cell line at a concentration of 10e-5 M,N,,624.0,80021,1,,CHEMBL624628,BAO_0000219,
5209,Autocuration,9615.0,In vivo,1,,,Cmax value after 2 mpk peroral administration to beagles,U,,,22224,0,,CHEMBL624629,BAO_0000218,
5210,Autocuration,9615.0,In vivo,1,,,Bioavailability,U,,,22224,0,,CHEMBL623551,BAO_0000218,
5211,Autocuration,9615.0,In vivo,1,,,Bioavailability after 1 mpk peroral administration to beagles,U,,,22224,0,,CHEMBL623552,BAO_0000218,
5212,Autocuration,9615.0,In vivo,1,,,Bioavailability after 2 mpk peroral administration to beagles,U,,,22224,0,,CHEMBL623553,BAO_0000218,
5213,Autocuration,9913.0,,1,,,Specificity constant of the BSA-catalyzed deprotonation of compound at pH 9,U,,,22224,0,,CHEMBL623554,BAO_0000019,
5214,Autocuration,9913.0,,1,,,Specificity constant of the bovine serum albumin catalyzed reaction expressed as (kcat/KM)/kuncat,U,,,22224,0,,CHEMBL623555,BAO_0000019,
5215,Autocuration,9913.0,,1,,,Michaelis-Menten kinetics of the bovine serum albumin catalyzed reaction of the compound,U,,,22224,0,,CHEMBL623556,BAO_0000019,
5216,Autocuration,9913.0,,1,,,Solubility against bovine alpha-chymotrypsin,U,,,22224,0,,CHEMBL623557,BAO_0000019,
5217,Autocuration,9913.0,,1,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,U,,,22224,0,,CHEMBL623558,BAO_0000019,
5218,Autocuration,9913.0,,1,,,Rate constant of the bovine serum albumin catalyzed reaction of the compound,U,,,22224,0,,CHEMBL623559,BAO_0000019,
5219,Autocuration,9913.0,,1,2106.0,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards calf spleen (CS-PDE) at a concentration of 20 microg,U,,,22224,0,,CHEMBL623560,BAO_0000221,
5220,Autocuration,9913.0,,1,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum,U,,,22224,0,,CHEMBL623561,BAO_0000019,
5221,Autocuration,9913.0,,1,,,Half life in culture medium containing 10% of heat inactivated foetal calf serum; ND=not determined,U,,,22224,0,,CHEMBL623562,BAO_0000019,
5222,Autocuration,9913.0,,1,,,Ability to get deaminated by adenosine deaminase (ADA); Expressed as t1/2,U,,,22224,0,,CHEMBL623563,BAO_0000019,
5223,Autocuration,9913.0,,1,2106.0,,Enzymatic stability was assessed with bovine spleen phosphodiesterase (BS PDE) exonuclase,U,,,22224,0,,CHEMBL623564,BAO_0000221,
5224,Autocuration,9913.0,,1,,,Half life in presence of 2 mg/mL BSA at pH 8.8,U,,,22224,0,,CHEMBL873806,BAO_0000019,
5225,Autocuration,9913.0,,1,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 1,U,,,22224,0,,CHEMBL623565,BAO_0000019,
5226,Autocuration,9913.0,,1,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2,U,,,22224,0,,CHEMBL623566,BAO_0000019,
5227,Autocuration,9913.0,,1,,,Half-life in RPMI 1640 containing 10% heat inactivated fetal calf serum culture medium at step 2; Not determined,U,,,22224,0,,CHEMBL623567,BAO_0000019,
5228,Autocuration,9913.0,,1,,,Half-life in the culture medium (RPMI 1640+10% fetal calf serum FCS),U,,,22224,0,,CHEMBL623568,BAO_0000019,
5229,Intermediate,9615.0,,1,1969.0,,AUC (Area Under Plasma concentration-time curve) was after oral administration at 5 mg/kg,N,,,50588,1,,CHEMBL623569,BAO_0000218,
5230,Intermediate,9615.0,,1,1969.0,,AUC after administration at 100 mg/kg/day in dogs,N,,,50588,1,,CHEMBL623570,BAO_0000218,
5231,Intermediate,9615.0,,1,1969.0,,AUC in dog at 0-24 hr by peroral administration at 3 mpk,N,,,50588,1,,CHEMBL624254,BAO_0000218,
5232,Intermediate,9615.0,,1,1969.0,,AUC value after 15 mg/kg iv dose in Dogs,N,,,50588,1,,CHEMBL624255,BAO_0000218,
5233,Intermediate,9615.0,,1,1969.0,,AUC value after 30 mg/kg po dose in Dogs,N,,,50588,1,,CHEMBL624256,BAO_0000218,
5234,Intermediate,9615.0,,1,1969.0,,AUC value after administration of 4 mg/Kg oral dose in dog,N,,,50588,1,,CHEMBL624257,BAO_0000218,
5235,Intermediate,9615.0,,1,1969.0,,AUC0-infinity after single intravenous bolus of 1 mg/kg in dogs,N,,,50588,1,,CHEMBL624258,BAO_0000218,
5236,Intermediate,9615.0,,1,,,Area Under Curve for the compound was determined in dogs at 1 mg/kg oral dosing; 25-50 ug min/mL,N,,,50588,1,,CHEMBL875277,BAO_0000218,
5237,Intermediate,9615.0,,1,,,Area under curve (AUC) value in dogs after an intravenous dose of 0.2 mg/Kg in 0.025 M aqueous methanesulfonic acid solution with 5% mannitol at a concentration of 0.2,N,,,50588,1,,CHEMBL622667,BAO_0000218,
5238,Intermediate,9615.0,,1,,,Area under curve by intravenous administration at a dose of 1 uM/kg in dog was determined,N,,,50588,1,,CHEMBL622668,BAO_0000218,
5239,Intermediate,9615.0,,1,,,Area under curve by oral administration at a dose of 10 uM/kg in dog was determined,N,,,50588,1,,CHEMBL622669,BAO_0000218,
5240,Intermediate,9615.0,,1,,,Area under curve determined in dogs after intravenous administration of 3 mg/kg,N,,,50588,1,,CHEMBL622670,BAO_0000218,
5241,Intermediate,9615.0,,1,,,Area under curve determined in dogs after oral administration of 10 mg/kg,N,,,50588,1,,CHEMBL622671,BAO_0000218,
5242,Intermediate,9615.0,,1,,,Area under curve of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,,,50588,1,,CHEMBL622672,BAO_0000218,
5243,Expert,9615.0,,1,,,Area under curve of compound determined in dog after iv administration at a dose of 10 mg/kg,N,,,50588,1,,CHEMBL622673,BAO_0000218,
5244,Expert,9615.0,,1,,,Area under curve of compound from zero time to infinity determined in dog after iv administration at a dose of 10 mg/kg,N,,,50588,1,,CHEMBL622674,BAO_0000218,
5245,Intermediate,9615.0,,1,,,Area under curve determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),N,,,50588,1,,CHEMBL622675,BAO_0000218,
5246,Intermediate,9615.0,,1,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration,N,,,50588,1,,CHEMBL622676,BAO_0000218,
5247,Intermediate,9615.0,,1,,,Area under curve determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),N,,,50588,1,,CHEMBL622677,BAO_0000218,
5248,Intermediate,9615.0,,1,,,Area under curve determined in dog at a dose of 5 mg/kg by oral administration,N,,,50588,1,,CHEMBL622678,BAO_0000218,
5249,Intermediate,9615.0,,1,,,Area under curve in dog after administration of 20 mg/kg dose through peroral route,N,,,50588,1,,CHEMBL622679,BAO_0000218,
5250,Intermediate,9615.0,,1,,,Area under curve in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,,,50588,1,,CHEMBL622680,BAO_0000218,
5251,Intermediate,9615.0,,1,,,Area under curve was determine after peroral administration at 10 mpk in dog,N,,,50588,1,,CHEMBL622681,BAO_0000218,
5252,Intermediate,9615.0,,1,,,Area under curve was determine after peroral administration at 5 mpk in dog,N,,,50588,1,,CHEMBL875278,BAO_0000218,
5253,Intermediate,9615.0,,1,,,Area under curve was determined,N,,,50588,1,,CHEMBL622682,BAO_0000218,
5254,Intermediate,9615.0,,1,,,Area under curve in dogs,N,,,50588,1,,CHEMBL622683,BAO_0000218,
5255,Intermediate,9615.0,,1,,,Area under curve in dogs at 10 mg/kg dose fo oral administration,N,,,50588,1,,CHEMBL622684,BAO_0000218,
5256,Intermediate,9615.0,,1,,,Area under curve in dogs at 10 mg/kg dose fo oral administration (Evokes hyperglycerolemia),N,,,50588,1,,CHEMBL622685,BAO_0000218,
5257,Intermediate,9615.0,,1,,,Area under curve in dogs at 3 mg/kg dose fo intravenous administration,N,,,50588,1,,CHEMBL622686,BAO_0000218,
5258,Intermediate,9615.0,,1,,,Area under curve was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,,,50588,1,,CHEMBL618344,BAO_0000218,
5259,Intermediate,9615.0,,1,,,Area under curve value in dog at a dose of 5 mg/kg,N,,,50588,1,,CHEMBL875582,BAO_0000218,
5260,Intermediate,9615.0,,1,,,Area under curve was determined after 0.1 mg/kg iv administration in dog,N,,,50588,1,,CHEMBL618345,BAO_0000218,
5261,Intermediate,9615.0,,1,,,Area under curve was determined after 0.3 mg/kg po administration in dog,N,,,50588,1,,CHEMBL618346,BAO_0000218,
5262,Intermediate,9615.0,,1,,,Area under curve was determined for compound after intravenous administration in dogs at 1.2 uM/kg,N,,,50588,1,,CHEMBL618347,BAO_0000218,
5263,Intermediate,9615.0,,1,,,Area under curve was determined for the compound by intravenous administration of 1.2 mg/kg in dog,N,,,50588,1,,CHEMBL618348,BAO_0000218,
5264,Autocuration,9606.0,,1,,,Tested for half life period at 37 degree Celsius in PBS buffer at 10.5 pH containing human serum esterase,U,,,22224,0,,CHEMBL618349,BAO_0000019,
5265,Autocuration,9606.0,,1,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,U,,,22224,0,,CHEMBL618350,BAO_0000019,
5266,Autocuration,9606.0,,1,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.0 pH containing human serum esterase,U,,,22224,0,,CHEMBL618351,BAO_0000019,
5267,Autocuration,9606.0,,1,,,Tested for half life period at 37 degree Celsius in PBS buffer at 8.8 pH containing human serum esterase,U,,,22224,0,,CHEMBL618352,BAO_0000019,
5268,Autocuration,9606.0,,1,178.0,,Time taken to reduce 50% of the concentration of compound in blood plasma,U,,,22224,0,,CHEMBL873494,BAO_0000221,
5269,Autocuration,9606.0,,1,1969.0,,"Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",U,,,22224,0,,CHEMBL618353,BAO_0000366,
5270,Autocuration,9606.0,,1,1969.0,,Half life in human plasma,U,,,22224,0,,CHEMBL618354,BAO_0000366,
5271,Autocuration,9606.0,,1,1969.0,,Half life in human plasma was reported,U,,,22224,0,,CHEMBL875583,BAO_0000366,
5272,Autocuration,9606.0,,1,1977.0,,Half life in human serum,U,,,22224,0,,CHEMBL618355,BAO_0000019,
5273,Autocuration,9606.0,,1,1969.0,,Half life upon exposure to human plasma,U,,,22224,0,,CHEMBL618356,BAO_0000366,
5274,Autocuration,9606.0,In vitro,1,,,t1/2 in human microsomes,U,Microsomes,,22224,0,,CHEMBL618357,BAO_0000251,
5275,Autocuration,9606.0,,1,1969.0,,Half life period in 80% human plasma at 37 degree Centigrade,U,,,22224,0,,CHEMBL618358,BAO_0000366,
5276,Autocuration,9606.0,,1,14.0,,Half-life for rate of hydrolysis was determined in in human skin homogenate (pH 7.4),U,,,22224,0,,CHEMBL618359,BAO_0000221,
5277,Autocuration,9606.0,In vitro,1,1969.0,,Half-life measured in in vitro Cathepsin B assay in human plasma,U,,,22224,0,,CHEMBL618360,BAO_0000366,
5278,Autocuration,9606.0,,1,,,Half-life at initial concentration of 5*10e-5 M in CEM cell extract,U,,,22224,0,,CHEMBL618361,BAO_0000019,
5279,Autocuration,9606.0,In vitro,1,2107.0,,Half-life determined by human liver microsome stability assay at a concentration of 5 uM,U,Microsomes,,22224,0,,CHEMBL618362,BAO_0000251,
5280,Autocuration,9606.0,,1,1969.0,,"Half-life in chemical and enzymatic hydrolysis to form L-DOPA, in 80% human plasma",U,,,22224,0,,CHEMBL618363,BAO_0000366,
5281,Autocuration,9606.0,,1,1969.0,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 1)",U,,,22224,0,,CHEMBL618364,BAO_0000366,
5282,Autocuration,9606.0,,1,1969.0,,"Half-life in chemical and enzymatic hydrolysis to form another compound (8)*, in 80% human plasma (experiment 2)",U,,,22224,0,,CHEMBL875584,BAO_0000366,
5283,Autocuration,9606.0,,1,,,Half-life in the CEM cell extracts,U,,,22224,0,,CHEMBL618365,BAO_0000019,
5284,Autocuration,9606.0,,1,1969.0,,Half-life was calculated by Human plasma stability assay at 37 degree Centigrade,U,,,22224,0,,CHEMBL873495,BAO_0000366,
5285,Autocuration,9606.0,,1,1969.0,,Half-life was calculated by Human plasma stability assay at 37 degree centigrade; Not hydrolyzed,U,,,22224,0,,CHEMBL618366,BAO_0000366,
5286,Autocuration,9606.0,,1,,,Half-life was determined,U,,,22224,0,,CHEMBL618367,BAO_0000019,
5287,Autocuration,9606.0,,1,178.0,,Half-life (human blood stability),U,,,22224,0,,CHEMBL618368,BAO_0000221,
5288,Autocuration,9606.0,,1,178.0,,Half-life (human blood stability); no data,U,,,22224,0,,CHEMBL618369,BAO_0000221,
5289,Autocuration,9606.0,,1,1969.0,,Half-life in human plasma,U,,,22224,0,,CHEMBL618370,BAO_0000366,
5290,Autocuration,9606.0,,1,,,CYP3A4 metabolism half-life (t1/2),U,,,22224,0,,CHEMBL618371,BAO_0000019,
5291,Autocuration,9606.0,,1,178.0,,Half-life was determined; 88% of parent remained after incubation for 120 min (human blood stability),U,,,22224,0,,CHEMBL618372,BAO_0000221,
5292,Autocuration,9606.0,In vitro,1,1969.0,,In vitro half life in human plasma,U,,,22224,0,,CHEMBL618373,BAO_0000366,
5293,Autocuration,9606.0,In vitro,1,1969.0,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in human plasma",U,,,22224,0,,CHEMBL618374,BAO_0000366,
5294,Autocuration,9606.0,In vitro,1,1969.0,,In vitro hydrolysis in human plasma,U,,,22224,0,,CHEMBL618375,BAO_0000366,
5295,Autocuration,9606.0,In vitro,1,1969.0,,In vitro hydrolysis in human plasma; no data,U,,,22224,0,,CHEMBL618376,BAO_0000366,
5296,Autocuration,9606.0,In vitro,1,2107.0,,In vitro metabolic stability at 5 uM was determined by incubating with human liver microsomes at 37 degree C,U,Microsomes,,22224,0,,CHEMBL618377,BAO_0000251,
5297,Autocuration,9606.0,,1,1969.0,,Plasma half life in human,U,,,22224,0,,CHEMBL618378,BAO_0000366,
5298,Autocuration,9606.0,,1,1969.0,,Stability after incubation with human plasma (at 37 degree C),U,,,22224,0,,CHEMBL618379,BAO_0000366,
5299,Autocuration,9606.0,,1,1969.0,,T1/2 was evaluated in human plasma,U,,,22224,0,,CHEMBL618380,BAO_0000366,
5300,Autocuration,9606.0,,1,1969.0,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I).",U,,,22224,0,,CHEMBL618381,BAO_0000366,
5301,Autocuration,9606.0,,1,1969.0,,"Tested for Biological half life in human plasma (stability to human renal dehydropeptidase I,DHP-I); Not determined",U,,,22224,0,,CHEMBL618382,BAO_0000366,
5302,Autocuration,9606.0,,1,,,Tested for half life period at 37 degree Centigrade in PBS buffer at 7.3 pH containing human serum esterase,U,,,22224,0,,CHEMBL618383,BAO_0000019,
5303,Autocuration,9606.0,In vitro,1,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase,U,,,22224,0,,CHEMBL618384,BAO_0000019,
5304,Autocuration,9606.0,In vitro,1,,,Tested in vitro for the time for half reactivation against human lysosomal alpha-glucosidase; ND=Not determined,U,,,22224,0,,CHEMBL618385,BAO_0000019,
5305,Autocuration,9606.0,,1,1969.0,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay,U,,,22224,0,,CHEMBL619099,BAO_0000366,
5306,Autocuration,9606.0,,1,1969.0,,The release rate of the free drug from the substrate in human plasma by human plasma stability assay; Not hydrolyzed,U,,,22224,0,,CHEMBL619100,BAO_0000366,
5307,Autocuration,9606.0,,1,,,Time taken for 50% to be consumed by serum PON1 was determined,U,,,22224,0,,CHEMBL619101,BAO_0000019,
5308,Autocuration,9606.0,,1,,,Time taken for 50% to be consumed by serum PON1; NH is Not hydrolysed,U,,,22224,0,,CHEMBL619102,BAO_0000019,
5309,Autocuration,9606.0,,1,2107.0,,Percent of the parent compound remaining after 20 mins incubation with human liver microsomes,U,Microsomes,,22224,0,,CHEMBL619103,BAO_0000251,
5310,Autocuration,10095.0,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,,22224,0,,CHEMBL619268,BAO_0000218,
5311,Autocuration,10095.0,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice blood upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,,22224,0,,CHEMBL619269,BAO_0000218,
5312,Autocuration,10095.0,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,,22224,0,,CHEMBL619270,BAO_0000218,
5313,Autocuration,10095.0,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice brain upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,,22224,0,,CHEMBL619271,BAO_0000218,
5314,Autocuration,10095.0,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,,22224,0,,CHEMBL875585,BAO_0000218,
5315,Autocuration,10095.0,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,,,22224,0,,CHEMBL619272,BAO_0000218,
5316,Intermediate,9606.0,,1,,,Compound tested for growth inhibition of renal cancer cell line 786-0,N,,391.0,80640,1,,CHEMBL619273,BAO_0000219,
5317,Intermediate,9606.0,,1,,,Compound was tested for 50% growth inhibition against human renal cancer 786-0 cell line,N,,391.0,80640,1,,CHEMBL619274,BAO_0000219,
5318,Expert,9606.0,,1,,,Concentration which reduced cell growth to 50 % of level against 786-0 renal cancer line,N,,391.0,80640,1,,CHEMBL619275,BAO_0000219,
5319,Intermediate,9606.0,,1,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-4 concentration",N,,391.0,80640,1,,CHEMBL619276,BAO_0000219,
5320,Intermediate,9606.0,,1,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-6 concentration",N,,391.0,80640,1,,CHEMBL619277,BAO_0000219,
5321,Intermediate,9606.0,,1,,,"Percent growth of NCI cell line, renal: 786-0 exposed for 48 hr at 10e-8 concentration",N,,391.0,80640,1,,CHEMBL619278,BAO_0000219,
5322,Intermediate,9606.0,,1,,,Tested for cytotoxicity against 786-0 cell lines in renal cancer,N,,391.0,80640,1,,CHEMBL619279,BAO_0000219,
5323,Intermediate,9606.0,,1,,,Tested in vitro for cytotoxicity in 786-0 cell line of Renal cancer,N,,391.0,80640,1,,CHEMBL858458,BAO_0000219,
5324,Expert,9606.0,,1,,,Cytotoxic effect on renal cancer line 786-0,N,,391.0,80640,1,,CHEMBL619280,BAO_0000219,
5325,Intermediate,9606.0,,1,,,In vitro antitumor activity against Renal cancer 786-0 cell lines by 6-day assay,N,,391.0,80640,1,,CHEMBL619281,BAO_0000219,
5326,Intermediate,9606.0,,1,,,Compound was evaluated for in vitro activity against 786-0 kidney cell lines (Human tumor cells ),N,,391.0,80640,1,,CHEMBL619282,BAO_0000219,
5327,Intermediate,9606.0,,1,,,"Cytotoxicity against NCI tumor panel, 786-0 renal cancer cell line",N,,391.0,80640,1,,CHEMBL619283,BAO_0000219,
5328,Intermediate,9606.0,,1,,,Concentration of compound that cause 50% cytotoxicity of 786-0 renal cancer cell line,N,,391.0,80640,1,,CHEMBL619284,BAO_0000219,
5329,Intermediate,9606.0,,1,,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration that inhibits 50% net cell growth).,N,,391.0,80640,1,,CHEMBL619285,BAO_0000219,
5330,Intermediate,9606.0,,1,,,Compound was tested for antitumor activity against 786-0 renal cancer cell line(molar concentration leading to 50% net cell death),N,,391.0,80640,1,,CHEMBL619286,BAO_0000219,
5331,Intermediate,9606.0,,1,,,Growth inhibition of the 786-O Renal cancer cell line for 2-day in vitro assay.,N,,391.0,80640,1,,CHEMBL619287,BAO_0000219,
5332,Intermediate,9606.0,,1,,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,N,,391.0,80640,1,,CHEMBL857455,BAO_0000219,
5333,Intermediate,9606.0,,1,,,The compound was tested in vitro for cytotoxic activity against 786-O cell line (human perirenal carcinoma),N,,391.0,80640,1,,CHEMBL883801,BAO_0000219,
5334,Intermediate,9606.0,,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression,N,,972.0,80641,1,,CHEMBL619288,BAO_0000219,
5335,Intermediate,9606.0,,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression (49% inhibition achieved at 100 micro g/mL),N,,972.0,80641,1,,CHEMBL619289,BAO_0000219,
5336,Intermediate,9606.0,,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells having only 3-5% antigen expression; <20% inhibition achieved,N,,972.0,80641,1,,CHEMBL619290,BAO_0000219,
5337,Intermediate,9606.0,,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H1: MSR-33),N,,972.0,80641,1,,CHEMBL619291,BAO_0000219,
5338,Intermediate,9606.0,,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H2: MSR-26),N,,972.0,80641,1,,CHEMBL619292,BAO_0000219,
5339,Intermediate,9606.0,,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate AH1.11 (Type H3: MSR-28); <20% inhibition achieved,N,,972.0,80641,1,,CHEMBL619293,BAO_0000219,
5340,Intermediate,9606.0,,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H1: MSR-33),N,,972.0,80641,1,,CHEMBL619294,BAO_0000219,
5341,Intermediate,9606.0,,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26),N,,972.0,80641,1,,CHEMBL619295,BAO_0000219,
5342,Intermediate,9606.0,,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H2: MSR-26) (less than 20% inhibition achieved),N,,972.0,80641,1,,CHEMBL619296,BAO_0000219,
5343,Intermediate,9606.0,,1,,,Tested for cytotoxicity against antigen positive 791T osteosarcoma cells of conjugate H1.11 (Type H3: MSR-28); <20% inhibition achieved,N,,972.0,80641,1,,CHEMBL619297,BAO_0000219,
5344,Intermediate,9606.0,,1,,,Growth inhibitory concentration against tumor cells in culture renal cancer 796-0 cell line,N,,391.0,80640,1,,CHEMBL619298,BAO_0000219,
5345,Intermediate,,,1,,,In vitro anticancer activity against 8 NCI CNS cancer cell lines; inactive,U,,,22226,0,,CHEMBL619299,BAO_0000019,
5346,Expert,9606.0,,1,,,Inhibition of cell growth in drug resistant 8226 myeloma cell line,N,,741.0,80433,1,,CHEMBL619300,BAO_0000219,
5347,Expert,9606.0,,1,,,Inhibition of cell growth in drug sensitive 8226 myeloma cell line,N,,741.0,80433,1,,CHEMBL619301,BAO_0000219,
5348,Intermediate,9606.0,,1,,,In vitro inhibition of tumor cell growth in the human myeloma 8226 system.,N,,741.0,80433,1,,CHEMBL619302,BAO_0000219,
5349,Intermediate,9606.0,,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,N,,741.0,80433,1,,CHEMBL619303,BAO_0000219,
5350,Intermediate,9606.0,,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,N,,741.0,80433,1,,CHEMBL619304,BAO_0000219,
5351,Intermediate,9606.0,,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),N,,741.0,80433,1,,CHEMBL857706,BAO_0000219,
5352,Intermediate,9606.0,,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),N,,741.0,80433,1,,CHEMBL619305,BAO_0000219,
5353,Intermediate,9606.0,,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),N,,741.0,80433,1,,CHEMBL619306,BAO_0000219,
5354,Intermediate,9606.0,,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,,741.0,80433,1,,CHEMBL619307,BAO_0000219,
5355,Intermediate,9606.0,,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,,741.0,80433,1,,CHEMBL619308,BAO_0000219,
5356,Intermediate,9606.0,,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),N,,741.0,80433,1,,CHEMBL619309,BAO_0000219,
5357,Intermediate,9606.0,,1,,,Effect on DNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),N,,741.0,80433,1,,CHEMBL619310,BAO_0000219,
5358,Intermediate,9606.0,,1,,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),N,,624.0,80021,1,,CHEMBL619311,BAO_0000219,
5359,Intermediate,9606.0,,1,,,Compound was tested for the growth inhibition of A498 renal tumor cell line,N,,624.0,80021,1,,CHEMBL619312,BAO_0000219,
5360,Intermediate,9606.0,,1,,,In vitro cytotoxicity against human tumor A498 cell line (renal cancer),N,,624.0,80021,1,,CHEMBL619313,BAO_0000219,
5361,Intermediate,9606.0,,1,,,In vitro inhibitory concentration against renal cancer cell line A498,N,,624.0,80021,1,,CHEMBL619314,BAO_0000219,
5362,Intermediate,9606.0,,1,,,Cytotoxicity against A 498 tumor cell line,N,,624.0,80021,1,,CHEMBL619959,BAO_0000219,
5363,Intermediate,9606.0,,1,,,In vitro antitumor activity against A498 human cancer cell line,N,,624.0,80021,1,,CHEMBL619960,BAO_0000219,
5364,Intermediate,9606.0,,1,,,In vitro antitumor activity against A498 human cancer cell line (Data from NCI-screening),N,,624.0,80021,1,,CHEMBL619961,BAO_0000219,
5365,Intermediate,9606.0,,1,,,Inhibitory dose required against A498 human tumor cell lines,N,,624.0,80021,1,,CHEMBL619962,BAO_0000219,
5366,Intermediate,9606.0,,1,,,Anticancer activity against one renal cancer (A498 cell line),N,,624.0,80021,1,,CHEMBL875586,BAO_0000219,
5367,Intermediate,9606.0,,1,,,In vitro cytotoxicity against melanoma A498 cell line,N,,624.0,80021,1,,CHEMBL619963,BAO_0000219,
5368,Intermediate,9606.0,,1,,,Compound was tested for growth inhibitory activity against A498 cell line,N,,624.0,80021,1,,CHEMBL619964,BAO_0000219,
5369,Intermediate,9606.0,,1,,,Compound tested for growth inhibition of renal cancer cell line A498,N,,624.0,80021,1,,CHEMBL620108,BAO_0000219,
5370,Intermediate,9606.0,,1,,,Compound was tested for 50% growth inhibition against human renal cancer A498 cell line,N,,624.0,80021,1,,CHEMBL620109,BAO_0000219,
5371,Intermediate,9606.0,,1,,,Growth inhibition of the A498 Renal cancer cell line for 2-day in vitro assay.,N,,624.0,80021,1,,CHEMBL620110,BAO_0000219,
5372,Intermediate,9606.0,,1,,,In vitro antitumor activity against Renal cancer A498 cell lines by 6-day assay,N,,624.0,80021,1,,CHEMBL620111,BAO_0000219,
5373,Intermediate,9606.0,,1,,,Tested for cytotoxicity against A498 cell lines in renal cancer,N,,624.0,80021,1,,CHEMBL620112,BAO_0000219,
5374,Intermediate,9606.0,,1,,,Tested in vitro for cytotoxicity in A498 cell line of Renal cancer,N,,624.0,80021,1,,CHEMBL620113,BAO_0000219,
5375,Expert,9606.0,,1,,,Cytotoxic effect on renal cancer lines A498,N,,624.0,80021,1,,CHEMBL620114,BAO_0000219,
5376,Intermediate,9606.0,,1,,,Antitumor activity was evaluated for reduction of growth of renal cancer (A498) cells at a concentration of 100 uM,N,,624.0,80021,1,,CHEMBL620115,BAO_0000219,
5377,Intermediate,9606.0,,1,,,Compound was evaluated for in vitro activity against A498 kidney cell lines (Human tumor cells ),N,,624.0,80021,1,,CHEMBL620116,BAO_0000219,
5378,Intermediate,9606.0,,1,,,Concentration of compound that cause 50% cytotoxicity of A498 renal cancer cell line,N,,624.0,80021,1,,CHEMBL620117,BAO_0000219,
5379,Intermediate,9606.0,,1,,,Growth inhibitory activity against A498-2LM human solid tumor cell line using MTT assay,N,,624.0,80021,1,,CHEMBL620118,BAO_0000219,
5380,Intermediate,9606.0,,1,,,Cytotoxicity against human kidney carcinoma cell lines A4982LM,N,,624.0,80021,1,,CHEMBL620119,BAO_0000219,
5381,Intermediate,9606.0,,1,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A498Rem- renal cell line using the MTT Cytotoxicity Assay,N,,624.0,80021,1,,CHEMBL620120,BAO_0000219,
5382,Expert,9606.0,,1,,,Antiproliferative activity in vitro against A549 (human non-small lung carcinoma) cell line.,N,,646.0,80682,1,,CHEMBL620121,BAO_0000219,
5383,Intermediate,9606.0,,1,,,Antitumor activity against A549 human lung carcinoma cell line,N,,646.0,80682,1,,CHEMBL620122,BAO_0000219,
5384,Intermediate,9606.0,,1,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 1,N,,646.0,80682,1,,CHEMBL620123,BAO_0000219,
5385,Intermediate,9606.0,,1,,,Antitumor activity against A549 human lung carcinoma cell line in experiment 2,N,,646.0,80682,1,,CHEMBL620124,BAO_0000219,
5386,Intermediate,9606.0,,1,,,"Concentration required to inhibit tumor growth in A549, human lung carcinoma (NSCLC) cell line",N,,646.0,80682,1,,CHEMBL620125,BAO_0000219,
5387,Expert,9606.0,,1,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay,N,,646.0,80682,1,,CHEMBL620126,BAO_0000219,
5388,Intermediate,9606.0,,1,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,,646.0,80682,1,,CHEMBL883027,BAO_0000219,
5389,Expert,9606.0,,1,,,In vitro cytotoxic activity against human lung A549 cell line,N,,646.0,80682,1,,CHEMBL620127,BAO_0000219,
5390,Intermediate,9606.0,,1,,,In vitro cytotoxic activity against human lung A549 cell line ( standard deviation in parenthesis),N,,646.0,80682,1,,CHEMBL620128,BAO_0000219,
5391,Intermediate,9606.0,,1,,,In vitro cytotoxic activity against human lung A549 cell line),N,,646.0,80682,1,,CHEMBL620129,BAO_0000219,
5392,Intermediate,9606.0,,1,,,In vitro cytotoxic activity against human lung A549 cell line;NT is not tested,N,,646.0,80682,1,,CHEMBL620130,BAO_0000219,
5393,Expert,9606.0,,1,,,In vitro cytotoxicity against human non small-cell-lung cell line A549.,N,,646.0,80682,1,,CHEMBL620131,BAO_0000219,
5394,Intermediate,9606.0,,1,,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors",N,,646.0,80682,1,,CHEMBL620132,BAO_0000219,
5395,Intermediate,9606.0,,1,,,"In vitro growth inhibition of human lung carcinoma cell line, A549 with low levels of folate receptors in folate deficient medium",N,,646.0,80682,1,,CHEMBL620133,BAO_0000219,
5396,Expert,9606.0,,1,,,Inhibition of A549 human lung carcinoma cell proliferation,N,,646.0,80682,1,,CHEMBL620134,BAO_0000219,
5397,Intermediate,9606.0,,1,,,Inhibitory activity against A549 lung adenocarcinoma cell line,N,,646.0,80682,1,,CHEMBL620135,BAO_0000219,
5398,Intermediate,9606.0,,1,,,Inhibitory concentration required to reduce A549 tumor cell growth by 50% in MTT assay,N,,646.0,80682,1,,CHEMBL620136,BAO_0000219,
5399,Intermediate,9606.0,,1,,,in vitro anticancer activity against cultured A549 human tumor(lung) cell line,N,,646.0,80682,1,,CHEMBL620137,BAO_0000219,
5400,Intermediate,9606.0,,1,,,in vitro inhibition of tumor cell growth in cultured A549 human tumor cell line,N,,646.0,80682,1,,CHEMBL620268,BAO_0000219,
5401,Intermediate,9606.0,,1,,,Cytotoxicity against A549 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,,646.0,80682,1,,CHEMBL620269,BAO_0000219,
5402,Intermediate,9606.0,,1,,,Cytotoxicity was evaluated against A549 non-small cell lung carcinoma human cancer cell line,N,,646.0,80682,1,,CHEMBL620270,BAO_0000219,
5403,Intermediate,9606.0,,1,,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,N,,646.0,80682,1,,CHEMBL620271,BAO_0000219,
5404,Expert,9606.0,,1,,,Inhibition of A549 cancer cell proliferation,N,,646.0,80682,1,,CHEMBL620272,BAO_0000219,
5405,Expert,9606.0,,1,,,Inhibition of A549 cancer cell proliferation (Not tested),N,,646.0,80682,1,,CHEMBL620273,BAO_0000219,
5406,Intermediate,9606.0,,1,,,Compound was tested for antiproliferative activity against human A549 cancer cell lines using MTT assay,N,,646.0,80682,1,,CHEMBL620274,BAO_0000219,
5407,Intermediate,9606.0,,1,,,In vitro inhibitory concentration required against human lung A549 carcinoma cells proliferation,N,,646.0,80682,1,,CHEMBL620275,BAO_0000219,
5408,Intermediate,9606.0,,1,,,Antiproliferative potency determined as inhibitory concentration against A549 cells,N,,646.0,80682,1,,CHEMBL620276,BAO_0000219,
5409,Intermediate,9606.0,,1,,,Percent assembly of bovine brain tubulin induced by compound at 10 uM versus that caused by 10 uM paclitaxel,N,,646.0,80682,1,,CHEMBL620277,BAO_0000219,
5410,Intermediate,9606.0,,1,,,Cytotoxicity against Renal cell lines A549 was determined,N,,646.0,80682,1,,CHEMBL620278,BAO_0000219,
5411,Intermediate,9615.0,,1,,,Area under curve was determined in dog after a 3 mg/kg of oral dose,N,,,50588,1,,CHEMBL620279,BAO_0000218,
5412,Intermediate,9615.0,,1,,,Area under curve was determined in dog after oral administration at 1 mg/kg,N,,,50588,1,,CHEMBL620280,BAO_0000218,
5413,Intermediate,9615.0,,1,,,Area under curve was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,,,50588,1,,CHEMBL620281,BAO_0000218,
5414,Intermediate,9615.0,,1,,,Area under curve was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,,,50588,1,,CHEMBL620282,BAO_0000218,
5415,Intermediate,9615.0,,1,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-2 mins),N,,,50588,1,,CHEMBL621134,BAO_0000218,
5416,Intermediate,9615.0,,1,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of ( 0-5 mins),N,,,50588,1,,CHEMBL621135,BAO_0000218,
5417,Intermediate,9615.0,,1,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of (0-15 mins),N,,,50588,1,,CHEMBL621136,BAO_0000218,
5418,Intermediate,9615.0,,1,,,Area under increased blood flow curve (AUC) at 1 microg ia at a duration of( 0-120 mins),N,,,50588,1,,CHEMBL621137,BAO_0000218,
5419,Intermediate,9615.0,,1,1969.0,,Area under plasma concentration time curve in dog upon oral administration,N,,,50588,1,,CHEMBL621138,BAO_0000218,
5420,Intermediate,9615.0,,1,1969.0,,Area under plasma concentration time curve was measured in dogs after an oral dose of 10 uM/kg,N,,,50588,1,,CHEMBL875587,BAO_0000218,
5421,Intermediate,9615.0,,1,,,Area under the curve for compound was evaluated in dog at a dose of 10 mg/kg.,N,,,50588,1,,CHEMBL621139,BAO_0000218,
5422,Intermediate,9615.0,,1,,,Area under the curve for compound was evaluated in dog at a dose of 20 mg/kg.,N,,,50588,1,,CHEMBL621140,BAO_0000218,
5423,Intermediate,9615.0,,1,,,Area under the curve for the compound was obtained when tested in dog,N,,,50588,1,,CHEMBL621141,BAO_0000218,
5424,Intermediate,9615.0,,1,,,Area under the curve at a dose of 1 mg/kg,N,,,50588,1,,CHEMBL621142,BAO_0000218,
5425,Intermediate,9615.0,,1,,,Area under the curve at a dose of 1 mg/kg (oral),N,,,50588,1,,CHEMBL621143,BAO_0000218,
5426,Intermediate,9615.0,,1,,,Area under the curve at i.v. dose of 0.2 mg/kg,N,,,50588,1,,CHEMBL621144,BAO_0000218,
5427,Intermediate,9615.0,,1,,,Area under the curve was measured in dog after an iv dose of 1 mg/kg,N,,,50588,1,,CHEMBL621145,BAO_0000218,
5428,Intermediate,9615.0,,1,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in dog,N,,,50588,1,,CHEMBL621146,BAO_0000218,
5429,Intermediate,9615.0,,1,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 1 mpk perorally,N,,,50588,1,,CHEMBL622567,BAO_0000218,
5430,Intermediate,9615.0,,1,,,Compound was evaluated for area under curve (total concentration) in dogs at a dose of 5 mpk perorally,N,,,50588,1,,CHEMBL622568,BAO_0000218,
5431,Intermediate,9615.0,,1,,,Compound was evaluated for area under the curve in dog blood.,N,,,50588,1,,CHEMBL622569,BAO_0000218,
5432,Intermediate,9615.0,,1,,,In vivo area under curve was calculated by peroral administration at 1 mg/kg in fasted dog,N,,,50588,1,,CHEMBL622570,BAO_0000218,
5433,Intermediate,9615.0,,1,1969.0,,AUC in dog after oral dose (1 mg/kg),N,,,50588,1,,CHEMBL622571,BAO_0000218,
5434,Intermediate,9615.0,,1,,,Pharmacokinetic (PK) property (AUC) was determined in dog at the single oral dose of 1 mg/kg,N,,,50588,1,,CHEMBL622572,BAO_0000218,
5435,Intermediate,9615.0,,1,,,"Pharmacokinetic data in dogs at dose of 1 mg/kg perorally, and the area under curve (AUC) was reported.",N,,,50588,1,,CHEMBL622573,BAO_0000218,
5436,Intermediate,9615.0,,1,,,Pharmacokinetic parameter AUC after intravenous administration to dogs,N,,,50588,1,,CHEMBL622574,BAO_0000218,
5437,Intermediate,9615.0,,1,,,Pharmacokinetic parameter AUC after oral administration to dogs,N,,,50588,1,,CHEMBL622575,BAO_0000218,
5438,Intermediate,9615.0,,1,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 17b,N,,,50588,1,,CHEMBL622576,BAO_0000218,
5439,Intermediate,9615.0,,1,,,Pharmacokinetic parameter AUC was determined in dog after oral administration of 2b,N,,,50588,1,,CHEMBL622577,BAO_0000218,
5440,Intermediate,9615.0,,1,,,Pharmacokinetic property (AUC) was measured in dog at the dose of 0.032 mg/kg p.o.,N,,,50588,1,,CHEMBL622578,BAO_0000218,
5441,Intermediate,9615.0,,1,,,Pharmacokinetic property in dogs after oral administration at 1 mg/kg,N,,,50588,1,,CHEMBL622579,BAO_0000218,
5442,Intermediate,9615.0,,1,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog",N,,,50588,1,,CHEMBL622580,BAO_0000218,
5443,Intermediate,9615.0,,1,,,"Tested for the pharmacokinetic data, area under the curve of concentration versus time in dog at dosage of 10 mpk",N,,,50588,1,,CHEMBL622581,BAO_0000218,
5444,Intermediate,9615.0,,1,,,Oral AUCN in dog ( (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,,,50588,1,,CHEMBL622582,BAO_0000218,
5445,Intermediate,9615.0,,1,,,Oral AUCN in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,,,50588,1,,CHEMBL622583,BAO_0000218,
5446,Intermediate,9615.0,,1,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),N,,,50588,1,,CHEMBL622584,BAO_0000218,
5447,Intermediate,9615.0,,1,,,Oral AUCN in dog (dosed at 0.5 mpk iv ),N,,,50588,1,,CHEMBL622585,BAO_0000218,
5448,Intermediate,9615.0,,1,,,Compound was evaluated for oral bioavailability in dog; 90-100,N,,,50588,1,,CHEMBL622586,BAO_0000218,
5449,Intermediate,9615.0,,1,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay,N,,,50588,1,,CHEMBL623281,BAO_0000218,
5450,Intermediate,9615.0,,1,,,Compound was tested for its cell permeability in the Madin-Darby canine kidney cell monolayer transport assay; Not determined,N,,,50588,1,,CHEMBL623282,BAO_0000218,
5451,Intermediate,9615.0,,1,,,PAPP (membrane permeability) in dog kidney cell monolayer assay,N,,,50588,1,,CHEMBL623283,BAO_0000218,
5452,Intermediate,9615.0,,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL623284,BAO_0000218,
5453,Intermediate,9615.0,,1,,,Bioavailability administered orally at a dose of 10 mg/kg to dogs,N,,,50588,1,,CHEMBL623285,BAO_0000218,
5454,Intermediate,9615.0,,1,1969.0,,Plasma protein binding towards dog plasma at 10 uM,N,,,50588,1,,CHEMBL623463,BAO_0000218,
5455,Intermediate,9615.0,,1,1969.0,,Plasma protein binding towards dog plasma at 100 uM,N,,,50588,1,,CHEMBL875952,BAO_0000218,
5456,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog (dose 4 mg/kg p.o.),N,,,50588,1,,CHEMBL621705,BAO_0000218,
5457,Intermediate,9615.0,In vivo,1,,,Bioavailability was determined after oral administration of compound 18 at a dose of 2 mg/kg to dog,N,,,50588,1,,CHEMBL621706,BAO_0000218,
5458,Intermediate,9615.0,In vivo,1,,,Bioavailability by oral administration at a dose of 10 uM/kg in dog was determined,N,,,50588,1,,CHEMBL621707,BAO_0000218,
5459,Intermediate,9615.0,In vivo,1,,,Bioavailability in dogs,N,,,50588,1,,CHEMBL621708,BAO_0000218,
5460,Intermediate,9615.0,In vivo,1,,,Bioavailability,N,,,50588,1,,CHEMBL621709,BAO_0000218,
5461,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 10 mg/kg),N,,,50588,1,,CHEMBL621710,BAO_0000218,
5462,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog after po administration at a dose of 10 mg/kg; nd is not determined,N,,,50588,1,,CHEMBL621711,BAO_0000218,
5463,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog (dose 10.0 mg/kg p.o.),N,,,50588,1,,CHEMBL621712,BAO_0000218,
5464,Intermediate,9615.0,In vivo,1,,,Bioavailability was measured in dogs after an oral dose of 10 uM/kg,N,,,50588,1,,CHEMBL621713,BAO_0000218,
5465,Intermediate,9615.0,In vivo,1,,,Bioavailability was obtained by the comparison of AUC of intravenous dosing and AUC of oral dosing in dog,N,,,50588,1,,CHEMBL621714,BAO_0000218,
5466,Autocuration,10095.0,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice kidney upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,,22224,0,,CHEMBL621715,BAO_0000218,
5467,Autocuration,10095.0,,1,2107.0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,,22224,0,,CHEMBL623717,BAO_0000218,
5468,Autocuration,10095.0,,1,2107.0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,,,22224,0,,CHEMBL623718,BAO_0000218,
5469,Autocuration,10095.0,,1,2107.0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice liver upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,,22224,0,,CHEMBL623719,BAO_0000218,
5470,Autocuration,10095.0,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,,22224,0,,CHEMBL623720,BAO_0000218,
5471,Autocuration,10095.0,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice lungs upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,,22224,0,,CHEMBL623721,BAO_0000218,
5472,Autocuration,10095.0,,1,2385.0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,,22224,0,,CHEMBL623722,BAO_0000218,
5473,Autocuration,10095.0,,1,2385.0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,,,22224,0,,CHEMBL623723,BAO_0000218,
5474,Autocuration,10095.0,,1,2385.0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice muscle upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,,22224,0,,CHEMBL618543,BAO_0000218,
5475,Autocuration,10095.0,,1,2106.0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,,22224,0,,CHEMBL618544,BAO_0000218,
5476,Autocuration,10095.0,,1,2106.0,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice spleen upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,,22224,0,,CHEMBL875155,BAO_0000218,
5477,Autocuration,10095.0,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 1 hour,U,,,22224,0,,CHEMBL618545,BAO_0000218,
5478,Autocuration,10095.0,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,,,22224,0,,CHEMBL618546,BAO_0000218,
5479,Autocuration,10095.0,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,,22224,0,,CHEMBL623529,BAO_0000218,
5480,Autocuration,10095.0,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 24 hour,U,,,22224,0,,CHEMBL623530,BAO_0000218,
5481,Autocuration,10095.0,,1,,,Compound was evaluated for the biodistribution of tumor-imaging agent in B16 melanoma bearing mice uvea upon intraveneous administration at 2.6 gmol/mice after 3 hour,U,,,22224,0,,CHEMBL621764,BAO_0000218,
5482,Autocuration,9527.0,,1,,,Compound (i.v.) was evaluated for elimination rate constants in brainstem of rhesus monkeys (Radiolabeled compound),U,,,22224,0,,CHEMBL621765,BAO_0000019,
5483,Autocuration,9527.0,,1,2037.0,,Compound (i.v.) was evaluated for elimination rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),U,,,22224,0,,CHEMBL621766,BAO_0000019,
5484,Autocuration,9527.0,,1,1870.0,,Compound (i.v.) was evaluated for elimination rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),U,,,22224,0,,CHEMBL621767,BAO_0000019,
5485,Autocuration,9527.0,,1,,,Compound (i.v.) was evaluated for elimination rate constants in jaw bone of rhesus monkeys; NA = not active (Radiolabeled compound),U,,,22224,0,,CHEMBL621768,BAO_0000019,
5486,Autocuration,9527.0,,1,2435.0,,Compound (i.v.) was evaluated for elimination rate constants in striatum of rhesus monkey (Radiolabeled compound),U,,,22224,0,,CHEMBL621769,BAO_0000019,
5487,Autocuration,9527.0,,1,,,Compound (i.v.) was evaluated for uptake rate constants in brainstem of rhesus monkeys (Radiolabeled compound),U,,,22224,0,,CHEMBL621770,BAO_0000019,
5488,Autocuration,9527.0,,1,2037.0,,Compound (i.v.) was evaluated for uptake rate constants in cerebellum of rhesus monkeys (Radiolabeled compound),U,,,22224,0,,CHEMBL621771,BAO_0000019,
5489,Autocuration,9527.0,,1,1870.0,,Compound (i.v.) was evaluated for uptake rate constants in frontal cortex of rhesus monkey (Radiolabeled compound),U,,,22224,0,,CHEMBL621772,BAO_0000019,
5490,Autocuration,9527.0,,1,,,Compound (i.v.) was evaluated for uptake rate constants in jaw bone of rhesus monkey (Radiolabeled compound),U,,,22224,0,,CHEMBL621773,BAO_0000019,
5491,Autocuration,9527.0,,1,2435.0,,Compound (i.v.) was evaluated for uptake rate constants in striatum of rhesus monkeys (Radiolabeled compound),U,,,22224,0,,CHEMBL621774,BAO_0000019,
5492,Autocuration,9527.0,,1,,,Compound was evaluated for oral bioavailability in rats,U,,,22224,0,,CHEMBL621775,BAO_0000218,
5493,Autocuration,9527.0,In vivo,1,1969.0,,Maximum concentration of compound found in plasma at 5 mg/kg after oral administration,U,,,22224,0,,CHEMBL621776,BAO_0000218,
5494,Autocuration,9527.0,,1,,,Half life period was evaluated in monkey,U,,,22224,0,,CHEMBL621777,BAO_0000019,
5495,Autocuration,9527.0,In vivo,1,,,Half-life in rhesus monkeys by intravenous administration of dose,U,,,22224,0,,CHEMBL875162,BAO_0000218,
5496,Intermediate,10090.0,,1,1969.0,,AUC (0-6 hr) after oral administration at 30 mg/kg in ICR mouse,N,,,50594,1,,CHEMBL621778,BAO_0000218,
5497,Intermediate,10090.0,,1,1969.0,,AUC after intraperitoneal administration of 100 mg/kg in mice,N,,,50594,1,,CHEMBL621779,BAO_0000218,
5498,Intermediate,10090.0,,1,1969.0,,AUC value was determined after oral administration,N,,,50594,1,,CHEMBL622479,BAO_0000218,
5499,Intermediate,10090.0,,1,,,Area under curve (AUC) determined at a dose 10 mg/kg administered intraperitoneally to mice,N,,,50594,1,,CHEMBL622480,BAO_0000218,
5500,Intermediate,10090.0,,1,,,Area under curve (AUC) was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),N,,,50594,1,,CHEMBL622481,BAO_0000218,
5501,Intermediate,10090.0,,1,,,Area under curve by ioral administration in mouse,N,,,50594,1,,CHEMBL622482,BAO_0000218,
5502,Intermediate,10090.0,,1,,,Area under curve by iv administration in mouse,N,,,50594,1,,CHEMBL622483,BAO_0000218,
5503,Intermediate,10090.0,,1,,,Area under curve at 0-8 hr in IRC mice after peroral administration,N,,,50594,1,,CHEMBL622484,BAO_0000218,
5504,Intermediate,10090.0,,1,,,Area under curve when injected i.p. in mice at a dose of 50 mg/kg,N,,,50594,1,,CHEMBL622641,BAO_0000218,
5505,Intermediate,10090.0,,1,,,Area under curve when injected intraperitoneally in BALB/C mice at a dose of 20 mg/kg,N,,,50594,1,,CHEMBL622642,BAO_0000218,
5506,Intermediate,10090.0,,1,,,Area under curve when injected intravenously in BALB/C mice at a dose of 20 mg/kg,N,,,50594,1,,CHEMBL622643,BAO_0000218,
5507,Intermediate,10090.0,,1,,,Area under curve when injected intravenously in mice at a dose of 20 mg/kg,N,,,50594,1,,CHEMBL622644,BAO_0000218,
5508,Intermediate,9606.0,,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,N,,741.0,80433,1,,CHEMBL622645,BAO_0000219,
5509,Intermediate,9606.0,,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,N,,741.0,80433,1,,CHEMBL622646,BAO_0000219,
5510,Intermediate,9606.0,,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),N,,741.0,80433,1,,CHEMBL621238,BAO_0000219,
5511,Intermediate,9606.0,,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),N,,741.0,80433,1,,CHEMBL621239,BAO_0000219,
5512,Intermediate,9606.0,,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),N,,741.0,80433,1,,CHEMBL621240,BAO_0000219,
5513,Intermediate,9606.0,,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,,741.0,80433,1,,CHEMBL621241,BAO_0000219,
5514,Intermediate,9606.0,,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),N,,741.0,80433,1,,CHEMBL621242,BAO_0000219,
5515,Intermediate,9606.0,,1,,,Effect on RNA synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),N,,741.0,80433,1,,CHEMBL620350,BAO_0000219,
5516,Intermediate,9606.0,,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.01 ug/mL,N,,741.0,80433,1,,CHEMBL620351,BAO_0000219,
5517,Intermediate,9606.0,,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL,N,,741.0,80433,1,,CHEMBL620352,BAO_0000219,
5518,Intermediate,9606.0,,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.1 ug/mL (*: >50% cell kill),N,,741.0,80433,1,,CHEMBL620353,BAO_0000219,
5519,Intermediate,9606.0,,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.3 ug/mL (*: >50% cell kill),N,,741.0,80433,1,,CHEMBL620354,BAO_0000219,
5520,Intermediate,9606.0,,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 0.5 ug/mL. (*: >1 log cell kill),N,,741.0,80433,1,,CHEMBL620355,BAO_0000219,
5521,Intermediate,9606.0,,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 10 ug/mL (*: >1 log cell kill),N,,741.0,80433,1,,CHEMBL620356,BAO_0000219,
5522,Intermediate,9606.0,,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >50% cell kill),N,,741.0,80433,1,,CHEMBL620357,BAO_0000219,
5523,Intermediate,9606.0,,1,,,Effect on protein synthesis was determined by incorporation of radioligand into 8226 human myeloma cells at a concentration of 1 ug/mL. (*: >1 log cell kill),N,,741.0,80433,1,,CHEMBL620358,BAO_0000219,
5524,Expert,9606.0,,1,,,In vitro inhibition of human 8226 myeloma tumor cell line growth.,N,,741.0,80433,1,,CHEMBL620359,BAO_0000219,
5525,Intermediate,9606.0,,1,,,In vitro inhibition of tumor cell growth in the human myeloma 8226/ADR system.,N,,741.0,80433,1,,CHEMBL620360,BAO_0000219,
5526,Intermediate,9606.0,,1,,,Cytotoxicity of compound against 8226/DOX1V cells,N,,741.0,80433,1,,CHEMBL620361,BAO_0000219,
5527,Intermediate,9606.0,,1,,,Cytotoxicity of compound against 8226/S cells,N,,741.0,80433,1,,CHEMBL620362,BAO_0000219,
5528,Intermediate,9606.0,,1,,,Inhibitory concentration against 8226 myeloma cancer cell line,N,,741.0,80433,1,,CHEMBL620363,BAO_0000219,
5529,Intermediate,9606.0,,1,,,Inhibitory concentration against 8226/Dox40 (Dox-Re) cancer cell line,N,,741.0,80433,1,,CHEMBL620364,BAO_0000219,
5530,Intermediate,9606.0,,1,,,Inhibition of cell growth was studied in human teratocarcinoma (833K).,N,,854.0,80647,1,,CHEMBL620365,BAO_0000219,
5531,Intermediate,9606.0,,1,,,Inhibition of cell growth was studied in human teratocarcinoma (833K); ND ='not determined',N,,854.0,80647,1,,CHEMBL620366,BAO_0000219,
5532,Expert,9606.0,,1,,,Tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells,N,,854.0,80647,1,,CHEMBL620367,BAO_0000219,
5533,Intermediate,9606.0,,1,,,The compound was tested in vitro for growth inhibitory activity against 833K (human teratorcarcinoma) cells; No data,N,,854.0,80647,1,,CHEMBL620368,BAO_0000219,
5534,Autocuration,,,1,,,Inhibitory activity against caspase-1,U,,,22226,0,,CHEMBL620369,BAO_0000019,
5535,Autocuration,1351.0,,1,,,Percent inhibition of DAla-DAla Ligase at 10e -3 M of the compound,H,,,45,8,,CHEMBL620370,BAO_0000357,
5536,Intermediate,9606.0,,1,,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM) for 72 hr using MTT assay,N,,705.0,80648,1,,CHEMBL620371,BAO_0000219,
5537,Intermediate,9606.0,,1,,,In vitro antiproliferative activity against 8701-BC human breast cancer cells at a concentration of (0-100 uM,N,,705.0,80648,1,,CHEMBL620372,BAO_0000219,
5538,Intermediate,,,1,,,In vitro anticancer activity against 9 NCI colon cancer cell lines; inactive,U,,,22226,0,,CHEMBL876492,BAO_0000019,
5539,Intermediate,,,1,,,In vitro anticancer activity against 9 NCI melanoma cell lines; inactive,U,,,22226,0,,CHEMBL620373,BAO_0000019,
5540,Intermediate,,,1,,,In vitro anticancer activity against 9 NCI renal cancer cell lines; inactive,U,,,22226,0,,CHEMBL620374,BAO_0000019,
5541,Autocuration,,,1,,,Inhibitory activity was determined against 9-cis-epoxycarotenoid dioxygenase (NCED) expressed in Escherichia coli in presence of 9''-cis-neo-xanthin,U,,,22226,0,,CHEMBL620375,BAO_0000019,
5542,Autocuration,1314.0,,1,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,U,,,22226,0,,CHEMBL857902,BAO_0000019,
5543,Autocuration,1314.0,,1,,,Minimum inhibitory concentration against Streptococcus pyogenes 930MLSB,U,,,22226,0,,CHEMBL620376,BAO_0000019,
5544,Autocuration,,,1,,,Percent inhibition against Cdc25C phosphatase at 50 uM of compound,H,,,11922,8,,CHEMBL620377,BAO_0000357,
5545,Intermediate,9606.0,,1,,,Tested for in vitro cytotoxic potency of compound in 9KB assay,N,,324.0,81115,1,,CHEMBL620378,BAO_0000219,
5546,Intermediate,9606.0,,1,,,Tested for in vitro cytotoxic potency of compound in 9KB assay,N,,324.0,81115,1,,CHEMBL620379,BAO_0000219,
5547,Autocuration,9606.0,,1,,,In vitro cytotoxicity of compound was tested against 9KB cells.,U,,,22226,0,,CHEMBL620380,BAO_0000219,
5548,Intermediate,10116.0,,1,,,Cytotoxic concentration against 9L cells was determined on day 3,N,,392.0,80653,1,,CHEMBL884006,BAO_0000219,
5549,Expert,10116.0,,1,,,Tested in vitro for anticancer activity against 9L cells,N,,392.0,80653,1,,CHEMBL620381,BAO_0000219,
5550,Expert,10116.0,,1,,,Tested in vitro for anticancer activity against 9L cells; Not determined,N,,392.0,80653,1,,CHEMBL620382,BAO_0000219,
5551,Intermediate,9606.0,,1,,,In vitro inhibitory activity against human A549 non-small cell lung tumor; Active,N,,646.0,80682,1,,CHEMBL620383,BAO_0000219,
5552,Intermediate,9606.0,,1,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; No inhibition,N,,646.0,80682,1,,CHEMBL876493,BAO_0000219,
5553,Intermediate,9606.0,,1,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Significant inhibition,N,,646.0,80682,1,,CHEMBL620384,BAO_0000219,
5554,Intermediate,9606.0,,1,,,The compound was tested in vitro for its cytotoxicity against human A-549 cancer cell line by MTT method at 1 uM concentration; Slight inhibition,N,,646.0,80682,1,,CHEMBL620385,BAO_0000219,
5555,Expert,9606.0,,1,,,Cytotoxicity against human lung carcinoma A549 cell line,N,,646.0,80682,1,,CHEMBL620386,BAO_0000219,
5556,Expert,9606.0,,1,,,Ability to induce human IL-6 assay in A549 lung carcinoma cell line.,D,,646.0,25,9,,CHEMBL620387,BAO_0000219,
5557,Expert,9606.0,,1,,,"Ability to induce human IL-6 assay in A549 lung carcinoma cell line; n.r.: not reported, EC50 values not reported in cases were %dex e 35%.",D,,646.0,25,9,,CHEMBL621404,BAO_0000219,
5558,Intermediate,9606.0,,1,,,"In vitro growth inhibition of A549, lung carcinoma",N,,646.0,80682,1,,CHEMBL621405,BAO_0000219,
5559,Intermediate,9606.0,,1,,,"In vitro growth inhibition of A549, lung carcinoma.",N,,646.0,80682,1,,CHEMBL621406,BAO_0000219,
5560,Expert,9606.0,,1,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,N,,646.0,80682,1,,CHEMBL621407,BAO_0000219,
5561,Intermediate,9606.0,,1,,,Cytotoxic activity against human lung cancer A549 cell line was determined,N,,646.0,80682,1,,CHEMBL621408,BAO_0000219,
5562,Expert,9606.0,,1,,,Cytotoxicity against human solid tumor lung carcinoma A549 cell line,N,,646.0,80682,1,,CHEMBL885345,BAO_0000219,
5563,Intermediate,9606.0,,1,,,Cytotoxicity concentration against human lung carcinoma A-549 cell line,N,,646.0,80682,1,,CHEMBL621409,BAO_0000219,
5564,Expert,9606.0,,1,,,Cytotoxicity in A549 (human carcinoma) cell line.,N,,646.0,80682,1,,CHEMBL876034,BAO_0000219,
5565,Intermediate,9606.0,,1,,,Cytotoxicity on lung carcinoma (A-549) cell line,N,,646.0,80682,1,,CHEMBL621410,BAO_0000219,
5566,Expert,9606.0,,1,,,Effective dose against 50% reduction in Human lung carcinoma (A-549) cell number after 3-day incubation.,N,,646.0,80682,1,,CHEMBL621411,BAO_0000219,
5567,Intermediate,9606.0,,1,,,Effective dose of compound against replication of A549 cell line was evaluated,N,,646.0,80682,1,,CHEMBL621412,BAO_0000219,
5568,Expert,9606.0,,1,,,In vitro cytotoxic activity was determined against lung carcinoma (A549) cell line,N,,646.0,80682,1,,CHEMBL621413,BAO_0000219,
5569,Intermediate,9606.0,,1,,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line),N,,646.0,80682,1,,CHEMBL621414,BAO_0000219,
5570,Intermediate,9606.0,,1,,,In vitro cytotoxicity evaluated against human lung cancer (A549 cell line); NA is not active,N,,646.0,80682,1,,CHEMBL621415,BAO_0000219,
5571,Intermediate,9606.0,,1,,,The compound was evaluated for antiproliferative activity against A549 cell line,N,,646.0,80682,1,,CHEMBL621416,BAO_0000219,
5572,Intermediate,9606.0,,1,,,The compound was tested for tumor cell growth inhibitory activity against human lung carcinoma (A549) cell line.,N,,646.0,80682,1,,CHEMBL621417,BAO_0000219,
5573,Intermediate,9606.0,,1,,,Concentration required for growth inhibition of human lung carcinoma cell line A549,N,,646.0,80682,1,,CHEMBL621418,BAO_0000219,
5574,Intermediate,9606.0,,1,,,Cytotoxic activity against A549/ATCC non-small cell-lung cancer cell line,N,,646.0,80682,1,,CHEMBL621419,BAO_0000219,
5575,Intermediate,9606.0,,1,,,Growth inhibition against A549 cell line was evaluated,N,,646.0,80682,1,,CHEMBL621420,BAO_0000219,
5576,Intermediate,9606.0,,1,,,Growth inhibitory activity against A549 human solid tumor cell line using MTT assay,N,,646.0,80682,1,,CHEMBL875823,BAO_0000219,
5577,Expert,9606.0,,1,,,Inhibition of anchorage independent growth of human tumor cell line A549 K-ras-transformed in soft agar,N,,646.0,80682,1,,CHEMBL621421,BAO_0000219,
5578,Intermediate,9606.0,,1,,,Inhibitor activity against A549 (Human lung carcinoma)cell line with varying concentration of the drug for 72 hrs,N,,646.0,80682,1,,CHEMBL621422,BAO_0000219,
5579,Expert,9606.0,,1,,,Chemosensitivity against DT-diaphorase rich A549 cell lines,N,,646.0,80682,1,,CHEMBL884014,BAO_0000219,
5580,Intermediate,9606.0,,1,,,Compound tested against A549 lung carcinoma in the sulforhodamine B assay.,N,,646.0,80682,1,,CHEMBL621423,BAO_0000219,
5581,Expert,9606.0,,1,,,In vitro cytotoxicity against human A549 (lung cancer) cell line.,N,,646.0,80682,1,,CHEMBL621424,BAO_0000219,
5582,Intermediate,9606.0,,1,,,In vitro antitumor activity against A549 (lung) human tumor cell lines.,N,,646.0,80682,1,,CHEMBL621425,BAO_0000219,
5583,Expert,9606.0,,1,,,In vitro cytotoxic activity against human lung carcinoma A549 cell line,N,,646.0,80682,1,,CHEMBL621426,BAO_0000219,
5584,Intermediate,9606.0,,1,,,Compound was tested against A549 lung cancer cell line in the sulforhodamine B assay.,N,,646.0,80682,1,,CHEMBL621427,BAO_0000219,
5585,Intermediate,9606.0,,1,,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,N,,646.0,80682,1,,CHEMBL621428,BAO_0000219,
5586,Expert,9606.0,,1,,,Tested against A549 lung carcinoma in the sulforhodamine B assay.,N,,646.0,80682,1,,CHEMBL621429,BAO_0000219,
5587,Intermediate,9606.0,,1,,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction),N,,646.0,80682,1,,CHEMBL621430,BAO_0000219,
5588,Intermediate,9606.0,,1,,,Compound was tested for cytotoxicity on A549 lung adenocarcinoma cell line using a proliferation assay (MTT reduction).,N,,646.0,80682,1,,CHEMBL621431,BAO_0000219,
5589,Intermediate,9606.0,,1,,,Compound was tested for inhibition of growth of human lung carcinoma cell line A549 up to a conc of 10 uM; NI means no inhibition,N,,646.0,80682,1,,CHEMBL621432,BAO_0000219,
5590,Expert,9606.0,,1,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line,N,,646.0,80682,1,,CHEMBL621433,BAO_0000219,
5591,Intermediate,9606.0,,1,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,N,,646.0,80682,1,,CHEMBL875824,BAO_0000219,
5592,Intermediate,9606.0,,1,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,N,,646.0,80682,1,,CHEMBL621434,BAO_0000219,
5593,Intermediate,9606.0,,1,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line; NA=Not assayed,N,,646.0,80682,1,,CHEMBL621435,BAO_0000219,
5594,Intermediate,9606.0,,1,,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay.,N,,646.0,80682,1,,CHEMBL621436,BAO_0000219,
5595,Intermediate,9606.0,,1,,,Compound was tested for potency against human lung A549 cells using sulforhodamine B assay; UA=Potency was so low that the IC50 was unachievable.,N,,646.0,80682,1,,CHEMBL621437,BAO_0000219,
5596,Intermediate,9606.0,,1,,,Compound was tested for the growth inhibition of A549 lung tumor cell line,N,,646.0,80682,1,,CHEMBL621438,BAO_0000219,
5597,Expert,9606.0,,1,,,Growth inhibition of human non-small-lung carcinoma (A549) cell line,N,,646.0,80682,1,,CHEMBL621439,BAO_0000219,
5598,Intermediate,9606.0,,1,,,Compound was tested against A549 lung carcinoma cell line in the sulforhodamine B assay.,N,,646.0,80682,1,,CHEMBL621440,BAO_0000219,
5599,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (conscious),N,,,50588,1,,CHEMBL621441,BAO_0000218,
5600,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for the oral bioavailability after oral administration in dog.,N,,,50588,1,,CHEMBL621442,BAO_0000218,
5601,Intermediate,9615.0,In vivo,1,,,Compound was tested for percent of oral bioavailability at 10 mg/ml dose in dogs,N,,,50588,1,,CHEMBL621443,BAO_0000218,
5602,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL621444,BAO_0000218,
5603,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL625133,BAO_0000218,
5604,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL625134,BAO_0000218,
5605,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (fasted),N,,,50588,1,,CHEMBL625135,BAO_0000218,
5606,Intermediate,9615.0,In vivo,1,,,Oral bioavailability after intravenous administration in dogs at 1.2 uM/kg,N,,,50588,1,,CHEMBL625136,BAO_0000218,
5607,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL625137,BAO_0000218,
5608,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL625138,BAO_0000218,
5609,Intermediate,9615.0,In vivo,1,,,Percent bioavailability in dog,N,,,50588,1,,CHEMBL625139,BAO_0000218,
5610,Intermediate,9615.0,In vivo,1,,,Percent oral bioavailability of intravenously administered compound (6 mg/kg) was tested in dog,N,,,50588,1,,CHEMBL872264,BAO_0000218,
5611,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL625140,BAO_0000218,
5612,Intermediate,9615.0,In vivo,1,,,The compound was evaluated for bioavailability in dogs; 34-44,N,,,50588,1,,CHEMBL624436,BAO_0000218,
5613,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog (dose 4 mg/kg p.o.),N,,,50588,1,,CHEMBL624437,BAO_0000218,
5614,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL872261,BAO_0000218,
5615,Intermediate,9615.0,,1,,,8 hour trough Blood level in dog was measured after administration of compound,N,,,50588,1,,CHEMBL624438,BAO_0000218,
5616,Intermediate,9615.0,In vivo,1,1969.0,,The compound was tested for maximum concentration ( Cmax ) in dog plasma.,N,,,50588,1,,CHEMBL624439,BAO_0000218,
5617,Intermediate,9615.0,,1,,,C24 after oral administration at 5 mg/kg,N,,,50588,1,,CHEMBL624440,BAO_0000218,
5618,Intermediate,9615.0,,1,,,Clearance after oral and iv dosing in dogs,N,,,50588,1,,CHEMBL624441,BAO_0000218,
5619,Intermediate,9615.0,,1,1969.0,,Clearance of the drug was measured in the plasma of dog,N,,,50588,1,,CHEMBL624442,BAO_0000218,
5620,Intermediate,9615.0,,1,,,Compound was evaluated for Clearance in dogs at a dose of 1 mpk intravenously,N,,,50588,1,,CHEMBL624443,BAO_0000218,
5621,Intermediate,9615.0,In vivo,1,,,CL (clearance) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,N,,,50588,1,,CHEMBL624444,BAO_0000218,
5622,Intermediate,9615.0,In vivo,1,,,Clearance of compound was determined in dogs,N,,,50588,1,,CHEMBL624445,BAO_0000218,
5623,Intermediate,9615.0,In vivo,1,,,Clearance on i.v. administration of 2 mg/kg was measured in dog,N,,,50588,1,,CHEMBL624446,BAO_0000218,
5624,Intermediate,9615.0,In vivo,1,,,Clearance of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,,,50588,1,,CHEMBL624447,BAO_0000218,
5625,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dog was determined,N,,,50588,1,,CHEMBL624448,BAO_0000218,
5626,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,,,50588,1,,CHEMBL624449,BAO_0000218,
5627,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dog after administration of 0.25 mg/kg iv,N,,,50588,1,,CHEMBL624450,BAO_0000218,
5628,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dog after administration of 1 mg/kg iv,N,,,50588,1,,CHEMBL875942,BAO_0000218,
5629,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dogs,N,,,50588,1,,CHEMBL624451,BAO_0000218,
5630,Intermediate,9615.0,In vivo,1,,,Plasma clearance by iv administration in dog at a dose of 0.3 mg/kg,N,,,50588,1,,CHEMBL624452,BAO_0000218,
5631,Intermediate,9615.0,In vivo,1,,,Plasma clearance was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,N,,,50588,1,,CHEMBL624453,BAO_0000218,
5632,Intermediate,9615.0,In vivo,1,,,Plasma clearance after 15 mg/kg iv dose in Dogs,N,,,50588,1,,CHEMBL624454,BAO_0000218,
5633,Intermediate,9615.0,In vivo,1,,,Plasma clearance after 30 mg/kg po dose in Dogs,N,,,50588,1,,CHEMBL624455,BAO_0000218,
5634,Intermediate,9615.0,In vivo,1,,,Plasma administration to dogs,N,,,50588,1,,CHEMBL624456,BAO_0000218,
5635,Intermediate,9615.0,In vivo,1,,,Plasma clearance was determined,N,,,50588,1,,CHEMBL624457,BAO_0000218,
5636,Intermediate,9615.0,In vivo,1,,,Systemic clearance after intravenous administration (0.5 mg/kg) was determined in dog,N,,,50588,1,,CHEMBL624458,BAO_0000218,
5637,Intermediate,9615.0,In vivo,1,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in dog,N,,,50588,1,,CHEMBL624459,BAO_0000218,
5638,Intermediate,9606.0,In vitro,1,2107.0,,Intrinsic clearance in human liver microsomes,S,Microsomes,,102164,2,,CHEMBL624460,BAO_0000251,
5639,Intermediate,9606.0,In vitro,1,2107.0,,Intrinsic clearance in human liver microsomes,S,Microsomes,,102164,2,,CHEMBL624461,BAO_0000251,
5640,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,N,,,50588,1,,CHEMBL875943,BAO_0000218,
5641,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,N,,,50588,1,,CHEMBL624462,BAO_0000218,
5642,Intermediate,9615.0,In vivo,1,,,Clearance in dog (dose 1 mg/kg i.v.),N,,,50588,1,,CHEMBL624463,BAO_0000218,
5643,Intermediate,9615.0,In vivo,1,,,Plasma clearance after oral administration (2.5 mg/kg) in dog was determined,N,,,50588,1,,CHEMBL624464,BAO_0000218,
5644,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,,,50588,1,,CHEMBL624465,BAO_0000218,
5645,Intermediate,9615.0,In vivo,1,,,Plasma clearance after peroral administration at 10 mpk in dog,N,,,50588,1,,CHEMBL624466,BAO_0000218,
5646,Intermediate,9615.0,In vivo,1,,,Plasma clearance after peroral administration at 5 mpk in dog,N,,,50588,1,,CHEMBL624467,BAO_0000218,
5647,Intermediate,9615.0,In vivo,1,,,Plasma clearance after peroral administration at 5 mg/kg in dog,N,,,50588,1,,CHEMBL624468,BAO_0000218,
5648,Intermediate,9615.0,In vivo,1,,,Plasma clearance was measured in dog,N,,,50588,1,,CHEMBL624469,BAO_0000218,
5649,Intermediate,9615.0,In vivo,1,,,Plasma clearance was measured in dog,N,,,50588,1,,CHEMBL624470,BAO_0000218,
5650,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic property (CLtot) was measured in dog at the dose of 0.032 mg/kg i.v.,N,,,50588,1,,CHEMBL624471,BAO_0000218,
5651,Intermediate,9615.0,In vivo,1,,,Total clearance was determined after 0.1 mg/kg iv administration in dog,N,,,50588,1,,CHEMBL624472,BAO_0000218,
5652,Intermediate,9615.0,In vivo,1,,,Clearance of compound after intravenous administration in dogs at 1.2 uM/kg,N,,,50588,1,,CHEMBL622775,BAO_0000218,
5653,Intermediate,9615.0,In vivo,1,,,Clearance after intravenous administration of 0.5 mg/kg in dog was determined,N,,,50588,1,,CHEMBL622776,BAO_0000218,
5654,Intermediate,9615.0,In vivo,1,,,Clearance after intravenous administration of 1.0 mg/kg in dog was determined,N,,,50588,1,,CHEMBL622777,BAO_0000218,
5655,Intermediate,9615.0,In vivo,1,,,Clearance after peroral administration of 0.2 mg/kg in dog was determined,N,,,50588,1,,CHEMBL622778,BAO_0000218,
5656,Intermediate,9615.0,In vivo,1,,,Clearance by intravenous administration of 1.2 mg/kg in dog,N,,,50588,1,,CHEMBL622779,BAO_0000218,
5657,Intermediate,9615.0,In vivo,1,,,Clearance by iv administration in dogs at a dose of 1 mg/kg,N,,,50588,1,,CHEMBL622780,BAO_0000218,
5658,Intermediate,9615.0,In vivo,1,1969.0,,Clearance value was evaluated in dog plasma,N,,,50588,1,,CHEMBL622781,BAO_0000218,
5659,Intermediate,9615.0,In vivo,1,,,Clearance was evaluated after i.v. administration in dog at a dose of 1 mg/kg,N,,,50588,1,,CHEMBL622782,BAO_0000218,
5660,Intermediate,9615.0,In vivo,1,1969.0,,Compound was tested for plasma clearance in dog,N,,,50588,1,,CHEMBL622783,BAO_0000218,
5661,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic property (Plasma clearance) was measured in dog,N,,,50588,1,,CHEMBL622784,BAO_0000218,
5662,Intermediate,10090.0,,1,,,Area under curve when injected perorally in mice at a dose of 50 mg/kg,N,,,50594,1,,CHEMBL622785,BAO_0000218,
5663,Intermediate,10090.0,,1,,,Area under curve when injected perorally in BALB/C mice at a dose of 50 mg/kg,N,,,50594,1,,CHEMBL622786,BAO_0000218,
5664,Intermediate,10090.0,,1,,,Area under curve value in mouse at a dose of 10 mg/kg,N,,,50594,1,,CHEMBL622787,BAO_0000218,
5665,Intermediate,10090.0,,1,,,Area under curve was determined at a dose of 100 mg/kg (i.p.) in Mice,N,,,50594,1,,CHEMBL875949,BAO_0000218,
5666,Intermediate,10090.0,,1,,,Area under curve was determined at a dose of 200 mg/kg (i.p.) in Mice,N,,,50594,1,,CHEMBL622788,BAO_0000218,
5667,Intermediate,10090.0,,1,,,Area under curve was determined for compound after intraperitoneal administration in mice at 18 uM/kg,N,,,50594,1,,CHEMBL622789,BAO_0000218,
5668,Intermediate,10090.0,,1,,,Area under curve was determined for compound after intraperitoneal administration in mice at 23 uM/kg,N,,,50594,1,,CHEMBL622790,BAO_0000218,
5669,Intermediate,10090.0,,1,,,Area under curve was determined for compound after intraperitoneal administration in mice at 25 uM/kg,N,,,50594,1,,CHEMBL622791,BAO_0000218,
5670,Intermediate,10090.0,,1,,,Area under curve was determined for compound after intraperitoneal administration in mice at 26 uM/kg,N,,,50594,1,,CHEMBL622792,BAO_0000218,
5671,Intermediate,10090.0,,1,,,Area under curve was determined for compound after intravenous administration in mice at 24 uM/kg,N,,,50594,1,,CHEMBL622793,BAO_0000218,
5672,Intermediate,10090.0,,1,,,Area under curve was determined for the compound at 24 mg/Kg,N,,,50594,1,,CHEMBL622794,BAO_0000218,
5673,Intermediate,10090.0,,1,,,Area under curve was determined for the compound at 40 mg/Kg,N,,,50594,1,,CHEMBL622795,BAO_0000218,
5674,Intermediate,10090.0,,1,,,Area under curve was determined for the compound at 5 mg/Kg,N,,,50594,1,,CHEMBL621803,BAO_0000218,
5675,Intermediate,10090.0,,1,,,Area under the curve for the compound is obtained at dose 25 mg/kg,N,,,50594,1,,CHEMBL621804,BAO_0000218,
5676,Intermediate,10090.0,,1,,,Area under the curve for the compound was obtained when tested in mouse,N,,,50594,1,,CHEMBL621805,BAO_0000218,
5677,Intermediate,10090.0,,1,,,Area under the curve of compound in mouse blood following i.v. administration of 10 mg/kg,N,,,50594,1,,CHEMBL621806,BAO_0000218,
5678,Intermediate,10090.0,,1,,,Area under the curve of compound in mouse blood following p.o. administration of 30 mg/kg,N,,,50594,1,,CHEMBL621807,BAO_0000218,
5679,Intermediate,10090.0,,1,,,Area under the curve was measured in mouse after an iv dose of 1 mg/kg,N,,,50594,1,,CHEMBL621808,BAO_0000218,
5680,Intermediate,10090.0,,1,,,Area under the curve was determined for the compound at a single subcutaneous administration of 40 mg/kg in mice,N,,,50594,1,,CHEMBL621809,BAO_0000218,
5681,Intermediate,10090.0,,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),N,,,50594,1,,CHEMBL621810,BAO_0000218,
5682,Intermediate,10090.0,,1,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,N,,,50594,1,,CHEMBL875164,BAO_0000218,
5683,Intermediate,10090.0,,1,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,N,,,50594,1,,CHEMBL621811,BAO_0000218,
5684,Intermediate,10090.0,,1,,,"Compound was evaluated for the pharmacokinetic parameter, area under curve",N,,,50594,1,,CHEMBL621812,BAO_0000218,
5685,Intermediate,10090.0,,1,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr ),N,,,50594,1,,CHEMBL621813,BAO_0000218,
5686,Intermediate,10090.0,,1,,,Evaluated for pharmacokinetic parameter area under curve in mouse at the dose 20 mg/kg (0-4 hr),N,,,50594,1,,CHEMBL621814,BAO_0000218,
5687,Intermediate,10090.0,,1,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 100 mg/kg,N,,,50594,1,,CHEMBL621815,BAO_0000218,
5688,Intermediate,10090.0,,1,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg,N,,,50594,1,,CHEMBL621816,BAO_0000218,
5689,Intermediate,10090.0,,1,,,In vivo area under curve (AUC) was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,N,,,50594,1,,CHEMBL621817,BAO_0000218,
5690,Intermediate,10090.0,,1,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse,N,,,50594,1,,CHEMBL621818,BAO_0000218,
5691,Intermediate,10090.0,,1,,,Pharmacokinetic activity (AUC) in vivo after intravenous administration of 10 mg/kg in mouse;ND=Not determined,N,,,50594,1,,CHEMBL621819,BAO_0000218,
5692,Intermediate,10090.0,,1,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice,N,,,50594,1,,CHEMBL621820,BAO_0000218,
5693,Intermediate,10090.0,,1,,,Pharmacokinetic activity (AUC) in vivo after peroral administration of 10 mg/kg in mice;ND=Not determined,N,,,50594,1,,CHEMBL621821,BAO_0000218,
5694,Intermediate,10090.0,,1,,,Pharmacokinetic property (AUC) was determined after ip administration of 32 mg/kg in mice,N,,,50594,1,,CHEMBL621822,BAO_0000218,
5695,Intermediate,10090.0,,1,,,Pharmacokinetic property (AUC) was determined after po administration of 32 mg/kg in mice,N,,,50594,1,,CHEMBL619474,BAO_0000218,
5696,Intermediate,10090.0,,1,,,"Reduction in area under curve was determined in DIO mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",N,,,50594,1,,CHEMBL619475,BAO_0000218,
5697,Intermediate,10090.0,,1,,,"Reduction in area under curve was determined in ob/ob mice by oral glucose tolerance test following a single i.p. dose (10 mg/kg, 30 min pre-treatment)",N,,,50594,1,,CHEMBL619476,BAO_0000218,
5698,Intermediate,10090.0,,1,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered intravenously in mice",N,,,50594,1,,CHEMBL619477,BAO_0000218,
5699,Intermediate,10090.0,,1,,,"The area under concentration-time curve(AUC) was determined at 5 mg/kg of compound dose, administered perorally in mice",N,,,50594,1,,CHEMBL619478,BAO_0000218,
5700,Intermediate,10090.0,,1,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered intravenously in mice",N,,,50594,1,,CHEMBL619479,BAO_0000218,
5701,Intermediate,10090.0,,1,,,"The area under concentration-time curve(AUC) was determined at 50 mg/kg of compound dose, administered perorally in mice",N,,,50594,1,,CHEMBL619480,BAO_0000218,
5702,Intermediate,10090.0,,1,,,The area under curve in vivo in mouse blood level after oral administration at dose 50 mk/kg e-1,N,,,50594,1,,CHEMBL619481,BAO_0000218,
5703,Intermediate,10090.0,,1,,,The area under curve in vivo in mouse blood level after subcutaneous administration at dose 50 mk/kg e-1,N,,,50594,1,,CHEMBL619482,BAO_0000218,
5704,Intermediate,10090.0,,1,,,Area under the curve was evaluated in mice after intravenous administration,N,,,50594,1,,CHEMBL619483,BAO_0000218,
5705,Intermediate,10090.0,,1,,,Area under the curve was evaluated in mice after oral administration,N,,,50594,1,,CHEMBL619484,BAO_0000218,
5706,Intermediate,10090.0,,1,1969.0,,AUC total value at a dose of 10 mg/kg intravenous administration in mice.,N,,,50594,1,,CHEMBL619485,BAO_0000218,
5707,Intermediate,10090.0,,1,1969.0,,AUC total value at a dose of 10 mg/kg peroral administration in mice.,N,,,50594,1,,CHEMBL619486,BAO_0000218,
5708,Intermediate,10090.0,,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for area under curve (AUCtot),N,,,50594,1,,CHEMBL619487,BAO_0000218,
5709,Intermediate,10090.0,,1,,,AUMC after intraperitoneal administration of 100 mg/kg in mice,N,,,50594,1,,CHEMBL619488,BAO_0000218,
5710,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution in blood was determined in mice after iv administration at 15 min Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL620106,BAO_0000218,
5711,Intermediate,,,1,,,The compound was tested in vitro for anticancer activity against 9L cells,N,,392.0,80653,1,,CHEMBL620107,BAO_0000219,
5712,Autocuration,10116.0,,1,,,Anti proliferation activity determined; Weak effect,U,,,22226,0,,CHEMBL620283,BAO_0000019,
5713,Autocuration,10116.0,,1,,,Inhibition of cell growth by compound at a concentration of 100 uM in 9Ltk+ cells; Completely stopped the process,U,,,22226,0,,CHEMBL875176,BAO_0000219,
5714,Autocuration,10116.0,,1,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells,U,,,22226,0,,CHEMBL620284,BAO_0000219,
5715,Autocuration,10116.0,,1,,,Inhibition of cell growth by compound at a concentration of 10 uM in 9Ltk+ cells; Completely stopped the process,U,,,22226,0,,CHEMBL623515,BAO_0000219,
5716,Autocuration,10090.0,,1,,,The cytotoxic activity was in vitro tested by 9PS assay method,U,,,22226,0,,CHEMBL623516,BAO_0000019,
5717,Autocuration,10090.0,,1,,,The cytotoxic activity was in vitro tested by 9PS assay method.,U,,,22226,0,,CHEMBL623517,BAO_0000019,
5718,Autocuration,,,1,,,Partition coefficient (logD6.5),U,,,22224,0,,CHEMBL857878,BAO_0000019,
5719,Expert,9606.0,,1,,,Inhibitory concentration in vitro for cytotoxic activity against A 2780 human ovarian carcinoma cells,N,,478.0,81034,1,,CHEMBL623518,BAO_0000219,
5720,Intermediate,9606.0,,1,,,Effective concentration against A 375 cell line growth (DFMO concentration is 5.0 mM),N,,455.0,80018,1,,CHEMBL624195,BAO_0000219,
5721,Expert,9606.0,,1,,,Inhibitory concentration required against A 431 human epidermoid carcinoma cell line,N,,500.0,80852,1,,CHEMBL624196,BAO_0000219,
5722,Expert,9606.0,,1,,,Inhibition of EGF-induced Tyrosine phosphorylation in A431 cells expressing EGF-R,D,,500.0,9,9,,CHEMBL624197,BAO_0000219,
5723,Intermediate,9606.0,,1,,,Compound was evaluated for in vitro cytotoxicity against A 498 cancer cell line,N,,624.0,80021,1,,CHEMBL624198,BAO_0000219,
5724,Intermediate,9606.0,,1,,,in vitro cytotoxicity against A 498 cancer cell line,N,,624.0,80021,1,,CHEMBL621287,BAO_0000219,
5725,Intermediate,9606.0,,1,,,In vitro cytotoxic activity against renal (A 498) cancer cell line.,N,,624.0,80021,1,,CHEMBL621288,BAO_0000219,
5726,Intermediate,9606.0,,1,,,Cytotoxic activity against A 498 renal cancer cell lines.,N,,624.0,80021,1,,CHEMBL876496,BAO_0000219,
5727,Intermediate,9606.0,,1,,,In vitro cytotoxicity was determined against A 498 human renal tumor cell line using NCI screen,N,,624.0,80021,1,,CHEMBL621289,BAO_0000219,
5728,Autocuration,1280.0,,1,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,U,,,22226,0,,CHEMBL621290,BAO_0000019,
5729,Autocuration,1280.0,,1,,,Minimum inhibitory concentration against Staphylococcus aureus A 5177 MLSB-i,U,,,22226,0,,CHEMBL621291,BAO_0000019,
5730,Autocuration,1280.0,,1,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,U,,,22226,0,,CHEMBL621292,BAO_0000019,
5731,Autocuration,1280.0,,1,,,Minimum inhibitory concentration against Staphylococcus aureus A 5278 MLSB-c,U,,,22226,0,,CHEMBL621293,BAO_0000019,
5732,Intermediate,9606.0,,1,,,Inhibitory concentration required against A 549 lung cancer cell line,N,,646.0,80682,1,,CHEMBL621294,BAO_0000219,
5733,Intermediate,9606.0,,1,,,Growth inhibition of A 549 cell line by MTT reduction for 3 days of incubation time,N,,646.0,80682,1,,CHEMBL621295,BAO_0000219,
5734,Intermediate,9606.0,,1,,,Growth inhibition of A 549 cell line by MTT reduction for 7 days of incubation time,N,,646.0,80682,1,,CHEMBL884007,BAO_0000219,
5735,Intermediate,9606.0,,1,,,In vitro cytotoxicity against lung cancer A 549 cell lines,N,,646.0,80682,1,,CHEMBL621296,BAO_0000219,
5736,Intermediate,9606.0,,1,,,Compound was tested for its cytotoxicity against A 549 cell line,N,,646.0,80682,1,,CHEMBL621297,BAO_0000219,
5737,Expert,9606.0,,1,,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.",N,,646.0,80682,1,,CHEMBL839828,BAO_0000219,
5738,Intermediate,9606.0,,1,,,"Cytotoxic activity against A 549 human lung tumor cell line, using sulforhodamine B (SRB) assay.; No data",N,,646.0,80682,1,,CHEMBL620397,BAO_0000219,
5739,Expert,9606.0,,1,,,In vitro cytotoxic activity against A 549 (non-small cell lung) using SRB (sulforhodamine B) assay,N,,646.0,80682,1,,CHEMBL620398,BAO_0000219,
5740,Intermediate,9606.0,,1,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,N,,646.0,80682,1,,CHEMBL620399,BAO_0000219,
5741,Expert,9606.0,,1,,,In vitro inhibition of A549 (human lung cancer) cell growth.,N,,646.0,80682,1,,CHEMBL620400,BAO_0000219,
5742,Intermediate,9606.0,,1,,,Cytotoxic related antitumor activity against human cancer cell lines A 549; No data available,N,,646.0,80682,1,,CHEMBL620401,BAO_0000219,
5743,Expert,9606.0,,1,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay,N,,646.0,80682,1,,CHEMBL620402,BAO_0000219,
5744,Expert,9606.0,,1,,,Tested for in vitro cytotoxicity against A 549 (human lung) tumor cell line using sulforhodamine B (SRB) assay; not active (> 100 uM),N,,646.0,80682,1,,CHEMBL620403,BAO_0000219,
5745,Autocuration,,,1,,,Tested against A II at (100 ng/kg iv) in Dawley rats (n=2). 24 h,U,,,22226,0,,CHEMBL620404,BAO_0000218,
5746,Autocuration,,In vivo,1,,,The duration of action for the % peak inhibition of A II pressor response for dose of 0.1 mg/kg intravenous administration in conscious dogs.,H,,,104694,4,,CHEMBL620405,BAO_0000218,
5747,Autocuration,,In vivo,1,,,The duration of action for the % peak inhibition of A II pressor response for dose of 1.0 mg/kg peroral administration in rhesus monkeys.,H,,,104694,4,,CHEMBL620406,BAO_0000218,
5748,Autocuration,,In vivo,1,,,The duration of action for the % peak inhibition of angiotensin II pressor response for dose of 0.1 mg/kg peroral administration in conscious rats.,H,,,104694,4,,CHEMBL620407,BAO_0000218,
5749,Autocuration,,In vivo,1,,,The compound was evaluated for the % peak inhibition of A II pressor response for dose of 0.3 mg/kg peroral administration in rhesus monkeys.,H,,,104694,4,,CHEMBL620408,BAO_0000218,
5750,Autocuration,,In vivo,1,,,The compound was evaluated for the percentage of inhibition of A II pressor response in rats for peroral administration.,H,,,104694,4,,CHEMBL620409,BAO_0000218,
5751,Expert,9606.0,,1,,,Inhibition of A-498 human Renal cell proliferation,N,,624.0,80021,1,,CHEMBL620410,BAO_0000219,
5752,Autocuration,10116.0,,1,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 0.1 uM",U,,,22226,0,,CHEMBL620411,BAO_0000019,
5753,Autocuration,10116.0,,1,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 1 uM",U,,,22226,0,,CHEMBL620412,BAO_0000019,
5754,Autocuration,10116.0,,1,,,"Membrane potential change (fluorescence-based in vitro assay using DIBAC4 as indicator) in A-10 smooth muscle cell, to estimate potassium channel opening activity at 10 uM",U,,,22226,0,,CHEMBL876596,BAO_0000019,
5755,Expert,9606.0,,1,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay,N,,622.0,80012,1,,CHEMBL620413,BAO_0000219,
5756,Intermediate,9606.0,,1,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,,622.0,80012,1,,CHEMBL620414,BAO_0000219,
5757,Intermediate,9606.0,,1,,,Cytotoxicity against A-172 glioblastomas using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,,622.0,80012,1,,CHEMBL620415,BAO_0000219,
5758,Expert,9606.0,,1,,,Concentration required to inhibit growth of human tumor A549 (NSCL) cell line.,N,,646.0,80682,1,,CHEMBL620416,BAO_0000219,
5759,Intermediate,9606.0,,1,,,Concentration which produces 50% inhibition of growth of human lung carcinoma cell line A549,N,,646.0,80682,1,,CHEMBL620417,BAO_0000219,
5760,Expert,9606.0,,1,,,Cytotoxic activity evaluated against A549 tumor cells,N,,646.0,80682,1,,CHEMBL620418,BAO_0000219,
5761,Intermediate,9606.0,,1,,,Cytotoxic potentiation of Topotecan (TP) by the compound in human lung carcinoma A549 cell line,N,,646.0,80682,1,,CHEMBL620419,BAO_0000219,
5762,Intermediate,9606.0,,1,,,Cytotoxicity against A549 cells when the drug is exposed for a time of 1 hr,N,,646.0,80682,1,,CHEMBL620420,BAO_0000219,
5763,Intermediate,9606.0,,1,,,Cytotoxicity against A549 cells when the drug is exposed for a time of 96 hrs,N,,646.0,80682,1,,CHEMBL620421,BAO_0000219,
5764,Intermediate,9606.0,,1,,,Cytotoxicity against A549 tumor cell line determined by WST-1 assay,N,,646.0,80682,1,,CHEMBL620422,BAO_0000219,
5765,Intermediate,9606.0,,1,,,Cytotoxicity of compound against A549 cell line,N,,646.0,80682,1,,CHEMBL620423,BAO_0000219,
5766,Expert,9606.0,,1,,,Cytotoxicity against human lung cell carcinoma A549 cell line,N,,646.0,80682,1,,CHEMBL620424,BAO_0000219,
5767,Intermediate,9606.0,,1,,,Cytotoxicity against human lung carcinoma A549 cell line using MTT assay,N,,646.0,80682,1,,CHEMBL620425,BAO_0000219,
5768,Intermediate,9606.0,,1,,,Cytotoxicity was evaluated in vitro against A549 (non-small cell lung carcinoma) human tumor cell lines,N,,646.0,80682,1,,CHEMBL620426,BAO_0000219,
5769,Intermediate,9606.0,,1,,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum,N,,646.0,80682,1,,CHEMBL620427,BAO_0000219,
5770,Intermediate,9606.0,,1,,,In vitro antitumor activity against A549 human non-small lung carcinoma cells containing 10% fetal bovine serum; Not determined,N,,646.0,80682,1,,CHEMBL620428,BAO_0000219,
5771,Intermediate,9606.0,,1,,,In vitro antitumor activity against A549 human NSCLC lung carcinoma cells,N,,646.0,80682,1,,CHEMBL620429,BAO_0000219,
5772,Expert,9606.0,,1,,,In vitro concentration required to inhibit the TNF-alpha-induced RANTES production in A549 human lung epithelium cell line,N,,646.0,80682,1,,CHEMBL620430,BAO_0000219,
5773,Expert,9606.0,,1,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,N,,646.0,80682,1,,CHEMBL839887,BAO_0000219,
5774,Intermediate,9606.0,,1,,,In vitro cytotoxicity against parental and drug resistant lung human tumor cell line A549,N,,646.0,80682,1,,CHEMBL620431,BAO_0000219,
5775,Intermediate,9606.0,,1,,,In vitro cytotoxicity of compound against human A549 (non small cell lung) cancer cell line after 72 hr of drug exposure,N,,646.0,80682,1,,CHEMBL884010,BAO_0000219,
5776,Intermediate,9606.0,,1,,,In vitro cytotoxicity against A549 (human lung cancer),N,,646.0,80682,1,,CHEMBL620538,BAO_0000219,
5777,Expert,9606.0,,1,,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,N,,646.0,80682,1,,CHEMBL620539,BAO_0000219,
5778,Intermediate,9606.0,,1,,,In vivo antiproliferative activity against A549 cell line,N,,646.0,80682,1,,CHEMBL623373,BAO_0000218,
5779,Intermediate,9606.0,,1,,,Inhibition of non-small-cell lung adenocarcinoma (A549),N,,646.0,80682,1,,CHEMBL623374,BAO_0000219,
5780,Intermediate,9606.0,,1,,,Inhibition of non-small-cell lung adenocarcinoma (A549) after 48-h treatment,N,,646.0,80682,1,,CHEMBL623375,BAO_0000219,
5781,Intermediate,9606.0,,1,,,Inhibition of the growth against human non-small-lung carcinoma (A549) cell line after 72 hr exposure,N,,646.0,80682,1,,CHEMBL623376,BAO_0000219,
5782,Intermediate,9606.0,,1,,,Inhibitory activity against A549 cell line using MTT assay(Wild type p53),N,,646.0,80682,1,,CHEMBL623377,BAO_0000219,
5783,Intermediate,9606.0,,1,,,Inhibitory activity against A549 epithelial Cancer cell line at the concentration 0-30 uM for 48 hr,N,,646.0,80682,1,,CHEMBL623378,BAO_0000219,
5784,Intermediate,9606.0,,1,,,Inhibitory activity of compound against human A549 lung carcinoma cell line.,N,,646.0,80682,1,,CHEMBL623379,BAO_0000219,
5785,Intermediate,9606.0,,1,,,Inhibitory activity against A549 lung cancer cell line,N,,646.0,80682,1,,CHEMBL623380,BAO_0000219,
5786,Intermediate,9606.0,,1,,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line,N,,646.0,80682,1,,CHEMBL623381,BAO_0000219,
5787,Intermediate,9606.0,,1,,,Inhibitory activity against Taxol-resistant A549 lung cancer cell line; not determined,N,,646.0,80682,1,,CHEMBL623382,BAO_0000219,
5788,Intermediate,9606.0,,1,,,Inhibitory concentration against A549 (lung cancer) cell line,N,,646.0,80682,1,,CHEMBL623383,BAO_0000219,
5789,Expert,9606.0,,1,,,In vitro cytotoxicity against A-549 (human lung carcinoma) cell line.,N,,646.0,80682,1,,CHEMBL623384,BAO_0000219,
5790,Intermediate,9606.0,,1,,,Tested in vitro for inhibitory effect on the growth of human A-549 cancer cell line,N,,646.0,80682,1,,CHEMBL623385,BAO_0000219,
5791,Expert,9606.0,,1,,,Activity against A549 cancer cell line.,N,,646.0,80682,1,,CHEMBL623386,BAO_0000219,
5792,Intermediate,9606.0,,1,,,The compound was evaluated for cytotoxicity against A549 cell line,N,,646.0,80682,1,,CHEMBL884105,BAO_0000219,
5793,Intermediate,9606.0,,1,,,The compound was examined for its ability to block tumor necrosis factor alpha (TNF alpha) induced IL-8 production in A549 human lung carcinoma cell line using an ELISA,N,,646.0,80682,1,,CHEMBL623387,BAO_0000219,
5794,Intermediate,9606.0,,1,,,The compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line,N,,646.0,80682,1,,CHEMBL621568,BAO_0000219,
5795,Intermediate,9606.0,,1,,,Growth inhibitory activity was measured for human A549 tumor cell line.,N,,646.0,80682,1,,CHEMBL621569,BAO_0000219,
5796,Intermediate,9606.0,,1,,,Inhibitory activity against A549 lung cancer cell line,N,,646.0,80682,1,,CHEMBL621570,BAO_0000219,
5797,Intermediate,9606.0,,1,,,Inhibitory activity against A549 cell line; inactive,N,,646.0,80682,1,,CHEMBL621571,BAO_0000219,
5798,Expert,9606.0,,1,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,N,,646.0,80682,1,,CHEMBL621572,BAO_0000219,
5799,Expert,9606.0,,1,,,Inhibition of NFkB (transcription factor) activation in A549 human lung carcinoma cell line at 20 uM,N,,646.0,80682,1,,CHEMBL621573,BAO_0000219,
5800,Intermediate,9606.0,,1,,,Compound was tested for its ability to inhibit tumor necrosis factor alpha (TNF alpha) induced apoptosis in A549 human lung carcinoma cell line at 20 uM concentration,N,,646.0,80682,1,,CHEMBL621574,BAO_0000219,
5801,Intermediate,9606.0,,1,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-4 (M/L),N,,646.0,80682,1,,CHEMBL621575,BAO_0000219,
5802,Intermediate,9606.0,,1,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-5 (M/L),N,,646.0,80682,1,,CHEMBL621576,BAO_0000219,
5803,Intermediate,9606.0,,1,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-6 (M/L),N,,646.0,80682,1,,CHEMBL621577,BAO_0000219,
5804,Intermediate,9606.0,,1,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-7 (M/L),N,,646.0,80682,1,,CHEMBL621578,BAO_0000219,
5805,Intermediate,9606.0,,1,,,In vitro cytotoxic activity against A549 tumor cell line by SRB assay at 72 hour at a concentration 10E-8 (M/L),N,,646.0,80682,1,,CHEMBL621579,BAO_0000219,
5806,Intermediate,9606.0,,1,,,In vitro percent inhibition evaluated against human lung cancer (A549 cell line) at >20 ug/mL,N,,646.0,80682,1,,CHEMBL621580,BAO_0000219,
5807,Intermediate,9615.0,In vivo,1,,,Plasma clearance (in vivo) in mongrel dogs was determined,N,,,50588,1,,CHEMBL621581,BAO_0000218,
5808,Intermediate,9615.0,In vivo,1,,,Plasma clearance was measured in dog,N,,,50588,1,,CHEMBL621582,BAO_0000218,
5809,Intermediate,9615.0,In vivo,1,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,N,,,50588,1,,CHEMBL621583,BAO_0000218,
5810,Intermediate,9615.0,In vivo,1,,,Plasma clearance in vivo in dog by intravenous administration at a dose of 1 mg/kg,N,,,50588,1,,CHEMBL621584,BAO_0000218,
5811,Intermediate,9615.0,In vivo,1,1969.0,,Tested for plasma clearance in dog,N,,,50588,1,,CHEMBL621585,BAO_0000218,
5812,Intermediate,9615.0,In vivo,1,,,The compound was tested for clearance in dog plasma.,N,,,50588,1,,CHEMBL621586,BAO_0000218,
5813,Intermediate,9615.0,In vivo,1,,,"The pharmacokinetic parameter, clearance was reported in dog after intravenous administration",N,,,50588,1,,CHEMBL875835,BAO_0000218,
5814,Intermediate,9615.0,In vivo,1,,,Clearance value of compound was determined after intravenous administration of 1 mg/kg/h in dog,N,,,50588,1,,CHEMBL621587,BAO_0000218,
5815,Intermediate,9615.0,In vivo,1,1969.0,,Compound was tested for its ability of plasma clearance when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),N,,,50588,1,,CHEMBL621588,BAO_0000218,
5816,Intermediate,9615.0,In vitro,1,2107.0,,In vitro clearance in dog liver microsomes,N,Microsomes,,50588,1,,CHEMBL621589,BAO_0000218,
5817,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 0.5 mg/kg administered intravenously in dog,N,,,50588,1,,CHEMBL621590,BAO_0000218,
5818,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic profile in terms of clearance was determined at a dose of 5 mg/kg administered intravenously in dog,N,,,50588,1,,CHEMBL621591,BAO_0000218,
5819,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dog,N,,,50588,1,,CHEMBL621592,BAO_0000218,
5820,Intermediate,9615.0,In vivo,1,,,Clearance rate in dog,N,,,50588,1,,CHEMBL621593,BAO_0000218,
5821,Intermediate,9615.0,In vivo,1,1969.0,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,N,,,50588,1,,CHEMBL621594,BAO_0000218,
5822,Intermediate,9615.0,In vivo,1,,,Clearance in dogs,N,,,50588,1,,CHEMBL621595,BAO_0000218,
5823,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dogs,N,,,50588,1,,CHEMBL621596,BAO_0000218,
5824,Intermediate,9615.0,In vivo,1,,,Plasma clearance was determined,N,,,50588,1,,CHEMBL621597,BAO_0000218,
5825,Intermediate,9615.0,In vivo,1,,,Lower clearance in dog (i.v.) at 0.5 mpk,N,,,50588,1,,CHEMBL621598,BAO_0000218,
5826,Intermediate,9615.0,In vivo,1,,,Plasma clearance in Beagle dogs,N,,,50588,1,,CHEMBL621599,BAO_0000218,
5827,Intermediate,9615.0,In vivo,1,,,Plasma clearance (Clp) in dog,N,,,50588,1,,CHEMBL875836,BAO_0000218,
5828,Intermediate,9615.0,In vivo,1,,,Plasma clearance (pharmacokinetic parameter) in dog (in vivo) at a dose of 1 mg/kg,N,,,50588,1,,CHEMBL621600,BAO_0000218,
5829,Intermediate,9615.0,In vivo,1,,,Plasma clearance (pharmacokinetic parameter) in dog was determined,N,,,50588,1,,CHEMBL621601,BAO_0000218,
5830,Intermediate,9615.0,In vivo,1,,,Plasma clearance for the compound was measured in dog after an iv dose of 1 mg/kg,N,,,50588,1,,CHEMBL618474,BAO_0000218,
5831,Intermediate,9615.0,In vivo,1,,,Plasma clearance of compound was determined in dog,N,,,50588,1,,CHEMBL618475,BAO_0000218,
5832,Intermediate,9615.0,In vivo,1,,,Plasma clearance after intravenous administration of 1 mg/kg in dog,N,,,50588,1,,CHEMBL624524,BAO_0000218,
5833,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,N,,,50588,1,,CHEMBL624525,BAO_0000218,
5834,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dog was determined,N,,,50588,1,,CHEMBL624526,BAO_0000218,
5835,Intermediate,9615.0,In vivo,1,,,Plasma clearance was calculated in dog,N,,,50588,1,,CHEMBL624527,BAO_0000218,
5836,Intermediate,9615.0,In vivo,1,,,Plasma clearance at the dose of 2 mg/kg in dog,N,,,50588,1,,CHEMBL624528,BAO_0000218,
5837,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dog,N,,,50588,1,,CHEMBL624529,BAO_0000218,
5838,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dog,N,,,50588,1,,CHEMBL624530,BAO_0000218,
5839,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dog; Unable to calculate,N,,,50588,1,,CHEMBL624531,BAO_0000218,
5840,Intermediate,9615.0,In vivo,1,,,Plasma clearance in rhesus monkey,N,,,50588,1,,CHEMBL624532,BAO_0000218,
5841,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,,,50588,1,,CHEMBL624533,BAO_0000218,
5842,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,,,50588,1,,CHEMBL624534,BAO_0000218,
5843,Intermediate,9615.0,In vivo,1,,,Plasma clearance in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,,,50588,1,,CHEMBL624535,BAO_0000218,
5844,Intermediate,9615.0,In vivo,1,,,Plasma clearance was evaluated in dog,N,,,50588,1,,CHEMBL624536,BAO_0000218,
5845,Intermediate,9615.0,In vivo,1,,,Plasma clearance was evaluated in dog; Not tested,N,,,50588,1,,CHEMBL624537,BAO_0000218,
5846,Intermediate,9615.0,In vivo,1,,,Plasma clearance was evaluated in rhesus,N,,,50588,1,,CHEMBL624538,BAO_0000218,
5847,Intermediate,9615.0,In vivo,1,,,Plasma clearance was evaluated in rhesus; Not tested,N,,,50588,1,,CHEMBL624539,BAO_0000218,
5848,Intermediate,9615.0,In vivo,1,,,Plasma clearance value was determined in dog after a 3 mg/kg of iv dose,N,,,50588,1,,CHEMBL624540,BAO_0000218,
5849,Intermediate,9615.0,In vivo,1,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,,50588,1,,CHEMBL624541,BAO_0000218,
5850,Intermediate,9615.0,In vivo,1,,,Plasma clearance was determined in Beagle dog at a dose of 1 mg/kg by iv administration,N,,,50588,1,,CHEMBL624542,BAO_0000218,
5851,Intermediate,9615.0,In vivo,1,,,Plasma clearance was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,,,50588,1,,CHEMBL624543,BAO_0000218,
5852,Intermediate,9615.0,In vivo,1,,,Clearance value at a dose of 0.2 mg/kg i.v.,N,,,50588,1,,CHEMBL624544,BAO_0000218,
5853,Intermediate,9615.0,In vivo,1,1969.0,,Cmax (Maximum (Peak) plasma drug concentration) was after oral administration at 5 mg/kg,N,,,50588,1,,CHEMBL624545,BAO_0000218,
5854,Intermediate,9615.0,In vivo,1,,,Cmax after oral dose of compound at 3 mg/kg in dogs,N,,,50588,1,,CHEMBL624546,BAO_0000218,
5855,Intermediate,9615.0,In vivo,1,,,Cmax after single intravenous bolus of 1 mg/kg in dogs,N,,,50588,1,,CHEMBL875957,BAO_0000218,
5856,Intermediate,9615.0,In vivo,1,,,Cmax of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,,,50588,1,,CHEMBL624547,BAO_0000218,
5857,Intermediate,9615.0,In vivo,1,,,Cmax in dog after administration of 0.25 mg/kg iv; ND = not determined,N,,,50588,1,,CHEMBL624548,BAO_0000218,
5858,Intermediate,9615.0,In vivo,1,,,Cmax in dog after administration of 1 mg/kg iv,N,,,50588,1,,CHEMBL624549,BAO_0000218,
5859,Intermediate,9615.0,In vivo,1,1969.0,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in dog,N,,,50588,1,,CHEMBL624550,BAO_0000218,
5860,Intermediate,9615.0,In vivo,1,,,Cmax on p.o. administration of 10 mg/kg was measured in dog,N,,,50588,1,,CHEMBL621613,BAO_0000218,
5861,Intermediate,9615.0,In vivo,1,,,Cmax was determine after peroral administration at 10 mpk in dog,N,,,50588,1,,CHEMBL621614,BAO_0000218,
5862,Intermediate,9615.0,In vivo,1,,,Cmax was determine after peroral administration at 5 mpk in dog,N,,,50588,1,,CHEMBL623431,BAO_0000218,
5863,Intermediate,9615.0,In vivo,1,,,Cmax was determine after peroral administration at 5 mg/kg in dog,N,,,50588,1,,CHEMBL623432,BAO_0000218,
5864,Intermediate,9615.0,In vivo,1,,,Cmax after 0.3 mg/kg po administration in dog,N,,,50588,1,,CHEMBL623433,BAO_0000218,
5865,Intermediate,9615.0,In vivo,1,,,Cmax after peroral administration in dogs at 2.4 uM/kg,N,,,50588,1,,CHEMBL623434,BAO_0000218,
5866,Intermediate,9615.0,In vivo,1,,,Cmax in dog after oral administration at 1 mg/kg,N,,,50588,1,,CHEMBL623435,BAO_0000218,
5867,Intermediate,9615.0,In vivo,1,,,Cmax in dog after oral administration at 1 mg/kg; Below the level of quantitation,N,,,50588,1,,CHEMBL623436,BAO_0000218,
5868,Intermediate,9615.0,In vivo,1,,,Cmax upon oral administration in male Beagle dog at 10 mg/kg,N,,,50588,1,,CHEMBL875958,BAO_0000218,
5869,Intermediate,9615.0,In vivo,1,,,Cmax value after 15 mg/kg iv dose in Dogs,N,,,50588,1,,CHEMBL623437,BAO_0000218,
5870,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution in blood was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL623438,BAO_0000218,
5871,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution in blood was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL623439,BAO_0000218,
5872,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution in bone was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL623440,BAO_0000218,
5873,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution in bone was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL623441,BAO_0000218,
5874,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution in bone was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL623442,BAO_0000218,
5875,Intermediate,10090.0,In vivo,1,,,Biodistribution in fat and fur was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL623469,BAO_0000218,
5876,Intermediate,10090.0,In vivo,1,,,Biodistribution in fat and fur was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL623470,BAO_0000218,
5877,Intermediate,10090.0,In vivo,1,,,Biodistribution in fat and fur was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL623471,BAO_0000218,
5878,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution in heart was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL623472,BAO_0000218,
5879,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution in heart was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL623473,BAO_0000218,
5880,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution in heart was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL623474,BAO_0000218,
5881,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution in kidney was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL623475,BAO_0000218,
5882,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution in kidney was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL623476,BAO_0000218,
5883,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution in kidney was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL623477,BAO_0000218,
5884,Intermediate,10090.0,In vivo,1,160.0,,Biodistribution in large intestine after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL621896,BAO_0000218,
5885,Intermediate,10090.0,In vivo,1,160.0,,Biodistribution in large intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL621897,BAO_0000218,
5886,Intermediate,10090.0,In vivo,1,160.0,,Biodistribution in large intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL621898,BAO_0000218,
5887,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution in liver was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL621899,BAO_0000218,
5888,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution in liver was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL621900,BAO_0000218,
5889,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution in liver was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL621901,BAO_0000218,
5890,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution in lung was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL621902,BAO_0000218,
5891,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution in lung was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL621903,BAO_0000218,
5892,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution in lung was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL622587,BAO_0000218,
5893,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution in muscle was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL620285,BAO_0000218,
5894,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution in muscle was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL875285,BAO_0000218,
5895,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution in muscle was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL620286,BAO_0000218,
5896,Intermediate,10090.0,In vivo,1,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL620287,BAO_0000218,
5897,Intermediate,10090.0,In vivo,1,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL620288,BAO_0000218,
5898,Intermediate,10090.0,In vivo,1,,,Biodistribution in pancreatic tissue was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL620289,BAO_0000218,
5899,Intermediate,10090.0,In vivo,1,160.0,,Biodistribution in small intestine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL620290,BAO_0000218,
5900,Intermediate,10090.0,In vivo,1,160.0,,Biodistribution in small intestine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL620291,BAO_0000218,
5901,Intermediate,10090.0,In vivo,1,160.0,,Biodistribution in small intestine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL620292,BAO_0000218,
5902,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution in spleen was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL620293,BAO_0000218,
5903,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution in spleen was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL620294,BAO_0000218,
5904,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution in spleen was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL618614,BAO_0000218,
5905,Intermediate,10090.0,In vivo,1,945.0,,Biodistribution in stomach was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL618615,BAO_0000218,
5906,Intermediate,10090.0,In vivo,1,945.0,,Biodistribution in stomach was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL618616,BAO_0000218,
5907,Expert,9606.0,,1,,,Cytotoxicity against A-172 human tumor cell lines,N,,622.0,80012,1,,CHEMBL618617,BAO_0000219,
5908,Intermediate,9606.0,,1,,,Compound was evaluated for the in vitro cytotoxicity against A-172 human glioblastoma cell line,N,,622.0,80012,1,,CHEMBL618618,BAO_0000219,
5909,Intermediate,9606.0,,1,,,Antiproliferative activity of compound was tested against rhabdomyosarcoma (A-204) human tumor cells,N,,623.0,80014,1,,CHEMBL618619,BAO_0000219,
5910,Intermediate,9606.0,,1,,,Tested for antiproliferative activity against A-2780 tumoral cell line,N,,478.0,81034,1,,CHEMBL618620,BAO_0000219,
5911,Intermediate,9606.0,,1,,,Inhibitory concentration against melanoma A-375 cell line for cytotoxicity was determined,N,,455.0,80018,1,,CHEMBL618621,BAO_0000219,
5912,Intermediate,9606.0,,1,,,Tested in vitro against A-375 cell line human melanoma,N,,455.0,80018,1,,CHEMBL618622,BAO_0000219,
5913,Expert,9606.0,,1,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay,N,,797.0,80019,1,,CHEMBL618623,BAO_0000219,
5914,Intermediate,9606.0,,1,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,,797.0,80019,1,,CHEMBL618624,BAO_0000219,
5915,Expert,9606.0,,1,,,In vitro cytotoxicity against human non small-cell-lung cell line A-427.,N,,797.0,80019,1,,CHEMBL618625,BAO_0000219,
5916,Intermediate,9606.0,,1,,,Cytotoxicity against A-427 nonsmall lung cell line using MTT colorimetric assay; NE is no effect at 1x 10 E-5,N,,797.0,80019,1,,CHEMBL618626,BAO_0000219,
5917,Intermediate,9606.0,,1,,,Antitumor activity on A-427 lung carcinoma cell lines,N,,797.0,80019,1,,CHEMBL618627,BAO_0000219,
5918,Intermediate,9606.0,,1,,,Cytotoxic activity against human A-427 lung tumor cell line,N,,797.0,80019,1,,CHEMBL618628,BAO_0000219,
5919,Expert,9606.0,,1,,,In vitro antitumor effects against human A-427 cell lines.,N,,797.0,80019,1,,CHEMBL618629,BAO_0000219,
5920,Expert,9606.0,,1,,,In vitro inhibition of A-427 (human lung cancer) cell growth.,N,,797.0,80019,1,,CHEMBL618630,BAO_0000219,
5921,Intermediate,9606.0,,1,,,Cytotoxic related antitumor activity against human cancer cell lines A-427; No data available,N,,797.0,80019,1,,CHEMBL618631,BAO_0000219,
5922,Intermediate,9606.0,,1,,,Cytotoxic activity of compound against A-427 lung human tumor cell line,N,,797.0,80019,1,,CHEMBL618632,BAO_0000219,
5923,Expert,9606.0,,1,,,Cytotoxicity measured for the growth inhibition of A-431 Human epidermoid carcinoma cell line,N,,500.0,80852,1,,CHEMBL618633,BAO_0000219,
5924,Intermediate,9606.0,,1,,,Cytotoxic activity was tested against human A-498 (Kidney carcinoma) cell line,N,,624.0,80021,1,,CHEMBL619315,BAO_0000219,
5925,Expert,9606.0,,1,,,Cytotoxicity against A-498 cell line in the purdue cell culture screen was determined,N,,624.0,80021,1,,CHEMBL619316,BAO_0000219,
5926,Intermediate,9606.0,,1,,,Cytotoxicity against human kidney carcinoma A-498cell lines,N,,624.0,80021,1,,CHEMBL619317,BAO_0000219,
5927,Intermediate,9606.0,,1,,,In vitro cytotoxic activity against A-498 (human kidney carcinoma) cell line,N,,624.0,80021,1,,CHEMBL619318,BAO_0000219,
5928,Intermediate,9606.0,,1,,,In vitro cytotoxicity against Renal A-498 human tumors following a 6 day exposure.,N,,624.0,80021,1,,CHEMBL619319,BAO_0000219,
5929,Intermediate,9606.0,,1,,,Antitumor cytotoxic activity against A-498 cell line was determined,N,,624.0,80021,1,,CHEMBL619739,BAO_0000219,
5930,Intermediate,9606.0,,1,,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure.,N,,624.0,80021,1,,CHEMBL619740,BAO_0000219,
5931,Intermediate,9606.0,,1,,,In vitro cytotoxicity against Renal A-498 human tumors following a 2 day exposure; ND is no data,N,,624.0,80021,1,,CHEMBL883158,BAO_0000219,
5932,Intermediate,9606.0,,1,,,Antiproliferative activity of compound was tested against renal cancer (A-498) human tumor cells,N,,624.0,80021,1,,CHEMBL884012,BAO_0000219,
5933,Intermediate,9606.0,,1,,,In vitro inhibitory activity against A-498 ovarian cancer cell lines,N,,624.0,80021,1,,CHEMBL619741,BAO_0000219,
5934,Intermediate,9606.0,,1,,,"Cytotoxicity against NCI tumor panel, A-498 renal cancer cell line",N,,624.0,80021,1,,CHEMBL619742,BAO_0000219,
5935,Intermediate,9606.0,,1,,,Inhibition of growth lung non-small cell carcinoma A-549 cell line,N,,646.0,80682,1,,CHEMBL876610,BAO_0000219,
5936,Intermediate,9606.0,,1,,,Inhibition of growth of lung non-small cell carcinoma A-549 cell line,N,,646.0,80682,1,,CHEMBL619743,BAO_0000219,
5937,Intermediate,9606.0,,1,,,In vitro antiproliferative activity against human A-549 NSCL cell line,N,,646.0,80682,1,,CHEMBL619744,BAO_0000219,
5938,Intermediate,9606.0,,1,,,In vitro antiproliferative activity against human A-549 NSCL cell line; NS = Not significant,N,,646.0,80682,1,,CHEMBL619745,BAO_0000219,
5939,Intermediate,9606.0,,1,,,Growth inhibition of A-549 human lung adenocarcinoma at 0.01 uM compound concentration in standard MTT assay,N,,646.0,80682,1,,CHEMBL619746,BAO_0000219,
5940,Intermediate,9606.0,,1,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay,N,,646.0,80682,1,,CHEMBL619747,BAO_0000219,
5941,Intermediate,9606.0,,1,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-6 M compound concentration in standard MTT assay; ND means No data,N,,646.0,80682,1,,CHEMBL619748,BAO_0000219,
5942,Intermediate,9606.0,,1,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay,N,,646.0,80682,1,,CHEMBL619749,BAO_0000219,
5943,Intermediate,9606.0,,1,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-7 M compound concentration in standard MTT assay; ND means No data,N,,646.0,80682,1,,CHEMBL619750,BAO_0000219,
5944,Intermediate,9606.0,,1,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay,N,,646.0,80682,1,,CHEMBL624014,BAO_0000219,
5945,Intermediate,9606.0,,1,,,Percent growth inhibition of A-549 human lung adenocarcinoma at 10e-8 M compound concentration in standard MTT assay; ND means No data,N,,646.0,80682,1,,CHEMBL624015,BAO_0000219,
5946,Expert,9606.0,,1,,,In vitro effective concentration required to reduce the number of human lung carcinoma (A-549) after 3-day incubation,N,,646.0,80682,1,,CHEMBL885344,BAO_0000219,
5947,Intermediate,9606.0,,1,,,In vitro effective concentration required to reduce the number of human lung carcinoma cells (A-549) after 3-day incubation,N,,646.0,80682,1,,CHEMBL623224,BAO_0000219,
5948,Intermediate,9606.0,,1,,,Cytotoxic activity against A-549 cell line,N,,646.0,80682,1,,CHEMBL623225,BAO_0000219,
5949,Intermediate,9606.0,,1,,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 0.01 to 0.03,N,,646.0,80682,1,,CHEMBL622698,BAO_0000219,
5950,Intermediate,9606.0,,1,,,Antitumor cytotoxicity was determined against the A-549(human lung carcinoma) cell line; Range: 10.4 to 118.1,N,,646.0,80682,1,,CHEMBL622699,BAO_0000219,
5951,Expert,9606.0,,1,,,"Cytotoxicity in vitro expressed as 50% reduction in cell number after a 3-day incubation, in human lung carcinoma A-549 cell line",N,,646.0,80682,1,,CHEMBL622700,BAO_0000219,
5952,Intermediate,9606.0,,1,,,Compound was tested for cytotoxic activity against human lung carcinoma (A-549),N,,646.0,80682,1,,CHEMBL622701,BAO_0000219,
5953,Intermediate,9606.0,,1,,,Compound was tested for its cytotoxic activity in MTT assay against A-549 cell line (human lung carcinoma),N,,646.0,80682,1,,CHEMBL622702,BAO_0000219,
5954,Intermediate,9606.0,,1,,,Cytotoxic activity against human lung carcinoma (A-549) cell line,N,,646.0,80682,1,,CHEMBL622703,BAO_0000219,
5955,Expert,9606.0,,1,,,Cytotoxic activity towards A-549 cells,N,,646.0,80682,1,,CHEMBL622704,BAO_0000219,
5956,Intermediate,9606.0,,1,,,"In vitro percent inhibition of A549, lung carcinoma.",N,,646.0,80682,1,,CHEMBL622705,BAO_0000219,
5957,Intermediate,9606.0,,1,,,"In vitro percent inhibition of A549, lung carcinoma",N,,646.0,80682,1,,CHEMBL622706,BAO_0000219,
5958,Intermediate,9606.0,,1,,,"In vitro percent inhibition of A549, lung carcinoma.",N,,646.0,80682,1,,CHEMBL622707,BAO_0000219,
5959,Intermediate,9606.0,,1,,,"In vitro percent inhibition of A549, lung carcinoma.; Range 18-23",N,,646.0,80682,1,,CHEMBL622708,BAO_0000219,
5960,Intermediate,9606.0,,1,,,Percentage inhibition against parental and drug resistant lung human tumor cell line A549 at 10 uM,N,,646.0,80682,1,,CHEMBL622709,BAO_0000219,
5961,Intermediate,9606.0,,1,,,Growth inhibition of the A549/ATCC non-small cell lung cancer cell line for 2-day in vitro assay.,N,,646.0,80682,1,,CHEMBL622710,BAO_0000219,
5962,Intermediate,9606.0,,1,,,In vitro antitumor activity against Non-small cell lung cancer A549/ATCC cell lines by 6-day assay,N,,646.0,80682,1,,CHEMBL622711,BAO_0000219,
5963,Intermediate,9606.0,,1,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 1.56-6.25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,,646.0,80682,1,,CHEMBL622712,BAO_0000218,
5964,Intermediate,9606.0,,1,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 25-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,,646.0,80682,1,,CHEMBL622713,BAO_0000218,
5965,Intermediate,9606.0,,1,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 3.12-12.5 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,,646.0,80682,1,,CHEMBL622714,BAO_0000218,
5966,Intermediate,9606.0,,1,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 6.25-25 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,,646.0,80682,1,,CHEMBL622715,BAO_0000218,
5967,Intermediate,9606.0,,1,,,"Antitumor activity against A549 non small cell carcinoma at dose range of 70-100 mg/kg on day 14, 21, 28; activity expressed as maximum tolerated dose",N,,646.0,80682,1,,CHEMBL622716,BAO_0000218,
5968,Intermediate,9606.0,,1,,,"Antitumor activity against A549 non small cell carcinoma on day 14, 21, 28; activity expressed as maximum tolerated dose; NT = Not tested",N,,646.0,80682,1,,CHEMBL622717,BAO_0000219,
5969,Intermediate,9606.0,,1,,,Optimal dose required to inhibit human non small cell lung A549 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q7dX3),N,,646.0,80682,1,,CHEMBL622718,BAO_0000218,
5970,Expert,9606.0,,1,,,Cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration,N,,646.0,80682,1,,CHEMBL622719,BAO_0000219,
5971,Intermediate,9606.0,,1,,,Compound was evaluated for cytotoxic potentiation factor of temoxolomide in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,N,,646.0,80682,1,,CHEMBL622720,BAO_0000219,
5972,Intermediate,9606.0,,1,,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration,N,,646.0,80682,1,,CHEMBL622721,BAO_0000219,
5973,Intermediate,9606.0,,1,,,Compound was evaluated for cytotoxic potentiation factor of topotecan in human A549 tumor cell line at 0.4 uM concentration; ND - not determined,N,,646.0,80682,1,,CHEMBL622722,BAO_0000219,
5974,Intermediate,9606.0,,1,,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,N,,646.0,80682,1,,CHEMBL876030,BAO_0000219,
5975,Intermediate,9606.0,,1,,,"Concentration required for 50% inhibition of proliferation of lung cancer cell line, A549 with respect to paclitaxel was tested in vitro after 72 hr of incubation",N,,646.0,80682,1,,CHEMBL620206,BAO_0000219,
5976,Expert,9606.0,,1,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-4 mol/L,N,,646.0,80682,1,,CHEMBL620207,BAO_0000219,
5977,Expert,9606.0,,1,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-5 mol/L,N,,646.0,80682,1,,CHEMBL620208,BAO_0000219,
5978,Expert,9606.0,,1,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-6 mol/L,N,,646.0,80682,1,,CHEMBL620209,BAO_0000219,
5979,Expert,9606.0,,1,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-7 mol/L,N,,646.0,80682,1,,CHEMBL620210,BAO_0000219,
5980,Expert,9606.0,,1,,,Inhibition ratio against A-549 cancer cell growth at a concentration of 10e-8 mol/L,N,,646.0,80682,1,,CHEMBL621639,BAO_0000219,
5981,Intermediate,9606.0,,1,,,Tested for cytotoxicity against human lung adenocarcinoma A549 cell line,N,,646.0,80682,1,,CHEMBL621640,BAO_0000219,
5982,Expert,9606.0,,1,,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,N,,646.0,80682,1,,CHEMBL621641,BAO_0000219,
5983,Expert,9606.0,,1,,,Cytotoxic effect on non-small-cell lung cancer cell line A549/ATCC,N,,646.0,80682,1,,CHEMBL621642,BAO_0000219,
5984,Intermediate,9606.0,,1,,,Cytotoxicity of compound in synergy in 94% BCNU (10 uM) against A549 cell line,N,,646.0,80682,1,,CHEMBL621643,BAO_0000219,
5985,Intermediate,9606.0,,1,,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line,N,,646.0,80682,1,,CHEMBL621644,BAO_0000219,
5986,Intermediate,9606.0,,1,,,Cytotoxicity of compound in synergy in BCNU (10 uM) against A549 cell line; No data,N,,646.0,80682,1,,CHEMBL621645,BAO_0000219,
5987,Intermediate,10090.0,,1,,,In vitro antiproliferative activity against A549 cell line,N,,646.0,80682,1,,CHEMBL621646,BAO_0000219,
5988,Intermediate,,,1,,,Synergism with indomethacin in A549 cells,N,,646.0,80682,1,,CHEMBL621647,BAO_0000219,
5989,Intermediate,,,1,,,Synergism with tolmetin in A549 cells,N,,646.0,80682,1,,CHEMBL621648,BAO_0000219,
5990,Intermediate,,,1,,,Synergism with sulindac in A549 cells,N,,646.0,80682,1,,CHEMBL621649,BAO_0000219,
5991,Intermediate,,,1,,,Antagonism of indomethacin in A549 cells,N,,646.0,80682,1,,CHEMBL621650,BAO_0000219,
5992,Intermediate,,,1,,,Antagonism of sulindac in A549 cells,N,,646.0,80682,1,,CHEMBL621651,BAO_0000219,
5993,Intermediate,,,1,,,Antagonism of tolmetin in A549 cells,N,,646.0,80682,1,,CHEMBL621652,BAO_0000219,
5994,Intermediate,,,1,,,Synergism with indomethacin in A549 cells,N,,646.0,80682,1,,CHEMBL621653,BAO_0000219,
5995,Intermediate,,,1,,,Synergism with sulindac in A549 cells,N,,646.0,80682,1,,CHEMBL621654,BAO_0000219,
5996,Intermediate,,,1,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tolmetin; Not available,N,,646.0,80682,1,,CHEMBL621655,BAO_0000219,
5997,Intermediate,9615.0,In vivo,1,,,Cmax value after 30 mg/kg po dose in Dogs,N,,,50588,1,,CHEMBL621656,BAO_0000218,
5998,Intermediate,9615.0,In vivo,1,,,Cmax value determined in dog at a dose of 0 mg/kg by oral administration along with indavir (10 mg/kg),N,,,50588,1,,CHEMBL621657,BAO_0000218,
5999,Intermediate,9615.0,In vivo,1,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration,N,,,50588,1,,CHEMBL621658,BAO_0000218,
6000,Intermediate,9615.0,In vivo,1,,,Cmax value determined in dog at a dose of 10 mg/kg by oral administration along with indavir (10 mg/kg),N,,,50588,1,,CHEMBL621659,BAO_0000218,
6001,Intermediate,9615.0,In vivo,1,,,Cmax value determined in dog at a dose of 5 mg/kg by oral administration,N,,,50588,1,,CHEMBL621660,BAO_0000218,
6002,Intermediate,9615.0,In vivo,1,,,Cmax value after administration of 4 mg/Kg oral dose in dog,N,,,50588,1,,CHEMBL621661,BAO_0000218,
6003,Intermediate,9615.0,In vivo,1,,,Cmax value in dog,N,,,50588,1,,CHEMBL621662,BAO_0000218,
6004,Intermediate,9615.0,In vivo,1,,,Cmax value in dogs after oral administration at 1 mg/kg,N,,,50588,1,,CHEMBL621663,BAO_0000218,
6005,Intermediate,9615.0,In vivo,1,,,Bioavailability as Cmax in dogs at 5 mg/kg oral dose,N,,,50588,1,,CHEMBL621664,BAO_0000218,
6006,Intermediate,9615.0,In vivo,1,1969.0,,Compound was evaluated for maximum observed plasma concentration at dose 27.5 mg/kg DMP323 equiv in dogs,N,,,50588,1,,CHEMBL621665,BAO_0000218,
6007,Intermediate,9615.0,In vivo,1,1969.0,,Compound was evaluated for maximum observed plasma concentration at dose 7.7 mg/kg DMP323 equiv in dogs,N,,,50588,1,,CHEMBL621666,BAO_0000218,
6008,Intermediate,9615.0,In vivo,1,,,Concentration maxima after oral dosing in dogs,N,,,50588,1,,CHEMBL621667,BAO_0000218,
6009,Intermediate,9615.0,In vivo,1,,,Concentration maxima after oral dosing in dogs; not available,N,,,50588,1,,CHEMBL876738,BAO_0000218,
6010,Intermediate,9615.0,In vivo,1,,,Concentration maxima after oral dosing in dogs; not available,N,,,50588,1,,CHEMBL621668,BAO_0000218,
6011,Intermediate,9615.0,In vivo,1,,,In vivo maximal concentration was calculated at 0.4 mg/kg in dog; Not absorbed,N,,,50588,1,,CHEMBL621669,BAO_0000218,
6012,Intermediate,9615.0,In vivo,1,,,In vivo maximal concentration was calculated at 0.6 mg/kg in dog; Not absorbed,N,,,50588,1,,CHEMBL621670,BAO_0000218,
6013,Intermediate,9615.0,In vivo,1,,,In vivo maximal concentration was calculated at 1 mg/kg in dog,N,,,50588,1,,CHEMBL621671,BAO_0000218,
6014,Intermediate,9615.0,In vivo,1,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Not absorbed,N,,,50588,1,,CHEMBL622360,BAO_0000218,
6015,Intermediate,9615.0,In vivo,1,,,In vivo maximal concentration was calculated at 1 mg/kg in dog; Poor absorption,N,,,50588,1,,CHEMBL622361,BAO_0000218,
6016,Intermediate,9615.0,In vivo,1,1969.0,,Cmax in dog plasma after oral dose (1 mg/kg),N,,,50588,1,,CHEMBL622362,BAO_0000218,
6017,Intermediate,9615.0,In vivo,1,1969.0,,Maximal concentration (Cmax) in dog plasma at a dose of 5 mg/kg,N,,,50588,1,,CHEMBL622363,BAO_0000218,
6018,Intermediate,9615.0,In vivo,1,1969.0,,Maximal plasma concentration at a dose of 1 mg/kg,N,,,50588,1,,CHEMBL622364,BAO_0000218,
6019,Intermediate,9615.0,In vivo,1,1969.0,,Maximal plasma concentration at a dose of 1 mg/kg (oral),N,,,50588,1,,CHEMBL622365,BAO_0000218,
6020,Intermediate,9615.0,In vivo,1,1969.0,,Maximal plasma concentration required for pharmacokinetic data in dogs at dose of 1 mg/kg perorally,N,,,50588,1,,CHEMBL622533,BAO_0000218,
6021,Intermediate,9615.0,In vivo,1,,,Maximum concentration of compound in dog was evaluated.,N,,,50588,1,,CHEMBL622534,BAO_0000218,
6022,Intermediate,9615.0,In vivo,1,,,Maximum concentration by oral administration at a dose of 10 uM/kg in dog was determined,N,,,50588,1,,CHEMBL622535,BAO_0000218,
6023,Intermediate,9615.0,In vivo,1,,,Maximum concentration in dog after administration of 20 mg/kg dose through peroral route,N,,,50588,1,,CHEMBL876739,BAO_0000218,
6024,Intermediate,9615.0,In vivo,1,,,Maximum concentration in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,,,50588,1,,CHEMBL622536,BAO_0000218,
6025,Intermediate,9615.0,In vivo,1,1969.0,,Maximum concentration obtained in dog plasma was determined,N,,,50588,1,,CHEMBL622537,BAO_0000218,
6026,Intermediate,9615.0,In vivo,1,,,Maximum concentration was determined,N,,,50588,1,,CHEMBL622538,BAO_0000218,
6027,Intermediate,9615.0,In vivo,1,,,Maximum concentration at the dose of 2 mg/kg in dog,N,,,50588,1,,CHEMBL627867,BAO_0000218,
6028,Intermediate,9615.0,In vivo,1,,,Maximum concentration was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,,,50588,1,,CHEMBL627868,BAO_0000218,
6029,Intermediate,9615.0,In vivo,1,1969.0,,Maximum concentration was evaluated in dog plasma,N,,,50588,1,,CHEMBL627869,BAO_0000218,
6030,Intermediate,9615.0,In vivo,1,,,Maximum concentration was evaluated after 75 min after administration in dog,N,,,50588,1,,CHEMBL627870,BAO_0000218,
6031,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration determined in dog after oral administration of 17b,N,,,50588,1,,CHEMBL627871,BAO_0000218,
6032,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration determined in dog after oral administration of 2b,N,,,50588,1,,CHEMBL627872,BAO_0000218,
6033,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration in dog,N,,,50588,1,,CHEMBL627873,BAO_0000218,
6034,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration of compound in dog following p.o. administration of 0.5 mg/kg,N,,,50588,1,,CHEMBL627874,BAO_0000218,
6035,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration of compound in dog following p.o. administration of 0.9 mg/kg,N,,,50588,1,,CHEMBL627875,BAO_0000218,
6036,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration of compound in dog following p.o. administration of 0.95 mg/kg,N,,,50588,1,,CHEMBL627876,BAO_0000218,
6037,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration of compound in dog following p.o. administration of 1 mg/kg,N,,,50588,1,,CHEMBL627877,BAO_0000218,
6038,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration of compound was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,,,50588,1,,CHEMBL627878,BAO_0000218,
6039,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration after oral administration to dogs at a dose of 10 mg/kg,N,,,50588,1,,CHEMBL627879,BAO_0000218,
6040,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,,,50588,1,,CHEMBL875355,BAO_0000218,
6041,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,,,50588,1,,CHEMBL627880,BAO_0000218,
6042,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,N,,,50588,1,,CHEMBL627881,BAO_0000218,
6043,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,N,,,50588,1,,CHEMBL627882,BAO_0000218,
6044,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,N,,,50588,1,,CHEMBL627883,BAO_0000218,
6045,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration was determined as in dogs at 1 mg/kg oral dosing Cmax; 0.05-0.2 ug/mL,N,,,50588,1,,CHEMBL628526,BAO_0000218,
6046,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration was determined in dogs at 1 mg/kg oral dosing; 0.05-0.2 ug/mL,N,,,50588,1,,CHEMBL628527,BAO_0000218,
6047,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) in dog (in vivo) at a dose of 1 mg/kg,N,,,50588,1,,CHEMBL628528,BAO_0000218,
6048,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) in dog at a dose of 0.5 mg/kg,N,,,50588,1,,CHEMBL628529,BAO_0000218,
6049,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) in dog at a dose of 0.7 mg/kg,N,,,50588,1,,CHEMBL628530,BAO_0000218,
6050,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) in dog at a dose of 1 mg/kg,N,,,50588,1,,CHEMBL625243,BAO_0000218,
6051,Expert,9615.0,In vivo,1,1969.0,,Maximum plasma drug concentration of compound determined in dog after iv administration at a dose of 10 mg/kg,N,,,50588,1,,CHEMBL625244,BAO_0000218,
6052,Intermediate,9615.0,In vivo,1,,,Maximum concentration by intravenous administration of 1.2 mg/kg in dog,N,,,50588,1,,CHEMBL625245,BAO_0000218,
6053,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic (PK) property (Cmax) was determined in dog at the single dose of 1 mg/kg,N,,,50588,1,,CHEMBL625246,BAO_0000218,
6054,Intermediate,10090.0,In vivo,1,945.0,,Biodistribution in stomach was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL625247,BAO_0000218,
6055,Intermediate,10090.0,In vivo,1,1088.0,,Biodistribution in urine was determined in mice after iv administration at 15 min; Value expressed as percent injected dose per gram,N,,,50594,1,,CHEMBL625248,BAO_0000218,
6056,Intermediate,10090.0,In vivo,1,1088.0,,Biodistribution in urine was determined in mice after iv administration at 1 hr; Value expressed as percent injected dose per gram; ND- No data,N,,,50594,1,,CHEMBL625249,BAO_0000218,
6057,Intermediate,10090.0,In vivo,1,1088.0,,Biodistribution in urine was determined in mice after iv administration at 2 hr; Value expressed as percent injected dose per gram; ND- No data,N,,,50594,1,,CHEMBL625250,BAO_0000218,
6058,Intermediate,10090.0,,1,,,Compound (0.09% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 120 min; No increase,N,,,50594,1,,CHEMBL625251,BAO_0000218,
6059,Intermediate,10090.0,,1,,,Compound (0.31% dose/g) was tested for accumulation in mice bone (Compound is radiolabeled) after 30 min; Low increase,N,,,50594,1,,CHEMBL875356,BAO_0000218,
6060,Intermediate,10090.0,,1,,,Compound (i.v.) was tested for maximum activity in mice (Radiolabeled compound),N,,,50594,1,,CHEMBL625252,BAO_0000218,
6061,Intermediate,10090.0,,1,178.0,,Compound was evaluated for elimination rate constants in vivo in whole blood of normal mice (Radiolabeled compound),N,,,50594,1,,CHEMBL625253,BAO_0000218,
6062,Intermediate,10090.0,,1,,,Compound was evaluated for rate of bone uptake after administration of radiolabeled in mice (Radiolabeled compound),N,,,50594,1,,CHEMBL625254,BAO_0000218,
6063,Intermediate,10090.0,,1,,,Compound was evaluated for rate of bone uptake in mice (Radiolabeled compound),N,,,50594,1,,CHEMBL625255,BAO_0000218,
6064,Intermediate,10090.0,,1,,,Compound was evaluated for rate of bone uptake in mice; NA - not active (Radiolabeled compound),N,,,50594,1,,CHEMBL625256,BAO_0000218,
6065,Intermediate,10090.0,,1,178.0,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice (Radiolabeled compound),N,,,50594,1,,CHEMBL625257,BAO_0000218,
6066,Intermediate,10090.0,,1,178.0,,Compound was evaluated for uptake rate constants in vivo in whole blood of normal mice; NA = not active (Radiolabeled compound),N,,,50594,1,,CHEMBL625258,BAO_0000218,
6067,Intermediate,10090.0,,1,,,Compound was evaluated for washout rate in mice (Radiolabeled compound),N,,,50594,1,,CHEMBL625259,BAO_0000218,
6068,Intermediate,10090.0,,1,,,Compound was evaluated for washout rate in mice after radiolabeled ligand injected,N,,,50594,1,,CHEMBL625260,BAO_0000218,
6069,Intermediate,10090.0,,1,,,"Maximum activity (i.v.) after in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",N,,,50594,1,,CHEMBL625261,BAO_0000218,
6070,Intermediate,10090.0,,1,,,"Maximum activity in mice, expressed as [(ID%-kg)/g] (Radiolabeled compound)",N,,,50594,1,,CHEMBL625262,BAO_0000218,
6071,Intermediate,10090.0,,1,,,"Residual activity in mice at 120 minutes, expressed as [(ID%-kg)/g] (Radiolabeled compound)",N,,,50594,1,,CHEMBL622639,BAO_0000218,
6072,Intermediate,10090.0,,1,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice,N,,,50594,1,,CHEMBL622640,BAO_0000218,
6073,Intermediate,10090.0,,1,,,Tested for plasma level after 90 min of 10 mg/kg dose administered in mice; Not detected.,N,,,50594,1,,CHEMBL622812,BAO_0000218,
6074,Intermediate,10090.0,,1,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice,N,,,50594,1,,CHEMBL622813,BAO_0000218,
6075,Intermediate,10090.0,,1,,,Tested for plasma level after 90 min of 30 mg/kg dose administered in mice; Not determined,N,,,50594,1,,CHEMBL622814,BAO_0000218,
6076,Intermediate,10090.0,,1,,,Time at maximum activity in mice (Radiolabeled compound),N,,,50594,1,,CHEMBL622815,BAO_0000218,
6077,Intermediate,10090.0,,1,,,Percent oral bioavailability was determined after administration of compound at 5 mg/kg perorally in mice,N,,,50594,1,,CHEMBL625342,BAO_0000218,
6078,Intermediate,10090.0,,1,,,Percent oral bioavailability was determined after administration of compound at 50 mg/kg perorally in mice,N,,,50594,1,,CHEMBL625343,BAO_0000218,
6079,Intermediate,10090.0,,1,,,Binding towards mouse plasma protein at 10 uM,N,,,50594,1,,CHEMBL877591,BAO_0000218,
6080,Intermediate,10090.0,,1,,,Binding towards mouse plasma protein at 100 uM,N,,,50594,1,,CHEMBL625344,BAO_0000218,
6081,Intermediate,10090.0,In vivo,1,,,Bioavailability was evaluated in mice after intravenous administration,N,,,50594,1,,CHEMBL625345,BAO_0000218,
6082,Intermediate,10090.0,In vivo,1,,,Bioavailability was evaluated in mice after oral administration,N,,,50594,1,,CHEMBL625346,BAO_0000218,
6083,Intermediate,10090.0,In vivo,1,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse,N,,,50594,1,,CHEMBL625347,BAO_0000218,
6084,Intermediate,10090.0,In vivo,1,,,Bioavailability was obtained by the comparison of AUC of subcutaneous dosing and AUC of oral dosing in mouse at dose 25 mg/kg,N,,,50594,1,,CHEMBL625348,BAO_0000218,
6085,Intermediate,10090.0,In vivo,1,,,Bioavailability at a dose of 10 mg/kg peroral administration in mice.,N,,,50594,1,,CHEMBL625349,BAO_0000218,
6086,Intermediate,10090.0,In vivo,1,,,Oral bioavailability in mouse,N,,,50594,1,,CHEMBL625350,BAO_0000218,
6087,Intermediate,10090.0,In vivo,1,,,Oral bioavailability after intravenous administration in mice at 24 uM/kg,N,,,50594,1,,CHEMBL882952,BAO_0000218,
6088,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of [123I]- labeled compound in mice brain was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL625351,BAO_0000218,
6089,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of [123I]- labeled compound in mice brain was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL625352,BAO_0000218,
6090,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of [123I]- labeled compound in mice brain was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL877592,BAO_0000218,
6091,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of [123I]- labeled compound in mice brain was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL625353,BAO_0000218,
6092,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of [123I]- labeled compound in mice brain was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL625354,BAO_0000218,
6093,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of [123I]- labeled compound in mice brain was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL626019,BAO_0000218,
6094,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of [123I]- labeled compound in mice heart was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL626020,BAO_0000218,
6095,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of [123I]- labeled compound in mice heart was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL626021,BAO_0000218,
6096,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of [123I]- labeled compound in mice heart was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL626022,BAO_0000218,
6097,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of [123I]- labeled compound in mice heart was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL626192,BAO_0000218,
6098,Intermediate,9606.0,,1,,,Cytotoxic activity was tested against human prostate cell line A-549 (lung carcinoma),N,,646.0,80682,1,,CHEMBL626193,BAO_0000219,
6099,Expert,9606.0,,1,,,Cytotoxicity against A-549 cell line in the purdue cell culture screen was determined,N,,646.0,80682,1,,CHEMBL626194,BAO_0000219,
6100,Intermediate,9606.0,,1,,,Cytotoxicity against human lung carcinoma A-549 cell lines,N,,646.0,80682,1,,CHEMBL626195,BAO_0000219,
6101,Intermediate,9606.0,,1,,,In vitro cytotoxic activity against A-549 (human lung carcinoma) cell line,N,,646.0,80682,1,,CHEMBL626196,BAO_0000219,
6102,Intermediate,9606.0,,1,,,In vitro cytotoxicity against human lung carcinoma cell line A-549,N,,646.0,80682,1,,CHEMBL626197,BAO_0000219,
6103,Intermediate,9606.0,,1,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 3.6*10e-5 M,N,,646.0,80682,1,,CHEMBL626198,BAO_0000219,
6104,Intermediate,9606.0,,1,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.2*10e-5M,N,,646.0,80682,1,,CHEMBL626199,BAO_0000219,
6105,Intermediate,9606.0,,1,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 4.3*10e-5M,N,,646.0,80682,1,,CHEMBL626200,BAO_0000219,
6106,Intermediate,9606.0,,1,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 5.0*10e-5M,N,,646.0,80682,1,,CHEMBL626201,BAO_0000219,
6107,Intermediate,9606.0,,1,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 6.1*10e-5 M,N,,646.0,80682,1,,CHEMBL626202,BAO_0000219,
6108,Intermediate,9606.0,,1,,,In vitro cytotoxicity against human lung carcinoma cell line A-549 at 7.4*10e-5 M,N,,646.0,80682,1,,CHEMBL626203,BAO_0000219,
6109,Intermediate,9606.0,,1,,,In vitro cytotoxicity against A-549 human lung cancer cells,N,,646.0,80682,1,,CHEMBL626204,BAO_0000219,
6110,Intermediate,9606.0,,1,,,In vitro cytotoxicity against human lung carcinoma (A-549) cell line,N,,646.0,80682,1,,CHEMBL624701,BAO_0000219,
6111,Intermediate,9606.0,,1,,,In vitro cytotoxicity in human tumor lung carcinoma A-549 cell lines,N,,646.0,80682,1,,CHEMBL624702,BAO_0000219,
6112,Expert,9606.0,,1,,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,N,,646.0,80682,1,,CHEMBL624703,BAO_0000219,
6113,Intermediate,9606.0,,1,,,Tested in vitro for cytotoxicity against A-549 lung cancer cells,N,,646.0,80682,1,,CHEMBL624704,BAO_0000219,
6114,Intermediate,9606.0,,1,,,The compound was tested for cytotoxicity against A-549 cell in human lung carcinoma,N,,646.0,80682,1,,CHEMBL624705,BAO_0000219,
6115,Expert,9606.0,,1,,,Cytotoxicity against human lung carcinoma cells (A-549) using SRB assay.,N,,646.0,80682,1,,CHEMBL624706,BAO_0000219,
6116,Intermediate,9606.0,,1,,,Antitumor cytotoxic activity against A-549 cell line was determined,N,,646.0,80682,1,,CHEMBL624707,BAO_0000219,
6117,Intermediate,9606.0,,1,,,"Tested for the cytotoxicity against the Non-small cell lung cancer cell line A-549, growth inhibition by 50% is reported",N,,646.0,80682,1,,CHEMBL624708,BAO_0000219,
6118,Intermediate,9606.0,,1,,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,N,,646.0,80682,1,,CHEMBL624709,BAO_0000219,
6119,Expert,9606.0,,1,,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,N,,646.0,80682,1,,CHEMBL884107,BAO_0000219,
6120,Intermediate,9606.0,,1,,,Antitumoral activity was assayed against A-549 cell line,N,,646.0,80682,1,,CHEMBL624710,BAO_0000219,
6121,Intermediate,9606.0,,1,,,Compound was evaluated for the cytotoxicity against A-549 tumor cell line after 3 days of incubation,N,,646.0,80682,1,,CHEMBL624711,BAO_0000219,
6122,Intermediate,9606.0,,1,,,Compound was tested for cytotoxicity against A-549 human solid tumor cell line,N,,646.0,80682,1,,CHEMBL624712,BAO_0000219,
6123,Expert,9606.0,,1,,,In vitro cytotoxicity against A549 (human lung carcinoma) cell line.,N,,646.0,80682,1,,CHEMBL624713,BAO_0000219,
6124,Intermediate,9606.0,,1,,,Compound was tested for inhibition of cell growth of A-549 cells,N,,646.0,80682,1,,CHEMBL624714,BAO_0000219,
6125,Intermediate,9606.0,,1,,,Compound was tested for its inhibitory effect on the growth of A-549 tumor cell line from lung.,N,,646.0,80682,1,,CHEMBL624715,BAO_0000219,
6126,Intermediate,9606.0,,1,,,Concentration required for 50% inhibition of growth in human lung carcinoma cell line was determined,N,,646.0,80682,1,,CHEMBL624716,BAO_0000219,
6127,Expert,9606.0,,1,,,In vitro cytotoxicity against A549-human lung carcinoma cells.,N,,646.0,80682,1,,CHEMBL619505,BAO_0000219,
6128,Expert,9606.0,,1,,,Cytotoxic activity against cultured cells of A-549 human lung carcinoma.,N,,646.0,80682,1,,CHEMBL619506,BAO_0000219,
6129,Intermediate,9606.0,,1,,,Cytotoxic activity against A-549 cell lines.,N,,646.0,80682,1,,CHEMBL619507,BAO_0000219,
6130,Expert,9606.0,,1,,,Cytotoxicity was measured against neoplastic cultured A-549 cells of human lung carcinoma.,N,,646.0,80682,1,,CHEMBL619508,BAO_0000219,
6131,Intermediate,9606.0,,1,,,Cytotoxicity against human A549 non small cell lung cell lines,N,,646.0,80682,1,,CHEMBL619509,BAO_0000219,
6132,Expert,9606.0,,1,,,Inhibition of cell growth in (A-549) lung cell line,N,,646.0,80682,1,,CHEMBL619510,BAO_0000219,
6133,Intermediate,9606.0,,1,,,Growth inhibitory effect of compound was measured on A-549 human lung adenocarcinoma cancer cell line,N,,646.0,80682,1,,CHEMBL619511,BAO_0000219,
6134,Intermediate,9606.0,,1,,,In vitro antitumor activity against A-549 tumor cells.,N,,646.0,80682,1,,CHEMBL619512,BAO_0000219,
6135,Expert,9606.0,,1,,,In vitro antitumor effects against human A-549 cell lines.,N,,646.0,80682,1,,CHEMBL619513,BAO_0000219,
6136,Intermediate,9606.0,,1,,,In vitro cytotoxic activity of compound against A-549 cell line,N,,646.0,80682,1,,CHEMBL619514,BAO_0000219,
6137,Intermediate,9606.0,,1,,,In vitro cytotoxicity against human lung carcinoma A-549 cell line,N,,646.0,80682,1,,CHEMBL619515,BAO_0000219,
6138,Intermediate,9606.0,,1,,,In vitro cytotoxicity against human non-small cell lung carcinoma A549,N,,646.0,80682,1,,CHEMBL619516,BAO_0000219,
6139,Intermediate,9606.0,,1,,,In vitro cytotoxicity against human A-549 cancer cell line was evaluated,N,,646.0,80682,1,,CHEMBL884005,BAO_0000219,
6140,Expert,9606.0,,1,,,In vitro cytotoxicity against the A-549 (human lung carcinoma) neoplastic cell line,N,,646.0,80682,1,,CHEMBL619517,BAO_0000219,
6141,Intermediate,9606.0,,1,,,Inhibitory concentration of compound against A-549 cell line,N,,646.0,80682,1,,CHEMBL619518,BAO_0000219,
6142,Intermediate,9606.0,,1,,,Tested for the cytostatic activity as inhibitory concentration against A-549 human pulmonary adenocarcinoma cells,N,,646.0,80682,1,,CHEMBL619519,BAO_0000219,
6143,Intermediate,9606.0,,1,,,cytotoxic activity against leukemia (A-549) cancer cell line,N,,646.0,80682,1,,CHEMBL876489,BAO_0000219,
6144,Expert,9606.0,,1,,,Tested in vitro for cytotoxic activity against lung carcinoma (A-549) cell line,N,,646.0,80682,1,,CHEMBL619520,BAO_0000219,
6145,Intermediate,9606.0,,1,,,Percent inhibition for cytotoxic activity against lung carcinoma (A-549) cell line,N,,646.0,80682,1,,CHEMBL619521,BAO_0000219,
6146,Intermediate,9606.0,,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.1(ug/ml),N,,646.0,80682,1,,CHEMBL619522,BAO_0000219,
6147,Intermediate,9606.0,,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 0.4(ug/ml),N,,646.0,80682,1,,CHEMBL619523,BAO_0000219,
6148,Intermediate,9606.0,,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 1.1 (ug/ml),N,,646.0,80682,1,,CHEMBL619524,BAO_0000219,
6149,Intermediate,9606.0,,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml),N,,646.0,80682,1,,CHEMBL619525,BAO_0000219,
6150,Intermediate,,,1,,,Drug interaction towards A549 cell line was determined in terms of combination index in presence of Tometin; Not available,N,,646.0,80682,1,,CHEMBL619526,BAO_0000219,
6151,Intermediate,9606.0,,1,,,Influence of PARP-1 cellular activity in human lung carcinoma A549 cells on %ADP Polymer formation at a concentration of 25 uM of the compound,N,,646.0,80682,1,,CHEMBL619527,BAO_0000219,
6152,Intermediate,9606.0,,1,,,Cytotoxicity against A549 cells; No cytotoxicity,N,,646.0,80682,1,,CHEMBL619528,BAO_0000219,
6153,Expert,9606.0,,1,,,Cytotoxicity against human lung carcinoma (A549) cell lines,N,,646.0,80682,1,,CHEMBL619529,BAO_0000219,
6154,Expert,9606.0,,1,,,Cytotoxicity against human lung carcinoma (A549) cell lines; Not active,N,,646.0,80682,1,,CHEMBL619530,BAO_0000219,
6155,Intermediate,9606.0,,1,,,In vitro anticancer activity against human lung (A549) cell line,N,,646.0,80682,1,,CHEMBL876490,BAO_0000219,
6156,Intermediate,9606.0,,1,,,Percent growth inhibition at 200 uM PARP inhibitor in A549 cells,N,,646.0,80682,1,,CHEMBL619531,BAO_0000219,
6157,Intermediate,9606.0,,1,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..006 uM compound concentration in A549 cells,N,,646.0,80682,1,,CHEMBL619532,BAO_0000219,
6158,Intermediate,9606.0,,1,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..03 uM compound concentration in A549 cells,N,,646.0,80682,1,,CHEMBL619533,BAO_0000219,
6159,Intermediate,9606.0,,1,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..15 uM compound concentration in A549 cells,N,,646.0,80682,1,,CHEMBL619534,BAO_0000219,
6160,Intermediate,9606.0,,1,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 0..4 uM compound concentration in A549 cells,N,,646.0,80682,1,,CHEMBL620164,BAO_0000219,
6161,Intermediate,9606.0,,1,,,Percent ADP-ribose polymer formation in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,N,,646.0,80682,1,,CHEMBL620165,BAO_0000219,
6162,Expert,9606.0,,1,,,Inhibition of A549 human lung tumor cell proliferation,N,,646.0,80682,1,,CHEMBL620166,BAO_0000219,
6163,Intermediate,9606.0,,1,,,"Concentration required to inhibit the lung A549 cell growth by 50%,P53 status of cell line used was wild-type. ",N,,646.0,80682,1,,CHEMBL620167,BAO_0000219,
6164,Expert,9606.0,,1,,,In vitro cytotoxicity against human tumor cell line A549,N,,646.0,80682,1,,CHEMBL620168,BAO_0000219,
6165,Intermediate,9606.0,,1,,,In vitro growth inhibitory activity against A549 human nonsmall cell lung carcinoma cells. ,N,,646.0,80682,1,,CHEMBL620338,BAO_0000219,
6166,Intermediate,9606.0,,1,,,Inhibitory concentration of compound against proliferation of lung carcinoma A549 cell line,N,,646.0,80682,1,,CHEMBL620339,BAO_0000219,
6167,Intermediate,9606.0,,1,,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells,N,,646.0,80682,1,,CHEMBL620340,BAO_0000219,
6168,Intermediate,9606.0,,1,,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells,N,,646.0,80682,1,,CHEMBL620341,BAO_0000219,
6169,Intermediate,9606.0,,1,,,Inhibitory concentration (solid phase) against TNF-alpha induced apoptosis of A549 cells: Not tested,N,,646.0,80682,1,,CHEMBL876491,BAO_0000219,
6170,Intermediate,9606.0,,1,,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,N,,646.0,80682,1,,CHEMBL620342,BAO_0000219,
6171,Intermediate,9606.0,,1,,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,N,,646.0,80682,1,,CHEMBL620343,BAO_0000219,
6172,Intermediate,9606.0,,1,,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,N,,646.0,80682,1,,CHEMBL620344,BAO_0000219,
6173,Intermediate,9606.0,,1,,,In vitro anticancer activity against human lung (A549) cell line,N,,646.0,80682,1,,CHEMBL620345,BAO_0000219,
6174,Intermediate,9606.0,,1,,,Inhibition of proliferation of A549 cells at concentration of 0.1 uM was determined,N,,646.0,80682,1,,CHEMBL620346,BAO_0000219,
6175,Intermediate,9606.0,,1,,,Inhibition of proliferation of A549 cells at concentration of 100 uM was determined,N,,646.0,80682,1,,CHEMBL620347,BAO_0000219,
6176,Intermediate,9606.0,,1,,,Inhibition of proliferation of A549 cells at concentration of 10 uM was determined,N,,646.0,80682,1,,CHEMBL620348,BAO_0000219,
6177,Intermediate,9606.0,,1,,,Inhibition of proliferation of A549 cells at concentration of 1 uM was determined,N,,646.0,80682,1,,CHEMBL620349,BAO_0000219,
6178,Intermediate,9606.0,,1,,,Inhibitory concentration (resynthesized pure material) against TNF-alpha induced apoptosis of A549 cells at 20 uM,N,,646.0,80682,1,,CHEMBL618667,BAO_0000219,
6179,Expert,9606.0,,1,,,Percentage inhibition of human lung carcinoma (A549) cell lines,N,,646.0,80682,1,,CHEMBL618668,BAO_0000219,
6180,Intermediate,9606.0,,1,,,Influence of PARP-1 cellular activity on NAD+ levels at a concentration of 25 uM of the compound,N,,646.0,80682,1,,CHEMBL876031,BAO_0000219,
6181,Intermediate,9606.0,,1,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM); ND denotes not determined",N,,646.0,80682,1,,CHEMBL618759,BAO_0000219,
6182,Intermediate,9606.0,,1,,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells; ND denotes not determined,N,,646.0,80682,1,,CHEMBL618760,BAO_0000219,
6183,Intermediate,9606.0,,1,,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells; ND denotes not determined,N,,646.0,80682,1,,CHEMBL619000,BAO_0000219,
6184,Intermediate,9606.0,,1,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TM)",N,,646.0,80682,1,,CHEMBL619001,BAO_0000219,
6185,Intermediate,9606.0,,1,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.006 uM",N,,646.0,80682,1,,CHEMBL619002,BAO_0000219,
6186,Intermediate,9606.0,,1,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.03 uM",N,,646.0,80682,1,,CHEMBL619003,BAO_0000219,
6187,Intermediate,9606.0,,1,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.15 uM",N,,646.0,80682,1,,CHEMBL619597,BAO_0000219,
6188,Intermediate,9606.0,,1,,,"Concentration that gives 50% growth inhibition in A549 cells, activity expressed as PF50 (TP) at 0.4 uM",N,,646.0,80682,1,,CHEMBL619598,BAO_0000219,
6189,Intermediate,9606.0,,1,,,Concentration that gives 50% growth inhibition (temozolomide alone/ (temozolomide + 0.4 uM of compound)) in A549 cells,N,,646.0,80682,1,,CHEMBL619599,BAO_0000219,
6190,Intermediate,9606.0,,1,,,Concentration that gives 50% growth inhibition (topotecan alone/ (topotecan + 0.4 uM of compound)) in A549 cells,N,,646.0,80682,1,,CHEMBL619600,BAO_0000219,
6191,Intermediate,9606.0,,1,,,Cytotoxicity potentiation of Topotecan in human lung carcinoma A549 cells by the compound as potentiation factor at 50% growth inhibition,N,,646.0,80682,1,,CHEMBL619601,BAO_0000219,
6192,Intermediate,9606.0,,1,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.006 uM compound concentration in A549 cells,N,,646.0,80682,1,,CHEMBL619602,BAO_0000219,
6193,Intermediate,9606.0,,1,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.03 uM compound concentration in A549 cells,N,,646.0,80682,1,,CHEMBL619603,BAO_0000219,
6194,Intermediate,9606.0,,1,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.15 uM compound concentration in A549 cells,N,,646.0,80682,1,,CHEMBL619604,BAO_0000219,
6195,Intermediate,9606.0,,1,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 0.4 uM compound concentration in A549 cells,N,,646.0,80682,1,,CHEMBL619605,BAO_0000219,
6196,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic activity (Cmax) (10 mg/kg) was determined in dog,N,,,50588,1,,CHEMBL619606,BAO_0000218,
6197,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic activity (Cmax) in dog,N,,,50588,1,,CHEMBL876032,BAO_0000218,
6198,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter Cmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),N,,,50588,1,,CHEMBL619607,BAO_0000218,
6199,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic property (Cmax) was measured in dog at the dose of 0.032 mg/kg,N,,,50588,1,,CHEMBL619608,BAO_0000218,
6200,Intermediate,9615.0,In vivo,1,,,Plasma clearance rate by iv administration in dog at a dose of 6 mg/kg,N,,,50588,1,,CHEMBL619609,BAO_0000218,
6201,Intermediate,9615.0,In vivo,1,1969.0,,Cmax in dog plasma after 30mg/kg oral dose,N,,,50588,1,,CHEMBL619610,BAO_0000218,
6202,Intermediate,9615.0,In vivo,1,178.0,,Tested for the peak blood level in dog,N,,,50588,1,,CHEMBL619611,BAO_0000218,
6203,Intermediate,9615.0,In vivo,1,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog",N,,,50588,1,,CHEMBL619612,BAO_0000218,
6204,Intermediate,9615.0,In vivo,1,,,"Tested for the pharmacokinetic data, maximum concentration (Cmax) in dog at dosage of 10 mpk",N,,,50588,1,,CHEMBL619613,BAO_0000218,
6205,Intermediate,9615.0,In vivo,1,178.0,,The peak blood concentration after 5 hr administration (2.5 mg/kg) in dog was determined,N,,,50588,1,,CHEMBL619614,BAO_0000218,
6206,Intermediate,9615.0,,1,,,Concentration in the plasma after intravenous administration of 1 mg/kg in dog,N,,,50588,1,,CHEMBL619615,BAO_0000218,
6207,Intermediate,9615.0,,1,,,Compound was evaluated for Plasma levels upon oral administration at 30 mg/kg in Dog at maximum of 0.3 hours,N,,,50588,1,,CHEMBL619616,BAO_0000218,
6208,Intermediate,9615.0,,1,1969.0,,Final plasma concentration in dogs after oral administration at 1 mg/kg,N,,,50588,1,,CHEMBL619617,BAO_0000218,
6209,Intermediate,9615.0,,1,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 300 min,N,,,50588,1,,CHEMBL619618,BAO_0000218,
6210,Intermediate,9615.0,,1,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 30 min,N,,,50588,1,,CHEMBL876033,BAO_0000218,
6211,Intermediate,9615.0,,1,,,Plasma concentration in dogs when measured 1 and 5 hours following initiation of reperfusion at 60 min,N,,,50588,1,,CHEMBL619619,BAO_0000218,
6212,Intermediate,9615.0,,1,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by dogs,N,,,50588,1,,CHEMBL619620,BAO_0000218,
6213,Intermediate,9615.0,,1,1088.0,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs,N,,,50588,1,,CHEMBL619621,BAO_0000218,
6214,Intermediate,9615.0,,1,1088.0,,Percent of radioactive dose in urine and feces excreted by 0-24 hr in dogs; NA is <10% inhibition at 1 uM for binding data,N,,,50588,1,,CHEMBL619622,BAO_0000218,
6215,Intermediate,9615.0,,1,1088.0,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by dogs; NA is <10% inhibition at 1 uM for binding data,N,,,50588,1,,CHEMBL618874,BAO_0000218,
6216,Intermediate,9615.0,In vivo,1,,,Absolute bioavailability was evaluated in dog,N,,,50588,1,,CHEMBL618875,BAO_0000218,
6217,Intermediate,9615.0,In vivo,1,,,Bioavailability after oral administration (2.5 mg/kg) in dog was determined,N,,,50588,1,,CHEMBL618876,BAO_0000218,
6218,Intermediate,9615.0,In vivo,1,,,Bioavailability after peroral administration (1 mg/kg) was determined in dog,N,,,50588,1,,CHEMBL618877,BAO_0000218,
6219,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog,N,,,50588,1,,CHEMBL618878,BAO_0000218,
6220,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog,N,,,50588,1,,CHEMBL618879,BAO_0000218,
6221,Intermediate,9615.0,In vivo,1,,,Bioavailability after intravenous administration in dogs,N,,,50588,1,,CHEMBL618880,BAO_0000218,
6222,Intermediate,9615.0,In vivo,1,,,Bioavailability after peroral administration in dogs,N,,,50588,1,,CHEMBL618881,BAO_0000218,
6223,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),N,,,50588,1,,CHEMBL618882,BAO_0000218,
6224,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog (Beagle) (male) (dose 3 mg/kg i.v. and 10 mg/kg p.o.) measured from 1 to 24 hr,N,,,50588,1,,CHEMBL624226,BAO_0000218,
6225,Intermediate,9615.0,In vivo,1,1969.0,,Bioavailability in plasma of male Beagle dogs treated with 3 mg/kg (i.v.) and 10 mg/kg (p.o.) measured from 1 to 24 hr; ND indicates not determined,N,,,50588,1,,CHEMBL624227,BAO_0000218,
6226,Intermediate,9615.0,In vivo,1,,,Bioavailability,N,,,50588,1,,CHEMBL624228,BAO_0000218,
6227,Intermediate,9615.0,In vivo,1,,,Bioavailability,N,,,50588,1,,CHEMBL624229,BAO_0000218,
6228,Intermediate,9615.0,In vivo,1,,,Bioavailability by intravenous administration of 1.2 mg/kg in dog,N,,,50588,1,,CHEMBL624230,BAO_0000218,
6229,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog,N,,,50588,1,,CHEMBL624231,BAO_0000218,
6230,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog,N,,,50588,1,,CHEMBL624232,BAO_0000218,
6231,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog,N,,,50588,1,,CHEMBL625127,BAO_0000218,
6232,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog,N,,,50588,1,,CHEMBL625128,BAO_0000218,
6233,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog,N,,,50588,1,,CHEMBL621675,BAO_0000218,
6234,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog (p.o.) at 2.0 mpk,N,,,50588,1,,CHEMBL621676,BAO_0000218,
6235,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog (dose 2 mg/kg p.o. and 0.5 mg/kg i.v.),N,,,50588,1,,CHEMBL621677,BAO_0000218,
6236,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,,,50588,1,,CHEMBL621678,BAO_0000218,
6237,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog,N,,,50588,1,,CHEMBL621679,BAO_0000218,
6238,Intermediate,9615.0,In vivo,1,,,Bioavailability was evaluated after oral administration in dog,N,,,50588,1,,CHEMBL621680,BAO_0000218,
6239,Intermediate,9615.0,In vivo,1,,,Bioavailability was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,,,50588,1,,CHEMBL621681,BAO_0000218,
6240,Intermediate,9615.0,In vivo,1,,,Bioavailability was evaluated in dog,N,,,50588,1,,CHEMBL876740,BAO_0000218,
6241,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog,N,,,50588,1,,CHEMBL621682,BAO_0000218,
6242,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog,N,,,50588,1,,CHEMBL621683,BAO_0000218,
6243,Intermediate,9615.0,In vivo,1,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),N,,,50588,1,,CHEMBL621684,BAO_0000218,
6244,Intermediate,9615.0,In vivo,1,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),N,,,50588,1,,CHEMBL621685,BAO_0000218,
6245,Intermediate,9615.0,In vivo,1,,,Bioavailability was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),N,,,50588,1,,CHEMBL621686,BAO_0000218,
6246,Intermediate,9615.0,In vivo,1,,,Bioavailability was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,,,50588,1,,CHEMBL621687,BAO_0000218,
6247,Intermediate,9615.0,In vivo,1,,,Bioavailability was evaluated in dog after peroral administration at a dose of 1 mg/kg,N,,,50588,1,,CHEMBL621688,BAO_0000218,
6248,Intermediate,9615.0,In vivo,1,,,Bioavailability of compound in dog was determined after peroral administration,N,,,50588,1,,CHEMBL621689,BAO_0000218,
6249,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL621690,BAO_0000218,
6250,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for oral bioavailability at different dose 27.5 mg/kg DMP323 equiv in dogs,N,,,50588,1,,CHEMBL621691,BAO_0000218,
6251,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for oral bioavailability at different dose 7.7 mg/kg DMP323 equiv in dogs,N,,,50588,1,,CHEMBL875941,BAO_0000218,
6252,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for oral bioavailability in dogs; 37-38 %,N,,,50588,1,,CHEMBL621692,BAO_0000218,
6253,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog,N,,,50588,1,,CHEMBL621693,BAO_0000218,
6254,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (1 mg/kg p.o. and 0.2 mg/kg i.v.),N,,,50588,1,,CHEMBL621694,BAO_0000218,
6255,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of [123I]- labeled compound in mice heart was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL621695,BAO_0000218,
6256,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of [123I]- labeled compound in mice heart was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL621696,BAO_0000218,
6257,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL621697,BAO_0000218,
6258,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL621698,BAO_0000218,
6259,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL623420,BAO_0000218,
6260,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL623421,BAO_0000218,
6261,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL623422,BAO_0000218,
6262,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of [123I]- labeled compound in mice kidneys was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL623423,BAO_0000218,
6263,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of [123I]- labeled compound in mice liver was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL623424,BAO_0000218,
6264,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of [123I]- labeled compound in mice liver was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL623425,BAO_0000218,
6265,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of [123I]- labeled compound in mice liver was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL623426,BAO_0000218,
6266,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of [123I]- labeled compound in mice liver was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL623427,BAO_0000218,
6267,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of [123I]- labeled compound in mice liver was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL623428,BAO_0000218,
6268,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of [123I]- labeled compound in mice liver was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL875947,BAO_0000218,
6269,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 1 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL623429,BAO_0000218,
6270,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 10 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL623430,BAO_0000218,
6271,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 15 sec of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL622588,BAO_0000218,
6272,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 2 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL622589,BAO_0000218,
6273,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 30 sec of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL622751,BAO_0000218,
6274,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of [123I]- labeled compound in mice lungs was determined after 5 min of administration; expressed in percent of injected dose per gram of organ,N,,,50594,1,,CHEMBL622752,BAO_0000218,
6275,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 1 hour,N,,42.0,50594,1,,CHEMBL622753,BAO_0000218,
6276,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 2 hours,N,,42.0,50594,1,,CHEMBL622647,BAO_0000218,
6277,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 30 minutes,N,,42.0,50594,1,,CHEMBL875163,BAO_0000218,
6278,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 4 hours,N,,42.0,50594,1,,CHEMBL622648,BAO_0000218,
6279,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice blood bearing S180 tumor cell line for 8 hours,N,,42.0,50594,1,,CHEMBL622649,BAO_0000218,
6280,Intermediate,10090.0,,1,955.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice brain bearing S180 tumor cell line for 1 hour,N,,42.0,50594,1,,CHEMBL622650,BAO_0000218,
6281,Intermediate,10090.0,,1,955.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 2 hours,N,,42.0,50594,1,,CHEMBL622651,BAO_0000218,
6282,Intermediate,10090.0,,1,955.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 30 minutes,N,,42.0,50594,1,,CHEMBL622652,BAO_0000218,
6283,Intermediate,10090.0,,1,955.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 4 hours,N,,42.0,50594,1,,CHEMBL622653,BAO_0000218,
6284,Intermediate,10090.0,,1,955.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice brain bearing S180 tumor cell line for 8 hours,N,,42.0,50594,1,,CHEMBL622654,BAO_0000218,
6285,Intermediate,10090.0,,1,948.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 1 hour,N,,42.0,50594,1,,CHEMBL622655,BAO_0000218,
6286,Intermediate,10090.0,,1,948.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 2 hours,N,,42.0,50594,1,,CHEMBL622656,BAO_0000218,
6287,Intermediate,10090.0,,1,948.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice heart bearing S180 tumor cell line for 30 minutes,N,,42.0,50594,1,,CHEMBL622657,BAO_0000218,
6288,Intermediate,10090.0,,1,948.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 4 hours,N,,42.0,50594,1,,CHEMBL622658,BAO_0000218,
6289,Intermediate,10090.0,,1,948.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice heart bearing S180 tumor cell line for 8 hours,N,,42.0,50594,1,,CHEMBL622659,BAO_0000218,
6290,Intermediate,10090.0,,1,2113.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 1 hour,N,,42.0,50594,1,,CHEMBL624630,BAO_0000218,
6291,Intermediate,10090.0,,1,2113.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice kidney bearing S180 tumor cell line for 2 hours,N,,42.0,50594,1,,CHEMBL624631,BAO_0000218,
6292,Intermediate,10090.0,,1,2113.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 30 minutes,N,,42.0,50594,1,,CHEMBL624632,BAO_0000218,
6293,Intermediate,9606.0,,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml) on,N,,646.0,80682,1,,CHEMBL624633,BAO_0000219,
6294,Intermediate,9606.0,,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 10(ug/ml)on,N,,646.0,80682,1,,CHEMBL624634,BAO_0000219,
6295,Intermediate,9606.0,,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml),N,,646.0,80682,1,,CHEMBL624635,BAO_0000219,
6296,Intermediate,9606.0,,1,,,Cytotoxic activity of compound against A-549 cell lines at concentration of 3.3 (ug/ml)),N,,646.0,80682,1,,CHEMBL624636,BAO_0000219,
6297,Expert,9606.0,,1,,,Antineoplastic activity against A-549 (human lung carcinoma) cell line.,N,,646.0,80682,1,,CHEMBL857055,BAO_0000219,
6298,Expert,9606.0,,1,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-4 mol/L,N,,646.0,80682,1,,CHEMBL624637,BAO_0000219,
6299,Expert,9606.0,,1,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-5 mol/L,N,,646.0,80682,1,,CHEMBL624638,BAO_0000219,
6300,Expert,9606.0,,1,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-6 mol/L,N,,646.0,80682,1,,CHEMBL874366,BAO_0000219,
6301,Expert,9606.0,,1,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-7 mol/L,N,,646.0,80682,1,,CHEMBL624639,BAO_0000219,
6302,Expert,9606.0,,1,,,In vitro rate of inhibition of A-549 tumor cell growth at 10E-8 mol/L,N,,646.0,80682,1,,CHEMBL624640,BAO_0000219,
6303,Intermediate,9606.0,,1,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.0625 uM,N,,646.0,80682,1,,CHEMBL624641,BAO_0000219,
6304,Intermediate,9606.0,,1,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.125 uM,N,,646.0,80682,1,,CHEMBL624642,BAO_0000219,
6305,Intermediate,9606.0,,1,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.25 uM,N,,646.0,80682,1,,CHEMBL624643,BAO_0000219,
6306,Intermediate,9606.0,,1,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 0.5 uM,N,,646.0,80682,1,,CHEMBL624644,BAO_0000219,
6307,Intermediate,9606.0,,1,,,Rate of inhibition of A-549 tumor cell growth at a concentration of 1 uM,N,,646.0,80682,1,,CHEMBL624645,BAO_0000219,
6308,Intermediate,9606.0,,1,,,The compound was evaluated for its cytotoxic potency against A-549 cell line,N,,646.0,80682,1,,CHEMBL619445,BAO_0000219,
6309,Expert,9606.0,,1,,,Cytotoxic concentration required to inhibit 50% cell growth in A-549 lung carcinoma cell lines,N,,646.0,80682,1,,CHEMBL839886,BAO_0000219,
6310,Intermediate,9606.0,,1,,,Cytotoxic activity of compound against A-549 tumor cell line.,N,,646.0,80682,1,,CHEMBL619446,BAO_0000219,
6311,Intermediate,9606.0,,1,,,In vitro cytotoxicity against Lung A-549 human tumors following a 6 day exposure.,N,,646.0,80682,1,,CHEMBL619447,BAO_0000219,
6312,Intermediate,9606.0,,1,,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure.,N,,646.0,80682,1,,CHEMBL619448,BAO_0000219,
6313,Intermediate,9606.0,,1,,,In vitro cytotoxicity against Lung A-549 human tumors following a 2 day exposure; ND is no data,N,,646.0,80682,1,,CHEMBL619449,BAO_0000219,
6314,Intermediate,9606.0,,1,,,Cytotoxic activity of compound against A-549 tumor cell line at conc. of 20 ug/mL,N,,646.0,80682,1,,CHEMBL619450,BAO_0000219,
6315,Intermediate,9606.0,,1,,,Compound was tested for cytotoxic activity against A-549 human lung carcinoma (ATCC:CCL-185),N,,646.0,80682,1,,CHEMBL619451,BAO_0000219,
6316,Expert,9606.0,,1,,,In vitro inhibitory concentration against cell culture of A-549 human lung carcinoma,N,,646.0,80682,1,,CHEMBL619452,BAO_0000219,
6317,Intermediate,9606.0,,1,,,Concentration for in vitro cytotoxicity against A-549 human lung tumor cells,N,,646.0,80682,1,,CHEMBL619453,BAO_0000219,
6318,Intermediate,9606.0,,1,,,Dose required for in vitro cytotoxic activity against A-549 lung carcinoma cells at concentration of 10 ug/ml; NA is no cytotoxicity,N,,646.0,80682,1,,CHEMBL874367,BAO_0000219,
6319,Intermediate,9606.0,,1,,,Cytotoxic concentration against A-549 tumor cells.,N,,646.0,80682,1,,CHEMBL619454,BAO_0000219,
6320,Intermediate,9606.0,,1,,,Cytotoxic concentration against A-549 tumor cells; Inactive at 10 ug/mL.,N,,646.0,80682,1,,CHEMBL619455,BAO_0000219,
6321,Intermediate,9606.0,,1,,,"Cytotoxicity against NCI tumor panel, A-549/ATCC non small-cell lung cancer cell line",N,,646.0,80682,1,,CHEMBL619456,BAO_0000219,
6322,Expert,470.0,,1,,,Minimum inhibitory concentration (lowest peptide concentration) required to prevent visible bacterial growth after 18 hr of incubation at 37 C in Mueller-Hinton broth against Acinetobacter baumannii 118A,N,,,50191,1,,CHEMBL619457,BAO_0000218,
6323,Intermediate,471.0,,1,,,Activity against Acinetobacter calcoaceticus (AC54),N,,,50192,1,,CHEMBL619458,BAO_0000218,
6324,Expert,5059.0,,1,,,In vitro antifungal activity against Aspergillus flavus CM74,N,,,50274,1,,CHEMBL619459,BAO_0000218,
6325,Expert,5059.0,,1,,,In vitro antifungal activity against Aspergillus flavus CM74,N,,,50274,1,,CHEMBL619460,BAO_0000218,
6326,Intermediate,746128.0,,1,,,Inhibitory activity tested against Aspergillus fumigatus at 256 ug/mL concentration,N,,,50416,1,,CHEMBL619461,BAO_0000218,
6327,Intermediate,746128.0,,1,,,In vitro minimum fungicidal concentration required to inhibit Aspergillus fumigatus(MFC),N,,,50416,1,,CHEMBL619462,BAO_0000218,
6328,Intermediate,746128.0,,1,,,Antimicrobial activity against Aspergillus fumigatus (MIC),N,,,50416,1,,CHEMBL620388,BAO_0000218,
6329,Intermediate,746128.0,,1,,,Antimicrobial activity against Aspergillus fumigatus (MIC),N,,,50416,1,,CHEMBL620389,BAO_0000218,
6330,Intermediate,746128.0,,1,,,In vitro antimicrobial activity against Aspergillus fumigatus (MIC),N,,,50416,1,,CHEMBL620390,BAO_0000218,
6331,Expert,746128.0,,1,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,N,,,50416,1,,CHEMBL620391,BAO_0000218,
6332,Expert,746128.0,,1,,,In vitro antifungal activity against Aspergillus fumigatus 48238E,N,,,50416,1,,CHEMBL621073,BAO_0000218,
6333,Intermediate,1655.0,,1,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces naeslundii 631,N,,,50296,1,,CHEMBL621074,BAO_0000218,
6334,Intermediate,1656.0,,1,,,Compound is evaluated for plaque-bactericidal index (PBI) against Actinomyces viscosus M-100,N,,,50366,1,,CHEMBL621075,BAO_0000218,
6335,Intermediate,6277.0,,1,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),N,,,50535,1,,CHEMBL619554,BAO_0000218,
6336,Intermediate,6277.0,,1,,,Tested in vivo for Acanthocheilonema viteae at 200 mg/kg X 5 days(perorally),N,,,50535,1,,CHEMBL619555,BAO_0000218,
6337,Intermediate,714.0,,1,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527,N,,,50169,1,,CHEMBL619556,BAO_0000218,
6338,Intermediate,714.0,,1,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2,N,,,50169,1,,CHEMBL619557,BAO_0000218,
6339,Intermediate,714.0,,1,,,Antibacterial activity determined as minimal inhibitory concentration (MIC) against Actinobacillus actinomycetecommitans ATCC 29527; value ranges from 1-2; ND is Not Determined,N,,,50169,1,,CHEMBL619558,BAO_0000218,
6340,Intermediate,9606.0,,1,,,Effect on NAD+ depletion (% remaining versus vehicle control) in presence of MNNG (25 uM) at 11 uM compound concentration in A549 cells,N,,646.0,80682,1,,CHEMBL619559,BAO_0000219,
6341,Intermediate,9606.0,,1,,,Percent ADP-ribose polymer formation at 25 uM compound concentration in A549 cells,N,,646.0,80682,1,,CHEMBL619560,BAO_0000219,
6342,Intermediate,9606.0,,1,,,% inhibition against A549 cells (lung cancer) at 0.04 ug/mL,N,,646.0,80682,1,,CHEMBL619561,BAO_0000219,
6343,Intermediate,9606.0,,1,,,% inhibition against A549 cells (lung cancer) at 0.4 ug/mL,N,,646.0,80682,1,,CHEMBL619562,BAO_0000219,
6344,Intermediate,9606.0,,1,,,% inhibition against A549 cells (lung cancer) at 4 ug/mL,N,,646.0,80682,1,,CHEMBL619563,BAO_0000219,
6345,Intermediate,9606.0,,1,,,GI values against A549 cells (lung cancer),N,,646.0,80682,1,,CHEMBL857457,BAO_0000219,
6346,Intermediate,9606.0,,1,,,Effect on NAD+ depletion (% remaining versus vehicle control) 25 uM compound concentration in A549 cells,N,,646.0,80682,1,,CHEMBL619564,BAO_0000219,
6347,Intermediate,9606.0,,1,,,Inhibitory activity against A549 human adenocarcinoma,N,,646.0,80682,1,,CHEMBL619565,BAO_0000219,
6348,Intermediate,9606.0,,1,,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 200 mg/kg,N,,646.0,80682,1,,CHEMBL619566,BAO_0000218,
6349,Intermediate,9606.0,,1,,,Evaluated for the antineoplastic activity against A549 lung (nonsmall cell) tumor xenograft in nude mice after administering 3 injections (intra peritoneally) at a dose of 100 mg/kg,N,,646.0,80682,1,,CHEMBL619567,BAO_0000218,
6350,Intermediate,9606.0,,1,,,Inhibitory activity against A549 lung adenocarcinoma cell line,N,,646.0,80682,1,,CHEMBL619568,BAO_0000219,
6351,Intermediate,9606.0,,1,,,Inhibitory activity against A549 lung adenocarcinoma cell line; not determined,N,,646.0,80682,1,,CHEMBL619569,BAO_0000219,
6352,Intermediate,9606.0,,1,,,Cytotoxicity against human A549 lung cells,N,,646.0,80682,1,,CHEMBL619570,BAO_0000219,
6353,Intermediate,9606.0,,1,,,In vivo percent inhibitory activity of intraperitoneally administered compound (50 mg/kg/day) against mice infected with A549 tumor,N,,646.0,80682,1,,CHEMBL619571,BAO_0000218,
6354,Expert,9606.0,,1,,,Growth inhibition of A549 (human lung carcinoma) cell line.,N,,646.0,80682,1,,CHEMBL619572,BAO_0000219,
6355,Expert,9606.0,,1,,,Effective dose required for inhibitory activity against A549 human tumor cell line.,N,,646.0,80682,1,,CHEMBL619573,BAO_0000219,
6356,Intermediate,9606.0,,1,,,Effective dose required for inhibitory activity against A549 human tumor cell line; Not active,N,,646.0,80682,1,,CHEMBL619574,BAO_0000219,
6357,Intermediate,9606.0,,1,,,Cytotoxicity was evaluated against A549 tumor cell lines; Inactive,N,,646.0,80682,1,,CHEMBL619575,BAO_0000219,
6358,Expert,9606.0,,1,,,Cytotoxicity evaluated against A549 tumor cell lines; significant activity,N,,646.0,80682,1,,CHEMBL619576,BAO_0000219,
6359,Intermediate,9606.0,,1,,,Cytotoxicity was evaluated against A549 tumor cell lines; Slightly active,N,,646.0,80682,1,,CHEMBL619577,BAO_0000219,
6360,Intermediate,9606.0,,1,,,In vitro inhibitory activity against A549 tumor cell culture,N,,646.0,80682,1,,CHEMBL619578,BAO_0000219,
6361,Intermediate,9606.0,,1,,,In vitro inhibitory activity against A549 tumor cell culture; IA= Inactive,N,,646.0,80682,1,,CHEMBL884009,BAO_0000219,
6362,Intermediate,9606.0,,1,,,Activity against human lung cancer with mutated beta-tubulin (A549-T2415),N,,646.0,80682,1,,CHEMBL619579,BAO_0000219,
6363,Intermediate,9606.0,,1,,,Growth inhibitory activity was determined against A549/ATCC cancer cell line of non-small cell lung cancer,N,,646.0,80682,1,,CHEMBL619580,BAO_0000219,
6364,Intermediate,9606.0,,1,,,Inhibition of growth of A549/ATCC nonsmall cell lung cancer cell line,N,,646.0,80682,1,,CHEMBL619581,BAO_0000219,
6365,Intermediate,9606.0,,1,,,In vitro antitumor activity against NSCL A549/ATCC tumor cell lines,N,,646.0,80682,1,,CHEMBL619582,BAO_0000219,
6366,Intermediate,9606.0,,1,,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells,N,,646.0,80682,1,,CHEMBL619583,BAO_0000219,
6367,Intermediate,9606.0,,1,,,Cytotoxicity evaluation against A549/ATCC non-small-cell lung cancer cells; No data,N,,646.0,80682,1,,CHEMBL876502,BAO_0000219,
6368,Intermediate,9606.0,,1,,,In vitro cytotoxicity against human Non-small cell lung cancer A549/ATCC cell line.,N,,646.0,80682,1,,CHEMBL619584,BAO_0000219,
6369,Intermediate,9606.0,,1,,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,N,,646.0,80682,1,,CHEMBL619585,BAO_0000219,
6370,Intermediate,9606.0,,1,,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,N,,646.0,80682,1,,CHEMBL619586,BAO_0000219,
6371,Intermediate,9606.0,,1,,,In vitro growth inhibition of compound was determined against A549/ATCC cell lines of non-small cell lung cancer,N,,646.0,80682,1,,CHEMBL619587,BAO_0000219,
6372,Intermediate,9606.0,,1,,,Tested for in vitro cytotoxicity against non-small cell lung cancer cell line A549/ATCC,N,,646.0,80682,1,,CHEMBL619588,BAO_0000219,
6373,Intermediate,9606.0,,1,,,Tested in vitro for cytotoxicity in A549/ATCC cell lines,N,,646.0,80682,1,,CHEMBL619589,BAO_0000219,
6374,Intermediate,9606.0,,1,,,inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line,N,,646.0,80682,1,,CHEMBL619590,BAO_0000219,
6375,Intermediate,9606.0,,1,,,Compound was evaluated for in vitro activity against A549/ATCC lung cancer cell lines (Human tumor cells ),N,,646.0,80682,1,,CHEMBL619591,BAO_0000219,
6376,Intermediate,9606.0,,1,,,Inhibition of the growth of non-small-cell lung cancer (A549/ATCC) cell line at 0.01 uM,N,,646.0,80682,1,,CHEMBL619592,BAO_0000219,
6377,Intermediate,9606.0,,1,,,Compound was evaluated for cytotoxic activity against non-small lung cancer A549/ATCC cell lines.,N,,646.0,80682,1,,CHEMBL619593,BAO_0000219,
6378,Intermediate,9606.0,,1,,,Tested for cytotoxic activity against non-small cell lung cancer A549/ATCC cell line,N,,646.0,80682,1,,CHEMBL620217,BAO_0000219,
6379,Intermediate,9606.0,,1,,,Compound tested for growth inhibition of non-small cell lung cancer cell line A549/ATCC,N,,646.0,80682,1,,CHEMBL620218,BAO_0000219,
6380,Intermediate,9606.0,,1,,,Compound was tested for 50% growth inhibition against human non-small cell lung cancer A549/ATCC cell line,N,,646.0,80682,1,,CHEMBL620219,BAO_0000219,
6381,Intermediate,9606.0,,1,,,Antitumor activity against A549/ATCC cell line,N,,646.0,80682,1,,CHEMBL620220,BAO_0000219,
6382,Intermediate,9606.0,,1,,,Tested for cytotoxicity against A549/ATCC cell lines in non-small-cell lung cancer,N,,646.0,80682,1,,CHEMBL625141,BAO_0000219,
6383,Expert,9606.0,,1,,,In vitro cytotoxicity against A549/ATCC cell line.,N,,646.0,80682,1,,CHEMBL625142,BAO_0000219,
6384,Intermediate,9606.0,,1,,,Tested in vitro for cytotoxicity in A549/ATCC cell line of Non-Small Cell Lung Cancer,N,,646.0,80682,1,,CHEMBL625143,BAO_0000219,
6385,Intermediate,9606.0,,1,,,In vitro inhibition of Non-Small Cell Lung Cancer A549/ATCC cell lines,N,,646.0,80682,1,,CHEMBL625144,BAO_0000219,
6386,Intermediate,9606.0,,1,,,Concentration of compound that cause 50% cytotoxicity of A549/ATCC non small cell lung cancer cell line,N,,646.0,80682,1,,CHEMBL622474,BAO_0000219,
6387,Intermediate,9606.0,,1,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A549Rem- cell line of lung using the MTT Cytotoxicity Assay,N,,646.0,80682,1,,CHEMBL884104,BAO_0000219,
6388,Autocuration,9606.0,,1,,,Cytotoxicity was evaluated against A649 human mammary carcinoma cells,U,,,22226,0,,CHEMBL622475,BAO_0000219,
6389,Intermediate,9615.0,In vivo,1,,,Compound was tested for oral bioavailability in dogs,U,,,22224,0,,CHEMBL622476,BAO_0000218,
6390,Intermediate,9615.0,In vivo,1,,,Compound was tested for orally bioavailable in dogs with a half life of 0.7 hr,N,,,50588,1,,CHEMBL875831,BAO_0000218,
6391,Intermediate,9615.0,In vivo,1,,,Compound was tested for orally bioavailable in dogs with a half life of 1.2h,N,,,50588,1,,CHEMBL622477,BAO_0000218,
6392,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL622478,BAO_0000218,
6393,Intermediate,9615.0,In vivo,1,,,Compound was tested for the oral bioavailability in dog; No availability,N,,,50588,1,,CHEMBL623172,BAO_0000218,
6394,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 5 mg/kg),N,,,50588,1,,CHEMBL623173,BAO_0000218,
6395,Intermediate,9615.0,In vivo,1,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,N,,,50588,1,,CHEMBL623174,BAO_0000218,
6396,Intermediate,9615.0,In vivo,1,,,Oral bioavailability (F%) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg; ND=not determined,N,,,50588,1,,CHEMBL623175,BAO_0000218,
6397,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in Beagle dogs after Per oral administration at dose of 50(mg/kg),N,,,50588,1,,CHEMBL623340,BAO_0000218,
6398,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 5 mg/kg),N,,,50588,1,,CHEMBL623341,BAO_0000218,
6399,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (p.o. dosing of 0.05 M citric acid/0.05 M hydrochloric acid solution),N,,,50588,1,,CHEMBL623342,BAO_0000218,
6400,Intermediate,9615.0,In vivo,1,,,Oral bioavailability of active FTIs in dogs,N,,,50588,1,,CHEMBL623343,BAO_0000218,
6401,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 5 mg/kg p.o. and 2 mg/kg i.v.),N,,,50588,1,,CHEMBL623344,BAO_0000218,
6402,Expert,9615.0,In vivo,1,,,Oral bioavailability of compound determined in dog after iv administration at a dose of 10 mg/kg,N,,,50588,1,,CHEMBL623345,BAO_0000218,
6403,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL875832,BAO_0000218,
6404,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL623346,BAO_0000218,
6405,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL623347,BAO_0000218,
6406,Intermediate,9615.0,In vivo,1,,,Oral bioavailability of compound was determined in dog; Not tested,N,,,50588,1,,CHEMBL623348,BAO_0000218,
6407,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL623349,BAO_0000218,
6408,Intermediate,9615.0,In vivo,1,,,Oral bioavailability (10 mg/kg) was determined in dog,N,,,50588,1,,CHEMBL623350,BAO_0000218,
6409,Intermediate,9615.0,In vivo,1,,,Oral bioavailability,N,,,50588,1,,CHEMBL623351,BAO_0000218,
6410,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dosed as neat powder in hard gelatin capsule),N,,,50588,1,,CHEMBL623352,BAO_0000218,
6411,Intermediate,9615.0,In vivo,1,,,Oral bioavailability administered in solution in rats,N,,,50588,1,,CHEMBL623353,BAO_0000218,
6412,Intermediate,9615.0,In vivo,1,,,Oral bioavailability after 30 mg/kg po dose in Dogs,N,,,50588,1,,CHEMBL875833,BAO_0000218,
6413,Intermediate,9615.0,In vivo,1,,,Oral bioavailability at a dose of 1 mg/kg in dogs,N,,,50588,1,,CHEMBL623354,BAO_0000218,
6414,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 1 mg/kg p.o.),N,,,50588,1,,CHEMBL623355,BAO_0000218,
6415,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in Dog; ND = not determined,N,,,50588,1,,CHEMBL623356,BAO_0000218,
6416,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL623357,BAO_0000218,
6417,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL623358,BAO_0000218,
6418,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL623359,BAO_0000218,
6419,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL623360,BAO_0000218,
6420,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dogs; No data,N,,,50588,1,,CHEMBL623361,BAO_0000218,
6421,Intermediate,9615.0,In vivo,1,,,Oral bioavailability measured in dogs,N,,,50588,1,,CHEMBL623362,BAO_0000218,
6422,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL623363,BAO_0000218,
6423,Intermediate,9615.0,In vivo,1,,,Oral bioavailability was calculated in dog,N,,,50588,1,,CHEMBL623364,BAO_0000218,
6424,Intermediate,9615.0,In vivo,1,,,Oral bioavailability after 0.3 mg/kg po administration in dog,N,,,50588,1,,CHEMBL875834,BAO_0000218,
6425,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (i.v. dosing),N,,,50588,1,,CHEMBL623365,BAO_0000218,
6426,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL623366,BAO_0000218,
6427,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in Beagle dog at a dose of 2 mg/kg by po administration,N,,,50588,1,,CHEMBL623367,BAO_0000218,
6428,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in Beagle dogs,N,,,50588,1,,CHEMBL623368,BAO_0000218,
6429,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL623369,BAO_0000218,
6430,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL623370,BAO_0000218,
6431,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL623371,BAO_0000218,
6432,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL623372,BAO_0000218,
6433,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL621351,BAO_0000218,
6434,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL621352,BAO_0000218,
6435,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL621353,BAO_0000218,
6436,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL621354,BAO_0000218,
6437,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL621355,BAO_0000218,
6438,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL621356,BAO_0000218,
6439,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL621357,BAO_0000218,
6440,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL621358,BAO_0000218,
6441,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dosed as a mixture of five compounds at 0.5 mg/kg each via i.v. only),N,,,50588,1,,CHEMBL621359,BAO_0000218,
6442,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),N,,,50588,1,,CHEMBL621360,BAO_0000218,
6443,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 0.5 mg/kg i.v. and 2.0 mg/kg p.o.),N,,,50588,1,,CHEMBL621361,BAO_0000218,
6444,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL621362,BAO_0000218,
6445,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL621363,BAO_0000218,
6446,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL621364,BAO_0000218,
6447,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 0.2 mg/kg i.v.),N,,,50588,1,,CHEMBL621166,BAO_0000218,
6448,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 1 mg/kg i.v.),N,,,50588,1,,CHEMBL621167,BAO_0000218,
6449,Intermediate,9615.0,In vivo,1,,,Oral bioavailability (F) in dogs,N,,,50588,1,,CHEMBL621168,BAO_0000218,
6450,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL621169,BAO_0000218,
6451,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog,N,,,50588,1,,CHEMBL875950,BAO_0000218,
6452,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 10 mg/kg),N,,,50588,1,,CHEMBL621170,BAO_0000218,
6453,Intermediate,9615.0,In vivo,1,,,Oral bioavailability after peroral administration at 5 mpk in Dog,N,,,50588,1,,CHEMBL621171,BAO_0000218,
6454,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 5 mg/kg),N,,,50588,1,,CHEMBL621172,BAO_0000218,
6455,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 10 mg/kg),N,,,50588,1,,CHEMBL621173,BAO_0000218,
6456,Intermediate,10090.0,,1,2113.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 4 hours,N,,42.0,50594,1,,CHEMBL621174,BAO_0000218,
6457,Intermediate,10090.0,,1,2113.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice kidney bearing S180 tumor cell line for 8 hours,N,,42.0,50594,1,,CHEMBL621175,BAO_0000218,
6458,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 1 hour,N,,42.0,50594,1,,CHEMBL621176,BAO_0000218,
6459,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 2 hours,N,,42.0,50594,1,,CHEMBL621177,BAO_0000218,
6460,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 30 minutes,N,,42.0,50594,1,,CHEMBL621178,BAO_0000218,
6461,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice liver bearing S180 tumor cell line for 4 hours,N,,42.0,50594,1,,CHEMBL621179,BAO_0000218,
6462,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice liver bearing S180 tumor cell line for 8 hours,N,,42.0,50594,1,,CHEMBL621180,BAO_0000218,
6463,Intermediate,10090.0,,1,2048.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 1 hour,N,,42.0,50594,1,,CHEMBL875951,BAO_0000218,
6464,Intermediate,10090.0,,1,2048.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 2 hours,N,,42.0,50594,1,,CHEMBL621181,BAO_0000218,
6465,Intermediate,10090.0,,1,2048.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 30 minutes,N,,42.0,50594,1,,CHEMBL621182,BAO_0000218,
6466,Intermediate,10090.0,,1,2048.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice lung bearing S180 tumor cell line for 4 hours,N,,42.0,50594,1,,CHEMBL621183,BAO_0000218,
6467,Intermediate,10090.0,,1,2048.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice lung bearing S180 tumor cell line for 8 hours,N,,42.0,50594,1,,CHEMBL621184,BAO_0000218,
6468,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 1 hour,N,,42.0,50594,1,,CHEMBL621185,BAO_0000218,
6469,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice muscle bearing S180 tumor cell line for 2 hours,N,,42.0,50594,1,,CHEMBL621186,BAO_0000218,
6470,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 30 minutes,N,,42.0,50594,1,,CHEMBL621187,BAO_0000218,
6471,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 4 hours,N,,42.0,50594,1,,CHEMBL621188,BAO_0000218,
6472,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice muscle bearing S180 tumor cell line for 8 hours,N,,42.0,50594,1,,CHEMBL621189,BAO_0000218,
6473,Intermediate,10090.0,,1,2106.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice spleen bearing S180 tumor cell line for 1 hour,N,,42.0,50594,1,,CHEMBL621190,BAO_0000218,
6474,Intermediate,10090.0,,1,2106.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 2 hours,N,,42.0,50594,1,,CHEMBL618520,BAO_0000218,
6475,Intermediate,10090.0,,1,2106.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 30 minutes,N,,42.0,50594,1,,CHEMBL621739,BAO_0000218,
6476,Intermediate,10090.0,,1,2106.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 4 hours,N,,42.0,50594,1,,CHEMBL621740,BAO_0000218,
6477,Intermediate,10090.0,,1,2106.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice spleen bearing S180 tumor cell line for 8 hours,N,,42.0,50594,1,,CHEMBL621741,BAO_0000218,
6478,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 1 hour,N,,42.0,50594,1,,CHEMBL621742,BAO_0000218,
6479,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 2 hours,N,,42.0,50594,1,,CHEMBL621743,BAO_0000218,
6480,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 30 minutes,N,,42.0,50594,1,,CHEMBL621744,BAO_0000218,
6481,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor bearing S180 tumor cell line for 4 hours,N,,42.0,50594,1,,CHEMBL621745,BAO_0000218,
6482,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor bearing S180 tumor cell line for 8 hours,N,,42.0,50594,1,,CHEMBL621746,BAO_0000218,
6483,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 1 hour,N,,42.0,50594,1,,CHEMBL621747,BAO_0000218,
6484,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 2 hours,N,,42.0,50594,1,,CHEMBL621748,BAO_0000218,
6485,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 30 minutes,N,,42.0,50594,1,,CHEMBL621749,BAO_0000218,
6486,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 4 hours,N,,42.0,50594,1,,CHEMBL621750,BAO_0000218,
6487,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/blood bearing S180 tumor cell line for 8 hours,N,,42.0,50594,1,,CHEMBL621751,BAO_0000218,
6488,Intermediate,10090.0,,1,948.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 1 hour,N,,42.0,50594,1,,CHEMBL621752,BAO_0000218,
6489,Intermediate,10090.0,,1,948.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/heart bearing S180 tumor cell line for 2 hours,N,,42.0,50594,1,,CHEMBL621753,BAO_0000218,
6490,Intermediate,10090.0,,1,948.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 30 minutes,N,,42.0,50594,1,,CHEMBL875955,BAO_0000218,
6491,Intermediate,10090.0,,1,948.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 4 hours,N,,42.0,50594,1,,CHEMBL621754,BAO_0000218,
6492,Intermediate,10090.0,,1,948.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/heart bearing S180 tumor cell line for 8 hours,N,,42.0,50594,1,,CHEMBL621755,BAO_0000218,
6493,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 1 hour,N,,42.0,50594,1,,CHEMBL621756,BAO_0000218,
6494,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 2 hours,N,,42.0,50594,1,,CHEMBL624199,BAO_0000218,
6495,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/liver bearing S180 tumor cell line for 30 minutes,N,,42.0,50594,1,,CHEMBL624200,BAO_0000218,
6496,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 4 hours,N,,42.0,50594,1,,CHEMBL624375,BAO_0000218,
6497,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/liver bearing S180 tumor cell line for 8 hours,N,,42.0,50594,1,,CHEMBL624376,BAO_0000218,
6498,Intermediate,10090.0,,1,2048.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 1 hour,N,,42.0,50594,1,,CHEMBL624377,BAO_0000218,
6499,Intermediate,10090.0,,1,2048.0,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/lung bearing S180 tumor cell line for 2 hours,N,,42.0,50594,1,,CHEMBL624378,BAO_0000218,
6500,Intermediate,107673.0,,1,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,,,50067,1,,CHEMBL857901,BAO_0000218,
6501,Intermediate,107673.0,,1,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,,,50067,1,,CHEMBL875274,BAO_0000218,
6502,Intermediate,107673.0,,1,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,,,50067,1,,CHEMBL624379,BAO_0000218,
6503,Intermediate,107673.0,,1,,,Compound tested for the antimicrobial activity against Acinetobacter anitratus,N,,,50067,1,,CHEMBL624380,BAO_0000218,
6504,Intermediate,471.0,,1,,,Activity against Acinetobacter calcoaceticus (AC54),N,,,50192,1,,CHEMBL624381,BAO_0000218,
6505,Intermediate,28377.0,,1,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates no prolonged biological activity,N,,,50714,1,,CHEMBL624382,BAO_0000218,
6506,Intermediate,28377.0,,1,,,Biological activity using the lizard skin (Anolis carolinensis) assay. The value indicates prolonged biological activity,N,,,50714,1,,CHEMBL624383,BAO_0000218,
6507,Intermediate,1655.0,,1,,,Chlorohexidine coefficient for Actinomyces naeslundii 631,N,,,50296,1,,CHEMBL624384,BAO_0000218,
6508,Intermediate,1655.0,,1,,,Chlorohexidine coefficient for Actinomyces naeslundii B74,N,,,50296,1,,CHEMBL624385,BAO_0000218,
6509,Intermediate,1655.0,,1,,,Chlorohexidine coefficient for Actinomyces naeslundii N/3,N,,,50296,1,,CHEMBL624386,BAO_0000218,
6510,Intermediate,1655.0,,1,,,Chlorohexidine coefficient for Actinomyces naeslundii N/9,N,,,50296,1,,CHEMBL624387,BAO_0000218,
6511,Intermediate,1655.0,,1,,,Plaque bactericidal index against Actinomyces naeslundii 631,N,,,50296,1,,CHEMBL624388,BAO_0000218,
6512,Intermediate,1655.0,,1,,,Plaque bactericidal index against Actinomyces naeslundii N/9,N,,,50296,1,,CHEMBL624389,BAO_0000218,
6513,Intermediate,1655.0,,1,,,Plaque bactericidal index against Actinomyces naeslundii B74,N,,,50296,1,,CHEMBL624390,BAO_0000218,
6514,Intermediate,1655.0,,1,,,Plaque bactericidal index against Actinomyces naeslundii N/3,N,,,50296,1,,CHEMBL875275,BAO_0000218,
6515,Intermediate,85549.0,,1,,,Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay,N,,,50056,1,,CHEMBL624391,BAO_0000218,
6516,Intermediate,85549.0,,1,,,"Compound was tested for its inhibitory activity using brine shrimp (Artemia salina) immobilization assay; highest level tested, showed <100% activity",N,,,50056,1,,CHEMBL623636,BAO_0000218,
6517,Intermediate,6253.0,,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 0 uM,N,,,50532,1,,CHEMBL623637,BAO_0000218,
6518,Intermediate,6253.0,,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 10 uM,N,,,50532,1,,CHEMBL623638,BAO_0000218,
6519,Intermediate,6253.0,,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 200 uM,N,,,50532,1,,CHEMBL623639,BAO_0000218,
6520,Intermediate,6253.0,,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 25 uM,N,,,50532,1,,CHEMBL623640,BAO_0000218,
6521,Intermediate,6253.0,,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 3 uM,N,,,50532,1,,CHEMBL623641,BAO_0000218,
6522,Intermediate,6253.0,,1,,,Effect on incorporation of [32Pi] by isolated Ascaris suum mitochondria at a concentration of 50 uM.,N,,,50532,1,,CHEMBL623642,BAO_0000218,
6523,Intermediate,6253.0,,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 0 uM,N,,,50532,1,,CHEMBL623643,BAO_0000218,
6524,Intermediate,6253.0,,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 10 uM,N,,,50532,1,,CHEMBL623644,BAO_0000218,
6525,Intermediate,6253.0,,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 200 uM,N,,,50532,1,,CHEMBL623645,BAO_0000218,
6526,Intermediate,6253.0,,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 25 uM,N,,,50532,1,,CHEMBL623646,BAO_0000218,
6527,Intermediate,6253.0,,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 3 uM,N,,,50532,1,,CHEMBL623647,BAO_0000218,
6528,Intermediate,6253.0,,1,,,Effect on succinate formation by isolated Ascaris suum mitochondria at a concentration of 50 uM,N,,,50532,1,,CHEMBL623648,BAO_0000218,
6529,Intermediate,1656.0,,1,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,N,,,50366,1,,CHEMBL623649,BAO_0000218,
6530,Intermediate,1656.0,,1,,,Compound is evaluated for minimal bactericidal concentration against plaque formation for Actinomyces viscosus,N,,,50366,1,,CHEMBL623650,BAO_0000218,
6531,Intermediate,1656.0,,1,,,Chlorohexidine coefficient for Actinomyces viscosus 8A06,N,,,50366,1,,CHEMBL623651,BAO_0000218,
6532,Expert,1656.0,,1,,,Chlorohexidine coefficient for Actinomyces viscosus M-100,N,,,50366,1,,CHEMBL623652,BAO_0000218,
6533,Intermediate,1656.0,,1,,,Chlorohexidine coefficient for Actinomyces viscosus M-626,N,,,50366,1,,CHEMBL623653,BAO_0000218,
6534,Intermediate,1656.0,,1,,,Chlorohexidine coefficient for Actinomyces viscosus T14V,N,,,50366,1,,CHEMBL623654,BAO_0000218,
6535,Intermediate,1656.0,,1,,,Plaque bactericidal index against Actinomyces viscosus 8A06,N,,,50366,1,,CHEMBL623655,BAO_0000218,
6536,Intermediate,1656.0,,1,,,Plaque bactericidal index against Actinomyces viscosus M-100,N,,,50366,1,,CHEMBL623656,BAO_0000218,
6537,Expert,1656.0,,1,,,Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient,N,,,50366,1,,CHEMBL623657,BAO_0000218,
6538,Intermediate,1656.0,,1,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; d=Not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",N,,,50366,1,,CHEMBL623658,BAO_0000218,
6539,Intermediate,1656.0,,1,,,"Plaque bactericidal index against Actinomyces viscosus M-100 measured as chlorohexidine coefficient; not bactericidal at highest concentration tested (0.2% w/v, 2min, 5 days)",N,,,50366,1,,CHEMBL623659,BAO_0000218,
6540,Intermediate,1656.0,,1,,,Plaque bactericidal index against Actinomyces viscosus 626,N,,,50366,1,,CHEMBL623660,BAO_0000218,
6541,Intermediate,1656.0,,1,,,Plaque bactericidal index against Actinomyces viscosus T14V,N,,,50366,1,,CHEMBL623661,BAO_0000218,
6542,Intermediate,6277.0,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 1.56 mg/kg/day(5 days) dose,N,,,50535,1,,CHEMBL875281,BAO_0000218,
6543,Intermediate,6277.0,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 100 mg/kg/day(5 days) dose,N,,,50535,1,,CHEMBL623662,BAO_0000218,
6544,Intermediate,6277.0,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 12.5 mg/kg/day(5 days) dose,N,,,50535,1,,CHEMBL623663,BAO_0000218,
6545,Intermediate,6277.0,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 200 mg/kg/day(5 days) dose,N,,,50535,1,,CHEMBL623664,BAO_0000218,
6546,Intermediate,6277.0,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 25 mg/kg/day(5 days) dose,N,,,50535,1,,CHEMBL623665,BAO_0000218,
6547,Intermediate,9606.0,,1,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A673Mer+ sarcoma cell line using the MTT Cytotoxicity Assay,N,,165.0,80023,1,,CHEMBL621856,BAO_0000219,
6548,Intermediate,9606.0,,1,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A704Rem- renal cell line using the MTT Cytotoxicity Assay,N,,645.0,80661,1,,CHEMBL620432,BAO_0000219,
6549,Autocuration,10116.0,,1,,,Tested for inhibition of ET-1 induced phosphoinositide (PI) turnover in A7r5 smooth muscle cells,U,,,22226,0,,CHEMBL620433,BAO_0000219,
6550,Intermediate,10090.0,,1,,,Inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,N,,625.0,80024,1,,CHEMBL620434,BAO_0000219,
6551,Intermediate,10090.0,,1,,,Percent inhibition of Forskolin-Induced cAMP production in A9 L cells expressing m2 receptors,N,,625.0,80024,1,,CHEMBL620435,BAO_0000219,
6552,Intermediate,9606.0,,1,,,Cytotoxicity against Beta- tubulin mutant expressing A9-PTX10 cell line of humans was tested,N,,625.0,80024,1,,CHEMBL620436,BAO_0000219,
6553,Intermediate,9606.0,,1,,,Percentage inhibition at higher concentration (100 nM) against Beta- tubulin mutant expressing A9-PTX10 cell line,N,,625.0,80024,1,,CHEMBL876597,BAO_0000219,
6554,Expert,9606.0,,1,,,Inhibition of human ovarian carcinoma (A90) FGF-R overexpressing cell proliferation,N,,874.0,81037,1,,CHEMBL620437,BAO_0000219,
6555,Expert,10090.0,,1,,,"Tested for stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells, activity expressed as EC50 mM.",N,,625.0,80024,1,,CHEMBL620438,BAO_0000219,
6556,Expert,10090.0,,1,,,Stimulating PI (phosphoinositol) hydrolysis in A9L-m1 cells.,N,,625.0,80024,1,,CHEMBL620439,BAO_0000219,
6557,Expert,10090.0,,1,,,Increase in phosphoinositide (PI) metabolism in A9L-m1 cells at 100 uM.,N,,625.0,80024,1,,CHEMBL619657,BAO_0000219,
6558,Intermediate,10090.0,,1,,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; - = Not determined,N,,625.0,80024,1,,CHEMBL619658,BAO_0000219,
6559,Intermediate,10090.0,,1,,,The increase in phosphoinositide (PI) metabolism in A9L-m1 cells was measured at 100 uM; i = inactive,N,,625.0,80024,1,,CHEMBL619659,BAO_0000219,
6560,Expert,,,1,,,"Increase in phosphoinositide (PI) metabolism in A9L-cholinergic receptor, muscarinic 3 expressing cells was measured at 100 uMolar",H,,,10649,8,,CHEMBL619660,BAO_0000019,
6561,Intermediate,10090.0,,1,,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; - = Not determined,N,,625.0,80024,1,,CHEMBL619661,BAO_0000219,
6562,Intermediate,10090.0,,1,,,The increase in phosphoinositide (PI) metabolism in A9L-m3 cells was measured at 100 uM; i = inactive,N,,625.0,80024,1,,CHEMBL619662,BAO_0000219,
6563,Intermediate,10029.0,,1,,,Ability to inhibit growth of AA-6 cells (a mutant cell line resistant to 8-azaadenine and lacks adenine phosphoryltransferase) was determined,N,,975.0,80663,1,,CHEMBL619663,BAO_0000219,
6564,Autocuration,9606.0,,1,,,Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied after 5 hrs of Incubation.,U,,,22226,0,,CHEMBL619664,BAO_0000219,
6565,Autocuration,9606.0,,1,,,"Intracellular phosphorylation (100 uM) in uninfected AA2 cells was studied, after 5 hrs of Incubation.",U,,,22226,0,,CHEMBL619665,BAO_0000219,
6566,Intermediate,9606.0,,1,,,Anti -HIV activity was measured against AA5/HIV-1(IIIB),N,,974.0,80662,1,,CHEMBL883244,BAO_0000219,
6567,Intermediate,9606.0,,1,,,Cytotoxicity was measured against AA5/HIV-1(IIIB),N,,974.0,80662,1,,CHEMBL884011,BAO_0000219,
6568,Intermediate,9606.0,,1,,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in AA5 EBV-infected B-cell,N,,974.0,80662,1,,CHEMBL619666,BAO_0000219,
6569,Intermediate,9606.0,,1,,,Compound was evaluated for the anti-HIV activity against HIV strain IIIB in U937 monocytic cell,N,,379.0,80566,1,,CHEMBL619667,BAO_0000219,
6570,Intermediate,10029.0,,1,,,Hypersensitivity factor obtained from in vitro cytotoxicities against Chinese hamster ovary derived AA8 / UV4 cell lines,N,,274.0,80578,1,,CHEMBL619668,BAO_0000219,
6571,Expert,10029.0,,1,,,"Inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",N,,185.0,80089,1,,CHEMBL619669,BAO_0000219,
6572,Intermediate,10029.0,,1,,,Average intracellular compound concentration when the hypoxic SER=1.6,N,,185.0,80089,1,,CHEMBL876608,BAO_0000219,
6573,Intermediate,10029.0,,1,,,Average intracellular compound concentration when the hypoxic SER=1.6.,N,,185.0,80089,1,,CHEMBL619670,BAO_0000219,
6574,Intermediate,10029.0,,1,,,Average intracellular compound concentration where the hypoxia sensitizer enhancement ratio (SER)=1.6,N,,185.0,80089,1,,CHEMBL619671,BAO_0000219,
6575,Intermediate,10029.0,,1,,,Average intracellular compound concentration where the sensitizer enhancement ratio (SER)=1.6 under hypoxia,N,,185.0,80089,1,,CHEMBL619672,BAO_0000219,
6576,Intermediate,10029.0,,1,,,Compound concentration at which sensitizer enhancement ratio =1.6 under hypoxia.,N,,185.0,80089,1,,CHEMBL619673,BAO_0000219,
6577,Intermediate,10029.0,,1,,,"Compound was tested for the concentration required to reduce cell survival under hypoxic conditions, using the cell line AA8 in the clonogenic assay.",N,,185.0,80089,1,,CHEMBL619674,BAO_0000219,
6578,Intermediate,10029.0,,1,,,"Concentration needed to reduce cell survival to 10% of control values, using 1 hour exposure of plateau phase AA8 cells at 10e6 cells/ml",N,,185.0,80089,1,,CHEMBL619675,BAO_0000219,
6579,Intermediate,10029.0,,1,,,Activity to reduce the surviving fraction to 10% (CT10) was used as an inverse measure of cytotoxic potency in aerobic conditions,N,,185.0,80089,1,,CHEMBL619676,BAO_0000219,
6580,Intermediate,10029.0,,1,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,N,,185.0,80089,1,,CHEMBL619677,BAO_0000219,
6581,Intermediate,10029.0,,1,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition,N,,185.0,80089,1,,CHEMBL619678,BAO_0000219,
6582,Intermediate,10029.0,,1,,,Compound concentration required to reduce cell survival to 10% of control values under hypoxic condition.,N,,185.0,80089,1,,CHEMBL619679,BAO_0000219,
6583,Expert,10029.0,,1,,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay,N,,185.0,80089,1,,CHEMBL619680,BAO_0000219,
6584,Intermediate,10029.0,,1,,,Concentration x time (uM h) to reduce cell survival to 10% of control values under hypoxic conditions by clonogenic assay. Inactive at the solubility limit,N,,185.0,80089,1,,CHEMBL621457,BAO_0000219,
6585,Expert,10029.0,,1,,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% controls in clonogenic assay,N,,185.0,80089,1,,CHEMBL876609,BAO_0000219,
6586,Intermediate,10029.0,,1,,,Cytotoxicity under aerobic conditions determined to reduce the AA8 cell survival to 10% of controls in clonogenic assay,N,,185.0,80089,1,,CHEMBL621458,BAO_0000219,
6587,Expert,36483.0,,1,,,Aerobic cytotoxicity was assessed in a growth inhibition assay using log phase cultures of the chinese hamster ovary fibroblast line AA8,N,,185.0,80089,1,,CHEMBL621459,BAO_0000219,
6588,Expert,10029.0,,1,,,Aerobic growth inhibition in Chinese hamster cell line AA8,N,,185.0,80089,1,,CHEMBL621460,BAO_0000219,
6589,Expert,10029.0,,1,,,Cytotoxicity against AA8 cell and IC50 values were determined as drug concentration required to inhibit cell protein to 50%.,N,,185.0,80089,1,,CHEMBL621461,BAO_0000219,
6590,Expert,10029.0,,1,,,Inhibition of growth under aerobic conditions in AA8 cells,N,,185.0,80089,1,,CHEMBL621462,BAO_0000219,
6591,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 10 mg/kg),N,,,50588,1,,CHEMBL621463,BAO_0000218,
6592,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog at 10 mg/kg of the compound,N,,,50588,1,,CHEMBL621464,BAO_0000218,
6593,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 5 uM/kg),N,,,50588,1,,CHEMBL621465,BAO_0000218,
6594,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 5 uM/kg),N,,,50588,1,,CHEMBL621466,BAO_0000218,
6595,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (mongrel),N,,,50588,1,,CHEMBL621467,BAO_0000218,
6596,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 10 mg/kg),N,,,50588,1,,CHEMBL621468,BAO_0000218,
6597,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 10 mg/kg),N,,,50588,1,,CHEMBL876734,BAO_0000218,
6598,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog,N,,,50588,1,,CHEMBL618476,BAO_0000218,
6599,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog (dose 1 mg/kg i.v.),N,,,50588,1,,CHEMBL618477,BAO_0000218,
6600,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic data for dose given to dogs intravenously (oral PK study in parentheses),N,,,50588,1,,CHEMBL618478,BAO_0000218,
6601,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic property (F) was measured in dog at the dose of 0.032 mg/kg,N,,,50588,1,,CHEMBL618479,BAO_0000218,
6602,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog,N,,,50588,1,,CHEMBL618480,BAO_0000218,
6603,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog (dose 3-10 mg/kg),N,,,50588,1,,CHEMBL618481,BAO_0000218,
6604,Intermediate,9615.0,In vivo,1,1969.0,,The compound was tested for bioavailability of compound in plasma of dog; Complete,N,,,50588,1,,CHEMBL618482,BAO_0000218,
6605,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL618483,BAO_0000218,
6606,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL618484,BAO_0000218,
6607,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog,N,,,50588,1,,CHEMBL618485,BAO_0000218,
6608,Intermediate,9615.0,In vivo,1,,,oral bioavailability was measured in dogs,N,,,50588,1,,CHEMBL618486,BAO_0000218,
6609,Intermediate,9615.0,,1,,,Compound was tested for plasma protein binding in dog; Not determined,N,,,50588,1,,CHEMBL618487,BAO_0000218,
6610,Intermediate,9615.0,,1,,,Compound was tested for plasma protein binding of dog,N,,,50588,1,,CHEMBL618488,BAO_0000218,
6611,Intermediate,9615.0,,1,,,Compound was tested for plasma protein binding of dog; Not determined,N,,,50588,1,,CHEMBL876735,BAO_0000218,
6612,Intermediate,9615.0,,1,,,Concentration in dogs after oral administration at dose of 1 mg/kg after 180 min.,N,,,50588,1,,CHEMBL618489,BAO_0000218,
6613,Intermediate,9615.0,In vivo,1,,,Apparent terminal elimination half-life in dog after administration of 20 mg/kg dose through peroral route,N,,,50588,1,,CHEMBL618490,BAO_0000218,
6614,Intermediate,9615.0,,1,,,Half life was determined,N,,,50588,1,,CHEMBL618491,BAO_0000218,
6615,Intermediate,9615.0,In vivo,1,,,Half life by ''Cr'' assay in dog at a dose of 5 mg/kg,N,,,50588,1,,CHEMBL618492,BAO_0000218,
6616,Intermediate,9615.0,,1,,,Half life was evaluated in dog,N,,,50588,1,,CHEMBL873354,BAO_0000218,
6617,Intermediate,9615.0,,1,,,Half life was determined,N,,,50588,1,,CHEMBL618493,BAO_0000218,
6618,Intermediate,9615.0,In vivo,1,,,Biodistribution of compound was measured in bile at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,,,50588,1,,CHEMBL618494,BAO_0000218,
6619,Intermediate,9615.0,In vivo,1,948.0,,Biodistribution of compound was measured in heart at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,,,50588,1,,CHEMBL618495,BAO_0000218,
6620,Intermediate,9615.0,In vivo,1,2113.0,,Biodistribution of compound was measured in kidney at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,,,50588,1,,CHEMBL618496,BAO_0000218,
6621,Intermediate,9615.0,In vivo,1,2107.0,,Biodistribution of compound was measured in liver at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,,,50588,1,,CHEMBL618497,BAO_0000218,
6622,Intermediate,9615.0,In vivo,1,2048.0,,Biodistribution of compound was measured in lung at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,,,50588,1,,CHEMBL618498,BAO_0000218,
6623,Intermediate,9615.0,In vivo,1,2106.0,,Biodistribution of compound was measured in spleen at 2 hr post-injection in canine deep vein thrombosis model (DVT),N,,,50588,1,,CHEMBL618499,BAO_0000218,
6624,Intermediate,9615.0,,1,,,LogP in dog,N,,,50588,1,,CHEMBL876736,BAO_0000218,
6625,Intermediate,9615.0,,1,,,Partition coefficient (logP),N,,,50588,1,,CHEMBL618500,BAO_0000218,
6626,Intermediate,9615.0,,1,,,Partition coefficient in dog,N,,,50588,1,,CHEMBL857831,BAO_0000218,
6627,Intermediate,9615.0,In vivo,1,,,Mean-residence time of compound after intravenous administration in dogs at 1.2 uM/kg,N,,,50588,1,,CHEMBL618501,BAO_0000218,
6628,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter MRT was determined in Beagle dogs after (po) administration of a dose of 28 (uM/kg),N,,,50588,1,,CHEMBL618502,BAO_0000218,
6629,Intermediate,9615.0,,1,,,In vitro metabolic stability determined after 30 min of incubation in dog hepatic microsomes,N,,,50588,1,,CHEMBL618503,BAO_0000218,
6630,Intermediate,9615.0,,1,,,Metabolism of compound in dog S9 microsomes ('++''indicates 20-50% largest observed peak),N,,,50588,1,,CHEMBL618504,BAO_0000218,
6631,Intermediate,9615.0,,1,,,Metabolism of compound in dog S9 microsomes ('++++' indicates largest observed peak),N,,,50588,1,,CHEMBL618505,BAO_0000218,
6632,Intermediate,9615.0,,1,,,Metabolism of compound in dog S9 microsomes; Trace,N,,,50588,1,,CHEMBL618506,BAO_0000218,
6633,Intermediate,9615.0,,1,2107.0,,In vitro metabolic potential in dog liver microsomes,N,,,50588,1,,CHEMBL618507,BAO_0000218,
6634,Intermediate,9615.0,In vivo,1,,,Oral bioavailability of perorally administered compound (10 mg/kg) was tested in dogs,N,,,50588,1,,CHEMBL876737,BAO_0000218,
6635,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL618508,BAO_0000218,
6636,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL618509,BAO_0000218,
6637,Intermediate,9615.0,In vivo,1,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,,50588,1,,CHEMBL618510,BAO_0000218,
6638,Intermediate,9615.0,In vivo,1,,,The compound was tested for bioavailability in dogs,N,,,50588,1,,CHEMBL618511,BAO_0000218,
6639,Intermediate,9615.0,In vivo,1,,,The compound was tested for oral bioavailability in dogs,N,,,50588,1,,CHEMBL618512,BAO_0000218,
6640,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog,N,,,50588,1,,CHEMBL618513,BAO_0000218,
6641,Intermediate,9615.0,,1,,,Compound was tested for percent protein binding (PB) in dog,N,,,50588,1,,CHEMBL618514,BAO_0000218,
6642,Intermediate,9615.0,,1,,,Apparent permeability coefficient (Papp) for apical to basolateral flux was determined in MadinDarby Canine Kidney cells,N,,,50588,1,,CHEMBL620052,BAO_0000218,
6643,Intermediate,9615.0,In vivo,1,1969.0,,Compound was evaluated for plasma clearance.,N,,,50588,1,,CHEMBL620053,BAO_0000218,
6644,Intermediate,9615.0,In vivo,1,1969.0,,The compound was tested for plasma clearance in dog,N,,,50588,1,,CHEMBL620054,BAO_0000218,
6645,Intermediate,9615.0,In vivo,1,1969.0,,The compound was tested for plasma clearance in dog at dose of 3-10 mgkg,N,,,50588,1,,CHEMBL620055,BAO_0000218,
6646,Intermediate,9615.0,,1,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in dog,N,,,50588,1,,CHEMBL620056,BAO_0000218,
6647,Intermediate,9615.0,,1,2107.0,,In vitro relative rate of metabolism was determined in dog liver microsomes,N,,,50588,1,,CHEMBL620057,BAO_0000218,
6648,Intermediate,9615.0,In vivo,1,,,Relative bioavailability after oral dose of compound at 3 mg/kg in dogs,N,,,50588,1,,CHEMBL618939,BAO_0000218,
6649,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,N,,,50588,1,,CHEMBL618940,BAO_0000218,
6650,Intermediate,9615.0,In vivo,1,,,Half life after intravenous administration in dogs at 1.2 uM/kg,N,,,50588,1,,CHEMBL618941,BAO_0000218,
6651,Intermediate,10090.0,,1,2048.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 30 minutes,N,,42.0,50594,1,,CHEMBL624473,BAO_0000218,
6652,Intermediate,10090.0,,1,2048.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 4 hours,N,,42.0,50594,1,,CHEMBL624474,BAO_0000218,
6653,Intermediate,10090.0,,1,2048.0,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/lung bearing S180 tumor cell line for 8 hours,N,,42.0,50594,1,,CHEMBL624475,BAO_0000218,
6654,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 1 hour,N,,42.0,50594,1,,CHEMBL624476,BAO_0000218,
6655,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 2 hours,N,,42.0,50594,1,,CHEMBL623478,BAO_0000218,
6656,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 30 minutes,N,,42.0,50594,1,,CHEMBL623479,BAO_0000218,
6657,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]-N4IPA in mice tumor/muscle bearing S180 tumor cell line for 4 hours,N,,42.0,50594,1,,CHEMBL623480,BAO_0000218,
6658,Intermediate,10090.0,,1,,,In vivo biodistribution of radiolabeled [99mTc]N4IPA in mice tumor/muscle bearing S180 tumor cell line for 8 hours,N,,42.0,50594,1,,CHEMBL623481,BAO_0000218,
6659,Intermediate,10090.0,,1,955.0,,C2 in brain of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL623482,BAO_0000218,
6660,Intermediate,10090.0,,1,2113.0,,C2 in kidney of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL623483,BAO_0000218,
6661,Intermediate,10090.0,,1,2107.0,,C2 in liver of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL623484,BAO_0000218,
6662,Intermediate,10090.0,,1,2048.0,,C2 in lungs of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL623485,BAO_0000218,
6663,Intermediate,10090.0,,1,2106.0,,C2 in spleen of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL623486,BAO_0000218,
6664,Intermediate,10090.0,In vivo,1,,,Plasma clearance in mouse,N,,,50594,1,,CHEMBL623487,BAO_0000218,
6665,Intermediate,10090.0,In vivo,1,,,Clearance of compound after intravenous administration in mice at 24 uM/kg,N,,,50594,1,,CHEMBL623488,BAO_0000218,
6666,Intermediate,10090.0,In vivo,1,,,Clearance from mouse blood following i.v. administration of 10 mg/kg,N,,,50594,1,,CHEMBL623489,BAO_0000218,
6667,Intermediate,10090.0,In vivo,1,,,Clearance was evaluated in mice after intravenous administration,N,,,50594,1,,CHEMBL875157,BAO_0000218,
6668,Intermediate,10090.0,In vivo,1,,,Clearance was evaluated in mice after oral administration,N,,,50594,1,,CHEMBL623490,BAO_0000218,
6669,Intermediate,10090.0,In vivo,1,,,Pharmacokinetic property (Plasma clearance) was measured in mouse,N,,,50594,1,,CHEMBL623491,BAO_0000218,
6670,Intermediate,10090.0,In vivo,1,,,Plasma clearance of compound was determined at 40 mg/Kg,N,,,50594,1,,CHEMBL623492,BAO_0000218,
6671,Intermediate,10090.0,In vivo,1,,,Plasma clearance of at 24 mg/Kg,N,,,50594,1,,CHEMBL623493,BAO_0000218,
6672,Intermediate,10090.0,In vivo,1,,,Plasma clearance at 24 mg/Kg,N,,,50594,1,,CHEMBL623494,BAO_0000218,
6673,Intermediate,10090.0,In vivo,1,,,Plasma clearance at 5 mg/Kg,N,,,50594,1,,CHEMBL623495,BAO_0000218,
6674,Intermediate,10090.0,In vivo,1,,,Plasma clearance in mice,N,,,50594,1,,CHEMBL623496,BAO_0000218,
6675,Intermediate,10090.0,In vivo,1,,,Plasma clearance value upon iv administration in mouse,N,,,50594,1,,CHEMBL623497,BAO_0000218,
6676,Intermediate,10090.0,In vivo,1,1969.0,,Total plasma clearance in mice,N,,,50594,1,,CHEMBL623498,BAO_0000218,
6677,Intermediate,10090.0,In vivo,1,,,Clearance in mouse,N,,,50594,1,,CHEMBL623499,BAO_0000218,
6678,Intermediate,10090.0,In vivo,1,,,Clearance value was determined,N,,,50594,1,,CHEMBL623500,BAO_0000218,
6679,Intermediate,10090.0,In vivo,1,,,Plasma clearance at a dose of 10 mg/kg intravenous administration in mice.,N,,,50594,1,,CHEMBL623501,BAO_0000218,
6680,Intermediate,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL875158,BAO_0000100,
6681,Intermediate,10090.0,In vivo,1,,,Plasma clearance for the compound was measured in mouse after an iv dose of 1 mg/kg,N,,,50594,1,,CHEMBL623502,BAO_0000218,
6682,Intermediate,10090.0,In vivo,1,,,Plasma clearance rate after intraperitoneal administration of 100 mg/kg in mice,N,,,50594,1,,CHEMBL623503,BAO_0000218,
6683,Intermediate,10090.0,In vivo,1,,,Plasma clearance was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,,,50594,1,,CHEMBL623504,BAO_0000218,
6684,Intermediate,10090.0,In vivo,1,,,In vivo total clearance was determined in murine septicemia at dose of 100 mg/kg,N,,,50594,1,,CHEMBL623505,BAO_0000218,
6685,Intermediate,10090.0,In vivo,1,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg,N,,,50594,1,,CHEMBL623506,BAO_0000218,
6686,Intermediate,10090.0,In vivo,1,,,In vivo total clearance was determined in murine septicemia at dose of 50 mg/kg;ND=not determined,N,,,50594,1,,CHEMBL623507,BAO_0000218,
6687,Intermediate,10090.0,In vivo,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for Cmax,N,,,50594,1,,CHEMBL623508,BAO_0000218,
6688,Intermediate,10090.0,In vivo,1,,,Cmax after oral administration at 30 mg/kg in ICR mouse,N,,,50594,1,,CHEMBL623509,BAO_0000218,
6689,Intermediate,10090.0,In vivo,1,,,Cmax after peroral administration in mice at 2.4 uM/kg,N,,,50594,1,,CHEMBL875159,BAO_0000218,
6690,Intermediate,10090.0,In vivo,1,955.0,,Cmax in brain of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL623510,BAO_0000218,
6691,Intermediate,10090.0,In vivo,1,2113.0,,Cmax in kidney of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL623511,BAO_0000218,
6692,Intermediate,10090.0,In vivo,1,2107.0,,Cmax in liver of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL623512,BAO_0000218,
6693,Intermediate,10090.0,In vivo,1,2048.0,,Cmax in lungs of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL623513,BAO_0000218,
6694,Intermediate,10090.0,In vivo,1,,,Cmax in mice at 18 uM/kg i.p. administration,N,,,50594,1,,CHEMBL623514,BAO_0000218,
6695,Intermediate,10090.0,In vivo,1,,,Cmax in mice at 23 uM/kg i.v. administration,N,,,50594,1,,CHEMBL622609,BAO_0000218,
6696,Intermediate,10090.0,In vivo,1,,,Cmax in mice at 24 uM/kg i.p. administration,N,,,50594,1,,CHEMBL622610,BAO_0000218,
6697,Intermediate,10090.0,In vivo,1,,,Cmax in mice at 25 uM/kg i.p. administration,N,,,50594,1,,CHEMBL621823,BAO_0000218,
6698,Intermediate,10090.0,In vivo,1,,,Cmax in mice at 26 uM/kg i.p. administration,N,,,50594,1,,CHEMBL621824,BAO_0000218,
6699,Intermediate,10090.0,In vivo,1,2106.0,,Cmax in spleen of mice at the oral dose of 50 mg/kg,N,,,50594,1,,CHEMBL621825,BAO_0000218,
6700,Intermediate,10090.0,In vivo,1,,,Cmax value at a dose of 10 mg/kg intravenous administration in mice.,N,,,50594,1,,CHEMBL621826,BAO_0000218,
6701,Intermediate,10090.0,In vivo,1,,,Cmax value at a dose of 10 mg/kg peroral administration in mice.,N,,,50594,1,,CHEMBL621827,BAO_0000218,
6702,Intermediate,10090.0,In vivo,1,,,Cmax value was determined,N,,,50594,1,,CHEMBL621828,BAO_0000218,
6703,Intermediate,10090.0,In vivo,1,,,Cmax value in IRC mice,N,,,50594,1,,CHEMBL621829,BAO_0000218,
6704,Intermediate,10090.0,In vivo,1,,,Cmax value was determined at a dose of 100 mg/kg (i.p.) in Mice,N,,,50594,1,,CHEMBL621830,BAO_0000218,
6705,Intermediate,10090.0,In vivo,1,,,Cmax value was determined at a dose of 200 mg/kg (i.p.) in Mice,N,,,50594,1,,CHEMBL621831,BAO_0000218,
6706,Intermediate,10090.0,In vivo,1,1969.0,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,N,,,50594,1,,CHEMBL621832,BAO_0000218,
6707,Intermediate,10090.0,In vivo,1,1969.0,,"Compound was evaluated for the pharmacokinetic parameter, maximum plasma concentration",N,,,50594,1,,CHEMBL624579,BAO_0000218,
6708,Intermediate,10090.0,In vivo,1,,,Evaluated for pharmacokinetic parameter Cmax in mouse at the dose 20 mg/kg,N,,,50594,1,,CHEMBL624580,BAO_0000218,
6709,Intermediate,6277.0,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 50 mg/kg/day(5 days) dose,N,,,50535,1,,CHEMBL624581,BAO_0000218,
6710,Intermediate,6277.0,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 6.25 mg/kg/day(5 days) dose,N,,,50535,1,,CHEMBL624582,BAO_0000218,
6711,Intermediate,6277.0,,1,,,anti-filarial Activity was measured against Acanthocheilonema viteae in jirds at 75 mg/kg/day(5 days) dose,N,,,50535,1,,CHEMBL624583,BAO_0000218,
6712,Intermediate,9606.0,,1,,,Inhibitory activity against human tumor cell line A0375 melanoma.,N,,455.0,80018,1,,CHEMBL624584,BAO_0000219,
6713,Expert,10116.0,,1,,,Displacement of [3H]N6-PIA binding from A1 receptor in whole rat brain membranes,D,Brain membranes,,12512,9,,CHEMBL624585,BAO_0000249,
6714,Expert,9606.0,,1,,,Forskolin-induced cAMP production at human A1 adenosine receptor,D,,,114,9,,CHEMBL875165,BAO_0000019,
6715,Autocuration,,,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1; change of less than 5% of allosteric enhancement.,H,,449.0,114,8,,CHEMBL619490,BAO_0000219,
6716,Autocuration,,,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,H,,449.0,114,8,,CHEMBL619491,BAO_0000219,
6717,Expert,,,1,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM,H,,449.0,114,8,,CHEMBL619492,BAO_0000219,
6718,Expert,,,1,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration,H,,449.0,114,8,,CHEMBL619493,BAO_0000219,
6719,Autocuration,,,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; An increase of cAmp content of cells,H,,449.0,114,8,,CHEMBL619494,BAO_0000219,
6720,Autocuration,,,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement,H,,449.0,114,8,,CHEMBL619495,BAO_0000219,
6721,Autocuration,,,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 0.1 uM concentration; change of less than 5% of allosteric enhancement.,H,,449.0,114,8,,CHEMBL619496,BAO_0000219,
6722,Expert,9606.0,,1,,,Percent response to 10 uM PD-81723 on CHO cells expressing human A1-adenosine receptor at 0.1 uM; An increase of cAmp content of cells,D,,449.0,114,9,,CHEMBL619497,BAO_0000219,
6723,Autocuration,,,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM,H,,449.0,114,8,,CHEMBL619498,BAO_0000219,
6724,Autocuration,,,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; change of less than 5% of allosteric enhancement.,H,,449.0,114,8,,CHEMBL619499,BAO_0000219,
6725,Expert,,,1,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration,H,,449.0,114,8,,CHEMBL619500,BAO_0000219,
6726,Autocuration,,,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM concentration; change of less than 5% of allosteric enhancement.,H,,449.0,114,8,,CHEMBL619501,BAO_0000219,
6727,Expert,,,1,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 1 uM; An increase of cAmp content of cells,H,,449.0,114,8,,CHEMBL619502,BAO_0000219,
6728,Autocuration,,,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM,H,,449.0,114,8,,CHEMBL619503,BAO_0000219,
6729,Autocuration,,,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,H,,449.0,114,8,,CHEMBL619504,BAO_0000219,
6730,Autocuration,,,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; change of less than 5% of allosteric enhancement.,H,,449.0,114,8,,CHEMBL621298,BAO_0000219,
6731,Expert,,,1,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration,H,,449.0,114,8,,CHEMBL621299,BAO_0000219,
6732,Autocuration,,,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; An increase of cAmp content of cells,H,,449.0,114,8,,CHEMBL621300,BAO_0000219,
6733,Autocuration,,,1,,,The compound was tested for its percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM concentration; change of less than 5% of allosteric enhancement.,H,,449.0,114,8,,CHEMBL621301,BAO_0000219,
6734,Expert,,,1,,,Percentage of response to 10 uM of PD-81723 on CHO cells expressing the cloned human A1-adenosine receptor at 10 uM; An increase of cAmp content of cells,H,,449.0,114,8,,CHEMBL621302,BAO_0000219,
6735,Intermediate,9986.0,,1,,,Ability to inhibit [125I]ET1 binding to vascular smooth muscle (vsm)- A10 cells,N,,164.0,80013,1,,CHEMBL621303,BAO_0000219,
6736,Autocuration,10116.0,,1,,,In vitro potassium channel opening activity in A10 (smooth muscle) cells,U,,164.0,22226,0,,CHEMBL621304,BAO_0000219,
6737,Autocuration,10116.0,,1,,,In vitro potassium channel opening activity in A10 (smooth muscle) cells; Inactive,U,,164.0,22226,0,,CHEMBL621305,BAO_0000219,
6738,Intermediate,10116.0,,1,,,Effect on membrane potential of mitochondria in A10 smooth muscle cells from rats,N,,164.0,80013,1,,CHEMBL621306,BAO_0000219,
6739,Intermediate,10116.0,,1,,,Effect on membrane potential of mitochondria of A10 smooth muscle cells in rats,N,,164.0,80013,1,,CHEMBL618444,BAO_0000219,
6740,Intermediate,10116.0,,1,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.001 uM,N,,164.0,80013,1,,CHEMBL618445,BAO_0000219,
6741,Intermediate,10029.0,,1,,,Compound was tested for aerobic growth inhibition against AA8 cells after 4 hr of exposure,N,,185.0,80089,1,,CHEMBL618446,BAO_0000219,
6742,Intermediate,10029.0,,1,,,Concentration required to reduce AA8 cell numbers to 50% of controls in a growth inhibition microassay,N,,185.0,80089,1,,CHEMBL618447,BAO_0000219,
6743,Intermediate,10029.0,,1,,,Concentration of the drug to inhibit chinese hamster ovary derived cell (AA8) growth in culture,N,,185.0,80089,1,,CHEMBL618448,BAO_0000219,
6744,Intermediate,10029.0,,1,,,Cytotoxicity in a growth inhibition assay against aerobic cultures of AA8 cells was determined,N,,185.0,80089,1,,CHEMBL618449,BAO_0000219,
6745,Intermediate,10029.0,,1,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,N,,185.0,80089,1,,CHEMBL618637,BAO_0000219,
6746,Intermediate,10029.0,,1,,,"Cytotoxicity in chinese hamster ovary tumor cell line-AA8, by growth inhibition assay.",N,,185.0,80089,1,,CHEMBL618638,BAO_0000219,
6747,Intermediate,10029.0,,1,,,Growth inhibition activity was measured in repair proficient AA8 cells under aerobic conditions (4 hours drug exposure),N,,185.0,80089,1,,CHEMBL618639,BAO_0000219,
6748,Expert,10029.0,,1,,,"Growth inhibition of aerobic AA8 cells, after 18 hours exposure",N,,185.0,80089,1,,CHEMBL618640,BAO_0000219,
6749,Expert,10029.0,,1,,,In vitro cellular toxicity against chinese hamster AA8 cell line after 4 hr of compound exposure,N,,185.0,80089,1,,CHEMBL618641,BAO_0000219,
6750,Intermediate,10029.0,,1,,,Inhibitory activity against AA8 cell growth in aerobic condition after 4 hr of exposure,N,,185.0,80089,1,,CHEMBL618642,BAO_0000219,
6751,Intermediate,10029.0,,1,,,Inhibitory activity against aerobic growth of AA8 cells.,N,,185.0,80089,1,,CHEMBL618643,BAO_0000219,
6752,Intermediate,10029.0,,1,,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,N,,185.0,80089,1,,CHEMBL884013,BAO_0000219,
6753,Expert,10029.0,,1,,,In vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,N,,185.0,80089,1,,CHEMBL622723,BAO_0000219,
6754,Intermediate,10029.0,,1,,,Tested for the in vitro cytotoxicity against transformed chinese hamster fibroblast line AA8,N,,185.0,80089,1,,CHEMBL622724,BAO_0000219,
6755,Expert,10029.0,,1,,,Tested for growth inhibition against AA8 tumor cell line(chinese hamster ovary).,N,,185.0,80089,1,,CHEMBL622725,BAO_0000219,
6756,Expert,10029.0,,1,,,Cytotoxicity against AA8 cell line,N,,185.0,80089,1,,CHEMBL622726,BAO_0000219,
6757,Intermediate,10029.0,,1,,,Hypersensitivity factor(HF) was determined as ratio of IC50(AA8) to IC50(UV4),N,,185.0,80089,1,,CHEMBL622727,BAO_0000219,
6758,Intermediate,10029.0,,1,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),N,,185.0,80089,1,,CHEMBL622728,BAO_0000219,
6759,Intermediate,10029.0,,1,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),N,,185.0,80089,1,,CHEMBL622729,BAO_0000219,
6760,Intermediate,10029.0,,1,,,In vitro therapeutic index (aerobic IC50 / hypoxic C1.6),N,,185.0,80089,1,,CHEMBL622730,BAO_0000219,
6761,Intermediate,10029.0,,1,,,Compound was evaluated for cytotoxicity against CHO AA8 cell lines for 4 hr at pH-7.4,N,,185.0,80089,1,,CHEMBL622731,BAO_0000219,
6762,Intermediate,10029.0,,1,,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,N,,185.0,80089,1,,CHEMBL622732,BAO_0000219,
6763,Intermediate,10029.0,,1,,,Compound was evaluated for in vitro cytotoxicities against Chinese hamster ovary derived AA8 cell lines.,N,,185.0,80089,1,,CHEMBL622733,BAO_0000219,
6764,Autocuration,10029.0,,1,,,Maximum tolerated dose (MTD) in C3H/HeN mice (single ip dose),U,,,22224,0,,CHEMBL622734,BAO_0000218,
6765,Expert,10029.0,,1,,,Concentration required to increase radiation sensitivity by 1.3 when AA8 cells are exposed to drug for 30 min before and during irradiation under hypoxic condition.,N,,185.0,80089,1,,CHEMBL622735,BAO_0000219,
6766,Autocuration,10029.0,,1,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under anoxic conditions,U,,185.0,22224,0,,CHEMBL618746,BAO_0000219,
6767,Autocuration,10029.0,,1,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under anoxic conditions,U,,185.0,22224,0,,CHEMBL618747,BAO_0000219,
6768,Autocuration,10029.0,,1,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under anoxic conditions,U,,185.0,22224,0,,CHEMBL620540,BAO_0000219,
6769,Autocuration,10029.0,,1,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 1 hr under aerobic conditions,U,,185.0,22224,0,,CHEMBL620541,BAO_0000219,
6770,Autocuration,10029.0,,1,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 3h under aerobic conditions,U,,185.0,22224,0,,CHEMBL620542,BAO_0000219,
6771,Autocuration,10029.0,,1,,,Oxygen dependence of cytotoxicity was assessed by clonogenic assay using stirred suspension cultures of AA8 cells after 4 hr under aerobic conditions,U,,185.0,22224,0,,CHEMBL620543,BAO_0000219,
6772,Autocuration,10029.0,,1,,,Ratio of oxygen dependence of cytotoxicities of AA8 cells in aerobic condition to anoxic condition,U,,185.0,22224,0,,CHEMBL618832,BAO_0000219,
6773,Expert,10029.0,,1,,,Concentration required to reduce AA8 cell survival by 10%,N,,185.0,80089,1,,CHEMBL618833,BAO_0000219,
6774,Autocuration,10029.0,,1,,,"Concentration required to reduce cell survival to 10% of controls under hypoxic conditions, using the AA8 (chinese hamster) aerobic cells",U,,185.0,22224,0,,CHEMBL618834,BAO_0000219,
6775,Autocuration,10029.0,,1,,,Tested for the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,U,,185.0,22224,0,,CHEMBL618835,BAO_0000219,
6776,Autocuration,10029.0,,1,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay,U,,185.0,22224,0,,CHEMBL618836,BAO_0000219,
6777,Autocuration,10029.0,,1,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 0.8-1.5,U,,185.0,22224,0,,CHEMBL618837,BAO_0000219,
6778,Autocuration,10029.0,,1,,,CT10 (air/N2) ratio of the product of the drug concentration to the exposure time needed to reduce cell survival to 10% of controls using AA8 cells at 10 E 6 /mL in the clonogenic assay; range is 1-2,U,,185.0,22224,0,,CHEMBL618838,BAO_0000219,
6779,Autocuration,10029.0,,1,,,Ability to reduce cell density of AA8 cells to 50% after 4 hr of exposure to air,U,,185.0,22224,0,,CHEMBL618839,BAO_0000219,
6780,Autocuration,10029.0,,1,,,Aerobic cytotoxic activity was evaluated by the growth inhibition of AA8 (chinese hamster) aerobic cells,U,,185.0,22224,0,,CHEMBL618840,BAO_0000219,
6781,Autocuration,10029.0,,1,,,"Compound was evaluated for the inhibition of cell growth in culture against Chinese hamster ovary derived cell line, AA8",U,,,22224,0,,CHEMBL618841,BAO_0000019,
6782,Autocuration,10029.0,,1,,,Concentration for 50% inhibition of AA8 cells growth under aerobic conditions after 18 hours exposure,U,,185.0,22224,0,,CHEMBL618842,BAO_0000219,
6783,Autocuration,10029.0,,1,,,Concentration required for 50% inhibition of growth of AA8 cells following 4 hr drug exposure,U,,185.0,22224,0,,CHEMBL618843,BAO_0000219,
6784,Intermediate,9615.0,In vivo,1,,,Half life period after 15 mg/kg iv dose in Dogs,N,,,50588,1,,CHEMBL618844,BAO_0000218,
6785,Intermediate,9615.0,In vivo,1,,,Half life period after 30 mg/kg po dose in Dogs,N,,,50588,1,,CHEMBL618845,BAO_0000218,
6786,Intermediate,9615.0,In vivo,1,,,Half life was measured after oral 2b administration (tested in 6 dogs),N,,,50588,1,,CHEMBL618846,BAO_0000218,
6787,Intermediate,9615.0,In vivo,1,,,Half life was measured in dog after oral 17b administration,N,,,50588,1,,CHEMBL618847,BAO_0000218,
6788,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter T max determined in dog after oral administration of 17b,N,,,50588,1,,CHEMBL618848,BAO_0000218,
6789,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter T max determined in dog after oral administration of 2b,N,,,50588,1,,CHEMBL618849,BAO_0000218,
6790,Intermediate,9615.0,In vivo,1,,,Tmax value after 15 mg/kg iv dose in Dogs,N,,,50588,1,,CHEMBL618850,BAO_0000218,
6791,Intermediate,9615.0,In vivo,1,,,Tmax value after 30 mg/kg po dose in Dogs,N,,,50588,1,,CHEMBL618851,BAO_0000218,
6792,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for its half life when administered intravenously in dog,N,,,50588,1,,CHEMBL873815,BAO_0000218,
6793,Intermediate,9615.0,In vivo,1,1969.0,,Compound was tested for plasma half life when administered in dog perorally (1 mg/kg) and intravenously (0.2 mg/kg),N,,,50588,1,,CHEMBL618852,BAO_0000218,
6794,Intermediate,9615.0,,1,,,Elimination Half-life of compound was determined in dog,N,,,50588,1,,CHEMBL618853,BAO_0000218,
6795,Intermediate,9615.0,In vivo,1,,,Half life of compound in dog following oral administration,N,,,50588,1,,CHEMBL618854,BAO_0000218,
6796,Intermediate,9615.0,,1,,,Half life of compound was determined in dog,N,,,50588,1,,CHEMBL618855,BAO_0000218,
6797,Intermediate,9615.0,,1,178.0,,Half life of compound was determined in dog blood,N,,,50588,1,,CHEMBL618856,BAO_0000218,
6798,Intermediate,9615.0,In vivo,1,,,Half life after oral and iv dosing in dogs,N,,,50588,1,,CHEMBL875827,BAO_0000218,
6799,Intermediate,9615.0,,1,,,Half life in dogs in hours,N,,,50588,1,,CHEMBL618857,BAO_0000218,
6800,Intermediate,9615.0,In vivo,1,,,Half life on i.v. administration of 2 mg/kg was measured in dog,N,,,50588,1,,CHEMBL618858,BAO_0000218,
6801,Intermediate,9615.0,In vivo,1,,,t1/2 in dog after oral dose (1 mg/kg),N,,,50588,1,,CHEMBL618859,BAO_0000218,
6802,Intermediate,9615.0,,1,,,Half life was evaluated in dog,N,,,50588,1,,CHEMBL618860,BAO_0000218,
6803,Intermediate,9615.0,In vivo,1,,,Half life period of compound was determined after intravenous administration at 2 mg/kg,N,,,50588,1,,CHEMBL618861,BAO_0000218,
6804,Intermediate,9615.0,In vivo,1,,,Half life period of compound was determined after peroral administration at 2 mg/kg,N,,,50588,1,,CHEMBL622539,BAO_0000218,
6805,Intermediate,9615.0,In vivo,1,,,Half life period (10 mg/kg) was determined in dog,N,,,50588,1,,CHEMBL622540,BAO_0000218,
6806,Intermediate,9615.0,In vivo,1,,,Half life period (10 mg/kg) was determined in dog,N,,,50588,1,,CHEMBL873803,BAO_0000218,
6807,Intermediate,9615.0,In vivo,1,,,Half life period by iv administration in dog at a dose of 0.3 mg/kg,N,,,50588,1,,CHEMBL873804,BAO_0000218,
6808,Intermediate,9615.0,In vivo,1,,,Half life period by po administration in dog at a dose of 0.3 mg/kg,N,,,50588,1,,CHEMBL624311,BAO_0000218,
6809,Intermediate,9615.0,,1,,,Half life period in dog,N,,,50588,1,,CHEMBL624312,BAO_0000218,
6810,Intermediate,9615.0,In vivo,1,,,Half life period in dogs after oral administration at 1 mg/kg,N,,,50588,1,,CHEMBL624313,BAO_0000218,
6811,Intermediate,9615.0,In vivo,1,,,Half life period was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,,,50588,1,,CHEMBL624314,BAO_0000218,
6812,Intermediate,9615.0,,1,,,Half-life of compound was determined in dogs,N,,,50588,1,,CHEMBL624315,BAO_0000218,
6813,Intermediate,9615.0,,1,1969.0,,Half-life in dog plasma,N,,,50588,1,,CHEMBL624316,BAO_0000218,
6814,Intermediate,9615.0,,1,,,Half-life in mongrel dogs was determined,N,,,50588,1,,CHEMBL624317,BAO_0000218,
6815,Intermediate,9615.0,In vivo,1,,,Half-life in dog upon oral administration,N,,,50588,1,,CHEMBL624318,BAO_0000218,
6816,Intermediate,9615.0,In vivo,1,,,Half-life in dog upon oral administration; Unable to calculate,N,,,50588,1,,CHEMBL624319,BAO_0000218,
6817,Intermediate,9615.0,,1,,,Half-life was measured in dog,N,,,50588,1,,CHEMBL624496,BAO_0000218,
6818,Intermediate,9615.0,,1,,,Half-life was measured in dog,N,,,50588,1,,CHEMBL624497,BAO_0000218,
6819,Intermediate,9615.0,,1,,,Half-recovery time (T1/2) of the vascular resistance decrease at ED30 in anesthetized dogs,N,,,50588,1,,CHEMBL624498,BAO_0000218,
6820,Intermediate,9615.0,In vivo,1,,,Oral half life was determined,N,,,50588,1,,CHEMBL624499,BAO_0000218,
6821,Intermediate,9615.0,In vivo,1,1969.0,,Plasma elimination half-life (08 h) was determined in canine following intravenous (iv) administration (1 mg/kg).,N,,,50588,1,,CHEMBL624500,BAO_0000218,
6822,Intermediate,9615.0,,1,1969.0,,Plasma half life was evaluated,N,,,50588,1,,CHEMBL624501,BAO_0000218,
6823,Intermediate,9615.0,,1,1969.0,,Plasma half life was evaluated in Dog,N,,,50588,1,,CHEMBL623666,BAO_0000218,
6824,Intermediate,9615.0,,1,1969.0,,Plasma half life was evaluated in dog,N,,,50588,1,,CHEMBL623667,BAO_0000218,
6825,Intermediate,9615.0,In vivo,1,,,T1/2 (Half-life) was after oral administration at 5 mg/kg,N,,,50588,1,,CHEMBL623668,BAO_0000218,
6826,Intermediate,9615.0,,1,,,Tested for the half life value in dog,N,,,50588,1,,CHEMBL623669,BAO_0000218,
6827,Intermediate,9615.0,In vivo,1,,,Maximum time at the dose of 2 mg/kg in dog,N,,,50588,1,,CHEMBL623670,BAO_0000218,
6828,Intermediate,9615.0,In vivo,1,,,Maximum time was evaluated against Beagle dog at a dose of 15 mg/kg after po administration,N,,,50588,1,,CHEMBL623671,BAO_0000218,
6829,Intermediate,9615.0,In vivo,1,178.0,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,,,50588,1,,CHEMBL875945,BAO_0000218,
6830,Intermediate,9615.0,In vivo,1,178.0,,Maximum time taken to reach maximum blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,,,50588,1,,CHEMBL623672,BAO_0000218,
6831,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic (PK) property (Tmax) was determined in dog at the single dose of 1 mg/kg,N,,,50588,1,,CHEMBL623673,BAO_0000218,
6832,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter Tmax was determined in Beagle dogs after (iv) administration of a dose of 28 (uM/kg),N,,,50588,1,,CHEMBL623674,BAO_0000218,
6833,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic property (Tmax) was measured in dog at the dose of 0.032 mg/kg p.o.,N,,,50588,1,,CHEMBL623675,BAO_0000218,
6834,Intermediate,9615.0,,1,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog",N,,,50588,1,,CHEMBL872526,BAO_0000218,
6835,Intermediate,9615.0,In vivo,1,,,"Tested for the pharmacokinetic data, time required to reach Cmax (Tmax) in dog at dosage of 10 mpk",N,,,50588,1,,CHEMBL623676,BAO_0000218,
6836,Intermediate,9615.0,In vivo,1,1969.0,,Time for maximum plasma concentration was measured in dogs after an oral dose of 10 uM/kg,N,,,50588,1,,CHEMBL623677,BAO_0000218,
6837,Intermediate,9615.0,In vivo,1,1969.0,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in male and female Beagle dogs.,N,,,50588,1,,CHEMBL623678,BAO_0000218,
6838,Intermediate,9615.0,,1,1969.0,,Time taken for maximum plasma concentration in dog,N,,,50588,1,,CHEMBL623679,BAO_0000218,
6839,Intermediate,9615.0,In vivo,1,,,Time to reach Cmax after oral administration to dogs,N,,,50588,1,,CHEMBL623680,BAO_0000218,
6840,Intermediate,9615.0,In vivo,1,1969.0,,Time to reach maximum plasma concentration was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,,,50588,1,,CHEMBL623681,BAO_0000218,
6841,Intermediate,9615.0,In vivo,1,,,Tmax (time to reach maximum concentration) was after oral administration at 5 mg/kg,N,,,50588,1,,CHEMBL623682,BAO_0000218,
6842,Intermediate,9615.0,In vivo,1,,,Tmax after peroral administration (1 mg/kg) was determined in dog,N,,,50588,1,,CHEMBL623683,BAO_0000218,
6843,Expert,9615.0,In vivo,1,,,Tmax of compound determined in dog after iv administration at a dose of 10 mg/kg,N,,,50588,1,,CHEMBL623684,BAO_0000218,
6844,Intermediate,9615.0,In vivo,1,,,Tmax by oral administration at a dose of 10 uM/kg in dog was determined,N,,,50588,1,,CHEMBL622745,BAO_0000218,
6845,Intermediate,9615.0,In vivo,1,,,Tmax after peroral administration in dogs at 2.4 uM/kg,N,,,50588,1,,CHEMBL622746,BAO_0000218,
6846,Intermediate,10090.0,In vivo,1,,,In vivo Cmax in mice at dose of 100 mg/kg,N,,,50594,1,,CHEMBL622747,BAO_0000218,
6847,Intermediate,10090.0,In vivo,1,,,In vivo Cmax in mice at dose of 50 mg/kg,N,,,50594,1,,CHEMBL622748,BAO_0000218,
6848,Intermediate,10090.0,In vivo,1,,,Maximal concentration determined at a dose 10 mg/kg administered intraperitoneally to mice,N,,,50594,1,,CHEMBL622749,BAO_0000218,
6849,Intermediate,10090.0,In vivo,1,1969.0,,Maximum plasma concentration was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),N,,,50594,1,,CHEMBL622750,BAO_0000218,
6850,Intermediate,10090.0,In vivo,1,1969.0,,Maximum concentration in plasma was determined after intraperitoneal administration of 100 mg/kg in mice,N,,,50594,1,,CHEMBL623411,BAO_0000218,
6851,Intermediate,10090.0,In vivo,1,1969.0,,Maximum concentration obtained in mouse plasma was determined,N,,,50594,1,,CHEMBL875946,BAO_0000218,
6852,Intermediate,10090.0,In vivo,1,1969.0,,Maximum concentration obtained in mouse plasma was determined at dose 25 mg/kg,N,,,50594,1,,CHEMBL623412,BAO_0000218,
6853,Intermediate,10090.0,In vivo,1,1969.0,,Maximum plasma concentration of compound was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,,,50594,1,,CHEMBL623413,BAO_0000218,
6854,Intermediate,10090.0,In vivo,1,1969.0,,Maximum plasma concentration when injected i.p. in mice at a dose of 50 mg/kg,N,,,50594,1,,CHEMBL623414,BAO_0000218,
6855,Intermediate,10090.0,In vivo,1,1969.0,,Maximum plasma concentration when injected intravenously in mice at a dose of 20 mg/kg,N,,,50594,1,,CHEMBL623415,BAO_0000218,
6856,Intermediate,10090.0,In vivo,1,1969.0,,Maximum plasma concentration when injected perorally in mice at a dose of 50 mg/kg,N,,,50594,1,,CHEMBL623416,BAO_0000218,
6857,Intermediate,10090.0,In vivo,1,1969.0,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intraperitoneal dose,N,,,50594,1,,CHEMBL623417,BAO_0000218,
6858,Intermediate,10090.0,In vivo,1,1969.0,,Maximal plasma concentration in BALB/C mice after 20 mg/kg intravenous dose,N,,,50594,1,,CHEMBL623418,BAO_0000218,
6859,Intermediate,10090.0,In vivo,1,1969.0,,Maximal plasma concentration in BALB/C mice after 50 mg/kg oral dose,N,,,50594,1,,CHEMBL623419,BAO_0000218,
6860,Intermediate,10090.0,In vivo,1,,,Peak concentration at a single subcutaneous administration of 40 mg/kg in mice,N,,,50594,1,,CHEMBL622816,BAO_0000218,
6861,Intermediate,10090.0,In vivo,1,,,Pharmacokinetic property (C(max)) was determined after ip administration of 32 mg/kg in mice,N,,,50594,1,,CHEMBL623313,BAO_0000218,
6862,Intermediate,10090.0,In vivo,1,,,Pharmacokinetic property (C(max)) was determined after po administration of 32 mg/kg in mice,N,,,50594,1,,CHEMBL623314,BAO_0000218,
6863,Intermediate,10090.0,In vivo,1,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg intravenously in mice,N,,,50594,1,,CHEMBL876788,BAO_0000218,
6864,Intermediate,10090.0,In vivo,1,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 5 mg/kg perorally in mice,N,,,50594,1,,CHEMBL623315,BAO_0000218,
6865,Intermediate,10090.0,In vivo,1,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg intravenously in mice,N,,,50594,1,,CHEMBL623316,BAO_0000218,
6866,Intermediate,10090.0,In vivo,1,,,Pharmacokinetic studies were carried out in vivo after administration of compound at 50 mg/kg perorally in mice,N,,,50594,1,,CHEMBL623317,BAO_0000218,
6868,Intermediate,10090.0,In vivo,1,,,Cmax in male mice after 2 mg/kg oral dose,N,,,50594,1,,CHEMBL623319,BAO_0000218,
6869,Intermediate,10090.0,In vivo,1,,,Plasma concentration of 5-FU in HT-3 (human cervical cancer) xenograft mice at 1.38 mg/kg oral dose co-administered with 135 mg/kg Capecitabine,N,,,50594,1,,CHEMBL623320,BAO_0000218,
6870,Intermediate,10090.0,In vivo,1,,,Tested for Cmax value at the dose of 10 mg/kg when administered perorally in mouse,N,,,50594,1,,CHEMBL623321,BAO_0000218,
6871,Intermediate,10090.0,,1,,,Concentration in plasma (systemic) following oral dose in mouse at 0.25 hr,N,,,50594,1,,CHEMBL623322,BAO_0000218,
6872,Intermediate,10090.0,,1,,,Concentration in plasma (systemic) following oral dose in mouse at 1 hr,N,,,50594,1,,CHEMBL623323,BAO_0000218,
6873,Intermediate,10090.0,,1,,,Concentration in plasma (systemic) following oral dose in mouse at 24 hr,N,,,50594,1,,CHEMBL623324,BAO_0000218,
6874,Intermediate,10090.0,,1,,,Concentration in plasma (systemic) following oral dose in mouse at 2 hr,N,,,50594,1,,CHEMBL623325,BAO_0000218,
6875,Intermediate,10090.0,,1,,,Concentration in plasma (systemic) following oral dose in mouse at 4 hr,N,,,50594,1,,CHEMBL623326,BAO_0000218,
6876,Intermediate,10090.0,,1,,,Concentration in plasma (systemic) following oral dose in mouse at 6 hr,N,,,50594,1,,CHEMBL623327,BAO_0000218,
6877,Intermediate,10090.0,,1,1969.0,,Maximum concentration in plasma upon oral administration in mouse,N,,,50594,1,,CHEMBL623328,BAO_0000218,
6878,Intermediate,10090.0,,1,1969.0,,Maximum plasma concentration was evaluated in mice after oral administration,N,,,50594,1,,CHEMBL623329,BAO_0000218,
6879,Intermediate,10090.0,In vivo,1,1969.0,,Maximum plasma concentration was evaluated in mice after intravenous administration; Cp max Not determined,N,,,50594,1,,CHEMBL623330,BAO_0000218,
6880,Intermediate,10090.0,,1,,,Dose at which the compound induced fecal excretion in mice,N,,,50594,1,,CHEMBL876789,BAO_0000218,
6893,Expert,10116.0,,1,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.01 uM,N,,164.0,80013,1,,CHEMBL623333,BAO_0000219,
6894,Expert,10116.0,,1,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 0.1 uM,N,,164.0,80013,1,,CHEMBL623334,BAO_0000219,
6895,Expert,10116.0,,1,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 1.0 uM,N,,164.0,80013,1,,CHEMBL627536,BAO_0000219,
6896,Expert,10116.0,,1,,,Percent decrease in fluorescence in a membrane potential assay using the A10 cell line derived from embryonic rat aorta at 10.0 uM,N,,164.0,80013,1,,CHEMBL627537,BAO_0000219,
6897,Intermediate,10116.0,,1,,,In vitro [14C]- creatine uptake (1 mM) was determined in rat A10 smooth muscle cells at a concentration of (1 mM),N,,164.0,80013,1,,CHEMBL627538,BAO_0000219,
6898,Intermediate,9606.0,,1,,,Cytotoxicity was evaluated against A121 ovarian carcinoma human cancer cell line,N,,393.0,80655,1,,CHEMBL884106,BAO_0000219,
6899,Intermediate,9606.0,,1,,,Anticancer activity against human ovarian carcinoma A121 cells,N,,393.0,80655,1,,CHEMBL625294,BAO_0000219,
6900,Intermediate,9606.0,,1,,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 16.6 mM,N,,393.0,80655,1,,CHEMBL625295,BAO_0000219,
6901,Intermediate,9606.0,,1,,,Cytotoxic effect (tumor cell growth inhibition) on the human cell line A121 ovarian carcinoma at the dose of of 83 mM,N,,393.0,80655,1,,CHEMBL625296,BAO_0000219,
6902,Expert,9606.0,,1,,,Growth inhibition of human ovarian carcinoma (A121) cell line,N,,393.0,80655,1,,CHEMBL625297,BAO_0000219,
6903,Expert,9606.0,,1,,,Concentration required to inhibit growth of human tumor A121 (ovarian) cell line.,N,,393.0,80655,1,,CHEMBL625298,BAO_0000219,
6904,Intermediate,9606.0,,1,,,Cytotoxicity against human A121 ovarian cells,N,,393.0,80655,1,,CHEMBL625960,BAO_0000219,
6905,Intermediate,9606.0,,1,,,Cytotoxicity was evaluated in vitro against A121 (ovarian carcinoma) human tumor cell lines,N,,393.0,80655,1,,CHEMBL625961,BAO_0000219,
6906,Intermediate,9606.0,,1,,,In vitro cytotoxicity against human ovarian carcinoma A21,N,,393.0,80655,1,,CHEMBL625962,BAO_0000219,
6907,Intermediate,9606.0,,1,,,Inhibition of the growth against human Ovarian Carcinoma (A121) cell line after 72 hr exposure,N,,393.0,80655,1,,CHEMBL624717,BAO_0000219,
6908,Intermediate,9606.0,,1,,,Inhibitory activity of compound against human A121 ovarian cell line.,N,,393.0,80655,1,,CHEMBL624718,BAO_0000219,
6909,Intermediate,9606.0,,1,,,Dose at which compound exhibits cytotoxicity in the A121 ovarian carcinoma cell line.,N,,393.0,80655,1,,CHEMBL624719,BAO_0000219,
6910,Intermediate,9606.0,,1,,,Inhibition of growth of human ovarian tumor cell line (A121) after 72 hr of drug exposure,N,,393.0,80655,1,,CHEMBL624720,BAO_0000219,
6911,Intermediate,9606.0,,1,,,Compound was evaluated for in vitro antiproliferative activity against A172 human CNS cancer cell line,N,,622.0,80012,1,,CHEMBL624721,BAO_0000219,
6912,Expert,9606.0,,1,,,In vitro cytotoxicity against A172 human tumor cell lines.,N,,622.0,80012,1,,CHEMBL624722,BAO_0000219,
6913,Intermediate,9606.0,,1,,,Growth inhibition time for A172 Human Glioma cell growth at concentration 5 uM,N,,622.0,80012,1,,CHEMBL877597,BAO_0000219,
6914,Intermediate,9606.0,,1,,,Compound was evaluated for cytotoxicity against human glioblastoma (A172) cell line,N,,622.0,80012,1,,CHEMBL624723,BAO_0000219,
6915,Intermediate,9606.0,,1,,,Evaluated for the inhibitory concentration required to cause growth inhibition of A172Mer- cell line of central nervous system (CNS) using the MTT Cytotoxicity Assay,N,,622.0,80012,1,,CHEMBL624724,BAO_0000219,
6916,Autocuration,9615.0,,1,,,Association constant against A2 adenosine receptor,H,,,104729,4,,CHEMBL624725,BAO_0000224,
6917,Intermediate,,,1,,,In vitro effective dose that causes 50% inhibition of growth of A2 cell line - amelanotic melanoma,N,,1085.0,80656,1,,CHEMBL624726,BAO_0000219,
6918,Autocuration,10116.0,,1,,,Ratio of Ki for adenosine A2 and A1 receptor binding,D,,,104713,5,,CHEMBL857535,BAO_0000224,
6919,Expert,9606.0,,1,,,In vitro cytotoxicity against A204 human rhabdomyosarcoma cancer cell line,N,,623.0,80014,1,,CHEMBL624727,BAO_0000219,
6920,Expert,9606.0,,1,,,In vitro antitumor activity against A204 rhabdomyosarcoma tumor cell line was determined,N,,623.0,80014,1,,CHEMBL624728,BAO_0000219,
6921,Intermediate,9606.0,,1,,,The compound was tested in vitro for antiproliferative activity against A2058 tumor cell lines,N,,404.0,80015,1,,CHEMBL624729,BAO_0000219,
6922,Intermediate,9606.0,,1,,,Growth inhibition against Human squamous cell line(A 253),N,,973.0,80657,1,,CHEMBL624730,BAO_0000219,
6923,Intermediate,9606.0,,1,,,Growth inhibition of human squamous carcinoma cell lines following continuous (120 hours) exposure to MTX and compound A253 cell line,N,,973.0,80657,1,,CHEMBL624731,BAO_0000219,
6924,Intermediate,9606.0,,1,,,The compound was tested for Growth inhibition of the human squamous cell carcinoma A253 cells,N,,973.0,80657,1,,CHEMBL624732,BAO_0000219,
6925,Intermediate,9606.0,,1,,,Growth inhibition of A253 cell lines.,N,,973.0,80657,1,,CHEMBL883245,BAO_0000219,
6926,Intermediate,9606.0,,1,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h),N,,973.0,80657,1,,CHEMBL624733,BAO_0000219,
6927,Intermediate,9606.0,,1,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,N,,973.0,80657,1,,CHEMBL624734,BAO_0000219,
6928,Intermediate,9606.0,,1,,,Growth inhibition of human squamous cell carcinoma A253 cells during continuous Exposure (0-12 h); ND means not determined,N,,973.0,80657,1,,CHEMBL624735,BAO_0000219,
6929,Intermediate,9606.0,,1,,,In vitro cytotoxicity causing 50% growth inhibition was determined against A270 (human ovarian cancer)cell line,N,,478.0,81034,1,,CHEMBL621780,BAO_0000219,
6930,Intermediate,9606.0,,1,,,Antitumor activity of compound for 96-h exposure in A2780 human ovarian cell line,N,,478.0,81034,1,,CHEMBL877598,BAO_0000219,
6931,Expert,9606.0,,1,,,Cytotoxic activity against A2780 human ovarian carcinoma cell line,N,,478.0,81034,1,,CHEMBL621781,BAO_0000219,
6932,Intermediate,9606.0,,1,,,Cytotoxicity against human cancer cell lines A2780 (ovarian),N,,478.0,81034,1,,CHEMBL621782,BAO_0000219,
6933,Expert,9606.0,,1,,,Growth and colony formation inhibition of A2780 ovarian cancer cell lines,N,,478.0,81034,1,,CHEMBL621783,BAO_0000219,
6934,Intermediate,9606.0,,1,,,Inhibition of cell growth in human ovarian carcinoma cell line (A2780) using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay,N,,478.0,81034,1,,CHEMBL621784,BAO_0000219,
6935,Intermediate,9606.0,,1,,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),N,,478.0,81034,1,,CHEMBL621785,BAO_0000219,
6936,Expert,9606.0,,1,,,Inhibition of A2780 / DDP-R human ovarian carcinoma cell proliferation,N,,478.0,81034,1,,CHEMBL621968,BAO_0000219,
6937,Expert,9606.0,,1,,,Inhibition of A2780 / TAX-R human ovarian carcinoma cell proliferation,N,,478.0,81034,1,,CHEMBL621969,BAO_0000219,
6938,Expert,9606.0,,1,,,Inhibition of A2780 / TAX-S human ovarian carcinoma cell proliferation,N,,478.0,81034,1,,CHEMBL621970,BAO_0000219,
6939,Intermediate,9606.0,,1,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 2,N,,478.0,81034,1,,CHEMBL621971,BAO_0000219,
6940,Intermediate,9606.0,,1,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 3,N,,478.0,81034,1,,CHEMBL621972,BAO_0000219,
6941,Intermediate,9606.0,,1,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 5,N,,478.0,81034,1,,CHEMBL884108,BAO_0000219,
6942,Autocuration,10029.0,,1,,,Cytotoxicity on AA8 cell growth (reduce cell number by 50%).,U,,,22224,0,,CHEMBL623826,BAO_0000019,
6943,Autocuration,10029.0,,1,,,Evaluated for cytotoxicity under aerobic conditions against AA8 cells using microassay,U,,185.0,22224,0,,CHEMBL623827,BAO_0000219,
6944,Autocuration,10029.0,,1,,,Evaluated for growth inhibition of AA8 cells under aerobic conditions,U,,185.0,22224,0,,CHEMBL623828,BAO_0000219,
6945,Autocuration,10029.0,,1,,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions,U,,185.0,22224,0,,CHEMBL623829,BAO_0000219,
6946,Autocuration,10029.0,,1,,,Evaluated for growth inhibition of AA8 cells under aerobic or hypoxic conditions (air/N2),U,,185.0,22224,0,,CHEMBL623830,BAO_0000219,
6947,Autocuration,10029.0,,1,,,Growth inhibition against CHO-derived cell line AA8,U,,,22224,0,,CHEMBL623831,BAO_0000019,
6948,Autocuration,10029.0,,1,,,Growth inhibition against CHO-derived cell line AA8 (Non toxic at solubility limit) [RB6145 used as positive control],U,,185.0,22224,0,,CHEMBL623832,BAO_0000219,
6949,Expert,36483.0,,1,,,Growth inhibition in CHO subline AA8 cells exposed for 18 hr under aerobic(air) conditions,N,,185.0,80089,1,,CHEMBL623833,BAO_0000219,
6950,Expert,10029.0,,1,,,Growth inhibitory activity against CHO subline AA8 cells exposed for 18 hr under aerobic conditions,N,,185.0,80089,1,,CHEMBL623834,BAO_0000219,
6951,Autocuration,10029.0,,1,,,Tested for the concentration of the drug to reduce cell numbers to 50 percent of controls against AA8 cells in the microassay,U,,185.0,22224,0,,CHEMBL623835,BAO_0000219,
6952,Autocuration,10029.0,,1,,,Growth inhibition of aerobic chinese hamster ovary fibroblast AA8 cell line using an exposure time of 18 hours,U,,185.0,22224,0,,CHEMBL623836,BAO_0000219,
6953,Autocuration,10029.0,,1,,,IC50 (air/N2) ratio of the drug to reduce cell numbers to 50 percent of controls using AA8 cells in the microassay,U,,185.0,22224,0,,CHEMBL623837,BAO_0000219,
6954,Expert,10029.0,,1,,,In vitro therapeutic index as ratio of CT10 and C1.3 calculated for AA8 cells.,N,,185.0,80089,1,,CHEMBL623838,BAO_0000219,
6955,Autocuration,,,1,,,compound was evaluated for association constant (Ka) of isolated serum protein AAG,H,,,12675,8,,CHEMBL623839,BAO_0000019,
6956,Autocuration,,,1,,,Number of binding sites (n) of isolated serum protein AAG,H,,,12675,8,,CHEMBL623840,BAO_0000019,
6957,Intermediate,,,1,,,Association constant for binding to AATT duplex,M,,,22222,3,,CHEMBL623841,BAO_0000225,
6958,Expert,9606.0,,1,,,Inhibition of ABAE human fibroblast cell proliferation,N,,416.0,100090,1,,CHEMBL623842,BAO_0000219,
6959,Intermediate,10090.0,,1,,,"Compound was evaluated for the antitumor activity against AC755 breast carcinoma for ip administration and daily x 10 schedule; Number of toxic deaths over total number of mice per group (T/C), 1/7 at dose of 25 mg/kg",N,,1064.0,80668,1,,CHEMBL623843,BAO_0000218,
6960,Expert,9986.0,,1,,,Percent change in total cholesterol(TC) versus (T0)- at which drug intervention begins at a dose of 25 mg/kg in the chronic cholesterol-fed rabbit model,D,,,102444,9,,CHEMBL618669,BAO_0000218,
6961,Expert,9986.0,In vivo,1,,,Oral bioactivity expressed as %inhibition after 4 hours of drug administration (dose 25 mg/kg) in rabbit bioassay,D,,,102444,9,,CHEMBL618670,BAO_0000218,
6962,Autocuration,,,1,,,Inhibitory activity against angiotensin-converting enzyme (ACE).,H,,,69,8,,CHEMBL618671,BAO_0000357,
6963,Autocuration,,,1,,,oral activity against angiotensin -converting enzyme ( ACE) and neutral endopeptidase in mouse.,H,,,69,8,,CHEMBL618672,BAO_0000357,
6964,Intermediate,9606.0,,1,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells,N,,978.0,80669,1,,CHEMBL618673,BAO_0000219,
6965,Intermediate,9606.0,,1,,,Effect against HIV-1 chronically infected promonocytic cell line ACH-2 cells in the presence of PMA(phorbol 12-myristate 13-acetate),N,,978.0,80669,1,,CHEMBL618674,BAO_0000219,
6966,Autocuration,11676.0,,1,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2,U,,998.0,22224,0,,CHEMBL618675,BAO_0000219,
6967,Autocuration,11676.0,,1,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2 in the presence of PMA(phorbol 12-myristate 13-acetate),U,,998.0,22224,0,,CHEMBL618676,BAO_0000219,
6968,Autocuration,11676.0,,1,,,Effect against HIV-1 expression in a chronically infected human T cell line ACH-2i n the presence of PMA(phorbol 12-myristate 13-acetate),U,,998.0,22224,0,,CHEMBL618677,BAO_0000219,
6969,Intermediate,9606.0,,1,,,Inhibition of growth of renal cancer ACHN cell line,N,,626.0,80025,1,,CHEMBL618678,BAO_0000219,
6970,Intermediate,9606.0,,1,,,Inhibition of growth of ACHN renal cancer cell line,N,,626.0,80025,1,,CHEMBL618679,BAO_0000219,
6971,Intermediate,9606.0,,1,,,Inhibitory concentration required against ACHN renal cancer cell line,N,,626.0,80025,1,,CHEMBL618680,BAO_0000219,
6972,Expert,9606.0,,1,,,Concentration required to inhibit growth of human renal (ACHN) cell line,N,,626.0,80025,1,,CHEMBL618681,BAO_0000219,
6973,Intermediate,9606.0,,1,,,Concentration required to inhibit growth of human renal (ACHN) cell line; nt = not tested,N,,626.0,80025,1,,CHEMBL618682,BAO_0000219,
6974,Intermediate,9606.0,,1,,,Cytotoxic activity against ACHN Renal cancer cell line,N,,626.0,80025,1,,CHEMBL618683,BAO_0000219,
6975,Intermediate,9606.0,,1,,,Cytotoxicity evaluation against ACHN renal cancer cells,N,,626.0,80025,1,,CHEMBL618684,BAO_0000219,
6976,Intermediate,9606.0,,1,,,In vitro antitumor activity against human renal ACHN cell line,N,,626.0,80025,1,,CHEMBL618685,BAO_0000219,
6977,Intermediate,9606.0,,1,,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,N,,626.0,80025,1,,CHEMBL876499,BAO_0000219,
6978,Intermediate,9606.0,,1,,,In vitro growth inhibition of compound was determined against ACHN cell lines of Renal cancer,N,,626.0,80025,1,,CHEMBL618686,BAO_0000219,
6979,Intermediate,9606.0,,1,,,"Tested for the cytotoxicity against the Renal cancer cell line ACHN, growth inhibition by 50% is reported",N,,626.0,80025,1,,CHEMBL618687,BAO_0000219,
6980,Intermediate,9606.0,,1,,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,N,,626.0,80025,1,,CHEMBL618688,BAO_0000219,
6981,Expert,9606.0,,1,,,Tested in vitro for cytotoxicity against human tumor cell line ACHN (renal).,N,,626.0,80025,1,,CHEMBL618689,BAO_0000219,
6982,Intermediate,9606.0,,1,,,The compound was tested in vitro for cytotoxicity against human tumor cell line ACHN (renal); Not determined,N,,626.0,80025,1,,CHEMBL618690,BAO_0000219,
6983,Intermediate,9606.0,,1,,,Antitumor activity was evaluated against human renal adenocarcinoma cell line ACHN.,N,,626.0,80025,1,,CHEMBL618691,BAO_0000219,
6984,Intermediate,9606.0,,1,,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),N,,626.0,80025,1,,CHEMBL619373,BAO_0000219,
6985,Intermediate,9606.0,,1,,,"Compound was tested for antiproliferative activity against ACHN, human renal adenocarcinoma",N,,626.0,80025,1,,CHEMBL884008,BAO_0000219,
6986,Intermediate,9606.0,,1,,,Compound was tested for its effect on the proliferation of ACHN human kidney adenocarcinoma,N,,626.0,80025,1,,CHEMBL619374,BAO_0000219,
6987,Intermediate,9606.0,,1,,,Compound was tested for the growth inhibition of ACHN renal tumor cell line,N,,626.0,80025,1,,CHEMBL619375,BAO_0000219,
6988,Intermediate,9606.0,,1,,,Compound was tested for the growth inhibition of ACHN renal tumor cell line; ND=Not determined,N,,626.0,80025,1,,CHEMBL619376,BAO_0000219,
6989,Intermediate,9606.0,,1,,,In vitro Growth Inhibitory activity against ACHN Human kidney cancer cell line,N,,626.0,80025,1,,CHEMBL619377,BAO_0000219,
6990,Intermediate,9606.0,,1,,,In vitro cytotoxicity against human renal adenocarcinoma (ACHN) tumor cell line,N,,626.0,80025,1,,CHEMBL619378,BAO_0000219,
6991,Intermediate,9615.0,In vivo,1,,,Tmax value after administration of 4 mg/Kg oral dose in dog,N,,,50588,1,,CHEMBL872527,BAO_0000218,
6992,Intermediate,9615.0,,1,,,"Time to peak response on lowering of vascular resistance, in dogs when administered intravenously",N,,,50588,1,,CHEMBL876500,BAO_0000218,
6993,Intermediate,9615.0,,1,,,Unbound plasma was determined in Beagle dog at a dose of 1 mg/kg by iv administration,N,,,50588,1,,CHEMBL619379,BAO_0000218,
6994,Intermediate,9615.0,In vivo,1,,,Volume distribution after 15 mg/kg iv dose in Dogs,N,,,50588,1,,CHEMBL619538,BAO_0000218,
6995,Intermediate,9615.0,In vivo,1,,,Volume distribution after 30 mg/kg po dose in Dogs,N,,,50588,1,,CHEMBL619539,BAO_0000218,
6996,Intermediate,9615.0,In vivo,1,,,Volume of distribution was determined in dog after a 3 mg/kg of iv dose,N,,,50588,1,,CHEMBL619540,BAO_0000218,
6997,Intermediate,9615.0,In vivo,1,,,Volume of distribution was determined by iv administration in dogs at a dose of 1 mg/kg,N,,,50588,1,,CHEMBL619541,BAO_0000218,
6998,Intermediate,9615.0,In vivo,1,,,Volume of distribution was evaluated in dog,N,,,50588,1,,CHEMBL619542,BAO_0000218,
6999,Intermediate,9615.0,In vivo,1,,,Terminal phase volume of distribution was measured in dog after an iv dose of 1 mg/kg,N,,,50588,1,,CHEMBL619543,BAO_0000218,
7000,Expert,9615.0,,1,,,Apparent volume of the central plasma compartment (Vc) of compound determined in dog after iv administration at a dose of 10 mg/kg,N,,,50588,1,,CHEMBL619544,BAO_0000218,
7001,Intermediate,9615.0,In vivo,1,,,The compound was tested for volume of distribution in dog,N,,,50588,1,,CHEMBL619545,BAO_0000218,
7002,Intermediate,9615.0,In vivo,1,,,The compound was tested for volume of distribution in dog at dose of 3-10 mgkg,N,,,50588,1,,CHEMBL619546,BAO_0000218,
7003,Intermediate,9615.0,In vivo,1,,,Vd (1 mg/kg) was determined in dog (in vivo),N,,,50588,1,,CHEMBL619547,BAO_0000218,
7004,Intermediate,9615.0,In vivo,1,,,Vd in dog,N,,,50588,1,,CHEMBL619548,BAO_0000218,
7005,Intermediate,9615.0,In vivo,1,,,Volume distribution was determined,N,,,50588,1,,CHEMBL619549,BAO_0000218,
7006,Intermediate,9615.0,In vivo,1,,,Volume of distribution in dog,N,,,50588,1,,CHEMBL619550,BAO_0000218,
7007,Intermediate,9615.0,In vivo,1,,,Volume of distribution by as 4 fold increase by iv administration in dogs,N,,,50588,1,,CHEMBL876501,BAO_0000218,
7008,Intermediate,9615.0,In vivo,1,,,Volume of distribution was determined in canine following intravenous (iv) administration of drug (1 mg/kg).,N,,,50588,1,,CHEMBL619551,BAO_0000218,
7009,Intermediate,9615.0,In vivo,1,,,Volume of distribution was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,,,50588,1,,CHEMBL619552,BAO_0000218,
7010,Intermediate,9615.0,In vivo,1,,,Volume distribution at the dose of 2 mg/kg in dog,N,,,50588,1,,CHEMBL619553,BAO_0000218,
7011,Intermediate,9615.0,In vivo,1,,,Steady state volume of distribution was determined,N,,,50588,1,,CHEMBL618722,BAO_0000218,
7012,Intermediate,9615.0,In vivo,1,,,Bioavailability as Vdss in dogs at 1 mg/kg intravenous dose,N,,,50588,1,,CHEMBL618723,BAO_0000218,
7013,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,N,,,50588,1,,CHEMBL618724,BAO_0000218,
7014,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,N,,,50588,1,,CHEMBL618725,BAO_0000218,
7015,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog (dose 1 mg/kg i.v.),N,,,50588,1,,CHEMBL618726,BAO_0000218,
7016,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Beagle dog (male),N,,,50588,1,,CHEMBL618727,BAO_0000218,
7017,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic property (vdss) was measured in dog,N,,,50588,1,,CHEMBL624233,BAO_0000218,
7018,Intermediate,9615.0,In vivo,1,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in dog,N,,,50588,1,,CHEMBL624234,BAO_0000218,
7019,Intermediate,9615.0,In vivo,1,,,Vdss was determined after iv 0.1 mg/kg administration in dog,N,,,50588,1,,CHEMBL624235,BAO_0000218,
7020,Intermediate,9615.0,In vivo,1,,,Volume displacement was calculated in dog,N,,,50588,1,,CHEMBL624236,BAO_0000218,
7021,Intermediate,9615.0,In vivo,1,,,Volume distribution (Vdss) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,N,,,50588,1,,CHEMBL624237,BAO_0000218,
7022,Intermediate,9615.0,In vivo,1,,,Volume distribution constant was determined,N,,,50588,1,,CHEMBL624238,BAO_0000218,
7023,Intermediate,9615.0,In vivo,1,,,Volume distribution at a dose of 1 uM/kg in dog was determined,N,,,50588,1,,CHEMBL624239,BAO_0000218,
7024,Intermediate,9615.0,In vivo,1,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,N,,,50588,1,,CHEMBL875829,BAO_0000218,
7025,Intermediate,9615.0,In vivo,1,,,Volume distribution in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,,,50588,1,,CHEMBL624240,BAO_0000218,
7026,Intermediate,9615.0,In vivo,1,,,Volume distribution (Vdss) was measured in dog,N,,,50588,1,,CHEMBL624241,BAO_0000218,
7027,Intermediate,9615.0,In vivo,1,,,Volume distribution (Vdss) was measured in dog,N,,,50588,1,,CHEMBL624242,BAO_0000218,
7028,Intermediate,9615.0,In vivo,1,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,,50588,1,,CHEMBL624243,BAO_0000218,
7029,Intermediate,9615.0,In vivo,1,,,Volume of distribution in steady state was determined in dog,N,,,50588,1,,CHEMBL624244,BAO_0000218,
7030,Intermediate,9615.0,In vivo,1,,,Volume of distribution of compound was determined in dog,N,,,50588,1,,CHEMBL624245,BAO_0000218,
7031,Intermediate,9615.0,In vivo,1,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,N,,,50588,1,,CHEMBL624246,BAO_0000218,
7032,Intermediate,9615.0,In vivo,1,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Beagle dog (male),N,,,50588,1,,CHEMBL624247,BAO_0000218,
7033,Intermediate,9615.0,In vivo,1,,,Volume of distribution (Vdss) was measured in dog,N,,,50588,1,,CHEMBL624248,BAO_0000218,
7034,Intermediate,9615.0,In vivo,1,,,Volumes of distribution in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,,,50588,1,,CHEMBL624249,BAO_0000218,
7035,Intermediate,9615.0,In vivo,1,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,,,50588,1,,CHEMBL624250,BAO_0000218,
7036,Intermediate,9615.0,In vivo,1,,,Volumes of distribution in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,,,50588,1,,CHEMBL624251,BAO_0000218,
7037,Intermediate,9615.0,,1,,,Maximum rate of depolarization of the upstroke of the action potential,N,,,50588,1,,CHEMBL624252,BAO_0000218,
7038,Intermediate,9615.0,In vivo,1,,,Steady state volume distribution in dog,N,,,50588,1,,CHEMBL624253,BAO_0000218,
7039,Intermediate,9615.0,In vivo,1,,,Steady state volume of distribution at a dose of 0.2 mg/kg i.v.,N,,,50588,1,,CHEMBL624950,BAO_0000218,
7040,Intermediate,9615.0,In vivo,1,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in dog,N,,,50588,1,,CHEMBL624951,BAO_0000218,
7041,Intermediate,9615.0,In vivo,1,,,Volume distribution in dog after administration of 0.25 mg/kg iv; ND = not determined,N,,,50588,1,,CHEMBL875830,BAO_0000218,
7042,Intermediate,9615.0,In vivo,1,,,Volume distribution in dog after administration of 1 mg/kg iv,N,,,50588,1,,CHEMBL624952,BAO_0000218,
7043,Intermediate,9615.0,In vivo,1,,,Volume of solubility in solution after intravenous administration in dogs at 1.2 uM/kg,N,,,50588,1,,CHEMBL624953,BAO_0000218,
7044,Intermediate,9615.0,In vivo,1,,,Vss after intravenous administration (0.5 mg/kg) was determined in dog,N,,,50588,1,,CHEMBL624954,BAO_0000218,
7045,Intermediate,9615.0,In vivo,1,,,Vss on i.v. administration of 2 mg/kg was measured in dog,N,,,50588,1,,CHEMBL624955,BAO_0000218,
7046,Intermediate,9615.0,,1,,,Vss was determined,N,,,50588,1,,CHEMBL624956,BAO_0000218,
7047,Intermediate,9615.0,,1,,,Vss in dog,N,,,50588,1,,CHEMBL625129,BAO_0000218,
7048,Intermediate,9615.0,In vivo,1,,,Volume of distribution was measured in dog after an iv dose of 1 mg/kg,N,,,50588,1,,CHEMBL625130,BAO_0000218,
7049,Intermediate,9615.0,In vivo,1,,,Volume distribution in dogs,N,,,50588,1,,CHEMBL625131,BAO_0000218,
7050,Intermediate,9615.0,In vivo,1,,,Volume of distribution in dog,N,,,50588,1,,CHEMBL625132,BAO_0000218,
7051,Intermediate,9615.0,In vivo,1,,,Tested for the oral bioavailability in dog,N,,,50588,1,,CHEMBL872263,BAO_0000218,
7060,Intermediate,10090.0,In vivo,1,,,Bioavailability of compound in mouse blood following p.o. administration of 30 mg/kg,N,,,50594,1,,CHEMBL624336,BAO_0000218,
7061,Intermediate,10090.0,In vivo,1,,,Bioavailability after i.p. administration of 50 mg/kg of dose in mice,N,,,50594,1,,CHEMBL624337,BAO_0000218,
7062,Intermediate,10090.0,In vivo,1,,,Bioavailability after peroral administration of 50 mg/kg of dose in mice,N,,,50594,1,,CHEMBL624338,BAO_0000218,
7063,Intermediate,10090.0,In vivo,1,,,Bioavailability was measured in mouse,N,,,50594,1,,CHEMBL624339,BAO_0000218,
7064,Intermediate,10090.0,In vivo,1,,,Bioavailability in mouse,N,,,50594,1,,CHEMBL624340,BAO_0000218,
7065,Intermediate,10090.0,In vivo,1,,,Bioavailability was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,,,50594,1,,CHEMBL624341,BAO_0000218,
7066,Intermediate,10090.0,In vivo,1,,,Bioavailability in mouse,N,,,50594,1,,CHEMBL624342,BAO_0000218,
7067,Intermediate,10090.0,In vivo,1,,,Compound was evaluated for its bioavailability in mice at a dose of 1 mg/kg,N,,,50594,1,,CHEMBL624343,BAO_0000218,
7068,Intermediate,10090.0,In vivo,1,,,Oral bioavailability in mouse,N,,,50594,1,,CHEMBL624344,BAO_0000218,
7069,Intermediate,10090.0,In vivo,1,,,Oral availability at 50 mg/kg po in male mice,N,,,50594,1,,CHEMBL624345,BAO_0000218,
7070,Intermediate,10090.0,In vivo,1,,,Oral bioavailability in mouse (dose 10 mg/kg),N,,,50594,1,,CHEMBL624346,BAO_0000218,
7071,Expert,10090.0,In vivo,1,,,Oral bioavailability of compound determined in mouse after iv administration at a dose of 10 mg/kg,N,,,50594,1,,CHEMBL624347,BAO_0000218,
7072,Intermediate,10090.0,In vivo,1,,,"Bioavailability in male mice, 2mg/kg oral and 1 mg/kg intravenous dose",N,,,50594,1,,CHEMBL624348,BAO_0000218,
7074,Intermediate,10090.0,In vivo,1,,,Oral bioavailability in mouse,N,,,50594,1,,CHEMBL622754,BAO_0000218,
7075,Intermediate,10090.0,In vivo,1,,,Oral bioavailability in vivo in mice;ND=Not determined,N,,,50594,1,,CHEMBL622755,BAO_0000218,
7076,Intermediate,10090.0,In vivo,1,,,Oral bioavailability in mouse at 10 mg/kg of the compound,N,,,50594,1,,CHEMBL622756,BAO_0000218,
7077,Intermediate,10090.0,In vivo,1,,,Bioavailability in mouse (BALB/C) (dose 50 mg/kg i.p.),N,,,50594,1,,CHEMBL622757,BAO_0000218,
7078,Intermediate,10090.0,In vivo,1,,,Bioavailability in mouse (BALB/C) (dose 20 mg/kg i.v.),N,,,50594,1,,CHEMBL622758,BAO_0000218,
7079,Intermediate,10090.0,In vivo,1,,,Tested for bioavailability of the compound,N,,,50594,1,,CHEMBL622759,BAO_0000218,
7080,Intermediate,10090.0,In vivo,1,,,Tested for half life at the dose of 10 mg/kg when administered intravenously,N,,,50594,1,,CHEMBL622760,BAO_0000218,
7081,Intermediate,10090.0,,1,1969.0,,The plasma half life of compound was determined on EDTA prepared by mouse plasma. ,N,,,50594,1,,CHEMBL622761,BAO_0000218,
7082,Intermediate,10090.0,,1,1969.0,,The plasma half life of compound was determined on heparin prepared by human plasma. ,N,,,50594,1,,CHEMBL622762,BAO_0000218,
7083,Intermediate,10090.0,,1,1969.0,,The plasma half life of compound was determined on heparin prepared by human plasma; Not degraded,N,,,50594,1,,CHEMBL622763,BAO_0000218,
7084,Intermediate,10090.0,,1,1969.0,,The plasma half life of compound was determined on heparin prepared by mouse plasma. ,N,,,50594,1,,CHEMBL622764,BAO_0000218,
7085,Intermediate,10090.0,,1,1969.0,,The plasma half life of compound was determined on heparin prepared by mouse plasma; Not degraded,N,,,50594,1,,CHEMBL622765,BAO_0000218,
7086,Intermediate,10090.0,,1,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 6 hours of exposure at 40 mg/Kg,N,,,50594,1,,CHEMBL622766,BAO_0000218,
7087,Intermediate,10090.0,,1,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 24 mg/Kg,N,,,50594,1,,CHEMBL622767,BAO_0000218,
7088,Intermediate,10090.0,,1,,,Inhibitory concentration of compound was determined after intravenous administration in mice after 8 hours of exposure at 5 mg/Kg,N,,,50594,1,,CHEMBL622768,BAO_0000218,
7089,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,,50594,1,,CHEMBL875948,BAO_0000218,
7090,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,,50594,1,,CHEMBL622769,BAO_0000218,
7091,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,,50594,1,,CHEMBL622770,BAO_0000218,
7092,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,,50594,1,,CHEMBL622771,BAO_0000218,
7093,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,,50594,1,,CHEMBL622772,BAO_0000218,
7094,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,,50594,1,,CHEMBL622773,BAO_0000218,
7095,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of intravenously injected [82Br]-labeled compound in blood of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,,50594,1,,CHEMBL622774,BAO_0000218,
7096,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,,50594,1,,CHEMBL621725,BAO_0000218,
7097,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,,,50594,1,,CHEMBL621726,BAO_0000218,
7098,Intermediate,9606.0,,1,,,cytotoxic activity toward A2780 ovarian human cell line resistant (R) to cisplatin in experiment 8,N,,478.0,81034,1,,CHEMBL621727,BAO_0000219,
7099,Expert,9606.0,,1,,,In vitro cytotoxicity against human ovarian carcinoma cell line A2780 using sulforhodamine B (SRB) assay,N,,478.0,81034,1,,CHEMBL622413,BAO_0000219,
7100,Intermediate,9606.0,,1,,,Compound was evaluated for cytotoxicity against A2780 cell line,N,,478.0,81034,1,,CHEMBL622414,BAO_0000219,
7101,Expert,9606.0,,1,,,Inhibition of A2780 cell clonogenic assay,N,,478.0,81034,1,,CHEMBL622415,BAO_0000219,
7102,Expert,9606.0,,1,,,Cytotoxic effect on ovarian cancer cell line (A2780),N,,478.0,81034,1,,CHEMBL884001,BAO_0000219,
7103,Intermediate,9606.0,,1,,,Concentration required to inhibit A2780 cell growth when compared with control after incubation for 96 hr at 37 C,N,,478.0,81034,1,,CHEMBL622416,BAO_0000219,
7104,Intermediate,9606.0,,1,,,"MDR-reversing activity was measured by vincristine accumulation in the multidrug resistant 2780AD, a subline of A2780 ovarian carcinoma cells at 10 mg/mL",N,,478.0,81034,1,,CHEMBL622417,BAO_0000219,
7105,Expert,9606.0,,1,,,50% growth inhibition of A2780 (Human ovarian carcinoma) cell line compared with untreated control cells,N,,478.0,81034,1,,CHEMBL622590,BAO_0000219,
7106,Expert,9606.0,,1,,,Antiproliferative activity against human A2780 cells,N,,478.0,81034,1,,CHEMBL622591,BAO_0000219,
7107,Expert,9606.0,,1,,,Inhibition of human A2780 cell proliferation,N,,478.0,81034,1,,CHEMBL622592,BAO_0000219,
7108,Expert,9606.0,,1,,,Antiproliferative effect against human A2780 cell line was determined in a whole cell 72 hr cytotoxicity assay,N,,478.0,81034,1,,CHEMBL622593,BAO_0000219,
7109,Expert,9606.0,,1,,,Inhibition of human A2780 cell proliferation (No data),N,,478.0,81034,1,,CHEMBL622594,BAO_0000219,
7110,Intermediate,9606.0,,1,,,Cell cytotoxicity was determined against human ovarian cancer (A2780) cell line,N,,478.0,81034,1,,CHEMBL622595,BAO_0000219,
7111,Intermediate,9606.0,,1,,,Compound was evaluated against human Ovarian carcinoma cell line A2780,N,,478.0,81034,1,,CHEMBL622596,BAO_0000219,
7112,Expert,9606.0,,1,,,Growth inhibition against A2780 wild-type ovarian cell lines,N,,478.0,81034,1,,CHEMBL622597,BAO_0000219,
7113,Intermediate,9606.0,,1,,,Compound was evaluated for growth inhibition against A2780 wild-type ovarian cell lines; No data,N,,478.0,81034,1,,CHEMBL622598,BAO_0000219,
7114,Autocuration,9606.0,,1,,,Inhibition of tubulin polymerization in human ovarian cancer cell lines,D,,,104766,5,,CHEMBL622599,BAO_0000019,
7115,Intermediate,9606.0,,1,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,N,,478.0,81034,1,,CHEMBL622600,BAO_0000219,
7116,Intermediate,9606.0,,1,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,N,,478.0,81034,1,,CHEMBL622601,BAO_0000219,
7117,Intermediate,9606.0,,1,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780,N,,478.0,81034,1,,CHEMBL622602,BAO_0000219,
7118,Intermediate,9606.0,,1,,,Compound was tested for in vitro growth inhibition of Ovarian carcinoma cell line panel A2780-R,N,,478.0,81034,1,,CHEMBL622603,BAO_0000219,
7119,Intermediate,9606.0,,1,,,Compound was tested for inhibitory activity against A2780 human ovarian carcinoma cell line; activity expressed in Mean IC50 values,N,,478.0,81034,1,,CHEMBL622604,BAO_0000219,
7120,Intermediate,9606.0,,1,,,Compound was tested for inhibitory activity against A2780cisR human ovarian carcinoma cell line; activity expressed in Mean IC50 values,N,,478.0,81034,1,,CHEMBL622605,BAO_0000219,
7121,Expert,9606.0,,1,,,In vitro inhibition of human ovarian cell line A2780,N,,478.0,81034,1,,CHEMBL622606,BAO_0000219,
7122,Expert,9606.0,,1,,,"In vitro inhibition of human ovarian cell line, resistant to cisplatin (A2780cisR).",N,,478.0,81034,1,,CHEMBL619463,BAO_0000219,
7123,Intermediate,9606.0,,1,,,Concentration of compound to inhibit the growth of human A2780 ovarian carcinoma cells(in vitro),N,,478.0,81034,1,,CHEMBL619464,BAO_0000219,
7124,Expert,9606.0,,1,,,Concentration required to inhibit A2780-cell growth by 50%,N,,478.0,81034,1,,CHEMBL619465,BAO_0000219,
7125,Expert,9606.0,,1,,,Concentration required to inhibit the cell growth by 50 % after 96 hr A2780 leukemic cells.,N,,478.0,81034,1,,CHEMBL619466,BAO_0000219,
7126,Expert,9606.0,,1,,,Cytotoxic effect on human ovarian (A2780) cancer cell line,N,,478.0,81034,1,,CHEMBL619467,BAO_0000219,
7127,Intermediate,9606.0,,1,,,Cytotoxic activity in a panel of Human ovarian tumor A2780 cell line after 96h of drug exposure,N,,478.0,81034,1,,CHEMBL619468,BAO_0000219,
7128,Expert,9606.0,,1,,,Cytotoxic potency required to inhibit A2780 cell growth by 50% after cell drug contact for 96 hrs,N,,478.0,81034,1,,CHEMBL619469,BAO_0000219,
7129,Expert,9606.0,,1,,,Cytotoxicity measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,N,,478.0,81034,1,,CHEMBL619470,BAO_0000219,
7130,Intermediate,9606.0,,1,,,Cytotoxicity activity of the compound was measured in human ovarian cell line A2780 using sulforhodamine B (SRB) assay,N,,478.0,81034,1,,CHEMBL619471,BAO_0000219,
7131,Intermediate,9606.0,,1,,,Cytotoxicity against human ovarian carcinoma A2780 cell line,N,,478.0,81034,1,,CHEMBL619472,BAO_0000219,
7132,Intermediate,9606.0,,1,,,"Cytotoxicity against A2780-C25, oxaliplatin-resistant Ovarian carcinoma cell line",N,,478.0,81034,1,,CHEMBL619473,BAO_0000219,
7133,Intermediate,9606.0,,1,,,"Cytotoxicity against A2780-CP3, cisplatin-resistant Ovarian carcinoma cell line",N,,478.0,81034,1,,CHEMBL874368,BAO_0000219,
7134,Intermediate,9606.0,,1,,,"Cytotoxicity against A2780-DX5, Doxorubicin-resistant Ovarian carcinoma cell line",N,,478.0,81034,1,,CHEMBL884003,BAO_0000219,
7135,Intermediate,9606.0,,1,,,"Cytotoxicity against A2780-WT, human ovarian carcinoma cell line",N,,478.0,81034,1,,CHEMBL622690,BAO_0000219,
7136,Intermediate,9606.0,,1,,,Cytotoxicity against ovarian carcinoma A2780 tumor cell lines,N,,478.0,81034,1,,CHEMBL622691,BAO_0000219,
7137,Intermediate,9606.0,,1,,,Dose of required to inhibit growth of cisplatin resistant human ovarian carcinoma (A2780 cisR) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,N,,478.0,81034,1,,CHEMBL622692,BAO_0000219,
7138,Intermediate,9606.0,,1,,,Dose of required to inhibit growth of human ovarian carcinoma (A2780) cell line with compound free controls as measured by the sulforhodamine B growth delay assay,N,,478.0,81034,1,,CHEMBL623406,BAO_0000219,
7139,Intermediate,9606.0,,1,,,"Growth inhibition in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant) using the 96 hour exposure sulforhodamine B (SRB) growth delay assay",N,,478.0,81034,1,,CHEMBL884004,BAO_0000219,
7140,Intermediate,9606.0,,1,,,In vitro Cytotoxic activity of compound in comparison with reference compounds in human cell line A2780,N,,478.0,81034,1,,CHEMBL623407,BAO_0000219,
7141,Intermediate,9606.0,,1,,,In vitro Growth Inhibitory activity against A2780 Human ovarian cancer cell line,N,,478.0,81034,1,,CHEMBL623408,BAO_0000219,
7142,Expert,9606.0,,1,,,In vitro antitumor activity against A2780 cell line.,N,,478.0,81034,1,,CHEMBL623409,BAO_0000219,
7143,Intermediate,9606.0,,1,,,In vitro cytotoxic activity against human tumor cell line A2780 after incubation for 96 hours,N,,478.0,81034,1,,CHEMBL623410,BAO_0000219,
7144,Expert,9606.0,,1,,,In vitro cytotoxicity against A2780 human ovarian cancer cell line,N,,478.0,81034,1,,CHEMBL623576,BAO_0000219,
7145,Intermediate,9606.0,,1,,,Inhibitory activity against kidney A-CHN tumor cell growth in culture,N,,626.0,80025,1,,CHEMBL623577,BAO_0000219,
7146,Intermediate,9606.0,,1,,,The IC50 value was measured on ACHN cell line in renal tumor type.,N,,626.0,80025,1,,CHEMBL623578,BAO_0000219,
7147,Intermediate,9606.0,,1,,,Concentration required for killing 50% of cells of renal ACHN cell lines was determined in vitro,N,,626.0,80025,1,,CHEMBL623579,BAO_0000219,
7148,Expert,9606.0,,1,,,In vitro lethal concentration against most sensitive ACHN cell line,N,,626.0,80025,1,,CHEMBL623580,BAO_0000219,
7149,Intermediate,9606.0,,1,,,Tested for cytotoxic activity against renal cancer ACHN cell line,N,,626.0,80025,1,,CHEMBL623581,BAO_0000219,
7150,Intermediate,9606.0,,1,,,Compound tested for growth inhibition of renal cancer cell line ACHN,N,,626.0,80025,1,,CHEMBL857456,BAO_0000219,
7151,Intermediate,9606.0,,1,,,Compound was tested for 50% growth inhibition against human renal cancer ACHN cell line,N,,626.0,80025,1,,CHEMBL623582,BAO_0000219,
7152,Intermediate,9606.0,,1,,,Growth inhibition of the ACHN Renal cancer cell line for 2-day in vitro assay.,N,,626.0,80025,1,,CHEMBL623583,BAO_0000219,
7153,Intermediate,9606.0,,1,,,In vitro anticancer activity against ACHN renal cancer cell line,N,,626.0,80025,1,,CHEMBL623584,BAO_0000219,
7154,Intermediate,9606.0,,1,,,In vitro antitumor activity against Renal cancer ACHN cell lines by 6-day assay,N,,626.0,80025,1,,CHEMBL623585,BAO_0000219,
7155,Intermediate,9606.0,,1,,,Percent selectivity was evaluated in renal ACHN cell lines,N,,626.0,80025,1,,CHEMBL623586,BAO_0000219,
7156,Intermediate,9606.0,,1,,,In vitro inhibitory activity against renal ACHN cancer cell line,N,,626.0,80025,1,,CHEMBL623587,BAO_0000219,
7157,Intermediate,9606.0,,1,,,Tested for cytotoxicity against ACHN cell lines in renal cancer,N,,626.0,80025,1,,CHEMBL875279,BAO_0000219,
7158,Intermediate,9606.0,,1,,,Tested for the in vitro cytotoxicity against ACHN renal cancer cell line,N,,626.0,80025,1,,CHEMBL623588,BAO_0000219,
7159,Intermediate,9606.0,,1,,,In vitro anti tumor activity against human tumor Renal cancer cell lines was determined,N,,626.0,80025,1,,CHEMBL623589,BAO_0000219,
7160,Intermediate,9606.0,,1,,,Tested in vitro for cytotoxicity in ACHN cell line of Renal cancer,N,,626.0,80025,1,,CHEMBL623590,BAO_0000219,
7161,Expert,9606.0,,1,,,Cytotoxic effect on renal cancer line ACHN,N,,626.0,80025,1,,CHEMBL623591,BAO_0000219,
7162,Intermediate,9606.0,,1,,,In vitro anti-cancer activity against ACHN(Renal) human tumor cell line,N,,626.0,80025,1,,CHEMBL623592,BAO_0000219,
7163,Intermediate,9606.0,,1,,,In vitro inhibition of Renal Cancer ACHN cell lines,N,,626.0,80025,1,,CHEMBL623593,BAO_0000219,
7164,Intermediate,9606.0,,1,,,Antitumor activity against human renal adenocarcinoma ACHN cells,N,,626.0,80025,1,,CHEMBL623594,BAO_0000219,
7165,Expert,9606.0,,1,,,Antitumor activity against human renal adenocarcinoma ACHN cells.,N,,626.0,80025,1,,CHEMBL621833,BAO_0000219,
7166,Intermediate,9606.0,,1,,,Inhibitory concentration required to decrease cell viability in cell growth culture against kidney cells ACHN,N,,626.0,80025,1,,CHEMBL621834,BAO_0000219,
7167,Intermediate,9606.0,,1,,,Compound was evaluated for in vitro activity against ACHN kidney cell lines (Human tumor cells ),N,,626.0,80025,1,,CHEMBL621835,BAO_0000219,
7168,Intermediate,9606.0,,1,,,"Cytotoxicity against NCI tumor panel, ACHN renal cancer cell line",N,,626.0,80025,1,,CHEMBL621836,BAO_0000219,
7169,Intermediate,9606.0,,1,,,Concentration of compound that cause 50% cytotoxicity of ACHN renal cancer cell line,N,,626.0,80025,1,,CHEMBL621837,BAO_0000219,
7170,Intermediate,9606.0,,1,,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration that inhibits 50% net cell growth).,N,,626.0,80025,1,,CHEMBL875280,BAO_0000219,
7171,Intermediate,9606.0,,1,,,Compound was tested for antitumor activity against ACHN renal cancer cell line(molar concentration leading to 50% net cell death).,N,,626.0,80025,1,,CHEMBL621838,BAO_0000219,
7172,Intermediate,9606.0,,1,,,Cytotoxicity was tested against renal cancer ACHN tumor cell lines.,N,,626.0,80025,1,,CHEMBL621839,BAO_0000219,
7173,Autocuration,,,1,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,U,,,22224,0,,CHEMBL621840,BAO_0000019,
7174,Autocuration,,,1,,,Compound tested for relative response using 1 uM ACh as agonist against AChM1 receptor.,H,,,10647,8,,CHEMBL621841,BAO_0000019,
7175,Expert,10358.0,,1,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV) in HEL (human erythroleukemia) cells.,N,,468.0,50529,1,,CHEMBL622979,BAO_0000218,
7176,Intermediate,10358.0,,1,,,Antiviral activity against AD169 strain of cytomegalovirus (CMV); ND=No data,N,,,50529,1,,CHEMBL876595,BAO_0000218,
7177,Autocuration,,,1,,,Compound was evaluated for its inhibitory activity against calf intestinal Adenosine deaminase (ADA),H,,,12159,8,,CHEMBL620221,BAO_0000357,
7178,Autocuration,,,1,,,Evaluated for the inhibition of calf intestinal Adenosine deaminase (ADA),H,,,12159,8,,CHEMBL620222,BAO_0000357,
7179,Intermediate,9913.0,,1,,,Inhibitory activity against ovarian tumor cell line ADDP after 72 hr continuous exposure to compound,N,,979.0,80670,1,,CHEMBL620506,BAO_0000219,
7180,Intermediate,10090.0,,1,,,Tumor growth inhibition activity after subcutaneous transplanted tumor in ADJ-PC6 plasmacytoma cells,N,,980.0,80671,1,,CHEMBL620507,BAO_0000219,
7181,Intermediate,10090.0,,1,,,Tumor growth inhibition activity after subcutaneously transplanted tumor in ADJ-PC6 plasmacytoma cells,N,,980.0,80671,1,,CHEMBL620508,BAO_0000219,
7182,Intermediate,10090.0,,1,,,"Compound was tested for dose producing 90% reduction in tumor weight, in ADJ/PC6 mouse plasma cell tumor",N,,980.0,80671,1,,CHEMBL620509,BAO_0000219,
7183,Intermediate,10090.0,,1,,,Compound was tested for inhibition against ADJ/PC6 mouse plasma cell tumor at the dose of 320 mg/Kg,N,,980.0,80671,1,,CHEMBL620510,BAO_0000219,
7184,Intermediate,10090.0,,1,,,Compound was tested for dose required to kill 50 % of ADJ/PC6 mouse plasma cell tumor in a group,N,,980.0,80671,1,,CHEMBL620511,BAO_0000219,
7185,Intermediate,10090.0,,1,,,In vitro incorporation of the [3H]thymidine into the ADJ/PC6 Plasmacytoma cells,N,,980.0,80671,1,,CHEMBL620512,BAO_0000219,
7186,Autocuration,10090.0,,1,,,Tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma,U,,,22224,0,,CHEMBL620513,BAO_0000019,
7187,Autocuration,10090.0,,1,,,The compound was tested for cytotoxicity against ADJ/PC6 mouse plasmacytoma; Not determined,U,,,22224,0,,CHEMBL620514,BAO_0000019,
7188,Autocuration,10090.0,,1,,,Tested for cytotoxicity against ADJ/PC6 plasmacytoma,U,,,22224,0,,CHEMBL620515,BAO_0000019,
7189,Autocuration,1423.0,In vivo,1,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),U,,,22224,0,,CHEMBL620516,BAO_0000218,
7190,Intermediate,9615.0,,1,1969.0,,AUC value in dog after IV administration at a dose of 5 mg/kg,N,,,50588,1,,CHEMBL620517,BAO_0000218,
7191,Intermediate,9615.0,,1,1969.0,,AUC value in dog after oral administration at a dose of 5 mg/kg,N,,,50588,1,,CHEMBL620518,BAO_0000218,
7192,Intermediate,9615.0,In vivo,1,,,Cmax value in dog after oral administration at a dose of 5 mg/kg,N,,,50588,1,,CHEMBL620519,BAO_0000218,
7193,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog after oral administration at a dose of 5 mg/kg,N,,,50588,1,,CHEMBL621386,BAO_0000218,
7194,Intermediate,9615.0,In vivo,1,,,Tmax value in dog after oral administration at a dose of 5 mg/kg,N,,,50588,1,,CHEMBL621387,BAO_0000218,
7195,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for its clearance when administered intravenously in dog,N,,,50588,1,,CHEMBL621388,BAO_0000218,
7196,Intermediate,9615.0,In vivo,1,,,Plasma clearance in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,,,50588,1,,CHEMBL621389,BAO_0000218,
7197,Intermediate,9615.0,In vivo,1,,,Plasma clearance was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),N,,,50588,1,,CHEMBL621390,BAO_0000218,
7198,Intermediate,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL621391,BAO_0000100,
7199,Intermediate,9615.0,,1,,,Half life in dog,N,,,50588,1,,CHEMBL621392,BAO_0000218,
7200,Intermediate,9615.0,,1,,,Time taken for EC90 was determined when tested in dog,N,,,50588,1,,CHEMBL621393,BAO_0000218,
7201,Intermediate,9615.0,,1,,,Half life (iv) was determined,N,,,50588,1,,CHEMBL621394,BAO_0000218,
7202,Intermediate,9615.0,,1,2107.0,,Loss of compound (%metabolized) after 30 min exposure to human liver microsomes,N,,,50588,1,,CHEMBL621395,BAO_0000218,
7203,Intermediate,9615.0,,1,,,Area under the curve was calculated in dog after iv administration,N,,,50588,1,,CHEMBL621396,BAO_0000218,
7204,Intermediate,9615.0,,1,,,Area under the curve was calculated in dog after peroral administration,N,,,50588,1,,CHEMBL621397,BAO_0000218,
7205,Intermediate,9615.0,,1,,,Dose-normalized area under curve in dog (p.o.) at 2.0 mpk,N,,,50588,1,,CHEMBL621398,BAO_0000218,
7206,Intermediate,9615.0,,1,,,pKa was evaluated in dog,N,,,50588,1,,CHEMBL618818,BAO_0000218,
7207,Intermediate,9615.0,,1,,,Compound was evaluated for pronounced GH response at 100 mg (n=6)(area under concentration curve was determined from 0-8 hr following morning and evening dosing with 25 mg of the compound,N,,,50588,1,,CHEMBL618819,BAO_0000218,
7208,Intermediate,9615.0,In vivo,1,,,Alpha-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,,,50588,1,,CHEMBL618820,BAO_0000218,
7209,Intermediate,9615.0,In vivo,1,,,Beta-elimination half-life in Beagle dogs after intravenous administration at a dose of 10 mg/kg,N,,,50588,1,,CHEMBL873810,BAO_0000218,
7210,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for half-life period in dogs at a dose of 5 mpk perorally,N,,,50588,1,,CHEMBL876606,BAO_0000218,
7211,Intermediate,9615.0,,1,,,Compound was evaluated for the half-life (t 1/2) in hours,N,,,50588,1,,CHEMBL618821,BAO_0000218,
7212,Intermediate,9615.0,In vivo,1,178.0,,Half life to reach the blood concentration was determined in dogs after oral administration (10 mg/kg) as a 0.05 M citric acid solution.,N,,,50588,1,,CHEMBL618822,BAO_0000218,
7213,Intermediate,9615.0,In vivo,1,178.0,,Half life to reach the blood concentration was determined in dogs after oral administration (8 mg/kg) as a 0.05 M citric acid solution.,N,,,50588,1,,CHEMBL618823,BAO_0000218,
7214,Intermediate,9615.0,In vivo,1,,,Half life after intravenous administration of 1 mg/kg in dog,N,,,50588,1,,CHEMBL618824,BAO_0000218,
7215,Intermediate,9615.0,,1,,,Half life was measured in dog,N,,,50588,1,,CHEMBL618825,BAO_0000218,
7216,Intermediate,9615.0,In vivo,1,,,Half life period in dog after 5 mg/kg dose,N,,,50588,1,,CHEMBL618826,BAO_0000218,
7217,Intermediate,9615.0,,1,,,Half life period was evaluated in dog; 4-4.8,N,,,50588,1,,CHEMBL618827,BAO_0000218,
7218,Intermediate,9615.0,In vivo,1,,,Half life was determined in dog after 1 mg/kg (i.v.) and 5 mg/kg (p.o.) administration,N,,,50588,1,,CHEMBL618828,BAO_0000218,
7219,Intermediate,9615.0,In vivo,1,,,Half-life was determined in dog after a3 mg/kg of iv dose,N,,,50588,1,,CHEMBL618829,BAO_0000218,
7220,Intermediate,9615.0,,1,,,Half-life was determined,N,,,50588,1,,CHEMBL618830,BAO_0000218,
7221,Intermediate,9615.0,,1,,,Half life in dogs,N,,,50588,1,,CHEMBL618831,BAO_0000218,
7222,Intermediate,9615.0,In vivo,1,1969.0,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 2 mg/kg tp dog,N,,,50588,1,,CHEMBL619489,BAO_0000218,
7223,Intermediate,9615.0,In vivo,1,,,Apparent half-life after single intravenous bolus of 1 mg/kg in dogs,N,,,50588,1,,CHEMBL619649,BAO_0000218,
7224,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for the half life period after iv administration in Beagle dog.,N,,,50588,1,,CHEMBL876607,BAO_0000218,
7225,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for the half life period after oral administration in conscious dog.,N,,,50588,1,,CHEMBL619650,BAO_0000218,
7226,Intermediate,9615.0,,1,,,Compound was tested for half life in dog,N,,,50588,1,,CHEMBL619651,BAO_0000218,
7227,Intermediate,9615.0,,1,,,Compound was tested for its half life in dog,N,,,50588,1,,CHEMBL619652,BAO_0000218,
7228,Intermediate,9615.0,In vivo,1,,,Half life of compound after both po and iv administration at a dose of 5 mg/kg and 2 mg/kg resp in dog,N,,,50588,1,,CHEMBL619653,BAO_0000218,
7229,Intermediate,9615.0,,1,,,Half life of compound in dog was determined,N,,,50588,1,,CHEMBL619654,BAO_0000218,
7230,Intermediate,9615.0,In vivo,1,,,Half life (iv) was determined,N,,,50588,1,,CHEMBL619655,BAO_0000218,
7231,Intermediate,9615.0,,1,178.0,,Half life following administration of 70 nM in canine whole blood (dose exceeding platelet binding capacity),N,,,50588,1,,CHEMBL619656,BAO_0000218,
7232,Intermediate,9615.0,In vivo,1,1969.0,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,N,,,50588,1,,CHEMBL873812,BAO_0000218,
7233,Intermediate,9615.0,In vivo,1,1969.0,,Half life in Dog plasma at a dosage 5 mg/kg after intravenous administration,N,,,50588,1,,CHEMBL621365,BAO_0000218,
7234,Intermediate,9615.0,,1,,,Half life in dog,N,,,50588,1,,CHEMBL621366,BAO_0000218,
7235,Intermediate,9615.0,,1,1969.0,,Half life in dog plasma,N,,,50588,1,,CHEMBL621367,BAO_0000218,
7236,Intermediate,9615.0,In vivo,1,1969.0,,Half life in dog plasma after administration of 0.25 mg/kg iv,N,,,50588,1,,CHEMBL621368,BAO_0000218,
7237,Intermediate,9615.0,In vivo,1,1969.0,,Half life in dog plasma after administration of 1 mg/kg iv,N,,,50588,1,,CHEMBL621369,BAO_0000218,
7238,Intermediate,9615.0,In vivo,1,1969.0,,Half life in dog plasma was determined at dose 10 mg/kg,N,,,50588,1,,CHEMBL621370,BAO_0000218,
7239,Intermediate,9615.0,,1,,,Half life in dog was determined,N,,,50588,1,,CHEMBL621371,BAO_0000218,
7240,Intermediate,9615.0,In vivo,1,,,Half life in dogs administered perorally (5 mg/kg) and intravenously (2 mg/kg),N,,,50588,1,,CHEMBL621372,BAO_0000218,
7241,Intermediate,9615.0,,1,1969.0,,Half life upon exposure to human plasma,N,,,50588,1,,CHEMBL621373,BAO_0000218,
7242,Intermediate,9615.0,,1,,,Half life was calculated in dog,N,,,50588,1,,CHEMBL621374,BAO_0000218,
7243,Intermediate,9615.0,,1,,,Half life was determined,N,,,50588,1,,CHEMBL621375,BAO_0000218,
7244,Intermediate,9615.0,,1,,,Half life was determined,N,,,50588,1,,CHEMBL621376,BAO_0000218,
7245,Intermediate,9615.0,In vivo,1,,,Half life by intravenous administration of 1.2 mg/kg in dog,N,,,50588,1,,CHEMBL619624,BAO_0000218,
7246,Intermediate,9615.0,,1,,,Half life in dog,N,,,50588,1,,CHEMBL875840,BAO_0000218,
7247,Intermediate,9615.0,,1,,,Half life in dog after intra venous administration of the compound,N,,,50588,1,,CHEMBL619625,BAO_0000218,
7248,Intermediate,9615.0,,1,,,Half life in dog after intra venous administration of the compound; ND means Not determined,N,,,50588,1,,CHEMBL619626,BAO_0000218,
7249,Intermediate,9615.0,In vivo,1,,,Half life in dog after po administration of the compound,N,,,50588,1,,CHEMBL619627,BAO_0000218,
7250,Intermediate,9615.0,In vivo,1,,,Half life in dog after po administration of the compound; ND means Not determined,N,,,50588,1,,CHEMBL873817,BAO_0000218,
7251,Intermediate,9615.0,In vivo,1,,,Half life in dog at the single oral dose of 1 mg/kg,N,,,50588,1,,CHEMBL619628,BAO_0000218,
7252,Intermediate,9615.0,,1,,,Half life in dogs,N,,,50588,1,,CHEMBL619629,BAO_0000218,
7253,Intermediate,9615.0,In vivo,1,,,Half life in dogs at 1 mg/kg oral dosing; 35-100 min,N,,,50588,1,,CHEMBL619630,BAO_0000218,
7254,Intermediate,9615.0,,1,,,Half life in rat,N,,,50588,1,,CHEMBL619631,BAO_0000218,
7255,Intermediate,9615.0,In vivo,1,,,Half life in dog (dosed as a mixture of five compounds at 0.5 mpk each via iv only),N,,,50588,1,,CHEMBL619632,BAO_0000218,
7256,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,,50594,1,,CHEMBL619633,BAO_0000218,
7257,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,,50594,1,,CHEMBL875841,BAO_0000218,
7258,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,,50594,1,,CHEMBL619634,BAO_0000218,
7259,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,,50594,1,,CHEMBL619635,BAO_0000218,
7260,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution of intravenously injected [82Br]-labeled compound in bone of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,,50594,1,,CHEMBL619636,BAO_0000218,
7261,Intermediate,10090.0,In vivo,1,10000004.0,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,,50594,1,,CHEMBL619637,BAO_0000218,
7262,Intermediate,10090.0,In vivo,1,10000004.0,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,,50594,1,,CHEMBL619638,BAO_0000218,
7263,Intermediate,10090.0,In vivo,1,10000004.0,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,,50594,1,,CHEMBL619639,BAO_0000218,
7264,Intermediate,10090.0,In vivo,1,10000004.0,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,,50594,1,,CHEMBL619640,BAO_0000218,
7265,Intermediate,10090.0,In vivo,1,10000004.0,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,,50594,1,,CHEMBL619641,BAO_0000218,
7266,Intermediate,10090.0,In vivo,1,10000004.0,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,,50594,1,,CHEMBL619642,BAO_0000218,
7267,Intermediate,10090.0,In vivo,1,10000004.0,,Biodistribution of intravenously injected [82Br]-labeled compound in gut of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,,50594,1,,CHEMBL619643,BAO_0000218,
7268,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,,50594,1,,CHEMBL619644,BAO_0000218,
7269,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,,50594,1,,CHEMBL621112,BAO_0000218,
7270,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,,50594,1,,CHEMBL621113,BAO_0000218,
7271,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,,50594,1,,CHEMBL621114,BAO_0000218,
7272,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,,50594,1,,CHEMBL621115,BAO_0000218,
7273,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,,50594,1,,CHEMBL621116,BAO_0000218,
7274,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of intravenously injected [82Br]-labeled compound in heart of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,,50594,1,,CHEMBL621117,BAO_0000218,
7275,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,,50594,1,,CHEMBL621118,BAO_0000218,
7276,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,,,50594,1,,CHEMBL621119,BAO_0000218,
7277,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,,50594,1,,CHEMBL621120,BAO_0000218,
7278,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,,50594,1,,CHEMBL621757,BAO_0000218,
7279,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,,50594,1,,CHEMBL621758,BAO_0000218,
7280,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,,50594,1,,CHEMBL621759,BAO_0000218,
7281,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of intravenously injected [82Br]-labeled compound in kidney of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,,50594,1,,CHEMBL621760,BAO_0000218,
7282,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,,50594,1,,CHEMBL621761,BAO_0000218,
7283,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,,50594,1,,CHEMBL621762,BAO_0000218,
7284,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,,50594,1,,CHEMBL621763,BAO_0000218,
7285,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,,50594,1,,CHEMBL624502,BAO_0000218,
7286,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,,50594,1,,CHEMBL624503,BAO_0000218,
7287,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,,50594,1,,CHEMBL624504,BAO_0000218,
7288,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of intravenously injected [82Br]-labeled compound in liver of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,,50594,1,,CHEMBL624505,BAO_0000218,
7289,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,,50594,1,,CHEMBL624506,BAO_0000218,
7290,Intermediate,9606.0,,1,,,In vitro cytotoxicity against A2780 (human ovarian cancer),N,,478.0,81034,1,,CHEMBL624507,BAO_0000219,
7291,Intermediate,9606.0,,1,,,In vitro cytotoxicity against the paclitaxel sensitive human breast carcinoma cell line A2780,N,,478.0,81034,1,,CHEMBL624508,BAO_0000219,
7292,Intermediate,9606.0,,1,,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780.,N,,478.0,81034,1,,CHEMBL624509,BAO_0000219,
7293,Intermediate,9606.0,,1,,,In vitro cytotoxicity against. ovarian carcinoma cell line A2780cisR (cisplatin resistant counter part of A2780).,N,,478.0,81034,1,,CHEMBL624510,BAO_0000219,
7294,Expert,9606.0,,1,,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cell line,N,,478.0,81034,1,,CHEMBL875956,BAO_0000219,
7295,Expert,9606.0,,1,,,In vitro cytotoxicity was tested against human Ovarian carcinoma A2780 cisplatin resistant cell line,N,,478.0,81034,1,,CHEMBL839885,BAO_0000219,
7296,Expert,9606.0,,1,,,In vitro cytotoxicity against A2780 ovarian cells using the sulforhodamine B(SRB) assay.,N,,478.0,81034,1,,CHEMBL624511,BAO_0000219,
7297,Intermediate,9606.0,,1,,,In vitro cytotoxicity against A2780 cell line,N,,478.0,81034,1,,CHEMBL624512,BAO_0000219,
7298,Intermediate,9606.0,,1,,,In vitro growth inhibitory activity against A2780 human ovarium carcinoma cell line was determined,N,,478.0,81034,1,,CHEMBL624513,BAO_0000219,
7299,Intermediate,9606.0,,1,,,In vitro inhibitory activity against human ovarian cancer A2780 cell line,N,,478.0,81034,1,,CHEMBL624514,BAO_0000219,
7300,Intermediate,9606.0,,1,,,In vivo cytotoxic concentration of compound against A2780 cell line after 72 hr exposure,N,,478.0,81034,1,,CHEMBL618547,BAO_0000218,
7301,Intermediate,9606.0,,1,,,"Inhibition of cell growth in human ovarian carcinoma cell line (A2780cisR,cisplatin-resistant)using the 96 hour continuous exposure sulforhodamine B (SRB) growth delay assay",N,,478.0,81034,1,,CHEMBL618548,BAO_0000219,
7302,Intermediate,9606.0,,1,,,Inhibition of tubulin polymerization in analogy of ca.,N,,478.0,81034,1,,CHEMBL618549,BAO_0000219,
7303,Intermediate,9606.0,,1,,,Inhibitory activity against ovarian tumor cell line A2780 after 72 hr continuous exposure to compound,N,,478.0,81034,1,,CHEMBL618550,BAO_0000219,
7304,Expert,9606.0,,1,,,Cytotoxic effect in ovarian cancer cell line (A2780),N,,478.0,81034,1,,CHEMBL618551,BAO_0000219,
7305,Intermediate,9606.0,,1,,,Tested for cytotoxicity against Ovarian carcinoma parental type A2780 cell line expressing MDR-1 (-) gene,N,,478.0,81034,1,,CHEMBL618552,BAO_0000219,
7306,Intermediate,9606.0,,1,,,Tested for the cytotoxicity in A2780 ovarian cell line,N,,478.0,81034,1,,CHEMBL618553,BAO_0000219,
7307,Intermediate,9606.0,,1,,,The compound was tested for cytotoxic activity against A2780 cell line(human ovarian carcinoma ),N,,478.0,81034,1,,CHEMBL618554,BAO_0000219,
7308,Intermediate,9606.0,,1,,,The compound was tested for cytotoxic activity against A2780/Cs cell line(human ovarian carcinoma,N,,478.0,81034,1,,CHEMBL618555,BAO_0000219,
7309,Intermediate,,,1,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma,N,,481.0,80017,1,,CHEMBL618556,BAO_0000219,
7310,Intermediate,,,1,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ),N,,481.0,80017,1,,CHEMBL618557,BAO_0000219,
7311,Intermediate,,,1,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma ); ND means no data,N,,481.0,80017,1,,CHEMBL618558,BAO_0000219,
7312,Intermediate,,,1,,,The compound was tested for cytotoxic activity against A2780cisR cell line(human ovarian carcinoma),N,,481.0,80017,1,,CHEMBL618559,BAO_0000219,
7313,Intermediate,9606.0,,1,,,In vivo log of cells killed after administration of compound in A2780 cell line,N,,478.0,81034,1,,CHEMBL618560,BAO_0000218,
7314,Intermediate,9606.0,In vivo,1,,,Compound was tested in vivo for maximum tolerated dose after i.v. administration twice a day for 5 days in A2780 cell line,N,,478.0,81034,1,,CHEMBL618561,BAO_0000218,
7315,Intermediate,9606.0,,1,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.;NA means not active,N,,478.0,81034,1,,CHEMBL618562,BAO_0000219,
7316,Intermediate,9606.0,,1,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines (at 5 uM );NA means not active,N,,478.0,81034,1,,CHEMBL618563,BAO_0000219,
7317,Intermediate,9606.0,,1,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines; ND means no data,N,,478.0,81034,1,,CHEMBL618564,BAO_0000219,
7318,Intermediate,9606.0,,1,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell lines. (at 5 uM ); ND means no data,N,,478.0,81034,1,,CHEMBL618565,BAO_0000219,
7319,Intermediate,9606.0,,1,,,Optimal dose required to inhibit human ovarian A2780 tumor growth after subcutaneous transplantation on athymic mice at 10 mg/kg (treatment schedule: q4dX2),N,,478.0,81034,1,,CHEMBL618566,BAO_0000218,
7320,Intermediate,9606.0,,1,,,Resistance factor was determined as IC50 cisplatin-resistant/parent for human A2780 ovarian cell line,N,,478.0,81034,1,,CHEMBL618567,BAO_0000219,
7321,Expert,9606.0,,1,,,Resistance index is IC50 ratio of A2780 cell line and A2780cisR cell line,N,,478.0,81034,1,,CHEMBL618568,BAO_0000219,
7322,Expert,9606.0,,1,,,Percentage tumor growth inhibition was calculated in respect to controls one week after the end of the treatment,N,,478.0,81034,1,,CHEMBL618569,BAO_0000219,
7323,Intermediate,9606.0,,1,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian cancer cell lines.,N,,478.0,81034,1,,CHEMBL621857,BAO_0000219,
7324,Intermediate,9606.0,,1,,,Compound was tested for Tubulin polymerization inhibition by using human ovarian carcinoma cell lines.,N,,478.0,81034,1,,CHEMBL621858,BAO_0000219,
7325,Intermediate,9606.0,,1,,,Percent of Tubulin polymerization inhibition by using human ovarian cancer cell lines at a concentration of 5 uM,N,,478.0,81034,1,,CHEMBL621859,BAO_0000219,
7326,Intermediate,9606.0,,1,,,"Colchicine Binding Inhibition ( CBI ) by using human ovarian cancer cell lines at 5 uM, (values are mean of 9 over 4 concentrations +/- SD)",N,,478.0,81034,1,,CHEMBL621860,BAO_0000219,
7327,Intermediate,9606.0,,1,,,Compound tested for colchicine Binding Inhibition by using human ovarian cancer cell line (at 5 uM ),N,,478.0,81034,1,,CHEMBL621861,BAO_0000219,
7328,Expert,9606.0,,1,,,"Tested for colchicine binding inhibition, using human ovarian cancer cell lines (at 5 uM )",N,,478.0,81034,1,,CHEMBL621862,BAO_0000219,
7329,Intermediate,9606.0,,1,,,Compound tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),N,,478.0,81034,1,,CHEMBL621863,BAO_0000219,
7330,Intermediate,9606.0,,1,,,Compound was tested for colchicine Binding Inhibition by using human ovarian carcinoma cell line (at 5 uM ),N,,478.0,81034,1,,CHEMBL621864,BAO_0000219,
7331,Intermediate,9606.0,,1,,,Compound was tested for colchicine binding inhibition by using human ovarian carcinoma cell line (at 5 uM ),N,,478.0,81034,1,,CHEMBL621865,BAO_0000219,
7332,Intermediate,10090.0,,1,,,In vitro antiproliferative activity against A2780 cell line,N,,478.0,81034,1,,CHEMBL621866,BAO_0000219,
7333,Expert,10090.0,,1,,,Maximum tolerated dose in A2780 tumor in mice after intraperitoneal administration daily for 8 days,N,,478.0,81034,1,,CHEMBL621867,BAO_0000219,
7334,Intermediate,9606.0,,1,,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C after 96 hr,N,,478.0,81034,1,,CHEMBL621868,BAO_0000219,
7335,Intermediate,9606.0,,1,,,In vitro cytotoxicity of compound was determined against A2780 cell lines at 37 degree C for 96 hr,N,,478.0,81034,1,,CHEMBL875282,BAO_0000219,
7336,Intermediate,9615.0,,1,,,Vc value in dog after IV administration at a dose of 5 mg/kg,N,,,50588,1,,CHEMBL621869,BAO_0000218,
7337,Intermediate,9615.0,In vivo,1,,,Half life period in dog after IV administration at a dose of 5 mg/kg,N,,,50588,1,,CHEMBL621870,BAO_0000218,
7338,Autocuration,9527.0,,1,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,U,,,22224,0,,CHEMBL621871,BAO_0000019,
7339,Autocuration,9527.0,,1,1969.0,,AUC (area under curve) evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,,22224,0,,CHEMBL621243,BAO_0000218,
7340,Autocuration,9527.0,,1,1969.0,,AUC (area under curve) compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,,22224,0,,CHEMBL621244,BAO_0000218,
7341,Autocuration,9541.0,In vivo,1,,,Area under curve determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,U,,,22224,0,,CHEMBL621245,BAO_0000218,
7342,Autocuration,9541.0,In vivo,1,,,Area under curve determined after peroral administration at a dose of 10 mg/kg in cynomolgus monkey,U,,,22224,0,,CHEMBL621246,BAO_0000218,
7343,Autocuration,9541.0,In vivo,1,,,Area under curve determined after peroral administration at a dose of 3 mg/kg in cynomolgus monkey,U,,,22224,0,,CHEMBL621247,BAO_0000218,
7344,Autocuration,10116.0,In vivo,1,,,Oral Bioavailability in rat,U,,,22224,0,,CHEMBL618386,BAO_0000218,
7345,Autocuration,9527.0,,1,,,Area under curve was evaluated against Cynomolgus monkey at a dose of 15 mg/kg after po administration,U,,,22224,0,,CHEMBL618387,BAO_0000218,
7346,Autocuration,9527.0,,1,,,Area under curve value in monkey at a dose of 5 mg/kg,U,,,22224,0,,CHEMBL618388,BAO_0000218,
7347,Autocuration,9527.0,,1,,,Area under curve was determined in monkey after a 3 mg/kg of oral dose,U,,,22224,0,,CHEMBL618389,BAO_0000218,
7348,Autocuration,9527.0,,1,,,Area under curve was determined using trapezoidal rule after intravenous administration in cynomolgus monkeys,U,,,22224,0,,CHEMBL618574,BAO_0000019,
7349,Autocuration,9527.0,,1,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys,U,,,22224,0,,CHEMBL618575,BAO_0000019,
7350,Autocuration,9527.0,,1,,,Area under curve was determined using trapezoidal rule after oral administration in cynomolgus monkeys; ND means Not determined,U,,,22224,0,,CHEMBL618576,BAO_0000019,
7351,Autocuration,9527.0,,1,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in monkey,U,,,22224,0,,CHEMBL618577,BAO_0000218,
7352,Autocuration,9527.0,,1,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in monkey,U,,,22224,0,,CHEMBL876487,BAO_0000218,
7353,Autocuration,9527.0,,1,,,Area under the curve was measured in monkey after an iv dose of 1 mg/kg,U,,,22224,0,,CHEMBL618578,BAO_0000218,
7354,Autocuration,9527.0,,1,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,,,22224,0,,CHEMBL618579,BAO_0000218,
7355,Autocuration,9527.0,,1,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,,,22224,0,,CHEMBL618580,BAO_0000019,
7356,Autocuration,9527.0,,1,,,Pharmacokinetic parameter Cmax was measured after administration into monkey at 3 mg/kg,U,,,22224,0,,CHEMBL618581,BAO_0000218,
7357,Autocuration,9527.0,,1,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in cynomolgus monkeys (0 to 24 hr) p.o.,U,,,22224,0,,CHEMBL618582,BAO_0000218,
7358,Autocuration,9527.0,,1,,,Area under curve value 24 hr after 2 mg/kg iv administration in monkeys,U,,,22224,0,,CHEMBL618583,BAO_0000218,
7359,Autocuration,9527.0,,1,,,Area under curve value 24 hr after 2 mg/kg oral administration in monkeys,U,,,22224,0,,CHEMBL618584,BAO_0000218,
7360,Autocuration,9527.0,In vivo,1,,,Oral AUCN in monkey (dosed at 0.5 mpk iv ),U,,,22224,0,,CHEMBL618585,BAO_0000218,
7361,Autocuration,9527.0,,1,,,Bioavailability was reported in cynomolgus monkeys (ratio of AUC in oral administration to that of intravenous administration),U,,,22224,0,,CHEMBL618586,BAO_0000218,
7362,Autocuration,9527.0,In vivo,1,,,Half life compared to Cilastatin evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,,22224,0,,CHEMBL618587,BAO_0000218,
7363,Autocuration,9527.0,In vivo,1,,,Half life evaluated in Rhesus monkeys at the dose of 10 mg/kg by iv bolus injection,U,,,22224,0,,CHEMBL618588,BAO_0000218,
7364,Autocuration,9527.0,,1,,,Binding towards monkey plasma protein at 10 uM,U,,,22224,0,,CHEMBL618589,BAO_0000019,
7365,Autocuration,9527.0,,1,,,Binding towards monkey plasma protein at 100 uM,U,,,22224,0,,CHEMBL618590,BAO_0000019,
7366,Autocuration,9527.0,In vivo,1,,,Apparent bioavailability in squirrel monkey was determined,U,,,22224,0,,CHEMBL872262,BAO_0000218,
7367,Autocuration,9527.0,In vivo,1,,,Bioavailability was determined after oral administration of compound 18 at a dose of 1 mg/kg to rhesus monkey,U,,,22224,0,,CHEMBL618591,BAO_0000218,
7368,Autocuration,9443.0,In vivo,1,,,Bioavailability in monkey (dose 2 mg/kg),U,,,22224,0,,CHEMBL618592,BAO_0000218,
7369,Autocuration,9527.0,In vivo,1,,,Compound at a dose 3 mg/kg was administered to monkey and was evaluated for bioavailability after administration into monkey at 3 mg/kg,U,,,22224,0,,CHEMBL876488,BAO_0000218,
7370,Autocuration,9527.0,In vivo,1,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female cynomolgus monkey,U,,,22224,0,,CHEMBL618593,BAO_0000218,
7371,Autocuration,9443.0,In vivo,1,,,Bioavailability in monkey (i.d. dosing),U,,,22224,0,,CHEMBL618594,BAO_0000218,
7372,Autocuration,9527.0,In vivo,1,,,Oral bioavailability after 5 mg/kg in cynomolgus monkey was determined,U,,,22224,0,,CHEMBL618595,BAO_0000218,
7373,Autocuration,9527.0,,1,,,Clearance of the drug was measured in cynomolgus,U,,,22224,0,,CHEMBL621469,BAO_0000019,
7374,Autocuration,9527.0,In vivo,1,,,Clearance was estimated in two squirrel monkeys after iv administration at 5 mg/kg,U,,,22224,0,,CHEMBL621470,BAO_0000218,
7375,Autocuration,9527.0,In vivo,1,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female cynomolgus monkey,U,,,22224,0,,CHEMBL621471,BAO_0000218,
7376,Autocuration,9544.0,In vivo,1,1969.0,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,,,22224,0,,CHEMBL621472,BAO_0000218,
7377,Autocuration,9527.0,In vivo,1,,,Plasma clearance in rhesus monkey was determined,U,,,22224,0,,CHEMBL621473,BAO_0000218,
7378,Autocuration,9527.0,In vivo,1,,,Plasma clearance in monkey after administration of 1 mg/kg iv,U,,,22224,0,,CHEMBL621474,BAO_0000218,
7379,Autocuration,9527.0,In vivo,1,,,Plasma clearance in cynomolgus monkey,U,,,22224,0,,CHEMBL621475,BAO_0000218,
7380,Autocuration,9527.0,In vivo,1,,,Plasma clearance after oral administration (2.5 mg/kg) in monkey was determined,U,,,22224,0,,CHEMBL621476,BAO_0000218,
7381,Autocuration,9527.0,In vivo,1,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,U,,,22224,0,,CHEMBL624290,BAO_0000218,
7382,Autocuration,9527.0,In vivo,1,,,The total clearance was determined after intravenous administration in cynomolgus monkeys,U,,,22224,0,,CHEMBL624291,BAO_0000218,
7383,Autocuration,9527.0,In vivo,1,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means Not applicable,U,,,22224,0,,CHEMBL624292,BAO_0000218,
7384,Autocuration,9527.0,In vivo,1,,,The total clearance was determined after oral administration in cynomolgus monkeys; NA means not applicable,U,,,22224,0,,CHEMBL624293,BAO_0000218,
7385,Autocuration,9527.0,In vivo,1,,,Tested for Clearance upon iv administration to african green monkey,U,,,22224,0,,CHEMBL624294,BAO_0000218,
7386,Autocuration,9527.0,In vivo,1,,,Clearance in monkey,U,,,22224,0,,CHEMBL624295,BAO_0000218,
7387,Intermediate,9615.0,In vivo,1,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,,,50588,1,,CHEMBL624296,BAO_0000218,
7388,Intermediate,9615.0,In vivo,1,,,Half life in dog (dosed at 0.5 mpk iv and 2.0 mpk orally),N,,,50588,1,,CHEMBL624297,BAO_0000218,
7389,Intermediate,9615.0,In vivo,1,,,Half life was evaluated after intravenous administration to dogs,N,,,50588,1,,CHEMBL624298,BAO_0000218,
7390,Intermediate,9615.0,,1,,,Half life was evaluated in dog,N,,,50588,1,,CHEMBL624299,BAO_0000218,
7391,Intermediate,9615.0,,1,,,Half life was evaluated in dog,N,,,50588,1,,CHEMBL624300,BAO_0000218,
7392,Intermediate,9615.0,In vivo,1,,,Half life period (t1/2) of compound was determined after intravenous administration in average of two dogs at a dose of 1 mg/kg,N,,,50588,1,,CHEMBL624301,BAO_0000218,
7393,Intermediate,9615.0,In vivo,1,,,Half life period after intravenous administration (1 mg/kg) was determined in dog (in vivo),N,,,50588,1,,CHEMBL624302,BAO_0000218,
7394,Intermediate,9615.0,In vivo,1,,,Half life period after intravenous administration in dog,N,,,50588,1,,CHEMBL876026,BAO_0000218,
7395,Intermediate,9615.0,In vivo,1,,,Half life period after oral administration (2.5 mg/kg) in dog was determined,N,,,50588,1,,CHEMBL624303,BAO_0000218,
7396,Intermediate,9615.0,,1,,,Half life period at a dose of 1 uM/kg in dog was determined,N,,,50588,1,,CHEMBL624304,BAO_0000218,
7397,Intermediate,9615.0,In vivo,1,,,Half life period was determine after peroral administration at 10 mpk in dog,N,,,50588,1,,CHEMBL624305,BAO_0000218,
7398,Intermediate,9615.0,In vivo,1,,,Half life period was determine after peroral administration at 5 mpk in dog,N,,,50588,1,,CHEMBL624306,BAO_0000218,
7399,Intermediate,9615.0,,1,,,Half life period was determined,N,,,50588,1,,CHEMBL624307,BAO_0000218,
7400,Intermediate,9615.0,,1,,,Half life period was determined,N,,,50588,1,,CHEMBL624308,BAO_0000218,
7401,Intermediate,9615.0,In vivo,1,,,Half life period by iv administration in dog at a dose of 6 mg/kg,N,,,50588,1,,CHEMBL624309,BAO_0000218,
7402,Intermediate,9615.0,,1,,,Half life period was evaluated in dog,N,,,50588,1,,CHEMBL624310,BAO_0000218,
7403,Intermediate,9615.0,In vivo,1,,,Half life period was determined in Beagle dog at a dose of 1 mg/kg by iv administration,N,,,50588,1,,CHEMBL625003,BAO_0000218,
7404,Intermediate,9615.0,In vivo,1,,,Half life period was determined in Beagle dogs after (iv) administration of a dose of 12 (uM/kg),N,,,50588,1,,CHEMBL625004,BAO_0000218,
7405,Intermediate,9615.0,In vivo,1,,,Half life time after intravenous administration (0.5 mg/kg) was determined in dog,N,,,50588,1,,CHEMBL625005,BAO_0000218,
7406,Intermediate,9615.0,In vivo,1,,,Half-life period by oral administration at a dose of 10 uM/kg in dog was determined,N,,,50588,1,,CHEMBL873813,BAO_0000218,
7407,Intermediate,9615.0,In vivo,1,,,Half-life after oral dose of compound at 3 mg/kg in dogs,N,,,50588,1,,CHEMBL625006,BAO_0000218,
7408,Intermediate,9615.0,In vivo,1,,,Half-life of compound in dog following p.o. administration of 0.5 mg/kg,N,,,50588,1,,CHEMBL625007,BAO_0000218,
7409,Intermediate,9615.0,In vivo,1,,,Half-life of compound in dog following p.o. administration of 0.9 mg/kg,N,,,50588,1,,CHEMBL876027,BAO_0000218,
7410,Intermediate,9615.0,In vivo,1,,,Half-life of compound in dog following p.o. administration of 0.95 mg/kg,N,,,50588,1,,CHEMBL625008,BAO_0000218,
7411,Intermediate,9615.0,In vivo,1,,,Half-life of compound in dog following p.o. administration of 1 mg/kg,N,,,50588,1,,CHEMBL625009,BAO_0000218,
7412,Intermediate,9615.0,,1,1969.0,,Half-life of compound in plasma of dog was determined,N,,,50588,1,,CHEMBL625010,BAO_0000218,
7413,Intermediate,9615.0,,1,,,Half-life of compound was determined in dogs,N,,,50588,1,,CHEMBL625011,BAO_0000218,
7414,Intermediate,9615.0,In vivo,1,,,Half-life after administration of 4 mg/Kg oral dose in dog,N,,,50588,1,,CHEMBL621553,BAO_0000218,
7415,Intermediate,9615.0,In vivo,1,,,Half-life after intravenous administration of 1 mg/kg/h in dog,N,,,50588,1,,CHEMBL621554,BAO_0000218,
7416,Intermediate,9615.0,,1,,,Half-life in Dog,N,,,50588,1,,CHEMBL621555,BAO_0000218,
7417,Intermediate,9615.0,,1,,,Half-life in Dog,N,,,50588,1,,CHEMBL621556,BAO_0000218,
7418,Intermediate,9615.0,,1,,,Half-life in dog,N,,,50588,1,,CHEMBL621557,BAO_0000218,
7419,Intermediate,9615.0,In vivo,1,,,Half-life in dog after oral administration at 1 mg/kg,N,,,50588,1,,CHEMBL621558,BAO_0000218,
7420,Intermediate,9615.0,In vivo,1,,,Half-life in dog after oral administration at 1 mg/kg; nd is not determined,N,,,50588,1,,CHEMBL621559,BAO_0000218,
7421,Intermediate,9615.0,,1,,,Half-life in dogs,N,,,50588,1,,CHEMBL621560,BAO_0000218,
7422,Intermediate,9615.0,,1,,,Half-life in dogs; ND indicates not determined,N,,,50588,1,,CHEMBL876028,BAO_0000218,
7423,Intermediate,9615.0,,1,1969.0,,Half-life in plasma of dog,N,,,50588,1,,CHEMBL621561,BAO_0000218,
7424,Intermediate,9615.0,,1,1969.0,,Half-life in plasma of dog at dose of 3-10 mgkg,N,,,50588,1,,CHEMBL621562,BAO_0000218,
7425,Intermediate,9615.0,In vivo,1,,,Half-life was evaluated after i.v. administration in dog at a dose of 1 mg/kg,N,,,50588,1,,CHEMBL621563,BAO_0000218,
7426,Intermediate,9615.0,In vivo,1,,,Half-life was measured in dog after an iv dose of 1 mg/kg,N,,,50588,1,,CHEMBL621564,BAO_0000218,
7427,Intermediate,9615.0,In vivo,1,,,Half-life was measured in dogs after an oral dose of 10 uM/kg,N,,,50588,1,,CHEMBL621565,BAO_0000218,
7428,Intermediate,9615.0,In vivo,1,,,Half-life in vivo in dog by intravenous administration at a dose of 0.2 mg/kg,N,,,50588,1,,CHEMBL621566,BAO_0000218,
7429,Intermediate,9615.0,In vivo,1,,,Half-life in vivo in dog by intravenous administration at a dose of 1 mg/kg,N,,,50588,1,,CHEMBL621567,BAO_0000218,
7430,Intermediate,9615.0,In vivo,1,,,Half-life of the compound after 0.3 mg/kg po administration in dog,N,,,50588,1,,CHEMBL622978,BAO_0000218,
7431,Intermediate,9615.0,In vivo,1,,,Half-life period after intravenous administration of 0.5 mg/kg in dog was determined,N,,,50588,1,,CHEMBL873814,BAO_0000218,
7432,Intermediate,9615.0,In vivo,1,,,Half-life period after intravenous administration of 1.0 mg/kg in dog was determined,N,,,50588,1,,CHEMBL623219,BAO_0000218,
7433,Intermediate,9615.0,In vivo,1,,,Half-life period after peroral administration of 0.2 mg/kg in dog was determined,N,,,50588,1,,CHEMBL624477,BAO_0000218,
7434,Intermediate,9615.0,,1,,,t1/2 in dog,N,,,50588,1,,CHEMBL624478,BAO_0000218,
7435,Intermediate,9615.0,,1,,,Half-life period measured in dogs,N,,,50588,1,,CHEMBL624479,BAO_0000218,
7436,Intermediate,9615.0,In vivo,1,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration,N,,,50588,1,,CHEMBL624480,BAO_0000218,
7437,Intermediate,9615.0,In vivo,1,,,Half-life period in dog after 2 mg/kg by oral and 0.5 mg/kg by intravenous administration; ND is not determined,N,,,50588,1,,CHEMBL623595,BAO_0000218,
7438,Intermediate,9615.0,In vivo,1,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,,50588,1,,CHEMBL623596,BAO_0000218,
7439,Intermediate,9615.0,In vitro,1,1969.0,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in dog plasma",N,,,50588,1,,CHEMBL623597,BAO_0000218,
7440,Intermediate,9615.0,In vivo,1,,,In vivo half life period was calculated at 1 mg/kg in dog,N,,,50588,1,,CHEMBL623598,BAO_0000218,
7441,Intermediate,9615.0,In vivo,1,,,In vivo half life period was calculated at 1 mg/kg in dog; ND=Not determined,N,,,50588,1,,CHEMBL623599,BAO_0000218,
7442,Intermediate,9615.0,In vivo,1,,,Longer half-life in dog (i.v.) at 0.5 mpk,N,,,50588,1,,CHEMBL623600,BAO_0000218,
7443,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog (dose 5 uM/kg),N,,,50588,1,,CHEMBL623601,BAO_0000218,
7444,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,N,,,50588,1,,CHEMBL623602,BAO_0000218,
7445,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic data at 1 mg/kg dose given to dogs intravenously,N,,,50588,1,,CHEMBL623603,BAO_0000218,
7446,Intermediate,9615.0,In vivo,1,,,Bioavailability in dog (dose 1 mg/kg i.v.),N,,,50588,1,,CHEMBL623604,BAO_0000218,
7447,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,,,50594,1,,CHEMBL623605,BAO_0000218,
7448,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,,50594,1,,CHEMBL623606,BAO_0000218,
7449,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,,50594,1,,CHEMBL623607,BAO_0000218,
7450,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,,50594,1,,CHEMBL623608,BAO_0000218,
7451,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,,50594,1,,CHEMBL623609,BAO_0000218,
7452,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of intravenously injected [82Br]-labeled compound in lung of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,,50594,1,,CHEMBL623610,BAO_0000218,
7453,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,,50594,1,,CHEMBL623611,BAO_0000218,
7454,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.5 hours,N,,,50594,1,,CHEMBL623612,BAO_0000218,
7455,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,,50594,1,,CHEMBL623613,BAO_0000218,
7456,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,,50594,1,,CHEMBL623614,BAO_0000218,
7457,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,,50594,1,,CHEMBL623615,BAO_0000218,
7458,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,,50594,1,,CHEMBL623616,BAO_0000218,
7459,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of intravenously injected [82Br]-labeled compound in muscle of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,,50594,1,,CHEMBL623617,BAO_0000218,
7460,Intermediate,10090.0,In vivo,1,14.0,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,,50594,1,,CHEMBL875944,BAO_0000218,
7461,Intermediate,10090.0,In vivo,1,14.0,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,,50594,1,,CHEMBL623618,BAO_0000218,
7462,Intermediate,10090.0,In vivo,1,14.0,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,,50594,1,,CHEMBL623619,BAO_0000218,
7463,Intermediate,10090.0,In vivo,1,14.0,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,,50594,1,,CHEMBL623620,BAO_0000218,
7464,Intermediate,10090.0,In vivo,1,14.0,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,,50594,1,,CHEMBL623621,BAO_0000218,
7465,Intermediate,10090.0,In vivo,1,14.0,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,,50594,1,,CHEMBL623622,BAO_0000218,
7466,Intermediate,10090.0,In vivo,1,14.0,,Biodistribution of intravenously injected [82Br]-labeled compound in skin of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,,50594,1,,CHEMBL623623,BAO_0000218,
7467,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,,50594,1,,CHEMBL623624,BAO_0000218,
7468,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,,50594,1,,CHEMBL618521,BAO_0000218,
7469,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,,50594,1,,CHEMBL618522,BAO_0000218,
7470,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,,50594,1,,CHEMBL618523,BAO_0000218,
7471,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,,50594,1,,CHEMBL618524,BAO_0000218,
7472,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,,50594,1,,CHEMBL618525,BAO_0000218,
7473,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of intravenously injected [82Br]-labeled compound in spleen of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,,50594,1,,CHEMBL624586,BAO_0000218,
7474,Intermediate,10090.0,In vivo,1,945.0,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.25 hours,N,,,50594,1,,CHEMBL624587,BAO_0000218,
7475,Intermediate,10090.0,In vivo,1,945.0,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 0.50 hours,N,,,50594,1,,CHEMBL624588,BAO_0000218,
7476,Intermediate,10090.0,In vivo,1,945.0,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 1 hours,N,,,50594,1,,CHEMBL624589,BAO_0000218,
7477,Intermediate,10090.0,In vivo,1,945.0,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 2 hours,N,,,50594,1,,CHEMBL624590,BAO_0000218,
7478,Intermediate,10090.0,In vivo,1,945.0,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 24 hours,N,,,50594,1,,CHEMBL624591,BAO_0000218,
7479,Intermediate,10090.0,In vivo,1,945.0,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 4 hours,N,,,50594,1,,CHEMBL624592,BAO_0000218,
7480,Intermediate,10090.0,In vivo,1,945.0,,Biodistribution of intravenously injected [82Br]-labeled compound in stomach of BDF1 female mice bearing subcutaneous Lewis lung carcinoma after 8 hours,N,,,50594,1,,CHEMBL624593,BAO_0000218,
7481,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL624594,BAO_0000218,
7482,Intermediate,10116.0,In vivo,1,,,Tested for the bioavailability in rat,N,,,50597,1,,CHEMBL624595,BAO_0000218,
7483,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),N,,,50597,1,,CHEMBL624596,BAO_0000218,
7484,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL624597,BAO_0000218,
7485,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL624598,BAO_0000218,
7486,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 3-10 mg/kg),N,,,50597,1,,CHEMBL624599,BAO_0000218,
7487,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL875166,BAO_0000218,
7488,Intermediate,10116.0,In vivo,1,1969.0,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,,,50597,1,,CHEMBL624600,BAO_0000218,
7489,Intermediate,10116.0,In vivo,1,1969.0,,Apparent terminal elimination half-life in rat plasma after administration of 50 mg/kg dose through subcutaneous route,N,,,50597,1,,CHEMBL624601,BAO_0000218,
7490,Intermediate,10116.0,In vivo,1,,,Half life after oral administration was determined in rats at 6 mg/kg,N,,,50597,1,,CHEMBL624602,BAO_0000218,
7491,Intermediate,10116.0,,1,,,Half life was determined,N,,,50597,1,,CHEMBL624603,BAO_0000218,
7492,Intermediate,10116.0,In vivo,1,,,Half life the of compound was determined by ''Cr'' assay in rat at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL624604,BAO_0000218,
7493,Intermediate,10116.0,In vivo,1,1969.0,,Plasma half life in rat at oral dose 2.8 mg/mk body weight,N,,,50597,1,,CHEMBL624605,BAO_0000218,
7494,Intermediate,10116.0,,1,,,Half life in rats,N,,,50597,1,,CHEMBL624606,BAO_0000218,
7495,Intermediate,10116.0,In vivo,1,178.0,,Half-lives were estimated from the elimination phase of the blood conc-time curve after oral administration,N,,,50597,1,,CHEMBL624607,BAO_0000218,
7496,Intermediate,10116.0,,1,,,Hill coefficient of the compound,N,,,50597,1,,CHEMBL624608,BAO_0000218,
7497,Intermediate,10116.0,,1,178.0,,Compound was tested for percent hydrolysis in whole blood after a time interval of 0.5 min,N,,,50597,1,,CHEMBL624609,BAO_0000218,
7498,Intermediate,10116.0,,1,178.0,,Compound was tested for percent hydrolysis in whole blood after a time interval of 180.0 min,N,,,50597,1,,CHEMBL624610,BAO_0000218,
7499,Intermediate,10116.0,,1,178.0,,Compound was tested for percent hydrolysis in whole blood after a time interval of 2.0 min,N,,,50597,1,,CHEMBL624611,BAO_0000218,
7500,Intermediate,10116.0,,1,178.0,,Compound was tested for percent hydrolysis in whole blood after a time interval of 5.0 min,N,,,50597,1,,CHEMBL624612,BAO_0000218,
7501,Intermediate,10116.0,,1,178.0,,Compound was tested for percent hydrolysis in whole blood after a time interval of 60.0 min,N,,,50597,1,,CHEMBL875167,BAO_0000218,
7502,Intermediate,10116.0,,1,178.0,,Compound was tested for percent hydrolysis in whole blood after a time interval of 7.0 min,N,,,50597,1,,CHEMBL624613,BAO_0000218,
7503,Intermediate,10116.0,,1,178.0,,"Compound was tested for percent hydrolysis in whole blood, after a time interval of 15.0 min",N,,,50597,1,,CHEMBL624614,BAO_0000218,
7504,Intermediate,10116.0,,1,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,N,,,50597,1,,CHEMBL624392,BAO_0000218,
7505,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/organ,N,,,50597,1,,CHEMBL624393,BAO_0000218,
7506,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/organ,N,,,50597,1,,CHEMBL624394,BAO_0000218,
7507,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/organ,N,,,50597,1,,CHEMBL624395,BAO_0000218,
7508,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/organ,N,,,50597,1,,CHEMBL624396,BAO_0000218,
7509,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/organ,N,,,50597,1,,CHEMBL624397,BAO_0000218,
7510,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution of [123I]-label in rat thyroid was reported at 0.33 hr post injection. Value shown is %ID/organ,N,,,50597,1,,CHEMBL624398,BAO_0000218,
7511,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution of [123I]-label in rat thyroid was reported at 1 hr post injection. Value shown is %ID/organ,N,,,50597,1,,CHEMBL624399,BAO_0000218,
7512,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution of [123I]-label in rat thyroid was reported at 2 hr post injection. Value shown is %ID/organ,N,,,50597,1,,CHEMBL624400,BAO_0000218,
7513,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution of [123I]-label in rat thyroid was reported at 24 hr post injection. Value shown is %ID/organ,N,,,50597,1,,CHEMBL624401,BAO_0000218,
7514,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution of [123I]-label in rat thyroid was reported at 4 hr post injection. Value shown is %ID/organ,N,,,50597,1,,CHEMBL624402,BAO_0000218,
7515,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in normal rat blood in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL624403,BAO_0000218,
7516,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in normal rat blood in the presence of 0.01 M Gd/0.05 M lig,N,,,50597,1,,CHEMBL624404,BAO_0000218,
7517,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in normal rat blood in the presence of NAC Gd 0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL624405,BAO_0000218,
7518,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in normal rat bone in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL624406,BAO_0000218,
7519,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in normal rat bone in the presence of 0.01 M Gd/0.05 M lig,N,,,50597,1,,CHEMBL624407,BAO_0000218,
7520,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in normal rat bone in the presence of NAC Gd 0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL624408,BAO_0000218,
7521,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in normal rat heart in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL618644,BAO_0000218,
7522,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in normal rat heart in the presence of 0.01 M Gd/0.05 M lig,N,,,50597,1,,CHEMBL618645,BAO_0000218,
7523,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in normal rat heart in the presence of NAC Gd 0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL618646,BAO_0000218,
7524,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in normal rat kidney in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL618647,BAO_0000218,
7525,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in normal rat kidney in the presence of 0.01 M Gd/0.05 M lig,N,,,50597,1,,CHEMBL618648,BAO_0000218,
7526,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in normal rat kidney in the presence of NAC Gd 0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL618649,BAO_0000218,
7527,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in normal rat liver in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL618650,BAO_0000218,
7528,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in normal rat liver in the presence of 0.01 M Gd/0.05 M lig,N,,,50597,1,,CHEMBL618651,BAO_0000218,
7529,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in normal rat liver in the presence of NAC Gd 0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL876497,BAO_0000218,
7530,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in normal rat lung in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL618652,BAO_0000218,
7531,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in normal rat lung in the presence of 0.01 M Gd/0.05 M lig,N,,,50597,1,,CHEMBL618653,BAO_0000218,
7532,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in normal rat lung in the presence of NAC Gd 0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL618654,BAO_0000218,
7533,Intermediate,10116.0,,1,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats; Not tested,N,,,50597,1,,CHEMBL618655,BAO_0000218,
7534,Intermediate,10116.0,,1,,,Compound was tested for solubility in water,N,,,50597,1,,CHEMBL618656,BAO_0000218,
7535,Intermediate,,,1,,,Solubility in phosphate buffered saline (1% DMSO) at pH 6.5 (24 hr equilibration),U,,,22229,0,,CHEMBL618657,BAO_0000100,
7536,Intermediate,10116.0,,1,,,Solubility was determined,N,,,50597,1,,CHEMBL618658,BAO_0000218,
7537,Intermediate,10116.0,,1,,,solubility in water (ug/mL) at 37 degree C.,N,,,50597,1,,CHEMBL618659,BAO_0000218,
7538,Intermediate,10116.0,,1,,,First pass metabolism and metabolic bioavailability using rat hepatic microsomes,N,,,50597,1,,CHEMBL618660,BAO_0000218,
7539,Intermediate,10116.0,,1,,,In vitro stability relative to (+)-AJ76 in rat hepatocyte assay,N,,,50597,1,,CHEMBL618661,BAO_0000218,
7540,Intermediate,10116.0,,1,,,Half life in rats,N,,,50597,1,,CHEMBL873807,BAO_0000218,
7541,Intermediate,10116.0,,1,,,Half life in Dawley rat,N,,,50597,1,,CHEMBL618662,BAO_0000218,
7542,Intermediate,10116.0,In vivo,1,,,Half life period after 3 mg/kg iv administration,N,,,50597,1,,CHEMBL618663,BAO_0000218,
7543,Intermediate,10116.0,In vivo,1,,,Half life period after 3 mg/kg iv administration in rat,N,,,50597,1,,CHEMBL618664,BAO_0000218,
7544,Intermediate,10116.0,In vivo,1,,,Half life period after 3 mg/kg iv administration in the rat,N,,,50597,1,,CHEMBL618665,BAO_0000218,
7545,Intermediate,10116.0,,1,,,Half life period in female Sprague-Dawley rats,N,,,50597,1,,CHEMBL876498,BAO_0000218,
7546,Intermediate,10116.0,,1,,,Half life period in rat,N,,,50597,1,,CHEMBL618666,BAO_0000218,
7547,Intermediate,10116.0,,1,,,Half-life in rats was determined,N,,,50597,1,,CHEMBL620440,BAO_0000218,
7548,Intermediate,10116.0,,1,,,Half-life in rats with metabolic oxidation,N,,,50597,1,,CHEMBL620441,BAO_0000218,
7549,Intermediate,10116.0,,1,,,Half-life in rats,N,,,50597,1,,CHEMBL620442,BAO_0000218,
7550,Intermediate,10116.0,In vivo,1,,,T 1/2 at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,N,,,50597,1,,CHEMBL620443,BAO_0000218,
7551,Intermediate,10116.0,In vivo,1,,,T 1/2 at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,N,,,50597,1,,CHEMBL620444,BAO_0000218,
7552,Intermediate,10116.0,In vivo,1,,,T max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,N,,,50597,1,,CHEMBL620445,BAO_0000218,
7553,Intermediate,10116.0,In vivo,1,,,T max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,N,,,50597,1,,CHEMBL620446,BAO_0000218,
7554,Intermediate,10116.0,,1,1969.0,,Biological half-life measured in plasma of rat,N,,,50597,1,,CHEMBL620447,BAO_0000218,
7555,Intermediate,10116.0,,1,1969.0,,Biological half-life measured in plasma of rat; 22-25,N,,,50597,1,,CHEMBL621129,BAO_0000218,
7556,Intermediate,10116.0,,1,1969.0,,Biological half-life measured in plasma of rat; 9-16,N,,,50597,1,,CHEMBL621130,BAO_0000218,
7557,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for its half life when administered intravenously in rat,N,,,50597,1,,CHEMBL873808,BAO_0000218,
7558,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 8 h,N,,,50597,1,,CHEMBL876598,BAO_0000218,
7559,Intermediate,10116.0,In vivo,1,,,Evaluated for pharmacokinetic parameter half-life in rat at the dose 50 mg/kg,N,,,50597,1,,CHEMBL621131,BAO_0000218,
7560,Intermediate,10116.0,In vivo,1,,,Half life (T1/2) after oral administration in rat,N,,,50597,1,,CHEMBL621132,BAO_0000218,
7561,Intermediate,10116.0,In vivo,1,,,Half life of compound after iv administration of 20 mg/kg dose in rat,N,,,50597,1,,CHEMBL621133,BAO_0000218,
7562,Expert,10116.0,In vivo,1,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL621312,BAO_0000218,
7563,Intermediate,10116.0,,1,,,Half life of compound was determined in rat,N,,,50597,1,,CHEMBL621313,BAO_0000218,
7564,Intermediate,10116.0,,1,178.0,,Half life of compound was determined in rat blood,N,,,50597,1,,CHEMBL621314,BAO_0000218,
7565,Intermediate,10116.0,In vivo,1,,,Half life at 1 mg/kg was determined in rat,N,,,50597,1,,CHEMBL621315,BAO_0000218,
7566,Intermediate,10116.0,In vivo,1,,,Half life at 10 mg/kg was determined in rat,N,,,50597,1,,CHEMBL621316,BAO_0000218,
7567,Intermediate,10116.0,,1,,,Half life in rats,N,,,50597,1,,CHEMBL621317,BAO_0000218,
7568,Intermediate,10116.0,,1,,,Half life in rats in hours,N,,,50597,1,,CHEMBL621318,BAO_0000218,
7569,Intermediate,10116.0,In vivo,1,,,Half life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,N,,,50597,1,,CHEMBL621319,BAO_0000218,
7570,Intermediate,10116.0,In vivo,1,,,Half life was calculated at a single intravenous administration of 20 mg/kg in rat,N,,,50597,1,,CHEMBL621377,BAO_0000218,
7571,Intermediate,10116.0,,1,,,Half life was determined,N,,,50597,1,,CHEMBL621378,BAO_0000218,
7572,Intermediate,10116.0,In vivo,1,,,Half life after i.v. administration,N,,,50597,1,,CHEMBL876599,BAO_0000218,
7573,Intermediate,10116.0,In vivo,1,,,Half life in rat after intravenous administration at a concentration 0.5 mg/kg,N,,,50597,1,,CHEMBL621379,BAO_0000218,
7574,Intermediate,10116.0,,1,1969.0,,Half life in rat plasma,N,,,50597,1,,CHEMBL621380,BAO_0000218,
7575,Intermediate,10116.0,,1,1969.0,,Half life in rat plasma; Not detected,N,,,50597,1,,CHEMBL621381,BAO_0000218,
7576,Intermediate,10116.0,,1,,,Half life in rats,N,,,50597,1,,CHEMBL618515,BAO_0000218,
7577,Intermediate,10116.0,In vivo,1,,,Half life period of compound was determined after peroral administration,N,,,50597,1,,CHEMBL618516,BAO_0000218,
7578,Intermediate,10116.0,In vivo,1,,,Half life period of compound was determined at a dose of 3 mg/kg by intravenous administration,N,,,50597,1,,CHEMBL618517,BAO_0000218,
7579,Intermediate,10116.0,,1,,,Half life period in rat,N,,,50597,1,,CHEMBL618518,BAO_0000218,
7580,Intermediate,10116.0,In vivo,1,,,Half life period was evaluated against Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,N,,,50597,1,,CHEMBL618519,BAO_0000218,
7581,Intermediate,10116.0,In vivo,1,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,N,,,50597,1,,CHEMBL618698,BAO_0000218,
7582,Intermediate,10116.0,In vivo,1,,,Half life period was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration; Not available,N,,,50597,1,,CHEMBL618862,BAO_0000218,
7583,Intermediate,10116.0,In vivo,1,,,Half life period was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,N,,,50597,1,,CHEMBL618863,BAO_0000218,
7584,Intermediate,10116.0,In vivo,1,,,Half life period was determined for compound after intravenous administration in rats at 24 uM/kg,N,,,50597,1,,CHEMBL618864,BAO_0000218,
7585,Intermediate,10116.0,In vivo,1,,,Half life time in rat the dose of 2 mg/kg,N,,,50597,1,,CHEMBL618865,BAO_0000218,
7586,Intermediate,10116.0,In vivo,1,,,Half-life 24 hr after 10 mg/kg iv administration in rats,N,,,50597,1,,CHEMBL618866,BAO_0000218,
7587,Intermediate,10116.0,In vivo,1,,,Half-life 24 hr after 2 mg/kg iv administration in rats,N,,,50597,1,,CHEMBL618867,BAO_0000218,
7588,Intermediate,10116.0,,1,,,Half-life consistent with the observed metabolic steady state in rats,N,,,50597,1,,CHEMBL875828,BAO_0000218,
7589,Intermediate,10116.0,In vivo,1,,,Half-life following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,N,,,50597,1,,CHEMBL618868,BAO_0000218,
7590,Intermediate,10116.0,,1,,,Half-life for oxidative metabolic stability was determined using male human,N,,,50597,1,,CHEMBL618869,BAO_0000218,
7591,Intermediate,10116.0,In vivo,1,,,"Half-life in fischer rats at 5 mg/kg dose, administered intravenously",N,,,50597,1,,CHEMBL618870,BAO_0000218,
7592,Intermediate,10116.0,,1,1969.0,,Half-life in rat plasma,N,,,50597,1,,CHEMBL618871,BAO_0000218,
7593,Intermediate,10116.0,,1,1969.0,,Half-life in rat plasma was determined,N,,,50597,1,,CHEMBL618872,BAO_0000218,
7594,Intermediate,10116.0,,1,,,Half-life in rats was determined,N,,,50597,1,,CHEMBL873816,BAO_0000218,
7595,Autocuration,,,1,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by gavage method in dog,U,,,22224,0,,CHEMBL618873,BAO_0000218,
7596,Autocuration,,,1,,,Area under curve after oral dose of 0.1 mg//kg,U,,,22224,0,,CHEMBL621602,BAO_0000019,
7597,Autocuration,,,1,,,Area under curve after oral dose of 0.3 mg/kg,U,,,22224,0,,CHEMBL621603,BAO_0000218,
7598,Autocuration,,,1,,,Area under curve after oral dose of 1 mg/kg,U,,,22224,0,,CHEMBL621604,BAO_0000218,
7599,Autocuration,,,1,,,Area under curve after oral dose of 10 mg/kg,U,,,22224,0,,CHEMBL621605,BAO_0000218,
7600,Autocuration,,,1,,,Area under curve after oral dose of 23.4 mg/kg,U,,,22224,0,,CHEMBL621606,BAO_0000218,
7601,Autocuration,,,1,,,Area under curve after oral dose of 3 mg/kg,U,,,22224,0,,CHEMBL621607,BAO_0000218,
7602,Autocuration,,,1,,,Area under curve after oral dose of 3.87 mg/kg,U,,,22224,0,,CHEMBL621608,BAO_0000218,
7603,Autocuration,,,1,,,Area under curve was determined,U,,,22224,0,,CHEMBL621609,BAO_0000019,
7604,Autocuration,,,1,,,Area under curve at a dose of 10 mg/kg,U,,,22224,0,,CHEMBL621610,BAO_0000218,
7605,Intermediate,10116.0,,1,,,Area under curve was determined; ND=No data,N,,,50597,1,,CHEMBL621611,BAO_0000218,
7606,Intermediate,10116.0,,1,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,N,,,50597,1,,CHEMBL621612,BAO_0000218,
7607,Intermediate,10116.0,,1,,,Area under curve was evaluated in rat brain when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,N,,,50597,1,,CHEMBL622308,BAO_0000218,
7608,Intermediate,10116.0,,1,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,N,,,50597,1,,CHEMBL622309,BAO_0000218,
7609,Intermediate,10116.0,,1,,,Area under curve was evaluated in rat brain when administered intravenously at a dose of 10 mg/kg for infinite hours,N,,,50597,1,,CHEMBL622310,BAO_0000218,
7610,Intermediate,10116.0,,1,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,N,,,50597,1,,CHEMBL622311,BAO_0000218,
7611,Intermediate,10116.0,,1,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 100 mg/kg for infinite hours; Not calculated,N,,,50597,1,,CHEMBL622312,BAO_0000218,
7612,Intermediate,10116.0,,1,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,N,,,50597,1,,CHEMBL622931,BAO_0000218,
7613,Intermediate,10116.0,,1,,,Area under curve was evaluated in rat brain when administered perorally at a dose of 10 mg/kg for infinite hours; Not calculated,N,,,50597,1,,CHEMBL622932,BAO_0000218,
7614,Intermediate,10116.0,,1,1969.0,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for 4 or 6 hours,N,,,50597,1,,CHEMBL622736,BAO_0000218,
7615,Intermediate,10116.0,,1,1969.0,,Area under curve was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg for infinite hours,N,,,50597,1,,CHEMBL622737,BAO_0000218,
7616,Intermediate,10116.0,,1,1969.0,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for 4 or 6 hours,N,,,50597,1,,CHEMBL622738,BAO_0000218,
7617,Intermediate,10116.0,,1,1969.0,,Area under curve was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg for infinite hours,N,,,50597,1,,CHEMBL622739,BAO_0000218,
7618,Intermediate,10116.0,,1,1969.0,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for 4 or 6 hours,N,,,50597,1,,CHEMBL622740,BAO_0000218,
7619,Intermediate,10116.0,,1,1969.0,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 100 mg/kg for infinite hours,N,,,50597,1,,CHEMBL622741,BAO_0000218,
7620,Intermediate,10116.0,,1,1969.0,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for 4 or 6 hours,N,,,50597,1,,CHEMBL622742,BAO_0000218,
7621,Intermediate,10116.0,,1,1969.0,,Area under curve was evaluated in rat plasma when administered perorally at a dose of 10 mg/kg for infinite hours,N,,,50597,1,,CHEMBL622743,BAO_0000218,
7622,Intermediate,10090.0,,1,1969.0,,AUC in mice,N,,,50594,1,,CHEMBL622744,BAO_0000218,
7623,Autocuration,,,1,,,Area under curve was measured from the graph obtained from concentration Vs time,U,,,22224,0,,CHEMBL624134,BAO_0000019,
7624,Autocuration,,,1,,,Area under curve value of compound per hour after oral administration,U,,,22224,0,,CHEMBL624135,BAO_0000019,
7625,Intermediate,10116.0,,1,,,Area under curve was determined after oral administration in rats,N,,,50597,1,,CHEMBL624136,BAO_0000218,
7626,Intermediate,10116.0,,1,,,Area under curve was determined after oral administration in rats; No data,N,,,50597,1,,CHEMBL624137,BAO_0000218,
7627,Intermediate,10116.0,,1,,,Area under curve was determined after oral administration in rats;No data,N,,,50597,1,,CHEMBL624320,BAO_0000218,
7628,Intermediate,9615.0,,1,,,Area under curve was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,N,,,50588,1,,CHEMBL624321,BAO_0000218,
7629,Intermediate,10116.0,,1,,,Area under curve was determined for the compound after iv dose of 4.74 mg/kg in rats,N,,,50597,1,,CHEMBL624322,BAO_0000218,
7630,Intermediate,10116.0,,1,,,Area under curve was determined for the compound after iv dose of 5.06 in rats,N,,,50597,1,,CHEMBL624323,BAO_0000218,
7631,Intermediate,10116.0,,1,,,Area under curve was determined for the compound after iv dose of 5.10 mg/kg in rats,N,,,50597,1,,CHEMBL624324,BAO_0000218,
7632,Intermediate,10116.0,,1,,,Area under curve was determined for the compound after po dose of 5.01 mg/kg in rats,N,,,50597,1,,CHEMBL624325,BAO_0000218,
7633,Intermediate,10116.0,,1,,,Area under curve was determined for the compound after po dose of 5.03 mg/kg in rats,N,,,50597,1,,CHEMBL624326,BAO_0000218,
7634,Intermediate,10116.0,,1,,,Area under curve was determined for the compound after po dose of 5.22 mg/kg in rats,N,,,50597,1,,CHEMBL624327,BAO_0000218,
7635,Intermediate,10116.0,,1,,,Area under curve was determined for the compound after po dose of 5.46 mg/kg in rats,N,,,50597,1,,CHEMBL624328,BAO_0000218,
7636,Intermediate,9615.0,,1,,,Area under curve was determined in Dogs after peroral administration,N,,,50588,1,,CHEMBL627848,BAO_0000218,
7637,Intermediate,10116.0,,1,,,Area under curve was determined in Rats after peroral administration,N,,,50597,1,,CHEMBL627849,BAO_0000218,
7638,Intermediate,10116.0,,1,,,Area under curve was determined in carotid blood of rat when administered intradermally,N,,,50597,1,,CHEMBL627850,BAO_0000218,
7639,Intermediate,10116.0,,1,,,Area under curve was determined in portal blood of rat when administered intradermally,N,,,50597,1,,CHEMBL627851,BAO_0000218,
7640,Intermediate,10090.0,,1,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,N,,,50594,1,,CHEMBL627852,BAO_0000218,
7641,Intermediate,10090.0,,1,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,N,,,50594,1,,CHEMBL627853,BAO_0000218,
7642,Intermediate,10090.0,,1,,,Area under curve was determined using 0.4% Methyl cellulose (MC) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),N,,,50594,1,,CHEMBL627854,BAO_0000218,
7643,Intermediate,10090.0,,1,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg,N,,,50594,1,,CHEMBL627855,BAO_0000218,
7644,Intermediate,10090.0,,1,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered intravenously to nude mice at a dose of 25 mg/kg (run time 7 hr),N,,,50594,1,,CHEMBL627856,BAO_0000218,
7645,Intermediate,10090.0,,1,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg,N,,,50594,1,,CHEMBL875339,BAO_0000218,
7646,Intermediate,10090.0,,1,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (Run time = 7 hr),N,,,50594,1,,CHEMBL627857,BAO_0000218,
7647,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 65 mins after i.v. administration,N,,,50597,1,,CHEMBL627858,BAO_0000218,
7648,Intermediate,10116.0,,1,178.0,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in blood; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627859,BAO_0000218,
7649,Intermediate,10116.0,,1,955.0,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in brain; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627860,BAO_0000218,
7650,Intermediate,10116.0,,1,948.0,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in heart; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627019,BAO_0000218,
7651,Intermediate,10116.0,,1,2107.0,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in liver; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627020,BAO_0000218,
7652,Intermediate,10116.0,,1,2048.0,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in lung; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627021,BAO_0000218,
7653,Intermediate,10116.0,,1,2385.0,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in muscle; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627022,BAO_0000218,
7654,Intermediate,10116.0,,1,,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in skin; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627023,BAO_0000218,
7655,Intermediate,10116.0,,1,2106.0,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in spleen; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627024,BAO_0000218,
7656,Intermediate,10116.0,,1,2046.0,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in thyroid; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627025,BAO_0000218,
7657,Intermediate,10116.0,,1,2113.0,,In vivo biodistribution in rats after an intravenous injection at 15 min was determined in kidney; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627026,BAO_0000218,
7658,Intermediate,10116.0,,1,178.0,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in blood; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627027,BAO_0000218,
7659,Intermediate,10116.0,,1,955.0,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in brain; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627028,BAO_0000218,
7660,Intermediate,10116.0,,1,948.0,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in heart; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627029,BAO_0000218,
7661,Intermediate,10116.0,,1,2113.0,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in kidney; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627030,BAO_0000218,
7662,Intermediate,10116.0,,1,2107.0,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in liver; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627031,BAO_0000218,
7663,Intermediate,10116.0,,1,2048.0,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in lung; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627032,BAO_0000218,
7664,Intermediate,10116.0,,1,2385.0,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in muscle; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627033,BAO_0000218,
7665,Intermediate,10116.0,,1,,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in skin; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627034,BAO_0000218,
7666,Intermediate,10116.0,,1,2106.0,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in spleen; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627035,BAO_0000218,
7667,Intermediate,10116.0,,1,2046.0,,In vivo biodistribution in rats after an intravenous injection at 2 min was determined in thyroid; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627036,BAO_0000218,
7668,Intermediate,10116.0,,1,178.0,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in blood; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL875340,BAO_0000218,
7669,Intermediate,10116.0,,1,948.0,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in heart; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627037,BAO_0000218,
7670,Intermediate,10116.0,,1,2113.0,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in kidney; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627038,BAO_0000218,
7671,Intermediate,10116.0,,1,2107.0,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in liver; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627039,BAO_0000218,
7672,Intermediate,10116.0,,1,2385.0,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in muscle; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL627040,BAO_0000218,
7673,Intermediate,10116.0,,1,2106.0,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in spleen; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL624663,BAO_0000218,
7674,Intermediate,10116.0,,1,2046.0,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in thyroid; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL625963,BAO_0000218,
7675,Intermediate,10116.0,,1,955.0,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in brain; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL876799,BAO_0000218,
7676,Intermediate,10116.0,,1,2048.0,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in lung; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL626133,BAO_0000218,
7677,Intermediate,10116.0,,1,,,In vivo biodistribution in rats after an intravenous injection at 60 min was determined in skin; Expressed as percent dose/organ,N,,,50597,1,,CHEMBL626134,BAO_0000218,
7678,Intermediate,10116.0,,1,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,N,,,50597,1,,CHEMBL626135,BAO_0000218,
7679,Intermediate,10116.0,,1,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg,N,,,50597,1,,CHEMBL626136,BAO_0000218,
7680,Intermediate,10116.0,,1,,,In vivo concentration in rat liver exposure 8 hour after oral administration 50 mg/kg; Below detection limit,N,,,50597,1,,CHEMBL626137,BAO_0000218,
7681,Intermediate,10116.0,,1,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,N,,,50597,1,,CHEMBL626138,BAO_0000218,
7682,Intermediate,10116.0,,1,,,In vivo concentration in rat plasma exposure at 8 hour after oral administration 50 mg/kg,N,,,50597,1,,CHEMBL626139,BAO_0000218,
7683,Intermediate,10116.0,In vivo,1,,,C max at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,N,,,50597,1,,CHEMBL626140,BAO_0000218,
7684,Intermediate,10116.0,In vivo,1,,,C max at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,N,,,50597,1,,CHEMBL626141,BAO_0000218,
7685,Intermediate,10116.0,,1,,,C24h in rat p.o. at 20 mg/kg concentration,N,,,50597,1,,CHEMBL626142,BAO_0000218,
7686,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in normal rat muscle in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL627930,BAO_0000218,
7687,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in normal rat muscle in the presence of 0.01 M Gd/0.05 M lig,N,,,50597,1,,CHEMBL627931,BAO_0000218,
7688,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in normal rat muscle in the presence of NAC Gd 0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL627932,BAO_0000218,
7689,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in normal rat spleen in the presence of 0.005 M Gd/0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL627933,BAO_0000218,
7690,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in normal rat spleen in the presence of 0.01 M Gd/0.05 M lig,N,,,50597,1,,CHEMBL627934,BAO_0000218,
7691,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in normal rat spleen in the presence of NAC Gd 0.01 M lig at 2 hr,N,,,50597,1,,CHEMBL627935,BAO_0000218,
7692,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of 0.001 M/0.008 M GdDTPA-AEP,N,,,50597,1,,CHEMBL627936,BAO_0000218,
7693,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of 0.01 M GdDTPA-BDP,N,,,50597,1,,CHEMBL627937,BAO_0000218,
7694,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of 0.01 M/0.01 M GdDTPA-AEP,N,,,50597,1,,CHEMBL627938,BAO_0000218,
7695,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of 0.05 M Gd/0.15 M lig,N,,,50597,1,,CHEMBL627939,BAO_0000218,
7696,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of 0.05 M GdDTPA-BDP,N,,,50597,1,,CHEMBL627940,BAO_0000218,
7697,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of 0.05 M/0.05 M GdDTPA-AEP,N,,,50597,1,,CHEMBL627941,BAO_0000218,
7698,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of 0.05 M/0.08 M GdDTPA-HPDP,N,,,50597,1,,CHEMBL876800,BAO_0000218,
7699,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of 0.10 M GdDTPA-BDP,N,,,50597,1,,CHEMBL627942,BAO_0000218,
7700,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of 0.10 M/0.11 M GdDTPA-AEP,N,,,50597,1,,CHEMBL627943,BAO_0000218,
7701,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of 50 Gd/kg at 15 min,N,,,50597,1,,CHEMBL627944,BAO_0000218,
7702,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of 50 Gd/kg at 2 hr,N,,,50597,1,,CHEMBL627945,BAO_0000218,
7703,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of 50 Gd/kg at 6 hr,N,,,50597,1,,CHEMBL628584,BAO_0000218,
7704,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of GdDTPA at 15 min,N,,,50597,1,,CHEMBL628585,BAO_0000218,
7705,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of GdDTPA at 1 hr,N,,,50597,1,,CHEMBL628586,BAO_0000218,
7706,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of GdDTPA at 30 min,N,,,50597,1,,CHEMBL628587,BAO_0000218,
7707,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of GdDTPA at 4 hr,N,,,50597,1,,CHEMBL628588,BAO_0000218,
7708,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 15 min,N,,,50597,1,,CHEMBL628589,BAO_0000218,
7709,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 30 min,N,,,50597,1,,CHEMBL625304,BAO_0000218,
7710,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of GdDTPA-BDP at 4 hr,N,,,50597,1,,CHEMBL625305,BAO_0000218,
7711,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of GdDTPA-BDPat 1 hr,N,,,50597,1,,CHEMBL625306,BAO_0000218,
7712,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 15 min,N,,,50597,1,,CHEMBL625307,BAO_0000218,
7713,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 30 min,N,,,50597,1,,CHEMBL625308,BAO_0000218,
7714,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of GdDTPA-HPDP at 4 hr,N,,,50597,1,,CHEMBL627740,BAO_0000218,
7715,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of GdDTPA-HPDPat 1 hr,N,,,50597,1,,CHEMBL627741,BAO_0000218,
7716,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of NAC Gd/0.01 M GdDTPA-HPDP,N,,,50597,1,,CHEMBL627742,BAO_0000218,
7717,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of NCA Gd/0.01 M lip,N,,,50597,1,,CHEMBL627743,BAO_0000218,
7718,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood in the presence of NCAGd/0.01 M lig,N,,,50597,1,,CHEMBL627744,BAO_0000218,
7719,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of 0.01 M GdDTPA-BDP,N,,,50597,1,,CHEMBL627745,BAO_0000218,
7720,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of 0.01 M/0.01 M GdDTPA-AEP,N,,,50597,1,,CHEMBL627746,BAO_0000218,
7721,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of 0.01 M/0.08 M GdDTPA-AEP,N,,,50597,1,,CHEMBL627747,BAO_0000218,
7722,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of 0.05 M Gd/0.15 M lig,N,,,50597,1,,CHEMBL876810,BAO_0000218,
7723,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of 0.05 M GdDTPA-BDP,N,,,50597,1,,CHEMBL627748,BAO_0000218,
7724,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of 0.05 M/0.05 M GdDTPA-AEP,N,,,50597,1,,CHEMBL627749,BAO_0000218,
7725,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of 0.05 M/0.08 M GdDTPA-HPDP,N,,,50597,1,,CHEMBL627750,BAO_0000218,
7726,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of 0.10 M GdDTPA-BDP,N,,,50597,1,,CHEMBL618728,BAO_0000218,
7727,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of 0.10 M/0.11 M GdDTPA-AEP,N,,,50597,1,,CHEMBL618729,BAO_0000218,
7728,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of GdDTPA at 15 min,N,,,50597,1,,CHEMBL618730,BAO_0000218,
7729,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of GdDTPA at 1 hr,N,,,50597,1,,CHEMBL618731,BAO_0000218,
7730,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of GdDTPA at 30 min,N,,,50597,1,,CHEMBL618732,BAO_0000218,
7731,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of GdDTPA at 4 hr,N,,,50597,1,,CHEMBL618733,BAO_0000218,
7732,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 15 min,N,,,50597,1,,CHEMBL618734,BAO_0000218,
7733,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 1 hr,N,,,50597,1,,CHEMBL618735,BAO_0000218,
7734,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 30 min,N,,,50597,1,,CHEMBL876602,BAO_0000218,
7735,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of GdDTPA-BDP at 4 hr,N,,,50597,1,,CHEMBL618736,BAO_0000218,
7736,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 15 min,N,,,50597,1,,CHEMBL618737,BAO_0000218,
7737,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 1 hr,N,,,50597,1,,CHEMBL618738,BAO_0000218,
7738,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 30 min,N,,,50597,1,,CHEMBL618739,BAO_0000218,
7739,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of GdDTPA-HPDP at 4 hr,N,,,50597,1,,CHEMBL618740,BAO_0000218,
7740,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of NAC Gd/0.01 M GdDTPA-HPDP,N,,,50597,1,,CHEMBL618741,BAO_0000218,
7741,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of NCA Gd/0.01 M lip,N,,,50597,1,,CHEMBL618742,BAO_0000218,
7742,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution in rat bone in the presence of NCAGd/0.01 M lig,N,,,50597,1,,CHEMBL618743,BAO_0000218,
7743,Intermediate,10116.0,In vivo,1,1969.0,,Half-life from rat plasma at a single oral dose of 25 mg/kg,N,,,50597,1,,CHEMBL618744,BAO_0000218,
7744,Intermediate,10116.0,,1,,,Half-life in male rat,N,,,50597,1,,CHEMBL618745,BAO_0000218,
7745,Intermediate,10116.0,In vivo,1,,,Half-life in rat after peroral administration at 10 mg/kg concentration,N,,,50597,1,,CHEMBL620479,BAO_0000218,
7746,Intermediate,10116.0,In vivo,1,,,Half-life in rat after peroral administration at 5 mg/kg concentration,N,,,50597,1,,CHEMBL620480,BAO_0000218,
7747,Intermediate,10116.0,In vivo,1,,,Half-life in rat at a dose of 3 mg/kg,N,,,50597,1,,CHEMBL620481,BAO_0000218,
7748,Intermediate,10116.0,,1,,,Half-life was evaluated in rats,N,,,50597,1,,CHEMBL620482,BAO_0000218,
7749,Intermediate,10116.0,,1,,,Half-life was measured in rat,N,,,50597,1,,CHEMBL876603,BAO_0000218,
7750,Intermediate,10116.0,In vivo,1,,,Half-life period for the compound was determined in rats at 50 mg/kg dose,N,,,50597,1,,CHEMBL620483,BAO_0000218,
7751,Intermediate,10116.0,In vivo,1,,,Half-life period in rats after intravenous administration at 5 mg/kg,N,,,50597,1,,CHEMBL620484,BAO_0000218,
7752,Intermediate,10116.0,In vivo,1,,,Half-life period in rat at 10 mg/kg,N,,,50597,1,,CHEMBL620485,BAO_0000218,
7753,Intermediate,10116.0,In vivo,1,,,"Half-life period was determined in rats at 10 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL620486,BAO_0000218,
7754,Intermediate,10116.0,In vivo,1,,,"Half-life period was determined in rats at 20 mg/kg, i.p. dose",N,,,50597,1,,CHEMBL620487,BAO_0000218,
7755,Intermediate,10116.0,In vivo,1,,,"Half-life period was determined in rats at 2 mg/kg, i.v. dose",N,,,50597,1,,CHEMBL620488,BAO_0000218,
7756,Intermediate,10116.0,In vivo,1,,,Half-life time in rat the dose of 2 mg/kg,N,,,50597,1,,CHEMBL620489,BAO_0000218,
7757,Intermediate,10116.0,In vivo,1,,,Half-life was estimated from the elimination phase of the oral [C] vs time curves in 4 rats,N,,,50597,1,,CHEMBL620490,BAO_0000218,
7758,Intermediate,10116.0,In vivo,1,,,In vivo activity against Staphylococcus aureus when administered orally for 1 hr in rat at a dose of 15 mg/kg,N,,,50597,1,,CHEMBL620491,BAO_0000218,
7759,Intermediate,10116.0,In vivo,1,1969.0,,"In vivo half life of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",N,,,50597,1,,CHEMBL876604,BAO_0000218,
7760,Intermediate,10116.0,In vivo,1,,,Oral half life was determined,N,,,50597,1,,CHEMBL620492,BAO_0000218,
7761,Intermediate,10116.0,In vivo,1,,,"Pharmacokinetic Parameter, half life period measured in Female Wistar Rats at 100 mg/kg by po administration",N,,,50597,1,,CHEMBL620493,BAO_0000218,
7762,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (t1/2) in rat,N,,,50597,1,,CHEMBL620494,BAO_0000218,
7763,Intermediate,10116.0,,1,1969.0,,Plasma elimination half-life was determined,N,,,50597,1,,CHEMBL620495,BAO_0000218,
7764,Intermediate,10116.0,In vivo,1,1969.0,,Plasma elimination half-life was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,N,,,50597,1,,CHEMBL620496,BAO_0000218,
7765,Intermediate,10116.0,In vivo,1,1969.0,,Plasma half life was observed after intravenous administration in rat,N,,,50597,1,,CHEMBL620497,BAO_0000218,
7766,Intermediate,10116.0,,1,1969.0,,Plasma half-life was determined,N,,,50597,1,,CHEMBL620498,BAO_0000218,
7767,Intermediate,10116.0,In vivo,1,1969.0,,Plasma half-life following oral administration in Fisher rats,N,,,50597,1,,CHEMBL620499,BAO_0000218,
7768,Intermediate,10116.0,,1,1969.0,,Plasma half-life in rat,N,,,50597,1,,CHEMBL620500,BAO_0000218,
7769,Intermediate,10116.0,In vivo,1,1969.0,,Plasmatic Half-life after intravenous administration to rat,N,,,50597,1,,CHEMBL873809,BAO_0000218,
7770,Intermediate,10116.0,In vivo,1,,,T1/2 (half life) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,N,,,50597,1,,CHEMBL620501,BAO_0000218,
7771,Intermediate,10116.0,In vivo,1,,,Terminal half life after intravenous administration (1 mg/kg) in rat,N,,,50597,1,,CHEMBL620502,BAO_0000218,
7772,Intermediate,10116.0,In vivo,1,,,Terminal half life in Rat at a oral dose of 5 mg/kg,N,,,50597,1,,CHEMBL620503,BAO_0000218,
7773,Intermediate,10116.0,In vivo,1,,,Terminal phase half-life was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,N,,,50597,1,,CHEMBL620504,BAO_0000218,
7774,Intermediate,10116.0,In vivo,1,,,Tested for half life value after intravenous administration at dose of 0.2 mg/kg in rat,N,,,50597,1,,CHEMBL876605,BAO_0000218,
7775,Intermediate,10116.0,In vivo,1,,,Tested for half life value after oral administration at dosage of 4 mg/kg in rat,N,,,50597,1,,CHEMBL620505,BAO_0000218,
7776,Intermediate,10116.0,In vivo,1,1969.0,,plasma half life was observed after intravenous administration in rat,N,,,50597,1,,CHEMBL873811,BAO_0000218,
7777,Expert,10116.0,In vivo,1,,,Half life of compound determined in rat after iv administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL624016,BAO_0000218,
7778,Intermediate,10116.0,,1,,,Half life of compound determined in rat,N,,,50597,1,,CHEMBL624017,BAO_0000218,
7779,Intermediate,10116.0,,1,,,Mean residence time determined in rat,N,,,50597,1,,CHEMBL624018,BAO_0000218,
7780,Intermediate,10116.0,,1,,,Plasma half life determined in rat,N,,,50597,1,,CHEMBL624019,BAO_0000218,
7781,Intermediate,10116.0,In vivo,1,955.0,,Compound was evaluated for Tmax in brain after intravenous administration in male rats,N,,,50597,1,,CHEMBL624020,BAO_0000218,
7782,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for pharmacokinetic parameter maximum time period,N,,,50597,1,,CHEMBL624201,BAO_0000218,
7783,Intermediate,10116.0,In vivo,1,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,N,,,50597,1,,CHEMBL872528,BAO_0000218,
7784,Intermediate,10116.0,In vivo,1,,,In vivo Tmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL624202,BAO_0000218,
7785,Intermediate,10116.0,In vivo,1,,,In vivo Tmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL624203,BAO_0000218,
7786,Intermediate,10116.0,In vivo,1,,,In vivo Tmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL624350,BAO_0000218,
7787,Intermediate,10116.0,In vivo,1,,,In vivo Tmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL621320,BAO_0000218,
7788,Intermediate,10116.0,In vivo,1,,,In vivo maximum time required for clearance of compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,N,,,50597,1,,CHEMBL621321,BAO_0000218,
7789,Intermediate,10116.0,,1,,,Maximum time (Tmax) required to reach Cmax in rats,N,,,50597,1,,CHEMBL621322,BAO_0000218,
7790,Intermediate,10116.0,In vivo,1,,,Maximum time constant was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,N,,,50597,1,,CHEMBL621323,BAO_0000218,
7791,Intermediate,10116.0,In vivo,1,,,Maximum time of clearance of compound in rats after peroral administration,N,,,50597,1,,CHEMBL621324,BAO_0000218,
7792,Intermediate,10116.0,,1,,,Maximum time at the dose of 2 mg/kg in rat,N,,,50597,1,,CHEMBL621325,BAO_0000218,
7793,Intermediate,10116.0,In vivo,1,1969.0,,Maximum time to achieve peak plasma concentration was determined in rat at 1 mg/kg,N,,,50597,1,,CHEMBL875837,BAO_0000218,
7794,Intermediate,10116.0,In vivo,1,1969.0,,Maximum time to achieve peak plasma concentration was determined in rat at 10 mg/kg,N,,,50597,1,,CHEMBL621326,BAO_0000218,
7795,Intermediate,10116.0,In vivo,1,,,Tmax in Guinea pig (PO dose),N,,,50597,1,,CHEMBL621327,BAO_0000218,
7796,Intermediate,10116.0,In vivo,1,,,"Pharmacokinetic Parameter, Tmax is the time at which maximum concentration (Cmax) is reached in Female Wistar Rats at 100 mg/kg by po administration",N,,,50597,1,,CHEMBL621328,BAO_0000218,
7797,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter (Tmax) in rat,N,,,50597,1,,CHEMBL621329,BAO_0000218,
7798,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter (Tmax) was estimated,N,,,50597,1,,CHEMBL621330,BAO_0000218,
7799,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (Tmax) in rat,N,,,50597,1,,CHEMBL621331,BAO_0000218,
7800,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (Tmax) was measured in rat at the dose of 0.32 mg/kg p.o.,N,,,50597,1,,CHEMBL621332,BAO_0000218,
7801,Intermediate,10116.0,In vivo,1,,,T max in Rat at a oral dose of 5 mg/kg,N,,,50597,1,,CHEMBL621333,BAO_0000218,
7802,Intermediate,10116.0,In vivo,1,,,T max was determined at 10 mg/kg po dose in rats,N,,,50597,1,,CHEMBL621334,BAO_0000218,
7803,Intermediate,10090.0,,1,,,Area under curve was determined using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. Compound was administered orally to nude mice at a dose of 25 mg/kg (run time 7 hr),N,,,50594,1,,CHEMBL621335,BAO_0000218,
7804,Intermediate,9615.0,,1,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in dogs,N,,,50588,1,,CHEMBL621336,BAO_0000218,
7805,Intermediate,10116.0,,1,,,Area under curve was evaluated after intravenous injection of 1 mg/kg of compound in rats,N,,,50597,1,,CHEMBL621337,BAO_0000218,
7806,Intermediate,9615.0,,1,,,Area under curve was measured after i.v. administration into Beagle dog.,N,,,50588,1,,CHEMBL621338,BAO_0000218,
7807,Intermediate,9615.0,,1,,,Area under curve was measured after iv administration into Beagle dog,N,,,50588,1,,CHEMBL875838,BAO_0000218,
7808,Intermediate,9615.0,,1,,,Area under curve was measured after po administration into Beagle dog,N,,,50588,1,,CHEMBL621339,BAO_0000218,
7809,Intermediate,9615.0,,1,,,Area under curve was measured after po administration into Beagle dog.,N,,,50588,1,,CHEMBL621340,BAO_0000218,
7810,Autocuration,,,1,,,Area under curve was measured at peroral dose of 3 mg/kg,U,,,22224,0,,CHEMBL621341,BAO_0000218,
7811,Autocuration,,,1,,,Area under curve was measured by using concentration Vs time,U,,,22224,0,,CHEMBL621342,BAO_0000019,
7812,Autocuration,,,1,,,Area under curve was measured by using concentration Vs time; not tested,U,,,22224,0,,CHEMBL621343,BAO_0000019,
7813,Intermediate,10090.0,,1,,,Area under curve(AUC) was measured in mice after oral administration (50 mg/kg),N,,,50594,1,,CHEMBL621344,BAO_0000218,
7814,Intermediate,10090.0,,1,,,Area under curve(AUC) was measured in mice after oral administration.,N,,,50594,1,,CHEMBL621345,BAO_0000218,
7815,Autocuration,,,1,,,Area under curve(AUC) value of the compound,U,,,22224,0,,CHEMBL621346,BAO_0000019,
7816,Autocuration,,,1,,,Area under curve(AUC) value of the compound in dogs at 0.5 mg/kg dose upon oral administration,U,,,22224,0,,CHEMBL621347,BAO_0000218,
7817,Intermediate,9615.0,,1,,,Area under curve(AUC) value of the compound in dogs at 1 mg/kg dose upon oral administration,N,,,50588,1,,CHEMBL621348,BAO_0000218,
7818,Autocuration,,,1,178.0,,Area under curve(carotid artery) was determined by the availability in blood,U,,,22224,0,,CHEMBL621349,BAO_0000019,
7819,Autocuration,,,1,178.0,,Area under curve(carotid artery) was determined by the availability in blood; ND means no data,U,,,22224,0,,CHEMBL621350,BAO_0000019,
7820,Autocuration,,,1,178.0,,Area under curve(carotid artery) was determined by the availability in blood; No data,U,,,22224,0,,CHEMBL875839,BAO_0000019,
7821,Autocuration,,,1,178.0,,Area under curve(portal vein) was determined by the availability in blood,U,,,22224,0,,CHEMBL620211,BAO_0000019,
7822,Autocuration,,,1,178.0,,Area under curve(portal vein) was determined by the availability in blood; ND means no data,U,,,22224,0,,CHEMBL620212,BAO_0000019,
7823,Autocuration,,,1,178.0,,Area under curve(portal vein) was determined by the availability in blood; No data,U,,,22224,0,,CHEMBL620213,BAO_0000019,
7824,Intermediate,9544.0,,1,1969.0,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",N,,,50797,1,,CHEMBL620214,BAO_0000218,
7825,Intermediate,9544.0,,1,1969.0,,"Area under plasma concentration vs time curve observed in Rhesus monkeys after, iv administration of single 30 mg/kg dose",N,,,50797,1,,CHEMBL620215,BAO_0000218,
7826,Intermediate,9544.0,,1,1969.0,,Area under plasma concentration vs time curve observed in Rhesus monkeys after oral administration of single 30 mg/kg dose,N,,,50797,1,,CHEMBL620216,BAO_0000218,
7827,Intermediate,9615.0,,1,1969.0,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, iv administration of single 15 mg/kg dose",N,,,50588,1,,CHEMBL620888,BAO_0000218,
7828,Intermediate,9615.0,,1,1969.0,,"Area under plasma concentration vs time curve observed in female mongrel dogs after, oral administration of single 15 mg/kg dose",N,,,50588,1,,CHEMBL620889,BAO_0000218,
7829,Autocuration,,,1,1969.0,,Area under plasma concentration vs time curve observed in rats for 0-3 h,U,,,22224,0,,CHEMBL620890,BAO_0000019,
7830,Intermediate,10116.0,,1,1969.0,,Area under plasma time curve determined in male rat,N,,,50597,1,,CHEMBL620891,BAO_0000218,
7831,Autocuration,,,1,,,Area under the MAP curve measured over 5 min.,U,,,22224,0,,CHEMBL620892,BAO_0000019,
7832,Intermediate,10090.0,,1,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through iv route in mice,N,,,50594,1,,CHEMBL621079,BAO_0000218,
7833,Intermediate,10090.0,,1,,,Area under the concentration time curve (AUC) taken for 0-24 hr was measured when administered through oral route in mice,N,,,50594,1,,CHEMBL621080,BAO_0000218,
7834,Intermediate,9615.0,,1,,,Area under the concentration vs time curve in dog at 10 mg/kg oral dose,N,,,50588,1,,CHEMBL621081,BAO_0000218,
7835,Intermediate,10026.0,,1,,,Area under the concentration vs time curve in hamster at 10 mg/kg oral dose,N,,,100712,1,,CHEMBL621082,BAO_0000218,
7836,Intermediate,10116.0,,1,,,Area under the concentration vs time curve in rat at 10 mg/kg oral dose,N,,,50597,1,,CHEMBL621083,BAO_0000218,
7837,Intermediate,9615.0,,1,,,Area under the concentration-time curve from time zero to infinity after intravenous administration of 2.5 mg/kg in dogs,N,,,50588,1,,CHEMBL621084,BAO_0000218,
7838,Intermediate,9615.0,,1,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fasted dogs,N,,,50588,1,,CHEMBL621085,BAO_0000218,
7839,Intermediate,9615.0,,1,,,Area under the concentration-time curve from time zero to infinity in oral (5 mg/kg) fed dogs,N,,,50588,1,,CHEMBL621086,BAO_0000218,
7840,Intermediate,9615.0,,1,,,Area under the concentration/ time determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),N,,,50588,1,,CHEMBL621087,BAO_0000218,
7841,Intermediate,9615.0,,1,,,Area under the concentration/ time in plasma after oral administration in dog (25 mg/kg),N,,,50588,1,,CHEMBL622607,BAO_0000218,
7842,Intermediate,9615.0,,1,,,Serum AUC in marmosets (IV dose),N,,,50588,1,,CHEMBL622608,BAO_0000218,
7843,Autocuration,,,1,,,Area under the curve after intravenous administration at a dose of 10 umol/kg,U,,,22224,0,,CHEMBL624481,BAO_0000019,
7844,Autocuration,,,1,,,Area under the curve after intravenous administration at a dose of 2 umol/kg,U,,,22224,0,,CHEMBL624482,BAO_0000019,
7845,Autocuration,,,1,,,Area under the curve after intravenous administration at a dose of 4 umol/kg,U,,,22224,0,,CHEMBL624483,BAO_0000019,
7846,Autocuration,,,1,,,Area under the curve after intravenous administration at a dose of 40 umol/kg,U,,,22224,0,,CHEMBL624484,BAO_0000019,
7847,Autocuration,,,1,,,Area under the curve after intravenous administration at a dose of 5 umol/kg,U,,,22224,0,,CHEMBL624485,BAO_0000019,
7848,Intermediate,10116.0,,1,,,Area under the curve for fumarate salt was evaluated in F344 Rats.,N,,,50597,1,,CHEMBL624486,BAO_0000218,
7849,Autocuration,,,1,,,Area under the curve for the compound was calculated.,U,,,22224,0,,CHEMBL624487,BAO_0000019,
7850,Autocuration,,,1,,,Area under the curve in concentration/ time,U,,,22224,0,,CHEMBL624488,BAO_0000019,
7851,Intermediate,10116.0,,1,,,Area under the curve administered intraintestinal in rats.,N,,,50597,1,,CHEMBL624489,BAO_0000218,
7852,Intermediate,10116.0,,1,,,Area under the curve administered intravenously in rats.,N,,,50597,1,,CHEMBL625184,BAO_0000218,
7853,Autocuration,,,1,,,Area under the curve during intravenous administration,U,,,22224,0,,CHEMBL625185,BAO_0000019,
7854,Autocuration,,,1,,,Area under the curve during intravenous administration; Not determined,U,,,22224,0,,CHEMBL875954,BAO_0000019,
7855,Autocuration,,,1,,,Area under the curve during systemic administration,U,,,22224,0,,CHEMBL625186,BAO_0000019,
7856,Autocuration,,,1,,,Area under the curve during systemic administration; Not determined,U,,,22224,0,,CHEMBL625187,BAO_0000019,
7857,Autocuration,,,1,,,Area under the curve was calculated for the compound.,U,,,22224,0,,CHEMBL625188,BAO_0000019,
7858,Intermediate,9615.0,,1,,,Area under the curve was determined after intravenous administration of 1.8 mg/kg in male Beagle dogs,N,,,50588,1,,CHEMBL625189,BAO_0000218,
7859,Intermediate,9615.0,,1,,,Area under the curve was determined after intravenous administration of 10 mg/kg in male Beagle dogs,N,,,50588,1,,CHEMBL625190,BAO_0000218,
7860,Intermediate,10116.0,,1,,,Area under the curve was determined after intravenous administration of 2.5 mg/kg in male Dawley rats,N,,,50597,1,,CHEMBL621733,BAO_0000218,
7861,Intermediate,10116.0,,1,,,Area under the curve was determined after intravenous administration of 2.6 mg/kg in male Dawley rats,N,,,50597,1,,CHEMBL621734,BAO_0000218,
7862,Intermediate,10116.0,,1,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate after oral administration to male F344 rats,N,,,50597,1,,CHEMBL621735,BAO_0000218,
7863,Intermediate,10116.0,,1,1969.0,,Clearance of the drug was measured in the plasma of rat; No data,N,,,50597,1,,CHEMBL621736,BAO_0000218,
7864,Intermediate,10116.0,,1,1969.0,,The pharmacokinetic parameter plasma clearance in vivo in rats,N,,,50597,1,,CHEMBL621737,BAO_0000218,
7865,Intermediate,10116.0,,1,,,Plasma clearance at the dose of 2 mg/kg in rat,N,,,50597,1,,CHEMBL621738,BAO_0000218,
7866,Intermediate,10116.0,In vivo,1,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,N,,,50597,1,,CHEMBL622806,BAO_0000218,
7867,Intermediate,10116.0,In vivo,1,,,CL (clearance) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,N,,,50597,1,,CHEMBL623519,BAO_0000218,
7868,Intermediate,10116.0,In vivo,1,,,CL at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,N,,,50597,1,,CHEMBL623520,BAO_0000218,
7869,Intermediate,10116.0,In vivo,1,,,Clearance measured after intravenous bolus administration of 50 mg/kg of compound to rats,N,,,50597,1,,CHEMBL623521,BAO_0000218,
7870,Intermediate,10116.0,In vivo,1,,,Clearance in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,N,,,50597,1,,CHEMBL623522,BAO_0000218,
7871,Intermediate,10116.0,In vivo,1,,,Clearance rate in rat,N,,,50597,1,,CHEMBL623523,BAO_0000218,
7872,Intermediate,10116.0,In vivo,1,,,Clearance rate in rat,N,,,50597,1,,CHEMBL623690,BAO_0000218,
7873,Intermediate,10116.0,In vivo,1,,,Clearance (Cl) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL623691,BAO_0000218,
7874,Intermediate,10116.0,In vivo,1,,,Clearance (Cl) of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL623692,BAO_0000218,
7875,Intermediate,10116.0,In vivo,1,,,Clearance (Cl) of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL623693,BAO_0000218,
7876,Intermediate,10116.0,In vivo,1,,,Clearance (Cl) of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL623694,BAO_0000218,
7877,Intermediate,10116.0,In vivo,1,,,Clearance of compound after iv administration of 20 mg/kg dose in rat,N,,,50597,1,,CHEMBL623695,BAO_0000218,
7878,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to female wistar rats,N,,,50597,1,,CHEMBL623696,BAO_0000218,
7879,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for clearance after treatment with iv dose of 1 mgkg to male wistar rats,N,,,50597,1,,CHEMBL623697,BAO_0000218,
7880,Intermediate,9544.0,In vivo,1,1969.0,,Compound was tested for its plasma clearance rate in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,,,22224,0,,CHEMBL623698,BAO_0000218,
7881,Intermediate,10116.0,In vivo,1,1969.0,,Compound was tested for its plasma clearance rate in Sprague Dawley rats,U,,,22224,0,,CHEMBL623699,BAO_0000218,
7882,Intermediate,10116.0,In vivo,1,,,Mean (%CV) PK parameters for CL(mL/min/kg).,N,,,50597,1,,CHEMBL623700,BAO_0000218,
7883,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic studies were carried out to determine the clearance after administration at 20 mg/kg intravenously in rat,N,,,50597,1,,CHEMBL623701,BAO_0000218,
7884,Intermediate,10116.0,In vivo,1,1969.0,,Pharmacokinetic parameter plasma clearance was determined at when a dose of 1 mg/kg is administered,N,,,50597,1,,CHEMBL623702,BAO_0000218,
7885,Intermediate,10116.0,In vivo,1,,,Plasma Clearance measured at steady-state following iv infusion at 0.6 mg/kg/h in rats,N,,,50597,1,,CHEMBL623703,BAO_0000218,
7886,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat was determined,N,,,50597,1,,CHEMBL623704,BAO_0000218,
7887,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat after administration of 2 mg/kg iv,N,,,50597,1,,CHEMBL623705,BAO_0000218,
7888,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat after administration of 2 mg/kg iv,N,,,50597,1,,CHEMBL623706,BAO_0000218,
7889,Intermediate,10116.0,In vivo,1,,,Plasma clearance was determined,N,,,50597,1,,CHEMBL623707,BAO_0000218,
7890,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat,N,,,50597,1,,CHEMBL623708,BAO_0000218,
7891,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat after intravenous administration at a concentration 0.5 mg/kg,N,,,50597,1,,CHEMBL623709,BAO_0000218,
7892,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat by iv administration,N,,,50597,1,,CHEMBL623710,BAO_0000218,
7893,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat by iv administration at a dose of 3 mg/kg,N,,,50597,1,,CHEMBL623711,BAO_0000218,
7894,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat p.o.,N,,,50597,1,,CHEMBL623712,BAO_0000218,
7895,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rats,N,,,50597,1,,CHEMBL623713,BAO_0000218,
7896,Intermediate,10116.0,In vivo,1,,,Plasma clearance was determined; ND denotes no data,N,,,50597,1,,CHEMBL623714,BAO_0000218,
7897,Intermediate,10116.0,In vivo,1,,,Plasma clearance was determined; ND denotes not determined,N,,,50597,1,,CHEMBL623715,BAO_0000218,
7898,Intermediate,10116.0,In vivo,1,,,Plasma clearance was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,N,,,50597,1,,CHEMBL623716,BAO_0000218,
7899,Intermediate,10116.0,In vivo,1,,,Plasma clearance was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,N,,,50597,1,,CHEMBL622980,BAO_0000218,
7900,Intermediate,10116.0,In vivo,1,,,Plasma administration to rats,N,,,50597,1,,CHEMBL622981,BAO_0000218,
7901,Intermediate,10116.0,In vivo,1,,,Plasma clearance of the compound in female Sprague-Dawley rats,N,,,50597,1,,CHEMBL622982,BAO_0000218,
7902,Intermediate,10116.0,In vivo,1,,,Plasma clearance was observed after intravenous administration in rat,N,,,50597,1,,CHEMBL622983,BAO_0000218,
7903,Intermediate,10116.0,In vivo,1,,,Systemic clearance after intravenous administration (5.0 mg/kg) was determined in rat,N,,,50597,1,,CHEMBL622984,BAO_0000218,
7904,Intermediate,10116.0,In vivo,1,,,Tested for systemic clearance upon intravenous administration of 5.0 mg/Kg dose in rat,N,,,50597,1,,CHEMBL622985,BAO_0000218,
7905,Intermediate,10116.0,In vivo,1,1969.0,,plasma clearance was observed after intravenous administration in rat,N,,,50597,1,,CHEMBL623631,BAO_0000218,
7906,Intermediate,10116.0,In vivo,1,,,In vivo CL/F determined,N,,,50597,1,,CHEMBL623632,BAO_0000218,
7907,Intermediate,10116.0,In vivo,1,1969.0,,Pharmacokinetic parameter plasma clearance was determined at 2 mg/kg i.v. dose in rats,N,,,50597,1,,CHEMBL623633,BAO_0000218,
7908,Intermediate,10116.0,In vivo,1,1969.0,,Pharmacokinetic parameter plasma clearance was determined at 5 mg/kg i.v. dose in rats,N,,,50597,1,,CHEMBL623634,BAO_0000218,
7909,Intermediate,10116.0,In vivo,1,,,Compound was tested for the lower blood clearance in rat,N,,,50597,1,,CHEMBL623635,BAO_0000218,
7910,Intermediate,10116.0,In vivo,1,,,Evaluated for the low clearance in rat (in vivo),N,,,50597,1,,CHEMBL621195,BAO_0000218,
7911,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (CLb)of the compound was determined in rat,N,,,50597,1,,CHEMBL621196,BAO_0000218,
7912,Intermediate,10116.0,In vivo,1,,,Rapid clearance after intravenous administration in rat was determined,N,,,50597,1,,CHEMBL875287,BAO_0000218,
7913,Intermediate,10116.0,In vivo,1,,,Clearance measured in rat,N,,,50597,1,,CHEMBL621197,BAO_0000218,
7914,Intermediate,10116.0,In vivo,1,1969.0,,Compound was evaluated for plasma clearance in rat,N,,,50597,1,,CHEMBL621198,BAO_0000218,
7915,Intermediate,10116.0,In vivo,1,1969.0,,Low plasma clearance was calculated in rat,N,,,50597,1,,CHEMBL621199,BAO_0000218,
7916,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (Clp) in rat,N,,,50597,1,,CHEMBL621200,BAO_0000218,
7917,Intermediate,10116.0,In vivo,1,,,Plasma clearance in dog at a dose of 1 uM/kg in rat was determined,N,,,50597,1,,CHEMBL621201,BAO_0000218,
7918,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat at a dose of 10 uM/kg in rat was determined,N,,,50597,1,,CHEMBL621202,BAO_0000218,
7919,Intermediate,10116.0,In vivo,1,,,Plasma clearance after IV dosing at 0.5 mg/kg in rat,N,,,50597,1,,CHEMBL621203,BAO_0000218,
7920,Intermediate,10116.0,In vivo,1,,,Plasma clearance after IV dosing at 1 mg/kg in rat,N,,,50597,1,,CHEMBL621204,BAO_0000218,
7921,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of 0.01 M Gd/0.01 M GdDTPA-AEP,N,,,50597,1,,CHEMBL621205,BAO_0000218,
7922,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of 0.01 M GdDTPA-BDP,N,,,50597,1,,CHEMBL621206,BAO_0000218,
7923,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of 0.01 M/0.08 M GdDTPA-AEP,N,,,50597,1,,CHEMBL621207,BAO_0000218,
7924,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of 0.05 M /0.05 M GdDTPA-AEP,N,,,50597,1,,CHEMBL621208,BAO_0000218,
7925,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of 0.05 M Gd/0.15 M lig,N,,,50597,1,,CHEMBL621209,BAO_0000218,
7926,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of 0.05 M GdDTPA-BDP,N,,,50597,1,,CHEMBL876484,BAO_0000218,
7927,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of 0.05 M/0.08 M GdDTPA-HPDP,N,,,50597,1,,CHEMBL621210,BAO_0000218,
7928,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of 0.10 M GdDTPA-BDP,N,,,50597,1,,CHEMBL621211,BAO_0000218,
7929,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of 0.10 M/0.11 M GdDTPA-AEP,N,,,50597,1,,CHEMBL621212,BAO_0000218,
7930,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of GdDTPA at 15 min,N,,,50597,1,,CHEMBL621213,BAO_0000218,
7931,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of GdDTPA at 1 hr,N,,,50597,1,,CHEMBL621214,BAO_0000218,
7932,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of GdDTPA at 30 min,N,,,50597,1,,CHEMBL621215,BAO_0000218,
7933,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of GdDTPA at 4 hr,N,,,50597,1,,CHEMBL621216,BAO_0000218,
7934,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 1 hr,N,,,50597,1,,CHEMBL621217,BAO_0000218,
7935,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 30 min,N,,,50597,1,,CHEMBL621218,BAO_0000218,
7936,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of GdDTPA-BDP at 4 hr,N,,,50597,1,,CHEMBL621219,BAO_0000218,
7937,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of GdDTPA-BDPat 15 min,N,,,50597,1,,CHEMBL621220,BAO_0000218,
7938,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 1 hr,N,,,50597,1,,CHEMBL621221,BAO_0000218,
7939,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 30 min,N,,,50597,1,,CHEMBL621222,BAO_0000218,
7940,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of GdDTPA-HPDP at 4 hr,N,,,50597,1,,CHEMBL621223,BAO_0000218,
7941,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of GdDTPA-HPDPat 15 min,N,,,50597,1,,CHEMBL876485,BAO_0000218,
7942,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of NAC Gd/0.01 M GdDTPA-HPDP,N,,,50597,1,,CHEMBL621224,BAO_0000218,
7943,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of NCA Gd/0.01 M lip,N,,,50597,1,,CHEMBL621225,BAO_0000218,
7944,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart in the presence of NCAGd/0.01 M lig,N,,,50597,1,,CHEMBL621226,BAO_0000218,
7945,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney in the presence of 0.01 M GdDTPA-BDP,N,,,50597,1,,CHEMBL621227,BAO_0000218,
7946,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney in the presence of 0.01 M/0.01 M GdDTPA-AEP,N,,,50597,1,,CHEMBL621228,BAO_0000218,
7947,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney in the presence of 0.01 M/0.08 M GdDTPA-AEP,N,,,50597,1,,CHEMBL621229,BAO_0000218,
7948,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney in the presence of 0.05 M Gd/0.15 M lig,N,,,50597,1,,CHEMBL621230,BAO_0000218,
7949,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney in the presence of 0.05 M GdDTPA-BDP; ND=No data,N,,,50597,1,,CHEMBL621231,BAO_0000218,
7950,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney in the presence of 0.05 M/0.05 M GdDTPA-AEP,N,,,50597,1,,CHEMBL621232,BAO_0000218,
7951,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney in the presence of 0.05 M/0.08 M GdDTPA-HPDP,N,,,50597,1,,CHEMBL621233,BAO_0000218,
7952,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney in the presence of 0.10 M GdDTPA-BDP,N,,,50597,1,,CHEMBL621234,BAO_0000218,
7953,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,N,,,50597,1,,CHEMBL621235,BAO_0000218,
7954,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney in the presence of NAC Gd/0.01 M GdDTPA-HPDP,N,,,50597,1,,CHEMBL621236,BAO_0000218,
7955,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney in the presence of NCA Gd/0.01 M lip,N,,,50597,1,,CHEMBL621237,BAO_0000218,
7956,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney in the presence of NCAGd/0.01 M lig,N,,,50597,1,,CHEMBL876486,BAO_0000218,
7957,Intermediate,10116.0,In vivo,1,160.0,,Biodistribution in rat l. intestine in the presence of 0.01 M carrier at 1 hr,N,,,50597,1,,CHEMBL622436,BAO_0000218,
7958,Intermediate,10116.0,In vivo,1,160.0,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 2 hr,N,,,50597,1,,CHEMBL622437,BAO_0000218,
7959,Intermediate,10116.0,In vivo,1,160.0,,Biodistribution in rat l. intestine in the presence of 50 Gd/kg at 6 hr,N,,,50597,1,,CHEMBL622438,BAO_0000218,
7960,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver by in the presence 50 Gd/kg at 15 min,N,,,50597,1,,CHEMBL622439,BAO_0000218,
7961,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver by in the presence of 0.05 M Gd/0.15 M lig,N,,,50597,1,,CHEMBL622440,BAO_0000218,
7962,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver by in the presence of NCAGd/0.01 M lig,N,,,50597,1,,CHEMBL622441,BAO_0000218,
7963,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of 0.001 M/0.008 M GdDTPA-AEP,N,,,50597,1,,CHEMBL622442,BAO_0000218,
7964,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of 0.01 M GdDTPA-BDP,N,,,50597,1,,CHEMBL622443,BAO_0000218,
7965,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of 0.01 M/0.01 M GdDTPA-AEP,N,,,50597,1,,CHEMBL622444,BAO_0000218,
7966,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of 0.05 M GdDTPA-BDP,N,,,50597,1,,CHEMBL622445,BAO_0000218,
7967,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of 0.05 M/0.05 M GdDTPA-AEP,N,,,50597,1,,CHEMBL622446,BAO_0000218,
7968,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of 0.05 M/0.08 M GdDTPA-HPDP,N,,,50597,1,,CHEMBL622447,BAO_0000218,
7969,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of 0.10 M GdDTPA-BDP,N,,,50597,1,,CHEMBL622448,BAO_0000218,
7970,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of 0.10 M/0.11 M GdDTPA-AEP; ND=No data,N,,,50597,1,,CHEMBL622449,BAO_0000218,
7971,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of 50 Gd/kg at 2 hr,N,,,50597,1,,CHEMBL622450,BAO_0000218,
7972,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of 50 Gd/kg at at 6 hr,N,,,50597,1,,CHEMBL622451,BAO_0000218,
7973,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of GdDTPA at 15 min,N,,,50597,1,,CHEMBL622452,BAO_0000218,
7974,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of GdDTPA at 1 hr,N,,,50597,1,,CHEMBL622453,BAO_0000218,
7975,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of GdDTPA at 30 min,N,,,50597,1,,CHEMBL622454,BAO_0000218,
7976,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of GdDTPA at 4 hr,N,,,50597,1,,CHEMBL622455,BAO_0000218,
7977,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 15 min,N,,,50597,1,,CHEMBL876024,BAO_0000218,
7978,Intermediate,10116.0,In vivo,1,,,T max was determined at 3 mg/kg po dose in rats,N,,,50597,1,,CHEMBL622456,BAO_0000218,
7979,Intermediate,10116.0,In vivo,1,,,"The Tmax value in female wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL622457,BAO_0000218,
7980,Intermediate,10116.0,In vivo,1,,,"The Tmax value in male wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL622458,BAO_0000218,
7981,Intermediate,10116.0,,1,,,The time to reach maximum concentration of compound was measured at the dose of 100 umol/kg,N,,,50597,1,,CHEMBL622459,BAO_0000218,
7982,Intermediate,10116.0,,1,,,The time to reach maximum concentration of compound was measured at the dose of 300 umol/kg,N,,,50597,1,,CHEMBL873343,BAO_0000218,
7983,Intermediate,10116.0,,1,,,The time to reach maximum concentration of compound was measured at the dose of 30 umol/kg,N,,,50597,1,,CHEMBL622460,BAO_0000218,
7984,Intermediate,10116.0,,1,1969.0,,Time for maximum plasma concentration determined in rat,N,,,50597,1,,CHEMBL622461,BAO_0000218,
7985,Intermediate,10116.0,In vivo,1,1969.0,,Time for maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,N,,,50597,1,,CHEMBL622462,BAO_0000218,
7986,Intermediate,10116.0,In vivo,1,,,Time of maximum concentration of the drug when administered orally a dose of 10 mg/kg to a fasting rat,N,,,50597,1,,CHEMBL622463,BAO_0000218,
7987,Intermediate,10116.0,In vivo,1,,,Time of maximum concentration of the drug when administered orally a dose of 1 mg/kg to a fasting rat,N,,,50597,1,,CHEMBL622464,BAO_0000218,
7988,Intermediate,10116.0,In vivo,1,,,Time of maximum concentration of the drug when administered orally a dose of 30 mg/kg,N,,,50597,1,,CHEMBL622465,BAO_0000218,
7989,Intermediate,10116.0,In vivo,1,,,Time of maximum concentration of the drug when administered orally a dose of 3 mg/kg to a fasting rat,N,,,50597,1,,CHEMBL622466,BAO_0000218,
7990,Intermediate,10116.0,In vivo,1,,,Time of maximum concentration of the drug when administered orally at dose of 3 mg/kg,N,,,50597,1,,CHEMBL622467,BAO_0000218,
7991,Intermediate,10116.0,,1,1969.0,,Time of maximum plasma concentration in rat,N,,,50597,1,,CHEMBL622468,BAO_0000218,
7992,Intermediate,10116.0,,1,1969.0,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 10 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL876025,BAO_0000218,
7993,Intermediate,10116.0,,1,1969.0,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 20 mg/kg, i.p. dose",N,,,50597,1,,CHEMBL622469,BAO_0000218,
7994,Intermediate,10116.0,,1,1969.0,,"Time required by compound for reaching maximum plasma concentration was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",N,,,50597,1,,CHEMBL622470,BAO_0000218,
7995,Intermediate,10116.0,In vivo,1,,,Time required to reach maximum concentration (Cmax) after oral administration in rat,N,,,50597,1,,CHEMBL622471,BAO_0000218,
7996,Intermediate,10116.0,,1,1969.0,,Time required to reach maximum concentration in rat plasma,N,,,50597,1,,CHEMBL622472,BAO_0000218,
7997,Intermediate,10116.0,In vivo,1,1969.0,,Time taken by the compound to achieve maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,N,,,50597,1,,CHEMBL622473,BAO_0000218,
7998,Intermediate,10116.0,In vivo,1,1969.0,,Time taken by the compound to achieve maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,N,,,50597,1,,CHEMBL624282,BAO_0000218,
7999,Intermediate,10116.0,In vivo,1,1969.0,,Time taken for maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,N,,,50597,1,,CHEMBL624283,BAO_0000218,
8000,Intermediate,10116.0,In vivo,1,1969.0,,Time taken for maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,N,,,50597,1,,CHEMBL624284,BAO_0000218,
8001,Intermediate,10116.0,In vivo,1,1969.0,,Time taken to reach maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,N,,,50597,1,,CHEMBL624285,BAO_0000218,
8002,Intermediate,10116.0,In vivo,1,,,Time to reach Cmax after oral administration to rats,N,,,50597,1,,CHEMBL624286,BAO_0000218,
8003,Intermediate,10116.0,In vivo,1,,,Time to reach Cmax when a dose of 1 mg/kg is administered orally,N,,,50597,1,,CHEMBL624287,BAO_0000218,
8004,Intermediate,10116.0,,1,,,Time to reach maximum concentration following oral administration of 200 mg/kg in rat; value ranges from 2-4,N,,,50597,1,,CHEMBL624288,BAO_0000218,
8005,Intermediate,10116.0,In vivo,1,1969.0,,Time to reach maximum plasma concentration was evaluated at an intravenous dose of 3 mg/kg; Not applicable,N,,,50597,1,,CHEMBL624289,BAO_0000218,
8006,Intermediate,10116.0,In vivo,1,1969.0,,Time to reach maximum plasma concentration was evaluated at an oral dose of 30 mg/kg,N,,,50597,1,,CHEMBL873344,BAO_0000218,
8007,Intermediate,10116.0,In vivo,1,,,Tmax after peroral administration (10 mg/kg) was determined in rat,N,,,50597,1,,CHEMBL619623,BAO_0000218,
8008,Expert,10116.0,In vivo,1,,,Tmax of compound determined in rat after iv administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL621399,BAO_0000218,
8009,Intermediate,10116.0,In vivo,1,,,Tmax by oral administration at a dose of 100 uM/kg in rat was determined,N,,,50597,1,,CHEMBL621400,BAO_0000218,
8010,Intermediate,10116.0,In vivo,1,,,"Tmax in fischer rats at 5 mg/kg dose, administered intravenously",N,,,50597,1,,CHEMBL621401,BAO_0000218,
8011,Intermediate,10116.0,,1,,,Tmax was determined,N,,,50597,1,,CHEMBL621402,BAO_0000218,
8012,Intermediate,10116.0,,1,,,Tmax was determined,N,,,50597,1,,CHEMBL621403,BAO_0000218,
8013,Intermediate,10116.0,In vivo,1,,,Tmax after oral administration in rat,N,,,50597,1,,CHEMBL621121,BAO_0000218,
8014,Intermediate,10116.0,In vivo,1,,,Tmax after peroral administration in rats at 2.4 uM/kg,N,,,50597,1,,CHEMBL872525,BAO_0000218,
8015,Intermediate,10116.0,,1,,,Tmax in male rat,N,,,50597,1,,CHEMBL621122,BAO_0000218,
8016,Intermediate,10116.0,In vivo,1,,,Tmax in rat at 10 mg/kg,N,,,50597,1,,CHEMBL621123,BAO_0000218,
8017,Intermediate,10116.0,In vivo,1,,,Tmax in rat by po administration at a dose of 40 mg/kg,N,,,50597,1,,CHEMBL621124,BAO_0000218,
8018,Intermediate,10116.0,,1,,,Tmax in rats,N,,,50597,1,,CHEMBL621125,BAO_0000218,
8019,Intermediate,10116.0,In vivo,1,,,Tmax was measured in rats after peroral administration at 5 mg/kg,N,,,50597,1,,CHEMBL621126,BAO_0000218,
8020,Intermediate,10116.0,In vivo,1,,,Tmax value after oral dose at a dose of 10 mg/kg in rats.,N,,,50597,1,,CHEMBL621127,BAO_0000218,
8021,Intermediate,10116.0,In vivo,1,,,Tmax value after administration of 20 mg/Kg oral dose in rat,N,,,50597,1,,CHEMBL621128,BAO_0000218,
8022,Intermediate,10116.0,In vivo,1,,,Tmax value at a dose of 10 mg/kg in male SD rats,N,,,50597,1,,CHEMBL618263,BAO_0000218,
8023,Intermediate,10116.0,In vivo,1,,,Tmax value at a dose of 100 mg/kg in male SD rats,N,,,50597,1,,CHEMBL618264,BAO_0000218,
8024,Intermediate,10116.0,In vivo,1,,,Tmax value at a dose of 50 mg/kg in male SD rats,N,,,50597,1,,CHEMBL618265,BAO_0000218,
8025,Intermediate,10116.0,In vivo,1,1969.0,,Total concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,,,50597,1,,CHEMBL618266,BAO_0000218,
8026,Intermediate,10116.0,In vivo,1,,,time required to reach maximum concentration (Cmax) after oral administration in rat,N,,,50597,1,,CHEMBL618267,BAO_0000218,
8027,Intermediate,10116.0,,1,1088.0,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg ( 0-24 hr ),N,,,50597,1,,CHEMBL618450,BAO_0000218,
8028,Intermediate,10116.0,,1,1088.0,,Evaluated for pharmacokinetic parameter urine recovery in rat at the dose 50 mg/kg (0-24 hr),N,,,50597,1,,CHEMBL618451,BAO_0000218,
8029,Intermediate,10116.0,,1,,,Unbound plasma was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,N,,,50597,1,,CHEMBL618452,BAO_0000218,
8030,Intermediate,10116.0,,1,1088.0,,Amount of urine output was measured in rat at a dose of 1 mg/kg/po,N,,,50597,1,,CHEMBL618453,BAO_0000218,
8031,Intermediate,10116.0,,1,1088.0,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po,N,,,50597,1,,CHEMBL618454,BAO_0000218,
8032,Intermediate,10116.0,,1,1088.0,,Amount of urine output was measured in rat at a dose of 10 mg/kg/po; NT-Not tested,N,,,50597,1,,CHEMBL618455,BAO_0000218,
8033,Intermediate,10116.0,In vivo,1,,,Volume of distribution was determined in rat after a 3 mg/kg of iv dose,N,,,50597,1,,CHEMBL618456,BAO_0000218,
8034,Intermediate,10116.0,In vivo,1,,,Compound distribution in rat tissues was determined,N,,,50597,1,,CHEMBL618457,BAO_0000218,
8035,Intermediate,10116.0,In vivo,1,,,Volume of distribution was evaluated in rat,N,,,50597,1,,CHEMBL618458,BAO_0000218,
8036,Intermediate,10116.0,,1,,,Area under the curve was determined after intravenous administration of 2.7 mg/kg in male Dawley rats,N,,,50597,1,,CHEMBL618459,BAO_0000218,
8037,Intermediate,10116.0,,1,,,Area under the curve was determined after intravenous administration of 2.8 mg/kg in male Dawley rats,N,,,50597,1,,CHEMBL876733,BAO_0000218,
8038,Intermediate,9615.0,,1,,,Area under the curve was determined after intravenous administration of 4.9 mg/kg in male Beagle dogs,N,,,50588,1,,CHEMBL618460,BAO_0000218,
8039,Intermediate,10116.0,,1,,,Area under the curve was determined after intravenous administration of 5.1 mg/kg in male Dawley rats,N,,,50597,1,,CHEMBL618461,BAO_0000218,
8040,Autocuration,,,1,,,Area under the curve was determined after oral administration (300 uM/Kg),U,,,22224,0,,CHEMBL618462,BAO_0000019,
8041,Intermediate,10116.0,,1,,,Area under the curve was determined after peroral administration of 5.0 mg/kg in male Dawley rats,N,,,50597,1,,CHEMBL618463,BAO_0000218,
8042,Intermediate,10116.0,,1,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in mal Dawley rats,N,,,50597,1,,CHEMBL618464,BAO_0000218,
8043,Intermediate,10116.0,,1,,,Area under the curve was determined after peroral administration of 5.1 mg/kg in male Dawley rats,N,,,50597,1,,CHEMBL618465,BAO_0000218,
8044,Intermediate,10116.0,,1,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in mal Dawley rats,N,,,50597,1,,CHEMBL618466,BAO_0000218,
8045,Intermediate,10116.0,,1,,,Area under the curve was determined after peroral administration of 5.2 mg/kg in male Dawley rats,N,,,50597,1,,CHEMBL618467,BAO_0000218,
8046,Intermediate,10116.0,,1,,,Area under the curve was determined for the compound after iv dose of 4.97 mg/kg in rats,N,,,50597,1,,CHEMBL618468,BAO_0000218,
8047,Intermediate,9615.0,,1,1969.0,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 100 mg/kg,N,,,50588,1,,CHEMBL618469,BAO_0000218,
8048,Intermediate,9615.0,,1,1969.0,,Area under the plasma concentration was determined in fasted Beagle dogs after peroral administration of 20 mg/kg,N,,,50588,1,,CHEMBL618470,BAO_0000218,
8049,Autocuration,,,1,,,Plasma drug AUC in rat (PO dose),U,,,22224,0,,CHEMBL618471,BAO_0000218,
8050,Intermediate,10090.0,,1,,,Area under the tumor growth curve (AUC) in the B-6 Melanoma Model in C57/b1 mice at the dose of 1 mg/kg.,N,,,50594,1,,CHEMBL618472,BAO_0000218,
8051,Autocuration,,,1,,,Area under was determined at a dose of 30 mg/kg,U,,,22224,0,,CHEMBL618473,BAO_0000218,
8052,Intermediate,9669.0,,1,,,Average area under curve for compound at 1 mg/kg dose intravenous administration to Ferret,N,,,50506,1,,CHEMBL621699,BAO_0000218,
8053,Intermediate,10116.0,,1,,,Average area under curve for the compound at 10 mg/kg dose after intraduodenal administration to rat,N,,,50597,1,,CHEMBL621700,BAO_0000218,
8054,Intermediate,10116.0,,1,,,Average area under curve for the compound at 1 mg/kg dose after intravenous administration to rat,N,,,50597,1,,CHEMBL621701,BAO_0000218,
8055,Intermediate,9669.0,,1,,,Average area under curve at 10 mg/kg dose after intraduodenal administration to Ferret,N,,,50506,1,,CHEMBL621702,BAO_0000218,
8056,Intermediate,9615.0,,1,,,Average area under curve at 10 mg/kg intraduodenal administration to salt depleted dog,N,,,50588,1,,CHEMBL621703,BAO_0000218,
8057,Intermediate,9615.0,,1,,,Average area under curve at 1 mg/kg intravenous administration to salt depleted dog,N,,,50588,1,,CHEMBL621704,BAO_0000218,
8058,Intermediate,10116.0,,1,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 1.0(pmol/g/h)",N,,,50597,1,,CHEMBL624259,BAO_0000218,
8059,Intermediate,10116.0,,1,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 2.0(pmol/g/h)",N,,,50597,1,,CHEMBL624260,BAO_0000218,
8060,Intermediate,10116.0,,1,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 4.0(pmol/g/h)",N,,,50597,1,,CHEMBL624430,BAO_0000218,
8061,Intermediate,10116.0,,1,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 5.0(pmol/g/h)",N,,,50597,1,,CHEMBL624431,BAO_0000218,
8062,Intermediate,10116.0,,1,,,"Bioavailability in male Sprague-Dawley rats, after the iv administration at a dose of 54.0(pmol/g/h)",N,,,50597,1,,CHEMBL624432,BAO_0000218,
8063,Intermediate,10116.0,,1,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 10.0(pmol/g/h)",N,,,50597,1,,CHEMBL624433,BAO_0000218,
8064,Intermediate,10116.0,,1,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 20.0(pmol/g/h)",N,,,50597,1,,CHEMBL624434,BAO_0000218,
8065,Intermediate,10116.0,,1,,,"Bioavailability in male Sprague-Dawley rats, after the po administration at a dose of 40.0(pmol/g/h)",N,,,50597,1,,CHEMBL624435,BAO_0000218,
8066,Intermediate,10090.0,,1,,,Bioavailability in mouse brain after intravenous administration of 105.1 mg/kg of dose,N,,,50594,1,,CHEMBL618570,BAO_0000218,
8067,Intermediate,10090.0,,1,,,Bioavailability in mouse brain after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),N,,,50594,1,,CHEMBL618571,BAO_0000218,
8068,Intermediate,10090.0,,1,,,Bioavailability in mouse brain after oral administration of 100 mg/kg of dose,N,,,50594,1,,CHEMBL618572,BAO_0000218,
8069,Intermediate,10090.0,,1,,,Bioavailability in mouse brain after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),N,,,50594,1,,CHEMBL618573,BAO_0000218,
8070,Intermediate,10090.0,,1,,,Bioavailability in mouse serum after intravenous administration of 105.1 mg/kg of dose,N,,,50594,1,,CHEMBL619267,BAO_0000218,
8071,Intermediate,10090.0,,1,,,Bioavailability in mouse serum after intravenous administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),N,,,50594,1,,CHEMBL619431,BAO_0000218,
8072,Intermediate,10090.0,,1,,,Bioavailability in mouse serum after oral administration of 100 mg/kg of dose,N,,,50594,1,,CHEMBL619432,BAO_0000218,
8073,Intermediate,10090.0,,1,,,Bioavailability in mouse serum after oral administration of equimolar doses of ( 2'F-ara-ddI + 2'F-ara-ddP),N,,,50594,1,,CHEMBL619433,BAO_0000218,
8074,Autocuration,,,1,1969.0,,AUC in mice after oral dose (50 mg/kg),U,,,22224,0,,CHEMBL619434,BAO_0000218,
8075,Intermediate,10090.0,,1,1977.0,,Blood level after oral administration in mice (50 mg/kg) was determined by bioassay procedure and represent total activity present in the serum,N,,,50594,1,,CHEMBL619435,BAO_0000218,
8076,Autocuration,,,1,1969.0,,AUC (0-4 hr) ug/ml/h,U,,,22224,0,,CHEMBL619436,BAO_0000019,
8077,Intermediate,10116.0,,1,,,Compound at a dose of 10 mg/kg was orally administered to rats and Area under curve was reported,N,,,50597,1,,CHEMBL619437,BAO_0000218,
8078,Autocuration,,,1,,,Compound evaluated for AUC = Area under the nucleoside serum or brain concentration versus time curve after iv administration,U,,,22224,0,,CHEMBL619438,BAO_0000218,
8079,Intermediate,10090.0,,1,,,Compound was evaluated for Area under curve in mice,N,,,50594,1,,CHEMBL619439,BAO_0000218,
8080,Intermediate,10116.0,,1,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,N,,,50597,1,,CHEMBL619440,BAO_0000218,
8081,Autocuration,,,1,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,U,,,22224,0,,CHEMBL619441,BAO_0000218,
8082,Intermediate,10116.0,,1,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,N,,,50597,1,,CHEMBL619442,BAO_0000218,
8083,Autocuration,,,1,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 1,U,,,22224,0,,CHEMBL875156,BAO_0000019,
8084,Autocuration,,,1,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 0.5 mpk on day 4,U,,,22224,0,,CHEMBL619443,BAO_0000019,
8085,Autocuration,,,1,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 1,U,,,22224,0,,CHEMBL619444,BAO_0000019,
8086,Autocuration,,,1,,,Compound was evaluated for area under curve of growth hormone release after chronic oral dosing at 1.0 mpk on day 4,U,,,22224,0,,CHEMBL623464,BAO_0000019,
8087,Intermediate,10090.0,,1,,,Compound was evaluated for area under curve when administered through oral route in mouse,N,,,50594,1,,CHEMBL623465,BAO_0000218,
8088,Intermediate,10116.0,In vivo,1,,,Plasma clearance after oral administration at a dose of 2 mg/kg in rat; no data,N,,,50597,1,,CHEMBL623466,BAO_0000218,
8089,Intermediate,10116.0,In vivo,1,,,Plasma clearance after oral administration at a dose of 4 mg/kg in rat; no data,N,,,50597,1,,CHEMBL623467,BAO_0000218,
8090,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat,N,,,50597,1,,CHEMBL623468,BAO_0000218,
8091,Intermediate,10116.0,In vivo,1,,,Plasma clearance was evaluated in vivo in rat at a dose of 5 mg/kg by intra venous administration,N,,,50597,1,,CHEMBL622660,BAO_0000218,
8092,Intermediate,10116.0,In vivo,1,,,Plasma clearance rate in Sprague-Dawley rats,N,,,50597,1,,CHEMBL622661,BAO_0000218,
8093,Intermediate,10116.0,In vivo,1,,,CLtot at a dose of 4 mg/kg in Rat Plasma after iv administration,N,,,50597,1,,CHEMBL622662,BAO_0000218,
8094,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (total body clearance) in rat,N,,,50597,1,,CHEMBL622663,BAO_0000218,
8095,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (CLtot)of the compound was measured in rat at the dose of 0.32 mg/kg i.v.,N,,,50597,1,,CHEMBL622664,BAO_0000218,
8096,Intermediate,10116.0,,1,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,N,,,50597,1,,CHEMBL622665,BAO_0000218,
8097,Intermediate,10116.0,,1,,,In vivo concentration in rat liver exposure 0-8 hour after oral administration 50 mg/kg,N,,,50597,1,,CHEMBL622666,BAO_0000218,
8098,Intermediate,10116.0,In vivo,1,,,Cl in rat i.v. at 2 mg/kg concentration,N,,,50597,1,,CHEMBL621615,BAO_0000218,
8099,Intermediate,10116.0,In vivo,1,,,Clearance of compound after intravenous administration in rats at 24 uM/kg,N,,,50597,1,,CHEMBL621616,BAO_0000218,
8100,Intermediate,10116.0,In vivo,1,,,Clearance was determined,N,,,50597,1,,CHEMBL621617,BAO_0000218,
8101,Intermediate,10116.0,In vivo,1,,,Clearance by intravenous administration of 3.4 mg/kg in rat,N,,,50597,1,,CHEMBL621618,BAO_0000218,
8102,Intermediate,10116.0,In vivo,1,,,Clearance was evaluated after i.v. administration in rat at a dose of 1 mg/kg,N,,,50597,1,,CHEMBL621619,BAO_0000218,
8103,Intermediate,10116.0,In vivo,1,,,Clearance rate after i.v. administration in rats,N,,,50597,1,,CHEMBL621620,BAO_0000218,
8104,Intermediate,10116.0,In vivo,1,,,Clearance was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,N,,,50597,1,,CHEMBL621786,BAO_0000218,
8105,Intermediate,10116.0,In vivo,1,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,N,,,50597,1,,CHEMBL621787,BAO_0000218,
8106,Intermediate,10116.0,In vivo,1,,,Clearance (Cl) of compound after 2 h iv infusion of 8.4 mg/kg in three rat,N,,,50597,1,,CHEMBL621788,BAO_0000218,
8107,Intermediate,10116.0,In vivo,1,,,Clearance (Cl) after oral administration in rat,N,,,50597,1,,CHEMBL621789,BAO_0000218,
8108,Intermediate,10116.0,In vivo,1,,,Compound clearance in rats was measured after intravenous administration at 3 mg/kg,N,,,50597,1,,CHEMBL621790,BAO_0000218,
8109,Intermediate,10116.0,In vivo,1,1969.0,,Compound was tested for plasma clearance in rat,N,,,50597,1,,CHEMBL621791,BAO_0000218,
8110,Intermediate,10116.0,In vitro,1,,,In vitro microsome metabolism clearance in rat was determined,N,Microsomes,,50597,1,,CHEMBL621792,BAO_0000218,
8111,Intermediate,10116.0,In vitro,1,,,In vitro microsome metabolism clearance in rat was determined; ND denotes no data,N,Microsomes,,50597,1,,CHEMBL621793,BAO_0000218,
8112,Intermediate,10116.0,In vivo,1,,,In vivo Clearance (Cl) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL621794,BAO_0000218,
8113,Intermediate,10116.0,In vivo,1,1969.0,,In vivo plasma clearance was determined,N,,,50597,1,,CHEMBL621795,BAO_0000218,
8114,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (Clearance) for the compound (5 mg/kg iv) was determined in rats,N,,,50597,1,,CHEMBL621796,BAO_0000218,
8115,Intermediate,10116.0,In vivo,1,2107.0,,Pharmacokinetic property (Clearance) in rat hepatocyte i.v.,N,,401.0,50597,1,,CHEMBL621797,BAO_0000218,
8116,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (Plasma clearance) was measured in rat,N,,,50597,1,,CHEMBL621798,BAO_0000218,
8117,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (clearance) in rat i.v.,N,,,50597,1,,CHEMBL621799,BAO_0000218,
8118,Intermediate,10116.0,In vivo,1,,,"Plasma Clearance was evaluated in rats, iv",N,,,50597,1,,CHEMBL621800,BAO_0000218,
8119,Intermediate,10116.0,In vivo,1,,,Plasma clearance (in vivo) in rats was determined,N,,,50597,1,,CHEMBL621801,BAO_0000218,
8120,Intermediate,10116.0,In vivo,1,,,Plasma clearance for the compound was calculated at a single intravenous administration of 20 mg/kg in rat,N,,,50597,1,,CHEMBL621802,BAO_0000218,
8121,Intermediate,10116.0,In vivo,1,,,Plasma clearance was determined,N,,,50597,1,,CHEMBL618596,BAO_0000218,
8122,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat after peroral administration at 10 mg/kg concentration,N,,,50597,1,,CHEMBL618597,BAO_0000218,
8123,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat after peroral administration at 5 mg/kg concentration,N,,,50597,1,,CHEMBL618598,BAO_0000218,
8124,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rats,N,,,50597,1,,CHEMBL618599,BAO_0000218,
8125,Intermediate,10116.0,In vivo,1,,,Plasma clearance rate determined in rat,N,,,50597,1,,CHEMBL618600,BAO_0000218,
8126,Intermediate,10116.0,In vivo,1,,,Plasma clearance was determined in rat,N,,,50597,1,,CHEMBL618601,BAO_0000218,
8127,Intermediate,10116.0,In vivo,1,,,Plasma clearance was determined,N,,,50597,1,,CHEMBL618602,BAO_0000218,
8128,Intermediate,10116.0,In vivo,1,,,Plasma clearance value in rat,N,,,50597,1,,CHEMBL618603,BAO_0000218,
8129,Intermediate,10116.0,Ex vivo,1,2107.0,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,N,,,50597,1,,CHEMBL618604,BAO_0000218,
8130,Intermediate,10116.0,In vivo,1,,,Clearance in rat,N,,,50597,1,,CHEMBL618605,BAO_0000218,
8131,Intermediate,10116.0,In vivo,1,,,Total body clearance in rat i.v. at 2 mg/kg concentration,N,,,50597,1,,CHEMBL618606,BAO_0000218,
8132,Intermediate,10116.0,In vivo,1,,,Clearance of compound in rats after intravenous administration,N,,,50597,1,,CHEMBL618607,BAO_0000218,
8133,Intermediate,10116.0,In vivo,1,,,Clearance after iv administration to rats,N,,,50597,1,,CHEMBL618608,BAO_0000218,
8134,Intermediate,10116.0,In vivo,1,,,Clearance at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,N,,,50597,1,,CHEMBL618609,BAO_0000218,
8135,Intermediate,10116.0,In vivo,1,,,Clearance at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,N,,,50597,1,,CHEMBL618610,BAO_0000218,
8136,Intermediate,10116.0,In vivo,1,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,N,,,50597,1,,CHEMBL618611,BAO_0000218,
8137,Intermediate,10116.0,In vivo,1,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,N,,,50597,1,,CHEMBL618612,BAO_0000218,
8138,Intermediate,10116.0,In vivo,1,,,Clearance at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,N,,,50597,1,,CHEMBL618613,BAO_0000218,
8139,Intermediate,10116.0,In vivo,1,,,Clearance at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,N,,,50597,1,,CHEMBL621076,BAO_0000218,
8140,Intermediate,10116.0,In vivo,1,,,Clearance at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,N,,,50597,1,,CHEMBL621077,BAO_0000218,
8141,Intermediate,10116.0,In vivo,1,,,"Clearance in fischer rats at 5 mg/kg dose, administered intravenously",N,,,50597,1,,CHEMBL621078,BAO_0000218,
8142,Intermediate,10116.0,In vivo,1,,,Clearance in rat,N,,,50597,1,,CHEMBL621251,BAO_0000218,
8143,Intermediate,10116.0,In vivo,1,,,Clearance in rat after oral administration at 10 mg/kg,N,,,50597,1,,CHEMBL621252,BAO_0000218,
8144,Intermediate,10116.0,In vivo,1,,,Clearance in rat.,N,,,50597,1,,CHEMBL621253,BAO_0000218,
8145,Intermediate,10116.0,In vivo,1,,,Clearance rate following an oral dose of 20 mg/kg in rats,N,,,50597,1,,CHEMBL621254,BAO_0000218,
8146,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for the rate of clearance in rat upon intravenous administration.,N,,,50597,1,,CHEMBL621255,BAO_0000218,
8147,Intermediate,10116.0,In vivo,1,1969.0,,Compound was tested for plasma clearance in rats after 5 mg/kg of intravenous dosing,N,,,50597,1,,CHEMBL621256,BAO_0000218,
8148,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 1 hr,N,,,50597,1,,CHEMBL621257,BAO_0000218,
8149,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 30 min,N,,,50597,1,,CHEMBL621258,BAO_0000218,
8150,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of GdDTPA-BDP at 4 hr,N,,,50597,1,,CHEMBL621259,BAO_0000218,
8151,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 15 min,N,,,50597,1,,CHEMBL621260,BAO_0000218,
8152,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 1 hr,N,,,50597,1,,CHEMBL876494,BAO_0000218,
8153,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 30 min,N,,,50597,1,,CHEMBL621261,BAO_0000218,
8154,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of GdDTPA-HPDP at 4 hr,N,,,50597,1,,CHEMBL621262,BAO_0000218,
8155,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of NAC Gd/0.01 M GdDTPA-HPDP,N,,,50597,1,,CHEMBL621263,BAO_0000218,
8156,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver in the presence of NCA Gd/0.01 M lip,N,,,50597,1,,CHEMBL621264,BAO_0000218,
8157,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle in the presence of 0.01 M GdDTPA-BDP,N,,,50597,1,,CHEMBL621265,BAO_0000218,
8158,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle in the presence of 0.05 M Gd/0.15 M lig,N,,,50597,1,,CHEMBL621266,BAO_0000218,
8159,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle in the presence of 0.05 M GdDTPA-BDP,N,,,50597,1,,CHEMBL621267,BAO_0000218,
8160,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle in the presence of 0.10 M GdDTPA-BDP,N,,,50597,1,,CHEMBL621268,BAO_0000218,
8161,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 1 hr,N,,,50597,1,,CHEMBL621269,BAO_0000218,
8162,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle in the presence of GdDTPA-BDP at 4 hr,N,,,50597,1,,CHEMBL621270,BAO_0000218,
8163,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 15 min,N,,,50597,1,,CHEMBL621271,BAO_0000218,
8164,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle in the presence of GdDTPA-BDPat 30 min,N,,,50597,1,,CHEMBL621272,BAO_0000218,
8165,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 1 hr,N,,,50597,1,,CHEMBL621273,BAO_0000218,
8166,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle in the presence of GdDTPA-HPDP at 4 hr,N,,,50597,1,,CHEMBL621274,BAO_0000218,
8167,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 15 min,N,,,50597,1,,CHEMBL876495,BAO_0000218,
8168,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle in the presence of GdDTPA-HPDPat 30 min,N,,,50597,1,,CHEMBL621275,BAO_0000218,
8169,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle in the presence of NCA Gd/0.01 M lip,N,,,50597,1,,CHEMBL621276,BAO_0000218,
8170,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle in the presence of NCAGd/0.01 M lig,N,,,50597,1,,CHEMBL621277,BAO_0000218,
8171,Intermediate,10116.0,In vivo,1,160.0,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 2 hr,N,,,50597,1,,CHEMBL621278,BAO_0000218,
8172,Intermediate,10116.0,In vivo,1,160.0,,Biodistribution in rat s. intestine in the presence of 50 Gd/kg at 6 hr,N,,,50597,1,,CHEMBL621279,BAO_0000218,
8173,Intermediate,10116.0,In vivo,1,160.0,,Biodistribution in rat s. intestine in the presence of NCA (No carrier added),N,,,50597,1,,CHEMBL621280,BAO_0000218,
8174,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in rat spleen in the presence of 0.01 M GdDTPA-BDP,N,,,50597,1,,CHEMBL621281,BAO_0000218,
8175,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in rat spleen in the presence of 0.05 M Gd/0.15 M lig; ND=No data,N,,,50597,1,,CHEMBL621282,BAO_0000218,
8176,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in rat spleen in the presence of 0.05 M GdDTPA-BDP; ND=No data,N,,,50597,1,,CHEMBL621283,BAO_0000218,
8177,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in rat spleen in the presence of 0.10 M GdDTPA-BDP,N,,,50597,1,,CHEMBL621284,BAO_0000218,
8178,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 15 min,N,,,50597,1,,CHEMBL621285,BAO_0000218,
8179,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 2 hr,N,,,50597,1,,CHEMBL621286,BAO_0000218,
8180,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in rat spleen in the presence of 50 Gd/kg at 6 hr,N,,,50597,1,,CHEMBL623220,BAO_0000218,
8181,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in rat spleen in the presence of NCA Gd/0.01 M lip,N,,,50597,1,,CHEMBL623221,BAO_0000218,
8182,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in rat spleen in the presence of NCAGd/0.01 M lig,N,,,50597,1,,CHEMBL876029,BAO_0000218,
8183,Intermediate,10116.0,In vivo,1,945.0,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 15 min,N,,,50597,1,,CHEMBL623222,BAO_0000218,
8184,Intermediate,10116.0,In vivo,1,945.0,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 2 hr,N,,,50597,1,,CHEMBL623223,BAO_0000218,
8185,Intermediate,10116.0,In vivo,1,945.0,,Biodistribution in rat stomach in the presence of 50 Gd/kg at 6 h; ND=No data,N,,,50597,1,,CHEMBL621445,BAO_0000218,
8186,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of [123I]-label in rat blood was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621446,BAO_0000218,
8187,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of [123I]-label in rat blood was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621447,BAO_0000218,
8188,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of [123I]-label in rat blood was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL619681,BAO_0000218,
8189,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of [123I]-label in rat blood was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL619682,BAO_0000218,
8190,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of [123I]-label in rat blood was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL619683,BAO_0000218,
8191,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of [123I]-label in rat brain was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL619684,BAO_0000218,
8192,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of [123I]-label in rat brain was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL619685,BAO_0000218,
8193,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of [123I]-label in rat brain was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL619686,BAO_0000218,
8194,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of [123I]-label in rat brain was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL619687,BAO_0000218,
8195,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of [123I]-label in rat brain was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL619688,BAO_0000218,
8196,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of [123I]-label in rat heart was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL619689,BAO_0000218,
8197,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of [123I]-label in rat heart was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL619690,BAO_0000218,
8198,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of [123I]-label in rat heart was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL619691,BAO_0000218,
8199,Intermediate,10116.0,In vivo,1,,,Terminal phase volume of distribution was measured in rat after an iv dose of 1 mg/kg,N,,,50597,1,,CHEMBL619692,BAO_0000218,
8200,Expert,10116.0,,1,,,Apparent volume of the central plasma compartment (Vc) of compound determined in rat after iv administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL619693,BAO_0000218,
8201,Intermediate,10116.0,In vivo,1,,,Vc value after IV dose at a dose of 5 mg/kg in rats.,N,,,50597,1,,CHEMBL619694,BAO_0000218,
8202,Intermediate,10116.0,In vivo,1,,,Apparent volume of distribution at 10 mg/kg in rat upon intravenous administration,N,,,50597,1,,CHEMBL619695,BAO_0000218,
8203,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for pharmacokinetic parameter volume of distribution,N,,,50597,1,,CHEMBL619696,BAO_0000218,
8204,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for volume of distribution in rat,N,,,50597,1,,CHEMBL619697,BAO_0000218,
8205,Intermediate,10116.0,In vivo,1,,,Steady state volume distribution was determined; steady state(ss),N,,,50597,1,,CHEMBL619698,BAO_0000218,
8206,Intermediate,10116.0,In vivo,1,,,Steady state volume of distribution after iv administration to rats,N,,,50597,1,,CHEMBL619699,BAO_0000218,
8207,Intermediate,10116.0,In vivo,1,,,Steady state volume of distribution dosing at 3 mg/kg iv,N,,,50597,1,,CHEMBL619700,BAO_0000218,
8208,Intermediate,10116.0,In vivo,1,,,The compound was evaluated for volume of distribution in rat,N,,,50597,1,,CHEMBL619701,BAO_0000218,
8209,Intermediate,10116.0,In vivo,1,,,The compound was tested for volume of distribution in rat,N,,,50597,1,,CHEMBL619702,BAO_0000218,
8210,Intermediate,10116.0,In vivo,1,,,The compound was tested for volume of distribution in rat at dose of 3-10 mgkg,N,,,50597,1,,CHEMBL620335,BAO_0000218,
8211,Intermediate,10116.0,In vivo,1,,,Volume distribution (VD) after oral administration in rat,N,,,50597,1,,CHEMBL620336,BAO_0000218,
8212,Intermediate,10116.0,In vivo,1,,,Volume distribution of compound in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,N,,,50597,1,,CHEMBL620337,BAO_0000218,
8213,Intermediate,10116.0,In vivo,1,,,Volume distribution in rat,N,,,50597,1,,CHEMBL620520,BAO_0000218,
8214,Intermediate,10116.0,In vivo,1,,,Volume distribution in rat,N,,,50597,1,,CHEMBL620521,BAO_0000218,
8215,Intermediate,10116.0,In vivo,1,,,Volume distribution in rat after peroral administration at 10 mg/kg,N,,,50597,1,,CHEMBL875825,BAO_0000218,
8216,Intermediate,10116.0,In vivo,1,,,Volume distribution in rat after peroral administration at 5 mg/kg,N,,,50597,1,,CHEMBL620522,BAO_0000218,
8217,Intermediate,10116.0,In vivo,1,,,Volume distribution was evaluated after i.v. administration in rat at a dose of 1 mg/kg,N,,,50597,1,,CHEMBL620523,BAO_0000218,
8218,Intermediate,10116.0,In vivo,1,,,Volume of distribution in rat.,N,,,50597,1,,CHEMBL620524,BAO_0000218,
8219,Intermediate,10116.0,In vivo,1,,,Volume of distribution in rat,N,,,50597,1,,CHEMBL620525,BAO_0000218,
8220,Intermediate,10116.0,In vivo,1,,,Volume of distribution in rat,N,,,50597,1,,CHEMBL620526,BAO_0000218,
8221,Intermediate,10116.0,In vivo,1,,,Volume of distribution in rat by iv administration,N,,,50597,1,,CHEMBL620527,BAO_0000218,
8222,Intermediate,10116.0,In vivo,1,,,Volume of distribution in rats,N,,,50597,1,,CHEMBL620528,BAO_0000218,
8223,Intermediate,10116.0,In vivo,1,,,Volume of distribution was determined in female Sprague-Dawley rats following intravenous (iv) administration of drug (1 mg/kg).,N,,,50597,1,,CHEMBL620529,BAO_0000218,
8224,Intermediate,10116.0,,1,,,Volume distribution at the dose of 2 mg/kg in rat,N,,,50597,1,,CHEMBL620530,BAO_0000218,
8225,Intermediate,10116.0,In vivo,1,,,Steady state volume of distribution was determined,N,,,50597,1,,CHEMBL620531,BAO_0000218,
8226,Intermediate,9544.0,In vivo,1,,,Compound was tested for its plasma volume distribution in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po,U,,,22224,0,,CHEMBL620532,BAO_0000218,
8227,Intermediate,10116.0,In vivo,1,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats,U,,,22224,0,,CHEMBL620533,BAO_0000218,
8228,Intermediate,10116.0,In vivo,1,,,Compound was tested for its plasma volume distribution in Sprague Dawley rats; ND is not determined,U,,,22224,0,,CHEMBL620534,BAO_0000218,
8229,Intermediate,10116.0,In vivo,1,,,Mean (%CV) PK parameters for Vdss(mL/kg).,N,,,50597,1,,CHEMBL620535,BAO_0000218,
8230,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter Vdss was determined at 2 mg/kg i.v. dose in rats,N,,,50597,1,,CHEMBL875826,BAO_0000218,
8231,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter Vdss was determined at 5 mg/kg i.v. dose in rats,N,,,50597,1,,CHEMBL620536,BAO_0000218,
8232,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,N,,,50597,1,,CHEMBL620537,BAO_0000218,
8233,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter volume of distribution was reported in Sprague-Dawley rat; ND=Not determined,N,,,50597,1,,CHEMBL618526,BAO_0000218,
8234,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (Vdss) for the compound (5 mg/kg iv) was determined in rats,N,,,50597,1,,CHEMBL618527,BAO_0000218,
8235,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (Vdss) in rat,N,,,50597,1,,CHEMBL618528,BAO_0000218,
8236,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (vdss) was measured in rat,N,,,50597,1,,CHEMBL618529,BAO_0000218,
8237,Intermediate,10116.0,In vivo,1,,,Steady state volume of distribution for the compound after intravenous administration of 1 mg/kg in rat,N,,,50597,1,,CHEMBL618530,BAO_0000218,
8238,Intermediate,10116.0,In vivo,1,,,Volume of distribution in rat,N,,,50597,1,,CHEMBL618531,BAO_0000218,
8239,Intermediate,10116.0,In vivo,1,,,The pharmacokinetic parameter volume of distribution in vivo in rats,N,,,50597,1,,CHEMBL618532,BAO_0000218,
8240,Intermediate,10116.0,In vivo,1,,,Vdss at a dose of 4 mg/kg in Rat Plasma after iv administration,N,,,50597,1,,CHEMBL618533,BAO_0000218,
8241,Intermediate,10116.0,In vivo,1,,,Vdss in rat i.v. at 2 mg/kg concentration,N,,,50597,1,,CHEMBL618534,BAO_0000218,
8242,Intermediate,10116.0,In vivo,1,,,Volume distribution after intravenous administration (1 mg/kg) in rat,N,,,50597,1,,CHEMBL618535,BAO_0000218,
8243,Intermediate,10116.0,In vivo,1,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,N,,,50597,1,,CHEMBL618536,BAO_0000218,
8244,Intermediate,10116.0,In vivo,1,,,Volume distribution of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,N,,,50597,1,,CHEMBL618537,BAO_0000218,
8245,Intermediate,10116.0,In vivo,1,,,Volume distribution at a dose of 10 uM/kg in rat was determined,N,,,50597,1,,CHEMBL618538,BAO_0000218,
8246,Intermediate,10116.0,In vivo,1,,,Volume distribution in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,N,,,50597,1,,CHEMBL618539,BAO_0000218,
8247,Intermediate,10116.0,In vivo,1,,,Volume distribution was calculated in rat,N,,,50597,1,,CHEMBL618540,BAO_0000218,
8248,Intermediate,10116.0,In vivo,1,,,Volume distribution was determined,N,,,50597,1,,CHEMBL618541,BAO_0000218,
8249,Intermediate,10116.0,In vivo,1,,,Volume of distribution after intravenous administration was evaluated in rat,N,,,50597,1,,CHEMBL618542,BAO_0000218,
8250,Intermediate,10116.0,In vivo,1,,,Volume of distribution at steady state was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,,50597,1,,CHEMBL622544,BAO_0000218,
8251,Intermediate,10116.0,In vivo,1,,,"Volume of distribution at steady state was determined in rats at 10 mg/kg, p.o. dose; n/a: not applicable",N,,,50597,1,,CHEMBL622545,BAO_0000218,
8252,Intermediate,10116.0,In vivo,1,,,"Volume of distribution at steady state was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",N,,,50597,1,,CHEMBL622546,BAO_0000218,
8253,Intermediate,10116.0,In vivo,1,,,"Volume of distribution at steady state was determined in rats at 2 mg/kg, i.v. dose",N,,,50597,1,,CHEMBL622547,BAO_0000218,
8254,Intermediate,10116.0,In vivo,1,,,Volume of distribution in steady state was determined in rat,N,,,50597,1,,CHEMBL622548,BAO_0000218,
8255,Intermediate,10116.0,In vivo,1,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration,N,,,50597,1,,CHEMBL622549,BAO_0000218,
8256,Intermediate,10116.0,In vivo,1,,,Volume of distribution in steady state was determined in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,N,,,50597,1,,CHEMBL622550,BAO_0000218,
8257,Intermediate,10090.0,,1,,,Compound was evaluated for area under curve when administered through oral route to mouse,N,,,50594,1,,CHEMBL622551,BAO_0000218,
8258,Intermediate,10116.0,,1,,,Compound was evaluated for area under curve doses in rat at 100 mg/kg po,N,,,50597,1,,CHEMBL622552,BAO_0000218,
8259,Intermediate,10116.0,,1,,,Compound was evaluated for area under curve doses in rat at 50 mg/kg po,N,,,50597,1,,CHEMBL622553,BAO_0000218,
8260,Autocuration,,In vivo,1,,,Compound was evaluated for its bioavailability after oral administration (100 mg) to Beagle dogs,U,,,22224,0,,CHEMBL622554,BAO_0000218,
8261,Intermediate,9615.0,,1,,,Compound was evaluated for its bioavailability after oral administration (200 mg) to Beagle dogs,N,,,50588,1,,CHEMBL622555,BAO_0000218,
8262,Intermediate,10090.0,,1,,,Compound was evaluated for the area under the concentration - time curve by administering intravenously at 25 mg/kg in mice,N,,,50594,1,,CHEMBL622556,BAO_0000218,
8263,Intermediate,10090.0,,1,,,Compound was evaluated for the area under the concentration - time curve by administering orally at 25 mg/kg in mice,N,,,50594,1,,CHEMBL622557,BAO_0000218,
8264,Intermediate,10090.0,,1,178.0,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg intramuscular administration to mice,N,,,50594,1,,CHEMBL622558,BAO_0000218,
8265,Intermediate,10090.0,,1,178.0,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to mice,N,,,50594,1,,CHEMBL622559,BAO_0000218,
8266,Intermediate,9615.0,,1,,,Compound was evaluated in vivo in for its concentration using Area under the time-concentration curve after 40 mg/kg peroral administration to dogs.,N,,,50588,1,,CHEMBL622560,BAO_0000218,
8267,Intermediate,10116.0,,1,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose,N,,,50597,1,,CHEMBL622561,BAO_0000218,
8268,Intermediate,10116.0,,1,,,Compound was tested for area under concentration -time curve from time 0 to time infinity in three male Wistar rats at a single 5 mg/kg oral gavage dose. ,N,,,50597,1,,CHEMBL622562,BAO_0000218,
8269,Intermediate,10116.0,,1,,,Compound was tested for area under concentration -time curve from time 0 to time of last detectable concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,N,,,50597,1,,CHEMBL622563,BAO_0000218,
8270,Autocuration,,,1,,,Concentration of compound in Central nervous system,U,,,22224,0,,CHEMBL622564,BAO_0000019,
8271,Autocuration,,,1,,,Concentration of compound in Central nervous system; Not detectable,U,,,22224,0,,CHEMBL622565,BAO_0000019,
8272,Intermediate,10090.0,,1,,,"Concentration of diester in the blood, following oral administration in mice",N,,,50594,1,,CHEMBL622566,BAO_0000218,
8273,Intermediate,10090.0,,1,,,"Concentration of monoester in the blood, following oral administration in mice",N,,,50594,1,,CHEMBL624515,BAO_0000218,
8274,Intermediate,10090.0,,1,,,Concentration of the 9-[2-(Phosphonomethoxy)ethoxy]adenine in the blood following oral administration in mice,N,,,50594,1,,CHEMBL624516,BAO_0000218,
8275,Autocuration,,,1,,,Evaluated for Pharmacokinetic property: Area under the curve,U,,,22224,0,,CHEMBL624517,BAO_0000019,
8276,Intermediate,10090.0,,1,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after a peroral dose of 25 mg/kg in nude mice,N,,,50594,1,,CHEMBL624518,BAO_0000218,
8277,Intermediate,9541.0,,1,,,In vivo antitumor efficacy expressed as plasma area under the curve 0.4 hr after iv dose of 25 mg/kg in nude mice,N,,,100710,1,,CHEMBL624519,BAO_0000218,
8278,Intermediate,9541.0,,1,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after iv dose of 5 mg/kg expressed as Area under the curve,N,,,100710,1,,CHEMBL624520,BAO_0000218,
8279,Intermediate,9541.0,,1,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 10 mg/kg expressed as Area under the curve,N,,,100710,1,,CHEMBL624521,BAO_0000218,
8280,Intermediate,9541.0,,1,,,In vivo antitumor efficacy in cynomolgus monkeys 0-48 hr after peroral dose of 5 mg/kg expressed as Area under the curve,N,,,100710,1,,CHEMBL624522,BAO_0000218,
8281,Intermediate,9541.0,,1,,,In vivo antitumor efficacy in cynomolgus monkeys 0-8 hours after peroral dose of 25 mg/kg expressed as Area under the curve,N,,,100710,1,,CHEMBL624523,BAO_0000218,
8282,Intermediate,9541.0,,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",N,,,100710,1,,CHEMBL624409,BAO_0000218,
8283,Intermediate,9541.0,,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-8 hr)",N,,,100710,1,,CHEMBL624410,BAO_0000218,
8284,Intermediate,9541.0,,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",N,,,100710,1,,CHEMBL624411,BAO_0000218,
8285,Intermediate,9541.0,,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, iv and the total drug exposure was determined. (0-8 hr)",N,,,100710,1,,CHEMBL623531,BAO_0000218,
8286,Intermediate,9541.0,,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as the micronised free base in corn oil, perorally and the total drug exposure was determined (0-8 hr)",N,,,100710,1,,CHEMBL623532,BAO_0000218,
8287,Intermediate,9541.0,,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, intravenously and the total drug exposure was determined (0-8 hr)",N,,,100710,1,,CHEMBL623533,BAO_0000218,
8288,Intermediate,9541.0,,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-8 hr)",N,,,100710,1,,CHEMBL623534,BAO_0000218,
8289,Intermediate,10090.0,,1,,,In vivo antitumor efficacy in nude mice 0-24 hr after intravenous dose of 25 mg/kg expressed as Area under the curve,N,,,50594,1,,CHEMBL623535,BAO_0000218,
8290,Intermediate,10090.0,,1,,,In vivo antitumor efficacy in nude mice 0-24 hr after iperoral dose of 25 mg/kg expressed as Area under the curve,N,,,50594,1,,CHEMBL623536,BAO_0000218,
8291,Intermediate,10090.0,,1,,,In vivo antitumor efficacy in nude mice 0-24 hr after iv dose of 25 mg/kg expressed as Area under the curve,N,,,50594,1,,CHEMBL623537,BAO_0000218,
8292,Intermediate,10090.0,,1,,,In vivo antitumor efficacy in nude mice 0-24 hr after peroral dose of 25 mg/kg expressed as Area under the curve,N,,,50594,1,,CHEMBL623538,BAO_0000218,
8293,Intermediate,10090.0,,1,,,In vivo antitumor efficacy in nude mice after peroral dose of 10 mg/kg expressed as Area under the curve,N,,,50594,1,,CHEMBL623539,BAO_0000218,
8294,Intermediate,10090.0,,1,,,In vivo antitumor efficacy in nude mice after peroral dose of 25 mg/kg expressed as Area under the curve,N,,,50594,1,,CHEMBL623540,BAO_0000218,
8295,Intermediate,10090.0,,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined.",N,,,50594,1,,CHEMBL623541,BAO_0000218,
8296,Intermediate,10090.0,,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-24hr)",N,,,50594,1,,CHEMBL623542,BAO_0000218,
8297,Intermediate,10090.0,,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, iv and the total drug exposure was determined. (0-4 hr)",N,,,50594,1,,CHEMBL623543,BAO_0000218,
8298,Intermediate,10090.0,,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined",N,,,50594,1,,CHEMBL623544,BAO_0000218,
8299,Intermediate,10090.0,,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-24hr)",N,,,50594,1,,CHEMBL623545,BAO_0000218,
8300,Intermediate,10090.0,,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the total drug exposure was determined (0-4 hr)",N,,,50594,1,,CHEMBL623546,BAO_0000218,
8301,Intermediate,10116.0,In vivo,1,1969.0,,Evaluated for plasma clearance after iv administration of 5 mg/kg to male Sprague-Dawley rats,N,,,50597,1,,CHEMBL623547,BAO_0000218,
8302,Intermediate,10116.0,In vivo,1,,,High i.v. clearance in Dawley rats,N,,,50597,1,,CHEMBL623548,BAO_0000218,
8303,Intermediate,10116.0,In vitro,1,2107.0,,In vitro clearance in rat liver microsomes,N,Microsomes,,50597,1,,CHEMBL623549,BAO_0000218,
8304,Intermediate,10116.0,In vitro,1,2107.0,,Intrinsic clearance in rat liver microsomes was determined,N,Microsomes,,50597,1,,CHEMBL623550,BAO_0000218,
8305,Intermediate,10116.0,In vitro,1,2107.0,,Intrinsic clearance in rat hepatocytes was determined,N,,401.0,50597,1,,CHEMBL875276,BAO_0000218,
8306,Intermediate,10116.0,In vivo,1,,,Plasma Clearance was determined,N,,,50597,1,,CHEMBL621872,BAO_0000218,
8307,Intermediate,10116.0,In vivo,1,,,Plasma clearance after intravenous administration of 0.4 mg/kg of dose in rats was determined,N,,,50597,1,,CHEMBL621873,BAO_0000218,
8308,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat.,N,,,50597,1,,CHEMBL621874,BAO_0000218,
8309,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rats,N,,,50597,1,,CHEMBL621875,BAO_0000218,
8310,Intermediate,10116.0,In vivo,1,,,Plasma clearance was estimated from the AUC after 5 mg/kg intravenous dosing in rats,N,,,50597,1,,CHEMBL621876,BAO_0000218,
8311,Intermediate,10116.0,In vivo,1,,,Plasma clearance was evaluated after 10 uM/kg of intra arterial administration,N,,,50597,1,,CHEMBL621877,BAO_0000218,
8312,Intermediate,10116.0,In vivo,1,,,Plasma clearance was measured in rat,N,,,50597,1,,CHEMBL621878,BAO_0000218,
8313,Intermediate,10116.0,In vivo,1,,,Clearance after iv administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,N,,,50597,1,,CHEMBL621879,BAO_0000218,
8314,Intermediate,10116.0,In vivo,1,1969.0,,"Tested for the plasma clearance in Dawley rat at a dose of 1 mg/kg intravenous, 2 mg/kg orally",N,,,50597,1,,CHEMBL621880,BAO_0000218,
8315,Intermediate,10116.0,In vivo,1,,,The clearance rate in mature male rat at a intravenous dose of 3 mg/kg,N,,,50597,1,,CHEMBL621881,BAO_0000218,
8316,Intermediate,10116.0,In vivo,1,,,Total body clearance was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,N,,,50597,1,,CHEMBL621882,BAO_0000218,
8317,Intermediate,10116.0,In vivo,1,,,Total clearance at 1 mg/kg was determined in rat,N,,,50597,1,,CHEMBL875283,BAO_0000218,
8318,Intermediate,10116.0,In vivo,1,,,Total clearance at 10 mg/kg was determined in rat,N,,,50597,1,,CHEMBL621883,BAO_0000218,
8319,Intermediate,10116.0,In vivo,1,,,Clearance in rat,N,,,50597,1,,CHEMBL621884,BAO_0000218,
8320,Intermediate,10116.0,In vivo,1,,,Plasma clearance rate determined in rats,N,,,50597,1,,CHEMBL621885,BAO_0000218,
8321,Intermediate,10116.0,In vivo,1,,,Clearance of compound in rat was evaluated,N,,,50597,1,,CHEMBL621886,BAO_0000218,
8322,Intermediate,10116.0,In vivo,1,1969.0,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,N,,,50597,1,,CHEMBL621887,BAO_0000218,
8323,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (blood clearance) in rat,N,,,50597,1,,CHEMBL621888,BAO_0000218,
8324,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat,N,,,50597,1,,CHEMBL621889,BAO_0000218,
8325,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rats,N,,,50597,1,,CHEMBL621890,BAO_0000218,
8326,Intermediate,10116.0,In vitro,1,2107.0,,Intrinsic clearance of compound against NADPH-fortified rat liver microsomes,N,Microsomes,,50597,1,,CHEMBL621891,BAO_0000218,
8327,Intermediate,10116.0,In vivo,1,,,Clearance in Dawley rat,N,,,50597,1,,CHEMBL621892,BAO_0000218,
8328,Intermediate,10116.0,In vivo,1,,,Clearance rat,N,,,50597,1,,CHEMBL621893,BAO_0000218,
8329,Intermediate,10116.0,In vivo,1,,,Clearance rat (dosed at 0.5 mpk IV and 2.0 mpk po.),N,,,50597,1,,CHEMBL621894,BAO_0000218,
8330,Intermediate,10116.0,In vivo,1,,,Clearance rat; Not determined,N,,,50597,1,,CHEMBL621895,BAO_0000218,
8331,Intermediate,10116.0,In vivo,1,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.,N,,,50597,1,,CHEMBL875284,BAO_0000218,
8332,Intermediate,10116.0,In vivo,1,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND means not determined,N,,,50597,1,,CHEMBL618699,BAO_0000218,
8333,Intermediate,10116.0,In vivo,1,,,Clearance rate was determined in rat at a dose of 1 mpk i.v.; ND=not determined,N,,,50597,1,,CHEMBL618700,BAO_0000218,
8334,Intermediate,10116.0,In vivo,1,,,Clearance was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,N,,,50597,1,,CHEMBL618701,BAO_0000218,
8335,Intermediate,10116.0,In vivo,1,1969.0,,"Clearance in plasma calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",N,,,50597,1,,CHEMBL876600,BAO_0000218,
8336,Intermediate,10116.0,In vivo,1,,,Clearance of compound in rat after 1 mg/kg i.v. administration,N,,,50597,1,,CHEMBL618702,BAO_0000218,
8337,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for Hepatic clearance in rat,N,,,50597,1,,CHEMBL618703,BAO_0000218,
8338,Intermediate,10116.0,In vivo,1,,,In vivo clearance after 5 mg/kg dose,N,,,50597,1,,CHEMBL618704,BAO_0000218,
8339,Intermediate,10116.0,In vivo,1,1969.0,,Compound was tested for plasma clearance in rats,N,,,50597,1,,CHEMBL618705,BAO_0000218,
8340,Intermediate,10116.0,In vivo,1,,,Hepatic clearance after intravenous administration was evaluated in rat,N,,,50597,1,,CHEMBL618706,BAO_0000218,
8341,Intermediate,10116.0,In vivo,1,,,Lower clearance in rat (i.v.) at 0.5 mpk,N,,,50597,1,,CHEMBL618707,BAO_0000218,
8342,Intermediate,10116.0,In vivo,1,1969.0,,Pharmacokinetic parameter expressed as plasma clearance in rat,N,,,50597,1,,CHEMBL618708,BAO_0000218,
8343,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (Clp) in rat,N,,,50597,1,,CHEMBL618709,BAO_0000218,
8344,Intermediate,10116.0,In vivo,1,,,Plasma clearance in Sprague-Dawley rats,N,,,50597,1,,CHEMBL618710,BAO_0000218,
8345,Intermediate,10116.0,In vivo,1,,,Plasma clearance (Clp) in rat,N,,,50597,1,,CHEMBL618711,BAO_0000218,
8346,Intermediate,10116.0,In vivo,1,,,Plasma clearance for the compound was measured in rat after an iv dose of 1 mg/kg,N,,,50597,1,,CHEMBL618712,BAO_0000218,
8347,Intermediate,10116.0,In vivo,1,,,Plasma clearance in fasted male Sprague dawely rats on administration of 0.5 mg/Kg i.v. of the compound,N,,,50597,1,,CHEMBL618713,BAO_0000218,
8348,Intermediate,10116.0,In vivo,1,,,Plasma clearance after intravenous administration of 1 mg/kg in rat,N,,,50597,1,,CHEMBL618714,BAO_0000218,
8349,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,N,,,50597,1,,CHEMBL618715,BAO_0000218,
8350,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat was determined,N,,,50597,1,,CHEMBL618716,BAO_0000218,
8351,Intermediate,10116.0,In vivo,1,,,Plasma clearance measured in rat,N,,,50597,1,,CHEMBL876601,BAO_0000218,
8352,Intermediate,10116.0,In vivo,1,,,Plasma clearance was calculated in rat,N,,,50597,1,,CHEMBL618717,BAO_0000218,
8353,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat,N,,,50597,1,,CHEMBL618718,BAO_0000218,
8354,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat,N,,,50597,1,,CHEMBL618719,BAO_0000218,
8355,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat,N,,,50597,1,,CHEMBL618720,BAO_0000218,
8356,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat,N,,,50597,1,,CHEMBL618721,BAO_0000218,
8357,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rats,N,,,50597,1,,CHEMBL621477,BAO_0000218,
8358,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat,N,,,50597,1,,CHEMBL621478,BAO_0000218,
8359,Intermediate,10116.0,In vivo,1,,,Plasma clearance was evaluated in rat,N,,,50597,1,,CHEMBL621479,BAO_0000218,
8360,Intermediate,10116.0,In vivo,1,,,Plasma clearance was evaluated in rat; Not tested,N,,,50597,1,,CHEMBL621480,BAO_0000218,
8361,Intermediate,10116.0,In vivo,1,,,Plasma clearance rate was determined for the compound in rat,N,,,50597,1,,CHEMBL621481,BAO_0000218,
8362,Intermediate,10116.0,In vivo,1,,,"Plasma clearance rate was determined in rats at 10mg/kg, p.o. dose; n/a: not applicable",N,,,50597,1,,CHEMBL621482,BAO_0000218,
8363,Intermediate,10116.0,In vivo,1,,,"Plasma clearance rate was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",N,,,50597,1,,CHEMBL621483,BAO_0000218,
8364,Intermediate,10116.0,In vivo,1,,,"Plasma clearance rate was determined in rats at 2 mg/kg, i.v. dose",N,,,50597,1,,CHEMBL621484,BAO_0000218,
8365,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of [123I]-label in rat heart was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621485,BAO_0000218,
8366,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of [123I]-label in rat heart was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621486,BAO_0000218,
8367,Intermediate,10116.0,In vivo,1,160.0,,Biodistribution of [123I]-label in rat intestine was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621487,BAO_0000218,
8368,Intermediate,10116.0,In vivo,1,160.0,,Biodistribution of [123I]-label in rat intestine was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621488,BAO_0000218,
8369,Intermediate,10116.0,In vivo,1,160.0,,Biodistribution of [123I]-label in rat intestine was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621489,BAO_0000218,
8370,Intermediate,10116.0,In vivo,1,160.0,,Biodistribution of [123I]-label in rat intestine was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621490,BAO_0000218,
8371,Intermediate,10116.0,In vivo,1,160.0,,Biodistribution of [123I]-label in rat intestine was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621491,BAO_0000218,
8372,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of [123I]-label in rat kidneys was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621492,BAO_0000218,
8373,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of [123I]-label in rat kidneys was reported at 1 h post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621493,BAO_0000218,
8374,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of [123I]-label in rat kidneys was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621494,BAO_0000218,
8375,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of [123I]-label in rat kidneys was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621495,BAO_0000218,
8376,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of [123I]-label in rat kidneys was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621496,BAO_0000218,
8377,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of [123I]-label in rat liver was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621497,BAO_0000218,
8378,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of [123I]-label in rat liver was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621498,BAO_0000218,
8379,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of [123I]-label in rat liver was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL621499,BAO_0000218,
8380,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of [123I]-label in rat liver was reported at 24 h post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL618634,BAO_0000218,
8381,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of [123I]-label in rat liver was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL618635,BAO_0000218,
8382,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of [123I]-label in rat lung was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL618636,BAO_0000218,
8383,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of [123I]-label in rat lung was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL619737,BAO_0000218,
8384,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of [123I]-label in rat lung was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL619738,BAO_0000218,
8385,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of [123I]-label in rat lung was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL624329,BAO_0000218,
8386,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of [123I]-label in rat lung was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL624330,BAO_0000218,
8387,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of [123I]-label in rat muscle was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL624331,BAO_0000218,
8388,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of [123I]-label in rat muscle was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL624332,BAO_0000218,
8389,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of [123I]-label in rat muscle was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL624333,BAO_0000218,
8390,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of [123I]-label in rat muscle was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL624334,BAO_0000218,
8391,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of [123I]-label in rat muscle was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL624335,BAO_0000218,
8392,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of [123I]-label in rat spleen was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620016,BAO_0000218,
8393,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of [123I]-label in rat spleen was reported at 1 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620169,BAO_0000218,
8394,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of [123I]-label in rat spleen was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620170,BAO_0000218,
8395,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of [123I]-label in rat spleen was reported at 24 h post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620171,BAO_0000218,
8396,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of [123I]-label in rat spleen was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620172,BAO_0000218,
8397,Intermediate,10116.0,In vivo,1,945.0,,Biodistribution of [123I]-label in rat stomach was reported at 0.33 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620173,BAO_0000218,
8398,Intermediate,10116.0,In vivo,1,945.0,,Biodistribution of [123I]-label in rat stomach was reported at 1 h post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620174,BAO_0000218,
8399,Intermediate,10116.0,In vivo,1,945.0,,Biodistribution of [123I]-label in rat stomach was reported at 2 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620175,BAO_0000218,
8400,Intermediate,10116.0,In vivo,1,945.0,,Biodistribution of [123I]-label in rat stomach was reported at 24 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620176,BAO_0000218,
8401,Intermediate,10116.0,In vivo,1,945.0,,Biodistribution of [123I]-label in rat stomach was reported at 4 hr post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620177,BAO_0000218,
8402,Intermediate,10116.0,,1,2037.0,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620178,BAO_0000218,
8403,Intermediate,10116.0,,1,2037.0,,Distribution of [123I]-label in rat brain (cerebellum) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620179,BAO_0000218,
8404,Intermediate,10116.0,,1,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620180,BAO_0000218,
8405,Intermediate,10116.0,In vivo,1,,,Volume of distribution of compound in rat after 1 mg/kg i.v. administration,N,,,50597,1,,CHEMBL620181,BAO_0000218,
8406,Intermediate,10116.0,In vivo,1,,,Volume of distribution of compound in rats after intravenous administration,N,,,50597,1,,CHEMBL620182,BAO_0000218,
8407,Intermediate,10116.0,In vivo,1,,,Volume of distribution in rat,N,,,50597,1,,CHEMBL620183,BAO_0000218,
8408,Intermediate,10116.0,In vivo,1,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.,N,,,50597,1,,CHEMBL620184,BAO_0000218,
8409,Intermediate,10116.0,In vivo,1,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND means not determined,N,,,50597,1,,CHEMBL620185,BAO_0000218,
8410,Intermediate,10116.0,In vivo,1,,,Volume of distribution was determined in rat at a dose of 1 mpk i.v.; ND=not determined,N,,,50597,1,,CHEMBL620186,BAO_0000218,
8411,Intermediate,10116.0,In vivo,1,,,Volume of distribution was determined in Dawley rat,N,,,50597,1,,CHEMBL620187,BAO_0000218,
8412,Intermediate,10116.0,In vivo,1,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,N,,,50597,1,,CHEMBL620188,BAO_0000218,
8413,Intermediate,10116.0,In vivo,1,,,Volume of distribution was reported in Sprague-Dawley rat,N,,,50597,1,,CHEMBL620189,BAO_0000218,
8414,Intermediate,10116.0,In vivo,1,,,Volumes of distribution in rat after peroral administration,N,,,50597,1,,CHEMBL620190,BAO_0000218,
8415,Intermediate,10116.0,In vivo,1,,,Volumes of distribution in rat after po administration,N,,,50597,1,,CHEMBL620191,BAO_0000218,
8416,Intermediate,10116.0,In vivo,1,,,Volumes of distribution in rat after po administration; Not determined,N,,,50597,1,,CHEMBL620192,BAO_0000218,
8417,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (Volume) in rat i.v.,N,,,50597,1,,CHEMBL620193,BAO_0000218,
8418,Intermediate,10116.0,In vivo,1,,,Apparent volume of distribution when 3 mg/Kg dose was administered intravenously,N,,,50597,1,,CHEMBL620194,BAO_0000218,
8419,Intermediate,10116.0,In vivo,1,,,"Volume distribution in fischer rats at 5 mg/kg dose, administered intravenously",N,,,50597,1,,CHEMBL876730,BAO_0000218,
8420,Intermediate,10116.0,In vivo,1,,,Volume distribution in rat after oral administration at 10 mg/kg,N,,,50597,1,,CHEMBL620195,BAO_0000218,
8421,Intermediate,10116.0,In vivo,1,,,Evaluated for Volume of distribution after iv administration of 5 mg/kg to male Sprague-Dawley rats,N,,,50597,1,,CHEMBL620196,BAO_0000218,
8422,Intermediate,10116.0,In vivo,1,,,Tested for volume of distribution after intravenous administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,N,,,50597,1,,CHEMBL620197,BAO_0000218,
8423,Intermediate,10116.0,In vivo,1,,,Volume of distribution after oral administration of 6 mg/kg of dose in rats was determined,N,,,50597,1,,CHEMBL620198,BAO_0000218,
8424,Intermediate,10116.0,In vivo,1,,,Volume of distribution in rats,N,,,50597,1,,CHEMBL620199,BAO_0000218,
8425,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to female wistar rats,N,,,50597,1,,CHEMBL620200,BAO_0000218,
8426,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for volume of distribution (steady state) after treatment with iv dose of 1 mgkg to male wistar rats,N,,,50597,1,,CHEMBL620201,BAO_0000218,
8427,Intermediate,10116.0,In vivo,1,,,In vivo Volume distribution (Vss) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL620202,BAO_0000218,
8428,Intermediate,10116.0,In vivo,1,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL620203,BAO_0000218,
8429,Intermediate,10116.0,In vivo,1,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat;no value,N,,,50597,1,,CHEMBL620204,BAO_0000218,
8430,Intermediate,10116.0,In vivo,1,,,In vivo Volume distribution (Vss) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL620205,BAO_0000218,
8431,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter (Vss) in rat,N,,,50597,1,,CHEMBL624664,BAO_0000218,
8432,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (Volume) in rat i.v.,N,,,50597,1,,CHEMBL624665,BAO_0000218,
8433,Intermediate,10116.0,,1,,,Pharmacokinetic property (Vss) in rat,N,,,50597,1,,CHEMBL624666,BAO_0000218,
8434,Intermediate,10116.0,In vivo,1,,,Steady state volume distribution (Vss) of compound after 2 hr iv infusion of 8.4 mg/kg in three rat,N,,,50597,1,,CHEMBL624667,BAO_0000218,
8435,Intermediate,10116.0,In vivo,1,,,Steady state volume distribution (Vss) of compound after iv administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL624668,BAO_0000218,
8436,Intermediate,10116.0,In vivo,1,,,Steady state volume distribution (Vss) of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL624669,BAO_0000218,
8437,Intermediate,10116.0,In vivo,1,,,Steady state volume distribution (Vss) of compound(9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL624670,BAO_0000218,
8438,Intermediate,10116.0,In vivo,1,,,Steady state volume distribution (Vss) of compound(9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL624671,BAO_0000218,
8439,Intermediate,10116.0,In vivo,1,,,Steady state volume distribution in rat,N,,,50597,1,,CHEMBL624672,BAO_0000218,
8440,Intermediate,10116.0,In vivo,1,1969.0,,"Steady state volume of distribution calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv.",N,,,50597,1,,CHEMBL624673,BAO_0000218,
8441,Intermediate,10116.0,In vivo,1,,,Steady state volume of distribution determined in rat,N,,,50597,1,,CHEMBL624674,BAO_0000218,
8442,Intermediate,10116.0,In vivo,1,,,Steady-state volume of distribution was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,N,,,50597,1,,CHEMBL624675,BAO_0000218,
8443,Intermediate,10116.0,In vivo,1,,,Tested for volume of distribution at steady state upon intravenous administration of 5.0 mg/Kg dose in rat,N,,,50597,1,,CHEMBL621728,BAO_0000218,
8444,Intermediate,10116.0,,1,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined,N,,,50597,1,,CHEMBL621729,BAO_0000218,
8445,Intermediate,10116.0,,1,,,Volume at steady state distribution by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat was determined; NC means not calculated,N,,,50597,1,,CHEMBL621730,BAO_0000218,
8446,Intermediate,10116.0,In vivo,1,,,Volume distribution in rat after administration of 2 mg/kg iv,N,,,50597,1,,CHEMBL621731,BAO_0000218,
8447,Intermediate,10116.0,In vivo,1,,,Volume distribution in rat after administration of 2 mg/kg iv,N,,,50597,1,,CHEMBL621732,BAO_0000218,
8448,Intermediate,10116.0,In vivo,1,,,Volume in steady state distribution value was determined,N,,,50597,1,,CHEMBL621908,BAO_0000218,
8449,Intermediate,10116.0,In vivo,1,,,Volume in steady state distribution value was determined; ND denotes no data,N,,,50597,1,,CHEMBL875347,BAO_0000218,
8450,Intermediate,10116.0,In vivo,1,,,Volume in steady state distribution value was determined; ND denotes not determined,N,,,50597,1,,CHEMBL621909,BAO_0000218,
8451,Intermediate,10116.0,In vivo,1,,,Volume of distribution at a steady state measured after intravenous bolus administration of 50 mg/kg of compound to rats,N,,,50597,1,,CHEMBL621910,BAO_0000218,
8452,Intermediate,10116.0,In vivo,1,,,Volume of distribution at steady state was evaluated in rats,N,,,50597,1,,CHEMBL621911,BAO_0000218,
8453,Intermediate,10116.0,In vivo,1,,,Volume of distribution at steady state was observed after intravenous administration in rat,N,,,50597,1,,CHEMBL621912,BAO_0000218,
8454,Intermediate,10116.0,In vivo,1,,,Volume of distribution in steady state was determined in rat,N,,,50597,1,,CHEMBL621913,BAO_0000218,
8455,Intermediate,10116.0,In vivo,1,,,Volume of distribution in steady state was determined in rat,N,,,50597,1,,CHEMBL621914,BAO_0000218,
8456,Intermediate,10116.0,In vivo,1,,,Volume of distribution after i.v. administration,N,,,50597,1,,CHEMBL621915,BAO_0000218,
8457,Intermediate,10116.0,In vivo,1,,,Volume of distribution was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after iv administration,N,,,50597,1,,CHEMBL621916,BAO_0000218,
8458,Intermediate,10090.0,In vivo,1,2107.0,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,,,50594,1,,CHEMBL621917,BAO_0000218,
8459,Intermediate,10090.0,In vivo,1,2107.0,,"Biodistribution of compound (oxidized form) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL621918,BAO_0000218,
8460,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of compound (oxidized form) in spleen tissue,N,,,50594,1,,CHEMBL621919,BAO_0000218,
8461,Intermediate,10090.0,In vivo,1,2106.0,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL621920,BAO_0000218,
8462,Intermediate,10090.0,In vivo,1,2106.0,,"Biodistribution of compound (oxidized form) in spleen tissue, animals were sacrificed 10 minutes after dosing, in DMSO solution",N,,,50594,1,,CHEMBL621921,BAO_0000218,
8463,Intermediate,10090.0,In vivo,1,2106.0,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,,50594,1,,CHEMBL622401,BAO_0000218,
8464,Intermediate,10090.0,In vivo,1,2106.0,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO sol.",N,,,50594,1,,CHEMBL875348,BAO_0000218,
8465,Intermediate,10090.0,In vivo,1,2106.0,,"Biodistribution of compound (oxidized form) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO solution",N,,,50594,1,,CHEMBL622402,BAO_0000218,
8466,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood,N,,,50594,1,,CHEMBL622403,BAO_0000218,
8467,Intermediate,10090.0,In vivo,1,178.0,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in blood tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,,50594,1,,CHEMBL622404,BAO_0000218,
8468,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues,N,,,50594,1,,CHEMBL622405,BAO_0000218,
8469,Intermediate,10090.0,In vivo,1,955.0,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 10 minutes after dosing, in DMSO",N,,,50594,1,,CHEMBL622406,BAO_0000218,
8470,Intermediate,10090.0,In vivo,1,955.0,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in brain tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,,50594,1,,CHEMBL622407,BAO_0000218,
8471,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues,N,,,50594,1,,CHEMBL622408,BAO_0000218,
8472,Intermediate,10090.0,In vivo,1,948.0,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 10 minutes after dosing, in DMSO",N,,,50594,1,,CHEMBL622409,BAO_0000218,
8473,Intermediate,10090.0,In vivo,1,948.0,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in heart tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,,50594,1,,CHEMBL622410,BAO_0000218,
8474,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney,N,,,50594,1,,CHEMBL622411,BAO_0000218,
8475,Intermediate,10090.0,In vivo,1,2113.0,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing in DMSO",N,,,50594,1,,CHEMBL627864,BAO_0000218,
8476,Intermediate,10090.0,In vivo,1,2113.0,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in kidney tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,,50594,1,,CHEMBL627865,BAO_0000218,
8477,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver,N,,,50594,1,,CHEMBL627866,BAO_0000218,
8478,Intermediate,10090.0,In vivo,1,2107.0,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in liver tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,,50594,1,,CHEMBL627751,BAO_0000218,
8479,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen,N,,,50594,1,,CHEMBL627752,BAO_0000218,
8480,Intermediate,10090.0,In vivo,1,2106.0,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing in DMSO",N,,,50594,1,,CHEMBL627753,BAO_0000218,
8481,Intermediate,10090.0,In vivo,1,2106.0,,"Biodistribution of compound (total concentration of both oxidized and reduced forms) in spleen tissues, animals were sacrificed 60 minutes after dosing, in DMSO",N,,,50594,1,,CHEMBL627754,BAO_0000218,
8482,Intermediate,10090.0,,1,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK2 murine fibrosarcoma cells,N,,,50594,1,,CHEMBL627755,BAO_0000218,
8483,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of radioactivity in normal mice (ICR) brain after 1 hour of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL627756,BAO_0000218,
8484,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL627757,BAO_0000218,
8485,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of radioactivity in normal mice (ICR) brain after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL627758,BAO_0000218,
8486,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of radioactivity in normal mice (ICR) brain after 24 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL627759,BAO_0000218,
8487,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of radioactivity in normal mice (ICR) brain after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL627760,BAO_0000218,
8488,Intermediate,10090.0,In vivo,1,955.0,,Biodistribution of radioactivity in normal mice (ICR) brain after 6 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL627761,BAO_0000218,
8489,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of radioactivity in normal mice (ICR) heart after 1 hour of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL876811,BAO_0000218,
8490,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL627762,BAO_0000218,
8491,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of radioactivity in normal mice (ICR) heart after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL627763,BAO_0000218,
8492,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of radioactivity in normal mice (ICR) heart after 24 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL627764,BAO_0000218,
8493,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of radioactivity in normal mice (ICR) heart after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL627765,BAO_0000218,
8494,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution of radioactivity in normal mice (ICR) heart after 6 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL627766,BAO_0000218,
8495,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of radioactivity in normal mice (ICR) kidney after 1 hour of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL627767,BAO_0000218,
8496,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL627768,BAO_0000218,
8497,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of radioactivity in normal mice (ICR) kidney after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL628422,BAO_0000218,
8498,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of radioactivity in normal mice (ICR) kidney after 24 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL628423,BAO_0000218,
8499,Intermediate,10116.0,In vivo,1,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing) in Dawley rat,N,,,50597,1,,CHEMBL628424,BAO_0000218,
8500,Intermediate,10116.0,In vivo,1,,,Plasma clearance value at intravenous dose of 1 mg/kg (2 mg/kg po (cassette dosing)) in Dawley rat,N,,,50597,1,,CHEMBL628425,BAO_0000218,
8501,Intermediate,10116.0,In vivo,1,,,Plasma clearance value was determined in rat after a 3 mg/kg of iv dose,N,,,50597,1,,CHEMBL628426,BAO_0000218,
8502,Intermediate,10116.0,In vivo,1,,,Plasma clearance was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,,50597,1,,CHEMBL628427,BAO_0000218,
8503,Intermediate,10116.0,In vivo,1,,,Plasma clearance was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,N,,,50597,1,,CHEMBL626938,BAO_0000218,
8504,Intermediate,10116.0,In vivo,1,,,Plasma clearance was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,N,,,50597,1,,CHEMBL626939,BAO_0000218,
8505,Intermediate,10116.0,In vivo,1,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,N,,,50597,1,,CHEMBL626940,BAO_0000218,
8506,Intermediate,10116.0,In vivo,1,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,N,,,50597,1,,CHEMBL626941,BAO_0000218,
8507,Intermediate,10116.0,In vivo,1,,,Plasma clearance was reported in Sprague-Dawley rat,N,,,50597,1,,CHEMBL626942,BAO_0000218,
8508,Intermediate,10116.0,In vivo,1,,,Plasma clearance after intravenous administration (1 mg/kg) in rat,N,,,50597,1,,CHEMBL876812,BAO_0000218,
8509,Intermediate,10116.0,In vivo,1,,,Plasma clearance of compound in rats was evaluated,N,,,50597,1,,CHEMBL626943,BAO_0000218,
8510,Intermediate,10116.0,In vivo,1,,,Plasma clearance of compound in rats was evaluated; ND indicates not determined,N,,,50597,1,,CHEMBL626944,BAO_0000218,
8511,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration,N,,,50597,1,,CHEMBL626945,BAO_0000218,
8512,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,N,,,50597,1,,CHEMBL626946,BAO_0000218,
8513,Intermediate,10116.0,In vivo,1,,,Plasma clearance rate in Sprague-Dawley rats,N,,,50597,1,,CHEMBL626856,BAO_0000218,
8514,Intermediate,10116.0,In vivo,1,,,Plasma clearance was determined in rat after intravenous administration (0.5 mg/kg),N,,,50597,1,,CHEMBL626857,BAO_0000218,
8515,Intermediate,10116.0,In vivo,1,1969.0,,The compound was evaluated for plasma clearance in rat,N,,,50597,1,,CHEMBL626858,BAO_0000218,
8516,Intermediate,10116.0,In vivo,1,1969.0,,Total plasma clearance in rat,N,,,50597,1,,CHEMBL627018,BAO_0000218,
8517,Intermediate,10116.0,In vivo,1,178.0,,Absorption behavior was judged by the peak blood concentration determined after oral dose of 30 mg/kg in rats.,N,,,50597,1,,CHEMBL625331,BAO_0000218,
8518,Intermediate,10116.0,In vivo,1,178.0,,Blood level after a 10 mg/kg oral dose in rat expressed as Cmax was determined,N,,,50597,1,,CHEMBL625332,BAO_0000218,
8519,Intermediate,10116.0,In vivo,1,,,C max was determined at 10 mg/kg po dose in rats,N,,,50597,1,,CHEMBL877590,BAO_0000218,
8520,Intermediate,10116.0,In vivo,1,,,C max was determined at 3 mg/kg po dose in rats,N,,,50597,1,,CHEMBL625333,BAO_0000218,
8521,Intermediate,10116.0,In vivo,1,,,Cmax after repeated oral dose of compound at 1 mg/kg in rats,N,,,50597,1,,CHEMBL625334,BAO_0000218,
8522,Intermediate,10116.0,In vivo,1,,,Cmax after single intravenous bolus of 1 mg/kg in rats,N,,,50597,1,,CHEMBL625335,BAO_0000218,
8523,Intermediate,10116.0,In vivo,1,,,Cmax of compound at 5 mg/kg after po administration was determined in rat,N,,,50597,1,,CHEMBL625336,BAO_0000218,
8524,Intermediate,10116.0,In vivo,1,,,Cmax 24 hr after 10 mg/kg oral administration in rats,N,,,50597,1,,CHEMBL625337,BAO_0000218,
8525,Intermediate,10116.0,In vivo,1,,,Cmax 24 hr after 2 mg/kg oral administration in rats,N,,,50597,1,,CHEMBL625338,BAO_0000218,
8526,Intermediate,10116.0,In vivo,1,1969.0,,Cmax in plasma was determined upon peroral administration of 10.0 mg/Kg dose in rat,N,,,50597,1,,CHEMBL625339,BAO_0000218,
8527,Intermediate,10116.0,In vivo,1,,,Cmax in rat after administration of 2 mg/kg iv,N,,,50597,1,,CHEMBL625340,BAO_0000218,
8528,Intermediate,10116.0,In vivo,1,,,Cmax in rat after administration of 2 mg/kg iv,N,,,50597,1,,CHEMBL625341,BAO_0000218,
8529,Intermediate,10116.0,In vivo,1,,,Cmax in rats determined 6 hours after oral dosing of 20 mg/kg,N,,,50597,1,,CHEMBL622687,BAO_0000218,
8530,Intermediate,10116.0,In vivo,1,1969.0,,Cmax wa determined in rat plasma at 30 mg/kg after po administration,N,,,50597,1,,CHEMBL622688,BAO_0000218,
8531,Intermediate,10116.0,In vivo,1,178.0,,Cmax was calculated as maximum concentration reached in the blood after oral administration to male F344 rats,N,,,50597,1,,CHEMBL622689,BAO_0000218,
8532,Intermediate,10116.0,In vivo,1,178.0,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate after oral administration to male F344 rats,N,,,50597,1,,CHEMBL620295,BAO_0000218,
8533,Intermediate,10116.0,In vivo,1,,,Cmax after 10 mg/kg oral administration in rat,N,,,50597,1,,CHEMBL620296,BAO_0000218,
8534,Intermediate,10116.0,In vivo,1,,,Cmax after IV dosing at 0.5 mg/kg in rat; no data,N,,,50597,1,,CHEMBL620297,BAO_0000218,
8535,Intermediate,10116.0,In vivo,1,,,Cmax after IV dosing at 1 mg/kg in rat; no data,N,,,50597,1,,CHEMBL620298,BAO_0000218,
8536,Intermediate,10116.0,In vivo,1,,,Cmax after oral administration at 20 mpk in rats,N,,,50597,1,,CHEMBL620299,BAO_0000218,
8537,Intermediate,10116.0,In vivo,1,,,Cmax after oral administration at 20 mpk in rats; Not performed.,N,,,50597,1,,CHEMBL620300,BAO_0000218,
8538,Intermediate,10116.0,In vivo,1,,,Cmax after oral administration at 20 mpk in rats d; Not performed.,N,,,50597,1,,CHEMBL620301,BAO_0000218,
8539,Intermediate,10116.0,In vivo,1,,,Cmax after oral administration in rat,N,,,50597,1,,CHEMBL620302,BAO_0000218,
8540,Intermediate,10116.0,In vivo,1,,,Cmax after oral administration at a dose of 2 mg/kg in rat,N,,,50597,1,,CHEMBL620303,BAO_0000218,
8541,Intermediate,10116.0,In vivo,1,,,Cmax after oral administration at a dose of 4 mg/kg in rat,N,,,50597,1,,CHEMBL620304,BAO_0000218,
8542,Intermediate,10116.0,In vivo,1,,,Cmax in rats after 20 mg/kg oral dose,N,,,50597,1,,CHEMBL620305,BAO_0000218,
8543,Intermediate,10116.0,In vivo,1,,,Cmax after peroral administration in rats at 2.4 uM/kg,N,,,50597,1,,CHEMBL620306,BAO_0000218,
8544,Intermediate,10116.0,In vivo,1,,,Cmax at the dose of 2 mg/Kg administered perorally in rats,N,,,50597,1,,CHEMBL620307,BAO_0000218,
8545,Intermediate,10116.0,In vivo,1,,,Cmax at the dose of 5 mg/Kg administered perorally in rats,N,,,50597,1,,CHEMBL620308,BAO_0000218,
8546,Intermediate,10116.0,In vivo,1,,,Cmax by administering at 20 mg/kg p.o. in rats,N,,,50597,1,,CHEMBL620309,BAO_0000218,
8547,Intermediate,10116.0,In vivo,1,,,Cmax in male rat,N,,,50597,1,,CHEMBL620310,BAO_0000218,
8548,Intermediate,10116.0,In vivo,1,,,Cmax in rat,N,,,50597,1,,CHEMBL620311,BAO_0000218,
8549,Intermediate,10116.0,In vivo,1,,,Cmax in rat,N,,,50597,1,,CHEMBL620312,BAO_0000218,
8550,Intermediate,10116.0,In vivo,1,,,Cmax in rat,N,,,50597,1,,CHEMBL620313,BAO_0000218,
8551,Intermediate,10116.0,In vivo,1,,,Cmax in rat at 10 mg/kg,N,,,50597,1,,CHEMBL620314,BAO_0000218,
8552,Intermediate,10116.0,In vivo,1,,,Cmax in rat at the dose of 1 mg/kg i.v.,N,,,50597,1,,CHEMBL620315,BAO_0000218,
8553,Intermediate,10116.0,In vivo,1,,,Cmax in rat by po administration at a dose of 40 mg/kg,N,,,50597,1,,CHEMBL620316,BAO_0000218,
8554,Intermediate,10116.0,In vivo,1,,,Cmax in rat p.o. at 20 mg/kg concentration,N,,,50597,1,,CHEMBL620317,BAO_0000218,
8555,Intermediate,10116.0,In vivo,1,,,Cmax in rats,N,,,50597,1,,CHEMBL620318,BAO_0000218,
8556,Intermediate,10116.0,In vivo,1,,,Cmax in rats,N,,,50597,1,,CHEMBL620319,BAO_0000218,
8557,Intermediate,10116.0,In vivo,1,,,Cmax was evaluated after 20 uM/kg of peroral administration,N,,,50597,1,,CHEMBL620320,BAO_0000218,
8558,Intermediate,10116.0,In vivo,1,,,Cmax was measured in rats after peroral administration at 3 mg/kg,N,,,50597,1,,CHEMBL620321,BAO_0000218,
8559,Intermediate,10116.0,In vivo,1,,,Cmax value after oral dose at a dose of 10 mg/kg in rats.,N,,,50597,1,,CHEMBL620322,BAO_0000218,
8560,Intermediate,10116.0,,1,,,Distribution of [123I]-label in rat brain (diencephalon) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620323,BAO_0000218,
8561,Intermediate,10116.0,,1,1870.0,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620324,BAO_0000218,
8562,Intermediate,10116.0,,1,1870.0,,Distribution of [123I]-label in rat brain (frontal cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620325,BAO_0000218,
8563,Intermediate,10116.0,,1,10000000.0,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620326,BAO_0000218,
8564,Intermediate,10116.0,,1,10000000.0,,Distribution of [123I]-label in rat brain (hippocampus) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620327,BAO_0000218,
8565,Intermediate,10116.0,,1,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620328,BAO_0000218,
8566,Intermediate,10116.0,,1,,,Distribution of [123I]-label in rat brain (medulla pons) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620329,BAO_0000218,
8567,Intermediate,10116.0,,1,1891.0,,Distribution of [123I]-label in rat brain (midbrain) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620330,BAO_0000218,
8568,Intermediate,10116.0,,1,1891.0,,Distribution of [123I]-label in rat brain (midbrain) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL875286,BAO_0000218,
8569,Intermediate,10116.0,,1,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620331,BAO_0000218,
8570,Intermediate,10116.0,,1,,,Distribution of [123I]-label in rat brain (posterior cortex) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620332,BAO_0000218,
8571,Intermediate,10116.0,,1,2435.0,,Distribution of [123I]-label in rat brain (striatum) was reported at 20 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620333,BAO_0000218,
8572,Intermediate,10116.0,,1,2435.0,,Distribution of [123I]-label in rat brain (striatum) was reported at 60 min post injection. Value shown is %ID/g of tissue,N,,,50597,1,,CHEMBL620334,BAO_0000218,
8573,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,,50597,1,,CHEMBL621015,BAO_0000218,
8574,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,,50597,1,,CHEMBL621016,BAO_0000218,
8575,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,,50597,1,,CHEMBL621191,BAO_0000218,
8576,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,,50597,1,,CHEMBL621192,BAO_0000218,
8577,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,,50597,1,,CHEMBL621193,BAO_0000218,
8578,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,,50597,1,,CHEMBL621194,BAO_0000218,
8579,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,,50597,1,,CHEMBL624204,BAO_0000218,
8580,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,,50597,1,,CHEMBL624205,BAO_0000218,
8581,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,,50597,1,,CHEMBL624206,BAO_0000218,
8582,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,,50597,1,,CHEMBL624207,BAO_0000218,
8583,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,,50597,1,,CHEMBL624208,BAO_0000218,
8584,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,,50597,1,,CHEMBL624209,BAO_0000218,
8585,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,,50597,1,,CHEMBL624210,BAO_0000218,
8586,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,,50597,1,,CHEMBL624211,BAO_0000218,
8587,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,,50597,1,,CHEMBL624212,BAO_0000218,
8588,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,,50597,1,,CHEMBL624213,BAO_0000218,
8589,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,,50597,1,,CHEMBL876611,BAO_0000218,
8590,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,,50597,1,,CHEMBL624214,BAO_0000218,
8591,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,,50597,1,,CHEMBL624215,BAO_0000218,
8592,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,,50597,1,,CHEMBL624216,BAO_0000218,
8593,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,,50597,1,,CHEMBL624217,BAO_0000218,
8594,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,,50597,1,,CHEMBL624218,BAO_0000218,
8595,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,,50597,1,,CHEMBL624219,BAO_0000218,
8596,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,,50597,1,,CHEMBL624220,BAO_0000218,
8597,Intermediate,10116.0,,1,178.0,,Radioactivity distribution in blood of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,,50597,1,,CHEMBL624221,BAO_0000218,
8598,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,,50597,1,,CHEMBL624222,BAO_0000218,
8599,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,,50597,1,,CHEMBL624223,BAO_0000218,
8600,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,,50597,1,,CHEMBL624224,BAO_0000218,
8601,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,,50597,1,,CHEMBL624225,BAO_0000218,
8602,Intermediate,10116.0,In vivo,1,,,Volume of solubility in solution after intravenous administration in rats at 24 uM/kg,N,,,50597,1,,CHEMBL622420,BAO_0000218,
8603,Intermediate,10116.0,In vivo,1,,,Volume of steady state distribution after i.v. administration in rats,N,,,50597,1,,CHEMBL622421,BAO_0000218,
8604,Intermediate,10116.0,In vivo,1,,,Vss after intravenous administration (5.0 mg/kg) was determined in rat,N,,,50597,1,,CHEMBL622422,BAO_0000218,
8605,Intermediate,10116.0,In vivo,1,,,Vss in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,N,,,50597,1,,CHEMBL622423,BAO_0000218,
8606,Intermediate,10116.0,In vivo,1,,,Vss was determined,N,,,50597,1,,CHEMBL622424,BAO_0000218,
8607,Intermediate,10116.0,In vivo,1,,,Vss in rat,N,,,50597,1,,CHEMBL622425,BAO_0000218,
8608,Intermediate,10116.0,In vivo,1,,,Vss was evaluated after 10 uM/kg of intra arterial administration,N,,,50597,1,,CHEMBL876612,BAO_0000218,
8609,Intermediate,10116.0,In vivo,1,,,volume of distribution at steady state was observed after intravenous administration in rat,N,,,50597,1,,CHEMBL622426,BAO_0000218,
8610,Intermediate,10116.0,In vivo,1,,,Volume of distribution was measured in rat after an iv dose of 1 mg/kg,N,,,50597,1,,CHEMBL622427,BAO_0000218,
8611,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic (PK) parameter Vz in rat,N,,,50597,1,,CHEMBL622428,BAO_0000218,
8612,Intermediate,10116.0,In vivo,1,,,Volume distribution in rats,N,,,50597,1,,CHEMBL622429,BAO_0000218,
8613,Intermediate,10116.0,In vivo,1,,,Volume of distribution in rat; No data,N,,,50597,1,,CHEMBL622430,BAO_0000218,
8614,Intermediate,10116.0,In vivo,1,,,Volume of distribution was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,N,,,50597,1,,CHEMBL622431,BAO_0000218,
8615,Intermediate,10116.0,,1,2116.0,,% absorption predicted from in vitro rat ileum transport studies,N,,,50597,1,,CHEMBL622432,BAO_0000218,
8616,Intermediate,10116.0,In vivo,1,,,Bioavailability at an iv dose of 12 mg/Kg and po dose of 23 mg/Kg,N,,,50597,1,,CHEMBL622433,BAO_0000218,
8617,Intermediate,10116.0,In vivo,1,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 15 mg/Kg,N,,,50597,1,,CHEMBL622434,BAO_0000218,
8618,Intermediate,10116.0,In vivo,1,,,Bioavailability at an iv dose of 14 mg/Kg and po dose of 28 mg/Kg,N,,,50597,1,,CHEMBL622435,BAO_0000218,
8619,Intermediate,10116.0,In vivo,1,,,Bioavailability (dose 15 mg/kg i.v. and 30 mg/kg p.o.),N,,,50597,1,,CHEMBL618748,BAO_0000218,
8620,Intermediate,10116.0,In vivo,1,,,Bioavailability at an iv dose of 15 mg/Kg and po dose of 30.2 mg/Kg,N,,,50597,1,,CHEMBL618749,BAO_0000218,
8621,Intermediate,10116.0,In vivo,1,,,Bioavailability at an iv dose of 15.6 mg/Kg and po dose of 31.2 mg/Kg,N,,,50597,1,,CHEMBL618750,BAO_0000218,
8622,Intermediate,10116.0,In vivo,1,,,Bioavailability at an iv dose of 15.7 mg/Kg and po dose of 31.4 mg/Kg,N,,,50597,1,,CHEMBL618751,BAO_0000218,
8623,Intermediate,10116.0,In vivo,1,,,Bioavailability at an iv dose of 16 mg/Kg and po dose of 35 mg/Kg,N,,,50597,1,,CHEMBL618752,BAO_0000218,
8624,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL618753,BAO_0000218,
8625,Intermediate,10116.0,In vivo,1,1969.0,,Oral bioavailability estimated by measurement of the circulating plasma levels of BMS-183920 after intravenous and oral dosing to rats for 4 determinations,N,,,50597,1,,CHEMBL618754,BAO_0000218,
8626,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL618755,BAO_0000218,
8627,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL618756,BAO_0000218,
8628,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL618757,BAO_0000218,
8629,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL618758,BAO_0000218,
8630,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 30 mg/kg),N,,,50597,1,,CHEMBL621088,BAO_0000218,
8631,Intermediate,10116.0,,1,,,Pharmacokinetic property (cLogP) in rat,N,,,50597,1,,CHEMBL621089,BAO_0000218,
8632,Intermediate,10116.0,,1,178.0,,Hyperglycemic activity and change in blood glucose concentration was reported 2 hours after administration of 100 mg/Kg perorally,N,,,50597,1,,CHEMBL621090,BAO_0000218,
8633,Intermediate,10116.0,,1,178.0,,Hyperglycemic activity and change in blood glucose concentration was reported 4 hours after administration of 100 mg/Kg perorally,N,,,50597,1,,CHEMBL621091,BAO_0000218,
8634,Intermediate,10116.0,In vivo,1,,,Clearance in rat.,N,,,50597,1,,CHEMBL876731,BAO_0000218,
8635,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for its clearance when administered intravenously in rat,N,,,50597,1,,CHEMBL621092,BAO_0000218,
8636,Intermediate,10116.0,In vivo,1,,,Plasma clearance in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL621093,BAO_0000218,
8637,Intermediate,10116.0,,1,,,Blood: Brain distribution ratio is determined in rat,N,,,50597,1,,CHEMBL621094,BAO_0000218,
8638,Intermediate,10116.0,,1,,,Blood: Brain distribution ratio is determined in rat; NQ: non quantifable,N,,,50597,1,,CHEMBL621095,BAO_0000218,
8639,Intermediate,10116.0,,1,,,Blood: Brain distribution ratio is determined in rat; NQ:non quantifable,N,,,50597,1,,CHEMBL621096,BAO_0000218,
8640,Intermediate,10116.0,In vivo,1,2113.0,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL621097,BAO_0000218,
8641,Intermediate,10116.0,,1,,,Percent dose excreted in 0-48 hours administered ip to male rat,N,,,50597,1,,CHEMBL621098,BAO_0000218,
8642,Intermediate,10116.0,,1,2037.0,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL621099,BAO_0000218,
8643,Intermediate,10116.0,,1,2037.0,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL621100,BAO_0000218,
8644,Intermediate,10116.0,,1,2037.0,,Uptake of radioligand [125I]-FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,,50597,1,,CHEMBL621101,BAO_0000218,
8645,Intermediate,10116.0,,1,2037.0,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL621102,BAO_0000218,
8646,Intermediate,10116.0,,1,2037.0,,Uptake of radioligand [125I]FIDA1 by cerebellum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL876732,BAO_0000218,
8647,Intermediate,10116.0,,1,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL621103,BAO_0000218,
8648,Intermediate,10116.0,,1,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL621104,BAO_0000218,
8649,Intermediate,10116.0,,1,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,,50597,1,,CHEMBL621105,BAO_0000218,
8650,Intermediate,10116.0,,1,,,Uptake of radioligand [125I]-FIDA1 by cortex in rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL621106,BAO_0000218,
8651,Intermediate,10116.0,,1,,,Uptake of radioligand [125I]FIDA1 by cortex in rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL621107,BAO_0000218,
8652,Intermediate,10116.0,,1,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL621108,BAO_0000218,
8653,Intermediate,10116.0,,1,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL621109,BAO_0000218,
8654,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of radioactivity in normal mice (ICR) kidney after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL621110,BAO_0000218,
8655,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution of radioactivity in normal mice (ICR) kidney after 6 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL621111,BAO_0000218,
8656,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of radioactivity in normal mice (ICR) liver after 1 hour of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL622541,BAO_0000218,
8657,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL622542,BAO_0000218,
8658,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of radioactivity in normal mice (ICR) liver after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL622543,BAO_0000218,
8659,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of radioactivity in normal mice (ICR) liver after 24 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL624412,BAO_0000218,
8660,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of radioactivity in normal mice (ICR) liver after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL624413,BAO_0000218,
8661,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution of radioactivity in normal mice (ICR) liver after 6 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL624414,BAO_0000218,
8662,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of radioactivity in normal mice (ICR) lung after 1 hour of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL624415,BAO_0000218,
8663,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL624416,BAO_0000218,
8664,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of radioactivity in normal mice (ICR) lung after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL624417,BAO_0000218,
8665,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of radioactivity in normal mice (ICR) lung after 24 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL624418,BAO_0000218,
8666,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of radioactivity in normal mice (ICR) lung after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL624419,BAO_0000218,
8667,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution of radioactivity in normal mice (ICR) lung after 6 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL624420,BAO_0000218,
8668,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of radioactivity in normal mice (ICR) muscle after 1 hr of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL624421,BAO_0000218,
8669,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL624422,BAO_0000218,
8670,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of radioactivity in normal mice (ICR) muscle after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL624423,BAO_0000218,
8671,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of radioactivity in normal mice (ICR) muscle after 24 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL625123,BAO_0000218,
8672,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of radioactivity in normal mice (ICR) muscle after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL625124,BAO_0000218,
8673,Intermediate,10090.0,In vivo,1,2385.0,,Biodistribution of radioactivity in normal mice (ICR) muscle after 6 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL625125,BAO_0000218,
8674,Intermediate,10090.0,In vivo,1,14.0,,Biodistribution of radioactivity in normal mice (ICR) skin after 1 hour of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL625126,BAO_0000218,
8675,Intermediate,10090.0,In vivo,1,14.0,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL626947,BAO_0000218,
8676,Intermediate,10090.0,In vivo,1,14.0,,Biodistribution of radioactivity in normal mice (ICR) skin after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL626948,BAO_0000218,
8677,Intermediate,10090.0,In vivo,1,14.0,,Biodistribution of radioactivity in normal mice (ICR) skin after 24 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL626949,BAO_0000218,
8678,Intermediate,10090.0,In vivo,1,14.0,,Biodistribution of radioactivity in normal mice (ICR) skin after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL626950,BAO_0000218,
8679,Intermediate,10090.0,In vivo,1,14.0,,Biodistribution of radioactivity in normal mice (ICR) skin after 6 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL626951,BAO_0000218,
8680,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of radioactivity in normal mice (ICR) spleen after 1 hour of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL626952,BAO_0000218,
8681,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL626953,BAO_0000218,
8682,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of radioactivity in normal mice (ICR) spleen after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL626954,BAO_0000218,
8683,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of radioactivity in normal mice (ICR) spleen after 24 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL626955,BAO_0000218,
8684,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of radioactivity in normal mice (ICR) spleen after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL626956,BAO_0000218,
8685,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution of radioactivity in normal mice (ICR) spleen after 6 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL626957,BAO_0000218,
8686,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of radioactivity in normal mice blood after 1 hour of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL626958,BAO_0000218,
8687,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of radioactivity in normal mice blood after 2 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL626959,BAO_0000218,
8688,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of radioactivity in normal mice blood after 2 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL626960,BAO_0000218,
8689,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of radioactivity in normal mice blood after 24 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL626961,BAO_0000218,
8690,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of radioactivity in normal mice blood after 30 minutes of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL627589,BAO_0000218,
8691,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution of radioactivity in normal mice blood after 6 hours of intravenous injection of [125I]-16(IMPY),N,,,50594,1,,CHEMBL627590,BAO_0000218,
8692,Intermediate,10090.0,,1,,,Time taken for EC90 was determined when tested in mouse,N,,,50594,1,,CHEMBL627591,BAO_0000218,
8693,Intermediate,10090.0,,1,,,Time taken for EC90 was determined when tested in mouse at dose 25 mg/kg,N,,,50594,1,,CHEMBL627592,BAO_0000218,
8694,Intermediate,10090.0,In vivo,1,,,At a dose 50 mg/kg (114 umol/kg) was administered intraperitoneally to mice and was evaluated for half life (T1/2),N,,,50594,1,,CHEMBL627593,BAO_0000218,
8695,Intermediate,10090.0,,1,,,Half life in mice,N,,,50594,1,,CHEMBL627594,BAO_0000218,
8696,Intermediate,10090.0,In vivo,1,,,Half life period in mouse after 10 mg/Kg dose,N,,,50594,1,,CHEMBL876813,BAO_0000218,
8697,Intermediate,10090.0,In vivo,1,,,Half life period in mouse after 10 mg/kg dose,N,,,50594,1,,CHEMBL627595,BAO_0000218,
8698,Intermediate,10090.0,In vivo,1,,,Half life was determined in mouse after 5 mg/kg (i.v.) and 6 mg/kg (p.o.) administration,N,,,50594,1,,CHEMBL627596,BAO_0000218,
8699,Intermediate,10116.0,In vivo,1,,,Cmax value at 5 mg/kg po was determined in rat,N,,,50597,1,,CHEMBL627597,BAO_0000218,
8700,Intermediate,10116.0,In vivo,1,,,Cmax value evaluated in rat,N,,,50597,1,,CHEMBL627598,BAO_0000218,
8701,Intermediate,10116.0,In vivo,1,955.0,,Cmax value was calculated by applying at a dose of 10 mg/Kg ip in rat brain,N,,,50597,1,,CHEMBL627599,BAO_0000218,
8702,Intermediate,10116.0,In vivo,1,,,Cmax value after administration of 20 mg/Kg oral dose in rat,N,,,50597,1,,CHEMBL627600,BAO_0000218,
8703,Intermediate,10116.0,In vivo,1,,,Cmax value at 1 mg/kg po in rat,N,,,50597,1,,CHEMBL627601,BAO_0000218,
8704,Intermediate,10116.0,In vivo,1,,,Cmax value at 5 mg/kg po in rat,N,,,50597,1,,CHEMBL627776,BAO_0000218,
8705,Intermediate,10116.0,In vivo,1,,,Cmax value at a dose of 10 mg/kg in male SD rats,N,,,50597,1,,CHEMBL627777,BAO_0000218,
8706,Intermediate,10116.0,In vivo,1,,,Cmax value at a dose of 100 mg/kg in male SD rats,N,,,50597,1,,CHEMBL627778,BAO_0000218,
8707,Intermediate,10116.0,In vivo,1,,,Cmax value at a dose of 50 mg/kg in male SD rats,N,,,50597,1,,CHEMBL627779,BAO_0000218,
8708,Intermediate,10116.0,In vivo,1,,,Cmax value in rats at 10 mg/kg,N,,,50597,1,,CHEMBL876814,BAO_0000218,
8709,Intermediate,10116.0,In vivo,1,,,Cmax value was evaluated in rats at a dose of 20 mg/kg,N,,,50597,1,,CHEMBL627780,BAO_0000218,
8710,Intermediate,10116.0,In vivo,1,,,Cmax value was determined after peroral administration of 20 mg/kg in rat,N,,,50597,1,,CHEMBL627781,BAO_0000218,
8711,Intermediate,10116.0,In vivo,1,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,N,,,50597,1,,CHEMBL627782,BAO_0000218,
8712,Intermediate,10116.0,In vivo,1,1969.0,,Compound was evaluated for its pharmacokinetic parameter maximum plasma concentration (Cmax) after oral administration to rats,N,,,50597,1,,CHEMBL627783,BAO_0000218,
8713,Intermediate,10116.0,In vivo,1,1969.0,,Compound was evaluated for maximal plasma concentration in rat upon 5 mg/kg upon oral administration,N,,,50597,1,,CHEMBL627784,BAO_0000218,
8714,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to female wistar rats,N,,,50597,1,,CHEMBL627785,BAO_0000218,
8715,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for maximum concentration after treatment with oral dose of 2 mgkg to male wistar rats,N,,,50597,1,,CHEMBL627786,BAO_0000218,
8716,Intermediate,10116.0,In vivo,1,1969.0,,Compound was evaluated for pharmacokinetic parameter maximum plasma concentration,N,,,50597,1,,CHEMBL627787,BAO_0000218,
8717,Intermediate,10116.0,In vivo,1,1969.0,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 0.5 hr,N,,,50597,1,,CHEMBL627788,BAO_0000218,
8718,Intermediate,10116.0,In vivo,1,1969.0,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 1 hr,N,,,50597,1,,CHEMBL626579,BAO_0000218,
8719,Intermediate,10116.0,In vivo,1,1969.0,,Compound was evaluated for plasma concentration in rats when administered at 20 mg/kg in methocel at 2 hr,N,,,50597,1,,CHEMBL626580,BAO_0000218,
8720,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for the pharmacokinetic property in rats after an oral dose of 10 mg/kg,N,,,50597,1,,CHEMBL876815,BAO_0000218,
8721,Intermediate,10116.0,In vivo,1,1969.0,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 1 hr,N,,,50597,1,,CHEMBL626581,BAO_0000218,
8722,Intermediate,10116.0,In vivo,1,1969.0,,Compound was tested for plasma concentration in rats when administered at 20 mg/kg in 1% methocel at 2 hr,N,,,50597,1,,CHEMBL626582,BAO_0000218,
8723,Intermediate,10116.0,In vivo,1,,,Evaluated for pharmacokinetic parameter Cmax in rat at the dose 50 mg/kg,N,,,50597,1,,CHEMBL626583,BAO_0000218,
8724,Intermediate,10116.0,In vivo,1,,,In vivo Cmax was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL626205,BAO_0000218,
8725,Intermediate,10116.0,In vivo,1,,,In vivo Cmax was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL626206,BAO_0000218,
8726,Intermediate,10116.0,In vivo,1,,,In vivo Cmax was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL626207,BAO_0000218,
8727,Intermediate,10116.0,In vivo,1,,,In vivo Cmax was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL623882,BAO_0000218,
8728,Intermediate,10116.0,In vivo,1,,,Maximal concentration in male Sprague-Dawley rats after 5 mg/kg intravenous dose,N,,,50597,1,,CHEMBL623883,BAO_0000218,
8729,Intermediate,10116.0,In vivo,1,,,Maximal concentration in male Sprague-Dawley rats after 10 mg/kg oral dose,N,,,50597,1,,CHEMBL623884,BAO_0000218,
8730,Intermediate,10116.0,In vivo,1,1969.0,,"In vivo maximum concentration of compound in rat plasma after a oral dose of 10 mg/kg (in water, N=4)",N,,,50597,1,,CHEMBL623885,BAO_0000218,
8731,Intermediate,10116.0,In vivo,1,1969.0,,In vivo maximum concentration in rat plasma exposure after oral administration 50 mg/kg,N,,,50597,1,,CHEMBL623886,BAO_0000218,
8732,Intermediate,10116.0,In vivo,1,,,Maximal concentration in rat was determined,N,,,50597,1,,CHEMBL623887,BAO_0000218,
8733,Intermediate,10116.0,In vivo,1,,,Maximal concentration after i.v. administration,N,,,50597,1,,CHEMBL623888,BAO_0000218,
8734,Intermediate,10116.0,In vivo,1,1969.0,,Maximal concentration (Cmax) in the rat plasma at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL623889,BAO_0000218,
8735,Intermediate,10116.0,In vivo,1,1969.0,,Maximal plasma concentration in rat after oral administration at 50 mg/kg,N,,,50597,1,,CHEMBL623890,BAO_0000218,
8736,Intermediate,10116.0,In vivo,1,1969.0,,Cmax in rat plasma after oral dose (50 mg/Kg),N,,,50597,1,,CHEMBL623891,BAO_0000218,
8737,Intermediate,10116.0,In vivo,1,1969.0,,Maximal plasma concentration was determined.,N,,,50597,1,,CHEMBL623892,BAO_0000218,
8738,Intermediate,10116.0,In vivo,1,1969.0,,Maximal plasma drug concentration was determined,N,,,50597,1,,CHEMBL623893,BAO_0000218,
8739,Intermediate,10116.0,In vivo,1,,,Maximal concentration in rats after peroral administration,N,,,50597,1,,CHEMBL877616,BAO_0000218,
8740,Intermediate,10116.0,In vivo,1,,,Maximum concentration in rat after 2 mg/kg peroral administration,N,,,50597,1,,CHEMBL623894,BAO_0000218,
8741,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration in rat plasma after 5 mg/kg oral gavage,N,,,50597,1,,CHEMBL623895,BAO_0000218,
8742,Intermediate,10116.0,In vivo,1,,,Maximum concentration of compound in rat was evaluated.,N,,,50597,1,,CHEMBL623896,BAO_0000218,
8743,Intermediate,10116.0,In vivo,1,,,Maximum concentration at 0.5 hr by peroral administration at a dose of 20 mg/kg in rats,N,,,50597,1,,CHEMBL623897,BAO_0000218,
8744,Intermediate,10116.0,In vivo,1,,,Maximum concentration at 2 hr by peroral administration at a dose of 20 mg/kg in rats,N,,,50597,1,,CHEMBL623898,BAO_0000218,
8745,Intermediate,10116.0,In vivo,1,,,Maximum concentration at 4 hr after administration of 5 mg/kg dose peroral in rat,N,,,50597,1,,CHEMBL623899,BAO_0000218,
8746,Intermediate,10116.0,In vivo,1,,,Maximum concentration at 4 hr by peroral administration at a dose of 20 mg/kg in rats,N,,,50597,1,,CHEMBL623900,BAO_0000218,
8747,Intermediate,10116.0,In vivo,1,,,Maximum concentration by oral administration at a dose of 100 uM/kg in rat was determined,N,,,50597,1,,CHEMBL623901,BAO_0000218,
8748,Intermediate,10116.0,In vivo,1,,,Maximum concentration was evaluated in rats,N,,,50597,1,,CHEMBL623902,BAO_0000218,
8749,Intermediate,10116.0,In vivo,1,1359.0,,Maximum concentration in CSF at 30 min following 24 mg/kg subcutaneous dose in rats,N,,,50597,1,,CHEMBL623903,BAO_0000218,
8750,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration in plasma at 30 min following 24 mg/kg subcutaneous dose in rats,N,,,50597,1,,CHEMBL623904,BAO_0000218,
8751,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration in plasma was evaluated in Sprague-Dawley rats at a dose of 15 mg/kg after po administration,N,,,50597,1,,CHEMBL877617,BAO_0000218,
8752,Intermediate,10116.0,In vivo,1,,,Maximum concentration in portal vein was determined at a concentration of 10 mg/kg in rats,N,,,50597,1,,CHEMBL623905,BAO_0000218,
8753,Intermediate,10116.0,In vivo,1,,,Maximum concentration in portal vein was determined at a concentration of 20 mg/kg in rats,N,,,50597,1,,CHEMBL623906,BAO_0000218,
8754,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,,,50597,1,,CHEMBL623907,BAO_0000218,
8755,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,,50597,1,,CHEMBL623908,BAO_0000218,
8756,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 30 min.,N,,,50597,1,,CHEMBL623909,BAO_0000218,
8757,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,,50597,1,,CHEMBL623910,BAO_0000218,
8758,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,,50597,1,,CHEMBL623911,BAO_0000218,
8759,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,,50597,1,,CHEMBL623912,BAO_0000218,
8760,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,,50597,1,,CHEMBL624616,BAO_0000218,
8761,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,,50597,1,,CHEMBL624617,BAO_0000218,
8762,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,,50597,1,,CHEMBL624618,BAO_0000218,
8763,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,,50597,1,,CHEMBL624619,BAO_0000218,
8764,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,,50597,1,,CHEMBL624794,BAO_0000218,
8765,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,,50597,1,,CHEMBL624795,BAO_0000218,
8766,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,,50597,1,,CHEMBL623921,BAO_0000218,
8767,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,,50597,1,,CHEMBL623922,BAO_0000218,
8768,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,,50597,1,,CHEMBL623923,BAO_0000218,
8769,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,,50597,1,,CHEMBL623924,BAO_0000218,
8770,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,,50597,1,,CHEMBL623925,BAO_0000218,
8771,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,,50597,1,,CHEMBL623926,BAO_0000218,
8772,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,,50597,1,,CHEMBL623927,BAO_0000218,
8773,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,,50597,1,,CHEMBL623928,BAO_0000218,
8774,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,,50597,1,,CHEMBL623929,BAO_0000218,
8775,Intermediate,10116.0,,1,,,Radioactivity distribution in bone of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,,50597,1,,CHEMBL623930,BAO_0000218,
8776,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,,50597,1,,CHEMBL623931,BAO_0000218,
8777,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,,50597,1,,CHEMBL622165,BAO_0000218,
8778,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,,50597,1,,CHEMBL621249,BAO_0000218,
8779,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,,50597,1,,CHEMBL621250,BAO_0000218,
8780,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,,50597,1,,CHEMBL621448,BAO_0000218,
8781,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,,50597,1,,CHEMBL621449,BAO_0000218,
8782,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,,50597,1,,CHEMBL621450,BAO_0000218,
8783,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,,50597,1,,CHEMBL621451,BAO_0000218,
8784,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,,50597,1,,CHEMBL621452,BAO_0000218,
8785,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,,50597,1,,CHEMBL621453,BAO_0000218,
8786,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,,50597,1,,CHEMBL621454,BAO_0000218,
8787,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,,50597,1,,CHEMBL621455,BAO_0000218,
8788,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,,50597,1,,CHEMBL621456,BAO_0000218,
8789,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,,50597,1,,CHEMBL625145,BAO_0000218,
8790,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,,50597,1,,CHEMBL875847,BAO_0000218,
8791,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,,50597,1,,CHEMBL625146,BAO_0000218,
8792,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,,50597,1,,CHEMBL625147,BAO_0000218,
8793,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,,50597,1,,CHEMBL625148,BAO_0000218,
8794,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,,50597,1,,CHEMBL625149,BAO_0000218,
8795,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,,50597,1,,CHEMBL625150,BAO_0000218,
8796,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,,50597,1,,CHEMBL625151,BAO_0000218,
8797,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,,50597,1,,CHEMBL625152,BAO_0000218,
8798,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,,50597,1,,CHEMBL625153,BAO_0000218,
8799,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,,50597,1,,CHEMBL625154,BAO_0000218,
8800,Intermediate,10116.0,,1,955.0,,Radioactivity distribution in brain of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,,50597,1,,CHEMBL625155,BAO_0000218,
8801,Intermediate,10116.0,,1,,,Uptake of radioligand [125I]FIDA1 by hippo-campus in rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,,50597,1,,CHEMBL625156,BAO_0000218,
8802,Intermediate,10116.0,,1,,,Uptake of radioligand [125I]-FIDA1 by hippo-campus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL624354,BAO_0000218,
8803,Intermediate,10116.0,,1,10000000.0,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL624355,BAO_0000218,
8804,Intermediate,10116.0,,1,10000000.0,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL624356,BAO_0000218,
8805,Intermediate,10116.0,,1,10000000.0,,Uptake of radioligand [125I]-FIDA1 by hippocampus in rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL624357,BAO_0000218,
8806,Intermediate,10116.0,,1,10000000.0,,Uptake of radioligand [125I]FIDA1 by hippocampus in rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL624358,BAO_0000218,
8807,Intermediate,10116.0,,1,2435.0,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL624359,BAO_0000218,
8808,Intermediate,10116.0,,1,2435.0,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL624360,BAO_0000218,
8809,Intermediate,10116.0,,1,2435.0,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,,50597,1,,CHEMBL624361,BAO_0000218,
8810,Intermediate,10116.0,,1,2435.0,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL624362,BAO_0000218,
8811,Intermediate,10116.0,,1,2435.0,,Uptake of radioligand [125I]FIDA1 by striatum in rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL624363,BAO_0000218,
8812,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL624364,BAO_0000218,
8813,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL624365,BAO_0000218,
8814,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL624366,BAO_0000218,
8815,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of radioligand [125I]FIDA1 in blood of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL624367,BAO_0000218,
8816,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL624368,BAO_0000218,
8817,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL624369,BAO_0000218,
8818,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,,50597,1,,CHEMBL624370,BAO_0000218,
8819,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL625069,BAO_0000218,
8820,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of radioligand [125I]FIDA1 in brain of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL625070,BAO_0000218,
8821,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of radioligand [125I]-FIDA1 in heart of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL626051,BAO_0000218,
8822,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL626052,BAO_0000218,
8823,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,,50597,1,,CHEMBL626053,BAO_0000218,
8824,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL626054,BAO_0000218,
8825,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of radioligand [125I]FIDA1 in heart of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL626055,BAO_0000218,
8826,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL626056,BAO_0000218,
8827,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of radioligand [125I]-FIDA1 in kidney of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL626057,BAO_0000218,
8828,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL625193,BAO_0000218,
8829,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of radioligand [125I]FIDA1 in kidney of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL625194,BAO_0000218,
8830,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL625195,BAO_0000218,
8831,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL625196,BAO_0000218,
8832,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,,50597,1,,CHEMBL625197,BAO_0000218,
8833,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL625198,BAO_0000218,
8834,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of radioligand [125I]FIDA1 in liver of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL627929,BAO_0000218,
8835,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL627074,BAO_0000218,
8836,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL627075,BAO_0000218,
8837,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,,50597,1,,CHEMBL627076,BAO_0000218,
8838,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL627077,BAO_0000218,
8839,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of radioligand [125I]FIDA1 in lung of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL627078,BAO_0000218,
8840,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 2 rats),N,,,50597,1,,CHEMBL627079,BAO_0000218,
8841,Intermediate,10090.0,In vivo,1,,,Half life (t1/2) determined at a dose 10 mg/kg administered intraperitoneally to mice,N,,,50594,1,,CHEMBL873824,BAO_0000218,
8842,Intermediate,10090.0,In vivo,1,1969.0,,Half life in mouse plasma was determined at dose 25 mg/kg,N,,,50594,1,,CHEMBL627080,BAO_0000218,
8843,Intermediate,10090.0,,1,,,Half life was determined,N,,,50594,1,,CHEMBL627081,BAO_0000218,
8844,Intermediate,10090.0,In vivo,1,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,N,,,50594,1,,CHEMBL627082,BAO_0000218,
8845,Intermediate,10090.0,In vivo,1,,,Half-life in male mice after 1 mg/kg intravenous dose,N,,,50594,1,,CHEMBL627083,BAO_0000218,
8847,Intermediate,10090.0,,1,1969.0,,Half life in mice plasma,N,,,50594,1,,CHEMBL627085,BAO_0000218,
8848,Intermediate,10090.0,,1,,,Half life in mouse,N,,,50594,1,,CHEMBL627086,BAO_0000218,
8849,Intermediate,10090.0,In vivo,1,1969.0,,Half life in mouse plasma at dose 25 mg/kg,N,,,50594,1,,CHEMBL627087,BAO_0000218,
8850,Intermediate,10090.0,In vivo,1,,,Half life when injected i.p. in mice at a dose of 50 mg/kg was determined,N,,,50594,1,,CHEMBL627088,BAO_0000218,
8851,Intermediate,10090.0,In vivo,1,,,Half life when injected intravenously in mice at a dose of 20 mg/kg was determined,N,,,50594,1,,CHEMBL627089,BAO_0000218,
8852,Intermediate,10090.0,In vivo,1,,,Half life when injected perorally in mice at a dose of 50 mg/kg was determined,N,,,50594,1,,CHEMBL627090,BAO_0000218,
8853,Intermediate,10090.0,In vivo,1,,,Half life was determined in mice at a single subcutaneous administration of 40 mg/kg (n=4),N,,,50594,1,,CHEMBL627091,BAO_0000218,
8854,Intermediate,10090.0,In vivo,1,,,"Half life was evaluated at 5 mg/kg of compound dose, administered perorally in mice",N,,,50594,1,,CHEMBL627092,BAO_0000218,
8855,Intermediate,10090.0,In vivo,1,,,"Half life was evaluated at 50 mg/kg of compound dose, administered perorally in mice",N,,,50594,1,,CHEMBL876785,BAO_0000218,
8856,Intermediate,10090.0,In vivo,1,,,Half-life by iv administration in mouse,N,,,50594,1,,CHEMBL627093,BAO_0000218,
8857,Intermediate,10090.0,In vivo,1,,,Half-life by oral administration in mouse,N,,,50594,1,,CHEMBL627094,BAO_0000218,
8858,Intermediate,10090.0,,1,,,Half-life in mice,N,,,50594,1,,CHEMBL627095,BAO_0000218,
8859,Intermediate,10090.0,,1,955.0,,Half-life using mouse brain homogenate,N,,,50594,1,,CHEMBL627096,BAO_0000218,
8860,Intermediate,10090.0,,1,,,Half-life was measured in mice,N,,,50594,1,,CHEMBL627097,BAO_0000218,
8861,Intermediate,10090.0,In vivo,1,,,Half-life was measured in mouse after an iv dose of 1 mg/kg,N,,,50594,1,,CHEMBL627098,BAO_0000218,
8862,Intermediate,10090.0,,1,178.0,,Half-life period was determined in mouse blood,N,,,50594,1,,CHEMBL627099,BAO_0000218,
8863,Intermediate,10090.0,,1,955.0,,"Half-times of inhibition of PEP in in an ex vivo enzyme studies, using mice brain",N,,,50594,1,,CHEMBL627100,BAO_0000218,
8864,Intermediate,10090.0,,1,1969.0,,Plasma half life in mouse,N,,,50594,1,,CHEMBL627101,BAO_0000218,
8865,Intermediate,10090.0,,1,,,Stability of the peptide in the presence of mouse serum,N,,,50594,1,,CHEMBL627102,BAO_0000218,
8866,Intermediate,10090.0,,1,,,Terminal half life of compound was determined in mouse,N,,,50594,1,,CHEMBL627103,BAO_0000218,
8867,Intermediate,10090.0,In vivo,1,,,Terminal half life was evaluated in mice after intravenous administration,N,,,50594,1,,CHEMBL627104,BAO_0000218,
8868,Intermediate,10090.0,In vivo,1,,,Terminal half life was evaluated in mice after oral administration,N,,,50594,1,,CHEMBL627105,BAO_0000218,
8869,Intermediate,10090.0,,1,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 5.,N,,,50594,1,,CHEMBL876786,BAO_0000218,
8870,Intermediate,10090.0,,1,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7.,N,,,50594,1,,CHEMBL873825,BAO_0000218,
8871,Intermediate,10090.0,,1,,,The compound was evaluated for half life (release of DOX) in mice at 37 degree Celsius at the pH 7; ND means no data,N,,,50594,1,,CHEMBL627106,BAO_0000218,
8872,Intermediate,10090.0,In vivo,1,,,half life period is evaluated by administering intravenously at 25 mg/kg in mice,N,,,50594,1,,CHEMBL626336,BAO_0000218,
8873,Intermediate,10090.0,In vivo,1,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice",N,,,50594,1,,CHEMBL877462,BAO_0000218,
8874,Intermediate,10090.0,In vivo,1,,,"Half life beta(2,4,6,8h) value was determined at a dose of 200 mg/kg (i.p.) in Mice; NC: not calculable",N,,,50594,1,,CHEMBL626337,BAO_0000218,
8875,Intermediate,10090.0,,1,,,Half life after intraperitoneal administration of 100 mg/kg in mice,N,,,50594,1,,CHEMBL626338,BAO_0000218,
8876,Intermediate,10090.0,In vivo,1,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.p. administration,N,,,50594,1,,CHEMBL626339,BAO_0000218,
8877,Intermediate,10090.0,In vivo,1,,,Half life in BALB/C mice at the dose of 20 mg/kg by i.v. administration,N,,,50594,1,,CHEMBL626340,BAO_0000218,
8878,Intermediate,10090.0,In vivo,1,,,Half life in BALB/C mice at the dose of 20 mg/kg by p.o. administration,N,,,50594,1,,CHEMBL625377,BAO_0000218,
8879,Intermediate,10090.0,In vivo,1,,,Half life in BALB/C mice at the dose of 50 mg/kg by i.p. administration,N,,,50594,1,,CHEMBL625378,BAO_0000218,
8880,Intermediate,10090.0,In vivo,1,,,Half life in BALB/C mice at the dose of 50 mg/kg by p.o. administration,N,,,50594,1,,CHEMBL625379,BAO_0000218,
8881,Autocuration,9823.0,,1,,,Metabolism of compound in mini pig S9 microsomes ('+''indicates <20% largest observed peak),U,Microsomes,,22224,0,,CHEMBL625380,BAO_0000251,
8882,Autocuration,9823.0,,1,,,Metabolism of compound in mini pig S9 microsomes ('++++' indicates largest observed peak),U,Microsomes,,22224,0,,CHEMBL625381,BAO_0000251,
8883,Autocuration,9823.0,,1,,,Stability to porcine renal DHP-I,U,,,22224,0,,CHEMBL625382,BAO_0000019,
8884,Autocuration,9823.0,In vivo,1,,,Compound was tested for its half-life period at an intravenous dose of 30 ug/kg,U,,,22224,0,,CHEMBL873828,BAO_0000218,
8885,Autocuration,9823.0,In vivo,1,,,Compound was tested for its half-life period at an intravenous dose of 3 ug/kg,U,,,22224,0,,CHEMBL625383,BAO_0000218,
8886,Autocuration,9823.0,,1,,,Half-life of the parent prodrug in porcine esterase solution,U,,,22224,0,,CHEMBL625384,BAO_0000019,
8887,Autocuration,9823.0,,1,,,"First order rate constant, k was determined in in pig liver Esterase",U,,,22224,0,,CHEMBL625385,BAO_0000019,
8888,Autocuration,9823.0,,1,2107.0,,Half life of the in pig liver Esterase,U,,,22224,0,,CHEMBL625386,BAO_0000221,
8889,Autocuration,9823.0,,1,2107.0,,Tested for half life period at 37 degree Celsius in PBS buffer at 11.8 pH containing porcine liver esterase,U,,,22224,0,,CHEMBL623571,BAO_0000221,
8890,Autocuration,9823.0,,1,2107.0,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH containing porcine liver esterase,U,,,22224,0,,CHEMBL623572,BAO_0000221,
8891,Autocuration,9823.0,,1,2107.0,,Tested for half life period at 37 degree Celsius in PBS buffer at 7.3 pH in containing porcine liver esterase,U,,,22224,0,,CHEMBL623573,BAO_0000221,
8892,Autocuration,9823.0,,1,2107.0,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay,U,,,22224,0,,CHEMBL623574,BAO_0000221,
8893,Autocuration,9823.0,,1,2107.0,,Compound was evaluated for esterase half-life (t 1/2) period using Pig Liver Esterase (PLE) assay; ND is not determined,U,,,22224,0,,CHEMBL623575,BAO_0000221,
8894,Autocuration,9823.0,,1,2107.0,,Half-life in the presence of pig liver esterase(PLE) was evaluated.,U,,,22224,0,,CHEMBL623749,BAO_0000221,
8895,Autocuration,9823.0,,1,2107.0,,Half-life in the presence of pig liver esterase(PLE) was evaluated; Stable,U,,,22224,0,,CHEMBL623750,BAO_0000221,
8896,Autocuration,9823.0,In vitro,1,2107.0,,Half-life in vitro in pig liver,U,,,22224,0,,CHEMBL623751,BAO_0000221,
8897,Autocuration,9823.0,,1,2107.0,,Half-life time was determined for esterase-catalyzed hydrolysis of the phenol ester bond in porcine liver esterase,U,,,22224,0,,CHEMBL623752,BAO_0000221,
8898,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration in rat plasma after administration of 50 mg/kg dose through subcutaneous route,N,,,50597,1,,CHEMBL623753,BAO_0000218,
8899,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration in rat plasma at 30 mg/Kg upon oral administration.,N,,,50597,1,,CHEMBL623754,BAO_0000218,
8900,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration in rat plasma was determined,N,,,50597,1,,CHEMBL623755,BAO_0000218,
8901,Intermediate,10116.0,In vivo,1,,,Maximum concentration in rats,N,,,50597,1,,CHEMBL623756,BAO_0000218,
8902,Intermediate,10116.0,In vivo,1,,,Maximum concentration in rats at 1-2 hours,N,,,50597,1,,CHEMBL623757,BAO_0000218,
8903,Intermediate,10116.0,In vivo,1,,,Maximum concentration in rats at 1 hr was determined when dosed at 20 mg/Kg perorally,N,,,50597,1,,CHEMBL623758,BAO_0000218,
8904,Intermediate,10116.0,In vivo,1,955.0,,Maximum concentration in whole brain at 30 min following 24 mg/kg subcutaneous dose in rats,N,,,50597,1,,CHEMBL623759,BAO_0000218,
8905,Intermediate,10116.0,In vivo,1,,,Maximum concentration at the dose of 2 mg/kg in rat,N,,,50597,1,,CHEMBL623760,BAO_0000218,
8906,Intermediate,10116.0,In vivo,1,,,Maximum concentration was evaluated in rats,N,,,50597,1,,CHEMBL623761,BAO_0000218,
8907,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 10 mg/kg to a fasting rat,N,,,50597,1,,CHEMBL623762,BAO_0000218,
8908,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 1 mg/kg to a fasting rat,N,,,50597,1,,CHEMBL877594,BAO_0000218,
8909,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 30 mg/kg,N,,,50597,1,,CHEMBL623763,BAO_0000218,
8910,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg,N,,,50597,1,,CHEMBL623764,BAO_0000218,
8911,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration of uncharged drug in plasma recorded in the period of 0-24 hr after administering orally a dose of 3 mg/kg to a fasting rat,N,,,50597,1,,CHEMBL623765,BAO_0000218,
8912,Intermediate,10116.0,In vivo,1,178.0,,Maximum concentration value was evaluated for high sustained blood levels in rat after 1 hr of administration,N,,,50597,1,,CHEMBL623766,BAO_0000218,
8913,Intermediate,10116.0,In vivo,1,178.0,,Maximum concentration value was evaluated for high sustained blood levels in rat after 2 hr of administration,N,,,50597,1,,CHEMBL623767,BAO_0000218,
8914,Intermediate,10116.0,In vivo,1,178.0,,Maximum concentration value was evaluated for high sustained blood levels in rat after 30 min of administration,N,,,50597,1,,CHEMBL623768,BAO_0000218,
8915,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) of compound (19.2 mg/kg) after po administration was determined Sprague-Dawley rat,N,,,50597,1,,CHEMBL623769,BAO_0000218,
8916,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) of compound (19.76 mg/kg) after po administration was determined Sprague-Dawley rat,N,,,50597,1,,CHEMBL623770,BAO_0000218,
8917,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) of compound (20.73 mg/kg) after po administration was determined Sprague-Dawley rat,N,,,50597,1,,CHEMBL623771,BAO_0000218,
8918,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) of compound (25 mg/kg) after po administration was determined Sprague-Dawley rat,N,,,50597,1,,CHEMBL623772,BAO_0000218,
8919,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) of compound (9.83 mg/kg) after iv administration was determined Sprague-Dawley rat,N,,,50597,1,,CHEMBL623773,BAO_0000218,
8920,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) of compound (9.84 mg/kg) after iv administration was determined Sprague-Dawley rat,N,,,50597,1,,CHEMBL623774,BAO_0000218,
8921,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) of compound (9.92 mg/kg) after iv administration was determined Sprague-Dawley rat,N,,,50597,1,,CHEMBL623775,BAO_0000218,
8922,Intermediate,10116.0,In vivo,1,,,Cmax in rat (PO dose),N,,,50597,1,,CHEMBL623776,BAO_0000218,
8923,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,,,50597,1,,CHEMBL622191,BAO_0000218,
8924,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,,,50597,1,,CHEMBL622192,BAO_0000218,
8925,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration determined in rat,N,,,50597,1,,CHEMBL622193,BAO_0000218,
8926,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration for the compound in solution form (formulation) was determined in rats at peroral dose of 5 mg/kg,N,,,50597,1,,CHEMBL622194,BAO_0000218,
8927,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration for the compound in suspension form (formulation) was determined in rats at peroral dose of 5 mg/kg,N,,,50597,1,,CHEMBL622195,BAO_0000218,
8928,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration in rat,N,,,50597,1,,CHEMBL622196,BAO_0000218,
8929,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration measured after intravenous bolus administration of 50 mg/kg of compound to rats,N,,,50597,1,,CHEMBL622197,BAO_0000218,
8930,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration of compound present in rats at the dose of 37 mg/kg in 15 min,N,,,50597,1,,CHEMBL622198,BAO_0000218,
8931,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration of compound present in rats at the dose of 38 mg/kg in 15 min,N,,,50597,1,,CHEMBL622199,BAO_0000218,
8932,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration of compound was measured in rat,N,,,50597,1,,CHEMBL622200,BAO_0000218,
8933,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration after 20 mg/kg oral administration in rat,N,,,50597,1,,CHEMBL622201,BAO_0000218,
8934,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration after oral administration to rats,N,,,50597,1,,CHEMBL623990,BAO_0000218,
8935,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,,,50597,1,,CHEMBL623991,BAO_0000218,
8936,Intermediate,10116.0,In vivo,1,1969.0,,"Maximum plasma concentration at a concentration of 3 mg/kg in rats, intravenously",N,,,50597,1,,CHEMBL623992,BAO_0000218,
8937,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,,,50597,1,,CHEMBL623993,BAO_0000218,
8938,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration at a concentration of 60 mg/kg perorally in rats along with control,N,,,50597,1,,CHEMBL623994,BAO_0000218,
8939,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration at a dose of 100 mg/kg in Rat Plasma after iv administration,N,,,50597,1,,CHEMBL623995,BAO_0000218,
8940,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration at a dose of 4 mg/kg in Rat Plasma after iv administration,N,,,50597,1,,CHEMBL623996,BAO_0000218,
8941,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration at a dose of 50 mg/kg in Rat Plasma after iv administration,N,,,50597,1,,CHEMBL623997,BAO_0000218,
8942,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration dosed orally in rats,N,,,50597,1,,CHEMBL623998,BAO_0000218,
8943,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration dosed orally in rats after 6 hours,N,,,50597,1,,CHEMBL623999,BAO_0000218,
8944,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration dosed orally in rats after 6 hours; ND is not detected,N,,,50597,1,,CHEMBL624000,BAO_0000218,
8945,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration at a 1 mg/kg oral dose in female Sprague-Dawley rats,N,,,50597,1,,CHEMBL624001,BAO_0000218,
8946,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration in rat after po administration,N,,,50597,1,,CHEMBL624002,BAO_0000218,
8947,Intermediate,10116.0,In vivo,1,1969.0,,"Maximum plasma concentration in rats at 10 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL624003,BAO_0000218,
8948,Intermediate,10116.0,In vivo,1,1969.0,,"Maximum plasma concentration in rats at 20mg/kg, i.p. dose",N,,,50597,1,,CHEMBL624004,BAO_0000218,
8949,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,,50597,1,,CHEMBL624005,BAO_0000218,
8950,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,,50597,1,,CHEMBL624006,BAO_0000218,
8951,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,,50597,1,,CHEMBL624007,BAO_0000218,
8952,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,,50597,1,,CHEMBL624008,BAO_0000218,
8953,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,,50597,1,,CHEMBL624009,BAO_0000218,
8954,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,,50597,1,,CHEMBL874387,BAO_0000218,
8955,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,,50597,1,,CHEMBL624010,BAO_0000218,
8956,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,N,,,50597,1,,CHEMBL624011,BAO_0000218,
8957,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,,50597,1,,CHEMBL624012,BAO_0000218,
8958,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,,50597,1,,CHEMBL624013,BAO_0000218,
8959,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,,50597,1,,CHEMBL624736,BAO_0000218,
8960,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,,50597,1,,CHEMBL624737,BAO_0000218,
8961,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,,50597,1,,CHEMBL624738,BAO_0000218,
8962,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,,50597,1,,CHEMBL624739,BAO_0000218,
8963,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,,50597,1,,CHEMBL624740,BAO_0000218,
8964,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,,50597,1,,CHEMBL624896,BAO_0000218,
8965,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,,50597,1,,CHEMBL624897,BAO_0000218,
8966,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,,50597,1,,CHEMBL624108,BAO_0000218,
8967,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,,50597,1,,CHEMBL624109,BAO_0000218,
8968,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,,50597,1,,CHEMBL624110,BAO_0000218,
8969,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,,50597,1,,CHEMBL624111,BAO_0000218,
8970,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,,50597,1,,CHEMBL624112,BAO_0000218,
8971,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,,50597,1,,CHEMBL624113,BAO_0000218,
8972,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,,50597,1,,CHEMBL619709,BAO_0000218,
8973,Intermediate,10116.0,,1,948.0,,Radioactivity distribution in heart of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,,50597,1,,CHEMBL619710,BAO_0000218,
8974,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,,50597,1,,CHEMBL619711,BAO_0000218,
8975,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,,50597,1,,CHEMBL619712,BAO_0000218,
8976,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,,50597,1,,CHEMBL619713,BAO_0000218,
8977,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,,50597,1,,CHEMBL619714,BAO_0000218,
8978,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,,50597,1,,CHEMBL619715,BAO_0000218,
8979,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,,50597,1,,CHEMBL619716,BAO_0000218,
8980,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,,50597,1,,CHEMBL619717,BAO_0000218,
8981,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,,50597,1,,CHEMBL619718,BAO_0000218,
8982,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,,50597,1,,CHEMBL619719,BAO_0000218,
8983,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,,50597,1,,CHEMBL875329,BAO_0000218,
8984,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,,50597,1,,CHEMBL619720,BAO_0000218,
8985,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,,50597,1,,CHEMBL619721,BAO_0000218,
8986,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,,50597,1,,CHEMBL619722,BAO_0000218,
8987,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,,50597,1,,CHEMBL619723,BAO_0000218,
8988,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,,50597,1,,CHEMBL619724,BAO_0000218,
8989,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,,50597,1,,CHEMBL619725,BAO_0000218,
8990,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,,50597,1,,CHEMBL619726,BAO_0000218,
8991,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,,50597,1,,CHEMBL619727,BAO_0000218,
8992,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,,50597,1,,CHEMBL619728,BAO_0000218,
8993,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,,50597,1,,CHEMBL619729,BAO_0000218,
8994,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL619730,BAO_0000218,
8995,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL619731,BAO_0000218,
8996,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,,50597,1,,CHEMBL619732,BAO_0000218,
8997,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL619733,BAO_0000218,
8998,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of radioligand [125I]FIDA1 in muscle of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL619734,BAO_0000218,
8999,Intermediate,10116.0,In vivo,1,14.0,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL619735,BAO_0000218,
9000,Intermediate,10116.0,In vivo,1,14.0,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL875330,BAO_0000218,
9001,Intermediate,10116.0,In vivo,1,14.0,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,,50597,1,,CHEMBL628465,BAO_0000218,
9002,Intermediate,10116.0,In vivo,1,14.0,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL628466,BAO_0000218,
9003,Intermediate,10116.0,In vivo,1,14.0,,Biodistribution of radioligand [125I]FIDA1 in skin of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL628467,BAO_0000218,
9004,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL628468,BAO_0000218,
9005,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL628469,BAO_0000218,
9006,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,,50597,1,,CHEMBL628470,BAO_0000218,
9007,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL628471,BAO_0000218,
9008,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of radioligand [125I]FIDA1 in spleen of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL628472,BAO_0000218,
9009,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 120 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL625191,BAO_0000218,
9010,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL625192,BAO_0000218,
9011,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 2 rats),N,,,50597,1,,CHEMBL875337,BAO_0000218,
9012,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 30 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL626341,BAO_0000218,
9013,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution of radioligand [125I]FIDA1 in thyroid of rat after 60 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL626342,BAO_0000218,
9014,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of radioligand [125I]-FIDA1 in liver of rat after 2 minutes after an intravenous injection is given (average of 3 rats),N,,,50597,1,,CHEMBL621943,BAO_0000218,
9015,Intermediate,10116.0,,1,,,Half life in rats,N,,,50597,1,,CHEMBL621944,BAO_0000218,
9016,Intermediate,10116.0,,1,,,Mean percent inhibition of joint damage reduction in fasted rats at 35 mg/kg administered orally twice daily,N,,,50597,1,,CHEMBL621945,BAO_0000218,
9017,Intermediate,10116.0,,1,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver),N,,,50597,1,,CHEMBL621946,BAO_0000218,
9018,Intermediate,10116.0,,1,,,Compound was evaluated for rate of clearance by using IPRL (Isolated Perfused Rat Liver); ND=Not determined,N,,,50597,1,,CHEMBL621947,BAO_0000218,
9019,Intermediate,10116.0,,1,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver),N,,,50597,1,,CHEMBL621948,BAO_0000218,
9020,Intermediate,10116.0,,1,,,Compound was evaluated for rate of clearance in IPRL (Isolated Perfused Rat Liver); ND=Not determined,N,,,50597,1,,CHEMBL621949,BAO_0000218,
9021,Intermediate,10116.0,,1,,,Rate constant (k) of clearance from isolated perfused rat liver (IPRL),N,,,50597,1,,CHEMBL621950,BAO_0000218,
9022,Intermediate,10116.0,,1,,,Tested for rate of clearance from isolated perfused rat liver (IPRL) and expressed in terms of rate constant (k); not determined,N,,,50597,1,,CHEMBL621951,BAO_0000218,
9023,Intermediate,10116.0,In vivo,1,178.0,,Maximal blood concentration after oral administration of a 30 uM/kg dose of compound,N,,,50597,1,,CHEMBL621952,BAO_0000218,
9024,Intermediate,10116.0,,1,2107.0,,Stability (%) in rat liver microsomes,N,,,50597,1,,CHEMBL621953,BAO_0000218,
9025,Intermediate,10116.0,,1,,,Area under curve was calculated after intravenous administration,N,,,50597,1,,CHEMBL621954,BAO_0000218,
9026,Intermediate,10116.0,,1,,,Area under the curve was calculated after iv administration in rat,N,,,50597,1,,CHEMBL621955,BAO_0000218,
9027,Intermediate,10116.0,,1,,,Area under the curve was calculated in rat after peroral administration,N,,,50597,1,,CHEMBL621956,BAO_0000218,
9028,Intermediate,10116.0,,1,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,N,,,50597,1,,CHEMBL621957,BAO_0000218,
9029,Intermediate,10116.0,,1,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral dose of 2 mg/Kg,N,,,50597,1,,CHEMBL621958,BAO_0000218,
9030,Intermediate,10116.0,,1,,,Dose-normalized AUC measured in fasted male Sprague dawely rats when the compound was administered at a peroral of 2 mg/Kg,N,,,50597,1,,CHEMBL621959,BAO_0000218,
9031,Intermediate,10116.0,,1,,,Dose-normalized area under curve in rat (i.v.) at 0.5 mpk,N,,,50597,1,,CHEMBL621960,BAO_0000218,
9032,Intermediate,10116.0,,1,,,Dose-normalized area under curve in rat (p.o.) at 2.0 mpk,N,,,50597,1,,CHEMBL621961,BAO_0000218,
9033,Intermediate,10116.0,,1,,,p value of the compound,N,,,50597,1,,CHEMBL621962,BAO_0000218,
9034,Intermediate,10116.0,,1,,,p value of the compound,N,,,50597,1,,CHEMBL876787,BAO_0000218,
9035,Intermediate,10116.0,,1,,,p value of the compound,N,,,50597,1,,CHEMBL621963,BAO_0000218,
9036,Intermediate,10116.0,,1,945.0,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,,,50597,1,,CHEMBL622637,BAO_0000218,
9037,Intermediate,10116.0,,1,945.0,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (20 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,,,50597,1,,CHEMBL622638,BAO_0000218,
9038,Intermediate,10116.0,,1,945.0,,pH of the gastric juice (Control value = 1.42+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,,,50597,1,,CHEMBL626561,BAO_0000218,
9039,Autocuration,9986.0,,1,,,Negative log of minimum effective dose (moles per kilogram) in rabbits (hypnotic),U,,,22224,0,,CHEMBL626562,BAO_0000019,
9040,Autocuration,9986.0,,1,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg ( 0-4 hr ),U,,,22224,0,,CHEMBL626563,BAO_0000218,
9041,Autocuration,9986.0,,1,,,Evaluated for pharmacokinetic parameter area under curve in rabbit at the dose 20 mg/kg (0-4 hr ),U,,,22224,0,,CHEMBL626564,BAO_0000218,
9042,Autocuration,9986.0,In vivo,1,,,Clearance was measured at the concentration of 1.11 mg/kg in rabbit blood sample,U,,,22224,0,,CHEMBL626565,BAO_0000218,
9043,Autocuration,9986.0,In vivo,1,,,Clearance was measured at the concentration of 2.0 mg/kg in rabbit blood sample,U,,,22224,0,,CHEMBL626566,BAO_0000218,
9044,Autocuration,9986.0,In vivo,1,,,Clearance rate in rabbits,U,,,22224,0,,CHEMBL626567,BAO_0000218,
9045,Autocuration,9986.0,In vivo,1,,,Plasma clearance was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,U,,,22224,0,,CHEMBL626568,BAO_0000218,
9046,Autocuration,9986.0,In vivo,1,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,U,,,22224,0,,CHEMBL626569,BAO_0000218,
9047,Autocuration,9986.0,In vivo,1,,,Clearance in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,U,,,22224,0,,CHEMBL626570,BAO_0000218,
9048,Autocuration,9986.0,In vivo,1,,,Clearance in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,U,,,22224,0,,CHEMBL626571,BAO_0000218,
9049,Autocuration,9986.0,In vivo,1,,,Evaluated for pharmacokinetic parameter Cmax in rabbit at the dose 20 mg/kg,U,,,22224,0,,CHEMBL626572,BAO_0000218,
9050,Autocuration,9986.0,In vivo,1,1969.0,,Maximum plasma concentration was determined in rabbit at a dose of 5 mg/kg/h administered i.v.,U,,,22224,0,,CHEMBL626573,BAO_0000218,
9051,Autocuration,9986.0,,1,2107.0,,Oxidation by dutch rabbit liver microsomes in presence of NADPH/O2,U,Microsomes,,22224,0,,CHEMBL626574,BAO_0000251,
9052,Autocuration,9986.0,,1,2107.0,,Oxidation by dutch rabbit liver microsomes in presence of cumene hydroperoxide,U,Microsomes,,22224,0,,CHEMBL626575,BAO_0000251,
9053,Autocuration,9986.0,,1,,,Dose at which bioavailability of intravenously administered compound was tested in rabbit,U,,,22224,0,,CHEMBL626576,BAO_0000218,
9054,Autocuration,9986.0,,1,,,Dose at which bioavailability of perorally administered compound was tested in rabbit,U,,,22224,0,,CHEMBL626577,BAO_0000218,
9055,Autocuration,9986.0,In vivo,1,,,The compound was tested for its bioavailability in rabbit (by oral dosage).,U,,,22224,0,,CHEMBL626578,BAO_0000218,
9056,Autocuration,9986.0,In vivo,1,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,U,,,22224,0,,CHEMBL625263,BAO_0000218,
9057,Autocuration,9986.0,In vivo,1,,,Mean retention time in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,U,,,22224,0,,CHEMBL625264,BAO_0000218,
9058,Autocuration,9986.0,In vivo,1,,,Mean retention time in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,U,,,22224,0,,CHEMBL625265,BAO_0000218,
9059,Autocuration,9986.0,,1,,,Metabolism of compound in rabbit S9 microsomes ('+''indicates <20% largest observed peak),U,Microsomes,,22224,0,,CHEMBL625266,BAO_0000251,
9060,Autocuration,9986.0,,1,,,Metabolism of compound in rabbit S9 microsomes ('++++' indicates largest observed peak),U,Microsomes,,22224,0,,CHEMBL876796,BAO_0000251,
9061,Autocuration,9986.0,In vivo,1,,,Evaluated for pharmacokinetic parameter half-life in rabbit at the dose 20 mg/kg,U,,,22224,0,,CHEMBL625267,BAO_0000218,
9062,Autocuration,9986.0,In vivo,1,1969.0,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 4.9 mg/kg,U,,,22224,0,,CHEMBL625268,BAO_0000218,
9063,Autocuration,9986.0,In vivo,1,1969.0,,Plasma half-life in male New Zealand white rabbits after administration via an indwelling catheter in an ear vein at 5 mg/kg,U,,,22224,0,,CHEMBL625269,BAO_0000218,
9064,Autocuration,9986.0,In vivo,1,1969.0,,Plasma half-life in male New Zealand white rabbits after i.v. administration at 2.0 mg/kg,U,,,22224,0,,CHEMBL624689,BAO_0000218,
9065,Autocuration,9986.0,In vivo,1,,,Evaluated for pharmacokinetic parameter tmax in rabbit at the dose 20 mg/kg,U,,,22224,0,,CHEMBL624690,BAO_0000218,
9066,Autocuration,9986.0,,1,1088.0,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg ( 0-24 hr ),U,,,22224,0,,CHEMBL624691,BAO_0000218,
9067,Autocuration,9986.0,,1,1088.0,,Evaluated for pharmacokinetic parameter urine recovery in rabbit at the dose 20 mg/kg (0-24 hr),U,,,22224,0,,CHEMBL624692,BAO_0000218,
9068,Autocuration,9986.0,In vivo,1,,,The compound was evaluated for volume of distribution in rabbit at a dose of 5 mg/kg/h administered i.v.,U,,,22224,0,,CHEMBL624693,BAO_0000218,
9069,Autocuration,9986.0,In vivo,1,,,Volume of distribution after intravenous administration of 1 mg/kg/h in dog,U,,,22224,0,,CHEMBL624694,BAO_0000218,
9070,Autocuration,9986.0,In vitro,1,,,In vitro Biological half-life in crude homogenate of rabbit renal cortex,U,,,22224,0,,CHEMBL877596,BAO_0000221,
9071,Autocuration,9986.0,,1,,,Time within which only 10% of the drug was degraded,U,,,22224,0,,CHEMBL624695,BAO_0000019,
9072,Autocuration,9986.0,,1,2107.0,,Half life period in rabbit liver homogenate,U,,,22224,0,,CHEMBL624696,BAO_0000221,
9073,Autocuration,9986.0,,1,,,Half life value in rabbits,U,,,22224,0,,CHEMBL624697,BAO_0000019,
9074,Autocuration,9986.0,In vivo,1,178.0,,Half-life was measured at the concentration of 1.11 mg/kg in rabbit blood sample,U,,,22224,0,,CHEMBL624698,BAO_0000218,
9075,Autocuration,9986.0,In vivo,1,178.0,,Half-life was measured at the concentration of 2.0 mg/kg in rabbit blood sample,U,,,22224,0,,CHEMBL624699,BAO_0000218,
9076,Autocuration,9986.0,In vivo,1,,,Half-life period in rabbits following intravenous administration at 2 mg/kg,U,,,22224,0,,CHEMBL624700,BAO_0000218,
9077,Intermediate,10116.0,,1,1969.0,,AUC 0-8 hr value in rats at 10 mg/kg,N,,,50597,1,,CHEMBL622903,BAO_0000218,
9078,Intermediate,10116.0,,1,1969.0,,AUC after administration at 2000 mg/kg/day in rats,N,,,50597,1,,CHEMBL622904,BAO_0000218,
9079,Intermediate,10116.0,,1,1969.0,,AUC of compound for a 2 mpk po dose of the sodium salt in rats.,N,,,50597,1,,CHEMBL622905,BAO_0000218,
9080,Intermediate,10116.0,,1,1969.0,,AUC at a dose of 10 mg/Kg administered intravenously in female hanover-wistar rat,N,,,50597,1,,CHEMBL622906,BAO_0000218,
9081,Intermediate,10116.0,,1,1969.0,,AUC at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,N,,,50597,1,,CHEMBL622907,BAO_0000218,
9082,Intermediate,10116.0,,1,1969.0,,AUC in rat after oral administration at 10.5 mg/kg dose,N,,,50597,1,,CHEMBL622908,BAO_0000218,
9083,Intermediate,10116.0,,1,1969.0,,AUC in rat after oral administration at 11.2 mg/kg dose,N,,,50597,1,,CHEMBL622909,BAO_0000218,
9084,Intermediate,10116.0,,1,1969.0,,AUC in rat after oral administration at 9.7 mg/kg dose,N,,,50597,1,,CHEMBL622910,BAO_0000218,
9085,Intermediate,10116.0,,1,955.0,,AUC in rat brain after oral administration at 10 mg/kg,N,,,50597,1,,CHEMBL622911,BAO_0000218,
9086,Intermediate,10116.0,,1,1969.0,,AUC in rat p.o.,N,,,50597,1,,CHEMBL622912,BAO_0000218,
9087,Intermediate,10116.0,,1,1969.0,,AUC in rat p.o. at 20 mg/kg concentration,N,,,50597,1,,CHEMBL622913,BAO_0000218,
9088,Intermediate,10116.0,,1,1969.0,,AUC in rat plasma after oral administration at 10 mg/kg,N,,,50597,1,,CHEMBL622914,BAO_0000218,
9089,Intermediate,10116.0,,1,1969.0,,AUC in rats,N,,,50597,1,,CHEMBL622915,BAO_0000218,
9090,Intermediate,10116.0,,1,1969.0,,AUC value after IV dose at a dose of 5 mg/kg in rats.,N,,,50597,1,,CHEMBL622916,BAO_0000218,
9091,Intermediate,10116.0,,1,1969.0,,AUC value after oral dose at a dose of 10 mg/kg in rats.,N,,,50597,1,,CHEMBL622917,BAO_0000218,
9092,Intermediate,10116.0,In vivo,1,1969.0,,"Maximum plasma concentration in rats at 2 mg/kg, i.v. dose; n/a: not applicable",N,,,50597,1,,CHEMBL622918,BAO_0000218,
9093,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration in rats when a oral dose of 200 mg/kg was given,N,,,50597,1,,CHEMBL622919,BAO_0000218,
9094,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration was evaluated in rat,N,,,50597,1,,CHEMBL622920,BAO_0000218,
9095,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,N,,,50597,1,,CHEMBL622921,BAO_0000218,
9096,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration reached by compound was determined after 2 mg/kg (p.o.) administration,N,,,50597,1,,CHEMBL622922,BAO_0000218,
9097,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration reached by compound was determined in rats at 50 mg/kg dose,N,,,50597,1,,CHEMBL622923,BAO_0000218,
9098,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,N,,,50597,1,,CHEMBL877604,BAO_0000218,
9099,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration was evaluated in rats at an intravenous dose of 3 mg/kg,N,,,50597,1,,CHEMBL622924,BAO_0000218,
9100,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration was evaluated in rats at an oral dose of 30 mg/kg,N,,,50597,1,,CHEMBL622925,BAO_0000218,
9101,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration was measured when a dose of 1 mg/kg is administered orally,N,,,50597,1,,CHEMBL622926,BAO_0000218,
9102,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) in rat (in vivo) at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL623625,BAO_0000218,
9103,Expert,10116.0,In vivo,1,1969.0,,Maximum plasma drug concentration of compound determined in rat after iv administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL623626,BAO_0000218,
9104,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma drug concentration was determined,N,,,50597,1,,CHEMBL623627,BAO_0000218,
9105,Intermediate,10116.0,In vivo,1,,,Maximum concentration by intravenous administration of 3.4 mg/kg in rat,N,,,50597,1,,CHEMBL623628,BAO_0000218,
9106,Intermediate,10116.0,In vivo,1,1969.0,,Mean peak plasma concentration was observed after intravenous administration in rat,N,,,50597,1,,CHEMBL623629,BAO_0000218,
9107,Intermediate,10116.0,In vivo,1,1969.0,,Mean peak plasma concentration was observed after oral administration in rat,N,,,50597,1,,CHEMBL623630,BAO_0000218,
9108,Intermediate,10116.0,In vivo,1,,,Peak concentration (Cmax) at a dose of 10 mg/kg in rats,N,,,50597,1,,CHEMBL623804,BAO_0000218,
9109,Intermediate,10116.0,In vivo,1,,,Peak concentration (Cmax) at a dose of 20 mg/kg in rats,N,,,50597,1,,CHEMBL623805,BAO_0000218,
9110,Intermediate,10116.0,In vivo,1,1969.0,,Peak oral plasma concentration was determined in rats by oral administration,N,,,50597,1,,CHEMBL623806,BAO_0000218,
9111,Intermediate,10116.0,In vivo,1,1969.0,,Peak plasma concentration (Cmax) was determined,N,,,50597,1,,CHEMBL623807,BAO_0000218,
9112,Intermediate,10116.0,In vivo,1,1969.0,,Peak plasma concentration (Cmax) following an oral dose of 20 mg/kg in rats,N,,,50597,1,,CHEMBL623808,BAO_0000218,
9113,Intermediate,10116.0,In vivo,1,1969.0,,Peak plasma concentration (Cmax) in rats,N,,,50597,1,,CHEMBL623809,BAO_0000218,
9114,Intermediate,10116.0,In vivo,1,1969.0,,Peak plasma concentration at 1 mg/kg peroral administration,N,,,50597,1,,CHEMBL623810,BAO_0000218,
9115,Intermediate,10116.0,In vivo,1,1969.0,,Peak plasma concentration in rat,N,,,50597,1,,CHEMBL623811,BAO_0000218,
9116,Intermediate,10116.0,In vivo,1,1969.0,,"Pharmacokinetic Parameter, Cmax is observed maximum plasma concentration in Female Wistar Rats at 100 mg/kg by po administration",N,,,50597,1,,CHEMBL623812,BAO_0000218,
9117,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter Cmax was measured after administration into rat at 10 mg/kg,N,,,50597,1,,CHEMBL877605,BAO_0000218,
9118,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (Cmax) in rat,N,,,50597,1,,CHEMBL623813,BAO_0000218,
9119,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (Cmax) was measured in rat at the dose of 0.32 mg/kg p.o.,N,,,50597,1,,CHEMBL623814,BAO_0000218,
9120,Intermediate,10116.0,In vivo,1,,,Cmax in rat after 3mg/kg oral dose,N,,,50597,1,,CHEMBL623815,BAO_0000218,
9121,Intermediate,10116.0,In vivo,1,,,Clearance in Sprague-Dawley rats after 2mg/kg oral dose,N,,,50597,1,,CHEMBL623816,BAO_0000218,
9122,Intermediate,10116.0,In vivo,1,,,Cmax in rats after 20 mg/kg oral dose,N,,,50597,1,,CHEMBL623145,BAO_0000218,
9123,Intermediate,10116.0,In vivo,1,1969.0,,Cmax in rat plasma after 30mg/kg oral dose,N,,,50597,1,,CHEMBL623146,BAO_0000218,
9124,Intermediate,10116.0,In vivo,1,1969.0,,Plasma concentration after oral administration of 100 mg/kg to rats,N,,,50597,1,,CHEMBL623147,BAO_0000218,
9125,Intermediate,10116.0,In vivo,1,955.0,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,N,,,50597,1,,CHEMBL623042,BAO_0000218,
9126,Intermediate,10116.0,In vivo,1,,,Tested for the Cmax in rat at 10 mg/kg per orally,N,,,50597,1,,CHEMBL623043,BAO_0000218,
9127,Intermediate,10116.0,In vivo,1,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL623044,BAO_0000218,
9128,Intermediate,10116.0,In vivo,1,,,"The Cmax value in male wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL623045,BAO_0000218,
9129,Intermediate,10116.0,In vivo,1,,,Bioavailability as oral Cmax in rats at 30 mins,N,,,50597,1,,CHEMBL623046,BAO_0000218,
9130,Intermediate,10116.0,In vivo,1,,,Bioavailability as oral Cmax in rats at 6hr,N,,,50597,1,,CHEMBL623226,BAO_0000218,
9131,Intermediate,10116.0,In vivo,1,,,The maximum concentration of compound was measured at the dose of 100 umol/kg,N,,,50597,1,,CHEMBL623227,BAO_0000218,
9132,Intermediate,10116.0,In vivo,1,,,The maximum concentration of compound was measured at the dose of 300 umol/kg,N,,,50597,1,,CHEMBL623228,BAO_0000218,
9133,Intermediate,10116.0,In vivo,1,,,The maximum concentration of compound was measured at the dose of 30 umol/kg,N,,,50597,1,,CHEMBL623229,BAO_0000218,
9134,Intermediate,10116.0,In vivo,1,1969.0,,The maximum plasma levels for the compounds were determined by LC-MS.,N,,,50597,1,,CHEMBL623230,BAO_0000218,
9135,Intermediate,10116.0,In vivo,1,1969.0,,mean peak plasma concentration was observed after intravenous administration in rat,N,,,50597,1,,CHEMBL623231,BAO_0000218,
9136,Intermediate,10116.0,In vivo,1,1969.0,,mean peak plasma concentration was observed after oral administration in rat,N,,,50597,1,,CHEMBL623232,BAO_0000218,
9137,Intermediate,10116.0,,1,,,Concentration in the plasma after intravenous administration of 1 mg/kg in rat,N,,,50597,1,,CHEMBL623233,BAO_0000218,
9138,Intermediate,10116.0,,1,,,Concentration in plasma (portal) following oral dose in rats at 0.25 hr,N,,,50597,1,,CHEMBL623234,BAO_0000218,
9139,Intermediate,10116.0,,1,,,Concentration in plasma (portal) following oral dose in rats at 1 hr,N,,,50597,1,,CHEMBL623235,BAO_0000218,
9140,Intermediate,10116.0,,1,,,Concentration in plasma (portal) following oral dose in rats at 2 hr,N,,,50597,1,,CHEMBL623236,BAO_0000218,
9141,Intermediate,10116.0,,1,,,Concentration in plasma (systemic) following oral dose in rats at 0.25 hr,N,,,50597,1,,CHEMBL623237,BAO_0000218,
9142,Intermediate,10116.0,,1,,,Concentration in plasma (systemic) following oral dose in rats at 1 hr,N,,,50597,1,,CHEMBL623238,BAO_0000218,
9143,Intermediate,10116.0,,1,,,Concentration in plasma (systemic) following oral dose in rats at 2 hr,N,,,50597,1,,CHEMBL623239,BAO_0000218,
9144,Intermediate,10116.0,In vivo,1,1969.0,,Compound was evaluated for the plasma concentration in rats versus time curves (AUC) in vivo,U,,,22224,0,,CHEMBL623240,BAO_0000218,
9145,Intermediate,10116.0,,1,1898.0,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 2 hours",N,,,50597,1,,CHEMBL623241,BAO_0000218,
9146,Intermediate,10116.0,,1,1898.0,,"Concentration (30 mg/kg, p.o.) in rat hypothalamus after 6 hours",N,,,50597,1,,CHEMBL623242,BAO_0000218,
9147,Intermediate,10116.0,,1,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 2 hours",N,,,50597,1,,CHEMBL874394,BAO_0000218,
9148,Intermediate,10116.0,,1,,,"Concentration (30 mg/kg, p.o.) in rat plasma after 6 hours",N,,,50597,1,,CHEMBL623243,BAO_0000218,
9149,Intermediate,10116.0,,1,,,Kidney concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,,50597,1,,CHEMBL623244,BAO_0000218,
9150,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,,50597,1,,CHEMBL623245,BAO_0000218,
9151,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,,50597,1,,CHEMBL623246,BAO_0000218,
9152,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,,50597,1,,CHEMBL623247,BAO_0000218,
9153,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,,50597,1,,CHEMBL623248,BAO_0000218,
9154,Intermediate,10116.0,,1,2113.0,,Radioactivity distribution in kidney of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,,50597,1,,CHEMBL623249,BAO_0000218,
9155,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,,50597,1,,CHEMBL625072,BAO_0000218,
9156,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,,50597,1,,CHEMBL625073,BAO_0000218,
9157,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,,50597,1,,CHEMBL625074,BAO_0000218,
9158,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,,50597,1,,CHEMBL625075,BAO_0000218,
9159,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min.,N,,,50597,1,,CHEMBL625076,BAO_0000218,
9160,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,,50597,1,,CHEMBL625077,BAO_0000218,
9161,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,,50597,1,,CHEMBL625078,BAO_0000218,
9162,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,,50597,1,,CHEMBL874395,BAO_0000218,
9163,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,,50597,1,,CHEMBL625079,BAO_0000218,
9164,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,,50597,1,,CHEMBL625080,BAO_0000218,
9165,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,,50597,1,,CHEMBL625081,BAO_0000218,
9166,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,,50597,1,,CHEMBL625082,BAO_0000218,
9167,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,,50597,1,,CHEMBL625083,BAO_0000218,
9168,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,,50597,1,,CHEMBL625084,BAO_0000218,
9169,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,,50597,1,,CHEMBL625085,BAO_0000218,
9170,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,,50597,1,,CHEMBL625086,BAO_0000218,
9171,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,,50597,1,,CHEMBL625087,BAO_0000218,
9172,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,,50597,1,,CHEMBL625088,BAO_0000218,
9173,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,,50597,1,,CHEMBL622205,BAO_0000218,
9174,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,,50597,1,,CHEMBL622206,BAO_0000218,
9175,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,,50597,1,,CHEMBL622207,BAO_0000218,
9176,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,,50597,1,,CHEMBL622366,BAO_0000218,
9177,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,,50597,1,,CHEMBL622367,BAO_0000218,
9178,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,,50597,1,,CHEMBL875331,BAO_0000218,
9179,Intermediate,10116.0,,1,2107.0,,Radioactivity distribution in liver of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,,50597,1,,CHEMBL622368,BAO_0000218,
9180,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,,50597,1,,CHEMBL622369,BAO_0000218,
9181,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,,50597,1,,CHEMBL622370,BAO_0000218,
9182,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,,50597,1,,CHEMBL622371,BAO_0000218,
9183,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,,50597,1,,CHEMBL622372,BAO_0000218,
9184,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,,50597,1,,CHEMBL622373,BAO_0000218,
9185,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,,50597,1,,CHEMBL622374,BAO_0000218,
9186,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,,50597,1,,CHEMBL622375,BAO_0000218,
9187,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,N,,,50597,1,,CHEMBL622376,BAO_0000218,
9188,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,,50597,1,,CHEMBL622377,BAO_0000218,
9189,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,,50597,1,,CHEMBL622378,BAO_0000218,
9190,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,,50597,1,,CHEMBL622379,BAO_0000218,
9191,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,,50597,1,,CHEMBL622380,BAO_0000218,
9192,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,,50597,1,,CHEMBL622381,BAO_0000218,
9193,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,,50597,1,,CHEMBL622382,BAO_0000218,
9194,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 120 min,N,,,50597,1,,CHEMBL622383,BAO_0000218,
9195,Intermediate,10116.0,,1,945.0,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured ( 5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,,,50597,1,,CHEMBL875332,BAO_0000218,
9196,Intermediate,10116.0,,1,945.0,,pH of the gastric juice (Control value = 1.44+/-0.01) of stomach content of pylorus ligated rats was measured (10 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,,,50597,1,,CHEMBL622384,BAO_0000218,
9197,Intermediate,10116.0,,1,945.0,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (2.5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,,,50597,1,,CHEMBL622385,BAO_0000218,
9198,Intermediate,10116.0,,1,945.0,,pH of the gastric juice (control value = 1.39+/-0.02) of stomach content of pylorus ligated rats was measured (5 mg/kg po of the Compound was administered 1 hr before the pylorus ligation),N,,,50597,1,,CHEMBL622386,BAO_0000218,
9199,Intermediate,10116.0,,1,,,The compound was tested for the plasma binding in rat,N,,,50597,1,,CHEMBL622387,BAO_0000218,
9200,Intermediate,10116.0,,1,,,"Plasma concentration after intravenous aministration at 1hr, (1 mg/kg, n=3)",N,,,50597,1,,CHEMBL622388,BAO_0000218,
9201,Intermediate,10116.0,,1,,,"Plasma concentration after intravenous aministration at 30 min. (1 mg/kg, n=3)",N,,,50597,1,,CHEMBL622389,BAO_0000218,
9202,Intermediate,10116.0,,1,,,"Plasma concentration after intravenous aministration at 60 min. (1 mg/kg, n=3)",N,,,50597,1,,CHEMBL622390,BAO_0000218,
9203,Intermediate,10116.0,,1,,,Plasma concentration after oral aministration at 1 hr. (10 mg/kg),N,,,50597,1,,CHEMBL622391,BAO_0000218,
9204,Intermediate,10116.0,,1,,,Plasma concentration after oral aministration at 2 hr. (10 mg/kg),N,,,50597,1,,CHEMBL622392,BAO_0000218,
9205,Intermediate,10116.0,,1,,,Plasma concentration after oral aministration at 4 hr. (10 mg/kg),N,,,50597,1,,CHEMBL622393,BAO_0000218,
9206,Intermediate,10116.0,,1,,,Plasma level at 2 hr after administration of the compound,N,,,50597,1,,CHEMBL622394,BAO_0000218,
9207,Intermediate,10116.0,,1,,,plasma level at 2 hr after administration of the compound,N,,,50597,1,,CHEMBL622395,BAO_0000218,
9208,Intermediate,10116.0,,1,1977.0,,Stability in rat serum measured as % recovery at 1 min,N,,,50597,1,,CHEMBL622396,BAO_0000218,
9209,Intermediate,10116.0,,1,1977.0,,Stability in rat serum measured as % recovery at 10 min,N,,,50597,1,,CHEMBL624894,BAO_0000218,
9210,Intermediate,10116.0,,1,1977.0,,Stability in rat serum measured as % recovery at 10 mins,N,,,50597,1,,CHEMBL624895,BAO_0000218,
9211,Intermediate,10116.0,,1,1977.0,,Stability in rat serum measured as % recovery at 2 hr,N,,,50597,1,,CHEMBL624058,BAO_0000218,
9212,Intermediate,10116.0,,1,1977.0,,Stability in rat serum measured as % recovery at 3 min,N,,,50597,1,,CHEMBL624059,BAO_0000218,
9213,Intermediate,10116.0,,1,1977.0,,Stability in rat serum measured as % recovery at 3 mins,N,,,50597,1,,CHEMBL624060,BAO_0000218,
9214,Intermediate,10116.0,,1,1977.0,,Stability in rat serum measured as % recovery at 5 min,N,,,50597,1,,CHEMBL624061,BAO_0000218,
9215,Intermediate,10116.0,,1,1977.0,,Stability in rat serum measured as % recovery at 5 mins,N,,,50597,1,,CHEMBL624062,BAO_0000218,
9216,Intermediate,10116.0,In vivo,1,,,Alpha-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL624063,BAO_0000218,
9217,Intermediate,10116.0,In vivo,1,,,Beta-elimination half-life in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL624064,BAO_0000218,
9218,Intermediate,10116.0,,1,1969.0,,Half life in plasma was determined against ovariectomized rats; t 1/2 (h) is short in plasma,N,,,50597,1,,CHEMBL624065,BAO_0000218,
9219,Intermediate,10116.0,,1,1969.0,,Half life in plasma was determined against ovariectomized rats; t1/2 is longer in plasma.,N,,,50597,1,,CHEMBL624066,BAO_0000218,
9220,Intermediate,10116.0,In vivo,1,,,Half life tested in mature male rat at a dose of 30 mg/kg,N,,,50597,1,,CHEMBL877490,BAO_0000218,
9221,Intermediate,10116.0,In vivo,1,,,Half life after intravenous administration of 1 mg/kg in rat,N,,,50597,1,,CHEMBL874442,BAO_0000218,
9222,Intermediate,10116.0,In vivo,1,,,Half life period after administration (30 mg/kg) in rat,N,,,50597,1,,CHEMBL626890,BAO_0000218,
9223,Intermediate,10116.0,In vivo,1,,,Half life period in rat after 5 mg/Kg dose,N,,,50597,1,,CHEMBL626891,BAO_0000218,
9224,Intermediate,10116.0,In vivo,1,,,Half life period in rat after 5 mg/kg dose,N,,,50597,1,,CHEMBL626892,BAO_0000218,
9225,Intermediate,10116.0,,1,,,Half life period was determined,N,,,50597,1,,CHEMBL626893,BAO_0000218,
9226,Intermediate,10116.0,,1,,,Half life period was evaluated in rat,N,,,50597,1,,CHEMBL626894,BAO_0000218,
9227,Intermediate,10116.0,,1,,,Half life period was evaluated in rat; 0.5-1.0,N,,,50597,1,,CHEMBL626895,BAO_0000218,
9228,Intermediate,10116.0,,1,,,Half life period was evaluated in rat; 5.9-7.5,N,,,50597,1,,CHEMBL626896,BAO_0000218,
9229,Intermediate,10116.0,,1,1969.0,,Half-life in rat plasma,N,,,50597,1,,CHEMBL626897,BAO_0000218,
9230,Intermediate,10116.0,,1,,,Half-life time in rat was determined,N,,,50597,1,,CHEMBL626898,BAO_0000218,
9231,Intermediate,10116.0,In vivo,1,,,Terminal half-life after iv administration to rats,N,,,50597,1,,CHEMBL626899,BAO_0000218,
9232,Intermediate,10116.0,In vivo,1,,,Tested for iv terminal half-life dosed as a solution in male Han Wistar rats,N,,,50597,1,,CHEMBL626900,BAO_0000218,
9233,Intermediate,10116.0,,1,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg,N,,,50597,1,,CHEMBL626901,BAO_0000218,
9234,Intermediate,10116.0,In vivo,1,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 0.5 umol/kg (iv),N,,,50597,1,,CHEMBL626902,BAO_0000218,
9235,Intermediate,10116.0,In vivo,1,,,Time required to return to 50% inhibition of pressor response after AI-challenge in normotensive rats at 5 umol/kg (iv),N,,,50597,1,,CHEMBL626903,BAO_0000218,
9236,Intermediate,10116.0,In vivo,1,,,Time for peak concentration (tmax) at a dose of 10 mg/kg in rats,N,,,50597,1,,CHEMBL874443,BAO_0000218,
9237,Intermediate,10116.0,In vivo,1,,,Time for peak concentration (tmax) at a dose of 20 mg/kg in rats,N,,,50597,1,,CHEMBL626904,BAO_0000218,
9238,Intermediate,10116.0,,1,,,Half life in rats,N,,,50597,1,,CHEMBL626905,BAO_0000218,
9239,Intermediate,10116.0,In vivo,1,1969.0,,Apparent Half life was determined from the linear portion of the log plasma concentration-time profile after oral administration of compound 18 at a dose of 4 mg/kg to rat,N,,,50597,1,,CHEMBL873830,BAO_0000218,
9240,Intermediate,10116.0,In vivo,1,,,Apparent half-life after single intravenous bolus of 1 mg/kg in rats,N,,,50597,1,,CHEMBL626906,BAO_0000218,
9241,Intermediate,10116.0,In vivo,1,1969.0,,Apparent terminal elimination half-life in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,,,50597,1,,CHEMBL631076,BAO_0000218,
9242,Intermediate,10116.0,,1,1969.0,,Biological half-life was measured in plasma of rats,N,,,50597,1,,CHEMBL631077,BAO_0000218,
9243,Intermediate,10116.0,In vivo,1,,,Circulatory half life measured after intravenous bolus administration of 50 mg/kg of compound to rats,N,,,50597,1,,CHEMBL631078,BAO_0000218,
9244,Intermediate,10116.0,In vivo,1,,,Compound demonstarted an oral bioavailability of 6% with the half-life time as given in rats.,N,,,50597,1,,CHEMBL631079,BAO_0000218,
9245,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for half life (t1/2) upon intravenous administration of 1 mg/Kg in rats,N,,,50597,1,,CHEMBL631080,BAO_0000218,
9246,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to female wistar rats,N,,,50597,1,,CHEMBL631081,BAO_0000218,
9247,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for half life after treatment with iv dose of 1 mgkg to male wistar rats,N,,,50597,1,,CHEMBL631239,BAO_0000218,
9248,Intermediate,10116.0,,1,1969.0,,Compound was evaluated for plasma half life in rat,N,,,50597,1,,CHEMBL631240,BAO_0000218,
9249,Intermediate,10116.0,,1,1969.0,,AUC value at a dose of 5 mg/kg (p.o.) in rats,N,,,50597,1,,CHEMBL631241,BAO_0000218,
9250,Intermediate,10116.0,,1,1969.0,,AUC value after administration of 20 mg/Kg oral dose in rat,N,,,50597,1,,CHEMBL631242,BAO_0000218,
9251,Intermediate,10116.0,,1,1969.0,,AUC0-24 after repeated oral dose of compound at 1 mg/kg in rats,N,,,50597,1,,CHEMBL631243,BAO_0000218,
9252,Intermediate,10116.0,,1,1969.0,,AUC0-96 after administration at 50 mg/kg,N,,,50597,1,,CHEMBL874444,BAO_0000218,
9253,Intermediate,10116.0,,1,1969.0,,AUC0-infinity after single intravenous bolus of 1 mg/kg in rats,N,,,50597,1,,CHEMBL631244,BAO_0000218,
9254,Intermediate,10116.0,,1,,,"Absorption behavior was judged by the area under the curve, determined after oral dose of 30 mg/kg in rats.",N,,,50597,1,,CHEMBL631245,BAO_0000218,
9255,Intermediate,10116.0,,1,,,Area under curve (0-24 hr) at a dose of 10 mg/kg in male SD rats,N,,,50597,1,,CHEMBL627162,BAO_0000218,
9256,Intermediate,10116.0,,1,,,Area under curve (0-24 hr) at a dose of 100 mg/kg in male SD rats,N,,,50597,1,,CHEMBL627163,BAO_0000218,
9257,Intermediate,10116.0,,1,,,Area under curve (0-24 hr) at a dose of 50 mg/kg in male SD rats,N,,,50597,1,,CHEMBL627164,BAO_0000218,
9258,Intermediate,10116.0,,1,2113.0,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat kidney,N,,,50597,1,,CHEMBL627165,BAO_0000218,
9259,Intermediate,10116.0,,1,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat liver,N,,,50597,1,,CHEMBL627166,BAO_0000218,
9260,Intermediate,10116.0,,1,,,Area under curve (AUC) at a dose 1 mg/kg was determined in rat lung,N,,,50597,1,,CHEMBL627167,BAO_0000218,
9261,Intermediate,10116.0,,1,,,Area under curve (AUC) at a dose of 30 mg/kg in rats,N,,,50597,1,,CHEMBL627822,BAO_0000218,
9262,Intermediate,10116.0,,1,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,N,,,50597,1,,CHEMBL627823,BAO_0000218,
9263,Intermediate,10116.0,,1,,,Area under curve (AUC) was calculated using trapezoidal rule. at a dose of 10 mg/kg in rats,N,,,50597,1,,CHEMBL627824,BAO_0000218,
9264,Intermediate,10116.0,,1,,,Area under curve (AUC) was calculated using trapezoidal rule at a dose of 20 mg/kg in rats,N,,,50597,1,,CHEMBL627825,BAO_0000218,
9265,Intermediate,10116.0,,1,,,Area under curve (AUC0-24 h) after administration (30 mg/kg) in rat,N,,,50597,1,,CHEMBL627826,BAO_0000218,
9266,Intermediate,10116.0,,1,,,Area under curve (Pharmacokinetic property) was determined,N,,,50597,1,,CHEMBL627827,BAO_0000218,
9267,Intermediate,10116.0,,1,,,Area under curve (Pharmacokinetic property) of the compound; Not determined,N,,,50597,1,,CHEMBL627828,BAO_0000218,
9268,Intermediate,10116.0,,1,,,Area under curve after intravenous administration (1 mg/kg) in rat,N,,,50597,1,,CHEMBL627829,BAO_0000218,
9269,Intermediate,10116.0,,1,,,Area under curve by intravenous administration at a dose of 10 uM/kg in rat was determined,N,,,50597,1,,CHEMBL627830,BAO_0000218,
9270,Intermediate,10116.0,,1,,,Area under curve by oral administration at a dose of 100 uM/kg in rat was determined,N,,,50597,1,,CHEMBL627831,BAO_0000218,
9271,Intermediate,10116.0,,1,,,Area under curve in male SD rats was observed after oral administration in rat,N,,,50597,1,,CHEMBL627832,BAO_0000218,
9272,Intermediate,10116.0,,1,,,Area under curve of compound after iv administration of 20 mg/kg dose in rat,N,,,50597,1,,CHEMBL627833,BAO_0000218,
9273,Expert,10116.0,,1,,,Area under curve of compound determined in rat after iv administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL627834,BAO_0000218,
9274,Expert,10116.0,,1,,,Area under curve of compound from zero time to infinity determined in rat after iv administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL628004,BAO_0000218,
9275,Intermediate,10116.0,,1,,,Area under curve at 5 mg/kg po was determined in rat,N,,,50597,1,,CHEMBL628005,BAO_0000218,
9276,Intermediate,10116.0,,1,,,Area under curve in Rat at a oral dose of 5 mg/kg,N,,,50597,1,,CHEMBL628006,BAO_0000218,
9277,Intermediate,10116.0,,1,,,Area under curve in rat plasma after administration of 3.5 mg/kg dose through subcutaneous route,N,,,50597,1,,CHEMBL628007,BAO_0000218,
9278,Intermediate,10116.0,,1,,,Area under curve was determined,N,,,50597,1,,CHEMBL625676,BAO_0000218,
9279,Intermediate,10116.0,,1,,,Area under curve after 10 mg/kg oral administration in rat at 0-24 hr,N,,,50597,1,,CHEMBL631309,BAO_0000218,
9280,Intermediate,10116.0,,1,,,Area under curve after intravenous administration at 3 mg/kg,N,,,50597,1,,CHEMBL631310,BAO_0000218,
9281,Intermediate,10116.0,,1,,,Area under curve after peroral administration at 10 mg/kg in rat for 0-6 h,N,,,50597,1,,CHEMBL631311,BAO_0000218,
9282,Intermediate,10116.0,,1,,,Area under curve at 4 hr in rat,N,,,50597,1,,CHEMBL631312,BAO_0000218,
9283,Intermediate,10116.0,,1,,,Area under curve at a dose of 30 mg/kg,N,,,50597,1,,CHEMBL631313,BAO_0000218,
9284,Intermediate,10116.0,,1,,,Area under curve at the dose of 2 mg/Kg administered perorally in rats,N,,,50597,1,,CHEMBL631314,BAO_0000218,
9285,Intermediate,10116.0,,1,,,Area under curve at the dose of 5 mg/Kg administered perorally in rats,N,,,50597,1,,CHEMBL631315,BAO_0000218,
9286,Intermediate,10116.0,,1,,,Area under curve for a 2-mpk po dose in SD rats,N,,,50597,1,,CHEMBL631316,BAO_0000218,
9287,Intermediate,10116.0,,1,,,Area under curve in SD rats,N,,,50597,1,,CHEMBL631317,BAO_0000218,
9288,Intermediate,10116.0,,1,,,Area under curve in rat after oral administration at 13 mg/kg dose,N,,,50597,1,,CHEMBL874471,BAO_0000218,
9289,Intermediate,10116.0,,1,,,Area under curve in rat by po administration at 0-24 hr,N,,,50597,1,,CHEMBL631318,BAO_0000218,
9290,Intermediate,10116.0,,1,1969.0,,Area under curve in rat plasma,N,,,50597,1,,CHEMBL631319,BAO_0000218,
9291,Intermediate,10116.0,,1,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 10 mg/kg,N,,,50597,1,,CHEMBL631320,BAO_0000218,
9292,Intermediate,10116.0,,1,,,Area under curve in rat plasma for 0-4 hr after peroral administration at 5 mg/kg,N,,,50597,1,,CHEMBL631321,BAO_0000218,
9293,Intermediate,10116.0,,1,,,Area under curve was evaluated in rat at 3 mg/kg dose administered intravenously,N,,,50597,1,,CHEMBL631322,BAO_0000218,
9294,Intermediate,10116.0,,1,,,Area under curve was measured from the graph obtained from concentration Vs time after oral administration to male F344 rats,N,,,50597,1,,CHEMBL631323,BAO_0000218,
9295,Intermediate,10116.0,,1,,,Area under curve value in rat at a dose of 5 mg/kg,N,,,50597,1,,CHEMBL631324,BAO_0000218,
9296,Intermediate,10116.0,,1,,,Area under curve was determined after oral administration in rats,N,,,50597,1,,CHEMBL631325,BAO_0000218,
9297,Intermediate,10116.0,,1,,,Area under curve was determined after oral administration at a dose 10 mg/kg to male Sprague-Dawley rats,N,,,50597,1,,CHEMBL631326,BAO_0000218,
9298,Intermediate,10116.0,,1,,,Area under curve was determined after peroral administration in rat,N,,,50597,1,,CHEMBL631327,BAO_0000218,
9299,Intermediate,10116.0,,1,,,Area under curve was determined at a dose 30 mpk administered orally.,N,,,50597,1,,CHEMBL631328,BAO_0000218,
9300,Intermediate,10116.0,,1,,,Area under curve was determined for compound after intravenous administration in rats at 24 uM/kg,N,,,50597,1,,CHEMBL631329,BAO_0000218,
9301,Intermediate,10116.0,,1,,,Area under curve was determined for the compound by intravenous administration of 3.4 mg/kg in rat,N,,,50597,1,,CHEMBL627217,BAO_0000218,
9302,Intermediate,10116.0,,1,,,Area under curve was determined in male rat,N,,,50597,1,,CHEMBL626352,BAO_0000218,
9303,Intermediate,10116.0,,1,,,Area under curve was determined in rat after PO administration,N,,,50597,1,,CHEMBL626353,BAO_0000218,
9304,Intermediate,10116.0,,1,,,Area under curve was determined in rat after a 3 mg/kg of oral dose,N,,,50597,1,,CHEMBL626354,BAO_0000218,
9305,Intermediate,10116.0,,1,,,Area under curve was determined in rat after oral administration at a concentration 1 mg/kg,N,,,50597,1,,CHEMBL626355,BAO_0000218,
9306,Intermediate,10116.0,,1,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg,N,,,50597,1,,CHEMBL626356,BAO_0000218,
9307,Intermediate,10116.0,,1,,,Area under curve was determined in rat after oral administration at a concentration 30 mg/kg; NA= Not active,N,,,50597,1,,CHEMBL626357,BAO_0000218,
9308,Intermediate,10116.0,,1,,,Liver concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,,50597,1,,CHEMBL626358,BAO_0000218,
9309,Intermediate,10116.0,,1,,,Lung concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,,50597,1,,CHEMBL626359,BAO_0000218,
9310,Intermediate,10116.0,,1,1969.0,,Peak plasma concentration in rat at a dose of 3 mg/kg,N,,,50597,1,,CHEMBL626360,BAO_0000218,
9311,Intermediate,10116.0,,1,,,Plasma concentration at 2 hr in rats was evaluated.,N,,,50597,1,,CHEMBL626361,BAO_0000218,
9312,Intermediate,10116.0,,1,,,Plasma concentration at 2 hr in rats was evaluated; Not available,N,,,50597,1,,CHEMBL626362,BAO_0000218,
9313,Intermediate,10116.0,,1,,,Serum concentration was determined after 5 min. of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,,50597,1,,CHEMBL626363,BAO_0000218,
9314,Intermediate,10116.0,,1,,,Tested for concentration in brain after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,N,,,50597,1,,CHEMBL626970,BAO_0000218,
9315,Intermediate,10116.0,,1,,,Tested for concentration in brain after 2 hrs of intravenous administration (5 mg/kg) to male rats,N,,,50597,1,,CHEMBL626971,BAO_0000218,
9316,Intermediate,10116.0,,1,1969.0,,Tested for plasma concentration after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,N,,,50597,1,,CHEMBL626972,BAO_0000218,
9317,Intermediate,10116.0,,1,1969.0,,Tested for plasma concentration after 2 hrs of intravenous administration (5 mg/kg) to male rats,N,,,50597,1,,CHEMBL626973,BAO_0000218,
9318,Intermediate,10116.0,,1,1969.0,,Tested for plasma concentration in the after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,N,,,50597,1,,CHEMBL626974,BAO_0000218,
9319,Intermediate,10116.0,,1,1969.0,,Tested for plasma concentration in the after 2 hrs of intravenous administration (5 mg/kg) to male rats,N,,,50597,1,,CHEMBL874592,BAO_0000218,
9320,Intermediate,10116.0,,1,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C,N,,,50597,1,,CHEMBL626975,BAO_0000218,
9321,Intermediate,10116.0,,1,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Converted to an unknown compound,N,,,50597,1,,CHEMBL626976,BAO_0000218,
9322,Intermediate,10116.0,,1,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not determined,N,,,50597,1,,CHEMBL626977,BAO_0000218,
9323,Intermediate,10116.0,,1,,,Percentage converted to BMS-191011 after 30 min incubation in rat plasma at 37 degree C; Not tested,N,,,50597,1,,CHEMBL626978,BAO_0000218,
9324,Intermediate,10116.0,,1,,,PK study was carried to determine the relative absorption ranking in rat.,N,,,50597,1,,CHEMBL626979,BAO_0000218,
9325,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration in Rat at a oral dose of 5 mg/kg,N,,,50597,1,,CHEMBL626980,BAO_0000218,
9326,Intermediate,10116.0,,1,178.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.57-0.75 % dose/g",N,,,50597,1,,CHEMBL626981,BAO_0000218,
9327,Intermediate,10116.0,,1,178.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.63 % dose/g",N,,,50597,1,,CHEMBL626982,BAO_0000218,
9328,Intermediate,10116.0,,1,178.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.40-0.55 % dose/g",N,,,50597,1,,CHEMBL626983,BAO_0000218,
9329,Intermediate,10116.0,,1,178.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.28-0.37% dose/g",N,,,50597,1,,CHEMBL622522,BAO_0000218,
9330,Intermediate,10116.0,,1,178.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.56-0.74 % dose/g",N,,,50597,1,,CHEMBL622523,BAO_0000218,
9331,Intermediate,10116.0,,1,178.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in blood of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from % dose/g",N,,,50597,1,,CHEMBL622524,BAO_0000218,
9332,Intermediate,10116.0,,1,955.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.20-2.85 % dose/g",N,,,50597,1,,CHEMBL622525,BAO_0000218,
9333,Intermediate,10116.0,,1,955.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.16-1.76 % dose/g",N,,,50597,1,,CHEMBL622526,BAO_0000218,
9334,Intermediate,10116.0,,1,955.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.96-3.72 % dose/g",N,,,50597,1,,CHEMBL619849,BAO_0000218,
9335,Intermediate,10116.0,,1,955.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.57-3.59 % dose/g",N,,,50597,1,,CHEMBL619850,BAO_0000218,
9336,Intermediate,10116.0,,1,955.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.36-1.53 % dose/g",N,,,50597,1,,CHEMBL623864,BAO_0000218,
9337,Intermediate,10116.0,,1,955.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in brain of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.81-1.08 % dose/g",N,,,50597,1,,CHEMBL623865,BAO_0000218,
9338,Intermediate,10116.0,,1,948.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.84-0.98 % dose/g",N,,,50597,1,,CHEMBL623866,BAO_0000218,
9339,Intermediate,10116.0,,1,948.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.06-0.53 % dose/g",N,,,50597,1,,CHEMBL623867,BAO_0000218,
9340,Intermediate,10116.0,,1,948.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.22-1.48 % dose/g",N,,,50597,1,,CHEMBL877615,BAO_0000218,
9341,Intermediate,10116.0,,1,948.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.85-1.13 % dose/g",N,,,50597,1,,CHEMBL623868,BAO_0000218,
9342,Intermediate,10116.0,,1,948.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.55-0.63 % dose/g",N,,,50597,1,,CHEMBL623869,BAO_0000218,
9343,Intermediate,10116.0,,1,948.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in heart of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.33-0.42 % dose/g",N,,,50597,1,,CHEMBL623870,BAO_0000218,
9344,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,N,,,50597,1,,CHEMBL623871,BAO_0000218,
9345,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,,50597,1,,CHEMBL623872,BAO_0000218,
9346,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,,50597,1,,CHEMBL622129,BAO_0000218,
9347,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,,50597,1,,CHEMBL622130,BAO_0000218,
9348,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,,50597,1,,CHEMBL622131,BAO_0000218,
9349,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,,50597,1,,CHEMBL622132,BAO_0000218,
9350,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,,50597,1,,CHEMBL622133,BAO_0000218,
9351,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lung of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,,50597,1,,CHEMBL622134,BAO_0000218,
9352,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,,50597,1,,CHEMBL622135,BAO_0000218,
9353,Intermediate,10116.0,,1,2048.0,,Radioactivity distribution in lungs of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,,50597,1,,CHEMBL622136,BAO_0000218,
9354,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,,50597,1,,CHEMBL622137,BAO_0000218,
9355,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,,50597,1,,CHEMBL622138,BAO_0000218,
9356,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,,50597,1,,CHEMBL623017,BAO_0000218,
9357,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,,50597,1,,CHEMBL623018,BAO_0000218,
9358,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,,50597,1,,CHEMBL623019,BAO_0000218,
9359,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,,50597,1,,CHEMBL623020,BAO_0000218,
9360,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min.,N,,,50597,1,,CHEMBL623021,BAO_0000218,
9361,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min.,N,,,50597,1,,CHEMBL623022,BAO_0000218,
9362,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,,50597,1,,CHEMBL623023,BAO_0000218,
9363,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,,50597,1,,CHEMBL623024,BAO_0000218,
9364,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,,50597,1,,CHEMBL623025,BAO_0000218,
9365,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,,50597,1,,CHEMBL620545,BAO_0000218,
9366,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,,50597,1,,CHEMBL620546,BAO_0000218,
9367,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,,50597,1,,CHEMBL620547,BAO_0000218,
9368,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,,50597,1,,CHEMBL620548,BAO_0000218,
9369,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,,50597,1,,CHEMBL620549,BAO_0000218,
9370,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,,50597,1,,CHEMBL620550,BAO_0000218,
9371,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,N,,,50597,1,,CHEMBL620551,BAO_0000218,
9372,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,,50597,1,,CHEMBL620552,BAO_0000218,
9373,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,,50597,1,,CHEMBL620553,BAO_0000218,
9374,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,,50597,1,,CHEMBL620554,BAO_0000218,
9375,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,,50597,1,,CHEMBL875845,BAO_0000218,
9376,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,,50597,1,,CHEMBL620555,BAO_0000218,
9377,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,,50597,1,,CHEMBL620556,BAO_0000218,
9378,Intermediate,10116.0,,1,2385.0,,Radioactivity distribution in muscle of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,,50597,1,,CHEMBL620557,BAO_0000218,
9379,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,,50597,1,,CHEMBL620558,BAO_0000218,
9380,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,,50597,1,,CHEMBL620559,BAO_0000218,
9381,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,,50597,1,,CHEMBL622939,BAO_0000218,
9382,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,,50597,1,,CHEMBL622940,BAO_0000218,
9383,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,,50597,1,,CHEMBL622941,BAO_0000218,
9384,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,,50597,1,,CHEMBL622942,BAO_0000218,
9385,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,,50597,1,,CHEMBL622943,BAO_0000218,
9386,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,,50597,1,,CHEMBL622944,BAO_0000218,
9387,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,,50597,1,,CHEMBL622945,BAO_0000218,
9388,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,,50597,1,,CHEMBL622946,BAO_0000218,
9389,Intermediate,10116.0,,1,,,Compound was evaluated for terminal half life in rat,N,,,50597,1,,CHEMBL622947,BAO_0000218,
9390,Intermediate,10116.0,In vivo,1,1969.0,,Compound was evaluated in vivo in rat for the plasma half-life at a iv dose of 3 mg/kg and oral dose of 10 mg/kg and experiment by using concentration vs time curve,N,,,50597,1,,CHEMBL622948,BAO_0000218,
9391,Intermediate,10116.0,In vivo,1,1969.0,,Compound was evaluated in vivo in rat for the plasma half-life at a oral dose of 20 mg/kg experiment by using concentration vs time curve,N,,,50597,1,,CHEMBL622949,BAO_0000218,
9392,Intermediate,10116.0,,1,,,Compound was tested for its half life in rat,N,,,50597,1,,CHEMBL622950,BAO_0000218,
9393,Intermediate,9544.0,In vivo,1,1969.0,,Compound was tested for its plasma half life in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po; ND is not determined.,U,,,22224,0,,CHEMBL622951,BAO_0000218,
9394,Intermediate,10116.0,,1,1969.0,,Compound was tested for its plasma half life in Sprague Dawley rats,U,,,22224,0,,CHEMBL622952,BAO_0000366,
9395,Intermediate,10116.0,,1,1969.0,,Compound was tested for its plasma half life in Sprague Dawley rats; ND is not determined,U,,,22224,0,,CHEMBL622953,BAO_0000366,
9396,Intermediate,10116.0,,1,1969.0,,Compound was tested for plasma half-life period in rat,N,,,50597,1,,CHEMBL873818,BAO_0000218,
9397,Intermediate,10116.0,In vivo,1,,,Elimination half life after i.v. administration of compound in rats,N,,,50597,1,,CHEMBL622954,BAO_0000218,
9398,Intermediate,10116.0,In vivo,1,,,Elimination half-life after IV dosing at 0.5 mg/kg in rat,N,,,50597,1,,CHEMBL622955,BAO_0000218,
9399,Intermediate,10116.0,In vivo,1,,,Elimination half-life after IV dosing at 1 mg/kg in rat,N,,,50597,1,,CHEMBL875229,BAO_0000218,
9400,Intermediate,10116.0,In vivo,1,,,Elimination half-life after oral administration at a dose of 2 mg/kg in rat,N,,,50597,1,,CHEMBL622956,BAO_0000218,
9401,Intermediate,10116.0,In vivo,1,,,Elimination half-life after oral administration at a dose of 4 mg/kg in rat,N,,,50597,1,,CHEMBL622957,BAO_0000218,
9402,Intermediate,10116.0,In vivo,1,955.0,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,N,,,50597,1,,CHEMBL622958,BAO_0000218,
9403,Intermediate,10116.0,In vivo,1,1969.0,,Evaluated for half-life after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,N,,,50597,1,,CHEMBL622959,BAO_0000218,
9404,Intermediate,10116.0,In vivo,1,955.0,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,N,,,50597,1,,CHEMBL622960,BAO_0000218,
9405,Intermediate,10116.0,In vivo,1,1969.0,,Evaluated for half-life after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,N,,,50597,1,,CHEMBL622961,BAO_0000218,
9406,Intermediate,10116.0,In vivo,1,,,Evaluated for the half life in rat (in vivo),N,,,50597,1,,CHEMBL622962,BAO_0000218,
9407,Intermediate,10116.0,,1,,,Hafl life in rat,N,,,50597,1,,CHEMBL622963,BAO_0000218,
9408,Intermediate,10116.0,,1,,,Hafl life rat,N,,,50597,1,,CHEMBL622964,BAO_0000218,
9409,Intermediate,10116.0,,1,,,Hafl life rat,N,,,50597,1,,CHEMBL622965,BAO_0000218,
9410,Intermediate,10116.0,,1,,,Hafl life rat; Not determined,N,,,50597,1,,CHEMBL622966,BAO_0000218,
9411,Intermediate,10116.0,,1,,,Hafl life rat; Not determined,N,,,50597,1,,CHEMBL622967,BAO_0000218,
9412,Intermediate,10116.0,In vivo,1,2113.0,,Half life in kidney was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,,50597,1,,CHEMBL622968,BAO_0000218,
9413,Intermediate,10116.0,In vivo,1,2107.0,,Half life in liver was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,,50597,1,,CHEMBL622969,BAO_0000218,
9414,Intermediate,10116.0,In vivo,1,2048.0,,Half life in lung was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,,50597,1,,CHEMBL875327,BAO_0000218,
9415,Intermediate,10116.0,In vivo,1,,,Half life in rat after 1 mg/kg i.v. administration,N,,,50597,1,,CHEMBL628638,BAO_0000218,
9416,Intermediate,10116.0,In vivo,1,,,Half life in rat after 2 mg/kg peroral administration,N,,,50597,1,,CHEMBL628639,BAO_0000218,
9417,Intermediate,10116.0,In vivo,1,,,Half life in serum was determined after intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,,50597,1,,CHEMBL625840,BAO_0000218,
9418,Intermediate,10116.0,In vivo,1,,,Half life of 10 mg/kg oral dose determined in rats,N,,,50597,1,,CHEMBL625841,BAO_0000218,
9419,Intermediate,10116.0,In vivo,1,,,Half life of compound (10 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL625842,BAO_0000218,
9420,Intermediate,10116.0,In vivo,1,,,Half life of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL625843,BAO_0000218,
9421,Intermediate,10116.0,In vivo,1,,,Half life of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL625844,BAO_0000218,
9422,Intermediate,10116.0,In vivo,1,,,Half life of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL873822,BAO_0000218,
9423,Intermediate,10116.0,In vivo,1,,,Half life of compound (9.83 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL625845,BAO_0000218,
9424,Intermediate,10116.0,In vivo,1,,,Half life of compound (9.84 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL627059,BAO_0000218,
9425,Intermediate,10116.0,In vivo,1,,,Half life of compound (9.84 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL627060,BAO_0000218,
9426,Intermediate,10116.0,In vivo,1,,,Half life of compound (9.92 mg/kg) after iv administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL627061,BAO_0000218,
9427,Intermediate,10116.0,In vivo,1,,,Half life of compound at 5 mg/kg after po administration was determined in rat,N,,,50597,1,,CHEMBL627709,BAO_0000218,
9428,Intermediate,10116.0,In vivo,1,,,Half life of compound determined after intravenous administration to rat,N,,,50597,1,,CHEMBL627710,BAO_0000218,
9429,Intermediate,10116.0,,1,,,Half life of compound was determined in rat,N,,,50597,1,,CHEMBL627711,BAO_0000218,
9430,Intermediate,10116.0,In vivo,1,1969.0,,Half life at a dose of 4 mg/kg in Rat Plasma after iv administration,N,,,50597,1,,CHEMBL627712,BAO_0000218,
9431,Intermediate,10116.0,In vivo,1,,,Half life determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,,,50597,1,,CHEMBL627713,BAO_0000218,
9432,Intermediate,10116.0,In vivo,1,,,Half life determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,,,50597,1,,CHEMBL627714,BAO_0000218,
9433,Intermediate,9541.0,In vivo,1,,,Half life determined after intravenous administration at a dose of 3 mg/kg in cynomolgus monkey,U,,,22224,0,,CHEMBL627889,BAO_0000218,
9434,Intermediate,10116.0,In vivo,1,,,Half life determined in rat by intravenous administration,U,,,22224,0,,CHEMBL627890,BAO_0000218,
9435,Intermediate,10116.0,In vivo,1,,,Half life determined in rats after iv administration,N,,,50597,1,,CHEMBL627891,BAO_0000218,
9436,Intermediate,10116.0,In vivo,1,1969.0,,Half life in rat plasma after administration of 2 mg/kg iv,N,,,50597,1,,CHEMBL627892,BAO_0000218,
9437,Intermediate,10116.0,In vivo,1,1969.0,,Half life in rat plasma after administration of 2 mg/kg iv,N,,,50597,1,,CHEMBL627893,BAO_0000218,
9438,Intermediate,10116.0,,1,1969.0,,Half life in rat plasma was determined,N,,,50597,1,,CHEMBL627894,BAO_0000218,
9439,Intermediate,10116.0,,1,1969.0,,Half life in rat plasma was determined; NA means not applicable,N,,,50597,1,,CHEMBL627895,BAO_0000218,
9440,Intermediate,10116.0,,1,,,Half life in rat was tested,N,,,50597,1,,CHEMBL627896,BAO_0000218,
9441,Intermediate,10116.0,,1,1969.0,,Half life measured in rat plasma,N,,,50597,1,,CHEMBL627897,BAO_0000218,
9442,Intermediate,10116.0,,1,,,Half life recorded in rats,N,,,50597,1,,CHEMBL627898,BAO_0000218,
9443,Intermediate,10116.0,,1,,,Half life was calculated,N,,,50597,1,,CHEMBL627899,BAO_0000218,
9444,Intermediate,10116.0,,1,,,Half life was calculated in rat,N,,,50597,1,,CHEMBL873823,BAO_0000218,
9445,Intermediate,10116.0,,1,,,Half life was determined,N,,,50597,1,,CHEMBL627900,BAO_0000218,
9446,Intermediate,10116.0,In vivo,1,,,Half life after 10 mg/kg oral administration in rat,N,,,50597,1,,CHEMBL627901,BAO_0000218,
9447,Intermediate,10116.0,In vivo,1,,,Half life after administering orally a dose of 10 mg/kg to a fasting rat,N,,,50597,1,,CHEMBL627902,BAO_0000218,
9448,Intermediate,10116.0,In vivo,1,,,Half life after administering orally a dose of 30 mg/kg,N,,,50597,1,,CHEMBL627903,BAO_0000218,
9449,Intermediate,10116.0,,1,,,Area under the curve (Concentration) was determined for the compound as AUC with limits 0-8 after i.v. administration in rats,N,,,50597,1,,CHEMBL627904,BAO_0000218,
9450,Intermediate,10116.0,,1,,,Area under the curve determined under pharmacokinetic behavior of the 10 mg/kg oral dose of compound for 0-6 hours,N,,,50597,1,,CHEMBL627905,BAO_0000218,
9451,Intermediate,10116.0,,1,,,Area under the curve for the compound calculated from 0-24 hr after intravenous administration at a dose of 10 mg/kg in rat,N,,,50597,1,,CHEMBL627906,BAO_0000218,
9452,Intermediate,10116.0,,1,,,Area under the curve for the compound calculated from 0-24 hr after oral administration at a dose of 10 mg/kg in rat,N,,,50597,1,,CHEMBL627907,BAO_0000218,
9453,Intermediate,10116.0,,1,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL876783,BAO_0000218,
9454,Intermediate,10116.0,,1,,,Area under the curve for the compound calculated from 0-6 hr after oral administration at a dose of 10 mg/kg; activity was not determined,N,,,50597,1,,CHEMBL627908,BAO_0000218,
9455,Intermediate,10116.0,,1,,,Area under the curve measured after intravenous bolus administration of 50 mg/kg of compound to rats,N,,,50597,1,,CHEMBL627909,BAO_0000218,
9456,Intermediate,10116.0,,1,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats,N,,,50597,1,,CHEMBL627910,BAO_0000218,
9457,Intermediate,10116.0,,1,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-1),N,,,50597,1,,CHEMBL627911,BAO_0000218,
9458,Intermediate,10116.0,,1,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-2),N,,,50597,1,,CHEMBL627912,BAO_0000218,
9459,Intermediate,10116.0,,1,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(0-5),N,,,50597,1,,CHEMBL627913,BAO_0000218,
9460,Intermediate,10116.0,,1,,,Area under the curve in plasma after oral administration of 30 mg/kg at 1 hr interval during 6 hrs in rats(5-10),N,,,50597,1,,CHEMBL627914,BAO_0000218,
9461,Intermediate,10116.0,,1,,,Area under the curve was evaluated after 10 uM/kg of intra arterial administration,N,,,50597,1,,CHEMBL627915,BAO_0000218,
9462,Intermediate,10116.0,,1,,,Area under the curve was evaluated after 20 uM/kg of peroral administration,N,,,50597,1,,CHEMBL627916,BAO_0000218,
9463,Intermediate,10116.0,,1,,,Area under the curve was measured in rat after an iv dose of 1 mg/kg,N,,,50597,1,,CHEMBL627917,BAO_0000218,
9464,Intermediate,10116.0,,1,,,Area under the curve was calculated for the compound at a single intravenous administration of 20 mg/kg in rat,N,,,50597,1,,CHEMBL627918,BAO_0000218,
9465,Intermediate,10116.0,,1,,,Area under the curve was determined by administering the compound at a dose of 1 mg/kg intravenously in male wistar rat,N,,,50597,1,,CHEMBL627919,BAO_0000218,
9466,Intermediate,10116.0,,1,,,Area under the curve was evaluated at an intravenous dose of 3 mg/kg,N,,,50597,1,,CHEMBL627920,BAO_0000218,
9467,Intermediate,10116.0,,1,,,Area under the curve was evaluated at an oral dose of 30 mg/kg,N,,,50597,1,,CHEMBL627921,BAO_0000218,
9468,Intermediate,10116.0,,1,,,Area under the effect time curves from time 0-24 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,,,50597,1,,CHEMBL627922,BAO_0000218,
9469,Intermediate,10116.0,,1,,,Area under the effect time curves from time 0-24 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,,,50597,1,,CHEMBL876784,BAO_0000218,
9470,Intermediate,10116.0,,1,,,Area under the effect time curves from time 0-6 hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,,,50597,1,,CHEMBL627923,BAO_0000218,
9471,Intermediate,10116.0,,1,,,Area under the effect time curves from time 0-6 hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,,,50597,1,,CHEMBL626208,BAO_0000218,
9472,Intermediate,10116.0,,1,,,Area under the effect time curves from time 0-infinity hr determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,,,50597,1,,CHEMBL626209,BAO_0000218,
9473,Intermediate,10116.0,,1,,,Area under the effect time curves from time 0-infinity hr determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,,,50597,1,,CHEMBL626210,BAO_0000218,
9474,Intermediate,10116.0,,1,1969.0,,Area under the plasma concentration curve was evaluated in vivo in rat at a dose of 5 mg/kg by oral administration,N,,,50597,1,,CHEMBL627994,BAO_0000218,
9475,Intermediate,10116.0,,1,,,Bioavailability from area under the curve at time 0 to infinity after intravenous administration of 1 mg/kg in rat,N,,,50597,1,,CHEMBL627995,BAO_0000218,
9476,Intermediate,10116.0,,1,,,Blood level after a 10 mg/kg oral dose in rat expressed as AUC was determined,N,,,50597,1,,CHEMBL627996,BAO_0000218,
9477,Intermediate,10116.0,,1,,,Compound at a dose 10 mg/kg was administered orally to rat and the pharmacokinetic parameter area under curve (AUC) was measured,N,,,50597,1,,CHEMBL627997,BAO_0000218,
9478,Intermediate,10116.0,,1,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to female wistar rats,N,,,50597,1,,CHEMBL627998,BAO_0000218,
9479,Intermediate,10116.0,,1,,,Compound was evaluated for AUC after treatment with iv dose of 1 mgkg to male wistar rats,N,,,50597,1,,CHEMBL628640,BAO_0000218,
9480,Intermediate,10116.0,,1,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to female wistar rats,N,,,50597,1,,CHEMBL628641,BAO_0000218,
9481,Intermediate,10116.0,,1,,,Compound was evaluated for AUC after treatment with oral dose of 2 mgkg to male wistar rats,N,,,50597,1,,CHEMBL628642,BAO_0000218,
9482,Intermediate,10116.0,,1,,,Compound was evaluated for area under the curve expressed as (h*ug/ml),N,,,50597,1,,CHEMBL628643,BAO_0000218,
9483,Intermediate,10116.0,,1,,,Compound was tested for area under curve in rat,N,,,50597,1,,CHEMBL628644,BAO_0000218,
9484,Intermediate,10116.0,,1,,,Concentration in rat plasma after 5 mg/kg oral gavage for 8 hours,N,,,50597,1,,CHEMBL628645,BAO_0000218,
9485,Intermediate,10116.0,,1,,,Dose-normalized AUC was determined by po administration (10 mg/kg) in fasted male Sprague-Dawley rats,N,,,50597,1,,CHEMBL628646,BAO_0000218,
9486,Intermediate,10116.0,,1,,,Dose-normalized AUC was determined in rat after peroral administration (2 mg/kg),N,,,50597,1,,CHEMBL628647,BAO_0000218,
9487,Intermediate,10116.0,,1,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in brain; not determined,N,,,50597,1,,CHEMBL628648,BAO_0000218,
9488,Intermediate,10116.0,,1,,,Evaluated for AUC after iv administration of 1 mg/kg to male Sprague-Dawley rats in plasma,N,,,50597,1,,CHEMBL625358,BAO_0000218,
9489,Intermediate,10116.0,,1,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in brain,N,,,50597,1,,CHEMBL625359,BAO_0000218,
9490,Intermediate,10116.0,,1,,,Evaluated for AUC after iv administration of 5 mg/kg to male Sprague-Dawley rats in plasma,N,,,50597,1,,CHEMBL625360,BAO_0000218,
9491,Intermediate,10116.0,,1,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg ( 0-8 hr ),N,,,50597,1,,CHEMBL625361,BAO_0000218,
9492,Intermediate,10116.0,,1,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr ),N,,,50597,1,,CHEMBL625362,BAO_0000218,
9493,Intermediate,10116.0,,1,,,Evaluated for pharmacokinetic parameter area under curve in rat at the dose 50 mg/kg (0-8 hr),N,,,50597,1,,CHEMBL625363,BAO_0000218,
9494,Intermediate,10116.0,,1,,,Hepatic portal AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,N,,,50597,1,,CHEMBL625364,BAO_0000218,
9495,Intermediate,10116.0,,1,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL625365,BAO_0000218,
9496,Intermediate,10116.0,,1,,,In vivo Area under curve (AUC) was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL625366,BAO_0000218,
9497,Intermediate,10116.0,,1,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL625367,BAO_0000218,
9498,Intermediate,10116.0,,1,2113.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.98-2.56 % dose/g",N,,,50597,1,,CHEMBL625368,BAO_0000218,
9499,Intermediate,10116.0,,1,2113.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.15-1.43 % dose/g",N,,,50597,1,,CHEMBL625369,BAO_0000218,
9500,Intermediate,10116.0,,1,2113.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.43-4.52 % dose/g",N,,,50597,1,,CHEMBL625370,BAO_0000218,
9501,Intermediate,10116.0,,1,2113.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 2.12-3.14 % dose/g",N,,,50597,1,,CHEMBL625371,BAO_0000218,
9502,Intermediate,10116.0,,1,2113.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.40-1.60 % dose/g",N,,,50597,1,,CHEMBL625372,BAO_0000218,
9503,Intermediate,10116.0,,1,2113.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in kidney of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.74-0.85 % dose/g",N,,,50597,1,,CHEMBL625373,BAO_0000218,
9504,Intermediate,10116.0,,1,2107.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 1.31-1.45 % dose/g",N,,,50597,1,,CHEMBL625374,BAO_0000218,
9505,Intermediate,10116.0,,1,2107.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.90 % dose/g",N,,,50597,1,,CHEMBL877593,BAO_0000218,
9506,Intermediate,10116.0,,1,2107.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.02-2.78 % dose/g",N,,,50597,1,,CHEMBL625375,BAO_0000218,
9507,Intermediate,10116.0,,1,2107.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.64-2.38 % dose/g",N,,,50597,1,,CHEMBL625376,BAO_0000218,
9508,Intermediate,10116.0,,1,2107.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.95-1.07 % dose/g",N,,,50597,1,,CHEMBL621973,BAO_0000218,
9509,Intermediate,10116.0,,1,2107.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in liver of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.61-0.81 % dose/g",N,,,50597,1,,CHEMBL621974,BAO_0000218,
9510,Intermediate,10116.0,,1,2048.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 5.01-7.13 % dose/g",N,,,50597,1,,CHEMBL621975,BAO_0000218,
9511,Intermediate,10116.0,,1,2048.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.51-3.71 % dose/g",N,,,50597,1,,CHEMBL622166,BAO_0000218,
9512,Intermediate,10116.0,,1,2048.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 10.84-13.77 % dose/g",N,,,50597,1,,CHEMBL622167,BAO_0000218,
9513,Intermediate,10116.0,,1,2048.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.92-8.51% dose/g",N,,,50597,1,,CHEMBL622168,BAO_0000218,
9514,Intermediate,10116.0,,1,2048.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 3.37-3.94 % dose/g",N,,,50597,1,,CHEMBL622169,BAO_0000218,
9515,Intermediate,10116.0,,1,2048.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in lungs of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 1.87-2.12 % dose/g",N,,,50597,1,,CHEMBL622170,BAO_0000218,
9516,Intermediate,10116.0,,1,2046.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 37.97-75.23 % dose/g",N,,,50597,1,,CHEMBL622171,BAO_0000218,
9517,Intermediate,10116.0,,1,2046.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 5.03-36.88 % dose/g",N,,,50597,1,,CHEMBL622172,BAO_0000218,
9518,Intermediate,10116.0,,1,2046.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 13.20-17.31 % dose/g",N,,,50597,1,,CHEMBL622173,BAO_0000218,
9519,Intermediate,10116.0,,1,2046.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 7.87-16.51 % dose/g",N,,,50597,1,,CHEMBL622174,BAO_0000218,
9520,Intermediate,10116.0,,1,2046.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 81.37-166.09 % dose/g",N,,,50597,1,,CHEMBL622175,BAO_0000218,
9521,Intermediate,10116.0,,1,2046.0,,"Distribution of the radioiodinated compound expressed as percent dose per gram, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 31.90-39.98 % dose/g",N,,,50597,1,,CHEMBL622176,BAO_0000218,
9522,Intermediate,10116.0,,1,2046.0,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.41-0.83 % dose/g",N,,,50597,1,,CHEMBL622177,BAO_0000218,
9523,Intermediate,10116.0,,1,2046.0,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 30 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.05-0.38 % dose/g",N,,,50597,1,,CHEMBL622178,BAO_0000218,
9524,Intermediate,10116.0,,1,2046.0,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (10.7 uCi/animal); value ranges from 0.16-0.20 % dose/g",N,,,50597,1,,CHEMBL622179,BAO_0000218,
9525,Intermediate,10116.0,,1,2046.0,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 5 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.08-0.17 % dose/g",N,,,50597,1,,CHEMBL622180,BAO_0000218,
9526,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,,50597,1,,CHEMBL622181,BAO_0000218,
9527,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,,50597,1,,CHEMBL622182,BAO_0000218,
9528,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,,50597,1,,CHEMBL622183,BAO_0000218,
9529,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,,50597,1,,CHEMBL622184,BAO_0000218,
9530,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,,50597,1,,CHEMBL622185,BAO_0000218,
9531,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,,50597,1,,CHEMBL622186,BAO_0000218,
9532,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,,50597,1,,CHEMBL622187,BAO_0000218,
9533,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 5 min,N,,,50597,1,,CHEMBL625002,BAO_0000218,
9534,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of [18F]-fluoro-2-methylpropanoic acid after 60 min,N,,,50597,1,,CHEMBL622090,BAO_0000218,
9535,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,,50597,1,,CHEMBL622091,BAO_0000218,
9536,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,,50597,1,,CHEMBL622092,BAO_0000218,
9537,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,,50597,1,,CHEMBL622093,BAO_0000218,
9538,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,,50597,1,,CHEMBL622094,BAO_0000218,
9539,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,,50597,1,,CHEMBL622095,BAO_0000218,
9540,Intermediate,10116.0,,1,,,Radioactivity distribution in pancreas of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,,50597,1,,CHEMBL622264,BAO_0000218,
9541,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,,50597,1,,CHEMBL622265,BAO_0000218,
9542,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,,50597,1,,CHEMBL622266,BAO_0000218,
9543,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,,50597,1,,CHEMBL622267,BAO_0000218,
9544,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,,50597,1,,CHEMBL622268,BAO_0000218,
9545,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,,50597,1,,CHEMBL622269,BAO_0000218,
9546,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,,50597,1,,CHEMBL625071,BAO_0000218,
9547,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,,50597,1,,CHEMBL621621,BAO_0000218,
9548,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,,50597,1,,CHEMBL621622,BAO_0000218,
9549,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,,50597,1,,CHEMBL621623,BAO_0000218,
9550,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,,50597,1,,CHEMBL621624,BAO_0000218,
9551,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,,50597,1,,CHEMBL621625,BAO_0000218,
9552,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,,50597,1,,CHEMBL621626,BAO_0000218,
9553,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,,50597,1,,CHEMBL621627,BAO_0000218,
9554,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,,50597,1,,CHEMBL621628,BAO_0000218,
9555,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,,50597,1,,CHEMBL875328,BAO_0000218,
9556,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,,50597,1,,CHEMBL621629,BAO_0000218,
9557,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,,50597,1,,CHEMBL621630,BAO_0000218,
9558,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,,50597,1,,CHEMBL621631,BAO_0000218,
9559,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,,50597,1,,CHEMBL621632,BAO_0000218,
9560,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,,50597,1,,CHEMBL621633,BAO_0000218,
9561,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,,50597,1,,CHEMBL621634,BAO_0000218,
9562,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,,50597,1,,CHEMBL621635,BAO_0000218,
9563,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,,50597,1,,CHEMBL621636,BAO_0000218,
9564,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,,50597,1,,CHEMBL621637,BAO_0000218,
9565,Intermediate,10116.0,,1,2106.0,,Radioactivity distribution in spleen of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,,50597,1,,CHEMBL621638,BAO_0000218,
9566,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,,50597,1,,CHEMBL618883,BAO_0000218,
9567,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 30 min.,N,,,50597,1,,CHEMBL618884,BAO_0000218,
9568,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,,50597,1,,CHEMBL628627,BAO_0000218,
9569,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,,50597,1,,CHEMBL628628,BAO_0000218,
9570,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min.,N,,,50597,1,,CHEMBL628629,BAO_0000218,
9571,Intermediate,10116.0,In vivo,1,,,Half life after administering orally a dose of 3 mg/kg,N,,,50597,1,,CHEMBL628630,BAO_0000218,
9572,Intermediate,10116.0,In vivo,1,,,Half life after administering orally a dose of 3 mg/kg to a fasting rat,N,,,50597,1,,CHEMBL628631,BAO_0000218,
9573,Intermediate,10116.0,In vivo,1,,,Half life after administering intravenously a dose of 1 mg/kg,N,,,50597,1,,CHEMBL628632,BAO_0000218,
9574,Intermediate,10116.0,In vivo,1,,,Half life after oral dosing in rats,N,,,50597,1,,CHEMBL628633,BAO_0000218,
9575,Intermediate,10116.0,In vivo,1,,,Half life after the administered orally a dose of 1 mg/kg to a fasting rat,N,,,50597,1,,CHEMBL628634,BAO_0000218,
9576,Intermediate,10116.0,In vivo,1,,,Half life by intravenous administration of 3.4 mg/kg in rat,N,,,50597,1,,CHEMBL627789,BAO_0000218,
9577,Intermediate,10116.0,,1,,,Half life in rat,N,,,50597,1,,CHEMBL627790,BAO_0000218,
9578,Intermediate,10116.0,,1,,,Half life in rat,N,,,50597,1,,CHEMBL627791,BAO_0000218,
9579,Intermediate,10116.0,,1,,,Half life in rat,N,,,50597,1,,CHEMBL627792,BAO_0000218,
9580,Intermediate,10116.0,In vivo,1,,,Half life in rat after intravenous administration of the compound,N,,,50597,1,,CHEMBL627793,BAO_0000218,
9581,Intermediate,10116.0,In vivo,1,1969.0,,Half life in rat after intravenous administration of the compound; nf:unable to estimate plasma elimination half life,N,,,50597,1,,CHEMBL627794,BAO_0000218,
9582,Intermediate,10116.0,In vivo,1,,,Half life in rat after po administration of the compound,N,,,50597,1,,CHEMBL627795,BAO_0000218,
9583,Intermediate,10116.0,In vivo,1,,,Half life in rat after po administration of the compound; ND means Not determined,N,,,50597,1,,CHEMBL627796,BAO_0000218,
9584,Intermediate,10116.0,In vivo,1,1969.0,,Half life in rat after po administration of the compound; nf: unable to estimate plasma elimination half life,N,,,50597,1,,CHEMBL875335,BAO_0000218,
9585,Intermediate,10116.0,In vivo,1,1969.0,,Half life in rat after po administration of the compound; nf:unable to estimate plasma elimination half life,N,,,50597,1,,CHEMBL627797,BAO_0000218,
9586,Intermediate,10116.0,In vivo,1,,,Half life in rat i.v.,N,,,50597,1,,CHEMBL627798,BAO_0000218,
9587,Intermediate,10116.0,In vivo,1,,,Half life in rat i.v. at 2 mg/kg concentration,N,,,50597,1,,CHEMBL627799,BAO_0000218,
9588,Intermediate,10116.0,,1,,,Half life in rats,N,,,50597,1,,CHEMBL627800,BAO_0000218,
9589,Intermediate,10116.0,In vivo,1,,,Half life in rats after intravenous administration,N,,,50597,1,,CHEMBL627801,BAO_0000218,
9590,Intermediate,10116.0,In vivo,1,,,Half life in rats at the dose of 1.0 mpk by i.v. administration,N,,,50597,1,,CHEMBL627802,BAO_0000218,
9591,Expert,10116.0,,1,,,Half life in rat,N,,,50597,1,,CHEMBL627803,BAO_0000218,
9592,Intermediate,10116.0,In vivo,1,,,Half life was evaluated after intravenous administration to rats,N,,,50597,1,,CHEMBL873820,BAO_0000218,
9593,Intermediate,10116.0,,1,,,Half life was evaluated by addition of 2 mM of 2-mercaptoethanol for inactivation of semicarbazide-sensitive amine oxidase (SSAO),N,,,50597,1,,CHEMBL627804,BAO_0000218,
9594,Intermediate,10116.0,,1,,,Half life was evaluated in rat,N,,,50597,1,,CHEMBL627805,BAO_0000218,
9595,Intermediate,10116.0,,1,,,Half life was evaluated in rat,N,,,50597,1,,CHEMBL627806,BAO_0000218,
9596,Intermediate,10116.0,,1,,,Half life was evaluated in rat; Not tested,N,,,50597,1,,CHEMBL627107,BAO_0000218,
9597,Intermediate,10116.0,In vivo,1,,,Half life was evaluated when a dose of 1 mg/kg was administered intravenously to rats,N,,,50597,1,,CHEMBL627108,BAO_0000218,
9598,Intermediate,10116.0,In vivo,1,,,Half life was measured as time taken to reach the half of the initial dose in air pouch exudate after oral administration to male F344 rats,N,,,50597,1,,CHEMBL627109,BAO_0000218,
9599,Intermediate,10116.0,In vivo,1,178.0,,Half life was measured as time taken to reach the half of the initial dose in the blood after oral administration to male F344 rats,N,,,50597,1,,CHEMBL627110,BAO_0000218,
9600,Intermediate,9443.0,In vivo,1,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,U,,,22224,0,,CHEMBL627111,BAO_0000218,
9601,Intermediate,9443.0,In vivo,1,,,Half life was measured in monkey at dose of 10 mg/kg by po administration,U,,,22224,0,,CHEMBL627112,BAO_0000218,
9602,Intermediate,10116.0,In vivo,1,,,Half life was measured in rat at dose of 30 mg/kg by iv administration,U,,,22224,0,,CHEMBL627113,BAO_0000218,
9603,Intermediate,10116.0,In vivo,1,,,Half life was measured in rat at dose of 30 mg/kg by po administration,U,,,22224,0,,CHEMBL627114,BAO_0000218,
9604,Intermediate,10116.0,,1,,,Half life (t1/2) was determined,N,,,50597,1,,CHEMBL627115,BAO_0000218,
9605,Intermediate,10116.0,,1,,,Half life period at a dose of 10 uM/kg in rat was determined,N,,,50597,1,,CHEMBL627116,BAO_0000218,
9606,Intermediate,10116.0,In vivo,1,,,Half life period by oral administration at a dose of 100 uM/kg in rat was determined; ND is not determined,N,,,50597,1,,CHEMBL627117,BAO_0000218,
9607,Intermediate,10116.0,,1,,,Half life period was determined,N,,,50597,1,,CHEMBL627118,BAO_0000218,
9608,Intermediate,10116.0,In vivo,1,,,Half life period after intravenous administration at 20 mpk in rats,N,,,50597,1,,CHEMBL627119,BAO_0000218,
9609,Intermediate,10116.0,In vivo,1,,,Half life period after intravenous administration at 20 mpk in rats; Not performed.,N,,,50597,1,,CHEMBL627120,BAO_0000218,
9610,Intermediate,10116.0,In vivo,1,,,Half life period after intravenous administration in rat,N,,,50597,1,,CHEMBL626922,BAO_0000218,
9611,Intermediate,10116.0,In vivo,1,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,N,,,50597,1,,CHEMBL626923,BAO_0000218,
9612,Intermediate,10116.0,In vivo,1,,,Half life period as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,N,,,50597,1,,CHEMBL626924,BAO_0000218,
9613,Intermediate,10116.0,,1,1969.0,,Half life period in 80% rat plasma at 37 degree Centigrade,N,,,50597,1,,CHEMBL626925,BAO_0000218,
9614,Intermediate,10116.0,,1,,,Half life period in SD rats,N,,,50597,1,,CHEMBL626926,BAO_0000218,
9615,Intermediate,10116.0,,1,1969.0,,Half life period in human plasma at 25 degree Celsius temperature (pH 7.4),N,,,50597,1,,CHEMBL626927,BAO_0000218,
9616,Intermediate,10116.0,,1,1969.0,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4),N,,,50597,1,,CHEMBL626928,BAO_0000218,
9617,Intermediate,10116.0,,1,1969.0,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,N,,,50597,1,,CHEMBL626929,BAO_0000218,
9618,Intermediate,10116.0,,1,1969.0,,Half life period in human plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,N,,,50597,1,,CHEMBL626930,BAO_0000218,
9619,Intermediate,10116.0,,1,,,Half life period in rat,N,,,50597,1,,CHEMBL626931,BAO_0000218,
9620,Intermediate,10116.0,,1,,,Half life period in rat,N,,,50597,1,,CHEMBL626932,BAO_0000218,
9621,Intermediate,10116.0,,1,,,Half life period in rat,N,,,50597,1,,CHEMBL626933,BAO_0000218,
9622,Intermediate,10116.0,In vivo,1,,,Half life period in rat after oral administration at 10.5 mg/kg dose,N,,,50597,1,,CHEMBL873826,BAO_0000218,
9623,Intermediate,10116.0,In vivo,1,,,Half life period in rat after oral administration at 11.2 mg/kg dose,N,,,50597,1,,CHEMBL626934,BAO_0000218,
9624,Intermediate,10116.0,In vivo,1,,,Half life period in rat after oral administration at 13 mg/kg dose,N,,,50597,1,,CHEMBL626935,BAO_0000218,
9625,Intermediate,10116.0,In vivo,1,,,Half life period in rat after oral administration at 9.7 mg/kg dose,N,,,50597,1,,CHEMBL626936,BAO_0000218,
9626,Intermediate,10116.0,,1,,,In vivo Area under curve (AUC) was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL626937,BAO_0000218,
9627,Intermediate,10116.0,,1,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,N,,,50597,1,,CHEMBL625906,BAO_0000218,
9628,Intermediate,10116.0,,1,,,In vivo area under curve in rat plasma exposure after oral administration 50 mg/kg,N,,,50597,1,,CHEMBL625907,BAO_0000218,
9629,Intermediate,10116.0,,1,,,PK study was carried to determine AUC (area under curve) value in rat,N,,,50597,1,,CHEMBL625908,BAO_0000218,
9630,Intermediate,10116.0,,1,,,Pharmacokinetic parameter AUC after intravenous administration to rats,N,,,50597,1,,CHEMBL625909,BAO_0000218,
9631,Intermediate,10116.0,,1,,,Pharmacokinetic parameter AUC after oral administration to rats,N,,,50597,1,,CHEMBL625910,BAO_0000218,
9632,Intermediate,10116.0,,1,,,Pharmacokinetic parameter AUC was evaluated intravenous administration of 3 mg/kg,N,,,50597,1,,CHEMBL625911,BAO_0000218,
9633,Intermediate,10116.0,,1,,,Pharmacokinetic parameter AUC was evaluated when a dose of 10 mg/kg is administered orally to a fasting rat,N,,,50597,1,,CHEMBL625912,BAO_0000218,
9634,Intermediate,10116.0,,1,,,Pharmacokinetic parameter AUC was evaluated when a dose of 1 mg/kg is administered orally to a fasting rat,N,,,50597,1,,CHEMBL626538,BAO_0000218,
9635,Intermediate,10116.0,,1,,,Pharmacokinetic parameter AUC was evaluated when a dose of 30 mg/kg is administered orally,N,,,50597,1,,CHEMBL876794,BAO_0000218,
9636,Intermediate,10116.0,,1,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally,N,,,50597,1,,CHEMBL626539,BAO_0000218,
9637,Intermediate,10116.0,,1,,,Pharmacokinetic parameter AUC was evaluated when a dose of 3 mg/kg is administered orally to a fasting rat,N,,,50597,1,,CHEMBL626540,BAO_0000218,
9638,Intermediate,10116.0,,1,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into monkey at 3 mg/kg,N,,,50597,1,,CHEMBL626541,BAO_0000218,
9639,Intermediate,10116.0,,1,,,Pharmacokinetic parameter area under curve (AUC) was measured after administration into rat at 10 mg/kg,N,,,50597,1,,CHEMBL626542,BAO_0000218,
9640,Intermediate,10116.0,,1,,,Pharmacokinetic parameter area under curve was determined at 10 mg/kg po dose in rats,N,,,50597,1,,CHEMBL626543,BAO_0000218,
9641,Intermediate,10116.0,,1,,,Pharmacokinetic parameter area under curve was determined at 2 mg/kg i.v. dose in rats,N,,,50597,1,,CHEMBL626544,BAO_0000218,
9642,Intermediate,10116.0,,1,,,Pharmacokinetic parameter area under curve was determined at 3 mg/kg po dose in rats,N,,,50597,1,,CHEMBL626545,BAO_0000218,
9643,Intermediate,10116.0,,1,,,Pharmacokinetic parameter area under curve was determined at 5 mg/kg i.v. dose in rats,N,,,50597,1,,CHEMBL626546,BAO_0000218,
9644,Intermediate,10116.0,,1,,,Pharmacokinetic parameter area under curve was reported,N,,,50597,1,,CHEMBL626547,BAO_0000218,
9645,Intermediate,10116.0,,1,,,Pharmacokinetic property (AUC) in rat,N,,,50597,1,,CHEMBL626548,BAO_0000218,
9646,Intermediate,10116.0,,1,,,Pharmacokinetic property (AUC) was measured in rat at the dose of 0.32 mg/kg p.o.,N,,,50597,1,,CHEMBL626549,BAO_0000218,
9647,Intermediate,10116.0,,1,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.,N,,,50597,1,,CHEMBL626550,BAO_0000218,
9648,Intermediate,10116.0,,1,,,Pharmacokinetic property at the dose of 10 mg/kg (20% HPbetaCD) concentration in rat (0 to 6 hr) p.o.; Not tested,N,,,50597,1,,CHEMBL626551,BAO_0000218,
9649,Intermediate,10116.0,,1,,,Pharmacokinetic property was determined,N,,,50597,1,,CHEMBL623777,BAO_0000218,
9650,Intermediate,10116.0,,1,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg,N,,,50597,1,,CHEMBL623778,BAO_0000218,
9651,Intermediate,10116.0,,1,,,Pharmacokinetic property when administered intravenously in rat at 2 mg/kg; Not tested,N,,,50597,1,,CHEMBL623779,BAO_0000218,
9652,Intermediate,10116.0,,1,1969.0,,Pharmacokinetic property( plasma concentration) was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,N,,,50597,1,,CHEMBL623780,BAO_0000218,
9653,Intermediate,10116.0,,1,1969.0,,Pharmacokinetic property( plasma concentration) was determined upon 2 mg/kg in 1% methylcellulose peroral administration in rats,N,,,50597,1,,CHEMBL622015,BAO_0000218,
9654,Intermediate,10116.0,,1,1969.0,,Pharmacokinetic property( plasma concentration) was determined upon 3 mg/kg in 1% methylcellulose peroral administration in rats,N,,,50597,1,,CHEMBL622016,BAO_0000218,
9655,Intermediate,10116.0,,1,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.25 h",N,,,50597,1,,CHEMBL622017,BAO_0000218,
9656,Intermediate,10116.0,,1,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 0.5 h",N,,,50597,1,,CHEMBL622018,BAO_0000218,
9657,Intermediate,10116.0,,1,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 1 h",N,,,50597,1,,CHEMBL622019,BAO_0000218,
9658,Intermediate,10116.0,,1,,,"Pharmacokinetic property, AUC determined by rapid rat PK assay observed at 2 h",N,,,50597,1,,CHEMBL622020,BAO_0000218,
9659,Intermediate,10116.0,,1,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered intravenously,N,,,50597,1,,CHEMBL622021,BAO_0000218,
9660,Intermediate,10116.0,,1,,,Pharmacokinetic parameter AUC was determined when a dose of 1 mg/kg was administered orally,N,,,50597,1,,CHEMBL622022,BAO_0000218,
9661,Intermediate,10116.0,,1,,,Plasma concentration expressed as area under curve after intravenous administration was determined in rat,N,,,50597,1,,CHEMBL622023,BAO_0000218,
9662,Intermediate,10116.0,,1,,,Plasma concentration for the compound was determined in rats at 50 mg/kg dose,N,,,50597,1,,CHEMBL622024,BAO_0000218,
9663,Intermediate,10116.0,,1,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of solution (formulation of compound),N,,,50597,1,,CHEMBL622693,BAO_0000218,
9664,Intermediate,10116.0,,1,,,Plasma concentration was calculated in rats at a peroral dose of 5 mg/kg of suspension (formulation of compound),N,,,50597,1,,CHEMBL622694,BAO_0000218,
9665,Intermediate,10116.0,,1,,,"Plasma concentration was determined in rats at 10 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL622695,BAO_0000218,
9666,Intermediate,10116.0,,1,,,"Plasma concentration was determined in rats at 20 mg/kg, i.p. dose",N,,,50597,1,,CHEMBL622696,BAO_0000218,
9667,Intermediate,10116.0,,1,,,"Plasma concentration was determined in rats at 2 mg/kg, i.v. dose",N,,,50597,1,,CHEMBL622697,BAO_0000218,
9668,Intermediate,10116.0,,1,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (20 mg/kg, 30 min pre-treatment)",N,,,50597,1,,CHEMBL622874,BAO_0000218,
9669,Intermediate,10116.0,,1,,,"Reduction in area under curve was determined in fa/fa Zucker rats by oral glucose tolerance test following a single i.p. dose (30 mg/kg, 30 min pre-treatment)",N,,,50597,1,,CHEMBL622875,BAO_0000218,
9670,Intermediate,10116.0,,1,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,N,,,50597,1,,CHEMBL622876,BAO_0000218,
9671,Intermediate,10116.0,,1,,,Systemic AUC was determined by pharmacokinetic study conducted in portal vein cannulated rats,N,,,50597,1,,CHEMBL622877,BAO_0000218,
9672,Intermediate,10116.0,,1,,,Tested for concentration in brain after intravenous administration (4.7 mg/kg) to male rats,N,,,50597,1,,CHEMBL622878,BAO_0000218,
9673,Intermediate,10116.0,,1,1969.0,,Tested for plasma concentration after intravenous administration (4.7 mg/kg) to male rats,N,,,50597,1,,CHEMBL622879,BAO_0000218,
9674,Intermediate,10116.0,,1,,,Tested for the pharmacokinetic parameter in rat and expressed as area under curve,N,,,50597,1,,CHEMBL877602,BAO_0000218,
9675,Intermediate,10116.0,,1,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL622880,BAO_0000218,
9676,Intermediate,10116.0,,1,,,"The AUC(0-infinitive) value in male wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL622881,BAO_0000218,
9677,Intermediate,10116.0,,1,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL622882,BAO_0000218,
9678,Intermediate,10116.0,,1,,,"The AUC(0-t)value in male wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL622883,BAO_0000218,
9679,Intermediate,10116.0,,1,2046.0,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (10.7 uCi/animal); value ranges from 2.16-2.39% dose/g",N,,,50597,1,,CHEMBL622884,BAO_0000218,
9680,Intermediate,10116.0,,1,2046.0,,"Distribution of the radioiodinated compound expressed as percent dose per organ, in thyroid of unfasted rats after 60 mins of intravenous administration (11.5 uCi/animal); value ranges from 0.99-1.40 % dose/g",N,,,50597,1,,CHEMBL622885,BAO_0000218,
9681,Intermediate,10116.0,,1,,,Antidiuretic activity expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,N,,,50597,1,,CHEMBL622886,BAO_0000218,
9682,Intermediate,10116.0,,1,,,Antidiuretic activity expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,N,,,50597,1,,CHEMBL622887,BAO_0000218,
9683,Intermediate,10116.0,,1,1088.0,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,N,,,50597,1,,CHEMBL622888,BAO_0000218,
9684,Intermediate,10116.0,In vivo,1,178.0,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL622889,BAO_0000218,
9685,Intermediate,10116.0,In vivo,1,178.0,,"Biodistribution in Sprague-Dawley rat blood 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL622890,BAO_0000218,
9686,Intermediate,10116.0,In vivo,1,178.0,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL622891,BAO_0000218,
9687,Intermediate,10116.0,In vivo,1,178.0,,"Biodistribution in Sprague-Dawley rat blood 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL877603,BAO_0000218,
9688,Intermediate,10116.0,In vivo,1,955.0,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL622892,BAO_0000218,
9689,Intermediate,10116.0,In vivo,1,955.0,,"Biodistribution in Sprague-Dawley rat brain 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL622893,BAO_0000218,
9690,Intermediate,10116.0,In vivo,1,955.0,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL622894,BAO_0000218,
9691,Intermediate,10116.0,In vivo,1,955.0,,"Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL622895,BAO_0000218,
9692,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution in Sprague-Dawley rat brain 2 minutes after intravenous administration.,N,,,50597,1,,CHEMBL622896,BAO_0000218,
9693,Intermediate,10116.0,In vivo,1,948.0,,"Biodistribution in Sprague-Dawley rat heart 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL622897,BAO_0000218,
9694,Intermediate,10116.0,In vivo,1,948.0,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL622898,BAO_0000218,
9695,Intermediate,10116.0,In vivo,1,948.0,,"Biodistribution in Sprague-Dawley rat heart 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL622899,BAO_0000218,
9696,Intermediate,10116.0,In vivo,1,2113.0,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL622900,BAO_0000218,
9697,Intermediate,10116.0,In vivo,1,2113.0,,"Biodistribution in Sprague-Dawley rat kidneys(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL624114,BAO_0000218,
9698,Intermediate,10116.0,In vivo,1,2113.0,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL624115,BAO_0000218,
9699,Intermediate,10116.0,In vivo,1,2113.0,,"Biodistribution in Sprague-Dawley rat kidneys(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL624116,BAO_0000218,
9700,Intermediate,10116.0,In vivo,1,2107.0,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL624117,BAO_0000218,
9701,Intermediate,10116.0,In vivo,1,2107.0,,"Biodistribution in Sprague-Dawley rat liver 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL624118,BAO_0000218,
9702,Intermediate,10116.0,In vivo,1,2107.0,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL624119,BAO_0000218,
9703,Intermediate,10116.0,In vivo,1,2107.0,,"Biodistribution in Sprague-Dawley rat liver 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL624120,BAO_0000218,
9704,Intermediate,10116.0,In vivo,1,2048.0,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL624121,BAO_0000218,
9705,Intermediate,10116.0,In vivo,1,2048.0,,"Biodistribution in Sprague-Dawley rat lungs(2) 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL624122,BAO_0000218,
9706,Intermediate,10116.0,In vivo,1,2048.0,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL624123,BAO_0000218,
9707,Intermediate,10116.0,In vivo,1,2048.0,,"Biodistribution in Sprague-Dawley rat lungs(2) 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL624124,BAO_0000218,
9708,Intermediate,10116.0,In vivo,1,2385.0,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL624125,BAO_0000218,
9709,Intermediate,10116.0,In vivo,1,2385.0,,"Biodistribution in Sprague-Dawley rat muscle 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL624126,BAO_0000218,
9710,Intermediate,10116.0,In vivo,1,2385.0,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL624127,BAO_0000218,
9711,Intermediate,10116.0,In vivo,1,2385.0,,"Biodistribution in Sprague-Dawley rat muscle 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL624128,BAO_0000218,
9712,Intermediate,10116.0,In vivo,1,14.0,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL624129,BAO_0000218,
9713,Intermediate,10116.0,In vivo,1,14.0,,"Biodistribution in Sprague-Dawley rat skin 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL624130,BAO_0000218,
9714,Intermediate,10116.0,In vivo,1,14.0,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL622340,BAO_0000218,
9715,Intermediate,10116.0,In vivo,1,14.0,,"Biodistribution in Sprague-Dawley rat skin 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL622341,BAO_0000218,
9716,Intermediate,10116.0,In vivo,1,160.0,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL622342,BAO_0000218,
9717,Intermediate,10116.0,In vivo,1,160.0,,"Biodistribution in Sprague-Dawley rat small intestine 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL622343,BAO_0000218,
9718,Intermediate,10116.0,In vivo,1,160.0,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL622344,BAO_0000218,
9719,Intermediate,10116.0,In vivo,1,160.0,,"Biodistribution in Sprague-Dawley rat small intestine 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL622345,BAO_0000218,
9720,Intermediate,10116.0,In vivo,1,2106.0,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL622346,BAO_0000218,
9721,Intermediate,10116.0,In vivo,1,2106.0,,"Biodistribution in Sprague-Dawley rat spleen 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL622347,BAO_0000218,
9722,Intermediate,10116.0,In vivo,1,2106.0,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL622348,BAO_0000218,
9723,Intermediate,10116.0,In vivo,1,2106.0,,"Biodistribution in Sprague-Dawley rat spleen 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL622349,BAO_0000218,
9724,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 30 min.,N,,,50597,1,,CHEMBL622350,BAO_0000218,
9725,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min.,N,,,50597,1,,CHEMBL622351,BAO_0000218,
9726,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min.,N,,,50597,1,,CHEMBL622352,BAO_0000218,
9727,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 120 min.,N,,,50597,1,,CHEMBL622353,BAO_0000218,
9728,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 30 min.,N,,,50597,1,,CHEMBL622354,BAO_0000218,
9729,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 5 min.,N,,,50597,1,,CHEMBL622355,BAO_0000218,
9730,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of anti-[18F]FMACBC after 60 min.,N,,,50597,1,,CHEMBL622356,BAO_0000218,
9731,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 120 min.,N,,,50597,1,,CHEMBL622357,BAO_0000218,
9732,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 30 min.,N,,,50597,1,,CHEMBL622358,BAO_0000218,
9733,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 5 min.,N,,,50597,1,,CHEMBL622359,BAO_0000218,
9734,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of normal fischer rat after injection of syn-[18F]-FMACBC after 60 min.,N,,,50597,1,,CHEMBL874393,BAO_0000218,
9735,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,,50597,1,,CHEMBL622872,BAO_0000218,
9736,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,,50597,1,,CHEMBL622873,BAO_0000218,
9737,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,,50597,1,,CHEMBL623047,BAO_0000218,
9738,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,,50597,1,,CHEMBL623048,BAO_0000218,
9739,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,,50597,1,,CHEMBL623049,BAO_0000218,
9740,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,,50597,1,,CHEMBL623050,BAO_0000218,
9741,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,,50597,1,,CHEMBL623051,BAO_0000218,
9742,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,,50597,1,,CHEMBL623052,BAO_0000218,
9743,Intermediate,10116.0,,1,,,Radioactivity distribution in testis of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,,50597,1,,CHEMBL626343,BAO_0000218,
9744,Intermediate,10116.0,,1,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 120 min.,N,,,50597,1,,CHEMBL626344,BAO_0000218,
9745,Intermediate,10116.0,,1,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 5 min.,N,,,50597,1,,CHEMBL626345,BAO_0000218,
9746,Intermediate,10116.0,,1,,,Radioactivity distribution in tumor of normal fischer rat after injection of [18F]-fluoro-2-methyl-2-(methylamino)propanoic acid after 60 min.,N,,,50597,1,,CHEMBL626346,BAO_0000218,
9747,Intermediate,10116.0,,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 120 min,N,,,50597,1,,CHEMBL626347,BAO_0000218,
9748,Intermediate,10116.0,,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 5 min,N,,,50597,1,,CHEMBL626348,BAO_0000218,
9749,Intermediate,10116.0,,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of [18F]fluoro-2-methylpropanoic acid after 60 min,N,,,50597,1,,CHEMBL626349,BAO_0000218,
9750,Intermediate,10116.0,,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 120 min,N,,,50597,1,,CHEMBL626350,BAO_0000218,
9751,Intermediate,10116.0,,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 5 min,N,,,50597,1,,CHEMBL626351,BAO_0000218,
9752,Intermediate,10116.0,,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of anti-[18F]FMACBC after 60 min,N,,,50597,1,,CHEMBL627650,BAO_0000218,
9753,Intermediate,10116.0,,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 120 min,N,,,50597,1,,CHEMBL627651,BAO_0000218,
9754,Intermediate,10116.0,,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 5 min,N,,,50597,1,,CHEMBL627652,BAO_0000218,
9755,Intermediate,10116.0,,1,,,Radioactivity distribution in tumor of tumor-bearing fischer rat after injection of syn-[18F]-FMACBC after 60 min,N,,,50597,1,,CHEMBL627653,BAO_0000218,
9756,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr blocked time interval,N,,,50597,1,,CHEMBL627654,BAO_0000218,
9757,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr low time interval,N,,,50597,1,,CHEMBL627835,BAO_0000218,
9758,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat blood at 1 hr time interval,N,,,50597,1,,CHEMBL627836,BAO_0000218,
9759,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat blood at 3 hr time interval,N,,,50597,1,,CHEMBL627837,BAO_0000218,
9760,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr blocked time interval,N,,,50597,1,,CHEMBL627838,BAO_0000218,
9761,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr low time interval,N,,,50597,1,,CHEMBL875338,BAO_0000218,
9762,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat bone at 1 hr time interval,N,,,50597,1,,CHEMBL627839,BAO_0000218,
9763,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat bone at 3 hr time interval,N,,,50597,1,,CHEMBL627840,BAO_0000218,
9764,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr blocked time interval,N,,,50597,1,,CHEMBL627841,BAO_0000218,
9765,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr low time interval,N,,,50597,1,,CHEMBL627842,BAO_0000218,
9766,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat brain at 1 hr time interval,N,,,50597,1,,CHEMBL627843,BAO_0000218,
9767,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat brain at 3 hr time interval,N,,,50597,1,,CHEMBL627844,BAO_0000218,
9768,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr blocked time interval,N,,,50597,1,,CHEMBL627845,BAO_0000218,
9769,Intermediate,10116.0,In vivo,1,,,Half life period in rat by iv administration at a dose of 3 mg/kg,N,,,50597,1,,CHEMBL627846,BAO_0000218,
9770,Intermediate,10116.0,,1,1969.0,,Half life period in rat plasma at 25 degree Centigrade temperature (pH 7.4),N,,,50597,1,,CHEMBL627847,BAO_0000218,
9771,Intermediate,10116.0,,1,1969.0,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4),N,,,50597,1,,CHEMBL873821,BAO_0000218,
9772,Intermediate,10116.0,,1,1969.0,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,N,,,50597,1,,CHEMBL626079,BAO_0000218,
9773,Intermediate,10116.0,,1,1969.0,,Half life period in rat plasma at 37 degree Celsius temperature (pH 7.4); ND means no data,N,,,50597,1,,CHEMBL626080,BAO_0000218,
9774,Intermediate,10116.0,,1,1969.0,,Half life period was evaluated in rat plasma,N,,,50597,1,,CHEMBL626081,BAO_0000218,
9775,Intermediate,10116.0,,1,1969.0,,Half life period was evaluated in rat plasma; Not tested,N,,,50597,1,,CHEMBL875344,BAO_0000218,
9776,Intermediate,10116.0,,1,,,Half life period was evaluated in rats,N,,,50597,1,,CHEMBL626082,BAO_0000218,
9777,Intermediate,10116.0,In vivo,1,,,"Half life period was evaluated in rats, iv",N,,,50597,1,,CHEMBL626250,BAO_0000218,
9778,Intermediate,10116.0,In vivo,1,,,Half life period after intravenous administration at 5 mg/kg in rat,N,,,50597,1,,CHEMBL626251,BAO_0000218,
9779,Intermediate,10116.0,In vivo,1,,,Half life period was determined in Sprague-Dawley rats at a dose of 1 mg/kg by iv administration,N,,,50597,1,,CHEMBL626252,BAO_0000218,
9780,Intermediate,10116.0,In vivo,1,,,Half life period was determined in rat after iv administration at a dose of 5 mg/kg,N,,,50597,1,,CHEMBL626253,BAO_0000218,
9781,Intermediate,10116.0,,1,1969.0,,Half life stability of compound was evaluated in rat plasma,N,,,50597,1,,CHEMBL626254,BAO_0000218,
9782,Intermediate,10116.0,In vivo,1,,,Half life time after intravenous administration (5.0 mg/kg) was determined in rat,N,,,50597,1,,CHEMBL626255,BAO_0000218,
9783,Intermediate,10116.0,In vivo,1,,,Half life time was evaluated at 1 mg/kg of iv administration in Sprague-Dawley rats,N,,,50597,1,,CHEMBL626256,BAO_0000218,
9784,Intermediate,10116.0,In vivo,1,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,N,,,50597,1,,CHEMBL626257,BAO_0000218,
9785,Intermediate,10116.0,In vivo,1,,,Half life was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat; NC means not calculated,N,,,50597,1,,CHEMBL626258,BAO_0000218,
9786,Intermediate,10116.0,In vivo,1,,,Half life was measured in fasted male administration of compound 0.5 mg/Kg i.v.,N,,,50597,1,,CHEMBL626259,BAO_0000218,
9787,Intermediate,10116.0,In vivo,1,,,Half in rat i.v.,N,,,50597,1,,CHEMBL626260,BAO_0000218,
9788,Intermediate,10116.0,In vivo,1,,,Half period in rat after intravenous administration,N,,,50597,1,,CHEMBL875345,BAO_0000218,
9789,Intermediate,10116.0,In vivo,1,,,Half-life after repeated oral dose of compound at 1 mg/kg in rats,N,,,50597,1,,CHEMBL626261,BAO_0000218,
9790,Intermediate,10116.0,In vitro,1,2107.0,,Half-life measured in in vitro Cathepsin B assay in rat liver,N,,,50597,1,,CHEMBL626262,BAO_0000218,
9791,Intermediate,10116.0,,1,,,Half-life of compound was determined in rats,N,,,50597,1,,CHEMBL626263,BAO_0000218,
9792,Intermediate,10116.0,In vivo,1,,,Half-life at 10 mg/kg in rat upon intravenous administration,N,,,50597,1,,CHEMBL625270,BAO_0000218,
9793,Intermediate,10116.0,,1,,,Half-life determined in rat,N,,,50597,1,,CHEMBL625271,BAO_0000218,
9794,Intermediate,10116.0,,1,,,Half-life determined in rat,N,,,50597,1,,CHEMBL625272,BAO_0000218,
9795,Intermediate,10116.0,In vivo,1,955.0,,Half-life in brain after intravenous administration (4.7 mg/kg) to male rats,N,,,50597,1,,CHEMBL625273,BAO_0000218,
9796,Intermediate,10116.0,,1,1969.0,,"Half-life in chemical and enzymatic hydrolysis, in 80% rat plasma",N,,,50597,1,,CHEMBL625274,BAO_0000218,
9797,Intermediate,10116.0,In vivo,1,,,Half-life in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,N,,,50597,1,,CHEMBL625275,BAO_0000218,
9798,Intermediate,10116.0,In vivo,1,1969.0,,Half-life in plasma after intravenous administration (4.7 mg/kg) to male rats,N,,,50597,1,,CHEMBL625276,BAO_0000218,
9799,Intermediate,10116.0,,1,1969.0,,Half-life in rat plasma,N,,,50597,1,,CHEMBL625277,BAO_0000218,
9800,Intermediate,10116.0,,1,1969.0,,Half-life in rat plasma was determined,N,,,50597,1,,CHEMBL625278,BAO_0000218,
9801,Intermediate,10116.0,,1,1969.0,,Half-life in rat plasma; Not tested,N,,,50597,1,,CHEMBL625279,BAO_0000218,
9802,Intermediate,10116.0,,1,1977.0,,Half-life in rat serum,N,,,50597,1,,CHEMBL625280,BAO_0000218,
9803,Intermediate,10116.0,,1,1977.0,,Half-life in rat serum; na is not available,N,,,50597,1,,CHEMBL876797,BAO_0000218,
9804,Intermediate,10116.0,,1,,,Half-life was calculated in rat,N,,,50597,1,,CHEMBL625281,BAO_0000218,
9805,Intermediate,10116.0,,1,1969.0,,Half-life was calculated in rat plasma,N,,,50597,1,,CHEMBL873827,BAO_0000218,
9806,Intermediate,10116.0,,1,,,Half-life was determined,N,,,50597,1,,CHEMBL625282,BAO_0000218,
9807,Intermediate,10116.0,,1,,,Half-life was determined,N,,,50597,1,,CHEMBL625283,BAO_0000218,
9808,Intermediate,10116.0,In vivo,1,,,Half-life after administration of 20 mg/Kg oral dose in rat,N,,,50597,1,,CHEMBL625284,BAO_0000218,
9809,Intermediate,10116.0,In vivo,1,,,Half-life after administration of 3.2 mg/kg intravenously in male rat,N,,,50597,1,,CHEMBL625285,BAO_0000218,
9810,Intermediate,10116.0,In vivo,1,,,Half-life after intravenous administration in female rat,N,,,50597,1,,CHEMBL625286,BAO_0000218,
9811,Intermediate,10116.0,In vivo,1,,,Half-life after intravenous administration in male rat,N,,,50597,1,,CHEMBL625287,BAO_0000218,
9812,Intermediate,10116.0,In vivo,1,,,Half-life after intravenous dose in rat,N,,,50597,1,,CHEMBL625288,BAO_0000218,
9813,Intermediate,10116.0,,1,2107.0,,Half-life in a rat liver homogenate preparation,N,,,50597,1,,CHEMBL625289,BAO_0000218,
9814,Intermediate,10116.0,,1,1969.0,,Half-life in plasma of rat,N,,,50597,1,,CHEMBL625290,BAO_0000218,
9815,Intermediate,10116.0,,1,1969.0,,Half-life in plasma of rat at dose of 3-10 mgkg,N,,,50597,1,,CHEMBL876798,BAO_0000218,
9816,Intermediate,10116.0,,1,,,Half-life in rat,N,,,50597,1,,CHEMBL625291,BAO_0000218,
9817,Intermediate,10116.0,,1,,,Half-life in rat,N,,,50597,1,,CHEMBL625292,BAO_0000218,
9818,Intermediate,10116.0,,1,,,Half-life in rat,N,,,50597,1,,CHEMBL625293,BAO_0000218,
9819,Intermediate,10116.0,,1,,,Half-life in rat,N,,,50597,1,,CHEMBL622832,BAO_0000218,
9820,Intermediate,10116.0,,1,,,Half-life in rat,N,,,50597,1,,CHEMBL622833,BAO_0000218,
9821,Intermediate,10116.0,,1,,,Half-life in rat,N,,,50597,1,,CHEMBL622834,BAO_0000218,
9822,Intermediate,10116.0,In vivo,1,,,Half-life in rat after oral administration at 10 mg/kg,N,,,50597,1,,CHEMBL622835,BAO_0000218,
9823,Intermediate,10116.0,In vivo,1,,,Half-life in rat after po administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL622836,BAO_0000218,
9824,Intermediate,10116.0,In vivo,1,,,Half-life in rat after po administration at a dose of 10 mg/kg; nd is not determined,N,,,50597,1,,CHEMBL622837,BAO_0000218,
9825,Intermediate,10116.0,In vivo,1,,,Half-life in rat at 3 mg/kg dose administered intravenously,N,,,50597,1,,CHEMBL622838,BAO_0000218,
9826,Intermediate,10116.0,,1,955.0,,Half-life in rat brain homogenate,N,,,50597,1,,CHEMBL622839,BAO_0000218,
9827,Intermediate,10116.0,,1,1969.0,,Half-life in rat plasma,N,,,50597,1,,CHEMBL622840,BAO_0000218,
9828,Intermediate,10116.0,,1,,,Half-life in rats,N,,,50597,1,,CHEMBL622841,BAO_0000218,
9829,Intermediate,10116.0,,1,,,Half-life in Dawley rats,N,,,50597,1,,CHEMBL622842,BAO_0000218,
9830,Intermediate,10116.0,In vitro,1,1969.0,,Half-life in vitro in rat plasma,N,,,50597,1,,CHEMBL622843,BAO_0000218,
9831,Intermediate,10116.0,In vitro,1,1969.0,,Half-life in vitro in rat plasma; No detectable degradation over 2 hr; no detectable degradation over 2 hours,N,,,50597,1,,CHEMBL622844,BAO_0000218,
9832,Intermediate,10116.0,,1,,,"The area under concentration-time curve(AUC) was determined at 20 mg/kg of compound dose, administered intravenously in rat",N,,,50597,1,,CHEMBL622845,BAO_0000218,
9833,Intermediate,10116.0,,1,,,The area under the curve of compound was measured at the dose of 100 umol/kg,N,,,50597,1,,CHEMBL622846,BAO_0000218,
9834,Intermediate,10116.0,,1,,,The area under the curve of compound was measured at the dose of 300 umol/kg,N,,,50597,1,,CHEMBL622847,BAO_0000218,
9835,Intermediate,10116.0,,1,,,The area under the curve of compound was measured at the dose of 30 umol/kg,N,,,50597,1,,CHEMBL622848,BAO_0000218,
9836,Intermediate,10116.0,In vivo,1,,,Bioavailability as oral AUC in rats,N,,,50597,1,,CHEMBL622849,BAO_0000218,
9837,Intermediate,10116.0,,1,1969.0,,The plasma concentration versus time curve (AUC) was determined,N,,,50597,1,,CHEMBL622850,BAO_0000218,
9838,Intermediate,10116.0,,1,,,Total concentration in kidney was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,,50597,1,,CHEMBL876807,BAO_0000218,
9839,Intermediate,10116.0,,1,,,Total concentration in liver was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,,50597,1,,CHEMBL622851,BAO_0000218,
9840,Intermediate,10116.0,,1,,,Total concentration in lung was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,,50597,1,,CHEMBL622852,BAO_0000218,
9841,Intermediate,10116.0,,1,,,Total concentration in rat after 1 mg/kg i.v. administration in 24 hours,N,,,50597,1,,CHEMBL622853,BAO_0000218,
9842,Intermediate,10116.0,,1,,,Total concentration in rat after 2 mg/kg peroral administration in 24 hours,N,,,50597,1,,CHEMBL622854,BAO_0000218,
9843,Intermediate,10116.0,,1,,,Total concentration in serum was determined after 6 hr of intravenous administration to rats (n=4) at dose of 20 mg/kg,N,,,50597,1,,CHEMBL622855,BAO_0000218,
9844,Intermediate,10116.0,,1,1969.0,,"Pharmacokinetic Parameter, AUC (0-infinity) is the area under the plasma concentration versus time curve extrapolated to infinity in Female Wistar Rats at 100 mg/kg by po administration",N,,,50597,1,,CHEMBL622856,BAO_0000218,
9845,Intermediate,10116.0,,1,1969.0,,"Pharmacokinetic Parameter, AUC (0-t) is the area under the plasma concentration versus time curve in Female Wistar Rats at 100 mg/kg by po administration",N,,,50597,1,,CHEMBL622857,BAO_0000218,
9846,Intermediate,10116.0,,1,1969.0,,AUC in rat after po administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL622858,BAO_0000218,
9847,Intermediate,10116.0,,1,1969.0,,Area under the plasma concentration-time curve in rats after oral administration at 25 mg/kg,N,,,50597,1,,CHEMBL622859,BAO_0000218,
9848,Intermediate,10116.0,,1,,,Area under curve value 24 hr after 10 mg/kg iv administration in rats,N,,,50597,1,,CHEMBL622860,BAO_0000218,
9849,Intermediate,10116.0,,1,,,Area under curve value 24 hr after 10 mg/kg oral administration in rats,N,,,50597,1,,CHEMBL622861,BAO_0000218,
9850,Intermediate,10116.0,,1,,,Area under curve value 24 hr after 2 mg/kg iv administration in rats,N,,,50597,1,,CHEMBL622862,BAO_0000218,
9851,Intermediate,10116.0,,1,,,Area under curve value 24 hr after 2 mg/kg oral administration in rats,N,,,50597,1,,CHEMBL622863,BAO_0000218,
9852,Intermediate,10116.0,,1,,,Area under curve value 6 hr after po administration in rat,N,,,50597,1,,CHEMBL623817,BAO_0000218,
9853,Intermediate,10116.0,,1,,,Area under the curve at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,,,50597,1,,CHEMBL623818,BAO_0000218,
9854,Intermediate,10116.0,,1,,,"Area under the curve at a concentration of 3 mg/kg in rats, intravenously",N,,,50597,1,,CHEMBL623819,BAO_0000218,
9855,Intermediate,10116.0,,1,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,,,50597,1,,CHEMBL623820,BAO_0000218,
9856,Intermediate,10116.0,,1,,,Area under the curve at a concentration of 60 mg/kg perorally in rats along with control,N,,,50597,1,,CHEMBL623821,BAO_0000218,
9857,Intermediate,10116.0,,1,1969.0,,AUC normalized for dose (AUCN) in rat,N,,,50597,1,,CHEMBL623822,BAO_0000218,
9858,Intermediate,10116.0,,1,,,Area under curve in rat after p.o. administration,N,,,50597,1,,CHEMBL623823,BAO_0000218,
9859,Intermediate,10116.0,,1,,,Area under curve in rat after p.o. administration,N,,,50597,1,,CHEMBL623824,BAO_0000218,
9860,Intermediate,10116.0,,1,,,Area under curve in rat after p.o. administration; Not determined,N,,,50597,1,,CHEMBL623825,BAO_0000218,
9861,Intermediate,10116.0,,1,,,Area under curve in rat after peroral administration,N,,,50597,1,,CHEMBL622070,BAO_0000218,
9862,Intermediate,10116.0,,1,,,Area under curve (carotid artery) value of the compound,N,,,50597,1,,CHEMBL622071,BAO_0000218,
9863,Intermediate,10116.0,,1,,,Bioavailability expressed as the area under curve of rat carotid artery,N,,,50597,1,,CHEMBL622072,BAO_0000218,
9864,Intermediate,10116.0,,1,,,Area under curve in male SD rats was observed after intravenous administration in rat,N,,,50597,1,,CHEMBL622073,BAO_0000218,
9865,Intermediate,10116.0,,1,,,Area under curve of the compound was determined,N,,,50597,1,,CHEMBL622074,BAO_0000218,
9866,Intermediate,10116.0,,1,,,Compound was evaluated for its pharmacokinetic parameter maximum area under curve AUCmax,N,,,50597,1,,CHEMBL622075,BAO_0000218,
9867,Intermediate,10116.0,,1,1969.0,,Area under the plasma concentration-time curve in rats after oral administration at 20 mg/kg,N,,,50597,1,,CHEMBL622076,BAO_0000218,
9868,Intermediate,10116.0,,1,1969.0,,Area under the plasma concentration-time curve in rats following oral administration at 20 mg/kg,N,,,50597,1,,CHEMBL622077,BAO_0000218,
9869,Intermediate,10116.0,,1,,,Area under curve (portal vein) value of the compound,N,,,50597,1,,CHEMBL622078,BAO_0000218,
9870,Intermediate,10116.0,,1,,,Bioavailability expressed as the area under curve of rat portal vein,N,,,50597,1,,CHEMBL622079,BAO_0000218,
9871,Intermediate,10116.0,,1,1969.0,,Area Under plasma concentration time curve in rat upon peroral administration,N,,,50597,1,,CHEMBL622080,BAO_0000218,
9872,Intermediate,10116.0,,1,,,In vivo area under curve was determined for the compound after i.v. administration at a dose of 5 mg/kg in rats,N,,,50597,1,,CHEMBL877612,BAO_0000218,
9873,Intermediate,10116.0,,1,,,In vivo area under curve was determined for the compound after oral (po) administration at a dose of 10 mg/kg in rats,N,,,50597,1,,CHEMBL622081,BAO_0000218,
9874,Intermediate,10116.0,,1,,,Compound was evaluated for oral bioavailability in rats,N,,,50597,1,,CHEMBL622082,BAO_0000218,
9875,Intermediate,10116.0,,1,,,Compound was evaluated for oral bioavailability in rats after iv administration,N,,,50597,1,,CHEMBL622083,BAO_0000218,
9876,Intermediate,10116.0,,1,,,Compound was evaluated for oral bioavailability in rats; 30-80,N,,,50597,1,,CHEMBL622084,BAO_0000218,
9877,Intermediate,10116.0,,1,,,Compound was evaluated for oral bioavailability in rats; 50-60,N,,,50597,1,,CHEMBL622085,BAO_0000218,
9878,Intermediate,10116.0,,1,,,Compound was evaluated for oral bioavailability in rats; no data,N,,,50597,1,,CHEMBL622086,BAO_0000218,
9879,Intermediate,10116.0,,1,,,Compound was evaluated for oral bioavailability in rats; peptide,N,,,50597,1,,CHEMBL622087,BAO_0000218,
9880,Intermediate,10116.0,,1,178.0,,"Distribution of radioactivity in blood of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.03",N,,,50597,1,,CHEMBL622088,BAO_0000218,
9881,Intermediate,10116.0,,1,178.0,,"Distribution of radioactivity in blood of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range-0.9-1.03",N,,,50597,1,,CHEMBL622089,BAO_0000218,
9882,Intermediate,10116.0,,1,178.0,,"Distribution of radioactivity in blood of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.88-1.15",N,,,50597,1,,CHEMBL623685,BAO_0000218,
9883,Intermediate,10116.0,,1,178.0,,"Distribution of radioactivity in blood of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range = 0.71-0.87",N,,,50597,1,,CHEMBL623686,BAO_0000218,
9884,Intermediate,10116.0,In vivo,1,945.0,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL623687,BAO_0000218,
9885,Intermediate,10116.0,In vivo,1,945.0,,"Biodistribution in Sprague-Dawley rat stomach 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL623688,BAO_0000218,
9886,Intermediate,10116.0,In vivo,1,945.0,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL623689,BAO_0000218,
9887,Intermediate,10116.0,In vivo,1,945.0,,"Biodistribution in Sprague-Dawley rat stomach 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL622485,BAO_0000218,
9888,Intermediate,10116.0,In vivo,1,2046.0,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL622486,BAO_0000218,
9889,Intermediate,10116.0,In vivo,1,2046.0,,"Biodistribution in Sprague-Dawley rat thyroid 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL877613,BAO_0000218,
9890,Intermediate,10116.0,In vivo,1,2046.0,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL622487,BAO_0000218,
9891,Intermediate,10116.0,In vivo,1,2046.0,,"Biodistribution in Sprague-Dawley rat thyroid 2 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL622488,BAO_0000218,
9892,Intermediate,10116.0,In vivo,1,948.0,,"Biodistribution in Sprague-Dawley rats heart 15 minutes after intravenous administration, [99mTc]/[125I]IAP ratio)",N,,,50597,1,,CHEMBL622489,BAO_0000218,
9893,Intermediate,10116.0,,1,1088.0,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,N,,,50597,1,,CHEMBL622490,BAO_0000218,
9894,Intermediate,10116.0,,1,1088.0,,Compound was evaluated for percent dimer tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,N,,,50597,1,,CHEMBL622491,BAO_0000218,
9895,Intermediate,10116.0,,1,2107.0,,Compound was evaluated for percent dose tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in liver,N,,,50597,1,,CHEMBL622492,BAO_0000218,
9896,Intermediate,10116.0,,1,1088.0,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,N,,,50597,1,,CHEMBL622493,BAO_0000218,
9897,Intermediate,10116.0,,1,1088.0,,Compound was evaluated for percent thiol tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine; na - not available,N,,,50597,1,,CHEMBL622494,BAO_0000218,
9898,Intermediate,10116.0,,1,2385.0,,"Compound was evaluated for the biodistribution in Sprague-Dawley rats in muscle 15 minutes after intravenous administration, [99mTc]/[125I] IAP ratio)",N,,,50597,1,,CHEMBL622495,BAO_0000218,
9899,Intermediate,10116.0,,1,,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in rat kidney,N,,,50597,1,,CHEMBL622496,BAO_0000218,
9900,Intermediate,10116.0,,1,1088.0,,Compound was evaluated for tissue distribution 24 hours after a 50 mg/kg dose was administered intravenously in urine,N,,,50597,1,,CHEMBL622497,BAO_0000218,
9901,Intermediate,10116.0,,1,,,Percent of radioactive dose in urine and faeces excreted in 0-24 hr by rats,N,,,50597,1,,CHEMBL622498,BAO_0000218,
9902,Intermediate,10116.0,,1,1088.0,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats,N,,,50597,1,,CHEMBL624918,BAO_0000218,
9903,Intermediate,10116.0,,1,1088.0,,Percent of radioactive dose in urine and feces excreted in 0-24 hr by rats; NA is <10% inhibition at 1 uM for binding data,N,,,50597,1,,CHEMBL624919,BAO_0000218,
9904,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of compound in rat blood after 5 min of administration,N,,,50597,1,,CHEMBL624920,BAO_0000218,
9905,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of compound in rat blood after 5 min of administration.,N,,,50597,1,,CHEMBL624921,BAO_0000218,
9906,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of compound in rat brain after 5 min of administration,N,,,50597,1,,CHEMBL624922,BAO_0000218,
9907,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of compound in rat heart after 5 min of administration,N,,,50597,1,,CHEMBL624923,BAO_0000218,
9908,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of compound in rat heart after 5 min of administration.,N,,,50597,1,,CHEMBL624924,BAO_0000218,
9909,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of compound in rat kidney after 5 min of administration,N,,,50597,1,,CHEMBL624925,BAO_0000218,
9910,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of compound in rat kidney after 5 min of administration.,N,,,50597,1,,CHEMBL624926,BAO_0000218,
9911,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of compound in rat liver after 5 min of administration,N,,,50597,1,,CHEMBL624927,BAO_0000218,
9912,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of compound in rat liver after 5 min of administration.,N,,,50597,1,,CHEMBL874402,BAO_0000218,
9913,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of compound in rat lung after 5 min of administration,N,,,50597,1,,CHEMBL624928,BAO_0000218,
9914,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of compound in rat lung after 5 min of administration.,N,,,50597,1,,CHEMBL624929,BAO_0000218,
9915,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of compound in rat muscle after 5 min of administration,N,,,50597,1,,CHEMBL624930,BAO_0000218,
9916,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of compound in rat muscle after 5 min of administration.,N,,,50597,1,,CHEMBL624931,BAO_0000218,
9917,Intermediate,10116.0,,1,948.0,,In vivo heart distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,,50597,1,,CHEMBL624932,BAO_0000218,
9918,Intermediate,10116.0,,1,948.0,,In vivo heart distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,,50597,1,,CHEMBL624933,BAO_0000218,
9919,Intermediate,10116.0,,1,2107.0,,In vivo liver distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,,50597,1,,CHEMBL624934,BAO_0000218,
9920,Intermediate,10116.0,,1,2107.0,,In vivo liver distribution of total doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,,50597,1,,CHEMBL624935,BAO_0000218,
9921,Intermediate,10116.0,,1,,,In vivo plasma distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,,50597,1,,CHEMBL624936,BAO_0000218,
9922,Intermediate,10116.0,,1,,,In vivo plasma distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,,50597,1,,CHEMBL624937,BAO_0000218,
9923,Intermediate,10116.0,,1,2106.0,,In vivo spleen distribution of free doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,,50597,1,,CHEMBL624938,BAO_0000218,
9924,Intermediate,10116.0,,1,2106.0,,In vivo spleen distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,,50597,1,,CHEMBL624939,BAO_0000218,
9925,Intermediate,10116.0,,1,,,In vivo tumor distribution of free doxorubicin after 6 h intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,,50597,1,,CHEMBL624940,BAO_0000218,
9926,Intermediate,10116.0,,1,,,In vivo tumor distribution of total doxorubicin after 6 hr intravenous administration of 2.5 mg/kg of compound in rat bearing Walker 256 cells,N,,,50597,1,,CHEMBL874403,BAO_0000218,
9927,Intermediate,10116.0,,1,,,Compound was tested for the duration that the plasma drug concentrations remained above the IC95,N,,,50597,1,,CHEMBL624941,BAO_0000218,
9928,Intermediate,10116.0,,1,1088.0,,Dose required to lower urine osmolality to 300 mOsm/kg in rat,N,,,50597,1,,CHEMBL624942,BAO_0000218,
9929,Intermediate,10116.0,,1,1088.0,,Dose required to lower urine osmolality to 300 mOsm/kg in rat; NT=Not tested,N,,,50597,1,,CHEMBL624943,BAO_0000218,
9930,Intermediate,10116.0,In vivo,1,,,% Bioavailability after 1 day of the drug administration in rats,N,,,50597,1,,CHEMBL624944,BAO_0000218,
9931,Intermediate,10116.0,In vivo,1,,,% Bioavailability after 4 day of the drug administration in rats,N,,,50597,1,,CHEMBL624945,BAO_0000218,
9932,Intermediate,10116.0,In vivo,1,,,Absolute bioavailability was evaluated in rat,N,,,50597,1,,CHEMBL624946,BAO_0000218,
9933,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr low time interval,N,,,50597,1,,CHEMBL624947,BAO_0000218,
9934,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat fat at 1 hr time interval,N,,,50597,1,,CHEMBL624948,BAO_0000218,
9935,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat fat at 3 hr time interval,N,,,50597,1,,CHEMBL624949,BAO_0000218,
9936,Intermediate,10116.0,,1,2113.0,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr blocked time interval,N,,,50597,1,,CHEMBL622025,BAO_0000218,
9937,Intermediate,10116.0,,1,2113.0,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr low time interval,N,,,50597,1,,CHEMBL622026,BAO_0000218,
9938,Intermediate,10116.0,,1,2113.0,,Tissue biodistribution into estrogen-primed immature female rat kidney at 1 hr time interval,N,,,50597,1,,CHEMBL622027,BAO_0000218,
9939,Intermediate,10116.0,,1,2113.0,,Tissue biodistribution into estrogen-primed immature female rat kidney at 3 hr time interval,N,,,50597,1,,CHEMBL622028,BAO_0000218,
9940,Intermediate,10116.0,,1,2107.0,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr blocked time interval,N,,,50597,1,,CHEMBL622029,BAO_0000218,
9941,Intermediate,10116.0,,1,2107.0,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr low time interval,N,,,50597,1,,CHEMBL622208,BAO_0000218,
9942,Intermediate,10116.0,,1,2107.0,,Tissue biodistribution into estrogen-primed immature female rat liver at 1 hr time interval,N,,,50597,1,,CHEMBL622209,BAO_0000218,
9943,Intermediate,10116.0,,1,2107.0,,Tissue biodistribution into estrogen-primed immature female rat liver at 3 hr time interval,N,,,50597,1,,CHEMBL622210,BAO_0000218,
9944,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr blocked time interval,N,,,50597,1,,CHEMBL622211,BAO_0000218,
9945,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr low time interval,N,,,50597,1,,CHEMBL622212,BAO_0000218,
9946,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat lung at 1 hr time interval,N,,,50597,1,,CHEMBL622213,BAO_0000218,
9947,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat lung at 3 hr time interval,N,,,50597,1,,CHEMBL874404,BAO_0000218,
9948,Intermediate,10116.0,,1,2385.0,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr blocked time interval,N,,,50597,1,,CHEMBL620452,BAO_0000218,
9949,Intermediate,10116.0,,1,2385.0,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr low time interval,N,,,50597,1,,CHEMBL620453,BAO_0000218,
9950,Intermediate,10116.0,,1,2385.0,,Tissue biodistribution into estrogen-primed immature female rat muscle at 1 hr time interval,N,,,50597,1,,CHEMBL620454,BAO_0000218,
9951,Intermediate,10116.0,,1,2385.0,,Tissue biodistribution into estrogen-primed immature female rat muscle at 3 hr time interval,N,,,50597,1,,CHEMBL624067,BAO_0000218,
9952,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr blocked time interval,N,,,50597,1,,CHEMBL624068,BAO_0000218,
9953,Intermediate,10116.0,,1,992.0,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr low time interval,N,,,50597,1,,CHEMBL624069,BAO_0000218,
9954,Intermediate,10116.0,,1,992.0,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 1 hr time interval,N,,,50597,1,,CHEMBL624070,BAO_0000218,
9955,Intermediate,10116.0,,1,992.0,,Tissue biodistribution into estrogen-primed immature female rat ovaries at 3 hr time interval,N,,,50597,1,,CHEMBL624071,BAO_0000218,
9956,Intermediate,10116.0,,1,995.0,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr blocked time interval,N,,,50597,1,,CHEMBL624072,BAO_0000218,
9957,Intermediate,10116.0,,1,995.0,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr low time interval,N,,,50597,1,,CHEMBL624073,BAO_0000218,
9958,Intermediate,10116.0,,1,995.0,,Tissue biodistribution into estrogen-primed immature female rat uterus at 1 hr time interval,N,,,50597,1,,CHEMBL624788,BAO_0000218,
9959,Intermediate,10116.0,,1,995.0,,Tissue biodistribution into estrogen-primed immature female rat uterus at 3 hr time interval,N,,,50597,1,,CHEMBL624789,BAO_0000218,
9960,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr blocked time interval,N,,,50597,1,,CHEMBL624790,BAO_0000218,
9961,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr low time interval,N,,,50597,1,,CHEMBL624791,BAO_0000218,
9962,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 1 hr time interval,N,,,50597,1,,CHEMBL624792,BAO_0000218,
9963,Intermediate,10116.0,,1,,,Tissue biodistribution into estrogen-primed immature female rat uterus/blood at 3 hr time interval,N,,,50597,1,,CHEMBL624793,BAO_0000218,
9964,Intermediate,10116.0,,1,2385.0,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr blocked time interval,N,,,50597,1,,CHEMBL877491,BAO_0000218,
9965,Intermediate,10116.0,,1,2385.0,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr low time interval,N,,,50597,1,,CHEMBL624957,BAO_0000218,
9966,Intermediate,10116.0,,1,2385.0,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 1 hr time interval,N,,,50597,1,,CHEMBL624958,BAO_0000218,
9967,Intermediate,10116.0,,1,2385.0,,Tissue biodistribution into estrogen-primed immature female rat uterus/muscle at 3 hr time interval,N,,,50597,1,,CHEMBL624959,BAO_0000218,
9968,Intermediate,10116.0,,1,,,Dissociation constant was determined,N,,,50597,1,,CHEMBL624960,BAO_0000218,
9969,Intermediate,10116.0,,1,,,"Pharmacokinetic Parameter, Kel is elimination rate constant in Female Wistar Rats at 100 mg/kg by po administration",N,,,50597,1,,CHEMBL624961,BAO_0000218,
9970,Intermediate,10116.0,,1,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL624962,BAO_0000218,
9971,Intermediate,10116.0,,1,,,"The Kel value in male wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL624963,BAO_0000218,
9972,Intermediate,10116.0,,1,,,Observed rate constant in 80% rat plasma at 37 degree Centigrade,N,,,50597,1,,CHEMBL624964,BAO_0000218,
9973,Intermediate,10116.0,,1,,,LogP value was evaluated in the in situ rat gut perfusion assay,N,,,50597,1,,CHEMBL624965,BAO_0000218,
9974,Intermediate,10116.0,In vivo,1,,,In vivo retention time was evaluated for the compound after i.v. administration at a dose of 5 mg/kg was measured in rats,N,,,50597,1,,CHEMBL624966,BAO_0000218,
9975,Intermediate,10116.0,In vivo,1,,,Mean residence time (Pharmacokinetic property) after i.v. administration in rats,N,,,50597,1,,CHEMBL624967,BAO_0000218,
9976,Intermediate,10116.0,In vivo,1,,,Mean-residence time of compound after intravenous administration in rats at 24 uM/kg,N,,,50597,1,,CHEMBL624968,BAO_0000218,
9977,Intermediate,10116.0,,1,,,Mean residence time at a dose of 4 mg/kg in Rat Plasma after iv administration,N,,,50597,1,,CHEMBL624969,BAO_0000218,
9978,Expert,10116.0,,1,,,Streptococcal cell wall-washed arthritis model in rats at 10.0 mg/kg peroral dose,N,,,50597,1,,CHEMBL624970,BAO_0000218,
9979,Intermediate,10116.0,,1,,,Half-life was evaluated after 10 uM/kg of intra arterial administration,N,,,50597,1,,CHEMBL624971,BAO_0000218,
9980,Intermediate,10116.0,In vivo,1,,,Half-life was evaluated after 20 uM/kg of peroral administration,N,,,50597,1,,CHEMBL624972,BAO_0000218,
9981,Intermediate,10116.0,In vivo,1,,,Half-life was evaluated after i.v. administration in rat at a dose of 1 mg/kg,N,,,50597,1,,CHEMBL624973,BAO_0000218,
9982,Intermediate,10116.0,,1,1969.0,,Half-life was evaluated in plasma of rat,N,,,50597,1,,CHEMBL624974,BAO_0000218,
9983,Intermediate,10116.0,In vivo,1,,,Half-life was evaluated in rats at an intravenous dose of 3 mg/kg,N,,,50597,1,,CHEMBL624975,BAO_0000218,
9984,Intermediate,10116.0,In vivo,1,,,Half-life was evaluated in rats at an oral dose of 30 mg/kg,N,,,50597,1,,CHEMBL877492,BAO_0000218,
9985,Intermediate,10116.0,In vivo,1,,,Half-life was measured in rat after an iv dose of 1 mg/kg,N,,,50597,1,,CHEMBL624976,BAO_0000218,
9986,Intermediate,10116.0,In vivo,1,,,Half-life period of compound in rats after peroral administration,N,,,50597,1,,CHEMBL624977,BAO_0000218,
9987,Intermediate,10116.0,,1,1969.0,,Half-life period of compound was measured in rat plasma.,N,,,50597,1,,CHEMBL626848,BAO_0000218,
9988,Intermediate,10116.0,,1,1969.0,,Half-life period of compound was measured in rat plasma; ND is not determined,N,,,50597,1,,CHEMBL626849,BAO_0000218,
9989,Intermediate,10116.0,,1,1969.0,,Half-life period of compound was measured in rat plasma; not determined,N,,,50597,1,,CHEMBL626850,BAO_0000218,
9990,Intermediate,10116.0,In vivo,1,,,Half-life period in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,N,,,50597,1,,CHEMBL626851,BAO_0000218,
9991,Intermediate,10116.0,In vivo,1,,,Half-life period in rat by iv administration,N,,,50597,1,,CHEMBL626852,BAO_0000218,
9992,Intermediate,10116.0,In vivo,1,,,Half-life period in rats following intravenous administration at 2 mg/kg,N,,,50597,1,,CHEMBL626853,BAO_0000218,
9993,Intermediate,10116.0,In vivo,1,,,Half-life period was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,,50597,1,,CHEMBL626854,BAO_0000218,
9994,Intermediate,10116.0,,1,,,Half-life period was determined for the compound in rat,N,,,50597,1,,CHEMBL627486,BAO_0000218,
9995,Intermediate,10116.0,In vivo,1,,,"Half-life period was evaluated in rat, after administering 1 mg/kg intravenously",N,,,50597,1,,CHEMBL627487,BAO_0000218,
9996,Intermediate,10116.0,In vivo,1,,,"Half-life period was evaluated in rat, after administering 10 mg/kg orally",N,,,50597,1,,CHEMBL627488,BAO_0000218,
9997,Intermediate,10116.0,In vivo,1,,,Half-life value after IV dose at a dose of 5 mg/kg in rats.,N,,,50597,1,,CHEMBL627489,BAO_0000218,
9998,Intermediate,10116.0,In vivo,1,,,Half-life was determined by iv administration (1.5 mg/kg) in fasted male Sprague-Dawley rats,N,,,50597,1,,CHEMBL627490,BAO_0000218,
9999,Intermediate,10116.0,In vivo,1,,,Half-life was determined in rat after intravenous administration (0.5 mg/kg),N,,,50597,1,,CHEMBL873829,BAO_0000218,
10000,Intermediate,10116.0,In vivo,1,,,Half-life was determined in rat at a dose of 1 mpk i.v.,N,,,50597,1,,CHEMBL627655,BAO_0000218,
10001,Intermediate,10116.0,In vivo,1,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND means not determined,N,,,50597,1,,CHEMBL625994,BAO_0000218,
10002,Intermediate,10116.0,In vivo,1,,,Half-life was determined in rat at a dose of 1 mpk i.v.; ND=not determined,N,,,50597,1,,CHEMBL625995,BAO_0000218,
10003,Intermediate,10116.0,,1,,,Half-life in rat,N,,,50597,1,,CHEMBL625996,BAO_0000218,
10004,Intermediate,10116.0,In vitro,1,1969.0,,In vitro half life in rat plasma,N,,,50597,1,,CHEMBL625850,BAO_0000218,
10005,Intermediate,10116.0,In vitro,1,1969.0,,"In vitro half life at 1.5 -5.6ug/mL, 37 degree C in rat plasma",N,,,50597,1,,CHEMBL625851,BAO_0000218,
10006,Intermediate,10116.0,In vitro,1,,,In vitro half life in rat,N,,,50597,1,,CHEMBL625852,BAO_0000218,
10007,Intermediate,10116.0,In vivo,1,,,In vivo half life period after intravenous administration in rat,N,,,50597,1,,CHEMBL625853,BAO_0000218,
10008,Intermediate,10116.0,In vivo,1,,,In vivo half-life period for compound after i.v. administration at a dose of 5 mg/kg was measured in rats,N,,,50597,1,,CHEMBL625854,BAO_0000218,
10009,Intermediate,10116.0,In vivo,1,,,In vivo half-life period for compound after oral (po) administration at a dose of 10 mg/kg was measured in rats,N,,,50597,1,,CHEMBL874450,BAO_0000218,
10010,Intermediate,10116.0,In vivo,1,,,In vivo t1/2 was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL625855,BAO_0000218,
10011,Intermediate,10116.0,In vivo,1,,,In vivo t1/2 was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL625856,BAO_0000218,
10012,Intermediate,10116.0,In vivo,1,,,In vivo t1/2 was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL625857,BAO_0000218,
10013,Intermediate,10116.0,In vivo,1,,,In vivo t1/2 was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL873831,BAO_0000218,
10014,Intermediate,10116.0,In vivo,1,,,Longer half-life in rat (i.v.) at 0.5 mpk,N,,,50597,1,,CHEMBL625858,BAO_0000218,
10015,Intermediate,10116.0,In vivo,1,,,Longer half-life in rat (p.o.) at 2.0 mpk,N,,,50597,1,,CHEMBL625859,BAO_0000218,
10016,Intermediate,10116.0,,1,,,Pharmacokinetic property (half life) in rat,N,,,50597,1,,CHEMBL625860,BAO_0000218,
10017,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter half-life was determined at 10 mg/kg po dose in rats,N,,,50597,1,,CHEMBL625861,BAO_0000218,
10018,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter half-life was determined at 2 mg/kg i.v. dose in rats,N,,,50597,1,,CHEMBL625862,BAO_0000218,
10019,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter half-life was determined at 3 mg/kg po dose in rats,N,,,50597,1,,CHEMBL625863,BAO_0000218,
10020,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter half-life was determined at 5 mg/kg i.v. dose in rats,N,,,50597,1,,CHEMBL625864,BAO_0000218,
10021,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (t1/2) for the compound (5 mg/kg iv) was determined in rats,N,,,50597,1,,CHEMBL625865,BAO_0000218,
10022,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic half time was determined intravenously in rats.,N,,,50597,1,,CHEMBL625866,BAO_0000218,
10023,Intermediate,10116.0,In vivo,1,1969.0,,Plasma half life in rat after 5 mg/kg oral gavage; 6-8 hours,N,,,50597,1,,CHEMBL625867,BAO_0000218,
10024,Intermediate,10116.0,,1,1969.0,,Plasma half life of hydrolysis of the compound,N,,,50597,1,,CHEMBL625868,BAO_0000218,
10025,Intermediate,10116.0,In vivo,1,1969.0,,Plasma half life was reported after a intravenous dose of 1 mg/kg in Dawley rat,N,,,50597,1,,CHEMBL625869,BAO_0000218,
10026,Intermediate,10116.0,,1,1969.0,,Plasma half life period was calculated in rat,N,,,50597,1,,CHEMBL874451,BAO_0000218,
10027,Intermediate,10116.0,,1,1969.0,,Plasma half-life in Sprague-Dawley rats,N,,,50597,1,,CHEMBL625870,BAO_0000218,
10028,Intermediate,10116.0,,1,1969.0,,Plasma half-life in Sprague-Dawley rats; Not determined,N,,,50597,1,,CHEMBL625871,BAO_0000218,
10029,Intermediate,10116.0,,1,1969.0,,Plasma half-life in rats,N,,,50597,1,,CHEMBL625872,BAO_0000218,
10030,Intermediate,10116.0,,1,1969.0,,Plasma half-life in rats; <MQL,N,,,50597,1,,CHEMBL625873,BAO_0000218,
10031,Intermediate,10116.0,,1,1969.0,,Plasma half-life period (0-8 h) was determined,N,,,50597,1,,CHEMBL625874,BAO_0000218,
10032,Intermediate,10116.0,,1,1969.0,,Plasma half-life period (0-8 h) was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL625875,BAO_0000218,
10033,Intermediate,10116.0,In vivo,1,1969.0,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Sprague-Dawley rat,N,,,50597,1,,CHEMBL625876,BAO_0000218,
10034,Intermediate,10116.0,In vivo,1,1969.0,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Sprague-Dawley rat,N,,,50597,1,,CHEMBL631258,BAO_0000218,
10035,Intermediate,10116.0,,1,1969.0,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 h administration of the compound,N,,,50597,1,,CHEMBL631259,BAO_0000218,
10036,Intermediate,10116.0,,1,1969.0,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr administration of the compound; Not determined,N,,,50597,1,,CHEMBL631260,BAO_0000218,
10037,Intermediate,10116.0,,1,178.0,,"Distribution of radioactivity in blood of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range = 0.68-1.03",N,,,50597,1,,CHEMBL631261,BAO_0000218,
10038,Intermediate,10116.0,,1,178.0,,"Distribution of radioactivity in blood of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.45-0.48",N,,,50597,1,,CHEMBL631262,BAO_0000218,
10039,Intermediate,10116.0,,1,178.0,,"Distribution of radioactivity in blood of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range-0.81-1",N,,,50597,1,,CHEMBL631263,BAO_0000218,
10040,Intermediate,10116.0,,1,,,"Distribution of radioactivity in brain tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.007-0.008",N,,,50597,1,,CHEMBL631264,BAO_0000218,
10041,Intermediate,10116.0,,1,,,"Distribution of radioactivity in brain tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.18-0.22",N,,,50597,1,,CHEMBL631265,BAO_0000218,
10042,Intermediate,10116.0,,1,,,"Distribution of radioactivity in brain tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.77-0.97",N,,,50597,1,,CHEMBL631266,BAO_0000218,
10043,Intermediate,10116.0,,1,,,"Distribution of radioactivity in brain tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.08-0.13",N,,,50597,1,,CHEMBL631267,BAO_0000218,
10044,Intermediate,10116.0,,1,,,"Distribution of radioactivity in brain tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.25-0.37",N,,,50597,1,,CHEMBL631268,BAO_0000218,
10045,Intermediate,10116.0,,1,,,"Distribution of radioactivity in brain tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.03-0.04",N,,,50597,1,,CHEMBL631269,BAO_0000218,
10046,Intermediate,10116.0,,1,,,"Distribution of radioactivity in brain tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.74-0.94",N,,,50597,1,,CHEMBL631270,BAO_0000218,
10047,Intermediate,10116.0,,1,948.0,,"Distribution of radioactivity in heart tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",N,,,50597,1,,CHEMBL631271,BAO_0000218,
10048,Intermediate,10116.0,,1,948.0,,"Distribution of radioactivity in heart tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.5-0.63",N,,,50597,1,,CHEMBL631272,BAO_0000218,
10049,Intermediate,10116.0,,1,948.0,,"Distribution of radioactivity in heart tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.35-1.55",N,,,50597,1,,CHEMBL631273,BAO_0000218,
10050,Intermediate,10116.0,,1,948.0,,"Distribution of radioactivity in heart tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.24-0.38",N,,,50597,1,,CHEMBL631274,BAO_0000218,
10051,Intermediate,10116.0,,1,948.0,,"Distribution of radioactivity in heart tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.55-0.82",N,,,50597,1,,CHEMBL631275,BAO_0000218,
10052,Intermediate,10116.0,,1,948.0,,"Distribution of radioactivity in heart tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.16-0.2",N,,,50597,1,,CHEMBL626984,BAO_0000218,
10053,Intermediate,10116.0,,1,948.0,,"Distribution of radioactivity in heart tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.13-1.29",N,,,50597,1,,CHEMBL626985,BAO_0000218,
10054,Intermediate,10116.0,,1,2107.0,,"Distribution of radioactivity in liver tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.02",N,,,50597,1,,CHEMBL626986,BAO_0000218,
10055,Intermediate,10116.0,,1,2107.0,,"Distribution of radioactivity in liver tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.71-0.93",N,,,50597,1,,CHEMBL626987,BAO_0000218,
10056,Intermediate,10116.0,,1,2107.0,,"Distribution of radioactivity in liver tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.91-3.53",N,,,50597,1,,CHEMBL626988,BAO_0000218,
10057,Intermediate,10116.0,,1,2107.0,,"Distribution of radioactivity in liver tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.42-0.62",N,,,50597,1,,CHEMBL626989,BAO_0000218,
10058,Intermediate,10116.0,,1,2107.0,,"Distribution of radioactivity in liver tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.97-1.41",N,,,50597,1,,CHEMBL626990,BAO_0000218,
10059,Intermediate,10116.0,,1,2107.0,,"Distribution of radioactivity in liver tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.19-0.23",N,,,50597,1,,CHEMBL626991,BAO_0000218,
10060,Intermediate,10116.0,,1,2107.0,,"Distribution of radioactivity in liver tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 2.49-2.82",N,,,50597,1,,CHEMBL626992,BAO_0000218,
10061,Intermediate,10116.0,,1,2048.0,,"Distribution of radioactivity in lung tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 0.02-0.03",N,,,50597,1,,CHEMBL626993,BAO_0000218,
10062,Intermediate,10116.0,,1,2048.0,,"Distribution of radioactivity in lung tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.66-0.77",N,,,50597,1,,CHEMBL874593,BAO_0000218,
10063,Intermediate,10116.0,,1,2048.0,,"Distribution of radioactivity in lung tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 1.17-1.42",N,,,50597,1,,CHEMBL626994,BAO_0000218,
10064,Intermediate,10116.0,,1,2048.0,,"Distribution of radioactivity in lung tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.47-0.58",N,,,50597,1,,CHEMBL626995,BAO_0000218,
10065,Intermediate,10116.0,,1,2048.0,,"Distribution of radioactivity in lung tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.65-0.87",N,,,50597,1,,CHEMBL626190,BAO_0000218,
10066,Intermediate,10116.0,,1,2048.0,,"Distribution of radioactivity in lung tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 0.28-0.31",N,,,50597,1,,CHEMBL626191,BAO_0000218,
10067,Intermediate,10116.0,,1,2048.0,,"Distribution of radioactivity in lung tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 0.98-1.22",N,,,50597,1,,CHEMBL626364,BAO_0000218,
10068,Intermediate,10116.0,,1,2046.0,,"Distribution of radioactivity in thyroid tissue of rats at 1 day after an intravenous injection; Value expressed as mean % injected dose, Range- 406-499",N,,,50597,1,,CHEMBL626365,BAO_0000218,
10069,Intermediate,10116.0,,1,2046.0,,"Distribution of radioactivity in thyroid tissue of rats at 1 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 53.0-96",N,,,50597,1,,CHEMBL626366,BAO_0000218,
10070,Intermediate,10116.0,,1,2046.0,,"Distribution of radioactivity in thyroid tissue of rats at 2 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.65-8.0.8",N,,,50597,1,,CHEMBL626367,BAO_0000218,
10071,Intermediate,10116.0,,1,2046.0,,"Distribution of radioactivity in thyroid tissue of rats at 2 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 92-159",N,,,50597,1,,CHEMBL626368,BAO_0000218,
10072,Intermediate,10116.0,,1,2046.0,,"Distribution of radioactivity in thyroid tissue of rats at 30 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 18.74-30.84",N,,,50597,1,,CHEMBL626369,BAO_0000218,
10073,Intermediate,10116.0,,1,2046.0,,"Distribution of radioactivity in thyroid tissue of rats at 4 hr after an intravenous injection; Value expressed as mean % injected dose, Range- 156-207",N,,,50597,1,,CHEMBL626370,BAO_0000218,
10074,Intermediate,10116.0,In vivo,1,,,"Bioavailability (F) was evaluated in rat, after administering 1 mg/kg intravenously",N,,,50597,1,,CHEMBL626371,BAO_0000218,
10075,Intermediate,10116.0,In vivo,1,,,"Bioavailability (F) was evaluated in rat, after administering 10 mg/kg orally",N,,,50597,1,,CHEMBL626372,BAO_0000218,
10076,Intermediate,10116.0,In vivo,1,,,Bioavailability after a dose of 10 mg/kg p.o.,N,,,50597,1,,CHEMBL626373,BAO_0000218,
10077,Intermediate,10116.0,In vivo,1,,,Bioavailability after peroral administration (10 mg/kg) was determined in rat,N,,,50597,1,,CHEMBL626374,BAO_0000218,
10078,Intermediate,10116.0,In vivo,1,,,Bioavailability in fasted male administration of 2 mg/Kg of compound p.o.,N,,,50597,1,,CHEMBL626375,BAO_0000218,
10079,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 2 mg/kg),N,,,50597,1,,CHEMBL626376,BAO_0000218,
10080,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat po was determined,N,,,50597,1,,CHEMBL626377,BAO_0000218,
10081,Intermediate,10116.0,In vivo,1,,,Bioavailability of compound at 10 mg/kg in rat after oral administration,N,,,50597,1,,CHEMBL626378,BAO_0000218,
10082,Intermediate,10116.0,In vivo,1,,,Bioavailability of compound at 3 mg/kg in rat after i.v. administration,N,,,50597,1,,CHEMBL626379,BAO_0000218,
10083,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),N,,,50597,1,,CHEMBL626380,BAO_0000218,
10084,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 1 mg/kg i.v. and 2 mg/kg p.o.),N,,,50597,1,,CHEMBL626381,BAO_0000218,
10085,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL626382,BAO_0000218,
10086,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (Sprague-Dawley) (female),N,,,50597,1,,CHEMBL626383,BAO_0000218,
10087,Intermediate,10116.0,In vivo,1,,,Bioavailability in male Sprague-Dawley rats following an intravenous bolus dose at 10-20 mg/kg,N,,,50597,1,,CHEMBL874652,BAO_0000218,
10088,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 10-20 mg/kg),N,,,50597,1,,CHEMBL626384,BAO_0000218,
10089,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (Sprague-Dawley) (male) (dose 1 mg/kg i.v. and 3 mg/kg p.o.) measured from 0.3 to 6 hr,N,,,50597,1,,CHEMBL626385,BAO_0000218,
10090,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat at an oral dose of 2 mg/kg,N,,,50597,1,,CHEMBL626386,BAO_0000218,
10091,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL626387,BAO_0000218,
10092,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL626388,BAO_0000218,
10093,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL626389,BAO_0000218,
10094,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL626390,BAO_0000218,
10095,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat was reported at the dose of 6 mg/kg in 25% PEG-300,N,,,50597,1,,CHEMBL626391,BAO_0000218,
10096,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL626392,BAO_0000218,
10097,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL626393,BAO_0000218,
10098,Intermediate,10116.0,In vivo,1,,,Bioavailability was determined in rat,N,,,50597,1,,CHEMBL623026,BAO_0000218,
10099,Intermediate,10116.0,In vivo,1,,,Bioavailability,N,,,50597,1,,CHEMBL623027,BAO_0000218,
10100,Intermediate,10116.0,In vivo,1,,,Bioavailability,N,,,50597,1,,CHEMBL623028,BAO_0000218,
10101,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat after 1 day dosing,N,,,50597,1,,CHEMBL623029,BAO_0000218,
10102,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat after 4 day dosing,N,,,50597,1,,CHEMBL623030,BAO_0000218,
10103,Intermediate,10116.0,In vivo,1,,,Bioavailability after IV dosing at 0.5 mg/kg in rat; no data,N,,,50597,1,,CHEMBL623031,BAO_0000218,
10104,Intermediate,10116.0,In vivo,1,,,Bioavailability after IV dosing at 1 mg/kg in rat; no data,N,,,50597,1,,CHEMBL623032,BAO_0000218,
10105,Intermediate,10116.0,In vivo,1,,,Bioavailability after oral administration at a dose of 2 mg/kg in rat,N,,,50597,1,,CHEMBL623033,BAO_0000218,
10106,Intermediate,10116.0,In vivo,1,,,Bioavailability after oral administration at a dose of 4 mg/kg in rat,N,,,50597,1,,CHEMBL623034,BAO_0000218,
10107,Intermediate,10116.0,In vivo,1,,,Bioavailability at 4 hr after administration of 5 mg/kg dose peroral in rat,N,,,50597,1,,CHEMBL623035,BAO_0000218,
10108,Intermediate,10116.0,In vivo,1,,,Bioavailability at a dose of 10 mg/Kg administered perorally in female hanover-wistar rat,N,,,50597,1,,CHEMBL623036,BAO_0000218,
10109,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),N,,,50597,1,,CHEMBL623037,BAO_0000218,
10110,Intermediate,10116.0,In vivo,1,,,Bioavailability by intravenous administration of 3.4 mg/kg in rat,N,,,50597,1,,CHEMBL623038,BAO_0000218,
10111,Intermediate,10116.0,In vivo,1,1969.0,,Bioavailability from rat plasma at a single oral dose of 25 mg/kg,N,,,50597,1,,CHEMBL874385,BAO_0000218,
10112,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (Fisher) (fasted),N,,,50597,1,,CHEMBL623039,BAO_0000218,
10113,Intermediate,9443.0,In vivo,1,,,Bioavailability in monkey after po administration of 10 mg/kg dose,U,,,22224,0,,CHEMBL623040,BAO_0000218,
10114,Intermediate,9443.0,In vivo,1,,,Oral bioavailability in monkey (dose 10 mg/kg),U,,,22224,0,,CHEMBL623041,BAO_0000218,
10115,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL623741,BAO_0000218,
10116,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL623742,BAO_0000218,
10117,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL623743,BAO_0000218,
10118,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL623744,BAO_0000218,
10119,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 2.0 mg/kg p.o.),N,,,50597,1,,CHEMBL623745,BAO_0000218,
10120,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 5 mg/kg p.o. and 1 mg/kg i.v.),N,,,50597,1,,CHEMBL623746,BAO_0000218,
10121,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 5 mg/kg p.o.),N,,,50597,1,,CHEMBL623747,BAO_0000218,
10122,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat after po administration of 30 mg/kg dose,U,,,22224,0,,CHEMBL623748,BAO_0000218,
10123,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat after po administration of 30 mg/kg dose,U,,,22224,0,,CHEMBL623916,BAO_0000218,
10124,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat after 5 mg/kg by oral and 1 mg/kg by intravenous administration,N,,,50597,1,,CHEMBL623917,BAO_0000218,
10125,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 2 mg/kg i.v.),N,,,50597,1,,CHEMBL623918,BAO_0000218,
10126,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL874386,BAO_0000218,
10127,Intermediate,10116.0,In vivo,1,1969.0,,Bioavailability in rat; Only traces detected in rat plasma,N,,,50597,1,,CHEMBL623919,BAO_0000218,
10128,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL623920,BAO_0000218,
10129,Intermediate,10116.0,In vivo,1,,,Bioavailability upon oral administration of compound,N,,,50597,1,,CHEMBL623148,BAO_0000218,
10130,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 15 mg/kg),N,,,50597,1,,CHEMBL623149,BAO_0000218,
10131,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL623150,BAO_0000218,
10132,Intermediate,10116.0,In vivo,1,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fasting state",N,,,50597,1,,CHEMBL623151,BAO_0000218,
10133,Intermediate,10116.0,In vivo,1,,,"Bioavailability was evaluated in rats at a dose of 20 mg/kg, under fed state",N,,,50597,1,,CHEMBL623152,BAO_0000218,
10134,Expert,10116.0,,1,,,Streptococcal cell wall-washed arthritis model in rats at 3.0 mg/kg peroral dose,N,,,50597,1,,CHEMBL623153,BAO_0000218,
10135,Expert,10116.0,,1,,,Streptococcal cell wall-washed arthritis model in rats at 30.0 mg/kg peroral dose,N,,,50597,1,,CHEMBL623154,BAO_0000218,
10136,Intermediate,10116.0,,1,,,In vitro and metabolic stability was determined,N,,,50597,1,,CHEMBL623155,BAO_0000218,
10137,Intermediate,10116.0,,1,,,In vitro metabolic stability in rat hepatocytes,N,,,50597,1,,CHEMBL623156,BAO_0000218,
10138,Intermediate,10116.0,,1,,,In vitro metabolic stability in rat was measured as pmol/min/mg/protein,N,,,50597,1,,CHEMBL623157,BAO_0000218,
10139,Intermediate,10116.0,In vitro,1,2107.0,,Metabolic rate for compound was observed in rat hepatocytes,N,,401.0,50597,1,,CHEMBL623158,BAO_0000218,
10140,Intermediate,10116.0,,1,,,In vitro metabolic stability determined after 30 min of incubation in rat hepatic microsomes,N,,,50597,1,,CHEMBL623159,BAO_0000218,
10141,Intermediate,10116.0,,1,,,Metabolism of compound in rat S9 microsomes ('+''indicates <20% largest observed peak),N,,,50597,1,,CHEMBL874390,BAO_0000218,
10142,Intermediate,10116.0,,1,,,Metabolism of compound in rat S9 microsomes ('++++' indicates largest observed peak),N,,,50597,1,,CHEMBL623160,BAO_0000218,
10143,Intermediate,10116.0,,1,,,Metabolism of compound in rat S9 microsomes; Trace,N,,,50597,1,,CHEMBL623161,BAO_0000218,
10144,Intermediate,10116.0,,1,,,Metabolism was measured as percent loss at 4 hr in rat hepatocytes,N,,,50597,1,,CHEMBL623162,BAO_0000218,
10145,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HIAA,N,,,50597,1,,CHEMBL623163,BAO_0000218,
10146,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex 5-HT,N,,,50597,1,,CHEMBL623164,BAO_0000218,
10147,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DA,N,,,50597,1,,CHEMBL623165,BAO_0000218,
10148,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex DOPAC,N,,,50597,1,,CHEMBL623166,BAO_0000218,
10149,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex HVA,N,,,50597,1,,CHEMBL624983,BAO_0000218,
10150,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Frontal cortex NE,N,,,50597,1,,CHEMBL624984,BAO_0000218,
10151,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing at a dose of 10 mg/kg Hippocampus 5-HIAA,N,,,50597,1,,CHEMBL624985,BAO_0000218,
10152,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus 5-HT,N,,,50597,1,,CHEMBL622970,BAO_0000218,
10153,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below level of detection,N,,,50597,1,,CHEMBL622971,BAO_0000218,
10154,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DA; below the levels of detection,N,,,50597,1,,CHEMBL622972,BAO_0000218,
10155,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below level of detection,N,,,50597,1,,CHEMBL622973,BAO_0000218,
10156,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus DOPAC; below the levels of detection,N,,,50597,1,,CHEMBL622974,BAO_0000218,
10157,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below level of detection,N,,,50597,1,,CHEMBL622975,BAO_0000218,
10158,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus HVA; below the levels of detection,N,,,50597,1,,CHEMBL622976,BAO_0000218,
10159,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 10 mg/kg Hippocampus NE,N,,,50597,1,,CHEMBL622977,BAO_0000218,
10160,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HIAA,N,,,50597,1,,CHEMBL624351,BAO_0000218,
10161,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex 5-HT,N,,,50597,1,,CHEMBL624352,BAO_0000218,
10162,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,N,,,50597,1,,CHEMBL624353,BAO_0000218,
10163,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DOPAC,N,,,50597,1,,CHEMBL622397,BAO_0000218,
10164,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex HVA,N,,,50597,1,,CHEMBL622398,BAO_0000218,
10165,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex NE,N,,,50597,1,,CHEMBL622399,BAO_0000218,
10166,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Frontal cortex DA,N,,,50597,1,,CHEMBL622400,BAO_0000218,
10167,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HIAA,N,,,50597,1,,CHEMBL628428,BAO_0000218,
10168,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus 5-HT,N,,,50597,1,,CHEMBL628590,BAO_0000218,
10169,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below level of detection,N,,,50597,1,,CHEMBL628591,BAO_0000218,
10170,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DA; below the levels of detection,N,,,50597,1,,CHEMBL628592,BAO_0000218,
10171,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,N,,,50597,1,,CHEMBL628593,BAO_0000218,
10172,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection,N,,,50597,1,,CHEMBL875333,BAO_0000218,
10173,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,N,,,50597,1,,CHEMBL628594,BAO_0000218,
10174,Intermediate,10116.0,,1,1969.0,,Plasma half-life was determined in Sprague-Dawley rats after 0-8 hr of administration,N,,,50597,1,,CHEMBL628595,BAO_0000218,
10175,Intermediate,10116.0,,1,1969.0,,Stability in rat plasma was determined,N,,,50597,1,,CHEMBL628596,BAO_0000218,
10176,Intermediate,10116.0,,1,1969.0,,Stability in rat plasma was determined; ND= no data,N,,,50597,1,,CHEMBL628597,BAO_0000218,
10177,Intermediate,10116.0,,1,1969.0,,Tested for plasma half life period in rat (0-8 hr),N,,,50597,1,,CHEMBL628598,BAO_0000218,
10178,Intermediate,10116.0,,1,1969.0,,Tested for plasma half life period in rat (0-8 hr); Not determined,N,,,50597,1,,CHEMBL628599,BAO_0000218,
10179,Intermediate,10116.0,In vivo,1,,,Tested for t1/2 upon intravenous administration of 5.0 mg/Kg dose in rat,N,,,50597,1,,CHEMBL628600,BAO_0000218,
10180,Intermediate,10116.0,In vivo,1,,,Tested for t1/2 upon peroral administration of 10.0 mg/Kg dose in rat,N,,,50597,1,,CHEMBL628601,BAO_0000218,
10181,Intermediate,10116.0,,1,,,Tested for the half life in rat,N,,,50597,1,,CHEMBL628602,BAO_0000218,
10182,Intermediate,10116.0,In vitro,1,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase,N,,,50597,1,,CHEMBL628603,BAO_0000218,
10183,Intermediate,10116.0,In vitro,1,,,Tested in vitro for the time for half reactivation against rat small intestinal glucoamylase; ND=Not determined,N,,,50597,1,,CHEMBL628604,BAO_0000218,
10184,Intermediate,10116.0,In vitro,1,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase,N,,,50597,1,,CHEMBL628605,BAO_0000218,
10185,Intermediate,10116.0,In vitro,1,,,Tested in vitro for the time for half reactivation against rat small intestinal isomaltase; ND=Not determined,N,,,50597,1,,CHEMBL628606,BAO_0000218,
10186,Intermediate,10116.0,In vitro,1,,,Tested in vitro for the time for half reactivation against rat small intestinal sucrase,N,,,50597,1,,CHEMBL628607,BAO_0000218,
10187,Intermediate,10116.0,,1,,,The biological half life the compound was measured at the dose of 100 umol/kg,N,,,50597,1,,CHEMBL628608,BAO_0000218,
10188,Intermediate,10116.0,,1,,,The biological half life the compound was measured at the dose of 30 umol/kg,N,,,50597,1,,CHEMBL628609,BAO_0000218,
10189,Intermediate,10116.0,,1,1969.0,,The compound was evaluated for plasma half life period in rat,N,,,50597,1,,CHEMBL628610,BAO_0000218,
10190,Intermediate,10116.0,In vivo,1,,,"The half life value in female wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL873819,BAO_0000218,
10191,Intermediate,10116.0,In vivo,1,,,"The half life value in male wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL628611,BAO_0000218,
10192,Intermediate,10116.0,In vivo,1,,,The pharmacokinetic parameter half-life period in vivo in rats,N,,,50597,1,,CHEMBL628612,BAO_0000218,
10193,Intermediate,10116.0,In vivo,1,,,"The pharmacokinetic property, Half-life was determined",N,,,50597,1,,CHEMBL628613,BAO_0000218,
10194,Intermediate,10116.0,In vivo,1,,,"The pharmacokinetic property, Half-life in rat in vivo",N,,,50597,1,,CHEMBL628614,BAO_0000218,
10195,Intermediate,10116.0,In vivo,1,,,"The pharmacokinetic property, Half-life was determined; ND denotes no data",N,,,50597,1,,CHEMBL628615,BAO_0000218,
10196,Intermediate,10116.0,In vivo,1,,,"The pharmacokinetic property, Half-life was determined; ND denotes not determined",N,,,50597,1,,CHEMBL628616,BAO_0000218,
10197,Intermediate,10116.0,,1,1969.0,,The plasma half life period in rats,N,,,50597,1,,CHEMBL627924,BAO_0000218,
10198,Intermediate,10116.0,,1,2107.0,,The release rate of the free drug from the substrate in rat liver lysosomal preparation by rat liver lysosomal assay,N,,,50597,1,,CHEMBL627925,BAO_0000218,
10199,Intermediate,10116.0,In vivo,1,,,half life in rats at the dose of 1.0 mpk by i.v. administration; ND= not determined,N,,,50597,1,,CHEMBL627926,BAO_0000218,
10200,Intermediate,10116.0,,1,,,t1/2 (apparent elimination)of the compound was determined,N,,,50597,1,,CHEMBL627927,BAO_0000218,
10201,Intermediate,10116.0,,1,,,t1/2 value in rat,N,,,50597,1,,CHEMBL627928,BAO_0000218,
10202,Intermediate,10116.0,,1,,,Half life in rat,N,,,50597,1,,CHEMBL627539,BAO_0000218,
10203,Intermediate,10116.0,In vivo,1,1969.0,,"Half life period calculated from Time-Course plasma concentrations in rats at a dose of 2.5 mg/kg, iv",N,,,50597,1,,CHEMBL876790,BAO_0000218,
10204,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (t1/2beta) was measured in rat at the dose of 0.32 mg/kg i.v.,N,,,50597,1,,CHEMBL858186,BAO_0000218,
10205,Intermediate,10116.0,,1,,,Half-life period in fasted rats,N,,,50597,1,,CHEMBL627540,BAO_0000218,
10206,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to female wistar rats,N,,,50597,1,,CHEMBL627541,BAO_0000218,
10207,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for maximum time to reach Cmax after treatment with oral dose of 2 mgkg to male wistar rats,N,,,50597,1,,CHEMBL627715,BAO_0000218,
10208,Intermediate,10116.0,In vivo,1,,,Evaluated for pharmacokinetic parameter tmax in rat at the dose 50 mg/kg,N,,,50597,1,,CHEMBL627716,BAO_0000218,
10209,Intermediate,10116.0,,1,,,Maximum time required to achieve Cmax was determined in rat,N,,,50597,1,,CHEMBL627717,BAO_0000218,
10210,Intermediate,10116.0,In vivo,1,,,Time calculated to reach Cmax at a concentration of 15 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,,,50597,1,,CHEMBL627718,BAO_0000218,
10211,Intermediate,10116.0,In vivo,1,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with 100 mg/kg of compound 11,N,,,50597,1,,CHEMBL627719,BAO_0000218,
10212,Intermediate,10116.0,In vivo,1,,,Time calculated to reach Cmax at a concentration of 60 mg/kg perorally in rats along with control,N,,,50597,1,,CHEMBL627720,BAO_0000218,
10213,Intermediate,10116.0,In vivo,1,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration,N,,,50597,1,,CHEMBL627721,BAO_0000218,
10214,Intermediate,10116.0,In vivo,1,,,Time to reach maximum concentration in rat after 2 mg/kg peroral administration; 4-6,N,,,50597,1,,CHEMBL627722,BAO_0000218,
10215,Intermediate,10116.0,In vivo,1,,,Tmax of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL627723,BAO_0000218,
10216,Intermediate,10116.0,In vivo,1,,,Tmax of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL626058,BAO_0000218,
10217,Intermediate,10116.0,In vivo,1,,,Tmax of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL626059,BAO_0000218,
10218,Intermediate,10116.0,In vivo,1,,,Tmax of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL626060,BAO_0000218,
10219,Intermediate,10116.0,In vivo,1,1969.0,,Tmax at a dose of 4 mg/kg in Rat Plasma after iv administration,N,,,50597,1,,CHEMBL626061,BAO_0000218,
10220,Intermediate,10116.0,In vivo,1,,,Tmax determined after 0.3 mg/kg oral administration in potassium oxonate treated rats,N,,,50597,1,,CHEMBL876791,BAO_0000218,
10221,Intermediate,10116.0,In vivo,1,,,Tmax determined after 3 mg/kg oral administration in potassium oxonate treated rats,N,,,50597,1,,CHEMBL626062,BAO_0000218,
10222,Intermediate,10116.0,In vivo,1,,,Tmax at the dose of 2 mg/Kg administered perorally in rats,N,,,50597,1,,CHEMBL626063,BAO_0000218,
10223,Intermediate,10116.0,In vivo,1,,,Tmax at the dose of 5 mg/Kg administered perorally in rats,N,,,50597,1,,CHEMBL626064,BAO_0000218,
10224,Intermediate,10116.0,In vivo,1,1969.0,,tmax at a dose of 100 mg/kg in Rat Plasma after iv administration,N,,,50597,1,,CHEMBL626065,BAO_0000218,
10225,Intermediate,10116.0,In vivo,1,1969.0,,tmax at a dose of 50 mg/kg in Rat Plasma after iv administration,N,,,50597,1,,CHEMBL626066,BAO_0000218,
10226,Intermediate,10116.0,In vivo,1,,,tmax upon peroral administration of 10.0 mg/Kg dose in rat,N,,,50597,1,,CHEMBL626067,BAO_0000218,
10227,Intermediate,10116.0,,1,,,Percent total excretion of 3-(thiomethyl)acetaminophen glucuronide,N,,,50597,1,,CHEMBL626068,BAO_0000218,
10228,Intermediate,10116.0,,1,,,Percent total excretion of 3-(thiomethyl)acetaminophen sulfate,N,,,50597,1,,CHEMBL626069,BAO_0000218,
10229,Intermediate,10116.0,,1,,,Percent total excretion of 3-methoxyacetaminophen glucuronide,N,,,50597,1,,CHEMBL626070,BAO_0000218,
10230,Intermediate,10116.0,,1,,,Percent total excretion of N-methoxyacetaminophen glucuronide,N,,,50597,1,,CHEMBL626071,BAO_0000218,
10231,Intermediate,10116.0,,1,,,Percent total excretion of N-methoxyacetaminophen sulfate,N,,,50597,1,,CHEMBL626072,BAO_0000218,
10232,Intermediate,10116.0,,1,,,Percent total excretion of acetaminophen,N,,,50597,1,,CHEMBL626073,BAO_0000218,
10233,Intermediate,10116.0,,1,2046.0,,"Distribution of radioactivity in thyroid tissue of rats at 5 mins after an intravenous injection; Value expressed as mean % injected dose, Range- 6.19-7.22",N,,,50597,1,,CHEMBL626741,BAO_0000218,
10234,Intermediate,10116.0,,1,,,"Percent instability was measured by Rat S9 liver slice metabolism assay, in vitro",N,,,50597,1,,CHEMBL626742,BAO_0000218,
10235,Intermediate,10116.0,,1,,,Plasma clearance following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats,N,,,50597,1,,CHEMBL626743,BAO_0000218,
10236,Intermediate,10116.0,,1,,,Plasma concentration at 4 hr after 30 mg/kg post dosing in rat using HPLC/MS,N,,,50597,1,,CHEMBL876792,BAO_0000218,
10237,Intermediate,10116.0,,1,,,Volume of distribution following 10 mg/kg intravenous or 50 mg/kg oral dosing in rats was determined,N,,,50597,1,,CHEMBL626744,BAO_0000218,
10238,Intermediate,10116.0,,1,,,Compound was tested for antidiuretic activity in rats,N,,,50597,1,,CHEMBL626745,BAO_0000218,
10239,Intermediate,10116.0,In vivo,1,1969.0,,AUC in rat after 3mg/kg oral dose,N,,,50597,1,,CHEMBL626746,BAO_0000218,
10240,Intermediate,10116.0,,1,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 10 mg/kg,N,,,50597,1,,CHEMBL626747,BAO_0000218,
10241,Intermediate,10116.0,,1,,,Ratio in brain to that of rat plasma for 2 hr after peroral administration at 5 mg/kg,N,,,50597,1,,CHEMBL626748,BAO_0000218,
10242,Intermediate,10116.0,,1,,,Bioavailability administered orally at a dose of 10 mg/kg to rats,N,,,50597,1,,CHEMBL626749,BAO_0000218,
10243,Intermediate,10116.0,,1,,,Oral Bioavailability was determined,N,,,50597,1,,CHEMBL626750,BAO_0000218,
10244,Intermediate,10116.0,,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL626751,BAO_0000218,
10245,Intermediate,10116.0,,1,,,Oral bioavailability in rat; Not performed.,N,,,50597,1,,CHEMBL626913,BAO_0000218,
10246,Intermediate,10116.0,,1,,,Bioavailability,N,,,50597,1,,CHEMBL626914,BAO_0000218,
10247,Intermediate,10116.0,,1,,,Bioavailability was determined; ND denotes no data,N,,,50597,1,,CHEMBL626915,BAO_0000218,
10248,Intermediate,10116.0,,1,,,Biliary excretion when administered intravenously at a dose of 2.5 mg/kg in rats,N,,,50597,1,,CHEMBL626916,BAO_0000218,
10249,Intermediate,10116.0,,1,,,Biliary excretion when administered intravenously at a dose of 5 mg/kg in rats,N,,,50597,1,,CHEMBL626917,BAO_0000218,
10250,Intermediate,10116.0,,1,,,Binding towards rat plasma protein at 10 uM,N,,,50597,1,,CHEMBL626918,BAO_0000218,
10251,Intermediate,10116.0,,1,,,Binding towards rat plasma protein at 100 uM,N,,,50597,1,,CHEMBL626919,BAO_0000218,
10252,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 20 mg/kg p.o.),N,,,50597,1,,CHEMBL626920,BAO_0000218,
10253,Intermediate,10116.0,In vivo,1,,,Bioavailability was determined after oral administration of compound 18 at a dose of 4 mg/kg to rat,N,,,50597,1,,CHEMBL621976,BAO_0000218,
10254,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat after 5 mg/kg oral gavage,N,,,50597,1,,CHEMBL877599,BAO_0000218,
10255,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL621977,BAO_0000218,
10256,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 1 mg/kg i.v.),N,,,50597,1,,CHEMBL621978,BAO_0000218,
10257,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 3 mg/kg p.o.),N,,,50597,1,,CHEMBL621979,BAO_0000218,
10258,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL621980,BAO_0000218,
10259,Intermediate,10116.0,In vivo,1,,,Bioavailability of the compound in rats after administration of 30 mg/kg,N,,,50597,1,,CHEMBL621981,BAO_0000218,
10260,Intermediate,10116.0,In vivo,1,,,Bioavailability after administration of 10 mg/kg in rats,N,,,50597,1,,CHEMBL621982,BAO_0000218,
10261,Intermediate,10116.0,In vivo,1,,,Bioavailability after administration of 2 mg/kg in rats,N,,,50597,1,,CHEMBL882953,BAO_0000218,
10262,Intermediate,10116.0,In vivo,1,,,Bioavailability by oral administration at a dose of 100 uM/kg in rat was determined,N,,,50597,1,,CHEMBL621983,BAO_0000218,
10263,Intermediate,10116.0,In vivo,1,,,Bioavailability in dogs was determined; high,N,,,50597,1,,CHEMBL621984,BAO_0000218,
10264,Intermediate,10116.0,In vivo,1,,,Bioavailability in monkey after intravenous administration at 1 mpk,N,,,50597,1,,CHEMBL621985,BAO_0000218,
10265,Intermediate,10116.0,In vivo,1,,,Bioavailability in monkey after peroral administration at 10 mpk,N,,,50597,1,,CHEMBL621986,BAO_0000218,
10266,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat after intravenous administration at 1 mpk,N,,,50597,1,,CHEMBL621987,BAO_0000218,
10267,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat after intravenous administration at 2 mpk,N,,,50597,1,,CHEMBL877600,BAO_0000218,
10268,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat after peroral administration at 30 mpk,N,,,50597,1,,CHEMBL621988,BAO_0000218,
10269,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat after peroral administration at at 100 mpk,N,,,50597,1,,CHEMBL621989,BAO_0000218,
10270,Intermediate,10116.0,In vivo,1,,,Bioavailability in rats was evaluated,N,,,50597,1,,CHEMBL621990,BAO_0000218,
10271,Intermediate,10116.0,In vivo,1,,,Bioavailability was calculated after an intravenous dose of 0.3 mg/Kg in rats after 6 hr,N,,,50597,1,,CHEMBL621991,BAO_0000218,
10272,Intermediate,10116.0,In vivo,1,,,Bioavailability was calculated after an intravenous dose of 1 mg/Kg in rats after 6 hr,N,,,50597,1,,CHEMBL621992,BAO_0000218,
10273,Intermediate,10116.0,In vivo,1,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 4 hr,N,,,50597,1,,CHEMBL621993,BAO_0000218,
10274,Intermediate,10116.0,In vivo,1,,,Bioavailability was calculated after peroral dose of 3.0 mg/Kg in rats after 6 hr,N,,,50597,1,,CHEMBL621994,BAO_0000218,
10275,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL621995,BAO_0000218,
10276,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL621996,BAO_0000218,
10277,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 10 mg/kg),N,,,50597,1,,CHEMBL621997,BAO_0000218,
10278,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat after po administration at a dose of 10 mg/kg; nd is not determined,N,,,50597,1,,CHEMBL621998,BAO_0000218,
10279,Intermediate,10116.0,In vivo,1,,,Bioavailability upon peroral administration of 10.0 mg/Kg dose in rat,N,,,50597,1,,CHEMBL621999,BAO_0000218,
10280,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622000,BAO_0000218,
10281,Intermediate,10116.0,In vivo,1,,,Bioavailability was measured in rat after oral administration; 2-4,N,,,50597,1,,CHEMBL622001,BAO_0000218,
10282,Intermediate,10116.0,In vivo,1,,,Bioavailability was measured in rat after oral administration; 3-7,N,,,50597,1,,CHEMBL622002,BAO_0000218,
10283,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (intraduodenal administration),N,,,50597,1,,CHEMBL622003,BAO_0000218,
10284,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (intraduodenal administration),N,,,50597,1,,CHEMBL877601,BAO_0000218,
10285,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL624871,BAO_0000218,
10286,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622004,BAO_0000218,
10287,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg p.o.),N,,,50597,1,,CHEMBL882954,BAO_0000218,
10288,Intermediate,10116.0,In vivo,1,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally,N,,,50597,1,,CHEMBL622005,BAO_0000218,
10289,Intermediate,10116.0,In vivo,1,,,Bioavailability was evaluated when a dose of 3 mg/kg was administered orally to a fasting rat,N,,,50597,1,,CHEMBL622006,BAO_0000218,
10290,Intermediate,10116.0,In vivo,1,,,Bioavailability was measured in rat,N,,,50597,1,,CHEMBL622007,BAO_0000218,
10291,Intermediate,10116.0,In vivo,1,,,Bioavailability was reported,N,,,50597,1,,CHEMBL622008,BAO_0000218,
10292,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),N,,,50597,1,,CHEMBL622009,BAO_0000218,
10293,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),N,,,50597,1,,CHEMBL622010,BAO_0000218,
10294,Intermediate,10116.0,In vivo,1,,,Bioavailability was determined upon 10 mg/kg in 1% methylcellulose peroral administration in rats,N,,,50597,1,,CHEMBL622011,BAO_0000218,
10295,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 2 mg/kg in 1% methylcellulose p.o.),N,,,50597,1,,CHEMBL622012,BAO_0000218,
10296,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 3 mg/kg in 1% methylcellulose ),N,,,50597,1,,CHEMBL622013,BAO_0000218,
10297,Intermediate,10116.0,In vivo,1,,,Bioavailability was determined after intravenous administration at a dose 5 mg/kg to male Sprague-Dawley rats,N,,,50597,1,,CHEMBL622014,BAO_0000218,
10298,Intermediate,10116.0,In vivo,1,,,Bioavailability was determined at 3 mg/kg po dose in rats,N,,,50597,1,,CHEMBL624749,BAO_0000218,
10299,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 2 mg/kg),N,,,50597,1,,CHEMBL624750,BAO_0000218,
10300,Intermediate,10116.0,In vivo,1,,,"Bioavailability was determined in rats at 10 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL624751,BAO_0000218,
10301,Intermediate,10116.0,In vivo,1,,,"Bioavailability was determined in rats at 20 mg/kg, i.p. dose; n/a: not applicable",N,,,50597,1,,CHEMBL624752,BAO_0000218,
10302,Intermediate,10116.0,In vivo,1,,,"Bioavailability was determined in rats at 2 mg/kg, i.v. dose; n/a: not applicable",N,,,50597,1,,CHEMBL624753,BAO_0000218,
10303,Intermediate,10116.0,In vivo,1,,,Bioavailability was evaluated in rat after peroral administration at a dose of 1 mg/kg,N,,,50597,1,,CHEMBL624754,BAO_0000218,
10304,Intermediate,10116.0,In vivo,1,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,N,,,50597,1,,CHEMBL624755,BAO_0000218,
10305,Intermediate,10116.0,In vivo,1,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,N,,,50597,1,,CHEMBL624756,BAO_0000218,
10306,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL624757,BAO_0000218,
10307,Intermediate,10116.0,In vivo,1,,,Bioavailability was evaluated in rats at an intravenous dose of 3 mg/kg; Not applicable,N,,,50597,1,,CHEMBL624758,BAO_0000218,
10308,Intermediate,10116.0,In vivo,1,,,Bioavailability was evaluated in rats at an oral dose of 30 mg/kg,N,,,50597,1,,CHEMBL622270,BAO_0000218,
10309,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (Sprague-Dawley),N,,,50597,1,,CHEMBL622271,BAO_0000218,
10310,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat at the dose of 2 mg/kg,N,,,50597,1,,CHEMBL622272,BAO_0000218,
10311,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622273,BAO_0000218,
10312,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (cannulated) (dose 2 mg/kg),N,,,50597,1,,CHEMBL622274,BAO_0000218,
10313,Intermediate,10116.0,In vivo,1,,,Bioavailability value of compound in rats was determined after peroral administration,N,,,50597,1,,CHEMBL622275,BAO_0000218,
10314,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 20 mg/kg),N,,,50597,1,,CHEMBL622276,BAO_0000218,
10315,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622277,BAO_0000218,
10316,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 5 mg/kg),N,,,50597,1,,CHEMBL622278,BAO_0000218,
10317,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622279,BAO_0000218,
10318,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622280,BAO_0000218,
10319,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for oral bioavailability in rats; 15-27 %,N,,,50597,1,,CHEMBL624083,BAO_0000218,
10320,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for pharmacokinetic parameter percent bioavailability at 18 h,N,,,50597,1,,CHEMBL624084,BAO_0000218,
10321,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for pharmacokinetic property in rats after an oral dose of 10 mg/kg and the value was reported as oral bioavailability (F),N,,,50597,1,,CHEMBL624085,BAO_0000218,
10322,Intermediate,10116.0,In vivo,1,,,Compound was tested for bioavailability in rats,N,,,50597,1,,CHEMBL624086,BAO_0000218,
10323,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL624087,BAO_0000218,
10324,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL624088,BAO_0000218,
10325,Intermediate,9544.0,In vivo,1,,,Compound was tested for oral bioavailability in rhesus monkey at a dose of 0.75 mg/kg iv/ 1.5 mg/kg po.,U,,,22224,0,,CHEMBL624089,BAO_0000218,
10326,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v. and 2 mg/kg p.o.),U,,,22224,0,,CHEMBL624090,BAO_0000218,
10327,Intermediate,10116.0,In vivo,1,,,Evaluated for the bioavailability in rat (in vivo),N,,,50597,1,,CHEMBL624091,BAO_0000218,
10328,Intermediate,10116.0,In vivo,1,,,F value of compound in rats was determined after peroral administration,N,,,50597,1,,CHEMBL624092,BAO_0000218,
10329,Intermediate,10116.0,In vivo,1,,,In vivo Oral bioavailability (F)was determined after intravenous administration of compound (9.13+/-0.85 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL624093,BAO_0000218,
10330,Intermediate,10116.0,In vivo,1,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (158.5+/-2 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL624094,BAO_0000218,
10331,Intermediate,10116.0,In vivo,1,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (19.01+/-0.31 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL624095,BAO_0000218,
10332,Intermediate,10116.0,In vivo,1,,,In vivo Oral bioavailability (F)was determined after peroral administration of compound (76.4+/-2.6 mg/kg) in male Sprague-Dawley rat,N,,,50597,1,,CHEMBL624096,BAO_0000218,
10333,Intermediate,10116.0,In vivo,1,,,"In vivo percent of absolute bioavailability obtained from blood plasma levels analyzed by means of GC/MS (dose 5 uM/kg i.v. and 40 uM/kg, p.o.)",N,,,50597,1,,CHEMBL624097,BAO_0000218,
10334,Intermediate,10116.0,In vivo,1,,,Maximum fall in carotid flow in rat,N,,,50597,1,,CHEMBL624098,BAO_0000218,
10335,Intermediate,10116.0,In vivo,1,,,Oral Bioavailability after intravenous administration (1 mg/kg) in rat,N,,,50597,1,,CHEMBL874392,BAO_0000218,
10336,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 5 mg/kg),N,,,50597,1,,CHEMBL624099,BAO_0000218,
10337,Intermediate,10116.0,In vivo,1,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 16 mg/kg peroral administration,N,,,50597,1,,CHEMBL624100,BAO_0000218,
10338,Intermediate,10116.0,In vivo,1,,,Oral bioavailability (F%) of compound was determined as average of four rats at each dose of 5 mg/kg intravenous and 20 mg/kg peroral administration,N,,,50597,1,,CHEMBL624101,BAO_0000218,
10339,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (male Wistar),N,,,50597,1,,CHEMBL624102,BAO_0000218,
10340,Intermediate,10116.0,In vivo,1,,,Oral bioavailability after administration (30 mg/kg) in rat; good,N,,,50597,1,,CHEMBL624103,BAO_0000218,
10341,Intermediate,10116.0,In vivo,1,,,Oral bioavailability at the dose of 2 mg/kg in rat,N,,,50597,1,,CHEMBL624104,BAO_0000218,
10342,Intermediate,10116.0,In vivo,1,,,Oral bioavailability determined in rats,N,,,50597,1,,CHEMBL624105,BAO_0000218,
10343,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (male) (dose 50 mg/kg p.o.),N,,,50597,1,,CHEMBL624106,BAO_0000218,
10344,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose single 10 mg/kg),N,,,50597,1,,CHEMBL624107,BAO_0000218,
10345,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose single 10 mg/kg),N,,,50597,1,,CHEMBL623943,BAO_0000218,
10346,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 5 mg/kg,N,,,50597,1,,CHEMBL623944,BAO_0000218,
10347,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection,N,,,50597,1,,CHEMBL623945,BAO_0000218,
10348,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 1 week following acute dosing against at a dose of 20 mg/kg Hippocampus NE,N,,,50597,1,,CHEMBL623946,BAO_0000218,
10349,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HIAA,N,,,50597,1,,CHEMBL623947,BAO_0000218,
10350,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex 5-HT,N,,,50597,1,,CHEMBL623948,BAO_0000218,
10351,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DA,N,,,50597,1,,CHEMBL623949,BAO_0000218,
10352,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex DOPAC,N,,,50597,1,,CHEMBL623950,BAO_0000218,
10353,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex HVA,N,,,50597,1,,CHEMBL874398,BAO_0000218,
10354,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Frontal cortex NE,N,,,50597,1,,CHEMBL623951,BAO_0000218,
10355,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HIAA,N,,,50597,1,,CHEMBL623952,BAO_0000218,
10356,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus 5-HT,N,,,50597,1,,CHEMBL623953,BAO_0000218,
10357,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below level of detection,N,,,50597,1,,CHEMBL623954,BAO_0000218,
10358,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DA; below the levels of detection,N,,,50597,1,,CHEMBL623955,BAO_0000218,
10359,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below level of detection,N,,,50597,1,,CHEMBL623956,BAO_0000218,
10360,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus DOPAC; below the levels of detection,N,,,50597,1,,CHEMBL627807,BAO_0000218,
10361,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below level of detection,N,,,50597,1,,CHEMBL627808,BAO_0000218,
10362,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus HVA; below the levels of detection,N,,,50597,1,,CHEMBL627809,BAO_0000218,
10363,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed 2 weeks following sub-acute dosing against Hippocampus NE,N,,,50597,1,,CHEMBL627810,BAO_0000218,
10364,Intermediate,10116.0,,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HIAA",N,,,50597,1,,CHEMBL627811,BAO_0000218,
10365,Intermediate,10116.0,,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex 5-HT",N,,,50597,1,,CHEMBL627812,BAO_0000218,
10366,Intermediate,10116.0,,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DA",N,,,50597,1,,CHEMBL627813,BAO_0000218,
10367,Intermediate,10116.0,,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex DOPAC",N,,,50597,1,,CHEMBL627814,BAO_0000218,
10368,Intermediate,10116.0,,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex HVA",N,,,50597,1,,CHEMBL875336,BAO_0000218,
10369,Intermediate,10116.0,,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Frontal cortex NE",N,,,50597,1,,CHEMBL627815,BAO_0000218,
10370,Intermediate,10116.0,,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus 5-HIAA",N,,,50597,1,,CHEMBL627816,BAO_0000218,
10371,Intermediate,10116.0,,1,,,"Momoamine and metabolic levels observed at 3 h postdrug against, at a dose of 20 mg/kg Hippocampus 5-HT",N,,,50597,1,,CHEMBL627817,BAO_0000218,
10372,Intermediate,10116.0,,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DA; below the levels of detection",N,,,50597,1,,CHEMBL627818,BAO_0000218,
10373,Intermediate,10116.0,,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus DOPAC; below the levels of detection",N,,,50597,1,,CHEMBL627819,BAO_0000218,
10374,Intermediate,10116.0,,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus HVA; below the levels of detection",N,,,50597,1,,CHEMBL627820,BAO_0000218,
10375,Intermediate,10116.0,,1,,,"Momoamine and metabolic levels observed at 3 hr postdrug against, at a dose of 20 mg/kg Hippocampus NE",N,,,50597,1,,CHEMBL627821,BAO_0000218,
10376,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HIAA,N,,,50597,1,,CHEMBL628464,BAO_0000218,
10377,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex 5-HT,N,,,50597,1,,CHEMBL626239,BAO_0000218,
10378,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex DA,N,,,50597,1,,CHEMBL626240,BAO_0000218,
10379,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed at 3 h postdrug against at a dose of 20 mg/kg Frontal cortex DOPAC,N,,,50597,1,,CHEMBL626241,BAO_0000218,
10380,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex HVA,N,,,50597,1,,CHEMBL626242,BAO_0000218,
10381,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Frontal cortex NE,N,,,50597,1,,CHEMBL626243,BAO_0000218,
10382,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HIAA,N,,,50597,1,,CHEMBL626244,BAO_0000218,
10383,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus 5-HT; below level of detection,N,,,50597,1,,CHEMBL626907,BAO_0000218,
10384,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DA; below level of detection,N,,,50597,1,,CHEMBL626908,BAO_0000218,
10385,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus DOPAC; below level of detection,N,,,50597,1,,CHEMBL626909,BAO_0000218,
10386,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus HVA; below level of detection,N,,,50597,1,,CHEMBL626910,BAO_0000218,
10387,Intermediate,10116.0,,1,,,Percent total excretion of acetaminophen cysteine conjugate,N,,,50597,1,,CHEMBL875342,BAO_0000218,
10388,Intermediate,10116.0,,1,,,Percent total excretion of acetaminophen glucuronide,N,,,50597,1,,CHEMBL626911,BAO_0000218,
10389,Intermediate,10116.0,,1,,,Percent total excretion of acetaminophen sulfate,N,,,50597,1,,CHEMBL626912,BAO_0000218,
10390,Intermediate,10116.0,,1,,,Percent total excretion of acetaminophen-mercapturic acid,N,,,50597,1,,CHEMBL627065,BAO_0000218,
10391,Intermediate,10116.0,,1,1088.0,,Amount of urine output was measured in rat at a dose of 10 mg/kg administered orally,N,,,50597,1,,CHEMBL627066,BAO_0000218,
10392,Intermediate,10116.0,In vivo,1,,,Volume of distribution in Male Sprague-Dawley rats after intravenous administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL627067,BAO_0000218,
10393,Autocuration,8656.0,In vivo,1,2385.0,,Biodistribution of compound in rat muscle after 5 min of administration,U,,,22224,0,,CHEMBL627068,BAO_0000218,
10394,Autocuration,8656.0,In vivo,1,2385.0,,Biodistribution of compound in rat muscle after 5 min of administration.,U,,,22224,0,,CHEMBL627069,BAO_0000218,
10395,Autocuration,9940.0,In vivo,1,,,Plasma clearance was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),U,,,22224,0,,CHEMBL627070,BAO_0000218,
10396,Autocuration,9940.0,In vivo,1,,,Plasma clearance was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),U,,,22224,0,,CHEMBL627071,BAO_0000218,
10397,Autocuration,9940.0,In vivo,1,,,Bioavailability was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),U,,,22224,0,,CHEMBL627072,BAO_0000218,
10398,Autocuration,9940.0,In vivo,1,,,Bioavailability was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),U,,,22224,0,,CHEMBL627073,BAO_0000218,
10399,Autocuration,9940.0,In vivo,1,,,Volume of distribution was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),U,,,22224,0,,CHEMBL625387,BAO_0000218,
10400,Autocuration,9940.0,In vivo,1,,,Volume of distribution was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),U,,,22224,0,,CHEMBL625388,BAO_0000218,
10401,Autocuration,9940.0,In vivo,1,1969.0,,Plasma half-life period (0-8 h) was reported after intravenous administration at a dose of 1 mg/kg in Abraham sheep (female),U,,,22224,0,,CHEMBL625389,BAO_0000218,
10402,Autocuration,9940.0,In vivo,1,1969.0,,Plasma half-life period (0-8 h) was reported after oral administration at a dose of 2 mg/kg in Abraham sheep (female),U,,,22224,0,,CHEMBL875343,BAO_0000218,
10403,Intermediate,8570.0,,1,,,Biological half life period of compound was measured against snake venom phosphodiesterase (SVPDE),N,,,50497,1,,CHEMBL876795,BAO_0000218,
10404,Intermediate,8570.0,,1,,,Half life (t) of enzymatic phosphodiester hydrolysis of compound towards snake venom (SV-PDE) at a concentration of 4 microg,N,,,50497,1,,CHEMBL626552,BAO_0000218,
10405,Intermediate,8570.0,,1,,,Enzymatic stability was assessed with snake venom phosphodiesterase (SV PDE) exonuclase,N,,,50497,1,,CHEMBL626553,BAO_0000218,
10406,Autocuration,9606.0,,1,1969.0,,The human biological plasma half life of the compound,U,,,22224,0,,CHEMBL626554,BAO_0000366,
10407,Intermediate,10116.0,,1,1088.0,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,N,,,50597,1,,CHEMBL626555,BAO_0000218,
10408,Intermediate,10116.0,,1,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 120 min after iv administration compound,N,,,50597,1,,CHEMBL626556,BAO_0000218,
10409,Intermediate,10116.0,,1,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 15 after iv administration of compound,N,,,50597,1,,CHEMBL626557,BAO_0000218,
10410,Intermediate,10116.0,,1,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 240 min after iv administration compound,N,,,50597,1,,CHEMBL626558,BAO_0000218,
10411,Intermediate,10116.0,,1,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 30 min after iv administration of compound,N,,,50597,1,,CHEMBL626559,BAO_0000218,
10412,Intermediate,10116.0,,1,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 5 min after iv administration of compound,N,,,50597,1,,CHEMBL626560,BAO_0000218,
10413,Intermediate,10116.0,,1,,,Distribution of Se-75 activity in Adrenal of female Sprague-Dawley Rat 60 min after iv administration of compound,N,,,50597,1,,CHEMBL876803,BAO_0000218,
10414,Intermediate,10116.0,,1,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 120 min after iv administration compound,N,,,50597,1,,CHEMBL627964,BAO_0000218,
10415,Intermediate,10116.0,,1,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 15 min after iv administration of compound,N,,,50597,1,,CHEMBL627965,BAO_0000218,
10416,Intermediate,10116.0,,1,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 240 min after iv administration compound,N,,,50597,1,,CHEMBL627966,BAO_0000218,
10417,Intermediate,10116.0,,1,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 30 min after iv administration of compound,N,,,50597,1,,CHEMBL627967,BAO_0000218,
10418,Intermediate,10116.0,,1,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 5 min after iv administration of compound,N,,,50597,1,,CHEMBL627968,BAO_0000218,
10419,Intermediate,10116.0,,1,,,Distribution of Se-75 activity in Heart of female Sprague-Dawley Rat 60 min after iv administration of compound,N,,,50597,1,,CHEMBL627969,BAO_0000218,
10420,Intermediate,10116.0,,1,,,Distribution of Se-75 activity in Liver of female Sprague-Dawley Rat 5 min after iv administration of compound,N,,,50597,1,,CHEMBL627970,BAO_0000218,
10421,Intermediate,10116.0,,1,178.0,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 120 min after iv administration of compound,N,,,50597,1,,CHEMBL627971,BAO_0000218,
10422,Intermediate,10116.0,,1,178.0,,Distribution of Se-75 activity in blood of female Sprague-Dawley Rat 240 min after iv administration of compound,N,,,50597,1,,CHEMBL627972,BAO_0000218,
10423,Expert,9606.0,,1,,,Dissociation constant against binding to human cyclophilin A,D,,,180,9,,CHEMBL856029,BAO_0000357,
10424,Expert,9913.0,,1,,,Michaelis-Menten constant for inhibitory activity against bovine liver glyoxalase II,H,,,11591,8,,CHEMBL627973,BAO_0000019,
10425,Autocuration,,,1,,,-Log C was determined by performing the electroshock minimum test,U,,,22224,0,,CHEMBL627974,BAO_0000019,
10426,Autocuration,,,1,,,-Log C was determined by performing the foot shock test,U,,,22224,0,,CHEMBL627975,BAO_0000019,
10427,Autocuration,,,1,,,-Log C was determined by performing the incl screen test,U,,,22224,0,,CHEMBL627976,BAO_0000019,
10428,Autocuration,,,1,,,-Log C was determined by performing the maximum electroshock test,U,,,22224,0,,CHEMBL627977,BAO_0000019,
10429,Autocuration,,,1,,,-Log C was determined by performing the pentylenetetrazole test,U,,,22224,0,,CHEMBL627978,BAO_0000019,
10430,Autocuration,,,1,,,Tested for experimental arotinoid inhibitory dose,U,,,22224,0,,CHEMBL627979,BAO_0000019,
10431,Autocuration,,,1,,,Negative log transformed activity,U,,,22224,0,,CHEMBL876804,BAO_0000019,
10432,Autocuration,,,1,,,"Negative log of Langmuir's alpha constant (-log alpha), which is inversely proportional to the effective binding constant (protein binding)",U,,,22224,0,,CHEMBL627980,BAO_0000019,
10433,Intermediate,10141.0,,1,,,Dissociation constant was evaluated on guinea pig bladder at M3 muscarinic receptor,N,,,50512,1,,CHEMBL627981,BAO_0000218,
10434,Intermediate,10141.0,,1,,,Dissociation constant was evaluated on guinea pig heart (force) at M2 muscarinic receptor,N,,,50512,1,,CHEMBL627982,BAO_0000218,
10435,Intermediate,10141.0,,1,,,Dissociation constant was evaluated on guinea pig heart (rate) at M2 muscarinic receptor,N,,,50512,1,,CHEMBL627983,BAO_0000218,
10436,Intermediate,10141.0,,1,2116.0,,Dissociation constant was evaluated on guinea pig ileum at M3 muscarinic receptor,N,,,50512,1,,CHEMBL627984,BAO_0000218,
10437,Autocuration,,,1,,,Solubility in water was determined; values expressed as -log,U,,,22229,0,,CHEMBL627985,BAO_0000100,
10438,Autocuration,,,1,,,Ratio of Kcat to that of Km was determined,U,,,22224,0,,CHEMBL627986,BAO_0000019,
10439,Autocuration,,,1,,,Observed first order rate constant,U,,,22224,0,,CHEMBL627987,BAO_0000019,
10440,Autocuration,,,1,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours,U,,,22224,0,,CHEMBL627988,BAO_0000019,
10441,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to female wistar rats,N,,,50597,1,,CHEMBL627989,BAO_0000218,
10442,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for bioavailability after treatment with oral dose of 2 mgkg to male wistar rats,N,,,50597,1,,CHEMBL627990,BAO_0000218,
10443,Intermediate,10116.0,In vivo,1,,,Oral Bioavailability after administration of 10 mg/kg in male rat,N,,,50597,1,,CHEMBL876805,BAO_0000218,
10444,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 10 mg/kg i.v. and 50 mg/kg p.o.),N,,,50597,1,,CHEMBL627991,BAO_0000218,
10445,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL627992,BAO_0000218,
10446,Intermediate,10116.0,In vivo,1,,,Oral bioavailability after oral (po) administration at a dose of 10 mg/kg was measured in rats,N,,,50597,1,,CHEMBL627993,BAO_0000218,
10447,Intermediate,10116.0,In vivo,1,,,Oral bioavailability at 1 mg/kg was determined in rat,N,,,50597,1,,CHEMBL622817,BAO_0000218,
10448,Intermediate,10116.0,In vivo,1,,,Oral bioavailability at 10 mg/kg was determined in rat,N,,,50597,1,,CHEMBL622818,BAO_0000218,
10449,Intermediate,10116.0,In vivo,1,,,"Oral bioavailability in fischer rats at 30 mg/kg dose, administered perorally",N,,,50597,1,,CHEMBL622819,BAO_0000218,
10450,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL872267,BAO_0000218,
10451,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622820,BAO_0000218,
10452,Intermediate,10116.0,In vivo,1,,,Oral bioavailability after intravenous administration in rats at 24 uM/kg,N,,,50597,1,,CHEMBL622821,BAO_0000218,
10453,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622822,BAO_0000218,
10454,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622823,BAO_0000218,
10455,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622824,BAO_0000218,
10456,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat at a dose of 3 mg/kg,N,,,50597,1,,CHEMBL622825,BAO_0000218,
10457,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat after oral administration at 10 mg/kg,N,,,50597,1,,CHEMBL622901,BAO_0000218,
10458,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622902,BAO_0000218,
10459,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL621844,BAO_0000218,
10460,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in Dawley rats,N,,,50597,1,,CHEMBL621845,BAO_0000218,
10461,Intermediate,10116.0,In vivo,1,,,Oral bioavailability,N,,,50597,1,,CHEMBL621846,BAO_0000218,
10462,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 30 mg/kg),N,,,50597,1,,CHEMBL621847,BAO_0000218,
10463,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,N,,,50597,1,,CHEMBL877609,BAO_0000218,
10464,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 3 mg/kg i.v.),N,,,50597,1,,CHEMBL621848,BAO_0000218,
10465,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,N,,,50597,1,,CHEMBL621849,BAO_0000218,
10466,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),N,,,50597,1,,CHEMBL622030,BAO_0000218,
10467,Intermediate,10116.0,In vivo,1,,,Percent oral bioavailability determined in rats,N,,,50597,1,,CHEMBL622031,BAO_0000218,
10468,Intermediate,10116.0,In vivo,1,,,Tested for percent bioavailability after oral administration to Sprague-Dawley rat at dosage of 0.2 mg/kg,N,,,50597,1,,CHEMBL622032,BAO_0000218,
10469,Intermediate,10116.0,In vivo,1,,,The compound was evaluated for bioavailability in rats; 32-51,N,,,50597,1,,CHEMBL622033,BAO_0000218,
10470,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 20 mg/kg p.o.),N,,,50597,1,,CHEMBL622034,BAO_0000218,
10471,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622035,BAO_0000218,
10472,Intermediate,10116.0,In vivo,1,,,Bioavailability percent in rat at the dose of 2 mg/kg,N,,,50597,1,,CHEMBL882966,BAO_0000218,
10473,Intermediate,10116.0,In vivo,1,,,Bioavailability was evaluated after 20 uM/kg of peroral administration,N,,,50597,1,,CHEMBL622036,BAO_0000218,
10474,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622037,BAO_0000218,
10475,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622038,BAO_0000218,
10476,Intermediate,10116.0,In vivo,1,,,Bioavailability in rats,N,,,50597,1,,CHEMBL622039,BAO_0000218,
10477,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of radiolabeled compound in rat blood after 24 hr postinjection activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622040,BAO_0000218,
10478,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of radiolabeled compound in rat blood after 24 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622041,BAO_0000218,
10479,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of radiolabeled compound in rat blood after 2 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622042,BAO_0000218,
10480,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of radiolabeled compound in rat blood after 30 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622043,BAO_0000218,
10481,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of radiolabeled compound in rat blood after 5 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622044,BAO_0000218,
10482,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution of radiolabeled compound in rat bone after 24 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622045,BAO_0000218,
10483,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution of radiolabeled compound in rat bone after 2 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622046,BAO_0000218,
10484,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution of radiolabeled compound in rat bone after 30 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622047,BAO_0000218,
10485,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution of radiolabeled compound in rat bone after 5 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL877610,BAO_0000218,
10486,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of radiolabeled compound in rat brain after 24 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622048,BAO_0000218,
10487,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of radiolabeled compound in rat brain after 2 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622049,BAO_0000218,
10488,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of radiolabeled compound in rat brain after 30 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622050,BAO_0000218,
10489,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of radiolabeled compound in rat brain after 5 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622051,BAO_0000218,
10490,Intermediate,10116.0,In vivo,1,,,Biodistribution of radiolabeled compound in rat fat after 24 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622052,BAO_0000218,
10491,Intermediate,10116.0,In vivo,1,,,Biodistribution of radiolabeled compound in rat fat after 2 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622053,BAO_0000218,
10492,Intermediate,10116.0,In vivo,1,,,Biodistribution of radiolabeled compound in rat fat after 30 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622054,BAO_0000218,
10493,Intermediate,10116.0,In vivo,1,,,Biodistribution of radiolabeled compound in rat fat after 5 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622055,BAO_0000218,
10494,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rats was determined; High,N,,,50597,1,,CHEMBL622056,BAO_0000218,
10495,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in the rat was determined,N,,,50597,1,,CHEMBL622057,BAO_0000218,
10496,Intermediate,10116.0,In vivo,1,,,Oral bioavailability measured by the ratio of intravenous to oral area under concentration.,N,,,50597,1,,CHEMBL628008,BAO_0000218,
10497,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 10 mg/kg p.o. and 3 mg/kg i.v.),N,,,50597,1,,CHEMBL622058,BAO_0000218,
10498,Intermediate,10116.0,In vivo,1,,,Oral bioavailability of compound (19.2 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL622059,BAO_0000218,
10499,Intermediate,10116.0,In vivo,1,,,Oral bioavailability of compound (19.76 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL622060,BAO_0000218,
10500,Intermediate,10116.0,In vivo,1,,,Oral bioavailability of compound (20.73 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL622061,BAO_0000218,
10501,Intermediate,10116.0,In vivo,1,,,Oral bioavailability of compound (25 mg/kg) after po administration was determined in Sprague-Dawley rat,N,,,50597,1,,CHEMBL622062,BAO_0000218,
10502,Intermediate,10116.0,In vivo,1,,,Oral bioavailability of compound at a dose of 20 mg/kg was determined after oral administration in rat,N,,,50597,1,,CHEMBL622063,BAO_0000218,
10503,Expert,10116.0,In vivo,1,,,Oral bioavailability of compound determined in rat after iv administration at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL877611,BAO_0000218,
10504,Intermediate,10116.0,In vivo,1,,,Oral bioavailability of compound in Sprague Dawley rats,N,,,50597,1,,CHEMBL622064,BAO_0000218,
10505,Intermediate,10116.0,In vivo,1,,,Oral bioavailability of compound in rat,N,,,50597,1,,CHEMBL622065,BAO_0000218,
10506,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 2 mg/kg),N,,,50597,1,,CHEMBL622066,BAO_0000218,
10507,Intermediate,10116.0,In vivo,1,,,Oral bioavailability of compound in rat was determined,N,,,50597,1,,CHEMBL622067,BAO_0000218,
10508,Intermediate,10116.0,In vivo,1,,,Oral bioavailability of compound in rats,N,,,50597,1,,CHEMBL622068,BAO_0000218,
10509,Intermediate,10116.0,In vivo,1,,,Oral bioavailability of compound was determined in rats,N,,,50597,1,,CHEMBL622069,BAO_0000218,
10510,Intermediate,10116.0,In vivo,1,,,Oral bioavailability at a dose of 30 mg/kg in rats,N,,,50597,1,,CHEMBL624796,BAO_0000218,
10511,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 10 mg/kg),N,,,50597,1,,CHEMBL624797,BAO_0000218,
10512,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 10 mg/kg),N,,,50597,1,,CHEMBL623053,BAO_0000218,
10513,Intermediate,10116.0,In vivo,1,,,Oral bioavailability evaluated in rat,N,,,50597,1,,CHEMBL623054,BAO_0000218,
10514,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in fasted rat,N,,,50597,1,,CHEMBL623055,BAO_0000218,
10515,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in fed rat,N,,,50597,1,,CHEMBL623056,BAO_0000218,
10516,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (mature male) (dose 30 mg/kg),N,,,50597,1,,CHEMBL623057,BAO_0000218,
10517,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623058,BAO_0000218,
10518,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),N,,,50597,1,,CHEMBL623059,BAO_0000218,
10519,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat after administration of 10 mg/kg po,N,,,50597,1,,CHEMBL623060,BAO_0000218,
10520,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623061,BAO_0000218,
10521,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623062,BAO_0000218,
10522,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623063,BAO_0000218,
10523,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623064,BAO_0000218,
10524,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in ratrs,N,,,50597,1,,CHEMBL623065,BAO_0000218,
10525,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623066,BAO_0000218,
10526,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623067,BAO_0000218,
10527,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rats was determined; High,N,,,50597,1,,CHEMBL623068,BAO_0000218,
10528,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623069,BAO_0000218,
10529,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623070,BAO_0000218,
10530,Intermediate,10116.0,In vivo,1,,,Oral bioavailability was calculated in rat,N,,,50597,1,,CHEMBL623071,BAO_0000218,
10531,Intermediate,10116.0,In vivo,1,,,Oral bioavailability,N,,,50597,1,,CHEMBL623072,BAO_0000218,
10532,Intermediate,10116.0,In vivo,1,,,Oral bioavailability,N,,,50597,1,,CHEMBL623073,BAO_0000218,
10533,Intermediate,10116.0,In vivo,1,,,Oral bioavailability,N,,,50597,1,,CHEMBL623074,BAO_0000218,
10534,Intermediate,10116.0,In vivo,1,,,Oral bioavailability,N,,,50597,1,,CHEMBL623075,BAO_0000218,
10535,Intermediate,10116.0,In vivo,1,,,Oral bioavailability after i.v. administration,N,,,50597,1,,CHEMBL623076,BAO_0000218,
10536,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),N,,,50597,1,,CHEMBL623077,BAO_0000218,
10537,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley),N,,,50597,1,,CHEMBL623078,BAO_0000218,
10538,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in Sprague-Dawley rats,N,,,50597,1,,CHEMBL623079,BAO_0000218,
10539,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),N,,,50597,1,,CHEMBL623080,BAO_0000218,
10540,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),N,,,50597,1,,CHEMBL623081,BAO_0000218,
10541,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in Sprague-Dawley rats at a dose of 2 mg/kg by po administration,N,,,50597,1,,CHEMBL623082,BAO_0000218,
10542,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in fasted rat,N,,,50597,1,,CHEMBL874400,BAO_0000218,
10543,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in fed rat,N,,,50597,1,,CHEMBL623083,BAO_0000218,
10544,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623084,BAO_0000218,
10545,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623085,BAO_0000218,
10546,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623086,BAO_0000218,
10547,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623087,BAO_0000218,
10548,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623088,BAO_0000218,
10549,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623089,BAO_0000218,
10550,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623090,BAO_0000218,
10551,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623091,BAO_0000218,
10552,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623092,BAO_0000218,
10553,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623093,BAO_0000218,
10554,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL874401,BAO_0000218,
10555,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623094,BAO_0000218,
10556,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL623095,BAO_0000218,
10557,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat after peroral administration at 10 mg/kg,N,,,50597,1,,CHEMBL623096,BAO_0000218,
10558,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat after peroral administration at 5 mg/kg,N,,,50597,1,,CHEMBL624913,BAO_0000218,
10559,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 2.8 mg/kg p.o.),N,,,50597,1,,CHEMBL624914,BAO_0000218,
10560,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat by po administration at a dose of 40 mg/kg,N,,,50597,1,,CHEMBL624915,BAO_0000218,
10561,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat; Not measured,N,,,50597,1,,CHEMBL624916,BAO_0000218,
10562,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL624917,BAO_0000218,
10563,Intermediate,10116.0,,1,,,Momoamine and metabolic levels observed at 3 hr postdrug against at a dose of 20 mg/kg Hippocampus NE,N,,,50597,1,,CHEMBL625157,BAO_0000218,
10564,Intermediate,10116.0,,1,2107.0,,In vitro metabolic potential in rat liver microsomes,N,,,50597,1,,CHEMBL625158,BAO_0000218,
10565,Intermediate,10116.0,In vivo,1,,,"Oral availability was tested for plasma levels at a dose of 40 mg/kg, after 6 hr of in fed fisher rats.",N,,,50597,1,,CHEMBL625159,BAO_0000218,
10566,Intermediate,10116.0,In vivo,1,,,"In vivo percentage mean absolute bioavailability of compound in rat after an oral dose of 10 mg/kg (in water, N=4)",N,,,50597,1,,CHEMBL625160,BAO_0000218,
10567,Intermediate,10116.0,In vivo,1,,,Oral bioavailability of intravenously administered compound (3 mg/kg) was tested in rats,N,,,50597,1,,CHEMBL625161,BAO_0000218,
10568,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL625162,BAO_0000218,
10569,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL625163,BAO_0000218,
10570,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rats at 10 mg/kg,N,,,50597,1,,CHEMBL625164,BAO_0000218,
10571,Intermediate,10116.0,In vivo,1,,,Oral bioavailability was determined after 1 mg/kg (i.v.) / 2 mg/kg (p.o.) of compound administration,N,,,50597,1,,CHEMBL625165,BAO_0000218,
10572,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL625166,BAO_0000218,
10573,Intermediate,10116.0,,1,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis,N,,,50597,1,,CHEMBL625167,BAO_0000218,
10574,Intermediate,10116.0,,1,,,Tested for effective permeability across the rat intestinal membrane using mass balance analysis at 0.01 mM concentration,N,,,50597,1,,CHEMBL625168,BAO_0000218,
10575,Intermediate,10116.0,In vivo,1,,,Plasma clearance of the compound,N,,,50597,1,,CHEMBL625169,BAO_0000218,
10576,Intermediate,10116.0,In vivo,1,,,Plasma clearance at 10 mg/kg in rat upon intravenous administration,N,,,50597,1,,CHEMBL626264,BAO_0000218,
10577,Intermediate,10116.0,In vivo,1,,,Plasma clearance upon intravenous administration of 1 mg/Kg in rats,N,,,50597,1,,CHEMBL626265,BAO_0000218,
10578,Intermediate,10116.0,In vivo,1,1969.0,,The compound was tested for plasma clearance in rat,N,,,50597,1,,CHEMBL626266,BAO_0000218,
10579,Intermediate,10116.0,In vivo,1,1969.0,,The compound was tested for plasma clearance in rat at dose of 3-10 mgkg,N,,,50597,1,,CHEMBL626267,BAO_0000218,
10580,Intermediate,10116.0,,1,,,Plasma concentration upon oral administration of 1 mg/Kg in rats,N,,,50597,1,,CHEMBL626268,BAO_0000218,
10581,Intermediate,10116.0,,1,,,Peak plasma level between 0.5 and 1.0 hour in Dawley rats; value ranges from 1021-2551,N,,,50597,1,,CHEMBL626269,BAO_0000218,
10582,Intermediate,10116.0,,1,,,Plasma level after intravenous administration in rat model of FeCl3-induced carotid thrombosis,N,,,50597,1,,CHEMBL626270,BAO_0000218,
10583,Intermediate,10116.0,,1,,,Plasma protein binding was determined after intravenous administration of 1 mg/kg in rat,N,,,50597,1,,CHEMBL626271,BAO_0000218,
10584,Intermediate,10116.0,,1,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1",N,,,50597,1,,CHEMBL626272,BAO_0000218,
10585,Intermediate,10116.0,,1,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",N,,,50597,1,,CHEMBL626273,BAO_0000218,
10586,Intermediate,10116.0,,1,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not determined",N,,,50597,1,,CHEMBL875346,BAO_0000218,
10587,Intermediate,10116.0,,1,,,"Rat plasma cleavage data expressed as percentage of compound remains at 24 hr in PEG400/Water, 1:1; Not stable",N,,,50597,1,,CHEMBL626274,BAO_0000218,
10588,Intermediate,10116.0,,1,,,Compound was tested for protein binding in rat plasma,N,,,50597,1,,CHEMBL626275,BAO_0000218,
10589,Intermediate,10116.0,,1,,,Compound was evaluated for absorption of radioligand following oral administration to bile duct cannulated rat. ,N,,,50597,1,,CHEMBL624646,BAO_0000218,
10590,Intermediate,10116.0,,1,,,Compound was evaluated for absorption of radioligand upon oral administration to bile duct cannulated rats,N,,,50597,1,,CHEMBL624647,BAO_0000218,
10591,Intermediate,10116.0,,1,2107.0,,In vitro metabolism in rat liver microsomes was evaluated to determine diminishing of glucuronidation rate,N,,,50597,1,,CHEMBL624648,BAO_0000218,
10592,Intermediate,10116.0,,1,,,Area under curve ratio was determined (po/iv) in rat,N,,,50597,1,,CHEMBL624649,BAO_0000218,
10593,Intermediate,10116.0,,1,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 15 mins after i.v. administration,N,,,50597,1,,CHEMBL624650,BAO_0000218,
10594,Intermediate,10116.0,,1,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 2 mins after i.v. administration,N,,,50597,1,,CHEMBL624651,BAO_0000218,
10595,Intermediate,10116.0,,1,,,Blood by brain ratio of the radiolabeled compound (2-5 uCi) in rat 65 mins after i.v. administration,N,,,50597,1,,CHEMBL624652,BAO_0000218,
10596,Intermediate,10116.0,,1,,,Compound was tested for brain/plasma ratio after oral administration at 10 mg/kg,N,,,50597,1,,CHEMBL624653,BAO_0000218,
10597,Intermediate,10116.0,,1,,,Ratio of AUCbrain to AUCplasma,N,,,50597,1,,CHEMBL624654,BAO_0000218,
10598,Intermediate,10116.0,,1,,,Ratio of brain to plasma,N,,,50597,1,,CHEMBL624655,BAO_0000218,
10599,Intermediate,10116.0,,1,,,Ratio of the AUC values of brain and plasma after intravenous administration (4.7 mg/kg) to male rats was evaluated,N,,,50597,1,,CHEMBL624656,BAO_0000218,
10600,Intermediate,10116.0,,1,,,Ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,N,,,50597,1,,CHEMBL624657,BAO_0000218,
10601,Intermediate,10116.0,,1,,,Ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats was evaluated,N,,,50597,1,,CHEMBL624658,BAO_0000218,
10602,Intermediate,10116.0,,1,,,Selectivity ratio for biodistribution in brain and blood of rats after 15 minutes; Expressed as percent dose/gram ratio,N,,,50597,1,,CHEMBL624659,BAO_0000218,
10603,Intermediate,10116.0,,1,,,Selectivity ratio for biodistribution in brain and blood of rats after 2 minutes; Expressed as percent dose/gram ratio,N,,,50597,1,,CHEMBL624660,BAO_0000218,
10604,Intermediate,10116.0,,1,,,Selectivity ratio for biodistribution in brain and blood of rats after 60 minutes; Expressed as percent dose/gram ratio,N,,,50597,1,,CHEMBL624661,BAO_0000218,
10605,Intermediate,10116.0,,1,,,Steady state brain :blood ratio was determined,N,,,50597,1,,CHEMBL624662,BAO_0000218,
10606,Intermediate,10116.0,,1,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats,N,,,50597,1,,CHEMBL625199,BAO_0000218,
10607,Intermediate,10116.0,,1,,,Tested for ratio in brain and plasma after 0.25 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,N,,,50597,1,,CHEMBL625200,BAO_0000218,
10608,Intermediate,10116.0,,1,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats,N,,,50597,1,,CHEMBL625201,BAO_0000218,
10609,Intermediate,10116.0,,1,,,Tested for ratio in brain and plasma after 2 hrs of intravenous administration (5 mg/kg) to male rats; ND = not determined,N,,,50597,1,,CHEMBL625202,BAO_0000218,
10610,Intermediate,10116.0,,1,,,Percentage recovery after 3h incubation with rat hapatocytes was determined,N,,,50597,1,,CHEMBL625203,BAO_0000218,
10611,Intermediate,10116.0,,1,,,Percentage recovery in rat hepatic microsomal fractions under oxidative conditions after 1 hour,N,,,50597,1,,CHEMBL625204,BAO_0000218,
10612,Intermediate,10116.0,,1,,,Percentage recovery in rhesus monkey hepatic microsomal fractions under oxidative conditions after 1 hour,N,,,50597,1,,CHEMBL625205,BAO_0000218,
10613,Intermediate,10116.0,,1,,,Recovery rate from urine and bile was determined after iv administration at 20 mg/kg in rats,N,,,50597,1,,CHEMBL625206,BAO_0000218,
10614,Autocuration,,,1,,,"Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured, No site available for protein conjugation.",U,,,22224,0,,CHEMBL625207,BAO_0000019,
10615,Autocuration,,,1,,,Fraction of 88Y (%) released from chelate after incubation in serum for 15 hours; not measured.,U,,,22224,0,,CHEMBL625208,BAO_0000019,
10616,Intermediate,9606.0,,1,,,In vivo absorption in Caco-2 cell line monolayers was determined,N,,495.0,50587,1,,CHEMBL625209,BAO_0000218,
10617,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625210,BAO_0000100,
10618,Intermediate,10116.0,,1,,,Area under curve was determine after peroral administration at 10 mpk in Rat,N,,,50597,1,,CHEMBL625211,BAO_0000218,
10619,Intermediate,9544.0,,1,,,Area under curve was determine after peroral administration at 10 mpk in Rhesus,N,,,50797,1,,CHEMBL625212,BAO_0000218,
10620,Intermediate,10116.0,,1,,,Area under curve was determine after peroral administration at 160 mpk in Rat,N,,,50597,1,,CHEMBL625213,BAO_0000218,
10621,Intermediate,10116.0,,1,,,Area under curve was determine after peroral administration at 20 mpk in Rat,N,,,50597,1,,CHEMBL625214,BAO_0000218,
10622,Intermediate,10116.0,,1,,,Area under curve was determine after peroral administration at 50 mpk in Rat,N,,,50597,1,,CHEMBL874542,BAO_0000218,
10623,Autocuration,,,1,,,Calculated partition coefficient (clogP) (AlogP),U,,,22229,0,,CHEMBL625215,BAO_0000100,
10624,Autocuration,,,1,,,Activated partial thromboplastin time measured,U,,,22224,0,,CHEMBL625216,BAO_0000019,
10625,Autocuration,,,1,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4),U,,,22224,0,,CHEMBL625217,BAO_0000100,
10626,Autocuration,,,1,,,Compound was evaluated for the aqueous solubility (AS) in mg/mL (Measured in 0.2 M phosphate buffer of pH 7.4); ND=Not determined (AS mg/mL),U,,,22224,0,,CHEMBL625218,BAO_0000100,
10627,Intermediate,9615.0,,1,1969.0,,AUC (Area under curve) was determined after intravenous administration at a dose 1 mg/kg in dog,N,,,50588,1,,CHEMBL622864,BAO_0000218,
10628,Intermediate,10116.0,,1,1969.0,,AUC (Area under curve) was determined after intravenous administration at a dose 2 mg/kg in rat.,N,,,50597,1,,CHEMBL622865,BAO_0000218,
10629,Intermediate,10116.0,,1,1969.0,,AUC (Area under curve) was determined after peroral administration at a dose 10 mg/kg in rat.,N,,,50597,1,,CHEMBL622866,BAO_0000218,
10630,Intermediate,9615.0,,1,1969.0,,AUC (Area under curve) was determined after peroral administration at a dose 5 mg/kg in dog,N,,,50588,1,,CHEMBL622867,BAO_0000218,
10631,Intermediate,10141.0,,1,1969.0,,AUC (ng h/mL) value after oral administration of 10 mg/kg in guinea pig.,N,,,50512,1,,CHEMBL876808,BAO_0000218,
10632,Autocuration,,,1,955.0,,AUC in brain,U,,,22224,0,,CHEMBL627725,BAO_0000019,
10633,Autocuration,,,1,1977.0,,AUC in serum,U,,,22224,0,,CHEMBL627726,BAO_0000019,
10634,Autocuration,,,1,1969.0,,AUC was determined,U,,,22224,0,,CHEMBL627727,BAO_0000019,
10635,Autocuration,,,1,1969.0,,AUC of the compound.,U,,,22224,0,,CHEMBL627728,BAO_0000019,
10636,Autocuration,,,1,1969.0,,AUC value (0-4 hr),U,,,22224,0,,CHEMBL627729,BAO_0000019,
10637,Autocuration,,,1,1969.0,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 150 uMol/kg,",U,,,22224,0,,CHEMBL627730,BAO_0000019,
10638,Autocuration,,,1,1969.0,,AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,U,,,22224,0,,CHEMBL627731,BAO_0000019,
10639,Autocuration,,,1,1969.0,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 300 uMol/kg,",U,,,22224,0,,CHEMBL627732,BAO_0000019,
10640,Autocuration,,,1,1969.0,,"AUC was measured from the graph plotted against blood plasma concentration and time at the dose of 700 uMol/kg,",U,,,22224,0,,CHEMBL627733,BAO_0000019,
10641,Intermediate,10116.0,,1,1969.0,,AUC(area under curve) was determined after intravenous administration in rats,N,,,50597,1,,CHEMBL627734,BAO_0000218,
10642,Intermediate,10116.0,,1,1969.0,,AUC(area under curve) was determined after oral administration in rats,N,,,50597,1,,CHEMBL627735,BAO_0000218,
10643,Intermediate,10141.0,,1,1969.0,,AUC(ng h/mL)values after oral administration of 10 mg/kg in guinea pig.,N,,,50512,1,,CHEMBL627736,BAO_0000218,
10644,Intermediate,10116.0,,1,1969.0,,AUC(ng h/mL)values after oral administration of 10 mg/kg in rat.,N,,,50597,1,,CHEMBL876809,BAO_0000218,
10645,Autocuration,,,1,,,Area Under Curve after oral dosing of 100 uM/Kg,U,,,22224,0,,CHEMBL627737,BAO_0000019,
10646,Autocuration,,,1,,,Area Under Curve after oral dosing of 30 uM/Kg,U,,,22224,0,,CHEMBL627738,BAO_0000019,
10647,Autocuration,,,1,,,Area Under Curve was measured by ploting the graph between concentration verses time,U,,,22224,0,,CHEMBL627739,BAO_0000019,
10648,Intermediate,9615.0,,1,,,Area under concentration-time curve of compound was determined in dog at 25 mg/kg orally,N,,,50588,1,,CHEMBL626143,BAO_0000218,
10649,Autocuration,314293.0,,1,,,Area under concentration-time curve of compound was determined in monkey at 25 mg/kg orally,U,,,22224,0,,CHEMBL626144,BAO_0000218,
10650,Intermediate,9986.0,,1,,,Area under concentration-time curve of compound was determined in rabbit at 25 mg/kg orally,N,,,50592,1,,CHEMBL626145,BAO_0000218,
10651,Intermediate,10116.0,,1,,,Area under concentration-time curve of compound was determined in rat at 25 mg/kg orally,N,,,50597,1,,CHEMBL626146,BAO_0000218,
10652,Intermediate,10116.0,,1,178.0,,Area under curve (AUC) is the drug concentrations in blood samples of rats with arterial catheters at 5 min and 12 hr plotted against time,N,,,50597,1,,CHEMBL626147,BAO_0000218,
10653,Autocuration,,,1,,,Area under curve (AUC) was determined,U,,,22224,0,,CHEMBL626148,BAO_0000019,
10654,Autocuration,,,1,,,Area under curve (AUC) following ip administration at 1 mg/kg,U,,,22224,0,,CHEMBL626149,BAO_0000218,
10655,Autocuration,,,1,,,Area under curve (AUC) was determined; ND is Not determined,U,,,22224,0,,CHEMBL626150,BAO_0000019,
10656,Intermediate,9615.0,,1,,,Area under curve (AUC) was determined in dogs fed after intravenous administration of 25 mg/kg of the compound,N,,,50588,1,,CHEMBL626151,BAO_0000218,
10657,Intermediate,9615.0,,1,,,Area under curve (AUC) was determined in dogs fed after oral administration of 25 mg/kg of the compound,N,,,50588,1,,CHEMBL626152,BAO_0000218,
10658,Intermediate,9615.0,,1,,,Area under curve (AUC) was determined in fasted dogs after oral administration of 25 mg/kg of the compound,N,,,50588,1,,CHEMBL626153,BAO_0000218,
10659,Autocuration,,,1,,,Area under curve (AUR) was determined,U,,,22224,0,,CHEMBL626154,BAO_0000019,
10660,Autocuration,,,1,,,Area under curve at 1 uM/dg administered intravenously,U,,,22224,0,,CHEMBL626155,BAO_0000019,
10661,Autocuration,,,1,,,Area under curve at 10 uM/dg administered perorally,U,,,22224,0,,CHEMBL626156,BAO_0000019,
10662,Autocuration,,,1,,,Area under curve at 2 uM/dg administered intravenously,U,,,22224,0,,CHEMBL626157,BAO_0000019,
10663,Autocuration,,,1,,,Area under curve at 20 uM/dg administered perorally,U,,,22224,0,,CHEMBL626158,BAO_0000019,
10664,Intermediate,9615.0,,1,,,Area under curve at a peroral dose of 3 mg/kg in dog,N,,,50588,1,,CHEMBL626159,BAO_0000218,
10665,Intermediate,10116.0,,1,,,Area under curve at a peroral dose of 3 mg/kg in rat,N,,,50597,1,,CHEMBL626160,BAO_0000218,
10666,Intermediate,9615.0,,1,,,Area under curve at an iv dose of 1 mg/kg in dog,N,,,50588,1,,CHEMBL626161,BAO_0000218,
10667,Intermediate,10116.0,,1,,,Area under curve at an iv dose of 1 mg/kg in rat,N,,,50597,1,,CHEMBL626162,BAO_0000218,
10668,Autocuration,,,1,,,Area under curve gives the effective duration for the angiotensin II antagonist effect of the compound.,U,,,22224,0,,CHEMBL626163,BAO_0000019,
10669,Autocuration,,,1,,,Area under curve gives the effective duration for the angiotensin II antagonist effect.,U,,,22224,0,,CHEMBL626164,BAO_0000019,
10670,Intermediate,10090.0,,1,,,Area under curve measured as conc vs time after intravenous administration to mice.,N,,,50594,1,,CHEMBL626165,BAO_0000218,
10671,Intermediate,10090.0,,1,,,Area under curve measured as conc vs time after peroral administration to mice.,N,,,50594,1,,CHEMBL626166,BAO_0000218,
10672,Intermediate,9615.0,,1,,,Area under curve of acid 2a was determined by HPLC at a dosage of 2.27 mg/kg administered intravenously by bolus method in dog,N,,,50588,1,,CHEMBL626167,BAO_0000218,
10673,Intermediate,9615.0,,1,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by capsule method in dog,N,,,50588,1,,CHEMBL626168,BAO_0000218,
10674,Intermediate,9615.0,,1,,,Area under curve of acid 2a was determined by HPLC at a dosage of 5.45 mg/kg administered intragastrically by gavage method in dog,N,,,50588,1,,CHEMBL877463,BAO_0000218,
10675,Intermediate,9615.0,,1,,,Area under curve of acid 2a was determined by HPLC at a dosage of 54.5 mg/kg administered intragastrically by capsule method in dog,N,,,50588,1,,CHEMBL626169,BAO_0000218,
10676,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of radiolabeled compound in rat heart after 24 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL626170,BAO_0000218,
10677,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of radiolabeled compound in rat heart after 2 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL626171,BAO_0000218,
10678,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of radiolabeled compound in rat heart after 30 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL626172,BAO_0000218,
10679,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of radiolabeled compound in rat heart after 5 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL626173,BAO_0000218,
10680,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of radiolabeled compound in rat kidney after 24 hr postinjection activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL626174,BAO_0000218,
10681,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of radiolabeled compound in rat kidney after 24 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL626175,BAO_0000218,
10682,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of radiolabeled compound in rat kidney after 2 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL626176,BAO_0000218,
10683,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of radiolabeled compound in rat kidney after 30 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL626177,BAO_0000218,
10684,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of radiolabeled compound in rat kidney after 5 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622499,BAO_0000218,
10685,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of radiolabeled compound in rat liver after 24 hr postinjection activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622500,BAO_0000218,
10686,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of radiolabeled compound in rat liver after 24 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622501,BAO_0000218,
10687,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of radiolabeled compound in rat liver after 2 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622502,BAO_0000218,
10688,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of radiolabeled compound in rat liver after 30 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL622503,BAO_0000218,
10689,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of radiolabeled compound in rat liver after 5 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL877614,BAO_0000218,
10690,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of radiolabeled compound in rat lung after 24 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL624839,BAO_0000218,
10691,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of radiolabeled compound in rat lung after 2 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL624840,BAO_0000218,
10692,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of radiolabeled compound in rat lung after 30 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL624841,BAO_0000218,
10693,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of radiolabeled compound in rat lung after 5 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL624842,BAO_0000218,
10694,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of radiolabeled compound in rat muscle after 24 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL624843,BAO_0000218,
10695,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of radiolabeled compound in rat muscle after 2 hr activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL624844,BAO_0000218,
10696,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of radiolabeled compound in rat muscle after 30 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL624845,BAO_0000218,
10697,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of radiolabeled compound in rat muscle after 5 min activity expressed as %ID/Organ,N,,,50597,1,,CHEMBL621904,BAO_0000218,
10698,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 15 mins after i.v. administration,N,,,50597,1,,CHEMBL621905,BAO_0000218,
10699,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 2 mins after i.v. administration,N,,,50597,1,,CHEMBL874382,BAO_0000218,
10700,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat blood 65 mins after i.v. administration,N,,,50597,1,,CHEMBL621906,BAO_0000218,
10701,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 15 mins after i.v. administration,N,,,50597,1,,CHEMBL621907,BAO_0000218,
10702,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 2 mins after i.v. administration,N,,,50597,1,,CHEMBL622096,BAO_0000218,
10703,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat brain 65 mins after i.v. administration,N,,,50597,1,,CHEMBL622097,BAO_0000218,
10704,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 15 mins after i.v. administration,N,,,50597,1,,CHEMBL622098,BAO_0000218,
10705,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 2 mins after i.v. administration,N,,,50597,1,,CHEMBL622099,BAO_0000218,
10706,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat heart 65 mins after i.v. administration,N,,,50597,1,,CHEMBL622100,BAO_0000218,
10707,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 15 mins after i.v. administration,N,,,50597,1,,CHEMBL622101,BAO_0000218,
10708,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 2 mins after i.v. administration,N,,,50597,1,,CHEMBL622102,BAO_0000218,
10709,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat kidney 65 mins after i.v. administration,N,,,50597,1,,CHEMBL622103,BAO_0000218,
10710,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 15 mins after i.v. administration,N,,,50597,1,,CHEMBL622104,BAO_0000218,
10711,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 2 mins after i.v. administration,N,,,50597,1,,CHEMBL622105,BAO_0000218,
10712,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat liver 65 mins after i.v. administration,N,,,50597,1,,CHEMBL622106,BAO_0000218,
10713,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 15 mins after i.v. administration,N,,,50597,1,,CHEMBL622107,BAO_0000218,
10714,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 2 mins after i.v. administration,N,,,50597,1,,CHEMBL622108,BAO_0000218,
10715,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat lung 65 mins after i.v. administration,N,,,50597,1,,CHEMBL622109,BAO_0000218,
10716,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 15 mins after i.v. administration,N,,,50597,1,,CHEMBL622110,BAO_0000218,
10717,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 2 mins after i.v. administration,N,,,50597,1,,CHEMBL622111,BAO_0000218,
10718,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat muscle 65 mins after i.v. administration,N,,,50597,1,,CHEMBL874383,BAO_0000218,
10719,Intermediate,10116.0,In vivo,1,14.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 15 mins after i.v. administration,N,,,50597,1,,CHEMBL622112,BAO_0000218,
10720,Intermediate,10116.0,In vivo,1,14.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 2 mins after i.v. administration,N,,,50597,1,,CHEMBL622113,BAO_0000218,
10721,Intermediate,10116.0,In vivo,1,14.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat skin 65 mins after i.v. administration,N,,,50597,1,,CHEMBL622114,BAO_0000218,
10722,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 15 mins after i.v. administration,N,,,50597,1,,CHEMBL622115,BAO_0000218,
10723,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of the radiolabeled compound (2-5 uCi) in rat spleen 2 mins after i.v. administration,N,,,50597,1,,CHEMBL622116,BAO_0000218,
10724,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622117,BAO_0000218,
10725,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622118,BAO_0000218,
10726,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rats at 6 mg/kg,N,,,50597,1,,CHEMBL622119,BAO_0000218,
10727,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 6 mg/kg),N,,,50597,1,,CHEMBL622120,BAO_0000218,
10728,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rats at 6 mg/kg dose; Not tested,N,,,50597,1,,CHEMBL622121,BAO_0000218,
10729,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622122,BAO_0000218,
10730,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622123,BAO_0000218,
10731,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL622124,BAO_0000218,
10732,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL622125,BAO_0000218,
10733,Intermediate,10116.0,In vivo,1,,,Oral bioavailability,N,,,50597,1,,CHEMBL622126,BAO_0000218,
10734,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),N,,,50597,1,,CHEMBL620455,BAO_0000218,
10735,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL620456,BAO_0000218,
10736,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL620457,BAO_0000218,
10737,Intermediate,10116.0,In vivo,1,,,Oral bioavailability was evaluated; Not tested,N,,,50597,1,,CHEMBL620458,BAO_0000218,
10738,Intermediate,10116.0,In vivo,1,,,Oral bioavailability,N,,,50597,1,,CHEMBL620459,BAO_0000218,
10739,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat by oral dosing,N,,,50597,1,,CHEMBL620460,BAO_0000218,
10740,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 10 mg/kg p.o.),N,,,50597,1,,CHEMBL620461,BAO_0000218,
10741,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley),N,,,50597,1,,CHEMBL620462,BAO_0000218,
10742,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),N,,,50597,1,,CHEMBL620463,BAO_0000218,
10743,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 1 mg/kg i.v.),N,,,50597,1,,CHEMBL620464,BAO_0000218,
10744,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg),N,,,50597,1,,CHEMBL620465,BAO_0000218,
10745,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (dose 2 mg/kg p.o.),N,,,50597,1,,CHEMBL620466,BAO_0000218,
10746,Intermediate,10116.0,In vivo,1,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 1 mg/kg,N,,,50597,1,,CHEMBL620467,BAO_0000218,
10747,Intermediate,10116.0,In vivo,1,,,Oral bioavailability was calculated in Spragun Dawley rat at oral dosage of 2 mg/kg,N,,,50597,1,,CHEMBL620468,BAO_0000218,
10748,Intermediate,10116.0,In vivo,1,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in solution form,N,,,50597,1,,CHEMBL620469,BAO_0000218,
10749,Intermediate,10116.0,In vivo,1,,,Oral bioavailability was calculated in rats using an average of the intravenous AUC at peroral dose of 5 mgkg in suspension form,N,,,50597,1,,CHEMBL620470,BAO_0000218,
10750,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL620471,BAO_0000218,
10751,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL620472,BAO_0000218,
10752,Intermediate,10116.0,In vivo,1,,,Oral bioavailability of compound at 5 mg/kg after po administration was determined in rat,N,,,50597,1,,CHEMBL620473,BAO_0000218,
10753,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL620474,BAO_0000218,
10754,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (fasted male) (dose 10 mg/kg),N,,,50597,1,,CHEMBL620475,BAO_0000218,
10755,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL620476,BAO_0000218,
10756,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL620477,BAO_0000218,
10757,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat after oral administration at 10.5 mg/kg dose,N,,,50597,1,,CHEMBL620478,BAO_0000218,
10758,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat after oral administration at 11.2 mg/kg dose,N,,,50597,1,,CHEMBL618768,BAO_0000218,
10759,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat after oral administration at 13 mg/kg dose,N,,,50597,1,,CHEMBL618769,BAO_0000218,
10760,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat after oral administration at 9.7 mg/kg dose,N,,,50597,1,,CHEMBL618770,BAO_0000218,
10761,Intermediate,10116.0,In vivo,1,,,Oral bioavailability (dose 20 mg/kg p.o.),N,,,50597,1,,CHEMBL618771,BAO_0000218,
10762,Intermediate,10116.0,In vivo,1,,,Oral bioavailability was determined in rat after oral administration at a concentration 1 mg/kg,N,,,50597,1,,CHEMBL618772,BAO_0000218,
10763,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat at 10 mg/kg of the compound,N,,,50597,1,,CHEMBL618773,BAO_0000218,
10764,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat at a concentration of 15 mg/kg perorally in rat along with 100 mg/kg 11,N,,,50597,1,,CHEMBL875842,BAO_0000218,
10765,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 3 mg/kg i.v.),N,,,50597,1,,CHEMBL618774,BAO_0000218,
10766,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat at a concentration of 60 mg/kg perorally in rat along with 100 mg/kg 11,N,,,50597,1,,CHEMBL618775,BAO_0000218,
10767,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 60 mg/kg p.o.),N,,,50597,1,,CHEMBL618776,BAO_0000218,
10768,Intermediate,10116.0,In vivo,1,,,Percent bioavailability (F) in rats after iv administration,N,,,50597,1,,CHEMBL618777,BAO_0000218,
10769,Intermediate,10116.0,In vivo,1,,,Percent bioavailability (F) in rats after oral dose of 10 mg/kg,N,,,50597,1,,CHEMBL618778,BAO_0000218,
10770,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 5 uM/kg p.o.),N,,,50597,1,,CHEMBL618779,BAO_0000218,
10771,Intermediate,10116.0,In vivo,1,,,Oral bioavailability,N,,,50597,1,,CHEMBL618780,BAO_0000218,
10772,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat (dose 2 mg/kg p.o.),N,,,50597,1,,CHEMBL618781,BAO_0000218,
10773,Intermediate,10116.0,In vivo,1,,,Percent bioavailability at the dose of 5 mg/Kg administered perorally in rats,N,,,50597,1,,CHEMBL618782,BAO_0000218,
10774,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 20 mg/kg),N,,,50597,1,,CHEMBL618783,BAO_0000218,
10775,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL618784,BAO_0000218,
10776,Intermediate,10116.0,In vivo,1,,,Percent oral bioavailability evaluated in rat,N,,,50597,1,,CHEMBL618785,BAO_0000218,
10777,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL618786,BAO_0000218,
10778,Intermediate,10116.0,In vivo,1,,,Percent oral bioavailability in rat; Not determined,N,,,50597,1,,CHEMBL618787,BAO_0000218,
10779,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat,N,,,50597,1,,CHEMBL618788,BAO_0000218,
10780,Intermediate,10116.0,In vivo,1,,,Bioavailability in rat,N,,,50597,1,,CHEMBL618789,BAO_0000218,
10781,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a solution),N,,,50597,1,,CHEMBL618790,BAO_0000218,
10782,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (oral bioavailability) in rat (dose given as a suspension),N,,,50597,1,,CHEMBL618791,BAO_0000218,
10783,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic property (F) was measured in rat at the dose of 0.32 mg/kg,N,,,50597,1,,CHEMBL875843,BAO_0000218,
10784,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 20 mg/kg p.o.),N,,,50597,1,,CHEMBL618792,BAO_0000218,
10785,Intermediate,10116.0,In vivo,1,,,Cmax at a dose of 30 mg/kg in rat,N,,,50597,1,,CHEMBL623395,BAO_0000218,
10786,Autocuration,314293.0,In vivo,1,,,Cmax in monkeys at a dose of 1 mg/kg,U,,,22224,0,,CHEMBL623396,BAO_0000218,
10787,Intermediate,10116.0,In vivo,1,,,Cmax in rat,N,,,50597,1,,CHEMBL623397,BAO_0000218,
10788,Intermediate,10116.0,In vivo,1,,,Cmax in rats at a dose of 1 mg/kg,N,,,50597,1,,CHEMBL623398,BAO_0000218,
10789,Intermediate,10090.0,In vivo,1,,,Cmax was measured in mice after an oral dose of 50 mg/kg.,N,,,50594,1,,CHEMBL623399,BAO_0000218,
10790,Autocuration,,In vivo,1,,,"Cmax value at a dose of 12.7 uM/kg, po",U,,,22224,0,,CHEMBL623400,BAO_0000218,
10791,Autocuration,,In vivo,1,,,"Cmax value at a dose of 6.3 uM/kg, iv",U,,,22224,0,,CHEMBL623401,BAO_0000218,
10792,Autocuration,,In vivo,1,,,"Cmax value at a dose of 7.1 uM/kg, iv",U,,,22224,0,,CHEMBL623402,BAO_0000218,
10793,Autocuration,,In vivo,1,,,Cmax value of compound was determined after 1 hr,U,,,22224,0,,CHEMBL623403,BAO_0000218,
10794,Autocuration,,In vivo,1,,,Cmax value of the compound,U,,,22224,0,,CHEMBL623404,BAO_0000218,
10795,Intermediate,10116.0,In vivo,1,,,Cmax value administered intraintestinal in rats.,N,,,50597,1,,CHEMBL625997,BAO_0000218,
10796,Intermediate,10116.0,In vivo,1,,,Cmax value administered perorally was determined in rat; Not determined,N,,,50597,1,,CHEMBL625998,BAO_0000218,
10797,Autocuration,,In vivo,1,,,Cmax value at the dose of 2.3 mg/kg,U,,,22224,0,,CHEMBL625999,BAO_0000218,
10798,Autocuration,,In vivo,1,,,Cmax value at the dose of 5 mg/kg,U,,,22224,0,,CHEMBL626000,BAO_0000218,
10799,Autocuration,,In vivo,1,,,Cmax value in the period of 8 hr after dosing. ,U,,,22224,0,,CHEMBL626001,BAO_0000218,
10800,Autocuration,,In vivo,1,,,Cmax value at a oral dose of 20 mg/kg; Not tested,U,,,22224,0,,CHEMBL626002,BAO_0000218,
10801,Autocuration,,In vivo,1,,,Cmax value at a oral dose of 20 mg/kg,U,,,22224,0,,CHEMBL626003,BAO_0000218,
10802,Intermediate,10116.0,In vivo,1,,,Cmax value was determined between 15 and 30 minutes post administration in fisher rats; value ranges from 200-500,N,,,50597,1,,CHEMBL626004,BAO_0000218,
10803,Intermediate,10141.0,In vivo,1,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in guinea pig.,N,,,50512,1,,CHEMBL626005,BAO_0000218,
10804,Intermediate,10116.0,In vivo,1,,,Cmax(ng /mL)values after oral administration of 10 mg/kg in rat.,N,,,50597,1,,CHEMBL626006,BAO_0000218,
10805,Intermediate,10116.0,In vivo,1,1969.0,,Compound at a dose of 10 mg/kg was orally administered to rats and maximum plasma concentration was reported,N,,,50597,1,,CHEMBL626007,BAO_0000218,
10806,Intermediate,10090.0,In vivo,1,1969.0,,Compound was evaluated for maximum plasma concentration by administering orally at 25 mg/kg in mice,N,,,50594,1,,CHEMBL626008,BAO_0000218,
10807,Intermediate,9615.0,In vivo,1,2107.0,,Compound was evaluated for maximum plasma concentration levels in dogs for the orally delivered compound in 0.05 M citric acid,N,,,50588,1,,CHEMBL626009,BAO_0000218,
10808,Intermediate,9615.0,In vivo,1,,,Compound was evaluated in vivo for its concentration after a peroral administration 40 mg/kg in dogs.,N,,,50588,1,,CHEMBL626010,BAO_0000218,
10809,Intermediate,10090.0,In vivo,1,178.0,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a intramuscular administration 40 mg/kg in mice,N,,,50594,1,,CHEMBL626011,BAO_0000218,
10810,Intermediate,10090.0,In vivo,1,178.0,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration 40 mg/kg in mice,N,,,50594,1,,CHEMBL626012,BAO_0000218,
10811,Intermediate,10090.0,In vivo,1,178.0,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after a peroral administration of 40 mg/kg in mice,N,,,50594,1,,CHEMBL626013,BAO_0000218,
10812,Intermediate,10090.0,In vivo,1,178.0,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice,N,,,50594,1,,CHEMBL626014,BAO_0000218,
10813,Intermediate,10090.0,In vivo,1,178.0,,Compound was evaluated in vivo in blood samples from the orbital sinus for its concentration after an intramuscular administration of 40 mg/kg in mice.,N,,,50594,1,,CHEMBL877496,BAO_0000218,
10814,Intermediate,9615.0,In vivo,1,,,Compound was tested Growth Hormone(GH) release after 0.5 mg/kg administration (Po) in Beagle dogs,N,,,50588,1,,CHEMBL626015,BAO_0000218,
10815,Intermediate,9615.0,In vivo,1,,,Compound was tested Growth Hormone(GH) release after 10 mg/kg administration (Po) in Beagle dogs,N,,,50588,1,,CHEMBL626016,BAO_0000218,
10816,Intermediate,9615.0,In vivo,1,,,Compound was tested Growth Hormone(GH) release after 2.5 mg/kg administration (Po) in Beagle dogs,N,,,50588,1,,CHEMBL626017,BAO_0000218,
10817,Intermediate,9615.0,In vivo,1,1969.0,,Bioavailability as maximal plasma concentration in dogs,N,,,50588,1,,CHEMBL626018,BAO_0000218,
10818,Intermediate,9615.0,In vivo,1,1969.0,,Bioavailability as maximal plasma concentration in dogs,N,,,50588,1,,CHEMBL626692,BAO_0000218,
10819,Intermediate,10116.0,In vivo,1,1969.0,,Bioavailability as maximal plasma concentration in rats,N,,,50597,1,,CHEMBL626693,BAO_0000218,
10820,Autocuration,10116.0,In vivo,1,1969.0,,Bioavailability as maximal plasma concentration in rats,U,,,22224,0,,CHEMBL626694,BAO_0000218,
10821,Intermediate,9615.0,In vivo,1,178.0,,Compound was tested for maximum blood concentration after 0.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,N,,,50588,1,,CHEMBL626695,BAO_0000218,
10822,Intermediate,9615.0,In vivo,1,178.0,,Compound was tested for maximum blood concentration after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,N,,,50588,1,,CHEMBL626696,BAO_0000218,
10823,Intermediate,9615.0,In vivo,1,178.0,,Compound was tested for maximum blood concentration after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,N,,,50588,1,,CHEMBL626697,BAO_0000218,
10824,Intermediate,9615.0,In vivo,1,178.0,,Compound was tested for maximum concentration in blood after 0.5 mg/kg administration (Po) in Beagle dogs; nd = Not Detectable,N,,,50588,1,,CHEMBL626859,BAO_0000218,
10825,Intermediate,9615.0,In vivo,1,178.0,,Compound was tested for maximum concentration in blood after 10 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,N,,,50588,1,,CHEMBL626860,BAO_0000218,
10826,Intermediate,9615.0,In vivo,1,178.0,,Compound was tested for maximum concentration in blood after 2.5 mg/kg administration (Po) in Beagle dogs; nM/L maximum blood concentration,N,,,50588,1,,CHEMBL626861,BAO_0000218,
10827,Intermediate,10116.0,In vivo,1,,,Compound was tested for maximum observed concentration in three male Wistar rats at a single 5 mg/kg oral gavage dose,N,,,50597,1,,CHEMBL626296,BAO_0000218,
10828,Autocuration,,In vivo,1,,,Compound was tested for the max. conc. when administered perorally(po) 30 mg/kg,U,,,22224,0,,CHEMBL626297,BAO_0000218,
10829,Autocuration,,In vivo,1,1969.0,,Compound was tested for the max. plasma conc. when administered intraperitoneally (ip) 30 mg/kg.,U,,,22224,0,,CHEMBL626298,BAO_0000218,
10830,Intermediate,10116.0,In vivo,1,1969.0,,"Drug plasma level in rat was determined on the last day of dosing at 1,2,4.8 and 24 hr and ED50 was evaluated",N,,,50597,1,,CHEMBL626299,BAO_0000218,
10831,Intermediate,10116.0,In vivo,1,1969.0,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats after 30 min.,N,,,50597,1,,CHEMBL626300,BAO_0000218,
10832,Intermediate,10116.0,In vivo,1,1969.0,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats after 30 min.,N,,,50597,1,,CHEMBL626301,BAO_0000218,
10833,Intermediate,10116.0,In vivo,1,1969.0,,Effect of ip administration of compound on plasma concentration of corticosterone (CTS) in rats after 30 min.,N,,,50597,1,,CHEMBL626962,BAO_0000218,
10834,Intermediate,10116.0,In vivo,1,1969.0,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats after 30 min.,N,,,50597,1,,CHEMBL626963,BAO_0000218,
10835,Intermediate,10116.0,In vivo,1,1969.0,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats after 30 min.,N,,,50597,1,,CHEMBL626964,BAO_0000218,
10836,Intermediate,9541.0,In vivo,1,1969.0,,In vivo antitumor efficacy expressed as maximum plasma concentration 0.4 hr after a peroral dose of 25 mg/kg in cynomolgus monkeys,N,,,100710,1,,CHEMBL626965,BAO_0000218,
10837,Intermediate,10090.0,In vivo,1,1969.0,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,,,50594,1,,CHEMBL626966,BAO_0000218,
10838,Intermediate,10090.0,In vivo,1,1969.0,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,,,50594,1,,CHEMBL626967,BAO_0000218,
10839,Intermediate,9541.0,In vivo,1,1969.0,,In vivo antitumor efficacy expressed as maximum plasma concentration after a peroral dose of 10 mg/kg in cynomolgus monkeys,N,,,100710,1,,CHEMBL626968,BAO_0000218,
10840,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.89-1.24,N,,,50597,1,,CHEMBL626969,BAO_0000218,
10841,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-2.58,N,,,50597,1,,CHEMBL627126,BAO_0000218,
10842,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.24-0.28,N,,,50597,1,,CHEMBL631276,BAO_0000218,
10843,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.52-0.62,N,,,50597,1,,CHEMBL631277,BAO_0000218,
10844,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.68-0.84,N,,,50597,1,,CHEMBL631278,BAO_0000218,
10845,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.75-1.03,N,,,50597,1,,CHEMBL874457,BAO_0000218,
10846,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.96-2.46,N,,,50597,1,,CHEMBL631279,BAO_0000218,
10847,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.36-0.42,N,,,50597,1,,CHEMBL631280,BAO_0000218,
10848,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.82,N,,,50597,1,,CHEMBL631281,BAO_0000218,
10849,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.24-1.46,N,,,50597,1,,CHEMBL631968,BAO_0000218,
10850,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.36-3.96,N,,,50597,1,,CHEMBL631969,BAO_0000218,
10851,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.24-0.29,N,,,50597,1,,CHEMBL631970,BAO_0000218,
10852,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.39-0.74,N,,,50597,1,,CHEMBL631971,BAO_0000218,
10853,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.79-0.85,N,,,50597,1,,CHEMBL631972,BAO_0000218,
10854,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.64-0.86,N,,,50597,1,,CHEMBL630435,BAO_0000218,
10855,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.68-2.23,N,,,50597,1,,CHEMBL630436,BAO_0000218,
10856,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.19-0.23,N,,,50597,1,,CHEMBL630437,BAO_0000218,
10857,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.22-0.29,N,,,50597,1,,CHEMBL630438,BAO_0000218,
10858,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity in heart tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.75,N,,,50597,1,,CHEMBL630439,BAO_0000218,
10859,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.42-1.82,N,,,50597,1,,CHEMBL630440,BAO_0000218,
10860,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.24-3.12,N,,,50597,1,,CHEMBL630441,BAO_0000218,
10861,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.62-0.92,N,,,50597,1,,CHEMBL630442,BAO_0000218,
10862,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.12-2.04,N,,,50597,1,,CHEMBL625234,BAO_0000218,
10863,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.59-2.03,N,,,50597,1,,CHEMBL625235,BAO_0000218,
10864,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.14-1.4,N,,,50597,1,,CHEMBL625236,BAO_0000218,
10865,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.56-1.83,N,,,50597,1,,CHEMBL625237,BAO_0000218,
10866,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.58-0.73,N,,,50597,1,,CHEMBL626125,BAO_0000218,
10867,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.67-2.11,N,,,50597,1,,CHEMBL626126,BAO_0000218,
10868,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.64-3.43,N,,,50597,1,,CHEMBL626127,BAO_0000218,
10869,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.18-4.74,N,,,50597,1,,CHEMBL626128,BAO_0000218,
10870,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.62-1.13,N,,,50597,1,,CHEMBL626129,BAO_0000218,
10871,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.73-2.64,N,,,50597,1,,CHEMBL626130,BAO_0000218,
10872,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 13.02-19.07,N,,,50597,1,,CHEMBL626131,BAO_0000218,
10873,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.89-1.19,N,,,50597,1,,CHEMBL626132,BAO_0000218,
10874,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.17-1.48,N,,,50597,1,,CHEMBL626752,BAO_0000218,
10875,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.48-0.72,N,,,50597,1,,CHEMBL626753,BAO_0000218,
10876,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.57,N,,,50597,1,,CHEMBL626754,BAO_0000218,
10877,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity in kidney tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.99-1.24,N,,,50597,1,,CHEMBL626755,BAO_0000218,
10878,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.23-1.78,N,,,50597,1,,CHEMBL626756,BAO_0000218,
10879,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 2.43-2.92,N,,,50597,1,,CHEMBL626757,BAO_0000218,
10880,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.81-1.18,N,,,50597,1,,CHEMBL626758,BAO_0000218,
10881,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 1.37-1.74,N,,,50597,1,,CHEMBL626759,BAO_0000218,
10882,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 4.01-4.81,N,,,50597,1,,CHEMBL626760,BAO_0000218,
10883,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL626394,BAO_0000218,
10884,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration,N,,,50588,1,,CHEMBL626395,BAO_0000218,
10885,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration (0-6 hr),N,,,50588,1,,CHEMBL626396,BAO_0000218,
10886,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),N,,,50588,1,,CHEMBL626397,BAO_0000218,
10887,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),N,,,50588,1,,CHEMBL626398,BAO_0000218,
10888,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL626399,BAO_0000218,
10889,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration,N,,,50597,1,,CHEMBL874653,BAO_0000218,
10890,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL626400,BAO_0000218,
10891,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),N,,,50597,1,,CHEMBL626401,BAO_0000218,
10892,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),N,,,50597,1,,CHEMBL626402,BAO_0000218,
10893,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),N,,,50597,1,,CHEMBL626403,BAO_0000218,
10894,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL626404,BAO_0000218,
10895,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration,N,,,50597,1,,CHEMBL626405,BAO_0000218,
10896,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL625529,BAO_0000218,
10897,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),N,,,50597,1,,CHEMBL625530,BAO_0000218,
10898,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),N,,,50597,1,,CHEMBL625531,BAO_0000218,
10899,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),N,,,50597,1,,CHEMBL625532,BAO_0000218,
10900,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL625533,BAO_0000218,
10901,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration,N,,,50597,1,,CHEMBL875474,BAO_0000218,
10902,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL625534,BAO_0000218,
10903,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),N,,,50597,1,,CHEMBL625535,BAO_0000218,
10904,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),N,,,50597,1,,CHEMBL625536,BAO_0000218,
10905,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),N,,,50597,1,,CHEMBL625537,BAO_0000218,
10906,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL625538,BAO_0000218,
10907,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration,N,,,50597,1,,CHEMBL625539,BAO_0000218,
10908,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL625540,BAO_0000218,
10909,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),N,,,50597,1,,CHEMBL625541,BAO_0000218,
10910,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),N,,,50597,1,,CHEMBL625542,BAO_0000218,
10911,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),N,,,50597,1,,CHEMBL625543,BAO_0000218,
10912,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL625544,BAO_0000218,
10913,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.312 mg/kg after ip administration,N,,,50588,1,,CHEMBL625545,BAO_0000218,
10914,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),N,,,50588,1,,CHEMBL625546,BAO_0000218,
10915,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.625 mg/kg after ip administration,N,,,50588,1,,CHEMBL625547,BAO_0000218,
10916,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL625548,BAO_0000218,
10917,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL625549,BAO_0000218,
10918,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),N,,,50588,1,,CHEMBL625550,BAO_0000218,
10919,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL625551,BAO_0000218,
10920,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL875475,BAO_0000218,
10921,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL625552,BAO_0000218,
10922,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),N,,,50588,1,,CHEMBL625553,BAO_0000218,
10923,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),N,,,50588,1,,CHEMBL625554,BAO_0000218,
10924,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),N,,,50588,1,,CHEMBL625555,BAO_0000218,
10925,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL625556,BAO_0000218,
10926,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration,N,,,50588,1,,CHEMBL624986,BAO_0000218,
10927,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),N,,,50588,1,,CHEMBL624987,BAO_0000218,
10928,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),N,,,50588,1,,CHEMBL624988,BAO_0000218,
10929,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -2/-14,N,,,50588,1,,CHEMBL624989,BAO_0000218,
10930,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; -4/-4,N,,,50588,1,,CHEMBL624990,BAO_0000218,
10931,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3 range; 4/7,N,,,50588,1,,CHEMBL874391,BAO_0000218,
10932,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 1/3/10 range; -3/0/4,N,,,50588,1,,CHEMBL624991,BAO_0000218,
10933,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; -6/0,N,,,50588,1,,CHEMBL624992,BAO_0000218,
10934,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 10/31,N,,,50588,1,,CHEMBL624993,BAO_0000218,
10935,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 11/-19,N,,,50588,1,,CHEMBL624994,BAO_0000218,
10936,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 14/6,N,,,50588,1,,CHEMBL624995,BAO_0000218,
10937,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/25,N,,,50588,1,,CHEMBL624996,BAO_0000218,
10938,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 19/3,N,,,50588,1,,CHEMBL624997,BAO_0000218,
10939,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 2/16,N,,,50588,1,,CHEMBL624998,BAO_0000218,
10940,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 6/2,N,,,50588,1,,CHEMBL624999,BAO_0000218,
10941,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 7/26,N,,,50588,1,,CHEMBL882955,BAO_0000218,
10942,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/49,N,,,50588,1,,CHEMBL625000,BAO_0000218,
10943,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 8/8,N,,,50588,1,,CHEMBL625001,BAO_0000218,
10944,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/30 range; 9/-18,N,,,50588,1,,CHEMBL625089,BAO_0000218,
10945,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 10/60 range; 13/23,N,,,50588,1,,CHEMBL625090,BAO_0000218,
10946,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3 range,N,,,50588,1,,CHEMBL625091,BAO_0000218,
10947,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a dose of 3/10 range; -7/-11,N,,,50588,1,,CHEMBL625092,BAO_0000218,
10948,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 1/3 dose range; 6/-7,N,,,50588,1,,CHEMBL625093,BAO_0000218,
10949,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 10/30 dose range; -13/19,N,,,50588,1,,CHEMBL625094,BAO_0000218,
10950,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a of 3/10 dose range; 30/47,N,,,50588,1,,CHEMBL625095,BAO_0000218,
10951,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for its bioavailability in the dogs,N,,,50588,1,,CHEMBL625096,BAO_0000218,
10952,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for its bioavailability in the rats,N,,,50597,1,,CHEMBL625097,BAO_0000218,
10953,Autocuration,,In vivo,1,,,Compound was evaluated for oral bioavailability,U,,,22224,0,,CHEMBL882956,BAO_0000218,
10954,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for percentage of Oral bioavailability in rats,N,,,50597,1,,CHEMBL625098,BAO_0000218,
10955,Autocuration,10141.0,In vivo,1,,,Bioavailability in guinea pig,U,,,22224,0,,CHEMBL625099,BAO_0000218,
10956,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for the oral bioavailability in rat,N,,,50597,1,,CHEMBL625100,BAO_0000218,
10957,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for the oral bioavailability in dog,N,,,50588,1,,CHEMBL625101,BAO_0000218,
10958,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for the oral bioavailability in rat,N,,,50597,1,,CHEMBL874396,BAO_0000218,
10959,Autocuration,9615.0,In vivo,1,,,Bioavailability in dog (dosed i.v.),U,,,22224,0,,CHEMBL625102,BAO_0000218,
10960,Intermediate,9615.0,In vivo,1,,,Compound was tested for in vivo bioavailability in dog,N,,,50588,1,,CHEMBL625103,BAO_0000218,
10961,Intermediate,10026.0,In vivo,1,,,Compound was tested for in vivo bioavailability in hamsters,N,,,100712,1,,CHEMBL625104,BAO_0000218,
10962,Autocuration,314293.0,In vivo,1,,,Compound was tested for in vivo bioavailability in monkey,U,,,22224,0,,CHEMBL625105,BAO_0000218,
10963,Intermediate,10116.0,In vivo,1,,,Compound was tested for in vivo bioavailability in rat,N,,,50597,1,,CHEMBL625106,BAO_0000218,
10964,Autocuration,10090.0,In vivo,1,,,Oral bioavailability in mouse,U,,,22224,0,,CHEMBL625107,BAO_0000218,
10965,Intermediate,10090.0,In vivo,1,,,Compound was tested for percent of oral bioavailability in mice; 56-74,N,,,50594,1,,CHEMBL625108,BAO_0000218,
10966,Autocuration,10090.0,In vivo,1,,,Oral bioavailability in mouse (nude) (dose of 25 mg/kg),U,,,22224,0,,CHEMBL625109,BAO_0000218,
10967,Autocuration,9541.0,In vivo,1,,,Bioavailability in cynomolgus monkey (dose 25 mg/kg i.v.),U,,,22224,0,,CHEMBL625110,BAO_0000218,
10968,Autocuration,9541.0,In vivo,1,,,Bioavailability in cynomolgus monkey (dose 5 mg/kg i.v.),U,,,22224,0,,CHEMBL625111,BAO_0000218,
10969,Intermediate,10090.0,In vivo,1,,,Oral bioavailability in mouse (nude) (dose 25 mg/kg i.v.),N,,,50594,1,,CHEMBL625112,BAO_0000218,
10970,Intermediate,10090.0,In vivo,1,,,Oral bioavailability in nude mice,N,,,50594,1,,CHEMBL875334,BAO_0000218,
10971,Autocuration,9443.0,In vivo,1,,,Bioavailability in monkey (i.d. dosing),U,,,22224,0,,CHEMBL628617,BAO_0000218,
10972,Autocuration,10116.0,In vivo,1,,,Bioavailability in rat,U,,,22224,0,,CHEMBL628618,BAO_0000218,
10973,Autocuration,,In vivo,1,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 10%,U,,,22224,0,,CHEMBL628619,BAO_0000218,
10974,Autocuration,,In vivo,1,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 20%,U,,,22224,0,,CHEMBL628620,BAO_0000218,
10975,Intermediate,9541.0,In vivo,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 10 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",N,,,100710,1,,CHEMBL628621,BAO_0000218,
10976,Intermediate,9541.0,In vivo,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 25 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",N,,,100710,1,,CHEMBL628622,BAO_0000218,
10977,Intermediate,9541.0,In vivo,1,,,"In vivo antitumor efficacy in cynomolgus monkeys by injecting a dose of 5 mg/kg, as HCl salt in saline solution, perorally and the maximum drug concentration was determined",N,,,100710,1,,CHEMBL628623,BAO_0000218,
10978,Intermediate,9541.0,In vivo,1,1969.0,,Maximal plasma concentration in cynomolgus monkeys after 10 mg/kg oral dose,N,,,100710,1,,CHEMBL628624,BAO_0000218,
10979,Intermediate,10090.0,In vivo,1,1969.0,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,,,50594,1,,CHEMBL628625,BAO_0000218,
10980,Intermediate,9541.0,In vivo,1,1969.0,,Maximal plasma concentration in cynomolgus monkeys after 5 mg/kg oral dose,N,,,100710,1,,CHEMBL628626,BAO_0000218,
10981,Intermediate,10090.0,In vivo,1,1969.0,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,,,50594,1,,CHEMBL627041,BAO_0000218,
10982,Intermediate,10090.0,In vivo,1,1969.0,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,,,50594,1,,CHEMBL627042,BAO_0000218,
10983,Intermediate,10090.0,In vivo,1,1969.0,,Maximal plasma concentration in nude mice after 25 mg/kg oral dose,N,,,50594,1,,CHEMBL627043,BAO_0000218,
10984,Autocuration,,In vivo,1,1969.0,,In vivo evaluation of maximum plasma concentration at a dose of 10 mg/kg,U,,,22224,0,,CHEMBL627044,BAO_0000218,
10985,Intermediate,10090.0,In vivo,1,1969.0,,Cmax in mouse plasma,N,,,50594,1,,CHEMBL627045,BAO_0000218,
10986,Autocuration,,In vivo,1,1969.0,,Max plasma concentration was measured by 40 mg/kg dose of peroral administration.,U,,,22224,0,,CHEMBL627046,BAO_0000218,
10987,Intermediate,10116.0,In vivo,1,1969.0,,Maximal plasma concentration in rat,N,,,50597,1,,CHEMBL627047,BAO_0000218,
10988,Intermediate,10116.0,In vivo,1,1969.0,,Maximal plasma level when administered 1 mg/kg perorally (po) in rat,N,,,50597,1,,CHEMBL627048,BAO_0000218,
10989,Intermediate,10116.0,In vivo,1,,,Maximum concentration at an intraduodenal dose of 5.2 mg/kg in rat,N,,,50597,1,,CHEMBL627049,BAO_0000218,
10990,Intermediate,10116.0,In vivo,1,,,Maximum concentration at an intraduodenal dose of 6.6 mg/kg in rat,N,,,50597,1,,CHEMBL627050,BAO_0000218,
10991,Intermediate,10116.0,In vivo,1,,,Maximum concentration at an intravenous dose of 5.5 mg/kg in rat,N,,,50597,1,,CHEMBL627051,BAO_0000218,
10992,Intermediate,10116.0,In vivo,1,,,Maximum concentration at an intravenous dose of 6.5 mg/kg in rat,N,,,50597,1,,CHEMBL627052,BAO_0000218,
10993,Intermediate,10116.0,In vivo,1,,,Maximum concentration at an peroral dose of 6.2 mg/kg in rat,N,,,50597,1,,CHEMBL627053,BAO_0000218,
10994,Intermediate,10116.0,In vivo,1,,,Maximum concentration at an peroral dose of 6.3 mg/kg in rat,N,,,50597,1,,CHEMBL627054,BAO_0000218,
10995,Intermediate,10090.0,In vivo,1,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,N,,,50594,1,,CHEMBL627055,BAO_0000218,
10996,Intermediate,10090.0,In vivo,1,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,N,,,50594,1,,CHEMBL627056,BAO_0000218,
10997,Intermediate,10090.0,In vivo,1,,,Maximum concentration (Cmax) using 0.4% Methyl cellulose (MC) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg (micronized sample),N,,,50594,1,,CHEMBL627057,BAO_0000218,
10998,Intermediate,10090.0,In vivo,1,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered intravenously to nude mice at a dose of 25 mg/kg,N,,,50594,1,,CHEMBL627058,BAO_0000218,
10999,Intermediate,10090.0,In vivo,1,,,Maximum concentration (Cmax) using 20%aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle. compound was administered orally to nude mice at a dose of 25 mg/kg,N,,,50594,1,,CHEMBL626211,BAO_0000218,
11000,Autocuration,,In vivo,1,,,Maximum Concentration of the compound.,U,,,22224,0,,CHEMBL626212,BAO_0000218,
11001,Intermediate,9615.0,In vivo,1,,,Maximum Concentration was measured after iv administration into Beagle dog,N,,,50588,1,,CHEMBL626213,BAO_0000218,
11002,Intermediate,9615.0,In vivo,1,,,Maximum Concentration was measured after iv administration into Beagle dog.,N,,,50588,1,,CHEMBL626214,BAO_0000218,
11003,Intermediate,9615.0,In vivo,1,,,Maximum Concentration was measured after po administration into Beagle dog,N,,,50588,1,,CHEMBL626215,BAO_0000218,
11004,Intermediate,9615.0,In vivo,1,,,Maximum Concentration was measured after po administration into Beagle dog.,N,,,50588,1,,CHEMBL626216,BAO_0000218,
11005,Autocuration,,In vivo,1,178.0,,Maximum blood level reached after an dose of 10.6 uM/kg intravenously,U,,,22224,0,,CHEMBL626217,BAO_0000218,
11006,Autocuration,,In vivo,1,178.0,,Maximum blood level reached after an iv dose of 12.2 uM/kg,U,,,22224,0,,CHEMBL626218,BAO_0000218,
11007,Autocuration,,In vivo,1,178.0,,Maximum blood level reached after an oral dose 14.7 uM/kg oral route,U,,,22224,0,,CHEMBL626219,BAO_0000218,
11008,Autocuration,,In vivo,1,178.0,,Maximum blood level reached after an oral dose of 14.7 uM/kg intravenous route,U,,,22224,0,,CHEMBL626220,BAO_0000218,
11009,Autocuration,,In vivo,1,178.0,,Maximum blood level reached after an oral dose of 5.0 mg/kg,U,,,22224,0,,CHEMBL626221,BAO_0000218,
11010,Autocuration,,In vivo,1,178.0,,Maximum blood level reached at dose of 10.6 uM/kg orally,U,,,22224,0,,CHEMBL626222,BAO_0000218,
11011,Intermediate,10141.0,In vivo,1,,,Maximum concentration (Cmax) in guinea pigs at 2 mg/kg after oral administration,N,,,50512,1,,CHEMBL626223,BAO_0000218,
11012,Intermediate,10141.0,In vivo,1,,,Maximum concentration (Cmax) in guinea pigs at 3 mg/kg after oral administration,N,,,50512,1,,CHEMBL626224,BAO_0000218,
11013,Intermediate,10116.0,In vivo,1,955.0,,Maximum concentration achieved in rat brain when administered intraperitoneally at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL626225,BAO_0000218,
11014,Intermediate,10116.0,In vivo,1,955.0,,Maximum concentration achieved in rat brain when administered intravenously at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL626226,BAO_0000218,
11015,Intermediate,10116.0,In vivo,1,955.0,,Maximum concentration achieved in rat brain when administered perorally at a dose of 100 mg/kg,N,,,50597,1,,CHEMBL626227,BAO_0000218,
11016,Intermediate,10116.0,In vivo,1,955.0,,Maximum concentration achieved in rat brain when administered perorally at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL626228,BAO_0000218,
11017,Intermediate,10116.0,In vivo,1,,,Maximum concentration achieved in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL626229,BAO_0000218,
11018,Intermediate,10116.0,In vivo,1,,,Maximum concentration achieved in rat plasma when administered intravenously at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL626921,BAO_0000218,
11019,Intermediate,10116.0,In vivo,1,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 100 mg/kg,N,,,50597,1,,CHEMBL876793,BAO_0000218,
11020,Intermediate,10116.0,In vivo,1,,,Maximum concentration achieved in rat plasma when administered perorally at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL625309,BAO_0000218,
11021,Intermediate,1423.0,In vivo,1,,,Maximum concentration determined against Bacillus subtilis ATCC 6633 after oral administration in dog(25 mg/kg),N,,,50278,1,,CHEMBL625310,BAO_0000218,
11022,Autocuration,314293.0,In vivo,1,,,Maximum concentration determined in monkeys dosed intravenously with 30 mg/kg,U,,,22224,0,,CHEMBL625311,BAO_0000218,
11023,Intermediate,10116.0,In vivo,1,,,Maximum concentration determined in rats dosed intravenously with 20 mg/kg,N,,,50597,1,,CHEMBL625312,BAO_0000218,
11024,Autocuration,,In vivo,1,,,Maximum concentration for the bioavailability at a dose of 20 mg/kg administered orally,U,,,22224,0,,CHEMBL625313,BAO_0000218,
11025,Intermediate,10090.0,In vivo,1,,,Maximum concentration in male CD-1 mice after sc administration of 20 mg/kg,N,,,50594,1,,CHEMBL625314,BAO_0000218,
11026,Intermediate,10116.0,In vivo,1,,,Maximum concentration in male rats after iv administration of 20 mg/kg,N,,,50597,1,,CHEMBL625315,BAO_0000218,
11027,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.06-1.29,N,,,50597,1,,CHEMBL625316,BAO_0000218,
11028,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 1.77-2.08,N,,,50597,1,,CHEMBL625317,BAO_0000218,
11029,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.89,N,,,50597,1,,CHEMBL625318,BAO_0000218,
11030,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 1.57-1.66,N,,,50597,1,,CHEMBL625319,BAO_0000218,
11031,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.06-2.71,N,,,50597,1,,CHEMBL625320,BAO_0000218,
11032,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 2.98-3.22,N,,,50597,1,,CHEMBL625321,BAO_0000218,
11033,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.73-1.45,N,,,50597,1,,CHEMBL625322,BAO_0000218,
11034,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.03-1.31,N,,,50597,1,,CHEMBL876801,BAO_0000218,
11035,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 6.76-10.44,N,,,50597,1,,CHEMBL625323,BAO_0000218,
11036,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.47-1.17,N,,,50597,1,,CHEMBL625324,BAO_0000218,
11037,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 1.12-1.44,N,,,50597,1,,CHEMBL625325,BAO_0000218,
11038,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.38-0.57,N,,,50597,1,,CHEMBL625326,BAO_0000218,
11039,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.75-1.14,N,,,50597,1,,CHEMBL625327,BAO_0000218,
11040,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity in liver tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 1.36-1.74,N,,,50597,1,,CHEMBL625328,BAO_0000218,
11041,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.5,N,,,50597,1,,CHEMBL625329,BAO_0000218,
11042,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 3.10-3.77,N,,,50597,1,,CHEMBL625330,BAO_0000218,
11043,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.4-0.54,N,,,50597,1,,CHEMBL627774,BAO_0000218,
11044,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.58-0.86,N,,,50597,1,,CHEMBL627775,BAO_0000218,
11045,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.77-0.86,N,,,50597,1,,CHEMBL627949,BAO_0000218,
11046,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.86-1.13,N,,,50597,1,,CHEMBL627950,BAO_0000218,
11047,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 2.26-2.89,N,,,50597,1,,CHEMBL627951,BAO_0000218,
11048,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.54-0.7,N,,,50597,1,,CHEMBL627952,BAO_0000218,
11049,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.6-0.66,N,,,50597,1,,CHEMBL627953,BAO_0000218,
11050,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.35-1.74,N,,,50597,1,,CHEMBL627954,BAO_0000218,
11051,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 3.62-7.08,N,,,50597,1,,CHEMBL627955,BAO_0000218,
11052,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.47-0.56,N,,,50597,1,,CHEMBL627956,BAO_0000218,
11053,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.54-1.07,N,,,50597,1,,CHEMBL876802,BAO_0000218,
11054,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.76-0.91,N,,,50597,1,,CHEMBL627957,BAO_0000218,
11055,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.61-0.86,N,,,50597,1,,CHEMBL627958,BAO_0000218,
11056,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 2.11-3.79,N,,,50597,1,,CHEMBL627959,BAO_0000218,
11057,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.3-0.36,N,,,50597,1,,CHEMBL627960,BAO_0000218,
11058,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.36-0.44,N,,,50597,1,,CHEMBL627961,BAO_0000218,
11059,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity in lung tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.5-0.65,N,,,50597,1,,CHEMBL627962,BAO_0000218,
11060,Intermediate,10116.0,,1,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL627963,BAO_0000218,
11061,Intermediate,10116.0,,1,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL624759,BAO_0000218,
11062,Intermediate,10116.0,,1,,,Distribution of radiolabeled compound in intestinal contents of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL624760,BAO_0000218,
11063,Intermediate,10116.0,,1,,,Distribution of radiolabeled compound in intestinal contents of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL624761,BAO_0000218,
11064,Intermediate,10116.0,,1,,,Distribution of radiolabeled compound in intestinal contents of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL877607,BAO_0000218,
11065,Intermediate,10116.0,,1,2107.0,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL624762,BAO_0000218,
11066,Intermediate,10116.0,,1,2107.0,,Distribution of radiolabeled compound in liver of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL624763,BAO_0000218,
11067,Intermediate,10116.0,,1,2107.0,,Distribution of radiolabeled compound in liver of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL624764,BAO_0000218,
11068,Intermediate,10116.0,,1,2107.0,,Distribution of radiolabeled compound in liver of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL624765,BAO_0000218,
11069,Intermediate,10116.0,,1,2107.0,,Distribution of radiolabeled compound in liver of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL624766,BAO_0000218,
11070,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL624767,BAO_0000218,
11071,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration,N,,,50588,1,,CHEMBL624768,BAO_0000218,
11072,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),N,,,50588,1,,CHEMBL624769,BAO_0000218,
11073,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),N,,,50588,1,,CHEMBL624770,BAO_0000218,
11074,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),N,,,50588,1,,CHEMBL624771,BAO_0000218,
11075,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring K+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL624772,BAO_0000218,
11076,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration,N,,,50597,1,,CHEMBL624773,BAO_0000218,
11077,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL624774,BAO_0000218,
11078,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration (0-5 hr),N,,,50597,1,,CHEMBL624775,BAO_0000218,
11079,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),N,,,50597,1,,CHEMBL624776,BAO_0000218,
11080,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),N,,,50597,1,,CHEMBL624777,BAO_0000218,
11081,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL624778,BAO_0000218,
11082,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration,N,,,50597,1,,CHEMBL624779,BAO_0000218,
11083,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),N,,,50597,1,,CHEMBL624780,BAO_0000218,
11084,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),N,,,50597,1,,CHEMBL624781,BAO_0000218,
11085,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL877608,BAO_0000218,
11086,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration (0-5 hr),N,,,50597,1,,CHEMBL624782,BAO_0000218,
11087,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL624783,BAO_0000218,
11088,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration,N,,,50597,1,,CHEMBL624784,BAO_0000218,
11089,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL624785,BAO_0000218,
11090,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration (0-5 hr),N,,,50597,1,,CHEMBL624786,BAO_0000218,
11091,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),N,,,50597,1,,CHEMBL624787,BAO_0000218,
11092,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL628676,BAO_0000218,
11093,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration,N,,,50597,1,,CHEMBL621842,BAO_0000218,
11094,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL621843,BAO_0000218,
11095,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),N,,,50597,1,,CHEMBL623873,BAO_0000218,
11096,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),N,,,50597,1,,CHEMBL623874,BAO_0000218,
11097,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),N,,,50597,1,,CHEMBL623875,BAO_0000218,
11098,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL623876,BAO_0000218,
11099,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.312 mg/kg after ip administration,N,,,50588,1,,CHEMBL623877,BAO_0000218,
11100,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),N,,,50588,1,,CHEMBL623878,BAO_0000218,
11101,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.625 mg/kg after ip administration,N,,,50588,1,,CHEMBL623879,BAO_0000218,
11102,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL623880,BAO_0000218,
11103,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL623881,BAO_0000218,
11104,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration (0-6 hr),N,,,50588,1,,CHEMBL623957,BAO_0000218,
11105,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL623958,BAO_0000218,
11106,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL623959,BAO_0000218,
11107,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL623960,BAO_0000218,
11108,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration (0-6 hr),N,,,50588,1,,CHEMBL623961,BAO_0000218,
11109,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),N,,,50588,1,,CHEMBL623962,BAO_0000218,
11110,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),N,,,50588,1,,CHEMBL624676,BAO_0000218,
11111,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL624677,BAO_0000218,
11112,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration,N,,,50588,1,,CHEMBL624678,BAO_0000218,
11113,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration (0-6 hr),N,,,50588,1,,CHEMBL624679,BAO_0000218,
11114,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),N,,,50588,1,,CHEMBL624680,BAO_0000218,
11115,Autocuration,,In vivo,1,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 27%,U,,,22224,0,,CHEMBL624849,BAO_0000218,
11116,Autocuration,,In vivo,1,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 4%,U,,,22224,0,,CHEMBL624850,BAO_0000218,
11117,Autocuration,,In vivo,1,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 54%,U,,,22224,0,,CHEMBL874399,BAO_0000218,
11118,Autocuration,,In vivo,1,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 72%,U,,,22224,0,,CHEMBL624851,BAO_0000218,
11119,Autocuration,,In vivo,1,,,Measure of AUCpo/AUCiv x 100% of the parent compound before (free) and after (total) beta-glucuronidase treatment; total 76%,U,,,22224,0,,CHEMBL624852,BAO_0000218,
11120,Autocuration,10116.0,In vivo,1,,,Oral bioavailability in rat (dose 10 mg/kg),U,,,22224,0,,CHEMBL624853,BAO_0000218,
11121,Autocuration,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley),U,,,22224,0,,CHEMBL624854,BAO_0000218,
11122,Autocuration,10116.0,In vivo,1,,,Oral bioavailability in rat,U,,,22224,0,,CHEMBL624855,BAO_0000218,
11123,Autocuration,10116.0,In vivo,1,,,Oral bioavailability in rats was determined in vivo,U,,,22224,0,,CHEMBL624856,BAO_0000218,
11124,Autocuration,9615.0,In vivo,1,,,Oral bioavailability in dog,U,,,22224,0,,CHEMBL882957,BAO_0000218,
11125,Autocuration,314293.0,In vivo,1,,,Oral bioavailability of compound in monkey,U,,,22224,0,,CHEMBL624857,BAO_0000218,
11126,Intermediate,10116.0,In vivo,1,,,Oral bioavailability of compound in rat,N,,,50597,1,,CHEMBL622202,BAO_0000218,
11127,Autocuration,10116.0,In vivo,1,,,Bioavailability in rat of PMEA prodrug,U,,,22224,0,,CHEMBL622203,BAO_0000218,
11128,Intermediate,10116.0,In vivo,1,,,Oral bioavailability of compound was evaluated relative to that of PMEA in rat; Not determined due to lack of solubility,N,,,50597,1,,CHEMBL625522,BAO_0000218,
11129,Autocuration,9544.0,In vivo,1,,,Serum conc at 3 hours following 25 mg/kg dose,U,,,22224,0,,CHEMBL622868,BAO_0000218,
11130,Autocuration,9544.0,In vivo,1,1088.0,,Urine conc 0-5 hours following 25 mg/kg dose,U,,,22224,0,,CHEMBL622869,BAO_0000218,
11131,Autocuration,9544.0,In vivo,1,1088.0,,Urine conc 0-24 hours following 25 mg/kg dose,U,,,22224,0,,CHEMBL622870,BAO_0000218,
11132,Autocuration,9534.0,In vivo,1,,,Oral bioavailability in African green monkeys; 20-25,U,,,22224,0,,CHEMBL622871,BAO_0000218,
11133,Intermediate,9541.0,In vivo,1,,,Oral bioavailability in cynomolgus monkey.,N,,,100710,1,,CHEMBL620560,BAO_0000218,
11134,Autocuration,9615.0,In vivo,1,,,Oral bioavailability in dog,U,,,22224,0,,CHEMBL620561,BAO_0000218,
11135,Intermediate,9615.0,In vivo,1,,,Oral bioavailability in dog at 10 mg/kg oral dose,N,,,50588,1,,CHEMBL620562,BAO_0000218,
11136,Intermediate,10026.0,In vivo,1,,,Oral bioavailability in hamster at 10 mg/kg oral dose,N,,,100712,1,,CHEMBL620563,BAO_0000218,
11137,Intermediate,10116.0,In vivo,1,,,Oral bioavailability in rat at 10 mg/kg oral dose,N,,,50597,1,,CHEMBL620564,BAO_0000218,
11138,Autocuration,10116.0,In vivo,1,,,Oral bioavailability in rat,U,,,22224,0,,CHEMBL872265,BAO_0000218,
11139,Autocuration,10116.0,In vivo,1,,,Oral bioavailability in rat,U,,,22224,0,,CHEMBL620565,BAO_0000218,
11140,Autocuration,9347.0,In vivo,1,,,Oral bioavailability,U,,,22224,0,,CHEMBL620566,BAO_0000218,
11141,Autocuration,,In vivo,1,,,Oral bioavailability was determined; range 49-102%,U,,,22224,0,,CHEMBL620567,BAO_0000218,
11142,Intermediate,9615.0,In vivo,1,,,Oral bioavailability was determined in dogs,N,,,50588,1,,CHEMBL620568,BAO_0000218,
11143,Autocuration,10116.0,In vivo,1,,,Oral bioavailability in rat,U,,,22224,0,,CHEMBL620569,BAO_0000218,
11144,Autocuration,9347.0,In vivo,1,,,Oral bioavailability,U,,,22224,0,,CHEMBL620570,BAO_0000218,
11145,Autocuration,,In vivo,1,,,Oral bioavailability was determined; Not orally available,U,,,22224,0,,CHEMBL620571,BAO_0000218,
11146,Intermediate,10090.0,In vivo,1,,,Percent bioavailability was administered by using 0.4% Methyl cellulose (MC) as vehicle to nude mice at a dose of 25 mg/kg (micronized sample),N,,,50594,1,,CHEMBL620572,BAO_0000218,
11147,Autocuration,10090.0,In vivo,1,,,Bioavailability in mouse (nude) (dose 0.4% Methylcellulose (MC) as vehicle 25 mg/kg),U,,,22224,0,,CHEMBL620573,BAO_0000218,
11148,Autocuration,10090.0,In vivo,1,,,Bioavailability in mouse (nude) using 20% aqueous hydroxypropyl-beta-cyclodextrin (HPbetaCD) as vehicle 25 mg/kg,U,,,22224,0,,CHEMBL620574,BAO_0000218,
11149,Autocuration,9544.0,In vivo,1,,,Oral bioavailability in Rhesus monkey,U,,,22224,0,,CHEMBL620575,BAO_0000218,
11150,Autocuration,9615.0,In vivo,1,,,Oral bioavailability in dog (female mongrel),U,,,22224,0,,CHEMBL620576,BAO_0000218,
11151,Autocuration,,In vivo,1,,,Percent oral bioavailability of perorally administered compound (30 mg/kg) was tested,U,,,22224,0,,CHEMBL875846,BAO_0000218,
11152,Autocuration,9615.0,In vivo,1,,,Oral bioavailability in dog,U,,,22224,0,,CHEMBL620577,BAO_0000218,
11153,Autocuration,,In vivo,1,,,Percentage Bioavailability was evaluated.,U,,,22224,0,,CHEMBL620578,BAO_0000218,
11154,Autocuration,10116.0,In vivo,1,,,Bioavailability in rat administered i.d.,U,,,22224,0,,CHEMBL620579,BAO_0000218,
11155,Autocuration,9347.0,In vivo,1,,,Bioavailability,U,,,22224,0,,CHEMBL621248,BAO_0000218,
11156,Autocuration,9615.0,In vivo,1,,,Bioavailability in dog (male Beagle) i.v. administration,U,,,22224,0,,CHEMBL625390,BAO_0000218,
11157,Autocuration,10116.0,In vivo,1,,,"Bioavailability in rat (dose 20 mg/kg p.o. in 1% methocel, and 5 mg/kg i.v. in PEG400)",U,,,22224,0,,CHEMBL625391,BAO_0000218,
11158,Autocuration,9443.0,In vivo,1,,,Bioavailability in monkey (dose 10 mg/kg i.d. or 0.3 mg/kg i.v.),U,,,22224,0,,CHEMBL872266,BAO_0000218,
11159,Autocuration,10116.0,In vivo,1,,,Oral bioavailability in rat (Sprague-Dawley) (male),U,,,22224,0,,CHEMBL625392,BAO_0000218,
11160,Intermediate,10116.0,In vivo,1,,,The oral bioavailability was measured on rats after oral administration,N,,,50597,1,,CHEMBL625393,BAO_0000218,
11161,Intermediate,10116.0,In vivo,1,,,Bioavailability was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,N,,,50597,1,,CHEMBL625394,BAO_0000218,
11162,Intermediate,9544.0,In vivo,1,,,Bioavailability was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,N,,,50797,1,,CHEMBL625395,BAO_0000218,
11163,Autocuration,10116.0,In vivo,1,,,Bioavailability in rat (dose 10 mg/kg i.d.),U,,,22224,0,,CHEMBL625396,BAO_0000218,
11164,Autocuration,9615.0,In vivo,1,,,Bioavailability in dog (male Beagle) i.v. administration,U,,,22224,0,,CHEMBL625397,BAO_0000218,
11165,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 1 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL625398,BAO_0000218,
11166,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution in CD-1 mice was determined after 1 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL625399,BAO_0000218,
11167,Intermediate,10090.0,In vivo,1,2037.0,,Biodistribution in CD-1 mice was determined after 1 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL626074,BAO_0000218,
11168,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 1 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL626075,BAO_0000218,
11169,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration in plasma (Cmax) was evaluated in rat at an intravenous dose of 3 mg/kg and peroral dose of 5 mg/kg,N,,,50597,1,,CHEMBL626076,BAO_0000218,
11170,Intermediate,9544.0,In vivo,1,1969.0,,Maximum concentration in plasma (Cmax) was evaluated in rhesus monkey at an intravenous dose of 1 mg/kg and peroral dose of 1 mg/kg,N,,,50797,1,,CHEMBL626077,BAO_0000218,
11171,Intermediate,10116.0,In vivo,1,178.0,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 1 mg/kg in rat (normalized to a 1 mg/kg dose),N,,,50597,1,,CHEMBL626078,BAO_0000218,
11172,Autocuration,,In vivo,1,178.0,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 2.5 mg/kg in rat (normalized to a 1 mg/kg dose),U,,,22224,0,,CHEMBL625846,BAO_0000218,
11173,Autocuration,,In vivo,1,178.0,,Maximum concentration in whole blood recorded in the period 0-24 hr postdose of 5.0 mg/kg GP (normalized to a 1 mg/kg dose),U,,,22224,0,,CHEMBL625847,BAO_0000218,
11174,Expert,10116.0,In vivo,1,,,Maximum concentration observed in rats at an oral dose of 50 mg/kg,N,,,50597,1,,CHEMBL625848,BAO_0000218,
11175,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration of compound in plasma administered orally to rats,N,,,50597,1,,CHEMBL625849,BAO_0000218,
11176,Intermediate,9615.0,In vivo,1,1969.0,,"Maximum concentration (10 mg/kg, orally) in plasma of dogs",N,,,50588,1,,CHEMBL626023,BAO_0000218,
11177,Intermediate,9615.0,In vivo,1,1969.0,,"Maximum concentration (10 mg/kg, perorally) in plasma of dogs",N,,,50588,1,,CHEMBL626024,BAO_0000218,
11178,Intermediate,9615.0,In vivo,1,1969.0,,"Maximum concentration (5 mg/kg, intravenously) in plasma of dogs",N,,,50588,1,,CHEMBL626025,BAO_0000218,
11179,Autocuration,,In vivo,1,,,Maximum concentration after 10 mg/kg by oral administration,U,,,22224,0,,CHEMBL626026,BAO_0000218,
11180,Autocuration,,In vivo,1,,,Maximum concentration at a dose of 1.5 mg/kg,U,,,22224,0,,CHEMBL626027,BAO_0000218,
11181,Autocuration,,In vivo,1,,,Maximum concentration at a dose of 2.0 mg/kg,U,,,22224,0,,CHEMBL626028,BAO_0000218,
11182,Intermediate,9615.0,In vivo,1,1969.0,,Maximum concentration in dog plasma,N,,,50588,1,,CHEMBL626029,BAO_0000218,
11183,Autocuration,,In vivo,1,1969.0,,Maximum concentration in plasma after administration of 10 umol/kg dose perorally,U,,,22224,0,,CHEMBL626030,BAO_0000218,
11184,Autocuration,,In vivo,1,1969.0,,Maximum concentration in plasma after administration of 2 umol/kg dose intravenously,U,,,22224,0,,CHEMBL626031,BAO_0000218,
11185,Autocuration,,In vivo,1,1969.0,,Maximum concentration in plasma after administration of 4 umol/kg dose intravenously,U,,,22224,0,,CHEMBL626032,BAO_0000218,
11186,Autocuration,,In vivo,1,1969.0,,Maximum concentration in plasma after administration of 40 umol/kg dose perorally,U,,,22224,0,,CHEMBL626033,BAO_0000218,
11187,Autocuration,,In vivo,1,1969.0,,Maximum concentration in plasma after administration of 5 umol/kg dose intravenously,U,,,22224,0,,CHEMBL626034,BAO_0000218,
11188,Intermediate,9615.0,In vivo,1,1969.0,,Maximum concentration in plasma after oral administration in dog (25 mg/kg),N,,,50588,1,,CHEMBL626035,BAO_0000218,
11189,Autocuration,,In vivo,1,1969.0,,Maximum concentration in plasma at Tmax,U,,,22224,0,,CHEMBL626036,BAO_0000218,
11190,Expert,9615.0,In vivo,1,1969.0,,Maximum concentration in plasma recorded 0-6 hr post dose in dog at 10 mg/kg oral dose,N,,,50588,1,,CHEMBL626037,BAO_0000218,
11191,Intermediate,10026.0,In vivo,1,1969.0,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in hamster at 10 mg/kg oral dose,N,,,100712,1,,CHEMBL626038,BAO_0000218,
11192,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration in plasma recorded in the period 0-6 hr post dose in rat at 10 mg/kg oral dose,N,,,50597,1,,CHEMBL626039,BAO_0000218,
11193,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration in plasma was determined by oral administration to rats at 20 mg/kg,N,,,50597,1,,CHEMBL626040,BAO_0000218,
11194,Intermediate,9986.0,In vivo,1,1969.0,,Maximum concentration present in the rabbit plasma following peroral administration of 10 mg/kg,N,,,50592,1,,CHEMBL626041,BAO_0000218,
11195,Autocuration,,In vivo,1,,,Maximum concentration was calculated,U,,,22224,0,,CHEMBL626042,BAO_0000218,
11196,Autocuration,,In vivo,1,,,Maximum concentration was calculated.,U,,,22224,0,,CHEMBL626043,BAO_0000218,
11197,Autocuration,,In vivo,1,,,Maximum concentration at a peroral dose of 10 mg/kg,U,,,22224,0,,CHEMBL626044,BAO_0000218,
11198,Autocuration,,In vivo,1,,,Maximum concentration of the drug at 10 uM/dg administered perorally,U,,,22224,0,,CHEMBL626045,BAO_0000218,
11199,Autocuration,,In vivo,1,,,Maximum concentration of the drug at 2 uM/dg administered intravenously,U,,,22224,0,,CHEMBL626046,BAO_0000218,
11200,Intermediate,9615.0,In vivo,1,1969.0,,"Maximum concentration of the unchanged compound in dog plasma, recorded in the period 0-6 hr post dose.",N,,,50588,1,,CHEMBL626047,BAO_0000218,
11201,Intermediate,10026.0,In vivo,1,1969.0,,"Maximum concentration of the unchanged compound in hamster plasma, recorded in the period 0-6 hr post dose.",N,,,100712,1,,CHEMBL626048,BAO_0000218,
11202,Intermediate,10116.0,In vivo,1,1969.0,,"Maximum concentration of the unchanged compound in rat plasma, recorded in the period 0-6 hr post dose.",N,,,50597,1,,CHEMBL626049,BAO_0000218,
11203,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 60 mg/kg oral dose,N,,,50597,1,,CHEMBL626050,BAO_0000218,
11204,Intermediate,9615.0,In vivo,1,1969.0,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in dog at 5 mg/kg oral dose,N,,,50588,1,,CHEMBL874541,BAO_0000218,
11205,Intermediate,10026.0,In vivo,1,1969.0,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in hamster at 40 mg/kg oral dose,N,,,100712,1,,CHEMBL622826,BAO_0000218,
11206,Intermediate,10026.0,In vivo,1,1969.0,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose to hamster at 40 mg/kg oral dose,N,,,100712,1,,CHEMBL622827,BAO_0000218,
11207,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration of unchanged drug in plasma recorded in the period 0-6 hr of postdose in anesthetized rat at 25 mg/kg oral dose,N,,,50597,1,,CHEMBL622828,BAO_0000218,
11208,Intermediate,10116.0,In vivo,1,1969.0,,Maximum concentration of unchanged drug in rat plasma in the period 0-24 hr after dosing,N,,,50597,1,,CHEMBL622829,BAO_0000218,
11209,Intermediate,10116.0,In vivo,1,,,Maximum concentration reached following intravenous administration in male rat,N,,,50597,1,,CHEMBL876806,BAO_0000218,
11210,Intermediate,9615.0,In vivo,1,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 10 mg/kg dosage administered perorally in dog,N,,,50588,1,,CHEMBL622830,BAO_0000218,
11211,Intermediate,10116.0,In vivo,1,,,Maximum concentration was determined in an aqueous sodium hydroxide solution adjusted to pH 10 at 5 mg/kg dosage administered perorally in rats,N,,,50597,1,,CHEMBL622831,BAO_0000218,
11212,Intermediate,9615.0,In vivo,1,,,Maximum concentration was measured after peroral administration of 10 mg/kg of drug in male Beagle dogs,N,,,50588,1,,CHEMBL626794,BAO_0000218,
11213,Intermediate,10116.0,In vivo,1,,,Maximum concentration was measured after peroral administration of 5.0 mg/kg of drug in male Dawley rats,N,,,50597,1,,CHEMBL626795,BAO_0000218,
11214,Intermediate,10116.0,In vivo,1,,,Maximum concentration was measured after peroral administration of 5.1 mg/kg of drug in male Dawley rats,N,,,50597,1,,CHEMBL626796,BAO_0000218,
11215,Intermediate,10116.0,In vivo,1,,,Maximum concentration was measured after peroral administration of 5.2 mg/kg of drug in male Dawley rats,N,,,50597,1,,CHEMBL626797,BAO_0000218,
11216,Intermediate,10116.0,In vivo,1,,,Maximum drug concentration is determined after oral dosing in rats.,N,,,50597,1,,CHEMBL626798,BAO_0000218,
11217,Intermediate,9615.0,In vivo,1,,,Maximum observed concentration in oral (5 mg/kg) fasted dogs,N,,,50588,1,,CHEMBL626799,BAO_0000218,
11218,Intermediate,9615.0,In vivo,1,,,Maximum observed concentration in oral (5 mg/kg) fed dogs,N,,,50588,1,,CHEMBL626800,BAO_0000218,
11219,Autocuration,,In vivo,1,1969.0,,Maximum plasma concentration,U,,,22224,0,,CHEMBL626801,BAO_0000218,
11220,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) was determined in rats after intraduodenal administration of the drug,N,,,50597,1,,CHEMBL876816,BAO_0000218,
11221,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration following oral administration of 26.3 mg/kg in rats,N,,,50597,1,,CHEMBL626802,BAO_0000218,
11222,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration following oral administration of 3.8 mg/kg in Beagle dog,N,,,50588,1,,CHEMBL626803,BAO_0000218,
11223,Autocuration,,In vivo,1,1969.0,,Maximum plasma concentration following oral administration of 30 umol/kg,U,,,22224,0,,CHEMBL626804,BAO_0000218,
11224,Intermediate,10116.0,,1,1969.0,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose,N,,,50597,1,,CHEMBL626805,BAO_0000218,
11225,Intermediate,10116.0,,1,1969.0,,Distribution of radiolabeled compound in plasma of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL626309,BAO_0000218,
11226,Intermediate,10116.0,,1,1969.0,,Distribution of radiolabeled compound in plasma of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL626310,BAO_0000218,
11227,Intermediate,10116.0,,1,1969.0,,Distribution of radiolabeled compound in plasma of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL626311,BAO_0000218,
11228,Intermediate,10116.0,,1,1969.0,,Distribution of radiolabeled compound in plasma of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL626312,BAO_0000218,
11229,Intermediate,10116.0,,1,995.0,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL626313,BAO_0000218,
11230,Intermediate,10116.0,,1,995.0,,Distribution of radiolabeled compound in uterus of rat 1 hr after ip administration of dose and excess 8 microg of estradiol; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL626314,BAO_0000218,
11231,Intermediate,10116.0,,1,995.0,,Distribution of radiolabeled compound in uterus of rat 1 hr after iv administration of dose; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL626315,BAO_0000218,
11232,Intermediate,10116.0,,1,995.0,,Distribution of radiolabeled compound in uterus of rat 4 hr after ip administration of dose; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL626316,BAO_0000218,
11233,Intermediate,10116.0,,1,995.0,,Distribution of radiolabeled compound in uterus of rat 8 hr after ip administration of dose; fmol equivalents per 100 mg,N,,,50597,1,,CHEMBL626317,BAO_0000218,
11234,Intermediate,10116.0,,1,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Minus (-),N,,,50597,1,,CHEMBL626318,BAO_0000218,
11235,Intermediate,10116.0,,1,,,Distribution of rat erythrocytes for tube 2 on rate of aging in 2 mL of cell suspension; Plus (+),N,,,50597,1,,CHEMBL626319,BAO_0000218,
11236,Intermediate,10116.0,,1,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Minus (-),N,,,50597,1,,CHEMBL626320,BAO_0000218,
11237,Intermediate,10116.0,,1,,,Distribution of rat erythrocytes for tube 3 on rate of aging in 2 mL of cell suspension; Plus (+),N,,,50597,1,,CHEMBL875053,BAO_0000218,
11238,Intermediate,10116.0,,1,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Minus (-),N,,,50597,1,,CHEMBL626321,BAO_0000218,
11239,Intermediate,10116.0,,1,,,Distribution of rat erythrocytes for tube 4 on rate of aging in 2 mL of cell suspension; Plus (+),N,,,50597,1,,CHEMBL626322,BAO_0000218,
11240,Intermediate,10116.0,,1,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Minus (-),N,,,50597,1,,CHEMBL626323,BAO_0000218,
11241,Intermediate,10116.0,,1,,,Distribution of rat erythrocytes for tube 5 on rate of aging in 2 mL of cell suspension; Plus (+),N,,,50597,1,,CHEMBL626324,BAO_0000218,
11242,Intermediate,10116.0,,1,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Minus (-),N,,,50597,1,,CHEMBL626325,BAO_0000218,
11243,Intermediate,10116.0,,1,,,Distribution of rat erythrocytes for tube 6 on rate of aging in 2 mL of cell suspension; Plus (+),N,,,50597,1,,CHEMBL626326,BAO_0000218,
11244,Intermediate,10116.0,,1,,,Distribution of rat erythrocytes for tube 7 on rate of aging in 2 mL of cell suspension; Plus (+),N,,,50597,1,,CHEMBL626327,BAO_0000218,
11245,Intermediate,10116.0,,1,,,Distribution of rat erythrocytes for tube 1 on rate of aging in 2 mL of cell suspension; Minus (-),N,,,50597,1,,CHEMBL626328,BAO_0000218,
11246,Intermediate,10116.0,,1,178.0,,"Distribution in blood of rat 5 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL626329,BAO_0000218,
11247,Intermediate,10116.0,,1,178.0,,"Distribution in blood of rat, 15 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL626330,BAO_0000218,
11248,Intermediate,10116.0,,1,178.0,,"Distribution in blood of rat, 1 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL626331,BAO_0000218,
11249,Intermediate,10116.0,,1,178.0,,"Distribution in blood of rat, 2 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL626332,BAO_0000218,
11250,Intermediate,10116.0,,1,178.0,,"Distribution in blood of rat, 30 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL626333,BAO_0000218,
11251,Intermediate,10116.0,,1,178.0,,"Distribution in blood of rat, 4 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL626334,BAO_0000218,
11252,Intermediate,10116.0,,1,178.0,,"Distribution in blood of rat, 6 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL626335,BAO_0000218,
11253,Intermediate,10116.0,,1,178.0,,"Distribution in blood of rat, 8 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624798,BAO_0000218,
11254,Intermediate,10116.0,,1,955.0,,"Distribution in brain of rat, 15 min after intravenous administered, injected dose/gm",N,,,50597,1,,CHEMBL624799,BAO_0000218,
11255,Intermediate,10116.0,,1,955.0,,"Distribution in brain of rat, 1 hr after intravenous administered, injected dose/gm",N,,,50597,1,,CHEMBL624800,BAO_0000218,
11256,Intermediate,10116.0,,1,955.0,,"Distribution in brain of rat, 2 hr after intravenous administered, injected dose/gm",N,,,50597,1,,CHEMBL624801,BAO_0000218,
11257,Intermediate,10116.0,,1,955.0,,"Distribution in brain of rat, 30 min after intravenous administered, injected dose/gm",N,,,50597,1,,CHEMBL624802,BAO_0000218,
11258,Intermediate,10116.0,,1,955.0,,"Distribution in brain of rat, 4 hr after intravenous administered, injected dose/gm",N,,,50597,1,,CHEMBL624803,BAO_0000218,
11259,Intermediate,10116.0,,1,955.0,,"Distribution in brain of rat, 5 min after intravenous administered, injected dose/gm",N,,,50597,1,,CHEMBL624804,BAO_0000218,
11260,Intermediate,10116.0,,1,955.0,,"Distribution in brain of rat, 6 hr after intravenous administered, injected dose/gm",N,,,50597,1,,CHEMBL624805,BAO_0000218,
11261,Intermediate,10116.0,,1,955.0,,"Distribution in brain of rat, 8 hr after intravenous administered, injected dose/gm",N,,,50597,1,,CHEMBL624806,BAO_0000218,
11262,Intermediate,10116.0,,1,,,"Distribution in rat fat 15 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624807,BAO_0000218,
11263,Intermediate,10116.0,,1,,,"Distribution in rat fat 1 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624808,BAO_0000218,
11264,Intermediate,10116.0,,1,,,"Distribution in rat fat 2 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624809,BAO_0000218,
11265,Intermediate,10116.0,,1,,,"Distribution in rat fat 30 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624810,BAO_0000218,
11266,Intermediate,10116.0,,1,,,"Distribution in rat fat 4 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL877618,BAO_0000218,
11267,Intermediate,10116.0,,1,,,"Distribution in rat fat 5 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624811,BAO_0000218,
11268,Intermediate,10116.0,,1,,,"Distribution in rat fat 6 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624812,BAO_0000218,
11269,Intermediate,10116.0,,1,,,"Distribution in rat fat 8 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624813,BAO_0000218,
11270,Intermediate,10116.0,,1,,,"Distribution in rat heart 15 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624814,BAO_0000218,
11271,Intermediate,10116.0,,1,,,"Distribution in rat heart 1 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624815,BAO_0000218,
11272,Intermediate,10116.0,,1,,,"Distribution in rat heart 2 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624816,BAO_0000218,
11273,Intermediate,10116.0,,1,,,"Distribution in rat heart 30 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624817,BAO_0000218,
11274,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5.4 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL624818,BAO_0000218,
11275,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration,N,,,50588,1,,CHEMBL624819,BAO_0000218,
11276,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration (0-6 hr),N,,,50588,1,,CHEMBL624820,BAO_0000218,
11277,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0 - 6 hr),N,,,50588,1,,CHEMBL624821,BAO_0000218,
11278,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr ),N,,,50588,1,,CHEMBL624822,BAO_0000218,
11279,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Na+ excretion in dog at 5 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL624823,BAO_0000218,
11280,Intermediate,562.0,,1,,,Observed diffusion coefficient in organic solvent for Escherichia coli,N,,,50212,1,,CHEMBL624824,BAO_0000218,
11281,Intermediate,10116.0,,1,178.0,,"Concentration of compound in blood of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,,,50597,1,,CHEMBL624825,BAO_0000218,
11282,Intermediate,10116.0,,1,178.0,,"Concentration of compound in blood of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,,,50597,1,,CHEMBL624826,BAO_0000218,
11283,Intermediate,10116.0,,1,2081.0,,"Concentration of compound in left atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,,,50597,1,,CHEMBL876817,BAO_0000218,
11284,Intermediate,10116.0,,1,2081.0,,"Concentration of compound in left atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,,,50597,1,,CHEMBL624827,BAO_0000218,
11285,Intermediate,10116.0,,1,,,"Concentration of compound in left ventricle of of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,,,50597,1,,CHEMBL624828,BAO_0000218,
11286,Intermediate,10116.0,,1,,,"Concentration of compound in left ventricle of of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,,,50597,1,,CHEMBL624829,BAO_0000218,
11287,Intermediate,10116.0,,1,2107.0,,"Concentration of compound in liver of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,,,50597,1,,CHEMBL624830,BAO_0000218,
11288,Intermediate,10116.0,,1,2107.0,,"Concentration of compound in liver of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,,,50597,1,,CHEMBL624831,BAO_0000218,
11289,Intermediate,10116.0,,1,2081.0,,"Concentration of compound in right atrium of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,,,50597,1,,CHEMBL624832,BAO_0000218,
11290,Intermediate,10116.0,,1,2081.0,,"Concentration of compound in right atrium of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,,,50597,1,,CHEMBL624833,BAO_0000218,
11291,Intermediate,10116.0,,1,,,"Concentration of compound in right ventricle of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,,,50597,1,,CHEMBL624834,BAO_0000218,
11292,Intermediate,10116.0,,1,,,"Concentration of compound in right ventricle of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,,,50597,1,,CHEMBL624835,BAO_0000218,
11293,Intermediate,10116.0,,1,2106.0,,"Concentration of compound in spleen of rats, pretreated with 6-Hydroxydopamine assessed using [18F]- as radiotracer",N,,,50597,1,,CHEMBL624836,BAO_0000218,
11294,Intermediate,10116.0,,1,2106.0,,"Concentration of compound in spleen of rats, pretreated with desmethylimipramine, assessed using [18F]- as radiotracer;Dose/g",N,,,50597,1,,CHEMBL624837,BAO_0000218,
11295,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity of radiolabeled compound in blood of female rats 30 minutes after intravenous administration,N,,,50597,1,,CHEMBL624838,BAO_0000218,
11296,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity of radiolabeled compound in blood of female rats 5 minutes after intravenous administration,N,,,50597,1,,CHEMBL622188,BAO_0000218,
11297,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration,N,,,50597,1,,CHEMBL622189,BAO_0000218,
11298,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity of radiolabeled compound in heart of female rats 30 minutes after intravenous administration at,N,,,50597,1,,CHEMBL622190,BAO_0000218,
11299,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity of radiolabeled compound in heart of female rats 5 minutes after intravenous administration,N,,,50597,1,,CHEMBL625170,BAO_0000218,
11300,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,N,,,50597,1,,CHEMBL625171,BAO_0000218,
11301,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 30 minutes after intravenous administration,N,,,50597,1,,CHEMBL625172,BAO_0000218,
11302,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity of radiolabeled compound in kidney of female rats 5 minutes after intravenous administration,N,,,50597,1,,CHEMBL625173,BAO_0000218,
11303,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity of radiolabeled compound in liver of female rats 30 minutes after intravenous administration,N,,,50597,1,,CHEMBL625174,BAO_0000218,
11304,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration,N,,,50597,1,,CHEMBL625175,BAO_0000218,
11305,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity of radiolabeled compound in liver of female rats 5 minutes after intravenous administration at,N,,,50597,1,,CHEMBL625176,BAO_0000218,
11306,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,N,,,50597,1,,CHEMBL625177,BAO_0000218,
11307,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration,N,,,50597,1,,CHEMBL625178,BAO_0000218,
11308,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity of radiolabeled compound in lung of female rats 5 minutes after intravenous administration at,N,,,50597,1,,CHEMBL625179,BAO_0000218,
11309,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity of radiolabeled compound in lung of female rats 30 minutes after intravenous administration,N,,,50597,1,,CHEMBL625180,BAO_0000218,
11310,Autocuration,,,1,,,"Original dose appeared in the bile as unchanged compound, which was eliminated at a fairly constant rate over the first 4 hr following the iv administration",U,,,22224,0,,CHEMBL625181,BAO_0000218,
11311,Intermediate,10090.0,,1,1088.0,,Percentage of dose recovered after 0-6 hr in the urine of mice was measured.,N,,,50594,1,,CHEMBL625182,BAO_0000218,
11312,Intermediate,10116.0,,1,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL625183,BAO_0000218,
11313,Intermediate,10116.0,,1,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL875848,BAO_0000218,
11314,Intermediate,10116.0,,1,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL622260,BAO_0000218,
11315,Intermediate,10116.0,,1,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL622261,BAO_0000218,
11316,Intermediate,10116.0,,1,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL622262,BAO_0000218,
11317,Intermediate,10116.0,,1,2113.0,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL622263,BAO_0000218,
11318,Intermediate,10116.0,,1,2113.0,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL622418,BAO_0000218,
11319,Intermediate,10116.0,,1,2107.0,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL622419,BAO_0000218,
11320,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 1 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL623388,BAO_0000218,
11321,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution in CD-1 mice was determined after 1 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL623389,BAO_0000218,
11322,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 1 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL623390,BAO_0000218,
11323,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 120 minutes in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL623391,BAO_0000218,
11324,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution in CD-1 mice was determined after 120 minutes in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL623392,BAO_0000218,
11325,Intermediate,10090.0,In vivo,1,2037.0,,Biodistribution in CD-1 mice was determined after 120 minutes in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL623393,BAO_0000218,
11326,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 120 minutes in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL623394,BAO_0000218,
11327,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 120 minutes in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL618885,BAO_0000218,
11328,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution in CD-1 mice was determined after 120 minutes in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL618886,BAO_0000218,
11329,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 120 minutes in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL618887,BAO_0000218,
11330,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 30 minutes in Striatum (expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL619535,BAO_0000218,
11331,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution in CD-1 mice was determined after 30 minutes in blood (expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL619536,BAO_0000218,
11332,Intermediate,10090.0,In vivo,1,2037.0,,Biodistribution in CD-1 mice was determined after 30 minutes in cerebellum (expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL619537,BAO_0000218,
11333,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 30 minutes in cortex (expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL619705,BAO_0000218,
11334,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 30 minutes in femur (expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL619706,BAO_0000218,
11335,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution in CD-1 mice was determined after 30 minutes in liver (expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL619707,BAO_0000218,
11336,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 30 minutes in lung (expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL619708,BAO_0000218,
11337,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 5 minute in Striatum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL625219,BAO_0000218,
11338,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution in CD-1 mice was determined after 5 minute in blood(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL625220,BAO_0000218,
11339,Intermediate,10090.0,In vivo,1,2037.0,,Biodistribution in CD-1 mice was determined after 5 minute in cerebellum(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL625221,BAO_0000218,
11340,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 5 minute in cortex(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL625222,BAO_0000218,
11341,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 5 minute in femur(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL625223,BAO_0000218,
11342,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution in CD-1 mice was determined after 5 minute in liver(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL625224,BAO_0000218,
11343,Intermediate,10090.0,In vivo,1,,,Biodistribution in CD-1 mice was determined after 5 minute in lung(expressed as percent injected dose per gram normalized to a 25 g mouse),N,,,50594,1,,CHEMBL625225,BAO_0000218,
11344,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in Rat blood after 24 hours of iv administration,N,,,50597,1,,CHEMBL625226,BAO_0000218,
11345,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in Rat blood after 24 hours of iv administration; per g of tissue,N,,,50597,1,,CHEMBL625227,BAO_0000218,
11346,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in Rat blood after 30 minutes of iv administration,N,,,50597,1,,CHEMBL625228,BAO_0000218,
11347,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in Rat blood after 30 minutes of iv administration; per g of tissue,N,,,50597,1,,CHEMBL875354,BAO_0000218,
11348,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in Rat blood after 5 minutes of iv administration,N,,,50597,1,,CHEMBL625229,BAO_0000218,
11349,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in Rat blood after 5 minutes of iv administration; per g of tissue,N,,,50597,1,,CHEMBL625230,BAO_0000218,
11350,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in Rat heart after 24 hours of iv administration,N,,,50597,1,,CHEMBL625231,BAO_0000218,
11351,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in Rat heart after 24 hours of iv administration; per g of tissue,N,,,50597,1,,CHEMBL625900,BAO_0000218,
11352,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in Rat heart after 30 minutes of iv administration,N,,,50597,1,,CHEMBL625901,BAO_0000218,
11353,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in Rat heart after 30 minutes of iv administration; per g of tissue,N,,,50597,1,,CHEMBL625902,BAO_0000218,
11354,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in Rat heart after 5 minutes of iv administration,N,,,50597,1,,CHEMBL625903,BAO_0000218,
11355,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in Rat heart after 5 minutes of iv administration; per g of tissue,N,,,50597,1,,CHEMBL625904,BAO_0000218,
11356,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in Rat liver after 24 hours of iv administration,N,,,50597,1,,CHEMBL625905,BAO_0000218,
11357,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in Rat liver after 24 hours of iv administration; per g of tissue,N,,,50597,1,,CHEMBL627861,BAO_0000218,
11358,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in Rat liver after 30 minutes of iv administration,N,,,50597,1,,CHEMBL627862,BAO_0000218,
11359,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,N,,,50597,1,,CHEMBL627863,BAO_0000218,
11360,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in Rat liver after 30 minutes of iv administration,N,,,50597,1,,CHEMBL627769,BAO_0000218,
11361,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,N,,,50588,1,,CHEMBL627770,BAO_0000218,
11362,Intermediate,9541.0,In vivo,1,,,Cmax in cynomolgus monkey (PO dose),N,,,100710,1,,CHEMBL627771,BAO_0000218,
11363,Intermediate,10116.0,In vivo,1,,,Cmax in rat (PO dose),N,,,50597,1,,CHEMBL627772,BAO_0000218,
11364,Intermediate,10116.0,In vivo,1,,,Cmax in rat (PO dose),N,,,50597,1,,CHEMBL627773,BAO_0000218,
11365,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration in rats after an oral dose of 5 mg/kg,N,,,50597,1,,CHEMBL621922,BAO_0000218,
11366,Intermediate,10116.0,In vivo,1,1969.0,,Cmax in rat plasma after oral dose (10 mg/kg),N,,,50597,1,,CHEMBL621923,BAO_0000218,
11367,Autocuration,,In vivo,1,1969.0,,Cmax in plasma after oral dose (10 mg/kg),U,,,22224,0,,CHEMBL621924,BAO_0000218,
11368,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration of compound was determined in dog at 25 mg/kg orally,N,,,50588,1,,CHEMBL621925,BAO_0000218,
11369,Autocuration,314293.0,In vivo,1,1969.0,,Maximum plasma concentration of compound was determined in monkey at 25 mg/kg orally,U,,,22224,0,,CHEMBL621926,BAO_0000218,
11370,Intermediate,9986.0,In vivo,1,1969.0,,Maximum plasma concentration of compound was determined in rabbit at 25 mg/kg orally,N,,,50592,1,,CHEMBL621927,BAO_0000218,
11371,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration of compound was determined in rat at 25 mg/kg orally,N,,,50597,1,,CHEMBL621928,BAO_0000218,
11372,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration after p.o. (10 mpk) administration in rats.,N,,,50597,1,,CHEMBL621929,BAO_0000218,
11373,Intermediate,10090.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) after p.o. administration of 200 mg/kg in mice,N,,,50594,1,,CHEMBL621930,BAO_0000218,
11374,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration after oral dosing in rat,N,,,50597,1,,CHEMBL621931,BAO_0000218,
11375,Autocuration,,In vivo,1,1969.0,,Maximum plasma concentration evaluated in 100% PEG solution at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL621932,BAO_0000218,
11376,Autocuration,,In vivo,1,1969.0,,Maximum plasma concentration evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL621933,BAO_0000218,
11377,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration in dogs at 0.5 mg/kg dose upon oral administration,N,,,50588,1,,CHEMBL621934,BAO_0000218,
11378,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration in dogs at 1 mg/kg dose upon oral administration,N,,,50588,1,,CHEMBL621935,BAO_0000218,
11379,Intermediate,10116.0,In vivo,1,1969.0,,Maximum plasma concentration in rat upon oral administration of 40 mg/kg,N,,,50597,1,,CHEMBL621936,BAO_0000218,
11380,Autocuration,,In vivo,1,1969.0,,Maximum plasma concentration was determined,U,,,22224,0,,CHEMBL621937,BAO_0000218,
11381,Autocuration,,In vivo,1,1969.0,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL621938,BAO_0000218,
11382,Autocuration,,In vivo,1,1969.0,,Maximum plasma concentration was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL621939,BAO_0000218,
11383,Autocuration,,In vivo,1,1969.0,,Maximum plasma concentration was evaluated in 10% of PEG suspension at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL621940,BAO_0000218,
11384,Autocuration,,In vivo,1,1969.0,,Maximum plasma concentration was evaluated in 100% of PEG solution at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL621941,BAO_0000218,
11385,Autocuration,,In vivo,1,1969.0,,Maximum plasma concentration was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL621942,BAO_0000218,
11386,Autocuration,,In vivo,1,1969.0,,Maximum plasma concentration was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL626178,BAO_0000218,
11387,Autocuration,,In vivo,1,1969.0,,Maximum plasma concentration was evaluated in Hp-beta-CD solution at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL626179,BAO_0000218,
11388,Autocuration,,In vivo,1,1969.0,,Maximum plasma concentration was evaluated in saline solution at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL626180,BAO_0000218,
11389,Intermediate,10116.0,In vivo,1,1969.0,,Plasma Cmax in rat (PO dose),N,,,50597,1,,CHEMBL626181,BAO_0000218,
11390,Intermediate,10116.0,In vivo,1,,,Maximum serum concentration after po dose of 5.22 mg/kg in rats,N,,,50597,1,,CHEMBL626182,BAO_0000218,
11391,Intermediate,10116.0,In vivo,1,,,Maximum serum concentration after po dose of 5.46 mg/kg in rats,N,,,50597,1,,CHEMBL626183,BAO_0000218,
11392,Intermediate,10116.0,In vivo,1,,,Maximum serum concentration was determined for the compound after po dose of 5.01 mg/kg in rats,N,,,50597,1,,CHEMBL626184,BAO_0000218,
11393,Intermediate,10116.0,In vivo,1,,,Maximum serum concentration was determined for the compound after po dose of 5.03 mg/kg in rats,N,,,50597,1,,CHEMBL626185,BAO_0000218,
11394,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) was determined in dogs fed after oral administration of 25 mg/kg of the compound.,N,,,50588,1,,CHEMBL626186,BAO_0000218,
11395,Intermediate,9615.0,In vivo,1,1969.0,,Maximum plasma concentration (Cmax) was determined in fasted dogs after oral administration of 25 mg/kg of the compound.,N,,,50588,1,,CHEMBL877589,BAO_0000218,
11396,Autocuration,,In vivo,1,,,Maximum concentration of the drug at 1 uM/dg administered intravenously,U,,,22224,0,,CHEMBL626187,BAO_0000218,
11397,Autocuration,,In vivo,1,,,Maximum concentration of the drug at 20 uM/dg administered perorally,U,,,22224,0,,CHEMBL626188,BAO_0000218,
11398,Autocuration,,In vivo,1,,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg,U,,,22224,0,,CHEMBL626189,BAO_0000218,
11399,Autocuration,,In vivo,1,178.0,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,U,,,22224,0,,CHEMBL626855,BAO_0000218,
11400,Autocuration,,In vivo,1,178.0,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,U,,,22224,0,,CHEMBL623781,BAO_0000218,
11401,Autocuration,,In vivo,1,178.0,,Oral Bioavailability was measured as Maximal observed concentration (Cmax) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,U,,,22224,0,,CHEMBL623782,BAO_0000218,
11402,Intermediate,10116.0,In vivo,1,1969.0,,Oral absorption expressed as peak plasma conc (Cmax) after oral dosing of 50 mg/kg in rat,N,,,50597,1,,CHEMBL623783,BAO_0000218,
11403,Intermediate,9615.0,In vivo,1,1969.0,,Cmax in dog plasma after 1mg/kg oral dose,N,,,50588,1,,CHEMBL623784,BAO_0000218,
11404,Intermediate,9615.0,In vivo,1,1969.0,,Bioavailability as maximal plasma concentration in dogs after 2.5 mg/kg oral dose,N,,,50588,1,,CHEMBL623785,BAO_0000218,
11405,Intermediate,10116.0,In vivo,1,1969.0,,Bioavailability as maximal plasma concentration in rats after 10 mg/kg oral dose,N,,,50597,1,,CHEMBL623786,BAO_0000218,
11406,Intermediate,10116.0,In vivo,1,,,Oral maximum concentration in rat,N,,,50597,1,,CHEMBL623787,BAO_0000218,
11407,Intermediate,10116.0,In vivo,1,,,Oral maximum concentration in rat,N,,,50597,1,,CHEMBL623788,BAO_0000218,
11408,Intermediate,10090.0,In vivo,1,1969.0,,Oral plasma concentration in mice at 100 mg/kg dosage within 4-hr time frame.,N,,,50594,1,,CHEMBL623789,BAO_0000218,
11409,Intermediate,10090.0,In vivo,1,178.0,,Peak concentration in blood after intravenous administration to mice,N,,,50594,1,,CHEMBL623790,BAO_0000218,
11410,Intermediate,10090.0,In vivo,1,178.0,,Peak concentration in blood after peroral administration to mice,N,,,50594,1,,CHEMBL623791,BAO_0000218,
11411,Intermediate,10116.0,In vivo,1,1969.0,,Peak concentration in rat plasma was determined,N,,,50597,1,,CHEMBL623792,BAO_0000218,
11412,Autocuration,314293.0,In vivo,1,1969.0,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of monkey after oral administration of 0.05 mmol/kg,U,,,22224,0,,CHEMBL623793,BAO_0000218,
11413,Intermediate,10090.0,In vivo,1,1969.0,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of mouse after oral administration of 0.05 mmol/kg,N,,,50594,1,,CHEMBL623794,BAO_0000218,
11414,Intermediate,10116.0,In vivo,1,1969.0,,Peak plasma concentration expresses the ability of compound for the release of L-Dopa in the plasma of rat after oral administration of 0.05 mmol/kg,N,,,50597,1,,CHEMBL623795,BAO_0000218,
11415,Intermediate,10116.0,,1,,,"Distribution in rat heart 4 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623796,BAO_0000218,
11416,Intermediate,10116.0,,1,,,"Distribution in rat heart 5 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623797,BAO_0000218,
11417,Intermediate,10116.0,,1,,,"Distribution in rat heart 6 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623798,BAO_0000218,
11418,Intermediate,10116.0,,1,,,"Distribution in rat heart 8 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623799,BAO_0000218,
11419,Intermediate,10116.0,,1,160.0,,"Distribution in rat intestine 15 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624490,BAO_0000218,
11420,Intermediate,10116.0,,1,160.0,,"Distribution in rat intestine 1 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624491,BAO_0000218,
11421,Intermediate,10116.0,,1,160.0,,"Distribution in rat intestine 2 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624492,BAO_0000218,
11422,Intermediate,10116.0,,1,160.0,,"Distribution in rat intestine 30 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624493,BAO_0000218,
11423,Intermediate,10116.0,,1,160.0,,"Distribution in rat intestine 4 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL877595,BAO_0000218,
11424,Intermediate,10116.0,,1,160.0,,"Distribution in rat intestine 5 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624494,BAO_0000218,
11425,Intermediate,10116.0,,1,160.0,,"Distribution in rat intestine 6 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624495,BAO_0000218,
11426,Intermediate,10116.0,,1,160.0,,"Distribution in rat intestine 8 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624681,BAO_0000218,
11427,Intermediate,10116.0,,1,,,"Distribution in rat kidney, 15 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624682,BAO_0000218,
11428,Intermediate,10116.0,,1,,,"Distribution in rat kidney, 1 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624683,BAO_0000218,
11429,Intermediate,10116.0,,1,,,"Distribution in rat kidney, 2 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624684,BAO_0000218,
11430,Intermediate,10116.0,,1,,,"Distribution in rat kidney, 30 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624685,BAO_0000218,
11431,Intermediate,10116.0,,1,,,"Distribution in rat kidney, 4 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624686,BAO_0000218,
11432,Intermediate,10116.0,,1,,,"Distribution in rat kidney, 5 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624687,BAO_0000218,
11433,Intermediate,10116.0,,1,,,"Distribution in rat kidney, 6 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624688,BAO_0000218,
11434,Intermediate,10116.0,,1,,,"Distribution in rat kidney, 8 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL627161,BAO_0000218,
11435,Intermediate,10116.0,,1,,,"Distribution in rat liver 15 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL622127,BAO_0000218,
11436,Intermediate,10116.0,,1,,,"Distribution in rat liver 1 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL622128,BAO_0000218,
11437,Intermediate,10116.0,,1,,,"Distribution in rat liver 2 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL874384,BAO_0000218,
11438,Intermediate,10116.0,,1,,,"Distribution in rat liver 30 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624898,BAO_0000218,
11439,Intermediate,10116.0,,1,,,"Distribution in rat liver 4 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624899,BAO_0000218,
11440,Intermediate,10116.0,,1,,,"Distribution in rat liver 5 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624900,BAO_0000218,
11441,Intermediate,10116.0,,1,,,"Distribution in rat liver 6 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624901,BAO_0000218,
11442,Intermediate,10116.0,,1,,,"Distribution in rat liver 8 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624902,BAO_0000218,
11443,Intermediate,10116.0,,1,,,"Distribution in rat lungs 15 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624903,BAO_0000218,
11444,Intermediate,10116.0,,1,,,"Distribution in rat lungs 1 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624904,BAO_0000218,
11445,Intermediate,10116.0,,1,,,"Distribution in rat lungs 2 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624905,BAO_0000218,
11446,Intermediate,10116.0,,1,,,"Distribution in rat lungs 30 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624906,BAO_0000218,
11447,Intermediate,10116.0,,1,,,"Distribution in rat lungs 4 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624907,BAO_0000218,
11448,Intermediate,10116.0,,1,,,"Distribution in rat lungs 5 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624908,BAO_0000218,
11449,Intermediate,10116.0,,1,,,"Distribution in rat lungs 6 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624909,BAO_0000218,
11450,Intermediate,10116.0,,1,,,"Distribution in rat lungs 8 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624910,BAO_0000218,
11451,Intermediate,10116.0,,1,2385.0,,"Distribution in rat muscle 15 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624911,BAO_0000218,
11452,Intermediate,10116.0,,1,2385.0,,"Distribution in rat muscle 1 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL874388,BAO_0000218,
11453,Intermediate,10116.0,,1,2385.0,,"Distribution in rat muscle 2 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL624912,BAO_0000218,
11454,Intermediate,10116.0,,1,2385.0,,"Distribution in rat muscle 30 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL622930,BAO_0000218,
11455,Intermediate,10116.0,,1,2385.0,,"Distribution in rat muscle 4 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623121,BAO_0000218,
11456,Intermediate,10116.0,,1,2385.0,,"Distribution in rat muscle 5 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623122,BAO_0000218,
11457,Intermediate,10116.0,,1,2385.0,,"Distribution in rat muscle 6 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623123,BAO_0000218,
11458,Intermediate,10116.0,,1,2385.0,,"Distribution in rat muscle 8 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623124,BAO_0000218,
11459,Intermediate,10116.0,,1,,,"Distribution in rat pancreas 15 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623125,BAO_0000218,
11460,Intermediate,10116.0,,1,,,"Distribution in rat pancreas 1 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623126,BAO_0000218,
11461,Intermediate,10116.0,,1,,,"Distribution in rat pancreas 2 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623127,BAO_0000218,
11462,Intermediate,10116.0,,1,,,"Distribution in rat pancreas 30 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623128,BAO_0000218,
11463,Intermediate,10116.0,,1,,,"Distribution in rat pancreas 4 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623129,BAO_0000218,
11464,Intermediate,10116.0,,1,,,"Distribution in rat pancreas 5 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623130,BAO_0000218,
11465,Intermediate,10116.0,,1,,,"Distribution in rat pancreas 6 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623131,BAO_0000218,
11466,Intermediate,10116.0,,1,,,"Distribution in rat pancreas 8 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL623132,BAO_0000218,
11467,Intermediate,10116.0,,1,2107.0,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL623133,BAO_0000218,
11468,Intermediate,10116.0,,1,,,The distribution of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL623134,BAO_0000218,
11469,Intermediate,10116.0,,1,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL874389,BAO_0000218,
11470,Intermediate,10116.0,,1,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL623135,BAO_0000218,
11471,Intermediate,10116.0,,1,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL623136,BAO_0000218,
11472,Intermediate,10116.0,,1,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL623137,BAO_0000218,
11473,Intermediate,10116.0,,1,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL623138,BAO_0000218,
11474,Intermediate,10116.0,,1,2113.0,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL623139,BAO_0000218,
11475,Intermediate,10116.0,,1,2113.0,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL623140,BAO_0000218,
11476,Intermediate,10116.0,,1,2107.0,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL623141,BAO_0000218,
11477,Intermediate,10116.0,,1,2107.0,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL623142,BAO_0000218,
11478,Intermediate,10116.0,,1,,,The distribution of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL623143,BAO_0000218,
11479,Intermediate,10090.0,,1,1088.0,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in mouse.,N,,,50594,1,,CHEMBL623144,BAO_0000218,
11480,Intermediate,10116.0,,1,1088.0,,The total amount of penciclovir recovered in the urine over a 48-h period was determined by HPLC using a C18 reversed-phase column in rat.,N,,,50597,1,,CHEMBL623405,BAO_0000218,
11481,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat blood as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL624074,BAO_0000218,
11482,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL624075,BAO_0000218,
11483,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat brain as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL624076,BAO_0000218,
11484,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL624077,BAO_0000218,
11485,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat heart as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL624078,BAO_0000218,
11486,Intermediate,10116.0,,1,2113.0,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL624079,BAO_0000218,
11487,Intermediate,10116.0,,1,2113.0,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL624261,BAO_0000218,
11488,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL624262,BAO_0000218,
11489,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat liver as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL624263,BAO_0000218,
11490,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 30 min was evaluated in rat lung as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL624264,BAO_0000218,
11491,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat blood as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL624265,BAO_0000218,
11492,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL624266,BAO_0000218,
11493,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat brain as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL624267,BAO_0000218,
11494,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL624268,BAO_0000218,
11495,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat heart as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL875227,BAO_0000218,
11496,Intermediate,10116.0,,1,2113.0,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL624269,BAO_0000218,
11497,Intermediate,10116.0,,1,2113.0,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat kidney as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL624270,BAO_0000218,
11498,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose in the total organ,N,,,50597,1,,CHEMBL624271,BAO_0000218,
11499,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat liver as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL624272,BAO_0000218,
11500,Intermediate,10116.0,,1,,,The uptake of the 131 I-labeled compound at 5 min was evaluated in rat lung as Percent of injected dose per gram in the organ,N,,,50597,1,,CHEMBL624273,BAO_0000218,
11501,Intermediate,10116.0,,1,1088.0,,Urinary excretion in rat after 0-4 hours of oral administration at 50 mg/kg,N,,,50597,1,,CHEMBL624274,BAO_0000218,
11502,Intermediate,10116.0,,1,1088.0,,Urinary excretion in rat after 4-8 hours of oral administration at 50 mg/kg,N,,,50597,1,,CHEMBL624275,BAO_0000218,
11503,Intermediate,10116.0,,1,1088.0,,Urinary excretion in rat after 8-24 hours of oral administration at 50 mg/kg,N,,,50597,1,,CHEMBL624276,BAO_0000218,
11504,Intermediate,10116.0,,1,1088.0,,Urinary recovery expressed as percentage dose in male rats after iv administration of 20 mg/kg,N,,,50597,1,,CHEMBL624277,BAO_0000218,
11505,Autocuration,,,1,,,% dose converted to 2-amino-5-chlorophenyl sulfate,U,,,22224,0,,CHEMBL624278,BAO_0000019,
11506,Autocuration,,,1,,,% dose converted to 4-(S-amino-N-{[(4-chlorophenyl)amino]carbonyl}sulfonimidoyl)benzoic acid (compound 41),U,,,22224,0,,CHEMBL624279,BAO_0000019,
11507,Intermediate,10116.0,,1,1988.0,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",N,,,50597,1,,CHEMBL624280,BAO_0000218,
11508,Intermediate,10116.0,,1,1988.0,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",N,,,50597,1,,CHEMBL624281,BAO_0000218,
11509,Intermediate,10116.0,,1,1988.0,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",N,,,50597,1,,CHEMBL622933,BAO_0000218,
11510,Intermediate,10116.0,,1,1988.0,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",N,,,50597,1,,CHEMBL622934,BAO_0000218,
11511,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in Rat liver after 30 minutes of iv administration; per g of tissue,N,,,50597,1,,CHEMBL622935,BAO_0000218,
11512,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in Rat liver after 5 minutes of iv administration,N,,,50597,1,,CHEMBL622936,BAO_0000218,
11513,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in Rat liver after 5 minutes of iv administration; per g of tissue,N,,,50597,1,,CHEMBL875228,BAO_0000218,
11514,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in Rat lung after 24 hours of iv administration,N,,,50597,1,,CHEMBL622937,BAO_0000218,
11515,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in Rat lung after 24 hours of iv administration; per g of tissue,N,,,50597,1,,CHEMBL622938,BAO_0000218,
11516,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in Rat lung after 30 minutes of iv administration,N,,,50597,1,,CHEMBL619736,BAO_0000218,
11517,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in Rat lung after 30 minutes of iv administration; per g of tissue,N,,,50597,1,,CHEMBL625117,BAO_0000218,
11518,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in Rat lung after 5 minutes of iv administration,N,,,50597,1,,CHEMBL625118,BAO_0000218,
11519,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in Rat lung after 5 minutes of iv administration; per g of tissue,N,,,50597,1,,CHEMBL625119,BAO_0000218,
11520,Intermediate,10116.0,In vivo,1,2037.0,,"Biodistribution in rat cerebellum, expressed as percent I.D./g tissue",N,,,50597,1,,CHEMBL625120,BAO_0000218,
11521,Intermediate,10116.0,In vivo,1,,,"Biodistribution in rat superior coliculus, expressed as percent I.D./g tissue",N,,,50597,1,,CHEMBL625121,BAO_0000218,
11522,Intermediate,10116.0,In vivo,1,10000006.0,,"Biodistribution in rat thalamus, expressed as percent I.D./g tissue",N,,,50597,1,,CHEMBL625122,BAO_0000218,
11523,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,,50597,1,,CHEMBL622204,BAO_0000218,
11524,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,,50597,1,,CHEMBL877503,BAO_0000218,
11525,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution was measured in blood of rat by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,,50597,1,,CHEMBL627127,BAO_0000218,
11526,Autocuration,,In vivo,1,10000000.0,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 2 min,U,,,22224,0,,CHEMBL627128,BAO_0000218,
11527,Autocuration,,In vivo,1,10000000.0,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 30 min,U,,,22224,0,,CHEMBL627129,BAO_0000218,
11528,Autocuration,,In vivo,1,10000000.0,,Biodistribution was measured in hippocampus region(HP/CB) by injecting the radiolabeled compound intravenously and the value measured after 60 min,U,,,22224,0,,CHEMBL627130,BAO_0000218,
11529,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,,50597,1,,CHEMBL627131,BAO_0000218,
11530,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,,50597,1,,CHEMBL627132,BAO_0000218,
11531,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution was measured in rat brain by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,,50597,1,,CHEMBL627133,BAO_0000218,
11532,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,,50597,1,,CHEMBL627134,BAO_0000218,
11533,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,,50597,1,,CHEMBL627135,BAO_0000218,
11534,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution was measured in rat cerebellum by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,,50597,1,,CHEMBL627136,BAO_0000218,
11535,Intermediate,10116.0,In vivo,1,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,,50597,1,,CHEMBL628435,BAO_0000218,
11536,Intermediate,10116.0,In vivo,1,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,,50597,1,,CHEMBL628436,BAO_0000218,
11537,Intermediate,10116.0,In vivo,1,,,Biodistribution was measured in rat cortex by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,,50597,1,,CHEMBL628437,BAO_0000218,
11538,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,,50597,1,,CHEMBL628438,BAO_0000218,
11539,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,,50597,1,,CHEMBL628439,BAO_0000218,
11540,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution was measured in rat heart by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,,50597,1,,CHEMBL628440,BAO_0000218,
11541,Intermediate,10116.0,In vivo,1,10000000.0,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,,50597,1,,CHEMBL628441,BAO_0000218,
11542,Intermediate,10116.0,In vivo,1,10000000.0,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,,50597,1,,CHEMBL628442,BAO_0000218,
11543,Intermediate,10116.0,In vivo,1,10000000.0,,Biodistribution was measured in rat hippocampus by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,,50597,1,,CHEMBL628443,BAO_0000218,
11544,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,,50597,1,,CHEMBL628444,BAO_0000218,
11545,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,,50597,1,,CHEMBL628445,BAO_0000218,
11546,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution was measured in rat kidney by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,,50597,1,,CHEMBL877504,BAO_0000218,
11547,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,,50597,1,,CHEMBL628446,BAO_0000218,
11548,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,,50597,1,,CHEMBL626874,BAO_0000218,
11549,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution was measured in rat liver by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,,50597,1,,CHEMBL626875,BAO_0000218,
11550,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,,50597,1,,CHEMBL626876,BAO_0000218,
11551,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,,50597,1,,CHEMBL626877,BAO_0000218,
11552,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution was measured in rat lung by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,,50597,1,,CHEMBL626878,BAO_0000218,
11553,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,,50597,1,,CHEMBL626879,BAO_0000218,
11554,Autocuration,314293.0,In vivo,1,1969.0,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of monkey after oral administration of 0.05 mmol/kg,U,,,22224,0,,CHEMBL626880,BAO_0000218,
11555,Intermediate,10090.0,In vivo,1,1969.0,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of mouse after oral administration of 0.05 mmol/kg,N,,,50594,1,,CHEMBL626881,BAO_0000218,
11556,Intermediate,10116.0,In vivo,1,1969.0,,Peak plasma concentration expresses the ability of compound for the release of dopamine in the plasma of rat after oral administration of 0.05 mmol/kg,N,,,50597,1,,CHEMBL626882,BAO_0000218,
11557,Intermediate,9615.0,In vivo,1,1969.0,,Peak plasma concentration was measured in dogs,N,,,50588,1,,CHEMBL626883,BAO_0000218,
11558,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic Parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,,,50597,1,,CHEMBL626884,BAO_0000218,
11559,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,N,,,50597,1,,CHEMBL626885,BAO_0000218,
11560,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,N,,,50597,1,,CHEMBL626886,BAO_0000218,
11561,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter (Cmax ) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,N,,,50597,1,,CHEMBL626887,BAO_0000218,
11562,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter (Cmax) was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,,,50597,1,,CHEMBL626888,BAO_0000218,
11563,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 15 mg/kg to dog,N,,,50588,1,,CHEMBL626889,BAO_0000218,
11564,Autocuration,314293.0,In vivo,1,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 25 mg/kg to monkey,U,,,22224,0,,CHEMBL626761,BAO_0000218,
11565,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg abd antacid (CaCO3 dosed orally 10 min prior to and 60 min postdosing) to dog,N,,,50588,1,,CHEMBL626762,BAO_0000218,
11566,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 30 mg/kg to dog,N,,,50588,1,,CHEMBL626763,BAO_0000218,
11567,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 50 mg/kg to rat,N,,,50597,1,,CHEMBL626764,BAO_0000218,
11568,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter Cmax determined after intravenous administration of 60 mg/kg to rat,N,,,50597,1,,CHEMBL626765,BAO_0000218,
11569,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to dog,N,,,50588,1,,CHEMBL626766,BAO_0000218,
11570,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat,N,,,50597,1,,CHEMBL626767,BAO_0000218,
11571,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter Cmax determined after oral administration of 50 mg/kg to rat; No levels,N,,,50597,1,,CHEMBL626768,BAO_0000218,
11572,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter Cmax determined after peroral administration of 15 mg/kg to dog,N,,,50588,1,,CHEMBL626769,BAO_0000218,
11573,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to dog,N,,,50588,1,,CHEMBL874463,BAO_0000218,
11574,Autocuration,314293.0,In vivo,1,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey,U,,,22224,0,,CHEMBL626770,BAO_0000218,
11575,Autocuration,314293.0,In vivo,1,,,Pharmacokinetic parameter Cmax determined after peroral administration of 25 mg/kg to monkey; No levels,U,,,22224,0,,CHEMBL626771,BAO_0000218,
11576,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter Cmax determined after peroral administration of 50 mg/kg to rat,N,,,50597,1,,CHEMBL626772,BAO_0000218,
11577,Intermediate,9541.0,In vivo,1,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,N,,,100710,1,,CHEMBL626773,BAO_0000218,
11578,Intermediate,10090.0,In vivo,1,,,Pharmacokinetic parameter Cmax for the compound was evaluated in nude mice after oral administration. ,N,,,50594,1,,CHEMBL626774,BAO_0000218,
11579,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 375 mg/kg,N,,,50588,1,,CHEMBL626775,BAO_0000218,
11580,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter Cmax has been determined in fed Beagle dogs at a dose of 500 mg/kg,N,,,50588,1,,CHEMBL626776,BAO_0000218,
11581,Intermediate,10116.0,In vivo,1,,,Maximum concentration (Cmax) in rat when administered orally,N,,,50597,1,,CHEMBL626777,BAO_0000218,
11582,Autocuration,314293.0,In vivo,1,1969.0,,Maximal concentration in monkey plasma after 25 mg/kg oral dose,U,,,22224,0,,CHEMBL626778,BAO_0000218,
11583,Autocuration,10116.0,In vivo,1,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.17-0.20)",U,,,22224,0,,CHEMBL626779,BAO_0000218,
11584,Autocuration,10116.0,In vivo,1,,,"Mean Cmax in rats after 5 mg/kg oral dose, range (0.4-0.8)",U,,,22224,0,,CHEMBL626780,BAO_0000218,
11585,Autocuration,,In vivo,1,1969.0,,Cmax in rat plasma after single 5 mg/kg oral cassette gavage dose,U,,,22224,0,,CHEMBL626781,BAO_0000218,
11586,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic profile Cmax was evaluated in rats,N,,,50597,1,,CHEMBL632164,BAO_0000218,
11587,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in dog (25 mg/kg),N,,,50588,1,,CHEMBL632165,BAO_0000218,
11588,Intermediate,10090.0,In vivo,1,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration in mice (50 mg/kg),N,,,50594,1,,CHEMBL632166,BAO_0000218,
11589,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to dog (25 mg/kg),N,,,50588,1,,CHEMBL632167,BAO_0000218,
11590,Intermediate,10090.0,In vivo,1,,,Pharmacokinetic property(Cmax- maximum concentration) after oral administration to mice (50 mg/kg),N,,,50594,1,,CHEMBL632168,BAO_0000218,
11591,Autocuration,10116.0,In vivo,1,1969.0,,Cmax in rat plasma,U,,,22224,0,,CHEMBL632169,BAO_0000218,
11592,Intermediate,9615.0,In vivo,1,1969.0,,Cmax in dog plasma after 30mg/kg oral dose,N,,,50588,1,,CHEMBL632170,BAO_0000218,
11593,Intermediate,10116.0,In vivo,1,1969.0,,Cmax in rat plasma after 30mg/kg oral dose,N,,,50597,1,,CHEMBL632171,BAO_0000218,
11594,Intermediate,10116.0,In vivo,1,1969.0,,Plasma level in rats at 30 mg/kg,N,,,50597,1,,CHEMBL632172,BAO_0000218,
11595,Intermediate,10090.0,In vivo,1,1969.0,,Tested for maximum plasma concentration in mice,N,,,50594,1,,CHEMBL632173,BAO_0000218,
11596,Intermediate,10116.0,In vivo,1,,,"The Cmax value in female wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL632174,BAO_0000218,
11597,Intermediate,10116.0,In vivo,1,,,The Cmax values in female wistar rats.,N,,,50597,1,,CHEMBL632175,BAO_0000218,
11598,Intermediate,9615.0,In vivo,1,1969.0,,The Peak plasma concentration was measured in dogs after oral administration of 1 mg/kg dose,N,,,50588,1,,CHEMBL632176,BAO_0000218,
11599,Intermediate,10116.0,In vivo,1,1969.0,,The Peak plasma concentration was measured in rats after oral administration of 1 mg/kg dose,N,,,50597,1,,CHEMBL632177,BAO_0000218,
11600,Intermediate,10116.0,In vivo,1,1969.0,,The compound tested for maximum observed plasma concentration in rats and is expressed in microgram/mL.,N,,,50597,1,,CHEMBL632178,BAO_0000218,
11601,Intermediate,10116.0,In vivo,1,,,The compound was tested for Cmax value pharmacokinetic parameter in the male Sprague-Dawley rat.,N,,,50597,1,,CHEMBL632179,BAO_0000218,
11602,Intermediate,10116.0,In vivo,1,178.0,,The compound was tested for maximum blood level reached in rats at 15.9 uM/kg after peroral administration.,N,,,50597,1,,CHEMBL632180,BAO_0000218,
11603,Intermediate,10116.0,In vivo,1,178.0,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after intravenous administration.,N,,,50597,1,,CHEMBL632181,BAO_0000218,
11604,Intermediate,10116.0,In vivo,1,178.0,,The compound was tested for maximum blood level reached in rats at 15.9 uM/Kg after peroral administration.,N,,,50597,1,,CHEMBL632182,BAO_0000218,
11605,Autocuration,10090.0,In vivo,1,178.0,,The maximum concentration observed (Cmax) in the blood sample at indicated time point (tmax) at a dose 50 mg/Kg administered orally in mice.,U,,,22224,0,,CHEMBL632183,BAO_0000218,
11606,Intermediate,9615.0,In vivo,1,,,The maximum concentration of the compound was measured in dog at dose 5 mg/kg after peroral administration.,N,,,50588,1,,CHEMBL632184,BAO_0000218,
11607,Intermediate,10116.0,In vivo,1,,,The maximum concentration of the compound was measured in rat at dose 1 mg/kg after peroral administration.,N,,,50597,1,,CHEMBL874470,BAO_0000218,
11608,Intermediate,10116.0,,1,,,"Distribution in rat skin 15 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL631302,BAO_0000218,
11609,Intermediate,10116.0,,1,,,"Distribution in rat skin 1 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL631303,BAO_0000218,
11610,Intermediate,10116.0,,1,,,"Distribution in rat skin 2 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL631304,BAO_0000218,
11611,Intermediate,10116.0,,1,,,"Distribution in rat skin 30 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL631305,BAO_0000218,
11612,Intermediate,10116.0,,1,,,"Distribution in rat skin 4 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL631306,BAO_0000218,
11613,Intermediate,10116.0,,1,,,"Distribution in rat skin 5 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL631307,BAO_0000218,
11614,Intermediate,10116.0,,1,,,"Distribution in rat skin 6 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL631308,BAO_0000218,
11615,Intermediate,10116.0,,1,,,"Distribution in rat skin 8 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL625557,BAO_0000218,
11616,Intermediate,10116.0,,1,2106.0,,"Distribution in rat spleen 15 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL625558,BAO_0000218,
11617,Intermediate,10116.0,,1,2106.0,,"Distribution in rat spleen 1 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL625559,BAO_0000218,
11618,Intermediate,10116.0,,1,2106.0,,"Distribution in rat spleen 2 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL625560,BAO_0000218,
11619,Intermediate,10116.0,,1,2106.0,,"Distribution in rat spleen 30 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL625561,BAO_0000218,
11620,Intermediate,10116.0,,1,2106.0,,"Distribution in rat spleen 4 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL625562,BAO_0000218,
11621,Intermediate,10116.0,,1,2106.0,,"Distribution in rat spleen 5 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL875320,BAO_0000218,
11622,Intermediate,10116.0,,1,2106.0,,"Distribution in rat spleen 6 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL625563,BAO_0000218,
11623,Intermediate,10116.0,,1,2106.0,,"Distribution in rat spleen 8 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL625564,BAO_0000218,
11624,Intermediate,10116.0,,1,995.0,,"Distribution in rat uterus 15 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL625565,BAO_0000218,
11625,Intermediate,10116.0,,1,995.0,,"Distribution in rat uterus 1 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL625566,BAO_0000218,
11626,Intermediate,10116.0,,1,995.0,,"Distribution in rat uterus 2 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL625567,BAO_0000218,
11627,Intermediate,10116.0,,1,995.0,,"Distribution in rat uterus 30 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL625568,BAO_0000218,
11628,Intermediate,10116.0,,1,995.0,,"Distribution in rat uterus 4 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL628217,BAO_0000218,
11629,Intermediate,10116.0,,1,995.0,,"Distribution in rat uterus 5 min after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL628218,BAO_0000218,
11630,Intermediate,10116.0,,1,995.0,,"Distribution in rat uterus 6 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL628219,BAO_0000218,
11631,Intermediate,10116.0,,1,995.0,,"Distribution in rat uterus 8 hr after intravenous administration, injected dose/gm",N,,,50597,1,,CHEMBL628220,BAO_0000218,
11632,Autocuration,,,1,,,Distribution in the blood after 120 min of intravenous administration,U,,,22224,0,,CHEMBL628221,BAO_0000019,
11633,Autocuration,,,1,,,Distribution in the blood after 15 min of intravenous administration,U,,,22224,0,,CHEMBL628222,BAO_0000019,
11634,Autocuration,,,1,,,Distribution in the blood after 30 min of intravenous administration,U,,,22224,0,,CHEMBL628223,BAO_0000019,
11635,Autocuration,,,1,,,Distribution in the blood after 5 min of intravenous administration,U,,,22224,0,,CHEMBL628224,BAO_0000019,
11636,Autocuration,,,1,,,Distribution in the blood after 60 min of intravenous administration,U,,,22224,0,,CHEMBL628225,BAO_0000019,
11637,Autocuration,,,1,,,Distribution in the blood after 90 min of intravenous administration,U,,,22224,0,,CHEMBL628226,BAO_0000019,
11638,Autocuration,,,1,,,Distribution in the bone after 120 min of intravenous administration,U,,,22224,0,,CHEMBL628227,BAO_0000019,
11639,Autocuration,,,1,,,Distribution in the bone after 15 min of intravenous administration,U,,,22224,0,,CHEMBL875481,BAO_0000019,
11640,Autocuration,,,1,,,Distribution in the bone after 30 min of intravenous administration,U,,,22224,0,,CHEMBL628228,BAO_0000019,
11641,Autocuration,,,1,,,Distribution in the bone after 5 min of intravenous administration,U,,,22224,0,,CHEMBL628229,BAO_0000019,
11642,Autocuration,,,1,,,Distribution in the bone after 60 min of intravenous administration,U,,,22224,0,,CHEMBL628230,BAO_0000019,
11643,Autocuration,,,1,,,Distribution in the bone after 90 min of intravenous administration,U,,,22224,0,,CHEMBL628231,BAO_0000019,
11644,Autocuration,,,1,,,Distribution in the heart after 120 min of intravenous administration,U,,,22224,0,,CHEMBL628232,BAO_0000019,
11645,Autocuration,,,1,,,Distribution in the heart after 15 min of intravenous administration,U,,,22224,0,,CHEMBL628233,BAO_0000019,
11646,Autocuration,,,1,,,Distribution in the heart after 30 min of intravenous administration,U,,,22224,0,,CHEMBL628234,BAO_0000019,
11647,Autocuration,,,1,,,Distribution in the heart after 5 min of intravenous administration,U,,,22224,0,,CHEMBL628235,BAO_0000019,
11648,Autocuration,,,1,,,Distribution in the heart after 60 min of intravenous administration,U,,,22224,0,,CHEMBL628236,BAO_0000019,
11649,Autocuration,,,1,,,Distribution in the heart after 90 min of intravenous administration,U,,,22224,0,,CHEMBL628237,BAO_0000019,
11650,Autocuration,,,1,,,Distribution in the kidneys after 120 min of intravenous administration,U,,,22224,0,,CHEMBL628238,BAO_0000019,
11651,Autocuration,,,1,,,Distribution in the kidneys after 15 min of intravenous administration,U,,,22224,0,,CHEMBL628239,BAO_0000019,
11652,Autocuration,,,1,,,Distribution in the kidneys after 30 min of intravenous administration,U,,,22224,0,,CHEMBL628240,BAO_0000019,
11653,Autocuration,,,1,,,Distribution in the kidneys after 5 min of intravenous administration,U,,,22224,0,,CHEMBL628241,BAO_0000019,
11654,Autocuration,,,1,,,Distribution in the kidneys after 60 min of intravenous administration,U,,,22224,0,,CHEMBL628242,BAO_0000019,
11655,Autocuration,,,1,,,Distribution in the kidneys after 90 min of intravenous administration,U,,,22224,0,,CHEMBL875482,BAO_0000019,
11656,Autocuration,,,1,,,Distribution in the liver after 120 min of intravenous administration,U,,,22224,0,,CHEMBL628243,BAO_0000019,
11657,Autocuration,,,1,,,Distribution in the liver after 15 min of intravenous administration,U,,,22224,0,,CHEMBL628244,BAO_0000019,
11658,Autocuration,,,1,,,Distribution in the liver after 30 min of intravenous administration,U,,,22224,0,,CHEMBL628245,BAO_0000019,
11659,Autocuration,,,1,,,Distribution in the liver after 5 min of intravenous administration,U,,,22224,0,,CHEMBL628246,BAO_0000019,
11660,Autocuration,,,1,,,Distribution in the liver after 60 min of intravenous administration,U,,,22224,0,,CHEMBL628247,BAO_0000019,
11661,Autocuration,,,1,,,Distribution in the liver after 90 min of intravenous administration,U,,,22224,0,,CHEMBL628248,BAO_0000019,
11662,Autocuration,,,1,,,Distribution in the lung after 120 min of intravenous administration,U,,,22224,0,,CHEMBL628249,BAO_0000019,
11663,Intermediate,10090.0,,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, iv and the total drug exposure was determined. (0-24hr)",N,,,50594,1,,CHEMBL625452,BAO_0000218,
11664,Intermediate,10090.0,,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, as HCl salt in solution, perorally and the total drug exposure was determined (0-24hr)",N,,,50594,1,,CHEMBL625453,BAO_0000218,
11665,Intermediate,10090.0,,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, iv and the total drug exposure was determined. (0-24hr)",N,,,50594,1,,CHEMBL625454,BAO_0000218,
11666,Intermediate,10090.0,,1,,,"In vivo antitumor efficacy in nude mice by injecting a dose of 25 mg/kg, micronized free base in 20% HPbetaCD, perorally and the total drug exposure was determined (0-24hr)",N,,,50594,1,,CHEMBL623844,BAO_0000218,
11667,Intermediate,10116.0,,1,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 1 mg/kg (normalized to a 1 mg/kg dose) in rat,N,,,50597,1,,CHEMBL623845,BAO_0000218,
11668,Intermediate,10116.0,,1,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 2.5 mg/kg (normalized to a 1 mg/kg dose) in rat,N,,,50597,1,,CHEMBL623846,BAO_0000218,
11669,Autocuration,,,1,,,Integrated area under the blood concentration vs time curve for the period 0-24 hr postdose of 5.0 mg/kg (normalized to a 1 mg/kg dose) GP,U,,,22224,0,,CHEMBL623847,BAO_0000218,
11670,Intermediate,9541.0,,1,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,N,,,100710,1,,CHEMBL623848,BAO_0000218,
11671,Intermediate,9541.0,,1,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,N,,,100710,1,,CHEMBL623849,BAO_0000218,
11672,Intermediate,9541.0,,1,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,N,,,100710,1,,CHEMBL623850,BAO_0000218,
11673,Intermediate,9541.0,,1,,,Integrated area under the plasma drug level-time curve after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,N,,,100710,1,,CHEMBL623851,BAO_0000218,
11674,Autocuration,314293.0,,1,,,Integrated area under the plasma drug level-time curve was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,U,,,22224,0,,CHEMBL623852,BAO_0000218,
11675,Intermediate,9669.0,,1,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,N,,,50506,1,,CHEMBL624551,BAO_0000218,
11676,Intermediate,9669.0,,1,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",N,,,50506,1,,CHEMBL624552,BAO_0000218,
11677,Autocuration,314293.0,,1,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,U,,,22224,0,,CHEMBL624553,BAO_0000218,
11678,Autocuration,314293.0,,1,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey determined by renin inhibition assay,U,,,22224,0,,CHEMBL624554,BAO_0000218,
11679,Intermediate,10116.0,,1,,,Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,N,,,50597,1,,CHEMBL624555,BAO_0000218,
11680,Intermediate,10116.0,,1,,,"Integrated area under the plasma drug level-time curve was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",N,,,50597,1,,CHEMBL624741,BAO_0000218,
11681,Intermediate,9615.0,,1,,,"Intravenous integrated area under the concentration vs time curve, for compound in dog plasma",N,,,50588,1,,CHEMBL624742,BAO_0000218,
11682,Intermediate,10026.0,,1,,,"Intravenous integrated area under the concentration vs time curve, for compound in hamster plasma",N,,,100712,1,,CHEMBL624743,BAO_0000218,
11683,Intermediate,10116.0,,1,,,"Intravenous integrated area under the concentration vs time curve, for compound in rat plasma",N,,,50597,1,,CHEMBL877606,BAO_0000218,
11684,Autocuration,,,1,,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg,U,,,22224,0,,CHEMBL624744,BAO_0000218,
11685,Autocuration,,,1,178.0,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b = No compound detectable in blood above the detection limit of 0.1 uM,U,,,22224,0,,CHEMBL624745,BAO_0000218,
11686,Autocuration,,,1,178.0,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg; b denotes No compound detectable in blood above the detection limit of 0.1 uM,U,,,22224,0,,CHEMBL624746,BAO_0000218,
11687,Autocuration,,,1,178.0,,Oral Bioavailability was measured as area-under-curve(AUC) value at dose 125 mg/kg;b = No compound detectable in blood above the detection limit of 0.1 uM,U,,,22224,0,,CHEMBL624747,BAO_0000218,
11688,Autocuration,,,1,,,Oral absorption expressed as Area under curve was determined,U,,,22224,0,,CHEMBL624748,BAO_0000019,
11689,Intermediate,9615.0,,1,,,Oral absorption kinetics (AUC) was determined after administration of compound orally at 1 mg/kg in dogs,N,,,50588,1,,CHEMBL622504,BAO_0000218,
11690,Intermediate,9615.0,,1,,,"Oral integrated area under the concentration vs time curve, for compound in dog plasma",N,,,50588,1,,CHEMBL622505,BAO_0000218,
11691,Intermediate,10026.0,,1,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",N,,,100712,1,,CHEMBL622506,BAO_0000218,
11692,Intermediate,10026.0,,1,,,"Oral integrated area under the concentration vs time curve, for compound in hamster plasma",N,,,100712,1,,CHEMBL622507,BAO_0000218,
11693,Intermediate,10116.0,,1,,,"Oral integrated area under the concentration vs time curve, for compound in rat plasma",N,,,50597,1,,CHEMBL622508,BAO_0000218,
11694,Autocuration,,,1,,,Pharmacokinetic parameter AUC in mice following a single dose intravenous administration of the compound,U,,,22224,0,,CHEMBL622509,BAO_0000019,
11695,Intermediate,10116.0,,1,,,Pharmacokinetic Parameter [Area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,,,50597,1,,CHEMBL622510,BAO_0000218,
11696,Intermediate,10116.0,,1,,,Pharmacokinetic parameter (AUC) was determined after administering 1 mg/kg of compound intravenously in rat no.3 belonging to phenotype EM (extensive metabolizer),N,,,50597,1,,CHEMBL622511,BAO_0000218,
11697,Intermediate,9541.0,,1,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,N,,,100710,1,,CHEMBL622512,BAO_0000218,
11698,Intermediate,9541.0,,1,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,N,,,100710,1,,CHEMBL622513,BAO_0000218,
11699,Intermediate,9541.0,,1,,,Pharmacokinetic parameter AUC calculated in cynomolgus monkey when the compound was administered po at 5 mg/kg concentration,N,,,100710,1,,CHEMBL622514,BAO_0000218,
11700,Intermediate,9615.0,,1,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,N,,,50588,1,,CHEMBL622515,BAO_0000218,
11701,Intermediate,9615.0,,1,,,Pharmacokinetic parameter AUC calculated in dog when the compound was administered po at 5 mg/kg concentration,N,,,50588,1,,CHEMBL622516,BAO_0000218,
11702,Intermediate,10116.0,,1,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,N,,,50597,1,,CHEMBL622517,BAO_0000218,
11703,Intermediate,10116.0,,1,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 12 mg/kg concentration,N,,,50597,1,,CHEMBL622518,BAO_0000218,
11704,Intermediate,10116.0,,1,,,Pharmacokinetic parameter AUC calculated in rat when the compound was administered po at 20 mg/kg concentration,N,,,50597,1,,CHEMBL622519,BAO_0000218,
11705,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,,50597,1,,CHEMBL622520,BAO_0000218,
11706,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution was measured in rat muscle by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,,50597,1,,CHEMBL622521,BAO_0000218,
11707,Intermediate,10090.0,In vivo,1,14.0,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,,50594,1,,CHEMBL625113,BAO_0000218,
11708,Intermediate,10116.0,In vivo,1,14.0,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,,50597,1,,CHEMBL625114,BAO_0000218,
11709,Intermediate,10116.0,In vivo,1,14.0,,Biodistribution was measured in rat skin by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,,50597,1,,CHEMBL874397,BAO_0000218,
11710,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,,50597,1,,CHEMBL625115,BAO_0000218,
11711,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,,50597,1,,CHEMBL625116,BAO_0000218,
11712,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution was measured in rat spleen by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,,50597,1,,CHEMBL623932,BAO_0000218,
11713,Intermediate,10116.0,In vivo,1,2435.0,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,,50597,1,,CHEMBL623933,BAO_0000218,
11714,Intermediate,10116.0,In vivo,1,2435.0,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,,50597,1,,CHEMBL623934,BAO_0000218,
11715,Intermediate,10116.0,In vivo,1,2435.0,,Biodistribution was measured in rat striatum by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,,50597,1,,CHEMBL623935,BAO_0000218,
11716,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 2 min,N,,,50597,1,,CHEMBL623936,BAO_0000218,
11717,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 30 min,N,,,50597,1,,CHEMBL623937,BAO_0000218,
11718,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution was measured in rat thyroid by injecting the radiolabeled compound intravenously and the value measured after 60 min,N,,,50597,1,,CHEMBL623938,BAO_0000218,
11719,Intermediate,10090.0,,1,,,In vivo biodistribution in mice blood bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,,50594,1,,CHEMBL623939,BAO_0000218,
11720,Intermediate,10090.0,,1,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 10 ug/g,N,,,50594,1,,CHEMBL623940,BAO_0000218,
11721,Intermediate,10090.0,,1,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 20 ug/g,N,,,50594,1,,CHEMBL623941,BAO_0000218,
11722,Intermediate,10090.0,,1,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,,50594,1,,CHEMBL627216,BAO_0000218,
11723,Intermediate,10090.0,,1,,,In vivo biodistribution in mice blood bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,,50594,1,,CHEMBL623942,BAO_0000218,
11724,Intermediate,10090.0,,1,955.0,,In vivo biodistribution in mice brain bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,,50594,1,,CHEMBL618793,BAO_0000218,
11725,Intermediate,10090.0,,1,955.0,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,,50594,1,,CHEMBL618794,BAO_0000218,
11726,Intermediate,10090.0,,1,955.0,,In vivo biodistribution in mice brain bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,,50594,1,,CHEMBL618795,BAO_0000218,
11727,Intermediate,10090.0,,1,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,,50594,1,,CHEMBL618796,BAO_0000218,
11728,Intermediate,10090.0,,1,,,In vivo biodistribution in mice eyes bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,,50594,1,,CHEMBL618797,BAO_0000218,
11729,Intermediate,10090.0,,1,2113.0,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,N,,,50594,1,,CHEMBL618798,BAO_0000218,
11730,Intermediate,10090.0,,1,2113.0,,In vivo biodistribution in mice kidney bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,,50594,1,,CHEMBL618799,BAO_0000218,
11731,Intermediate,10090.0,,1,2113.0,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 10 ug/g,N,,,50594,1,,CHEMBL618800,BAO_0000218,
11732,Intermediate,10090.0,,1,2113.0,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 20 ug/g,N,,,50594,1,,CHEMBL618801,BAO_0000218,
11733,Intermediate,10090.0,,1,2113.0,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,,50594,1,,CHEMBL618802,BAO_0000218,
11734,Intermediate,10090.0,,1,2113.0,,In vivo biodistribution in mice kidney bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,,50594,1,,CHEMBL618803,BAO_0000218,
11735,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 10 microg of boron/g/day,N,,,50594,1,,CHEMBL618804,BAO_0000218,
11736,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution in mice liver bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,,50594,1,,CHEMBL618805,BAO_0000218,
11737,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 10 ug/g,N,,,50594,1,,CHEMBL618806,BAO_0000218,
11738,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 20 ug/g,N,,,50594,1,,CHEMBL618807,BAO_0000218,
11739,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,,50594,1,,CHEMBL618808,BAO_0000218,
11740,Intermediate,10090.0,,1,2107.0,,In vivo biodistribution in mice liver bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,,50594,1,,CHEMBL618809,BAO_0000218,
11741,Intermediate,10090.0,,1,2385.0,,In vivo biodistribution in mice muscle bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,,50594,1,,CHEMBL618810,BAO_0000218,
11742,Intermediate,10090.0,,1,2385.0,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 10 ug/g,N,,,50594,1,,CHEMBL618811,BAO_0000218,
11743,Intermediate,10090.0,,1,2385.0,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 20 ug/g,N,,,50594,1,,CHEMBL875844,BAO_0000218,
11744,Intermediate,10090.0,,1,2385.0,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,,50594,1,,CHEMBL618812,BAO_0000218,
11745,Intermediate,10090.0,,1,2385.0,,In vivo biodistribution in mice muscle bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,,50594,1,,CHEMBL618813,BAO_0000218,
11746,Intermediate,10090.0,,1,,,In vivo biodistribution in mice skin bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,,50594,1,,CHEMBL618814,BAO_0000218,
11747,Intermediate,10090.0,,1,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,,50594,1,,CHEMBL618815,BAO_0000218,
11748,Intermediate,10090.0,,1,,,In vivo biodistribution in mice skin bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,,50594,1,,CHEMBL618816,BAO_0000218,
11749,Intermediate,10090.0,,1,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,,50594,1,,CHEMBL618817,BAO_0000218,
11750,Intermediate,10090.0,,1,,,In vivo biodistribution in mice skin by pump bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,,50594,1,,CHEMBL620544,BAO_0000218,
11751,Intermediate,10116.0,In vivo,1,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intraperitoneal administration.,N,,,50597,1,,CHEMBL626230,BAO_0000218,
11752,Intermediate,10116.0,In vivo,1,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after intravenous administration.,N,,,50597,1,,CHEMBL626231,BAO_0000218,
11753,Intermediate,10116.0,In vivo,1,,,The maximum concentration of the compound was measured in rat at dose 30 mg/kg after peroral administration.,N,,,50597,1,,CHEMBL626232,BAO_0000218,
11754,Intermediate,9615.0,In vivo,1,1969.0,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on dog.,N,,,50588,1,,CHEMBL626233,BAO_0000218,
11755,Intermediate,10116.0,In vivo,1,1969.0,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat,N,,,50597,1,,CHEMBL626234,BAO_0000218,
11756,Intermediate,10116.0,In vivo,1,1969.0,,The maximum plasma concentration (Cmax) is the observed peak plasma concentration after an oral dose on rat.,N,,,50597,1,,CHEMBL875341,BAO_0000218,
11757,Intermediate,9606.0,In vivo,1,1969.0,,The maximum plasma concentration (100 mg/kg) administered orally in human,N,,,50587,1,,CHEMBL626235,BAO_0000218,
11758,Autocuration,9481.0,In vivo,1,1969.0,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in marmoset,U,,,22224,0,,CHEMBL626236,BAO_0000218,
11759,Autocuration,314293.0,In vivo,1,1969.0,,The maximum plasma concentration (12.5 mg/kg) administered intravenously in monkey,U,,,22224,0,,CHEMBL626237,BAO_0000218,
11760,Intermediate,9615.0,In vivo,1,1969.0,,The maximum plasma concentration (15 mg/kg) administered intravenously in dog,N,,,50588,1,,CHEMBL626238,BAO_0000218,
11761,Intermediate,9606.0,In vivo,1,1969.0,,The maximum plasma concentration (200 mg/kg) administered orally in human,N,,,50587,1,,CHEMBL622412,BAO_0000218,
11762,Intermediate,10116.0,In vivo,1,1969.0,,The maximum plasma concentration (25 mg/kg) administered intravenously in rat,N,,,50597,1,,CHEMBL623114,BAO_0000218,
11763,Autocuration,9481.0,In vivo,1,1969.0,,The maximum plasma concentration (25 mg/kg) administered orally in marmoset,U,,,22224,0,,CHEMBL623115,BAO_0000218,
11764,Autocuration,314293.0,In vivo,1,1969.0,,The maximum plasma concentration (25 mg/kg) administered orally in monkey,U,,,22224,0,,CHEMBL623116,BAO_0000218,
11765,Autocuration,9615.0,In vivo,1,1969.0,,The maximum plasma concentration (30 mg/kg) administered orally in dog,U,,,22224,0,,CHEMBL623117,BAO_0000218,
11766,Intermediate,9606.0,In vivo,1,1969.0,,The maximum plasma concentration (400 mg/kg) administered orally in human,N,,,50587,1,,CHEMBL623118,BAO_0000218,
11767,Intermediate,10116.0,In vivo,1,1969.0,,The maximum plasma concentration (50 mg/kg) administered orally in fasted rat,N,,,50597,1,,CHEMBL623119,BAO_0000218,
11768,Intermediate,10116.0,In vivo,1,1969.0,,The maximum plasma concentration (50 mg/kg) administered orally in rat,N,,,50597,1,,CHEMBL623120,BAO_0000218,
11769,Intermediate,9606.0,In vivo,1,1969.0,,The maximum plasma concentration (800 mg/kg) administered orally in human,N,,,50587,1,,CHEMBL623286,BAO_0000218,
11770,Intermediate,10116.0,In vivo,1,1969.0,,The maximum plasma concentration was measured on rats,N,,,50597,1,,CHEMBL623287,BAO_0000218,
11771,Intermediate,10116.0,In vivo,1,1969.0,,The maximum plasma concentration was measured on rats after oral administration,N,,,50597,1,,CHEMBL623288,BAO_0000218,
11772,Intermediate,10116.0,In vivo,1,1969.0,,Plasma drug Cmax in rat (PO dose),N,,,50597,1,,CHEMBL623289,BAO_0000218,
11773,Autocuration,,In vivo,1,,,Time taken to reach maximum concentration after administration of 2 umol/kg dose intravenously,U,,,22224,0,,CHEMBL623290,BAO_0000218,
11774,Intermediate,9615.0,In vivo,1,1969.0,,maximum Plasma concentration in Dog was determined after Peroral administration,N,,,50588,1,,CHEMBL623291,BAO_0000218,
11775,Intermediate,10116.0,In vivo,1,1969.0,,maximum Plasma concentration in Rats was determined after Peroral administration,N,,,50597,1,,CHEMBL623292,BAO_0000218,
11776,Intermediate,9615.0,In vivo,1,1969.0,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,N,,,50588,1,,CHEMBL623293,BAO_0000218,
11777,Autocuration,314293.0,In vivo,1,1969.0,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,U,,,22224,0,,CHEMBL623294,BAO_0000218,
11778,Intermediate,10116.0,In vivo,1,1969.0,,maximum concentration in plasma in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,N,,,50597,1,,CHEMBL623295,BAO_0000218,
11779,Intermediate,10090.0,In vivo,1,,,maximum concentration was measured when administered through oral route in mice,N,,,50594,1,,CHEMBL623296,BAO_0000218,
11780,Intermediate,10090.0,,1,,,Compound was evaluated for Cmax/Tmax when administered through oral route in mouse; Value is 0.93/1,N,,,50594,1,,CHEMBL875349,BAO_0000218,
11781,Autocuration,314293.0,,1,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.34/1,U,,,22224,0,,CHEMBL623297,BAO_0000019,
11782,Autocuration,314293.0,,1,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 0.81/1.6,U,,,22224,0,,CHEMBL623298,BAO_0000019,
11783,Autocuration,314293.0,,1,,,Compound was evaluated for Cmax/Tmax when administered through oral route to mouse; Value is 1.1/1.3,U,,,22224,0,,CHEMBL623299,BAO_0000019,
11784,Intermediate,10116.0,,1,,,Pharmacokinetic parameter was evaluated in rats,N,,,50597,1,,CHEMBL623300,BAO_0000218,
11785,Intermediate,10090.0,,1,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,N,,,50594,1,,CHEMBL623301,BAO_0000218,
11786,Intermediate,10090.0,,1,,,Plasma concentration at time-0 was measured in mice at 100 mg/kg after intraperitoneal administration with saline(pH=11.4) as vehicle,N,,,50594,1,,CHEMBL623302,BAO_0000218,
11787,Intermediate,10090.0,,1,,,Plasma concentration at time-0 was measured in mice at 120 mg/kg after intraperitoneal administration with 90% DMSO as vehicle,N,,,50594,1,,CHEMBL623303,BAO_0000218,
11788,Intermediate,10090.0,,1,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with saline(pH=11.4) as vehicle,N,,,50594,1,,CHEMBL623304,BAO_0000218,
11789,Intermediate,10090.0,,1,,,Plasma concentration at time-0 was measured in mice at 40 mg/kg after intravenous administration with 90% DMSO as vehicle,N,,,50594,1,,CHEMBL623305,BAO_0000218,
11790,Intermediate,10116.0,,1,1969.0,,Effect of ip administration of compound on plasma concentration of allo-pregnanolone (AP) in rats(Cerebral Cortex) after 30 min.,N,,,50597,1,,CHEMBL623306,BAO_0000218,
11791,Intermediate,10116.0,,1,1969.0,,Effect of ip administration of compound on plasma concentration of allotetrahydrodeoxy corticosterone(THDOC) in rats(Cerebral Cortex) after 30 min.,N,,,50597,1,,CHEMBL623307,BAO_0000218,
11792,Intermediate,10116.0,,1,1969.0,,Effect of ip administration of compound on plasma concentration of pregnenolone (PRE) in rats(Cerebral Cortex) after 30 min.,N,,,50597,1,,CHEMBL623308,BAO_0000218,
11793,Intermediate,10090.0,,1,1969.0,,Effect of ip administration of compound on plasma concentration of progesterone (PRO) in rats(Cerebral Cortex) after 30 min.,N,,,50594,1,,CHEMBL623309,BAO_0000218,
11794,Intermediate,10090.0,,1,,,Plasma Concentration after 120 min of oral administration to mice,N,,,50594,1,,CHEMBL623310,BAO_0000218,
11795,Intermediate,10090.0,,1,,,Plasma Concentration after 30 min of oral administration to mice,N,,,50594,1,,CHEMBL623311,BAO_0000218,
11796,Intermediate,9541.0,,1,,,Plasma Concentration after 60 min of oral administration to mice,N,,,100710,1,,CHEMBL623312,BAO_0000218,
11797,Intermediate,10090.0,,1,,,Plasma Concentration after 60 min of oral administration to mice; Not determined,N,,,50594,1,,CHEMBL875350,BAO_0000218,
11798,Intermediate,10090.0,,1,,,Plasma Concentration after 90 min of oral administration to mice,N,,,50594,1,,CHEMBL628635,BAO_0000218,
11799,Intermediate,10116.0,,1,,,Plasma concentration level in rat after 1 hour of oral administration at 50 mg/kg,N,,,50597,1,,CHEMBL628636,BAO_0000218,
11800,Intermediate,10116.0,,1,,,Plasma concentration level in rat after 15 hours of oral administration at 50 mg/kg,N,,,50597,1,,CHEMBL628637,BAO_0000218,
11801,Intermediate,10116.0,,1,,,Plasma concentration level in rat after 4 hours of oral administration at 50 mg/kg,N,,,50597,1,,CHEMBL628058,BAO_0000218,
11802,Intermediate,10116.0,,1,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 0-1 hr time,N,,,50597,1,,CHEMBL628059,BAO_0000218,
11803,Intermediate,10116.0,,1,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 1-2 hr time,N,,,50597,1,,CHEMBL628060,BAO_0000218,
11804,Autocuration,,,1,,,Distribution in the lung after 15 min of intravenous administration,U,,,22224,0,,CHEMBL628061,BAO_0000019,
11805,Autocuration,,,1,,,Distribution in the lung after 30 min of intravenous administration,U,,,22224,0,,CHEMBL628062,BAO_0000019,
11806,Autocuration,,,1,,,Distribution in the lung after 5 min of intravenous administration,U,,,22224,0,,CHEMBL628063,BAO_0000019,
11807,Autocuration,,,1,,,Distribution in the lung after 60 min of intravenous administration,U,,,22224,0,,CHEMBL628064,BAO_0000019,
11808,Autocuration,,,1,,,Distribution in the lung after 90 min of intravenous administration,U,,,22224,0,,CHEMBL628065,BAO_0000019,
11809,Autocuration,,,1,2385.0,,Distribution in the muscle after 120 min of intravenous administration,U,,,22224,0,,CHEMBL628066,BAO_0000019,
11810,Autocuration,,,1,2385.0,,Distribution in the muscle after 15 min of intravenous administration,U,,,22224,0,,CHEMBL628067,BAO_0000019,
11811,Intermediate,10090.0,,1,2385.0,,Distribution in the muscle after 30 min of intravenous administration,N,,,50594,1,,CHEMBL874646,BAO_0000218,
11812,Autocuration,,,1,2385.0,,Distribution in the muscle after 5 min of intravenous administration,U,,,22224,0,,CHEMBL628068,BAO_0000019,
11813,Autocuration,,,1,2385.0,,Distribution in the muscle after 60 min of intravenous administration,U,,,22224,0,,CHEMBL628069,BAO_0000019,
11814,Autocuration,,,1,2385.0,,Distribution in the muscle after 90 min of intravenous administration,U,,,22224,0,,CHEMBL628070,BAO_0000019,
11815,Autocuration,,,1,2106.0,,Distribution in the spleen after 120 min of intravenous administration,U,,,22224,0,,CHEMBL628071,BAO_0000019,
11816,Autocuration,,,1,2106.0,,Distribution in the spleen after 15 min of intravenous administration,U,,,22224,0,,CHEMBL628072,BAO_0000019,
11817,Autocuration,,,1,2106.0,,Distribution in the spleen after 30 min of intravenous administration,U,,,22224,0,,CHEMBL628073,BAO_0000019,
11818,Autocuration,,,1,2106.0,,Distribution in the spleen after 5 min of intravenous administration,U,,,22224,0,,CHEMBL628074,BAO_0000019,
11819,Autocuration,,,1,2106.0,,Distribution in the spleen after 60 min of intravenous administration,U,,,22224,0,,CHEMBL628075,BAO_0000019,
11820,Autocuration,,,1,2106.0,,Distribution in the spleen after 90 min of intravenous administration,U,,,22224,0,,CHEMBL628076,BAO_0000019,
11821,Intermediate,10116.0,,1,1235.0,,Evaluated for distribution at 0.5 hr after intravenous administration in adrenal cortex of female Sprague Dawley rats,N,,,50597,1,,CHEMBL628077,BAO_0000218,
11822,Intermediate,10116.0,,1,178.0,,Evaluated for distribution at 0.5 hr after intravenous administration in blood of female Sprague Dawley rats,N,,,50597,1,,CHEMBL628078,BAO_0000218,
11823,Intermediate,10116.0,,1,2107.0,,Evaluated for distribution at 0.5 hr after intravenous administration in liver of female Sprague Dawley rats,N,,,50597,1,,CHEMBL628079,BAO_0000218,
11824,Intermediate,10116.0,,1,992.0,,Evaluated for distribution at 0.5 hr after intravenous administration in ovary of female Sprague Dawley rats,N,,,50597,1,,CHEMBL628080,BAO_0000218,
11825,Intermediate,10116.0,,1,2046.0,,Evaluated for distribution at 0.5 hr after intravenous administration in thyroid of female Sprague Dawley rats,N,,,50597,1,,CHEMBL628081,BAO_0000218,
11826,Intermediate,10116.0,,1,1235.0,,Evaluated for distribution at 24 hours after intravenous administration in adrenal cortex of female Sprague Dawley rats,N,,,50597,1,,CHEMBL628082,BAO_0000218,
11827,Intermediate,10116.0,,1,178.0,,Evaluated for distribution at 24 hours after intravenous administration in blood of female Sprague Dawley rats,N,,,50597,1,,CHEMBL874647,BAO_0000218,
11828,Intermediate,10116.0,,1,2107.0,,Evaluated for distribution at 24 hours after intravenous administration in liver of female Sprague Dawley rats,N,,,50597,1,,CHEMBL626406,BAO_0000218,
11829,Intermediate,10116.0,,1,992.0,,Evaluated for distribution at 24 hours after intravenous administration in ovary of female Sprague Dawley rats,N,,,50597,1,,CHEMBL626407,BAO_0000218,
11830,Intermediate,10116.0,,1,2046.0,,Evaluated for distribution at 24 hours after intravenous administration in thyroid of female Sprague Dawley rats,N,,,50597,1,,CHEMBL626408,BAO_0000218,
11831,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.07-0.09",N,,,50597,1,,CHEMBL626409,BAO_0000218,
11832,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.10-0.13",N,,,50597,1,,CHEMBL626410,BAO_0000218,
11833,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.18-0.24",N,,,50597,1,,CHEMBL626411,BAO_0000218,
11834,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.19-0.24",N,,,50597,1,,CHEMBL626412,BAO_0000218,
11835,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.22-0.32",N,,,50597,1,,CHEMBL626413,BAO_0000218,
11836,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 30 minutes intravenous administration; dose/g, range 0.25-0.32",N,,,50597,1,,CHEMBL626414,BAO_0000218,
11837,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.10-0.14",N,,,50597,1,,CHEMBL626415,BAO_0000218,
11838,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.25-0.34",N,,,50597,1,,CHEMBL626416,BAO_0000218,
11839,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.27-0.33",N,,,50597,1,,CHEMBL627062,BAO_0000218,
11840,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.32-0.46",N,,,50597,1,,CHEMBL627063,BAO_0000218,
11841,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.40-0.45",N,,,50597,1,,CHEMBL627064,BAO_0000218,
11842,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 5 minutes intravenous administration; dose/g, range 0.44-0.52",N,,,50597,1,,CHEMBL627227,BAO_0000218,
11843,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.08-0.09",N,,,50597,1,,CHEMBL627228,BAO_0000218,
11844,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.12-0.14",N,,,50597,1,,CHEMBL627229,BAO_0000218,
11845,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.13-0.15",N,,,50597,1,,CHEMBL625792,BAO_0000218,
11846,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.20",N,,,50597,1,,CHEMBL625793,BAO_0000218,
11847,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.15-0.23",N,,,50597,1,,CHEMBL625794,BAO_0000218,
11848,Intermediate,10116.0,,1,178.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats blood after 60 minutes intravenous administration; dose/g, range 0.16-0.21",N,,,50597,1,,CHEMBL625795,BAO_0000218,
11849,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC for the compound after intravenous administration into BALB/c Mice in plasma samples.,N,,,50594,1,,CHEMBL625796,BAO_0000218,
11850,Intermediate,9615.0,,1,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 375 mg/kg,N,,,50588,1,,CHEMBL625797,BAO_0000218,
11851,Intermediate,9615.0,,1,,,Pharmacokinetic parameter AUC has been determined in fed Beagle dogs at a dose of 500 mg/kg,N,,,50588,1,,CHEMBL625798,BAO_0000218,
11852,Autocuration,,,1,,,Pharmacokinetic parameter AUC evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL875613,BAO_0000218,
11853,Autocuration,,,1,,,Pharmacokinetic parameter AUC was evaluated in 0.5% methylcellulose suspension at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL625799,BAO_0000218,
11854,Autocuration,,,1,,,Pharmacokinetic parameter AUC was evaluated in 10% PEG suspension at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL625800,BAO_0000218,
11855,Autocuration,,,1,,,Pharmacokinetic parameter AUC was evaluated in 100% PEG solution at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL625801,BAO_0000218,
11856,Autocuration,,,1,,,Pharmacokinetic parameter AUC was evaluated in DMA:H2O solution at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL625802,BAO_0000218,
11857,Autocuration,,,1,,,Pharmacokinetic parameter AUC was evaluated in HP-beta-CD solution at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL625803,BAO_0000218,
11858,Autocuration,,,1,,,Pharmacokinetic parameter AUC was evaluated in Hp-beta-CD solution,U,,,22224,0,,CHEMBL625804,BAO_0000019,
11859,Autocuration,,,1,,,Pharmacokinetic parameter AUC was evaluated in saline solution at a dose of 20 mg/kg orally,U,,,22224,0,,CHEMBL622530,BAO_0000218,
11860,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h); not detected,N,,,50594,1,,CHEMBL622531,BAO_0000218,
11861,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),N,,,50594,1,,CHEMBL622532,BAO_0000218,
11862,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),N,,,50594,1,,CHEMBL623176,BAO_0000218,
11863,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),N,,,50594,1,,CHEMBL623177,BAO_0000218,
11864,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),N,,,50594,1,,CHEMBL623178,BAO_0000218,
11865,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 112 mg/kg dose by intravenous administration using FMAddA as substrate in mice brain; AUC 0-r (mM.h); not detected,N,,,50594,1,,CHEMBL623179,BAO_0000218,
11866,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC (mM.h),N,,,50594,1,,CHEMBL623180,BAO_0000218,
11867,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),N,,,50594,1,,CHEMBL623181,BAO_0000218,
11868,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),N,,,50594,1,,CHEMBL624131,BAO_0000218,
11869,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration using 2`-F-ara-ddI as substrate in mice serum; AUC (mM.h),N,,,50594,1,,CHEMBL624132,BAO_0000218,
11870,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),N,,,50594,1,,CHEMBL624133,BAO_0000218,
11871,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h).,N,,,50594,1,,CHEMBL624846,BAO_0000218,
11872,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 20 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),N,,,50594,1,,CHEMBL624847,BAO_0000218,
11873,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),N,,,50594,1,,CHEMBL624848,BAO_0000218,
11874,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC (mM.h),N,,,50594,1,,CHEMBL625012,BAO_0000218,
11875,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice serum; AUC 0-r (mM.h),N,,,50594,1,,CHEMBL625013,BAO_0000218,
11876,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain; AUC 0-r (mM.h); not detected,N,,,50594,1,,CHEMBL625014,BAO_0000218,
11877,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC (mM.h),N,,,50594,1,,CHEMBL625015,BAO_0000218,
11878,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum; AUC 0-r (mM.h),N,,,50594,1,,CHEMBL625016,BAO_0000218,
11879,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral in mice brain; AUC (mM.h); not detected,N,,,50594,1,,CHEMBL625017,BAO_0000218,
11880,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration in mice brain; AUC 0-r (mM.h),N,,,50594,1,,CHEMBL625018,BAO_0000218,
11881,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by intravenous administration mice serum.; AUC 0-r (mM.h),N,,,50594,1,,CHEMBL625019,BAO_0000218,
11882,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice brain.; AUC 0-r (mM.h),N,,,50594,1,,CHEMBL625020,BAO_0000218,
11883,Intermediate,10090.0,,1,,,Pharmacokinetic parameter AUC was measured at 55 mg/kg dose by oral administration in mice serum.,N,,,50594,1,,CHEMBL625021,BAO_0000218,
11884,Intermediate,10116.0,,1,,,Pharmacokinetic parameter [area under curve (AUC)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,,,50597,1,,CHEMBL625022,BAO_0000218,
11885,Intermediate,10090.0,,1,,,Pharmacokinetic parameter area under the curve (0-24 hr) for the compound was evaluated in nude mice after oral administration. ,N,,,50594,1,,CHEMBL625023,BAO_0000218,
11886,Intermediate,9541.0,,1,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration,N,,,100710,1,,CHEMBL625024,BAO_0000218,
11887,Intermediate,9541.0,,1,,,Pharmacokinetic parameter area under the curve (0-48 h) for the compound was evaluated in nude cynomolgus monkeys after oral administration. ,N,,,100710,1,,CHEMBL627626,BAO_0000218,
11888,Autocuration,,,1,955.0,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,U,,,22224,0,,CHEMBL627627,BAO_0000218,
11889,Autocuration,,,1,1977.0,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in serum,U,,,22224,0,,CHEMBL627628,BAO_0000218,
11890,Autocuration,,,1,955.0,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,U,,,22224,0,,CHEMBL627629,BAO_0000218,
11891,Autocuration,,,1,1977.0,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in serum,U,,,22224,0,,CHEMBL627630,BAO_0000218,
11892,Autocuration,,,1,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/Kg orally; range (0.19-0.35),U,,,22224,0,,CHEMBL627631,BAO_0000019,
11893,Autocuration,,,1,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered 5 mg/kg intravenously; range (2.1-2.3),U,,,22224,0,,CHEMBL629515,BAO_0000218,
11894,Intermediate,10090.0,,1,2106.0,,In vivo biodistribution in mice spleen bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,,50594,1,,CHEMBL629516,BAO_0000218,
11895,Intermediate,10090.0,,1,2106.0,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,,50594,1,,CHEMBL629517,BAO_0000218,
11896,Intermediate,10090.0,,1,2106.0,,In vivo biodistribution in mice spleen bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,,50594,1,,CHEMBL629518,BAO_0000218,
11897,Intermediate,10090.0,,1,,,In vivo biodistribution in mice tumor bearing intracerebral GL261 gliomas at the dose of 30 ug/day,N,,,50594,1,,CHEMBL877499,BAO_0000218,
11898,Intermediate,10090.0,,1,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 20 ug/g,N,,,50594,1,,CHEMBL629519,BAO_0000218,
11899,Intermediate,10090.0,,1,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 30 ug/g,N,,,50594,1,,CHEMBL629520,BAO_0000218,
11900,Intermediate,10090.0,,1,,,In vivo biodistribution in mice tumor bearing subcutaneous B16 melanomas at the dose of 40 ug/g,N,,,50594,1,,CHEMBL629521,BAO_0000218,
11901,Intermediate,10090.0,,1,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Blood (B),N,,,50594,1,,CHEMBL629522,BAO_0000218,
11902,Intermediate,10090.0,,1,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Heart (H) and Lung (L),N,,,50594,1,,CHEMBL629523,BAO_0000218,
11903,Intermediate,10090.0,,1,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and Muscle (M),N,,,50594,1,,CHEMBL629524,BAO_0000218,
11904,Intermediate,10090.0,,1,,,Ratio of biodistributions in Athymic mice bearing human Tumor (KB) xenografts in Tumor (T) and blood (B),N,,,50594,1,,CHEMBL629525,BAO_0000218,
11905,Intermediate,10090.0,,1,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Blood (B),N,,,50594,1,,CHEMBL629526,BAO_0000218,
11906,Intermediate,10090.0,,1,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Heart (H) and Lung (L),N,,,50594,1,,CHEMBL629527,BAO_0000218,
11907,Intermediate,10090.0,,1,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and Muscle (M),N,,,50594,1,,CHEMBL629528,BAO_0000218,
11908,Intermediate,10090.0,,1,,,Ratio of biodistributions in Athymic mice bearing human Tumor (LS174T) xenografts in Tumor (T) and blood (B),N,,,50594,1,,CHEMBL629529,BAO_0000218,
11909,Intermediate,10090.0,,1,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Blood (B),N,,,50594,1,,CHEMBL629530,BAO_0000218,
11910,Intermediate,10090.0,,1,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Heart (H) and Lung (L),N,,,50594,1,,CHEMBL629531,BAO_0000218,
11911,Intermediate,10090.0,,1,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and Muscle (M),N,,,50594,1,,CHEMBL628656,BAO_0000218,
11912,Intermediate,10090.0,,1,,,Ratio of biodistributions in Athymic mice bearing human Tumor (TE671) xenografts in Tumor (T) and blood (B),N,,,50594,1,,CHEMBL628657,BAO_0000218,
11913,Intermediate,10116.0,In vivo,1,,,"Biodistribution in abdominal Dawley rat after 30min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL628658,BAO_0000218,
11914,Intermediate,10116.0,In vivo,1,,,"Biodistribution in abdominal of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL628659,BAO_0000218,
11915,Intermediate,10116.0,In vivo,1,,,"Biodistribution in abdominal of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL877500,BAO_0000218,
11916,Intermediate,10116.0,In vivo,1,,,"Biodistribution in abdominal of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL628660,BAO_0000218,
11917,Intermediate,10116.0,In vivo,1,,,"Biodistribution in abdominal of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL628661,BAO_0000218,
11918,Intermediate,10116.0,In vivo,1,,,"Biodistribution in abdominal of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL628662,BAO_0000218,
11919,Intermediate,10116.0,In vivo,1,,,"Biodistribution in abdominal of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL628663,BAO_0000218,
11920,Intermediate,10116.0,In vivo,1,,,"Biodistribution in abdominal of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL628664,BAO_0000218,
11921,Intermediate,10116.0,In vivo,1,178.0,,"Biodistribution in blood of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL628665,BAO_0000218,
11922,Intermediate,10116.0,In vivo,1,178.0,,"Biodistribution in blood of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL628666,BAO_0000218,
11923,Intermediate,10116.0,In vivo,1,178.0,,"Biodistribution in blood of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL628667,BAO_0000218,
11924,Intermediate,10116.0,In vivo,1,178.0,,"Biodistribution in blood of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL628668,BAO_0000218,
11925,Intermediate,10116.0,In vivo,1,178.0,,"Biodistribution in blood of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL628669,BAO_0000218,
11926,Intermediate,10116.0,In vivo,1,178.0,,"Biodistribution in blood of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL628670,BAO_0000218,
11927,Intermediate,10116.0,In vivo,1,178.0,,"Biodistribution in blood of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL628671,BAO_0000218,
11928,Intermediate,10116.0,In vivo,1,10000001.0,,"Biodistribution in bone of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL628672,BAO_0000218,
11929,Intermediate,10116.0,In vivo,1,10000001.0,,"Biodistribution in bone of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL630300,BAO_0000218,
11930,Intermediate,10116.0,In vivo,1,10000001.0,,"Biodistribution in bone of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629787,BAO_0000218,
11931,Intermediate,10116.0,In vivo,1,10000001.0,,"Biodistribution in bone of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629788,BAO_0000218,
11932,Intermediate,10116.0,In vivo,1,955.0,,"Biodistribution in brain of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629789,BAO_0000218,
11933,Intermediate,10116.0,In vivo,1,955.0,,"Biodistribution in brain of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629790,BAO_0000218,
11934,Intermediate,10116.0,In vivo,1,955.0,,"Biodistribution in brain of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629791,BAO_0000218,
11935,Intermediate,10116.0,In vivo,1,955.0,,"Biodistribution in brain of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629792,BAO_0000218,
11936,Intermediate,10116.0,In vivo,1,955.0,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629793,BAO_0000218,
11937,Intermediate,10116.0,In vivo,1,955.0,,"Biodistribution in brain of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629794,BAO_0000218,
11938,Intermediate,10116.0,,1,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 2-3 hr time,N,,,50597,1,,CHEMBL874459,BAO_0000218,
11939,Intermediate,10116.0,,1,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 3-4 hr time,N,,,50597,1,,CHEMBL629795,BAO_0000218,
11940,Intermediate,10116.0,,1,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 4-5 hr time,N,,,50597,1,,CHEMBL629796,BAO_0000218,
11941,Intermediate,10116.0,,1,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 5-6 hr time,N,,,50597,1,,CHEMBL629797,BAO_0000218,
11942,Intermediate,10116.0,,1,,,Biliary excretion after dosing at 10 mg/kg intravenously to conscious rats with Indwelling bile duct cannulae for 6-24 h time,N,,,50597,1,,CHEMBL629798,BAO_0000218,
11943,Intermediate,10116.0,In vivo,1,2369.0,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629799,BAO_0000218,
11944,Intermediate,10116.0,In vivo,1,2369.0,,Biodistribution studied in the adrenals of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629800,BAO_0000218,
11945,Intermediate,10116.0,In vivo,1,2369.0,,Biodistribution studied in the adrenals of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629801,BAO_0000218,
11946,Intermediate,10116.0,In vivo,1,2369.0,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour,N,,,50597,1,,CHEMBL629802,BAO_0000218,
11947,Intermediate,10116.0,In vivo,1,2369.0,,Biodistribution studied in the adrenals of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629803,BAO_0000218,
11948,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution studied in the blood of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629804,BAO_0000218,
11949,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution studied in the blood of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629805,BAO_0000218,
11950,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution studied in the blood of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629806,BAO_0000218,
11951,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution studied in the blood of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629807,BAO_0000218,
11952,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution studied in the blood of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629808,BAO_0000218,
11953,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution studied in the brain of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629809,BAO_0000218,
11954,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution studied in the brain of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629810,BAO_0000218,
11955,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution studied in the brain of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629811,BAO_0000218,
11956,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution studied in the brain of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629812,BAO_0000218,
11957,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution studied in the brain of immature Fischer female rats at 5 hou; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629813,BAO_0000218,
11958,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution studied in the brain of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL874460,BAO_0000218,
11959,Intermediate,10116.0,In vivo,1,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629814,BAO_0000218,
11960,Intermediate,10116.0,In vivo,1,,,Biodistribution studied in the fat of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629815,BAO_0000218,
11961,Intermediate,10116.0,In vivo,1,,,Biodistribution studied in the fat of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629816,BAO_0000218,
11962,Intermediate,10116.0,In vivo,1,,,Biodistribution studied in the fat of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL629817,BAO_0000218,
11963,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL626643,BAO_0000218,
11964,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution studied in the kidneys of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL626644,BAO_0000218,
11965,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution studied in the kidneys of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL626806,BAO_0000218,
11966,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution studied in the kidneys of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL626807,BAO_0000218,
11967,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution studied in the liver of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627261,BAO_0000218,
11968,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution studied in the liver of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627262,BAO_0000218,
11969,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution studied in the liver of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627263,BAO_0000218,
11970,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution studied in the liver of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627264,BAO_0000218,
11971,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627265,BAO_0000218,
11972,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution studied in the lungs of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627266,BAO_0000218,
11973,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution studied in the lungs of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627267,BAO_0000218,
11974,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution studied in the lungs of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627268,BAO_0000218,
11975,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627269,BAO_0000218,
11976,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution studied in the muscle of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627270,BAO_0000218,
11977,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 0.95-1.44",N,,,50597,1,,CHEMBL627271,BAO_0000218,
11978,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 1.39-2.43",N,,,50597,1,,CHEMBL627946,BAO_0000218,
11979,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.47-2.96",N,,,50597,1,,CHEMBL875472,BAO_0000218,
11980,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-3.69",N,,,50597,1,,CHEMBL627947,BAO_0000218,
11981,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 2.67-4.31",N,,,50597,1,,CHEMBL627948,BAO_0000218,
11982,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 30 minutes intravenous administration; dose/g, range 3.17-4.70",N,,,50597,1,,CHEMBL628113,BAO_0000218,
11983,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration.; dose/g, range 2.20-2.97",N,,,50597,1,,CHEMBL628114,BAO_0000218,
11984,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 0.90-1.46",N,,,50597,1,,CHEMBL628115,BAO_0000218,
11985,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.72-3.52",N,,,50597,1,,CHEMBL628116,BAO_0000218,
11986,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.78-3.62",N,,,50597,1,,CHEMBL628117,BAO_0000218,
11987,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 2.82-3.86",N,,,50597,1,,CHEMBL628118,BAO_0000218,
11988,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 5 minutes intravenous administration; dose/g, range 3.80-5.74",N,,,50597,1,,CHEMBL628119,BAO_0000218,
11989,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.05-1.57",N,,,50597,1,,CHEMBL628120,BAO_0000218,
11990,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 1.93-3.58",N,,,50597,1,,CHEMBL628121,BAO_0000218,
11991,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 2.88-4.32",N,,,50597,1,,CHEMBL628122,BAO_0000218,
11992,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3-3.70",N,,,50597,1,,CHEMBL627297,BAO_0000218,
11993,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.21-3.92",N,,,50597,1,,CHEMBL627298,BAO_0000218,
11994,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats heart after 60 minutes intravenous administration; dose/g, range 3.51-5.44",N,,,50597,1,,CHEMBL627299,BAO_0000218,
11995,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 0.24-0.31",N,,,50597,1,,CHEMBL627300,BAO_0000218,
11996,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 10.5-14.4",N,,,50597,1,,CHEMBL627301,BAO_0000218,
11997,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.28-7.41",N,,,50597,1,,CHEMBL627302,BAO_0000218,
11998,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 6.47-10.2",N,,,50597,1,,CHEMBL627303,BAO_0000218,
11999,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 7.21-7.95",N,,,50597,1,,CHEMBL627304,BAO_0000218,
12000,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 30 minutes intravenous administration; dose/g, range 8.28-10.72",N,,,50597,1,,CHEMBL627305,BAO_0000218,
12001,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 1.04-2.56",N,,,50597,1,,CHEMBL627306,BAO_0000218,
12002,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 10.7-16.9",N,,,50597,1,,CHEMBL623982,BAO_0000218,
12003,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 11.7-14.6",N,,,50597,1,,CHEMBL623983,BAO_0000218,
12004,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 14.4-20.1",N,,,50597,1,,CHEMBL623984,BAO_0000218,
12005,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 4.78-9.72",N,,,50597,1,,CHEMBL623985,BAO_0000218,
12006,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 5 minutes intravenous administration; dose/g, range 9.87-11.9",N,,,50597,1,,CHEMBL623986,BAO_0000218,
12007,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 0.17-0.25",N,,,50597,1,,CHEMBL623987,BAO_0000218,
12008,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 3.33-4.68",N,,,50597,1,,CHEMBL623988,BAO_0000218,
12009,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.59-8.81",N,,,50597,1,,CHEMBL623989,BAO_0000218,
12010,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 4.62-5.60",N,,,50597,1,,CHEMBL622215,BAO_0000218,
12011,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.02-6.57",N,,,50597,1,,CHEMBL622216,BAO_0000218,
12012,Intermediate,10116.0,,1,,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats kidneys after 60 minutes intravenous administration; dose/g, range 5.67-8.41",N,,,50597,1,,CHEMBL877481,BAO_0000218,
12013,Autocuration,,,1,,,Pharmacokinetic parameter was evaluated which is represented as AUC when administered orally a dose of 5 mg/kg; range (4.2-8.8),U,,,22224,0,,CHEMBL622217,BAO_0000218,
12014,Intermediate,10090.0,,1,,,Pharmacokinetic parameters was measured at 55 mg/kg dose by oral administration in mice serum.; AUC 0-r (mM.h),N,,,50594,1,,CHEMBL622218,BAO_0000218,
12015,Intermediate,10116.0,,1,,,Pharmacokinetic profile AUC was evaluated in rats,N,,,50597,1,,CHEMBL622219,BAO_0000218,
12016,Autocuration,,,1,,,Pharmacokinetic property (Area under curve),U,,,22224,0,,CHEMBL622220,BAO_0000019,
12017,Intermediate,9615.0,,1,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in dog (25 mg/kg).",N,,,50588,1,,CHEMBL622221,BAO_0000218,
12018,Intermediate,10090.0,,1,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration in mice (50 mg/kg).",N,,,50594,1,,CHEMBL622222,BAO_0000218,
12019,Intermediate,9615.0,,1,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to dog (25 mg/kg).",N,,,50588,1,,CHEMBL622223,BAO_0000218,
12020,Intermediate,10090.0,,1,,,"Pharmacokinetic property(AUC- area under curve, (micro g/mL/h)) after oral administration to mice (50 mg/kg).",N,,,50594,1,,CHEMBL622224,BAO_0000218,
12021,Autocuration,,,1,,,Plasma concentration (AUC) was determined,U,,,22224,0,,CHEMBL622225,BAO_0000019,
12022,Autocuration,,,1,,,Plasma concentration (AUC) was determined; Not detectable,U,,,22224,0,,CHEMBL622226,BAO_0000019,
12023,Intermediate,10141.0,,1,,,Prolongation of time to collapse in guinea pig treated with aerosolized histamine was measured in vivo as area under curve (AUC),N,,,50512,1,,CHEMBL624154,BAO_0000218,
12024,Intermediate,10116.0,,1,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg,N,,,50597,1,,CHEMBL624155,BAO_0000218,
12025,Intermediate,10116.0,,1,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 30 mg/kg; Not significant,N,,,50597,1,,CHEMBL624156,BAO_0000218,
12026,Intermediate,10116.0,,1,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 60 mg/kg,N,,,50597,1,,CHEMBL624157,BAO_0000218,
12027,Intermediate,10116.0,,1,,,Suppressor cell activity was measured as area under curve(AUC) in normal rats by a splenic cell coculture assay at a dose of 7.5 mg/kg,N,,,50597,1,,CHEMBL624158,BAO_0000218,
12028,Intermediate,10116.0,,1,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 1,N,,,50597,1,,CHEMBL624159,BAO_0000218,
12029,Intermediate,10116.0,,1,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 2,N,,,50597,1,,CHEMBL624160,BAO_0000218,
12030,Intermediate,10116.0,,1,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 3,N,,,50597,1,,CHEMBL624161,BAO_0000218,
12031,Intermediate,10116.0,,1,,,Tested for area under the curve (AUC) after intravenous bolus administration of 100 mg/kg in rat 4,N,,,50597,1,,CHEMBL624162,BAO_0000218,
12032,Intermediate,9615.0,,1,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Area Under Curve value) iv administration.,N,,,50588,1,,CHEMBL624163,BAO_0000218,
12033,Intermediate,10116.0,,1,,,"The AUC(0-infinitive) value in female wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL624164,BAO_0000218,
12034,Intermediate,10116.0,,1,,,The AUC(0-infinity) values in female wistar rats.,N,,,50597,1,,CHEMBL624165,BAO_0000218,
12035,Intermediate,10116.0,,1,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL624166,BAO_0000218,
12036,Intermediate,10116.0,,1,,,"The AUC(0-t)value in female wistar rat at 100 mg/kg, p.o. dose in mice",N,,,50597,1,,CHEMBL624167,BAO_0000218,
12037,Intermediate,10116.0,,1,,,The AUC(0-t)values in female wistar rats.,N,,,50597,1,,CHEMBL624168,BAO_0000218,
12038,Intermediate,10116.0,,1,,,The Area under the concentration time curve of compound was measured on rats,N,,,50597,1,,CHEMBL624169,BAO_0000218,
12039,Intermediate,9606.0,,1,,,The area under curve (100 mg/kg) administered orally in humans,N,,,50587,1,,CHEMBL624170,BAO_0000218,
12040,Autocuration,9481.0,,1,,,The area under curve (12.5 mg/kg) administered intravenously in marmoset,U,,,22224,0,,CHEMBL624171,BAO_0000218,
12041,Autocuration,314293.0,,1,,,The area under curve (12.5 mg/kg) administered intravenously in monkey,U,,,22224,0,,CHEMBL624172,BAO_0000218,
12042,Intermediate,9615.0,,1,,,The area under curve (15 mg/kg) administered intravenously in dog,N,,,50588,1,,CHEMBL624173,BAO_0000218,
12043,Intermediate,9606.0,,1,,,The area under curve (200 mg/kg) administered orally in humans,N,,,50587,1,,CHEMBL877488,BAO_0000218,
12044,Intermediate,10116.0,,1,,,The area under curve (25 mg/kg) administered intravenously in rat,N,,,50597,1,,CHEMBL624174,BAO_0000218,
12045,Autocuration,9481.0,,1,,,The area under curve (25 mg/kg) administered orally in marmoset,U,,,22224,0,,CHEMBL624175,BAO_0000218,
12046,Autocuration,314293.0,,1,,,The area under curve (25 mg/kg) administered orally in monkey,U,,,22224,0,,CHEMBL624176,BAO_0000218,
12047,Intermediate,9615.0,,1,,,The area under curve (30 mg/kg) administered orally in dog,N,,,50588,1,,CHEMBL624177,BAO_0000218,
12048,Intermediate,9606.0,,1,,,The area under curve (400 mg/kg) administered orally in humans,N,,,50587,1,,CHEMBL624178,BAO_0000218,
12049,Intermediate,10116.0,,1,,,The area under curve (50 mg/kg) administered orally in fasted rat,N,,,50597,1,,CHEMBL624179,BAO_0000218,
12050,Intermediate,10116.0,,1,,,The area under curve (50 mg/kg) administered orally in rat,N,,,50597,1,,CHEMBL627689,BAO_0000218,
12051,Intermediate,9606.0,,1,,,The area under curve (800 mg/kg) administered orally in humans,N,,,50587,1,,CHEMBL627690,BAO_0000218,
12052,Autocuration,,,1,,,The compound was evaluated for area under the curve,U,,,22224,0,,CHEMBL627691,BAO_0000019,
12053,Autocuration,9481.0,,1,,,The compound was evaluated for area under the curve in marmosets,U,,,22224,0,,CHEMBL627692,BAO_0000019,
12054,Autocuration,9481.0,,1,,,The compound was evaluated for area under the curve in marmosets,U,,,22224,0,,CHEMBL627693,BAO_0000019,
12055,Intermediate,10116.0,,1,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,N,,,50597,1,,CHEMBL627694,BAO_0000218,
12056,Intermediate,10116.0,,1,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po) in conscious spontaneously hypertensive rat,N,,,50597,1,,CHEMBL627695,BAO_0000218,
12057,Autocuration,,,1,,,The compound was tested for the area of the change in MABP versus time curve at dose 10 mg/kg (po),U,,,22224,0,,CHEMBL627696,BAO_0000218,
12058,Intermediate,10116.0,,1,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,N,,,50597,1,,CHEMBL627697,BAO_0000218,
12059,Intermediate,10116.0,,1,,,The compound was tested for the area of the change in MABP versus time curve at dose 30 mg/kg (po) in conscious spontaneously hypertensive rat,N,,,50597,1,,CHEMBL627698,BAO_0000218,
12060,Intermediate,10116.0,,1,,,The compound was tested for the area of the change in MABP versus time curve at dose 5 mg/kg (po) in conscious spontaneously hypertensive rat,N,,,50597,1,,CHEMBL627699,BAO_0000218,
12061,Intermediate,10116.0,,1,,,Total absorption was estimated by area under curve (AUC) after intravenous administration in rat,N,,,50597,1,,CHEMBL627700,BAO_0000218,
12062,Intermediate,10116.0,,1,,,Total drug exposure is determined after oral dosing in rats.,N,,,50597,1,,CHEMBL627701,BAO_0000218,
12063,Autocuration,,,1,,,Total drug exposure (5 mg/kg) when administered intravenously,U,,,22224,0,,CHEMBL627702,BAO_0000218,
12064,Autocuration,,,1,,,Total drug exposure (5 mg/kg) when administered orally,U,,,22224,0,,CHEMBL627703,BAO_0000218,
12065,Autocuration,314293.0,,1,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,U,,,22224,0,,CHEMBL626873,BAO_0000218,
12066,Intermediate,10116.0,,1,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,N,,,50597,1,,CHEMBL629583,BAO_0000218,
12067,Intermediate,9615.0,,1,,,area under curve in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,N,,,50588,1,,CHEMBL629584,BAO_0000218,
12068,Intermediate,9615.0,,1,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in dog,N,,,50588,1,,CHEMBL629585,BAO_0000218,
12069,Intermediate,10116.0,In vivo,1,955.0,,"Biodistribution in brain of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629586,BAO_0000218,
12070,Intermediate,10116.0,In vivo,1,955.0,,"Biodistribution in brain of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629587,BAO_0000218,
12071,Intermediate,10116.0,In vivo,1,,,"Biodistribution in fat of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629588,BAO_0000218,
12072,Intermediate,10116.0,In vivo,1,,,"Biodistribution in fat of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629589,BAO_0000218,
12073,Intermediate,10116.0,In vivo,1,,,"Biodistribution in fat of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629590,BAO_0000218,
12074,Intermediate,10116.0,In vivo,1,,,"Biodistribution in fat of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629591,BAO_0000218,
12075,Intermediate,10116.0,In vivo,1,,,"Biodistribution in fat of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629592,BAO_0000218,
12076,Intermediate,10116.0,In vivo,1,,,"Biodistribution in fat of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629593,BAO_0000218,
12077,Intermediate,10116.0,In vivo,1,,,"Biodistribution in fat of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629594,BAO_0000218,
12078,Intermediate,10116.0,In vivo,1,948.0,,"Biodistribution in heart of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL629595,BAO_0000218,
12079,Intermediate,10116.0,In vivo,1,948.0,,"Biodistribution in heart of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL630290,BAO_0000218,
12080,Intermediate,10116.0,In vivo,1,948.0,,"Biodistribution in heart of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627137,BAO_0000218,
12081,Intermediate,10116.0,In vivo,1,948.0,,"Biodistribution in heart of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627138,BAO_0000218,
12082,Intermediate,10116.0,In vivo,1,948.0,,"Biodistribution in heart of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627139,BAO_0000218,
12083,Intermediate,10116.0,In vivo,1,948.0,,"Biodistribution in heart of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627140,BAO_0000218,
12084,Intermediate,10116.0,In vivo,1,948.0,,"Biodistribution in heart of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627141,BAO_0000218,
12085,Intermediate,10116.0,In vivo,1,2113.0,,"Biodistribution in kidney of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627142,BAO_0000218,
12086,Intermediate,10116.0,In vivo,1,2113.0,,"Biodistribution in kidney of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627143,BAO_0000218,
12087,Intermediate,10116.0,In vivo,1,2113.0,,"Biodistribution in kidney of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL874449,BAO_0000218,
12088,Intermediate,10116.0,In vivo,1,2113.0,,"Biodistribution in kidney of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627144,BAO_0000218,
12089,Intermediate,10116.0,In vivo,1,2113.0,,"Biodistribution in kidney of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627145,BAO_0000218,
12090,Intermediate,10116.0,In vivo,1,2113.0,,"Biodistribution in kidney of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627146,BAO_0000218,
12091,Intermediate,10116.0,In vivo,1,2113.0,,"Biodistribution in kidney of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627147,BAO_0000218,
12092,Intermediate,10116.0,In vivo,1,2107.0,,"Biodistribution in liver of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627148,BAO_0000218,
12093,Intermediate,10116.0,In vivo,1,2048.0,,"Biodistribution in lung of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627149,BAO_0000218,
12094,Intermediate,10116.0,In vivo,1,2048.0,,"Biodistribution in lung of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL632160,BAO_0000218,
12095,Intermediate,10116.0,In vivo,1,2048.0,,"Biodistribution in lung of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL632161,BAO_0000218,
12096,Intermediate,10116.0,In vivo,1,2048.0,,"Biodistribution in lung of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL632162,BAO_0000218,
12097,Intermediate,10116.0,In vivo,1,2048.0,,"Biodistribution in lung of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL632163,BAO_0000218,
12098,Intermediate,10116.0,In vivo,1,2048.0,,"Biodistribution in lung of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL874469,BAO_0000218,
12099,Intermediate,10116.0,In vivo,1,2048.0,,"Biodistribution in lung of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627182,BAO_0000218,
12100,Intermediate,10116.0,In vivo,1,2385.0,,"Biodistribution in muscle of mature female Dawley rat after 10min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627183,BAO_0000218,
12101,Intermediate,10116.0,In vivo,1,2385.0,,"Biodistribution in muscle of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627184,BAO_0000218,
12102,Intermediate,10116.0,In vivo,1,2385.0,,"Biodistribution in muscle of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627185,BAO_0000218,
12103,Intermediate,10116.0,In vivo,1,2385.0,,"Biodistribution in muscle of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627186,BAO_0000218,
12104,Intermediate,10116.0,In vivo,1,2385.0,,"Biodistribution in muscle of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627187,BAO_0000218,
12105,Intermediate,10116.0,In vivo,1,2385.0,,"Biodistribution in muscle of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627188,BAO_0000218,
12106,Intermediate,10116.0,In vivo,1,2385.0,,"Biodistribution in muscle of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627189,BAO_0000218,
12107,Intermediate,10116.0,In vivo,1,,,"Biodistribution inl ilver of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627190,BAO_0000218,
12108,Intermediate,10116.0,In vivo,1,2107.0,,"Biodistribution inl iver of mature female Dawley rat after 15min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627191,BAO_0000218,
12109,Intermediate,10116.0,In vivo,1,2107.0,,"Biodistribution inl iver of mature female Dawley rat after 3 h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627192,BAO_0000218,
12110,Intermediate,10116.0,In vivo,1,2107.0,,"Biodistribution inl iver of mature female Dawley rat after 5min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL627193,BAO_0000218,
12111,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hou; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL874590,BAO_0000218,
12112,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution studied in the muscle of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627194,BAO_0000218,
12113,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution studied in the muscle of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627195,BAO_0000218,
12114,Intermediate,10116.0,In vivo,1,992.0,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627196,BAO_0000218,
12115,Intermediate,10116.0,In vivo,1,992.0,,Biodistribution studied in the ovaries of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627197,BAO_0000218,
12116,Intermediate,10116.0,In vivo,1,992.0,,Biodistribution studied in the ovaries of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627198,BAO_0000218,
12117,Intermediate,10116.0,In vivo,1,992.0,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour,N,,,50597,1,,CHEMBL627199,BAO_0000218,
12118,Intermediate,10116.0,In vivo,1,992.0,,Biodistribution studied in the ovaries of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627200,BAO_0000218,
12119,Intermediate,10116.0,In vivo,1,1969.0,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627201,BAO_0000218,
12120,Intermediate,10116.0,In vivo,1,1969.0,,Biodistribution studied in the plasma of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627202,BAO_0000218,
12121,Intermediate,10116.0,In vivo,1,1969.0,,Biodistribution studied in the plasma of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627203,BAO_0000218,
12122,Intermediate,10116.0,In vivo,1,1969.0,,Biodistribution studied in the plasma of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627204,BAO_0000218,
12123,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627205,BAO_0000218,
12124,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution studied in the spleen of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627206,BAO_0000218,
12125,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution studied in the spleen of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627207,BAO_0000218,
12126,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution studied in the spleen of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627208,BAO_0000218,
12127,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627209,BAO_0000218,
12128,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution studied in the thyroid of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627210,BAO_0000218,
12129,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution studied in the thyroid of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627211,BAO_0000218,
12130,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution studied in the thyroid of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627212,BAO_0000218,
12131,Intermediate,10116.0,In vivo,1,995.0,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hr +E2; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL627213,BAO_0000218,
12132,Intermediate,10116.0,In vivo,1,995.0,,Biodistribution studied in the uterus of immature Fischer female rats at 1 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL626599,BAO_0000218,
12133,Intermediate,10116.0,In vivo,1,995.0,,Biodistribution studied in the uterus of immature Fischer female rats at 2 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL626600,BAO_0000218,
12134,Intermediate,10116.0,In vivo,1,995.0,,Biodistribution studied in the uterus of immature Fischer female rats at 5 hour; activity is expressed as inductive dose / gram,N,,,50597,1,,CHEMBL626601,BAO_0000218,
12135,Autocuration,,,1,,,C(f=2) is the concentration at which the half life (t1/2) in the time course of inhibition of BChE by DFP increased by twofold in the presence of compound,U,,,22224,0,,CHEMBL627484,BAO_0000019,
12136,Intermediate,9541.0,,1,1969.0,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg),N,,,100710,1,,CHEMBL627485,BAO_0000218,
12137,Intermediate,9541.0,,1,1969.0,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not applicable,N,,,100710,1,,CHEMBL628147,BAO_0000218,
12138,Intermediate,9541.0,,1,1969.0,,Compound was tested for plasma concentration in CM-monkeys 7 hours after oral administration (50 mg/kg); Not determined,N,,,100710,1,,CHEMBL628148,BAO_0000218,
12139,Intermediate,9615.0,,1,1969.0,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg),N,,,50588,1,,CHEMBL628149,BAO_0000218,
12140,Intermediate,9615.0,,1,1969.0,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 1,N,,,50588,1,,CHEMBL628150,BAO_0000218,
12141,Intermediate,9615.0,,1,1969.0,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg) in experiment 2,N,,,50588,1,,CHEMBL628318,BAO_0000218,
12142,Intermediate,9615.0,,1,1969.0,,Compound was tested for plasma concentration in dogs 7 hours after oral administration (30 mg/kg); Not applicable,N,,,50588,1,,CHEMBL628319,BAO_0000218,
12143,Intermediate,9615.0,,1,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",N,,,50588,1,,CHEMBL875609,BAO_0000218,
12144,Autocuration,,,1,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10,U,,,22224,0,,CHEMBL628320,BAO_0000019,
12145,Autocuration,,,1,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 10.5,U,,,22224,0,,CHEMBL628321,BAO_0000019,
12146,Autocuration,,,1,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 6.8,U,,,22224,0,,CHEMBL628322,BAO_0000019,
12147,Autocuration,,,1,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.2,U,,,22224,0,,CHEMBL628323,BAO_0000019,
12148,Autocuration,,,1,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 7.6,U,,,22224,0,,CHEMBL628324,BAO_0000019,
12149,Autocuration,,,1,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 8.2,U,,,22224,0,,CHEMBL628325,BAO_0000019,
12150,Autocuration,,,1,,,Concentration distributed until decomposition of N-acetyl-N-hydroxy-p-aminophenol at pH 9.6,U,,,22224,0,,CHEMBL628326,BAO_0000019,
12151,Intermediate,9615.0,,1,1236.0,,"Concentration of compound in adrenal medulla of dog 2, after administering intravenously",N,,,50588,1,,CHEMBL628327,BAO_0000218,
12152,Intermediate,9615.0,,1,1236.0,,"Concentration of compound in adrenal medulla of dog1, after administering intravenously",N,,,50588,1,,CHEMBL628328,BAO_0000218,
12153,Intermediate,9615.0,,1,178.0,,"Concentration of compound in blood of dog 1, after administering intravenously",N,,,50588,1,,CHEMBL628329,BAO_0000218,
12154,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration.; dose/g, range 0.23-0.29",N,,,50597,1,,CHEMBL628330,BAO_0000218,
12155,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.22-0.30",N,,,50597,1,,CHEMBL628331,BAO_0000218,
12156,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.55-0.71",N,,,50597,1,,CHEMBL628332,BAO_0000218,
12157,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 0.57-0.72",N,,,50597,1,,CHEMBL628333,BAO_0000218,
12158,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 1.51-2.23",N,,,50597,1,,CHEMBL628334,BAO_0000218,
12159,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 30 minutes intravenous administration; dose/g, range 2.30-3.12",N,,,50597,1,,CHEMBL628335,BAO_0000218,
12160,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 0.93-1.20",N,,,50597,1,,CHEMBL628336,BAO_0000218,
12161,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.04-2.56",N,,,50597,1,,CHEMBL628337,BAO_0000218,
12162,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.06-1.70",N,,,50597,1,,CHEMBL628338,BAO_0000218,
12163,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 1.26-2.45",N,,,50597,1,,CHEMBL875610,BAO_0000218,
12164,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 3.12-4.56",N,,,50597,1,,CHEMBL628339,BAO_0000218,
12165,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 5 minutes intravenous administration; dose/g, range 4.12-6.30",N,,,50597,1,,CHEMBL628340,BAO_0000218,
12166,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.14-0.19",N,,,50597,1,,CHEMBL628341,BAO_0000218,
12167,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.15-0.19",N,,,50597,1,,CHEMBL622214,BAO_0000218,
12168,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.24-0.30",N,,,50597,1,,CHEMBL623167,BAO_0000218,
12169,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.44-0.54",N,,,50597,1,,CHEMBL623168,BAO_0000218,
12170,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 0.73-1.19",N,,,50597,1,,CHEMBL623169,BAO_0000218,
12171,Intermediate,10116.0,,1,2107.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats liver after 60 minutes intravenous administration; dose/g, range 1.08-2.31",N,,,50597,1,,CHEMBL623170,BAO_0000218,
12172,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration.; dose/g, range 0.34-0.47",N,,,50597,1,,CHEMBL627224,BAO_0000218,
12173,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.83-1.21",N,,,50597,1,,CHEMBL875634,BAO_0000218,
12174,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.91-1.74",N,,,50597,1,,CHEMBL627225,BAO_0000218,
12175,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 0.99-1.23",N,,,50597,1,,CHEMBL627226,BAO_0000218,
12176,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.07-1.30",N,,,50597,1,,CHEMBL626083,BAO_0000218,
12177,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 30 minutes intravenous administration; dose/g, range 1.12-1.39",N,,,50597,1,,CHEMBL626084,BAO_0000218,
12178,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.51-0.66",N,,,50597,1,,CHEMBL626085,BAO_0000218,
12179,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.95-1.49",N,,,50597,1,,CHEMBL626086,BAO_0000218,
12180,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 0.96-1.35",N,,,50597,1,,CHEMBL626087,BAO_0000218,
12181,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.18-1.44",N,,,50597,1,,CHEMBL626088,BAO_0000218,
12182,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.20-1.52",N,,,50597,1,,CHEMBL626089,BAO_0000218,
12183,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 5 minutes intravenous administration; dose/g, range 1.41-2.17",N,,,50597,1,,CHEMBL626090,BAO_0000218,
12184,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.28-0.33",N,,,50597,1,,CHEMBL626091,BAO_0000218,
12185,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.81-1.13",N,,,50597,1,,CHEMBL626092,BAO_0000218,
12186,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.83-2.11",N,,,50597,1,,CHEMBL626093,BAO_0000218,
12187,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.94-1.36",N,,,50597,1,,CHEMBL626094,BAO_0000218,
12188,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 0.97-1.54",N,,,50597,1,,CHEMBL626095,BAO_0000218,
12189,Intermediate,10116.0,,1,2048.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats lungs after 60 minutes intravenous administration; dose/g, range 1.07-1.26",N,,,50597,1,,CHEMBL626096,BAO_0000218,
12190,Autocuration,314293.0,,1,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in monkey,U,,,22224,0,,CHEMBL626097,BAO_0000218,
12191,Intermediate,10116.0,,1,,,area under curve in preclinical species was measured after oral administration at the given dose (0.5 mg/kg) in rat,N,,,50597,1,,CHEMBL626098,BAO_0000218,
12192,Autocuration,,,1,1969.0,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 27.5 mg/kg DMP323 equiv,U,,,22224,0,,CHEMBL626099,BAO_0000218,
12193,Autocuration,,,1,1969.0,,compound was evaluated for area under the plasma concentration vs. time curve at different dose 7.7 mg/kg DMP323 equiv,U,,,22224,0,,CHEMBL626100,BAO_0000218,
12194,Intermediate,9615.0,,1,1969.0,,AUC 0-inf in dog,N,,,50588,1,,CHEMBL626101,BAO_0000218,
12195,Intermediate,10141.0,,1,1969.0,,AUC 0-inf in guinea pig,N,,,50512,1,,CHEMBL626102,BAO_0000218,
12196,Intermediate,9615.0,,1,1969.0,,AUC 0-t in dog,N,,,50588,1,,CHEMBL626103,BAO_0000218,
12197,Intermediate,10141.0,,1,1969.0,,AUC 0-t in guinea pig,N,,,50512,1,,CHEMBL628391,BAO_0000218,
12198,Intermediate,10116.0,,1,,,The compound was tested for brain to plasma partition in rat,N,,,50597,1,,CHEMBL628392,BAO_0000218,
12199,Intermediate,10116.0,,1,,,The compound was tested for brain to plasma partition in rat.,N,,,50597,1,,CHEMBL628393,BAO_0000218,
12200,Autocuration,,,1,178.0,,Area under curve was determined for 0-6 hr duration using dihydralazine as reference drug for the peak blood pressure,U,,,22224,0,,CHEMBL628394,BAO_0000019,
12201,Intermediate,9615.0,,1,,,Area under concentration-time curve of compound was determined in dog at 5 mg/kg intravenously admn.,N,,,50588,1,,CHEMBL628395,BAO_0000218,
12202,Autocuration,314293.0,,1,,,Area under concentration-time curve of compound was determined in monkey at 5 mg/kg intravenously admn.,U,,,22224,0,,CHEMBL628396,BAO_0000218,
12203,Intermediate,9986.0,,1,,,Area under concentration-time curve of compound was determined in rabbit at 5 mg/kg intravenously admn.,N,,,50592,1,,CHEMBL628397,BAO_0000218,
12204,Intermediate,10116.0,,1,,,Area under concentration-time curve of compound was determined in rat at 5 mg/kg intravenously admn.,N,,,50597,1,,CHEMBL628398,BAO_0000218,
12205,Intermediate,9544.0,,1,,,Area under curve obtained at a dose of 10 mg/kg when administered orally to rhesus monkey,N,,,50797,1,,CHEMBL628399,BAO_0000218,
12206,Intermediate,9615.0,,1,,,The Plasma area under the compound concentration -time curve was measured in dogs after oral administration of 1 mg/kg dose,N,,,50588,1,,CHEMBL628400,BAO_0000218,
12207,Intermediate,10116.0,,1,,,The Plasma area under the compound concentration -time curve was measured in rats after oral administration of 1 mg/kg dose,N,,,50597,1,,CHEMBL874907,BAO_0000218,
12208,Autocuration,,,1,,,Area under curve of the compound was determined,U,,,22224,0,,CHEMBL628401,BAO_0000019,
12209,Autocuration,314293.0,,1,1969.0,,AUC in monkeys at a dose of 1 mg/kg,U,,,22224,0,,CHEMBL628402,BAO_0000218,
12210,Intermediate,10116.0,,1,1969.0,,AUC in rats at a dose of 1 mg/kg,N,,,50597,1,,CHEMBL628403,BAO_0000218,
12211,Autocuration,,,1,,,Compound was evaluated for the overall absorbance loss at pH of 2,U,,,22224,0,,CHEMBL628404,BAO_0000019,
12212,Autocuration,,,1,,,Compound was evaluated for the overall absorbance loss at pH of 4,U,,,22224,0,,CHEMBL628405,BAO_0000019,
12213,Autocuration,,,1,,,Compound was evaluated for the overall absorbance loss at pH of 7,U,,,22224,0,,CHEMBL628406,BAO_0000019,
12214,Intermediate,10116.0,,1,,,Compound was evaluated for its absorption in the rats,N,,,50597,1,,CHEMBL628407,BAO_0000218,
12215,Intermediate,10116.0,,1,1088.0,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,N,,,50597,1,,CHEMBL628408,BAO_0000218,
12216,Intermediate,10116.0,,1,1088.0,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight.,N,,,50597,1,,CHEMBL629171,BAO_0000218,
12217,Intermediate,10116.0,,1,1088.0,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of 0.1 mmol/kg of body weight per mole of pro drug,N,,,50597,1,,CHEMBL629172,BAO_0000218,
12218,Intermediate,10116.0,,1,1088.0,,Compound was evaluated for percent tranexamic acid recovered in rat urine within 24 hr after oral administration of per moiety tranexamic acid,N,,,50597,1,,CHEMBL629173,BAO_0000218,
12219,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum,N,,,50597,1,,CHEMBL629174,BAO_0000218,
12220,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; Range is 10-17,N,,,50597,1,,CHEMBL629175,BAO_0000218,
12221,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; Range is 10-18,N,,,50597,1,,CHEMBL629176,BAO_0000218,
12222,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; Range is 10-19,N,,,50597,1,,CHEMBL629177,BAO_0000218,
12223,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; Range is 12-15,N,,,50597,1,,CHEMBL629178,BAO_0000218,
12224,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; Range is 13-19,N,,,50597,1,,CHEMBL631869,BAO_0000218,
12225,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; Range is 14-17,N,,,50597,1,,CHEMBL631870,BAO_0000218,
12226,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; Range is 15-18,N,,,50597,1,,CHEMBL631871,BAO_0000218,
12227,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; Range is 2-5,N,,,50597,1,,CHEMBL631872,BAO_0000218,
12228,Autocuration,,,1,2116.0,,In vitro percent permeability into rat ileum; Range is 23-42,U,,,22224,0,,CHEMBL875775,BAO_0000221,
12229,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; Range is 28-36,N,,,50597,1,,CHEMBL631873,BAO_0000218,
12230,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; Range is 29-35,N,,,50597,1,,CHEMBL631874,BAO_0000218,
12231,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; Range is 46-66,N,,,50597,1,,CHEMBL631875,BAO_0000218,
12232,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; Range is 50-68,N,,,50597,1,,CHEMBL631876,BAO_0000218,
12233,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; Range is 78-81,N,,,50597,1,,CHEMBL631877,BAO_0000218,
12234,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; insol indicates not soluble in aqueous buffer,N,,,50597,1,,CHEMBL631878,BAO_0000218,
12235,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; nd indicates not detected,N,,,50597,1,,CHEMBL631879,BAO_0000218,
12236,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; nt indicates not detected,N,,,50597,1,,CHEMBL631880,BAO_0000218,
12237,Intermediate,10116.0,,1,,,In vitro percent permeability into rat ileum; nt indicates not tested,N,,,50597,1,,CHEMBL631881,BAO_0000218,
12238,Intermediate,10116.0,,1,,,Compound was tested for oral absorption in bile-duct cannulated rats,N,,,50597,1,,CHEMBL631882,BAO_0000218,
12239,Intermediate,10116.0,,1,,,Compound was tested for oral absorption in bile-duct cannulated rats.,N,,,50597,1,,CHEMBL630749,BAO_0000218,
12240,Intermediate,9606.0,,1,,,Oral absorption using Caco-2 cell monolayers.,N,,,50587,1,,CHEMBL630750,BAO_0000218,
12241,Intermediate,9606.0,,1,,,Percent of the drug absorbed after administration to humans was determined,N,,,50587,1,,CHEMBL630253,BAO_0000218,
12242,Intermediate,10116.0,,1,1969.0,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 120 minutes.,N,,,50597,1,,CHEMBL630254,BAO_0000218,
12243,Intermediate,10116.0,,1,1969.0,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 15 minutes.,N,,,50597,1,,CHEMBL630255,BAO_0000218,
12244,Intermediate,10116.0,,1,1969.0,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 180 minutes.,N,,,50597,1,,CHEMBL630256,BAO_0000218,
12245,Intermediate,10116.0,In vivo,1,2107.0,,"Biodistribution inl liver of mature female Dawley rat after 1h, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL875781,BAO_0000218,
12246,Intermediate,10116.0,In vivo,1,2107.0,,"Biodistribution inl liver of mature female Dawley rat after 30min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL630257,BAO_0000218,
12247,Intermediate,10116.0,In vivo,1,2107.0,,"Biodistribution inl liver of mature female Dawley rat after 45min, expressed as percent injected dose/g",N,,,50597,1,,CHEMBL630258,BAO_0000218,
12248,Intermediate,10116.0,,1,,,"Distribution of radioactivity in rat blood after 2 minutes of iv administration at the dose of 10.05-0.07 gram of tissue, expressed as percent injected dose per gram of tissue",N,,,50597,1,,CHEMBL630259,BAO_0000218,
12249,Intermediate,10116.0,,1,2435.0,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 1.89-3.73 g of tissue, expressed as percent injected dose per gram of tissue",N,,,50597,1,,CHEMBL630260,BAO_0000218,
12250,Intermediate,10116.0,,1,2435.0,,"Distribution of radioactivity in rat striatum after 5 minutes of iv administration at the dose of 3.44-4.80 g of tissue, expressed as percent injected dose per gram of tissue",N,,,50597,1,,CHEMBL630261,BAO_0000218,
12251,Intermediate,10116.0,,1,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat and 5-alpha-DHT was reported,N,,,50597,1,,CHEMBL630262,BAO_0000218,
12252,Intermediate,10116.0,,1,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 1 hour time,N,,,50597,1,,CHEMBL630263,BAO_0000218,
12253,Intermediate,10116.0,,1,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat blood at 2 hours time,N,,,50597,1,,CHEMBL630264,BAO_0000218,
12254,Intermediate,10116.0,,1,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 0.5 hours time,N,,,50597,1,,CHEMBL630265,BAO_0000218,
12255,Intermediate,10116.0,,1,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat fat at 4 hours time,N,,,50597,1,,CHEMBL630266,BAO_0000218,
12256,Intermediate,10116.0,,1,2113.0,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 0.5 hours time,N,,,50597,1,,CHEMBL630267,BAO_0000218,
12257,Intermediate,10116.0,,1,2113.0,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat kidney at 4 hours time,N,,,50597,1,,CHEMBL630268,BAO_0000218,
12258,Intermediate,10116.0,,1,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 1 hour time,N,,,50597,1,,CHEMBL630269,BAO_0000218,
12259,Intermediate,10116.0,,1,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat liver at 2 hours time,N,,,50597,1,,CHEMBL630270,BAO_0000218,
12260,Intermediate,10116.0,,1,2048.0,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 1 hour time,N,,,50597,1,,CHEMBL630141,BAO_0000218,
12261,Intermediate,10116.0,,1,2048.0,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat lung at 2 hours time,N,,,50597,1,,CHEMBL630142,BAO_0000218,
12262,Intermediate,10116.0,,1,2385.0,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 0.5 hours time,N,,,50597,1,,CHEMBL630143,BAO_0000218,
12263,Intermediate,10116.0,,1,2385.0,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat muscle at 4 hours time,N,,,50597,1,,CHEMBL630144,BAO_0000218,
12264,Intermediate,10116.0,,1,2367.0,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 0.5 hours time,N,,,50597,1,,CHEMBL630145,BAO_0000218,
12265,Intermediate,10116.0,,1,2367.0,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate at 4 hours time,N,,,50597,1,,CHEMBL630146,BAO_0000218,
12266,Intermediate,10116.0,,1,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood,N,,,50597,1,,CHEMBL630147,BAO_0000218,
12267,Intermediate,10116.0,,1,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 1 hours time,N,,,50597,1,,CHEMBL630148,BAO_0000218,
12268,Intermediate,10116.0,,1,,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat prostate/blood at 2 hours time,N,,,50597,1,,CHEMBL630149,BAO_0000218,
12269,Intermediate,10116.0,,1,2106.0,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 1 hour time,N,,,50597,1,,CHEMBL630150,BAO_0000218,
12270,Intermediate,10116.0,,1,2106.0,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat spleen at 2 hours time,N,,,50597,1,,CHEMBL630151,BAO_0000218,
12271,Intermediate,10116.0,,1,2046.0,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 0.5 hours time,N,,,50597,1,,CHEMBL632031,BAO_0000218,
12272,Intermediate,10116.0,,1,2046.0,,Distribution of tissue Radioactivity following Intravenous injection into castarted male rat thyroid at 4 hours time,N,,,50597,1,,CHEMBL632032,BAO_0000218,
12273,Intermediate,10116.0,,1,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat fat at 1 hour time,N,,,50597,1,,CHEMBL632033,BAO_0000218,
12274,Intermediate,10116.0,,1,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat kidney at 1 hour time,N,,,50597,1,,CHEMBL632034,BAO_0000218,
12275,Intermediate,10116.0,,1,2385.0,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat muscle at 1 hour time,N,,,50597,1,,CHEMBL632035,BAO_0000218,
12276,Intermediate,10116.0,,1,,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat prostrateat 1 hour time,N,,,50597,1,,CHEMBL632036,BAO_0000218,
12277,Intermediate,10116.0,,1,2046.0,,Distribution of tissue Radioactivity following subcutaneous injection of 500 mg of 5-alpha-DHT 15 min before the administration of the [125I]- tracer castarted male rat thyroid at 1 hour time,N,,,50597,1,,CHEMBL632037,BAO_0000218,
12278,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,N,,,50597,1,,CHEMBL632038,BAO_0000218,
12279,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,N,,,50597,1,,CHEMBL632039,BAO_0000218,
12280,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,N,,,50597,1,,CHEMBL632040,BAO_0000218,
12281,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,N,,,50597,1,,CHEMBL632041,BAO_0000218,
12282,Intermediate,9615.0,,1,178.0,,"Concentration of compound in blood of dog 2, after administering intravenously",N,,,50588,1,,CHEMBL632042,BAO_0000218,
12283,Intermediate,9615.0,,1,,,"Concentration of compound in left ventricle of dog 1, after administering intravenously",N,,,50588,1,,CHEMBL632043,BAO_0000218,
12284,Intermediate,9615.0,,1,,,"Concentration of compound in left ventricle of dog 2, after administering intravenously",N,,,50588,1,,CHEMBL632044,BAO_0000218,
12285,Intermediate,9615.0,,1,2107.0,,"Concentration of compound in liver of dog 1, after administering intravenously",N,,,50588,1,,CHEMBL632045,BAO_0000218,
12286,Intermediate,9615.0,,1,2107.0,,"Concentration of compound in liver of dog 2, after administering intravenously",N,,,50588,1,,CHEMBL632046,BAO_0000218,
12287,Intermediate,9615.0,,1,2048.0,,"Concentration of compound in lung of dog 1, after administering intravenously",N,,,50588,1,,CHEMBL632047,BAO_0000218,
12288,Intermediate,9615.0,,1,2048.0,,"Concentration of compound in lung of dog 2, after administering intravenously",N,,,50588,1,,CHEMBL632048,BAO_0000218,
12289,Intermediate,9615.0,,1,2385.0,,"Concentration of compound in muscle of dog 1, after administering intravenously",N,,,50588,1,,CHEMBL632049,BAO_0000218,
12290,Intermediate,9615.0,,1,2385.0,,"Concentration of compound in muscle of dog 2, after administering intravenously",N,,,50588,1,,CHEMBL876418,BAO_0000218,
12291,Intermediate,9615.0,,1,2106.0,,"Concentration of compound in spleen of dog 1,after administering intravenously",N,,,50588,1,,CHEMBL632050,BAO_0000218,
12292,Intermediate,9615.0,,1,2106.0,,"Concentration of compound in spleen of dog 2, after administering intravenously",N,,,50588,1,,CHEMBL632051,BAO_0000218,
12293,Autocuration,,,1,,,Concentration of liberated compound in serum after 120 min at the dose of 50 mg/kg (po).,U,,,22224,0,,CHEMBL632052,BAO_0000218,
12294,Autocuration,,,1,,,Concentration of liberated compound in serum after 240 min at the dose of 50 mg/kg (po).,U,,,22224,0,,CHEMBL632053,BAO_0000218,
12295,Autocuration,,,1,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,U,,,22224,0,,CHEMBL632054,BAO_0000218,
12296,Autocuration,,,1,,,Concentration of liberated compound in serum after 30 min at the dose of 50 mg/kg (po).,U,,,22224,0,,CHEMBL632055,BAO_0000218,
12297,Autocuration,,,1,,,Concentration of liberated compound in serum after 60 min at the dose of 50 mg/kg (po).,U,,,22224,0,,CHEMBL631181,BAO_0000218,
12298,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous after 1.5 hr,U,,,22224,0,,CHEMBL631182,BAO_0000218,
12299,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,U,,,22224,0,,CHEMBL631183,BAO_0000218,
12300,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,U,,,22224,0,,CHEMBL631184,BAO_0000218,
12301,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,U,,,22224,0,,CHEMBL629774,BAO_0000218,
12302,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,U,,,22224,0,,CHEMBL629775,BAO_0000218,
12303,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,U,,,22224,0,,CHEMBL876549,BAO_0000218,
12304,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,U,,,22224,0,,CHEMBL628172,BAO_0000218,
12305,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,U,,,22224,0,,CHEMBL628173,BAO_0000218,
12306,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous after 1.5 hr,U,,,22224,0,,CHEMBL628174,BAO_0000218,
12307,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 4.0 hr,U,,,22224,0,,CHEMBL628175,BAO_0000218,
12308,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,U,,,22224,0,,CHEMBL628176,BAO_0000218,
12309,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,U,,,22224,0,,CHEMBL628177,BAO_0000218,
12310,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,U,,,22224,0,,CHEMBL628178,BAO_0000218,
12311,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,U,,,22224,0,,CHEMBL628179,BAO_0000218,
12312,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg i intravenous dosage after 1.0 hr; insufficient gastric juice produced,U,,,22224,0,,CHEMBL628180,BAO_0000218,
12313,Autocuration,,,1,,,Concentration of radioactivity in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage a after 2.5 hr,U,,,22224,0,,CHEMBL628181,BAO_0000218,
12314,Autocuration,,,1,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,U,,,22224,0,,CHEMBL628182,BAO_0000218,
12315,Autocuration,,,1,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,U,,,22224,0,,CHEMBL628183,BAO_0000218,
12316,Autocuration,,,1,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr; ND means not determined,U,,,22224,0,,CHEMBL628184,BAO_0000218,
12317,Autocuration,,,1,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,U,,,22224,0,,CHEMBL628185,BAO_0000218,
12318,Autocuration,,,1,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,U,,,22224,0,,CHEMBL875617,BAO_0000218,
12319,Autocuration,,,1,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr; ND means not determined,U,,,22224,0,,CHEMBL628186,BAO_0000218,
12320,Autocuration,,,1,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,U,,,22224,0,,CHEMBL628187,BAO_0000218,
12321,Autocuration,,,1,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,U,,,22224,0,,CHEMBL628188,BAO_0000218,
12322,Autocuration,,,1,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,U,,,22224,0,,CHEMBL628189,BAO_0000218,
12323,Autocuration,,,1,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr; ND means not determined,U,,,22224,0,,CHEMBL628190,BAO_0000218,
12324,Autocuration,,,1,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,U,,,22224,0,,CHEMBL628191,BAO_0000218,
12325,Autocuration,,,1,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr; ND means not determined,U,,,22224,0,,CHEMBL626513,BAO_0000218,
12326,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 19-24",N,,,50597,1,,CHEMBL626514,BAO_0000218,
12327,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 26-40",N,,,50597,1,,CHEMBL626515,BAO_0000218,
12328,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 29-44",N,,,50597,1,,CHEMBL626516,BAO_0000218,
12329,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 32-42",N,,,50597,1,,CHEMBL626517,BAO_0000218,
12330,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 33-60",N,,,50597,1,,CHEMBL626518,BAO_0000218,
12331,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 30 minutes intravenous administration; dose/g, range 4-7",N,,,50597,1,,CHEMBL626519,BAO_0000218,
12332,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 13-18",N,,,50597,1,,CHEMBL626520,BAO_0000218,
12333,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 16-32",N,,,50597,1,,CHEMBL626521,BAO_0000218,
12334,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 22-25",N,,,50597,1,,CHEMBL626522,BAO_0000218,
12335,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 26-49",N,,,50597,1,,CHEMBL626523,BAO_0000218,
12336,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 29-36",N,,,50597,1,,CHEMBL626524,BAO_0000218,
12337,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 5 minutes intravenous administration; dose/g, range 5-8",N,,,50597,1,,CHEMBL626688,BAO_0000218,
12338,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 26-42",N,,,50597,1,,CHEMBL626689,BAO_0000218,
12339,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 30-53",N,,,50597,1,,CHEMBL626690,BAO_0000218,
12340,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 32-43",N,,,50597,1,,CHEMBL626691,BAO_0000218,
12341,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 35-53",N,,,50597,1,,CHEMBL627319,BAO_0000218,
12342,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 5-12",N,,,50597,1,,CHEMBL624052,BAO_0000218,
12343,Intermediate,10116.0,,1,2046.0,,"Evaluated for the distribution of radioactivity in tissues of female Fischer rats thyroid after 60 minutes intravenous administration; dose/g, range 55-102",N,,,50597,1,,CHEMBL624053,BAO_0000218,
12344,Intermediate,10116.0,,1,,,In vivo distribution of the drug in plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,,50597,1,,CHEMBL624054,BAO_0000218,
12345,Intermediate,10116.0,,1,,,In vivo distribution of the drug in plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,,50597,1,,CHEMBL624055,BAO_0000218,
12346,Intermediate,10116.0,,1,,,In vivo distribution of the drug in plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,,50597,1,,CHEMBL624056,BAO_0000218,
12347,Intermediate,10116.0,,1,995.0,,In vivo distribution of the drug in uterus was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,,50597,1,,CHEMBL624057,BAO_0000218,
12348,Intermediate,10116.0,,1,995.0,,In vivo distribution of the drug in uterus was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,,50597,1,,CHEMBL622281,BAO_0000218,
12349,Intermediate,10116.0,,1,995.0,,In vivo distribution of the drug in uterus was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,,50597,1,,CHEMBL622282,BAO_0000218,
12350,Intermediate,10116.0,,1,995.0,,In vivo distribution of the drug in uterus/plasma was determined at 1 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,,50597,1,,CHEMBL622283,BAO_0000218,
12351,Intermediate,10116.0,,1,995.0,,In vivo distribution of the drug in uterus/plasma was determined at 2 hr following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,,50597,1,,CHEMBL622284,BAO_0000218,
12352,Intermediate,10116.0,,1,995.0,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,,50597,1,,CHEMBL622285,BAO_0000218,
12353,Intermediate,10116.0,,1,995.0,,In vivo distribution of the drug in uterus/plasma was determined at 3h following injection of five microcurics of the radiolabeled [125 I] compound in rats,N,,,50597,1,,CHEMBL622286,BAO_0000218,
12354,Autocuration,,,1,,,Distribution coefficient (D %) between octanol and buffer of pH 7.4,U,,,22224,0,,CHEMBL622287,BAO_0000100,
12355,Intermediate,10090.0,,1,,,Partition coefficient (logD7.4),N,,,50594,1,,CHEMBL622288,BAO_0000218,
12356,Intermediate,10090.0,,1,,,"Percentage of radioactivity in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",N,,,50594,1,,CHEMBL622289,BAO_0000218,
12357,Intermediate,10090.0,,1,955.0,,"Percentage of radioactivity in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",N,,,50594,1,,CHEMBL622290,BAO_0000218,
12358,Intermediate,10090.0,,1,,,Percentage of radioactivity in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,N,,,50594,1,,CHEMBL622291,BAO_0000218,
12359,Intermediate,10090.0,,1,955.0,,Percentage of radioactivity in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,N,,,50594,1,,CHEMBL622292,BAO_0000218,
12360,Intermediate,10090.0,,1,,,"Percentage of total protein recovered in P1 subregion in mouse brain that contains nuclei and cell debris, after Jugular Vein Injection",N,,,50594,1,,CHEMBL622293,BAO_0000218,
12361,Intermediate,10090.0,,1,955.0,,"Percentage of total protein recovered in P2 subregion in mouse brain that contains myelin fragments, synaptosomes (pinched-nerve endings), and mitochondria after Jugular Vein Injection",N,,,50594,1,,CHEMBL622294,BAO_0000218,
12362,Intermediate,10090.0,,1,,,Percentage of total protein recovered in P3 subregion in mouse brain that contains microsomal fraction after Jugular Vein Injection,N,,,50594,1,,CHEMBL622295,BAO_0000218,
12363,Intermediate,10116.0,,1,955.0,,Percentage of total protein recovered in S3 which is the soluble fraction in mouse brain after Jugular Vein Injection,N,,,50597,1,,CHEMBL622296,BAO_0000218,
12364,Intermediate,10116.0,,1,1969.0,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 2 minutes.,N,,,50597,1,,CHEMBL874409,BAO_0000218,
12365,Intermediate,10116.0,,1,1969.0,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 240 minutes.,N,,,50597,1,,CHEMBL622297,BAO_0000218,
12366,Intermediate,10116.0,,1,1969.0,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 30 minutes.,N,,,50597,1,,CHEMBL622298,BAO_0000218,
12367,Intermediate,10116.0,,1,1969.0,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 45 minutes.,N,,,50597,1,,CHEMBL622299,BAO_0000218,
12368,Intermediate,10116.0,,1,1969.0,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 5 minutes.,N,,,50597,1,,CHEMBL622300,BAO_0000218,
12369,Intermediate,10116.0,,1,1969.0,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 60 minutes.,N,,,50597,1,,CHEMBL622301,BAO_0000218,
12370,Intermediate,10116.0,,1,1969.0,,1 mg/kg was administered intravenously in anesthetized rats and the concentration in plasma was determined after 90 minutes.,N,,,50597,1,,CHEMBL622302,BAO_0000218,
12371,Intermediate,10116.0,,1,1969.0,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 120 minutes.,N,,,50597,1,,CHEMBL622303,BAO_0000218,
12372,Intermediate,10116.0,,1,1969.0,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes.,N,,,50597,1,,CHEMBL622304,BAO_0000218,
12373,Intermediate,10116.0,,1,1969.0,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 15 minutes;nd=not determined,N,,,50597,1,,CHEMBL622305,BAO_0000218,
12374,Intermediate,10116.0,,1,1969.0,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 180 minutes.,N,,,50597,1,,CHEMBL622306,BAO_0000218,
12375,Intermediate,10116.0,,1,1969.0,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 2 minutes;nd=not determined,N,,,50597,1,,CHEMBL626864,BAO_0000218,
12376,Intermediate,10116.0,,1,1969.0,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes.,N,,,50597,1,,CHEMBL626865,BAO_0000218,
12377,Intermediate,10116.0,,1,1969.0,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 240 minutes;nd=not determined,N,,,50597,1,,CHEMBL626866,BAO_0000218,
12378,Intermediate,10116.0,,1,1969.0,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 30 minutes.,N,,,50597,1,,CHEMBL626867,BAO_0000218,
12379,Intermediate,10116.0,,1,1969.0,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes.,N,,,50597,1,,CHEMBL626868,BAO_0000218,
12380,Intermediate,10116.0,,1,1969.0,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 45 minutes;nd=not determined,N,,,50597,1,,CHEMBL626869,BAO_0000218,
12381,Intermediate,10116.0,,1,1969.0,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes.,N,,,50597,1,,CHEMBL626870,BAO_0000218,
12382,Intermediate,10116.0,,1,1969.0,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 5 minutes;nd=not determined,N,,,50597,1,,CHEMBL626871,BAO_0000218,
12383,Intermediate,10116.0,,1,1969.0,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 60 minutes.,N,,,50597,1,,CHEMBL626872,BAO_0000218,
12384,Intermediate,10116.0,,1,1969.0,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes.,N,,,50597,1,,CHEMBL632185,BAO_0000218,
12385,Intermediate,10116.0,,1,1969.0,,50 mg/kg was administered orally in anesthetized rats and the concentration in plasma was determined after 90 minutes;nd=not determined,N,,,50597,1,,CHEMBL632186,BAO_0000218,
12386,Autocuration,,,1,,,Amount of acetic acid produced by the compound,U,,,22224,0,,CHEMBL629310,BAO_0000019,
12387,Autocuration,,,1,,,Apparent first-order rate of solvolysis for the bipinnatin-A(A4) was determined,U,,,22224,0,,CHEMBL629311,BAO_0000019,
12388,Intermediate,10116.0,,1,,,Log of (Cbrain/Cblood) in rats,N,,,50597,1,,CHEMBL629312,BAO_0000218,
12389,Autocuration,,,1,,,Compound in absence of MPM cell homogenate at pH 3 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL629313,BAO_0000221,
12390,Autocuration,,,1,,,Compound in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL629314,BAO_0000221,
12391,Autocuration,,,1,,,Compound in absence of MPM cell homogenate at pH 7 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL629315,BAO_0000221,
12392,Autocuration,,,1,,,Compound in presence of MPM cells and in absence of inactivator at pH 8 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL629316,BAO_0000219,
12393,Autocuration,,,1,,,Compound treated in absence of MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL629317,BAO_0000221,
12394,Autocuration,,,1,,,Compound treated with MPM cell homogenate at pH 3 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL629318,BAO_0000019,
12395,Autocuration,,,1,,,Compound treated with MPM cell homogenate at pH 3.5 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL877497,BAO_0000019,
12396,Autocuration,,,1,,,Compound treated with MPM cell homogenate at pH 4 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL629319,BAO_0000019,
12397,Autocuration,,,1,,,Compound treated with MPM cell homogenate at pH 4.5 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL629320,BAO_0000019,
12398,Autocuration,,,1,,,Compound treated with MPM cell homogenate at pH 5 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL629496,BAO_0000019,
12399,Autocuration,,,1,,,Compound treated with MPM cell homogenate at pH 5.5 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL629497,BAO_0000019,
12400,Autocuration,,,1,,,Compound treated with MPM cell homogenate at pH 6 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL629498,BAO_0000019,
12401,Autocuration,,,1,,,Compound treated with MPM cell homogenate at pH 6.5 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL629499,BAO_0000019,
12402,Autocuration,,,1,,,Compound treated with MPM cell homogenate at pH 7 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL629500,BAO_0000019,
12403,Autocuration,,,1,,,Compound treated with MPM cell homogenate at pH 7.5 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL629501,BAO_0000019,
12404,Autocuration,,,1,,,Compound treated with MPM cell homogenate at pH 8 to isolate compound 4 (ng),U,,,22224,0,,CHEMBL629502,BAO_0000019,
12405,Autocuration,,In vivo,1,,,Compound was evaluated for its urinary recovery after oral administration (100 mg) to Beagle dogs,U,,,22224,0,,CHEMBL629503,BAO_0000218,
12406,Intermediate,9615.0,,1,,,Compound was evaluated for its urinary recovery after oral administration (200 mg) to Beagle dogs,N,,,50588,1,,CHEMBL629504,BAO_0000218,
12407,Autocuration,,,1,,,Compound was evaluated for the rate of degradation by Carboxypeptidase A.,U,,,22224,0,,CHEMBL629505,BAO_0000019,
12408,Autocuration,,,1,,,Compound was evaluated for total body clearance,U,,,22224,0,,CHEMBL629506,BAO_0000019,
12409,Autocuration,,,1,,,Compound was evaluated for volume of distribution at steady state,U,,,22224,0,,CHEMBL629507,BAO_0000019,
12410,Autocuration,,,1,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant KOH- was reported.,U,,,22224,0,,CHEMBL877498,BAO_0000019,
12411,Autocuration,,,1,,,Percentage of the diamine which is monoprotonated at pH 7.4,U,,,22224,0,,CHEMBL629508,BAO_0000019,
12412,Autocuration,,,1,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells,U,,,22224,0,,CHEMBL629509,BAO_0000019,
12413,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,N,,,50597,1,,CHEMBL629510,BAO_0000218,
12414,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,N,,,50597,1,,CHEMBL629511,BAO_0000218,
12415,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,N,,,50597,1,,CHEMBL629512,BAO_0000218,
12416,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,N,,,50597,1,,CHEMBL629513,BAO_0000218,
12417,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,N,,,50597,1,,CHEMBL629514,BAO_0000218,
12418,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 1 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,N,,,50597,1,,CHEMBL628447,BAO_0000218,
12419,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 10 minutes,N,,,50597,1,,CHEMBL628448,BAO_0000218,
12420,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 15 minutes,N,,,50597,1,,CHEMBL628449,BAO_0000218,
12421,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 20 minutes,N,,,50597,1,,CHEMBL631119,BAO_0000218,
12422,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 30 minutes,N,,,50597,1,,CHEMBL631120,BAO_0000218,
12423,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 microCi and activity calculated after 5 minutes,N,,,50597,1,,CHEMBL631121,BAO_0000218,
12424,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 min,N,,,50597,1,,CHEMBL874458,BAO_0000218,
12425,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,N,,,50597,1,,CHEMBL631122,BAO_0000218,
12426,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,N,,,50597,1,,CHEMBL631123,BAO_0000218,
12427,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 2 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,N,,,50597,1,,CHEMBL631124,BAO_0000218,
12428,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,N,,,50597,1,,CHEMBL631125,BAO_0000218,
12429,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,N,,,50597,1,,CHEMBL631290,BAO_0000218,
12430,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,N,,,50597,1,,CHEMBL631291,BAO_0000218,
12431,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 3 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,N,,,50597,1,,CHEMBL631292,BAO_0000218,
12432,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 10 minutes,N,,,50597,1,,CHEMBL631293,BAO_0000218,
12433,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 15 minutes,N,,,50597,1,,CHEMBL631294,BAO_0000218,
12434,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 20 minutes,N,,,50597,1,,CHEMBL631295,BAO_0000218,
12435,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 30 minutes,N,,,50597,1,,CHEMBL631296,BAO_0000218,
12436,Intermediate,10116.0,,1,178.0,,Amount of compound present in blood of rat 4 when administered intravenously at a dose of 2 mg containing approximately 3 uCi and activity calculated after 5 minutes,N,,,50597,1,,CHEMBL631297,BAO_0000218,
12437,Autocuration,,,1,,,Maximum biodistribution (Bmax) was determined.,U,,,22224,0,,CHEMBL631298,BAO_0000218,
12438,Intermediate,10090.0,,1,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 1.5625 (mg/kg) intravenous dose in 6 mice,N,,,50594,1,,CHEMBL631299,BAO_0000218,
12439,Intermediate,10090.0,,1,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 10 (mg/kg) intravenous dose in 6 mice,N,,,50594,1,,CHEMBL631300,BAO_0000218,
12440,Intermediate,10090.0,,1,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 3.125 (mg/kg) intravenous dose in 6 mice,N,,,50594,1,,CHEMBL631301,BAO_0000218,
12441,Intermediate,10090.0,,1,,,Mean difference between rectal temperature measured at time zero and rectal temperature measured at 10 min at 6.25 (mg/kg) intravenous dose in 6 mice,N,,,50594,1,,CHEMBL630291,BAO_0000218,
12442,Autocuration,,,1,,,Brain concentration after 0.25 hr at a dose of 10 mg/kg when administered intraperitoneally,U,,,22224,0,,CHEMBL630292,BAO_0000218,
12443,Autocuration,,,1,,,Brain concentration after 0.25 h at a dose of 10 mg/kg when administered intravenously,U,,,22224,0,,CHEMBL630293,BAO_0000218,
12444,Autocuration,,,1,,,Brain concentration after 0.5 h at a dose of 100 mg/kg when administered perorally,U,,,22224,0,,CHEMBL630294,BAO_0000218,
12445,Autocuration,,,1,,,Brain concentration after 0.5 h at a dose of 10 mg/kg when administered intraperitoneally,U,,,22224,0,,CHEMBL630295,BAO_0000218,
12446,Autocuration,,,1,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered intravenously,U,,,22224,0,,CHEMBL630296,BAO_0000218,
12447,Autocuration,,,1,,,Brain concentration after 0.5 hr at a dose of 10 mg/kg when administered perorally,U,,,22224,0,,CHEMBL626782,BAO_0000218,
12448,Autocuration,,,1,,,Brain concentration after 1 hr at a dose of 100 mg/kg when administered perorally,U,,,22224,0,,CHEMBL626783,BAO_0000218,
12449,Autocuration,,,1,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intraperitoneally,U,,,22224,0,,CHEMBL626784,BAO_0000218,
12450,Autocuration,,,1,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered intravenously,U,,,22224,0,,CHEMBL626785,BAO_0000218,
12451,Autocuration,,,1,,,Brain concentration after 1 hr at a dose of 10 mg/kg when administered perorally,U,,,22224,0,,CHEMBL626786,BAO_0000218,
12452,Autocuration,,,1,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,U,,,22224,0,,CHEMBL626787,BAO_0000218,
12453,Autocuration,,,1,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr; ND means not determined,U,,,22224,0,,CHEMBL626788,BAO_0000218,
12454,Autocuration,,,1,,,Concentration of radioactivity in plasma for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,U,,,22224,0,,CHEMBL625927,BAO_0000218,
12455,Intermediate,10116.0,,1,178.0,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL625928,BAO_0000218,
12456,Intermediate,10116.0,,1,178.0,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,,,50597,1,,CHEMBL625929,BAO_0000218,
12457,Intermediate,10116.0,,1,178.0,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected.,N,,,50597,1,,CHEMBL625930,BAO_0000218,
12458,Intermediate,10116.0,,1,178.0,,"Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound, Compound was found to be in trace amount.",N,,,50597,1,,CHEMBL625931,BAO_0000218,
12459,Intermediate,10116.0,,1,178.0,,Concentration 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected.,N,,,50597,1,,CHEMBL627230,BAO_0000218,
12460,Intermediate,10116.0,,1,178.0,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627231,BAO_0000218,
12461,Intermediate,10116.0,,1,178.0,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,,,50597,1,,CHEMBL627232,BAO_0000218,
12462,Intermediate,10116.0,,1,178.0,,Concentration 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected.,N,,,50597,1,,CHEMBL627233,BAO_0000218,
12463,Intermediate,10116.0,,1,178.0,,Concentration 5a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL875470,BAO_0000218,
12464,Intermediate,10116.0,,1,178.0,,Concentration 5a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627234,BAO_0000218,
12465,Intermediate,10116.0,,1,178.0,,Concentration 5b detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627235,BAO_0000218,
12466,Intermediate,10116.0,,1,178.0,,Concentration 5b detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627236,BAO_0000218,
12467,Intermediate,10116.0,,1,178.0,,Concentration 5c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627237,BAO_0000218,
12468,Intermediate,10116.0,,1,178.0,,Concentration 5c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627238,BAO_0000218,
12469,Intermediate,10116.0,,1,178.0,,Concentration 5d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627239,BAO_0000218,
12470,Intermediate,10116.0,,1,178.0,,Concentration 5d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627240,BAO_0000218,
12471,Intermediate,10116.0,,1,178.0,,Concentration 5e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627241,BAO_0000218,
12472,Intermediate,10116.0,,1,178.0,,Concentration 5e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627242,BAO_0000218,
12473,Intermediate,10116.0,,1,178.0,,Concentration 5f detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound; ND is Not Detected,N,,,50597,1,,CHEMBL627243,BAO_0000218,
12474,Intermediate,10116.0,,1,178.0,,Concentration 5f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,,,50597,1,,CHEMBL627244,BAO_0000218,
12475,Intermediate,10116.0,,1,178.0,,Concentration 6a detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627245,BAO_0000218,
12476,Intermediate,10116.0,,1,178.0,,Concentration 6a detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627246,BAO_0000218,
12477,Intermediate,10116.0,,1,178.0,,Concentration 6c detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627247,BAO_0000218,
12478,Intermediate,10116.0,,1,178.0,,Concentration 6c detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627248,BAO_0000218,
12479,Intermediate,10116.0,,1,178.0,,Concentration 6d detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627249,BAO_0000218,
12480,Intermediate,10116.0,,1,178.0,,Concentration 6d detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL625569,BAO_0000218,
12481,Intermediate,10116.0,,1,178.0,,Concentration 6e detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL625570,BAO_0000218,
12482,Intermediate,10116.0,,1,178.0,,Concentration 6e detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL625571,BAO_0000218,
12483,Intermediate,10116.0,,1,178.0,,Concentration 6f detected in blood of rat 1 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,,,50597,1,,CHEMBL625572,BAO_0000218,
12484,Intermediate,10116.0,,1,178.0,,Concentration 6f detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,,,50597,1,,CHEMBL625573,BAO_0000218,
12485,Intermediate,10116.0,,1,178.0,,Concentration detected in blood of rat 1 hr after an oral dose of 200 mg/kg,N,,,50597,1,,CHEMBL625574,BAO_0000218,
12486,Intermediate,10116.0,,1,178.0,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg; ND is Not Detected,N,,,50597,1,,CHEMBL626245,BAO_0000218,
12487,Intermediate,10116.0,,1,178.0,,Concentration detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL626246,BAO_0000218,
12488,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,U,,,22224,0,,CHEMBL626247,BAO_0000218,
12489,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,U,,,22224,0,,CHEMBL626248,BAO_0000218,
12490,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,U,,,22224,0,,CHEMBL626249,BAO_0000218,
12491,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,U,,,22224,0,,CHEMBL626420,BAO_0000218,
12492,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,U,,,22224,0,,CHEMBL626421,BAO_0000218,
12493,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,U,,,22224,0,,CHEMBL626422,BAO_0000218,
12494,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,U,,,22224,0,,CHEMBL626423,BAO_0000218,
12495,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,U,,,22224,0,,CHEMBL626424,BAO_0000218,
12496,Intermediate,9615.0,,1,,,Volume of distribution in Beagles dog at a dose of 1 mg/kg given intravenously,N,,,50588,1,,CHEMBL626425,BAO_0000218,
12497,Intermediate,10116.0,,1,,,Volume of distribution in CD rat at a dose of 5 mg/kg given intravenously,N,,,50597,1,,CHEMBL875476,BAO_0000218,
12498,Intermediate,9541.0,,1,,,Volume of distribution in Cynomolgus monkey at a dose of 5 mg/kg given intravenously,N,,,100710,1,,CHEMBL626426,BAO_0000218,
12499,Autocuration,,,1,,,Distribution coefficient and iron(III) complex was measured at an aqueous phase buffered at pH 7.4 and octanol,U,,,22224,0,,CHEMBL626427,BAO_0000100,
12500,Autocuration,,,1,,,Distribution coefficient was measured at an aqueous phase buffered at pH 7.4 and octanol,U,,,22224,0,,CHEMBL626428,BAO_0000100,
12501,Autocuration,,,1,,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in bile by subcutaneous dose of 150 umol/kg,U,,,22224,0,,CHEMBL626429,BAO_0000019,
12502,Autocuration,,,1,1088.0,,Iron clearance was stimulated by the compound was expressed as % distribution of excreted Fe in urine by subcutaneous dose of 150 umol/kg,U,,,22224,0,,CHEMBL625025,BAO_0000019,
12503,Intermediate,10116.0,,1,178.0,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL625026,BAO_0000218,
12504,Intermediate,10116.0,,1,178.0,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL625027,BAO_0000218,
12505,Intermediate,10116.0,,1,178.0,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL874410,BAO_0000218,
12506,Intermediate,10116.0,,1,178.0,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL625028,BAO_0000218,
12507,Intermediate,10116.0,,1,178.0,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL625029,BAO_0000218,
12508,Intermediate,10116.0,,1,178.0,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL625030,BAO_0000218,
12509,Intermediate,10116.0,,1,178.0,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL625031,BAO_0000218,
12510,Intermediate,10116.0,,1,178.0,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL625032,BAO_0000218,
12511,Intermediate,10116.0,,1,178.0,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL625033,BAO_0000218,
12512,Intermediate,10116.0,,1,178.0,,Concentration was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL625034,BAO_0000218,
12513,Intermediate,10116.0,,1,948.0,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624872,BAO_0000218,
12514,Intermediate,10116.0,,1,948.0,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624873,BAO_0000218,
12515,Intermediate,10116.0,,1,948.0,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL624874,BAO_0000218,
12516,Intermediate,10116.0,,1,948.0,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL624875,BAO_0000218,
12517,Intermediate,10116.0,,1,948.0,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624876,BAO_0000218,
12518,Intermediate,10116.0,,1,948.0,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL624877,BAO_0000218,
12519,Intermediate,10116.0,,1,948.0,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624878,BAO_0000218,
12520,Intermediate,10116.0,,1,948.0,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL624879,BAO_0000218,
12521,Intermediate,10116.0,,1,948.0,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624880,BAO_0000218,
12522,Intermediate,10116.0,,1,948.0,,Concentration was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 10 min (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624881,BAO_0000218,
12523,Intermediate,10116.0,,1,948.0,,"Concentration was measured in heart tissue of unfasted Fischer 344 rats, administered intravenous, after 5 minute (radiolabeled with [125I]-",N,,,50597,1,,CHEMBL624882,BAO_0000218,
12524,Intermediate,10116.0,,1,2113.0,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624883,BAO_0000218,
12525,Intermediate,10116.0,,1,2113.0,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL624884,BAO_0000218,
12526,Intermediate,10116.0,,1,2113.0,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624885,BAO_0000218,
12527,Intermediate,10116.0,,1,2113.0,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL624886,BAO_0000218,
12528,Intermediate,10116.0,,1,2113.0,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624887,BAO_0000218,
12529,Intermediate,10116.0,,1,2113.0,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL624888,BAO_0000218,
12530,Intermediate,10116.0,,1,2113.0,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624889,BAO_0000218,
12531,Intermediate,10116.0,,1,2113.0,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL624890,BAO_0000218,
12532,Intermediate,10116.0,,1,2113.0,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL621964,BAO_0000218,
12533,Intermediate,10116.0,,1,2113.0,,Concentration was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL621965,BAO_0000218,
12534,Intermediate,10116.0,,1,2107.0,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL621966,BAO_0000218,
12535,Intermediate,10116.0,,1,2107.0,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL621967,BAO_0000218,
12536,Intermediate,10116.0,,1,2107.0,,Concentration was measured in liver tissue f unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL622164,BAO_0000218,
12537,Autocuration,,,1,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (nucleic acids),U,,,22224,0,,CHEMBL623097,BAO_0000019,
12538,Autocuration,,,1,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid insoluble (protein),U,,,22224,0,,CHEMBL623098,BAO_0000019,
12539,Autocuration,,,1,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; acid soluble,U,,,22224,0,,CHEMBL623099,BAO_0000019,
12540,Autocuration,,,1,,,Distribution of radioactivity derived form [C14]-labeled compound taken up by 7800C1 cells; total uptake,U,,,22224,0,,CHEMBL623100,BAO_0000019,
12541,Intermediate,10116.0,,1,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated Number of new tumors observed",N,,,50597,1,,CHEMBL628673,BAO_0000218,
12542,Intermediate,10116.0,,1,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated complete percent remission indicates tumor not palpable.",N,,,50597,1,,CHEMBL628674,BAO_0000218,
12543,Intermediate,10116.0,,1,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated number of tumors at the beginning of the test.",N,,,50597,1,,CHEMBL628675,BAO_0000218,
12544,Intermediate,10116.0,,1,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated of percent static tumors indicates size of tumor 51-150% of the initial size",N,,,50597,1,,CHEMBL627644,BAO_0000218,
12545,Intermediate,10116.0,,1,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated partial percent remission indicates reduction of initial tumor size <=50%.",N,,,50597,1,,CHEMBL627645,BAO_0000218,
12546,Intermediate,10116.0,,1,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent progress in tumor size indicates >150% of the initial size",N,,,50597,1,,CHEMBL627646,BAO_0000218,
12547,Intermediate,10116.0,,1,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent static tumors indicates size of tumor 51-150% of the initial size",N,,,50597,1,,CHEMBL627647,BAO_0000218,
12548,Intermediate,10116.0,,1,,,"Effect was evaluated on the (DMBA)-induced carcinoma of the 8 Sprague-Dawley Rat, calculated percent tumor area measured as the average on the 28th day of therapy.",N,,,50597,1,,CHEMBL627648,BAO_0000218,
12549,Intermediate,10116.0,,1,,,Free level in rat plasma,N,,,50597,1,,CHEMBL627649,BAO_0000218,
12550,Autocuration,,,1,,,Level reaching in blood plasma of rat or human was determined,U,,,22224,0,,CHEMBL628313,BAO_0000019,
12551,Intermediate,10116.0,,1,,,Log (Cbrain/Cblood) in rats,N,,,50597,1,,CHEMBL628314,BAO_0000218,
12552,Autocuration,,,1,,,Mean percentage of compound transport through P-glycoprotein; expressed as p-glycoprotein affinity,U,,,22224,0,,CHEMBL628315,BAO_0000019,
12553,Autocuration,,,1,,,Mean percentage of compound transport through membrane; expressed as membrane transport,U,,,22224,0,,CHEMBL628316,BAO_0000019,
12554,Autocuration,,,1,,,Metabolic breakdown to the o-sulfate of p-chloroaniline (2-amino-5-chlorophenyl sulfate) by giving 100 mg/kg oral doses of the compound,U,,,22224,0,,CHEMBL628317,BAO_0000218,
12555,Autocuration,,,1,,,Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5,U,,,22224,0,,CHEMBL628473,BAO_0000019,
12556,Autocuration,,,1,,,"Michaelis-Menten constant was measured in the inactivation of HPK; Km x 10 e5, ND=Not determined",U,,,22224,0,,CHEMBL628474,BAO_0000019,
12557,Autocuration,,,1,,,Michaelis-Menten constant was measured in the inactivation of trypsin; Km x 10 e5,U,,,22224,0,,CHEMBL628475,BAO_0000019,
12558,Autocuration,,,1,,,Net water uptake by a carrier mediated transport (%cm) mechanism,U,,,22224,0,,CHEMBL628476,BAO_0000019,
12559,Autocuration,314293.0,,1,,,Peak concentration was determined in portal circulation after intraduodenal dose of 10 mg/kg in monkey,U,,,22224,0,,CHEMBL628477,BAO_0000218,
12560,Intermediate,9669.0,,1,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret,N,,,50506,1,,CHEMBL628478,BAO_0000218,
12561,Intermediate,9669.0,,1,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in ferret, determined by renin inhibition assay",N,,,50506,1,,CHEMBL628479,BAO_0000218,
12562,Autocuration,314293.0,,1,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey,U,,,22224,0,,CHEMBL628480,BAO_0000218,
12563,Autocuration,314293.0,,1,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in monkey, determined by renin inhibition assay",U,,,22224,0,,CHEMBL628481,BAO_0000218,
12564,Intermediate,10116.0,,1,,,Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat,N,,,50597,1,,CHEMBL628482,BAO_0000218,
12565,Intermediate,10116.0,,1,,,"Peak concentration was determined in systemic circulation after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",N,,,50597,1,,CHEMBL628483,BAO_0000218,
12566,Intermediate,10116.0,,1,1969.0,,"Peak plasma concentration at a dose of 10 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",N,,,50597,1,,CHEMBL628484,BAO_0000218,
12567,Intermediate,10116.0,,1,1969.0,,"Peak plasma concentration at a dose of 100 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",N,,,50597,1,,CHEMBL628485,BAO_0000218,
12568,Intermediate,9541.0,,1,1969.0,,"Peak plasma concentration at a dose of 20 mg/kg, oral route in monkey (Macaca fascicularis) suspended in carboxymethyl cellulose (CMC);Range is between (5.5-6)",N,,,100710,1,,CHEMBL628486,BAO_0000218,
12569,Intermediate,9606.0,,1,1969.0,,"Peak plasma concentration at a dose of 200 mg/kg, oral route in human",N,,,50587,1,,CHEMBL628487,BAO_0000218,
12570,Intermediate,10116.0,,1,1969.0,,"Peak plasma concentration at a dose of 25 mg/kg, ip route in rat suspended in carboxymethyl cellulose (CMC);ND is defined as no-data.",N,,,50597,1,,CHEMBL628488,BAO_0000218,
12571,Intermediate,10116.0,,1,1969.0,,"Peak plasma concentration at a dose of 25 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",N,,,50597,1,,CHEMBL628489,BAO_0000218,
12572,Intermediate,10116.0,,1,1969.0,,"Peak plasma concentration at a dose of 50 mg/kg, os route in rat suspended in carboxymethyl cellulose (CMC)",N,,,50597,1,,CHEMBL628490,BAO_0000218,
12573,Intermediate,9541.0,,1,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from portal circulation in salt-depleted cynomolgus monkeys using HPLC assay,N,,,100710,1,,CHEMBL628491,BAO_0000218,
12574,Intermediate,9541.0,,1,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using HPLC assay,N,,,100710,1,,CHEMBL877507,BAO_0000218,
12575,Autocuration,,,1,,,Peak plasma drug level after intraduodenal administration at a dose 10 mg/kg from systemic circulation in salt-depleted cynomolgus monkeys using renin inhibition assay,U,,,22224,0,,CHEMBL628492,BAO_0000218,
12576,Autocuration,314293.0,,1,,,% metabolized in monkey S-9 after 2 hours (10 ug/mL),U,,,22224,0,,CHEMBL628493,BAO_0000019,
12577,Autocuration,314293.0,,1,,,% metabolized in monkey S-9 after 2 hours (1 ug/ml),U,,,22224,0,,CHEMBL628494,BAO_0000019,
12578,Autocuration,314293.0,,1,,,% metabolized in monkey S-9 after 2 hours (10 ug/ml),U,,,22224,0,,CHEMBL628495,BAO_0000019,
12579,Intermediate,9606.0,,1,,,Permeability in Caco-2 assay at 10E-6,N,,,50587,1,,CHEMBL628496,BAO_0000218,
12580,Autocuration,,,1,955.0,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered intravenously in brain,U,,,22224,0,,CHEMBL628497,BAO_0000218,
12581,Autocuration,,,1,955.0,,Pharmacokinetic parameter after dosing of 100 mg/kg of compound administered orally in brain,U,,,22224,0,,CHEMBL628498,BAO_0000218,
12582,Autocuration,,,1,,,Plasma protein binding was determined,U,,,22224,0,,CHEMBL628499,BAO_0000019,
12583,Autocuration,,,1,,,Brain concentration after 2 hr at a dose of 100 mg/kg when administered perorally,U,,,22224,0,,CHEMBL627656,BAO_0000218,
12584,Autocuration,,,1,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intraperitoneally,U,,,22224,0,,CHEMBL627657,BAO_0000218,
12585,Autocuration,,,1,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered intravenously,U,,,22224,0,,CHEMBL626808,BAO_0000218,
12586,Autocuration,,,1,,,Brain concentration after 2 hr at a dose of 10 mg/kg when administered perorally,U,,,22224,0,,CHEMBL626809,BAO_0000218,
12587,Autocuration,,,1,,,Brain concentration after 4 hr at a dose of 100 mg/kg when administered perorally,U,,,22224,0,,CHEMBL626810,BAO_0000218,
12588,Autocuration,,,1,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intraperitoneally,U,,,22224,0,,CHEMBL626811,BAO_0000218,
12589,Autocuration,,,1,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered intravenously,U,,,22224,0,,CHEMBL874465,BAO_0000218,
12590,Autocuration,,,1,,,Brain concentration after 4 hr at a dose of 10 mg/kg when administered perorally,U,,,22224,0,,CHEMBL626812,BAO_0000218,
12591,Autocuration,,,1,,,Brain concentration after 6 hr at a dose of 100 mg/kg when administered perorally,U,,,22224,0,,CHEMBL626813,BAO_0000218,
12592,Autocuration,,,1,,,Brain concentration after 6 hr at a dose of 10 mg/kg when administered perorally,U,,,22224,0,,CHEMBL626814,BAO_0000218,
12593,Autocuration,,,1,,,Bullaticin index relates the IC50 values by normalizing to the value of bullatacin for easy comparison.,U,,,22224,0,,CHEMBL626815,BAO_0000019,
12594,Autocuration,,,1,,,Partition coefficient (logP),U,,,22224,0,,CHEMBL628566,BAO_0000019,
12595,Autocuration,,,1,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),U,,,22229,0,,CHEMBL628567,BAO_0000100,
12596,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL628568,BAO_0000100,
12597,Intermediate,9615.0,In vivo,1,,,C max in dog,N,,,50588,1,,CHEMBL628569,BAO_0000218,
12598,Intermediate,10141.0,In vivo,1,,,C max in guinea pig,N,,,50512,1,,CHEMBL628570,BAO_0000218,
12599,Autocuration,,In vivo,1,,,C max value was evaluated,U,,,22224,0,,CHEMBL628571,BAO_0000218,
12600,Autocuration,,In vivo,1,,,Cmax value after oral dose of 0.1 mg//kg,U,,,22224,0,,CHEMBL628572,BAO_0000218,
12601,Autocuration,,In vivo,1,,,Cmax value after oral dose of 0.3 mg/kg,U,,,22224,0,,CHEMBL628573,BAO_0000218,
12602,Autocuration,,In vivo,1,,,Cmax value after oral dose of 1 mg/kg,U,,,22224,0,,CHEMBL628574,BAO_0000218,
12603,Autocuration,,In vivo,1,,,Cmax value after oral dose of 10 mg/kg,U,,,22224,0,,CHEMBL628575,BAO_0000218,
12604,Autocuration,,In vivo,1,,,Cmax value after oral dose of 23.4 mg/kg,U,,,22224,0,,CHEMBL628576,BAO_0000218,
12605,Autocuration,,In vivo,1,,,Cmax value after oral dose of 3 mg/kg,U,,,22224,0,,CHEMBL628577,BAO_0000218,
12606,Autocuration,,In vivo,1,,,Cmax value after oral dose of 3.87 mg/kg,U,,,22224,0,,CHEMBL628578,BAO_0000218,
12607,Intermediate,9615.0,In vivo,1,,,Cmax value in female Beagle dogs,N,,,50588,1,,CHEMBL874466,BAO_0000218,
12608,Intermediate,10116.0,In vivo,1,,,Cmax value in male rats,N,,,50597,1,,CHEMBL628579,BAO_0000218,
12609,Intermediate,10116.0,In vivo,1,1969.0,,Cmax value in rat plasma when administered 20 mg/kg perorally,N,,,50597,1,,CHEMBL628580,BAO_0000218,
12610,Intermediate,9615.0,In vivo,1,1969.0,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,N,,,50588,1,,CHEMBL628581,BAO_0000218,
12611,Intermediate,9615.0,In vivo,1,1969.0,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,N,,,50588,1,,CHEMBL628582,BAO_0000218,
12612,Intermediate,9615.0,,1,,,Peak concentration of compound at Time = 0 was determined in dog at 5 mg/kg intravenously admn.,N,,,50588,1,,CHEMBL628583,BAO_0000218,
12613,Autocuration,314293.0,,1,,,Peak concentration of compound at Time = 0 was determined in monkey at 5 mg/kg intravenously admn.,U,,,22224,0,,CHEMBL625782,BAO_0000218,
12614,Intermediate,9986.0,,1,,,Peak concentration of compound at Time = 0 was determined in rabbit at 5 mg/kg intravenously admn.,N,,,50592,1,,CHEMBL625783,BAO_0000218,
12615,Intermediate,10116.0,,1,,,Peak concentration of compound at Time = 0 was determined in rat at 5 mg/kg intravenously admn.,N,,,50597,1,,CHEMBL625784,BAO_0000218,
12616,Intermediate,9544.0,,1,1969.0,,Total plasma concentration at 24 hr at a dose of 10 mg/kg when administered orally to rhesus monkey,N,,,50797,1,,CHEMBL625785,BAO_0000218,
12617,Intermediate,10116.0,,1,,,C5min (nM) value was determined in rats after intravenous dose of 5 mg/kg,N,,,50597,1,,CHEMBL625786,BAO_0000218,
12618,Autocuration,,,1,,,C6h was measured as concentration obtained after 6 hr of oral administration in air pouch exudate,U,,,22224,0,,CHEMBL874467,BAO_0000019,
12619,Intermediate,9615.0,,1,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 )",N,,,50588,1,,CHEMBL625787,BAO_0000218,
12620,Intermediate,12721.0,,1,,,cytotoxicity against HIV protease enzyme.,N,,,50677,1,,CHEMBL625964,BAO_0000218,
12621,Intermediate,10090.0,,1,,,Apparent clearance in mice after intravenous administration of 105.1 mg/kg of dose,N,,,50594,1,,CHEMBL625965,BAO_0000218,
12622,Intermediate,10090.0,,1,,,Apparent clearance in mice after oral administration of 100 mg/kg of dose,N,,,50594,1,,CHEMBL625966,BAO_0000218,
12623,Intermediate,9615.0,In vivo,1,1969.0,,The plasma clearance in dog.,N,,,50588,1,,CHEMBL625967,BAO_0000218,
12624,Intermediate,10116.0,In vivo,1,1969.0,,The plasma clearance in rat.,N,,,50597,1,,CHEMBL625968,BAO_0000218,
12625,Intermediate,10116.0,In vivo,1,1969.0,,Clearance from plasma in male Sprague-Dawley rats,N,,,50597,1,,CHEMBL625969,BAO_0000218,
12626,Intermediate,9541.0,In vivo,1,1969.0,,Clearance from plasma in male cynomolgus monkeys,N,,,100710,1,,CHEMBL625970,BAO_0000218,
12627,Intermediate,9615.0,In vivo,1,1969.0,,"Clearance of compound (5 mg/kg, intravenously), in dog plasma",N,,,50588,1,,CHEMBL625971,BAO_0000218,
12628,Intermediate,9615.0,In vivo,1,1969.0,,Clearance of compound in dog plasma,N,,,50588,1,,CHEMBL625972,BAO_0000218,
12629,Intermediate,9606.0,In vivo,1,1969.0,,Clearance of compound in human plasma,N,,,50587,1,,CHEMBL625973,BAO_0000218,
12630,Intermediate,9615.0,In vivo,1,,,Clearance of compound when administered intravenously as a mixture (five-in-one dose) to a single dog.,N,,,50588,1,,CHEMBL625974,BAO_0000218,
12631,Intermediate,9615.0,In vivo,1,,,Clearance of compound when administered intravenously as an individual dose to a single dog.,N,,,50588,1,,CHEMBL625975,BAO_0000218,
12632,Intermediate,9615.0,In vivo,1,1969.0,,"Clearance (10 mg/kg, intravenously) in dog plasma",N,,,50588,1,,CHEMBL625976,BAO_0000218,
12633,Intermediate,9615.0,In vivo,1,,,Clearance value in dog,N,,,50588,1,,CHEMBL625977,BAO_0000218,
12634,Intermediate,10141.0,In vivo,1,,,Clearance value in guinea pig,N,,,50512,1,,CHEMBL625978,BAO_0000218,
12635,Intermediate,10116.0,In vivo,1,,,Clearance values in rats after iv administration.,N,,,50597,1,,CHEMBL874468,BAO_0000218,
12636,Autocuration,,In vivo,1,1969.0,,Compound was tested for plasma clearance on administered orally as aqueous solutions at 1 mpk and by iv at 0.2 mpk,U,,,22224,0,,CHEMBL625421,BAO_0000218,
12637,Intermediate,9986.0,In vivo,1,,,In vivo clearance (5 mg/kg) was determined in rabbits,N,,,50592,1,,CHEMBL625422,BAO_0000218,
12638,Intermediate,10116.0,In vivo,1,,,Plasma Clearance rate was determined for the compound in rats,N,,,50597,1,,CHEMBL625423,BAO_0000218,
12639,Autocuration,9520.0,In vivo,1,,,Plasma Clearance rate was determined for the compound in squirrel monkeys,U,,,22224,0,,CHEMBL625424,BAO_0000218,
12640,Intermediate,10116.0,In vivo,1,,,Plasma clearance in rat,N,,,50597,1,,CHEMBL625425,BAO_0000218,
12641,Autocuration,,In vivo,1,,,Plasma clearance of the compound,U,,,22224,0,,CHEMBL625426,BAO_0000218,
12642,Intermediate,10141.0,In vivo,1,,,Plasma clearance in guinea pigs at 2 mg/kg after iv administration,N,,,50512,1,,CHEMBL625427,BAO_0000218,
12643,Intermediate,10141.0,In vivo,1,,,Plasma clearance in guinea pigs at 3 mg/kg after iv administration,N,,,50512,1,,CHEMBL625428,BAO_0000218,
12644,Autocuration,,In vivo,1,,,Plasma clearance was determined,U,,,22224,0,,CHEMBL625429,BAO_0000218,
12645,Intermediate,9615.0,In vivo,1,,,Plasma clearance rate (CL) was determined in dogs after intravenous administration of 25 mg/kg of the compound.,N,,,50588,1,,CHEMBL625430,BAO_0000218,
12646,Intermediate,10116.0,In vivo,1,,,Plasma clearance rate was determined for the compound in rats,N,,,50597,1,,CHEMBL625431,BAO_0000218,
12647,Autocuration,9520.0,In vivo,1,,,Plasma clearance rate was determined for the compound in squirrel monkeys,U,,,22224,0,,CHEMBL627307,BAO_0000218,
12648,Autocuration,,In vivo,1,,,Slow clearance (CL) was determined,U,,,22224,0,,CHEMBL627308,BAO_0000218,
12649,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 0.5 hr,U,,,22224,0,,CHEMBL627309,BAO_0000218,
12650,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr; insufficient gastric juice produced,U,,,22224,0,,CHEMBL627310,BAO_0000218,
12651,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,U,,,22224,0,,CHEMBL627311,BAO_0000218,
12652,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.0 hr,U,,,22224,0,,CHEMBL627312,BAO_0000218,
12653,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,U,,,22224,0,,CHEMBL627313,BAO_0000218,
12654,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,U,,,22224,0,,CHEMBL627314,BAO_0000218,
12655,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,U,,,22224,0,,CHEMBL627315,BAO_0000218,
12656,Autocuration,,,1,,,Concentration of thiocyanates in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,U,,,22224,0,,CHEMBL627316,BAO_0000218,
12657,Autocuration,,,1,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 0.5 hr,U,,,22224,0,,CHEMBL627317,BAO_0000218,
12658,Autocuration,,,1,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.0 hr,U,,,22224,0,,CHEMBL627318,BAO_0000218,
12659,Autocuration,,,1,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 1.5 hr,U,,,22224,0,,CHEMBL627999,BAO_0000218,
12660,Autocuration,,,1,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.0 hr,U,,,22224,0,,CHEMBL628000,BAO_0000218,
12661,Autocuration,,,1,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 2.5 hr,U,,,22224,0,,CHEMBL628001,BAO_0000218,
12662,Autocuration,,,1,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.0 hr,U,,,22224,0,,CHEMBL628002,BAO_0000218,
12663,Autocuration,,,1,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 3.5 hr,U,,,22224,0,,CHEMBL625610,BAO_0000218,
12664,Autocuration,,,1,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 0.2 mg/kg intravenous dosage after 4.0 hr,U,,,22224,0,,CHEMBL625611,BAO_0000218,
12665,Autocuration,,,1,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.0 hr,U,,,22224,0,,CHEMBL625612,BAO_0000218,
12666,Autocuration,,,1,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 1.5 hr,U,,,22224,0,,CHEMBL625613,BAO_0000218,
12667,Autocuration,,,1,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.0 hr,U,,,22224,0,,CHEMBL875479,BAO_0000218,
12668,Autocuration,,,1,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 3.5 hr,U,,,22224,0,,CHEMBL625614,BAO_0000218,
12669,Autocuration,,,1,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 4.0 hr,U,,,22224,0,,CHEMBL625615,BAO_0000218,
12670,Autocuration,,,1,,,Concentration of unlabelled compound in gastric juices for the C14 radiolabeled compound was determined at 4 mg/kg intravenous dosage after 2.5 hr,U,,,22224,0,,CHEMBL626302,BAO_0000218,
12671,Intermediate,10116.0,,1,178.0,,Cumulative concentration 6b and compound 1 detected in blood of rat 1 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL626303,BAO_0000218,
12672,Intermediate,10116.0,,1,178.0,,Cumulative concentration 6b and compound 1 detected in blood of rat 3 hr after an oral dose of 200 mg/kg of the compound,N,,,50597,1,,CHEMBL627420,BAO_0000218,
12673,Intermediate,10116.0,,1,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 1 hour relative to initial concentration of 1 uM,N,,,50597,1,,CHEMBL627421,BAO_0000218,
12674,Intermediate,10116.0,,1,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 24 hour relative to initial concentration of 1 uM,N,,,50597,1,,CHEMBL625695,BAO_0000218,
12675,Intermediate,10116.0,,1,,,Degradation of compound in incubations at 25 uM with normal rat liver microsomes after 4 hour relative to initial concentration of 1 uM,N,,,50597,1,,CHEMBL625696,BAO_0000218,
12676,Intermediate,10090.0,,1,955.0,,Distribution of compound in mice brain was measured after 1 hr,N,,,50594,1,,CHEMBL875606,BAO_0000218,
12677,Intermediate,10090.0,,1,955.0,,Distribution of compound in mice brain was measured after 24 hr r,N,,,50594,1,,CHEMBL625697,BAO_0000218,
12678,Intermediate,10090.0,,1,955.0,,Distribution of compound in mice brain was measured after 2 hr,N,,,50594,1,,CHEMBL625698,BAO_0000218,
12679,Intermediate,10090.0,,1,955.0,,Distribution of compound in mice brain was measured after 3 hr,N,,,50594,1,,CHEMBL625699,BAO_0000218,
12680,Intermediate,10090.0,,1,955.0,,Distribution of compound in mice brain was measured after 6 hr,N,,,50594,1,,CHEMBL625700,BAO_0000218,
12681,Intermediate,10090.0,,1,,,Distribution of compound in mice liver was measured after 1 hr,N,,,50594,1,,CHEMBL625701,BAO_0000218,
12682,Intermediate,10090.0,,1,,,Distribution of compound in mice liver was measured after 24 hr; b=Undetected,N,,,50594,1,,CHEMBL625702,BAO_0000218,
12683,Intermediate,10090.0,,1,,,Distribution of compound in mice liver was measured after 2 hr,N,,,50594,1,,CHEMBL625703,BAO_0000218,
12684,Intermediate,10090.0,,1,,,Distribution of compound in mice liver was measured after 3 hr,N,,,50594,1,,CHEMBL625704,BAO_0000218,
12685,Intermediate,10090.0,,1,,,Distribution of compound in mice liver was measured after 6 hr,N,,,50594,1,,CHEMBL625705,BAO_0000218,
12686,Intermediate,9615.0,,1,1236.0,,Distribution in dog adrenal medulla 30 min after administration.,N,,,50588,1,,CHEMBL625706,BAO_0000218,
12687,Intermediate,9615.0,,1,1236.0,,Distribution in dog adrenal medulla 72 hours after administration.,N,,,50588,1,,CHEMBL625707,BAO_0000218,
12688,Intermediate,9615.0,,1,,,Distribution in female dog Ovary 24 hours after administration.,N,,,50588,1,,CHEMBL625708,BAO_0000218,
12689,Intermediate,9615.0,,1,,,Distribution in female dog Ovary 72 hours after administration.,N,,,50588,1,,CHEMBL625709,BAO_0000218,
12690,Intermediate,9615.0,,1,,,Distribution in female dog adipose 24 hours after administration.,N,,,50588,1,,CHEMBL624180,BAO_0000218,
12691,Intermediate,9615.0,,1,,,Distribution in female dog adipose 72 hours after administration.,N,,,50588,1,,CHEMBL624181,BAO_0000218,
12692,Intermediate,9615.0,,1,1235.0,,Distribution in female dog adrenal cortex 72 hours after administration.,N,,,50588,1,,CHEMBL624182,BAO_0000218,
12693,Intermediate,9615.0,,1,1235.0,,Distribution in female dog adrenal cortex 72 hours after administration.,N,,,50588,1,,CHEMBL624183,BAO_0000218,
12694,Intermediate,10116.0,,1,2107.0,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL624184,BAO_0000218,
12695,Intermediate,10116.0,,1,2107.0,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL877489,BAO_0000218,
12696,Intermediate,10116.0,,1,2107.0,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624185,BAO_0000218,
12697,Intermediate,10116.0,,1,2107.0,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624186,BAO_0000218,
12698,Intermediate,10116.0,,1,2107.0,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL624187,BAO_0000218,
12699,Intermediate,10116.0,,1,2107.0,,Concentration was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624188,BAO_0000218,
12700,Intermediate,10116.0,,1,2048.0,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624189,BAO_0000218,
12701,Intermediate,10116.0,,1,2048.0,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624190,BAO_0000218,
12702,Intermediate,10116.0,,1,2048.0,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL624191,BAO_0000218,
12703,Intermediate,10116.0,,1,2048.0,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624192,BAO_0000218,
12704,Intermediate,10116.0,,1,2048.0,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL624193,BAO_0000218,
12705,Intermediate,10116.0,,1,2048.0,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624194,BAO_0000218,
12706,Intermediate,10116.0,,1,2048.0,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL624891,BAO_0000218,
12707,Intermediate,10116.0,,1,2048.0,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL624892,BAO_0000218,
12708,Intermediate,10116.0,,1,2048.0,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL624893,BAO_0000218,
12709,Intermediate,10116.0,,1,2048.0,,Concentration was measured in lungs tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL627632,BAO_0000218,
12710,Intermediate,10116.0,,1,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL627633,BAO_0000218,
12711,Intermediate,10116.0,,1,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL627634,BAO_0000218,
12712,Intermediate,10116.0,,1,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL627635,BAO_0000218,
12713,Intermediate,10116.0,,1,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL627636,BAO_0000218,
12714,Intermediate,10116.0,,1,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL626816,BAO_0000218,
12715,Intermediate,10116.0,,1,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626817,BAO_0000218,
12716,Intermediate,10116.0,,1,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL626818,BAO_0000218,
12717,Intermediate,10116.0,,1,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626819,BAO_0000218,
12718,Intermediate,10116.0,,1,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL626820,BAO_0000218,
12719,Intermediate,10116.0,,1,,,Concentration was measured in mean heart/blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626821,BAO_0000218,
12720,Intermediate,10116.0,,1,2046.0,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 10 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626822,BAO_0000218,
12721,Intermediate,10116.0,,1,2046.0,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626823,BAO_0000218,
12722,Intermediate,10116.0,,1,2046.0,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL626824,BAO_0000218,
12723,Intermediate,10116.0,,1,2046.0,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626825,BAO_0000218,
12724,Intermediate,10116.0,,1,2046.0,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL626826,BAO_0000218,
12725,Intermediate,10116.0,,1,2046.0,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 4 hr (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626827,BAO_0000218,
12726,Intermediate,10116.0,,1,2046.0,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL626828,BAO_0000218,
12727,Intermediate,10116.0,,1,2046.0,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626829,BAO_0000218,
12728,Intermediate,10116.0,,1,2046.0,,Concentration was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626830,BAO_0000218,
12729,Intermediate,10116.0,,1,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL627150,BAO_0000218,
12730,Intermediate,10116.0,,1,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL627151,BAO_0000218,
12731,Intermediate,10116.0,,1,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [123I]-,N,,,50597,1,,CHEMBL627152,BAO_0000218,
12732,Intermediate,10116.0,,1,,,Concentration was measured in tissue of unfasted Fischer 344 rats administered intravenously after 60 minute (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL627153,BAO_0000218,
12733,Autocuration,,,1,,,Rate of acetate production by the compound was determined,U,,,22224,0,,CHEMBL627154,BAO_0000019,
12734,Autocuration,,,1,,,Rate of acetate production by the compound was determined; Not determined,U,,,22224,0,,CHEMBL627155,BAO_0000019,
12735,Autocuration,,,1,,,Rate of hydrolysis of nitrocefin by compound was evaluated in water,U,,,22224,0,,CHEMBL627156,BAO_0000019,
12736,Autocuration,,,1,,,Reductive elimination of leaving group was determined at pH 7.4; expressed as loss of parent,U,,,22224,0,,CHEMBL627157,BAO_0000019,
12737,Intermediate,9986.0,,1,,,Relative concentration of compound (70 mg/Kg) in brain compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,N,,,50592,1,,CHEMBL627158,BAO_0000218,
12738,Intermediate,9986.0,,1,1969.0,,Relative concentration of compound (70 mg/Kg) in lung compared to concentration in plasma (160 ug/mL) at the time of tissue collection from rabbit; relative concentration,N,,,50592,1,,CHEMBL627159,BAO_0000218,
12739,Intermediate,10090.0,,1,,,Relative concentration of compound in brain compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,N,,,50594,1,,CHEMBL627160,BAO_0000218,
12740,Intermediate,10116.0,,1,,,Relative concentration of compound in brain compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,N,,,50597,1,,CHEMBL628540,BAO_0000218,
12741,Intermediate,10116.0,,1,1969.0,,Relative concentration of compound in lung compared to concentration in plasma (0.4 ug/mL) at the time of tissue collection from mice; relative concentration,N,,,50597,1,,CHEMBL628541,BAO_0000218,
12742,Intermediate,10116.0,,1,1969.0,,Relative concentration of compound in lung compared to concentration in plasma (3.5 ug/mL) at the time of tissue collection from mice; relative concentration,N,,,50597,1,,CHEMBL628542,BAO_0000218,
12743,Autocuration,,,1,,,Solubility after at a pH 1.2,U,,,22229,0,,CHEMBL628543,BAO_0000100,
12744,Autocuration,,,1,,,Solubility after at pH 1.2,U,,,22229,0,,CHEMBL628544,BAO_0000100,
12745,Autocuration,,,1,,,Solubility after injection of water,U,,,22229,0,,CHEMBL628545,BAO_0000100,
12746,Autocuration,,,1,,,Statistical significance of IC 50 values; Expressed as R value,U,,,22224,0,,CHEMBL628546,BAO_0000019,
12747,Autocuration,,,1,,,Systemic availability with respect to methyldopa was determined,U,,,22224,0,,CHEMBL874455,BAO_0000019,
12748,Intermediate,10116.0,,1,,,Tissue distribution of the in rat brain relative to plasma concentration of 1 ug/kg; relative concentration,N,,,50597,1,,CHEMBL628547,BAO_0000218,
12749,Intermediate,10116.0,,1,1969.0,,Tissue distribution of the in rat lung relative to plasma concentration of 1 ug/kg; relative concentration,N,,,50597,1,,CHEMBL628548,BAO_0000218,
12750,Intermediate,9986.0,,1,1988.0,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated",N,,,50592,1,,CHEMBL628549,BAO_0000218,
12751,Intermediate,9986.0,,1,1988.0,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit 1 liver, and radioactivity content in feces was estimated",N,,,50592,1,,CHEMBL628550,BAO_0000218,
12752,Intermediate,9986.0,,1,1988.0,,"100 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit3, and radioactivity content in feces was estimated at total hours",N,,,50592,1,,CHEMBL628551,BAO_0000218,
12753,Intermediate,9986.0,,1,1088.0,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit1, and radioactivity content in urine was estimated at 0-2 hr",N,,,50592,1,,CHEMBL628552,BAO_0000218,
12754,Intermediate,9986.0,,1,1088.0,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-24 hr",N,,,50592,1,,CHEMBL628553,BAO_0000218,
12755,Intermediate,9986.0,,1,1088.0,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 0-48 hr",N,,,50592,1,,CHEMBL628554,BAO_0000218,
12756,Intermediate,9986.0,,1,1088.0,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 24-48 h",N,,,50592,1,,CHEMBL628555,BAO_0000218,
12757,Intermediate,9986.0,,1,1088.0,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at 48-72 h",N,,,50592,1,,CHEMBL628556,BAO_0000218,
12758,Intermediate,9986.0,,1,2113.0,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit kidney, and radioactivity content in feces was estimated",N,,,50592,1,,CHEMBL628557,BAO_0000218,
12759,Intermediate,9986.0,,1,1988.0,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated",N,,,50592,1,,CHEMBL628558,BAO_0000218,
12760,Intermediate,9986.0,,1,1988.0,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 1 lung, and radioactivity content in feces was estimated at",N,,,50592,1,,CHEMBL628559,BAO_0000218,
12761,Intermediate,9986.0,,1,1988.0,,"100 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit1plasma, and radioactivity content in feces was estimated",N,,,50592,1,,CHEMBL628560,BAO_0000218,
12762,Intermediate,9986.0,,1,1088.0,,"100 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit3, and radioactivity content in urine was estimated at total hours",N,,,50592,1,,CHEMBL874456,BAO_0000218,
12763,Intermediate,9986.0,,1,1988.0,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at 0-48 hr",N,,,50592,1,,CHEMBL628561,BAO_0000218,
12764,Intermediate,9986.0,,1,1988.0,,"200 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit4, and radioactivity content in feces was estimated at total hours",N,,,50592,1,,CHEMBL628562,BAO_0000218,
12765,Intermediate,9986.0,,1,1088.0,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit2, and radioactivity content in urine was estimated at 0-4 hr",N,,,50592,1,,CHEMBL628563,BAO_0000218,
12766,Intermediate,9986.0,,1,1088.0,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at",N,,,50592,1,,CHEMBL628564,BAO_0000218,
12767,Intermediate,9986.0,,1,1088.0,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 24-48 h",N,,,50592,1,,CHEMBL628565,BAO_0000218,
12768,Intermediate,9986.0,,1,1088.0,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at 48-72 h",N,,,50592,1,,CHEMBL631248,BAO_0000218,
12769,Intermediate,9986.0,,1,1088.0,,"200 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit4, and radioactivity content in urine was estimated at total hours",N,,,50592,1,,CHEMBL631249,BAO_0000218,
12770,Intermediate,9986.0,,1,2113.0,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 kidney, and radioactivity content in feces was estimated",N,,,50592,1,,CHEMBL627214,BAO_0000218,
12771,Intermediate,9986.0,,1,1988.0,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 liver, and radioactivity content in feces was estimated",N,,,50592,1,,CHEMBL874591,BAO_0000218,
12772,Intermediate,9986.0,,1,1988.0,,"200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 lung, and radioactivity content in feces was estimated",N,,,50592,1,,CHEMBL627215,BAO_0000218,
12773,Intermediate,9986.0,,1,1988.0,,200 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit 2 plasma and radioactivity content in feces was estimated,N,,,50592,1,,CHEMBL625471,BAO_0000218,
12774,Intermediate,9986.0,,1,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 1,N,,,50592,1,,CHEMBL625472,BAO_0000218,
12775,Intermediate,9986.0,,1,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 3 by Gas-liquid chromatographic analysis,N,,,50592,1,,CHEMBL625473,BAO_0000218,
12776,Intermediate,9615.0,In vivo,1,,,Tested for pharmacokinetic parameter in fasted Beagle dogs (Clearance value of the compound) iv administration.,N,,,50588,1,,CHEMBL625474,BAO_0000218,
12777,Intermediate,9615.0,In vivo,1,,,The clearance was measured in dog at dose 5 mg/kg after intravenous administration.,N,,,50588,1,,CHEMBL625475,BAO_0000218,
12778,Intermediate,10116.0,In vivo,1,,,The clearance was measured in rat at dose 12 mg/kg after intravenous administration.,N,,,50597,1,,CHEMBL625476,BAO_0000218,
12779,Intermediate,10116.0,In vivo,1,,,The clearance was measured in rat at dose 1 mg/kg after intravenous administration.,N,,,50597,1,,CHEMBL625477,BAO_0000218,
12780,Intermediate,10116.0,In vivo,1,,,The clearance was measured in rat at dose 30 mg/kg after intravenous administration.,N,,,50597,1,,CHEMBL625478,BAO_0000218,
12781,Intermediate,10116.0,In vitro,1,,,The compound was evaluated for clearance value in rat isolated esophageal tunica muscularis mucose,N,,,50597,1,,CHEMBL625479,BAO_0000218,
12782,Intermediate,10116.0,In vitro,1,,,The compound was evaluated for the value in rat isolated esophageal tunica muscularis mucose,N,,,50597,1,,CHEMBL625480,BAO_0000218,
12783,Intermediate,10116.0,In vivo,1,1969.0,,The compound was tested for systemic plasma clearance(CL) in rats and is expressed in mL/min/kg.,N,,,50597,1,,CHEMBL625481,BAO_0000218,
12784,Intermediate,10116.0,In vivo,1,,,Total body clearance at an intravenous dose of 5.2 mg/kg in rat,N,,,50597,1,,CHEMBL625482,BAO_0000218,
12785,Intermediate,10116.0,In vivo,1,,,Total body clearance at an intravenous dose of 5.5 mg/kg in rat,N,,,50597,1,,CHEMBL625483,BAO_0000218,
12786,Intermediate,10116.0,In vivo,1,,,Total body clearance at an intravenous dose of 6.3 mg/kg in rat,N,,,50597,1,,CHEMBL625484,BAO_0000218,
12787,Intermediate,10116.0,In vivo,1,,,Total body clearance at an intravenous dose of 6.5 mg/kg in rat,N,,,50597,1,,CHEMBL625485,BAO_0000218,
12788,Intermediate,9615.0,In vivo,1,1969.0,,Total plasma clearance value was obtained after intravenous administration of 1.8 mg/kg of drug in male Beagle dogs,N,,,50588,1,,CHEMBL625486,BAO_0000218,
12789,Intermediate,10116.0,In vivo,1,1969.0,,Total plasma clearance value was obtained after intravenous administration of 2.5 mg/kg of drug in male Dawley rats,N,,,50597,1,,CHEMBL625487,BAO_0000218,
12790,Intermediate,10116.0,In vivo,1,1969.0,,Total plasma clearance value was obtained after intravenous administration of 2.6 mg/kg of drug in male Dawley rats,N,,,50597,1,,CHEMBL625488,BAO_0000218,
12791,Intermediate,10116.0,In vivo,1,1969.0,,Total plasma clearance value was obtained after intravenous administration of 2.7 mg/kg of drug in male Dawley rats,N,,,50597,1,,CHEMBL625489,BAO_0000218,
12792,Intermediate,10116.0,In vivo,1,1969.0,,Total plasma clearance value was obtained after intravenous administration of 2.8 mg/kg of drug in male Dawley rats,N,,,50597,1,,CHEMBL625490,BAO_0000218,
12793,Intermediate,9615.0,In vivo,1,1969.0,,Total plasma clearance value was obtained after intravenous administration of 4.9 mg/kg of drug in male Beagle dogs,N,,,50588,1,,CHEMBL625491,BAO_0000218,
12794,Intermediate,10116.0,In vivo,1,1969.0,,Total plasma clearance value was obtained after intravenous administration of 5.1 mg/kg of drug in male Dawley rats,N,,,50597,1,,CHEMBL625492,BAO_0000218,
12795,Intermediate,9606.0,In vivo,1,1969.0,,plasma clearance in human,N,,,50587,1,,CHEMBL625493,BAO_0000218,
12796,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given intravenously at dose 15 mg/kg,N,,,50597,1,,CHEMBL625494,BAO_0000218,
12797,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter (CL/F ) was evaluated in Spargue-Dawley rat when given peroral at dose 30 mg/kg,N,,,50597,1,,CHEMBL625495,BAO_0000218,
12798,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter (CL/F) was evaluated in Spargue-Dawley rat when given peroral at dose 80 mg/kg,N,,,50597,1,,CHEMBL625496,BAO_0000218,
12799,Autocuration,,,1,,,1-Octanol/water partition coefficient measured at 7.4,U,,,22229,0,,CHEMBL625497,BAO_0000100,
12800,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625498,BAO_0000100,
12801,Autocuration,,,1,,,Partition coefficient (logP),U,,,22224,0,,CHEMBL625499,BAO_0000019,
12802,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625500,BAO_0000100,
12803,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625501,BAO_0000100,
12804,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625502,BAO_0000100,
12805,Autocuration,,,1,,,Calculated partition coefficient (clogP) (relative to BAY K 8644),U,,,22229,0,,CHEMBL625503,BAO_0000100,
12806,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625504,BAO_0000100,
12807,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625505,BAO_0000100,
12808,Autocuration,,,1,,,Calculated partition coefficient of the compound,U,,,22229,0,,CHEMBL625506,BAO_0000100,
12809,Autocuration,,,1,,,Partition coefficient (logP),U,,,22224,0,,CHEMBL625507,BAO_0000019,
12810,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625508,BAO_0000100,
12811,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625509,BAO_0000100,
12812,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625510,BAO_0000100,
12813,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL883125,BAO_0000100,
12814,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625511,BAO_0000100,
12815,Autocuration,,,1,,,Partition coefficient of the compound,U,,,22224,0,,CHEMBL874650,BAO_0000019,
12816,Autocuration,,,1,,,Partition coefficient of the compound,U,,,22224,0,,CHEMBL625512,BAO_0000019,
12817,Autocuration,,,1,,,Partition coefficient of compound was determined,U,,,22224,0,,CHEMBL625513,BAO_0000019,
12818,Autocuration,,,1,,,Partition coefficient was determined,U,,,22224,0,,CHEMBL625514,BAO_0000019,
12819,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625515,BAO_0000100,
12820,Autocuration,,,1,,,partition coefficient of compound was determined,U,,,22229,0,,CHEMBL625516,BAO_0000100,
12821,Intermediate,9615.0,In vivo,1,,,The total body administered intravenously in dog,N,,,50588,1,,CHEMBL625517,BAO_0000218,
12822,Intermediate,10116.0,In vivo,1,,,The total body administered intravenously in rats,N,,,50597,1,,CHEMBL625518,BAO_0000218,
12823,Intermediate,10090.0,,1,,,Time taken for the administration to female NIH mice weighing 25-30 g.,N,,,50594,1,,CHEMBL625519,BAO_0000218,
12824,Autocuration,,,1,,,Time taken for the administration,U,,,22224,0,,CHEMBL625520,BAO_0000019,
12825,Intermediate,9615.0,In vivo,1,,,Total clearance of compound was determined in dog at 5 mg/kg intravenously admn.,N,,,50588,1,,CHEMBL874651,BAO_0000218,
12826,Autocuration,314293.0,In vivo,1,,,Total clearance of compound was determined in monkey at 5 mg/kg intravenously admn.,U,,,22224,0,,CHEMBL625521,BAO_0000218,
12827,Intermediate,9986.0,In vivo,1,,,Total clearance of compound was determined in rabbit at 5 mg/kg intravenously admn.,N,,,50592,1,,CHEMBL623171,BAO_0000218,
12828,Intermediate,10116.0,In vivo,1,,,Total clearance of compound was determined in rat at 5 mg/kg intravenously admn.,N,,,50597,1,,CHEMBL623853,BAO_0000218,
12829,Autocuration,,,1,,,Plasma clearance for the compound was determined.,U,,,22224,0,,CHEMBL623854,BAO_0000019,
12830,Autocuration,,,1,,,CLog P value of the compound,U,,,22224,0,,CHEMBL874405,BAO_0000100,
12831,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL623855,BAO_0000100,
12832,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL623856,BAO_0000100,
12833,Autocuration,,,1,,,ClogP value of the compound; nd ='no data',U,,,22224,0,,CHEMBL623857,BAO_0000100,
12834,Autocuration,,,1,,,ClogP value of the compound; nd ='not determined',U,,,22224,0,,CHEMBL623858,BAO_0000100,
12835,Autocuration,,,1,,,CLog P was determined,U,,,22224,0,,CHEMBL623859,BAO_0000100,
12836,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL839829,BAO_0000100,
12837,Autocuration,,,1,,,CLogP was calculated,U,,,22224,0,,CHEMBL623860,BAO_0000019,
12838,Autocuration,,,1,,,CLogP value was determined,U,,,22224,0,,CHEMBL623861,BAO_0000019,
12839,Autocuration,,,1,,,CLogP value was evaluated using http://esc.syrres.com/interkow/kowdemo.htm.,U,,,22224,0,,CHEMBL623862,BAO_0000019,
12840,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL874406,BAO_0000100,
12841,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL623863,BAO_0000100,
12842,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL624021,BAO_0000100,
12843,Intermediate,9615.0,,1,1236.0,,Distribution in female dog adrenal medulla 24 hours after administration.,N,,,50588,1,,CHEMBL624022,BAO_0000218,
12844,Intermediate,9615.0,,1,1236.0,,Distribution in female dog adrenal medulla 72 hours after administration.,N,,,50588,1,,CHEMBL624023,BAO_0000218,
12845,Intermediate,9615.0,,1,,,Distribution in female dog bile 24 hours after administration.,N,,,50588,1,,CHEMBL624024,BAO_0000218,
12846,Intermediate,9615.0,,1,,,Distribution in female dog bile 72 hr after administration.,N,,,50588,1,,CHEMBL624025,BAO_0000218,
12847,Intermediate,9615.0,,1,,,Distribution in female dog blood 24 hours after administration.,N,,,50588,1,,CHEMBL624026,BAO_0000218,
12848,Intermediate,9615.0,,1,,,Distribution in female dog blood 72 hours after administration.,N,,,50588,1,,CHEMBL624027,BAO_0000218,
12849,Intermediate,9615.0,,1,,,Distribution in female dog heart 24 hours after administration.,N,,,50588,1,,CHEMBL624028,BAO_0000218,
12850,Intermediate,9615.0,,1,,,Distribution in female dog heart 72 hours after administration.,N,,,50588,1,,CHEMBL624029,BAO_0000218,
12851,Intermediate,9615.0,,1,,,Distribution in female dog kidney 24 hours after administration.,N,,,50588,1,,CHEMBL624030,BAO_0000218,
12852,Intermediate,9615.0,,1,,,Distribution in female dog kidney 72 hours after administration.,N,,,50588,1,,CHEMBL624031,BAO_0000218,
12853,Intermediate,9615.0,,1,160.0,,Distribution in female dog large intestine 24 hours after administration.,N,,,50588,1,,CHEMBL624032,BAO_0000218,
12854,Intermediate,9615.0,,1,160.0,,Distribution in female dog large intestine 72 hours after administration.,N,,,50588,1,,CHEMBL874407,BAO_0000218,
12855,Intermediate,9615.0,,1,,,Distribution in female dog liver 24 hours after administration.,N,,,50588,1,,CHEMBL624033,BAO_0000218,
12856,Intermediate,9615.0,,1,,,Distribution in female dog liver 72 hours after administration.,N,,,50588,1,,CHEMBL624034,BAO_0000218,
12857,Intermediate,9615.0,,1,,,Distribution in female dog lung 24 hours after administration.,N,,,50588,1,,CHEMBL624035,BAO_0000218,
12858,Intermediate,9615.0,,1,,,Distribution in female dog lung 72 hours after administration.,N,,,50588,1,,CHEMBL624036,BAO_0000218,
12859,Intermediate,9615.0,,1,2385.0,,Distribution in female dog muscle 24 hours after administration.,N,,,50588,1,,CHEMBL624037,BAO_0000218,
12860,Intermediate,9615.0,,1,2385.0,,Distribution in female dog muscle 72 hours after administration.,N,,,50588,1,,CHEMBL624038,BAO_0000218,
12861,Intermediate,9615.0,,1,,,Distribution in female dog pancreas 24 hours after administration.,N,,,50588,1,,CHEMBL624039,BAO_0000218,
12862,Intermediate,9615.0,,1,,,Distribution in female dog pancreas 72 hours after administration.,N,,,50588,1,,CHEMBL624040,BAO_0000218,
12863,Intermediate,9615.0,,1,160.0,,Distribution in female dog small intestine 24 hours after administration.,N,,,50588,1,,CHEMBL624041,BAO_0000218,
12864,Intermediate,9615.0,,1,160.0,,Distribution in female dog small intestine 72 hours after administration.,N,,,50588,1,,CHEMBL624042,BAO_0000218,
12865,Intermediate,9615.0,,1,2106.0,,Distribution in female dog spleen 24 hours after administration.,N,,,50588,1,,CHEMBL624043,BAO_0000218,
12866,Intermediate,9615.0,,1,2106.0,,Distribution in female dog spleen 72 hours after administration.,N,,,50588,1,,CHEMBL624044,BAO_0000218,
12867,Intermediate,9615.0,,1,945.0,,Distribution in female dog stomach 24 hours after administration.,N,,,50588,1,,CHEMBL624045,BAO_0000218,
12868,Intermediate,9615.0,,1,945.0,,Distribution in female dog stomach 72 hours after administration.,N,,,50588,1,,CHEMBL624046,BAO_0000218,
12869,Intermediate,9615.0,,1,2046.0,,Distribution in female dog thyroid 24 hours after administration.,N,,,50588,1,,CHEMBL624047,BAO_0000218,
12870,Intermediate,9615.0,,1,2046.0,,Distribution in female dog thyroid 72 hours after administration.,N,,,50588,1,,CHEMBL624048,BAO_0000218,
12871,Intermediate,9615.0,,1,1088.0,,Distribution in female dog urine 24 hours after administration.,N,,,50588,1,,CHEMBL874408,BAO_0000218,
12872,Intermediate,9615.0,,1,1088.0,,Distribution in female dog urine 72 hr after administration.,N,,,50588,1,,CHEMBL624049,BAO_0000218,
12873,Autocuration,,,1,1969.0,,Mean plasma concentration measured 1 h following an oral dose of 30 mg/kg,U,,,22224,0,,CHEMBL624050,BAO_0000218,
12874,Autocuration,,,1,,,Plasma concentration at 7 hr after intravenous dosing,U,,,22224,0,,CHEMBL624051,BAO_0000019,
12875,Intermediate,10116.0,,1,,,Plasma concentration of 3 mg/kg iv after 0.25 hr in rats,N,,,50597,1,,CHEMBL623278,BAO_0000218,
12876,Intermediate,10116.0,,1,,,Plasma concentration of 3 mg/kg iv after 0.5 hr in rats,N,,,50597,1,,CHEMBL623279,BAO_0000218,
12877,Intermediate,10116.0,,1,,,Plasma concentration of 3 mg/kg iv after 1 hr in rats,N,,,50597,1,,CHEMBL623280,BAO_0000218,
12878,Intermediate,10116.0,,1,,,Plasma concentration of 3 mg/kg iv after 2 hr in rats,N,,,50597,1,,CHEMBL623963,BAO_0000218,
12879,Intermediate,10116.0,,1,,,Plasma concentration of 3 mg/kg iv after 4 hr in rats,N,,,50597,1,,CHEMBL623964,BAO_0000218,
12880,Intermediate,10116.0,,1,,,Plasma concentration of 3 mg/kg iv after 6 hr in rats,N,,,50597,1,,CHEMBL623965,BAO_0000218,
12881,Intermediate,10116.0,,1,,,Plasma concentration of 3 mg/kg po after 0.083 hr in rats,N,,,50597,1,,CHEMBL623966,BAO_0000218,
12882,Intermediate,10116.0,,1,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.083 h,N,,,50597,1,,CHEMBL874415,BAO_0000218,
12883,Intermediate,10116.0,,1,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.25 hr,N,,,50597,1,,CHEMBL623967,BAO_0000218,
12884,Intermediate,10116.0,,1,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 0.5 hr,N,,,50597,1,,CHEMBL623968,BAO_0000218,
12885,Intermediate,10116.0,,1,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 1 hr,N,,,50597,1,,CHEMBL623969,BAO_0000218,
12886,Intermediate,10116.0,,1,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 2 hr,N,,,50597,1,,CHEMBL628409,BAO_0000218,
12887,Intermediate,10116.0,,1,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 4 hr,N,,,50597,1,,CHEMBL628410,BAO_0000218,
12888,Intermediate,10116.0,,1,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 6 hr,N,,,50597,1,,CHEMBL628411,BAO_0000218,
12889,Intermediate,10116.0,,1,,,Plasma concentration after 3 mg/kg peroral dosing in rat at 8 hr,N,,,50597,1,,CHEMBL628412,BAO_0000218,
12890,Autocuration,,,1,,,Tested for the highest concentration at which toxicity was not observed or the concentration which provided the highest number of net grain counts,U,,,22224,0,,CHEMBL628413,BAO_0000019,
12891,Autocuration,,,1,1969.0,,The concentration in plasmat; Not determined,U,,,22224,0,,CHEMBL628414,BAO_0000019,
12892,Intermediate,10116.0,,1,,,Tissue level at 10 mg/kg/po in wistar rats in blood,N,,,50597,1,,CHEMBL628415,BAO_0000218,
12893,Intermediate,10116.0,,1,,,Tissue level at 10 mg/kg/po in wistar rats in brown fat,N,,,50597,1,,CHEMBL628416,BAO_0000218,
12894,Intermediate,10116.0,,1,,,Tissue level at 10 mg/kg/po in wistar rats in heart,N,,,50597,1,,CHEMBL628417,BAO_0000218,
12895,Intermediate,10116.0,,1,2107.0,,Tissue level at 10 mg/kg/po in wistar rats in liver,N,,,50597,1,,CHEMBL874908,BAO_0000218,
12896,Intermediate,10116.0,,1,,,Tissue level at 10 mg/kg/po in wistar rats in plasma,N,,,50597,1,,CHEMBL628418,BAO_0000218,
12897,Intermediate,10116.0,,1,2385.0,,Tissue level at 10 mg/kg/po in wistar rats in skeletal muscle,N,,,50597,1,,CHEMBL628419,BAO_0000218,
12898,Intermediate,10116.0,,1,,,Tissue level at 10 mg/kg/po in wistar rats in subcutaneous fat,N,,,50597,1,,CHEMBL628420,BAO_0000218,
12899,Autocuration,,,1,,,Water solubility at 37 degree C.,U,,,22224,0,,CHEMBL628421,BAO_0000019,
12900,Autocuration,,,1,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,U,,,22229,0,,CHEMBL626726,BAO_0000100,
12901,Autocuration,,,1,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,U,,,22229,0,,CHEMBL626727,BAO_0000100,
12902,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626728,BAO_0000218,
12903,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626729,BAO_0000218,
12904,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626730,BAO_0000218,
12905,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626731,BAO_0000218,
12906,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity was measured in blood tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626732,BAO_0000218,
12907,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626733,BAO_0000218,
12908,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626734,BAO_0000218,
12909,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626735,BAO_0000218,
12910,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL874909,BAO_0000218,
12911,Intermediate,10116.0,,1,948.0,,Distribution of radioactivity was measured in heart tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626736,BAO_0000218,
12912,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL626737,BAO_0000218,
12913,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL630999,BAO_0000218,
12914,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL631000,BAO_0000218,
12915,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL631001,BAO_0000218,
12916,Intermediate,10116.0,,1,2113.0,,Distribution of radioactivity was measured in kidney tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL631002,BAO_0000218,
12917,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL631003,BAO_0000218,
12918,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL631004,BAO_0000218,
12919,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL631005,BAO_0000218,
12920,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL631006,BAO_0000218,
12921,Intermediate,10116.0,,1,2107.0,,Distribution of radioactivity was measured in liver tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL631007,BAO_0000218,
12922,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL631008,BAO_0000218,
12923,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL631009,BAO_0000218,
12924,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL631010,BAO_0000218,
12925,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL631011,BAO_0000218,
12926,Intermediate,10116.0,,1,2048.0,,Distribution of radioactivity was measured in lung tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL631012,BAO_0000218,
12927,Intermediate,10116.0,,1,2046.0,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 15 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL630271,BAO_0000218,
12928,Intermediate,10116.0,,1,2046.0,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 2 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL630272,BAO_0000218,
12929,Intermediate,10116.0,,1,2046.0,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 30 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL630273,BAO_0000218,
12930,Intermediate,10116.0,,1,2046.0,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 5 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL630274,BAO_0000218,
12931,Intermediate,10116.0,,1,2046.0,,Distribution of radioactivity was measured in thyroid tissue of unfasted Fischer 344 rats administered intravenously after 60 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL630275,BAO_0000218,
12932,Intermediate,10116.0,,1,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 15 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL875782,BAO_0000218,
12933,Intermediate,10116.0,,1,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 2 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL630276,BAO_0000218,
12934,Intermediate,10116.0,,1,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 30 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL630277,BAO_0000218,
12935,Intermediate,10116.0,,1,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 5 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL630278,BAO_0000218,
12936,Intermediate,10116.0,,1,,,Mean heart/blood tissue of unfasted Fischer 344 rats administered intravenous after 60 minutes (radiolabeled with [125I]-,N,,,50597,1,,CHEMBL630279,BAO_0000218,
12937,Autocuration,,,1,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg,U,,,22224,0,,CHEMBL630280,BAO_0000019,
12938,Autocuration,,,1,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,U,,,22224,0,,CHEMBL630281,BAO_0000019,
12939,Intermediate,9986.0,,1,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 4 by Gas-liquid chromatographic analysis,N,,,50592,1,,CHEMBL630282,BAO_0000218,
12940,Intermediate,9986.0,,1,,,Percent of 3-Methyl-thiazolidin-2-ylideneamine as administered dose was reported in rabbit 2,N,,,50592,1,,CHEMBL630283,BAO_0000218,
12941,Autocuration,,,1,,,Alkylating activity (0.1 mM) was determined at pH 7.4; expressed as OD (540n m)/mM of drug),U,,,22224,0,,CHEMBL630284,BAO_0000019,
12942,Autocuration,,,1,,,Alkylating activity was determined,U,,,22224,0,,CHEMBL630285,BAO_0000019,
12943,Autocuration,,,1,,,Amount of metabolites in the microsomal medium after 90 min incubation of BTCP (500 uM),U,Microsomes,,22224,0,,CHEMBL630286,BAO_0000251,
12944,Intermediate,9986.0,,1,,,"Formation of metabolite by rabbit liver microsomal preparation in absence of NADPH, at 2 hours",N,,,50592,1,,CHEMBL630069,BAO_0000218,
12945,Intermediate,9986.0,,1,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of Co-O2 (90:10),at 2 hour",N,,,50592,1,,CHEMBL630070,BAO_0000218,
12946,Intermediate,9986.0,,1,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of N2,at 2 hour",N,,,50592,1,,CHEMBL630071,BAO_0000218,
12947,Intermediate,9986.0,,1,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of NADPH, at 2 hours",N,,,50592,1,,CHEMBL630072,BAO_0000218,
12948,Intermediate,9986.0,,1,,,"Formation of metabolite by rabbit liver microsomal preparation in presence of SKF525A,at 2 hour",N,,,50592,1,,CHEMBL875110,BAO_0000218,
12949,Intermediate,10116.0,,1,,,Compound was tested for antidiuretic activity in rats,N,,,50597,1,,CHEMBL630073,BAO_0000218,
12950,Autocuration,,,1,,,Compound was tested for inactivation kinetic values,U,,,22224,0,,CHEMBL630074,BAO_0000019,
12951,Autocuration,,In vivo,1,,,Compound was evaluated for the average apparent volume of distribution when administered through intravenous route,U,,,22224,0,,CHEMBL630075,BAO_0000218,
12952,Autocuration,,,1,,,Dissociation rate calculated from the first-order equation using the t1/2 value,U,,,22224,0,,CHEMBL630076,BAO_0000019,
12953,Autocuration,,,1,,,Compound was evaluated for pKa by titration of the compounds in 1:2 methyl alcohol and water,U,,,22229,0,,CHEMBL630077,BAO_0000100,
12954,Autocuration,,,1,,,Aqueous solubility was measured,U,,,22229,0,,CHEMBL630078,BAO_0000100,
12955,Autocuration,,,1,,,Aqueous solubility was measured at a pH 4,U,,,22229,0,,CHEMBL630079,BAO_0000100,
12956,Autocuration,,,1,,,Aqueous solubility (pH 7),U,,,22229,0,,CHEMBL630080,BAO_0000100,
12957,Autocuration,,,1,,,Aqueous solubility was measured at a pH 9,U,,,22229,0,,CHEMBL630081,BAO_0000100,
12958,Autocuration,,,1,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents",U,,,22224,0,,CHEMBL630082,BAO_0000019,
12959,Autocuration,,,1,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",U,,,22224,0,,CHEMBL630083,BAO_0000019,
12960,Autocuration,,,1,,,"Aqueous solubilities were determined by dissolving an crystalline hemisulfate and dichloride salts, respectively in water and adding acetate to pH 5.0, concentrations are expressed in free base equivalents.",U,,,22224,0,,CHEMBL630084,BAO_0000019,
12961,Autocuration,,,1,,,Aqueous solubility of the compound,U,,,22229,0,,CHEMBL629198,BAO_0000100,
12962,Autocuration,,,1,,,Aqueous solubility at 37 degree Celsius at pH 7.38,U,,,22229,0,,CHEMBL629199,BAO_0000100,
12963,Autocuration,,,1,,,Aqueous solubility in pH 7.4 phosphate buffer,U,,,22229,0,,CHEMBL629200,BAO_0000100,
12964,Intermediate,9615.0,,1,,,Mean arterial pressure response following 10 mg/kg intraduodenal administration to salt depleted dog,N,,,50588,1,,CHEMBL629201,BAO_0000218,
12965,Intermediate,9615.0,,1,,,Mean arterial pressure response following 1 mg/kg intravenous administration to salt depleted dog,N,,,50588,1,,CHEMBL629202,BAO_0000218,
12966,Intermediate,9606.0,,1,,,Percentage of aspirin formed during hydrolysis in 10% human plasma at pH 7.4 at 37 degrees celsius,N,,,50587,1,,CHEMBL875111,BAO_0000218,
12967,Intermediate,9606.0,,1,,,Percentage of aspirin formed during hydrolysis in undiluted human plasma at pH 7.4 at 37 degrees celsius,N,,,50587,1,,CHEMBL629203,BAO_0000218,
12968,Intermediate,9606.0,,1,,,The percentage of aspirin formed during hydrolysis in 100% human plasma at pH 7.4 at 37 degrees celsius,N,,,50587,1,,CHEMBL629204,BAO_0000218,
12969,Intermediate,9606.0,,1,,,The percentage of aspirin formed during hydrolysis in 20% human plasma at pH 7.4 at 37 degrees celsius,N,,,50587,1,,CHEMBL629205,BAO_0000218,
12970,Intermediate,9606.0,,1,,,The percentage of aspirin formed during hydrolysis in 60% human plasma at pH 7.4 at 37 degrees celsius,N,,,50587,1,,CHEMBL629206,BAO_0000218,
12971,Autocuration,,,1,,,The percentage of aspirin formed during hydrolysis in 80% human plasma at pH 7.4 at 37 degrees celsius,U,,,22224,0,,CHEMBL631185,BAO_0000019,
12972,Intermediate,10116.0,,1,,,Compound was evaluated for the average bile flow rat in rats,N,,,50597,1,,CHEMBL631186,BAO_0000218,
12973,Intermediate,9986.0,,1,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 15 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",N,,,50592,1,,CHEMBL631187,BAO_0000218,
12974,Intermediate,9986.0,,1,,,"Effect of compound on cartilage in surgically induced osteoarthritis (OA) model in rabbit at 25 mg/kg, value are relative to activity of RS-130830 (7.9+/-1.5) at 25 mg/kg",N,,,50592,1,,CHEMBL631188,BAO_0000218,
12975,Autocuration,,,1,,,Average half life period was determined,U,,,22224,0,,CHEMBL876419,BAO_0000019,
12976,Autocuration,,,1,,,Average half life period was determined,U,,,22224,0,,CHEMBL631189,BAO_0000019,
12977,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,N,,,50602,1,,CHEMBL631190,BAO_0000218,
12978,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 0.8 mg/kg per day.,N,,,50602,1,,CHEMBL631191,BAO_0000218,
12979,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day.,N,,,50602,1,,CHEMBL631192,BAO_0000218,
12980,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day.,N,,,50602,1,,CHEMBL632400,BAO_0000218,
12981,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,N,,,50602,1,,CHEMBL630564,BAO_0000218,
12982,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day.,N,,,50602,1,,CHEMBL630565,BAO_0000218,
12983,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day.,N,,,50602,1,,CHEMBL630566,BAO_0000218,
12984,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day.,N,,,50602,1,,CHEMBL631229,BAO_0000218,
12985,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day.,N,,,50602,1,,CHEMBL631230,BAO_0000218,
12986,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL876428,BAO_0000100,
12987,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL631231,BAO_0000100,
12988,Autocuration,,,1,,,Calculated partition coefficient (clogP) (MacLogP),U,,,22229,0,,CHEMBL631232,BAO_0000100,
12989,Autocuration,,,1,,,Hydrophilicity was determined,U,,,22224,0,,CHEMBL631233,BAO_0000019,
12990,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL631234,BAO_0000100,
12991,Autocuration,,,1,,,Increased absorption was determined,U,,,22224,0,,CHEMBL883126,BAO_0000019,
12992,Autocuration,,,1,,,Lipophilicity value was evaluated,U,,,22224,0,,CHEMBL631235,BAO_0000100,
12993,Autocuration,,,1,,,Log P value of the compound.,U,,,22224,0,,CHEMBL631236,BAO_0000100,
12994,Autocuration,,,1,,,Partition coefficient of compound was determined,U,,,22224,0,,CHEMBL631237,BAO_0000019,
12995,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL631238,BAO_0000100,
12996,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL876429,BAO_0000100,
12997,Autocuration,,,1,,,Partition coefficient was measured by medchem software; Not calculated,U,,,22224,0,,CHEMBL631414,BAO_0000019,
12998,Autocuration,,,1,,,Partition coefficient was measured by octanol-water using standard shake-flask method,U,,,22224,0,,CHEMBL631415,BAO_0000100,
12999,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL631416,BAO_0000100,
13000,Autocuration,,,1,,,Partition coefficient (logP),U,,,22224,0,,CHEMBL631417,BAO_0000019,
13001,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL631418,BAO_0000100,
13002,Autocuration,,,1,,,The Octanol/Water partition coefficient CLogP,U,,,22229,0,,CHEMBL631419,BAO_0000100,
13003,Autocuration,,,1,,,The pharmacokinetic parameter C Log p was reported,U,,,22224,0,,CHEMBL631420,BAO_0000019,
13004,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL631421,BAO_0000100,
13005,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL631422,BAO_0000100,
13006,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL631423,BAO_0000100,
13007,Intermediate,10116.0,In vivo,1,1969.0,,Clearance rate in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL876430,BAO_0000218,
13008,Intermediate,10116.0,In vivo,1,1969.0,,Clearance rate in rat plasma when administered intravenously at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL631424,BAO_0000218,
13009,Intermediate,9615.0,In vivo,1,1969.0,,Compound was administered intravenously in dog to evaluate plasma clearance values,N,,,50588,1,,CHEMBL631425,BAO_0000218,
13010,Autocuration,314293.0,In vivo,1,1969.0,,Compound was administered intravenously in monkey to evaluate plasma clearance values,U,,,22224,0,,CHEMBL631426,BAO_0000218,
13011,Intermediate,10090.0,In vivo,1,1969.0,,Compound was administered intravenously in mouse to evaluate plasma clearance values,N,,,50594,1,,CHEMBL631427,BAO_0000218,
13012,Intermediate,9615.0,In vivo,1,1969.0,,Compound was evaluated in vivo for plasma clearance in dog after intravenous dose at 2 mg/Kg,N,,,50588,1,,CHEMBL631428,BAO_0000218,
13013,Intermediate,9544.0,In vitro,1,2107.0,,Intrinsic clearance in Rhesus liver microsome,N,Microsomes,,50797,1,,CHEMBL631429,BAO_0000218,
13014,Intermediate,9615.0,In vitro,1,2107.0,,Intrinsic clearance in dog liver microsome,N,Microsomes,,50588,1,,CHEMBL631430,BAO_0000218,
13015,Intermediate,10116.0,In vitro,1,2107.0,,Intrinsic clearance in rat liver microsome,N,Microsomes,,50597,1,,CHEMBL631431,BAO_0000218,
13016,Intermediate,9544.0,In vivo,1,1969.0,,Low plasma clearance was calculated in rhesus monkey,N,,,50797,1,,CHEMBL631432,BAO_0000218,
13017,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic data at 0.5 mg/kg dose given to dogs intravenously.,N,,,50588,1,,CHEMBL631433,BAO_0000218,
13018,Autocuration,,In vivo,1,,,Plasma clearance after intravenous dose of 0.3 mg/kg,U,,,22224,0,,CHEMBL631434,BAO_0000218,
13019,Autocuration,,In vivo,1,,,Plasma clearance after intravenous dose of 1 mg/kg,U,,,22224,0,,CHEMBL631435,BAO_0000218,
13020,Autocuration,,In vivo,1,,,Plasma clearance after intravenous dose of 3 mg/kg,U,,,22224,0,,CHEMBL631436,BAO_0000218,
13021,Autocuration,,In vivo,1,,,Plasma clearance after intravenous dose of 3.87 mg/kg,U,,,22224,0,,CHEMBL631437,BAO_0000218,
13022,Intermediate,10116.0,In vivo,1,,,Plasma clearance after peroral administration at 10 mpk in Rat,N,,,50597,1,,CHEMBL631438,BAO_0000218,
13023,Intermediate,9544.0,In vivo,1,,,Plasma clearance after peroral administration at 10 mpk in Rhesus,N,,,50797,1,,CHEMBL876431,BAO_0000218,
13024,Intermediate,9615.0,In vivo,1,,,Plasma clearance after peroral administration at 10 mpk in dog,N,,,50588,1,,CHEMBL631439,BAO_0000218,
13025,Intermediate,10116.0,In vivo,1,,,Totla clearance of compound reported after 5 mg/kg i.v. dose in rat,N,,,50597,1,,CHEMBL631440,BAO_0000218,
13026,Autocuration,,,1,,,Compound was evaluated for physico-chemical property of Critical micellar concentration (CMC),U,,,22224,0,,CHEMBL631441,BAO_0000019,
13027,Autocuration,,,1,,,Critical Micellar concentration was determined,U,,,22224,0,,CHEMBL631442,BAO_0000019,
13028,Autocuration,,,1,,,Critical Micellar concentration of the compound. was determined,U,,,22224,0,,CHEMBL626525,BAO_0000019,
13029,Autocuration,,,1,,,Critical micelle concentration determined from the plots of the fluorescence intensity as a function of compound concentration,U,,,22224,0,,CHEMBL627168,BAO_0000019,
13030,Autocuration,,,1,,,Critical micellar concentration was measured in water by the dye solubilization method,U,,,22224,0,,CHEMBL875618,BAO_0000019,
13031,Autocuration,,,1,,,Hydrolysis turn over determined from the plots of the fluorescence assay quantified by HPLC,U,,,22224,0,,CHEMBL626612,BAO_0000019,
13032,Autocuration,,,1,,,CMR value (relative to BAY K 8644),U,,,22224,0,,CHEMBL626613,BAO_0000019,
13033,Autocuration,,,1,,,Carbamoylating activity was determined,U,,,22224,0,,CHEMBL626614,BAO_0000019,
13034,Autocuration,314293.0,,1,,,Hypotension peak is percentage change from predose baseline pressure observed after intraduodenal dose of 10 mg/kg in monkey,U,,,22224,0,,CHEMBL626615,BAO_0000218,
13035,Autocuration,,,1,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:10 at 0.1 to 0.2 degrees Centigrade.,U,,,22224,0,,CHEMBL626616,BAO_0000019,
13036,Autocuration,,,1,,,Compound was evaluated for induced thermal stabilization for compound: DNA ratio of 1:5 at 0.1 to 0.2 degrees Centigrade.,U,,,22224,0,,CHEMBL626617,BAO_0000019,
13037,Intermediate,9615.0,In vivo,1,1969.0,,Clearance from dog plasma after intravenous injection of 1 mg/kg of compound,N,,,50588,1,,CHEMBL626618,BAO_0000218,
13038,Intermediate,10116.0,In vivo,1,1969.0,,Clearance from rat plasma after intravenous injection of 1 mg/kg of compound,N,,,50597,1,,CHEMBL626619,BAO_0000218,
13039,Intermediate,9615.0,In vivo,1,,,"Clearance rate at 0.46 mg/kg, iv, in dogs",N,,,50588,1,,CHEMBL626620,BAO_0000218,
13040,Intermediate,10116.0,In vivo,1,,,"Clearance rate at 5.5 mg/kg, iv, in rat",N,,,50597,1,,CHEMBL626621,BAO_0000218,
13041,Intermediate,9541.0,In vivo,1,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 1 mg/kg concentration,N,,,100710,1,,CHEMBL626622,BAO_0000218,
13042,Intermediate,9541.0,In vivo,1,,,Pharmacokinetic parameter Cl calculated in cynomolgus monkey when the compound was administered intravenously at 0.5 mg/kg concentration,N,,,100710,1,,CHEMBL626623,BAO_0000218,
13043,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter Cl calculated in dog when the compound was administered intravenously at 2 mg/kg concentration,N,,,50588,1,,CHEMBL626624,BAO_0000218,
13044,Intermediate,10116.0,In vivo,1,,,Pharmacokinetic parameter Cl calculated in rat when the compound was administered intravenously at 5 mg/kg concentration,N,,,50597,1,,CHEMBL626625,BAO_0000218,
13045,Intermediate,10116.0,Ex vivo,1,2107.0,,Clearance rate constant using isolated perfused rat liver (IPRL) assay,N,,,50597,1,,CHEMBL626626,BAO_0000218,
13046,Autocuration,,In vivo,1,,,Tested for the total clearance of the compound,U,,,22224,0,,CHEMBL626627,BAO_0000218,
13047,Intermediate,9615.0,In vivo,1,,,The clearance was measured in dogs after intravenous administration of 1 mg/kg dose,N,,,50588,1,,CHEMBL626628,BAO_0000218,
13048,Autocuration,,In vivo,1,,,Total body clearance was determined,U,,,22224,0,,CHEMBL626629,BAO_0000218,
13049,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,N,,,50597,1,,CHEMBL626630,BAO_0000218,
13050,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,N,,,50597,1,,CHEMBL626631,BAO_0000218,
13051,Autocuration,,,1,,,Solubility of 10 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,U,,,22229,0,,CHEMBL626632,BAO_0000100,
13052,Autocuration,,,1,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,U,,,22229,0,,CHEMBL626633,BAO_0000100,
13053,Autocuration,,,1,,,Solubility of 150 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 8.0 hr,U,,,22229,0,,CHEMBL626634,BAO_0000100,
13054,Autocuration,,,1,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 13.5 hr,U,,,22229,0,,CHEMBL626635,BAO_0000100,
13055,Autocuration,,,1,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Celsius after 4.0 hr,U,,,22229,0,,CHEMBL626636,BAO_0000100,
13056,Autocuration,,,1,,,Solubility of 20 mg compound in aqueous buffer at pH 7.3 and 37 degree Centigrade after 8.0 hr,U,,,22229,0,,CHEMBL626637,BAO_0000100,
13057,Intermediate,4754.0,,1,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 10.9 uM/Kg/day),N,,,50339,1,,CHEMBL626638,BAO_0000218,
13058,Intermediate,4754.0,,1,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.3 uM/Kg/day,N,,,50339,1,,CHEMBL626639,BAO_0000218,
13059,Intermediate,4754.0,,1,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 23.3 uM/Kg/day,N,,,50339,1,,CHEMBL626640,BAO_0000218,
13060,Intermediate,4754.0,,1,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 4.8 uM/Kg/day,N,,,50339,1,,CHEMBL626641,BAO_0000218,
13061,Intermediate,4754.0,,1,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 9.2 uM/Kg/day,N,,,50339,1,,CHEMBL627272,BAO_0000218,
13062,Intermediate,4754.0,,1,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted uM/Kg/day,N,,,50339,1,,CHEMBL627273,BAO_0000218,
13063,Intermediate,4754.0,,1,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.027 (uM/kg/day),N,,,50339,1,,CHEMBL627441,BAO_0000218,
13064,Intermediate,4754.0,,1,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 0.27 (uM/kg/day),N,,,50339,1,,CHEMBL628355,BAO_0000218,
13065,Intermediate,4754.0,,1,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 13.3 (uM/kg/day),N,,,50339,1,,CHEMBL628356,BAO_0000218,
13066,Intermediate,4754.0,,1,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 2.7 (uM/kg/day),N,,,50339,1,,CHEMBL628357,BAO_0000218,
13067,Intermediate,4754.0,,1,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 22.1 (uM/kg/day),N,,,50339,1,,CHEMBL628358,BAO_0000218,
13068,Intermediate,4754.0,,1,,,In vivo activity against pneumocystis carinii was determined as toxicity which indicates the death of animals and counted cysts in a blinding protocol in lung tissue reported as % of saline treated control at a dose of 66.3 (uM/kg/day),N,,,50339,1,,CHEMBL622307,BAO_0000218,
13069,Autocuration,,,1,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0,U,,,22224,0,,CHEMBL622527,BAO_0000019,
13070,Autocuration,,,1,,,Conversion rate by hydrolysis of compound in plasma after 2 hr at a pH of 1.0; Not detectable,U,,,22224,0,,CHEMBL622528,BAO_0000019,
13071,Autocuration,,,1,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4,U,,,22224,0,,CHEMBL622529,BAO_0000019,
13072,Autocuration,,,1,,,Conversion rate by hydrolysis of compound in plasma after 4 hr at a pH of 7.4; Not detectable,U,,,22224,0,,CHEMBL622992,BAO_0000019,
13073,Autocuration,,,1,,,Conversion rate by hydrolysis of compound in plasma after 6 hr. ,U,,,22224,0,,CHEMBL622993,BAO_0000019,
13074,Autocuration,,,1,,,Conversion rate by hydrolysis of compound in plasma after 6 h; Not detectable,U,,,22224,0,,CHEMBL622994,BAO_0000019,
13075,Intermediate,10116.0,,1,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in rat liver homogenate",N,,,50597,1,,CHEMBL622995,BAO_0000218,
13076,Intermediate,10116.0,,1,,,"In vitro rate constant, correlation coefficient for the conversion to progesterone in whole rat blood.",N,,,50597,1,,CHEMBL622996,BAO_0000218,
13077,Intermediate,10116.0,,1,,,"In vitro rate constant, correlation coefficient for the disappearance in rat liver homogenate",N,,,50597,1,,CHEMBL622997,BAO_0000218,
13078,Intermediate,10116.0,,1,,,"In vitro rate constant, correlation coefficient for the disappearance in rat brain homogenate",N,,,50597,1,,CHEMBL622998,BAO_0000218,
13079,Autocuration,,,1,,,Cp max following ip administration at 1 mg/kg,U,,,22224,0,,CHEMBL622999,BAO_0000218,
13080,Autocuration,,In vivo,1,1969.0,,Maximum concentration in plasma was reported at 0.5 hour,U,,,22224,0,,CHEMBL623000,BAO_0000218,
13081,Autocuration,,In vivo,1,1969.0,,Maximum concentration in plasma was reported at 2 hour,U,,,22224,0,,CHEMBL623001,BAO_0000218,
13082,Intermediate,10090.0,,1,,,Cellular uptake kinetics of Porphycenes saturation cell level (cs) in SSK3 murine fibrosarcoma cells,N,,,50594,1,,CHEMBL623002,BAO_0000218,
13083,Autocuration,,,1,,,Aqueous solubility in 25 mM N-glycyl-glycine and 10 mM MgSO4 (pH 7.8),U,,,22229,0,,CHEMBL623003,BAO_0000100,
13084,Autocuration,,,1,,,Steady state concentration was evaluated,U,,,22224,0,,CHEMBL623004,BAO_0000019,
13085,Autocuration,,,1,,,Partition coefficient (logP),U,,,22224,0,,CHEMBL623005,BAO_0000019,
13086,Autocuration,,,1,,,Partition coefficient (logD7.4),U,,,22224,0,,CHEMBL623006,BAO_0000019,
13087,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of {18]Fluoro-CGP 12388 (60 minutes post injection) in liver of male wistar rats,N,,,50597,1,,CHEMBL623007,BAO_0000218,
13088,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in bone of male wistar rats,N,,,50597,1,,CHEMBL623008,BAO_0000218,
13089,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cerebellum of male wistar rats,N,,,50597,1,,CHEMBL876654,BAO_0000218,
13090,Intermediate,10116.0,In vivo,1,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in cortex of male wistar rats,N,,,50597,1,,CHEMBL623009,BAO_0000218,
13091,Intermediate,10116.0,In vivo,1,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in fat of male wistar rats,N,,,50597,1,,CHEMBL623010,BAO_0000218,
13092,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in heart of male wistar rats,N,,,50597,1,,CHEMBL623011,BAO_0000218,
13093,Intermediate,10116.0,In vivo,1,160.0,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in intestine of male wistar rats,N,,,50597,1,,CHEMBL623012,BAO_0000218,
13094,Autocuration,,,1,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,U,,,22224,0,,CHEMBL623013,BAO_0000019,
13095,Autocuration,,,1,,,Antidiuretic activity was determined expressed as Na+(sodium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,U,,,22224,0,,CHEMBL623014,BAO_0000019,
13096,Autocuration,,,1,1088.0,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 10 mg/Kg,U,,,22224,0,,CHEMBL623015,BAO_0000019,
13097,Autocuration,,,1,1088.0,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 100 mg/Kg,U,,,22224,0,,CHEMBL623016,BAO_0000019,
13098,Autocuration,,,1,1088.0,,Antidiuretic activity was determined expressed as volume of urine excreted in mL was reported at a dose of 25 mg/Kg,U,,,22224,0,,CHEMBL624858,BAO_0000019,
13099,Intermediate,10116.0,,1,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 10 mg/Kg.,N,,,50597,1,,CHEMBL624859,BAO_0000218,
13100,Intermediate,10116.0,,1,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg,N,,,50597,1,,CHEMBL624860,BAO_0000218,
13101,Intermediate,10116.0,,1,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,N,,,50597,1,,CHEMBL624861,BAO_0000218,
13102,Intermediate,10116.0,,1,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg,N,,,50597,1,,CHEMBL624862,BAO_0000218,
13103,Intermediate,10116.0,,1,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli equivalents was reported for a duration of 5 hours after administration of a dose of 25 mg/Kg.,N,,,50597,1,,CHEMBL624863,BAO_0000218,
13104,Intermediate,10116.0,,1,,,Antidiuretic activity was determined in SH rats expressed as K(+) (potassium) excreted in milli euivalents was reported for a duration of 5 hours after administration of a dose of 100 mg/Kg.,N,,,50597,1,,CHEMBL876655,BAO_0000218,
13105,Intermediate,9615.0,,1,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,N,,,50588,1,,CHEMBL624864,BAO_0000218,
13106,Intermediate,9615.0,,1,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,N,,,50588,1,,CHEMBL624865,BAO_0000218,
13107,Intermediate,9615.0,,1,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,N,,,50588,1,,CHEMBL624866,BAO_0000218,
13108,Expert,9615.0,,1,,,Salidiuretic activity in dog following i.v. dosing at 5 mg/kg,N,,,50588,1,,CHEMBL624867,BAO_0000218,
13109,Intermediate,9615.0,,1,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,N,,,50588,1,,CHEMBL624868,BAO_0000218,
13110,Intermediate,9615.0,,1,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600- 799,N,,,50588,1,,CHEMBL628450,BAO_0000218,
13111,Intermediate,9615.0,,1,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,N,,,50588,1,,CHEMBL628451,BAO_0000218,
13112,Intermediate,9615.0,,1,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,N,,,50588,1,,CHEMBL628452,BAO_0000218,
13113,Intermediate,9615.0,,1,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,N,,,50588,1,,CHEMBL628453,BAO_0000218,
13114,Intermediate,9615.0,,1,,,Compound administered intravenously at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; act above 5 mg/kg,N,,,50588,1,,CHEMBL628454,BAO_0000218,
13115,Intermediate,9615.0,,1,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog,N,,,50588,1,,CHEMBL628455,BAO_0000218,
13116,Intermediate,9615.0,,1,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 0-99,N,,,50588,1,,CHEMBL628456,BAO_0000218,
13117,Intermediate,9615.0,,1,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-249,N,,,50588,1,,CHEMBL628457,BAO_0000218,
13118,Intermediate,9615.0,,1,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 100-299,N,,,50588,1,,CHEMBL877505,BAO_0000218,
13119,Intermediate,9615.0,,1,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 250-399,N,,,50588,1,,CHEMBL628458,BAO_0000218,
13120,Intermediate,9615.0,,1,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 400-599,N,,,50588,1,,CHEMBL628459,BAO_0000218,
13121,Intermediate,9615.0,,1,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 600-799,N,,,50588,1,,CHEMBL628460,BAO_0000218,
13122,Intermediate,9615.0,,1,,,Compound administered intravenously was evaluated for salidiuretic activity measured as sodium ion excretion in Dog; Value ranges from 800-899,N,,,50588,1,,CHEMBL628461,BAO_0000218,
13123,Autocuration,,,1,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 16.5 mg/kg",U,,,22224,0,,CHEMBL628462,BAO_0000218,
13124,Intermediate,9615.0,,1,,,Compound administered orally at a dose of 1 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,N,,,50588,1,,CHEMBL628463,BAO_0000218,
13125,Expert,10116.0,,1,,,"Evaluated for salidiuretic activity measured as sodium ion excretion in Rat, administered orally at a dose of 50 mg/kg",N,,,50597,1,,CHEMBL625666,BAO_0000218,
13126,Autocuration,,,1,,,Compound administered orally at a dose of 5 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,U,,,22224,0,,CHEMBL625667,BAO_0000218,
13127,Expert,10116.0,,1,,,Compound administered orally at a dose of 81 mg/kg was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,N,,,50597,1,,CHEMBL625668,BAO_0000218,
13128,Intermediate,10116.0,,1,,,Compound administered orally was evaluated for salidiuretic activity measured as sodium ion excretion in Rat,N,,,50597,1,,CHEMBL625669,BAO_0000218,
13129,Autocuration,,,1,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry,U,,,22224,0,,CHEMBL625670,BAO_0000019,
13130,Intermediate,10116.0,,1,,,Compound was tested for diuretic activity in potassium content of the 3-h sample was measured by flame photometry in rat,N,,,50597,1,,CHEMBL625671,BAO_0000218,
13131,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day.,N,,,50602,1,,CHEMBL625672,BAO_0000218,
13132,Intermediate,10298.0,,1,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously,N,,,50602,1,,CHEMBL625673,BAO_0000218,
13133,Intermediate,10298.0,,1,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 0.8 mg/kg administered subcutaneously.,N,,,50602,1,,CHEMBL625674,BAO_0000218,
13134,Intermediate,10298.0,,1,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously,N,,,50602,1,,CHEMBL625675,BAO_0000218,
13135,Intermediate,10298.0,,1,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,N,,,50602,1,,CHEMBL627637,BAO_0000218,
13136,Intermediate,10298.0,,1,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered orally.,N,,,50602,1,,CHEMBL627638,BAO_0000218,
13137,Intermediate,10298.0,,1,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously,N,,,50602,1,,CHEMBL627639,BAO_0000218,
13138,Intermediate,10298.0,,1,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered subcutaneously.,N,,,50602,1,,CHEMBL627640,BAO_0000218,
13139,Intermediate,10298.0,,1,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 3.1 mg/kg administered orally.,N,,,50602,1,,CHEMBL627641,BAO_0000218,
13140,Intermediate,10298.0,,1,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,N,,,50602,1,,CHEMBL627642,BAO_0000218,
13141,Intermediate,10298.0,,1,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 50 mg/kg administered orally.,N,,,50602,1,,CHEMBL877506,BAO_0000218,
13142,Intermediate,10090.0,,1,,,Efficacy was evaluated against Systemic HSV-1 infection in mice at a daily dose of 12.5 mg/kg administered subcutaneously.,N,,,50594,1,,CHEMBL627275,BAO_0000218,
13143,Intermediate,9669.0,,1,,,"Average area under curve value dosed at 0.3 mg/kg, iv in ferrets.",N,,,50506,1,,CHEMBL627643,BAO_0000218,
13144,Intermediate,9669.0,,1,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",N,,,50506,1,,CHEMBL631246,BAO_0000218,
13145,Intermediate,9669.0,,1,,,"Average area under curve value dosed at 10 mg/kg, id in ferrets.",N,,,50506,1,,CHEMBL631247,BAO_0000218,
13146,Intermediate,9669.0,,1,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,N,,,50506,1,,CHEMBL629532,BAO_0000218,
13147,Intermediate,9669.0,,1,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from arterial blood).,N,,,50506,1,,CHEMBL629533,BAO_0000218,
13148,Intermediate,9669.0,,1,,,Average peak plasma drug concentration after id dose of 10 mg/kg in ferrets(Plasma samples collected from portal blood).,N,,,50506,1,,CHEMBL629534,BAO_0000218,
13149,Intermediate,9669.0,,1,,,Average peak plasma drug concentration after iv dose of 0.3 mg/kg in ferrets.,N,,,50506,1,,CHEMBL629535,BAO_0000218,
13150,Autocuration,,,1,,,Pharmacokinetic parameter :drug bound to plasma was reported,U,,,22224,0,,CHEMBL625932,BAO_0000019,
13151,Autocuration,,,1,,,compound was evaluated for drug bound in plasma,U,,,22224,0,,CHEMBL625933,BAO_0000019,
13152,Intermediate,10116.0,,1,,,The Brain concentration compared to plasma concentration in rats after oral administration of 1 mg/kg dose,N,,,50597,1,,CHEMBL625934,BAO_0000218,
13153,Autocuration,9347.0,,1,,,Bioavailability,U,,,22224,0,,CHEMBL625935,BAO_0000218,
13154,Intermediate,10116.0,,1,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported,N,,,50597,1,,CHEMBL625936,BAO_0000218,
13155,Intermediate,10116.0,,1,,,Compound at a dose of 10 mg/kg was orally administered to rats and Bioavailability was reported; Not tested,N,,,50597,1,,CHEMBL625937,BAO_0000218,
13156,Intermediate,9615.0,,1,,,Oral bioavailability in Beagle dogs at oral dose of 20 mg/kg and an intravenous dose of 5 mg/kg was administered,N,,,50588,1,,CHEMBL625938,BAO_0000218,
13157,Intermediate,10116.0,,1,1970.0,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-1 hr after the treatment.,N,,,50597,1,,CHEMBL625939,BAO_0000218,
13158,Intermediate,10116.0,,1,1970.0,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-2 hr after the treatment.,N,,,50597,1,,CHEMBL625940,BAO_0000218,
13159,Intermediate,10116.0,,1,1970.0,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-3 hr after the treatment.,N,,,50597,1,,CHEMBL874464,BAO_0000218,
13160,Intermediate,10116.0,,1,1970.0,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-4 hr after the treatment.,N,,,50597,1,,CHEMBL625941,BAO_0000218,
13161,Intermediate,10116.0,,1,1970.0,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-5 hr after the treatment.,N,,,50597,1,,CHEMBL625942,BAO_0000218,
13162,Intermediate,10116.0,,1,1970.0,,Percent biliary excretion property by administering intravenously to rats was reported as amount of unchanged form of compound detected in bile samples collected at 0-6 hr after the treatment.,N,,,50597,1,,CHEMBL625943,BAO_0000218,
13163,Intermediate,9606.0,,1,1977.0,,In vitro protein binding in human serum at 5 ug/ml,N,,,50587,1,,CHEMBL625944,BAO_0000218,
13164,Autocuration,,,1,,,Serum protein binding ability was measured,U,,,22224,0,,CHEMBL625945,BAO_0000019,
13165,Autocuration,,,1,,,The ability binding to plasma (Binding classified based on injection of compound at 80 concentration.),U,,,22224,0,,CHEMBL625946,BAO_0000019,
13166,Autocuration,9615.0,In vivo,1,,,Oral bioavailability in dog,U,,,22224,0,,CHEMBL625947,BAO_0000218,
13167,Intermediate,10116.0,In vivo,1,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,N,,,50597,1,,CHEMBL625948,BAO_0000218,
13168,Autocuration,,In vivo,1,,,Absolute oral bioavailability at an iv dose of 14 mg/kg,U,,,22224,0,,CHEMBL625949,BAO_0000218,
13169,Autocuration,,In vivo,1,,,Absolute oral bioavailability at an iv dose of 15.2 mg/kg,U,,,22224,0,,CHEMBL625950,BAO_0000218,
13170,Autocuration,9347.0,In vivo,1,,,Oral bioavailability (dose 15 mg/kg i.v.),U,,,22224,0,,CHEMBL625951,BAO_0000218,
13171,Autocuration,,In vivo,1,,,Absolute oral bioavailability at an peroral dose of 15 mg/kg orally.,U,,,22224,0,,CHEMBL625952,BAO_0000218,
13172,Autocuration,,In vivo,1,,,Absolute oral bioavailability at an peroral dose of 30 mg/kg orally,U,,,22224,0,,CHEMBL625953,BAO_0000218,
13173,Autocuration,,In vivo,1,,,Absolute oral bioavailability at an peroral dose of 30.2 mg/kg orally.,U,,,22224,0,,CHEMBL625954,BAO_0000218,
13174,Autocuration,,In vivo,1,,,Absolute oral bioavailability at an peroral dose of 30.3 mg/kg orally.,U,,,22224,0,,CHEMBL882959,BAO_0000218,
13175,Intermediate,9615.0,In vivo,1,,,Apparent bioavailability in dogs at 15 mg/kg in an iv vs po dosing regimen,N,,,50588,1,,CHEMBL625955,BAO_0000218,
13176,Autocuration,9669.0,In vivo,1,,,Bioavailability in ferret,U,,,22224,0,,CHEMBL625956,BAO_0000218,
13177,Intermediate,9541.0,In vivo,1,,,Bioavailability after intraduodenal administration at a dose 10 mg/kg in cynomolgus monkeys using renin inhibition assay,N,,,100710,1,,CHEMBL625957,BAO_0000218,
13178,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,N,,,50597,1,,CHEMBL625958,BAO_0000218,
13179,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,N,,,50597,1,,CHEMBL625959,BAO_0000218,
13180,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,N,,,50597,1,,CHEMBL626642,BAO_0000218,
13181,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,N,,,50597,1,,CHEMBL631330,BAO_0000218,
13182,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,N,,,50597,1,,CHEMBL631331,BAO_0000218,
13183,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,N,,,50597,1,,CHEMBL631332,BAO_0000218,
13184,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,N,,,50597,1,,CHEMBL631333,BAO_0000218,
13185,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,N,,,50597,1,,CHEMBL632018,BAO_0000218,
13186,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,N,,,50597,1,,CHEMBL632019,BAO_0000218,
13187,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,N,,,50597,1,,CHEMBL632020,BAO_0000218,
13188,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,N,,,50597,1,,CHEMBL632021,BAO_0000218,
13189,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,N,,,50597,1,,CHEMBL632022,BAO_0000218,
13190,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,N,,,50597,1,,CHEMBL632023,BAO_0000218,
13191,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,N,,,50597,1,,CHEMBL632024,BAO_0000218,
13192,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,N,,,50597,1,,CHEMBL874472,BAO_0000218,
13193,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,N,,,50597,1,,CHEMBL632025,BAO_0000218,
13194,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,N,,,50597,1,,CHEMBL632026,BAO_0000218,
13195,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,N,,,50597,1,,CHEMBL632027,BAO_0000218,
13196,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,N,,,50597,1,,CHEMBL632028,BAO_0000218,
13197,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,N,,,50597,1,,CHEMBL626430,BAO_0000218,
13198,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,N,,,50597,1,,CHEMBL626431,BAO_0000218,
13199,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,N,,,50597,1,,CHEMBL626432,BAO_0000218,
13200,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,N,,,50597,1,,CHEMBL626433,BAO_0000218,
13201,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,N,,,50597,1,,CHEMBL626434,BAO_0000218,
13202,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,N,,,50597,1,,CHEMBL627280,BAO_0000218,
13203,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,N,,,50597,1,,CHEMBL627281,BAO_0000218,
13204,Intermediate,10116.0,,1,,,Mean Chlorine excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,N,,,50597,1,,CHEMBL627282,BAO_0000218,
13205,Autocuration,,,1,,,Total body clearance was measured at given dose,U,,,22224,0,,CHEMBL627283,BAO_0000019,
13206,Autocuration,,,1,,,Total body clearance was measured at given dose.,U,,,22224,0,,CHEMBL627284,BAO_0000218,
13207,Intermediate,10116.0,,1,,,Metabolic clearance from the body in rat,N,,,50597,1,,CHEMBL627285,BAO_0000218,
13208,Autocuration,,In vivo,1,,,Renal clearance from the body,U,,,22224,0,,CHEMBL627286,BAO_0000218,
13209,Intermediate,10116.0,In vivo,1,,,Renal clearance from the body in rat,N,,,50597,1,,CHEMBL875477,BAO_0000218,
13210,Intermediate,10116.0,In vivo,1,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 12 mg/kg in rat,N,,,50597,1,,CHEMBL627287,BAO_0000218,
13211,Intermediate,9615.0,In vivo,1,,,Tested for pharmacokinetic parameter to calculate the total body clearance at a dosage of 2.5 mg/kg in dog,N,,,50588,1,,CHEMBL627288,BAO_0000218,
13212,Intermediate,10116.0,,1,,,Total clearance from the body in rat,N,,,50597,1,,CHEMBL627289,BAO_0000218,
13213,Intermediate,10116.0,In vivo,1,1969.0,,Clearance into cortex from rat plasma or PBS,N,,,50597,1,,CHEMBL627290,BAO_0000218,
13214,Autocuration,,In vivo,1,,,Clearance at an iv dose of 15 mg/Kg and po dose of 120 mg/Kg,U,,,22224,0,,CHEMBL627291,BAO_0000218,
13215,Autocuration,,In vivo,1,,,Clearance at an iv dose of 15 mg/Kg and po dose of 240 mg/Kg,U,,,22224,0,,CHEMBL627292,BAO_0000218,
13216,Autocuration,,In vivo,1,,,Clearance at an iv dose of 15 mg/Kg and po dose of 29.1 mg/Kg,U,,,22224,0,,CHEMBL627293,BAO_0000218,
13217,Autocuration,,In vivo,1,,,Clearance at an iv dose of 15 mg/Kg and po dose of 30 mg/Kg,U,,,22224,0,,CHEMBL627294,BAO_0000218,
13218,Autocuration,,In vivo,1,,,Clearance at an iv dose of 15 mg/Kg and po dose of 60 mg/Kg,U,,,22224,0,,CHEMBL875478,BAO_0000218,
13219,Autocuration,,In vivo,1,,,Clearance was determined,U,,,22224,0,,CHEMBL627295,BAO_0000218,
13220,Intermediate,10090.0,In vivo,1,,,Clearance was measured in mouse after administration of compound 20 mg/kg intravenously,N,,,50594,1,,CHEMBL627296,BAO_0000218,
13221,Intermediate,9986.0,In vivo,1,,,Clearance was measured in rabbit after administration of compound 20 mg/kg intravenously,N,,,50592,1,,CHEMBL626119,BAO_0000218,
13222,Intermediate,10116.0,In vivo,1,,,Clearance was measured in rat after administration of compound 20 mg/kg intravenously,N,,,50597,1,,CHEMBL626120,BAO_0000218,
13223,Intermediate,10116.0,In vivo,1,,,Clearance in rat after iv dose (100 ug/kg),N,,,50597,1,,CHEMBL626121,BAO_0000218,
13224,Autocuration,10141.0,In vivo,1,,,Clearance in guinea pig,U,,,22224,0,,CHEMBL626122,BAO_0000218,
13225,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for clearance in rat,N,,,50597,1,,CHEMBL626123,BAO_0000218,
13226,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for the clearance in dog,N,,,50588,1,,CHEMBL623456,BAO_0000218,
13227,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for the clearance in rat,N,,,50597,1,,CHEMBL623457,BAO_0000218,
13228,Intermediate,10116.0,In vivo,1,,,Compound was tested in vivo for clearance after iv administration in the rat,N,,,50597,1,,CHEMBL623458,BAO_0000218,
13229,Autocuration,,In vivo,1,,,IV clearance determined at an iv dose of 14 mg/kg,U,,,22224,0,,CHEMBL623459,BAO_0000218,
13230,Autocuration,,In vivo,1,,,IV clearance determined at an iv dose of 15.2 mg/kg,U,,,22224,0,,CHEMBL875484,BAO_0000218,
13231,Autocuration,,In vivo,1,,,IV clearance determined at an iv dose of 15 mg/kg,U,,,22224,0,,CHEMBL623460,BAO_0000218,
13232,Autocuration,,In vivo,1,,,IV clearance determined at an peroral dose of 30 mg/kg.,U,,,22224,0,,CHEMBL623461,BAO_0000218,
13233,Autocuration,,In vivo,1,,,IV clearance determined at an peroral dose of 30.2 mg/kg.,U,,,22224,0,,CHEMBL623462,BAO_0000218,
13234,Autocuration,,In vivo,1,,,IV clearance determined at an peroral dose of 30.3 mg/kg.,U,,,22224,0,,CHEMBL627386,BAO_0000218,
13235,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in kidney of male wistar rats,N,,,50597,1,,CHEMBL627387,BAO_0000218,
13236,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in liver of male wistar rats,N,,,50597,1,,CHEMBL627388,BAO_0000218,
13237,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in lung of male wistar rats,N,,,50597,1,,CHEMBL627389,BAO_0000218,
13238,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in muscle of male wistar rats,N,,,50597,1,,CHEMBL627390,BAO_0000218,
13239,Intermediate,10116.0,In vivo,1,1969.0,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in plasma of male wistar rats,N,,,50597,1,,CHEMBL627391,BAO_0000218,
13240,Intermediate,10116.0,In vivo,1,,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in red blood cells of male wistar rats,N,,,50597,1,,CHEMBL627392,BAO_0000218,
13241,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in spleen of male wistar rats,N,,,50597,1,,CHEMBL627393,BAO_0000218,
13242,Intermediate,10116.0,In vivo,1,3126.0,,Biodistribution of [11C]-CGP- 12388 (10 minutes post injection) in trachea of male wistar rats,N,,,50597,1,,CHEMBL627394,BAO_0000218,
13243,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in bone of male wistar rats,N,,,50597,1,,CHEMBL627395,BAO_0000218,
13244,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cerebellum of male wistar rats,N,,,50597,1,,CHEMBL875485,BAO_0000218,
13245,Intermediate,10116.0,In vivo,1,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in cortex of male wistar rats,N,,,50597,1,,CHEMBL627396,BAO_0000218,
13246,Intermediate,10116.0,In vivo,1,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in fat of male wistar rats,N,,,50597,1,,CHEMBL627397,BAO_0000218,
13247,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in heart of male wistar rats,N,,,50597,1,,CHEMBL627398,BAO_0000218,
13248,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in intestine bone of male wistar rats,N,,,50597,1,,CHEMBL627399,BAO_0000218,
13249,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in kidney of male wistar rats,N,,,50597,1,,CHEMBL627400,BAO_0000218,
13250,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in liver of male wistar rats,N,,,50597,1,,CHEMBL627401,BAO_0000218,
13251,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in lung of male wistar rats,N,,,50597,1,,CHEMBL627402,BAO_0000218,
13252,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in muscle of male wistar rats,N,,,50597,1,,CHEMBL627403,BAO_0000218,
13253,Intermediate,10116.0,In vivo,1,1969.0,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in plasma of male wistar rats,N,,,50597,1,,CHEMBL627404,BAO_0000218,
13254,Intermediate,10116.0,In vivo,1,,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in red blood cells of male wistar rats,N,,,50597,1,,CHEMBL623101,BAO_0000218,
13255,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in spleen of male wistar rats,N,,,50597,1,,CHEMBL877480,BAO_0000218,
13256,Intermediate,10116.0,In vivo,1,3126.0,,Biodistribution of [11C]-CGP- 12388 (60 minutes post injection) in trachea of male wistar rats,N,,,50597,1,,CHEMBL623102,BAO_0000218,
13257,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in bone of male wistar rats,N,,,50597,1,,CHEMBL623103,BAO_0000218,
13258,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cerebellum of male wistar rats,N,,,50597,1,,CHEMBL623104,BAO_0000218,
13259,Intermediate,10116.0,In vivo,1,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in cortex of male wistar rats,N,,,50597,1,,CHEMBL623105,BAO_0000218,
13260,Intermediate,10116.0,In vivo,1,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in fat of male wistar rats,N,,,50597,1,,CHEMBL623106,BAO_0000218,
13261,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in heart of male wistar rats,N,,,50597,1,,CHEMBL623107,BAO_0000218,
13262,Intermediate,10116.0,In vivo,1,160.0,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in intestine of male wistar rats,N,,,50597,1,,CHEMBL623108,BAO_0000218,
13263,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in kidney of male wistar rats,N,,,50597,1,,CHEMBL623109,BAO_0000218,
13264,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in liver of male wistar rats,N,,,50597,1,,CHEMBL623110,BAO_0000218,
13265,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in lung of male wistar rats,N,,,50597,1,,CHEMBL623111,BAO_0000218,
13266,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in muscle of male wistar rats,N,,,50597,1,,CHEMBL625060,BAO_0000218,
13267,Intermediate,10116.0,In vivo,1,1969.0,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in plasma of male wistar rats,N,,,50597,1,,CHEMBL625061,BAO_0000218,
13268,Intermediate,10116.0,In vivo,1,,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in red blood cells of male wistar rats,N,,,50597,1,,CHEMBL625062,BAO_0000218,
13269,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in spleen of male wistar rats,N,,,50597,1,,CHEMBL625063,BAO_0000218,
13270,Intermediate,10116.0,In vivo,1,3126.0,,Biodistribution of [18]Fluoro-CGP 12388 (10 minutes post injection) in trachea of male wistar rats,N,,,50597,1,,CHEMBL625064,BAO_0000218,
13271,Intermediate,10116.0,In vivo,1,10000001.0,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in bone of male wistar rats,N,,,50597,1,,CHEMBL625065,BAO_0000218,
13272,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cerebellum of male wistar rats,N,,,50597,1,,CHEMBL625066,BAO_0000218,
13273,Intermediate,10116.0,In vivo,1,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in cortex of male wistar rats,N,,,50597,1,,CHEMBL625067,BAO_0000218,
13274,Intermediate,10116.0,In vivo,1,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in fat of male wistar rats,N,,,50597,1,,CHEMBL625068,BAO_0000218,
13275,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in heart of male wistar rats,N,,,50597,1,,CHEMBL622159,BAO_0000218,
13276,Intermediate,10116.0,In vivo,1,160.0,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in intestine of male wistar rats,N,,,50597,1,,CHEMBL622160,BAO_0000218,
13277,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in kidney of male wistar rats,N,,,50597,1,,CHEMBL622161,BAO_0000218,
13278,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in lung of male wistar rats,N,,,50597,1,,CHEMBL622162,BAO_0000218,
13279,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in muscle of male wistar rats,N,,,50597,1,,CHEMBL622163,BAO_0000218,
13280,Intermediate,10116.0,In vivo,1,1969.0,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in plasma of male wistar rats,N,,,50597,1,,CHEMBL622313,BAO_0000218,
13281,Intermediate,10116.0,In vivo,1,,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in red blood cells of male wistar rats,N,,,50597,1,,CHEMBL622314,BAO_0000218,
13282,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in spleen of male wistar rats,N,,,50597,1,,CHEMBL622315,BAO_0000218,
13283,Intermediate,10116.0,In vivo,1,3126.0,,Biodistribution of [18]Fluoro-CGP 12388 (60 minutes post injection) in trachea of male wistar rats,N,,,50597,1,,CHEMBL622316,BAO_0000218,
13284,Intermediate,562.0,,1,,,Normal diffusion coefficient in water for Escherichia coli,N,,,50212,1,,CHEMBL877486,BAO_0000218,
13285,Autocuration,,,1,,,Average max percent decrease in RVR (renal vascular resistance) was determined,U,,,22224,0,,CHEMBL622317,BAO_0000019,
13286,Autocuration,,,1,,,Average max percent decrease in RVR (renal vascular resistance) was determined.,U,,,22224,0,,CHEMBL622318,BAO_0000019,
13287,Autocuration,,,1,,,In vitro stability to pepsin promoting hydrolysis after 1 hr incubation time,U,,,22224,0,,CHEMBL622319,BAO_0000019,
13288,Autocuration,,,1,,,In vitro stability to pepsin promoting hydrolysis after 2 hr incubation time,U,,,22224,0,,CHEMBL622320,BAO_0000019,
13289,Autocuration,,,1,,,In vitro stability to pepsin promoting hydrolysis after 64h incubation time,U,,,22224,0,,CHEMBL622321,BAO_0000019,
13290,Autocuration,,,1,,,In vitro stability to pepsin promoting hydrolysis after 84 hr incubation time,U,,,22224,0,,CHEMBL622322,BAO_0000019,
13291,Autocuration,,,1,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry,U,,,22224,0,,CHEMBL622323,BAO_0000019,
13292,Intermediate,10116.0,,1,,,Compound was tested for diuretic activity in sodium content of the 3-h sample was measured by flame photometry in rat,N,,,50597,1,,CHEMBL622324,BAO_0000218,
13293,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",N,,,50588,1,,CHEMBL622325,BAO_0000218,
13294,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",N,,,50588,1,,CHEMBL622326,BAO_0000218,
13295,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 10.0 mg/kg, po",N,,,50588,1,,CHEMBL877487,BAO_0000218,
13296,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",N,,,50588,1,,CHEMBL622327,BAO_0000218,
13297,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3.0 mg/kg, po",N,,,50588,1,,CHEMBL622328,BAO_0000218,
13298,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",N,,,50588,1,,CHEMBL622329,BAO_0000218,
13299,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",N,,,50588,1,,CHEMBL622330,BAO_0000218,
13300,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 0.3mg/kg, po",N,,,50588,1,,CHEMBL622331,BAO_0000218,
13301,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",N,,,50588,1,,CHEMBL622332,BAO_0000218,
13302,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded dogs at 3 mg/kg, po",N,,,50588,1,,CHEMBL622333,BAO_0000218,
13303,Autocuration,314293.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",U,,,22224,0,,CHEMBL627658,BAO_0000218,
13304,Autocuration,314293.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 10mg/kg, po",U,,,22224,0,,CHEMBL630428,BAO_0000218,
13305,Autocuration,314293.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",U,,,22224,0,,CHEMBL630429,BAO_0000218,
13306,Autocuration,314293.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 30 mg/kg, po",U,,,22224,0,,CHEMBL630430,BAO_0000218,
13307,Autocuration,314293.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded monkey at 3 mg/kg, po",U,,,22224,0,,CHEMBL630431,BAO_0000218,
13308,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",N,,,50597,1,,CHEMBL630432,BAO_0000218,
13309,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",N,,,50597,1,,CHEMBL630433,BAO_0000218,
13310,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",N,,,50597,1,,CHEMBL630434,BAO_0000218,
13311,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",N,,,50597,1,,CHEMBL629372,BAO_0000218,
13312,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 100.0mg/kg, po",N,,,50597,1,,CHEMBL629553,BAO_0000218,
13313,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",N,,,50597,1,,CHEMBL629554,BAO_0000218,
13314,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",N,,,50597,1,,CHEMBL874447,BAO_0000218,
13315,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",N,,,50597,1,,CHEMBL629555,BAO_0000218,
13316,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",N,,,50597,1,,CHEMBL629556,BAO_0000218,
13317,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 h in urine of normotensive saline loaded rats at 30.0 mg/kg, po",N,,,50597,1,,CHEMBL629557,BAO_0000218,
13318,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",N,,,50597,1,,CHEMBL629558,BAO_0000218,
13319,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",N,,,50597,1,,CHEMBL629559,BAO_0000218,
13320,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Cl- during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",N,,,50597,1,,CHEMBL629560,BAO_0000218,
13321,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.03mg/kg, po",N,,,50588,1,,CHEMBL629561,BAO_0000218,
13322,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",N,,,50588,1,,CHEMBL629562,BAO_0000218,
13323,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.3mg/kg, po",N,,,50588,1,,CHEMBL629563,BAO_0000218,
13324,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",N,,,50588,1,,CHEMBL629564,BAO_0000218,
13325,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10.0mg/kg, po",N,,,50588,1,,CHEMBL629565,BAO_0000218,
13326,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",N,,,50588,1,,CHEMBL629566,BAO_0000218,
13327,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded dogs at 1 mg/kg, po",N,,,50588,1,,CHEMBL629567,BAO_0000218,
13328,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",N,,,50588,1,,CHEMBL629568,BAO_0000218,
13329,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 30mg/kg, po",N,,,50588,1,,CHEMBL629569,BAO_0000218,
13330,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",N,,,50588,1,,CHEMBL629570,BAO_0000218,
13331,Autocuration,314293.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",U,,,22224,0,,CHEMBL629571,BAO_0000218,
13332,Autocuration,10116.0,In vivo,1,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,U,,,22224,0,,CHEMBL629572,BAO_0000218,
13333,Autocuration,10116.0,In vivo,1,,,% bioavailability in rat after oral dose (10 mg/kg) 0 - 6 h.,U,,,22224,0,,CHEMBL629573,BAO_0000218,
13334,Autocuration,9347.0,In vivo,1,,,Bioavailability (dose 20 mg/kg),U,,,22224,0,,CHEMBL629574,BAO_0000218,
13335,Autocuration,9615.0,In vivo,1,,,Bioavailability in dog,U,,,22224,0,,CHEMBL629575,BAO_0000218,
13336,Autocuration,10116.0,In vivo,1,,,Bioavailability in rat (Sprague-Dawley) (male),U,,,22224,0,,CHEMBL874448,BAO_0000218,
13337,Autocuration,9443.0,In vivo,1,,,Bioavailability in monkey (dose 10 mg/kg i.d.),U,,,22224,0,,CHEMBL629576,BAO_0000218,
13338,Autocuration,10116.0,In vivo,1,,,Bioavailability in rat,U,,,22224,0,,CHEMBL629577,BAO_0000218,
13339,Autocuration,10116.0,In vivo,1,,,Bioavailability in rat,U,,,22224,0,,CHEMBL629578,BAO_0000218,
13340,Autocuration,9615.0,In vivo,1,,,Bioavailability in dog (dose 3.0 mg/kg p.o.),U,,,22224,0,,CHEMBL629579,BAO_0000218,
13341,Autocuration,9615.0,In vivo,1,,,Bioavailability in dog (dose of 1.0 mg/kg i.v.) 0.5 hr,U,,,22224,0,,CHEMBL882958,BAO_0000218,
13342,Intermediate,9598.0,In vivo,1,,,Bioavailability was calculated after peroral dose of 10 mg/Kg in chimp,N,,,50505,1,,CHEMBL629580,BAO_0000218,
13343,Autocuration,9347.0,In vivo,1,,,Bioavailability,U,,,22224,0,,CHEMBL629581,BAO_0000218,
13344,Autocuration,9520.0,In vivo,1,,,Bioavailability in squirrel monkey,U,,,22224,0,,CHEMBL629582,BAO_0000218,
13345,Intermediate,9615.0,In vivo,1,,,Bioavailability was evaluated in dog,N,,,50588,1,,CHEMBL628522,BAO_0000218,
13346,Intermediate,10026.0,In vivo,1,,,Bioavailability was evaluated in hamster,N,,,100712,1,,CHEMBL625432,BAO_0000218,
13347,Autocuration,10116.0,In vivo,1,,,Bioavailability in rat,U,,,22224,0,,CHEMBL625433,BAO_0000218,
13348,Intermediate,10116.0,In vivo,1,1969.0,,Bioavailability was evaluated in rat plasma when administered intraperitoneally at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL625434,BAO_0000218,
13349,Intermediate,10116.0,In vivo,1,1969.0,,Bioavailability was evaluated in rat plasma when administered intravenously at a dose of 10 mg/kg; <Tr>,N,,,50597,1,,CHEMBL625435,BAO_0000218,
13350,Autocuration,10116.0,In vivo,1,,,Bioavailability in rat (dose 10 mg/kg p.o.),U,,,22224,0,,CHEMBL625436,BAO_0000218,
13351,Intermediate,9541.0,In vivo,1,,,Bioavailability was measured in cynomolgus monkeys.,N,,,100710,1,,CHEMBL874588,BAO_0000218,
13352,Intermediate,10090.0,In vivo,1,,,Bioavailability was measured in nude mice.,N,,,50594,1,,CHEMBL625437,BAO_0000218,
13353,Autocuration,9669.0,In vivo,1,,,Bioavailability in ferret (dose 10 mg/kg i.d.),U,,,22224,0,,CHEMBL625438,BAO_0000218,
13354,Autocuration,314293.0,In vivo,1,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose),U,,,22224,0,,CHEMBL625439,BAO_0000218,
13355,Autocuration,314293.0,In vivo,1,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 0.3 mg/kg intravenous dose), determined by renin inhibition assay",U,,,22224,0,,CHEMBL625440,BAO_0000218,
13356,Autocuration,314293.0,In vivo,1,,,Bioavailability was determined after intraduodenal dose of 10 mg/kg in monkey (compared to 1 mg/kg intravenous dose),U,,,22224,0,,CHEMBL625441,BAO_0000218,
13357,Autocuration,10116.0,In vivo,1,,,Bioavailability in rat (dose 10 mg/kg i.d.),U,,,22224,0,,CHEMBL625442,BAO_0000218,
13358,Intermediate,10116.0,In vivo,1,,,"Bioavailability was determined after intraduodenal dose of 10 mg/kg in rat, determined by renin inhibition assay",N,,,50597,1,,CHEMBL625443,BAO_0000218,
13359,Autocuration,,In vivo,1,,,Bioavailability was determined; extremely poor,U,,,22224,0,,CHEMBL625444,BAO_0000218,
13360,Intermediate,10090.0,In vivo,1,,,% bioavailability in mice after oral administration of prodrug,N,,,50594,1,,CHEMBL625445,BAO_0000218,
13361,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose 10/30 range (low/high); -21/-5,N,,,50588,1,,CHEMBL625446,BAO_0000218,
13362,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -2/6,N,,,50588,1,,CHEMBL882960,BAO_0000218,
13363,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -4/-14,N,,,50588,1,,CHEMBL625447,BAO_0000218,
13364,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3 range (low/high); -5/-12,N,,,50588,1,,CHEMBL625448,BAO_0000218,
13365,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 1/3/10 range (low/high); -1/-7/-11,N,,,50588,1,,CHEMBL625449,BAO_0000218,
13366,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high),N,,,50588,1,,CHEMBL874589,BAO_0000218,
13367,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -1/-9,N,,,50588,1,,CHEMBL625450,BAO_0000218,
13368,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -11/-28,N,,,50588,1,,CHEMBL625451,BAO_0000218,
13369,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/-29,N,,,50588,1,,CHEMBL626584,BAO_0000218,
13370,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -13/30,N,,,50588,1,,CHEMBL626585,BAO_0000218,
13371,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-18,N,,,50588,1,,CHEMBL626586,BAO_0000218,
13372,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -16/-35,N,,,50588,1,,CHEMBL626587,BAO_0000218,
13373,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -19/-50,N,,,50588,1,,CHEMBL626588,BAO_0000218,
13374,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -21/-29,N,,,50588,1,,CHEMBL626589,BAO_0000218,
13375,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -24/-56,N,,,50588,1,,CHEMBL626590,BAO_0000218,
13376,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -25/-33,N,,,50588,1,,CHEMBL626591,BAO_0000218,
13377,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -3/-13,N,,,50588,1,,CHEMBL627181,BAO_0000218,
13378,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -5/-47,N,,,50588,1,,CHEMBL628083,BAO_0000218,
13379,Autocuration,,In vivo,1,,,IV clearance determined at an peroral dose of 15 mg/kg.,U,,,22224,0,,CHEMBL628084,BAO_0000218,
13380,Expert,102285.0,In vivo,1,,,Mouse oral clearance was measured against Hymenolepiasis nana.,N,,,50064,1,,CHEMBL628085,BAO_0000218,
13381,Expert,6339.0,In vivo,1,,,Mouse oral clearance was measured against Nematospiroides dubius,N,,,50545,1,,CHEMBL628086,BAO_0000218,
13382,Autocuration,,In vivo,1,,,Mouse oral clearance was measured against N. dubius; NT is Not Tested,U,,,22224,0,,CHEMBL628087,BAO_0000218,
13383,Intermediate,10090.0,In vivo,1,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,N,,,50594,1,,CHEMBL628088,BAO_0000218,
13384,Autocuration,,In vivo,1,,,Mouse oral clearance was measured against N. nana; NT is Not Tested,U,,,22224,0,,CHEMBL628089,BAO_0000218,
13385,Autocuration,,In vivo,1,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 10 J/cm e2 ultraviolet-A radiation,U,,,22224,0,,CHEMBL628090,BAO_0000218,
13386,Autocuration,,In vivo,1,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 6 J/cm e2 ultraviolet-A radiation,U,,,22224,0,,CHEMBL628091,BAO_0000218,
13387,Autocuration,,In vivo,1,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 8 J/cm e2 ultraviolet-A radiation,U,,,22224,0,,CHEMBL628092,BAO_0000218,
13388,Autocuration,,In vivo,1,,,Percentage of clearance of psoriatic lesions by 8-methoxypsoralen (8-MOP) for comparison at dose of 9 J/cm e2 ultraviolet-A radiation,U,,,22224,0,,CHEMBL628093,BAO_0000218,
13389,Autocuration,,In vivo,1,,,Percentage of clearance of psoriatic lesions by the compound at dose of 10 J/cm e2 ultraviolet-A radiation,U,,,22224,0,,CHEMBL875607,BAO_0000218,
13390,Autocuration,,In vivo,1,,,Percentage of clearance of psoriatic lesions by the compound at dose of 4 J/cm e2 ultraviolet-A radiation,U,,,22224,0,,CHEMBL625710,BAO_0000218,
13391,Autocuration,,In vivo,1,,,Percentage of clearance of psoriatic lesions by the compound at dose of 6 J/cm e2 ultraviolet-A radiation,U,,,22224,0,,CHEMBL625711,BAO_0000218,
13392,Autocuration,,In vivo,1,,,Percentage of clearance of psoriatic lesions by the compound at dose of 8 J/cm e2 ultraviolet-A radiation,U,,,22224,0,,CHEMBL625712,BAO_0000218,
13393,Autocuration,,In vivo,1,,,Percentage of clearance of psoriatic lesions by the compound at dose of 9 J/cm e2 ultraviolet-A radiation,U,,,22224,0,,CHEMBL625713,BAO_0000218,
13394,Intermediate,9615.0,In vivo,1,,,Pharmacokinetic parameter clearance was determined in fed Beagle dogs after iv administration of 1.5 mg/kg,N,,,50588,1,,CHEMBL625714,BAO_0000218,
13395,Intermediate,9544.0,In vivo,1,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in Rhesus monkey,N,,,50797,1,,CHEMBL625715,BAO_0000218,
13396,Intermediate,10116.0,In vivo,1,,,Plasma clearance after intravenous administration dosing (30 mg/kg) in rat,N,,,50597,1,,CHEMBL625716,BAO_0000218,
13397,Intermediate,10116.0,In vivo,1,,,Plasma clearance after intravenous administration iv dosing of 3 mg/kg in rat,N,,,50597,1,,CHEMBL625717,BAO_0000218,
13398,Intermediate,10116.0,In vivo,1,,,Plasma clearance was determined for the compound in rats,N,,,50597,1,,CHEMBL625718,BAO_0000218,
13399,Intermediate,10116.0,In vivo,1,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 1,N,,,50597,1,,CHEMBL625719,BAO_0000218,
13400,Intermediate,10116.0,In vivo,1,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 2,N,,,50597,1,,CHEMBL625720,BAO_0000218,
13401,Intermediate,10116.0,In vivo,1,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 3,N,,,50597,1,,CHEMBL625721,BAO_0000218,
13402,Intermediate,10116.0,In vivo,1,,,Tested for total body clearance (CL) after intravenous bolus administration of 100 mg/kg in rat 4,N,,,50597,1,,CHEMBL625722,BAO_0000218,
13403,Intermediate,10116.0,In vivo,1,,,The compound was tested for systemic clearance pharmacokinetic parameter in the male Sprague-Dawley rat.,N,,,50597,1,,CHEMBL625723,BAO_0000218,
13404,Intermediate,6339.0,In vivo,1,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.0125 concentration of diet.,N,,,50545,1,,CHEMBL625724,BAO_0000218,
13405,Intermediate,6339.0,In vivo,1,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.025 concentration of diet.,N,,,50545,1,,CHEMBL625725,BAO_0000218,
13406,Intermediate,6339.0,In vivo,1,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.05 concentration of diet.,N,,,50545,1,,CHEMBL625726,BAO_0000218,
13407,Intermediate,6339.0,In vivo,1,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.1 concentration of diet.,N,,,50545,1,,CHEMBL875608,BAO_0000218,
13408,Intermediate,6339.0,In vivo,1,,,Titration of anthelmintic activity against Nematospiroides dubius in mice at 0.2 concentration of diet.,N,,,50545,1,,CHEMBL625727,BAO_0000218,
13409,Autocuration,10116.0,In vivo,1,1088.0,,Urinary clearance was determined in rat at 100 mg/kg os dosage;ND is defined as no-data.,U,,,22224,0,,CHEMBL625728,BAO_0000218,
13410,Autocuration,10116.0,In vivo,1,,,Total clearance was determined in rat at 10 mg/kg intraperitoneal dosage,U,,,22224,0,,CHEMBL625729,BAO_0000218,
13411,Autocuration,10116.0,In vivo,1,,,Total clearance was determined in rat at 25 mg/kg os dosage;ND is defined as no-data.,U,,,22224,0,,CHEMBL625730,BAO_0000218,
13412,Autocuration,10116.0,In vivo,1,1088.0,,Urinary clearance was determined in rat at 10 mg/kg intraperitoneal dosage,U,,,22224,0,,CHEMBL625731,BAO_0000218,
13413,Autocuration,10116.0,In vivo,1,1088.0,,Urinary clearance was determined in rat at 25 mg/kg os dosage,U,,,22224,0,,CHEMBL626417,BAO_0000218,
13414,Intermediate,9606.0,In vivo,1,1088.0,,Urinary clearance was determined at 100 mg/kg oral dosage in human,N,,,50587,1,,CHEMBL626418,BAO_0000218,
13415,Intermediate,9615.0,In vivo,1,1088.0,,Urinary clearance was determined at 20 mg/kg oral dosage in dog(beagle);ND is defined as no-data.,N,,,50588,1,,CHEMBL626419,BAO_0000218,
13416,Intermediate,9615.0,In vivo,1,1969.0,,Plasma concentration in dogs after 2 hr at 30mg/kg oral dose,N,,,50588,1,,CHEMBL626592,BAO_0000218,
13417,Intermediate,10116.0,In vivo,1,1969.0,,Plasma concentration in rats after 7 hr at 30mg/kg oral dose,N,,,50597,1,,CHEMBL626593,BAO_0000218,
13418,Intermediate,10116.0,In vivo,1,,,Clearance was determined by administering the compound intravenously at a dose of 1 mg/kg in male wistar rat,N,,,50597,1,,CHEMBL626594,BAO_0000218,
13419,Intermediate,9615.0,In vivo,1,,,Clearance rate in dogs,N,,,50588,1,,CHEMBL625035,BAO_0000218,
13420,Autocuration,,In vitro,1,,,Compound was measured for intrinsic clearance,U,,,22224,0,,CHEMBL625036,BAO_0000019,
13421,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625037,BAO_0000100,
13422,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625038,BAO_0000100,
13423,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625039,BAO_0000100,
13424,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625040,BAO_0000100,
13425,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625041,BAO_0000100,
13426,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625042,BAO_0000100,
13427,Autocuration,,,1,,,Partition coefficient of the compound,U,,,22224,0,,CHEMBL874411,BAO_0000019,
13428,Autocuration,,,1,,,Permeability,U,,,22224,0,,CHEMBL625043,BAO_0000019,
13429,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625044,BAO_0000100,
13430,Autocuration,,,1,,,Partition coefficient (logD),U,,,22224,0,,CHEMBL625045,BAO_0000019,
13431,Autocuration,,,1,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),U,,,22229,0,,CHEMBL625046,BAO_0000100,
13432,Autocuration,,,1,,,Calculated partition coefficient (clogP) (CLOGP3 V3.4),U,,,22229,0,,CHEMBL625047,BAO_0000100,
13433,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625048,BAO_0000100,
13434,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625049,BAO_0000100,
13435,Autocuration,,,1,,,Calculated logarithm of partition coefficient (P) was determined,U,,,22229,0,,CHEMBL625050,BAO_0000100,
13436,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625051,BAO_0000100,
13437,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL874412,BAO_0000100,
13438,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625052,BAO_0000100,
13439,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL625053,BAO_0000100,
13440,Autocuration,,,1,,,In vitro stability to pepsin promoting hydrolysis after 8 hr incubation time,U,,,22224,0,,CHEMBL623250,BAO_0000019,
13441,Autocuration,,,1,,,In vitro stability to trypsin promoting hydrolysis after 1 hr incubation time,U,,,22224,0,,CHEMBL623251,BAO_0000019,
13442,Autocuration,,,1,,,In vitro stability to trypsin promoting hydrolysis after 2 hr incubation time,U,,,22224,0,,CHEMBL623252,BAO_0000019,
13443,Autocuration,,,1,,,In vitro stability to trypsin promoting hydrolysis after 64h incubation time,U,,,22224,0,,CHEMBL623253,BAO_0000019,
13444,Autocuration,,,1,,,In vitro stability to trypsin promoting hydrolysis after 84 hr incubation time,U,,,22224,0,,CHEMBL623254,BAO_0000019,
13445,Autocuration,,,1,,,In vitro stability to trypsin promoting hydrolysis after 8 hr incubation time,U,,,22224,0,,CHEMBL623255,BAO_0000019,
13446,Autocuration,,,1,,,Percent degradation of compound at a pH of 1 over a 18 hr period,U,,,22224,0,,CHEMBL626831,BAO_0000019,
13447,Autocuration,,,1,,,Percent degradation of compound at pH of 1 over an 18 hr period,U,,,22224,0,,CHEMBL877494,BAO_0000019,
13448,Autocuration,,,1,,,Delta Logarithm of Partition Coefficient value was determined.,U,,,22224,0,,CHEMBL626832,BAO_0000019,
13449,Autocuration,,,1,,,Delta logPoct-cyc,U,,,22224,0,,CHEMBL626833,BAO_0000019,
13450,Autocuration,,,1,,,Lipophilicity estimated on reversed phase TLC,U,,,22224,0,,CHEMBL626834,BAO_0000100,
13451,Autocuration,,,1,,,Delta Tm value ( Tmdrug-DNA )-TmDNA ) was obtained for the covalently cross-linked compound in the absence of formaldehyde using calf thymus DNA.,U,,,22224,0,,CHEMBL626835,BAO_0000019,
13452,Autocuration,,,1,,,Delta logPoct-cyc,U,,,22224,0,,CHEMBL626836,BAO_0000019,
13453,Autocuration,,,1,,,Change in logarithm of partition coefficient of the compound,U,,,22229,0,,CHEMBL626837,BAO_0000100,
13454,Autocuration,,,1,,,Delta logD (pH 6.5),U,,,22224,0,,CHEMBL626838,BAO_0000019,
13455,Autocuration,,,1,,,"Partition coefficient by standard shake-flask techniquesat 37 C, using octanol and cyclohexane",U,,,22224,0,,CHEMBL626839,BAO_0000100,
13456,Autocuration,,,1,,,Oxygen pressure at which hemoglobin is 50% oxygenated; negative sign indicates that P50 of modified Hb is lower than that of unmodified Hb,U,,,22224,0,,CHEMBL626840,BAO_0000019,
13457,Autocuration,,,1,,,Deoxyribose-damaging property as a measure of hydroxyl-radical formation (uM of malondialdehyde/mmol of deoxyribose released by 75 uM test compound),U,,,22224,0,,CHEMBL626841,BAO_0000019,
13458,Autocuration,,,1,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in nine cells,U,,,22224,0,,CHEMBL626842,BAO_0000219,
13459,Autocuration,,,1,,,Peak depolarizations produced by injections of 100 micro M Ins p3 isomers in six cells,U,,,22224,0,,CHEMBL626843,BAO_0000219,
13460,Intermediate,10116.0,,1,,,Amount of deuterium retained was reported after normal workup in beta-naphthoflavone-treated male rats with the substrate rac 7-D,N,,,50597,1,,CHEMBL626844,BAO_0000218,
13461,Intermediate,10116.0,,1,,,Amount of deuterium retained was reported after normal workup in rats,N,,,50597,1,,CHEMBL877495,BAO_0000218,
13462,Intermediate,10116.0,,1,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats,N,,,50597,1,,CHEMBL626845,BAO_0000218,
13463,Intermediate,10116.0,,1,,,Amount of deuterium retained was reported after reincubation followed by normal workup in phenobarbital treated male rats with rac 8-D,N,,,50597,1,,CHEMBL626846,BAO_0000218,
13464,Intermediate,10116.0,,1,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,N,,,50597,1,,CHEMBL626847,BAO_0000218,
13465,Intermediate,10116.0,,1,,,Compound incubated with microsomal preparations from beta-naphthoflavone-treated male rats with the substrate rac 7-D and the amount of deuterium retained was reported after reincubation followed by normal workup,N,,,50597,1,,CHEMBL628677,BAO_0000218,
13466,Intermediate,10116.0,,1,,,Compound incubated with microsomal preparations from phenobarbital treated male rats with the substrate rac 8-D and the amount of deuterium retained was reported after normal workup,N,,,50597,1,,CHEMBL628678,BAO_0000218,
13467,Autocuration,,,1,,,Compound was subjected to electrochemical oxidation,U,,,22224,0,,CHEMBL628679,BAO_0000019,
13468,Autocuration,,,1,,,Compound was subjected to photochemical oxidation,U,,,22224,0,,CHEMBL628680,BAO_0000019,
13469,Autocuration,,,1,,,Oxidation of compound by Chloroperoxidase in presence of ethylperoxide,U,,,22224,0,,CHEMBL628681,BAO_0000019,
13470,Autocuration,,,1,,,Oxidation of compound by horseradish peroxidase in presence of hydroperoxide,U,,,22224,0,,CHEMBL628682,BAO_0000019,
13471,Autocuration,,,1,,,Oxidation of compound by methemoglobin in presence of hydroperoxide,U,,,22224,0,,CHEMBL628683,BAO_0000019,
13472,Intermediate,10116.0,,1,,,Percent diffusion through fuzzy rat skin after 48 h of incubation,N,,,50597,1,,CHEMBL628684,BAO_0000218,
13473,Autocuration,,,1,,,Dissociation constant (pKa),U,,,22229,0,,CHEMBL877501,BAO_0000100,
13474,Autocuration,,,1,,,Dissociation constant value of the compound; ND means not determined.,U,,,22224,0,,CHEMBL628685,BAO_0000100,
13475,Intermediate,10116.0,,1,178.0,,% distribution of the radioiron in blood of rat followed by intravenous injection of chelating agent,N,,,50597,1,,CHEMBL628686,BAO_0000218,
13476,Intermediate,10116.0,,1,178.0,,% distribution of the radioiron in blood of rats followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,N,,,50597,1,,CHEMBL628687,BAO_0000218,
13477,Intermediate,10116.0,,1,,,% distribution of the radioiron in rat kidney followed by intravenous injection of chelating agent,N,,,50597,1,,CHEMBL628688,BAO_0000218,
13478,Intermediate,10116.0,,1,,,% distribution of the radioiron in rat kidney followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,N,,,50597,1,,CHEMBL628689,BAO_0000218,
13479,Intermediate,10116.0,,1,2107.0,,% distribution of the radioiron in rat liver followed by intravenous injection of chelating agent,N,,,50597,1,,CHEMBL628690,BAO_0000218,
13480,Intermediate,10116.0,,1,2107.0,,% distribution of the radioiron in rat liver followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,N,,,50597,1,,CHEMBL629363,BAO_0000218,
13481,Intermediate,10116.0,,1,2106.0,,% distribution of the radioiron in rat spleen followed by intravenous injection of chelating agent,N,,,50597,1,,CHEMBL629364,BAO_0000218,
13482,Intermediate,10116.0,,1,2106.0,,% distribution of the radioiron in rat spleen followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,N,,,50597,1,,CHEMBL629365,BAO_0000218,
13483,Intermediate,10116.0,,1,,,% excretion of ferritin determined in faces of rat followed by intravenous injection of chelating agent,N,,,50597,1,,CHEMBL629366,BAO_0000218,
13484,Intermediate,10116.0,,1,1088.0,,% excretion of ferritin determined in urine of rat followed by intravenous injection of chelating agent,N,,,50597,1,,CHEMBL629367,BAO_0000218,
13485,Intermediate,10116.0,,1,1988.0,,% excretion of radioiron determined in feces of rat followed by intravenous injection of transferrin pre-incubated with 10 mg of chelating agent,N,,,50597,1,,CHEMBL629368,BAO_0000218,
13486,Intermediate,10116.0,,1,1088.0,,% excretion of radioiron determined in urine of rat followed by intravenous injection of transferrin preincubated with 10 mg of chelating agent,N,,,50597,1,,CHEMBL877502,BAO_0000218,
13487,Intermediate,10090.0,,1,2037.0,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cerebellum,N,,,50594,1,,CHEMBL629369,BAO_0000218,
13488,Intermediate,10090.0,,1,955.0,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into cortex,N,,,50594,1,,CHEMBL629370,BAO_0000218,
13489,Autocuration,314293.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded monkey at 10 mg/kg, po",U,,,22224,0,,CHEMBL629371,BAO_0000218,
13490,Autocuration,314293.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",U,,,22224,0,,CHEMBL626276,BAO_0000218,
13491,Autocuration,314293.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",U,,,22224,0,,CHEMBL626277,BAO_0000218,
13492,Autocuration,314293.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",U,,,22224,0,,CHEMBL631250,BAO_0000218,
13493,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",N,,,50597,1,,CHEMBL631251,BAO_0000218,
13494,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 0.3mg/kg, po",N,,,50597,1,,CHEMBL631252,BAO_0000218,
13495,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 1.0 mg/kg, po",N,,,50597,1,,CHEMBL631253,BAO_0000218,
13496,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 10.0mg/kg, po",N,,,50597,1,,CHEMBL631254,BAO_0000218,
13497,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",N,,,50597,1,,CHEMBL631255,BAO_0000218,
13498,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 2.1 mg/kg, po",N,,,50597,1,,CHEMBL631256,BAO_0000218,
13499,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 20.8mg/kg, po",N,,,50597,1,,CHEMBL631257,BAO_0000218,
13500,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 207.6 mg/kg, po",N,,,50597,1,,CHEMBL628009,BAO_0000218,
13501,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 3.0mg/kg, po",N,,,50597,1,,CHEMBL628010,BAO_0000218,
13502,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",N,,,50597,1,,CHEMBL628011,BAO_0000218,
13503,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 h in urine of normotensive saline loaded rats at 6.9 mg/kg, po",N,,,50597,1,,CHEMBL628012,BAO_0000218,
13504,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 69.2mg/kg, po",N,,,50597,1,,CHEMBL628013,BAO_0000218,
13505,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of K+ during 0-6 hr in urine of normotensive saline loaded rats at 691.9mg/kg, po",N,,,50597,1,,CHEMBL628014,BAO_0000218,
13506,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.03 mg/kg, po",N,,,50588,1,,CHEMBL628015,BAO_0000218,
13507,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 0.1 mg/kg, po",N,,,50588,1,,CHEMBL628016,BAO_0000218,
13508,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 0.3 mg/kg, po",N,,,50588,1,,CHEMBL874461,BAO_0000218,
13509,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 1.0 mg/kg, po",N,,,50588,1,,CHEMBL628017,BAO_0000218,
13510,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 10.0mg/kg, po",N,,,50588,1,,CHEMBL628018,BAO_0000218,
13511,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 10mg/kg, po",N,,,50588,1,,CHEMBL628019,BAO_0000218,
13512,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 1 mg/kg, po",N,,,50588,1,,CHEMBL628020,BAO_0000218,
13513,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded dogs at 30 mg/kg, po",N,,,50588,1,,CHEMBL628021,BAO_0000218,
13514,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3mg/kg, po",N,,,50588,1,,CHEMBL628022,BAO_0000218,
13515,Intermediate,9615.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded dogs at 3.0mg/kg, po",N,,,50588,1,,CHEMBL628023,BAO_0000218,
13516,Autocuration,314293.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 100 mg/kg, po",U,,,22224,0,,CHEMBL628024,BAO_0000218,
13517,Autocuration,314293.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 10mg/kg, po",U,,,22224,0,,CHEMBL628025,BAO_0000218,
13518,Autocuration,314293.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 1 mg/kg, po",U,,,22224,0,,CHEMBL628026,BAO_0000218,
13519,Autocuration,314293.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 30mg/kg, po",U,,,22224,0,,CHEMBL628027,BAO_0000218,
13520,Autocuration,314293.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded monkey at 3mg/kg, po",U,,,22224,0,,CHEMBL628028,BAO_0000218,
13521,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 0.1 mg/kg, po",N,,,50597,1,,CHEMBL628029,BAO_0000218,
13522,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 0.3 mg/kg, po",N,,,50597,1,,CHEMBL628030,BAO_0000218,
13523,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 1.0mg/kg, po",N,,,50597,1,,CHEMBL628031,BAO_0000218,
13524,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 10.0 mg/kg, po",N,,,50597,1,,CHEMBL628032,BAO_0000218,
13525,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 100.0 mg/kg, po",N,,,50597,1,,CHEMBL628033,BAO_0000218,
13526,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 2.08 mg/kg, po",N,,,50597,1,,CHEMBL628034,BAO_0000218,
13527,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 207.6mg/kg, po",N,,,50597,1,,CHEMBL628035,BAO_0000218,
13528,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 3.0 mg/kg, po",N,,,50597,1,,CHEMBL628036,BAO_0000218,
13529,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 30.0mg/kg, po",N,,,50597,1,,CHEMBL874462,BAO_0000218,
13530,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -8/-38,N,,,50588,1,,CHEMBL628037,BAO_0000218,
13531,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 13/-25,N,,,50588,1,,CHEMBL628123,BAO_0000218,
13532,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); 27/-15,N,,,50588,1,,CHEMBL628124,BAO_0000218,
13533,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/30 range (low/high); -2/-19,N,,,50588,1,,CHEMBL628125,BAO_0000218,
13534,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 10/60 range (low/high); -3/-4,N,,,50588,1,,CHEMBL628126,BAO_0000218,
13535,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3 range (low/high),N,,,50588,1,,CHEMBL628127,BAO_0000218,
13536,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); -9/24,N,,,50588,1,,CHEMBL628128,BAO_0000218,
13537,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as heart rate (HR) at a dose of 3/10 range (low/high); 3/-1,N,,,50588,1,,CHEMBL628129,BAO_0000218,
13538,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/030 range (low/high); 12/23,N,,,50588,1,,CHEMBL628130,BAO_0000218,
13539,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 1/3,N,,,50588,1,,CHEMBL628131,BAO_0000218,
13540,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 6/16,N,,,50588,1,,CHEMBL628132,BAO_0000218,
13541,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3 range (low/high); 7/14,N,,,50588,1,,CHEMBL628133,BAO_0000218,
13542,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 1/3/10 range (low/high); 4/4/23,N,,,50588,1,,CHEMBL628134,BAO_0000218,
13543,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 10/14,N,,,50588,1,,CHEMBL628135,BAO_0000218,
13544,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/15,N,,,50588,1,,CHEMBL628136,BAO_0000218,
13545,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 11/44,N,,,50588,1,,CHEMBL628137,BAO_0000218,
13546,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 14/28,N,,,50588,1,,CHEMBL628138,BAO_0000218,
13547,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 15-28,N,,,50588,1,,CHEMBL628139,BAO_0000218,
13548,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 2/3,N,,,50588,1,,CHEMBL628140,BAO_0000218,
13549,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 26/32,N,,,50588,1,,CHEMBL628141,BAO_0000218,
13550,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/1,N,,,50588,1,,CHEMBL628142,BAO_0000218,
13551,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 5/12,N,,,50588,1,,CHEMBL628143,BAO_0000218,
13552,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 6/7,N,,,50588,1,,CHEMBL628144,BAO_0000218,
13553,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 7/6,N,,,50588,1,,CHEMBL628145,BAO_0000218,
13554,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/12,N,,,50588,1,,CHEMBL628146,BAO_0000218,
13555,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 8/27,N,,,50588,1,,CHEMBL625355,BAO_0000218,
13556,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/14,N,,,50588,1,,CHEMBL625356,BAO_0000218,
13557,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/30 range (low/high); 9/16,N,,,50588,1,,CHEMBL625357,BAO_0000218,
13558,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 10/60 range (low/high); 12/23,N,,,50588,1,,CHEMBL625527,BAO_0000218,
13559,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3 range (low/high),N,,,50588,1,,CHEMBL875473,BAO_0000218,
13560,Intermediate,9615.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 10/22,N,,,50588,1,,CHEMBL625528,BAO_0000218,
13561,Intermediate,10116.0,In vivo,1,,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as left ventricular functional refractory period (LV-FRP) at a dose of 3/10 range (low/high); 4/12,N,,,50597,1,,CHEMBL626304,BAO_0000218,
13562,Intermediate,9615.0,In vivo,1,1637.0,,Compound was evaluated for intraduodenal bioavailability in anesthetized dogs measured as mean blood pressure at a 10/30 dose range; 11/-11,N,,,50588,1,,CHEMBL624138,BAO_0000218,
13563,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL624139,BAO_0000100,
13564,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL624140,BAO_0000100,
13565,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL624141,BAO_0000100,
13566,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL624142,BAO_0000100,
13567,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL624143,BAO_0000100,
13568,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL624144,BAO_0000100,
13569,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL624145,BAO_0000100,
13570,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL624146,BAO_0000100,
13571,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL624147,BAO_0000100,
13572,Autocuration,,,1,,,Calculated partition coefficient (clogP) (MacLogP),U,,,22229,0,,CHEMBL883123,BAO_0000100,
13573,Autocuration,,,1,,,Partition coefficient (logP),U,,,22224,0,,CHEMBL624148,BAO_0000019,
13574,Autocuration,,,1,,,Kinetic parameter was determined,U,,,22224,0,,CHEMBL874416,BAO_0000019,
13575,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL624149,BAO_0000100,
13576,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL624150,BAO_0000100,
13577,Autocuration,,,1,,,Lipophilicity was determined,U,,,22224,0,,CHEMBL624151,BAO_0000100,
13578,Autocuration,,,1,,,Lipophilicity was determined,U,,,22224,0,,CHEMBL624152,BAO_0000100,
13579,Autocuration,,,1,,,Lipophilicity was determined,U,,,22224,0,,CHEMBL622139,BAO_0000100,
13580,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL622140,BAO_0000100,
13581,Autocuration,,,1,,,Lipophilicity was determined,U,,,22224,0,,CHEMBL622141,BAO_0000100,
13582,Autocuration,,,1,,,Lipophilicity in octanol-water,U,,,22224,0,,CHEMBL622142,BAO_0000100,
13583,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL622143,BAO_0000100,
13584,Autocuration,,,1,,,Octanol-water partition coefficient was determined,U,,,22229,0,,CHEMBL622144,BAO_0000100,
13585,Autocuration,,,1,,,Partition coefficient (logP),U,,,22224,0,,CHEMBL877473,BAO_0000019,
13586,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL622145,BAO_0000100,
13587,Autocuration,,,1,,,Partition coefficient was determined; ND means not determined,U,,,22224,0,,CHEMBL622146,BAO_0000019,
13588,Autocuration,,,1,,,Calculated partition coefficient (clogP),U,,,22229,0,,CHEMBL622147,BAO_0000100,
13589,Autocuration,,,1,,,Partition coefficient of the compound,U,,,22224,0,,CHEMBL622148,BAO_0000019,
13590,Autocuration,,,1,,,Permeability was determined,U,,,22224,0,,CHEMBL883124,BAO_0000019,
13591,Autocuration,,,1,,,The compound was evaluated for the partition coefficient,U,,,22229,0,,CHEMBL622149,BAO_0000100,
13592,Autocuration,,,1,,,Partition coefficient (logP),U,,,22224,0,,CHEMBL622150,BAO_0000019,
13593,Autocuration,,,1,,,The lipophilicity was reported,U,,,22224,0,,CHEMBL622151,BAO_0000100,
13594,Autocuration,,,1,,,logarithm of the octanol-water partition coefficient for the compound,U,,,22229,0,,CHEMBL622152,BAO_0000100,
13595,Autocuration,,,1,,,Clogp value was determined,U,,,22224,0,,CHEMBL622153,BAO_0000019,
13596,Autocuration,,In vivo,1,,,Clp at a dose of 1.5 mg/kg,U,,,22224,0,,CHEMBL877474,BAO_0000218,
13597,Autocuration,,In vivo,1,,,Clp at a dose of 2.0 mg/kg,U,,,22224,0,,CHEMBL622154,BAO_0000218,
13598,Autocuration,,In vivo,1,1969.0,,"Clp, plasma clearance at a dose of 10 mg/kg",U,,,22224,0,,CHEMBL622155,BAO_0000218,
13599,Autocuration,,In vivo,1,1969.0,,"Clp, plasma clearance at a dose of 50 mg/kg",U,,,22224,0,,CHEMBL622156,BAO_0000218,
13600,Intermediate,10116.0,In vivo,1,1969.0,,Compound was tested for plasma clearance in rat,N,,,50597,1,,CHEMBL622157,BAO_0000218,
13601,Intermediate,10116.0,In vivo,1,1969.0,,Compound was tested for plasma clearance in rat; Not determined,N,,,50597,1,,CHEMBL622158,BAO_0000218,
13602,Intermediate,10116.0,In vivo,1,,,Plasma clearance (pharmacokinetic parameter) in rat (in vivo) at a dose of 10 mg/kg,N,,,50597,1,,CHEMBL622807,BAO_0000218,
13603,Intermediate,9544.0,In vivo,1,,,Plasma clearance (pharmacokinetic parameter) in rhesus (in vivo) at a dose of 5 mg/kg,N,,,50797,1,,CHEMBL622808,BAO_0000218,
13604,Autocuration,,In vivo,1,,,Plasma clearance by iv administration at a dose 0.003 ug/mL,U,,,22224,0,,CHEMBL622809,BAO_0000218,
13605,Autocuration,,In vivo,1,,,Plasma clearance determined,U,,,22224,0,,CHEMBL622810,BAO_0000218,
13606,Intermediate,10026.0,In vivo,1,,,Plasma clearance after iv administration at 3 mg/kg in hamster,N,,,100712,1,,CHEMBL876653,BAO_0000218,
13607,Intermediate,10026.0,In vivo,1,,,Plasma clearance after iv administration at 4 mg/kg in hamster,N,,,100712,1,,CHEMBL622811,BAO_0000218,
13608,Intermediate,10116.0,In vivo,1,,,Rate of clearance in rat was determined,N,,,50597,1,,CHEMBL622986,BAO_0000218,
13609,Intermediate,10116.0,In vivo,1,1969.0,,Total plasma clearance Clp was determined for the compound after iv dose of 5.06 mg/kg in rats,N,,,50597,1,,CHEMBL622987,BAO_0000218,
13610,Intermediate,10116.0,In vivo,1,1969.0,,Total plasma clearance after iv dose of 5.10 mg/kg in rats,N,,,50597,1,,CHEMBL622988,BAO_0000218,
13611,Intermediate,10116.0,In vivo,1,1969.0,,Total plasma clearance was determined for the compound after iv dose of 4.74 mg/kg in rats,N,,,50597,1,,CHEMBL622989,BAO_0000218,
13612,Intermediate,10116.0,In vivo,1,1969.0,,Total plasma clearance was determined for the compound after iv dose of 4.97 mg/kg in rats,N,,,50597,1,,CHEMBL622990,BAO_0000218,
13613,Autocuration,314293.0,In vivo,1,1969.0,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.01 mg/kg) in monkey,U,,,22224,0,,CHEMBL622991,BAO_0000218,
13614,Intermediate,10116.0,In vivo,1,1969.0,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.05 mg/kg) in rat,N,,,50597,1,,CHEMBL622227,BAO_0000218,
13615,Intermediate,9615.0,In vivo,1,1969.0,,plasma clearance in preclinical species was measured after Intravenous administration at the given dose (0.1 mg/kg) in dog,N,,,50588,1,,CHEMBL622228,BAO_0000218,
13616,Intermediate,10116.0,In vivo,1,,,Clpl value in rat,N,,,50597,1,,CHEMBL622229,BAO_0000218,
13617,Intermediate,10141.0,In vivo,1,,,Cmax (ng /mL) value after oral administration of 10 mg/kg in guinea pig.,N,,,50512,1,,CHEMBL622230,BAO_0000218,
13618,Intermediate,10116.0,In vivo,1,,,Cmax after an oral dose of 10 uM/Kg in male Sprague-Dawley rats,N,,,50597,1,,CHEMBL622231,BAO_0000218,
13619,Intermediate,9541.0,In vivo,1,,,Cmax after an oral dose of 10 uM/Kg in male cynomolgus monkeys,N,,,100710,1,,CHEMBL622232,BAO_0000218,
13620,Autocuration,,In vivo,1,,,Cmax in minutes at a iv dose of 1.0(pmol/g/h).,U,,,22224,0,,CHEMBL622233,BAO_0000218,
13621,Autocuration,,In vivo,1,,,Cmax in minutes at a iv dose of 2.0(pmol/g/h).,U,,,22224,0,,CHEMBL622234,BAO_0000218,
13622,Autocuration,,In vivo,1,,,Cmax in minutes at a iv dose of 4.0(pmol/g/h).,U,,,22224,0,,CHEMBL622235,BAO_0000218,
13623,Autocuration,,In vivo,1,,,Cmax in minutes at a iv dose of 5.0(pmol/g/h).,U,,,22224,0,,CHEMBL622236,BAO_0000218,
13624,Autocuration,,In vivo,1,,,Cmax in minutes at a iv dose of 54.0(pmol/g/h).,U,,,22224,0,,CHEMBL622237,BAO_0000218,
13625,Autocuration,,In vivo,1,,,Cmax in minutes at a po dose of 10.0(pmol/g/h).,U,,,22224,0,,CHEMBL877482,BAO_0000218,
13626,Autocuration,,In vivo,1,,,Cmax in minutes at a po dose of 20.0(pmol/g/h).,U,,,22224,0,,CHEMBL622238,BAO_0000218,
13627,Autocuration,,In vivo,1,,,Cmax in minutes at a po dose of 40.0(pmol/g/h).,U,,,22224,0,,CHEMBL622239,BAO_0000218,
13628,Autocuration,,In vivo,1,178.0,,Cmax was calculated as maximum concentration reached in the blood,U,,,22224,0,,CHEMBL622240,BAO_0000218,
13629,Autocuration,,In vivo,1,178.0,,Cmax was calculated as maximum concentration reached in the blood in air pouch exudate,U,,,22224,0,,CHEMBL622241,BAO_0000218,
13630,Intermediate,10116.0,In vivo,1,,,Cmax was determine after peroral administration at 10 mpk in Rat,N,,,50597,1,,CHEMBL631013,BAO_0000218,
13631,Intermediate,9544.0,In vivo,1,,,Cmax was determine after peroral administration at 10 mpk in Rhesus,N,,,50797,1,,CHEMBL631014,BAO_0000218,
13632,Intermediate,9615.0,In vivo,1,,,Cmax was determine after peroral administration at 10 mpk in dog,N,,,50588,1,,CHEMBL631015,BAO_0000218,
13633,Intermediate,10116.0,In vivo,1,,,Cmax was determine after peroral administration at 160 mpk in Rat,N,,,50597,1,,CHEMBL631016,BAO_0000218,
13634,Intermediate,10116.0,In vivo,1,,,Cmax was determine after peroral administration at 20 mpk in Rat,N,,,50597,1,,CHEMBL631017,BAO_0000218,
13635,Intermediate,10116.0,In vivo,1,,,Cmax was determine after peroral administration at 50 mpk in Rat,N,,,50597,1,,CHEMBL631018,BAO_0000218,
13636,Autocuration,,In vivo,1,,,Cmax was determined,U,,,22224,0,,CHEMBL631019,BAO_0000218,
13637,Intermediate,10090.0,,1,955.0,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hippocampus,N,,,50594,1,,CHEMBL875761,BAO_0000218,
13638,Intermediate,10090.0,,1,955.0,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into hypothalamus,N,,,50594,1,,CHEMBL631020,BAO_0000218,
13639,Intermediate,10090.0,,1,955.0,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into pons and medulla,N,,,50594,1,,CHEMBL631669,BAO_0000218,
13640,Intermediate,10090.0,,1,955.0,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into rest of the brain,N,,,50594,1,,CHEMBL631670,BAO_0000218,
13641,Intermediate,10090.0,,1,2435.0,,Distribution of analyte (pmol/mg) in mouse brain regions after Jugular Vein Injection into striatum,N,,,50594,1,,CHEMBL631671,BAO_0000218,
13642,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.31-0.4,N,,,50597,1,,CHEMBL631672,BAO_0000218,
13643,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.97-1.12,N,,,50597,1,,CHEMBL631673,BAO_0000218,
13644,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.35-0.37,N,,,50597,1,,CHEMBL631856,BAO_0000218,
13645,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.72-1.03,N,,,50597,1,,CHEMBL631857,BAO_0000218,
13646,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.95-1.06,N,,,50597,1,,CHEMBL631858,BAO_0000218,
13647,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.35-0.4,N,,,50597,1,,CHEMBL631859,BAO_0000218,
13648,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.73-0.85,N,,,50597,1,,CHEMBL631860,BAO_0000218,
13649,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.65-0.83,N,,,50597,1,,CHEMBL631861,BAO_0000218,
13650,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.69-0.84,N,,,50597,1,,CHEMBL631862,BAO_0000218,
13651,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.46,N,,,50597,1,,CHEMBL631863,BAO_0000218,
13652,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 1.38-1.5,N,,,50597,1,,CHEMBL631864,BAO_0000218,
13653,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.34-0.48,N,,,50597,1,,CHEMBL631865,BAO_0000218,
13654,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.58-1.17,N,,,50597,1,,CHEMBL631866,BAO_0000218,
13655,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 1.0-1.24,N,,,50597,1,,CHEMBL629360,BAO_0000218,
13656,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.28-0.37,N,,,50597,1,,CHEMBL629361,BAO_0000218,
13657,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.54-0.63,N,,,50597,1,,CHEMBL629362,BAO_0000218,
13658,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.25-0.32,N,,,50597,1,,CHEMBL630740,BAO_0000218,
13659,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.49-0.58,N,,,50597,1,,CHEMBL630741,BAO_0000218,
13660,Intermediate,10116.0,,1,178.0,,Distribution of radioactivity in blood tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.58-0.77,N,,,50597,1,,CHEMBL630742,BAO_0000218,
13661,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 0.20-0.25,N,,,50597,1,,CHEMBL630743,BAO_0000218,
13662,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injection by intravenously; value ranges from 1.05-1.25,N,,,50597,1,,CHEMBL630744,BAO_0000218,
13663,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.03,N,,,50597,1,,CHEMBL630745,BAO_0000218,
13664,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.03-0.06,N,,,50597,1,,CHEMBL630746,BAO_0000218,
13665,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 15 min injecton by intravenously; 0.34-0.5,N,,,50597,1,,CHEMBL630747,BAO_0000218,
13666,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.17-0.20,N,,,50597,1,,CHEMBL630748,BAO_0000218,
13667,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injection by intravenously; value ranges from 0.81-1.26,N,,,50597,1,,CHEMBL632056,BAO_0000218,
13668,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.03-0.06,N,,,50597,1,,CHEMBL632057,BAO_0000218,
13669,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 30 min injecton by intravenously; 0.18-0.36,N,,,50597,1,,CHEMBL632058,BAO_0000218,
13670,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.28-0.37,N,,,50597,1,,CHEMBL632059,BAO_0000218,
13671,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injection by intravenously; value ranges from 0.97-2.17,N,,,50597,1,,CHEMBL632060,BAO_0000218,
13672,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.02-0.03,N,,,50597,1,,CHEMBL632061,BAO_0000218,
13673,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.05-0.07,N,,,50597,1,,CHEMBL629207,BAO_0000218,
13674,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 5 min injecton by intravenously; 0.35-0.72,N,,,50597,1,,CHEMBL629208,BAO_0000218,
13675,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.15-0.19,N,,,50597,1,,CHEMBL629209,BAO_0000218,
13676,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injection by intravenously; value ranges from 0.76-1.42,N,,,50597,1,,CHEMBL629210,BAO_0000218,
13677,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.02-0.03,N,,,50597,1,,CHEMBL629211,BAO_0000218,
13678,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.03-0.06,N,,,50597,1,,CHEMBL629212,BAO_0000218,
13679,Intermediate,10116.0,,1,,,Distribution of radioactivity in brain tissues of Sprague-Dawley rats after 60 min injecton by intravenously; 0.05-0.06,N,,,50597,1,,CHEMBL629213,BAO_0000218,
13680,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 hr in urine of normotensive saline loaded rats at 6.9mg/kg, po",N,,,50597,1,,CHEMBL629214,BAO_0000218,
13681,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 69.2 mg/kg, po",N,,,50597,1,,CHEMBL629215,BAO_0000218,
13682,Intermediate,10116.0,,1,1088.0,,"Diuretic activity was evaluated by measuring amount of Na+ during 0-6 h in urine of normotensive saline loaded rats at 691.9 mg/kg, po",N,,,50597,1,,CHEMBL635154,BAO_0000218,
13683,Intermediate,10116.0,,1,,,Oral diuretic activity measured by Na+ excretion in Rat at 9 mg/kg after ip administration (0-5 hr),N,,,50597,1,,CHEMBL629216,BAO_0000218,
13684,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration,N,,,50597,1,,CHEMBL629217,BAO_0000218,
13685,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL629218,BAO_0000218,
13686,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration (0-5 hr),N,,,50597,1,,CHEMBL629219,BAO_0000218,
13687,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0 - 5 hr),N,,,50597,1,,CHEMBL629220,BAO_0000218,
13688,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr ),N,,,50597,1,,CHEMBL629221,BAO_0000218,
13689,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 27 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL631127,BAO_0000218,
13690,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration,N,,,50597,1,,CHEMBL631128,BAO_0000218,
13691,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL631129,BAO_0000218,
13692,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration (0-5 hr),N,,,50597,1,,CHEMBL631130,BAO_0000218,
13693,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0 - 5 hr),N,,,50597,1,,CHEMBL631131,BAO_0000218,
13694,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr ),N,,,50597,1,,CHEMBL631132,BAO_0000218,
13695,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 3 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL631133,BAO_0000218,
13696,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration,N,,,50597,1,,CHEMBL631134,BAO_0000218,
13697,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL875120,BAO_0000218,
13698,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration (0-5 hr),N,,,50597,1,,CHEMBL631135,BAO_0000218,
13699,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0 - 5 hr),N,,,50597,1,,CHEMBL631136,BAO_0000218,
13700,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr ),N,,,50597,1,,CHEMBL631137,BAO_0000218,
13701,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 81 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL631138,BAO_0000218,
13702,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration,N,,,50597,1,,CHEMBL631139,BAO_0000218,
13703,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL631140,BAO_0000218,
13704,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration (0-5 hr),N,,,50597,1,,CHEMBL631141,BAO_0000218,
13705,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0 - 5 hr),N,,,50597,1,,CHEMBL631142,BAO_0000218,
13706,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr ),N,,,50597,1,,CHEMBL631143,BAO_0000218,
13707,Intermediate,10116.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in Rat at 9 mg/kg after ip administration ( 0-5 hr),N,,,50597,1,,CHEMBL631144,BAO_0000218,
13708,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.312 mg/kg after ip administration,N,,,50588,1,,CHEMBL631145,BAO_0000218,
13709,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.3 mg/kg after ip administration (0-6 hr),N,,,50588,1,,CHEMBL631146,BAO_0000218,
13710,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.625 mg/kg after ip administration,N,,,50588,1,,CHEMBL631147,BAO_0000218,
13711,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 0.6 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL631148,BAO_0000218,
13712,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1.8 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL631149,BAO_0000218,
13713,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration (0-6 hr),N,,,50588,1,,CHEMBL631150,BAO_0000218,
13714,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 10 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL631151,BAO_0000218,
13715,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 16.2 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL631152,BAO_0000218,
13716,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL631443,BAO_0000218,
13717,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration (0-6 hr),N,,,50588,1,,CHEMBL631444,BAO_0000218,
13718,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0 - 6 hr),N,,,50588,1,,CHEMBL631445,BAO_0000218,
13719,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg after ip administration ( 0-6 hr ),N,,,50588,1,,CHEMBL631446,BAO_0000218,
13720,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 1 mg/kg g after ip administration (0-6 hr),N,,,50588,1,,CHEMBL631447,BAO_0000218,
13721,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 20 mg/kg after ip administration ( 0-6 hr),N,,,50588,1,,CHEMBL631448,BAO_0000218,
13722,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration,N,,,50588,1,,CHEMBL631449,BAO_0000218,
13723,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration (0-6 hr),N,,,50588,1,,CHEMBL631450,BAO_0000218,
13724,Intermediate,9615.0,,1,,,Oral diuretic activity was evaluated by measuring Cl- excretion in dog at 2 mg/kg after ip administration ( 0 - 6 hr),N,,,50588,1,,CHEMBL629724,BAO_0000218,
13725,Intermediate,10090.0,In vivo,1,14.0,,"Biodistribution in mice skin, after 24 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,,50594,1,,CHEMBL629725,BAO_0000218,
13726,Intermediate,10090.0,In vivo,1,14.0,,"Biodistribution in mice skin, after 48 hr of intravenous administration of 1-2 ug ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,,50594,1,,CHEMBL629726,BAO_0000218,
13727,Intermediate,10090.0,In vivo,1,2106.0,,"Biodistribution in mice spleen, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,,50594,1,,CHEMBL629727,BAO_0000218,
13728,Intermediate,10090.0,In vivo,1,2106.0,,"Biodistribution in mice spleen, after 1 hr of intravenous aadministration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,,50594,1,,CHEMBL630404,BAO_0000218,
13729,Intermediate,10090.0,In vivo,1,2106.0,,"Biodistribution in mice spleen, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,,50594,1,,CHEMBL630405,BAO_0000218,
13730,Intermediate,10090.0,In vivo,1,2106.0,,"Biodistribution in mice spleen, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,,50594,1,,CHEMBL630406,BAO_0000218,
13731,Intermediate,10090.0,In vivo,1,945.0,,"Biodistribution in mice stomach, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,,50594,1,,CHEMBL630407,BAO_0000218,
13732,Intermediate,10090.0,In vivo,1,945.0,,"Biodistribution in mice stomach, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,,50594,1,,CHEMBL630573,BAO_0000218,
13733,Intermediate,10090.0,In vivo,1,945.0,,"Biodistribution in mice stomach, after 24 hr of intravenous administration of 1-2 ug of ofcompound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,,50594,1,,CHEMBL630574,BAO_0000218,
13734,Intermediate,10090.0,In vivo,1,945.0,,"Biodistribution in mice stomach, after 48 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,,50594,1,,CHEMBL630575,BAO_0000218,
13735,Intermediate,10090.0,In vivo,1,,,"Biodistribution in mice tail, after 12 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,,50594,1,,CHEMBL630576,BAO_0000218,
13736,Intermediate,10090.0,In vivo,1,,,"Biodistribution in mice tail, after 1 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,,50594,1,,CHEMBL630577,BAO_0000218,
13737,Intermediate,10090.0,In vivo,1,,,"Biodistribution in mice tail, after 24 hr of intravenous administration of 1-2 ug of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,,50594,1,,CHEMBL630578,BAO_0000218,
13738,Intermediate,10090.0,In vivo,1,,,"Biodistribution in mice tail, after 48 hr of intravenous administration of compound (entrapped in bovine brain sphingomyelin/ cholesterol multilamellar vehicles)",N,,,50594,1,,CHEMBL630579,BAO_0000218,
13739,Intermediate,10090.0,,1,2113.0,,Percent of injected 238-Plutonium(IV) in mice kidney at 24 hr (orally administered),N,,,50594,1,,CHEMBL630580,BAO_0000218,
13740,Intermediate,10090.0,,1,2113.0,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 h,N,,,50594,1,,CHEMBL630581,BAO_0000218,
13741,Intermediate,10090.0,,1,2113.0,,Percent of injected 238-Plutonium(IV) in mice kidneys at 24 hr (orally administered),N,,,50594,1,,CHEMBL630582,BAO_0000218,
13742,Intermediate,10090.0,,1,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 h,N,,,50594,1,,CHEMBL630583,BAO_0000218,
13743,Intermediate,10090.0,,1,,,Percent of injected 238-Plutonium(IV) in mice liver at 24 hr (orally administered),N,,,50594,1,,CHEMBL630584,BAO_0000218,
13744,Intermediate,10090.0,,1,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 h,N,,,50594,1,,CHEMBL630585,BAO_0000218,
13745,Intermediate,10090.0,,1,,,Percent of injected 238-Plutonium(IV) in mice skeleton at 24 hr (orally administered),N,,,50594,1,,CHEMBL630586,BAO_0000218,
13746,Intermediate,10090.0,,1,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 h,N,,,50594,1,,CHEMBL630587,BAO_0000218,
13747,Intermediate,10090.0,,1,,,Percent of injected 238-Plutonium(IV) in mice soft tissue at 24 hr (orally administered),N,,,50594,1,,CHEMBL630588,BAO_0000218,
13748,Intermediate,10090.0,,1,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 h,N,,,50594,1,,CHEMBL630589,BAO_0000218,
13749,Intermediate,10090.0,,1,,,Percent of injected 238-Plutonium(IV) in mice whole body at 24 hr (orally administered),N,,,50594,1,,CHEMBL630590,BAO_0000218,
13750,Autocuration,,,1,1988.0,,Removal of 238-Plutonium(IV) in feces at 24 h,U,,,22224,0,,CHEMBL630591,BAO_0000019,
13751,Autocuration,,,1,1988.0,,Removal of 238-Plutonium(IV) in feces at 24 hr (orally administered),U,,,22224,0,,CHEMBL630592,BAO_0000019,
13752,Autocuration,,,1,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 h,U,,,22224,0,,CHEMBL630593,BAO_0000019,
13753,Autocuration,,,1,,,Removal of 238-Plutonium(IV) in gastrointestinal (GI) contents at 24 hr (orally administered),U,,,22224,0,,CHEMBL630594,BAO_0000019,
13754,Autocuration,,,1,1088.0,,Removal of 238-Plutonium(IV) in urine 0-4 h (orally administered),U,,,22224,0,,CHEMBL630595,BAO_0000019,
13755,Autocuration,,,1,1088.0,,Removal of 238-Plutonium(IV) in urine 4-24 hr (orally administered),U,,,22224,0,,CHEMBL630596,BAO_0000019,
13756,Autocuration,,,1,1088.0,,Removal of 238-Plutonium(IV) in urine after 0-24 h,U,,,22224,0,,CHEMBL630597,BAO_0000019,
13757,Autocuration,,,1,1088.0,,Removal of 238-Plutonium(IV) in urine after 0-24 hr (orally administered),U,,,22224,0,,CHEMBL630598,BAO_0000019,
13758,Autocuration,,,1,1088.0,,Removal of 238-Plutonium(IV) in urine after 0-4 h,U,,,22224,0,,CHEMBL630599,BAO_0000019,
13759,Autocuration,,,1,1088.0,,Removal of 238-Plutonium(IV) in urine after 0-4 hr (orally administered),U,,,22224,0,,CHEMBL630600,BAO_0000019,
13760,Autocuration,,,1,1088.0,,Removal of 238-Plutonium(IV) in urine after 4-24 h,U,,,22224,0,,CHEMBL630601,BAO_0000019,
13761,Autocuration,,,1,1088.0,,Removal of 238-Plutonium(IV) in urine after 4-24 hr (orally administered),U,,,22224,0,,CHEMBL630602,BAO_0000019,
13762,Autocuration,,,1,1088.0,,Removal of 238-Plutonium(IV) in urine at 0-4 hr (orally administered),U,,,22224,0,,CHEMBL630603,BAO_0000019,
13763,Autocuration,,,1,1088.0,,Removal of 238-Plutonium(IV) in urine at 4-24 hr (orally administered),U,,,22224,0,,CHEMBL630604,BAO_0000019,
13764,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL624869,BAO_0000218,
13765,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL624870,BAO_0000218,
13766,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL623189,BAO_0000218,
13767,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL623190,BAO_0000218,
13768,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL623191,BAO_0000218,
13769,Intermediate,10116.0,In vivo,1,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL623192,BAO_0000218,
13770,Intermediate,10116.0,In vivo,1,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL623193,BAO_0000218,
13771,Intermediate,10116.0,In vivo,1,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL623194,BAO_0000218,
13772,Intermediate,10116.0,In vivo,1,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL623195,BAO_0000218,
13773,Intermediate,10116.0,In vivo,1,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL623196,BAO_0000218,
13774,Intermediate,10116.0,,1,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 15 microCi of the drug and 15 micro g of estradiol,N,,,50597,1,,CHEMBL623197,BAO_0000218,
13775,Intermediate,10116.0,,1,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,N,,,50597,1,,CHEMBL623198,BAO_0000218,
13776,Intermediate,10116.0,,1,,,Tested in vivo for the biodistribution in rat uterus/blood at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,N,,,50597,1,,CHEMBL623199,BAO_0000218,
13777,Intermediate,10116.0,,1,2385.0,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 100 microCi of drug in 10%ethanol saline,N,,,50597,1,,CHEMBL623200,BAO_0000218,
13778,Intermediate,10116.0,,1,2385.0,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 120 microCi of drug in 10%ethanol saline,N,,,50597,1,,CHEMBL623201,BAO_0000218,
13779,Intermediate,10116.0,,1,2385.0,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 15 microCi of drug in 10%ethanol saline,N,,,50597,1,,CHEMBL623202,BAO_0000218,
13780,Intermediate,10116.0,,1,2385.0,,Tested in vivo for the biodistribution in rat uterus/muscle after 3 hours following an intravenous dose of 50 microCi of drug in 10%ethanol saline,N,,,50597,1,,CHEMBL623203,BAO_0000218,
13781,Intermediate,10116.0,,1,2385.0,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of drug in 10%ethanol saline,N,,,50597,1,,CHEMBL623204,BAO_0000218,
13782,Intermediate,10116.0,,1,2385.0,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 100 microCi of the drug and 15 ug of estradiol,N,,,50597,1,,CHEMBL623205,BAO_0000218,
13783,Intermediate,10116.0,,1,2385.0,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,N,,,50597,1,,CHEMBL623206,BAO_0000218,
13784,Intermediate,10116.0,,1,2385.0,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 120 microCi of the drug and 15 micro g of estradiol,N,,,50597,1,,CHEMBL623207,BAO_0000218,
13785,Intermediate,10116.0,,1,2385.0,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 15 microCi of the drug and 15 ug of estradiol,N,,,50597,1,,CHEMBL623208,BAO_0000218,
13786,Intermediate,10116.0,,1,2385.0,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,N,,,50597,1,,CHEMBL623209,BAO_0000218,
13787,Intermediate,10116.0,,1,2385.0,,Tested in vivo for the biodistribution in rat uterus/muscle at 1 hour after intravenous dose of 50 microCi of the drug and 15 ug of estradiol,N,,,50597,1,,CHEMBL623210,BAO_0000218,
13788,Intermediate,10116.0,,1,,,Tested in vivo for the biodistribution in rat fat at 1 hour after intravenous dose of 50 microCi of drug in 10%ethanol saline,N,,,50597,1,,CHEMBL623211,BAO_0000218,
13789,Intermediate,10116.0,,1,995.0,,Tested in vivo for the biodistribution in rat uterus at 1 hour after intravenous dose of 120 microCi of drug in 10%ethanol saline,N,,,50597,1,,CHEMBL623212,BAO_0000218,
13790,Autocuration,,,1,,,Tested in vitro for intrinsic activity relative to quinpirole,U,,,22224,0,,CHEMBL623213,BAO_0000019,
13791,Autocuration,,,1,,,"Relative ion enhancement, determined in pulsed ultrafiltration",U,,,22224,0,,CHEMBL623214,BAO_0000019,
13792,Autocuration,,,1,,,% ionization at the pH 7.4 at 37 degree Centigrade,U,,,22224,0,,CHEMBL623215,BAO_0000019,
13793,Autocuration,,,1,,,Percentage ionization was measured,U,,,22224,0,,CHEMBL623216,BAO_0000019,
13794,Intermediate,9913.0,,1,,,Association constant of binding of compound with calf thymus DNA was determined by using equilibrium dialysis.,N,,,50591,1,,CHEMBL623217,BAO_0000218,
13795,Autocuration,,,1,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 Pseudo-first-order rate constant,U,,,22224,0,,CHEMBL623218,BAO_0000019,
13796,Autocuration,,,1,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer Pseudo-first-order rate constant,U,,,22224,0,,CHEMBL623913,BAO_0000019,
13797,Autocuration,,,1,,,Compound was autooxidized for 2 hour at 37 degree Celsius in pH 7.4 phosphate buffer pseudo-first-order rate constant 0.1 mM EDTA,U,,,22224,0,,CHEMBL623914,BAO_0000019,
13798,Autocuration,,,1,,,Compound was evaluated for the partition coefficient in octanol/water,U,,,22229,0,,CHEMBL623915,BAO_0000100,
13799,Autocuration,,,1,,,Compound was evaluated for the partition coefficient in octanol/water (1-octanol / 10 mM phosphate buffer at pH 7.4),U,,,22229,0,,CHEMBL624080,BAO_0000100,
13800,Autocuration,,,1,,,Equilibrium constant measured by the pulse radiolysis at pH 7,U,,,22224,0,,CHEMBL624081,BAO_0000019,
13801,Intermediate,9606.0,,1,,,In vitro hydrolytic rate constant determined in human blood,N,,,50587,1,,CHEMBL624082,BAO_0000218,
13802,Intermediate,9606.0,,1,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of human plasma,N,,,50587,1,,CHEMBL625054,BAO_0000218,
13803,Autocuration,,,1,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of hydrogen peroxide,U,,,22224,0,,CHEMBL877485,BAO_0000019,
13804,Intermediate,10090.0,,1,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse brain homogenate,N,,,50594,1,,CHEMBL625055,BAO_0000218,
13805,Intermediate,10090.0,,1,,,In vitro oxidation of compound to its pyridinium salt (3) in presence of mouse liver homogenate,N,,,50594,1,,CHEMBL625056,BAO_0000218,
13806,Intermediate,9606.0,,1,,,In vitro oxidation of compound in presence of human plasma,N,,,50587,1,,CHEMBL625057,BAO_0000218,
13807,Autocuration,,,1,,,In vitro oxidation of compound in presence of hydrogen peroxide,U,,,22224,0,,CHEMBL625058,BAO_0000019,
13808,Intermediate,10090.0,,1,,,In vitro oxidation of compound in presence of mouse brain homogenate,N,,,50594,1,,CHEMBL625059,BAO_0000218,
13809,Intermediate,10090.0,,1,,,In vitro oxidation of compound in presence of mouse liver homogenate,N,,,50594,1,,CHEMBL629536,BAO_0000218,
13810,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,N,,,50597,1,,CHEMBL629537,BAO_0000218,
13811,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,N,,,50597,1,,CHEMBL629538,BAO_0000218,
13812,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,N,,,50597,1,,CHEMBL629539,BAO_0000218,
13813,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,N,,,50597,1,,CHEMBL874445,BAO_0000218,
13814,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,N,,,50597,1,,CHEMBL629540,BAO_0000218,
13815,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,N,,,50597,1,,CHEMBL629541,BAO_0000218,
13816,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,N,,,50597,1,,CHEMBL629542,BAO_0000218,
13817,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,N,,,50597,1,,CHEMBL630243,BAO_0000218,
13818,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,N,,,50597,1,,CHEMBL630244,BAO_0000218,
13819,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,N,,,50597,1,,CHEMBL630245,BAO_0000218,
13820,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,N,,,50597,1,,CHEMBL630246,BAO_0000218,
13821,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,N,,,50597,1,,CHEMBL630247,BAO_0000218,
13822,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,N,,,50597,1,,CHEMBL630248,BAO_0000218,
13823,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood at 240 minutes after dose administration.,N,,,50597,1,,CHEMBL630249,BAO_0000218,
13824,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood at 30 minutes after dose administration.,N,,,50597,1,,CHEMBL630250,BAO_0000218,
13825,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood at 360 minutes after dose administration.,N,,,50597,1,,CHEMBL630251,BAO_0000218,
13826,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood at 3 hr after dose administration.,N,,,50597,1,,CHEMBL630252,BAO_0000218,
13827,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood at 60 minutes after dose administration.,N,,,50597,1,,CHEMBL630408,BAO_0000218,
13828,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution in rat cerebellum at 120 minutes after dose administration.,N,,,50597,1,,CHEMBL630409,BAO_0000218,
13829,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution in rat cerebellum at 1440 minutes after dose administration.,N,,,50597,1,,CHEMBL874446,BAO_0000218,
13830,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution in rat cerebellum at 15 minutes after dose administration.,N,,,50597,1,,CHEMBL630410,BAO_0000218,
13831,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution in rat cerebellum at 240 minutes after dose administration.,N,,,50597,1,,CHEMBL630411,BAO_0000218,
13832,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution in rat cerebellum at 30 minutes after dose administration.,N,,,50597,1,,CHEMBL630412,BAO_0000218,
13833,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution in rat cerebellum at 360 minutes after dose administration.,N,,,50597,1,,CHEMBL630413,BAO_0000218,
13834,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution in rat cerebellum at 3 hr after dose administration.,N,,,50597,1,,CHEMBL630414,BAO_0000218,
13835,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution in rat cerebellum at 60 minutes after dose administration.,N,,,50597,1,,CHEMBL630415,BAO_0000218,
13836,Intermediate,10116.0,In vivo,1,,,Biodistribution in rat cortex at 120 minutes after dose administration.,N,,,50597,1,,CHEMBL630416,BAO_0000218,
13837,Intermediate,10116.0,In vivo,1,,,Biodistribution in rat cortex at 1440 minutes after dose administration.,N,,,50597,1,,CHEMBL630417,BAO_0000218,
13838,Intermediate,10116.0,In vivo,1,,,Biodistribution in rat cortex at 15 minutes after dose administration.,N,,,50597,1,,CHEMBL630418,BAO_0000218,
13839,Intermediate,10116.0,In vivo,1,,,Biodistribution in rat cortex at 240 minutes after dose administration.,N,,,50597,1,,CHEMBL630419,BAO_0000218,
13840,Intermediate,10116.0,In vivo,1,,,Biodistribution in rat cortex at 30 minutes after dose administration.,N,,,50597,1,,CHEMBL630420,BAO_0000218,
13841,Intermediate,10116.0,In vivo,1,,,Biodistribution in rat cortex at 360 minutes after dose administration.,N,,,50597,1,,CHEMBL630421,BAO_0000218,
13842,Intermediate,10116.0,In vivo,1,,,Biodistribution in rat cortex at 3 hr after dose administration.,N,,,50597,1,,CHEMBL630422,BAO_0000218,
13843,Intermediate,10116.0,In vivo,1,,,Biodistribution in rat cortex at 60 minutes after dose administration.,N,,,50597,1,,CHEMBL630423,BAO_0000218,
13844,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart at 120 minutes after dose administration.,N,,,50597,1,,CHEMBL630424,BAO_0000218,
13845,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart at 15 minutes after dose administration.,N,,,50597,1,,CHEMBL630425,BAO_0000218,
13846,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart at 240 minutes after dose administration.,N,,,50597,1,,CHEMBL629462,BAO_0000218,
13847,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart at 30 minutes after dose administration.,N,,,50597,1,,CHEMBL630426,BAO_0000218,
13848,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart at 360 minutes after dose administration.,N,,,50597,1,,CHEMBL630427,BAO_0000218,
13849,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart at 3 hr after dose administration.,N,,,50597,1,,CHEMBL625877,BAO_0000218,
13850,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart at 60 minutes after dose administration.,N,,,50597,1,,CHEMBL625878,BAO_0000218,
13851,Intermediate,10116.0,In vivo,1,10000000.0,,Biodistribution in rat hippocampus at 1440 minutes after dose administration.,N,,,50597,1,,CHEMBL625879,BAO_0000218,
13852,Intermediate,10116.0,In vivo,1,10000000.0,,Biodistribution in rat hippocampus at 240 minutes after dose administration.,N,,,50597,1,,CHEMBL625880,BAO_0000218,
13853,Intermediate,10116.0,In vivo,1,10000000.0,,Biodistribution in rat hippocampus at 30 minutes after dose administration.,N,,,50597,1,,CHEMBL625881,BAO_0000218,
13854,Intermediate,10116.0,In vivo,1,10000000.0,,Biodistribution in rat hippocampus at 360 minutes after dose administration.,N,,,50597,1,,CHEMBL625882,BAO_0000218,
13855,Intermediate,10116.0,In vivo,1,10000000.0,,Biodistribution in rat hippocampus at 15 minutes after dose administration.,N,,,50597,1,,CHEMBL625883,BAO_0000218,
13856,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney at 120 minutes after dose administration.,N,,,50597,1,,CHEMBL625884,BAO_0000218,
13857,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney at 1440 minutes after dose administration.,N,,,50597,1,,CHEMBL625885,BAO_0000218,
13858,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney at 15 minutes after dose administration.,N,,,50597,1,,CHEMBL628649,BAO_0000218,
13859,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney at 240 minutes after dose administration.,N,,,50597,1,,CHEMBL628650,BAO_0000218,
13860,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney at 30 minutes after dose administration.,N,,,50597,1,,CHEMBL628651,BAO_0000218,
13861,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney at 360 minutes after dose administration.,N,,,50597,1,,CHEMBL628652,BAO_0000218,
13862,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney at 60 minutes after dose administration.,N,,,50597,1,,CHEMBL628653,BAO_0000218,
13863,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver at 120 minutes after dose administration.,N,,,50597,1,,CHEMBL628654,BAO_0000218,
13864,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver at 1440 minutes after dose administration.,N,,,50597,1,,CHEMBL628655,BAO_0000218,
13865,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver at 15 minutes after dose administration.,N,,,50597,1,,CHEMBL625238,BAO_0000218,
13866,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver at 240 minutes after dose administration.,N,,,50597,1,,CHEMBL625239,BAO_0000218,
13867,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver at 30 minutes after dose administration.,N,,,50597,1,,CHEMBL625240,BAO_0000218,
13868,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver at 360 minutes after dose administration.,N,,,50597,1,,CHEMBL625241,BAO_0000218,
13869,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver at 60 minutes after dose administration.,N,,,50597,1,,CHEMBL625242,BAO_0000218,
13870,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in rat lung at 120 minutes after dose administration.,N,,,50597,1,,CHEMBL874587,BAO_0000218,
13871,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in rat lung at 1440 minutes after dose administration.,N,,,50597,1,,CHEMBL625405,BAO_0000218,
13872,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in rat lung at 15 minutes after dose administration.,N,,,50597,1,,CHEMBL625406,BAO_0000218,
13873,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in rat lung at 240 minutes after dose administration.,N,,,50597,1,,CHEMBL625407,BAO_0000218,
13874,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in rat lung at 30 minutes after dose administration.,N,,,50597,1,,CHEMBL625408,BAO_0000218,
13875,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in rat lung at 360 minutes after dose administration.,N,,,50597,1,,CHEMBL625409,BAO_0000218,
13876,Intermediate,10116.0,,1,1515.0,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of calcium deficient buffer,N,,,50597,1,,CHEMBL625410,BAO_0000218,
13877,Intermediate,10116.0,,1,1515.0,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of nifedipine,N,,,50597,1,,CHEMBL625411,BAO_0000218,
13878,Intermediate,10116.0,,1,1515.0,,Percent of maximal contractile response to compound in rat thoracic aorta strips in the presence of verapamil,N,,,50597,1,,CHEMBL625412,BAO_0000218,
13879,Intermediate,10116.0,,1,1515.0,,Percent of maximal contractile response to compound in rat thoracic aorta strips presence of PBZ and CIR,N,,,50597,1,,CHEMBL625413,BAO_0000218,
13880,Intermediate,10116.0,,1,1515.0,,Percent of maximal contractile response to compound in rat thoracic aorta strips v,N,,,50597,1,,CHEMBL625414,BAO_0000218,
13881,Intermediate,10116.0,,1,1515.0,,Percent of maximal contractile response to compound with phenoxybenzamine pretreatment on rat thoracic aorta strips,N,,,50597,1,,CHEMBL625415,BAO_0000218,
13882,Intermediate,10116.0,,1,1515.0,,Percent of maximal contractile response to compound without phenoxybenzamine pretreatment on rat thoracic aorta strips,N,,,50597,1,,CHEMBL625416,BAO_0000218,
13883,Intermediate,10116.0,,1,1088.0,,% of the total radioactive dose of compound present in the 0-24 hour urine after a single 5 mg/kg dose administered intravenously in rats,N,,,50597,1,,CHEMBL625417,BAO_0000218,
13884,Intermediate,10116.0,,1,1988.0,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through feces,N,,,50597,1,,CHEMBL625418,BAO_0000218,
13885,Intermediate,10116.0,,1,1088.0,,Compound at the dose 10 mg/kg administered intraperitoneally was evaluated for the excretion rate in rats in 7 days through urine,N,,,50597,1,,CHEMBL625419,BAO_0000218,
13886,Intermediate,10116.0,,1,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 1 mg/kg,N,,,50597,1,,CHEMBL625420,BAO_0000218,
13887,Intermediate,10116.0,,1,,,Compound was evaluated for the biliary excretion in the anesthetized rats in 6 hours after intravenous doses 10 mg/kg,N,,,50597,1,,CHEMBL626996,BAO_0000218,
13888,Intermediate,10116.0,,1,1988.0,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through feces",N,,,50597,1,,CHEMBL626997,BAO_0000218,
13889,Intermediate,10116.0,,1,1088.0,,"Compound was evaluated for the cumulative excretion rate in rats at the dose 10 mg/kg, intraperitoneally for 18 days through urine",N,,,50597,1,,CHEMBL626998,BAO_0000218,
13890,Intermediate,10116.0,,1,,,"Compound was evaluated for the in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour biliary excretion",N,,,50597,1,,CHEMBL626999,BAO_0000218,
13891,Intermediate,10090.0,,1,,,faecal levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-30h,N,,,50594,1,,CHEMBL627000,BAO_0000218,
13892,Intermediate,10090.0,,1,,,fecal levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-30h,N,,,50594,1,,CHEMBL627001,BAO_0000218,
13893,Intermediate,10090.0,,1,,,fecal levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-30h,N,,,50594,1,,CHEMBL627002,BAO_0000218,
13894,Intermediate,10090.0,,1,,,fecal levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-30h,N,,,50594,1,,CHEMBL627003,BAO_0000218,
13895,Intermediate,10090.0,,1,1088.0,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-24 hr,N,,,50594,1,,CHEMBL627004,BAO_0000218,
13896,Intermediate,10090.0,,1,1088.0,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 0-6 hr,N,,,50594,1,,CHEMBL627005,BAO_0000218,
13897,Intermediate,10090.0,,1,1088.0,,urine levels excreted after administration of 2-(3-bromophenyl)thiazolidine(500 mg/kg) to mice measured at 24-30 hr,N,,,50594,1,,CHEMBL874594,BAO_0000218,
13898,Intermediate,10090.0,,1,1088.0,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-24 hr,N,,,50594,1,,CHEMBL627006,BAO_0000218,
13899,Intermediate,10090.0,,1,1088.0,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 0-6 hr,N,,,50594,1,,CHEMBL627007,BAO_0000218,
13900,Intermediate,10090.0,,1,1088.0,,urine levels excreted after administration of 2-phenylthiazolidine (500 mg/kg) to mice measured at 24-30 hr,N,,,50594,1,,CHEMBL627884,BAO_0000218,
13901,Intermediate,10090.0,,1,1088.0,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-24 hr,N,,,50594,1,,CHEMBL627885,BAO_0000218,
13902,Intermediate,10090.0,,1,1088.0,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 0-6 hr,N,,,50594,1,,CHEMBL627886,BAO_0000218,
13903,Intermediate,10090.0,,1,1088.0,,urine levels excreted after administration of benzaldehyde (250 mg/kg) to mice measured at 24-30 hr,N,,,50594,1,,CHEMBL627887,BAO_0000218,
13904,Intermediate,10090.0,,1,1088.0,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-24 hr,N,,,50594,1,,CHEMBL627888,BAO_0000218,
13905,Intermediate,10090.0,,1,1088.0,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 0-6 hr,N,,,50594,1,,CHEMBL628057,BAO_0000218,
13906,Intermediate,10090.0,,1,1088.0,,urine levels excreted after administration of cysteamine (175 mg/kg) to mice measured at 24-30 hr,N,,,50594,1,,CHEMBL627405,BAO_0000218,
13907,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,N,,,50588,1,,CHEMBL627406,BAO_0000218,
13908,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,N,,,50588,1,,CHEMBL627407,BAO_0000218,
13909,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,N,,,50588,1,,CHEMBL627408,BAO_0000218,
13910,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,N,,,50588,1,,CHEMBL627409,BAO_0000218,
13911,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,N,,,50588,1,,CHEMBL875486,BAO_0000218,
13912,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,N,,,50588,1,,CHEMBL627410,BAO_0000218,
13913,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,N,,,50588,1,,CHEMBL627411,BAO_0000218,
13914,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,N,,,50588,1,,CHEMBL627412,BAO_0000218,
13915,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,N,,,50588,1,,CHEMBL627413,BAO_0000218,
13916,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,N,,,50588,1,,CHEMBL627414,BAO_0000218,
13917,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 10.1 uM/Kg of drug,N,,,50588,1,,CHEMBL627415,BAO_0000218,
13918,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 102 uM/Kg of drug,N,,,50588,1,,CHEMBL627416,BAO_0000218,
13919,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.40 uM/Kg of drug,N,,,50588,1,,CHEMBL627417,BAO_0000218,
13920,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 3.76 uM/Kg of drug,N,,,50588,1,,CHEMBL627418,BAO_0000218,
13921,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 34.1 uM/Kg of drug,N,,,50588,1,,CHEMBL627419,BAO_0000218,
13922,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 50.8 uM/Kg of drug,N,,,50588,1,,CHEMBL627320,BAO_0000218,
13923,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 68.1 uM/Kg of drug,N,,,50588,1,,CHEMBL627321,BAO_0000218,
13924,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL627322,BAO_0000218,
13925,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL627323,BAO_0000218,
13926,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL627491,BAO_0000218,
13927,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL627492,BAO_0000218,
13928,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL627493,BAO_0000218,
13929,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL627494,BAO_0000218,
13930,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL627495,BAO_0000218,
13931,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL627496,BAO_0000218,
13932,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL627497,BAO_0000218,
13933,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL627498,BAO_0000218,
13934,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL627499,BAO_0000218,
13935,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL627500,BAO_0000218,
13936,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL627501,BAO_0000218,
13937,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL625616,BAO_0000218,
13938,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL625617,BAO_0000218,
13939,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL625618,BAO_0000218,
13940,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL625619,BAO_0000218,
13941,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL625620,BAO_0000218,
13942,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL625621,BAO_0000218,
13943,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL625622,BAO_0000218,
13944,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL625788,BAO_0000218,
13945,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL625789,BAO_0000218,
13946,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL625790,BAO_0000218,
13947,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL625791,BAO_0000218,
13948,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL622334,BAO_0000218,
13949,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL622335,BAO_0000218,
13950,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL622336,BAO_0000218,
13951,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution in thyroid of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL622337,BAO_0000218,
13952,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution in thyroid of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL622338,BAO_0000218,
13953,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution in thyroid of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL622339,BAO_0000218,
13954,Intermediate,10116.0,In vivo,1,,,Biodistribution in uterus / blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL624153,BAO_0000218,
13955,Intermediate,10116.0,In vivo,1,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL628430,BAO_0000218,
13956,Intermediate,10116.0,In vivo,1,,,Biodistribution in uterus / blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL628431,BAO_0000218,
13957,Intermediate,10116.0,In vivo,1,,,Biodistribution in uterus / blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL628432,BAO_0000218,
13958,Intermediate,10116.0,In vivo,1,,,Biodistribution in uterus / blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL628433,BAO_0000218,
13959,Intermediate,10116.0,In vivo,1,2106.0,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,,,50597,1,,CHEMBL628434,BAO_0000218,
13960,Intermediate,10116.0,In vivo,1,2106.0,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,,,50597,1,,CHEMBL626789,BAO_0000218,
13961,Intermediate,10116.0,In vivo,1,2106.0,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2)",N,,,50597,1,,CHEMBL626790,BAO_0000218,
13962,Intermediate,10116.0,In vivo,1,2106.0,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,,,50597,1,,CHEMBL626791,BAO_0000218,
13963,Intermediate,10116.0,In vivo,1,2106.0,,"Biodistribution in uterus / spleen, muscle, lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,,,50597,1,,CHEMBL626792,BAO_0000218,
13964,Intermediate,10116.0,In vivo,1,2106.0,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,,,50597,1,,CHEMBL626793,BAO_0000218,
13965,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,N,,,50597,1,,CHEMBL627436,BAO_0000218,
13966,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,N,,,50597,1,,CHEMBL627437,BAO_0000218,
13967,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,N,,,50597,1,,CHEMBL627438,BAO_0000218,
13968,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,N,,,50597,1,,CHEMBL627439,BAO_0000218,
13969,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,N,,,50597,1,,CHEMBL627440,BAO_0000218,
13970,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,N,,,50597,1,,CHEMBL627602,BAO_0000218,
13971,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,N,,,50597,1,,CHEMBL627603,BAO_0000218,
13972,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,N,,,50597,1,,CHEMBL627604,BAO_0000218,
13973,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,N,,,50597,1,,CHEMBL627605,BAO_0000218,
13974,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,N,,,50597,1,,CHEMBL627606,BAO_0000218,
13975,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,N,,,50597,1,,CHEMBL627607,BAO_0000218,
13976,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,N,,,50597,1,,CHEMBL627608,BAO_0000218,
13977,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,N,,,50597,1,,CHEMBL627609,BAO_0000218,
13978,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,N,,,50597,1,,CHEMBL627610,BAO_0000218,
13979,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,N,,,50597,1,,CHEMBL627611,BAO_0000218,
13980,Intermediate,10116.0,,1,,,Mean potassium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,N,,,50597,1,,CHEMBL627612,BAO_0000218,
13981,Autocuration,,,1,,,Octanol:water partition coefficient is evaluated,U,,,22229,0,,CHEMBL627613,BAO_0000100,
13982,Autocuration,,,1,,,Partition coefficient in 1-octanol/water system,U,,,22224,0,,CHEMBL627614,BAO_0000100,
13983,Autocuration,,,1,,,Partition coefficient in 1-octanol/water system measured using radio active compounds,U,,,22224,0,,CHEMBL627615,BAO_0000100,
13984,Autocuration,,,1,,,Partition coefficient in octanol/water system was determined,U,,,22224,0,,CHEMBL627616,BAO_0000100,
13985,Autocuration,,,1,,,Partition coefficient in octanol/water system was determined using [14C]-labeled compounds.,U,,,22224,0,,CHEMBL627617,BAO_0000100,
13986,Autocuration,,,1,,,Pseudo-first-order rate constant at pH 10 and 35 degrees Centigrade,U,,,22224,0,,CHEMBL627618,BAO_0000019,
13987,Autocuration,,,1,,,"Pseudo-first-order rate constant at pH 10, micro=0.5, 35 degrees Centigrade",U,,,22224,0,,CHEMBL627619,BAO_0000019,
13988,Autocuration,,,1,,,Pseudo-first-order rate constant of the compound,U,,,22224,0,,CHEMBL627620,BAO_0000019,
13989,Autocuration,,,1,,,Pseudo-first-order rate constant with 1-min time point,U,,,22224,0,,CHEMBL627621,BAO_0000019,
13990,Autocuration,,,1,,,Pseudo-first-order rate constant without 1-min time point,U,,,22224,0,,CHEMBL627622,BAO_0000019,
13991,Autocuration,,,1,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 0.5 mM EDTA,U,,,22224,0,,CHEMBL627623,BAO_0000019,
13992,Autocuration,,,1,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 50 mM EDTA,U,,,22224,0,,CHEMBL627624,BAO_0000019,
13993,Autocuration,,,1,,,Pseudo-first-order rate constant was determined in pH 7.4 phosphate buffer in presence 70 mM EDTA,U,,,22224,0,,CHEMBL627625,BAO_0000019,
13994,Autocuration,,,1,,,Rate constants determined using 31P NMR Kinetics experiments at 37 degrees Centigrade,U,,,22224,0,,CHEMBL628523,BAO_0000019,
13995,Autocuration,,,1,,,The alkaline hydrolysis second order rate constant(K OH) of the compound,U,,,22224,0,,CHEMBL628524,BAO_0000019,
13996,Autocuration,,,1,,,The efflux rate constant of the compound,U,,,22224,0,,CHEMBL628525,BAO_0000019,
13997,Autocuration,,,1,,,The reaction rate constant (K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,U,,,22224,0,,CHEMBL625732,BAO_0000019,
13998,Autocuration,,,1,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,U,,,22224,0,,CHEMBL625733,BAO_0000019,
13999,Autocuration,,,1,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine,U,,,22224,0,,CHEMBL625734,BAO_0000019,
14000,Autocuration,,,1,,,The reaction rate constant(K) by measuring competition with nitroblue tetrazolium of the superoxide radicals formed by xanthine oxidase/xanthine; ND= not determined,U,,,22224,0,,CHEMBL625913,BAO_0000019,
14001,Autocuration,,,1,,,Association constant was evaluated towards synthetic peptidoglycan analogue Ac2-Lys-D-Ala-D-Ala,U,,,22224,0,,CHEMBL625914,BAO_0000019,
14002,Autocuration,,,1,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of electroneutral DMPC in PBSbuffer at pH 7.4 and 37 C,U,,,22224,0,,CHEMBL625915,BAO_0000019,
14003,Autocuration,,,1,,,Equilibrium association (binding) constant interacting with Unilamellar Vesicles of negatively charged DMPG in PBS buffer at pH 7.4 and 37 C,U,,,22224,0,,CHEMBL625916,BAO_0000019,
14004,Autocuration,,,1,,,Evaluated for the mustard reactivity by determining rate constant for hydrolysis of mustard in aqueous acetone (K H),U,,,22224,0,,CHEMBL625917,BAO_0000019,
14005,Autocuration,,,1,,,"Effective biomolecular rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL625918,BAO_0000019,
14006,Autocuration,,,1,,,"Effective biomolecular rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL625919,BAO_0000019,
14007,Autocuration,,,1,,,"Effective biomolecular rate constant at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL625920,BAO_0000019,
14008,Autocuration,,,1,,,"Effective biomolecular rate constant at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL874453,BAO_0000019,
14009,Autocuration,,,1,,,"Effective biomolecular rate constant in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL625921,BAO_0000019,
14010,Autocuration,,,1,,,Evaluated for the mustard reactivity by determining rate constant for alkylation of 4-(4-nitrobenzyl)pyridine using NBP alkylation assay,U,,,22224,0,,CHEMBL625922,BAO_0000019,
14011,Autocuration,,,1,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL625923,BAO_0000019,
14012,Autocuration,,,1,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL625924,BAO_0000019,
14013,Autocuration,,,1,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 0.790 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL625925,BAO_0000019,
14014,Autocuration,,,1,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator at the concentration 1.00 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL625926,BAO_0000019,
14015,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in rat lung at 60 minutes after dose administration.,N,,,50597,1,,CHEMBL627704,BAO_0000218,
14016,Intermediate,10116.0,In vivo,1,,,Biodistribution in rat pons/medulla at 120 minutes after dose administration.,N,,,50597,1,,CHEMBL627705,BAO_0000218,
14017,Intermediate,10116.0,In vivo,1,,,Biodistribution in rat pons/medulla at 15 minutes after dose administration.,N,,,50597,1,,CHEMBL627706,BAO_0000218,
14018,Intermediate,10116.0,In vivo,1,,,Biodistribution in rat pons/medulla at 240 minutes after dose administration.,N,,,50597,1,,CHEMBL627707,BAO_0000218,
14019,Intermediate,10116.0,In vivo,1,,,Biodistribution in rat pons/medulla at 30 minutes after dose administration.,N,,,50597,1,,CHEMBL627708,BAO_0000218,
14020,Intermediate,10116.0,In vivo,1,,,Biodistribution in rat pons/medulla at 360 minutes after dose administration.,N,,,50597,1,,CHEMBL628361,BAO_0000218,
14021,Intermediate,10116.0,In vivo,1,,,Biodistribution in rat pons/medulla at 60 minutes after dose administration.,N,,,50597,1,,CHEMBL628362,BAO_0000218,
14022,Intermediate,10116.0,In vivo,1,2435.0,,Biodistribution in rat striatum at 120 minutes after dose administration.,N,,,50597,1,,CHEMBL628363,BAO_0000218,
14023,Intermediate,10116.0,In vivo,1,2435.0,,Biodistribution in rat striatum at 1440 minutes after dose administration.,N,,,50597,1,,CHEMBL628364,BAO_0000218,
14024,Intermediate,10116.0,In vivo,1,2435.0,,Biodistribution in rat striatum at 15 minutes after dose administration.,N,,,50597,1,,CHEMBL628365,BAO_0000218,
14025,Intermediate,10116.0,In vivo,1,2435.0,,Biodistribution in rat striatum at 240 minutes after dose administration.,N,,,50597,1,,CHEMBL874454,BAO_0000218,
14026,Intermediate,10116.0,In vivo,1,2435.0,,Biodistribution in rat striatum at 30 minutes after dose administration.,N,,,50597,1,,CHEMBL628531,BAO_0000218,
14027,Intermediate,10116.0,In vivo,1,2435.0,,Biodistribution in rat striatum at 360 minutes after dose administration.,N,,,50597,1,,CHEMBL628532,BAO_0000218,
14028,Intermediate,10116.0,In vivo,1,2435.0,,Biodistribution in rat striatum at 3 hr after dose administration.,N,,,50597,1,,CHEMBL628533,BAO_0000218,
14029,Intermediate,10116.0,In vivo,1,2435.0,,Biodistribution in rat striatum at 60 minutes after dose administration.,N,,,50597,1,,CHEMBL628534,BAO_0000218,
14030,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution in rat thyroid at 120 minutes after dose administration.,N,,,50597,1,,CHEMBL628535,BAO_0000218,
14031,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution in rat thyroid at 1440 minutes after dose administration.,N,,,50597,1,,CHEMBL628536,BAO_0000218,
14032,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution in rat thyroid at 15 minutes after dose administration.,N,,,50597,1,,CHEMBL628537,BAO_0000218,
14033,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution in rat thyroid at 240 minutes after dose administration.,N,,,50597,1,,CHEMBL628538,BAO_0000218,
14034,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution in rat thyroid at 30 minutes after dose administration.,N,,,50597,1,,CHEMBL628539,BAO_0000218,
14035,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution in rat thyroid at 360 minutes after dose administration.,N,,,50597,1,,CHEMBL630297,BAO_0000218,
14036,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution in rat thyroid at 60 minutes after dose administration.,N,,,50597,1,,CHEMBL630298,BAO_0000218,
14037,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution in rest of brain of rat 120 minutes after dose administration.,N,,,50597,1,,CHEMBL630299,BAO_0000218,
14038,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution in rest of brain of rat at 1440 minutes after dose administration.,N,,,50597,1,,CHEMBL628094,BAO_0000218,
14039,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution in rest of brain of rat at 15 minutes after dose administration.,N,,,50597,1,,CHEMBL628095,BAO_0000218,
14040,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution in rest of brain of rat at 240 minutes after dose administration.,N,,,50597,1,,CHEMBL874648,BAO_0000218,
14041,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution in rest of brain of rat at 30 minutes after dose administration.,N,,,50597,1,,CHEMBL628096,BAO_0000218,
14042,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution in rest of brain of rat at 360 minutes after dose administration.,N,,,50597,1,,CHEMBL628097,BAO_0000218,
14043,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution in rest of brain of rat at 60 minutes after dose administration.,N,,,50597,1,,CHEMBL628098,BAO_0000218,
14044,Autocuration,,,1,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (10:1)",U,,,22224,0,,CHEMBL628099,BAO_0000019,
14045,Autocuration,,,1,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 6.5, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",U,,,22224,0,,CHEMBL628100,BAO_0000019,
14046,Autocuration,,,1,,,Mean rate constant for the hydrolysis of compound in buffers at pH 7.4 at 37 degrees Centigrade in incubation mixture - d(A)-d(T) (10:!),U,,,22224,0,,CHEMBL628101,BAO_0000019,
14047,Autocuration,,,1,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - 5'-GMP/5'-CMP (1:1)",U,,,22224,0,,CHEMBL628102,BAO_0000019,
14048,Autocuration,,,1,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(A)-d(T) (1:1)",U,,,22224,0,,CHEMBL628103,BAO_0000019,
14049,Autocuration,,,1,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (10:1)",U,,,22224,0,,CHEMBL628104,BAO_0000019,
14050,Autocuration,,,1,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(C) (1:1)",U,,,22224,0,,CHEMBL628105,BAO_0000019,
14051,Autocuration,,,1,,,"Mean rate constant for the hydrolysis of compound in buffers at pH 7.4, at 37 degrees Celsius in incubation mixture - d(G)-d(T) (10:1)",U,,,22224,0,,CHEMBL628106,BAO_0000019,
14052,Intermediate,10116.0,,1,1088.0,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,N,,,50597,1,,CHEMBL628107,BAO_0000218,
14053,Autocuration,,,1,1088.0,,Mean urine volume excretion in conscious rats at a dose of 0.3 mg/kg given orally,U,,,22224,0,,CHEMBL628108,BAO_0000218,
14054,Intermediate,10116.0,,1,1088.0,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,N,,,50597,1,,CHEMBL628109,BAO_0000218,
14055,Autocuration,,,1,1088.0,,Mean urine volume excretion in conscious rats at a dose of 1.0 mg/kg given orally,U,,,22224,0,,CHEMBL625299,BAO_0000218,
14056,Intermediate,10116.0,,1,1088.0,,Mean urine volume excretion in conscious rats at a dose of 10 mg/kg given orally,N,,,50597,1,,CHEMBL625300,BAO_0000218,
14057,Intermediate,10116.0,,1,1088.0,,Mean urine volume excretion in conscious rats at a dose of 100 mg/kg given orally,N,,,50597,1,,CHEMBL625301,BAO_0000218,
14058,Intermediate,10116.0,,1,1088.0,,Mean urine volume excretion in conscious rats at a dose of 3.0 mg/kg given orally,N,,,50597,1,,CHEMBL625302,BAO_0000218,
14059,Intermediate,10116.0,,1,1088.0,,Mean urine volume excretion in conscious rats at a dose of 30 mg/kg given orally,N,,,50597,1,,CHEMBL874649,BAO_0000218,
14060,Intermediate,10116.0,,1,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes,N,,,50597,1,,CHEMBL625303,BAO_0000218,
14061,Intermediate,10116.0,,1,,,In vitro metabolic stability of the test compound was evaluated after incubation in the presence of freshly isolated rat hepatocytes; NA= Not tested,N,,,50597,1,,CHEMBL625463,BAO_0000218,
14062,Intermediate,9606.0,,1,2107.0,,In vitro metabolism in human liver microsomes,N,,,50587,1,,CHEMBL625464,BAO_0000218,
14063,Intermediate,9606.0,,1,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated.,N,,,50587,1,,CHEMBL625465,BAO_0000218,
14064,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.06 uM/Kg of drug,N,,,50588,1,,CHEMBL625466,BAO_0000218,
14065,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of dogs after peroral administration of 9.6 uM/Kg of drug,N,,,50588,1,,CHEMBL625467,BAO_0000218,
14066,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after intravenous administration of 7.94 uM/Kg of drug,N,,,50597,1,,CHEMBL625468,BAO_0000218,
14067,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 0 uM/Kg of drug,N,,,50597,1,,CHEMBL625469,BAO_0000218,
14068,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.01 uM/Kg of drug,N,,,50597,1,,CHEMBL625470,BAO_0000218,
14069,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 1.13 uM/Kg of drug,N,,,50597,1,,CHEMBL632418,BAO_0000218,
14070,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 10.1 uM/Kg of drug,N,,,50597,1,,CHEMBL627250,BAO_0000218,
14071,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 102 uM/Kg of drug,N,,,50597,1,,CHEMBL627251,BAO_0000218,
14072,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 105 uM/Kg of drug,N,,,50597,1,,CHEMBL627252,BAO_0000218,
14073,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 11.3 uM/Kg of drug,N,,,50597,1,,CHEMBL627253,BAO_0000218,
14074,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 113 uM/Kg of drug,N,,,50597,1,,CHEMBL627254,BAO_0000218,
14075,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 19.5 uM/Kg of drug,N,,,50597,1,,CHEMBL875471,BAO_0000218,
14076,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 195 uM/Kg of drug,N,,,50597,1,,CHEMBL627255,BAO_0000218,
14077,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 21.7 uM/Kg of drug,N,,,50597,1,,CHEMBL627256,BAO_0000218,
14078,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 217 uM/Kg of drug,N,,,50597,1,,CHEMBL627257,BAO_0000218,
14079,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 23.9 uM/Kg of drug,N,,,50597,1,,CHEMBL627258,BAO_0000218,
14080,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 239 uM/Kg of drug,N,,,50597,1,,CHEMBL627259,BAO_0000218,
14081,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 24.9 uM/Kg of drug,N,,,50597,1,,CHEMBL627260,BAO_0000218,
14082,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 249 uM/Kg of drug,N,,,50597,1,,CHEMBL623256,BAO_0000218,
14083,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 25.9 uM/Kg of drug,N,,,50597,1,,CHEMBL874413,BAO_0000218,
14084,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 259 uM/Kg of drug,N,,,50597,1,,CHEMBL623257,BAO_0000218,
14085,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 26.5 uM/Kg of drug,N,,,50597,1,,CHEMBL623258,BAO_0000218,
14086,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 265 uM/Kg of drug,N,,,50597,1,,CHEMBL623259,BAO_0000218,
14087,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27 uM/Kg of drug,N,,,50597,1,,CHEMBL623260,BAO_0000218,
14088,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 27.9 uM/Kg of drug,N,,,50597,1,,CHEMBL623261,BAO_0000218,
14089,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 270 uM/Kg of drug,N,,,50597,1,,CHEMBL623262,BAO_0000218,
14090,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 279 uM/Kg of drug,N,,,50597,1,,CHEMBL623263,BAO_0000218,
14091,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.2 uM/Kg of drug,N,,,50597,1,,CHEMBL623264,BAO_0000218,
14092,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.22 uM/Kg of drug,N,,,50597,1,,CHEMBL623265,BAO_0000218,
14093,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 28.9 uM/Kg of drug,N,,,50597,1,,CHEMBL623266,BAO_0000218,
14094,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 282 uM/Kg of drug,N,,,50597,1,,CHEMBL623267,BAO_0000218,
14095,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 289 uM/Kg of drug,N,,,50597,1,,CHEMBL623268,BAO_0000218,
14096,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.40 uM/Kg of drug,N,,,50597,1,,CHEMBL623269,BAO_0000218,
14097,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 3.76 uM/Kg of drug,N,,,50597,1,,CHEMBL623270,BAO_0000218,
14098,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 30.2 uM/Kg of drug,N,,,50597,1,,CHEMBL623271,BAO_0000218,
14099,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 302 uM/Kg of drug,N,,,50597,1,,CHEMBL623272,BAO_0000218,
14100,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 31.6 uM/Kg of drug,N,,,50597,1,,CHEMBL623273,BAO_0000218,
14101,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 316 uM/Kg of drug,N,,,50597,1,,CHEMBL623274,BAO_0000218,
14102,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 32.4 uM/Kg of drug,N,,,50597,1,,CHEMBL874414,BAO_0000218,
14103,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 324 uM/Kg of drug,N,,,50597,1,,CHEMBL623275,BAO_0000218,
14104,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.0 uM/Kg of drug,N,,,50597,1,,CHEMBL629150,BAO_0000218,
14105,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.1 uM/Kg of drug,N,,,50597,1,,CHEMBL623276,BAO_0000218,
14106,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 34.8 uM/Kg of drug,N,,,50597,1,,CHEMBL623277,BAO_0000218,
14107,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 341 uM/Kg of drug,N,,,50597,1,,CHEMBL623112,BAO_0000218,
14108,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 348 uM/Kg of drug,N,,,50597,1,,CHEMBL623113,BAO_0000218,
14109,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 37.6 uM/Kg of drug,N,,,50597,1,,CHEMBL623800,BAO_0000218,
14110,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 58.4 uM/Kg of drug,N,,,50597,1,,CHEMBL623801,BAO_0000218,
14111,Intermediate,10116.0,In vivo,1,2106.0,,"Biodistribution in uterus / spleen, muscle, lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol",N,,,50597,1,,CHEMBL623802,BAO_0000218,
14112,Intermediate,10116.0,In vivo,1,995.0,,Biodistribution in uterus of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL623803,BAO_0000218,
14113,Intermediate,10116.0,In vivo,1,995.0,,Biodistribution in uterus of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL623970,BAO_0000218,
14114,Intermediate,10116.0,In vivo,1,995.0,,Biodistribution in uterus of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL623971,BAO_0000218,
14115,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 10 min post injection (Average of three to five animals),N,,,50597,1,,CHEMBL623972,BAO_0000218,
14116,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 30 min post injection (Average of three to five animals),N,,,50597,1,,CHEMBL623973,BAO_0000218,
14117,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 5 min post injection (Average of three to five animals),N,,,50597,1,,CHEMBL623974,BAO_0000218,
14118,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of 99m Tc complexes in rat and radio activity in blood at 60 min post injection (Average of three to five animals),N,,,50597,1,,CHEMBL623975,BAO_0000218,
14119,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 10 min post injection (Average of three to five animals),N,,,50597,1,,CHEMBL623976,BAO_0000218,
14120,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 30 min post injection (Average of three to five animals),N,,,50597,1,,CHEMBL623977,BAO_0000218,
14121,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 5 min post injection (Average of three to five animals),N,,,50597,1,,CHEMBL623978,BAO_0000218,
14122,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of 99m Tc complexes in rat and radio activity in brain at 60 min post injection (Average of three to five animals),N,,,50597,1,,CHEMBL623979,BAO_0000218,
14123,Intermediate,10116.0,In vivo,1,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 10 min post injection (Average of three to five animals),N,,,50597,1,,CHEMBL623980,BAO_0000218,
14124,Intermediate,10116.0,In vivo,1,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 30 min post injection (Average of three to five animals),N,,,50597,1,,CHEMBL623981,BAO_0000218,
14125,Intermediate,10116.0,In vivo,1,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 5 min post injection (Average of three to five animals),N,,,50597,1,,CHEMBL626278,BAO_0000218,
14126,Intermediate,10116.0,In vivo,1,,,Biodistribution of 99m Tc complexes in rat and radio activity in brain/blood at 60 min post injection (Average of three to five animals),N,,,50597,1,,CHEMBL626279,BAO_0000218,
14127,Intermediate,10090.0,In vivo,1,,,Biodistribution in mice bladder plus excreted urine was determined,N,,,50594,1,,CHEMBL626280,BAO_0000218,
14128,Intermediate,10090.0,,1,,,"Percentage biodistribution in mouse blood, 10 minutes post injection",N,,,50594,1,,CHEMBL626281,BAO_0000218,
14129,Intermediate,10090.0,,1,,,"Percentage biodistribution in mouse blood, 30 minutes post injection",N,,,50594,1,,CHEMBL626282,BAO_0000218,
14130,Intermediate,10090.0,,1,,,"Percentage biodistribution in mouse blood, 5 minutes post injection",N,,,50594,1,,CHEMBL626283,BAO_0000218,
14131,Intermediate,10090.0,,1,,,"Percentage biodistribution in mouse blood, 60 minutes post injection",N,,,50594,1,,CHEMBL626284,BAO_0000218,
14132,Intermediate,10090.0,,1,955.0,,"Percentage biodistribution in mouse brain, 10 minutes post injection",N,,,50594,1,,CHEMBL626285,BAO_0000218,
14133,Intermediate,10090.0,,1,955.0,,"Percentage biodistribution in mouse brain, 30 minutes post injection",N,,,50594,1,,CHEMBL626286,BAO_0000218,
14134,Intermediate,10090.0,,1,955.0,,"Percentage biodistribution in mouse brain, 5 minutes post injection",N,,,50594,1,,CHEMBL626287,BAO_0000218,
14135,Intermediate,10090.0,,1,955.0,,"Percentage biodistribution in mouse brain, 60 minutes post injection",N,,,50594,1,,CHEMBL626288,BAO_0000218,
14136,Intermediate,10090.0,,1,,,"Percentage biodistribution in mouse heart, 10 minutes post injection",N,,,50594,1,,CHEMBL626289,BAO_0000218,
14137,Intermediate,10090.0,,1,,,"Percentage biodistribution in mouse heart, 30 minutes post injection",N,,,50594,1,,CHEMBL626290,BAO_0000218,
14138,Intermediate,10090.0,,1,,,"Percentage biodistribution in mouse heart, 5 minutes post injection",N,,,50594,1,,CHEMBL626291,BAO_0000218,
14139,Intermediate,10090.0,,1,,,"Percentage biodistribution in mouse heart, 60 minutes post injection",N,,,50594,1,,CHEMBL839888,BAO_0000218,
14140,Intermediate,10090.0,,1,160.0,,"Percentage biodistribution in mouse intestine, 10 minutes post injection",N,,,50594,1,,CHEMBL626292,BAO_0000218,
14141,Intermediate,10090.0,,1,160.0,,"Percentage biodistribution in mouse intestine, 30 minutes post injection",N,,,50594,1,,CHEMBL626293,BAO_0000218,
14142,Intermediate,10090.0,,1,160.0,,"Percentage biodistribution in mouse intestine, 5 minutes post injection",N,,,50594,1,,CHEMBL626294,BAO_0000218,
14143,Intermediate,10090.0,,1,160.0,,"Percentage biodistribution in mouse intestine, 60 minutes post injection",N,,,50594,1,,CHEMBL626295,BAO_0000218,
14144,Intermediate,10090.0,,1,2107.0,,"Percentage biodistribution in mouse liver, 10 minutes post injection",N,,,50594,1,,CHEMBL627659,BAO_0000218,
14145,Intermediate,10090.0,,1,2107.0,,"Percentage biodistribution in mouse liver, 30 minutes of post injection",N,,,50594,1,,CHEMBL627660,BAO_0000218,
14146,Intermediate,10090.0,,1,2107.0,,"Percentage biodistribution in mouse liver, 5 minutes post injection",N,,,50594,1,,CHEMBL627661,BAO_0000218,
14147,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution in mice liver at 60 minutes of post injection,N,,,50594,1,,CHEMBL627662,BAO_0000218,
14148,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution in mice lungs at 10 min of post injection,N,,,50594,1,,CHEMBL627663,BAO_0000218,
14149,Intermediate,10090.0,,1,,,"Percentage biodistribution in mouse lung, 30 minutes post injection",N,,,50594,1,,CHEMBL627664,BAO_0000218,
14150,Intermediate,10090.0,,1,,,"Percentage biodistribution in mousee lung, 5 minutes post injection",N,,,50594,1,,CHEMBL627665,BAO_0000218,
14151,Intermediate,10090.0,In vivo,1,2048.0,,Biodistribution in mice lungs at 60 min of post injection,N,,,50594,1,,CHEMBL627666,BAO_0000218,
14152,Intermediate,10090.0,,1,2106.0,,Percentage biodistribution in mouse spleen,N,,,50594,1,,CHEMBL627667,BAO_0000218,
14153,Intermediate,10090.0,,1,945.0,,Percentage biodistribution in mouse stomach,N,,,50594,1,,CHEMBL627668,BAO_0000218,
14154,Intermediate,10090.0,,1,1088.0,,Mean biodistribution and elimination data in urine was reported 24 h after administering compound intravenously in tumor-bearing female BALB-C mice.,N,,,50594,1,,CHEMBL627669,BAO_0000218,
14155,Autocuration,,In vivo,1,1255.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bladder,U,,,22224,0,,CHEMBL627670,BAO_0000218,
14156,Autocuration,,In vivo,1,178.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in blood,U,,,22224,0,,CHEMBL627671,BAO_0000218,
14157,Autocuration,,In vivo,1,1474.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in bone,U,,,22224,0,,CHEMBL627672,BAO_0000218,
14158,Autocuration,,In vivo,1,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in fat,U,,,22224,0,,CHEMBL627673,BAO_0000218,
14159,Autocuration,,In vivo,1,2113.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in kidney,U,,,22224,0,,CHEMBL627674,BAO_0000218,
14160,Autocuration,,In vivo,1,2107.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in liver,U,,,22224,0,,CHEMBL627675,BAO_0000218,
14161,Autocuration,,In vivo,1,2048.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in lung,U,,,22224,0,,CHEMBL627676,BAO_0000218,
14162,Autocuration,,In vivo,1,2385.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in muscle,U,,,22224,0,,CHEMBL627677,BAO_0000218,
14163,Autocuration,,,1,,,"Biomolecular rate constant for reactivation and measure of the inherent reactivity of the oximate form of the reactivator in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL627678,BAO_0000019,
14164,Intermediate,10116.0,,1,1977.0,,Affinity for protein binding expressed as association constant in fresh rat serum,N,,,50597,1,,CHEMBL627679,BAO_0000218,
14165,Autocuration,,,1,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,U,,,22224,0,,CHEMBL627680,BAO_0000019,
14166,Autocuration,,,1,,,Kinetic constant (Kcat) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,U,,,22224,0,,CHEMBL627681,BAO_0000019,
14167,Autocuration,,,1,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation,U,,,22224,0,,CHEMBL627682,BAO_0000019,
14168,Autocuration,,,1,,,Inactivation constant (Kinact) was calculated by inhibition of monoamino oxidase B (MAO B) at saturation; Inactive,U,,,22224,0,,CHEMBL627683,BAO_0000019,
14169,Autocuration,,,1,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4,U,,,22224,0,,CHEMBL627684,BAO_0000019,
14170,Autocuration,,,1,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 2.4; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",U,,,22224,0,,CHEMBL874441,BAO_0000019,
14171,Autocuration,,,1,,,The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; No cyclization detected over 4 h,U,,,22224,0,,CHEMBL627685,BAO_0000019,
14172,Autocuration,,,1,,,"The observed pseudo-first-order rate constants of compound for cyclization reaction at pH 6.8; Significant cyclization occurred during nitro reduction, precluding isolation of the pure amine and determination of rate constants",U,,,22224,0,,CHEMBL627686,BAO_0000019,
14173,Autocuration,,,1,,,Apparent rate constant Koff for inactivation of dTMP synthase.,U,,,22224,0,,CHEMBL627687,BAO_0000019,
14174,Autocuration,,,1,,,The irreversible inhibitor activity by second order rate equation.,U,,,22224,0,,CHEMBL627688,BAO_0000019,
14175,Intermediate,10116.0,,1,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 1 mg/kg concentration,N,,,50597,1,,CHEMBL628038,BAO_0000218,
14176,Intermediate,10116.0,,1,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at 5 mg/kg concentration,N,,,50597,1,,CHEMBL628039,BAO_0000218,
14177,Intermediate,10116.0,,1,,,Compound was tested for oral diuretic effect on spontaneously hypertensive rats by measuring the potassium excretion at vehicle concentration,N,,,50597,1,,CHEMBL628040,BAO_0000218,
14178,Autocuration,,,1,,,Dissociation rate calculated from the first-order equation using t1/2 value,U,,,22224,0,,CHEMBL628041,BAO_0000019,
14179,Autocuration,,,1,,,The compound was tested for Binding constant against DNA,U,,,22224,0,,CHEMBL630226,BAO_0000019,
14180,Autocuration,,,1,,,First order rate constant for cyclization of the compound,U,,,22224,0,,CHEMBL628042,BAO_0000019,
14181,Autocuration,,,1,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,U,,,22224,0,,CHEMBL625232,BAO_0000019,
14182,Autocuration,,,1,,,First order rate constant of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,U,,,22224,0,,CHEMBL625233,BAO_0000019,
14183,Autocuration,,,1,,,Hydrolysis rate constant was determined,U,,,22224,0,,CHEMBL625979,BAO_0000019,
14184,Autocuration,,,1,,,Observed first order rate constant,U,,,22224,0,,CHEMBL625980,BAO_0000019,
14185,Autocuration,,,1,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,U,,,22224,0,,CHEMBL625981,BAO_0000019,
14186,Autocuration,,,1,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,U,,,22224,0,,CHEMBL625982,BAO_0000019,
14187,Autocuration,,,1,,,Second-order rate constant for attack on PNPA at 25 degree Centigrade,U,,,22224,0,,CHEMBL625983,BAO_0000019,
14188,Autocuration,,,1,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL625984,BAO_0000019,
14189,Autocuration,,,1,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL625985,BAO_0000019,
14190,Autocuration,,,1,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL625986,BAO_0000019,
14191,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL625987,BAO_0000019,
14192,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL625988,BAO_0000019,
14193,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL625989,BAO_0000019,
14194,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL625990,BAO_0000019,
14195,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL625991,BAO_0000019,
14196,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL625992,BAO_0000019,
14197,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL625993,BAO_0000019,
14198,Autocuration,,,1,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL631973,BAO_0000019,
14199,Autocuration,,,1,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL632143,BAO_0000019,
14200,Autocuration,,,1,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL632144,BAO_0000019,
14201,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL632145,BAO_0000019,
14202,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL632146,BAO_0000019,
14203,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL632147,BAO_0000019,
14204,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL632148,BAO_0000019,
14205,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL632149,BAO_0000019,
14206,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL632150,BAO_0000019,
14207,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL632151,BAO_0000019,
14208,Intermediate,9606.0,,1,,,Metabolism (NADH oxidation) by recombinant human NAD(P)H: quinone oxidoreductase (NQO1) is evaluated; not detected,N,,,50587,1,,CHEMBL632152,BAO_0000218,
14209,Intermediate,9606.0,,1,,,Metabolism after 30 min of incubation with human liver microsomes in the absence of cofactor NADH (2.0 mM) at a concentration of 25 uM,N,,,50587,1,,CHEMBL632153,BAO_0000218,
14210,Intermediate,9606.0,,1,,,Metabolism after 30 min of incubation with human liver microsomes in the presence of cofactor NADH (2.0 mM) at a concentration of 25 uM,N,,,50587,1,,CHEMBL632154,BAO_0000218,
14211,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Tested mice 10,N,,,50602,1,,CHEMBL632155,BAO_0000218,
14212,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 12.5 mg/kg per day; Total mice tested 10,N,,,50602,1,,CHEMBL632156,BAO_0000218,
14213,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 3.1 mg/kg per day; Tested mice 10,N,,,50602,1,,CHEMBL632157,BAO_0000218,
14214,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Tested mice 10,N,,,50602,1,,CHEMBL632158,BAO_0000218,
14215,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at a dose 50 mg/kg per day; Total mice tested 10,N,,,50602,1,,CHEMBL632159,BAO_0000218,
14216,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 0.8 mg/kg per day; Tested mice 10,N,,,50602,1,,CHEMBL626305,BAO_0000218,
14217,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered orally at dose 3.1 mg/kg per day; Total mice tested 10,N,,,50602,1,,CHEMBL626306,BAO_0000218,
14218,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.02 mg/kg per day; Tested mice 10,N,,,50602,1,,CHEMBL626307,BAO_0000218,
14219,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.06 mg/kg per day; Tested mice 10,N,,,50602,1,,CHEMBL626308,BAO_0000218,
14220,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 0.25 mg/kg per day; Tested mice 10,N,,,50602,1,,CHEMBL626479,BAO_0000218,
14221,Intermediate,10298.0,,1,,,Efficacy was evaluated against Oraficial HSV-1 infection in mice with lesions administered topically at a dose 1 mg/kg per day; Tested mice 10,N,,,50602,1,,CHEMBL626480,BAO_0000218,
14222,Autocuration,,,1,,,Calculated partition coefficient (clogP) (MlogP),U,,,22229,0,,CHEMBL626481,BAO_0000100,
14223,Autocuration,,,1,,,Equipotent potent ratio relative to carbachol (nicotinic activity),U,,,22224,0,,CHEMBL626482,BAO_0000019,
14224,Intermediate,9615.0,,1,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 ); NA denotes not available",N,,,50588,1,,CHEMBL626483,BAO_0000218,
14225,Intermediate,9615.0,,1,,,"Concentration after 8 hour (bioavailability in dog, compound was delivered orally in 0.05 M citric acid at 10 mg/Kg. n=2 );NA denotes not available",N,,,50588,1,,CHEMBL626484,BAO_0000218,
14226,Autocuration,,,1,,,Solubility at pH 7.4 in micro g/mL;NA denotes available,U,,,22229,0,,CHEMBL626485,BAO_0000100,
14227,Autocuration,,,1,,,Solubility at pH 7.4 in micro g/mL;NA denotes not available,U,,,22229,0,,CHEMBL626486,BAO_0000100,
14228,Autocuration,,,1,,,Solubility at pH 7.4 in ug/mL;NA denotes not available,U,,,22229,0,,CHEMBL626487,BAO_0000100,
14229,Intermediate,9615.0,In vivo,1,1969.0,,Maximal plasma concentration in dogs at 10mg/kg oral dose 0.05M citric acid,N,,,50588,1,,CHEMBL626488,BAO_0000218,
14230,Intermediate,10116.0,,1,1977.0,,Affinity for protein binding expressed as association constant in fresh rat serum; ND is Not Determined.,N,,,50597,1,,CHEMBL626489,BAO_0000218,
14231,Autocuration,,,1,,,Area under the MAP curve measured over 5 min; ND means Not determined,U,,,22224,0,,CHEMBL626490,BAO_0000019,
14232,Autocuration,,,1,,,Lipophilicity expressed as the negative logarithm of the equilibrium constant; ND denotes no data.,U,,,22224,0,,CHEMBL626491,BAO_0000100,
14233,Autocuration,,,1,,,The apparent partition coefficient(D) in cyclohexane-0.05 M phosphate buffer (pH 7.4) at 21 degree celsius; not determined,U,,,22229,0,,CHEMBL626492,BAO_0000100,
14234,Autocuration,,,1,,,Half-life was measured in the presence of NADPH at 20 uM; No inhibition,U,,,22224,0,,CHEMBL626493,BAO_0000019,
14235,Intermediate,10116.0,In vivo,1,,,Half life after oral administration to Sprague-Dawley rats; NT is Not tested,N,,,50597,1,,CHEMBL626494,BAO_0000218,
14236,Autocuration,,In vivo,1,,,Half life after oral tested,U,,,22224,0,,CHEMBL626495,BAO_0000218,
14237,Intermediate,10116.0,,1,1969.0,,Half life was determined in plasma of rat; NT indicates not tested,N,,,50597,1,,CHEMBL626496,BAO_0000218,
14238,Intermediate,10116.0,In vivo,1,,,Oral bioavailability after oral administration to Sprague-Dawley rats; NT is Not tested,N,,,50597,1,,CHEMBL626497,BAO_0000218,
14239,Autocuration,,In vivo,1,,,Oral bioavailability after oral tested,U,,,22224,0,,CHEMBL626498,BAO_0000218,
14240,Intermediate,10116.0,,1,,,The bioavailability in rats at 15.9 uM/Kg after intravenous administration; NT=Not tested (F),N,,,50597,1,,CHEMBL626499,BAO_0000218,
14241,Intermediate,10116.0,,1,,,The compound was tested for volume of distribution in rat at 15.9 uM/Kg after peroral administration; NT=Not tested (Vd L/Kg),N,,,50597,1,,CHEMBL626500,BAO_0000218,
14242,Intermediate,10116.0,,1,1969.0,,half life was determined in plasma of rat; NT indicates not tested,N,,,50597,1,,CHEMBL626501,BAO_0000218,
14243,Intermediate,10116.0,,1,1969.0,,half life was determined in plasma of rat; NT means not tested,N,,,50597,1,,CHEMBL626502,BAO_0000218,
14244,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); Value 0.41/2.32,N,,,50597,1,,CHEMBL626503,BAO_0000218,
14245,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); inactive,N,,,50597,1,,CHEMBL626504,BAO_0000218,
14246,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.17/0.43,N,,,50597,1,,CHEMBL626505,BAO_0000218,
14247,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.2/0.38,N,,,50597,1,,CHEMBL626506,BAO_0000218,
14248,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.26/0.23,N,,,50597,1,,CHEMBL626507,BAO_0000218,
14249,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.28/0.26,N,,,50597,1,,CHEMBL626508,BAO_0000218,
14250,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.31/0.35,N,,,50597,1,,CHEMBL626509,BAO_0000218,
14251,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.35/2.88,N,,,50597,1,,CHEMBL875480,BAO_0000218,
14252,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.29,N,,,50597,1,,CHEMBL626510,BAO_0000218,
14253,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.47,N,,,50597,1,,CHEMBL626511,BAO_0000218,
14254,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.36/0.49,N,,,50597,1,,CHEMBL626512,BAO_0000218,
14255,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.38/0.23,N,,,50597,1,,CHEMBL628208,BAO_0000218,
14256,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.39/0.22,N,,,50597,1,,CHEMBL628209,BAO_0000218,
14257,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/0.48,N,,,50597,1,,CHEMBL628210,BAO_0000218,
14258,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/1.49,N,,,50597,1,,CHEMBL628211,BAO_0000218,
14259,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.41/2.06,N,,,50597,1,,CHEMBL628212,BAO_0000218,
14260,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.42/0.65,N,,,50597,1,,CHEMBL628213,BAO_0000218,
14261,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 65.2 uM/Kg of drug,N,,,50597,1,,CHEMBL628214,BAO_0000218,
14262,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.6 uM/Kg of drug,N,,,50597,1,,CHEMBL628215,BAO_0000218,
14263,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 71.8 uM/Kg of drug,N,,,50597,1,,CHEMBL628216,BAO_0000218,
14264,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 74.8 uM/Kg of drug,N,,,50597,1,,CHEMBL626595,BAO_0000218,
14265,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 77.5 uM/Kg of drug,N,,,50597,1,,CHEMBL626596,BAO_0000218,
14266,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 79.4 uM/Kg of drug,N,,,50597,1,,CHEMBL626597,BAO_0000218,
14267,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 80.9 uM/Kg of drug,N,,,50597,1,,CHEMBL626598,BAO_0000218,
14268,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 83.8 uM/Kg of drug,N,,,50597,1,,CHEMBL622242,BAO_0000218,
14269,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.5 uM/Kg of drug,N,,,50597,1,,CHEMBL622243,BAO_0000218,
14270,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 84.7 uM/Kg of drug,N,,,50597,1,,CHEMBL622244,BAO_0000218,
14271,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.7 uM/Kg of drug,N,,,50597,1,,CHEMBL622245,BAO_0000218,
14272,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 86.9 uM/Kg of drug,N,,,50597,1,,CHEMBL622246,BAO_0000218,
14273,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 9.06 uM/Kg of drug,N,,,50597,1,,CHEMBL622247,BAO_0000218,
14274,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 90.6 uM/Kg of drug,N,,,50597,1,,CHEMBL622248,BAO_0000218,
14275,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 94.9 uM/Kg of drug,N,,,50597,1,,CHEMBL877483,BAO_0000218,
14276,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of chlorine in urine of rats after peroral administration of 97.1 uM/Kg of drug,N,,,50597,1,,CHEMBL622249,BAO_0000218,
14277,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,N,,,50588,1,,CHEMBL622250,BAO_0000218,
14278,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,N,,,50588,1,,CHEMBL622251,BAO_0000218,
14279,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,N,,,50588,1,,CHEMBL622252,BAO_0000218,
14280,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,N,,,50588,1,,CHEMBL622253,BAO_0000218,
14281,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,N,,,50588,1,,CHEMBL622254,BAO_0000218,
14282,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,N,,,50588,1,,CHEMBL622255,BAO_0000218,
14283,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,N,,,50588,1,,CHEMBL622256,BAO_0000218,
14284,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,N,,,50588,1,,CHEMBL622257,BAO_0000218,
14285,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,N,,,50588,1,,CHEMBL622258,BAO_0000218,
14286,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,N,,,50588,1,,CHEMBL622259,BAO_0000218,
14287,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,N,,,50588,1,,CHEMBL622927,BAO_0000218,
14288,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,N,,,50588,1,,CHEMBL622928,BAO_0000218,
14289,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,N,,,50588,1,,CHEMBL622929,BAO_0000218,
14290,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.06 uM/Kg of drug,N,,,50588,1,,CHEMBL623182,BAO_0000218,
14291,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,N,,,50588,1,,CHEMBL623183,BAO_0000218,
14292,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 0 uM/Kg of drug,N,,,50597,1,,CHEMBL623184,BAO_0000218,
14293,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.01 uM/Kg of drug,N,,,50597,1,,CHEMBL623185,BAO_0000218,
14294,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 1.13 uM/Kg of drug,N,,,50597,1,,CHEMBL877484,BAO_0000218,
14295,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 10.1 uM/Kg of drug,N,,,50597,1,,CHEMBL627274,BAO_0000218,
14296,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 102 uM/Kg of drug,N,,,50597,1,,CHEMBL623186,BAO_0000218,
14297,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 105 uM/Kg of drug,N,,,50597,1,,CHEMBL623187,BAO_0000218,
14298,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 11.3 uM/Kg of drug,N,,,50597,1,,CHEMBL623188,BAO_0000218,
14299,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 113 uM/Kg of drug,N,,,50597,1,,CHEMBL628055,BAO_0000218,
14300,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 19.5 uM/Kg of drug,N,,,50597,1,,CHEMBL628056,BAO_0000218,
14301,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 195 uM/Kg of drug,N,,,50597,1,,CHEMBL628200,BAO_0000218,
14302,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 21.7 uM/Kg of drug,N,,,50597,1,,CHEMBL628201,BAO_0000218,
14303,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 217 uM/Kg of drug,N,,,50597,1,,CHEMBL628202,BAO_0000218,
14304,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 23.9 uM/Kg of drug,N,,,50597,1,,CHEMBL628203,BAO_0000218,
14305,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 239 uM/Kg of drug,N,,,50597,1,,CHEMBL628204,BAO_0000218,
14306,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 24.9 uM/Kg of drug,N,,,50597,1,,CHEMBL628205,BAO_0000218,
14307,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 249 uM/Kg of drug,N,,,50597,1,,CHEMBL628206,BAO_0000218,
14308,Autocuration,,In vivo,1,2367.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d),U,,,22224,0,,CHEMBL628207,BAO_0000218,
14309,Autocuration,,In vivo,1,2367.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/biood,U,,,22224,0,,CHEMBL627220,BAO_0000218,
14310,Autocuration,,In vivo,1,2385.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (d)/muscle,U,,,22224,0,,CHEMBL627221,BAO_0000218,
14311,Autocuration,,In vivo,1,2367.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v),U,,,22224,0,,CHEMBL627222,BAO_0000218,
14312,Autocuration,,In vivo,1,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/blood,U,,,22224,0,,CHEMBL627223,BAO_0000218,
14313,Autocuration,,In vivo,1,2385.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in prostate (v)/muscle,U,,,22224,0,,CHEMBL632062,BAO_0000218,
14314,Autocuration,,In vivo,1,2106.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 1 hour in spleen,U,,,22224,0,,CHEMBL632063,BAO_0000218,
14315,Autocuration,,In vivo,1,1255.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bladder,U,,,22224,0,,CHEMBL632064,BAO_0000218,
14316,Autocuration,,In vivo,1,178.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in blood,U,,,22224,0,,CHEMBL632065,BAO_0000218,
14317,Autocuration,,In vivo,1,1474.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in bone,U,,,22224,0,,CHEMBL632066,BAO_0000218,
14318,Autocuration,,In vivo,1,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in fat,U,,,22224,0,,CHEMBL632067,BAO_0000218,
14319,Autocuration,,In vivo,1,2113.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in kidney,U,,,22224,0,,CHEMBL629188,BAO_0000218,
14320,Autocuration,,In vivo,1,2107.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in liver,U,,,22224,0,,CHEMBL629189,BAO_0000218,
14321,Autocuration,,In vivo,1,2048.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in lung,U,,,22224,0,,CHEMBL629190,BAO_0000218,
14322,Autocuration,,In vivo,1,2385.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in muscle,U,,,22224,0,,CHEMBL629191,BAO_0000218,
14323,Autocuration,,In vivo,1,2367.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d),U,,,22224,0,,CHEMBL629192,BAO_0000218,
14324,Autocuration,,In vivo,1,2385.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (d)/muscle,U,,,22224,0,,CHEMBL629193,BAO_0000218,
14325,Autocuration,,In vivo,1,2367.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v),U,,,22224,0,,CHEMBL629194,BAO_0000218,
14326,Autocuration,,In vivo,1,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/blood,U,,,22224,0,,CHEMBL629195,BAO_0000218,
14327,Autocuration,,In vivo,1,2385.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in prostate (v)/muscle,U,,,22224,0,,CHEMBL629373,BAO_0000218,
14328,Autocuration,,In vivo,1,2106.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked) in spleen,U,,,22224,0,,CHEMBL629374,BAO_0000218,
14329,Autocuration,,In vivo,1,2367.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (blocked)i n prostate (d)/biood,U,,,22224,0,,CHEMBL629375,BAO_0000218,
14330,Autocuration,,In vivo,1,1255.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bladder,U,,,22224,0,,CHEMBL629376,BAO_0000218,
14331,Autocuration,,In vivo,1,178.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in blood,U,,,22224,0,,CHEMBL629377,BAO_0000218,
14332,Autocuration,,In vivo,1,1474.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in bone,U,,,22224,0,,CHEMBL629378,BAO_0000218,
14333,Autocuration,,In vivo,1,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in fat,U,,,22224,0,,CHEMBL629379,BAO_0000218,
14334,Autocuration,,In vivo,1,2113.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in kidney,U,,,22224,0,,CHEMBL629151,BAO_0000218,
14335,Autocuration,,In vivo,1,2107.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in liver,U,,,22224,0,,CHEMBL629152,BAO_0000218,
14336,Autocuration,,In vivo,1,2048.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in lung,U,,,22224,0,,CHEMBL629153,BAO_0000218,
14337,Autocuration,,In vivo,1,2385.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in muscle,U,,,22224,0,,CHEMBL629154,BAO_0000218,
14338,Autocuration,,In vivo,1,2367.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d),U,,,22224,0,,CHEMBL629155,BAO_0000218,
14339,Autocuration,,In vivo,1,2367.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/biood,U,,,22224,0,,CHEMBL629156,BAO_0000218,
14340,Autocuration,,In vivo,1,2385.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (d)/muscle,U,,,22224,0,,CHEMBL629157,BAO_0000218,
14341,Autocuration,,In vivo,1,2367.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v),U,,,22224,0,,CHEMBL629158,BAO_0000218,
14342,Autocuration,,In vivo,1,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/blood,U,,,22224,0,,CHEMBL629159,BAO_0000218,
14343,Autocuration,,In vivo,1,2385.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in prostate (v)/muscle,U,,,22224,0,,CHEMBL629160,BAO_0000218,
14344,Autocuration,,In vivo,1,2106.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour (low) in spleen,U,,,22224,0,,CHEMBL629161,BAO_0000218,
14345,Autocuration,,In vivo,1,1255.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bladder,U,,,22224,0,,CHEMBL629162,BAO_0000218,
14346,Autocuration,,In vivo,1,178.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in blood,U,,,22224,0,,CHEMBL629163,BAO_0000218,
14347,Autocuration,,In vivo,1,1474.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in bone,U,,,22224,0,,CHEMBL629164,BAO_0000218,
14348,Autocuration,,In vivo,1,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in fat,U,,,22224,0,,CHEMBL629165,BAO_0000218,
14349,Autocuration,,In vivo,1,2107.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in liver,U,,,22224,0,,CHEMBL629166,BAO_0000218,
14350,Autocuration,,In vivo,1,2048.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in lung,U,,,22224,0,,CHEMBL629167,BAO_0000218,
14351,Autocuration,,In vivo,1,2385.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in muscle,U,,,22224,0,,CHEMBL629168,BAO_0000218,
14352,Autocuration,,,1,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM,U,,,22224,0,,CHEMBL629169,BAO_0000019,
14353,Autocuration,,,1,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 100 uM; no inhibition is observed at this concentration,U,,,22224,0,,CHEMBL629170,BAO_0000019,
14354,Autocuration,,,1,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM,U,,,22224,0,,CHEMBL631153,BAO_0000019,
14355,Autocuration,,,1,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 10 uM; too active and complete inhibition is observed,U,,,22224,0,,CHEMBL875121,BAO_0000019,
14356,Autocuration,,,1,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM,U,,,22224,0,,CHEMBL631154,BAO_0000019,
14357,Autocuration,,,1,,,Compound was tested for the pseudo first-order rate constants for the inhibition of the cleavage step (k2) of the hammerhead ribozyme at a concentration of 1 uM; too active and complete inhibition is observed,U,,,22224,0,,CHEMBL631155,BAO_0000019,
14358,Autocuration,,,1,,,Hydrolysis rate constant was determined,U,,,22224,0,,CHEMBL631156,BAO_0000019,
14359,Autocuration,,,1,,,"K2, The intrinsic biomolecular reactivation rate constant on VX at 25 degree Centigrade",U,,,22224,0,,CHEMBL631157,BAO_0000019,
14360,Autocuration,,,1,,,"K2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",U,,,22224,0,,CHEMBL631158,BAO_0000019,
14361,Autocuration,,,1,,,"K2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",U,,,22224,0,,CHEMBL631159,BAO_0000019,
14362,Autocuration,,,1,,,Observed second order rate constant,U,,,22224,0,,CHEMBL631160,BAO_0000019,
14363,Autocuration,,,1,,,Rate constant (cyclization rate) in CD3CN-deuterated phosphate buffer at pH 7.4,U,,,22224,0,,CHEMBL631161,BAO_0000019,
14364,Autocuration,,,1,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 24 degree celsius,U,,,22224,0,,CHEMBL631162,BAO_0000019,
14365,Autocuration,,,1,,,Rate constant for decay of compound was determined in 50 mM phosphate buffer (pH 7.4) at 37 degree celsius,U,,,22224,0,,CHEMBL630313,BAO_0000019,
14366,Autocuration,,,1,,,"k2, The intrinsic biomolecular reactivation rate constant on paraxon at 25 degree Centigrade",U,,,22224,0,,CHEMBL630314,BAO_0000019,
14367,Autocuration,,,1,,,"k2, The intrinsic biomolecular reactivation rate constant on sarin at 25 degree Centigrade",U,,,22224,0,,CHEMBL630315,BAO_0000019,
14368,Autocuration,,,1,,,Kinetic parameter of epimerization at a salt concentration (0.01 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL630316,BAO_0000019,
14369,Autocuration,,,1,,,Kinetic parameter of epimerization at a salt concentration (0.1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL630986,BAO_0000019,
14370,Autocuration,,,1,,,Kinetic parameter of epimerization at a salt concentration (1 M) of in Tris.HCl buffer(pH 9.0) and 37 degree C (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL630987,BAO_0000019,
14371,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.0(or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL630988,BAO_0000019,
14372,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 10.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL630989,BAO_0000019,
14373,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 11.3 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL630990,BAO_0000019,
14374,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 7.5 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL630991,BAO_0000019,
14375,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 8.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL630992,BAO_0000019,
14376,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.0 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL630993,BAO_0000019,
14377,Autocuration,,,1,,,Kinetic parameter of epimerization in Tris.HCl buffer at a pH 9.6 (or )in RMPI 1640 cell culture medium containing 10%FCS,U,,,22224,0,,CHEMBL630994,BAO_0000019,
14378,Intermediate,10116.0,,1,,,Rate constants of compound was determined at muscarinic receptor in the rat cerebral cortex,N,,,50597,1,,CHEMBL630995,BAO_0000218,
14379,Autocuration,,,1,,,Association constant for compound at 31 degree C was determined,U,,,22224,0,,CHEMBL629252,BAO_0000019,
14380,Autocuration,,,1,,,Calculated antagonist equilibrium dissociation constant of the compound,U,,,22224,0,,CHEMBL629253,BAO_0000019,
14381,Autocuration,,,1,,,Calculated antagonist equilibrium dissociation constant of the compound; No statistically significant antagonism observed,U,,,22224,0,,CHEMBL629944,BAO_0000019,
14382,Intermediate,10141.0,,1,3126.0,,Dissociation constants vs LTE4 on guinea pig trachea,N,,,50512,1,,CHEMBL629945,BAO_0000218,
14383,Autocuration,,,1,,,"Tested for hydrolysis in presence of boric acid by UV spectrophotometry, dissociation constant was evaluated at the pH < 8",U,,,22224,0,,CHEMBL629946,BAO_0000019,
14384,Autocuration,,,1,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 8.5",U,,,22224,0,,CHEMBL629947,BAO_0000019,
14385,Autocuration,,,1,,,"Tested for hydrolysis in presence of boric acid, rate constant was evaluated at the pH 9.5",U,,,22224,0,,CHEMBL629948,BAO_0000019,
14386,Autocuration,,,1,,,"Tested for hydrolysis in presence of phenylboronic acid, rate constant was evaluated at the pH 9.5",U,,,22224,0,,CHEMBL856024,BAO_0000019,
14387,Autocuration,,,1,,,Affinity constant KD value was derived from TMP,U,,,22224,0,,CHEMBL629949,BAO_0000019,
14388,Autocuration,,,1,,,Apparent dissociation (binding) rate constant was evaluated,U,,,22224,0,,CHEMBL629950,BAO_0000019,
14389,Autocuration,,,1,,,Dissociation constant (KD) of the compound,U,,,22224,0,,CHEMBL630127,BAO_0000100,
14390,Autocuration,,,1,,,Dissociation constant determined by heteronuclear 1H/15N correlation NMR spectroscopy,U,,,22224,0,,CHEMBL630128,BAO_0000100,
14391,Autocuration,,,1,,,Dissociation constant from ESR titration experiments,U,,,22224,0,,CHEMBL630129,BAO_0000100,
14392,Autocuration,,,1,,,Dissociation constant was evaluated which is similar to Ki (inhibitory constant),U,,,22224,0,,CHEMBL630130,BAO_0000019,
14393,Autocuration,,,1,,,Dissociation constant was evaluated.,U,,,22224,0,,CHEMBL875234,BAO_0000100,
14394,Autocuration,,,1,,,Dissociation constant was reported,U,,,22224,0,,CHEMBL630131,BAO_0000100,
14395,Intermediate,10116.0,,1,,,Dissociation constant was determined in rat pituitary cells.,N,,,50597,1,,CHEMBL630132,BAO_0000218,
14396,Autocuration,,,1,,,Equilibrium dissociation constant of CA complex for enantiomer 1 of compound,U,,,22224,0,,CHEMBL630133,BAO_0000019,
14397,Autocuration,,,1,,,Equilibrium dissociation constant of CA complex for enantiomer 2 of compound,U,,,22224,0,,CHEMBL630134,BAO_0000019,
14398,Autocuration,,,1,,,Equilibrium dissociation constant of the compound,U,,,22224,0,,CHEMBL630135,BAO_0000019,
14399,Autocuration,,,1,,,Equilibrium dissociation constant was determined,U,,,22224,0,,CHEMBL630136,BAO_0000019,
14400,Autocuration,,,1,,,Kinetic constant KD was evaluated,U,,,22224,0,,CHEMBL630137,BAO_0000019,
14401,Autocuration,,,1,,,Tested for dissociation constant of the compound; Value ranges from 0.1-0.3,U,,,22224,0,,CHEMBL630138,BAO_0000019,
14402,Autocuration,,,1,,,Equilibrium association constant interacting with unilamellar vesicles of electroneutral in PBS buffer at pH 7.4,U,,,22224,0,,CHEMBL630139,BAO_0000019,
14403,Autocuration,,,1,,,Rate constant for hydrolysis in aqueous acetone.,U,,,22224,0,,CHEMBL630140,BAO_0000019,
14404,Autocuration,,,1,,,Disassociation constant (KI) was obtained from Cheng and Prusoff equation for quercetin trypsin complex,U,,,22224,0,,CHEMBL875235,BAO_0000019,
14405,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.43/2.86,N,,,50597,1,,CHEMBL876439,BAO_0000218,
14406,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.44/2.68,N,,,50597,1,,CHEMBL630605,BAO_0000218,
14407,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.45/1.55,N,,,50597,1,,CHEMBL630606,BAO_0000218,
14408,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.48/0.95,N,,,50597,1,,CHEMBL630607,BAO_0000218,
14409,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.5/1.79,N,,,50597,1,,CHEMBL630608,BAO_0000218,
14410,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.51/0.66,N,,,50597,1,,CHEMBL630609,BAO_0000218,
14411,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.52/2.02,N,,,50597,1,,CHEMBL630610,BAO_0000218,
14412,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.61//0.37,N,,,50597,1,,CHEMBL630611,BAO_0000218,
14413,Intermediate,10116.0,,1,,,Mean sodium excretion in rats (Control/Drug treatment value); value 0.71/0.36,N,,,50597,1,,CHEMBL629552,BAO_0000218,
14414,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 0 mg/kg po and vehicle dosed at 0 umol/kg,N,,,50597,1,,CHEMBL629733,BAO_0000218,
14415,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 30.23 umol/kg,N,,,50597,1,,CHEMBL629734,BAO_0000218,
14416,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 33.59 umol/kg,N,,,50597,1,,CHEMBL629735,BAO_0000218,
14417,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 37.13 umol/kg,N,,,50597,1,,CHEMBL629736,BAO_0000218,
14418,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 10 mg/kg po and vehicle dosed at 39.48 umol/kg,N,,,50597,1,,CHEMBL629737,BAO_0000218,
14419,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 483.72 umol/kg,N,,,50597,1,,CHEMBL629738,BAO_0000218,
14420,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg,N,,,50597,1,,CHEMBL629739,BAO_0000218,
14421,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 594.07 umol/kg; Not determined,N,,,50597,1,,CHEMBL629740,BAO_0000218,
14422,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 160 mg/kg po and vehicle dosed at 631.76 umol/kg,N,,,50597,1,,CHEMBL629741,BAO_0000218,
14423,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 7.56 umol/kg,N,,,50597,1,,CHEMBL629742,BAO_0000218,
14424,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 8.4 umol/kg,N,,,50597,1,,CHEMBL629743,BAO_0000218,
14425,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.28 umol/kg,N,,,50597,1,,CHEMBL629744,BAO_0000218,
14426,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 2.5 mg/kg po and vehicle dosed at 9.87 umol/kg,N,,,50597,1,,CHEMBL629745,BAO_0000218,
14427,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 60.46 umol/kg,N,,,50597,1,,CHEMBL629746,BAO_0000218,
14428,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 67.18 umol/kg,N,,,50597,1,,CHEMBL629747,BAO_0000218,
14429,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 74.26 umol/kg,N,,,50597,1,,CHEMBL629748,BAO_0000218,
14430,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 20 mg/kg po and vehicle dosed at 78.97 umol/kg,N,,,50597,1,,CHEMBL629749,BAO_0000218,
14431,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 120.93 umol/kg,N,,,50597,1,,CHEMBL629750,BAO_0000218,
14432,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 134.35 umol/kg,N,,,50597,1,,CHEMBL629751,BAO_0000218,
14433,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 148.52 umol/kg,N,,,50597,1,,CHEMBL629752,BAO_0000218,
14434,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 40 mg/kg po and vehicle dosed at 157.94 umol/kg,N,,,50597,1,,CHEMBL629753,BAO_0000218,
14435,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 15.12 umol/kg,N,,,50597,1,,CHEMBL629754,BAO_0000218,
14436,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 16.79 umol/kg,N,,,50597,1,,CHEMBL629755,BAO_0000218,
14437,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 18.56 umol/kg,N,,,50597,1,,CHEMBL629756,BAO_0000218,
14438,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 5 mg/kg po and vehicle dosed at 19.74 umol/kg,N,,,50597,1,,CHEMBL629757,BAO_0000218,
14439,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 241.86 umol/kg,N,,,50597,1,,CHEMBL629758,BAO_0000218,
14440,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 268.71 umol/kg,N,,,50597,1,,CHEMBL629759,BAO_0000218,
14441,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 297.03 umol/kg,N,,,50597,1,,CHEMBL629760,BAO_0000218,
14442,Intermediate,10116.0,,1,,,Mean sodium excretion in rats when compound administered at 80 mg/kg po and vehicle dosed at 315.88 umol/kg,N,,,50597,1,,CHEMBL876443,BAO_0000218,
14443,Intermediate,9615.0,,1,,,Na+ excretion mequiv /kg in 6 conscious female dogs administered perorally during 0-6 hr,N,,,50588,1,,CHEMBL629761,BAO_0000218,
14444,Intermediate,9615.0,,1,,,Na+ excretion mequiv /kg in conscious female dogs administered perorally during 0-6 hr,N,,,50588,1,,CHEMBL629762,BAO_0000218,
14445,Intermediate,10090.0,,1,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,N,,,50594,1,,CHEMBL629763,BAO_0000218,
14446,Intermediate,10090.0,,1,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,N,,,50594,1,,CHEMBL629764,BAO_0000218,
14447,Intermediate,10090.0,,1,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 2 ml/kg perorally,N,,,50594,1,,CHEMBL629765,BAO_0000218,
14448,Intermediate,10090.0,,1,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 50 ml/kg perorally,N,,,50594,1,,CHEMBL629766,BAO_0000218,
14449,Intermediate,10090.0,,1,,,Na+ excretion mequiv /kg in saline-loaded mice administered at a dose 10 ml/kg perorally,N,,,50594,1,,CHEMBL629767,BAO_0000218,
14450,Intermediate,9615.0,,1,,,Na+ excretion mequiv/kg in 4 conscious female dogs administered perorally during 0-6 hr,N,,,50588,1,,CHEMBL629768,BAO_0000218,
14451,Intermediate,10090.0,,1,,,Na+ excretion mequiv/kg in 4 saline-loaded mice administered at a dose 50 ml/kg perorally,N,,,50594,1,,CHEMBL629769,BAO_0000218,
14452,Intermediate,9615.0,,1,,,Na+ excretion mequiv/kg in 6 conscious female dogs administered perorally during 0-6 hr,N,,,50588,1,,CHEMBL629770,BAO_0000218,
14453,Intermediate,9615.0,,1,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 0.3 ml/kg perorally,N,,,50588,1,,CHEMBL629771,BAO_0000218,
14454,Intermediate,10090.0,,1,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,N,,,50594,1,,CHEMBL629772,BAO_0000218,
14455,Intermediate,10090.0,,1,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 10 ml/kg perorally,N,,,50594,1,,CHEMBL629773,BAO_0000218,
14456,Intermediate,10090.0,,1,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 2 ml/kg perorally,N,,,50594,1,,CHEMBL625455,BAO_0000218,
14457,Intermediate,10090.0,,1,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 250 ml/kg perorally,N,,,50594,1,,CHEMBL625456,BAO_0000218,
14458,Intermediate,10090.0,,1,,,Na+ excretion mequiv/kg in saline-loaded mice administered at a dose 3 ml/kg perorally,N,,,50594,1,,CHEMBL625457,BAO_0000218,
14459,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 25.9 uM/Kg of drug,N,,,50597,1,,CHEMBL625458,BAO_0000218,
14460,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 259 uM/Kg of drug,N,,,50597,1,,CHEMBL625459,BAO_0000218,
14461,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 26.5 uM/Kg of drug,N,,,50597,1,,CHEMBL875483,BAO_0000218,
14462,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 265 uM/Kg of drug,N,,,50597,1,,CHEMBL634779,BAO_0000218,
14463,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27 uM/Kg of drug,N,,,50597,1,,CHEMBL625460,BAO_0000218,
14464,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 27.9 uM/Kg of drug,N,,,50597,1,,CHEMBL626117,BAO_0000218,
14465,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 270 uM/Kg of drug,N,,,50597,1,,CHEMBL626118,BAO_0000218,
14466,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 279 uM/Kg of drug,N,,,50597,1,,CHEMBL628342,BAO_0000218,
14467,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.2 uM/Kg of drug,N,,,50597,1,,CHEMBL628343,BAO_0000218,
14468,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.22 uM/Kg of drug,N,,,50597,1,,CHEMBL628344,BAO_0000218,
14469,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 28.9 uM/Kg of drug,N,,,50597,1,,CHEMBL628345,BAO_0000218,
14470,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 282 uM/Kg of drug,N,,,50597,1,,CHEMBL628346,BAO_0000218,
14471,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 289 uM/Kg of drug,N,,,50597,1,,CHEMBL628347,BAO_0000218,
14472,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.40 uM/Kg of drug,N,,,50597,1,,CHEMBL628348,BAO_0000218,
14473,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 3.76 uM/Kg of drug,N,,,50597,1,,CHEMBL628349,BAO_0000218,
14474,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 30.2 uM/Kg of drug,N,,,50597,1,,CHEMBL875611,BAO_0000218,
14475,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 302 uM/Kg of drug,N,,,50597,1,,CHEMBL628350,BAO_0000218,
14476,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 31.6 uM/Kg of drug,N,,,50597,1,,CHEMBL628351,BAO_0000218,
14477,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 316 uM/Kg of drug,N,,,50597,1,,CHEMBL628352,BAO_0000218,
14478,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 32.4 uM/Kg of drug,N,,,50597,1,,CHEMBL628353,BAO_0000218,
14479,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 324 uM/Kg of drug,N,,,50597,1,,CHEMBL628354,BAO_0000218,
14480,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.0 uM/Kg of drug,N,,,50597,1,,CHEMBL626667,BAO_0000218,
14481,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.1 uM/Kg of drug,N,,,50597,1,,CHEMBL626668,BAO_0000218,
14482,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 34.8 uM/Kg of drug,N,,,50597,1,,CHEMBL626669,BAO_0000218,
14483,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 341 uM/Kg of drug,N,,,50597,1,,CHEMBL626670,BAO_0000218,
14484,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 348 uM/Kg of drug,N,,,50597,1,,CHEMBL626671,BAO_0000218,
14485,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 37.6 uM/Kg of drug,N,,,50597,1,,CHEMBL626672,BAO_0000218,
14486,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 50.8 uM/Kg of drug,N,,,50597,1,,CHEMBL626673,BAO_0000218,
14487,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 58.4 uM/Kg of drug,N,,,50597,1,,CHEMBL626674,BAO_0000218,
14488,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 65.2 uM/Kg of drug,N,,,50597,1,,CHEMBL626675,BAO_0000218,
14489,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 68.1 uM/Kg of drug,N,,,50597,1,,CHEMBL626676,BAO_0000218,
14490,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 7.94 uM/Kg of drug,N,,,50597,1,,CHEMBL626677,BAO_0000218,
14491,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.6 uM/Kg of drug,N,,,50597,1,,CHEMBL626678,BAO_0000218,
14492,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 71.8 uM/Kg of drug,N,,,50597,1,,CHEMBL626679,BAO_0000218,
14493,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 74.8 uM/Kg of drug,N,,,50597,1,,CHEMBL875612,BAO_0000218,
14494,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 77.5 uM/Kg of drug,N,,,50597,1,,CHEMBL626680,BAO_0000218,
14495,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 79.4 uM/Kg of drug,N,,,50597,1,,CHEMBL626681,BAO_0000218,
14496,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 80.9 uM/Kg of drug,N,,,50597,1,,CHEMBL626682,BAO_0000218,
14497,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 83.8 uM/Kg of drug,N,,,50597,1,,CHEMBL626683,BAO_0000218,
14498,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.5 uM/Kg of drug,N,,,50597,1,,CHEMBL626684,BAO_0000218,
14499,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 84.7 uM/Kg of drug,N,,,50597,1,,CHEMBL626685,BAO_0000218,
14500,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.7 uM/Kg of drug,N,,,50597,1,,CHEMBL626686,BAO_0000218,
14501,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 86.9 uM/Kg of drug,N,,,50597,1,,CHEMBL626687,BAO_0000218,
14502,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 9.06 uM/Kg of drug,N,,,50597,1,,CHEMBL624978,BAO_0000218,
14503,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 90.6 uM/Kg of drug,N,,,50597,1,,CHEMBL624979,BAO_0000218,
14504,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 94.9 uM/Kg of drug,N,,,50597,1,,CHEMBL624980,BAO_0000218,
14505,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of potassium in urine of rats after peroral administration of 97.1 uM/Kg of drug,N,,,50597,1,,CHEMBL624981,BAO_0000218,
14506,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 52.4 uM/Kg of drug,N,,,50588,1,,CHEMBL624982,BAO_0000218,
14507,Autocuration,,In vivo,1,2367.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d),U,,,22224,0,,CHEMBL627564,BAO_0000218,
14508,Autocuration,,In vivo,1,2367.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v),U,,,22224,0,,CHEMBL627565,BAO_0000218,
14509,Autocuration,,In vivo,1,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/blood,U,,,22224,0,,CHEMBL627566,BAO_0000218,
14510,Autocuration,,In vivo,1,2385.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (v)/muscle,U,,,22224,0,,CHEMBL627567,BAO_0000218,
14511,Autocuration,,In vivo,1,2106.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in spleen,U,,,22224,0,,CHEMBL627568,BAO_0000218,
14512,Autocuration,,In vivo,1,2113.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hr in kidney,U,,,22224,0,,CHEMBL627569,BAO_0000218,
14513,Autocuration,,In vivo,1,1255.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bladder,U,,,22224,0,,CHEMBL627570,BAO_0000218,
14514,Autocuration,,In vivo,1,178.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in blood,U,,,22224,0,,CHEMBL627571,BAO_0000218,
14515,Autocuration,,In vivo,1,1474.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in bone,U,,,22224,0,,CHEMBL627572,BAO_0000218,
14516,Autocuration,,In vivo,1,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in fat,U,,,22224,0,,CHEMBL627573,BAO_0000218,
14517,Autocuration,,In vivo,1,2113.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in kidney,U,,,22224,0,,CHEMBL627574,BAO_0000218,
14518,Autocuration,,In vivo,1,2107.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in liver,U,,,22224,0,,CHEMBL627575,BAO_0000218,
14519,Autocuration,,In vivo,1,2048.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in lung,U,,,22224,0,,CHEMBL627576,BAO_0000218,
14520,Autocuration,,In vivo,1,2385.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in muscle,U,,,22224,0,,CHEMBL627577,BAO_0000218,
14521,Autocuration,,In vivo,1,2367.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d),U,,,22224,0,,CHEMBL627578,BAO_0000218,
14522,Autocuration,,In vivo,1,2367.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/biood,U,,,22224,0,,CHEMBL627579,BAO_0000218,
14523,Autocuration,,In vivo,1,2385.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (d)/muscle,U,,,22224,0,,CHEMBL627580,BAO_0000218,
14524,Autocuration,,In vivo,1,2367.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v),U,,,22224,0,,CHEMBL627581,BAO_0000218,
14525,Autocuration,,In vivo,1,,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/blood,U,,,22224,0,,CHEMBL627582,BAO_0000218,
14526,Autocuration,,In vivo,1,2385.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in prostate (v)/muscle,U,,,22224,0,,CHEMBL627583,BAO_0000218,
14527,Autocuration,,In vivo,1,2106.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 4 hour in spleen,U,,,22224,0,,CHEMBL627584,BAO_0000218,
14528,Autocuration,,In vivo,1,2367.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/biood,U,,,22224,0,,CHEMBL627585,BAO_0000218,
14529,Autocuration,,In vivo,1,2385.0,,%ID/g is percent injected dose per gram of tissue and in vivo distribution of compound obtained after 2 hour in prostate (d)/muscle,U,,,22224,0,,CHEMBL627586,BAO_0000218,
14530,Intermediate,10116.0,In vivo,1,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 200 nmol of WAY 100635,N,,,50597,1,,CHEMBL627587,BAO_0000218,
14531,Intermediate,10116.0,In vivo,1,,,Biodistribution of the Radiolabeled FBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,N,,,50597,1,,CHEMBL627588,BAO_0000218,
14532,Intermediate,10116.0,In vivo,1,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 200 nmol of WAY 100635,N,,,50597,1,,CHEMBL628250,BAO_0000218,
14533,Intermediate,10116.0,In vivo,1,,,Biodistribution of the Radiolabeled FBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,N,,,50597,1,,CHEMBL628251,BAO_0000218,
14534,Intermediate,10116.0,In vivo,1,10000000.0,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 200 nmol of WAY 100635,N,,,50597,1,,CHEMBL628252,BAO_0000218,
14535,Intermediate,10116.0,In vivo,1,10000000.0,,Biodistribution of the Radiolabeled FBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,N,,,50597,1,,CHEMBL628253,BAO_0000218,
14536,Intermediate,10116.0,In vivo,1,1898.0,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 200 nmol of WAY 100635,N,,,50597,1,,CHEMBL628254,BAO_0000218,
14537,Intermediate,10116.0,In vivo,1,1898.0,,Biodistribution of the Radiolabeled FBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,N,,,50597,1,,CHEMBL877493,BAO_0000218,
14538,Intermediate,10116.0,In vivo,1,,,Biodistribution of the Radiolabeled FCWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,N,,,50597,1,,CHEMBL628255,BAO_0000218,
14539,Intermediate,10116.0,In vivo,1,,,Biodistribution of the Radiolabeled FCWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,N,,,50597,1,,CHEMBL628256,BAO_0000218,
14540,Intermediate,10116.0,In vivo,1,10000000.0,,Biodistribution of the Radiolabeled FCWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,N,,,50597,1,,CHEMBL628257,BAO_0000218,
14541,Intermediate,10116.0,In vivo,1,1898.0,,Biodistribution of the Radiolabeled FCWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635,N,,,50597,1,,CHEMBL628258,BAO_0000218,
14542,Intermediate,10116.0,In vivo,1,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat Cerebellum at 30 min co-injected with 50 nmol of WAY 100635,N,,,50597,1,,CHEMBL628259,BAO_0000218,
14543,Intermediate,10116.0,In vivo,1,,,Biodistribution of the Radiolabeled MeFBWAY compound in rat cortex at 30 min co-injected with 50 nmol of WAY 100635,N,,,50597,1,,CHEMBL628429,BAO_0000218,
14544,Intermediate,10116.0,In vivo,1,10000000.0,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hippocampus at 30 min co-injected with 50 nmol of WAY 100635,N,,,50597,1,,CHEMBL626862,BAO_0000218,
14545,Intermediate,10116.0,In vivo,1,1898.0,,Biodistribution of the Radiolabeled MeFBWAY compound in rat hypothalamus at 30 min co-injected with 50 nmol of WAY 100635; Not determined,N,,,50597,1,,CHEMBL626863,BAO_0000218,
14546,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum,N,,,50597,1,,CHEMBL625886,BAO_0000218,
14547,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution of the [11C]-radiolabeled compound in rat cerebellum co-injected with 50 nM of WAY 100635.,N,,,50597,1,,CHEMBL625887,BAO_0000218,
14548,Intermediate,10116.0,In vivo,1,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex,N,,,50597,1,,CHEMBL625888,BAO_0000218,
14549,Intermediate,10116.0,In vivo,1,,,Biodistribution of the [11C]-radiolabeled compound in rat cortex co-injected with 50 nM of WAY 100635.,N,,,50597,1,,CHEMBL625889,BAO_0000218,
14550,Intermediate,10116.0,In vivo,1,10000000.0,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus,N,,,50597,1,,CHEMBL625890,BAO_0000218,
14551,Intermediate,10116.0,In vivo,1,10000000.0,,Biodistribution of the [11C]-radiolabeled compound in rat hippocampus co-injected with 50 nM of WAY 100635.,N,,,50597,1,,CHEMBL625891,BAO_0000218,
14552,Intermediate,10116.0,In vivo,1,1898.0,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus,N,,,50597,1,,CHEMBL625892,BAO_0000218,
14553,Intermediate,10116.0,In vivo,1,1898.0,,Biodistribution of the [11C]-radiolabeled compound in rat hypothalamus co-injected with 50 nM of WAY 100635.,N,,,50597,1,,CHEMBL625893,BAO_0000218,
14554,Intermediate,10116.0,In vivo,1,2037.0,,Biodistribution of the [18F]-radiolabeled compound in rat cerebellum,N,,,50597,1,,CHEMBL625894,BAO_0000218,
14555,Intermediate,10116.0,In vivo,1,,,Biodistribution of the [18F]-radiolabeled compound in rat cortex,N,,,50597,1,,CHEMBL625895,BAO_0000218,
14556,Autocuration,,,1,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,U,,,22224,0,,CHEMBL625896,BAO_0000019,
14557,Autocuration,,,1,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 8.5(Apparent inhibition constant)",U,,,22224,0,,CHEMBL625897,BAO_0000019,
14558,Autocuration,,,1,,,"Tested for hydrolysis in presence of boric acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",U,,,22224,0,,CHEMBL625898,BAO_0000019,
14559,Autocuration,,,1,,,"Tested for hydrolysis in presence of phenylboronic acid, dissociation constant was evaluated at the pH 9.5(Apparent inhibition constant)",U,,,22224,0,,CHEMBL625899,BAO_0000019,
14560,Autocuration,,,1,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,U,,,22224,0,,CHEMBL626124,BAO_0000019,
14561,Intermediate,562.0,,1,,,Ability to inhibit Escherichia coli adenylate kinase II activity expressed as half maximal velocity,N,,,50212,1,,CHEMBL628500,BAO_0000218,
14562,Intermediate,10116.0,,1,,,"Ability to inhibit rat adenylate kinase II, activity expressed as half-maximal velocity",N,,,50597,1,,CHEMBL857856,BAO_0000218,
14563,Intermediate,10116.0,,1,,,"Ability to inhibit rat adenylate kinase III, activity expressed as half-maximal velocity",N,,,50597,1,,CHEMBL628501,BAO_0000218,
14564,Autocuration,,,1,,,"Compound was evaluated for the Michaelis-Menten constant, Km in a generic protein phosphatase stopped assay system",U,,,22224,0,,CHEMBL628502,BAO_0000019,
14565,Autocuration,,,1,,,Kinetic parameter KM (nM) for the MAO-B catalyzed oxidation of the compound.,U,,,22224,0,,CHEMBL628503,BAO_0000019,
14566,Autocuration,,,1,,,Kinetic parameter KM at pH 7.4 and 37 degree Centigrade,U,,,22224,0,,CHEMBL628504,BAO_0000019,
14567,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",U,,,22224,0,,CHEMBL628505,BAO_0000019,
14568,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as KM",U,,,22224,0,,CHEMBL874452,BAO_0000019,
14569,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as KM; Not determined",U,,,22224,0,,CHEMBL628506,BAO_0000019,
14570,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as KM; Not determined",U,,,22224,0,,CHEMBL628507,BAO_0000019,
14571,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as KM",U,,,22224,0,,CHEMBL628508,BAO_0000019,
14572,Autocuration,,,1,,,Michaelis constant (KM) was evaluated,U,,,22224,0,,CHEMBL628509,BAO_0000019,
14573,Autocuration,,,1,,,Reaction rate parameter value for phosphate with transfer with respect to ATP,U,,,22224,0,,CHEMBL628510,BAO_0000019,
14574,Autocuration,,,1,,,Substrate concentration for half maximal velocity was reported for rat hexokinase I,U,,,22224,0,,CHEMBL628511,BAO_0000019,
14575,Autocuration,,,1,,,Substrate concentration for half maximal velocity was reported for rat hexokinase II,U,,,22224,0,,CHEMBL628512,BAO_0000019,
14576,Autocuration,,,1,,,Substrate concentration for half maximal velocity was reported for rat hexokinase III,U,,,22224,0,,CHEMBL628513,BAO_0000019,
14577,Autocuration,,,1,,,Substrate concentration for half maximal velocity was reported for yeast hexokinase,U,,,22224,0,,CHEMBL628514,BAO_0000019,
14578,Autocuration,,,1,,,Pseudo-first-order rate constant for alkylation of NBP in 50% aqueous acetone at 66 degrees celsius with 50 uM and 25 uM of NBP.,U,,,22224,0,,CHEMBL628515,BAO_0000019,
14579,Autocuration,,,1,,,Rate constant for alkylation of 4-(4-nitrobenzyl)pyridine,U,,,22224,0,,CHEMBL628516,BAO_0000019,
14580,Autocuration,,,1,,,Bimolecular rate constant (KOH) at 25 degree C (m = 0.5),U,,,22224,0,,CHEMBL628517,BAO_0000019,
14581,Autocuration,,,1,,,its bimolecular rate constant (KOH) at 25 degree C (m = 0.5),U,,,22224,0,,CHEMBL628518,BAO_0000019,
14582,Autocuration,,,1,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer,U,,,22224,0,,CHEMBL628519,BAO_0000019,
14583,Autocuration,,,1,,,Acid dissociation constant evaluated towards Hematin mu-oxo dimer; Not available,U,,,22224,0,,CHEMBL628520,BAO_0000019,
14584,Autocuration,,,1,,,Binding constant was determined,U,,,22224,0,,CHEMBL628521,BAO_0000019,
14585,Autocuration,,,1,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree Centigrade,U,,,22224,0,,CHEMBL630443,BAO_0000019,
14586,Autocuration,,,1,,,Alkylation of 4-(4-nitrobenzyl)pyridine (NBP) by the compound at a temperature of 66 degree centigrade; Not determined,U,,,22224,0,,CHEMBL630444,BAO_0000019,
14587,Autocuration,,,1,,,Rate constant with triethylamine at 30 degree C in 0.1 M potassium chloride was expressed as Kamine,U,,,22224,0,,CHEMBL857732,BAO_0000019,
14588,Autocuration,,,1,,,Octanol-water apparent distribution coefficient measured in TRIS buffer at a pH 7.4.,U,,,22224,0,,CHEMBL630445,BAO_0000100,
14589,Autocuration,,,1,,,Catalytic rate constant of the compound,U,,,22224,0,,CHEMBL630446,BAO_0000019,
14590,Autocuration,,,1,,,inactivation rate constant calculated from experimental IC50 value for dipeptidyl peptidase IV inhibition,U,,,22224,0,,CHEMBL630447,BAO_0000019,
14591,Autocuration,,,1,,,Catalytic constant expressed as Kinetic behavior of enzyme (PicK/6-His),U,,,22224,0,,CHEMBL630448,BAO_0000019,
14592,Autocuration,,,1,,,Catalytic rate constant against phospholipase A2 was determined,U,,,22224,0,,CHEMBL630449,BAO_0000019,
14593,Autocuration,,,1,,,"Compound was evaluated for catalytic constant, Kcat",U,,,22224,0,,CHEMBL630450,BAO_0000019,
14594,Autocuration,,,1,,,Compound was tested for hydrolysis by acetylcholinesterase and the kinetic constant (kcat) which is a first-order rate constant was determined,U,,,22224,0,,CHEMBL630451,BAO_0000019,
14595,Autocuration,,,1,,,Kcat calculated from 0.693/T1/2,U,,,22224,0,,CHEMBL630452,BAO_0000019,
14596,Autocuration,,,1,,,Kcat was determined,U,,,22224,0,,CHEMBL630453,BAO_0000019,
14597,Autocuration,,,1,,,Kcat against class A PCI beta-lactamase catalyzed lactone hydrolysis,U,,,22224,0,,CHEMBL630454,BAO_0000019,
14598,Autocuration,,,1,,,Kcat against class A TEM beta-lactamase catalyzed lactone hydrolysis,U,,,22224,0,,CHEMBL630455,BAO_0000019,
14599,Autocuration,,,1,,,Kcat against class C P99 beta-lactamase catalyzed lactone hydrolysis,U,,,22224,0,,CHEMBL631487,BAO_0000019,
14600,Autocuration,,,1,,,Kcat value was determined,U,,,22224,0,,CHEMBL631488,BAO_0000019,
14601,Autocuration,,,1,,,Kinetic constant for the hydrolysis by the catalyst CPA was evaluated,U,,,22224,0,,CHEMBL876440,BAO_0000019,
14602,Autocuration,,,1,,,Kinetic constant for the hydrolysis by the catalyst McAbIIF9D8 was evaluated,U,,,22224,0,,CHEMBL631489,BAO_0000019,
14603,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",U,,,22224,0,,CHEMBL857742,BAO_0000019,
14604,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat",U,,,22224,0,,CHEMBL631490,BAO_0000019,
14605,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat; Not determined",U,,,22224,0,,CHEMBL631491,BAO_0000019,
14606,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat; Not determined",U,,,22224,0,,CHEMBL631492,BAO_0000019,
14607,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat",U,,,22224,0,,CHEMBL631493,BAO_0000019,
14608,Autocuration,,,1,,,Kinetic parameter for rate of conversion to PABA was determined,U,,,22224,0,,CHEMBL631494,BAO_0000019,
14609,Autocuration,,,1,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,U,,,22224,0,,CHEMBL631495,BAO_0000019,
14610,Intermediate,10116.0,,1,1988.0,,"Compound was evaluated for the percentage of feces excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",N,,,50597,1,,CHEMBL631496,BAO_0000218,
14611,Intermediate,10116.0,,1,1088.0,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 0-24 hr",N,,,50597,1,,CHEMBL631497,BAO_0000218,
14612,Intermediate,10116.0,,1,1088.0,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after intravenous administration of compound dose (1 mg/kg) at 24-48 hr",N,,,50597,1,,CHEMBL631498,BAO_0000218,
14613,Intermediate,10116.0,,1,1088.0,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 0-24 hr",N,,,50597,1,,CHEMBL629776,BAO_0000218,
14614,Intermediate,10116.0,,1,1088.0,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 24-48 hr",N,,,50597,1,,CHEMBL629777,BAO_0000218,
14615,Intermediate,10116.0,,1,1088.0,,"Compound was evaluated for the percentage of urine excretion of radioactivity, by male Sprague-Dawley rats after oral administration of compound dose (1 mg/kg) at 48-72 hr",N,,,50597,1,,CHEMBL629778,BAO_0000218,
14616,Intermediate,10116.0,,1,,,Cumulative dose excreted after intraduodenal administration at 0-0.5 hours in rats,N,,,50597,1,,CHEMBL630456,BAO_0000218,
14617,Intermediate,10116.0,,1,,,Cumulative dose excreted after intraduodenal administration at 0.5-1.0 hours in rats,N,,,50597,1,,CHEMBL630457,BAO_0000218,
14618,Intermediate,10116.0,,1,,,Cumulative dose excreted after intraduodenal administration at 1.0-1.5 hours in rats,N,,,50597,1,,CHEMBL630458,BAO_0000218,
14619,Intermediate,10116.0,,1,,,Cumulative dose excreted after intraduodenal administration at 1.5-2.0 hours in rats,N,,,50597,1,,CHEMBL630459,BAO_0000218,
14620,Intermediate,10116.0,,1,,,Cumulative dose excreted after intraduodenal administration at 2-3 hours in rats,N,,,50597,1,,CHEMBL630460,BAO_0000218,
14621,Intermediate,10116.0,,1,,,Cumulative dose excreted after intraduodenal administration at 3-4 hours in rats,N,,,50597,1,,CHEMBL876550,BAO_0000218,
14622,Intermediate,10116.0,,1,,,Cumulative dose excreted after intraduodenal administration at 4-6 hours in rats,N,,,50597,1,,CHEMBL630461,BAO_0000218,
14623,Intermediate,10116.0,,1,,,Cumulative dose excreted after intraduodenal administration at 6-8 hours in rats,N,,,50597,1,,CHEMBL630462,BAO_0000218,
14624,Intermediate,10116.0,,1,,,Cumulative dose excreted after intraduodenal administration at 8-24 hours in rats,N,,,50597,1,,CHEMBL630463,BAO_0000218,
14625,Intermediate,10116.0,,1,,,Cumulative dose excreted after intravenous administration at 0-0.5 hours in rats,N,,,50597,1,,CHEMBL630464,BAO_0000218,
14626,Intermediate,10116.0,,1,,,Cumulative dose excreted after intravenous administration at 0.5-1 hours in rats,N,,,50597,1,,CHEMBL630465,BAO_0000218,
14627,Intermediate,10116.0,,1,,,Cumulative dose excreted after intravenous administration at 1.0-1.5 hours in rats,N,,,50597,1,,CHEMBL630466,BAO_0000218,
14628,Intermediate,10116.0,,1,,,Cumulative dose excreted after intravenous administration at 1.5-2 hours in rats,N,,,50597,1,,CHEMBL630467,BAO_0000218,
14629,Intermediate,10116.0,,1,,,Cumulative dose excreted after intravenous administration at 2-3 hours in rats,N,,,50597,1,,CHEMBL630633,BAO_0000218,
14630,Intermediate,10116.0,,1,,,Cumulative dose excreted after intravenous administration at 3-4 hours in rats,N,,,50597,1,,CHEMBL630634,BAO_0000218,
14631,Intermediate,10116.0,,1,,,Cumulative dose excreted after intravenous administration at 4-6 hours in rats,N,,,50597,1,,CHEMBL630635,BAO_0000218,
14632,Intermediate,10116.0,,1,,,Cumulative dose excreted after intravenous administration at 6-8 hours in rats,N,,,50597,1,,CHEMBL630636,BAO_0000218,
14633,Intermediate,10116.0,,1,,,Cumulative dose excreted after intravenous administration at 8-24 hours in rats,N,,,50597,1,,CHEMBL630637,BAO_0000218,
14634,Intermediate,9986.0,,1,1988.0,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",N,,,50592,1,,CHEMBL630638,BAO_0000218,
14635,Intermediate,9986.0,,1,1988.0,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",N,,,50592,1,,CHEMBL630639,BAO_0000218,
14636,Intermediate,9986.0,,1,1988.0,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",N,,,50592,1,,CHEMBL630640,BAO_0000218,
14637,Intermediate,9986.0,,1,1988.0,,"10 mg/kg of [14C]- radiolabeled compound was intravenously (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",N,,,50592,1,,CHEMBL876551,BAO_0000218,
14638,Intermediate,9986.0,,1,1088.0,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated (total)",N,,,50592,1,,CHEMBL630641,BAO_0000218,
14639,Intermediate,9986.0,,1,1088.0,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",N,,,50592,1,,CHEMBL630642,BAO_0000218,
14640,Intermediate,9986.0,,1,1088.0,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",N,,,50592,1,,CHEMBL630643,BAO_0000218,
14641,Intermediate,9986.0,,1,1088.0,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",N,,,50592,1,,CHEMBL630644,BAO_0000218,
14642,Intermediate,9986.0,,1,1088.0,,"10 mg/kg of [14C]- radiolabeled compound was intravenously injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",N,,,50592,1,,CHEMBL630645,BAO_0000218,
14643,Intermediate,9986.0,,1,1988.0,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated (total)",N,,,50592,1,,CHEMBL625599,BAO_0000218,
14644,Intermediate,9986.0,,1,1988.0,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 0-24 h",N,,,50592,1,,CHEMBL625600,BAO_0000218,
14645,Intermediate,9986.0,,1,1988.0,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 24-48 h",N,,,50592,1,,CHEMBL625601,BAO_0000218,
14646,Intermediate,9986.0,,1,1988.0,,"25 mg/kg of [14C]- radiolabeled compound was orally (gavage) injected in rabbit, and radioactivity content in feces was estimated at 48-72 h",N,,,50592,1,,CHEMBL625602,BAO_0000218,
14647,Intermediate,9986.0,,1,1088.0,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated (total)",N,,,50592,1,,CHEMBL627470,BAO_0000218,
14648,Intermediate,9986.0,,1,1088.0,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 0-6 h",N,,,50592,1,,CHEMBL627471,BAO_0000218,
14649,Intermediate,9986.0,,1,1088.0,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 24-48 h",N,,,50592,1,,CHEMBL627472,BAO_0000218,
14650,Intermediate,9986.0,,1,1088.0,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 48-72 h",N,,,50592,1,,CHEMBL627473,BAO_0000218,
14651,Intermediate,9986.0,,1,1088.0,,"25 mg/kg of [14C]- radiolabeled compound was perorally injected in rabbit, and radioactivity content in urine was estimated at 6-24 h",N,,,50592,1,,CHEMBL627474,BAO_0000218,
14652,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL627475,BAO_0000218,
14653,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in rat blood post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL627476,BAO_0000218,
14654,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 11.9 uM/Kg of drug,N,,,50588,1,,CHEMBL627477,BAO_0000218,
14655,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 2.49 uM/Kg of drug,N,,,50588,1,,CHEMBL627478,BAO_0000218,
14656,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 26.2 uM/Kg of drug,N,,,50588,1,,CHEMBL627479,BAO_0000218,
14657,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 3.03 uM/Kg of drug,N,,,50588,1,,CHEMBL627480,BAO_0000218,
14658,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 30.3 uM/Kg of drug,N,,,50588,1,,CHEMBL627481,BAO_0000218,
14659,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 34.1 uM/Kg of drug,N,,,50588,1,,CHEMBL627482,BAO_0000218,
14660,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 7.85 uM/Kg of drug,N,,,50588,1,,CHEMBL627483,BAO_0000218,
14661,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 8.47 uM/Kg of drug,N,,,50588,1,,CHEMBL875636,BAO_0000218,
14662,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after intravenous administration of 9.09 uM/Kg of drug,N,,,50588,1,,CHEMBL625764,BAO_0000218,
14663,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 10.1 uM/Kg of drug,N,,,50588,1,,CHEMBL625765,BAO_0000218,
14664,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 102 uM/Kg of drug,N,,,50588,1,,CHEMBL625766,BAO_0000218,
14665,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.40 uM/Kg of drug,N,,,50588,1,,CHEMBL625767,BAO_0000218,
14666,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 3.76 uM/Kg of drug,N,,,50588,1,,CHEMBL625768,BAO_0000218,
14667,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 34.1 uM/Kg of drug,N,,,50588,1,,CHEMBL625769,BAO_0000218,
14668,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 50.8 uM/Kg of drug,N,,,50588,1,,CHEMBL625770,BAO_0000218,
14669,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 68.1 uM/Kg of drug,N,,,50588,1,,CHEMBL625771,BAO_0000218,
14670,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.060 uM/Kg of drug,N,,,50588,1,,CHEMBL625772,BAO_0000218,
14671,Intermediate,9615.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of dogs after peroral administration of 9.6 uM/Kg of drug,N,,,50588,1,,CHEMBL625773,BAO_0000218,
14672,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after intravenous administration of 7.94 uM/Kg of drug,N,,,50597,1,,CHEMBL625774,BAO_0000218,
14673,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 0 uM/Kg of drug,N,,,50597,1,,CHEMBL625775,BAO_0000218,
14674,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.01 uM/Kg of drug,N,,,50597,1,,CHEMBL625776,BAO_0000218,
14675,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 1.13 uM/Kg of drug,N,,,50597,1,,CHEMBL625777,BAO_0000218,
14676,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 10.1 uM/Kg of drug,N,,,50597,1,,CHEMBL625778,BAO_0000218,
14677,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 102 uM/Kg of drug,N,,,50597,1,,CHEMBL625779,BAO_0000218,
14678,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 105 uM/Kg of drug,N,,,50597,1,,CHEMBL625780,BAO_0000218,
14679,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 11.3 uM/Kg of drug,N,,,50597,1,,CHEMBL625781,BAO_0000218,
14680,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 113 uM/Kg of drug,N,,,50597,1,,CHEMBL875637,BAO_0000218,
14681,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 19.5 uM/Kg of drug,N,,,50597,1,,CHEMBL626473,BAO_0000218,
14682,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 195 uM/Kg of drug,N,,,50597,1,,CHEMBL626474,BAO_0000218,
14683,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 21.7 uM/Kg of drug,N,,,50597,1,,CHEMBL626475,BAO_0000218,
14684,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 217 uM/Kg of drug,N,,,50597,1,,CHEMBL626476,BAO_0000218,
14685,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 23.9 uM/Kg of drug,N,,,50597,1,,CHEMBL634397,BAO_0000218,
14686,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 239 uM/Kg of drug,N,,,50597,1,,CHEMBL626477,BAO_0000218,
14687,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 24.9 uM/Kg of drug,N,,,50597,1,,CHEMBL631069,BAO_0000218,
14688,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 249 uM/Kg of drug,N,,,50597,1,,CHEMBL631070,BAO_0000218,
14689,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 25.9 uM/Kg of drug,N,,,50597,1,,CHEMBL631071,BAO_0000218,
14690,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 259 uM/Kg of drug,N,,,50597,1,,CHEMBL631072,BAO_0000218,
14691,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 26.5 uM/Kg of drug,N,,,50597,1,,CHEMBL631073,BAO_0000218,
14692,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 265 uM/Kg of drug,N,,,50597,1,,CHEMBL631074,BAO_0000218,
14693,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27 uM/Kg of drug,N,,,50597,1,,CHEMBL631075,BAO_0000218,
14694,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 27.9 uM/Kg of drug,N,,,50597,1,,CHEMBL631725,BAO_0000218,
14695,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 270 uM/Kg of drug,N,,,50597,1,,CHEMBL631726,BAO_0000218,
14696,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 279 uM/Kg of drug,N,,,50597,1,,CHEMBL631727,BAO_0000218,
14697,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.2 uM/Kg of drug,N,,,50597,1,,CHEMBL631728,BAO_0000218,
14698,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 28.9 uM/Kg of drug,N,,,50597,1,,CHEMBL631729,BAO_0000218,
14699,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 282 uM/Kg of drug,N,,,50597,1,,CHEMBL631730,BAO_0000218,
14700,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 289 uM/Kg of drug,N,,,50597,1,,CHEMBL631731,BAO_0000218,
14701,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.40 uM/Kg of drug,N,,,50597,1,,CHEMBL631910,BAO_0000218,
14702,Intermediate,10116.0,In vivo,1,10000000.0,,Biodistribution of the [18F]-radiolabeled compound in rat hippocampus,N,,,50597,1,,CHEMBL631911,BAO_0000218,
14703,Intermediate,10116.0,In vivo,1,1898.0,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus,N,,,50597,1,,CHEMBL631912,BAO_0000218,
14704,Intermediate,10116.0,In vivo,1,1898.0,,Biodistribution of the [18F]-radiolabeled compound in rat hypothalamus; Not determined,N,,,50597,1,,CHEMBL631913,BAO_0000218,
14705,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631914,BAO_0000218,
14706,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631915,BAO_0000218,
14707,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL875778,BAO_0000218,
14708,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631916,BAO_0000218,
14709,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631917,BAO_0000218,
14710,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631918,BAO_0000218,
14711,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631919,BAO_0000218,
14712,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL631920,BAO_0000218,
14713,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631921,BAO_0000218,
14714,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631922,BAO_0000218,
14715,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution in blood of immature femalee rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL631923,BAO_0000218,
14716,Intermediate,10116.0,In vivo,1,,,Biodistribution in fat of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631924,BAO_0000218,
14717,Intermediate,10116.0,In vivo,1,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630234,BAO_0000218,
14718,Intermediate,10116.0,In vivo,1,,,Biodistribution in fat of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL630235,BAO_0000218,
14719,Intermediate,10116.0,In vivo,1,,,Biodistribution in fat of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630236,BAO_0000218,
14720,Intermediate,10116.0,In vivo,1,,,Biodistribution in fat of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630237,BAO_0000218,
14721,Intermediate,10116.0,In vivo,1,,,Biodistribution in fat of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630238,BAO_0000218,
14722,Intermediate,10116.0,In vivo,1,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630239,BAO_0000218,
14723,Intermediate,10116.0,In vivo,1,,,Biodistribution in fat of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL630303,BAO_0000218,
14724,Intermediate,10116.0,In vivo,1,,,Biodistribution in fat of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630304,BAO_0000218,
14725,Intermediate,10116.0,In vivo,1,,,Biodistribution in fat of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630305,BAO_0000218,
14726,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630306,BAO_0000218,
14727,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630307,BAO_0000218,
14728,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL630308,BAO_0000218,
14729,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630309,BAO_0000218,
14730,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL629309,BAO_0000218,
14731,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL629993,BAO_0000218,
14732,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL629994,BAO_0000218,
14733,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL629995,BAO_0000218,
14734,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631993,BAO_0000218,
14735,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631994,BAO_0000218,
14736,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in kidney of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631995,BAO_0000218,
14737,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of Iimmature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL631996,BAO_0000218,
14738,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of Iimmature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631997,BAO_0000218,
14739,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631998,BAO_0000218,
14740,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631999,BAO_0000218,
14741,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL632000,BAO_0000218,
14742,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL632001,BAO_0000218,
14743,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL874424,BAO_0000218,
14744,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL632002,BAO_0000218,
14745,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL632003,BAO_0000218,
14746,Autocuration,,,1,,,Rate acceleration expressed as ratio of Kcat to Kuncat was evaluated,U,,,22224,0,,CHEMBL632004,BAO_0000019,
14747,Autocuration,,,1,,,Compound was tested for amidase rate in the presence of N62C fully characterised enzyme,U,,,22224,0,,CHEMBL632005,BAO_0000019,
14748,Autocuration,,,1,,,Compound was tested for amidase rate in the presence of N62C screen enzyme,U,,,22224,0,,CHEMBL632006,BAO_0000019,
14749,Autocuration,,,1,,,Compound was tested for amidase rate in the presence of S166C fully characterised enzyme,U,,,22224,0,,CHEMBL632007,BAO_0000019,
14750,Autocuration,,,1,,,Compound was tested for amidase rate in the presence of S166C screen enzyme,U,,,22224,0,,CHEMBL632008,BAO_0000019,
14751,Autocuration,,,1,,,Compound was tested for esterase rate in the presence of N62C fully characterised enzyme,U,,,22224,0,,CHEMBL632009,BAO_0000019,
14752,Autocuration,,,1,,,Compound was tested for esterase rate in the presence of N62C screen enzyme,U,,,22224,0,,CHEMBL632010,BAO_0000019,
14753,Autocuration,,,1,,,Compound was tested for esterase rate in the presence of S166C fully characterised enzyme,U,,,22224,0,,CHEMBL857750,BAO_0000019,
14754,Autocuration,,,1,,,Compound was tested for esterase rate in the presence of S166C screen enzyme,U,,,22224,0,,CHEMBL632011,BAO_0000019,
14755,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 0.25% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",U,,,22224,0,,CHEMBL632012,BAO_0000019,
14756,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",U,,,22224,0,,CHEMBL632013,BAO_0000019,
14757,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 6C2 as catalyst was expressed as Kcat/KM",U,,,22224,0,,CHEMBL632014,BAO_0000019,
14758,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 10% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",U,,,22224,0,,CHEMBL629622,BAO_0000019,
14759,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/KM",U,,,22224,0,,CHEMBL629623,BAO_0000019,
14760,Autocuration,,,1,,,"Rate constant at 30 degree C in phosphate buffer pH 7.1, 0.5 % acetonitrile was expressed as Kcat/KM",U,,,22224,0,,CHEMBL629624,BAO_0000019,
14761,Autocuration,,,1,,,Ratio of Kcat to that of Km was determined,U,,,22224,0,,CHEMBL629625,BAO_0000019,
14762,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 1% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",U,,,22224,0,,CHEMBL629626,BAO_0000019,
14763,Autocuration,,,1,,,"Kinetic parameter for antibody-catalyzed Kemp elimination, at pH 7.1, 30C, using 5% acetonitrile and 4B2 as catalyst was expressed as Kcat/Kuncat",U,,,22224,0,,CHEMBL629627,BAO_0000019,
14764,Autocuration,,,1,,,"Compound was evaluated for constant, Kd",U,,,22224,0,,CHEMBL629628,BAO_0000019,
14765,Autocuration,,,1,,,Deacylation rate constant(Kd fast) was determined by proflavin displacement assay,U,,,22224,0,,CHEMBL629629,BAO_0000019,
14766,Autocuration,,,1,,,Deacylation rate constant(Kd slow) was determined by proflavin displacement assay,U,,,22224,0,,CHEMBL629630,BAO_0000019,
14767,Autocuration,,,1,,,Dissociation Constant of compound determined,U,,,22224,0,,CHEMBL856030,BAO_0000019,
14768,Autocuration,,,1,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined,U,,,22224,0,,CHEMBL629631,BAO_0000019,
14769,Autocuration,,,1,,,Dissociation constant for the binding of compound to PDZ3 from PSD-95 was determined; No data,U,,,22224,0,,CHEMBL629632,BAO_0000019,
14770,Autocuration,,,1,,,Dissociation constant of compound with Fructose was determined,U,,,22224,0,,CHEMBL629633,BAO_0000100,
14771,Autocuration,,,1,,,Dissociation constant of compound with Fructose was determined; Not determined,U,,,22224,0,,CHEMBL629634,BAO_0000100,
14772,Autocuration,,,1,,,Dissociation constant of compound with Lactulose was determined,U,,,22224,0,,CHEMBL629635,BAO_0000100,
14773,Autocuration,,,1,,,Dissociation constant of compound with Lactulose was determined; Not determined,U,,,22224,0,,CHEMBL629636,BAO_0000100,
14774,Autocuration,,,1,,,Dissociation constant of the Compound,U,,,22224,0,,CHEMBL629637,BAO_0000100,
14775,Autocuration,,,1,,,Dissociation constant by non-linear regression analysis,U,,,22224,0,,CHEMBL629638,BAO_0000100,
14776,Autocuration,,,1,,,Dissociation constant was determined,U,,,22224,0,,CHEMBL629639,BAO_0000100,
14777,Autocuration,,,1,,,Dissociation constant of the compound; value ranges from 0.81-1.2 nM,U,,,22224,0,,CHEMBL629640,BAO_0000100,
14778,Autocuration,,,1,,,Dissociation constant was determined,U,,,22224,0,,CHEMBL629641,BAO_0000100,
14779,Autocuration,,,1,,,Dissociation constant was determined,U,,,22224,0,,CHEMBL631344,BAO_0000100,
14780,Intermediate,10116.0,,1,2385.0,,Equilibrium dissociation constant based on membrane concentration in rat smooth muscle,N,,,50597,1,,CHEMBL631345,BAO_0000218,
14781,Autocuration,,,1,,,The dissociation constant determined by fluorescence displacement assay,U,,,22224,0,,CHEMBL631346,BAO_0000019,
14782,Autocuration,,,1,,,kd value surface plasmon resonance (SPR) method,U,,,22224,0,,CHEMBL631524,BAO_0000019,
14783,Intermediate,10116.0,,1,2385.0,,Equilibrium dissociation constant based on aqueous concentration in rat smooth muscle,N,,,50597,1,,CHEMBL631525,BAO_0000218,
14784,Autocuration,,,1,,,First dissociation constant of the binding of compound to V30M TTR,U,,,22224,0,,CHEMBL631526,BAO_0000019,
14785,Autocuration,,,1,,,Second dissociation constant of the binding of compound to V30M TTR,U,,,22224,0,,CHEMBL631527,BAO_0000019,
14786,Autocuration,,,1,,,"Compound was evaluated for equilibrium constant, Ke",U,,,22224,0,,CHEMBL631528,BAO_0000019,
14787,Autocuration,,,1,1898.0,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus,U,,,22224,0,,CHEMBL631529,BAO_0000019,
14788,Autocuration,,,1,1898.0,,Equilibrium constant from the dorsal raphe and the ventromedial hypothalamus; inactive,U,,,22224,0,,CHEMBL631530,BAO_0000019,
14789,Autocuration,,,1,,,Keff is the effective biomolecular rate constant on VX for reactivation at pH 7.8 at 25 degree Centigrade,U,,,22224,0,,CHEMBL631531,BAO_0000019,
14790,Autocuration,,,1,,,Keff is the effective biomolecular rate constant on paraxon for reactivation at pH 7.8 at 25 degree Centigrade,U,,,22224,0,,CHEMBL631532,BAO_0000019,
14791,Autocuration,,,1,,,Keff is the effective biomolecular rate constant on sarin for reactivation at pH 7.8 at 25 degree Centigrade,U,,,22224,0,,CHEMBL631533,BAO_0000019,
14792,Intermediate,10090.0,,1,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,N,,,50594,1,,CHEMBL876552,BAO_0000218,
14793,Intermediate,10090.0,,1,,,In vitro biotransformation of compound along with coformycin in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,N,,,50594,1,,CHEMBL631534,BAO_0000218,
14794,Intermediate,10090.0,,1,,,In vitro biotransformation of compound in mice brain homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,N,,,50594,1,,CHEMBL631535,BAO_0000218,
14795,Intermediate,10090.0,,1,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,N,,,50594,1,,CHEMBL631536,BAO_0000218,
14796,Intermediate,10090.0,,1,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)-6-hypoxanthine(ara-H) analyte,N,,,50594,1,,CHEMBL631537,BAO_0000218,
14797,Intermediate,10090.0,,1,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-A) analyte,N,,,50594,1,,CHEMBL631538,BAO_0000218,
14798,Intermediate,10090.0,,1,,,In vitro biotransformation of compound in mice liver homogenate 9-(beta-D-arabinifuranosyl)adenine(ara-H) analyte,N,,,50594,1,,CHEMBL631539,BAO_0000218,
14799,Intermediate,10090.0,,1,,,In vitro biotransformation of compound in mice serum 9-(beta-D-arabinifuranosyl)-6-azidopurine(6-AAP) analyte,N,,,50594,1,,CHEMBL631540,BAO_0000218,
14800,Intermediate,10116.0,,1,,,Pharmacokinetic Parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,,,50597,1,,CHEMBL625637,BAO_0000218,
14801,Intermediate,10116.0,,1,,,Pharmacokinetic parameter [Kel(1/h)] was evaluated at 10 mg/kg (p.o.) in Wistar rats,N,,,50597,1,,CHEMBL625638,BAO_0000218,
14802,Intermediate,10116.0,,1,,,"The Kel value in female wistar rat at 100 mg/kg, p.o. dose",N,,,50597,1,,CHEMBL625639,BAO_0000218,
14803,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution in rat brain post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625640,BAO_0000218,
14804,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution in rat brain post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625641,BAO_0000218,
14805,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625642,BAO_0000218,
14806,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution in rat heart post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625643,BAO_0000218,
14807,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625644,BAO_0000218,
14808,Intermediate,10116.0,In vivo,1,2113.0,,Biodistribution in rat kidney post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625645,BAO_0000218,
14809,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625646,BAO_0000218,
14810,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in rat liver post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625647,BAO_0000218,
14811,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in rat lung post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625648,BAO_0000218,
14812,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in rat lung post intravenous injection for 60 min of [99mTc]-TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625649,BAO_0000218,
14813,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625650,BAO_0000218,
14814,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in rat muscle post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625651,BAO_0000218,
14815,Intermediate,10116.0,In vivo,1,14.0,,Biodistribution in rat skin post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625652,BAO_0000218,
14816,Intermediate,10116.0,In vivo,1,14.0,,Biodistribution in rat skin post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625653,BAO_0000218,
14817,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in rat spleen post intravenous injection for 2 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625654,BAO_0000218,
14818,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in rat spleen post intravenous injection for 60 min of [99mTc]TRODAT ligand expressed as percent dose per organ,N,,,50597,1,,CHEMBL625655,BAO_0000218,
14819,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of Compound in rat blood after 15 minutes of administration,N,,,50597,1,,CHEMBL625656,BAO_0000218,
14820,Intermediate,10116.0,In vivo,1,178.0,,Biodistribution of Compound in rat blood after 2 minutes of administration,N,,,50597,1,,CHEMBL625657,BAO_0000218,
14821,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of Compound in rat brain after 15 minutes of administration,N,,,50597,1,,CHEMBL625658,BAO_0000218,
14822,Intermediate,10116.0,In vivo,1,955.0,,Biodistribution of Compound in rat brain after 2 minutes of administration,N,,,50597,1,,CHEMBL625659,BAO_0000218,
14823,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of Compound in rat heart after 15 minutes of administration,N,,,50597,1,,CHEMBL625660,BAO_0000218,
14824,Intermediate,10116.0,In vivo,1,948.0,,Biodistribution of Compound in rat heart after 2 minutes of administration,N,,,50597,1,,CHEMBL625661,BAO_0000218,
14825,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of Compound in rat liver after 15 minutes of administration,N,,,50597,1,,CHEMBL625662,BAO_0000218,
14826,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution of Compound in rat liver after 2 minutes of administration,N,,,50597,1,,CHEMBL625663,BAO_0000218,
14827,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of Compound in rat lung after 15 minutes of administration,N,,,50597,1,,CHEMBL875621,BAO_0000218,
14828,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution of Compound in rat lung after 2 minutes of administration,N,,,50597,1,,CHEMBL628382,BAO_0000218,
14829,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of Compound in rat muscle after 15 minutes of administration,N,,,50597,1,,CHEMBL628383,BAO_0000218,
14830,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution of Compound in rat muscle after 2 minutes of administration,N,,,50597,1,,CHEMBL628384,BAO_0000218,
14831,Intermediate,10116.0,,1,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 2 mins,N,,,50597,1,,CHEMBL628385,BAO_0000218,
14832,Intermediate,10116.0,,1,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 30 mins,N,,,50597,1,,CHEMBL875753,BAO_0000218,
14833,Intermediate,10116.0,,1,,,Brain uptake of [99mTc]TRODAT in rat expressed as percent dose per organ at time of 60 mins,N,,,50597,1,,CHEMBL628386,BAO_0000218,
14834,Intermediate,10116.0,,1,,,Organ distribution in rat blood 2 minutes after intravenous injection,N,,,50597,1,,CHEMBL628387,BAO_0000218,
14835,Intermediate,10116.0,,1,,,Organ distribution in rat blood 2 hr after intravenous injection,N,,,50597,1,,CHEMBL628388,BAO_0000218,
14836,Intermediate,10116.0,,1,,,Organ distribution in rat blood 30 minutes after intravenous injection,N,,,50597,1,,CHEMBL628389,BAO_0000218,
14837,Intermediate,10116.0,,1,,,Organ distribution in rat blood 30 min after intravenous injection,N,,,50597,1,,CHEMBL632756,BAO_0000218,
14838,Intermediate,10116.0,,1,,,Organ distribution in rat brain 2 minutes after intravenous injection,N,,,50597,1,,CHEMBL628390,BAO_0000218,
14839,Intermediate,10116.0,,1,,,Organ distribution in rat brain 2 hr after intravenous injection,N,,,50597,1,,CHEMBL631811,BAO_0000218,
14840,Intermediate,10116.0,,1,,,Organ distribution in rat brain 30 minutes after intravenous injection,N,,,50597,1,,CHEMBL631812,BAO_0000218,
14841,Intermediate,10116.0,,1,,,Organ distribution in rat heart 2 minutes after intravenous injection,N,,,50597,1,,CHEMBL631813,BAO_0000218,
14842,Intermediate,10116.0,,1,,,Organ distribution in rat heart 2 hr after intravenous injection,N,,,50597,1,,CHEMBL631814,BAO_0000218,
14843,Intermediate,10116.0,,1,,,Organ distribution in rat heart 30 minutes after intravenous injection,N,,,50597,1,,CHEMBL631815,BAO_0000218,
14844,Intermediate,10116.0,,1,,,Organ distribution in rat kidney 2 minutes after intravenous injection,N,,,50597,1,,CHEMBL631816,BAO_0000218,
14845,Intermediate,10116.0,,1,,,Organ distribution in rat kidney 2 hr after intravenous injection,N,,,50597,1,,CHEMBL875758,BAO_0000218,
14846,Intermediate,10116.0,,1,,,Organ distribution in rat kidney 30 minutes after intravenous injection,N,,,50597,1,,CHEMBL631817,BAO_0000218,
14847,Intermediate,10116.0,,1,2107.0,,Organ distribution in rat liver 2 minutes after intravenous injection,N,,,50597,1,,CHEMBL631818,BAO_0000218,
14848,Intermediate,10116.0,,1,2107.0,,Organ distribution in rat liver 2 hr after intravenous injection,N,,,50597,1,,CHEMBL631819,BAO_0000218,
14849,Intermediate,10116.0,,1,2107.0,,Organ distribution in rat liver 30 minutes after intravenous injection,N,,,50597,1,,CHEMBL631820,BAO_0000218,
14850,Intermediate,10116.0,,1,,,Organ distribution in rat lung 2 minutes after intravenous injection,N,,,50597,1,,CHEMBL631821,BAO_0000218,
14851,Intermediate,10116.0,,1,,,Organ distribution in rat lung 2 hr after intravenous injection,N,,,50597,1,,CHEMBL631822,BAO_0000218,
14852,Intermediate,10116.0,,1,,,Organ distribution in rat lung 30 minutes after intravenous injection,N,,,50597,1,,CHEMBL631823,BAO_0000218,
14853,Intermediate,10116.0,,1,2385.0,,Organ distribution in rat muscle 2 minutes after intravenous injection,N,,,50597,1,,CHEMBL631824,BAO_0000218,
14854,Intermediate,10116.0,,1,2385.0,,Organ distribution in rat muscle 2 hr after intravenous injection,N,,,50597,1,,CHEMBL631825,BAO_0000218,
14855,Intermediate,10116.0,,1,2385.0,,Organ distribution in rat muscle 30 minutes after intravenous injection,N,,,50597,1,,CHEMBL631826,BAO_0000218,
14856,Intermediate,10090.0,In vivo,1,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Blood (B),N,,,50594,1,,CHEMBL631827,BAO_0000218,
14857,Intermediate,10090.0,In vivo,1,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Heart (H),N,,,50594,1,,CHEMBL631828,BAO_0000218,
14858,Intermediate,10090.0,In vivo,1,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Lung (L),N,,,50594,1,,CHEMBL631829,BAO_0000218,
14859,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 3.76 uM/Kg of drug,N,,,50597,1,,CHEMBL875759,BAO_0000218,
14860,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 30.20 uM/Kg of drug,N,,,50597,1,,CHEMBL631830,BAO_0000218,
14861,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 302 uM/Kg of drug,N,,,50597,1,,CHEMBL631831,BAO_0000218,
14862,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 31.6 uM/Kg of drug,N,,,50597,1,,CHEMBL631832,BAO_0000218,
14863,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 316 uM/Kg of drug,N,,,50597,1,,CHEMBL631833,BAO_0000218,
14864,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 32.4 uM/Kg of drug,N,,,50597,1,,CHEMBL631834,BAO_0000218,
14865,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 324 uM/Kg of drug,N,,,50597,1,,CHEMBL631835,BAO_0000218,
14866,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.0 uM/Kg of drug,N,,,50597,1,,CHEMBL631836,BAO_0000218,
14867,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.1 uM/Kg of drug,N,,,50597,1,,CHEMBL631837,BAO_0000218,
14868,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 34.8 uM/Kg of drug,N,,,50597,1,,CHEMBL631838,BAO_0000218,
14869,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 341 uM/Kg of drug,N,,,50597,1,,CHEMBL631839,BAO_0000218,
14870,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 348 uM/Kg of drug,N,,,50597,1,,CHEMBL631840,BAO_0000218,
14871,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 37.6 uM/Kg of drug,N,,,50597,1,,CHEMBL631841,BAO_0000218,
14872,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 58.4 uM/Kg of drug,N,,,50597,1,,CHEMBL631842,BAO_0000218,
14873,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 65.2 uM/Kg of drug,N,,,50597,1,,CHEMBL631843,BAO_0000218,
14874,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.6 uM/Kg of drug,N,,,50597,1,,CHEMBL631844,BAO_0000218,
14875,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 71.8 uM/Kg of drug,N,,,50597,1,,CHEMBL631845,BAO_0000218,
14876,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 74.8 uM/Kg of drug,N,,,50597,1,,CHEMBL631846,BAO_0000218,
14877,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 77.5 uM/Kg of drug,N,,,50597,1,,CHEMBL875760,BAO_0000218,
14878,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 79.4 uM/Kg of drug,N,,,50597,1,,CHEMBL632199,BAO_0000218,
14879,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 80.9 uM/Kg of drug,N,,,50597,1,,CHEMBL631847,BAO_0000218,
14880,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 83.8 uM/Kg of drug,N,,,50597,1,,CHEMBL631848,BAO_0000218,
14881,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.5 uM/Kg of drug,N,,,50597,1,,CHEMBL628707,BAO_0000218,
14882,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 84.7 uM/Kg of drug,N,,,50597,1,,CHEMBL628708,BAO_0000218,
14883,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.7 uM/Kg of drug,N,,,50597,1,,CHEMBL628709,BAO_0000218,
14884,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 86.9 uM/Kg of drug,N,,,50597,1,,CHEMBL628710,BAO_0000218,
14885,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 9.06 uM/Kg of drug,N,,,50597,1,,CHEMBL628711,BAO_0000218,
14886,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 90.6 uM/Kg of drug,N,,,50597,1,,CHEMBL628712,BAO_0000218,
14887,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 94.9 uM/Kg of drug,N,,,50597,1,,CHEMBL628713,BAO_0000218,
14888,Intermediate,10116.0,,1,1088.0,,Total electrolytic excretion of sodium in urine of rats after peroral administration of 97.1 uM/Kg of drug,N,,,50597,1,,CHEMBL628714,BAO_0000218,
14889,Intermediate,10116.0,,1,,,"excretion rate in rats after the dose of 5 mg/kg intravenously, at the dose 4 hour Rate of biliary excretion; 0.06-0.15%/h",N,,,50597,1,,CHEMBL628715,BAO_0000218,
14890,Autocuration,,,1,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 3.75-120 uM,U,,,22224,0,,CHEMBL629179,BAO_0000019,
14891,Autocuration,,,1,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 30 uM,U,,,22224,0,,CHEMBL629180,BAO_0000019,
14892,Autocuration,,,1,,,Extent rates of formation of metabolic intermediate Cytochrome P-450 at compound concentration of 7.5-120 uM,U,,,22224,0,,CHEMBL875108,BAO_0000019,
14893,Autocuration,,,1,1235.0,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629181,BAO_0000019,
14894,Autocuration,,,1,1235.0,,Percent lipid extracted at 0.5 hr from adrenal cortex liver using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629182,BAO_0000019,
14895,Autocuration,,,1,,,Percent lipid extracted at 0.5 hr from liver plasma using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629183,BAO_0000019,
14896,Autocuration,,,1,,,Percent lipid extracted at 0.5 hr from liver using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629184,BAO_0000019,
14897,Autocuration,,,1,1235.0,,Percent lipid extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629185,BAO_0000019,
14898,Autocuration,,,1,1235.0,,Percent lipid extracted at 24 hours from adrenal cortex liver using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629186,BAO_0000019,
14899,Autocuration,,,1,,,Percent lipid extracted at 24 hours from liverliver using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629187,BAO_0000019,
14900,Autocuration,,,1,,,Percent lipid extracted at 24 hours from plasma using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629887,BAO_0000019,
14901,Autocuration,,,1,,,Percent lipid extracted at 24 hours from plasmaliver using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629888,BAO_0000019,
14902,Autocuration,,,1,,,Percent lipid extracted at 24 hr from liver using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629889,BAO_0000019,
14903,Autocuration,,,1,1235.0,,Percent parent compound extracted at 0.5 hr from adrenal cortex using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629890,BAO_0000019,
14904,Autocuration,,,1,,,Percent parent compound extracted at 0.5 hr from liver using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629891,BAO_0000019,
14905,Autocuration,,,1,,,Percent parent compound extracted at 0.5 hr from plasma using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629892,BAO_0000019,
14906,Autocuration,,,1,1235.0,,Percent parent compound extracted at 24 hours from adrenal cortex using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629893,BAO_0000019,
14907,Autocuration,,,1,,,Percent parent compound extracted at 24 hours from liver using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629894,BAO_0000019,
14908,Autocuration,,,1,,,Percent parent compound extracted at 24 hours from plasma using CHCl3/CH3OH.,U,,,22224,0,,CHEMBL629895,BAO_0000019,
14909,Autocuration,9615.0,In vivo,1,,,"+Ratio of intravenous to oral integrated area under the concentration vs time curve, for compound in dog plasma",U,,,22224,0,,CHEMBL875109,BAO_0000218,
14910,Autocuration,9541.0,In vivo,1,,,Absolute bioavailability in male cynomolgus monkeys,U,,,22224,0,,CHEMBL629896,BAO_0000218,
14911,Autocuration,10116.0,In vivo,1,,,Absolute bioavailability in maleSprague-Dawley rats,U,,,22224,0,,CHEMBL629897,BAO_0000218,
14912,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL629898,BAO_0000218,
14913,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630057,BAO_0000218,
14914,Intermediate,10116.0,In vivo,1,2107.0,,Biodistribution in liver of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630058,BAO_0000218,
14915,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in lungs of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630059,BAO_0000218,
14916,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630060,BAO_0000218,
14917,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in lungs of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL630061,BAO_0000218,
14918,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in lungs of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630062,BAO_0000218,
14919,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in lungs of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630063,BAO_0000218,
14920,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in lungs of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630064,BAO_0000218,
14921,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630065,BAO_0000218,
14922,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in lungs of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL630066,BAO_0000218,
14923,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in lungs of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630067,BAO_0000218,
14924,Intermediate,10116.0,In vivo,1,2048.0,,Biodistribution in lungs of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630068,BAO_0000218,
14925,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in muscle of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631113,BAO_0000218,
14926,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631114,BAO_0000218,
14927,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in muscle of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL631115,BAO_0000218,
14928,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in muscle of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL631116,BAO_0000218,
14929,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in muscle of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630528,BAO_0000218,
14930,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in muscle of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630529,BAO_0000218,
14931,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630530,BAO_0000218,
14932,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in muscle of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL630531,BAO_0000218,
14933,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in muscle of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630532,BAO_0000218,
14934,Intermediate,10116.0,In vivo,1,2385.0,,Biodistribution in muscle of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630533,BAO_0000218,
14935,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution in normal mice blood after 120 hr,N,,,50594,1,,CHEMBL630534,BAO_0000218,
14936,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution in normal mice blood after 24 hr,N,,,50594,1,,CHEMBL630535,BAO_0000218,
14937,Intermediate,10090.0,In vivo,1,178.0,,Biodistribution in normal mice blood after 4 hr,N,,,50594,1,,CHEMBL630536,BAO_0000218,
14938,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution in normal mice bone after 120 hr,N,,,50594,1,,CHEMBL630537,BAO_0000218,
14939,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution in normal mice bone after 24 hr,N,,,50594,1,,CHEMBL630538,BAO_0000218,
14940,Intermediate,10090.0,In vivo,1,10000001.0,,Biodistribution in normal mice bone after 4 hr,N,,,50594,1,,CHEMBL630539,BAO_0000218,
14941,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution in normal mice heart after 120 hr,N,,,50594,1,,CHEMBL630540,BAO_0000218,
14942,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution in normal mice heart after 24 hr,N,,,50594,1,,CHEMBL630541,BAO_0000218,
14943,Intermediate,10090.0,In vivo,1,948.0,,Biodistribution in normal mice heart after 4 hr,N,,,50594,1,,CHEMBL630542,BAO_0000218,
14944,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution in normal mice kidney after 120 hr,N,,,50594,1,,CHEMBL630543,BAO_0000218,
14945,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution in normal mice kidney after 24 hr,N,,,50594,1,,CHEMBL630544,BAO_0000218,
14946,Intermediate,10090.0,In vivo,1,2113.0,,Biodistribution in normal mice kidney after 4 hr,N,,,50594,1,,CHEMBL630545,BAO_0000218,
14947,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution in normal mice liver after 120 hr,N,,,50594,1,,CHEMBL630546,BAO_0000218,
14948,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution in normal mice liver after 24 hr,N,,,50594,1,,CHEMBL630547,BAO_0000218,
14949,Intermediate,10090.0,In vivo,1,2107.0,,Biodistribution in normal mice liver after 4 hr,N,,,50594,1,,CHEMBL630548,BAO_0000218,
14950,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution in normal mice spleen after 120 hr,N,,,50594,1,,CHEMBL630549,BAO_0000218,
14951,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution in normal mice spleen after 24 hr,N,,,50594,1,,CHEMBL630550,BAO_0000218,
14952,Intermediate,10090.0,In vivo,1,2106.0,,Biodistribution in normal mice spleen after 4 hr,N,,,50594,1,,CHEMBL876426,BAO_0000218,
14953,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in spleen of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630551,BAO_0000218,
14954,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630552,BAO_0000218,
14955,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in spleen of Immature Female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL630553,BAO_0000218,
14956,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in spleen of Immature Female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630554,BAO_0000218,
14957,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in spleen of Immature Female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630555,BAO_0000218,
14958,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in spleen of immature female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630556,BAO_0000218,
14959,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630557,BAO_0000218,
14960,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in spleen of immature female rat after 1 hr administration of 3 micro Ci (111 kBq) in the presence of (+E2),N,,,50597,1,,CHEMBL630558,BAO_0000218,
14961,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in spleen of immature female rat after 3 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630559,BAO_0000218,
14962,Intermediate,10116.0,In vivo,1,2106.0,,Biodistribution in spleen of immature female rat after 5 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL630560,BAO_0000218,
14963,Intermediate,10116.0,In vivo,1,2046.0,,Biodistribution in thyroid of Immature Female rat after 12 hour administration of 3 micro Ci (111 kBq) in the absence of 60 microg estradiol,N,,,50597,1,,CHEMBL876427,BAO_0000218,
14964,Intermediate,10116.0,,1,,,The Kel values in female wistar rats.,N,,,50597,1,,CHEMBL630561,BAO_0000218,
14965,Autocuration,,,1,,,The equilibrium constant pair at a pH of 7.0 and temperature of 25 degree Centigrade,U,,,22224,0,,CHEMBL630562,BAO_0000019,
14966,Autocuration,,,1,,,Hydrolysis rate constant of the compound,U,,,22224,0,,CHEMBL630563,BAO_0000019,
14967,Autocuration,,,1,,,Headecane/water partition coefficient expressed as the equilibrium ratio of the molar concentration in n-hexadecane to that in the buffer,U,,,22229,0,,CHEMBL629673,BAO_0000100,
14968,Autocuration,,,1,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0, T=66 degree Centigrade",U,,,22224,0,,CHEMBL629674,BAO_0000019,
14969,Autocuration,,,1,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree Centigrade",U,,,22224,0,,CHEMBL629675,BAO_0000019,
14970,Autocuration,,,1,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; No data",U,,,22224,0,,CHEMBL629676,BAO_0000019,
14971,Autocuration,,,1,,,"Hydrolysis in acetone/water (50:50) at a pH of 8.0,T =66 degree centigrade; Not determined",U,,,22224,0,,CHEMBL629677,BAO_0000019,
14972,Autocuration,,,1,,,Apparent inactivation rate constant was evaluated,U,,,22224,0,,CHEMBL629678,BAO_0000019,
14973,Autocuration,,,1,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 25 degree Centigrade.,U,,,22224,0,,CHEMBL629679,BAO_0000019,
14974,Autocuration,,,1,,,Compound was evaluated for equilibrium constant K obtained from the ratio of reverse rate constants at 37 degree Centigrade,U,,,22224,0,,CHEMBL629680,BAO_0000019,
14975,Autocuration,,,1,,,Compound was evaluated for the Ki value for peptide alcohol for competitive inhibition in the presence of Mn2+ ions at pH 7.5,U,,,22224,0,,CHEMBL629681,BAO_0000019,
14976,Autocuration,,,1,,,Compound was tested for the inhibition of antibody-catalyzed hydrolysis.,U,,,22224,0,,CHEMBL629682,BAO_0000019,
14977,Autocuration,,,1,,,DBH (dopamine beta-hydroxylase) activity expressed as Ki value determined by degree to which compound inhibited conversion of tyramine to octopamine,U,,,22224,0,,CHEMBL629683,BAO_0000019,
14978,Autocuration,,,1,,,Dissociation constant against constrictor response to the compound blocked competitively by phentolamine for alpha-mediated events,U,,,22224,0,,CHEMBL629684,BAO_0000019,
14979,Autocuration,,,1,,,Dissociation constant was determined,U,,,22224,0,,CHEMBL629685,BAO_0000100,
14980,Autocuration,,,1,,,Dissociation constant was determined,U,,,22224,0,,CHEMBL629686,BAO_0000100,
14981,Autocuration,,,1,,,Dissociation constant at pH 7.4,U,,,22224,0,,CHEMBL872932,BAO_0000100,
14982,Autocuration,,,1,,,Dissociation constant in presence of 1 mM dithiothreitol,U,,,22224,0,,CHEMBL629687,BAO_0000100,
14983,Autocuration,,,1,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,U,,,22224,0,,CHEMBL872931,BAO_0000019,
14984,Autocuration,,,1,,,Kinetic Parameter Ki for Inhibition of Type 1 5-alpha-reductase,U,,,22224,0,,CHEMBL628151,BAO_0000019,
14985,Autocuration,,,1,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,U,,,22224,0,,CHEMBL628152,BAO_0000019,
14986,Autocuration,,,1,,,Kinetic Parameter Ki for Inhibition of Type-2 5-alpha-reductase,U,,,22224,0,,CHEMBL628153,BAO_0000019,
14987,Autocuration,,,1,,,Kinetic constant for aromatization of androstenedione,U,,,22224,0,,CHEMBL628154,BAO_0000019,
14988,Autocuration,,,1,,,Kinetic constant for aromatization of testosterone,U,,,22224,0,,CHEMBL628155,BAO_0000019,
14989,Autocuration,,,1,,,Kinetic parameter for hydrolysis of 1 by Antibody 2D10 after addition of compound 12,U,,,22224,0,,CHEMBL628156,BAO_0000019,
14990,Autocuration,,,1,,,Local inhibition constant was determined,U,,,22224,0,,CHEMBL628157,BAO_0000019,
14991,Intermediate,4932.0,,1,,,Rate of inactivation of sterol methyl transferase from Saccharomyces cerevisiae using mechanism based inhibitor,N,,,50347,1,,CHEMBL857533,BAO_0000218,
14992,Autocuration,,,1,,,Dissociation constant value of the compound,U,,,22224,0,,CHEMBL628158,BAO_0000100,
14993,Autocuration,,,1,964.0,,In vitro permeability through cornea without epithelium,U,,,22224,0,,CHEMBL628159,BAO_0000019,
14994,Autocuration,,,1,964.0,,In vitro permeability through intact cornea,U,,,22224,0,,CHEMBL875616,BAO_0000019,
14995,Intermediate,9986.0,,1,964.0,,Evaluated for first order rate constant (Kin) for transcorneal penetration in anesthetized rabbits,N,,,50592,1,,CHEMBL628160,BAO_0000218,
14996,Autocuration,,,1,,,Rate of enzyme inactivation for the compound was determined,U,,,22224,0,,CHEMBL628161,BAO_0000019,
14997,Autocuration,,,1,964.0,,In vitro permeability through cornea without epithelium,U,,,22224,0,,CHEMBL628162,BAO_0000019,
14998,Autocuration,,,1,964.0,,In vitro permeability through intact cornea,U,,,22224,0,,CHEMBL628163,BAO_0000019,
14999,Autocuration,,,1,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0300 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL628164,BAO_0000019,
15000,Autocuration,,,1,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0384 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL628165,BAO_0000019,
15001,Autocuration,,,1,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0395 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL628166,BAO_0000019,
15002,Autocuration,,,1,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0500 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL628167,BAO_0000019,
15003,Autocuration,,,1,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.050 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL628168,BAO_0000019,
15004,Autocuration,,,1,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0767 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL628169,BAO_0000019,
15005,Autocuration,,,1,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0790 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL628170,BAO_0000019,
15006,Autocuration,,,1,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.0800 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL628171,BAO_0000019,
15007,Autocuration,,,1,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.100 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL627434,BAO_0000019,
15008,Autocuration,,,1,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.200 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL627435,BAO_0000019,
15009,Autocuration,,,1,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.300 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL628110,BAO_0000019,
15010,Autocuration,,,1,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.384 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL628111,BAO_0000019,
15011,Autocuration,,,1,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.395 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL628112,BAO_0000019,
15012,Autocuration,,,1,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.500 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL628260,BAO_0000019,
15013,Autocuration,,,1,,,"Kinetic constant(1/ K obsd (min)) was calculated for the observed reaction rate constant at the concentration 0.767 mM [HOX] in the conditions of 25degreeC,pH 7.6",U,,,22224,0,,CHEMBL628261,BAO_0000019,
15014,Intermediate,10090.0,In vivo,1,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Muscle (M),N,,,50594,1,,CHEMBL628262,BAO_0000218,
15015,Intermediate,9606.0,In vivo,1,,,Biodistribution in athymic mice bearing Human Tumor (KB) Xenografts 1 hour after injection in Tumor (T) cells,N,,,50587,1,,CHEMBL628263,BAO_0000218,
15016,Intermediate,10090.0,In vivo,1,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Blood (B),N,,,50594,1,,CHEMBL628264,BAO_0000218,
15017,Intermediate,10090.0,In vivo,1,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Heart (H),N,,,50594,1,,CHEMBL628265,BAO_0000218,
15018,Intermediate,10090.0,In vivo,1,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Lung (L),N,,,50594,1,,CHEMBL628266,BAO_0000218,
15019,Intermediate,10090.0,In vivo,1,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Muscle (M),N,,,50594,1,,CHEMBL628267,BAO_0000218,
15020,Intermediate,10090.0,In vivo,1,,,Biodistribution in athymic mice bearing Human Tumor (LS174T) Xenografts 1 hour after injection in Tumor (T) cells,N,,,50594,1,,CHEMBL628268,BAO_0000218,
15021,Intermediate,10090.0,In vivo,1,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Blood (B),N,,,50594,1,,CHEMBL628269,BAO_0000218,
15022,Intermediate,10090.0,In vivo,1,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Heart (H),N,,,50594,1,,CHEMBL628270,BAO_0000218,
15023,Intermediate,10090.0,In vivo,1,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Lung (L),N,,,50594,1,,CHEMBL628271,BAO_0000218,
15024,Intermediate,10090.0,In vivo,1,,,Biodistribution in athymic mice bearing Human Tumor (TE671) Xenografts 1 hour after injection in Muscle (M),N,,,50594,1,,CHEMBL628272,BAO_0000218,
